


APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)



APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

34th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
OFFICE OF GENERIC DRUGS

2014

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2013.

34th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
OFFICE OF GENERIC DRUGS

2014

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

CONTENTS

PAGE

PREFACE TO THIRTY FOURTH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Statistical Criteria for Bioequivalence	viii
1.4 Reference Listed Drug.....	x
1.5 General Policies and Legal Status	xi
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes	xiii
1.8 Description of Special Situations.....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiii
1.11 Discontinued Section.....	xxiii
1.12 Changes to the Orange Book.....	xxiii
1.13 Availability of the Edition.....	xxiv
2 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY FOURTH EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register*

on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Labeling and Program Support, HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7620 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products are given tentative approvals. The Agency will not include drug products with tentative approval in the List. Tentative approval lists are available at [ANDA \(Generic\) Drug Approvals](#). When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same

¹ Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

dosage form, route of administration and are identical in strength or concentration (e.g., chlorthalidone hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes

available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36

adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (C_{max}), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and C_{max}) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (C_{max} and AUC). The confidence interval for both pharmacokinetic parameters, AUC and C_{max} , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and C_{max}) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted

in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and C_{max} . The observed average differences between the reference and generic products were $+ 3.47\%$ (SD 2.84) for $AUC_{(0-t)}$, $+ 3.25\%$ (SD 2.97) for $AUC_{(0-inf)}$, and $+ 4.29\%$ (SD 3.72) for C_{max} (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which is purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List.

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no

therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however,

independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the

application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be

pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1**, **AB2**, **AB3**, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic

drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%,

dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for

such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have

demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine

sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBOTT	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBOTT	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHEROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or exclusivity, e.g. a second RLD that was selected when the in vivo determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

Waived exclusivity. If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons***" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book Staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update

We can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book Query](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 33rd Edition List have been added to the Discontinued Drug Product List appearing in the 34th Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	<u>MEPERIDINE HYDROCHLORIDE</u>				
DOSAGE FORM; ROUTE OF ADMINISTRATION	INJECTABLE;INJECTION				
TRADE OR GENERIC NAMES	<u>HEXANON</u>				
REFERENCE LISTED DRUG	<u>AP</u> + PAGE PHARMA	<u>25MG/ML</u>	<u>N013111</u>	<u>001</u>	AUG 22, 1983
	<u>AP</u> +	<u>50MG/ML</u>	<u>N013111</u>	<u>002</u>	AUG 22, 1983
	<u>AP</u> +	<u>75MG/ML</u>	<u>N013111</u>	<u>003</u>	AUG 22, 1983
	<u>AP</u> +	<u>100MG/ML</u>	<u>N013111</u>	<u>004</u>	JAN 04, 1989
THERAPEUTIC EQUIVALENCE (TE) CODE FOR MULTISOURCE PRODUCT	<u>AP</u> GREENBERG PHARM	<u>25MG/ML</u>	<u>A064890</u>	001	FEB 29, 1987
	<u>AP</u>	<u>50MG/ML</u>	<u>A064890</u>	002	FEB 29, 1987
	<u>AP</u>	<u>75MG/ML</u>	<u>A064890</u>	003	FEB 29, 1987
	<u>AP</u>	<u>100MG/ML</u>	<u>A064890</u>	004	MAR 08, 1992
SINGLE SOURCE PRODUCT (NO TE CODE)	<u>AP</u> MIN LLC	10MG/ML	A099225	001	DEC 12, 1995
	<u>AP</u> JOHNSON MED	<u>25MG/ML</u>	<u>A099226</u>	<u>001</u>	NOV 27, 1993
	<u>AP</u> KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999
APPLICANT					
AVAILABLE STRENGTH(S) OF A PRODUCT					
APPLICATION NUMBER AND PRODUCT NUMBER					
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY					
APPROVAL DATE					

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY ACTIVE INGREDIENT	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>		
PRODUCT INFORMATION	→	[	TABLET; ORAL	
			HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL	
			REINWALD	25MG;15MG;0.1MG
				A069808 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULAZINE

AB URSA **500MG** **A042222** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SOUTH 500MG A067627 001

PRODUCTS CONSIDERED THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

3-1 (of 362)

ABACAVIR SULFATE

SOLUTION; ORAL

ZIAGEN

+ VIVV HLTHCARE

EQ 20MG BASE/ML

N020978 001 Dec 17, 1998

TABLET; ORAL

ABACAVIR SULFATEAB APOTEX INCEQ 300MG BASEA201570 001 Dec 17, 2012AB AUROBINDO PHARMA LTDEQ 300MG BASEA077844 001 Dec 17, 2012AB HETERO LABS LTD IIIEQ 300MG BASEA091560 001 Sep 13, 2013AB MYLAN PHARMS INCEQ 300MG BASEA091294 001 Jun 18, 2012ZIAGENAB + VIVV HLTHCAREEQ 300MG BASEN020977 001 Dec 17, 1998ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM

+ VIVV HLTHCARE

EQ 600MG BASE; 300MG

N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEAB LUPIN LTDEQ 300MG BASE; 150MG; 300MGA202912 001 Dec 05, 2013TRIZIVIRAB + VIVV HLTHCAREEQ 300MG BASE; 150MG; 300MGN021205 001 Nov 14, 2000ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+ JANSSEN BIOTECH

250MG

N202379 001 Apr 28, 2011

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUMAB BARR LABS DIV TEVA333MGA200143 001 Nov 18, 2013AB GLENMARK GENERICS333MGA202229 001 Jul 16, 2013CAMPRALAB + FOREST LABS333MGN021431 001 Jul 29, 2004ACARBOSE

TABLET; ORAL

ACARBOSEAB EMCURE PHARMS LTD25MGA202271 001 Feb 07, 2012AB50MGA202271 002 Feb 07, 2012AB100MGA202271 003 Feb 07, 2012AB IMPAX LABS25MGA078441 001 May 14, 2009AB50MGA078441 002 May 14, 2009AB100MGA078441 003 May 14, 2009AB MYLAN25MGA091053 001 Jan 06, 2011AB50MGA091053 002 Jan 06, 2011AB100MGA091053 003 Jan 06, 2011AB ROXANE25MGA078470 001 May 07, 2008AB50MGA078470 002 May 07, 2008AB100MGA078470 003 May 07, 2008AB STRIDES ARCOLAB LTD25MGA090912 001 Jul 27, 2011AB50MGA090912 002 Jul 27, 2011AB100MGA090912 003 Jul 27, 2011AB VIRTUS PHARM25MGA091343 001 Oct 17, 2013AB50MGA091343 002 Oct 17, 2013AB100MGA091343 003 Oct 17, 2013AB WATSON LABS25MGA077532 001 May 07, 2008AB50MGA077532 002 May 07, 2008AB100MGA077532 003 May 07, 2008PRECOSEAB + BAYER HLTHCARE25MGN020482 004 May 29, 1997AB50MGN020482 001 Sep 06, 1995AB100MGN020482 002 Sep 06, 1995ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDEAB AMNEAL PHARMEQ 200MG BASEA075047 001 Dec 30, 1999ABEQ 400MG BASEA075047 002 Dec 30, 1999AB MYLANEQ 200MG BASEA074288 001 Apr 24, 1995ABEQ 400MG BASEA074288 002 Apr 24, 1995AB WATSON LABSEQ 200MG BASEA074007 001 Oct 18, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-2 (of 362)

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

AB		<u>EQ 400MG BASE</u>	<u>A074007</u>	<u>002</u>	Oct 18, 1995

SECTRAL

AB	PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917</u>	<u>001</u>	Dec 28, 1984

AB	+	<u>EQ 400MG BASE</u>	<u>N018917</u>	<u>003</u>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

OFIRMEV

+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

+	VALEANT	650MG; 50MG	A088831	001	Jun 19, 1985

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

+	NEXGEN PHARMA	300MG; 50MG	A090956	001	Aug 23, 2011

BUTAPAP

+	MIKART	325MG; 50MG	A089987	001	Oct 26, 1992

+		650MG; 50MG	A089988	001	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986

+	NEXGEN PHARMA	300MG; 50MG; 40MG	A040885	001	Nov 16, 2009

ESGIC-PLUS

+	MIKART	500MG; 50MG; 40MG	A040085	001	Mar 28, 1996

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387	001	Jan 31, 2003

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	LANNETT HOLDINGS INC	<u>325MG; 50MG; 40MG</u>	<u>A200243</u>	<u>001</u>	Sep 13, 2012

AA	MALLINCKRODT	<u>325MG; 50MG; 40MG</u>	<u>A087804</u>	<u>001</u>	Jan 24, 1985

AA	MIKART	<u>325MG; 50MG; 40MG</u>	<u>A089175</u>	<u>001</u>	Jan 21, 1987

AA	MIRROR PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A040864</u>	<u>001</u>	Dec 01, 2008

AA	VINTAGE PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A040511</u>	<u>001</u>	Aug 27, 2003

AA		<u>500MG; 50MG; 40MG</u>	<u>A040513</u>	<u>001</u>	Aug 25, 2003

AA	WATSON LABS	<u>500MG; 50MG; 40MG</u>	<u>A040267</u>	<u>001</u>	Jul 30, 1998

AA	WEST WARD	<u>325MG; 50MG; 40MG</u>	<u>A089718</u>	<u>001</u>	Jun 12, 1995

ESGIC-PLUS

AA	+	<u>MIKART</u>	<u>500MG; 50MG; 40MG</u>	<u>A089451</u>	<u>001</u>	May 23, 1988

FIORICET

AA	+	<u>WATSON PHARMS</u>	<u>325MG; 50MG; 40MG</u>	<u>A088616</u>	<u>001</u>	Nov 09, 1984

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	750MG; 50MG; 40MG	A040496	001	Dec 23, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	NEXGEN PHARMA INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A076560</u>	<u>001</u>	Jun 10, 2004

AB	VINTAGE PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075929</u>	<u>001</u>	Apr 22, 2002

AB	WEST WARD	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075618</u>	<u>001</u>	Mar 23, 2001

FIORICET W/ CODEINE

AB	+	<u>WATSON LABS INC</u>	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N020232</u>	<u>001</u>	Jul 30, 1992

PHRENILIN WITH CAFFEINE AND CODEINE

AB	VALEANT	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A074911</u>	<u>001</u>	Aug 22, 2001

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	HI TECH PHARMA	<u>120MG/5ML; 12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996

AA	MIKART	<u>120MG/5ML; 12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992

AA	+	<u>PHARM ASSOC</u>	<u>120MG/5ML; 12MG/5ML</u>	<u>A087508</u>	<u>001</u>

AA	VINTAGE PHARMS	<u>120MG/5ML; 12MG/5ML</u>	<u>A091238</u>	<u>001</u>	Nov 10, 2011

AA	WOCKHARDT	<u>120MG/5ML; 12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-3 (of 362)

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

CAPITAL AND CODEINE

+ VALEANT PHARMS LLC 120MG/5ML; 12MG/5ML

A086024 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG; 30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u>	AUROLIFE PHARMA LLC	<u>300MG; 15MG</u>	<u>A202800</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		<u>300MG; 30MG</u>	<u>A202800</u>	<u>002</u>	Apr 15, 2013
<u>AA</u>		<u>300MG; 60MG</u>	<u>A202800</u>	<u>003</u>	Apr 15, 2013
<u>AA</u>	+ MALLINCKRODT INC	<u>300MG; 15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG; 30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG; 60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	RANBAXY	<u>300MG; 30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG; 60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG; 15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG; 30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	+ VINTAGE	<u>300MG; 60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG; 15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG; 30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG; 60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
	<u>TYLENOL W/ CODEINE NO. 3</u>				
<u>AA</u>	+ JANSEN PHARMS	<u>300MG; 30MG</u>	<u>A085055</u>	<u>003</u>	
	<u>TYLENOL W/ CODEINE NO. 4</u>				
<u>AA</u>	JANSEN PHARMS	<u>300MG; 60MG</u>	<u>A085055</u>	<u>004</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	BOCA PHARMA LLC	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>	MALLINCKRODT	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040418</u>	<u>001</u>	Jun 27, 2001
<u>AA</u>	+ MIKART	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>	+ PAI	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A081051</u>	<u>001</u>	Aug 28, 1992
<u>AA</u>		<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013
<u>AA</u>	PHARM ASSOC	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040182</u>	<u>001</u>	Mar 13, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040520</u>	<u>001</u>	Oct 30, 2003
<u>AA</u>	VISTAPHARM	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
	+ MIKART	<u>300MG/15ML; 10MG/15ML</u>	<u>A040881</u>	<u>001</u>	Feb 25, 2010
	+ PHARM ASSOC	<u>325MG/15ML; 10MG/15ML</u>	<u>A040834</u>	<u>001</u>	Apr 18, 2008

TABLET; ORAL

ANEXSIA

<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A089160</u>	<u>001</u>	Apr 23, 1987
<u>AA</u>		<u>750MG; 10MG</u>	<u>A040468</u>	<u>001</u>	Oct 31, 2002
	<u>ANEXSIA 5/325</u>				
<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
	<u>ANEXSIA 7.5/325</u>				
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
	<u>ANEXSIA 7.5/650</u>				
<u>AA</u>	MALLINCKRODT	<u>650MG; 7.5MG</u>	<u>A089725</u>	<u>001</u>	Sep 30, 1987

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 5MG</u>	<u>A040729</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040748</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040813</u>	<u>001</u>	Feb 23, 2007
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040754</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040757</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040769</u>	<u>001</u>	Aug 28, 2006
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201013</u>	<u>002</u>	Apr 11, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201013</u>	<u>003</u>	Apr 11, 2012
<u>AA</u>	BOCA PHARMA LLC	<u>300MG; 5MG</u>	<u>A090415</u>	<u>001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A090415</u>	<u>002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 10MG</u>	<u>A090415</u>	<u>003</u>	Jan 24, 2011
<u>AA</u>	CARACO	<u>325MG; 5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 5MG</u>	<u>A090265</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A090265</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 10MG</u>	<u>A090265</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A090380</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>650MG; 10MG</u>	<u>A090380</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>660MG; 10MG</u>	<u>A090380</u>	<u>003</u>	Dec 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-4 (of 362)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A090380</u>	<u>004</u>	Dec 23, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>		<u>500MG; 5MG</u>	<u>A040084</u>	<u>002</u>	Jun 01, 1995
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040201</u>	<u>001</u>	Feb 27, 1998
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040201</u>	<u>002</u>	Feb 27, 1998
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040084</u>	<u>004</u>	Oct 16, 1996
<u>AA</u>	+	<u>660MG; 10MG</u>	<u>A040084</u>	<u>003</u>	Jul 29, 1996
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040084</u>	<u>001</u>	Jun 01, 1995
<u>AA</u>	+	<u>300MG; 5MG</u>	<u>A040658</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>	+	<u>300MG; 7.5MG</u>	<u>A040556</u>	<u>002</u>	Mar 24, 2006
<u>AA</u>	+	<u>300MG; 10MG</u>	<u>A040556</u>	<u>001</u>	Jun 23, 2004
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>	+	<u>500MG; 7.5MG</u>	<u>A089699</u>	<u>001</u>	Aug 25, 1989
<u>AA</u>	+	<u>650MG; 7.5MG</u>	<u>A089689</u>	<u>001</u>	Jun 29, 1988
<u>AA</u>	+	<u>650MG; 10MG</u>	<u>A081223</u>	<u>001</u>	May 29, 1992
<u>AA</u>	TRIS PHARMA INC	<u>325MG; 5MG</u>	<u>A202214</u>	<u>001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202214</u>	<u>002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202214</u>	<u>003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 5MG</u>	<u>A040655</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>500MG; 2.5MG</u>	<u>A040144</u>	<u>002</u>	Apr 25, 1997
<u>AA</u>		<u>500MG; 5MG</u>	<u>A089971</u>	<u>001</u>	Dec 02, 1988
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040144</u>	<u>001</u>	Feb 22, 1996
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040356</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040155</u>	<u>001</u>	Apr 14, 1997
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040143</u>	<u>001</u>	Feb 22, 1996
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040358</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040157</u>	<u>001</u>	Apr 12, 1996
<u>AA</u>	WATSON LABS	<u>500MG; 2.5MG</u>	<u>A081079</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>		<u>500MG; 5MG</u>	<u>A089883</u>	<u>001</u>	Dec 01, 1988
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A081080</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040148</u>	<u>002</u>	Feb 14, 1997
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040094</u>	<u>001</u>	Sep 29, 1995
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040094</u>	<u>002</u>	Sep 29, 1995
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040094</u>	<u>003</u>	Aug 08, 2000
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A081083</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>	+	<u>750MG; 10MG</u>	<u>A040094</u>	<u>004</u>	Mar 22, 1999
<u>AA</u>	WATSON LABS FLORIDA	<u>660MG; 10MG</u>	<u>A040495</u>	<u>001</u>	May 28, 2003
<u>LORTAB</u>					
<u>AA</u>	UCB INC	<u>500MG; 5MG</u>	<u>A087722</u>	<u>001</u>	Jul 09, 1982
<u>AA</u>	+	<u>500MG; 10MG</u>	<u>A040100</u>	<u>001</u>	Jan 26, 1996
<u>NORCO</u>					
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040099</u>	<u>001</u>	Jun 25, 1997
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040148</u>	<u>003</u>	Sep 12, 2000
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040148</u>	<u>001</u>	Feb 14, 1997
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	+	<u>325MG; 2.5MG</u>	A040846	001	Jun 09, 2010
ZYDONE					
	+	<u>400MG; 5MG</u>	A040288	001	Nov 27, 1998
	+	<u>400MG; 7.5MG</u>	A040288	002	Nov 27, 1998
	+	<u>400MG; 10MG</u>	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	DURAMED PHARMS BARR	<u>500MG; 5MG</u>	<u>A040289</u>	<u>001</u>	Mar 16, 1999
<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A040257</u>	<u>001</u>	Aug 04, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG; 5MG</u>	<u>A040106</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>500MG; 5MG</u>	<u>A040234</u>	<u>001</u>	Oct 30, 1997
<u>ROXILOX</u>					
<u>AA</u>	ROXANE	<u>500MG; 5MG</u>	<u>A040061</u>	<u>001</u>	Jul 03, 1995
<u>TYLOX</u>					
<u>AA</u>	+	<u>500MG; 5MG</u>	<u>A088790</u>	<u>001</u>	Dec 12, 1984
SOLUTION; ORAL					
<u>ROXICET</u>					
<u>AA</u>	+	<u>325MG/5ML; 5MG/5ML</u>	<u>A089351</u>	<u>001</u>	Dec 03, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-5 (of 362)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCET

AA	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983
<u>OXYCODONE AND ACETAMINOPHEN</u>					
AA	ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<u>A201447</u>	<u>001</u>	Apr 12, 2013
AA		<u>325MG; 5MG</u>	<u>A201447</u>	<u>002</u>	Apr 12, 2013
AA		<u>325MG; 7.5MG</u>	<u>A201447</u>	<u>003</u>	Apr 12, 2013
AA		<u>325MG; 10MG</u>	<u>A201447</u>	<u>004</u>	Apr 12, 2013
AA	ACTAVIS TOTOWA	<u>325MG; 7.5MG</u>	<u>A040800</u>	<u>001</u>	Apr 03, 2012
AA		<u>325MG; 10MG</u>	<u>A040800</u>	<u>002</u>	Apr 03, 2012
AA	ALVOGEN INC	<u>325MG; 7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
AA		<u>325MG; 10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
AA	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
AA		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
AA		<u>500MG; 7.5MG</u>	<u>A040789</u>	<u>001</u>	Nov 27, 2007
AA		<u>650MG; 10MG</u>	<u>A040789</u>	<u>002</u>	Nov 27, 2007
AA	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972</u>	<u>001</u>	Jul 15, 2013
AA		<u>325MG; 5MG</u>	<u>A201972</u>	<u>002</u>	Jul 15, 2013
AA		<u>325MG; 7.5MG</u>	<u>A201972</u>	<u>003</u>	Jul 15, 2013
AA		<u>325MG; 10MG</u>	<u>A201972</u>	<u>004</u>	Jul 15, 2013
AA	CARACO	<u>325MG; 2.5MG</u>	<u>A090535</u>	<u>001</u>	Dec 26, 2013
AA		<u>325MG; 5MG</u>	<u>A090535</u>	<u>002</u>	Dec 26, 2013
AA		<u>325MG; 7.5MG</u>	<u>A090535</u>	<u>003</u>	Dec 26, 2013
AA		<u>325MG; 10MG</u>	<u>A090535</u>	<u>004</u>	Dec 26, 2013
AA	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
AA		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
AA		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
AA		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
AA		<u>500MG; 7.5MG</u>	<u>A090177</u>	<u>005</u>	Oct 20, 2008
AA		<u>650MG; 10MG</u>	<u>A090177</u>	<u>006</u>	Oct 20, 2008
AA	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
AA		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
AA		<u>500MG; 7.5MG</u>	<u>A040550</u>	<u>001</u>	Jun 30, 2004
AA		<u>650MG; 10MG</u>	<u>A040550</u>	<u>002</u>	Jun 30, 2004
AA	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733</u>	<u>001</u>	Jul 11, 2013
AA		<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
AA		<u>325MG; 7.5MG</u>	<u>A090734</u>	<u>001</u>	Jul 11, 2013
AA		<u>325MG; 10MG</u>	<u>A090734</u>	<u>002</u>	Jul 11, 2013
AA	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
AA		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
AA		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003
AA		<u>500MG; 7.5MG</u>	<u>A040371</u>	<u>001</u>	Dec 29, 2000
AA		<u>650MG; 10MG</u>	<u>A040371</u>	<u>002</u>	Dec 29, 2000

PERCOCET

AA	+	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
AA	+		<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
AA	+		<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
AA	+		<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001
AA	+		<u>500MG; 7.5MG</u>	<u>A040341</u>	<u>001</u>	Jul 26, 1999
AA	+		<u>650MG; 10MG</u>	<u>A040341</u>	<u>002</u>	Jul 26, 1999

ROXICET

AA	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
<u>OXYCODONE AND ACETAMINOPHEN</u>					
	+	MIKART	300MG; 2.5MG	A040608	001 Dec 30, 2005
	+		300MG; 5MG	A040608	002 Dec 30, 2005
	+		300MG; 7.5MG	A040608	003 Dec 30, 2005
	+		300MG; 10MG	A040608	004 Dec 30, 2005
	+		400MG; 5MG	A040687	001 Apr 27, 2006
	+		400MG; 7.5MG	A040698	001 Apr 27, 2006
	+		400MG; 10MG	A040692	001 Apr 27, 2006
			500MG; 10MG	A040676	001 Apr 19, 2006

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

AB	GAVIS PHARMS	<u>650MG; EQ 25MG BASE</u>	<u>A076202</u>	<u>001</u>	Aug 02, 2002
AB	+	WATSON LABS	<u>650MG; EQ 25MG BASE</u>	<u>A074699</u>	<u>001</u> Mar 24, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-6 (of 362)

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
AB	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
AB	CARACO	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
AB	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
AB	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
AB	PAR PHARM	<u>325MG; 37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
AB	WATSON LABS	<u>325MG; 37.5MG</u>	<u>A076914</u>	<u>001</u>	Jul 26, 2006
AB	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012

ULTRACET

AB	+ JANSSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779</u>	<u>001</u>	Jul 14, 2011
AB	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008

DIAMOX

AB	+ DURAMED PHARMS BARR	<u>500MG</u>	<u>N012945</u>	<u>001</u>	

TABLET; ORAL

ACETAZOLAMIDE

AB	LANNETT	<u>250MG</u>	<u>A084840</u>	<u>001</u>	
AB	MUTUAL PHARM	<u>125MG</u>	<u>A089752</u>	<u>001</u>	Jun 22, 1988
AB	TARO	<u>125MG</u>	<u>A040195</u>	<u>001</u>	May 28, 1997
AB	+	<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
AP	SAGENT AGILA	<u>EQ 500MG BASE/VIAL</u>	<u>A200880</u>	<u>001</u>	May 09, 2012
AP	+ X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
AT	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
AT	HOSPIRA	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

AT	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
AT	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
AT	+ WOCKHARDT	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

AT	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

+	BAUSCH AND LOMB	<u>2%; 0.79%</u>	<u>A040063</u>	<u>001</u>	Feb 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

AT	ACTAVIS MID ATLANTIC	<u>2%; 1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982

HYDROCORTISONE AND ACETIC ACID

AT	TARO	<u>2%; 1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
AT	VINTAGE	<u>2%; 1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

AT	+ HI TECH PHARMA	<u>2%; 1%</u>	<u>N012770</u>	<u>001</u>	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

+	WATSON LABS	<u>250MG</u>	<u>A071893</u>	<u>001</u>	Nov 25, 1987
+		<u>500MG</u>	<u>A071894</u>	<u>001</u>	Nov 25, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-7 (of 362)

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+ MISSION PHARMA

250MG

N018749 001 May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+ BAUSCH AND LOMB

20MG/VIAL

N020213 001 Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTEAP + CUMBERLAND PHARMS6GM/30ML (200MG/ML)N021539 001 Jan 23, 2004ACETYLCYSTEINEAP INNOPHARMA LICENSING
SOLUTION; INHALATION, ORAL6GM/30ML (200MG/ML)A200644 001 Nov 07, 2012ACETYLCYSTEINEAN BEDFORD10%A072323 001 Apr 30, 1992AN20%A072324 001 Apr 30, 1992AN

HOSPIRA

10%A073664 001 Aug 30, 1994AN20%A074037 001 Aug 30, 1994AN

INNOPHARMA LICENSING

20%A203853 001 Jun 21, 2012AN

+ LUITPOLD

10%A072489 001 Jul 28, 1995AN

+

20%A072547 001 Jul 28, 1995ACITRETIN

CAPSULE; ORAL

ACITRETINAB BARR LABS INC10MGA091455 001 Apr 04, 2013AB25MGA091455 002 Apr 04, 2013AB

TEVA PHARMS USA

17.5MGA202897 001 Apr 04, 2013AB22.5MGA202897 002 Apr 04, 2013SORIATANEAB STIEFEL LABS INC10MGN019821 001 Oct 28, 1996AB17.5MGN019821 003 Aug 06, 2009AB22.5MGN019821 004 Aug 06, 2009AB

+

25MGN019821 002 Oct 28, 1996ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+ FOREST LABS INC

0.375MG/INH

N202450 001 Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ ACTIENT PHARMS

8MG; 60MG

N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIRAB APOTEX INC200MGA075677 001 Sep 28, 2005AB

DAVA PHARMS INC

200MGA074833 001 Apr 22, 1997AB

MYLAN

200MGA074727 001 Apr 22, 1997AB

RANBAXY

200MGA074975 001 Sep 30, 1998AB

STASON

200MGA075090 001 Jan 26, 1999AB

TEVA

200MGA074578 001 Apr 22, 1997ZOVIRAXAB + GLAXOSMITHKLINE200MGN018828 001 Jan 25, 1985

CREAM; TOPICAL

ZOVIRAX

+ VALEANT BERMUDA

5%

N021478 001 Dec 30, 2002

OINTMENT; TOPICAL

ACYCLOVIRAB MYLAN PHARMS INC5%A202459 001 Apr 03, 2013ZOVIRAXAB + VALEANT BERMUDA5%N018604 001 Mar 29, 1982

SUSPENSION; ORAL

ACYCLOVIRAB ACTAVIS MID ATLANTIC200MG/5MLA074738 001 Apr 28, 1997AB

HI TECH PHARMA

200MG/5MLA077026 001 Jun 07, 2005ZOVIRAXAB + DELCOR ASSET200MG/5MLN019909 001 Dec 22, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-8 (of 362)

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168</u>	<u>001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168</u>	<u>002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>800MG</u>	<u>A203834</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998
<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>ZOVIRAX</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>400MG</u>	<u>N020089</u>	<u>001</u>	Apr 30, 1991
<u>AB</u>	+	<u>800MG</u>	<u>N020089</u>	<u>002</u>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A203701</u>	<u>001</u>	Oct 11, 2013
<u>AP</u>	BEDFORD	<u>EQ 1GM BASE/VIAL</u>	<u>A074596</u>	<u>001</u>	Apr 22, 1997
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A074596</u>	<u>002</u>	Apr 22, 1997
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074930</u>	<u>001</u>	May 13, 1998
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A075015</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A074913</u>	<u>002</u>	Oct 15, 1997
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A074913</u>	<u>001</u>	Oct 15, 1997
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
	+	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A090824</u>	<u>001</u>	Jun 30, 2010
<u>DIFFERIN</u>					
<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020748</u>	<u>001</u>	May 26, 2000
GEL; TOPICAL					
<u>ADAPALENE</u>					
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A091314</u>	<u>001</u>	Jul 01, 2010
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.1%</u>	<u>A090962</u>	<u>001</u>	Jun 02, 2010
<u>AB</u>	TOLMAR	<u>0.3%</u>	<u>A200298</u>	<u>001</u>	Jun 14, 2012
<u>DIFFERIN</u>					
<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020380</u>	<u>001</u>	May 31, 1996
<u>AB</u>	+	<u>0.3%</u>	<u>N021753</u>	<u>001</u>	Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO

+	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

<u>AB</u>	SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A202051</u>	<u>001</u>	Aug 29, 2013
<u>HEPSERA</u>					
<u>AB</u>	+	<u>10MG</u>	<u>N021449</u>	<u>001</u>	Sep 20, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-9 (of 362)

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP	+	ASTELLAS	<u>3MG/ML</u>	<u>N019937</u>	<u>002</u>	Oct 30, 1989

ADENOSCAN

AP	+	ASTELLAS	<u>3MG/ML</u>	<u>N020059</u>	<u>001</u>	May 18, 1995

ADENOSINE

AP		AKORN	<u>3MG/ML</u>	<u>A078076</u>	<u>001</u>	Oct 31, 2008

AP		BEDFORD	<u>3MG/ML</u>	<u>A076404</u>	<u>001</u>	Jun 16, 2004

AP		FRESENIUS KABI USA	<u>3MG/ML</u>	<u>A077133</u>	<u>001</u>	Apr 27, 2005

AP		GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283</u>	<u>001</u>	Jun 14, 2007

AP		HIKMA MAPLE	<u>3MG/ML</u>	<u>A076500</u>	<u>001</u>	Jun 16, 2004

AP		LUITPOLD	<u>3MG/ML</u>	<u>A090010</u>	<u>001</u>	Apr 28, 2009

AP		STRIDES ARCOLAB LTD	<u>3MG/ML</u>	<u>A078686</u>	<u>001</u>	May 13, 2009

AP		TEVA PHARMS USA	<u>3MG/ML</u>	<u>A077425</u>	<u>001</u>	Aug 29, 2013

AP		WOCKHARDT	<u>3MG/ML</u>	<u>A090220</u>	<u>001</u>	Jul 20, 2009

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

		BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013

			EQ 30MG BASE	N201292	002	Jul 12, 2013

+			EQ 40MG BASE	N201292	003	Jul 12, 2013

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+		AMEDRA PHARMS	200MG	N020666	001	Jun 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+		GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

		ISO TEX	100uCi/10ML (10uCi/ML)	N017836	003	Jun 08, 2004

			500uCi/0.5ML	N017836	001	

+			1,000uCi/ML	N017836	002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+		ISO TEX	0.5mCi/VIAL	N017837	001	

+			1mCi/VIAL	N017837	002	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004

PROVENTIL-HFA

BX	+	3M	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996

VENTOLIN HFA

BX	+	GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

SOLUTION; INHALATION

ACCUNEB

AN	+	DEY	<u>EQ 0.021% BASE</u>	<u>N020949</u>	<u>002</u>	Apr 30, 2001

AN	+		<u>EQ 0.042% BASE</u>	<u>N020949</u>	<u>001</u>	Apr 30, 2001

ALBUTEROL SULFATE

AN	+	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050</u>	<u>001</u>	Jun 18, 1998

AN		HI TECH PHARMA	<u>EQ 0.083% BASE</u>	<u>A075063</u>	<u>001</u>	Feb 09, 1999

AN			<u>EQ 0.5% BASE</u>	<u>A074543</u>	<u>001</u>	Jan 15, 1998

AN		LANDELA PHARM	<u>EQ 0.083% BASE</u>	<u>A077569</u>	<u>001</u>	Apr 04, 2006

AN	+	MYLAN SPECLT	<u>EQ 0.083% BASE</u>	<u>A072652</u>	<u>001</u>	Feb 21, 1992

AN		NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355</u>	<u>002</u>	Mar 31, 2010

AN			<u>EQ 0.042% BASE</u>	<u>A076355</u>	<u>001</u>	Jun 28, 2004

AN			<u>EQ 0.083% BASE</u>	<u>A074880</u>	<u>001</u>	Sep 17, 1997

AN			<u>EQ 0.5% BASE</u>	<u>A075664</u>	<u>001</u>	Jun 26, 2001

AN		RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839</u>	<u>001</u>	Dec 16, 2008

AN		TEVA PHARMS	<u>EQ 0.083% BASE</u>	<u>A075343</u>	<u>001</u>	Nov 09, 1999

AN		WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772</u>	<u>001</u>	Sep 25, 2007

AN			<u>EQ 0.042% BASE</u>	<u>A077772</u>	<u>002</u>	Sep 25, 2007

AN		WATSON LABS INC	<u>EQ 0.083% BASE</u>	<u>A076370</u>	<u>001</u>	Nov 24, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-10 (of 362)

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 2MG BASE/5ML</u>	<u>A074454</u>	<u>001</u>	Sep 25, 1995
<u>AA</u>	AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241</u>	<u>001</u>	May 12, 2010
<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749</u>	<u>001</u>	Jan 30, 1998
<u>AA</u>	+ TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419</u>	<u>001</u>	Mar 30, 1992
<u>AA</u>	VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105</u>	<u>001</u>	Dec 27, 2006
<u>AA</u>	VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788</u>	<u>001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MUTUAL PHARM	<u>EQ 2MG BASE</u>	<u>A072637</u>	<u>002</u>	Dec 05, 1989
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A072637</u>	<u>001</u>	Dec 05, 1989
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A072894</u>	<u>002</u>	Jan 17, 1991
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>A072894</u>	<u>001</u>	Jan 17, 1991
<u>AB</u>	WATSON LABS	<u>EQ 2MG BASE</u>	<u>A072764</u>	<u>001</u>	Aug 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A078092</u>	<u>002</u>	Jan 29, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078092</u>	<u>001</u>	Jan 29, 2007

VOSPIRE ER

<u>AB</u>	DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130</u>	<u>002</u>	Sep 26, 2002
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>A076130</u>	<u>003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

+ BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N020291	001	Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	CIPLA LTD	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	NEPHRON	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE; 0.017%</u>	<u>A202496</u>	<u>001</u>	Oct 01, 2012
<u>AN</u>	TEVA PHARMS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076724</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	WATSON LABS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077063</u>	<u>001</u>	Dec 31, 2007

DUONEB

<u>AN</u>	+ DEY	<u>EQ 0.083% BASE; 0.017%</u>	<u>N020950</u>	<u>001</u>	Mar 21, 2001
SPRAY, METERED; INHALATION					
COMBIVENT RESPIMAT					
+ BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH; 0.02MG/INH	N021747	001	Oct 07, 2011	

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+ ALLERGAN	0.25%	N022134	001	Jul 28, 2010

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N018707</u>	<u>001</u>	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ACLOVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N018702</u>	<u>001</u>	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

<u>AP</u>	+ B BRAUN	<u>5ML/100ML; 5GM/100ML</u>	<u>N004589</u>	<u>004</u>	
ALCOHOL 10% AND DEXTROSE 5%					
+ B BRAUN	10ML/100ML; 5GM/100ML	N004589	006		

PRESCRIPTION DRUG PRODUCT LIST

3-11 (of 362)

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA	ROXANE	<u>EQ 70MG BASE/75ML</u>	A090520 001	Feb 25, 2013

FOSAMAX

AA	+ MERCK	<u>EQ 70MG BASE/75ML</u>	N021575 001	Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

AB	APOTEX	<u>EQ 5MG BASE</u>	A077982 001	Aug 04, 2008

AB		<u>EQ 10MG BASE</u>	A077982 002	Aug 04, 2008

AB		<u>EQ 35MG BASE</u>	A077982 003	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A077982 004	Aug 04, 2008

AB	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	A090124 001	Aug 04, 2008

AB		<u>EQ 35MG BASE</u>	A090124 002	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A090124 003	Aug 04, 2008

AB	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	A090258 001	Sep 24, 2009

AB		<u>EQ 10MG BASE</u>	A090258 002	Sep 24, 2009

AB		<u>EQ 35MG BASE</u>	A090258 003	Sep 24, 2009

AB		<u>EQ 70MG BASE</u>	A090258 004	Sep 24, 2009

AB	CADISTA PHARMS	<u>EQ 5MG BASE</u>	A090557 001	Feb 18, 2010

AB		<u>EQ 10MG BASE</u>	A090557 002	Feb 18, 2010

AB		<u>EQ 35MG BASE</u>	A090557 003	Feb 18, 2010

AB		<u>EQ 70MG BASE</u>	A090557 004	Feb 18, 2010

AB	CIPLA LTD	<u>EQ 5MG BASE</u>	A076768 001	Aug 04, 2008

AB		<u>EQ 10MG BASE</u>	A076768 002	Aug 04, 2008

AB		<u>EQ 35MG BASE</u>	A076768 003	Aug 04, 2008

AB		<u>EQ 40MG BASE</u>	A076768 004	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A076768 005	Aug 04, 2008

AB	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	A079109 001	Aug 04, 2008

AB		<u>EQ 10MG BASE</u>	A079109 002	Aug 04, 2008

AB		<u>EQ 35MG BASE</u>	A079049 001	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A079049 002	Aug 04, 2008

AB	MYLAN	<u>EQ 5MG BASE</u>	A076584 001	Aug 04, 2008

AB		<u>EQ 10MG BASE</u>	A076584 002	Aug 04, 2008

AB		<u>EQ 35MG BASE</u>	A076584 003	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A076584 004	Aug 04, 2008

AB	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	A090022 001	Sep 10, 2008

AB		<u>EQ 10MG BASE</u>	A090022 002	Sep 10, 2008

AB		<u>EQ 35MG BASE</u>	A090022 003	Sep 10, 2008

AB		<u>EQ 70MG BASE</u>	A090022 004	Sep 10, 2008

AB	TEVA PHARMS	<u>EQ 5MG BASE</u>	A075710 001	Feb 06, 2008

AB		<u>EQ 10MG BASE</u>	A075710 002	Feb 06, 2008

AB		<u>EQ 35MG BASE</u>	A075710 003	Feb 06, 2008

AB		<u>EQ 40MG BASE</u>	A075710 004	Feb 06, 2008

AB		<u>EQ 70MG BASE</u>	A075710 005	Feb 06, 2008

AB	WATSON LABS	<u>EQ 35MG BASE</u>	A076984 001	Aug 04, 2008

AB		<u>EQ 40MG BASE</u>	A076984 002	Aug 04, 2008

AB		<u>EQ 70MG BASE</u>	A076984 003	Aug 04, 2008

FOSAMAX

AB	+ MERCK AND CO INC	<u>EQ 70MG BASE</u>	N020560 005	Oct 20, 2000

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA

EQ 70MG BASE

N202344 001 Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005

+

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP	+ AKORN	<u>EQ 0.5MG BASE/ML</u>	N019353 001	Dec 29, 1986

ALFENTANIL

AP	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	A075221 001	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	<u>10MG</u>	A079013 001	Jul 18, 2011

AB	AUROBINDO PHARMA LTD	<u>10MG</u>	A079060 001	Aug 30, 2012

AB	INVAGEN PHARMS	<u>10MG</u>	A090284 001	Jan 17, 2012

AB	MYLAN	<u>10MG</u>	A079014 001	Jul 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-12 (of 362)

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	10MG	A079057	001	Jul 18, 2011
AB	TEVA PHARMS	10MG	A079056	001	Jul 18, 2011
AB	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011
AB	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012

UROXATRAL

AB	+	COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

	NOVARTIS	EQ 150MG BASE	N021985	001	Mar 05, 2007
+		EQ 300MG BASE	N021985	002	Mar 05, 2007

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE	N022545	001	Aug 26, 2010
		EQ 150MG BASE; EQ 10MG BASE	N022545	002	Aug 26, 2010
		EQ 300MG BASE; EQ 5MG BASE	N022545	003	Aug 26, 2010
+		EQ 300MG BASE; EQ 10MG BASE	N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE; 12.5MG	N200045	001	Dec 21, 2010
		EQ 300MG BASE; EQ 5MG BASE; 12.5MG	N200045	002	Dec 21, 2010
		EQ 300MG BASE; EQ 5MG BASE; 25MG	N200045	003	Dec 21, 2010
		EQ 300MG BASE; EQ 10MG BASE; 12.5MG	N200045	004	Dec 21, 2010
+		EQ 300MG BASE; EQ 10MG BASE; 25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

	NOVARTIS	EQ 150MG BASE; 12.5MG	N022107	001	Jan 18, 2008
		EQ 150MG BASE; 25MG	N022107	002	Jan 18, 2008
+		EQ 300MG BASE; 12.5MG	N022107	003	Jan 18, 2008
+		EQ 300MG BASE; 25MG	N022107	004	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

	NOVARTIS	EQ 150MG BASE; 160MG	N022217	001	Sep 16, 2009
+		EQ 300MG BASE; 320MG	N022217	002	Sep 16, 2009

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013
AB		300MG	A203154	002	May 06, 2013
AB	APOTEX INC	100MG	A077353	001	Sep 08, 2005
AB		300MG	A077353	002	Sep 08, 2005
AB	CARACO	100MG	A078390	001	Aug 30, 2007
AB		300MG	A078390	002	Aug 30, 2007
AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011
AB		300MG	A090637	002	Mar 16, 2011
AB	MUTUAL PHARM	100MG	A071449	001	Jan 09, 1987
AB		300MG	A071450	001	Jan 09, 1987
AB	MYLAN	100MG	A018659	001	Oct 24, 1986
AB		300MG	A018659	002	Oct 24, 1986
AB	NORTHSTAR HLTHCARE	100MG	A078253	001	Sep 11, 2007
AB		300MG	A078253	002	Sep 11, 2007
AB	VINTAGE PHARMS	100MG	A075798	001	Jun 27, 2003
AB		300MG	A075798	002	Jun 27, 2003
AB	WATSON LABS	100MG	N018832	002	Sep 28, 1984
AB		300MG	N018877	001	Sep 28, 1984

LOPURIN

AB	DR REDDYS LA	100MG	A071586	001	Apr 02, 1987
AB		300MG	A071587	001	Apr 02, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-13 (of 362)

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB	PROMETHEUS LABS	100MG	N016084	001	
AB	+	300MG	N016084	002	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP	BEDFORD LABS	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004
AP	+	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN PHARMS

EQ 6.25MG BASE

N021001 001 May 07, 2001

+

EQ 12.5MG BASE

N021001 002 May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA

EQ 6.25MG BASE

N022271 001 Jan 25, 2013

EQ 12.5MG BASE

N022271 002 Jan 25, 2013

+

EQ 25MG BASE

N022271 003 Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+ TAKEDA PHARMS USA

EQ 12.5MG BASE; 1GM

N203414 002 Jan 25, 2013

EQ 12.5MG BASE; 500MG

N203414 001 Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN1

TAKEDA PHARMS USA

EQ 12.5MG BASE; EQ 15MG BASE

N022426 004 Jan 25, 2013

EQ 12.5MG BASE; EQ 30MG BASE

N022426 005 Jan 25, 2013

EQ 12.5MG BASE; EQ 45MG BASE

N022426 006 Jan 25, 2013

EQ 25MG BASE; EQ 15MG BASE

N022426 001 Jan 25, 2013

EQ 25MG BASE; EQ 30MG BASE

N022426 002 Jan 25, 2013

+

EQ 25MG BASE; EQ 45MG BASE

N022426 003 Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTROXEX

PROMETHEUS LABS

EQ 0.5MG BASE

N021107 002 Dec 23, 2003

+

EQ 1MG BASE

N021107 001 Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 0.03MG/ML

N021163 001 May 18, 2000

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 30MCG/ML

N021559 001 Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+ ROXANE

1MG/ML

A074312 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993
AB		0.5MG	A074342	002	Oct 31, 1993
AB		1MG	A074342	003	Oct 31, 1993
AB		2MG	A074342	004	Oct 31, 1993
AB	APOTEX INC	0.25MG	A077741	001	Jan 19, 2007
AB		0.5MG	A077741	002	Jan 19, 2007
AB		1MG	A077741	003	Jan 19, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-14 (of 362)

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A077741</u>	<u>004</u>	Jan 19, 2007
<u>AB</u>	BOCA PHARMA LLC	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-15 (of 362)

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

NIRAVAM

<u>AB</u>	UCB INC	<u>0.25MG</u>	<u>N021726</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.5MG</u>	<u>N021726</u>	<u>002</u>	Jan 19, 2005
<u>AB</u>	+	<u>1MG</u>	<u>N021726</u>	<u>003</u>	Jan 19, 2005
<u>AB</u>		<u>2MG</u>	<u>N021726</u>	<u>004</u>	Jan 19, 2005

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	BEDFORD	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998
<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	ACTIENT PHARMS	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>	

CAVERJECT

	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996

CAVERJECT IMPULSE

	PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002
		0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

+	ACTIENT PHARMS	0.01MG/VIAL	N020649	005	Jul 30, 1998
+		0.02MG/VIAL	N020649	006	Jul 30, 1998
+		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996
		0.25MG	N020700	002	Nov 19, 1996
		0.5MG	N020700	003	Nov 19, 1996
+		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	EISAI INC	50MG	N019926	001	Dec 26, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-16 (of 362)

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS

12MG

N021775 001 May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDEAB BANNER PHARMACAPS100MGA078720 001 May 29, 2008AB SANDOZ100MGA071293 001 Feb 18, 1987AB + USL PHARMA100MGA070589 001 Aug 05, 1986

SYRUP; ORAL

AMANTADINE HYDROCHLORIDEAA + CAROLINA MEDCL50MG/5MLA075819 001 Sep 11, 2002AA + HI TECH PHARMA50MG/5MLA074170 001 Oct 28, 1994AA + MIKART50MG/5MLA074028 001 Jun 28, 1993AA + PHARM ASSOC50MG/5MLA074509 001 Jul 17, 1995AA + SILARX50MG/5MLA076352 001 Sep 10, 2004AA + VINTAGE50MG/5MLA077992 001 Dec 12, 2006AA + WOCKHARDT50MG/5MLA075060 001 Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

+ USL PHARMA

100MG

A076186 001 Dec 16, 2002

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

+ SANOFI AVENTIS US

10MG

N010155 002

AMBRISENTAN

TABLET; ORAL

LETAIRIS

GILEAD

5MG

N022081 001 Jun 15, 2007

+

10MG

N022081 002 Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDEAB + FOUGERA PHARMS0.1%A076065 001 May 15, 2003AB TARO PHARM INDS0.1%A076229 001 May 31, 2002

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS

0.1%

A076329 001 Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDEAB + FOUGERA PHARMS0.1%A076096 001 Nov 19, 2002AB TARO PHARM INDS0.1%A076367 001 Mar 19, 2003AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINEAP SUN PHARMA GLOBAL500MG/VIALA077126 001 Mar 14, 2008ETHYOLAP + MEDIMMUNE500MG/VIALN020221 001 Dec 08, 1995AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATEAP + BEDFORDEQ 50MG BASE/MLA063313 001 Apr 11, 1994AP +EQ 250MG BASE/MLA063315 001 Apr 11, 1994AP EMCURE PHARMS LTDEQ 250MG BASE/MLA204040 001 Dec 12, 2013AP TEVA PHARMS USAEQ 250MG BASE/MLA064045 002 Sep 28, 1993AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDEAB + PAR PHARM5MGA070346 001 Jan 22, 1986AB SIGMAPHARM LABS LLC5MGA079133 001 Jan 30, 2009MIDAMORAB PADDOCK LLC5MGN018200 001

PRESCRIPTION DRUG PRODUCT LIST

3-17 (of 362)

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	BARR	EQ 5MG ANHYDROUS; 50MG	A071111 001	May 10, 1988
AB	+ MYLAN	EQ 5MG ANHYDROUS; 50MG	A073209 001	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15% (150GM/1000ML)	A091112 001	Apr 13, 2012
	15% (300GM/2000ML)	A091112 002	Apr 13, 2012
AMINOSYN 10%			
HOSPIRA	10% (10GM/100ML)	N017673 003	
AMINOSYN 10% (PH6)			
HOSPIRA	10% (10GM/100ML)	N017673 008	Nov 18, 1985
AMINOSYN 3.5%			
HOSPIRA	3.5% (3.5GM/100ML)	N017789 004	
AMINOSYN 5%			
HOSPIRA	5% (5GM/100ML)	N017673 001	
AMINOSYN 7%			
HOSPIRA	7% (7GM/100ML)	N017673 002	
AMINOSYN 7% (PH6)			
HOSPIRA	7% (7GM/100ML)	N017673 006	Nov 18, 1985
AMINOSYN 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 004	
AMINOSYN 8.5% (PH6)			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 007	Nov 18, 1985
AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	
BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4% (4GM/100ML)	N018684 001	Sep 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
HEPATASOL 8%			
BAXTER HLTHCARE	8% (8GM/100ML)	A020360 001	Apr 04, 1996
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
RENAMIN W/O ELECTROLYTES			
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493 007	Oct 15, 1982

PRESCRIPTION DRUG PRODUCT LIST

3-18 (of 362)

AMINO ACIDS

INJECTABLE; INJECTION

TRAVASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	
TROPHAMINE				
+ B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984
TROPHAMINE 10%				
+ B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE				
B BRAUN	3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%; 10GM/100ML	N020734	002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%; 25GM/100ML	N020734	005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%; 5GM/100ML	N020734	001	Sep 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-19 (of 362)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES			
B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M			
HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789 003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES			
B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML	N016822 003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES			
HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES			
HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437 005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493 003	
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N017493 001	
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173 002	Oct 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N017493 002	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES			
HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES			
HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673 005	

PRESCRIPTION DRUG PRODUCT LIST

3-20 (of 362)

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	LUITPOLD	<u>250MG/ML</u>	<u>A071192</u>	<u>001</u>	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	+ HOSPIRA	<u>250MG/ML</u>	<u>A070010</u>	<u>001</u>	Mar 09, 1987

SYRUP; ORAL

AMICAR

AA	+ CLOVER PHARMS	<u>1.25GM/5ML</u>	<u>N015230</u>	<u>002</u>	

AMINOCAPROIC ACID

AA	MIKART	<u>1.25GM/5ML</u>	<u>A074759</u>	<u>001</u>	Sep 02, 1998

TABLET; ORAL

AMICAR

AB	CLOVER PHARMS	<u>500MG</u>	<u>N015197</u>	<u>001</u>	

AMINOCAPROIC

AB	MIKART	<u>500MG</u>	<u>A075602</u>	<u>001</u>	May 24, 2001

AMICAR

	+ CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

	+ MERCK	20%	N005619	001	

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

	+ DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	+ HOSPIRA	<u>25MG/ML</u>	<u>A087242</u>	<u>001</u>	Oct 26, 1983

AP	LUITPOLD	<u>25MG/ML</u>	<u>A087600</u>	<u>001</u>	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

	+ JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AP	+ AKORN	<u>50MG/ML</u>	<u>A076232</u>	<u>001</u>	Jul 05, 2006

AP	+ FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075761</u>	<u>001</u>	Oct 15, 2002

AP	+ GLAND PHARMA LTD	<u>50MG/ML</u>	<u>A077161</u>	<u>001</u>	Apr 20, 2005

AP	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A077234</u>	<u>001</u>	Feb 25, 2008

AP	+ HOSPIRA	<u>50MG/ML</u>	<u>A075955</u>	<u>001</u>	Oct 18, 2002

AP	HOSPIRA INC	<u>50MG/ML</u>	<u>A203884</u>	<u>001</u>	Nov 25, 2013

AP		<u>50MG/ML</u>	<u>A203885</u>	<u>001</u>	Nov 25, 2013

AP	+ MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A076217</u>	<u>001</u>	Oct 15, 2002

AP	WOCKHARDT	<u>50MG/ML</u>	<u>A077610</u>	<u>001</u>	Oct 30, 2008

AP		<u>50MG/ML</u>	<u>A077834</u>	<u>001</u>	Oct 30, 2008

NEXTERONE

AP	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N022325</u>	<u>001</u>	Dec 24, 2008

	+	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010

	+	360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	APOTEX CORP	<u>200MG</u>	<u>A078578</u>	<u>001</u>	Nov 06, 2008

AB	BARR	<u>200MG</u>	<u>A075389</u>	<u>001</u>	Jan 25, 2001

AB	MURTY PHARMS	<u>200MG</u>	<u>A077069</u>	<u>001</u>	Apr 08, 2005

AB		<u>400MG</u>	<u>A077069</u>	<u>002</u>	Apr 08, 2005

AB	MYLAN	<u>200MG</u>	<u>A075188</u>	<u>001</u>	Feb 24, 1999

AB	SANDOZ	<u>200MG</u>	<u>A075315</u>	<u>001</u>	Dec 23, 1998

AB		<u>400MG</u>	<u>A075315</u>	<u>002</u>	Jun 30, 2000

AB	TARO	<u>100MG</u>	<u>A075424</u>	<u>002</u>	Dec 18, 2002

AB		<u>200MG</u>	<u>A075424</u>	<u>001</u>	Mar 30, 2001

AB		<u>400MG</u>	<u>A076362</u>	<u>001</u>	Nov 29, 2002

AB	TEVA PHARMS	<u>200MG</u>	<u>A074739</u>	<u>001</u>	Nov 30, 1998

AB	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A079029</u>	<u>001</u>	Sep 16, 2008

CORDARONE

AB	+ WYETH PHARMS INC	<u>200MG</u>	<u>N018972</u>	<u>001</u>	Dec 24, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-21 (of 362)

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

PACERONE

<u>AB</u>	UPSHER SMITH	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>		<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998
	AMIODARONE HYDROCHLORIDE				
	TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	CARACO	<u>10MG</u>	<u>A040816</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>50MG</u>	<u>A040816</u>	<u>003</u>	Jun 27, 2008
<u>AB</u>		<u>75MG</u>	<u>A040816</u>	<u>004</u>	Jun 27, 2008
<u>AB</u>		<u>100MG</u>	<u>A040816</u>	<u>005</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040816</u>	<u>006</u>	Jun 27, 2008
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089398</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>50MG</u>	<u>A089400</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089401</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089402</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089403</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE; 5MG	A071297	002	Dec 10, 1986
	+	EQ 25MG BASE; 10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG; 2MG	A071443	002	Nov 10, 1988
		10MG; 4MG	A071443	003	Nov 10, 1988
	+	25MG; 2MG	A071443	004	Nov 10, 1988
	+	25MG; 4MG	A071443	005	Nov 10, 1988
	+	50MG; 4MG	A071443	001	Nov 10, 1988

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-22 (of 362)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CARACO	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771</u>	<u>003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380</u>	<u>001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380</u>	<u>002</u>	Apr 13, 2012
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	PURACAP PHARM	<u>EQ 2.5MG BASE</u>	<u>A078131</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078131</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078131</u>	<u>003</u>	Sep 04, 2007
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	SECAN PHARMS	<u>EQ 5MG BASE</u>	<u>A090752</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245</u>	<u>001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245</u>	<u>002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245</u>	<u>003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	WORLD GEN	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-23 (of 362)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007

NORVASC

<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>001</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>002</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>003</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>011</u>	Nov 29, 2013

CADUET

<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>009</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>010</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>011</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>001</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>002</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>003</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>004</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>005</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>006</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>007</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431</u>	<u>001</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A091431</u>	<u>002</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A091431</u>	<u>003</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091431</u>	<u>004</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A091431</u>	<u>005</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A091431</u>	<u>006</u>	Dec 30, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A202239</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A202239</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202239</u>	<u>004</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202239</u>	<u>005</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202239</u>	<u>006</u>	Sep 05, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183</u>	<u>003</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A090149</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183</u>	<u>004</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090149</u>	<u>002</u>	Jul 05, 2011
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466</u>	<u>001</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466</u>	<u>002</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466</u>	<u>003</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078466</u>	<u>005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466</u>	<u>004</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078466</u>	<u>006</u>	Jul 05, 2011
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375</u>	<u>001</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077375</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077375</u>	<u>003</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A079047</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077375</u>	<u>004</u>	May 21, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A079047</u>	<u>002</u>	Jul 05, 2011
<u>AB</u>	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381</u>	<u>001</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078381</u>	<u>002</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381</u>	<u>003</u>	Jul 29, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-24 (of 362)

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		<u>EQ 5MG BASE;40MG</u>	<u>A078381</u>	<u>005</u>	Jul 29, 2010
AB		<u>EQ 10MG BASE;20MG</u>	<u>A078381</u>	<u>004</u>	Jul 29, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A078381</u>	<u>006</u>	Jul 29, 2010
AB	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179</u>	<u>001</u>	May 18, 2007
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077179</u>	<u>002</u>	May 18, 2007
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077179</u>	<u>003</u>	May 18, 2007
AB		<u>EQ 5MG BASE;40MG</u>	<u>A077179</u>	<u>005</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077179</u>	<u>004</u>	May 18, 2007
AB		<u>EQ 10MG BASE;40MG</u>	<u>A077179</u>	<u>006</u>	Jul 05, 2011
AB	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890</u>	<u>001</u>	Oct 14, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077890</u>	<u>002</u>	Oct 14, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077890</u>	<u>003</u>	Oct 14, 2010
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077890</u>	<u>004</u>	Oct 14, 2010
AB	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364</u>	<u>001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;40MG</u>	<u>A090364</u>	<u>002</u>	Jul 05, 2011
<u>LOTREL</u>					
AB	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364</u>	<u>002</u>	Mar 03, 1995
AB		<u>EQ 5MG BASE;10MG</u>	<u>N020364</u>	<u>003</u>	Mar 03, 1995
AB		<u>EQ 5MG BASE;20MG</u>	<u>N020364</u>	<u>004</u>	Mar 03, 1995
AB		<u>EQ 5MG BASE;40MG</u>	<u>N020364</u>	<u>007</u>	Apr 11, 2006
AB		<u>EQ 10MG BASE;20MG</u>	<u>N020364</u>	<u>005</u>	Jun 20, 2002
AB	+	<u>EQ 10MG BASE;40MG</u>	<u>N020364</u>	<u>006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

AB	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314</u>	<u>001</u>	Apr 30, 2009
AB		<u>5MG;25MG;160MG</u>	<u>N022314</u>	<u>002</u>	Apr 30, 2009
AB		<u>10MG;12.5MG;160MG</u>	<u>N022314</u>	<u>003</u>	Apr 30, 2009
AB		<u>10MG;25MG;160MG</u>	<u>N022314</u>	<u>004</u>	Apr 30, 2009
AB	+	<u>10MG;25MG;320MG</u>	<u>N022314</u>	<u>005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AZOR

	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 5MG BASE;80MG</u>	<u>A201586</u>	<u>003</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;40MG</u>	<u>A201586</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;80MG</u>	<u>A201586</u>	<u>004</u>	Jan 08, 2014
AB	TORRENT PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A202517</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 5MG BASE;80MG</u>	<u>A202517</u>	<u>003</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202517</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;80MG</u>	<u>A202517</u>	<u>004</u>	Jan 08, 2014
<u>TWYNSTA</u>					
AB	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401</u>	<u>001</u>	Oct 16, 2009
AB		<u>EQ 5MG BASE;80MG</u>	<u>N022401</u>	<u>003</u>	Oct 16, 2009
AB		<u>EQ 10MG BASE;40MG</u>	<u>N022401</u>	<u>002</u>	Oct 16, 2009
AB	+	<u>EQ 10MG BASE;80MG</u>	<u>N022401</u>	<u>004</u>	Oct 16, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-25 (of 362)

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090144</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090011</u>	<u>002</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090011</u>	<u>004</u>	Mar 28, 2013

EXFORGE

<u>AB</u>	NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990</u>	<u>002</u>	Jun 20, 2007
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>N021990</u>	<u>004</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990</u>	<u>003</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990</u>	<u>005</u>	Jun 20, 2007

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435</u>	<u>001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435</u>	<u>002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435</u>	<u>005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435</u>	<u>003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435</u>	<u>004</u>	Sep 25, 2012

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700</u>	<u>001</u>	Feb 25, 2013
<u>AP</u>	+	<u>FEINSTEIN</u>	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119</u>	Aug 23, 2007
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938</u>	<u>001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321</u>	<u>001</u>	Feb 25, 2013
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812</u>	<u>001</u>	Jun 27, 2013
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829</u>	<u>001</u>	Feb 07, 2006

LAC-HYDRIN

<u>AB</u>	+	RANBAXY	<u>EQ 12% BASE</u>	<u>N020508</u>	Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575</u>	<u>001</u>	Jun 11, 2002

LAC-HYDRIN

<u>AB</u>	+	RANBAXY	<u>EQ 12% BASE</u>	<u>N019155</u>	Apr 24, 1985

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	WATSON LABS	25MG	A072688	001	Aug 28, 1992
		50MG	A072689	001	Aug 28, 1992
		100MG	A072690	001	Aug 28, 1992
+		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTIBIOTICS	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065016</u>	<u>001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016</u>	<u>002</u>	Apr 08, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-26 (of 362)

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>		<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
<u>AB</u>					
<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	TEVA PHARMS USA	<u>500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG</u>	<u>A200218</u>	<u>001</u>	Aug 30, 2013

PREVPAC

<u>AB</u>	+	TAKEDA PHARMS USA	<u>500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,</u>	<u>N050757</u>	<u>001</u>	Dec 02, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-27 (of 362)

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVPAC30MGAMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ GASTROENTERO

500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG

N050824 001 Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>	WOCKHARDT EU OPERATN	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>N050725</u>	<u>001</u>	May 31, 1996

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>N050725</u>	<u>002</u>	May 31, 1996

AUGMENTIN ES-600

<u>AB</u>	DR REDDYS LABS INC	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001

SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012
<u>AB</u>	RANBAXY	<u>875MG;EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>	SANDOZ INC	<u>500MG;EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002
<u>AB</u>	TEVA PHARMS USA	<u>875MG;EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984

AUGMENTIN '500'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>500MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984

AUGMENTIN '875'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>875MG;EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG;EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003
<u>AB</u>	SANDOZ	<u>200MG;EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002
<u>AB</u>	TEVA	<u>200MG;EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005
<u>AB</u>	+	<u>400MG;EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-28 (of 362)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG;EQ 31.25MG BASE</u>	<u>N050597 001</u>	Jul 22, 1985

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG;EQ 28.5MG BASE</u>	<u>N050726 001</u>	May 31, 1996

AUGMENTIN '250'

<u>AB</u>	DR REDDYS LABS INC	<u>250MG;EQ 62.5MG BASE</u>	<u>N050597 002</u>	Jul 22, 1985

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG;EQ 57MG BASE</u>	<u>N050726 002</u>	May 31, 1996

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227 001</u>	Apr 21, 2010

AUGMENTIN XR

<u>AB</u>	+ DR REDDYS LABS INC	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785 001</u>	Sep 25, 2002

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

<u>AB</u>	SHIRE	<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>N021303 001</u>	Oct 11, 2001

ADDERALL XR 15

<u>AB</u>	SHIRE	<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>N021303 006</u>	May 22, 2002

ADDERALL XR 20

<u>AB</u>	SHIRE	<u>5MG;5MG;5MG;5MG</u>	<u>N021303 002</u>	Oct 11, 2001

ADDERALL XR 25

<u>AB</u>	SHIRE	<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>N021303 004</u>	May 22, 2002

ADDERALL XR 30

<u>AB</u>	+ SHIRE	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>N021303 003</u>	Oct 11, 2001

ADDERALL XR 5

<u>AB</u>	SHIRE	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>N021303 005</u>	May 22, 2002

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

<u>AB</u>	TEVA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077488 001</u>	Apr 29, 2013

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077488 002</u>	Apr 29, 2013

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077488 003</u>	Apr 29, 2013

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077488 004</u>	Apr 29, 2013

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077488 005</u>	Apr 29, 2013

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077488 006</u>	Apr 29, 2013

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077302 001</u>	Jun 22, 2012

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077302 002</u>	Jun 22, 2012

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077302 003</u>	Jun 22, 2012

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077302 004</u>	Jun 22, 2012

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077302 005</u>	Jun 22, 2012

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077302 006</u>	Jun 22, 2012

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	BARR LABS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A076536 001</u>	Feb 12, 2013

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A076536 002</u>	Feb 12, 2013

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A076536 003</u>	Feb 12, 2013

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A076536 004</u>	Feb 12, 2013

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A076536 005</u>	Feb 12, 2013

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A076536 006</u>	Feb 12, 2013

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	AUROLIFE PHARMA LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A202424 001</u>	Nov 27, 2013

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A202424 002</u>	Nov 27, 2013

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A202424 003</u>	Nov 27, 2013

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A202424 004</u>	Nov 27, 2013

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A202424 005</u>	Nov 27, 2013

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A202424 006</u>	Nov 27, 2013

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A202424 007</u>	Nov 27, 2013

<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422 001</u>	Feb 11, 2002

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422 005</u>	Mar 19, 2003

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422 002</u>	Feb 11, 2002

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422 006</u>	Mar 19, 2003

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422 007</u>	Mar 19, 2003

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422 003</u>	Feb 11, 2002

<u>AB</u>	+ COREPHARMA	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422 004</u>	Feb 11, 2002

<u>AB</u>		<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444 001</u>	Jun 19, 2002

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444 002</u>	Jun 19, 2002

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444 003</u>	Jun 19, 2002

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444 004</u>	Jun 19, 2002

<u>AB</u>	MALLINCKRODT INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440 001</u>	Oct 07, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-29 (of 362)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440</u>	<u>002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440</u>	<u>003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440</u>	<u>004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440</u>	<u>005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440</u>	<u>006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440</u>	<u>007</u>	Oct 07, 2003
<u>AB</u>	MUTUAL PHARM	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480</u>	<u>001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480</u>	<u>002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480</u>	<u>003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480</u>	<u>004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480</u>	<u>005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480</u>	<u>006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480</u>	<u>007</u>	Sep 09, 2003
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439</u>	<u>004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439</u>	<u>001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439</u>	<u>002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439</u>	<u>003</u>	Jun 14, 2002

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

ARBOR PHARMS INC

5MG

A200166 001 Aug 09, 2012

+

10MG

A200166 002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

+ X GEN PHARMS

50MG/VIAL

A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ SIGMA TAU

5MG/ML

N050724 001 Nov 20, 1995

AMPHOTEC

+ ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996

+

100MG/VIAL

N050729 002 Nov 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+ ASTELLAS

50MG/VIAL

N050740 001 Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090884</u>	<u>002</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090884</u>	<u>003</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090889</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090884</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A065499</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A063145</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	IBI	<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 10MG BASE/VIAL</u>	<u>A201404</u>	<u>001</u>	Dec 20, 2013
<u>AP</u>	+ SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-30 (of 362)

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
AP	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340</u>	<u>001</u>	Sep 20, 2010
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340</u>	<u>002</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010
AP	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
AP	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
AP	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375</u>	<u>001</u>	Dec 21, 2011
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653</u>	<u>001</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375</u>	<u>002</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653</u>	<u>002</u>	Dec 21, 2011
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646</u>	<u>001</u>	Dec 21, 2011
AP	IBI	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
AP	MYLAN INSTITUTIONAL	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
AP	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
<u>UNASYN</u>					
AP	+ PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901</u>	<u>002</u>	Feb 27, 1992
AP	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
AP	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
AP	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
AP	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
AB	+	<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
AB	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
AB		<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	+	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	<u>EQ 0.5MG BASE</u>	<u>N020333</u>	<u>001</u>	Mar 14, 1997
<u>ANAGRELIDE HYDROCHLORIDE</u>					
AB	BARR	<u>EQ 0.5MG BASE</u>	<u>A076530</u>	<u>001</u>	Apr 18, 2005
AB		<u>EQ 1MG BASE</u>	<u>A076530</u>	<u>002</u>	Apr 18, 2005
AB	IMPAX LABS	<u>EQ 0.5MG BASE</u>	<u>A076910</u>	<u>001</u>	Apr 18, 2005
AB		<u>EQ 1MG BASE</u>	<u>A076910</u>	<u>002</u>	Apr 18, 2005
AB	IVAX SUB TEVA PHARMS	<u>EQ 0.5MG BASE</u>	<u>A076468</u>	<u>001</u>	Apr 18, 2005
AB	+	<u>EQ 1MG BASE</u>	<u>A076468</u>	<u>002</u>	Apr 18, 2005
AB	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A076811</u>	<u>001</u>	Apr 18, 2005
AB		<u>EQ 1MG BASE</u>	<u>A076811</u>	<u>002</u>	Apr 18, 2005
AB	MYLAN PHARMS INC	<u>EQ 0.5MG BASE</u>	<u>A077613</u>	<u>001</u>	Jun 27, 2006
AB		<u>EQ 1MG BASE</u>	<u>A077613</u>	<u>002</u>	Jun 27, 2006

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	<u>1MG</u>	<u>A090568</u>	<u>001</u>	Jun 28, 2010
AB	APOTEX INC	<u>1MG</u>	<u>A200654</u>	<u>001</u>	May 11, 2012
AB	DR REDDYS LABS LTD	<u>1MG</u>	<u>A090732</u>	<u>001</u>	Jun 28, 2010
AB	FRESENIUS KABI ONCOL	<u>1MG</u>	<u>A090088</u>	<u>001</u>	Jun 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-31 (of 362)

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<u>AB</u>	MYLAN	<u>1MG</u>	<u>A091051</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	NATCO PHARMA LTD	<u>1MG</u>	<u>A079220</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	ROXANE	<u>1MG</u>	<u>A078485</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A079007</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	SANTOS BIOTECH	<u>1MG</u>	<u>A078944</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A091177</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A078058</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	THREE RIVERS PHARMS	<u>1MG</u>	<u>A091164</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A078984</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1MG</u>	<u>A078921</u>	<u>001</u>	Jun 28, 2010

ARIMIDEX

<u>AB</u>	+ ASTRAZENECA	<u>1MG</u>	<u>N020541</u>	<u>001</u>	Dec 27, 1995

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON

50MG/VIAL

N021632 001 Feb 17, 2006

+

100MG/VIAL

N021632 002 Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

BRISTOL MYERS SQUIBB

2.5MG

N202155 001 Dec 28, 2012

+

5MG

N202155 002 Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+ US WORLDMEDS

30MG/3ML (10MG/ML)

N021264 002 Apr 20, 2004

APRACLOPIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLOPIDINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.5% BASE</u>	<u>A077764</u>	<u>001</u>	Mar 12, 2009
	<u>IOPIDINE</u>				
<u>AT</u>	+ ALCON	<u>EQ 0.5% BASE</u>	<u>N020258</u>	<u>001</u>	Jul 30, 1993
	+	EQ 1% BASE	N019779	001	Dec 31, 1987

APREPITANT

CAPSULE; ORAL

APREPITANT

<u>AB</u>	SANDOZ	<u>40MG</u>	<u>A090999</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>80MG</u>	<u>A090999</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>125MG</u>	<u>A090999</u>	<u>003</u>	Sep 24, 2012
	<u>EMEND</u>				
<u>AB</u>	MERCK	<u>40MG</u>	<u>N021549</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>80MG</u>	<u>N021549</u>	<u>001</u>	Mar 26, 2003
<u>AB</u>	+	<u>125MG</u>	<u>N021549</u>	<u>002</u>	Mar 26, 2003

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+ SUNOVION

EQ 0.015MG BASE/2ML

N021912 001 Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION

ACOYA

<u>AP</u>	+ PFIZER	<u>250MG/2.5ML (100MG/ML)</u>	<u>N020883</u>	<u>001</u>	Jun 30, 2000

ARGATROBAN

<u>AP</u>	HIKMA PHARM CO LTD	<u>250MG/2.5ML (100MG/ML)</u>	<u>N203049</u>	<u>001</u>	Jan 05, 2012

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

+ EAGLE PHARMS

50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011

+ SANDOZ

125MG/125ML (1MG/ML)

N022485 001 May 09, 2011

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+ PHARMACIA AND UPJOHN

10GM/100ML

N016931 001

PRESCRIPTION DRUG PRODUCT LIST

3-32 (of 362)

ARIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013
+	400MG/VIAL	N202971 002	Feb 28, 2013

INJECTABLE; INTRAMUSCULAR

ABILIFY

+	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866 001	Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+	OTSUKA	1MG/ML	N021713 001	Dec 10, 2004

TABLET; ORAL

ABILIFY

OTSUKA

2MG

N021436 006 Nov 15, 2002

+

5MG

N021436 005 Nov 15, 2002

+

10MG

N021436 001 Nov 15, 2002

15MG

N021436 002 Nov 15, 2002

20MG

N021436 003 Nov 15, 2002

30MG

N021436 004 Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

+

OTSUKA

10MG

N021729 002 Jun 07, 2006

15MG

N021729 003 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012

AB

150MG

A200043 002 Jun 01, 2012

AB

250MG

A200043 003 Jun 01, 2012

NUVIGIL

AB CEPHALON

50MG

N021875 001 Jun 15, 2007

AB

150MG

N021875 003 Jun 15, 2007

AB

+

250MG

N021875 004 Jun 15, 2007

ARMODAFINIL

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+	CEPHALON	1MG/ML	N021248 001	Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+	NOVARTIS	20MG; 120MG	N022268 001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP HOSPIRA

4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)

A079138 001 Jun 18, 2010

SEPTOCAINE

AP + DEPROCO

4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)

N020971 001 Apr 03, 2000

ORABLOC

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)

N022466 001 Feb 26, 2010

+

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+

DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)

N022010 001 Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+

SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+

SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL

N021646 001 Jan 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-33 (of 362)

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA

80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA

20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML

N008809 006 Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA

200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA

200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML

N021643 001 Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

ORGANON SUB MERCK

EQ 5MG BASE

N022117 001 Aug 13, 2009

+

EQ 10MG BASE

N022117 002 Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA + WATSON LABS INC

325MG; 50MG; 40MG

N017534 005 Apr 16, 1986

LANORINAL

AA LANNETT

325MG; 50MG; 40MG

A086996 002 Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA + WEST WARD

325MG; 50MG; 40MG

A086162 002 Feb 16, 1984

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB NEXGEN PHARMA INC

325MG; 50MG; 40MG; 30MG

A075231 001 Nov 30, 2001

AB STEVENS J

325MG; 50MG; 40MG; 30MG

A074951 001 Aug 31, 1998

AB WATSON LABS

325MG; 50MG; 40MG; 30MG

A074359 001 Aug 31, 1995

FIORINAL W/CODEINE

AB + WATSON LABS INC

325MG; 50MG; 40MG; 30MG

N019429 003 Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ CARACO

356.4MG; 30MG; 16MG

N011483 004 Sep 06, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-34 (of 362)

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC

AB	MEDICIS	385MG; 30MG; 25MG	N013416 003	Oct 27, 1982

NORGESIC FORTE

AB	+ MEDICIS	770MG; 60MG; 50MG	N013416 004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	SANDOZ	385MG; 30MG; 25MG	A074654 001	Dec 31, 1996

AB		770MG; 60MG; 50MG	A074654 002	Dec 31, 1996

AB	STEVENS J	385MG; 30MG; 25MG	A074988 001	Apr 30, 1999

AB		770MG; 60MG; 50MG	A074988 002	Apr 30, 1999

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	HERITAGE PHARMS INC	325MG; 200MG	A089594 001	Mar 31, 1989

AB	MIRROR PHARMS	325MG; 200MG	A040832 001	Jan 07, 2010

AB	PROSAM LABS	325MG; 200MG	A040252 001	Dec 10, 1997

AB	SANDOZ	325MG; 200MG	A040116 001	Apr 25, 1996

SOMA COMPOUND

AB	+ MEDA PHARMS	325MG; 200MG	N012365 005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG; 200MG; 16MG	A040860 001	Jan 07, 2010

AB	PROSAM LABS	325MG; 200MG; 16MG	A040283 001	Dec 29, 1998

AB	SANDOZ	325MG; 200MG; 16MG	A040118 001	Apr 16, 1996

SOMA COMPOUND W/ CODEINE

AB	+ MEDA PHARMS	325MG; 200MG; 16MG	N012366 002	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOL

AB	+ BOEHRINGER INGELHEIM	25MG; 200MG	N020884 001	Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

AB	BARR	25MG; 200MG	A078804 001	Aug 14, 2009

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

	+ STEVENS J	325MG; 400MG	A081145 001	Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG; 4.8355MG	A091670 001	Mar 16, 2011

AA	WATSON LABS	325MG; 4.8355MG	A090084 001	Mar 22, 2011

PERCODAN

AA	+ ENDO PHARMS	325MG; 4.8355MG	N007337 007	Aug 05, 2005

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	WATSON LABS	325MG; 4.5MG; 0.38MG	A040255 001	Feb 27, 1998

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567 001	Jun 20, 2003

		EQ 150MG BASE	N021567 002	Jun 20, 2003

		EQ 200MG BASE	N021567 003	Jun 20, 2003

	+	EQ 300MG BASE	N021567 004	Oct 16, 2006

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	AUROBINDO PHARMA	25MG	A078512 001	Oct 31, 2007

AB		50MG	A078512 002	Oct 31, 2007

AB		100MG	A078512 003	Oct 31, 2007

AB	CARACO	25MG	A078210 001	Jul 10, 2007

AB		50MG	A078210 002	Jul 10, 2007

AB		100MG	A078210 003	Jul 10, 2007

AB	DAVA PHARMS INC	25MG	A074099 001	Apr 28, 1992

AB		50MG	A073542 001	Dec 19, 1991

AB		100MG	A073543 001	Dec 19, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-35 (of 362)

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499</u>	<u>001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073456</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052</u>	<u>001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005
<u>TENORMIN</u>					
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG; 25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992
<u>TENORETIC 100</u>					
<u>AB</u>	+	<u>100MG; 25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
<u>TENORETIC 50</u>					
<u>AB</u>	ASTRAZENECA	<u>50MG; 25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY	10MG	N021411	002	Nov 26, 2002
	18MG	N021411	003	Nov 26, 2002
	25MG	N021411	004	Nov 26, 2002
	40MG	N021411	005	Nov 26, 2002
+	60MG	N021411	006	Nov 26, 2002
	80MG	N021411	007	Feb 14, 2005
	100MG	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548</u>	<u>004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650</u>	<u>002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650</u>	<u>003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 10MG BASE</u>	<u>A091624</u>	<u>001</u>	Apr 05, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-36 (of 362)

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624</u>	<u>002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624</u>	<u>003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624</u>	<u>004</u>	Apr 05, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226</u>	<u>004</u>	May 29, 2012
<u>AB</u>	RANBAXY LABS LTD	<u>EQ 10MG BASE</u>	<u>A076477</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477</u>	<u>002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575</u>	<u>004</u>	May 29, 2012
<u>LIPITOR</u>					
<u>AB</u>	PFIZER	<u>EQ 10MG BASE</u>	<u>N020702</u>	<u>001</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020702</u>	<u>002</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020702</u>	<u>003</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N020702</u>	<u>004</u>	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013
		EQ 20MG BASE;10MG	N200153	002	May 03, 2013
		EQ 40MG BASE;10MG	N200153	003	May 03, 2013
	+	EQ 80MG BASE;10MG	N200153	004	May 03, 2013

ATOVAQUONE

SUSPENSION; ORAL

MEPRON

	+	GLAXOSMITHKLINE LLC	750MG/5ML	N020500	001	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>250MG;100MG</u>	<u>A091211</u>	<u>001</u>	Jan 12, 2011
<u>MALARONE</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>250MG;100MG</u>	<u>N021078</u>	<u>001</u>	Jul 14, 2000
MALARONE PEDIATRIC					
	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

<u>AP</u>	+	BEDFORD	<u>10MG/ML</u>	<u>A074901</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>		HOSPIRA INC	<u>10MG/ML</u>	<u>A090761</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091489</u>	<u>001</u>	Feb 17, 2012
<u>ATRACURIUM BESYLATE PRESERVATIVE FREE</u>						
<u>AP</u>	+	BEDFORD	<u>10MG/ML</u>	<u>A074900</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>		HOSPIRA INC	<u>10MG/ML</u>	<u>A090782</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091488</u>	<u>001</u>	Feb 17, 2012

ATROPINE

INJECTABLE; INJECTION

ATROPEN

	+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
	+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
	+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
	+		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	HOSPIRA	0.05MG/ML	N021146	002	Jul 09, 2001
	+	0.1MG/ML	N021146	001	Jul 09, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-37 (of 362)

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ VALEANT

0.025MG; 1MG

N017744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA + ROXANE0.025MG/5ML; 2.5MG/5MLA087708 001 May 03, 1982

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA LANNETT0.025MG; 2.5MGA085372 001AA MYLAN0.025MG; 2.5MGA085762 001AA PAR PHARM0.025MG; 2.5MGA040357 001 May 02, 2000LOMOTILAA + GD SEARLE LLC0.025MG; 2.5MGN012462 001LONOXAA SANDOZ0.025MG; 2.5MGA085311 002ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+ MYLAN INSTITUTIONAL

0.14MG/ML; 10MG/ML

N019678 001 Nov 06, 1991

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+ MERIDIAN MEDCL

2.1MG/0.7ML; 600MG/2ML

N021983 001 Sep 28, 2006

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ PROMETHEUS LABS

3MG

N018689 001 May 24, 1985

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

50MG

N202276 001 Apr 27, 2012

100MG

N202276 002 Apr 27, 2012

+

200MG

N202276 003 Apr 27, 2012

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

1MG

N202324 001 Jan 27, 2012

+

5MG

N202324 002 Jan 27, 2012

AZACITIDINE

INJECTABLE; IV-SC

AZACITIDINEAP DR REDDYS LABS LTD100MG/VIALA201537 001 Sep 16, 2013VIDAZAAP + CELGENE100MG/VIALN050794 001 May 19, 2004AZATHIOPRINE

TABLET; ORAL

AZASANAB AAIPHARMA LLC25MGA075252 002 Feb 03, 2003AB50MGA075252 001 Jun 07, 1999AB75MGA075252 003 Feb 03, 2003AB100MGA075252 004 Feb 03, 2003AZATHIOPRINEAB MYLAN50MGA075568 001 Dec 13, 1999AB ROXANE50MGA074069 001 Feb 16, 1996AB ZYDUS PHARMS USA25MGA077621 002 Sep 05, 2008AB50MGA077621 001 Mar 15, 2007AB75MGA077621 003 Sep 05, 2008AB100MGA077621 004 Sep 05, 2008IMURANAB + PROMETHEUS LABS50MGN016324 001

PRESCRIPTION DRUG PRODUCT LIST

3-38 (of 362)

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ BEDFORD

EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995

AZELAIC ACID

CREAM; TOPICAL

AZELEX

+ ALLERGAN

20%

N020428 001 Sep 13, 1995

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N021470 001 Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE**AT** ALCON PHARMA0.05%A202305 001 May 31, 2012**AT** APOTEX INC0.05%A078621 001 Aug 03, 2009**AT** SUN PHARMA GLOBAL0.05%A078738 001 Jun 21, 2010OPTIVAR**AT** + MEDA PHARMS0.05%N021127 001 May 22, 2000

SPRAY, METERED; NASAL

ASTELIN**AB** + MEDA PHARMSEQ 0.125MG BASE/SPRAYN020114 001 Nov 01, 1996ASTEPRO**AB** + MEDA PHARMSEQ 0.1876MG BASE/SPRAYN022371 001 Aug 31, 2009AZELASTINE HYDROCHLORIDE**AB** APOTEX INCEQ 0.125MG BASE/SPRAYA077954 001 Apr 30, 2009**AB**EQ 0.1876MG BASE/SPRAYA201846 001 Aug 31, 2012**AB** SUN PHARMA GLOBALEQ 0.125MG BASE/SPRAYA090423 001 May 23, 2012AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+ MEDA PHARMS

EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY

N202236 001 May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011

+

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011

+

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN**AB** PLIVAEQ 100MG BASE/5MLA065246 002 Jul 05, 2006**AB**EQ 200MG BASE/5MLA065246 001 Jul 05, 2006**AB** TEVA PHARMSEQ 100MG BASE/5MLA065419 001 Jun 24, 2008**AB**EQ 200MG BASE/5MLA065419 002 Jun 24, 2008ZITHROMAX**AB** PFIZEREQ 100MG BASE/5MLN050710 001 Oct 19, 1995**AB** +EQ 200MG BASE/5MLN050710 002 Oct 19, 1995

+

EQ 1GM BASE/PACKET

N050693 001 Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCIN**AP** FRESENIUS KABI USAEQ 500MG BASE/VIALA065179 001 Dec 13, 2005**AP** GLAND PHARMA LTDEQ 500MG BASE/VIALA065501 001 Nov 09, 2009**AP** HOSPIRAEQ 500MG BASE/VIALA065500 001 Jun 26, 2009**AP**EQ 500MG BASE/VIALA065511 001 Jun 26, 2009**AP** SAGENT STRIDESEQ 500MG BASE/VIALA065506 001 Mar 24, 2009**AP** SUN PHARM INDS LTDEQ 500MG BASE/VIALA090923 001 Apr 02, 2013ZITHROMAX**AP** + PFIZEREQ 500MG BASE/VIALN050733 001 Jan 30, 1997

SOLUTION/DROPS; OPHTHALMIC

AZASITE

+ OAK PHARMS AKORN

1%

N050810 001 Apr 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-39 (of 362)

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	APOTEX CORP	<u>EQ 250MG BASE</u>	<u>A065507</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065509</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065508</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A065365</u>	<u>001</u>	May 30, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065366</u>	<u>001</u>	May 30, 2007
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065360</u>	<u>001</u>	Jan 08, 2007
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065218</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302</u>	<u>003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784</u>	<u>001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730</u>	<u>001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580</u>	<u>003</u>	Dec 31, 1986

AZTREONAM

<u>AP</u>	BEDFORD	<u>1GM/VIAL</u>	<u>A065286</u>	<u>001</u>	Mar 23, 2011
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065286</u>	<u>002</u>	Mar 23, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439</u>	<u>002</u>	Jun 18, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065439</u>	<u>003</u>	Jun 18, 2010

AZACTAM IN PLASTIC CONTAINER

+ BRISTOL MYERS SQUIBB

20MG/ML

N050632 002 May 24, 1989

+

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

FRESENIUS KABI USA

500MG/VIAL

A065439 001 Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>	X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153</u>	<u>001</u>	May 09, 1997

BACITRACIN

<u>AP</u>	FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116</u>	<u>001</u>	Dec 03, 2002
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733</u>	<u>002</u>
<u>AP</u>	SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211</u>	<u>001</u>	May 11, 2010
	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	

OINTMENT; OPHTHALMIC

BACITRACIN

<u>AT</u>		AKORN	<u>500 UNITS/GM</u>	<u>A203257</u>	<u>001</u>	Dec 13, 2013
<u>AT</u>	+	PERRIGO CO TENNESSEE	<u>500 UNITS/GM</u>	<u>A061212</u>	<u>001</u>	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<u>AT</u>	AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213</u>	<u>001</u>	Jul 25, 2012
<u>AT</u>	+ BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068</u>	<u>001</u>	Oct 30, 1995

OINTMENT; TOPICAL

CORTISPORIN

+ MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-40 (of 362)

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>	AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088</u>	<u>001</u>	Feb 06, 2004
<u>AT</u>	+ BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064</u>	<u>001</u>	Oct 30, 1995
<u>AT</u>	PERRIGO CO TENNESSEE	<u>400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM</u>	<u>A060764</u>	<u>002</u>	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<u>AT</u>	AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028</u>	<u>001</u>	Jan 30, 1995
<u>AT</u>	+ BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046</u>	<u>001</u>	Jan 26, 1995
<u>AT</u>	PERRIGO CO TENNESSEE	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022</u>	<u>001</u>	Feb 27, 2002

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+ PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE;10,000 UNITS/GM	A062166	002	

BACLOFEN

INJECTABLE;INTRATHECAL

GABLOFEN

<u>AP</u>	MALLINCKRODT INC	<u>0.05MG/ML</u>	<u>N022462</u>	<u>001</u>	Nov 19, 2010
<u>AP</u>		<u>0.5MG/ML</u>	<u>N022462</u>	<u>002</u>	Nov 19, 2010
<u>AP</u>		<u>2MG/ML</u>	<u>N022462</u>	<u>003</u>	Nov 19, 2010

LIORESAL

<u>AP</u>	+ MEDTRONIC NEURO	<u>0.05MG/ML</u>	<u>N020075</u>	<u>003</u>	Nov 07, 1996
<u>AP</u>	+	<u>0.5MG/ML</u>	<u>N020075</u>	<u>001</u>	Jun 17, 1992
<u>AP</u>	+	<u>2MG/ML</u>	<u>N020075</u>	<u>002</u>	Jun 17, 1992

GABLOFEN

	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012

TABLET;ORAL

BACLOFEN

<u>AB</u>	CARACO	<u>10MG</u>	<u>A077984</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077862</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A078146</u>	<u>001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971</u>	<u>002</u>	Oct 26, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072235</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	LANNETT	<u>10MG</u>	<u>A078220</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241</u>	<u>001</u>	Dec 20, 2005
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077181</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>20MG</u>	<u>A077121</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A090334</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090334</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078504</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>	PROSAM LABS	<u>10MG</u>	<u>A077089</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A074584</u>	<u>001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584</u>	<u>002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077156</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072824</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		<u>20MG</u>	<u>A072825</u>	<u>001</u>	Sep 18, 1991

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077807</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ROXANE	<u>750MG</u>	<u>A077806</u>	<u>001</u>	Dec 28, 2007

COLAZAL

<u>AB</u>	+ SALIX PHARMS	<u>750MG</u>	<u>N020610</u>	<u>001</u>	Jul 18, 2000

TABLET;ORAL

GIAZO

	+ SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-41 (of 362)

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

+ WYETH PHARMS PFIZER EQ 20MG BASE; 0.45MG

N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ TEVA BRANDED PHARM 0.04MG/INH

N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM 0.08MG/INH

N020911 001 Sep 15, 2000

AEROSOL, METERED; NASAL

QNASL

+ TEVA BRANDED PHARM 0.08MG/ACTUATION

N202813 001 Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY

N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

+ JANSSEN THERAP EQ 100MG BASE

N204384 001 Dec 28, 2012

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128</u>	<u>001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128</u>	<u>002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128</u>	<u>003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128</u>	<u>004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212</u>	<u>001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212</u>	<u>002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212</u>	<u>003</u>	May 22, 2008
<u>AB</u>	BIOKEY	<u>5MG</u>	<u>A076820</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820</u>	<u>004</u>	Feb 03, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG</u>	<u>A076267</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008
	<u>LOTENSIN</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851</u>	<u>001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-42 (of 362)

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

<u>AB</u>		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483</u>	<u>003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483</u>	<u>004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004

LOTENSIN HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033</u>	<u>001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+ CEPHALON

25MG/VIAL

N022249 002 May 01, 2009

+

100MG/VIAL

N022249 001 Mar 20, 2008

SOLUTION; IV (INFUSION)

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647</u>	<u>001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647</u>	<u>002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688</u>	<u>002</u>	Feb 15, 2008

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833</u>	<u>001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG; 80MG</u>	<u>A077833</u>	<u>002</u>	Mar 30, 2007

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
<u>AA</u>	CARACO	<u>100MG</u>	<u>A040587</u>	<u>001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587</u>	<u>002</u>	Mar 19, 2008
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851</u>	<u>001</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851</u>	<u>003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
<u>AA</u>	THE PHARMA NETWORK	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040749</u>	<u>001</u>	Jul 25, 2007
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+	PFIZER	<u>100MG</u>	<u>N011210</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3-43 (of 362)

BENZONATATE

CAPSULE; ORAL

TESSALON

<u>AA</u>	+	<u>200MG</u>	<u>N011210</u>	<u>003</u>	Jun 25, 1999
	BENZONATATE				
	MIKART	150MG	A040851	002	Nov 09, 2009

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

<u>AB</u>	VALEANT BERMUDA	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000
	<u>CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>				
<u>AB</u>	MYLAN PHARMS INC	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
<u>AB</u>	PERRIGO ISRAEL	<u>5%;1.2%</u>	<u>A090979</u>	<u>001</u>	Jun 26, 2012
	<u>DUAC</u>				
<u>AB</u>	+ STIEFEL	<u>5%;1.2%</u>	<u>N050741</u>	<u>001</u>	Aug 26, 2002
	BENZACLIN				
BT	+ VALEANT BERMUDA	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
	ACANYA				
	+ DOW PHARM	2.5%;1.2%	N050819	001	Oct 23, 2008

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+	VALEANT INTL	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984
		<u>ERYTHROMYCIN AND BENZOYL PEROXIDE</u>				
<u>AB</u>		TOLMAR	<u>5%;3%</u>	<u>A065112</u>	<u>001</u>	Mar 29, 2004
		BENZAMYCIN PAK				
	+	VALEANT LUXEMBOURG	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	EMCURE PHARMS LTD	<u>50MG</u>	<u>A202061</u>	<u>001</u>	Jan 27, 2012
<u>AA</u>	IMPAX LABS	<u>50MG</u>	<u>A040845</u>	<u>001</u>	Nov 18, 2008
<u>AA</u>	KVK TECH	<u>50MG</u>	<u>A090968</u>	<u>001</u>	Jul 20, 2010
<u>AA</u>	MALLINCKRODT INC	<u>50MG</u>	<u>A040773</u>	<u>001</u>	Apr 25, 2007
<u>AA</u>	MIKART	<u>25MG</u>	<u>A090473</u>	<u>001</u>	Sep 15, 2010
<u>AA</u>		<u>50MG</u>	<u>A090473</u>	<u>002</u>	Sep 15, 2010
<u>AA</u>	PADDOCK	<u>50MG</u>	<u>A040578</u>	<u>001</u>	Apr 17, 2006
<u>AA</u>	TEDOR PHARM	<u>50MG</u>	<u>A040747</u>	<u>001</u>	Mar 30, 2007
<u>DIDREX</u>					
<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A091152</u>	<u>001</u>	Mar 29, 2010
<u>AP</u>	NAVINTA LLC	<u>1MG/ML</u>	<u>A091525</u>	<u>001</u>	Feb 05, 2013

COGENTIN

<u>AP</u>	+	OAK PHARMS AKORN	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>	COREPHARMA	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>	EXCELLIUM	<u>0.5MG</u>	<u>A090168</u>	<u>001</u>	Nov 28, 2012
<u>AA</u>		<u>1MG</u>	<u>A090168</u>	<u>002</u>	Nov 28, 2012
<u>AA</u>		<u>2MG</u>	<u>A090168</u>	<u>003</u>	Nov 28, 2012
<u>AA</u>	INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>		<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>		<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>	PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>	+ USL PHARMA	<u>0.5MG</u>	<u>A040103</u>	<u>001</u>	Dec 12, 1996
<u>AA</u>	+	<u>1MG</u>	<u>A040103</u>	<u>002</u>	Dec 12, 1996
<u>AA</u>	+	<u>2MG</u>	<u>A040103</u>	<u>003</u>	Dec 12, 1996
<u>AA</u>	VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>		<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>		<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-44 (of 362)

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ ISTA PHARMS INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE**AB** LUITPOLD**3MG/ML; EQ 3MG BASE/ML****A090747 001** Jul 31, 2009**CELESTONE SOLUSPAN****AB** + MERCK SHARP DOHME**3MG/ML; EQ 3MG BASE/ML****N014602 001**BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** ACTAVIS MID ATLANTIC**EQ 0.05% BASE****A070885 001** Feb 03, 1987**AB** + FOUGERA PHARMS**EQ 0.05% BASE****N019137 001** Jun 26, 1984**AB** TARO**EQ 0.05% BASE****A073552 001** Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** FOUGERA PHARMS**EQ 0.05% BASE****A076215 001** Dec 09, 2003**AB** GLENMARK GENERICS**EQ 0.05% BASE****A078930 001** Sep 23, 2008**AB** PERRIGO NEW YORK**EQ 0.05% BASE****A076592 001** Dec 09, 2003**AB** TARO**EQ 0.05% BASE****A076543 001** Dec 09, 2003**AB** TOLMAR**EQ 0.05% BASE****A076603 001** Jan 23, 2004**DIPROLENE AF****AB** + MERCK SHARP DOHME**EQ 0.05% BASE****N019555 001** Apr 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** + FOUGERA PHARMS**EQ 0.05% BASE****A075276 001** May 13, 2003**AB** TARO**EQ 0.05% BASE****A076508 001** Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** ACTAVIS MID ATLANTIC**EQ 0.05% BASE****A070281 001** Jul 31, 1985**AB** + FOUGERA**EQ 0.05% BASE****A070275 001** Aug 12, 1985**AB** PERRIGO NEW YORK**EQ 0.05% BASE****A072538 001** Jan 31, 1990**AB** TEVA**EQ 0.05% BASE****A071467 001** Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** FOUGERA PHARMS**EQ 0.05% BASE****A077111 001** May 21, 2007**AB** TARO**EQ 0.05% BASE****A077477 001** May 21, 2007**DIPROLENE****AB** + MERCK SHARP DOHME**EQ 0.05% BASE****N019716 001** Aug 01, 1988

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE**AB** ACTAVIS MID ATLANTIC**EQ 0.05% BASE****A071012 001** Feb 03, 1987**AB** + FOUGERA**EQ 0.05% BASE****N019141 001** Sep 04, 1984**AB** TARO**EQ 0.05% BASE****A074271 001** Sep 15, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-45 (of 362)

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995
AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999
AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004

DIPROLENE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N018741 001	Jul 27, 1983

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TOLMAR	0.064%; 0.005%	A201615 001	Jan 14, 2013
AB	+ LEO PHARMA AS	0.064%; 0.005%	N021852 001	Jan 09, 2006
	SUSPENSION; TOPICAL			
	TACLONEX			
	+ LEO PHARMA AS	0.064%; 0.005%	N022185 001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE; 1%	A076002 001	Aug 02, 2002
AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A075502 001	Jun 05, 2001
AB	TARO	EQ 0.05% BASE; 1%	A075673 001	May 29, 2001

LOTTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N018827 001	Jul 10, 1984

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A076516 001	Jun 16, 2005
AB	TARO	EQ 0.05% BASE; 1%	A076493 001	Jul 28, 2004

LOTTRISONE

AB	+ SCHERING CORP	EQ 0.05% BASE; 1%	N020010 001	Dec 08, 2000

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO	0.12%	A078337 001	Nov 26, 2012
AB	+ DELCOR ASSET	0.12%	N020934 001	Feb 28, 1999

CREAM; TOPICAL

BETA-VAL

AB	TEVA	EQ 0.1% BASE	N018642 001	Mar 24, 1983

BETAMETHASONE VALERATE

AB	+ FOUGERA	EQ 0.1% BASE	N018861 001	Aug 31, 1983

DERMABET

AB	TARO	EQ 0.1% BASE	A072041 001	Jan 06, 1988

VALNAC

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070050 001	Oct 10, 1984

LOTION; TOPICAL

BETA-VAL

AB	TEVA	EQ 0.1% BASE	A070072 001	Jun 27, 1985

BETAMETHASONE VALERATE

AB	+ FOUGERA	EQ 0.1% BASE	N018866 001	Aug 31, 1983

AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070051 001	Oct 10, 1984

AB	+ FOUGERA	EQ 0.1% BASE	N018865 001	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	AKORN	EQ 0.5% BASE	A075386 001	Jun 30, 2000
AT	BAUSCH AND LOMB	EQ 0.5% BASE	A075630 001	Apr 12, 2001
AT	WOCKHARDT	EQ 0.5% BASE	A078694 001	Nov 16, 2009

BETOPTIC

AT	+ ALCON	EQ 0.5% BASE	N019270 001	Aug 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

	+ ALCON	EQ 0.25% BASE	N019845 001	Dec 29, 1989

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

AB	EPIC PHARMA	10MG	A075541 001	Oct 22, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-46 (of 362)

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	+		<u>20MG</u>	<u>A075541</u>	<u>002</u>	Oct 22, 1999
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A078962</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>20MG</u>	<u>A078962</u>	<u>002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>		AMNEAL PHARM	<u>5MG</u>	<u>A040855</u>	<u>001</u>	Nov 21, 2007
<u>AA</u>			<u>10MG</u>	<u>A040855</u>	<u>002</u>	Nov 21, 2007
<u>AA</u>			<u>25MG</u>	<u>A040855</u>	<u>003</u>	Nov 21, 2007
<u>AA</u>			<u>50MG</u>	<u>A040855</u>	<u>004</u>	Nov 21, 2007
<u>AA</u>		CARACO	<u>5MG</u>	<u>A040897</u>	<u>001</u>	Apr 22, 2009
<u>AA</u>			<u>10MG</u>	<u>A040897</u>	<u>002</u>	Apr 22, 2009
<u>AA</u>			<u>25MG</u>	<u>A040897</u>	<u>003</u>	Apr 22, 2009
<u>AA</u>			<u>50MG</u>	<u>A040897</u>	<u>004</u>	Apr 22, 2009
<u>AA</u>		EMCURE USA	<u>5MG</u>	<u>A091256</u>	<u>001</u>	May 04, 2010
<u>AA</u>			<u>10MG</u>	<u>A091256</u>	<u>002</u>	May 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A091256</u>	<u>003</u>	May 04, 2010
<u>AA</u>			<u>50MG</u>	<u>A091256</u>	<u>004</u>	May 04, 2010
<u>AA</u>		IMPAX LABS	<u>5MG</u>	<u>A040739</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>10MG</u>	<u>A040741</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>25MG</u>	<u>A040740</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>50MG</u>	<u>A040721</u>	<u>004</u>	Nov 01, 2006
<u>AA</u>		LANNETT	<u>10MG</u>	<u>A040704</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>			<u>25MG</u>	<u>A040678</u>	<u>003</u>	Mar 27, 2008
<u>AA</u>		PHARMAX	<u>5MG</u>	<u>A040725</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>10MG</u>	<u>A040726</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>25MG</u>	<u>A040727</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>50MG</u>	<u>A040728</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		UPSHER SMITH	<u>5MG</u>	<u>A040633</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>10MG</u>	<u>A040634</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>25MG</u>	<u>A040635</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>50MG</u>	<u>A040636</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		WOCKHARDT	<u>5MG</u>	<u>A040532</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>10MG</u>	<u>A040533</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>25MG</u>	<u>A040534</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>50MG</u>	<u>A040518</u>	<u>001</u>	Sep 29, 2003

DUVOID

<u>AA</u>		WELLSPRING PHARM	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>			<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>			<u>50MG</u>	<u>A085882</u>	<u>003</u>	

URECHOLINE

<u>AA</u>	+	ODYSSEY PHARMS	<u>5MG</u>	<u>A089095</u>	<u>001</u>	Dec 19, 1985
<u>AA</u>	+		<u>10MG</u>	<u>A088440</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+		<u>25MG</u>	<u>A088441</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+		<u>50MG</u>	<u>A089096</u>	<u>001</u>	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+ VALEANT LUXEMBOURG 75MG

N021055 001 Dec 29, 1999

GEL; TOPICAL

TARGRETIN

+ VALEANT LUXEMBOURG 1%

N021056 001 Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>50MG</u>	<u>A078917</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>		FRESENIUS KABI ONCOL	<u>50MG</u>	<u>A079045</u>	<u>001</u>	May 13, 2010
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A079185</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		ROXANE	<u>50MG</u>	<u>A078285</u>	<u>001</u>	Mar 24, 2011
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A078575</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		TEVA	<u>50MG</u>	<u>A076932</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u>	<u>001</u>	Jul 06, 2009

CASODEX

<u>AB</u>	+	ASTRAZENECA	<u>50MG</u>	<u>N020498</u>	<u>001</u>	Oct 04, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-47 (of 362)

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

+ ALLERGAN

0.01%

N022184 001 Aug 31, 2010

+

0.03%

N021275 001 Mar 16, 2001

SOLUTION/DROPS;TOPICAL

LATISSE

+ ALLERGAN

0.03%

N022369 001 Dec 24, 2008

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL

AKINETON

+ ABBVIE

2MG

N012003 001

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

HALFLYTELY

+ BRAINTREE

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM
;N/A,5.6GM

N021551 003 Jul 16, 2010

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+ APTALIS PHARMA US

140MG;125MG;125MG

N050786 001 Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

+ PROMETHEUS LABS

262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,5
00MG

N050719 001 Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATEAB AUROBINDO PHARMA5MGA077910 001 Dec 27, 2006AB 10MGA077910 002 Dec 27, 2006AB MYLAN 5MGA075831 001 Dec 14, 2005AB 10MGA075831 002 Dec 14, 2005AB SANDOZ 5MGA075643 001 Nov 16, 2000AB 10MGA075643 002 Nov 16, 2000AB TEVA PHARMS 5MGA075644 001 Jun 26, 2001AB 10MGA075644 002 Jun 26, 2001AB UNICHEM PHARMS (USA) 5MGA078635 001 Aug 18, 2009AB 10MGA078635 002 Aug 18, 2009ZEBETAAB TEVA WOMENS5MGN019982 002 Jul 31, 1992AB + 10MGN019982 001 Jul 31, 1992BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDEAB MYLAN 2.5MG;6.25MGA075768 001 Sep 25, 2000AB 5MG;6.25MGA075768 002 Sep 25, 2000AB 10MG;6.25MGA075768 003 Sep 25, 2000AB SANDOZ 2.5MG;6.25MGA075579 001 Sep 25, 2000AB 5MG;6.25MGA075579 002 Sep 25, 2000AB 10MG;6.25MGA075579 003 Sep 25, 2000AB UNICHEM 2.5MG;6.25MGA079106 001 Jul 28, 2010AB 5MG;6.25MGA079106 002 Jul 28, 2010AB 10MG;6.25MGA079106 003 Jul 28, 2010AB WATSON LABS 2.5MG;6.25MGA075469 001 Sep 25, 2000AB 5MG;6.25MGA075469 002 Sep 25, 2000AB 10MG;6.25MGA075469 003 Sep 25, 2000ZIACAB TEVA WOMENS2.5MG;6.25MGN020186 003 Mar 26, 1993AB 5MG;6.25MGN020186 001 Mar 26, 1993AB + 10MG;6.25MGN020186 002 Mar 26, 1993BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

+ MEDICINES CO

250MG/VIAL

N020873 001 Dec 15, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-48 (of 362)

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP	BEDFORD	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u>	Oct 17, 2001
AP		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u>	Oct 17, 2001
AP	+ FRESENIUS KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u>	Jan 28, 2008
AP	+	<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u>	Jan 28, 2008
AP	HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u>	Mar 10, 2000
AP		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u>	Mar 10, 2000
AP	TEVA PHARMS USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u>	Jun 27, 2000
AP		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003

BOSENTAN

TABLET; ORAL

TRACLEER

	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001
+		125MG	N021290	002	Nov 20, 2001

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012
+		EQ 500MG BASE	N203341	002	Sep 04, 2012

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
+		200MG/100ML	N019121	002	Apr 29, 1986
+		400MG/100ML	N019121	003	Apr 29, 1986

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	ALLERGAN	<u>0.15%</u>	<u>N021262</u>	<u>001</u>	Mar 16, 2001

BRIMONIDINE TARTRATE

AT		AKORN	<u>0.2%</u>	<u>A076439</u>	<u>001</u>	Mar 14, 2006
AT		ALCON PHARMS LTD	<u>0.2%</u>	<u>A076254</u>	<u>001</u>	Sep 16, 2003
AT	+	BAUSCH AND LOMB	<u>0.2%</u>	<u>A076260</u>	<u>001</u>	May 28, 2003
AT		SANDOZ	<u>0.2%</u>	<u>A078075</u>	<u>001</u>	Jan 30, 2008

OOLIANA

AT		ALCON PHARMS LTD	<u>0.15%</u>	<u>N021764</u>	<u>001</u>	May 22, 2006
		ALPHAGAN P				
	+	ALLERGAN	0.1%	N021770	001	Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+	ALCON RES LTD	0.2%; 1%	N204251	001	Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+	ALLERGAN	0.2%; EQ 0.5% BASE	N021398	001	Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+	ALCON PHARMS LTD	1%	N020816	001	Apr 01, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-49 (of 362)

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT	COASTAL PHARMS	EQ 0.09% ACID	A201211 001	May 11, 2011
AT	LUITPOLD	EQ 0.09% ACID	A202030 001	Jan 09, 2013
	BROMDAY			
	+ ISTA PHARMS INC	EQ 0.09% ACID	N021664 002	Oct 16, 2010
	PROLENSA			
	+ BAUSCH AND LOMB	EQ 0.07% ACID	N203168 001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	MYLAN	EQ 5MG BASE	A077226 001	Apr 04, 2005
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A078899 001	Jul 30, 2008

PARLODEL

AB	+ US PHARMS HOLDINGS I	EQ 5MG BASE	N017962 002	Mar 01, 1982

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	LEK PHARMS	EQ 2.5MG BASE	A074631 001	Jan 13, 1998
AB	MYLAN	EQ 2.5MG BASE	A076962 001	Sep 24, 2004
AB	PADDOCK LLC	EQ 2.5MG BASE	A077646 001	Oct 01, 2008
	<u>PARLODEL</u>			
AB	+ US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962 001	
	CYCLOSET			
	+ VEROSCIENCE	EQ 0.8MG BASE	N020866 001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

	+ WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811 001	Jun 07, 1985

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB	MYLAN	3MG	A090410 001	May 16, 2011
	<u>ENTOCORT EC</u>			
AB	+ ASTRAZENECA	3MG	N021324 001	Oct 02, 2001
	POWDER, METERED;INHALATION			
	PULMICORT FLEXHALER			
	ASTRAZENECA	0.08MG/INH	N021949 001	Jul 12, 2006
	+	0.16MG/INH	N021949 002	Jul 12, 2006
	SPRAY, METERED;NASAL			
	RHINOCORT			
	+ ASTRAZENECA	0.032MG/INH	N020746 001	Oct 01, 1999
	SUSPENSION;INHALATION			

BUDESONIDE

AN	SANDOZ	0.25MG/2ML	A201966 003	Sep 27, 2013
AN		0.5MG/2ML	A201966 002	Sep 27, 2013
AN		1MG/2ML	A201966 001	Sep 27, 2013
AN	TEVA PHARMS	0.25MG/2ML	A077519 001	Nov 18, 2008
AN		0.5MG/2ML	A077519 002	Nov 18, 2008
AN	WATSON LABS INC	0.25MG/2ML	A078404 001	Jul 31, 2012
AN		0.5MG/2ML	A078404 002	Jul 31, 2012

PULMICORT RESPULES

AN	ASTRAZENECA	0.25MG/2ML	N020929 001	Aug 08, 2000
AN		0.5MG/2ML	N020929 002	Aug 08, 2000
AN	+	1MG/2ML	N020929 003	Aug 08, 2000
	TABLET, EXTENDED RELEASE;ORAL			
	UCERIS			
	+ SANTARUS	9MG	N203634 001	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

SYMBICORT

	+ ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929 001	Jul 21, 2006
	+	0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+ BEDFORD	0.25MG/ML	A074441 001	Jan 27, 1995
AP	HIKMA MAPLE	0.25MG/ML	A079196 001	Apr 30, 2008
AP	HOSPIRA	0.25MG/ML	A074332 001	Oct 31, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-50 (of 362)

BUMETANIDE

TABLET; ORAL

BUMETANIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>		<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>		<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996
<u>AB</u>		<u>1MG</u>	<u>A074700</u>	<u>002</u>	Nov 21, 1996
<u>AB</u>	+	<u>2MG</u>	<u>A074700</u>	<u>003</u>	Nov 21, 1996

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	PACIRA PHARMS INC	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.25%</u>	<u>A070583</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070586</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070590</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>N018053</u>	<u>002</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070584</u>	<u>001</u>	Feb 17, 1986
<u>AP</u>		<u>0.5%</u>	<u>A070597</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>A070609</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>N018053</u>	<u>001</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070585</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>A070587</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>N018053</u>	<u>003</u>	
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091503</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091503</u>	<u>002</u>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895</u>	<u>001</u>	Nov 05, 2013
<u>AP</u>		<u>0.5%</u>	<u>A203895</u>	<u>002</u>	Nov 05, 2013
<u>AP</u>		<u>0.75%</u>	<u>A203895</u>	<u>003</u>	Nov 05, 2013
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091487</u>	<u>002</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091487</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.75%</u>	<u>A091487</u>	<u>003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>001</u>
<u>AP</u>	+		<u>0.5%</u>	<u>N016964</u>	<u>006</u>

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>012</u>
<u>AP</u>	+		<u>0.5%</u>	<u>N016964</u>	<u>005</u>
<u>AP</u>	+		<u>0.75%</u>	<u>N016964</u>	<u>009</u>

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810</u>	<u>001</u>	Dec 11, 1987

MARCAINE

<u>AP</u>	+	HOSPIRA	<u>0.75%</u>	<u>N018692</u>	<u>001</u>	May 04, 1984

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.75%</u>	<u>A071202</u>	<u>001</u>	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	Jun 16, 1988
<u>AP</u>			<u>0.5%;0.005MG/ML</u>	<u>A071170</u>	<u>001</u>	Jun 16, 1988
	+		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-51 (of 362)

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	A077250 001	Sep 27, 2006

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

AP	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	N022046 001	Jul 13, 1983

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	N016964 004	

AP	+	<u>0.5%;0.0091MG/ML</u>	N016964 008	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	N016964 013	

AP	+	<u>0.5%;0.0091MG/ML</u>	N016964 007	

AP	+	<u>0.75%;0.0091MG/ML</u>	N016964 010	

SENSORCAINE

AP	FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	A070966 001	Oct 13, 1987

AP		<u>0.25%;0.0091MG/ML</u>	A070967 001	Oct 13, 1987

AP		<u>0.5%;0.0091MG/ML</u>	A070968 001	Oct 13, 1987

AP		<u>0.5%;0.0091MG/ML</u>	N018304 004	Sep 02, 1983

AP		<u>0.75%;0.0091MG/ML</u>	N018304 005	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

PURDUE PHARMA LP	5MCG/HR	N021306 001	Jun 30, 2010

	10MCG/HR	N021306 002	Jun 30, 2010

	15MCG/HR	N021306 004	Jul 25, 2013

+	20MCG/HR	N021306 003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

AP	+ RECKITT BENCKISER	<u>EQ 0.3MG BASE/ML</u>	N018401 001	

BUPRENORPHINE HYDROCHLORIDE

AP	BEDFORD	<u>EQ 0.3MG BASE/ML</u>	A076931 001	Mar 02, 2005

AP	HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	A074137 001	Jun 03, 1996

AP	LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	A078331 001	Mar 27, 2007

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	BARR	<u>EQ 2MG BASE</u>	A090360 001	May 07, 2010

AB		<u>EQ 8MG BASE</u>	A090360 002	May 07, 2010

AB	ETHYPHARM	<u>EQ 2MG BASE</u>	A090622 001	Sep 24, 2010

AB		<u>EQ 8MG BASE</u>	A090622 002	Sep 24, 2010

AB	ROXANE	<u>EQ 2MG BASE</u>	A078633 001	Oct 08, 2009

AB	+	<u>EQ 8MG BASE</u>	A078633 002	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010

	EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012

	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010

+	EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A091422 001	Feb 22, 2013

AB	+	<u>EQ 8MG BASE;EQ 2MG BASE</u>	A091422 002	Feb 22, 2013

AB	AMNEAL PHARMS	<u>EQ 8MG BASE;EQ 2MG BASE</u>	A203136 002	Feb 22, 2013

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A203136 001	Feb 22, 2013

ZUBSOLV

OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013

+	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

VALEANT BERMUDA	174MG	N022108 001	Apr 23, 2008

	348MG	N022108 002	Apr 23, 2008

+	522MG	N022108 003	Apr 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-52 (of 362)

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143</u>	<u>001</u>	Jan 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A076143</u>	<u>002</u>	Jan 17, 2006
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491</u>	<u>002</u>	Apr 17, 2000
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A075584</u>	<u>001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584</u>	<u>002</u>	Feb 07, 2000

WELLBUTRIN

<u>AB</u>	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644</u>	<u>002</u>	Dec 30, 1985
<u>AB</u>	+	<u>100MG</u>	<u>N018644</u>	<u>003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459</u>	<u>001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459</u>	<u>002</u>	Jun 09, 2011
<u>AB1</u>		<u>200MG</u>	<u>A091459</u>	<u>003</u>	Jun 09, 2011
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711</u>	<u>001</u>	Dec 03, 2004
<u>AB1</u>	JUBILANT LIFE	<u>100MG</u>	<u>A202774</u>	<u>001</u>	Oct 11, 2013
<u>AB1</u>		<u>150MG</u>	<u>A202774</u>	<u>002</u>	Oct 11, 2013
<u>AB1</u>		<u>200MG</u>	<u>A202774</u>	<u>003</u>	Oct 11, 2013
<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A090325</u>	<u>001</u>	Apr 08, 2010
<u>AB1</u>		<u>150MG</u>	<u>A090325</u>	<u>002</u>	Apr 08, 2010
<u>AB1</u>		<u>200MG</u>	<u>A090325</u>	<u>003</u>	Apr 08, 2010
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	WATSON LABS FLORIDA	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010
<u>AB1</u>	WOCKHARDT LTD	<u>100MG</u>	<u>A201331</u>	<u>001</u>	Aug 30, 2012
<u>AB1</u>		<u>150MG</u>	<u>A201331</u>	<u>002</u>	Aug 30, 2012
<u>AB1</u>		<u>200MG</u>	<u>A201331</u>	<u>003</u>	Aug 30, 2012

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	JUBILANT LIFE	<u>150MG</u>	<u>A202775</u>	<u>001</u>	Oct 11, 2013
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941</u>	<u>001</u>	May 03, 2010
<u>AB2</u>	WATSON LABS FLORIDA	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009

ZYBAN

<u>AB2</u>	+	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711</u>	<u>003</u>	May 14, 1997

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	WATSON LABS	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>	+	<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003

BUPROPION HYDROCHLORIDE

BX	WATSON LABS	300MG	A077715	002	Jun 13, 2007
	FORFIVO XL				
	+	EDGEMONT PHARMS LLC	N022497	001	Nov 10, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-53 (of 362)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	A078246 001	Feb 27, 2009
AB		10MG	A078246 002	Feb 27, 2009
AB		15MG	A078246 003	Feb 27, 2009
AB		30MG	A078246 004	Feb 27, 2009
AB	MYLAN	5MG	A075272 001	Mar 01, 2002
AB		5MG	A075467 001	Feb 28, 2002
AB		7.5MG	A075467 002	Mar 28, 2001
AB		10MG	A075272 002	Mar 01, 2002
AB		10MG	A075467 003	Feb 28, 2002
AB		15MG	A075272 003	Mar 28, 2001
AB		15MG	A075467 004	Feb 28, 2002
AB		30MG	A076008 001	Jun 28, 2001
AB	PROSAM LABS	30MG	A078302 001	Dec 17, 2007
AB	TEVA	5MG	A075022 001	Feb 28, 2002
AB		10MG	A075022 002	Feb 28, 2002
AB	+	15MG	A075022 003	Feb 28, 2002
AB		30MG	A075022 004	Mar 25, 2004
AB	WATSON LABS	5MG	A074253 001	Mar 28, 2001
AB		10MG	A074253 002	Mar 28, 2001
AB		15MG	A074253 003	Mar 13, 2002

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ OTSUKA PHARM

6MG/ML

N020954 001 Feb 04, 1999

TABLET; ORAL

MYLERAN

+ ASPEN GLOBAL

2MG

N009386 001

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG/5ML

A085380 001

TABLET; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG

N000793 004

+

50MG

N000793 003

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ MYLAN

1%

N020524 001 Oct 18, 1996

MENTAX-TC

+ MYLAN

1%

N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	BEDFORD	2MG/ML	A075046 001	Aug 12, 1998
AP	HIKMA FARMACEUTICA	1MG/ML	A078400 001	May 01, 2009
AP		2MG/ML	A078247 001	Apr 29, 2009
AP		2MG/ML	A078400 002	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	BEDFORD	1MG/ML	A075045 001	Aug 12, 1998
AP		2MG/ML	A075045 002	Aug 12, 1998
AP	HOSPIRA	1MG/ML	A074626 001	Jan 23, 1997
AP		2MG/ML	A074626 002	Jan 23, 1997

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	+	MYLAN	1MG/SPRAY	A075759 001	Aug 08, 2001
AB		NOVEX	1MG/SPRAY	A075499 001	Dec 04, 2002
AB		ROXANE	1MG/SPRAY	A075824 001	Mar 12, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-54 (of 362)

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

+ SANOFI AVENTIS US 60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503 001	Mar 08, 2013
AB	IMPAX LABS INC	0.5MG	A077843 001	Jul 03, 2007
AB	IVAX SUB TEVA PHARMS	0.5MG	A077750 001	Mar 07, 2007
AB	MYLAN PHARMS INC	0.5MG	A202947 001	Dec 02, 2013
AB	+ PAR PHARM	0.5MG	A076310 001	Dec 29, 2005
AB	WATSON LABS	0.5MG	A078035 001	Apr 21, 2008

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

EXELIXIS

EQ 20MG BASE

N203756 001 Nov 29, 2012

+

EQ 80MG BASE

N203756 002 Nov 29, 2012

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999

CAFFEINE CITRATE

AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077997 001	Jul 20, 2007
AP	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077906 001	May 15, 2007
AP	PADDOCK LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233 001	Sep 21, 2006
AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012
AP	SUN PHARMA GLOBAL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077 001	Sep 30, 2009

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000

CAFFEINE CITRATE

AA	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A078002 001	Jan 31, 2008
AA	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064 001	Nov 20, 2009
AA	PADDOCK LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304 001	Sep 21, 2006
AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012
AA	SUN PHARMA GLOBAL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357 001	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+ CREALTA PHARMS LLC

100MG; 2MG

A086557 001 Oct 04, 1983

TABLET; ORAL

CAFERGOT

AA	+ SANDOZ	100MG; 1MG	A084294 001	

ERGOTAMINE TARTRATE AND CAFFEINE

AA	MIKART	100MG; 1MG	A040590 001	Sep 16, 2005
AA	WEST WARD	100MG; 1MG	A040510 001	Sep 17, 2004

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+ STIEFEL LABS INC

0.005%

N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996

OINTMENT; TOPICAL

CALCIPOTRIENE

+ GLENMARK GENERICS

0.005%

A090633 001 Mar 24, 2010

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008
AT	G AND W LABS INC	0.005%	A078468 001	Mar 24, 2011
AT	HI TECH PHARMA	0.005%	A077579 001	Nov 19, 2009
AT	TOLMAR	0.005%	A077029 001	Nov 20, 2009
AT	+ LEO PHARM	0.005%	N020611 001	Mar 03, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-55 (of 362)

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+ NOVARTIS

200 IU/ML

N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMONAB APOTEX INC200 IU/SPRAYA076396 001 Nov 17, 2008AB PAR PHARM200 IU/SPRAYA076979 001 Jun 08, 2009MIACALCINAB + NOVARTIS200 IU/SPRAYN020313 002 Aug 17, 1995CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

+ UPSHER SMITH

200 IU/SPRAY

N021406 001 Aug 12, 2005

CALCITRIOL

CAPSULE; ORAL

CALCITRIOLAB BANNER PHARMACAPS0.25MCGA091174 001 May 24, 2013AB0.5MCGA091174 002 May 24, 2013AB ROXANE0.25MCGA076917 001 Mar 27, 2006AB TEVA0.25MCGA075765 001 Oct 12, 2001AB0.5MCGA075765 002 Oct 12, 2001ROCALTROLAB VALIDUS PHARMS0.25MCGN018044 001AB +0.5MCGN018044 002

INJECTABLE; INJECTION

CALCIJEXAP + ABBVIE0.001MG/MLN018874 001 Sep 25, 1986AP +0.002MG/MLN018874 002 Sep 25, 1986CALCITRIOLAP AKORN0.001MG/MLA078066 001 Jan 29, 2008AP0.002MG/MLA078066 002 Jan 29, 2008AP FRESENIUS KABI USA0.001MG/MLA075836 001 Dec 31, 2002AP0.002MG/MLA075836 002 Dec 31, 2002AP FRESENIUS MEDCL0.001MG/MLA075766 001 Feb 20, 2003AP0.002MG/MLA075766 002 Feb 20, 2003AP LUITPOLD0.001MG/MLA075746 001 Sep 26, 2003AP0.002MG/MLA075746 002 Sep 26, 2003AP ROCKWELL MEDCL0.001MG/MLA076206 001 Sep 17, 2003AP0.001MG/MLA077102 001 Feb 08, 2006AP SAGENT PHARMS0.002MG/MLA075823 002 Mar 31, 2003AP0.002MG/ML

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOLAA ROXANE1MCG/MLA076242 001 Jul 18, 2003ROCALTROLAA + VALIDUS PHARMS1MCG/MLN021068 001 Nov 20, 1998CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATEAB INVAGEN PHARMSEQ 169MG CALCIUMA203135 001 Feb 07, 2013AB PADDOCK LLCEQ 169MG CALCIUMA091312 001 Jun 01, 2012AB ROXANEEQ 169MG CALCIUMA077728 001 Feb 26, 2008PHOSLO GELCAPSAB + FRESENIUS MEDCLEQ 169MG CALCIUMN021160 003 Apr 02, 2001

SOLUTION; ORAL

PHOSLYRA

+ FRESENIUS MEDCL

EQ 169MG CALCIUM/5ML

N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATEAB INVAGEN PHARMSEQ 169MG CALCIUMA202420 001 Feb 05, 2013AB PADDOCK LLCEQ 169MG CALCIUMA091561 001 Apr 13, 2011ELIPHOSAB + CYPRESS PHARMEQ 169MG CALCIUMA078502 001 Nov 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-56 (of 362)

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA

100MG/ML

N021117 001 Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS**AT** + ALCON**0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML****N018469 001****ENDOSOL EXTRA****AT** + AKORN**0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML****N020079 001** Nov 27, 1991CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML

N021703 010 Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML

N021703 011 Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML

N021703 013 Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 006 Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 002 Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 003 Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 015 Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 004 Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 014 Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS

5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 001 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATHIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

+ ALCON PHARMS LTD

0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML

N022193 001 Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN

37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML

N019864 001 Jun 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-57 (of 362)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 001	Aug 26, 1983
+		510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 002	Aug 26, 1983
+		510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 004	Aug 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 002	
AT		25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 001	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 004	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 001	Aug 19, 1992

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 003	
AT		25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 002	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 005	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 002	Aug 19, 1992

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 007	Jun 24, 1988

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018379 001	
AT		25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 003	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 006	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N020171 003	Aug 19, 1992

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018379 004	Jul 07, 1982

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018379 005	Jul 07, 1982

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018379 008	Jun 24, 1988

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018379 006	Jul 07, 1982

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N017512 001	

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N017512 003	

PRESCRIPTION DRUG PRODUCT LIST

3-58 (of 362)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SOLUTION; INTRAPERITONEAL

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 002

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 001 Dec 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 007 Jul 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 008 Jul 09, 1984

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 010 Nov 18, 1985

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 009 Jul 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 004

AT 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020163 001 Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 005

AT 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020163 002 Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 011 Nov 18, 1985

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 006

AT 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020163 003 Dec 04, 1992

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 007 Jan 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 005 Nov 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 009 Jan 29, 1986

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 002 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 003 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 004 Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ LUKARE MEDICAL LLC 0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML N020577 001 Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

+ B BRAUN 20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML N018258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML N018254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML N020000 001 Apr 17, 1992

AP BAXTER HLTHCARE 33MG/100ML; 5GM/100ML; 30MG/100ML; N016695 001

PRESCRIPTION DRUG PRODUCT LIST

3-59 (of 362)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER**860MG/100ML**CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017608 001</u>	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019634 003</u>	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016679 001</u>	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985

AP		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985

AP	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988

AP		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 008</u>	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985

AP	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 004</u>	Oct 17, 1988

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	<u>10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML</u>	<u>N019634 001</u>	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 002</u>	Apr 05, 1985

		<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 003</u>	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 001</u>	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+	HOSPIRA	<u>16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML</u>	<u>N018895 001</u>	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

+	B BRAUN	<u>35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML</u>	<u>N019718 001</u>	Sep 29, 1989

SOLUTION; IRRIGATION

BALANCED SALT

AT	AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006

AT	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010

BSS

AT	+	ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	<u>36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML</u>	<u>N017438 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-60 (of 362)

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	A075323	001	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	N018608	001	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N020002	001	Apr 17, 1992
AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N016693	001	
AP	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N018251	001	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N018156	001	
AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N018495	001	Feb 19, 1982
AT	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	N017635	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N019632	001	Feb 29, 1988
AP	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N016682	001	
AP	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N017641	001	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+ B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N018681	001	Dec 27, 1982
AT	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N018494	001	Feb 19, 1982
AT	+	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N018921	001	Apr 03, 1984
AT	+	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N019933	001	Aug 29, 1989
AT	+ HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N019416	001	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N020521	001	Jul 01, 1998

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+		300MG	N204042	002	Mar 29, 2013

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	<u>4MG</u>	N020838	001	Jun 04, 1998
AB		<u>8MG</u>	N020838	002	Jun 04, 1998
AB		<u>16MG</u>	N020838	003	Jun 04, 1998
AB	+	<u>32MG</u>	N020838	004	Jun 04, 1998

CANDESARTAN CILEXETIL

AB	APOTEX INC	<u>4MG</u>	A202079	001	Jan 10, 2014
AB		<u>8MG</u>	A202079	002	Jan 10, 2014
AB		<u>16MG</u>	A202079	003	Jan 10, 2014
AB		<u>32MG</u>	A202079	004	Jan 10, 2014
AB	SANDOZ	<u>4MG</u>	A078702	001	May 03, 2013
AB		<u>8MG</u>	A078702	002	May 03, 2013
AB		<u>16MG</u>	A078702	003	May 03, 2013
AB		<u>32MG</u>	A078702	004	May 03, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-61 (of 362)

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	ASTRAZENECA	<u>16MG;12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>		<u>32MG;12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	<u>32MG;25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>16MG;12.5MG</u>	<u>A202884</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A202884</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;25MG</u>	<u>A202884</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>16MG;12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>		<u>32MG;25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>	MYLAN LABS	<u>16MG;12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649</u>	<u>002</u>	Sep 16, 2013

XELODA

<u>AB</u>	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>500MG</u>	<u>N020896</u>	<u>002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+ AKORN

EQ 1GM BASE/VIAL

N050095 001

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+ ACORDA

8%

N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPOTEN

<u>AB</u>	PAR PHARM	<u>12.5MG</u>	<u>N018343</u>	<u>005</u>	Jan 17, 1985
<u>AB</u>		<u>25MG</u>	<u>N018343</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>N018343</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018343</u>	<u>003</u>	

CAPTOPRIL

<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A074737</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>25MG</u>	<u>A074737</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>50MG</u>	<u>A074737</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A074737</u>	<u>004</u>	Oct 28, 1998
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074434</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	SANDOZ	<u>12.5MG</u>	<u>A074363</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>25MG</u>	<u>A074363</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>50MG</u>	<u>A074363</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>		<u>100MG</u>	<u>A074363</u>	<u>004</u>	Nov 09, 1995
<u>AB</u>	STASON	<u>12.5MG</u>	<u>A074677</u>	<u>004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677</u>	<u>002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677</u>	<u>001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677</u>	<u>003</u>	May 30, 1997
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386</u>	<u>001</u>	May 23, 1996
<u>AB</u>		<u>12.5MG</u>	<u>A074451</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386</u>	<u>002</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074451</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386</u>	<u>003</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074451</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386</u>	<u>004</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074451</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A074505</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505</u>	<u>002</u>	Feb 13, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-62 (of 362)

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>		<u>50MG</u>	<u>A074505</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

<u>AB</u>	APOTHECON	<u>25MG;15MG</u>	<u>N018709</u>	<u>001</u>	Oct 12, 1984

CAPOZIDE 25/25

<u>AB</u>	+ APOTHECON	<u>25MG;25MG</u>	<u>N018709</u>	<u>002</u>	Oct 12, 1984

CAPOZIDE 50/15

<u>AB</u>	+ APOTHECON	<u>50MG;15MG</u>	<u>N018709</u>	<u>004</u>	Oct 12, 1984

CAPOZIDE 50/25

<u>AB</u>	APOTHECON	<u>50MG;25MG</u>	<u>N018709</u>	<u>003</u>	Oct 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074896</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074896</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896</u>	<u>003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG;15MG</u>	<u>A074827</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827</u>	<u>003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON

0.01%

N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986</u>	<u>001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986</u>	<u>002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986</u>	<u>003</u>	Nov 25, 2011
<u>AB</u>	NOSTRUM	<u>100MG</u>	<u>A076697</u>	<u>001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697</u>	<u>002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697</u>	<u>003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106</u>	<u>001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106</u>	<u>002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106</u>	<u>003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592</u>	<u>003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712</u>	<u>003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712</u>	<u>002</u>	Sep 30, 1997
	EQUETRO				
	VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004
		200MG	N021710	002	Dec 10, 2004
	+	300MG	N021710	003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>	+				
<u>AB</u>	NOVARTIS	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987
	TERIL				
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005
	EPITOL				
<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-63 (of 362)

CARBAMAZEPINE

TABLET; ORAL

TEGRETOL

AB	+	NOVARTIS	200MG	<u>N016608</u>	<u>001</u>	
		CARBAMAZEPINE				
		TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
			300MG	A077272	003	Dec 07, 2005
			400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB		TARO PHARM INDS	100MG	<u>A075687</u>	<u>001</u>	Oct 24, 2000
AB		TORRENT PHARMS	100MG	<u>A075712</u>	<u>001</u>	Jul 05, 2001

EPITOL

AB		TEVA	100MG	<u>A073524</u>	<u>001</u>	Jul 29, 1992

TEGRETOL

AB	+	NOVARTIS	100MG	<u>N018281</u>	<u>001</u>	
		CARBAMAZEPINE				
	+	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		TARO	100MG	<u>A078115</u>	<u>001</u>	Mar 31, 2009
AB			200MG	<u>A078115</u>	<u>002</u>	Mar 31, 2009
AB			400MG	<u>A078115</u>	<u>003</u>	Mar 31, 2009

TEGRETOL-XR

AB		NOVARTIS	100MG	<u>N020234</u>	<u>001</u>	Mar 25, 1996
AB			200MG	<u>N020234</u>	<u>002</u>	Mar 25, 1996
AB	+		400MG	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

LODOSYN

+	ATON	25MG	<u>N017830</u>	<u>001</u>	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	25MG; 200MG; 100MG	<u>A079085</u>	<u>001</u>	May 10, 2012
AB			37.5MG; 200MG; 150MG	<u>A079085</u>	<u>002</u>	May 10, 2012
AB		WOCKHARDT LTD	12.5MG; 200MG; 50MG	<u>A090786</u>	<u>001</u>	Nov 20, 2012
AB			18.75MG; 200MG; 75MG	<u>A090833</u>	<u>001</u>	Nov 20, 2012
AB			25MG; 200MG; 100MG	<u>A090833</u>	<u>002</u>	Nov 20, 2012
AB			31.25MG; 200MG; 125MG	<u>A090833</u>	<u>003</u>	Nov 20, 2012
AB			37.5MG; 200MG; 150MG	<u>A090833</u>	<u>004</u>	Nov 20, 2012
AB			50MG; 200MG; 200MG	<u>A090833</u>	<u>005</u>	Nov 20, 2012

STALEVO 100

AB		ORION PHARMA	25MG; 200MG; 100MG	<u>N021485</u>	<u>002</u>	Jun 11, 2003

STALEVO 125

AB		ORION PHARMA	31.25MG; 200MG; 125MG	<u>N021485</u>	<u>006</u>	Aug 29, 2008

STALEVO 150

AB		ORION PHARMA	37.5MG; 200MG; 150MG	<u>N021485</u>	<u>003</u>	Jun 11, 2003

STALEVO 200

AB	+	ORION PHARMA	50MG; 200MG; 200MG	<u>N021485</u>	<u>004</u>	Aug 02, 2007

STALEVO 50

AB	+	ORION PHARMA	12.5MG; 200MG; 50MG	<u>N021485</u>	<u>001</u>	Jun 11, 2003

STALEVO 75

AB		ORION PHARMA	18.75MG; 200MG; 75MG	<u>N021485</u>	<u>005</u>	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	10MG; 100MG	<u>A074260</u>	<u>001</u>	Sep 03, 1993
AB			25MG; 100MG	<u>A074260</u>	<u>002</u>	Sep 03, 1993
AB			25MG; 250MG	<u>A074260</u>	<u>003</u>	Sep 03, 1993
AB		APOTEX INC	10MG; 100MG	<u>A077120</u>	<u>001</u>	Jun 02, 2008
AB			25MG; 100MG	<u>A077120</u>	<u>002</u>	Jun 02, 2008
AB			25MG; 250MG	<u>A077120</u>	<u>003</u>	Jun 02, 2008
AB		MYLAN	10MG; 100MG	<u>A090324</u>	<u>001</u>	Sep 28, 2009
AB			25MG; 100MG	<u>A090324</u>	<u>002</u>	Sep 28, 2009
AB			25MG; 250MG	<u>A090324</u>	<u>003</u>	Sep 28, 2009
AB		SUN PHARM INDS	10MG; 100MG	<u>A078536</u>	<u>001</u>	Oct 28, 2008
AB			25MG; 100MG	<u>A078536</u>	<u>002</u>	Oct 28, 2008
AB			25MG; 250MG	<u>A078536</u>	<u>003</u>	Oct 28, 2008
AB		TEVA	10MG; 100MG	<u>A073618</u>	<u>001</u>	Aug 28, 1992
AB			25MG; 100MG	<u>A073589</u>	<u>001</u>	Aug 28, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-64 (of 362)

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		<u>25MG; 250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992

SINEMET

<u>AB</u>	MERCK SHARP DOHME	<u>10MG; 100MG</u>	<u>N017555</u>	<u>001</u>	

<u>AB</u>		<u>25MG; 100MG</u>	<u>N017555</u>	<u>003</u>	

<u>AB</u>	+	<u>25MG; 250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG; 100MG</u>	<u>A202323</u>	<u>001</u>	Feb 08, 2013

<u>AB</u>		<u>50MG; 200MG</u>	<u>A202323</u>	<u>002</u>	Feb 08, 2013

<u>AB</u>	APOTEX	<u>25MG; 100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004

<u>AB</u>		<u>50MG; 200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004

<u>AB</u>	IMPAX LABS	<u>25MG; 100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004

<u>AB</u>		<u>50MG; 200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004

<u>AB</u>	MYLAN	<u>25MG; 100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000

<u>AB</u>		<u>50MG; 200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999

<u>AB</u>	SUN PHARM INDS	<u>25MG; 100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007

<u>AB</u>		<u>50MG; 200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG; 100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992

<u>AB</u>	+	<u>50MG; 200MG</u>	<u>N019856</u>	<u>001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	IMPAX LABS	<u>10MG; 100MG</u>	<u>A090631</u>	<u>001</u>	Jun 08, 2010

<u>AB</u>		<u>25MG; 100MG</u>	<u>A090631</u>	<u>002</u>	Jun 08, 2010

<u>AB</u>		<u>25MG; 250MG</u>	<u>A090631</u>	<u>003</u>	Jun 08, 2010

<u>AB</u>	MYLAN	<u>10MG; 100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008

<u>AB</u>		<u>25MG; 100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008

<u>AB</u>		<u>25MG; 250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008

<u>AB</u>	SUN PHARM INDS	<u>10MG; 100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009

<u>AB</u>		<u>25MG; 100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009

<u>AB</u>		<u>25MG; 250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009

PARCOPA

<u>AB</u>	UCB INC	<u>10MG; 100MG</u>	<u>A076699</u>	<u>001</u>	Aug 27, 2004

<u>AB</u>		<u>25MG; 100MG</u>	<u>A076699</u>	<u>002</u>	Aug 27, 2004

<u>AB</u>	+	<u>25MG; 250MG</u>	<u>A076699</u>	<u>003</u>	Aug 27, 2004

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA LLC	<u>4MG/5ML</u>	<u>A040814</u>	<u>001</u>	Feb 26, 2008

<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418</u>	<u>001</u>	May 04, 2010

<u>AA</u>	+	<u>MIKART</u>	<u>A040458</u>	<u>001</u>	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA LLC	<u>4MG</u>	<u>A040639</u>	<u>002</u>	May 30, 2008

<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417</u>	<u>001</u>	Aug 23, 2010

<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010

<u>AA</u>	LYNROSE LABS	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011

<u>AA</u>	+	<u>MIKART</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

<u>AP</u>	BEDFORD	<u>50MG/VIAL</u>	<u>A076099</u>	<u>001</u>	Oct 14, 2004

<u>AP</u>		<u>150MG/VIAL</u>	<u>A076099</u>	<u>002</u>	Oct 14, 2004

<u>AP</u>		<u>450MG/VIAL</u>	<u>A076099</u>	<u>003</u>	Oct 14, 2004

<u>AP</u>	CIPLA LTD	<u>50MG/VIAL</u>	<u>A077383</u>	<u>001</u>	Jan 27, 2006

<u>AP</u>		<u>150MG/VIAL</u>	<u>A077383</u>	<u>002</u>	Jan 27, 2006

<u>AP</u>		<u>450MG/VIAL</u>	<u>A077383</u>	<u>003</u>	Jan 27, 2006

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A076235</u>	<u>001</u>	Oct 14, 2004

<u>AP</u>		<u>150MG/VIAL</u>	<u>A076235</u>	<u>002</u>	Oct 14, 2004

<u>AP</u>		<u>450MG/VIAL</u>	<u>A076235</u>	<u>003</u>	Oct 14, 2004

<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/VIAL</u>	<u>A091510</u>	<u>001</u>	May 29, 2012

<u>AP</u>		<u>150MG/VIAL</u>	<u>A091510</u>	<u>002</u>	May 29, 2012

<u>AP</u>		<u>450MG/VIAL</u>	<u>A091510</u>	<u>003</u>	May 29, 2012

<u>AP</u>	SANDOZ	<u>50MG/VIAL</u>	<u>A076959</u>	<u>001</u>	Mar 18, 2005

<u>AP</u>		<u>150MG/VIAL</u>	<u>A076959</u>	<u>002</u>	Mar 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-65 (of 362)

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

<u>AP</u>		<u>450MG/VIAL</u>	<u>A076959</u>	<u>003</u>	Mar 18, 2005
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A076162</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	+	<u>150MG/VIAL</u>	<u>A076162</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/VIAL</u>	<u>A076162</u>	<u>003</u>	Oct 14, 2004

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/5ML (10MG/ML)</u>	<u>A078732</u>	<u>001</u>	Feb 06, 2012
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078732</u>	<u>002</u>	Feb 06, 2012
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078732</u>	<u>003</u>	Feb 06, 2012
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078732</u>	<u>004</u>	Feb 06, 2012
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	BEDFORD LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432</u>	<u>001</u>	Sep 29, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432</u>	<u>002</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432</u>	<u>003</u>	Sep 29, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077998</u>	<u>001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998</u>	<u>002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998</u>	<u>003</u>	Apr 24, 2007
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063</u>	<u>001</u>	Nov 09, 2011
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063</u>	<u>002</u>	Nov 09, 2011
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063</u>	<u>003</u>	Nov 09, 2011
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063</u>	<u>004</u>	Nov 09, 2011
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631</u>	<u>001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631</u>	<u>002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631</u>	<u>003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631</u>	<u>004</u>	Dec 02, 2008
<u>AP</u>	SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077096</u>	<u>001</u>	Jun 14, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077096</u>	<u>002</u>	Jun 14, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077096</u>	<u>003</u>	Jun 14, 2005
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077096</u>	<u>004</u>	Jun 03, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A077139</u>	<u>001</u>	Sep 21, 2005
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139</u>	<u>002</u>	Sep 21, 2005
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139</u>	<u>003</u>	Sep 21, 2005
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139</u>	<u>004</u>	Sep 21, 2005
	+	ONCO THERAPIES LTD	A091478	001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001	

PRESCRIPTION DRUG PRODUCT LIST

3-66 (of 362)

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS

60MG/VIAL

N202714 001 Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE

200MG

N022562 001 Mar 18, 2010

CARISOPRODOL

TABLET; ORAL

CARISOPRODOLAA ACCEL RX LABS350MGA040576 001 Jun 07, 2005AA AUROBINDO PHARMA350MGA040792 001 Aug 06, 2009AA MIRROR PHARMS350MGA040823 001 Oct 22, 2008AA MUTUAL PHARM350MGA089346 001 Oct 17, 1991AA SUN PHARM INDS LTD350MGA040755 001 Feb 27, 2007AA VINTAGE PHARMS350MGA040245 001 Sep 08, 1997AA WATSON LABS350MGA087499 001 Apr 20, 1982SOMAAA MEDA PHARMS350MGN011792 001

+

250MG

N011792 004 Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ ARBOR PHARMS LLC

7.7MG

N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ EMCURE PHARMS LTD

100MG/VIAL

N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDEAT ALCON1%A075476 001 Jan 03, 2000AT BAUSCH AND LOMB1%A075546 001 Jan 20, 2000OCUPRESSAT + NOVARTIS1%N019972 001 May 23, 1990CARVEDILOL

TABLET; ORAL

CARVEDILOLAB APOTEX INC3.125MGA078165 001 Sep 05, 2007AB6.25MGA078165 002 Sep 05, 2007AB12.5MGA078165 003 Sep 05, 2007AB25MGA078165 004 Sep 05, 2007AB AUROBINDO PHARMA3.125MGA078332 001 Sep 05, 2007AB6.25MGA078332 002 Sep 05, 2007AB12.5MGA078332 003 Sep 05, 2007AB25MGA078332 004 Sep 05, 2007AB BEXIMCO USA3.125MGA078384 001 Sep 05, 2007AB6.25MGA078384 002 Sep 05, 2007AB12.5MGA078384 003 Sep 05, 2007AB25MGA078384 004 Sep 05, 2007AB CARACO3.125MGA077346 004 Sep 05, 2007AB6.25MGA077346 001 Sep 05, 2007AB12.5MGA077346 002 Sep 05, 2007AB25MGA077346 003 Sep 05, 2007AB CIPLA LTD3.125MGA077474 001 Sep 05, 2007AB6.25MGA077474 002 Sep 05, 2007AB12.5MGA077474 003 Sep 05, 2007AB25MGA077474 004 Sep 05, 2007AB DR REDDYS LABS LTD3.125MGA076649 001 Sep 05, 2007AB6.25MGA076649 002 Sep 05, 2007AB12.5MGA076649 003 Sep 05, 2007AB25MGA076649 004 Sep 05, 2007AB GLENMARK GENERICS3.125MGA078251 001 Sep 05, 2007AB6.25MGA078251 002 Sep 05, 2007AB12.5MGA078251 003 Sep 05, 2007AB25MGA078251 004 Sep 05, 2007AB HIKMA3.125MGA077887 001 Sep 07, 2007AB6.25MGA077887 002 Sep 07, 2007AB12.5MGA077887 003 Sep 07, 2007AB25MGA077887 004 Sep 07, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-67 (of 362)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240</u>	<u>003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240</u>	<u>004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007
<u>COREG</u>					
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SB PHARMCO

10MG

N022012 001 Oct 20, 2006

20MG

N022012 002 Oct 20, 2006

+

40MG

N022012 003 Oct 20, 2006

80MG

N022012 004 Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+ MERCK

50MG/VIAL

N021227 001 Jan 26, 2001

+

70MG/VIAL

N021227 002 Jan 26, 2001

CEFACIOR

CAPSULE; ORAL

CEFACIOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACIOR

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	<u>A065412</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065412</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 375MG BASE/5ML</u>	<u>A065412</u>	<u>004</u>	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACIOR

TEVA

EQ 375MG BASE

A065058 001 Sep 04, 2002

+

EQ 500MG BASE

A065058 002 Sep 04, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-68 (of 362)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A062291</u>	<u>001</u>	
<u>AB</u>	+ TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065349</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE/5ML</u>	<u>A065115</u>	<u>002</u>	Mar 26, 2003
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065115</u>	<u>003</u>	Mar 26, 2003
		EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003

TABLET; ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
	+ TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065303</u>	<u>002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065303</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065047</u>	<u>002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143</u>	<u>001</u>	Oct 18, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065047</u>	<u>001</u>	Sep 18, 2001
<u>AP</u>	+ HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065226</u>	<u>002</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065244</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065247</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065226</u>	<u>001</u>	Apr 21, 2005
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062831</u>	<u>002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062831</u>	<u>001</u>	Dec 09, 1988
<u>AP</u>	STERI PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A063207</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063208</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A063209</u>	<u>002</u>	Apr 30, 1999
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063214</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063216</u>	<u>001</u>	Dec 27, 1991

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A061773</u>	<u>003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773</u>	<u>004</u>	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A061773</u>	<u>002</u>	

ANCEF IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
+	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+ B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
	EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012

CEFAZOLIN SODIUM

+ SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
+	EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	+ SANDOZ	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-69 (of 362)

CEFDINIR

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

+

200MG

400MG

N021222 001 Aug 29, 2001

N021222 002 Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065369</u>	<u>002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268</u>	<u>001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369</u>	<u>003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268</u>	<u>002</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065369</u>	<u>001</u>	Jun 18, 2007
<u>MAXIPIME</u>					
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

EQ 1GM BASE/VIAL

N050821 001 May 06, 2010

EQ 2GM BASE/VIAL

N050821 002 May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 1GM BASE/50ML (EQ 20MG BASE/ML)

N050817 001 Aug 05, 2008

+

EQ 2GM BASE/100ML (EQ 20MG BASE/ML)

N050817 002 Aug 05, 2008

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

SUPRAX

+ LUPIN LTD

500MG/5ML

N202091 001 Feb 20, 2013

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004

200MG/5ML

A065355 001 Apr 10, 2007

TABLET; ORAL

SUPRAX

+ LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

+

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

<u>AP</u>	HIKMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065072</u>	<u>002</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065072</u>	<u>003</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065071</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065072</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065197</u>	<u>001</u>	Aug 29, 2006

CEFOTAXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065290</u>	<u>002</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065293</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065290</u>	<u>003</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065293</u>	<u>002</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065292</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065290</u>	<u>001</u>	Aug 11, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-70 (of 362)

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	LUPIN	<u>EQ 1GM BASE/VIAL</u>	<u>A065124</u>	<u>002</u>	Sep 24, 2003
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A065124</u>	<u>003</u>	Sep 24, 2003
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A065124</u>	<u>001</u>	Sep 24, 2003
AP	WOCKHARDT	<u>EQ 2GM BASE/VIAL</u>	<u>A065197</u>	<u>003</u>	Jun 20, 2008
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A065197</u>	<u>002</u>	Jun 20, 2008

CLAFORAN

AP	+	SANOFI AVENTIS US	<u>EQ 1GM BASE/VIAL</u>	<u>A062659</u>	<u>001</u>	Jan 13, 1987
AP	+		<u>EQ 1GM BASE/VIAL</u>	<u>N050547</u>	<u>002</u>	
AP	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062659</u>	<u>002</u>	Jan 13, 1987
AP	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050547</u>	<u>003</u>	
AP	+		<u>EQ 10GM BASE/VIAL</u>	<u>N050547</u>	<u>004</u>	Dec 29, 1983
AP	+		<u>EQ 500MG BASE/VIAL</u>	<u>N050547</u>	<u>001</u>	
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+	SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	+		EQ 40MG BASE/ML	N050596	004	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

AP	+	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374</u>	<u>001</u>	Aug 09, 2007
AP	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065374</u>	<u>002</u>	Aug 09, 2007
AP	+		<u>EQ 10GM BASE/VIAL</u>	<u>A065375</u>	<u>001</u>	Aug 09, 2007
AP		WEST-WARD PHARM CORP	<u>EQ 1GM BASE/VIAL</u>	<u>A091031</u>	<u>001</u>	Oct 26, 2011
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A091031</u>	<u>002</u>	Oct 26, 2011
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A091030</u>	<u>001</u>	Oct 26, 2011
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER						
	+	B BRAUN	EQ 1GM BASE/VIAL	A065430	001	Aug 09, 2007
	+		EQ 2GM BASE/VIAL	A065430	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	+	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414</u>	<u>001</u>	Jun 12, 2009
AP	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065414</u>	<u>002</u>	Jun 12, 2009
AP	+		<u>EQ 10GM BASE/VIAL</u>	<u>A065415</u>	<u>001</u>	May 19, 2010
AP		ANTIBIOTICOS BRASIL	<u>EQ 1GM BASE/VIAL</u>	<u>A065467</u>	<u>001</u>	Aug 31, 2011
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A065467</u>	<u>002</u>	Aug 31, 2011
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A065464</u>	<u>001</u>	Aug 31, 2011
AP		HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238</u>	<u>001</u>	Mar 12, 2010
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A065238</u>	<u>002</u>	Mar 12, 2010
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A065239</u>	<u>001</u>	Mar 02, 2010
AP		HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
AP		HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313</u>	<u>001</u>	Jan 23, 2006
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A065313</u>	<u>002</u>	Jan 23, 2006
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A065312</u>	<u>001</u>	Feb 13, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP		B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214</u>	<u>001</u>	Mar 10, 2006
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A065214</u>	<u>002</u>	Mar 10, 2006
MEFOXIN IN PLASTIC CONTAINER						
	+	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	+		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB		AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
AB			<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007
AB		RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082</u>	<u>001</u>	May 31, 2002
AB			<u>EQ 100MG BASE/5ML</u>	<u>A065082</u>	<u>002</u>	May 31, 2002
AB		SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
AB	+		<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

AB		AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
AB			<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
AB		ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
AB			<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
AB		RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083</u>	<u>001</u>	Aug 20, 2003
AB			<u>EQ 200MG BASE</u>	<u>A065083</u>	<u>002</u>	Aug 20, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-71 (of 362)

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351</u>	<u>002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

CEREXA

+

400MG/VIAL

600MG/VIAL

N200327 001 Oct 29, 2010

N200327 002 Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>		<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008

FORTAZ

<u>AP</u>	+	COVIS PHARMA	<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+		<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986
<u>AP</u>		<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN

+

EQ 1GM BASE

EQ 2GM BASE

N050823 001 Jun 13, 2011

N050823 002 Jun 13, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-72 (of 362)

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+ COVIS PHARMA

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP AKORN INC

EQ 1GM BASE/VIAL

A065305 003 Jan 11, 2008

AP

EQ 2GM BASE/VIAL

A065305 004 Jan 11, 2008

AP

EQ 250MG BASE/VIAL

A065305 001 Jan 11, 2008

AP

EQ 500MG BASE/VIAL

A065305 002 Jan 11, 2008

AP BEDFORD

EQ 1GM BASE/VIAL

A065465 003 Aug 18, 2008

AP

EQ 2GM BASE/VIAL

A065465 004 Aug 18, 2008

AP

EQ 250MG BASE/VIAL

A065465 001 Aug 18, 2008

AP

EQ 500MG BASE/VIAL

A065465 002 Aug 18, 2008

AP FRESenius KABI USA

EQ 250MG BASE/VIAL

A065245 001 Feb 15, 2006

AP HIKMA FARMACEUTICA

EQ 1GM BASE/VIAL

A065342 003 Jan 10, 2008

AP

EQ 2GM BASE/VIAL

A065342 004 Jan 10, 2008

AP

EQ 250MG BASE/VIAL

A065342 001 Jan 10, 2008

AP

EQ 500MG BASE/VIAL

A065342 002 Jan 10, 2008

AP HOSPIRA INC

EQ 1GM BASE/VIAL

A065230 003 Aug 02, 2005

AP

EQ 2GM BASE/VIAL

A065230 004 Aug 02, 2005

AP

EQ 250MG BASE/VIAL

A065230 001 Aug 02, 2005

AP

EQ 500MG BASE/VIAL

A065230 002 Aug 02, 2005

AP LUPIN

EQ 1GM BASE/VIAL

A065125 003 Sep 30, 2003

AP

EQ 2GM BASE/VIAL

A065125 004 Sep 30, 2003

AP

EQ 250MG BASE/VIAL

A065125 001 Sep 30, 2003

AP

EQ 500MG BASE/VIAL

A065125 002 Sep 30, 2003

AP + SANDOZ

EQ 1GM BASE/VIAL

A065169 003 May 09, 2005

AP +

EQ 2GM BASE/VIAL

A065169 004 May 09, 2005

AP +

EQ 250MG BASE/VIAL

A065169 001 May 09, 2005

AP +

EQ 500MG BASE/VIAL

A065169 002 May 09, 2005

AP TEVA PHARMS USA

EQ 1GM BASE/VIAL

A065227 003 Mar 15, 2007

AP

EQ 2GM BASE/VIAL

A065227 004 Mar 15, 2007

AP

EQ 250MG BASE/VIAL

A065227 001 Mar 15, 2007

AP

EQ 500MG BASE/VIAL

A065227 002 Mar 15, 2007

AP WOCKHARDT

EQ 2GM BASE/VIAL

A065391 003 Apr 12, 2007

AP

EQ 250MG BASE/VIAL

A065391 001 Apr 12, 2007

AP

EQ 500MG BASE/VIAL

A065391 002 Apr 12, 2007

INJECTABLE; INJECTION

CEFTRIAXONE

AP ACS DOBFAR

EQ 1GM BASE/VIAL

A065329 002 Jul 24, 2008

AP

EQ 2GM BASE/VIAL

A065329 003 Jul 24, 2008

AP

EQ 10GM BASE/VIAL

A065328 001 Jul 24, 2008

AP

EQ 500MG BASE/VIAL

A065329 001 Jul 24, 2008

AP BEDFORD

EQ 10GM BASE/VIAL

A065475 001 Aug 18, 2008

AP HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005

AP

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012

AP

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005

AP

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012

AP

EQ 10GM BASE/VIAL

A065232 001 Aug 02, 2005

AP LUPIN

EQ 10GM BASE/VIAL

A065263 001 Sep 12, 2006

AP + SANDOZ

EQ 10GM BASE/VIAL

A065168 001 May 17, 2005

AP + SANDOZ INC

EQ 1GM BASE/VIAL

A065204 001 May 03, 2005

AP +

EQ 2GM BASE/VIAL

A065204 002 May 03, 2005

AP STERI PHARMA

EQ 10GM BASE/VIAL

A065269 001 Feb 28, 2007

AP STRIDES ARCOLAB LTD

EQ 10GM BASE/VIAL

A091068 001 Jan 07, 2013

AP WOCKHARDT

EQ 1GM BASE/VIAL

A065180 001 May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP + B BRAUN

EQ 1GM BASE/VIAL

N050796 001 Apr 20, 2005

AP +

EQ 2GM BASE/VIAL

N050796 002 Apr 20, 2005

ROCEPHIN

AP + HOFFMANN LA ROCHE

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-73 (of 362)

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A063239</u>	<u>002</u>	Aug 13, 1993
CEFTRIAXONE IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE/5ML</u>	<u>N050672</u>	<u>001</u>	Jun 30, 1994
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>N050672</u>	<u>002</u>	Apr 29, 1997
<u>CEFUROXIME AXETIL</u>					
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065323</u>	<u>001</u>	Feb 05, 2008
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065323</u>	<u>002</u>	Feb 05, 2008

TABLET; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605</u>	<u>001</u>	Dec 28, 1987
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N050605</u>	<u>002</u>	Dec 28, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050605</u>	<u>003</u>	Dec 28, 1987
<u>CEFUROXIME AXETIL</u>					
<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069</u>	<u>001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069</u>	<u>002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308</u>	<u>002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308</u>	<u>003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135</u>	<u>001</u>	Jul 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065135</u>	<u>002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359</u>	<u>002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359</u>	<u>003</u>	Feb 15, 2008
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE</u>	<u>A065118</u>	<u>001</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065118</u>	<u>002</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065118</u>	<u>003</u>	Apr 25, 2003
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065190</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065190</u>	<u>002</u>	Oct 18, 2004
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166</u>	<u>003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004
<u>AB</u>	STERI PHARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997

ZINACEF

<u>AB</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983

CEFUROXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483</u>	<u>001</u>	Oct 15, 2008

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	<u>B BRAUN</u>	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483</u>	<u>002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>	STERI PHARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997
<u>AP</u>	TEVA PHARMS	<u>EQ 7.5GM BASE/VIAL</u>	<u>A064191</u>	<u>001</u>	Apr 16, 1998

ZINACEF

<u>AP</u>	+	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

	+	COVIS PHARMA	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-74 (of 362)

CELECOXIB

CAPSULE;ORAL

CELEBREX

GD SEARLE

50MG

N020998 004 Dec 15, 2006

100MG

N020998 001 Dec 31, 1998

200MG

N020998 002 Dec 31, 1998

+

400MG

N020998 003 Aug 29, 2002

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXINAB ALKEM LABS LTDEQ 250MG BASEA090836 001 Dec 20, 2010ABEQ 500MG BASEA090836 002 Dec 20, 2010ABEQ 750MG BASEA090836 004 Mar 29, 2013AB AUROBINDO PHARMA LTDEQ 250MG BASEA065253 001 Nov 16, 2005ABEQ 500MG BASEA065253 002 Nov 16, 2005AB BELCHER PHARMSEQ 250MG BASEA062713 001 Jul 15, 1988ABEQ 500MG BASEA062713 002 Jul 15, 1988AB FACTA FARMAEQ 250MG BASEA062118 001ABEQ 500MG BASEA062118 002AB HIKMAEQ 250MG BASEA065215 001 Jan 24, 2006ABEQ 500MG BASEA065215 002 Jan 24, 2006AB LUPINEQ 250MG BASEA065229 001 Nov 25, 2005ABEQ 500MG BASEA065229 002 Nov 25, 2005AB ORCHID HLTHCAREEQ 250MG BASEA065248 001 Jun 28, 2005ABEQ 500MG BASEA065248 002 Jun 28, 2005AB RANBAXYEQ 250MG BASEA065007 001 Sep 16, 1999ABEQ 500MG BASEA065007 002 Sep 16, 1999AB STEVENS JEQ 250MG BASEA062870 001 Mar 17, 1988AB SUN PHARM INDS (IN)EQ 250MG BASEA062791 001 Jun 11, 1987ABEQ 500MG BASEA062791 002 Jun 11, 1987AB TEVAEQ 250MG BASEA062702 001 Feb 13, 1987ABEQ 500MG BASEA062702 002 Feb 13, 1987AB YUNG SHIN PHARMEQ 250MG BASEA065152 001 Feb 24, 2005ABEQ 500MG BASEA065152 002 Feb 24, 2005KEFLEXAB SHIONOGI INCEQ 250MG BASEN050405 002ABEQ 500MG BASEN050405 003AB +EQ 750MG BASEN050405 005 May 12, 2006

CEPHALEXIN

ALKEM LABS LTD

EQ 333MG BASE

A090836 003 Mar 29, 2013

FOR SUSPENSION;ORAL

CEPHALEXINAB FACTA FARMAEQ 125MG BASE/5MLA062117 002AB +EQ 250MG BASE/5MLA062117 003AB HIKMA PHARMSEQ 125MG BASE/5MLA065444 001 Aug 28, 2009ABEQ 250MG BASE/5MLA065444 002 Aug 28, 2009AB LUPINEQ 125MG BASE/5MLA065234 001 Aug 17, 2005ABEQ 250MG BASE/5MLA065234 002 Aug 17, 2005AB ORCHID HLTHCAREEQ 125MG BASE/5MLA065326 001 Jul 10, 2006ABEQ 250MG BASE/5MLA065326 002 Jul 10, 2006AB RANBAXYEQ 125MG BASE/5MLA065081 001 Jul 27, 2001ABEQ 250MG BASE/5MLA065081 002 Jul 27, 2001AB TEVAEQ 125MG BASE/5MLA062703 001 Feb 13, 1987ABEQ 250MG BASE/5MLA062703 002 Feb 13, 1987AB YUNG SHIN PHARMEQ 125MG BASE/5MLA065336 001 Jul 25, 2007ABEQ 250MG BASE/5MLA065336 002 Jul 25, 2007

TABLET;ORAL

CEPHALEXIN

TEVA

EQ 250MG BASE

A063023 001 Jan 12, 1989

+

EQ 500MG BASE

A063024 001 Jan 12, 1989

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDEAA AMNEAL PHARMS5MG/5MLA090766 001 Oct 07, 2009AA BIO PHARM INC5MG/5MLA078870 001 Apr 27, 2009AA BRECKENRIDGE PHARM5MG/5MLA078488 001 Oct 06, 2008AA CARACO5MG/5MLA090191 001 Nov 12, 2009AA PERRIGO R AND D5MG/5MLA078398 001 Jun 17, 2008AA SILARX5MG/5MLA078876 001 May 11, 2012AA TARO5MG/5MLA076601 001 Jun 20, 2008AA TEVA PHARMS5MG/5MLA077279 001 May 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-75 (of 362)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	VINTAGE	<u>5MG/5ML</u>	<u>A078496</u>	<u>001</u>	Sep 25, 2009
AA	WOCKHARDT	<u>5MG/5ML</u>	<u>A078757</u>	<u>001</u>	Aug 28, 2009
ZYRTEC					
AA	+ MCNEIL CONSUMER	<u>5MG/5ML</u>	<u>N020346</u>	<u>001</u>	Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

	+ EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

AB	APOTEX INC	<u>30MG</u>	<u>A091260</u>	<u>001</u>	Aug 25, 2011
CEVIMELINE HYDROCHLORIDE					
AB	ROXANE	<u>30MG</u>	<u>A091591</u>	<u>001</u>	Jul 08, 2013
EVOXAC					
AB	+ DAIICHI SANKYO	<u>30MG</u>	<u>N020989</u>	<u>002</u>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

	+ NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+ ASPEN GLOBAL INC	2MG	N010669	002	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	+ FRESenius KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	BARR	<u>5MG</u>	<u>A084768</u>	<u>001</u>	
AB		<u>10MG</u>	<u>A083116</u>	<u>001</u>	
AB		<u>25MG</u>	<u>A084769</u>	<u>001</u>	
AB	USL PHARMA	<u>10MG</u>	<u>A084623</u>	<u>001</u>	
AB	WATSON LABS	<u>5MG</u>	<u>A086383</u>	<u>001</u>	
AB		<u>10MG</u>	<u>A086294</u>	<u>001</u>	
AB		<u>25MG</u>	<u>A086382</u>	<u>001</u>	
LIBRIUM					
AB	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461</u>	<u>001</u>	
AB		<u>10MG</u>	<u>A085472</u>	<u>001</u>	
AB	+	<u>25MG</u>	<u>A085475</u>	<u>001</u>	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	<u>0.12%</u>	<u>A074356</u>	<u>001</u>	May 07, 1996
AT	LYNE	<u>0.12%</u>	<u>A074291</u>	<u>001</u>	Dec 28, 1995
AT	TEVA	<u>0.12%</u>	<u>A074522</u>	<u>001</u>	Dec 15, 1995
AT	WOCKHARDT	<u>0.12%</u>	<u>A075006</u>	<u>001</u>	Mar 03, 2004
AT	XTTRIUM	<u>0.12%</u>	<u>A077789</u>	<u>001</u>	Jun 18, 2009
PAROEX					
AT	SUNSTAR AMERICAS	<u>0.12%</u>	<u>A076434</u>	<u>001</u>	Nov 29, 2005
PERIDEX					
AT	+ 3M	<u>0.12%</u>	<u>N019028</u>	<u>001</u>	Aug 13, 1986
PERIOGARD					
AT	COLGATE	<u>0.12%</u>	<u>A073695</u>	<u>001</u>	Jan 14, 1994
TABLET; DENTAL					
PERIOCHIP					
	+ DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-76 (of 362)

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP	BEDFORD	2%	A040273 001	Sep 09, 1998
AP		3%	A040273 002	Sep 09, 1998
AP	HOSPIRA	2%	A087447 001	Apr 16, 1982
AP		3%	A087446 001	Apr 16, 1982

NESACAINE

AP	FRESENIUS KABI USA	2%	N009435 002	

NESACAINE-MPF

AP	+ FRESENIUS KABI USA	2%	N009435 006	May 02, 1996
AP	+ NESACAINE	3%	N009435 007	May 02, 1996
	+ FRESENIUS KABI USA	1%	N009435 001	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

AA	+ SANOFI AVENTIS US	EQ 300MG BASE	N006002 001	

CHLOROQUINE PHOSPHATE

AA	IMPAX LABS	EQ 150MG BASE	A080880 001	
AA		EQ 300MG BASE	A040516 001	Aug 29, 2003
AA	IPCA LABS LTD	EQ 150MG BASE	A090610 001	Dec 03, 2009
AA		EQ 300MG BASE	A090249 001	Dec 03, 2009
AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011
AA	+ WEST WARD	EQ 150MG BASE	A083082 001	
AA		EQ 300MG BASE	A083082 002	Sep 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

	+ SALIX PHARMS	250MG/5ML	N011870 001	

TABLET; ORAL

CHLOROTHIAZIDE

	+ MYLAN	250MG	A084388 001	
		500MG	A084217 001	

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090896 001	Oct 16, 2009
AP	LUITPOLD	EQ 500MG BASE/VIAL	A020561 001	Apr 22, 2013
AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011
	DIURIL			
AP	+ OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145 005	

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307 001	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

ZUTRIPRO

	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439 001	Jun 08, 2011

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

	HI TECH PHARMA CO	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007
		EQ 8MG MALEATE; EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	TRIS PHARMA INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091632 001	Oct 01, 2010

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012

TUSSIONEX PENNKINETIC

AB	+ UCB INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N019111 001	Dec 31, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-77 (of 362)

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ HIKMA MAPLE

25MG/ML

A083329 001

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP SANDOZ

10MG

A080439 001

BP

25MG

A080439 002

BP

50MG

A080439 003

BP +

100MG

A080439 004

BP

200MG

A080439 005

BP USL PHARMA

10MG

A083386 001

BP

25MG

A084112 001

BP

50MG

A084113 001

BP

100MG

A084114 001

BP

200MG

A084115 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDEAB MYLAN100MGA088549 002 Jun 01, 1984AB250MGA088549 001 Jun 01, 1984AB PLIVA100MGA088921 001 Apr 12, 1985AB250MGA088922 001 Apr 12, 1985DIABINESEAB PFIZER100MGN011641 003AB +250MGN011641 006CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

MYLAN

25MG

A086831 002

+

50MG

A086831 001

THALITONE

+ CITRON PHARMA LLC

15MG

N019574 001 Dec 20, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN

15MG; 0.1MG

A071325 003 Feb 09, 1987

15MG; 0.2MG

A071325 002 Feb 09, 1987

+

15MG; 0.3MG

A071325 001 Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONEAA BARR500MGA089895 001 May 04, 1988AA WATSON LABS500MGA040137 001 Aug 09, 1996AA500MGA081040 001 Aug 22, 1989AA500MGA089859 001 May 04, 1988PARAFON FORTE DSCAA + JANSSEN R AND D500MGN011529 002 Jun 15, 1987

CHLORZOXAZONE

MIKART

375MG

A040861 001 Jun 01, 2010

750MG

A040861 002 Jun 01, 2010

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINEAB PAR PHARMEQ 4GM RESIN/PACKETA077204 001 Aug 26, 2005ABEQ 4GM RESIN/SCOOPFULA077204 002 Aug 26, 2005AB + SANDOZEQ 4GM RESIN/PACKETA074557 001 Aug 15, 1996ABEQ 4GM RESIN/SCOOPFULA074557 002 Aug 15, 1996CHOLESTYRAMINE LIGHTAB PAR PHARMEQ 4GM RESIN/PACKETA077203 001 Aug 26, 2005ABEQ 4GM RESIN/SCOOPFULA077203 002 Aug 26, 2005AB + SANDOZEQ 4GM RESIN/PACKETA074558 001 Aug 15, 1996ABEQ 4GM RESIN/SCOOPFULA074558 002 Aug 15, 1996PREVALITEAB UPSHER SMITHEQ 4GM RESIN/PACKETA073263 001 Feb 22, 1996ABEQ 4GM RESIN/SCOOPFULA073263 002 Oct 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-78 (of 362)

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

+ MCPRF

4-33.1mCi/ML

N203155 001 Sep 12, 2012

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACIDAB ANCHEN PHARMSEQ 45MG FENOFIBRIC ACIDA201573 002 Jul 18, 2013ABEQ 135MG FENOFIBRIC ACIDA201573 001 Jul 18, 2013AB LUPIN LTDEQ 45MG FENOFIBRIC ACIDA200750 001 Dec 04, 2013ABEQ 135MG FENOFIBRIC ACIDA200750 002 Dec 04, 2013AB MYLAN PHARMS INCEQ 45MG FENOFIBRIC ACIDA200913 001 Mar 25, 2013ABEQ 135MG FENOFIBRIC ACIDA200913 002 Mar 25, 2013TRILIPIXAB ABBVIEEQ 45MG FENOFIBRIC ACIDN022224 001 Dec 15, 2008AB +EQ 135MG FENOFIBRIC ACIDN022224 002 Dec 15, 2008CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+ EMD SERONO

EQ 0.25MG /0.5ML

N021149 002 Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.004MG CHROMIUM/ML

N018961 001 Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

+

0.16MG/INH

N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+ TAKEDA GMBH

0.037MG/INH

N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+ TAKEDA GMBH

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROXAB FOUGERA PHARMS0.77%A076435 001 Dec 29, 2004AB G AND W LABS INC0.77%A078463 001 Dec 20, 2010AB GLENMARK PHARMS0.77%A090273 001 Nov 10, 2009AB PERRIGO0.77%A077364 001 Mar 03, 2006AB TARO0.77%A076790 001 Apr 12, 2005LOPROXAB + MEDIMETRIKS PHARMS0.77%N018748 001 Dec 30, 1982

GEL; TOPICAL

CICLOPIROXAB FOUGERA PHARMS0.77%A077896 001 Jun 10, 2008AB GLENMARK GENERICS0.77%A091595 001 Feb 29, 2012AB PADDOCK LLC0.77%A078266 001 Jan 07, 2009LOPROXAB + MEDICIS0.77%N020519 001 Jul 21, 1997

SHAMPOO; TOPICAL

CICLOPIROXAT FOUGERA PHARMS1%A090146 001 May 25, 2010AT PERRIGO1%A078594 001 Feb 16, 2010AT TARO1%A090269 001 Feb 23, 2011AT WATSON LABS INC1%A090490 001 Nov 24, 2009LOPROXAT + MEDICIS1%N021159 001 Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROXAT ACTAVIS MID ATLANTIC8%A078046 001 Sep 18, 2007AT CIPLA LTD8%A078124 001 Sep 18, 2007AT G AND W LABS8%A078233 001 Sep 18, 2007AT HI TECH PHARMA8%A078270 001 Sep 18, 2007AT PERRIGO NEW YORK8%A077623 001 Sep 18, 2007AT TARO PHARM INDS8%A078144 001 Sep 18, 2007AT TOLMAR8%A077687 001 Sep 18, 2007AT VERSAPHARM8%A078975 001 Feb 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-79 (of 362)

CICLOPIROX

SOLUTION; TOPICAL

PENLAC

<u>AT</u>	+	VALEANT BERMUDA	<u>8%</u>	<u>N021022</u>	<u>001</u>	Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROX

<u>AB</u>		FOUGERA PHARMS	<u>0.77%</u>	<u>A076422</u>	<u>001</u>	Aug 06, 2004
<u>AB</u>		PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>		TARO	<u>0.77%</u>	<u>A077092</u>	<u>001</u>	Aug 10, 2005

LOPROX

<u>AB</u>	+	MEDIMETRIKS PHARMS	<u>0.77%</u>	<u>N019824</u>	<u>001</u>	Dec 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 75MG BASE/ML</u>	<u>A202501</u>	<u>001</u>	Jul 26, 2012
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 75MG BASE/ML</u>	<u>A201276</u>	<u>001</u>	Jun 27, 2012

VISTIDE

<u>AP</u>	+	GILEAD SCIENCES INC	<u>EQ 75MG BASE/ML</u>	<u>N020638</u>	<u>001</u>	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

IMIPENEM AND CILASTATIN

<u>AP</u>		ACS DOBFAR	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A090577</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>			<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A090577</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>		HOSPIRA INC	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A090825</u>	<u>001</u>	Nov 16, 2011
<u>AP</u>			<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A090825</u>	<u>002</u>	Nov 16, 2011
<u>AP</u>			<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A091007</u>	<u>001</u>	Nov 16, 2011

PRIMAXIN

<u>AP</u>		MERCK	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A062756</u>	<u>001</u>	Jan 08, 1987
<u>AP</u>	+		<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>N050587</u>	<u>001</u>	Nov 26, 1985
<u>AP</u>			<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A062756</u>	<u>002</u>	Jan 08, 1987
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>N050587</u>	<u>002</u>	Nov 26, 1985
<u>AP</u>			<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>N050630</u>	<u>001</u>	Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>		APOTEX INC	<u>50MG</u>	<u>A077030</u>	<u>001</u>	Dec 10, 2004
<u>AB</u>			<u>100MG</u>	<u>A077030</u>	<u>002</u>	Dec 10, 2004
<u>AB</u>		BIOKEY	<u>50MG</u>	<u>A077722</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>			<u>100MG</u>	<u>A077831</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>			<u>100MG</u>	<u>A077708</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A077323</u>	<u>002</u>	Apr 20, 2006
<u>AB</u>			<u>100MG</u>	<u>A077323</u>	<u>001</u>	Apr 20, 2006
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A077019</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>			<u>100MG</u>	<u>A077019</u>	<u>002</u>	Nov 23, 2004
<u>AB</u>		PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898</u>	<u>001</u>	Oct 29, 2007
<u>AB</u>			<u>100MG</u>	<u>A077898</u>	<u>002</u>	Oct 29, 2007
<u>AB</u>		ROXANE	<u>50MG</u>	<u>A077024</u>	<u>001</u>	May 17, 2005
<u>AB</u>			<u>100MG</u>	<u>A077024</u>	<u>002</u>	May 17, 2005
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>			<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>		TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>			<u>100MG</u>	<u>A077027</u>	<u>002</u>	Nov 24, 2004

PLETAL

<u>AB</u>	+	OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u>	Jan 15, 1999
<u>AB</u>	+		<u>100MG</u>	<u>N020863</u>	<u>002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>		APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u>	Dec 18, 1998
<u>AB</u>			<u>300MG</u>	<u>A074890</u>	<u>002</u>	Dec 18, 1998
<u>AB</u>			<u>400MG</u>	<u>A074890</u>	<u>003</u>	Dec 18, 1998
<u>AB</u>			<u>800MG</u>	<u>A074890</u>	<u>004</u>	Dec 18, 1998
<u>AB</u>		DAVA PHARMS INC	<u>300MG</u>	<u>A074340</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>			<u>400MG</u>	<u>A074340</u>	<u>002</u>	Jun 23, 1995
<u>AB</u>			<u>800MG</u>	<u>A074339</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>200MG</u>	<u>A074424</u>	<u>001</u>	Jul 28, 1995
<u>AB</u>			<u>300MG</u>	<u>A074424</u>	<u>002</u>	Jul 28, 1995
<u>AB</u>			<u>400MG</u>	<u>A074424</u>	<u>003</u>	Jul 28, 1995
<u>AB</u>			<u>800MG</u>	<u>A074424</u>	<u>004</u>	Jul 28, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-80 (of 362)

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>200MG</u>	<u>A074568</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>		<u>300MG</u>	<u>A074568</u>	<u>002</u>	Feb 27, 1997
<u>AB</u>		<u>400MG</u>	<u>A074568</u>	<u>003</u>	Feb 27, 1997
<u>AB</u>		<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994

TAGAMET

<u>AB</u>	GLAXOSMITHKLINE	<u>200MG</u>	<u>N017920</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>N017920</u>	<u>003</u>	
<u>AB</u>		<u>400MG</u>	<u>N017920</u>	<u>004</u>	Dec 14, 1983
<u>AB</u>	+	<u>800MG</u>	<u>N017920</u>	<u>005</u>	Apr 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u>	Apr 25, 1996
	SOLUTION; ORAL				
	<u>CIMETIDINE HYDROCHLORIDE</u>				
<u>AA</u>	+	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>	TEVA	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u>	Sep 26, 1996
<u>AA</u>	WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

EQ 30MG BASE

N021688 001 Mar 08, 2004

EQ 60MG BASE

N021688 002 Mar 08, 2004

+

EQ 90MG BASE

N021688 003 Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

BAYER HLTHCARE

250MG/5ML

N020780 001 Sep 26, 1997

+

500MG/5ML

N020780 002 Sep 26, 1997

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+	BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990
		<u>CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+ ALCON PHARMS LTD

EQ 0.3% BASE

N020369 001 Mar 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	ALCON PHARMS LTD	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-81 (of 362)

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT	AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
AT	BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
AT	FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
AT	HITECH PHARMA	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005
AT	NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
AT	PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598</u>	<u>001</u>	Jan 16, 2008

SOLUTION/DROPS;OTIC

CETRAXAL

+ WRASER PHARMS

EQ 0.2% BASE

N021918 001 May 01, 2009

TABLET;ORAL

CIPRO

AB	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
AB		<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
AB	+	<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
AB		<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

AB	APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
AB	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
AB		<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
AB		<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
AB	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
AB	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
AB	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
AB	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
AB	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
AB		<u>EQ 250MG BASE</u>	<u>A075685</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A075685</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A075685</u>	<u>001</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
AB	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004
AB	TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
AB		<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
AB	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
AB	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
AB		<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
AB		<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
AB		<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+ ALCON PHARMS LTD

EQ 0.2% BASE;1%

N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166</u>	<u>002</u>	Nov 27, 2007
AB		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166</u>	<u>001</u>	Nov 27, 2007
AB	DR REDDYS LABS LTD	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701</u>	<u>001</u>	Mar 26, 2007
AB	+	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183</u>	<u>001</u>	Mar 22, 2007
AB	+	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183</u>	<u>002</u>	Mar 22, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-82 (of 362)

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

<u>AB</u>	WATSON LABS FLORIDA	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077417</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077809</u>	<u>001</u>	Nov 30, 2010

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

+	ALCON PHARMS LTD	0.3%;0.1%	N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159</u>	<u>001</u>	Feb 03, 2012

CISATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154</u>	<u>001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154</u>	<u>002</u>	Feb 03, 2012

NIMBEX

<u>AP</u>	+	ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551</u>	<u>001</u>	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

<u>AP</u>	+	ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551</u>	<u>003</u>	Dec 15, 1995
<u>AP</u>	+		<u>EQ 10MG BASE/ML</u>	<u>N020551</u>	<u>002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075036</u>	<u>001</u>	Nov 07, 2000	
<u>AP</u>	+	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735</u>	<u>001</u>	Jul 16, 1999
<u>AP</u>	HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057</u>	<u>004</u>	Nov 08, 1988	
<u>AP</u>	ONCO THERAPIES LTD	<u>1MG/ML</u>	<u>A091062</u>	<u>001</u>	Apr 18, 2012	
<u>AP</u>	PHARMACHEMIE	<u>1MG/ML</u>	<u>A074656</u>	<u>001</u>	May 16, 2000	

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007
		EQ 20MG BASE	A077668	002	Feb 28, 2007
+		EQ 40MG BASE	A077668	003	Feb 28, 2007

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812</u>	<u>001</u>	Aug 28, 2006	
<u>AA</u>	+	ROXANE	<u>EQ 10MG BASE/5ML</u>	<u>A077043</u>	<u>001</u>	Dec 13, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629</u>	<u>001</u>	Jun 15, 2006	

TABLET; ORAL

CELEXA

<u>AB</u>	FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822</u>	<u>001</u>	Apr 27, 2000
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020822</u>	<u>002</u>	Jul 17, 1998
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020822</u>	<u>003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289</u>	<u>003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077046</u>	<u>002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046</u>	<u>003</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	CARACO	<u>EQ 10MG BASE</u>	<u>A077032</u>	<u>001</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077032</u>	<u>002</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077032</u>	<u>003</u>	Nov 12, 2004
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A077044</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045</u>	<u>003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045</u>	<u>002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045</u>	<u>001</u>	Apr 29, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654</u>	<u>003</u>	Feb 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-83 (of 362)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	INVAGEN PHARMS	EQ 10MG BASE	A077534 001	Oct 03, 2006
AB		EQ 20MG BASE	A077534 002	Oct 03, 2006
AB		EQ 40MG BASE	A077534 003	Oct 03, 2006
AB	MYLAN	EQ 10MG BASE	A077039 001	Feb 03, 2005
AB		EQ 10MG BASE	A077042 001	Nov 05, 2004
AB		EQ 20MG BASE	A077039 002	Feb 03, 2005
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004
AB		EQ 40MG BASE	A077039 003	Feb 03, 2005
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004
AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037 001	Nov 05, 2004
AB		EQ 20MG BASE	A077037 002	Nov 05, 2004
AB		EQ 40MG BASE	A077037 003	Nov 05, 2004
AB	PLIVA	EQ 10MG BASE	A077232 001	Oct 31, 2005
AB		EQ 20MG BASE	A077232 002	Oct 31, 2005
AB		EQ 40MG BASE	A077232 003	Oct 31, 2005
AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004
AB		EQ 20MG BASE	A077048 002	Nov 16, 2004
AB		EQ 40MG BASE	A077048 003	Nov 16, 2004
AB	TORRENT PHARMS	EQ 10MG BASE	A078216 001	Mar 27, 2007
AB		EQ 20MG BASE	A078216 002	Mar 27, 2007
AB		EQ 40MG BASE	A078216 003	Mar 27, 2007
AB	WATSON LABS	EQ 10MG BASE	A077034 001	Jun 30, 2005
AB		EQ 20MG BASE	A077034 002	Jun 30, 2005
AB		EQ 40MG BASE	A077034 003	Jun 30, 2005

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML; 198MG/100ML; 3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP	BEDFORD	1MG/ML	A075405 001	Feb 28, 2000
AP	+ FRESENIUS KABI USA	1MG/ML	A076571 001	Apr 22, 2004
AP	ONCO THERAPIES LTD	1MG/ML	A200510 001	Oct 06, 2011

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

AB	ABBVIE	125MG/5ML	N050698 001	Dec 23, 1993
AB	+	250MG/5ML	N050698 002	Dec 23, 1993
	CLARITHROMYCIN			
AB	RANBAXY	125MG/5ML	A065382 001	Aug 30, 2007
AB		250MG/5ML	A065382 002	Aug 30, 2007
AB	SANDOZ	125MG/5ML	A065283 002	Sep 04, 2007
AB		250MG/5ML	A065283 003	Sep 04, 2007

TABLET; ORAL

BIAXIN

AB	+	250MG	N050662 001	Oct 31, 1991
AB	+	500MG	N050662 002	Oct 31, 1991

CLARITHROMYCIN

AB	ALLIED PHARMA INC	250MG	A202710 001	Jun 10, 2013
AB		500MG	A202710 002	Jun 10, 2013
AB	APOTEX CORP	250MG	A065384 001	Aug 20, 2007
AB		500MG	A065384 002	Aug 20, 2007
AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012
AB		500MG	A065489 002	Jul 25, 2012
AB	MYLAN	250MG	A065195 001	Mar 11, 2005
AB		500MG	A065195 002	Mar 11, 2005
AB	RANBAXY	250MG	A065174 001	Sep 24, 2004
AB		500MG	A065174 002	Sep 24, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-84 (of 362)

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>		<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+ ABBVIE	<u>500MG</u>	<u>N050775</u>	<u>001</u>	Mar 03, 2000

CLARITHROMYCIN

<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

	+ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
	+	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
	+	EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985

TIMENTIN IN PLASTIC CONTAINER

	+ GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	+ TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994
<u>AA</u>	WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

	+ MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+	50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
	+	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091225</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091225</u>	<u>003</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-85 (of 362)

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

AA	+	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644</u>	<u>001</u>	Apr 07, 1986

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	<u>EQ 75MG BASE/5ML</u>	<u>A202409</u>	<u>001</u>	Apr 30, 2013

AA		LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821</u>	<u>001</u>	Aug 28, 2012

AA		PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902</u>	<u>001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PERRIGO UK FINCO	<u>1%</u>	<u>A090785</u>	<u>001</u>	Mar 31, 2010

EVOCLIN

AT	+	DELCOR ASSET	<u>1%</u>	<u>N050801</u>	<u>001</u>	Oct 22, 2004

CREAM;VAGINAL

CLEOCIN

AB	+	PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004

CLINDESSE

	+	KV PHARM	<u>EQ 2% BASE</u>	<u>N050793</u>	<u>001</u>	Nov 30, 2004

GEL;TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000

CLINDAGEL

BT	+	PRECISION DERMAT	<u>EQ 1% BASE</u>	<u>N050782</u>	<u>001</u>	Nov 27, 2000

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987

AP	+		<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	<u>EQ 6MG BASE/ML</u>	<u>N050639</u>	<u>001</u>	Aug 30, 1989

AP	+		<u>EQ 12MG BASE/ML</u>	<u>N050639</u>	<u>002</u>	Aug 30, 1989

AP	+		<u>EQ 18MG BASE/ML</u>	<u>N050639</u>	<u>003</u>	Apr 10, 1991

CLINDAMYCIN PHOSPHATE

AP		BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206</u>	<u>001</u>	Sep 24, 2004

AP		FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346</u>	<u>001</u>	Mar 29, 2007

AP			<u>EQ 150MG BASE/ML</u>	<u>A065347</u>	<u>001</u>	May 09, 2007

AP		HIKMA MAPLE	<u>EQ 150MG BASE/ML</u>	<u>A062889</u>	<u>001</u>	Apr 25, 1988

AP		HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800</u>	<u>001</u>	Jul 24, 1987

AP			<u>EQ 150MG BASE/ML</u>	<u>A062801</u>	<u>001</u>	Jul 24, 1987

AP			<u>EQ 150MG BASE/ML</u>	<u>A062943</u>	<u>001</u>	Sep 29, 1988

AP		SAGENT STRIDES	<u>EQ 150MG BASE/ML</u>	<u>A090108</u>	<u>001</u>	Sep 30, 2011

AP			<u>EQ 150MG BASE/ML</u>	<u>A090109</u>	<u>001</u>	Sep 30, 2011

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048</u>	<u>001</u>	Apr 04, 2013

AP			<u>EQ 12MG BASE/ML</u>	<u>A203048</u>	<u>002</u>	Apr 04, 2013

AP			<u>EQ 18MG BASE/ML</u>	<u>A203048</u>	<u>003</u>	Apr 04, 2013

AP		SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692</u>	<u>001</u>	May 31, 2012

AP			<u>EQ 12MG BASE/ML</u>	<u>A201692</u>	<u>002</u>	May 31, 2012

AP			<u>EQ 18MG BASE/ML</u>	<u>A201692</u>	<u>003</u>	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

	+	ABRAXIS PHARM	<u>EQ 900MG BASE/100ML</u>	<u>N050635</u>	<u>001</u>	Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600</u>	<u>001</u>	May 31, 1989

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067</u>	<u>001</u>	Jan 31, 2002

SOLUTION;TOPICAL

CLEOCIN T

AT	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u>	<u>001</u>	

CLINDA-DERM

AT		PADDOCK LLC	<u>EQ 1% BASE</u>	<u>A063329</u>	<u>001</u>	Sep 30, 1992

CLINDAMYCIN PHOSPHATE

AT		FOUGERA	<u>EQ 1% BASE</u>	<u>A064159</u>	<u>001</u>	Jun 05, 1997

AT		FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065254</u>	<u>001</u>	Feb 14, 2006

AT		PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050</u>	<u>001</u>	Nov 30, 1995

AT		TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184</u>	<u>001</u>	Mar 31, 2004

AT		WOCKHARDT	<u>EQ 1% BASE</u>	<u>A063304</u>	<u>001</u>	Jul 15, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-86 (of 362)

CLINDAMYCIN PHOSPHATE

SUPPOSITORY; VAGINAL

CLEOCIN

+ PHARMACIA AND UPJOHN 100MG
SWAB; TOPICAL

N050767 001 Aug 13, 1999

CLEOCIN**AT** PHARMACIA AND UPJOHN **EQ 1% BASE****N050537 002** Feb 22, 1994CLINDAMYCIN PHOSPHATE**AT** PERRIGO NEW YORK **EQ 1% BASE****A065049 001** May 25, 2000**AT** VERSAPHARM **EQ 1% BASE****A065513 001** Jun 17, 2010CLINDETS**AT** PERRIGO **EQ 1% BASE****A064136 001** Sep 30, 1996CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX + STIEFEL GSK 1.2%; 0.025%

N050803 001 Jul 16, 2010

ZIANA

BX + MEDICIS 1.2%; 0.025%

N050802 001 Nov 07, 2006

CLOBAZAM

SUSPENSION; ORAL

ONFI

+ LUNDBECK LLC 2.5MG/ML

N203993 001 Dec 14, 2012

TABLET; ORAL

ONFI

+ LUNDBECK LLC 10MG

N202067 002 Oct 21, 2011

+ 20MG

N202067 003 Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE**AB1** PERRIGO ISRAEL **0.05%****A077763 001** Mar 10, 2008OLUX**AB1** + STIEFEL LABS INC **0.05%****N021142 001** May 26, 2000CLOBETASOL PROPIONATE**AB2** PERRIGO ISRAEL **0.05%****A201402 001** Aug 14, 2012OLUX E**AB2** + DELCOR ASSET **0.05%****N022013 001** Jan 12, 2007

CREAM; TOPICAL

CLOBETASOL PROPIONATE**AB1** FOUGERA **0.05%****A074392 001** Sep 30, 1996**AB1** TARO **0.05%****A074249 001** Jul 08, 1996CORMAX**AB1** HI TECH PHARMA **0.05%****A074220 001** May 16, 1997TEMOVATE**AB1** + FOUGERA PHARMS **0.05%****N019322 001** Dec 27, 1985CLOBETASOL PROPIONATE (EMOLLIENT)**AB2** FOUGERA PHARMS **0.05%****A075430 001** May 26, 1999**AB2** TARO **0.05%****A075633 001** May 17, 2000EMBELINE E**AB2** HI TECH PHARMA **0.05%****A075325 001** Dec 24, 1998TEMOVATE E**AB2** + FOUGERA PHARMS **0.05%****N020340 001** Jun 17, 1994

GEL; TOPICAL

CLOBETASOL PROPIONATE**AB** FOUGERA PHARMS **0.05%****A075368 001** Feb 15, 2000**AB** PERRIGO **0.05%****A075027 001** Oct 31, 1997**AB** TARO **0.05%****A075279 001** May 28, 1999EMBELINE**AB** HI TECH PHARMA **0.05%****A076141 001** Apr 12, 2002TEMOVATE**AB** + FOUGERA PHARMS **0.05%****N020337 001** Apr 29, 1994

LOTION; TOPICAL

CLOBETASOL PROPIONATE**AB** ACTAVIS MID ATLANTIC **0.05%****A078223 001** Dec 04, 2008**AB** TARO **0.05%****A200302 001** Jul 02, 2012CLOBEX**AB** + GALDERMA LABS LP **0.05%****N021535 001** Jul 24, 2003

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE**AB** FOUGERA PHARMS **0.05%****A074407 001** Feb 23, 1996**AB** TARO **0.05%****A074248 001** Jul 12, 1996**AB** TEVA PHARMS **0.05%****A074089 001** Feb 16, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-87 (of 362)

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

EMBELINE

AB	HI TECH PHARMA	0.05%	A074221 001	Mar 31, 1995

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	A078854 001	Jun 07, 2011

AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012

CLOBEX

AB	+ GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999

AT	TARO	0.05%	A075224 001	Nov 16, 1998

AT		0.05%	A075363 001	Dec 29, 2000

AT	TOLMAR	0.05%	A076977 001	Aug 05, 2005

AT	WOCKHARDT	0.05%	A075205 001	Nov 13, 1998

EMBELINE

AT	+ HI TECH PHARMA	0.05%	A074222 001	Dec 06, 1995

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT	PADDOCK LLC	0.05%	A090898 001	Jun 16, 2011

CLOBEX

AT	+ GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

	+ PROMIUS PHARMA LLC	0.1%	N017765 001	

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

	+ GENZYME	20MG/20ML (1MG/ML)	N021673 001	Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

	+ NOVARTIS	50MG	N019500 002	Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

AB	+ SANOFI AVENTIS US	50MG	N016131 002	

CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	A075528 001	Aug 30, 1999

SEROPHENE

AB	EMD SERONO	50MG	N018361 001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	MALLINCKRODT LLC	25MG	N019906 001	Dec 29, 1989

AB	+	50MG	N019906 002	Dec 29, 1989

AB		75MG	N019906 003	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB	MYLAN	25MG	A074947 001	Apr 30, 1998

AB		50MG	A074947 002	Apr 30, 1998

AB		75MG	A074947 003	Apr 30, 1998

AB	SANDOZ	25MG	A074364 001	Mar 29, 1996

AB		50MG	A074364 002	Mar 29, 1996

AB		75MG	A074364 003	Mar 29, 1996

AB	TARO	25MG	A074694 001	Dec 31, 1996

AB		50MG	A074694 002	Dec 31, 1996

AB		75MG	A074694 003	Dec 31, 1996

AB	TEVA	25MG	A074958 001	Aug 26, 1997

AB		50MG	A074958 002	Aug 26, 1997

AB		75MG	A074958 003	Aug 26, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-88 (of 362)

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	CARACO	<u>0.5MG</u>	<u>A075423</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423</u>	<u>003</u>	Apr 27, 2001
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150</u>	<u>001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150</u>	<u>002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150</u>	<u>003</u>	Oct 05, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A074940</u>	<u>001</u>	Oct 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074940</u>	<u>002</u>	Oct 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074940</u>	<u>003</u>	Oct 30, 1997
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090</u>	<u>003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166</u>	<u>002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166</u>	<u>003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167</u>	<u>001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167</u>	<u>002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673</u>	<u>001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673</u>	<u>002</u>	Jul 08, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-89 (of 362)

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300</u>	<u>002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>A091104</u>	<u>001</u>	Oct 08, 2009
<u>AP</u>		<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>A091104</u>	<u>002</u>	Oct 08, 2009

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368</u>	<u>001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368</u>	<u>002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368</u>	<u>003</u>	Dec 06, 2011
<u>AB</u>	CARLSBAD	<u>0.1MG</u>	<u>A202297</u>	<u>001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297</u>	<u>002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297</u>	<u>003</u>	Jun 13, 2013
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
<u>AB</u>	WATSON LABS	<u>0.3MG</u>	<u>A070963</u>	<u>001</u>	Jul 08, 1986

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984</u>	<u>001</u>	Sep 30, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202984</u>	<u>002</u>	Sep 30, 2013

KAPVAY

<u>AB</u>	+	CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331</u>	<u>003</u>	Sep 28, 2010
<u>AB</u>			<u>0.2MG</u>	<u>N022331</u>	<u>004</u>	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202925</u>	<u>002</u>	Mar 27, 2013
<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 75MG BASE</u>	<u>A090307</u>	<u>001</u>	May 28, 2013
<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274</u>	<u>001</u>	May 17, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540</u>	<u>001</u>	May 17, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273</u>	<u>001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023</u>	<u>001</u>	May 17, 2012
<u>AB</u>	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216</u>	<u>001</u>	May 17, 2012
<u>AB</u>	MUTUAL PHARM	<u>EQ 75MG BASE</u>	<u>A078133</u>	<u>001</u>	Jun 10, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077665</u>	<u>002</u>	May 17, 2012
<u>AB</u>	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004</u>	<u>001</u>	May 17, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844</u>	<u>001</u>	May 17, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266</u>	<u>001</u>	Aug 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202266</u>	<u>002</u>	Nov 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-90 (of 362)

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686 001	Oct 10, 2012

PLAVIX

AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	MYLAN	3.75MG	A071858 002	Jul 17, 1987
AB		7.5MG	A071858 003	Jul 17, 1987
AB		15MG	A071858 001	Jul 17, 1987
AB	RANBAXY	3.75MG	A076911 001	Sep 29, 2004
AB		7.5MG	A076911 002	Sep 29, 2004
AB		15MG	A076911 003	Sep 29, 2004
AB	TARO	3.75MG	A075731 003	Apr 27, 2000
AB		7.5MG	A075731 002	Apr 27, 2000
AB		15MG	A075731 001	Apr 27, 2000
AB	WATSON LABS	3.75MG	A071852 001	Feb 09, 1988
AB		7.5MG	A071853 001	Feb 09, 1988
AB		15MG	A071854 001	Feb 09, 1988

GEN-XENE

AB	ALRA	3.75MG	A071787 001	Apr 26, 1988
AB		7.5MG	A071788 001	Apr 26, 1988
AB		15MG	A071789 001	Apr 26, 1988

TRANXENE

AB	RECORDATI RARE	3.75MG	N017105 006	
AB		7.5MG	N017105 007	
AB	+	15MG	N017105 008	

CLOTTRIMAZOLE

CREAM;TOPICAL

CLOTTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008
AB	GLENMARK PHARMS	1%	A090219 001	Aug 03, 2010
AB	+	1%	A072640 001	Aug 31, 1993

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT	+	TARO	1%	A074580 001	Jul 29, 1996
AT		TEVA	1%	A073306 001	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTTRIMAZOLE

AB	PADDOCK LLC	10MG	A076763 001	Oct 28, 2005	
AB	+	ROXANE	10MG	A076387 001	Jul 29, 2004

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

+	JAZZ PHARMS III	50MG/ML	N203479 001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB	CARACO	25MG	A075713 001	Nov 15, 2002
AB		50MG	A075713 003	Aug 19, 2005
AB		100MG	A075713 002	Nov 15, 2002
AB	IVAX SUB TEVA PHARMS	25MG	A074949 001	Nov 26, 1997
AB		50MG	A074949 004	Apr 25, 2005
AB		50MG	A076809 003	Dec 16, 2005
AB		100MG	A074949 002	Nov 26, 1997
AB		100MG	A076809 002	Dec 16, 2005
AB	MYLAN	25MG	A075417 001	May 27, 1999
AB		100MG	A075417 002	May 27, 1999

CLOZARIL

AB	NOVARTIS	25MG	N019758 001	Sep 26, 1989
AB	+	100MG	N019758 002	Sep 26, 1989

CLOZAPINE

IVAX SUB TEVA PHARMS	12.5MG	A074949 003	Jul 31, 2003
	200MG	A076809 001	Dec 16, 2005

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007
	25MG	N021590 001	Feb 10, 2004
+	100MG	N021590 002	Feb 10, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-91 (of 362)

CLOZAPINETABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO ODT150MG
200MGN021590 005 Jul 09, 2010
N021590 006 Jul 09, 2010COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
STRIBILD

+ GILEAD SCIENCES INC 150MG; 150MG; 200MG; 300MG

N203100 001 Aug 27, 2012

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** VINTAGE 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040660 001** Dec 07, 2006PROMETH VC W/ CODEINE**AA** + ACTAVIS MID ATLANTIC 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A088764 001** Oct 31, 1984CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE**AA** + ACTAVIS MID ATLANTIC 10MG/5ML; 6.25MG/5ML **A088763 001** Oct 31, 1984**AA** AMNEAL PHARMS 10MG/5ML; 6.25MG/5ML **A200894 001** Apr 24, 2013**AA** CARACO 10MG/5ML; 6.25MG/5ML **A090180 001** Mar 17, 2010**AA** HI TECH PHARMA 10MG/5ML; 6.25MG/5ML **A040151 001** Aug 26, 1997**AA** TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML **A200386 001** Jun 29, 2012**AA** WOCKHARDT 10MG/5ML; 6.25MG/5ML **A088875 001** Dec 17, 1984PROMETHAZINE WITH CODEINE**AA** VINTAGE 10MG/5ML; 6.25MG/5ML **A040650 001** Jan 31, 2006CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC 10MG/5ML; 30MG/5ML; 1.25MG/5ML

A088704 001 Mar 22, 1985

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+ ROXANE 30MG/5ML

N202245 001 Jun 30, 2011

TABLET; ORAL

CODEINE SULFATE

ROXANE 15MG

N022402 001 Jul 16, 2009

30MG

N022402 002 Jul 16, 2009

+ 60MG

N022402 003 Jul 16, 2009

COLCHICINE

TABLET; ORAL

COLCRYS

+ TAKEDA PHARMS USA 0.6MG

N022352 001 Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID**AB** + WATSON LABS 0.5MG; 500MG **A084279 001**PROBENECID AND COLCHICINE**AB** MIRROR PHARMS 0.5MG; 500MG **A040618 001** May 13, 2008COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

DAIICHI SANKYO 1.875GM/PACKET

N022362 001 Oct 02, 2009

+ 3.75GM/PACKET

N022362 002 Oct 02, 2009

TABLET; ORAL

WELCHOL

+ DAIICHI SANKYO 625MG

N021176 001 May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID**AB** PHARMACIA AND UPJOHN 5GM/SCOOPFUL **N017563 003** Sep 22, 1995**AB** + 5GM/PACKET **N017563 004** Sep 22, 1995COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS 5GM/SCOOPFUL **A077277 001** May 02, 2006**AB** 5GM/PACKET **A077277 002** May 02, 2006

FLAVORED COLESTID

PHARMACIA AND UPJOHN

5GM/PACKET
5GM/SCOOPFULN017563 001
N017563 002

PRESCRIPTION DRUG PRODUCT LIST

3-92 (of 362)

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

AB	+	PHARMACIA AND UPJOHN	1GM	N020222	001	Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	1GM	A077510	001	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP		EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012

AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A065364	001	Apr 17, 2008

AP		PADDOCK LLC	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004

AP		X GEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999

COLY-MYCIN M

AP	+	JHP PHARMS	EQ 150MG BASE/VIAL	N050108	002	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	JHP PHARMS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+	ASTELLAS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680	001	Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

+	FERRING	EQ 0.1MG BASE/VIAL	N020162	001	May 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+	QUESTCOR PHARMS	80 UNITS/ML	N008372	008	

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+	WEST WARD	25MG	A080776	002	

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001	

COSYNTROPIN

AP		MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009

AP		SANDOZ	0.25MG/VIAL	A202147	001	Jun 29, 2012

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008

CRIZOTINIB

CAPSULE; ORAL

XALKORI

PF PRISM CV	200MG	N202570	001	Aug 26, 2011

+		250MG	N202570	002	Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+	SALIX PHARMS	125MG	N202292	001	Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA		MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013

AA		PACK PHARMS LLC	100MG/5ML	A202583	001	Oct 27, 2011

GASTROCROM

AA	+	MEDA PHARMS	100MG/5ML	N020479	001	Feb 29, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-93 (of 362)

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

<u>AN</u>	BAUSCH AND LOMB	<u>10MG/ML</u>	<u>A075585</u>	<u>001</u>	Dec 21, 2000
<u>AN</u>	DEY	<u>10MG/ML</u>	<u>A074209</u>	<u>001</u>	Apr 26, 1994
<u>AN</u>	+ TEVA PHARMS	<u>10MG/ML</u>	<u>A075271</u>	<u>001</u>	Jan 18, 2000
<u>AN</u>	WATSON LABS	<u>10MG/ML</u>	<u>A076469</u>	<u>001</u>	Jun 17, 2005
<u>AN</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A075346</u>	<u>001</u>	Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROLOM

<u>AT</u>	BAUSCH AND LOMB	<u>4%</u>	<u>A074443</u>	<u>001</u>	Jan 30, 1995

CROMOLYN SODIUM

<u>AT</u>	AKORN	<u>4%</u>	<u>A074706</u>	<u>001</u>	Apr 29, 1998
<u>AT</u>	ALCON	<u>4%</u>	<u>A075282</u>	<u>001</u>	Jun 16, 1999

OPTICROM

<u>AT</u>	+ ALLERGAN	<u>4%</u>	<u>N018155</u>	<u>001</u>	Oct 03, 1984

CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY

10%

N006927 001

LOTION; TOPICAL

CROTAN

<u>AT</u>	SUMMERS	<u>10%</u>	<u>A087204</u>	<u>001</u>	

EURAX

<u>AT</u>	+ RANBAXY	<u>10%</u>	<u>N009112</u>	<u>003</u>	

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

<u>AP</u>	+ LUITPOLD	<u>1MG/ML</u>	<u>A080737</u>	<u>001</u>	

VIBISONE

<u>AP</u>	+ FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A080557</u>	<u>003</u>	

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM

0.5MG/SPRAY

N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

<u>AB</u>	IVAX INTL	<u>15MG</u>	<u>N021777</u>	<u>001</u>	Feb 01, 2007

<u>AB</u>	+	<u>30MG</u>	<u>N021777</u>	<u>002</u>	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A090738</u>	<u>001</u>	Apr 18, 2011

<u>AB</u>		<u>30MG</u>	<u>A090738</u>	<u>002</u>	Apr 18, 2011

<u>AB</u>	TWI PHARMS INC	<u>15MG</u>	<u>A091281</u>	<u>001</u>	Jan 31, 2013

<u>AB</u>		<u>30MG</u>	<u>A091281</u>	<u>002</u>	Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26, 2008

<u>AB</u>		<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26, 2008

<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A090478</u>	<u>001</u>	Jul 23, 2010

<u>AB</u>		<u>10MG</u>	<u>A090478</u>	<u>002</u>	Jul 23, 2010

<u>AB</u>	JUBILANT CADISTA	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19, 2006

<u>AB</u>		<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19, 2006

<u>AB</u>	KVK TECH	<u>5MG</u>	<u>A078048</u>	<u>001</u>	Feb 28, 2011

<u>AB</u>		<u>10MG</u>	<u>A078048</u>	<u>002</u>	Feb 28, 2011

<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06, 2006

<u>AB</u>		<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23, 1995

<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A073144</u>	<u>002</u>	Feb 03, 2006

<u>AB</u>		<u>7.5MG</u>	<u>A073144</u>	<u>003</u>	Mar 25, 2013

<u>AB</u>	+	<u>10MG</u>	<u>A073144</u>	<u>001</u>	May 30, 1991

<u>AB</u>	ORIT LABS LLC	<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18, 2008

<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421</u>	<u>001</u>	Sep 29, 1995

<u>AB</u>	PROSAM LABS	<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04, 2005

<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12, 2008

<u>AB</u>		<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12, 2008

<u>AB</u>		<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12, 2008

<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-94 (of 362)

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		10MG	A077797	002	Feb 28, 2007
AB	WATSON LABS	5MG	A071611	002	Feb 03, 2006
AB		7.5MG	A071611	003	Feb 03, 2006
AB		10MG	A071611	001	May 03, 1989

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT	AKORN	1%	A040164	001	Jan 13, 1997

CYCLOGYL

AT	+	ALCON	1%	A084110	001

PENTOLAIR

AT	BAUSCH AND LOMB	1%	A040075	001	Apr 29, 1994

CYCLOGYL

+	ALCON	0.5%	A084109	001

+	ALCON LABS INC	2%	A084108	001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

+	ALCON	0.2%; 1%	A084300	001

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

	ROXANE	25MG	N203856	001	Sep 16, 2013

+		50MG	N203856	002	Sep 16, 2013

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	+	BAXTER HLTHCARE	1GM/VIAL	A040745	002	May 21, 2008

AP	+		2GM/VIAL	A040745	003	May 21, 2008

AP	+		500MG/VIAL	A040745	001	May 21, 2008

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	1GM/VIAL	N012142	004	Aug 30, 1982

AP	+		2GM/VIAL	N012142	005	Aug 30, 1982

AP	+		500MG/VIAL	N012142	003	

TABLET; ORAL

CYCLOPHOSPHAMIDE

	ROXANE	25MG	A040032	001	Aug 17, 1999

+		50MG	A040032	002	Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+	PURDUE GMP	250MG	A060593	001

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	IVAX SUB TEVA PHARMS	25MG	A065110	003	Mar 29, 2005

AB1		50MG	A065110	001	Mar 29, 2005

AB1		100MG	A065110	002	Mar 29, 2005

AB1	SANDOZ	25MG	A065017	002	Jan 13, 2000

AB1		100MG	A065017	001	Jan 13, 2000

AB1	WATSON LABS INC	25MG	A065044	002	Dec 20, 2000

AB1		100MG	A065044	001	Dec 20, 2000

GENGRAF

AB1	ABBVIE	25MG	A065003	001	May 12, 2000

AB1		50MG	A065003	002	May 12, 2000

AB1		100MG	A065003	003	May 12, 2000

NEORAL

AB1	NOVARTIS	25MG	N050715	001	Jul 14, 1995

AB1	+	100MG	N050715	002	Jul 14, 1995

CYCLOSPORINE

AB2	APOTEX	25MG	A065040	001	May 09, 2002

AB2		100MG	A065040	002	May 09, 2002

SANDIMMUNE

AB2	NOVARTIS	25MG	N050625	001	Mar 02, 1990

AB2	+	100MG	N050625	002	Mar 02, 1990

BX		50MG	N050625	003	Nov 23, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-95 (of 362)

CYCLOSPORINE

EMULSION;OPHTHALMIC

RESTASIS

+ ALLERGAN

0.05%

N050790 001 Dec 23, 2002

INJECTABLE;INJECTION

CYCLOSPORINEAP BEDFORD50MG/MLA065004 001 Oct 29, 1999AP LUITPOLD50MG/MLA065151 001 Oct 07, 2003SANDIMMUNEAP + NOVARTIS50MG/MLN050573 001 Nov 14, 1983

SOLUTION;ORAL

CYCLOSPORINEAB1 ABBVIE100MG/MLA065025 001 Mar 03, 2000AB1 IVAX SUB TEVA PHARMS100MG/MLA065078 001 Mar 25, 2005AB1 WATSON LABS100MG/MLA065054 001 Dec 18, 2001NEORALAB1 + NOVARTIS100MG/MLN050716 001 Jul 14, 1995CYCLOSPORINEAB2 WOCKHARDT100MG/MLA065133 001 Sep 17, 2004SANDIMMUNEAB2 + NOVARTIS100MG/MLN050574 001 Nov 14, 1983CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDEAA + LYNE2MG/5MLA040668 001 Jun 28, 2006AA PHARM ASSOC2MG/5MLA091295 001 Mar 28, 2013

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDEAA COREPHARMA4MGA040537 001 Sep 30, 2003AA + IVAX SUB TEVA PHARMS4MGA087056 001AA PAR PHARM4MGA087129 001AA STASON PHARMS4MGA040644 001 May 30, 2006CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

MYLAN

EQ 50MG BASE

N020392 001 Aug 15, 1994

+

EQ 150MG BASE

N020392 002 Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

RAPTOR PHARMS

EQ 25MG BASE

N203389 001 Apr 30, 2013

+

EQ 75MG BASE

N203389 002 Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+ SIGMA TAU

EQ 0.44% BASE

N200740 001 Oct 02, 2012

CYTARABINE

INJECTABLE;INJECTION

CYTARABINEAP BEDFORD1GM/VIALA074245 001 Aug 31, 1994AP2GM/VIALA074245 002 Aug 31, 1994AP100MG/VIALA071471 001 Aug 02, 1989AP500MG/VIALA071472 001 Aug 02, 1989AP + FRESENIUS KABI USA100MG/MLA076512 001 Jan 15, 2004AP + HOSPIRA20MG/MLA071868 001 Jun 04, 1990AP +20MG/MLA072168 001 Aug 31, 1990AP +20MG/MLA072945 001 Feb 28, 1994AP100MG/MLA075383 001 Nov 22, 1999AP ONCO THERAPIES LTD20MG/MLA200914 001 Dec 13, 2011AP20MG/MLA200915 001 Dec 13, 2011AP20MG/MLA200916 001 Dec 13, 2011AP100MG/MLA201784 001 Jan 30, 2012CYTOSAR-UAP + TEVA PHARMS USA1GM/VIALA075206 004 Dec 30, 1998AP +2GM/VIALA075206 003 Dec 30, 1998AP100MG/VIALA075206 001 Dec 30, 1998AP +500MG/VIALA075206 002 Dec 30, 1998

INJECTABLE, LIPOSOMAL;INJECTION

DEPOCYT

+ PACIRA PHARMS INC

10MG/ML

N021041 001 Apr 01, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-96 (of 362)

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

BOEHRINGER INGELHEIM EQ 75MG BASE
+ EQ 150MG BASE

N022512 001 Oct 19, 2010
N022512 002 Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

GLAXOSMITHKLINE EQ 50MG BASE
+ EQ 75MG BASE

N202806 001 May 29, 2013
N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINEAP BEDFORD200MG/VIALA075812 001 Jun 15, 2001AP500MG/VIALA075812 002 Oct 31, 2002AP FRESENIUS KABI USA100MG/VIALA075371 001 Aug 27, 1999AP200MG/VIALA075371 002 Aug 27, 1999AP HOSPIRA200MG/VIALA075940 001 Oct 18, 2001AP TEVA PHARMS USA200MG/VIALA075259 002 Aug 27, 1998AP +500MG/VIALA075259 001 Sep 22, 2000DTIC-DOMEAP + BAYER HLTHCARE100MG/VIALN017575 001AP +200MG/VIALN017575 002DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGENAP + RECORDATI RARE0.5MG/VIALN050682 001DACTINOMYCINAP BEDFORD0.5MG/VIALA090304 001 Mar 16, 2010AP LUITPOLD0.5MG/VIALA202562 001 Aug 23, 2013DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+ ACORDA 10MG

N022250 001 Jan 22, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+ KING PHARMS 350MG/VIAL; 150MG/VIAL

N050748 001 Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC 2,500IU/0.2ML (12,500IU/ML)
5,000IU/0.2ML (25,000IU/ML)
7,500IU/0.3ML (25,000IU/ML)
10,000IU/ML (10,000IU/ML)
12,500IU/0.5ML (25,000IU/ML)
15,000IU/0.6ML (25,000IU/ML)
18,000IU/0.72ML (25,000IU/ML)
95,000IU/3.8ML (25,000IU/ML)

N020287 001 Dec 22, 1994
N020287 003 Mar 18, 1996
N020287 005 Apr 04, 2002
N020287 004 Jan 30, 1998
N020287 009 May 01, 2007
N020287 010 May 01, 2007
N020287 011 May 01, 2007
N020287 006 Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOLAB BARR50MGA074582 003 May 29, 1998AB100MGA074582 002 May 29, 1998AB +200MGA074582 001 Aug 09, 1996AB LANNETT50MGA078214 001 Apr 19, 2007AB100MGA078214 002 Apr 19, 2007AB200MGA077246 001 Sep 28, 2005DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUMAB JHP PHARMS25MGN017443 001AB50MGN017443 003AB +100MGN017443 002DANTROLENE SODIUMAB IMPAX LABS25MGA076856 001 Mar 01, 2005AB50MGA076856 002 Mar 01, 2005AB100MGA076856 003 Mar 01, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-97 (of 362)

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

<u>AB</u>	MIKAH PHARMA	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005

INJECTABLE; INJECTION

DANTRIUM

<u>AP</u>	+ JHP PHARMS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	

DANTROLENE SODIUM

<u>AP</u>	US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN

5%

N021794 001 Jul 07, 2005

TABLET; ORAL

DAPSONE

JACOBUS

25MG

A086841 001

+

100MG

A086842 001

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

+ CUBIST

500MG/VIAL

N021572 002 Sep 12, 2003

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

WARNER CHILCOTT LLC

EQ 7.5MG BASE

N021513 001 Dec 22, 2004

+

EQ 15MG BASE

N021513 002 Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 100MG BASE/ML

N202895 001 Dec 16, 2011

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 75MG BASE

N021976 004 Dec 18, 2008

EQ 150MG BASE

N021976 005 Dec 18, 2008

EQ 600MG BASE

N021976 002 Feb 25, 2008

+

EQ 800MG BASE

N021976 006 Nov 09, 2012

DASATINIB

TABLET; ORAL

SPRYCEL

BRISTOL MYERS SQUIBB

20MG

N021986 001 Jun 28, 2006

50MG

N021986 002 Jun 28, 2006

70MG

N021986 003 Jun 28, 2006

80MG

N021986 005 Oct 28, 2010

100MG

N021986 004 May 30, 2008

+

140MG

N021986 006 Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+ GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

<u>AP</u>	+ BEDFORD	<u>EQ 20MG BASE/VIAL</u>	<u>A064103</u>	<u>001</u>	Feb 03, 1995

DAUNORUBICIN HYDROCHLORIDE

<u>AP</u>	+ BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>N050731</u>	<u>001</u>	Jan 30, 1998

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/VIAL</u>	<u>A065000</u>	<u>001</u>	May 25, 1999

<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A065035</u>	<u>001</u>	Jan 24, 2000

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/VIAL</u>	<u>A065034</u>	<u>001</u>	Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

<u>AP</u>	+ EISAI INC	<u>50MG/VIAL</u>	<u>N021790</u>	<u>001</u>	May 02, 2006

DECITABINE

<u>AP</u>	DR REDDYS LABS LTD	<u>50MG/VIAL</u>	<u>A203131</u>	<u>001</u>	Jul 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-98 (of 362)

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

EXJADE

NOVARTIS

125MG

N021882 001 Nov 02, 2005

250MG

N021882 002 Nov 02, 2005

+

500MG

N021882 003 Nov 02, 2005

DEFERIPRONE

TABLET; ORAL

FERRIPROX

+ AOPHARMA INC

500MG

N021825 001 Oct 14, 2011

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATEAP BEDFORD2GM/VIALA078086 002 May 30, 2007AP500MG/VIALA078086 001 May 30, 2007AP FRESENIUS KABI USA2GM/VIALA078718 002 Sep 15, 2009AP500MG/VIALA078718 001 Sep 15, 2009AP HOSPIRA2GM/VIALA076019 002 Mar 17, 2004AP500MG/VIALA076019 001 Mar 17, 2004AP WATSON LABS2GM/VIALA076806 002 Mar 31, 2006AP500MG/VIALA076806 001 Mar 31, 2006DESFERALAP + NOVARTIS2GM/VIALN016267 002 May 25, 2000AP +500MG/VIALN016267 001DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

FERRING

EQ 80MG BASE/VIAL

N022201 001 Dec 24, 2008

+

EQ 120MG BASE/VIAL

N022201 002 Dec 24, 2008

DELAVIDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

VIIV HLTHCARE

100MG

N020705 001 Apr 04, 1997

+

200MG

N020705 002 Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDEAB AMNEAL PHARM150MGA065425 001 Feb 27, 2008AB +300MGA065425 002 Feb 27, 2008AB BARR150MGA065171 001 Dec 13, 2004AB300MGA065171 002 Dec 13, 2004AB IMPAX LABS150MGA065094 001 Mar 22, 2004AB300MGA065094 002 Mar 22, 2004AB VERSAPHARM150MGA065389 001 Dec 01, 2008AB300MGA065389 002 Dec 01, 2008DESFLURANE

LIQUID; INHALATION

SUPRANE

+ BAXTER HLTHCARE

99.9%

N020118 001 Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDEAB ACTAVIS TOTOWA10MGA074430 001 Feb 09, 1996AB25MGA071601 001 Jun 05, 1987AB50MGA071588 001 Jun 05, 1987AB75MGA071602 001 Oct 05, 1987AB100MGA071766 001 Oct 05, 1987AB150MGA074430 002 Feb 09, 1996AB SANDOZ10MGA072099 001 May 24, 1988AB25MGA072100 001 May 24, 1988AB50MGA072101 001 May 24, 1988AB75MGA072102 001 Jun 20, 1988AB100MGA072103 001 Jun 20, 1988AB150MGA072104 001 Jun 20, 1988NORPRAMINAB SANOFI AVENTIS US10MGN014399 007 Feb 11, 1982AB25MGN014399 001AB50MGN014399 003AB75MGN014399 004

PRESCRIPTION DRUG PRODUCT LIST

3-99 (of 362)

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

NORPRAMIN

<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	MARATHON PHARMS LLC	15MG/VIAL	N021271	001	Apr 04, 2003

DESLORATADINE

SYRUP; ORAL

CLARINEX

+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004

TABLET; ORAL

CLARINEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001

DESLORATADINE

<u>AB</u>		BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A078351</u>	<u>001</u>	Feb 10, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		PERRIGO R AND D	<u>5MG</u>	<u>A078361</u>	<u>001</u>	Dec 22, 2011
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>		MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005

<u>AB</u>	+		<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002

DESLORATADINE

<u>AB</u>		REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>			<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG; 240MG</u>	<u>N021605</u>	<u>001</u>	Mar 03, 2005

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

<u>AB</u>		DR REDDYS LABS LTD	<u>5MG; 240MG</u>	<u>A078366</u>	<u>001</u>	Apr 26, 2011

CLARINEX-D 12 HOUR

+	MERCK SHARP DOHME	2.5MG; 120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+	SANOFI AVENTIS US	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984

DESMOPRESSIN ACETATE

<u>AP</u>		HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000

<u>AP</u>		SUN PHARM INDS LTD	<u>0.004MG/ML</u>	<u>A091280</u>	<u>001</u>	Jan 25, 2013

<u>AP</u>		TEVA PHARMS USA	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

<u>AB</u>	+	SANOFI AVENTIS US	<u>0.01%</u>	<u>N017922</u>	<u>001</u>	

DESMOPRESSIN ACETATE

<u>AB</u>		SUN PHARM INDS	<u>0.01%</u>	<u>A077212</u>	<u>001</u>	Apr 12, 2012

DESMOPRESSIN ACETATE

<u>AB</u>		SUN PHARMA GLOBAL	<u>0.01%</u>	<u>A078271</u>	<u>001</u>	Dec 23, 2013

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+	SANOFI AVENTIS US	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996

DESMOPRESSIN ACETATE

<u>AB</u>	+	BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

<u>AB</u>		APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005

MINIRIN

<u>AB</u>	+	FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002

STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007

TABLET; ORAL

DDAVP

<u>AB</u>		SANOFI AVENTIS US	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995

<u>AB</u>	+		<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-100 (of 362)

DESMOPRESSIN ACETATE

TABLET;ORAL

DESMOPRESSIN ACETATE

<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006
<u>AB</u>	TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>	WATSON LABS	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005
	FERRING	0.1MG	N021795	001	May 08, 2008
	+	0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

CYCLESSA

<u>AB</u>	+ ORGANON USA INC	<u>0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000

DESOGEN

<u>AB</u>	ORGANON USA INC	<u>0.15MG;0.03MG</u>	<u>N020071</u>	<u>002</u>	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	DURAMED PHARMS BARR	<u>0.15MG;0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999
<u>AB</u>	FAMY CARE LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202296</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>	NOVAST LABS LTD	<u>0.15MG;0.03MG</u>	<u>A091234</u>	<u>001</u>	Jul 12, 2013
<u>AB</u>	WATSON LABS	<u>0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG</u>	<u>A076916</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A077182</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>		<u>0.15MG;0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005
	<u>EMOQUETTE</u>				
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.15MG;0.03MG</u>	<u>A076675</u>	<u>001</u>	Feb 25, 2011
	<u>ENSKYCE</u>				
<u>AB</u>	LUPIN LTD	<u>0.15MG;0.03MG</u>	<u>A201887</u>	<u>001</u>	Mar 07, 2013
	<u>KARIVA</u>				
<u>AB</u>	BARR	<u>0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002
	<u>MIRCETTE</u>				
<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG</u>	<u>N020713</u>	<u>001</u>	Apr 22, 1998
	<u>ORTHO-CEPT</u>				
<u>AB</u>	+ JANSSEN PHARMS	<u>0.15MG;0.03MG</u>	<u>N020301</u>	<u>002</u>	Dec 14, 1992
	<u>PIMTREA</u>				
<u>AB</u>	NOVAST LABS LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091247</u>	<u>001</u>	Aug 01, 2013
	<u>VELIVET</u>				
<u>AB</u>	DURAMED PHARMS BARR	<u>0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004
	<u>VIORELE</u>				
<u>AB</u>	GLENMARK GENERICS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091346</u>	<u>001</u>	Apr 02, 2012

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

+ STIEFEL LABS INC

0.05%

N021978 001 Sep 19, 2006

CREAM;TOPICAL

DESONIDE

<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992
	<u>DESOWEN</u>				
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984
	GEL;TOPICAL				
	DESONATE				
	+ BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006
	LOTION;TOPICAL				
	<u>DESONIDE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
	<u>DESOWEN</u>				
<u>AB</u>	+ GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992
	OINTMENT;TOPICAL				
	<u>DESONIDE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994
	<u>DESOWEN</u>				
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-101 (of 362)

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010
AB	PERRIGO NEW YORK	0.25%	A076510	001	Jul 01, 2003

TOPICORT

AB	+ TARO	0.25%	A073193	001	Nov 30, 1990
	+	0.05%	A073210	001	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

AB	PERRIGO NEW YORK	0.05%	A077552	001	Jan 09, 2006
AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011

TOPICORT

AB	+ TARO	0.05%	A074904	001	Jul 14, 1998

OINTMENT; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078657	001	Sep 28, 2012
AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013

TOPICORT

AB	+ TARO	0.25%	A074286	001	Jun 07, 1996
	+ TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985

SPRAY; TOPICAL

TOPICORT

	+ TARO	0.25%	N204141	001	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+	100MG	N204150	002	Mar 04, 2013

KHEDEZLA

BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC		100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE FUMARATE

	+ TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013
	+	EQ 100MG BASE	N205208	002	Oct 11, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

PRISTIQ

	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008
	+	EQ 100MG BASE	N021992	002	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

	+ ROXANE	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011
AA	+ STI PHARMA LLC	0.5MG/5ML	A084754	001	
AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011
AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

	+ ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

SOLUTION; ORAL

DEXAMETHASONE

	+ ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

	+ ALCON	0.1%	N013422	001	

TABLET; ORAL

DEXAMETHASONE

AB	ECR	1.5MG	A040700	001	Aug 15, 2008
AB	ROXANE	1.5MG	A084610	001	
BP	PAR PHARM	0.5MG	A088148	001	Apr 28, 1983
BP		0.75MG	A088160	001	Apr 28, 1983
BP		1.5MG	A088237	001	Apr 28, 1983
BP		4MG	A088238	001	Apr 28, 1983
BP	+	6MG	A088481	001	Nov 28, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-102 (of 362)

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

BP	ROXANE	0.5MG	A084611	001	
BP		0.75MG	A084613	001	
BP		1MG	A088306	001	Sep 15, 1983
BP		2MG	A087916	001	Aug 26, 1982
BP		4MG	A084612	001	
BP	+	6MG	A088316	001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<u>AP</u>	AGILA SPECILTS	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>	+	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A087440</u>	<u>001</u>	Jul 21, 1982

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<u>AT</u>	+	ALCON PHARMS LTD	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771</u>	<u>001</u>	Jan 16, 1985
<u>AT</u>		BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069</u>	<u>001</u>	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

<u>AT</u>	+	FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	
<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>						
<u>AT</u>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994
<u>AT</u>		PERRIGO CO TENNESSEE	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

<u>AT</u>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995

MAXITROL

<u>AT</u>		ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984
<u>AT</u>	+	FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>	

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

+ ALCON 0.1%;0.3%

N050616 001 Sep 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

<u>AB</u>	+	ALCON	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

<u>AB</u>		BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999

TOBRADEX ST

+ ALCON PHARMS LTD 0.05%;0.3%

N050818 001 Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

+ WOCKHARDT 2MG/5ML

A088251 001 Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

TAKEDA PHARMS 30MG

N022287 001 Jan 30, 2009

+ 60MG

N022287 002 Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

+	HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038	001	Dec 17, 1999
+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992</u>	<u>003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992</u>	<u>004</u>	Nov 18, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>30MG</u>	<u>A202580</u>	<u>001</u>	Aug 28, 2013
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908</u>	<u>001</u>	Nov 19, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-103 (of 362)

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A078908</u>	<u>002</u>	Nov 19, 2013
<u>AB</u>		<u>20MG</u>	<u>A078908</u>	<u>003</u>	Nov 19, 2013
<u>AB</u>		<u>40MG</u>	<u>A202731</u>	<u>002</u>	Nov 19, 2013
<u>AB</u>	WATSON LABS INC	<u>30MG</u>	<u>A079108</u>	<u>005</u>	Nov 21, 2013

FOCALIN XR

<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N021802</u>	<u>001</u>	May 26, 2005
<u>AB</u>		<u>10MG</u>	<u>N021802</u>	<u>002</u>	May 26, 2005
<u>AB</u>		<u>15MG</u>	<u>N021802</u>	<u>004</u>	Aug 01, 2006
<u>AB</u>		<u>20MG</u>	<u>N021802</u>	<u>003</u>	May 26, 2005
<u>AB</u>		<u>30MG</u>	<u>N021802</u>	<u>005</u>	Oct 23, 2009
<u>AB</u>	+	<u>40MG</u>	<u>N021802</u>	<u>006</u>	Aug 11, 2010
		25MG	N021802	008	Apr 21, 2011
		35MG	N021802	007	Apr 21, 2011

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107</u>	<u>003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107</u>	<u>001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107</u>	<u>002</u>	Jan 29, 2007

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278</u>	<u>001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278</u>	<u>002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278</u>	<u>003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A076068</u>	<u>001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068</u>	<u>002</u>	Sep 28, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752</u>	<u>001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752</u>	<u>002</u>	Oct 19, 2011

ZINECARD

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212</u>	<u>001</u>	May 26, 1995
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N020212</u>	<u>002</u>	May 26, 1995
		TOTECT				
	+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078</u>	<u>003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901</u>	<u>001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>	BARR	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>		<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>	BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+	<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>	MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>		<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>	MIKART	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>		<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
		2.5MG	A090533	001	Oct 25, 2011
		7.5MG	A090533	003	Oct 25, 2011
		15MG	A090533	005	Oct 25, 2011
		20MG	A090533	006	Oct 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-104 (of 362)

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

30MG

A090533 007 Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN**AA** + ACTAVIS MID ATLANTIC 15MG/5ML; 6.25MG/5ML**A088762 001** Oct 31, 1984PROMETHAZINE DM**AA** VINTAGE 15MG/5ML; 6.25MG/5ML**A040649 001** Feb 14, 2006PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE**AA** AMNEAL PHARMS 15MG/5ML; 6.25MG/5ML**A090575 001** Feb 08, 2011**AA** HI TECH PHARMA 15MG/5ML; 6.25MG/5ML**A040027 001** Jul 31, 1996**AA** TRIS PHARMA INC 15MG/5ML; 6.25MG/5ML**A091687 001** Jun 28, 2012PROMETHAZINE W/ DEXTROMETHORPHAN**AA** WOCKHARDT 15MG/5ML; 6.25MG/5ML**A088864 001** Jan 04, 1985DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

NUDEXTA

+ AVANIR PHARMS 20MG; 10MG

N021879 001 Oct 29, 2010

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER**AP** + B BRAUN 10GM/100ML**N019626 004** Feb 02, 1988**AP** + BAXTER HLTHCARE 10GM/100ML**N016694 001****AP** + HOSPIRA 10GM/100ML**N018080 001**DEXTROSE 20% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 20GM/100ML**N017521 004****AP** + HOSPIRA 20GM/100ML**N018564 001** Mar 23, 1982DEXTROSE 30% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 30GM/100ML**N017521 003****AP** + HOSPIRA 30GM/100ML**N019345 001** Jan 26, 1985DEXTROSE 40% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 40GM/100ML**N017521 002****AP** + HOSPIRA 40GM/100ML**N018562 001** Mar 23, 1982DEXTROSE 5% IN PLASTIC CONTAINER**AP** + B BRAUN 5GM/100ML**N016730 001****AP** + 5GM/100ML**N019626 002** Feb 02, 1988**AP** + 50MG/ML**N016730 002****AP** + BAXTER HLTHCARE 5GM/100ML**N016673 001****AP** + 5GM/100ML**N020179 001** Dec 07, 1992**AP** + 50MG/ML**N016673 003** Oct 30, 1985**AP** + 50MG/ML**N020179 002** Dec 07, 1992**AP** + HOSPIRA 5GM/100ML**N019466 001** Jul 15, 1985**AP** + 5GM/100ML**N019479 001** Sep 17, 1985**AP** + 50MG/ML**N016367 002****AP** + 50MG/ML**N019222 001** Jul 13, 1984DEXTROSE 50% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 50GM/100ML**N017521 001****AP** + 50GM/100ML**N020047 001** Jul 02, 1991**AP** + HOSPIRA 50GM/100ML**N018563 001** Mar 23, 1982**AP** + 50GM/100ML**N019894 001** Dec 26, 1989**AP** + 500MG/ML**N019445 001** Jun 03, 1986DEXTROSE 60% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 60GM/100ML**N017521 005** Mar 26, 1982DEXTROSE 70% IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 70GM/100ML**N017521 006** Mar 26, 1982**AP** + 70GM/100ML**N020047 003** Jul 02, 1991**AP** + HOSPIRA 70GM/100ML**N018561 001** Mar 23, 1982**AP** + 70GM/100ML**N019893 001** Dec 26, 1989

DEXTROSE 25%

+ HOSPIRA 250MG/ML

N019445 002 Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML

N017385 001

PRESCRIPTION DRUG PRODUCT LIST

3-105 (of 362)

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/
100ML

N017610 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/1
00ML; 320MG/100ML

N019873 001 Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/
100ML; 180MG/100ML; 280MG/100ML; 16MG/100M
L

N019515 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE

5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/1
00ML; 12MG/100ML; 260MG/100ML

N017484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/1
00ML; 260MG/100ML; 25MG/100ML

N019513 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/1
00ML; 140MG/100ML

N019844 001 Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/1
00ML; 530MG/100ML; 500MG/100ML

N019843 001 Aug 09, 1993

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/1
00ML; 526MG/100ML; 502MG/100ML

N017609 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/1
00ML; 526MG/100ML; 502MG/100ML

N017451 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP

BAXTER HLTHCARE

5GM/100ML; 75MG/100ML

N017634 004

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP

BAXTER HLTHCARE

5GM/100ML; 150MG/100ML

N017634 001

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP

BAXTER HLTHCARE

5GM/100ML; 224MG/100ML

N017634 003

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP

BAXTER HLTHCARE

5GM/100ML; 300MG/100ML

N017634 002

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

B BRAUN

5GM/100ML; 75MG/100ML

N018744 001 Nov 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

B BRAUN

5GM/100ML; 150MG/100ML

N018744 002 Nov 09, 1982

AP

5GM/100ML; 150MG/100ML

N019699 004 Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

B BRAUN

5GM/100ML; 300MG/100ML

N018744 004 Nov 09, 1982

AP

5GM/100ML; 300MG/100ML

N019699 006 Sep 29, 1989

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

HOSPIRA

5GM/100ML; 224MG/100ML

N018371 003

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 149MG/100ML

N018371 001

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 298MG/100ML

N018371 002

PRESCRIPTION DRUG PRODUCT LIST

3-106(of 362)

<u>DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE</u>					
INJECTABLE; INJECTION					
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG	N019870 001	Jun 10, 1993		
	/100ML; 91MG/100ML				
<u>DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE</u>					
INJECTABLE; INJECTION					
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER					
BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG	N018840 001	Jun 29, 1983		
	/100ML; 220MG/100ML				
<u>DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>					
INJECTABLE; INJECTION					
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ</u>					
AP BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037 006	Apr 13, 1982		
AP	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037 007	Apr 13, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)</u>					
AP BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037 004			
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ</u>					
AP BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037 008	Apr 13, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)</u>					
AP BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037 001			
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ</u>					
AP BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037 005	Apr 13, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ</u>					
AP BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037 009	Apr 13, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ</u>					
AP BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037 002			
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)</u>					
AP BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037 003			
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 330MG/100ML	N018629 005	Mar 23, 1982		
AP	5GM/100ML; 150MG/100ML; 330MG/100ML	N018629 002	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 330MG/100ML	N018629 003	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 330MG/100ML	N018629 004	Mar 23, 1982		
AP	5GM/100ML; 300MG/100ML; 330MG/100ML	N018629 006	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 330MG/100ML	N018629 007	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 330MG/100ML	N018629 008	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 330MG/100ML	N018629 001	Mar 23, 1982		
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 010			
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N019630 008	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N019630 014	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N019630 020	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 75MG/100ML; 900MG/100ML	N019630 026	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N019630 010	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N019630 016	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N019630 022	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 150MG/100ML; 900MG/100ML	N019630 028	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N019630 012	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N019630 018	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N019630 024	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP B BRAUN	5GM/100ML; 300MG/100ML; 900MG/100ML	N019630 030	Feb 17, 1988		
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 005	Apr 28, 1982		
AP	5GM/100ML; 150MG/100ML; 450MG/100ML	N018008 006	Apr 28, 1982		

PRESCRIPTION DRUG PRODUCT LIST

3-107 (of 362)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 005</u>	Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 009</u>	Jul 05, 1983

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019308 004</u>	Apr 05, 1985
<u>AP</u>		<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 002</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 002</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 004</u>	Mar 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 006</u>	Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 006</u>	Mar 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 007</u>	Apr 28, 1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 010</u>	Jul 05, 1983
<u>AP</u>		<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 007</u>	Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 005</u>	Apr 05, 1985
<u>AP</u>		<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 003</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 005</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 008</u>	Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008 008</u>	Apr 28, 1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 002</u>	

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019308 006</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 007</u>	Mar 24, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 009</u>	Apr 28, 1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 003</u>	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 007</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 009</u>	Mar 24, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 004</u>	
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 008</u>	Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 004</u>	Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 001</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 001</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 003</u>	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-108 (of 362)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 450MG/100ML		N019630 039 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 900MG/100ML		N019630 045 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 110MG/100ML; 300MG/100ML		N019630 050 May 07, 1992
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 110MG/100ML		N019630 003 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 200MG/100ML		N019630 009 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 330MG/100ML		N019630 015 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 450MG/100ML		N019630 021 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 900MG/100ML		N019630 027 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 200MG/100ML		N019630 034 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 450MG/100ML		N019630 040 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 900MG/100ML		N019630 046 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 150MG/100ML; 300MG/100ML		N019630 051 May 07, 1992
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 150MG/100ML; 110MG/100ML		N019630 004 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 200MG/100ML		N019630 035 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 450MG/100ML		N019630 041 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 900MG/100ML		N019630 047 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 220MG/100ML; 300MG/100ML		N019630 052 May 07, 1992
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 110MG/100ML		N019630 005 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML		N019630 011 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML		N019630 017 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML		N019630 023 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 900MG/100ML		N019630 029 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 200MG/100ML		N019630 036 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 450MG/100ML		N019630 042 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 900MG/100ML		N019630 048 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 300MG/100ML; 300MG/100ML		N019630 053 May 07, 1992
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 300MG/100ML; 110MG/100ML		N019630 006 Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 74.5MG/100ML; 225MG/100ML		N018365 002 Jul 05, 1983
	5GM/100ML; 149MG/100ML; 225MG/100ML		N018365 006 Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100ML		N018876 001 Jan 17, 1986
	5GM/100ML; 149MG/100ML; 300MG/100ML		N018876 006 Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 224MG/100ML; 225MG/100ML		N018365 008 Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML		N018876 007 Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 149MG/100ML; 225MG/100ML		N018365 001
	5GM/100ML; 298MG/100ML; 225MG/100ML		N018365 009 Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML		N018876 008 Mar 28, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-109 (of 362)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002 Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365 003 Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003 Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N018365 004 Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876 004 Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 005 Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 007 Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005 Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 009 Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>	<u>N019631 015</u>	Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>	<u>N016696 001</u>	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631 004</u>	Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697 001</u>	

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631 007</u>	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631 008</u>	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631 009</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>	<u>N017607 001</u>	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631 010</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>	<u>N017585 001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689 001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687 001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683 001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>	<u>N016678 001</u>	

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		

B BRAUN	10GM/100ML;110MG/100ML	N019631 011 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		

B BRAUN	10GM/100ML;200MG/100ML	N019631 012 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		

B BRAUN	10GM/100ML;330MG/100ML	N019631 013 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		

B BRAUN	10GM/100ML;450MG/100ML	N019631 014 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		

B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		

B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		

B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		

B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005 Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		

B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016 Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		

B BRAUN	5GM/100ML;110MG/100ML	N019631 006 Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		

HOSPIRA	5GM/100ML;225MG/100ML	N017606 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		

HOSPIRA	5GM/100ML;300MG/100ML	N017799 001

PRESCRIPTION DRUG PRODUCT LIST

3-110 (of 362)

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAPIN

BRACCO

30%

N010040 018

CYSTOGRAPIN DILUTE

BRACCO

18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R**AP** + MALLINCKRODT**66%;10%****N019292 001** Sep 29, 1989RENOGRAFIN-76**AP** + BRACCO**66%;10%****N010040 001**

SOLUTION; ORAL, RECTAL

GASTROGRAFIN**AA** + BRACCO**66%;10%****N011245 003**MD-GASTROVIEW**AA** MALLINCKRODT**66%;10%****A087388 001**DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAPHIN

+ BRACCO

52.7%;26.8%

N011324 002

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

+ ROXANE

5MG/ML

A071415 001 Apr 03, 1987

GEL; RECTAL

DIASTAT

VALEANT

2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

DIASTAT ACUDIAL

VALEANT

10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

+

20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM**AP** + HOSPIRA**5MG/ML****A071583 001** Oct 13, 1987**AP****5MG/ML****A072079 001** Dec 20, 1988

SOLUTION; ORAL

DIAZEPAM

+ ROXANE

5MG/5ML

A070928 001 Apr 03, 1987

TABLET; ORAL

DIAZEPAM**AB** BARR**2MG****A070152 001** Nov 01, 1985**AB****10MG****A070154 001** Nov 01, 1985**AB** DAVA PHARMS INC**2MG****A070226 001** Sep 26, 1985**AB** IVAX SUB TEVA PHARMS**2MG****A071307 001** Dec 10, 1986**AB****5MG****A071321 001** Dec 10, 1986**AB****10MG****A071322 001** Dec 10, 1986**AB** MYLAN**2MG****A070325 002** Sep 04, 1985**AB****5MG****A070325 003** Sep 04, 1985**AB****10MG****A070325 001** Sep 04, 1985**AB** VINTAGE PHARMS**2MG****A077749 001** Mar 31, 2006**AB****5MG****A077749 002** Mar 31, 2006**AB****10MG****A077749 003** Mar 31, 2006**AB** WATSON LABS**2MG****A071134 001** Feb 03, 1987**AB****5MG****A071135 001** Feb 03, 1987**AB****10MG****A071136 001** Feb 03, 1987VALIUM**AB** ROCHE**2MG****N013263 002****AB****5MG****N013263 004****AB** +**10MG****N013263 006**DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+ TEVA BRANDED PHARM

50MG/ML

N017453 001

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

IROKO PHARMS LLC

18MG

N204592 001 Oct 18, 2013

+

35MG

N204592 002 Oct 18, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-111 (of 362)

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+ INST BIOCHEM 1.3% N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+ DEPOMED INC 25MG N022202 001 Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA

+ NAUTILUS NEUROSCIENC 50MG N022165 001 Jun 17, 2009

TABLET; ORAL

CATAFLAMAB + NOVARTIS 50MG N020142 002 Nov 24, 1993DICLOFENAC POTASSIUMAB APOTEX 50MG A076561 001 Mar 18, 2004AB MYLAN 50MG A075463 001 Jul 26, 1999AB SANDOZ 50MG A075229 001 Nov 20, 1998AB TEVA 50MG A075219 001 Aug 06, 1998DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUMAB TOLMAR 3% A200936 001 Oct 28, 2013SOLARAZEAB + FOUGERA PHARMS 3% N021005 001 Oct 16, 2000

VOLTAREN

+ NOVARTIS 1% N022122 001 Oct 17, 2007

SOLUTION; TOPICAL

PENNSAID

+ MALLINCKRODT 1.5% N020947 001 Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUMAT AKORN 0.1% A077845 001 Apr 17, 2008AT ALCON PHARMS LTD 0.1% A078031 001 Feb 06, 2008AT BAUSCH AND LOMB 0.1% A078792 001 Dec 28, 2007AT NEXUS PHARMS 0.1% A078553 001 Dec 28, 2007VOLTARENAT + NOVARTIS 0.1% N020037 001 Mar 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 50MG A074514 001 Mar 26, 1996AB 75MG A074514 002 Mar 26, 1996AB CARLSBAD 25MG A075185 002 Nov 13, 1998AB 50MG A075185 003 Nov 13, 1998AB 75MG A075185 001 Nov 13, 1998AB MYLAN PHARMS INC 50MG A075281 002 Feb 12, 2002AB 75MG A075281 003 Feb 12, 2002AB + SANDOZ 25MG A074376 001 Sep 28, 1995AB + 50MG A074376 002 Sep 28, 1995AB + 75MG A074394 001 Nov 30, 1995AB UNIQUE PHARM LABS 25MG A090066 001 Dec 01, 2010AB 50MG A090066 002 Dec 01, 2010AB 75MG A077863 003 Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 100MG A075910 001 Jan 07, 2002AB DEXCEL LTD 100MG A076201 001 Nov 06, 2002AB MYLAN 100MG A076152 001 Dec 13, 2001AB VALEANT INTL 100MG A075492 001 Feb 11, 2000VOLTAREN-XRAB + NOVARTIS 100MG N020254 001 Mar 08, 1996DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTECAB GD SEARLE LLC 50MG; 0.2MG N020607 001 Dec 24, 1997AB + 75MG; 0.2MG N020607 002 Dec 24, 1997DICLOFENAC SODIUM AND MISOPROSTOLAB SANDOZ 50MG; 0.2MG A200158 001 May 09, 2013AB 75MG; 0.2MG A200158 002 May 09, 2013AB WATSON LABS INC 50MG; 0.2MG A201089 001 Jul 09, 2012AB 75MG; 0.2MG A201089 002 Jul 09, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-112 (of 362)

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

<u>AB</u>	+	APTALIS PHARMA US	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AB</u>		LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+	APTALIS PHARMA US	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
		<u>BENTYL PRESERVATIVE FREE</u>				
<u>AP</u>	+	APTALIS PHARMA US	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)</u>				
<u>AP</u>		BEDFORD	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003

SYRUP; ORAL

BENTYL

<u>AA</u>	+	APTALIS PHARMA US	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AA</u>		MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005

TABLET; ORAL

BENTYL

<u>AB</u>	+	APTALIS PHARMA US	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AB</u>		LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>		MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094</u>	<u>004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167</u>	<u>003</u>	Dec 03, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>125MG</u>	<u>A090788</u>	<u>001</u>	Apr 08, 2010
<u>AB</u>		<u>200MG</u>	<u>A090788</u>	<u>002</u>	Apr 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090788</u>	<u>003</u>	Apr 08, 2010
<u>AB</u>		<u>400MG</u>	<u>A090788</u>	<u>004</u>	Apr 08, 2010

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183</u>	<u>001</u>	Oct 31, 2000
<u>AB</u>		<u>200MG</u>	<u>N021183</u>	<u>002</u>	Oct 31, 2000
<u>AB</u>		<u>250MG</u>	<u>N021183</u>	<u>003</u>	Oct 31, 2000
<u>AB</u>	+	<u>400MG</u>	<u>N021183</u>	<u>004</u>	Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112</u>	<u>001</u>	Mar 08, 2007

VIDEX

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>10MG/ML</u>	<u>N020156</u>	<u>001</u>	Oct 09, 1991

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

	AUROBINDO	100MG	A077275	001	Aug 14, 2012
		150MG	A077275	002	Aug 14, 2012
	+	200MG	A077275	003	Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

+	BAYER HLTHCARE	2MG; 3MG; N/A; 1MG; 2MG; 2MG; 3MG; N/A	N022252	001	May 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-113 (of 362)

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	AVANTHI INC	25MG	A201212	001	Dec 22, 2010
AA	COREPHARMA	25MG	A040828	001	Nov 05, 2008
AA	LANNETT HOLDINGS INC	25MG	A200177	001	Jul 18, 2011

TENUATE

AA	+ WATSON PHARMS	25MG	N011722	002	

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

AB	LANNETT HOLDINGS INC	75MG	A091680	001	Oct 24, 2011

TENUATE DOSPAN

AB	+ WATSON PHARMS	75MG	N012546	001	

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+ FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002

BX	+ TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999

AB	+ TARO	0.05%	A075331	001	May 14, 1999

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012

AB	+ TEVA	500MG	A073673	001	Jul 31, 1992

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+ ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008

DIGOXIN

ELIXIR; ORAL

DIGOXIN

	+ ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004

INJECTABLE; INJECTION

DIGOXIN

AP	HIKMA MAPLE	0.25MG/ML	A083391	001	

AP	SANDOZ	0.25MG/ML	A040481	001	Aug 21, 2003

LANOXIN

AP	+ COVIS PHARMA	0.25MG/ML	N009330	002	

LANOXIN PEDIATRIC

	+ COVIS PHARMA	0.1MG/ML	N009330	004	

TABLET; ORAL

DIGOXIN

AB	HIKMA PHARMS	0.125MG	A077002	002	Oct 30, 2007

AB		0.25MG	A077002	001	Oct 30, 2007

AB	IMPAX LABS	0.125MG	A078556	001	Jul 20, 2009

AB		0.25MG	A078556	002	Jul 20, 2009

AB	STEVENS J	0.125MG	A076268	001	Jul 26, 2002

AB		0.25MG	A076268	002	Jul 26, 2002

LANOXIN

AB	COVIS PHARMA	0.125MG	N020405	002	Sep 30, 1997

AB	+	0.25MG	N020405	004	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+ VALEANT	1MG/ML	N005929	001	

DIHYDROERGOTAMINE MESYLATE

AP	BEDFORD LABS	1MG/ML	A040453	001	Jun 09, 2003

AP	PADDOCK LLC	1MG/ML	A040475	001	Apr 28, 2003

SPRAY, METERED; NASAL

MIGRANAL

	+ VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-114 (of 362)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILACOR XR

<u>AB2</u>	WATSON LABS	<u>120MG</u>	<u>N020092</u>	<u>001</u>	May 29, 1992
<u>AB2</u>		<u>180MG</u>	<u>N020092</u>	<u>002</u>	May 29, 1992
<u>AB2</u>	+	<u>240MG</u>	<u>N020092</u>	<u>003</u>	May 29, 1992

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>	MYLAN	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>		<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>		<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998
<u>AB2</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074852</u>	<u>001</u>	Oct 10, 1997
<u>AB2</u>		<u>180MG</u>	<u>A074852</u>	<u>002</u>	Oct 10, 1997
<u>AB2</u>		<u>240MG</u>	<u>A074852</u>	<u>003</u>	Oct 10, 1997

CARDIZEM CD

<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999

CARTIA XT

<u>AB3</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILT-CD

<u>AB3</u>	APOTEX	<u>120MG</u>	<u>A076151</u>	<u>001</u>	May 20, 2004
<u>AB3</u>		<u>180MG</u>	<u>A076151</u>	<u>002</u>	May 20, 2004
<u>AB3</u>		<u>240MG</u>	<u>A076151</u>	<u>003</u>	May 20, 2004
<u>AB3</u>		<u>300MG</u>	<u>A076151</u>	<u>004</u>	May 20, 2004

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS INC	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB4</u>	NESHER PHARMS	<u>120MG</u>	<u>A076563</u>	<u>002</u>	Sep 12, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076563</u>	<u>003</u>	Sep 12, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076563</u>	<u>004</u>	Sep 12, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076563</u>	<u>005</u>	Sep 12, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076563</u>	<u>006</u>	Sep 12, 2006
<u>AB4</u>		<u>420MG</u>	<u>A076563</u>	<u>001</u>	Sep 12, 2006
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-115 (of 362)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

<u>AB4</u>	<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>	<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>	<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>	<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT INTL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998	
<u>AP</u>	+	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>		HIKMA MAPLE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
	+	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
	+	TEVA PHARMS USA	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	AKORN	10%	N005939	001	

PRESCRIPTION DRUG PRODUCT LIST

3-116 (of 362)

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

BIOGEN IDEC INC	120MG	N204063 001	Mar 27, 2013
+	240MG	N204063 002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

AT	MYLAN INSTITUTIONAL	50%	A076185 001	Nov 29, 2002

RIMSO-50

AT	+	MYLAN INSTITUTIONAL	50%	N017788 001

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617 001	Dec 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995

SUPPOSITORY; VAGINAL

PROSTIN E2

+	PHARMACIA AND UPJOHN	20MG	N017810 001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	A080738 001	

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	PHARM ASSOC	12.5MG/5ML	A087513 001	Feb 10, 1982

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	APP PHARMS	50MG/ML	A040466 001	May 28, 2002

AP	+	HIKMA MAPLE	50MG/ML	A080817 002

AP	HOSPIRA	50MG/ML	A040140 001	Nov 20, 1998

AP	MYLAN INSTITUTIONAL	50MG/ML	A040498 001	Jul 12, 2005

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BD RX	50MG/ML	A091526 001	Mar 26, 2013

AP	INTL MEDICATION	50MG/ML	A084094 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AT	AKORN	0.1%	A074382 001	Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

AT	FALCON PHARMS	0.1%	A073636 001	Jun 30, 1994

PROPINE

AT	+	ALLERGAN	0.1%	N018239 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	+	BEDFORD	5MG/ML	A074939 001	Apr 13, 1998

AP	FRESENIUS KABI USA	5MG/ML	A074956 001	Sep 30, 1998

AP	HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLE

AB	BARR	25MG	A087184 001	Oct 03, 1990

AB		50MG	A087716 001	Oct 03, 1990

AB		75MG	A087717 001	Oct 03, 1990

AB	GLENMARK GENERICS	25MG	A088999 001	Feb 05, 1991

AB		50MG	A089000 001	Feb 05, 1991

AB		75MG	A089001 001	Feb 05, 1991

AB	IMPAX LABS	25MG	A040782 001	Jul 18, 2007

AB		50MG	A040782 002	Jul 18, 2007

AB		75MG	A040782 003	Jul 18, 2007

AB	LANNETT	25MG	A040898 001	Apr 23, 2008

AB		50MG	A040898 002	Apr 23, 2008

AB		75MG	A040898 003	Apr 23, 2008

AB	MURTY PHARMS	25MG	A040733 001	Feb 13, 2007

AB		50MG	A040733 002	Feb 13, 2007

AB		75MG	A040733 003	Feb 13, 2007

AB	PUREPAC PHARM	25MG	A089425 001	Jul 12, 1990

AB	WATSON LABS	50MG	A087160 001	Jun 07, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-117 (of 362)

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>		<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008

PERSANTINE

<u>AB</u>	BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>		<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+	<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985

NORPACE

<u>AB</u>	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
			EQ 100MG BASE	<u>N018655</u>	<u>001</u>	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>	ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	+	<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012

DISULFIRAM

<u>AB</u>	ALVOGEN PINE BROOK	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989

DIVALPROEX SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554</u>	<u>001</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090554</u>	<u>002</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090554</u>	<u>003</u>	Apr 21, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-118 (of 362)

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163</u>	<u>001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163</u>	<u>002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163</u>	<u>003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445</u>	<u>001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993
<u>AP</u>	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292</u>	<u>001</u>	Feb 16, 1995
<u>AP</u>	WATSON LABS	<u>EQ 12.5MG BASE/ML</u>	<u>A074114</u>	<u>001</u>	Nov 30, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020269</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020269</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020269</u>	<u>003</u>	Oct 19, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/0.5ML (40MG/ML)</u>	<u>N201195</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		<u>20MG/ML (20MG/ML)</u>	<u>N201195</u>	<u>003</u>	Apr 20, 2012
<u>AP</u>		<u>80MG/2ML (40MG/ML)</u>	<u>N201195</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N201195</u>	<u>004</u>	Apr 20, 2012
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>N201195</u>	<u>005</u>	Apr 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-119 (of 362)

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACTAVIS INC	<u>20MG/ML (20MG/ML)</u>	<u>N203551</u>	<u>001</u>	Apr 12, 2013
AP		<u>80MG/4ML (20MG/ML)</u>	<u>N203551</u>	<u>002</u>	Apr 12, 2013
AP	+ HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234</u>	<u>001</u>	Mar 08, 2011
AP	+	<u>80MG/8ML (10MG/ML)</u>	<u>N022234</u>	<u>002</u>	Mar 08, 2011
AP	+	<u>160MG/16ML (10MG/ML)</u>	<u>N022234</u>	<u>003</u>	Mar 08, 2011
AP	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525</u>	<u>001</u>	Jun 29, 2011
AP		<u>80MG/8ML (10MG/ML)</u>	<u>N201525</u>	<u>002</u>	Jun 29, 2011
AP		<u>160MG/16ML (10MG/ML)</u>	<u>N201525</u>	<u>003</u>	Jun 29, 2011

TAXOTERE

AP	+ SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449</u>	<u>003</u>	Aug 03, 2010
AP	+	<u>80MG/4ML (20MG/ML)</u>	<u>N020449</u>	<u>004</u>	Aug 02, 2010
AP	+	<u>160MG/8ML (20MG/ML)</u>	<u>N020449</u>	<u>005</u>	Apr 13, 2012
	DOCEFREZ				
	+ SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011
	+	80MG/VIAL	N022534	002	May 03, 2011
	DOCETAXEL				
	ACTAVIS INC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013

DOFETILIDE

CAPSULE; ORAL

TIKOSYN

	PFIZER	0.125MG	N020931	001	Oct 01, 1999
		0.25MG	N020931	002	Oct 01, 1999
	+	0.5MG	N020931	003	Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

	+ SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
	+	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
	+	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL

ANZEMET

	SANOFI AVENTIS US	50MG	N020623	001	Sep 11, 1997
	+	100MG	N020623	002	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

	+ VIIV HLTHCARE	EQ 50MG BASE	N204790	001	Aug 12, 2013

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

AB	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
AB	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
AB	+	<u>23MG</u>	<u>N022568</u>	<u>001</u>	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201724</u>	<u>001</u>	Feb 25, 2013
AB		<u>10MG</u>	<u>A201724</u>	<u>002</u>	Feb 25, 2013
AB	APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
AB		<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
AB	AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
AB	CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
AB	CSPC OUYI PHARM CO	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
AB		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
AB	DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
AB		<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
AB	HIKMA PHARMS	<u>5MG</u>	<u>A090247</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A090247</u>	<u>002</u>	May 31, 2011
AB	INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
AB		<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
AB	JUBILANT LIFE	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
AB	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
AB		<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
AB	MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
AB		<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-120 (of 362)

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>23MG</u>	<u>A202542</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	VIVIMED LABS	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004
	<u>DONEPEZIL HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175</u>	<u>002</u>	May 10, 2011

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982
<u>AP</u>	+	LUITPOLD	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+	HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

	+	B BRAUN	<u>40MG/100ML</u>	<u>N019099</u>	<u>001</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	<u>640MG/100ML</u>	<u>N019615</u>	<u>004</u>	Mar 27, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-121 (of 362)

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

SHIONOGI INC

250MG/VIAL

N022106 002 Oct 05, 2010

+

500MG/VIAL

N022106 001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDEAT ALCON PHARMS LTDEQ 2% BASEA078981 001 Apr 13, 2009AT BAUSCH AND LOMBEQ 2% BASEA090143 001 Jun 25, 2009AT HI TECH PHARMAEQ 2% BASEA077846 001 Oct 28, 2008AT LUITPOLDEQ 2% BASEA079186 001 Nov 18, 2009AT SANDOZEQ 2% BASEA078748 001 Nov 06, 2008AT TEVA PHARMSEQ 2% BASEA078756 001 Dec 04, 2008AT ZACH SYSTEMSEQ 2% BASEA091034 001 Dec 04, 2013TRUSOPTAT + MERCKEQ 2% BASEN020408 001 Dec 09, 1994DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPTAT + OAK PHARMS AKORNEQ 2% BASE; EQ 0.5% BASEN020869 001 Apr 07, 1998DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEAT ALCON RESEQ 2% BASE; EQ 0.5% BASEA090604 001 Nov 18, 2009AT BAUSCH AND LOMBEQ 2% BASE; EQ 0.5% BASEA090037 001 Jul 14, 2009AT HI TECH PHARMAEQ 2% BASE; EQ 0.5% BASEA077847 001 Oct 28, 2008AT SANDOZEQ 2% BASE; EQ 0.5% BASEA078749 001 Nov 06, 2008AT TEVA PHARMSEQ 2% BASE; EQ 0.5% BASEA078704 001 Sep 28, 2009AT ZACH SYSTEMSEQ 2% BASE; EQ 0.5% BASEA091180 001 Dec 04, 2013

COSOPT PF

+ OAK PHARMS AKORN

EQ 2% BASE; EQ 0.5% BASE

N202667 001 Feb 01, 2012

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAMAP + HIKMA MAPLE20MG/MLN014879 001DOXAPRAM HYDROCHLORIDEAP BEDFORD20MG/MLA076266 001 Jan 10, 2003AP WATSON LABS20MG/MLA073529 001 Jan 30, 1992DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURAAB + PFIZEREQ 1MG BASEN019668 001 Nov 02, 1990ABEQ 2MG BASEN019668 002 Nov 02, 1990ABEQ 4MG BASEN019668 003 Nov 02, 1990ABEQ 8MG BASEN019668 004 Nov 02, 1990DOXAZOSIN MESYLATEAB APOTEXEQ 1MG BASEA075580 001 Oct 18, 2000ABEQ 2MG BASEA075580 002 Oct 18, 2000ABEQ 4MG BASEA075580 003 Oct 18, 2000ABEQ 8MG BASEA075580 004 Oct 18, 2000AB DAVA PHARMS INCEQ 1MG BASEA076161 001 Jun 10, 2004ABEQ 2MG BASEA076161 002 Jun 10, 2004ABEQ 4MG BASEA076161 003 Jun 10, 2004ABEQ 8MG BASEA076161 004 Jun 10, 2004AB

MYLAN

EQ 1MG BASEA075509 001 Oct 19, 2000ABEQ 2MG BASEA075509 002 Oct 19, 2000ABEQ 4MG BASEA075509 003 Oct 19, 2000ABEQ 8MG BASEA075509 004 Oct 19, 2000AB PLIVAEQ 1MG BASEA075750 001 Jun 08, 2001ABEQ 2MG BASEA075750 002 Jun 08, 2001ABEQ 4MG BASEA075750 003 Jun 08, 2001ABEQ 8MG BASEA075750 004 Jun 08, 2001AB TEVAEQ 1MG BASEA075536 001 Oct 18, 2000ABEQ 2MG BASEA075536 002 Oct 18, 2000ABEQ 4MG BASEA075536 003 Oct 18, 2000ABEQ 8MG BASEA075536 004 Oct 18, 2000

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

PFIZER

EQ 4MG BASE

N021269 001 Feb 22, 2005

+

EQ 8MG BASE

N021269 002 Feb 22, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-122 (of 362)

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
	PAR PHARM	EQ 150MG BASE	A071669 001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>	+	TEVA PHARMS	<u>A071609 001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013

SILENOR

<u>AB</u>	PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	ROXANE	<u>0.5MCG</u>	<u>A091433 001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433 002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433 003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>		<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	HIKMA PHARMS LLC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
	<u>HECTOROL</u>			
<u>AP</u>	+	GENZYME CORP	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>
		2MCG/ML (2MCG/ML)	N021027 002	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515 001</u>	Nov 08, 2012
<u>AP</u>	+	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989
<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>	+	<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	ONCO THERAPIES LTD	<u>2MG/ML</u>	<u>A200901 001</u>	Feb 14, 2012
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170 001</u>	Oct 28, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SANDOZ INC	<u>2MG/ML</u>	<u>A200146 001</u>	Jul 18, 2012
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>	+	SUN PHARMA GLOBAL	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>
<u>AB</u>	+		<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>

PRESCRIPTION DRUG PRODUCT LIST

3-123 (of 362)

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065</u>	<u>001</u>	Feb 17, 2011
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A090855</u>	<u>001</u>	Jul 01, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778</u>	<u>001</u>	Jun 08, 2012
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065055</u>	<u>003</u>	Jul 15, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A065041</u>	<u>001</u>	Apr 28, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065041</u>	<u>002</u>	Apr 28, 2000

MONODOX

<u>AB</u>	AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989

ORACEA

<u>AB</u>	+	<u>40MG</u>	<u>N050805</u>	<u>001</u>	May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454</u>	<u>001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678</u>	<u>001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+	<u>EQ 25MG BASE/5ML</u>	<u>N050006</u>	<u>001</u>	

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605</u>	<u>003</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605</u>	<u>004</u>	Dec 20, 2011
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285</u>	<u>003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285</u>	<u>004</u>	Jul 30, 2008
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377</u>	<u>003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070</u>	<u>001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070</u>	<u>003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070</u>	<u>002</u>	Dec 15, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065070</u>	<u>004</u>	Jul 14, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065356</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356</u>	<u>003</u>	May 31, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+	PFIZER	<u>EQ 50MG BASE/5ML</u>	<u>N050480</u>	<u>001</u>	

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500</u>	<u>002</u>	Sep 11, 1984
<u>AB</u>	HIKMA PHARMS	<u>EQ 50MG BASE</u>	<u>A062396</u>	<u>002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396</u>	<u>001</u>	May 07, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 50MG BASE</u>	<u>A062031</u>	<u>002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031</u>	<u>001</u>	

VIBRAMYCIN

<u>AB</u>	PFIZER	<u>EQ 50MG BASE</u>	<u>N050007</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050007</u>	<u>002</u>	
	DOXYCYCLINE HYCLATE				
	+	<u>EQ 20MG BASE</u>	<u>A065103</u>	<u>001</u>	May 13, 2005
	CAPSULE, DELAYED RELEASE; ORAL				
	DOXYCYCLINE HYCLATE				
	MEDICIS	<u>EQ 75MG BASE</u>	<u>A065281</u>	<u>001</u>	Dec 21, 2005
	+	<u>EQ 100MG BASE</u>	<u>A065281</u>	<u>002</u>	Dec 21, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-124 (of 362)

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXY 100

AP	+	FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475</u>	<u>001</u>	Dec 09, 1983

DOXYCYCLINE

AP		AGILA SPECLTS	<u>EQ 100MG BASE/VIAL</u>	<u>A091406</u>	<u>001</u>	Aug 21, 2012

AP	+	BEDFORD	<u>EQ 100MG BASE/VIAL</u>	<u>A062569</u>	<u>001</u>	Mar 09, 1988

DOXY 200

+	FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A062475</u>	<u>002</u>	Dec 09, 1983

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+	TOLMAR	50MG	<u>N050751</u>	<u>001</u>	Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB		BLU CARIBE INC	<u>EQ 100MG BASE</u>	<u>A062269</u>	<u>002</u>	Nov 08, 1982

AB		CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505</u>	<u>001</u>	Sep 11, 1984

AB		COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182</u>	<u>001</u>	May 13, 2005

AB	+	HIKMA PHARMS	<u>EQ 100MG BASE</u>	<u>A065095</u>	<u>001</u>	Jul 02, 2003

AB		IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163</u>	<u>001</u>	May 13, 2005

AB		LANNETT	<u>EQ 20MG BASE</u>	<u>A065277</u>	<u>001</u>	Nov 10, 2005

AB		LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287</u>	<u>001</u>	Feb 28, 2006

AB		MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677</u>	<u>001</u>	Jul 10, 1986

AB		MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134</u>	<u>001</u>	May 13, 2005

AB		VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538</u>	<u>001</u>	Apr 07, 1986

AB		WATSON LABS INC FL	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983

PERIOSTAT

AB	+	GALDERMA LABS LP	<u>EQ 20MG BASE</u>	<u>N050783</u>	<u>001</u>	Feb 02, 2001

TABLET, DELAYED RELEASE; ORAL

DORYX

AB		MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795</u>	<u>001</u>	May 06, 2005

AB			<u>EQ 100MG BASE</u>	<u>N050795</u>	<u>002</u>	May 06, 2005

AB	+		<u>EQ 150MG BASE</u>	<u>N050795</u>	<u>003</u>	Jun 20, 2008

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134</u>	<u>001</u>	Dec 14, 2011

AB			<u>EQ 100MG BASE</u>	<u>A090134</u>	<u>002</u>	Dec 14, 2011

AB		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856</u>	<u>001</u>	Apr 30, 2013

AB			<u>EQ 100MG BASE</u>	<u>A200856</u>	<u>002</u>	Apr 30, 2013

AB			<u>EQ 150MG BASE</u>	<u>A200856</u>	<u>003</u>	Apr 30, 2013

AB		IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505</u>	<u>001</u>	Dec 28, 2010

AB			<u>EQ 100MG BASE</u>	<u>A090505</u>	<u>002</u>	Dec 28, 2010

AB		MYLAN	<u>EQ 75MG BASE</u>	<u>A090431</u>	<u>001</u>	Dec 28, 2010

AB			<u>EQ 100MG BASE</u>	<u>A090431</u>	<u>002</u>	Dec 28, 2010

AB		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052</u>	<u>001</u>	Feb 08, 2012

DORYX

		MAYNE PHARMA	<u>EQ 80MG BASE</u>	<u>N050795</u>	<u>004</u>	Apr 11, 2013

			<u>EQ 200MG BASE</u>	<u>N050795</u>	<u>005</u>	Apr 11, 2013

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+	DUCHESNAY	10MG; 10MG	<u>N021876</u>	<u>001</u>	Apr 08, 2013

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB		INSYS THERAP	<u>2.5MG</u>	<u>A078501</u>	<u>001</u>	Aug 19, 2011

AB			<u>5MG</u>	<u>A078501</u>	<u>002</u>	Aug 19, 2011

AB			<u>10MG</u>	<u>A078501</u>	<u>003</u>	Aug 19, 2011

AB		SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008

AB			<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008

AB			<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

AB		ABBVIE	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985

AB	+		<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985

AB			<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+	SANOFI AVENTIS US	<u>EQ 400MG BASE</u>	<u>N022425</u>	<u>001</u>	Jul 01, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-125 (of 362)

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988
AP	LUITPOLD	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988

INAPSINE

AP	+ AKORN INC	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>	

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

	BAYER HLTHCARE	0.25MG; 0.5MG	N021355	001	Feb 29, 2012
+		0.5MG; 1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	<u>3MG; 0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009
AB	WATSON LABS	<u>3MG; 0.02MG</u>	<u>A078833</u>	<u>001</u>	Nov 28, 2011
<u>LORYNA</u>					
AB	SANDOZ	<u>3MG; 0.02MG</u>	<u>A079221</u>	<u>001</u>	Mar 28, 2011
<u>YAZ</u>					
AB	+ BAYER HLTHCARE	<u>3MG; 0.02MG</u>	<u>N021676</u>	<u>001</u>	Mar 16, 2006

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	<u>3MG; 0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008
AB	LUPIN LTD	<u>3MG; 0.03MG</u>	<u>A201663</u>	<u>001</u>	Dec 18, 2012
AB	WATSON LABS	<u>3MG; 0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010
<u>SYEDA</u>					
AB	SANDOZ	<u>3MG; 0.03MG</u>	<u>A090114</u>	<u>001</u>	Mar 28, 2011
<u>YASMIN</u>					
AB	+ BAYER HLTHCARE	<u>3MG; 0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

+	BAYER HLTHCARE	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	N022532	001	Sep 24, 2010
<u>SAFYRAL</u>					
	BAYER HLTHCARE	3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	N022574	001	Dec 16, 2010

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

AB	LILLY	<u>EQ 20MG BASE</u>	<u>N021427</u>	<u>001</u>	Aug 03, 2004
AB		<u>EQ 30MG BASE</u>	<u>N021427</u>	<u>002</u>	Aug 03, 2004
AB	+	<u>EQ 60MG BASE</u>	<u>N021427</u>	<u>004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776</u>	<u>001</u>	Dec 17, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090776</u>	<u>002</u>	Dec 17, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090776</u>	<u>003</u>	Dec 17, 2013
AB	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090778</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090778</u>	<u>003</u>	Dec 11, 2013
AB	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A090723</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090723</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090723</u>	<u>003</u>	Dec 11, 2013
AB	LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090694</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090694</u>	<u>004</u>	Dec 11, 2013
AB	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A090745</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090745</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090745</u>	<u>003</u>	Dec 11, 2013
AB	TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090783</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090783</u>	<u>003</u>	Dec 11, 2013
AB	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774</u>	<u>001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090774</u>	<u>002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090774</u>	<u>003</u>	Dec 11, 2013
AB	ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 20MG BASE</u>	<u>A090739</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 30MG BASE</u>	<u>A090728</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 30MG BASE</u>	<u>A090739</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 60MG BASE</u>	<u>A090728</u>	<u>003</u>	Jan 08, 2014
AB		<u>EQ 60MG BASE</u>	<u>A090739</u>	<u>003</u>	Jan 08, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-126 (of 362)

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

LUPIN LTD

EQ 40MG BASE

A090694 003 Dec 11, 2013

DUTASTERIDE

CAPSULE; ORAL

AVODART**AB** + GLAXOSMITHKLINE **0.5MG****N021319 001** Nov 20, 2001DUTASTERIDE**AB** BANNER PHARMACAPS **0.5MG****A200899 001** May 30, 2013**AB** BARR **0.5MG****A090095 001** Dec 21, 2010DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

JALYN

+ GLAXOSMITHKLINE

0.5MG; 0.4MG

N022460 001 Jun 14, 2010

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

MEDA PHARMS

200MG

A084566 001

+

400MG

A084566 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+ WYETH PHARMS INC

0.125%

N011963 001

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+ AMDERMA PHARMS

1%

N205175 001 Oct 24, 2013

CREAM; TOPICAL

ECONAZOLE NITRATE**AB** + FOUGERA PHARMS **1%****A076075 001** Nov 26, 2002**AB** IGI LABS INC **1%****A076574 001** Dec 17, 2004**AB** PERRIGO NEW YORK **1%****A076479 001** Jun 23, 2004**AB** TARO **1%****A076005 001** Nov 26, 2002EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+ MEDICIS

200MG/ML

N008922 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON**AP** MYLAN INSTITUTIONAL **10MG/ML****A088873 001** Aug 06, 1985TENSILON**AP** + VALEANT PHARMS **10MG/ML****N007959 001**TENSILON PRESERVATIVE FREE**AP** + VALEANT PHARMS **10MG/ML****N007959 002**EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

50MG

N020972 001 Sep 17, 1998

+

200MG

N020972 003 Sep 17, 1998

TABLET; ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB

600MG

N021360 002 Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD

600MG; 200MG; 300MG

N021937 001 Jul 12, 2006

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-127 (of 362)

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

PFIZER IRELAND

EQ 20MG BASE

N021016 001 Dec 26, 2002

+

EQ 40MG BASE

N021016 002 Dec 26, 2002

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

EQ 25MG ACID

N022291 001 Nov 20, 2008

+

EQ 50MG ACID

N022291 002 Nov 20, 2008

EQ 75MG ACID

N022291 003 Sep 08, 2009

EQ 100MG ACID

N022291 005 Nov 16, 2012

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+ ALCON

0.05%

N020706 001 Dec 29, 1997

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+ GILEAD

200MG

N021500 001 Jul 02, 2003

SOLUTION; ORAL

EMTRIVA

+ GILEAD

10MG/ML

N021896 001 Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC

200MG; EQ 25MG BASE; 300MG

N202123 001 Aug 10, 2011

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD

200MG; 300MG

N021752 001 Aug 02, 2004

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ SILVERGATE PHARMS

1MG/ML

N204308 001 Aug 13, 2013

TABLET; ORAL

ENALAPRIL MALEATE**AB** APOTEX**2.5MG****A075178 002** Mar 23, 2001**AB****5MG****A075178 001** Mar 23, 2001**AB****10MG****A075178 003** Mar 23, 2001**AB****20MG****A075178 004** Mar 23, 2001**AB** MYLAN**2.5MG****A075480 001** Aug 22, 2000**AB****5MG****A075480 002** Aug 22, 2000**AB****10MG****A075480 003** Aug 22, 2000**AB****20MG****A075480 004** Aug 22, 2000**AB** TARO**2.5MG****A075657 001** Jan 23, 2001**AB****5MG****A075657 002** Jan 23, 2001**AB****10MG****A075657 003** Jan 23, 2001**AB****20MG****A075657 004** Jan 23, 2001**AB** TEVA**2.5MG****A075479 001** Aug 22, 2000**AB****5MG****A075479 002** Aug 22, 2000**AB****10MG****A075479 003** Aug 22, 2000**AB****20MG****A075479 004** Aug 22, 2000**AB** WATSON LABS**2.5MG****A075501 001** Aug 22, 2000**AB****5MG****A075501 002** Aug 22, 2000**AB****10MG****A075501 003** Aug 22, 2000**AB****20MG****A075501 004** Aug 22, 2000**AB** WOCKHARDT USA**2.5MG****A075483 001** Aug 22, 2000**AB****5MG****A075483 002** Aug 22, 2000**AB****10MG****A075483 003** Aug 22, 2000**AB****20MG****A075483 004** Aug 22, 2000VASOTEC**AB** VALEANT INTL**2.5MG****N018998 005** Jul 26, 1988**AB****5MG****N018998 001** Dec 24, 1985**AB****10MG****N018998 002** Dec 24, 1985**AB** +**20MG****N018998 003** Dec 24, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-128 (of 362)

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486</u>	<u>002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909</u>	<u>001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u>	Sep 18, 2001
<u>VASERETIC</u>					
<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578</u>	<u>001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074396</u>	<u>001</u>	Jul 29, 1994
<u>ETHRANE</u>						
<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017087</u>	<u>001</u>	

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660</u>	<u>001</u>	Nov 28, 2011
<u>LOVENOX</u>					
<u>AB</u>	SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164</u>	<u>009</u>	Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684</u>	<u>001</u>	Sep 19, 2011
AP		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684</u>	<u>002</u>	Sep 19, 2011
AP		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684</u>	<u>003</u>	Sep 19, 2011
AP		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684</u>	<u>004</u>	Sep 19, 2011
AP		<u>100MG/ML (100MG/ML)</u>	<u>A076684</u>	<u>005</u>	Sep 19, 2011
AP		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684</u>	<u>006</u>	Sep 19, 2011
AP		<u>150MG/ML (150MG/ML)</u>	<u>A076684</u>	<u>007</u>	Sep 19, 2011
AP	SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857</u>	<u>002</u>	Jul 23, 2010
AP		<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857</u>	<u>003</u>	Jul 23, 2010
AP		<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857</u>	<u>004</u>	Jul 23, 2010
AP		<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857</u>	<u>005</u>	Jul 23, 2010
AP		<u>100MG/ML (100MG/ML)</u>	<u>A077857</u>	<u>001</u>	Jul 23, 2010
AP		<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857</u>	<u>006</u>	Jul 23, 2010
AP		<u>150MG/ML (150MG/ML)</u>	<u>A077857</u>	<u>007</u>	Jul 23, 2010
<u>LOVENOX (PRESERVATIVE FREE)</u>					
AP	SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164</u>	<u>001</u>	Mar 29, 1993
AP		<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164</u>	<u>002</u>	Jan 30, 1998
AP		<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164</u>	<u>003</u>	Mar 27, 1998
AP		<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164</u>	<u>004</u>	Mar 27, 1998
AP	+	<u>100MG/ML (100MG/ML)</u>	<u>N020164</u>	<u>005</u>	Mar 27, 1998
AP		<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164</u>	<u>007</u>	Jun 02, 2000
AP		<u>150MG/ML (150MG/ML)</u>	<u>N020164</u>	<u>008</u>	Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+	ORION PHARMA	<u>200MG</u>	<u>N020796</u>	<u>001</u>	Oct 19, 1999

ENTACAPONE

<u>AB</u>		MYLAN PHARMS INC	<u>200MG</u>	<u>A202394</u>	<u>001</u>	May 13, 2013
<u>AB</u>		SUN PHARMA GLOBAL	<u>200MG</u>	<u>A090690</u>	<u>001</u>	Jul 16, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-129 (of 362)

ENTACAPONE

TABLET; ORAL

ENTACAPONE

AB	WOCKHARDT LTD	200MG	A078941	001	Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

TABLET; ORAL

BARACLUDE

	BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005

+		1MG	N021797	002	Mar 29, 2005

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+	ASTELLAS	40MG	N203415	001	Aug 31, 2012

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003

EPINASTINE HYDROCHLORIDE

AT		APOTEX	0.05%	A090919	001	Oct 31, 2011

AT		BRECKENRIDGE PHARM	0.05%	A090870	001	Mar 14, 2011

AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011

AT		SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+	JHP PHARMS	1MG/ML	N204200	001	Dec 07, 2012

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009

BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009

AUVI-Q

BX	+	SANOFI AVENTIS US	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012

BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012

EPIPEN

BX	+	MYLAN SPECLT	0.3MG/DELIVERY	N019430	001	Dec 22, 1987

EPIPEN JR.

BX	+	MYLAN SPECLT	0.15MG/DELIVERY	N019430	002	Dec 22, 1987

TWINJECT 0.15

BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004

TWINJECT 0.3

BX	+	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003

ADRENALIN

+	JHP PHARMS LLC	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+	DEPROCO	EQ 0.02MG BASE/ML; 2%	A088389	001	Jan 22, 1985

LIGNOSPAN STANDARD

+	DEPROCO	EQ 0.01MG BASE/ML; 2%	A088390	001	Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP	+	DENTSPLY PHARM	0.005MG/ML; 4%	N021383	001	

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	0.005MG/ML; 4%	A078959	001	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		EASTMAN KODAK	0.01MG/ML; 2%	A040057	002	Feb 26, 1993

AP			0.02MG/ML; 2%	A040057	001	Feb 26, 1993

AP		HOSPIRA	0.005MG/ML; 0.5%	A089635	001	Jun 21, 1988

AP			0.005MG/ML; 1.5%	A088571	001	Sep 13, 1985

AP			0.005MG/ML; 1.5%	A089645	001	Jun 21, 1988

AP			0.005MG/ML; 2%	A089651	001	Jun 21, 1988

AP			0.01MG/ML; 1%	A089644	001	Jun 21, 1988

AP			0.01MG/ML; 2%	A078772	001	May 12, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-130 (of 362)

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>		<u>0.01MG/ML;2%</u>	<u>A089646</u>	<u>001</u>	Jun 21, 1988
<u>AP</u>		<u>0.02MG/ML;2%</u>	<u>A078772</u>	<u>002</u>	May 12, 2008

OCTOCAINE

<u>AP</u>	+	SEPTODONT	<u>0.01MG/ML;2%</u>	<u>A084048</u>	<u>001</u>
<u>AP</u>	+		<u>0.02MG/ML;2%</u>	<u>A084048</u>	<u>002</u>

XYLOCAINE W/ EPINEPHRINE

<u>AP</u>	+	FRESENIUS KABI USA	<u>0.005MG/ML;0.5%</u>	<u>N006488</u>	<u>012</u>
<u>AP</u>	+		<u>0.005MG/ML;1%</u>	<u>N006488</u>	<u>018</u>
<u>AP</u>	+		<u>0.005MG/ML;1.5%</u>	<u>N006488</u>	<u>017</u>
<u>AP</u>	+		<u>0.005MG/ML;2%</u>	<u>N006488</u>	<u>019</u>
<u>AP</u>	+		<u>0.01MG/ML;1%</u>	<u>N006488</u>	<u>004</u>
<u>AP</u>	+		<u>0.02MG/ML;2%</u>	<u>N006488</u>	<u>005</u>

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

<u>AP</u>	+	PFIZER INC	<u>200MG/100ML (2MG/ML)</u>	<u>N050778</u>	<u>001</u>	Sep 15, 1999
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>N050778</u>	<u>002</u>	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		ACTAVIS TOTOWA	<u>10MG/5ML (2MG/ML)</u>	<u>A065445</u>	<u>001</u>	Sep 18, 2008
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065445</u>	<u>002</u>	Sep 18, 2008
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065445</u>	<u>003</u>	Sep 18, 2008
<u>AP</u>		AKORN INC	<u>50MG/25ML (2MG/ML)</u>	<u>A090163</u>	<u>001</u>	Jun 24, 2009
<u>AP</u>		BEDFORD	<u>50MG/25ML (2MG/ML)</u>	<u>A065289</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065289</u>	<u>002</u>	Jun 27, 2007
<u>AP</u>		CIPLA LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A065361</u>	<u>001</u>	Oct 22, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065361</u>	<u>002</u>	Oct 22, 2007
<u>AP</u>		EBEWE PHARMA	<u>50MG/25ML (2MG/ML)</u>	<u>A065339</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065339</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		FRESENIUS KABI ONCOL	<u>200MG/100ML (2MG/ML)</u>	<u>A065411</u>	<u>001</u>	Aug 20, 2007
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065411</u>	<u>002</u>	Aug 20, 2007
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/5ML (2MG/ML)</u>	<u>A065408</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065408</u>	<u>002</u>	Oct 15, 2007
<u>AP</u>			<u>150MG/75ML (2MG/ML)</u>	<u>A065408</u>	<u>003</u>	Oct 15, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065408</u>	<u>004</u>	Oct 15, 2007
<u>AP</u>		HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075</u>	<u>001</u>	Mar 25, 2010
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A090075</u>	<u>002</u>	Mar 25, 2010
<u>AP</u>		HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343</u>	<u>001</u>	Apr 19, 2007
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065343</u>	<u>002</u>	Apr 19, 2007
<u>AP</u>			<u>150MG/75ML (2MG/ML)</u>	<u>A065343</u>	<u>003</u>	Apr 19, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065343</u>	<u>004</u>	Apr 19, 2007
<u>AP</u>		MUSTAFA NEVSAT	<u>50MG/25ML (2MG/ML)</u>	<u>A090266</u>	<u>001</u>	Apr 15, 2011
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A090266</u>	<u>002</u>	Apr 15, 2011
<u>AP</u>		ONCO THERAPIES LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599</u>	<u>001</u>	Mar 12, 2012
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A091599</u>	<u>002</u>	Mar 12, 2012
<u>AP</u>		TEVA PHARMS USA	<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

+ HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>		APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>			<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008

INSPIRA

<u>AB</u>		GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+		<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>		TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>			<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008

FLOLAN

<u>AP</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995
<u>AP</u>	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-131 (of 362)

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

+ ACTELION PHARMS LTD

EQ 0.5MG BASE/VIAL

N022260 002 Jun 28, 2012

+

EQ 1.5MG BASE/VIAL

N022260 001 Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE**AB** MYLAN PHARMS INC**EQ 400MG BASE****A202012 001** Nov 16, 2011**AB****EQ 600MG BASE****A202012 002** Nov 16, 2011TEVETEN**AB** ABBVIE**EQ 400MG BASE****N020738 005** Dec 22, 1997**AB** +**EQ 600MG BASE****N020738 006** May 27, 1999EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

+ ABBVIE

600MG; 12.5MG

N021268 001 Nov 01, 2001

+

600MG; 25MG

N021268 002 Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ SCHERING

2MG/ML

N020718 001 May 18, 1998

+

75MG/100ML

N020718 002 May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL**AA** + SANOFI AVENTIS US**50,000 IU****N003444 001**ERGOCALCIFEROL**AA** ORIT LABS LLC**50,000 IU****A040833 001** May 20, 2009**AA** SIGMAPHARM LABS LLC**50,000 IU****A091004 001** Jul 14, 2010**AA** STRIDES ARCOLAB LTD**50,000 IU****A090455 001** Aug 03, 2010**AA** SUN PHARM INDS INC**50,000 IU****A040865 001** Dec 29, 2009VITAMIN D**AA** BANNER PHARMACAPS**50,000 IU****A080704 001**ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES**AB** MUTUAL PHARM**1MG****A081113 001** Oct 31, 1991HYDERGINE**AB** + NOVARTIS**1MG****N017993 001**

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

WATSON LABS

0.5MG

A087233 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC

2MG

A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+ EISAI INC

1MG/2ML (0.5MG/ML)

N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

OSI PHARMS

EQ 25MG BASE

N021743 001 Nov 18, 2004

EQ 100MG BASE

N021743 002 Nov 18, 2004

+

EQ 150MG BASE

N021743 003 Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

+ MERCK SHARP DOHME

EQ 1GM BASE/VIAL

N021337 001 Nov 21, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-132 (of 362)

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC**AB** + MAYNE PHARMA **250MG** **N050536 001**ERYTHROMYCIN**AB** ARBOR PHARMS INC **250MG** **A062746 001** Dec 22, 1986
GEL;TOPICALERYGEL**AT** + DELCOR ASSET CORP **2%** **N050617 001** Oct 21, 1987ERYTHROMYCIN**AT** FOUGERA PHARMS **2%** **A064184 001** Sep 30, 1997**AT** PERRIGO **2%** **A063211 001** Jan 29, 1993

OINTMENT;OPHTHALMIC

ERYTHROMYCIN**AT** AKORN **0.5%** **A064030 001** Jul 18, 1996**AT** BAUSCH AND LOMB **0.5%** **A064067 001** Jul 29, 1994**AT** + PERRIGO CO TENNESSEE **0.5%** **A062447 001** Sep 26, 1983

OINTMENT;TOPICAL

AKNE-MYCIN

+ DOW PHARM

2%

N050584 001 Jan 10, 1985

SOLUTION;TOPICAL

C-SOLVE-2**AT** FOUGERA PHARMS **2%** **A062468 001** Jul 03, 1985ERYTHRA-DERM**AT** PADDOCK LLC **2%** **A062687 001** Feb 05, 1988ERYTHRO-STATIN**AT** HI TECH PHARMA **2%** **A064101 001** Oct 22, 1996ERYTHROMYCIN**AT** + FOUGERA PHARMS **2%** **A064187 001** Sep 30, 1997**AT** PERRIGO NEW YORK **2%** **A063038 001** Jan 11, 1991**AT** WOCKHARDT **2%** **A062825 001** Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN**AT** + FOUGERA PHARMS **2%** **A065320 001** Jul 25, 2006**AT** + PERRIGO **2%** **A064126 001** Jul 03, 1996**AT** VERSAPHARM **2%** **A090215 001** May 12, 2010

TABLET;ORAL

ERYTHROMYCIN

ARBOR PHARMS INC

250MG

A061621 001

+

500MG

A061621 002

TABLET, COATED PARTICLES;ORAL

PCE

ARBOR PHARMS INC

333MG

N050611 001 Sep 09, 1986

+

500MG

N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

+ ARBOR PHARMS INC

250MG

A062298 001

+

333MG

A062298 003 Mar 29, 1982

+

500MG

A062298 002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.**AB** ARBOR PHARMS INC **EQ 200MG BASE/5ML** **N050207 001**ERYPED**AB** ARBOR PHARMS INC **EQ 200MG BASE/5ML** **N050207 003** Mar 30, 1987

+

EQ 400MG BASE/5ML

N050207 002

SUSPENSION;ORAL

E.E.S. 200**AB** ARBOR PHARMS INC **EQ 200MG BASE/5ML** **A061639 001**E.E.S. 400**AB** + ARBOR PHARMS INC **EQ 400MG BASE/5ML** **A061639 002**PEDIAMYCIN**AB** ARBOR PHARMS INC **EQ 200MG BASE/5ML** **A062304 001**PEDIAMYCIN 400**AB** ARBOR PHARMS INC **EQ 400MG BASE/5ML** **A062304 002**

TABLET;ORAL

E.E.S. 400

BX + ARBOR PHARMS INC EQ 400MG BASE A061905 002 Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS INC EQ 400MG BASE A061904 001

PRESCRIPTION DRUG PRODUCT LIST

3-133 (of 362)

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR

EQ 200MG BASE/5ML; EQ 600MG BASE/5ML

A062759 001 May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCINAP + HOSPIRAEQ 1GM BASE/VIALA062638 002 Oct 31, 1986APEQ 500MG BASE/VIALA062638 001 Oct 31, 1986AP +EQ 500MG BASE/VIALN050609 001 Sep 24, 1986ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

+ ARBOR PHARMS INC

EQ 250MG BASE

A060359 001

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATEAA AMNEAL PHARMSEQ 5MG BASE/5MLA202227 001 Mar 14, 2012AA AUROBINDO PHARMA LTDEQ 5MG BASE/5MLA079062 001 Apr 02, 2012AA HETERO LABS LTD IIIEQ 5MG BASE/5MLA202221 001 Jun 12, 2012AA SILARX PHARMS INCEQ 5MG BASE/5MLA090477 001 Jun 12, 2013AA TAROEQ 5MG BASE/5MLA079121 001 May 03, 2012LEXAPROAA + FOREST LABSEQ 5MG BASE/5MLN021365 001 Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATEAB ACCORD HLTHCAREEQ 5MG BASEA202389 001 Sep 11, 2012ABEQ 10MG BASEA202389 002 Sep 11, 2012ABEQ 20MG BASEA202389 003 Sep 11, 2012AB APOTEX INCEQ 5MG BASEA078777 001 Sep 11, 2012ABEQ 10MG BASEA078777 002 Sep 11, 2012ABEQ 20MG BASEA078777 003 Sep 11, 2012AB AUROBINDO PHARMA LTDEQ 5MG BASEA090432 001 Sep 11, 2012ABEQ 10MG BASEA090432 002 Sep 11, 2012ABEQ 20MG BASEA090432 003 Sep 11, 2012AB HIKMA PHARMSEQ 5MG BASEA078766 001 Sep 11, 2012ABEQ 10MG BASEA078766 002 Sep 11, 2012ABEQ 20MG BASEA078766 003 Sep 11, 2012AB INVAGEN PHARMSEQ 5MG BASEA078604 001 Sep 11, 2012ABEQ 10MG BASEA078604 002 Sep 11, 2012ABEQ 20MG BASEA078604 003 Sep 11, 2012AB IVAX SUB TEVA PHARMSEQ 5MG BASEA076765 001 Mar 14, 2012ABEQ 10MG BASEA076765 002 Mar 14, 2012ABEQ 20MG BASEA076765 003 Mar 14, 2012AB JUBILANT ORGANOSYSEQ 5MG BASEA202280 001 Sep 12, 2012ABEQ 10MG BASEA202280 002 Sep 12, 2012ABEQ 20MG BASEA202280 003 Sep 12, 2012AB LUPIN LTDEQ 5MG BASEA078169 001 Sep 11, 2012ABEQ 10MG BASEA078169 002 Sep 11, 2012ABEQ 20MG BASEA078169 003 Sep 11, 2012AB MACLEODS PHARMS LTDEQ 5MG BASEA202210 001 Sep 11, 2012ABEQ 10MG BASEA202210 002 Sep 11, 2012ABEQ 20MG BASEA202210 003 Sep 11, 2012AB STI PHARMA LLCEQ 5MG BASEA077512 001 Sep 12, 2012ABEQ 10MG BASEA077512 002 Sep 12, 2012ABEQ 20MG BASEA077512 003 Sep 12, 2012AB TORRENT PHARMS LTDEQ 5MG BASEA090939 001 Sep 11, 2012ABEQ 10MG BASEA090939 002 Sep 11, 2012ABEQ 20MG BASEA090939 003 Sep 11, 2012AB ZYDUS PHARMS USA INCEQ 5MG BASEA077734 001 Sep 11, 2012ABEQ 10MG BASEA077734 002 Sep 11, 2012ABEQ 20MG BASEA077734 003 Sep 11, 2012LEXAPROAB FOREST LABSEQ 5MG BASEN021323 001 Aug 14, 2002ABEQ 10MG BASEN021323 002 Aug 14, 2002AB +EQ 20MG BASEN021323 003 Aug 14, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-134 (of 362)

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIO

SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
	400MG	N022416 002	Nov 08, 2013
	600MG	N022416 003	Nov 08, 2013
+	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386 006</u>	Feb 25, 2003

ESMOLOL HYDROCHLORIDE

<u>AP</u>		BEDFORD LABS	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004

<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005

<u>AP</u>		MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

ASTRAZENECA	EQ 20MG BASE	N021153 001	Feb 20, 2001

+	EQ 40MG BASE	N021153 002	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011

	EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011

	EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008

	EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006

+	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE; 375MG</u>	<u>A202461 001</u>	Sep 27, 2013

<u>AB</u>		<u>EQ 20MG BASE; 500MG</u>	<u>A202461 002</u>	Sep 27, 2013

VIMOVO

<u>AB</u>	HORIZON PHARMA	<u>EQ 20MG BASE; 375MG</u>	<u>N022511 002</u>	Apr 30, 2010

<u>AB</u>	+	<u>EQ 20MG BASE; 500MG</u>	<u>N022511 001</u>	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE/VIAL</u>	<u>A200882 001</u>	Mar 18, 2013

<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A200882 002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+	ASTRAZENECA	<u>EQ 20MG BASE/VIAL</u>	<u>N021689 001</u>	Mar 31, 2005

<u>AP</u>	+		<u>EQ 40MG BASE/VIAL</u>	<u>N021689 002</u>	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

HANMI PHARM CO LTD	EQ 20MG BASE	N202342 001	Aug 06, 2013

+	EQ 40MG BASE	N202342 002	Aug 06, 2013

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826 001</u>	Jul 03, 1997

<u>AB</u>		<u>2MG</u>	<u>A074826 002</u>	Jul 03, 1997

<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921 001</u>	Jul 10, 1997

<u>AB</u>	+	<u>2MG</u>	<u>A074921 002</u>	Jul 10, 1997

<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818 001</u>	Aug 19, 1997

<u>AB</u>		<u>2MG</u>	<u>A074818 002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375 005</u>	May 27, 2003

<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375 006</u>	May 27, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-135 (of 362)

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

AB	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
AB		<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006

VIVELLE

AB1	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323</u>	<u>002</u>	Oct 28, 1994
AB1		<u>0.1MG/24HR</u>	<u>N020323</u>	<u>004</u>	Oct 28, 1994

VIVELLE-DOT

AB1	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
AB1	+	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

AB2	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
AB2		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
AB2		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
AB2	+	<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

AB2	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
AB2		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
AB2		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
AB2		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

ALORA

BX	WATSON LABS	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986

VIVELLE-DOT

BX	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002
BX		0.0375MG/24HR	N020538	005	Jan 08, 1999
BX		0.075MG/24HR	N020538	007	Jan 08, 1999

MENOSTAR

+	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004

MINIVELLE

	NOVEN	0.0375MG/24HR	N203752	001	Oct 29, 2012
		0.05MG/24HR	N203752	003	Oct 29, 2012
		0.075MG/24HR	N203752	002	Oct 29, 2012
+		0.1MG/24HR	N203752	004	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

	UPSHER SMITH	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTROGEL

+	ASCEND	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

+	KV PHARM	1.53MG/SPRAY	N022014	001	Jul 27, 2007

TABLET;ORAL

ESTRADIOL

AB	BARR LABS INC	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
AB		<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
AB	+	<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
AB	MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
AB		<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
AB		<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999
AB	USL PHARMA	<u>0.5MG</u>	<u>A040297</u>	<u>001</u>	Apr 17, 2002
AB		<u>1MG</u>	<u>A040297</u>	<u>002</u>	Apr 17, 2002
AB		<u>2MG</u>	<u>A040297</u>	<u>003</u>	Apr 17, 2002
AB	WATSON LABS	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
AB		<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
AB		<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-136 (of 362)

ESTRADIOL

TABLET;VAGINAL

VAGIFEM

+ NOVO NORDISK INC

10MCG

N020908 002 Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

WARNER IRELAND

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003

+

EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003

TABLET;ORAL

FEMTRACE

WARNER CHILCOTT LLC

0.45MG

N021633 001 Aug 20, 2004

0.9MG

N021633 002 Aug 20, 2004

+

1.8MG

N021633 003 Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOLAO + PHARMACIA AND UPJOHN5MG/MLA085470 003ESTRADIOL CYPIONATEAO WATSON LABS5MG/MLA085620 001ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL

ESTRASORB

+ MEDICIS

0.25%

N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGENAO + JHP PHARMS10MG/MLN009402 002AO +20MG/MLN009402 004AO +40MG/MLN009402 003ESTRADIOL VALERATEAO LUITPOLD20MG/MLA090920 001 Jan 19, 2010AO40MG/MLA090920 002 Jan 19, 2010AO SANDOZ10MG/MLA040628 001 Oct 04, 2007AO20MG/MLA040628 002 Oct 04, 2007AO40MG/MLA040628 003 Oct 04, 2007ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

+ BAYER HLTHCARE

0.045MG/24HR;0.015MG/24HR

N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

NOVARTIS

0.05MG/24HR;0.14MG/24HR

N020870 001 Aug 07, 1998

+

0.05MG/24HR;0.25MG/24HR

N020870 002 Aug 07, 1998

TABLET;ORAL

ACTIVELLAAB NOVO NORDISK INC0.5MG;0.1MGN020907 002 Dec 28, 2006AB +1MG;0.5MGN020907 001 Nov 18, 1998ESTRADIOL AND NORETHINDRONE ACETATEAB BARR1MG;0.5MGA079193 001 May 11, 2010AB BRECKENRIDGE PHARM0.5MG;0.1MGA078324 002 Jun 09, 2011AB1MG;0.5MGA078324 001 Apr 17, 2008AB TEVA PHARMS USA0.5MG;0.1MGA200747 001 Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATEAB BARR1MG,1MG;1MG,1MG;N/A,0.09MGA076812 001 Apr 29, 2005PREFESTAB + TEVA WOMENS1MG,1MG;1MG,1MG;N/A,0.09MGN021040 001 Oct 22, 1999ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

+ PHARMACIA AND UPJOHN

EQ 140MG PHOSPHATE

N018045 001

PRESCRIPTION DRUG PRODUCT LIST

3-137 (of 362)

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM

N020216 001

INJECTABLE; INJECTION

PREMARIN

+ WYETH PHARMS INC 25MG/VIAL

N010402 001

TABLET; ORAL

PREMARIN

WYETH PHARMS INC 0.3MG

N004782 003

0.45MG

N004782 006 Jul 16, 2003

+ 0.625MG

N004782 004

+ 0.9MG

N004782 005 Jan 26, 1984

+ 1.25MG

N004782 001

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM 0.3MG

N020992 001 Jun 21, 2002

0.45MG

N020992 005 Feb 05, 2004

0.625MG

N020992 002 Mar 24, 1999

0.9MG

N020992 003 Mar 24, 1999

+ 1.25MG

N020992 004 Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA WOMENS 0.3MG

N021443 001 Dec 20, 2004

0.45MG

N021443 002 Dec 20, 2004

0.625MG

N021443 003 May 10, 2004

0.9MG

N021443 005 Apr 27, 2007

+ 1.25MG

N021443 004 May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG; 0.625MG; 0.625MG; 0.625MG; N/A, 5MG

N020527 002 Nov 17, 1995

PREMPRO

+ WYETH PHARMS INC 0.3MG; 1.5MG

N020527 005 Jun 04, 2003

+ 0.45MG; 1.5MG

N020527 004 Mar 12, 2003

+ 0.625MG; 0.625MG; 2.5MG; 2.5MG

N020527 001 Nov 17, 1995

+ 0.625MG; 0.625MG; 5MG; 5MG

N020527 003 Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS 0.3MG

A084951 001

0.625MG

A084948 001

1.25MG

A084950 001

+ 2.5MG

A084949 001

ESTROPIPATE

TABLET; ORAL

ESTROPIPATEAB BARR 0.75MGA040135 001 Nov 27, 1996AB 1.5MGA040135 002 Nov 27, 1996AB 3MGA040135 003 Nov 27, 1996AB MYLAN 0.75MGA040359 001 Aug 26, 1999AB 1.5MGA040359 002 Aug 26, 1999AB WATSON LABS 0.75MGA081213 001 Sep 23, 1993AB 1.5MGA081214 001 Sep 23, 1993AB 3MGA081215 001 Sep 23, 1993AB 6MGA081216 001 Sep 23, 1993OGEN .625AB PHARMACIA AND UPJOHN 0.75MGA083220 001OGEN 1.25AB PHARMACIA AND UPJOHN 1.5MGA083220 002OGEN 2.5AB + PHARMACIA AND UPJOHN 3MGA083220 003OGEN 5AB PHARMACIA AND UPJOHN 6MGA083220 004

PRESCRIPTION DRUG PRODUCT LIST

3-138 (of 362)

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A091151</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>		<u>2MG</u>	<u>A091151</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		<u>3MG</u>	<u>A091151</u>	<u>003</u>	Mar 26, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>1MG</u>	<u>A091103</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>		<u>2MG</u>	<u>A091103</u>	<u>002</u>	Apr 03, 2013
<u>AB</u>		<u>3MG</u>	<u>A091103</u>	<u>003</u>	Apr 03, 2013

LUNESTA

<u>AB</u>	SUNOVION PHARMS INC	<u>1MG</u>	<u>N021476</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>2MG</u>	<u>N021476</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>	+	<u>3MG</u>	<u>N021476</u>	<u>003</u>	Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

+ ATON

EQ 50MG BASE/VIAL

N016093 001

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

+ ATON

25MG

N016092 001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>	BARR	<u>400MG</u>	<u>A076057</u>	<u>001</u>	Nov 26, 2001
<u>AB</u>	LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>400MG</u>	<u>A078939</u>	<u>002</u>	Jun 17, 2009

MYAMBUTOL

<u>AB</u>	STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>	
<u>AB</u>	+	<u>400MG</u>	<u>N016320</u>	<u>003</u>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+ QOL MEDCL

50MG/ML

N019357 001 Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A076785</u>	<u>001</u>	May 23, 2005
<u>AB</u>	<u>ZOVIA 1/35E-28</u>	<u>0.035MG;1MG</u>	<u>A072721</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>			
	ZOVIA 1/50E-28				
	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991

ETHINYL ESTRADIOL; ETNOGESTREL

RING; VAGINAL

NUVARING

+ ORGANON USA INC

0.015MG;0.12MG

N021187 001 Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

<u>AB</u>	LUPIN LTD	<u>0.03MG;0.01MG;0.15MG,N/A</u>	<u>A091467</u>	<u>001</u>	Apr 10, 2013

INTROVALE

<u>AB</u>	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079064</u>	<u>001</u>	Sep 27, 2010

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	LUPIN LTD	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A091674</u>	<u>001</u>	Oct 26, 2011
<u>AB</u>		<u>0.03MG;0.15MG</u>	<u>A091440</u>	<u>001</u>	Oct 23, 2012
<u>AB</u>	WATSON LABS	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A200407</u>	<u>001</u>	Oct 25, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

<u>AB</u>	WATSON LABS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A078834</u>	<u>001</u>	May 31, 2011

LOSEASONIQUE

<u>AB</u>	TEVA BRANDED PHARM	<u>0.01MG;0.02MG;0.1MG</u>	<u>N022262</u>	<u>001</u>	Oct 24, 2008

QUASENSE

<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101</u>	<u>001</u>	Sep 06, 2006

SEASONALE

<u>AB</u>	+	TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544</u>	<u>001</u>	Sep 05, 2003

SEASONIQUE

<u>AB</u>	+	TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.03MG,0.01MG;0.15MG,N/A</u>	<u>N021840</u>	<u>001</u>	May 25, 2006

LEVONORGESTREL AND ETHINYL ESTRADIOL

+ WATSON LABS

0.02MG;0.09MG

A079218 001 Jun 06, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-139 (of 362)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

QUARTETTE

+ TEVA BRANDED PHARM

0.02MG; 0.15MG

N204061 001 Mar 28, 2013

TABLET; ORAL-28

ALTAVERA**AB** SANDOZ0.03MG; 0.15MGA079102 001 Aug 03, 2010ENPRESSE-28**AB** DURAMED PHARMS BARR0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.125MGA075809 002 Jul 16, 2001KURVELO**AB** LUPIN LTD0.03MG; 0.15MGA091408 001 Oct 17, 2012LEVONEST**AB** NOVAST LABS LTD0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.125MGA090719 001 Dec 29, 2010LEVONORGESTREL AND ETHINYL ESTRADIOL**AB** FAMY CARE LTD0.03MG; 0.15MGA091663 001 Dec 21, 2012LEVORA 0.15/30-28**AB** WATSON LABS0.03MG; 0.15MGA073594 001 Dec 13, 1993MARLISSA**AB** GLENMARK GENERICS0.03MG; 0.15MGA091452 001 Feb 29, 2012MYZILRA**AB** VINTAGE PHARMS LLC0.03MG; 0.04MG; 0.03MG; 0.05MG; 0.075MG; 0.125MGA077502 001 Nov 23, 2011NORDETTE-28**AB** + TEVA BRANDED PHARM0.03MG; 0.15MGN018782 001 Jul 21, 1982PORTIA-28**AB** BARR0.03MG; 0.15MGA075866 002 May 23, 2002TRIVORA-28**AB** + WATSON LABS0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.125MGA074538 002 Dec 18, 1997AVIANE-28**AB1** DURAMED PHARMS BARR0.02MG; 0.1MGA075796 001 Apr 30, 2001FALMINA**AB1** NOVAST LABS LTD0.02MG; 0.1MGA090721 001 Mar 28, 2012LEVONORGESTREL AND ETHINYL ESTRADIOL**AB1** FAMY CARE LTD0.02MG; 0.1MGA200245 001 Oct 09, 2013**AB1** LUPIN LTD0.02MG; 0.1MGA091425 001 Jan 18, 2013**AB1** + WATSON LABS0.02MG; 0.1MGA076625 001 Nov 18, 2004ORSYTHIA**AB1** VINTAGE PHARMS LLC0.02MG; 0.1MGA077099 001 May 11, 2011LESSINA-28**AB2** BARR0.02MG; 0.1MGA075803 002 Mar 20, 2002LEVONORGESTREL AND ETHINYL ESTRADIOL**AB2** + WATSON LABS0.02MG; 0.1MGA077681 001 May 31, 2006ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+ JANSSEN PHARMS

0.75MG; 6MG

N021180 001 Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21**AB** WATSON LABS0.035MG; 1MGA071480 001 Apr 12, 1988NORETHINDRONE AND ETHINYL ESTRADIOL**AB** WATSON LABS0.035MG; 1MGA070685 001 Jan 29, 1987NORINYL 1+35 21-DAY**AB** WATSON LABS0.035MG; 1MGN017565 001NORTREL 1/35-21**AB** BARR0.035MG; 1MGA072693 001 Feb 28, 1992

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG; 0.4MG

A078379 001 Feb 23, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS

0.035MG; 0.035MG; 0.5MG; 1MG

A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS

0.035MG; 0.035MG; 0.5MG; 1MG

A071041 001 Sep 24, 1991

NORTREL 7/7/7

BARR

0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG

A075478 001 Aug 30, 2002

TABLET; ORAL-28

ALYACEN 1/35**AB** GLENMARK GENERICS0.035MG; 1MGA091634 001 Jan 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-140 (of 362)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 7/7/7

AB	GLENMARK GENERICS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A091636</u>	<u>001</u>	Jan 19, 2012

ARANELLE

AB	BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004

BALZIVA-28

AB	BARR	<u>0.035MG;0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004

BREVICON 28-DAY

AB	WATSON LABS	<u>0.035MG;0.5MG</u>	<u>N017743</u>	<u>001</u>	

BRIELLYN

AB	GLENMARK GENERICS	<u>0.035MG;0.4MG</u>	<u>A090538</u>	<u>001</u>	Mar 22, 2011

CYCLAFEM 1/35

AB	VINTAGE PHARMS LLC	<u>0.035MG;1MG</u>	<u>A076337</u>	<u>001</u>	Nov 12, 2010

CYCLAFEM 7/7/7

AB	VINTAGE PHARMS LLC	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A076338</u>	<u>001</u>	Nov 16, 2010

DASETTA 1/35

AB	NOVAST LABS LTD	<u>0.035MG;1MG</u>	<u>A090948</u>	<u>001</u>	Dec 22, 2011

DASETTA 7/7/7

AB	NOVAST LABS LTD	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A090946</u>	<u>001</u>	Dec 22, 2011

GILDAGIA

AB	VINTAGE PHARMS	<u>0.035MG;0.4MG</u>	<u>A078376</u>	<u>001</u>	Nov 06, 2012

MODICON 28

AB	+ JANSSEN PHARMS	<u>0.035MG;0.5MG</u>	<u>N017735</u>	<u>001</u>	

NORETHIN 1/35E-28

AB	WATSON LABS	<u>0.035MG;1MG</u>	<u>A071481</u>	<u>001</u>	Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	+ FAMY CARE LTD	<u>0.05MG;1MG</u>	<u>A203006</u>	<u>001</u>	Aug 05, 2013

AB	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010

AB		<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987

AB		<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A076393</u>	<u>001</u>	Feb 04, 2010

AB		<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987

NORINYL 1+35 28-DAY

AB	WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	

NORTREL 0.5/35-28

AB	BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992

NORTREL 1/35-28

AB	BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992

NORTREL 7/7/7

AB	BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002

ORTHO-NOVUM 1/35-28

AB	+ JANSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	

ORTHO-NOVUM 7/7/7-28

AB	+ JANSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984

OVCON-35

AB	+ WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N017716</u>	<u>001</u>	

PHILITH

AB	NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011

PIRMELLA 1/35

AB	LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512</u>	<u>001</u>	Apr 24, 2013

PIRMELLA 7/7/7

AB	LUPIN LTD	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A201510</u>	<u>001</u>	Apr 24, 2013

TRI-NORINYL 28-DAY

AB	+ WATSON LABS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984

VYFEMLA

AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013

WERA

AB	NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

	WATSON LABS	<u>0.035MG;0.035MG;0.5MG;1MG</u>	<u>A071044</u>	<u>001</u>	Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	WATSON LABS	<u>0.035MG;0.035MG;0.035MG;0.035MG;0.5MG;1MG;0.5MG;1MG</u>	<u>A071042</u>	<u>001</u>	Sep 24, 1991

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+ WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-141 (of 362)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
AB	BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
	+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LOESTRIN 24 FE

AB	+ WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
	FEMHRT				
	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
	LO LOESTRIN FE				
	+ WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
	+ BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009

TABLET; ORAL-21

JUNEL 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003

JUNEL 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003

LARIN 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202995</u>	<u>001</u>	Dec 04, 2013

LOESTRIN 21 1.5/30

AB	WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017875</u>	<u>001</u>	

LOESTRIN 21 1/20

AB	WARNER CHILCOTT LLC	<u>0.02MG;1MG</u>	<u>N017876</u>	<u>001</u>	

MICROGESTIN 1.5/30

AB	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>002</u>	Jul 30, 2003

MICROGESTIN 1/20

AB	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>002</u>	Jul 30, 2003

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202771</u>	<u>001</u>	Nov 06, 2013

TRI-LEGEST 21

	BARR	0.02MG;0.035MG;0.03MG;1MG;1MG;1MG	A076405	001	Oct 26, 2007

TABLET; ORAL-28

ESTROSTEP FE

AB	+ WARNER CHILCOTT LLC	<u>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</u>	<u>N020130</u>	<u>002</u>	Oct 09, 1996

GILDESS FE 1.5/30

AB	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>001</u>	Apr 28, 2005

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>001</u>	May 20, 2005

JUNEL FE 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076064</u>	<u>001</u>	Sep 18, 2003

JUNEL FE 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076081</u>	<u>001</u>	Sep 18, 2003

LARIN FE 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A091453</u>	<u>001</u>	Aug 23, 2013

LARIN FE 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A091454</u>	<u>001</u>	Aug 26, 2013

LOESTRIN FE 1.5/30

AB	+ WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017355</u>	<u>001</u>	

LOESTRIN FE 1/20

AB	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N017354</u>	<u>001</u>	

MICROGESTIN FE 1.5/30

AB	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>001</u>	Feb 05, 2001

MICROGESTIN FE 1/20

AB	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>001</u>	Feb 05, 2001

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202772</u>	<u>001</u>	Nov 14, 2013

AB	WATSON LABS	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629</u>	<u>001</u>	Mar 18, 2010

TRI-LEGEST FE

AB	BARR	<u>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</u>	<u>A076105</u>	<u>001</u>	Oct 26, 2007

TABLET, CHEWABLE; ORAL

MINASTRIN 24 FE

	+ WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2013

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

	+ WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-142 (of 362)

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A200494 001	Jun 17, 2011

TABLET; ORAL-28

ESTARYLLA

AB	SANDOZ	<u>0.035MG;0.25MG</u>	A090794 001	Jan 30, 2013

MONO-LINYAH

AB	NOVAST LABS LTD	<u>0.035MG;0.25MG</u>	A090523 001	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	<u>0.035MG;0.25MG</u>	A200538 001	Apr 05, 2012

AB	LUPIN PHARMS	<u>0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG</u>	A200541 001	Jun 25, 2012

AB	WATSON LABS	<u>0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG</u>	A090479 001	Mar 09, 2011

AB		<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A076626 001	Aug 17, 2006

AB		<u>0.035MG;0.25MG</u>	A076627 001	Aug 17, 2006

ORTHO CYCLEN-28

AB	+ JANSSSEN PHARMS	<u>0.035MG;0.25MG</u>	N019653 002	Dec 29, 1989

ORTHO TRI-CYCLEN

AB	+ JANSSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	N019697 001	Jul 03, 1992

ORTHO TRI-CYCLEN LO

AB	+ JANSSSEN PHARMS	<u>0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG</u>	N021241 001	Aug 22, 2002

PREVIFEM

AB	VINTAGE PHARMS LLC	<u>0.035MG;0.25MG</u>	A076334 001	Jan 09, 2004

SPRINTEC

AB	BARR	<u>0.035MG;0.25MG</u>	A075804 001	Sep 25, 2002

TRI-ESTARYLLA

AB	SANDOZ	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A090793 001	Jan 30, 2013

TRI-LINYAH

AB	NOVAST LABS LTD	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A090524 001	May 30, 2012

TRI-PREVIFEM

AB	VINTAGE PHARMS LLC	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A076335 001	Mar 26, 2004

TRI-SPRINTEC

AB	BARR	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	A075808 001	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	A075840 001	Nov 30, 2001

LOW-OGESTREL-21

AB	+ WATSON LABS	<u>0.03MG;0.3MG</u>	A075288 001	Jul 28, 1999

TABLET; ORAL-28

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	A075840 002	Nov 30, 2001

ELINEST

AB	NOVAST LABS LTD	<u>0.03MG;0.3MG</u>	A091105 001	Mar 28, 2012

LO/OVRAL-28

AB	WYETH PHARMS	<u>0.03MG;0.3MG</u>	N017802 001	

LOW-OGESTREL-28

AB	WATSON LABS	<u>0.03MG;0.3MG</u>	A075288 002	Jul 28, 1999

OGESTREL 0.5/50-28

	+ WATSON LABS	0.05MG;0.5MG	A075406 002	Dec 15, 1999

ETHIONAMIDE

TABLET; ORAL

TRECATOR

	+ WYETH PHARMS INC	250MG	N013026 002	

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	BANNER PHARMACAPS	<u>250MG</u>	A040430 001	Oct 28, 2002

AB	VERSAPHARM	<u>250MG</u>	A040686 001	May 28, 2008

AB	ZYDUS PHARMS USA INC	<u>250MG</u>	A200892 001	Sep 25, 2012

ZARONTIN

AB	+ PARKE DAVIS	<u>250MG</u>	N012380 001	

PRESCRIPTION DRUG PRODUCT LIST

3-143 (of 362)

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

AA	MIKART	250MG/5ML	A040506 001	Dec 22, 2003
AA	PHARM ASSOC	250MG/5ML	A040253 001	Nov 22, 2000
AA	TEVA PHARMS	250MG/5ML	A081306 001	Jul 30, 1993

ZARONTIN

AA	+ PARKE DAVIS	250MG/5ML	A080258 001	

ETHOTOIN

TABLET; ORAL

PEGANONE

	+ RECORDATI RARE	250MG	N010841 001	

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB	PROCTER AND GAMBLE	200MG	N017831 001	
AB	+	400MG	N017831 002	

ETIDRONATE DISODIUM

AB	MYLAN	200MG	A075800 001	Jan 24, 2003
AB		400MG	A075800 002	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB	APOTEX	200MG	A075419 001	Jul 28, 2000
AB		300MG	A075419 002	Jul 28, 2000
AB	TARO	200MG	A075078 001	Apr 30, 1998
AB	+	300MG	A075078 002	Apr 30, 1998
AB	TEVA	300MG	A075126 002	Sep 16, 1999

TABLET; ORAL

ETODOLAC

AB	APOTEX INC	400MG	A076004 001	Dec 03, 2002
AB		500MG	A076004 002	Dec 03, 2002
AB	MYLAN	400MG	A075104 001	Feb 06, 1998
AB		500MG	A075104 002	Nov 20, 1998
AB	SANDOZ	400MG	A074903 001	Apr 11, 1997
AB		500MG	A074903 002	Apr 19, 1999
AB	TARO PHARM INDS	400MG	A075074 001	Mar 11, 1998
AB	+	500MG	A075074 002	Apr 25, 2000
AB	TEVA	400MG	A075009 001	Nov 26, 1997
AB		500MG	A075009 002	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB	TARO	400MG	A076174 001	Mar 13, 2003
AB		500MG	A076174 002	Mar 13, 2003
AB		600MG	A076174 003	Mar 13, 2003
AB	TEVA	400MG	A075665 003	Feb 05, 2001
AB		500MG	A075665 002	Jul 31, 2000
AB	+	600MG	A075665 001	Jul 31, 2000

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+ HOSPIRA	2MG/ML	N018227 001	Sep 07, 1982

ETOMIDATE

AP	BEDFORD	2MG/ML	A074593 001	Nov 04, 1996
AP	JHP PHARMS LLC	2MG/ML	A091297 001	Jun 20, 2012
AP	LUITPOLD	2MG/ML	A078867 001	Dec 22, 2009
AP	STRIDES ARCOLAB LTD	2MG/ML	A078289 001	Jan 02, 2009

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

	+ ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006

NEXPLANON

	+ ORGANON USA INC	68MG/IMPLANT	N021529 002	May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-144 (of 362)

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+ MYLAN

50MG

A075635 001 Sep 19, 2001

INJECTABLE; INJECTION

ETOPOSIDEAP ACCORD HLTHCARE20MG/MLA074513 001 Mar 14, 1996AP BEDFORD20MG/MLA074290 001 Jul 17, 1995AP + FRESENIUS KABI USA20MG/MLA074983 001 Sep 30, 1998AP TEVA PHARMS USA20MG/MLA074284 001 Feb 10, 1994AP20MG/MLA074529 001 Jul 24, 1996ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

+ BRISTOL MYERS SQUIBB

EQ 100MG BASE/VIAL

N020457 001 May 17, 1996

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D

25MG

N022187 003 Mar 26, 2012

100MG

N022187 001 Jan 18, 2008

+

200MG

N022187 002 Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

2.5MG

N022334 003 Jul 09, 2010

5MG

N022334 001 Mar 30, 2009

7.5MG

N022334 004 Mar 30, 2012

+

10MG

N022334 002 Mar 30, 2009

ZORTRESS

NOVARTIS

0.25MG

N021560 001 Apr 20, 2010

0.5MG

N021560 002 Apr 20, 2010

+

0.75MG

N021560 003 Apr 20, 2010

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM

2MG

N203985 001 Aug 29, 2012

3MG

N203985 002 Aug 29, 2012

+

5MG

N203985 003 Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASINAB + PHARMACIA AND UPJOHN25MGN020753 001 Oct 21, 1999EXEMESTANEAB ROXANE25MGA077431 001 Apr 01, 2011EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN

2MG/VIAL

N022200 001 Jan 27, 2012

INJECTABLE; SUBCUTANEOUS

BYETTA

+ AMYLIN

300MCG/1.2ML (250MCG/ML)

N021773 001 Apr 28, 2005

+

600MCG/2.4ML (250MCG/ML)

N021773 002 Apr 28, 2005

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG; 10MG

N021687 001 Jul 23, 2004

10MG; 20MG

N021687 002 Jul 23, 2004

10MG; 40MG

N021687 003 Jul 23, 2004

+

10MG; 80MG

N021687 004 Jul 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-145 (of 362)

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011

200MG

N022345 002 Jun 10, 2011

300MG

N022345 003 Jun 10, 2011

+

400MG

N022345 004 Jun 10, 2011

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIRAB APOTEX125MGA091480 001 Jul 22, 2011AB250MGA091480 002 Jul 22, 2011AB500MGA091480 003 Jul 22, 2011AB AUROBINDO PHARMA LTD125MGA091114 001 Mar 21, 2011AB250MGA091114 002 Mar 21, 2011AB500MGA091114 003 Mar 21, 2011AB CIPLA LTD125MGA078278 001 Mar 21, 2011AB250MGA078278 002 Mar 21, 2011AB500MGA078278 003 Mar 21, 2011AB MACLEODS PHARMS LTD125MGA201022 001 Jan 12, 2012AB250MGA201022 002 Jan 12, 2012AB500MGA201022 003 Jan 12, 2012AB MYLAN125MGA201333 001 Mar 24, 2011AB250MGA201333 002 Mar 24, 2011AB500MGA201333 003 Mar 24, 2011AB ROXANE125MGA090128 001 Mar 21, 2011AB250MGA090128 002 Mar 21, 2011AB500MGA090128 003 Mar 21, 2011AB TEVA PHARMS125MGA077487 001 Aug 24, 2007AB250MGA077487 002 Aug 24, 2007AB500MGA077487 003 Aug 24, 2007FAMVIRAB NOVARTIS125MGN020363 003 Dec 11, 1995AB250MGN020363 001 Apr 26, 1996AB +500MGN020363 002 Jun 29, 1994FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINEAB LUPIN LTD40MG/5MLA090440 001 Jun 29, 2010AB NAVINTA LLC40MG/5MLA091020 001 May 27, 2010PEPCIDAB + SALIX PHARMS40MG/5MLN019527 001 Feb 02, 1987

INJECTABLE; INJECTION

FAMOTIDINEAP AGILA SPECLTS10MG/MLA078641 001 Jun 25, 2008AP BEDFORD10MG/MLA075651 001 Apr 16, 2001AP10MG/MLA075684 001 Apr 16, 2001AP FRESENIUS KABI USA10MG/MLA075709 001 Apr 16, 2001AP + HIKMA MAPLE10MG/MLA075488 001 Apr 16, 2001FAMOTIDINE PRESERVATIVE FREEAP AGILA SPECLTS10MG/MLA078642 001 Jun 25, 2008AP BEDFORD10MG/MLA075622 001 Apr 16, 2001AP BEN VENUE10MG/MLA075825 001 Apr 17, 2001AP FRESENIUS KABI USA10MG/MLA075813 001 Apr 16, 2001AP + HIKMA MAPLE10MG/MLA075486 001 Apr 16, 2001FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINERAP + BAXTER HLTHCARE0.4MG/MLA075591 001 May 10, 2001

SUSPENSION; ORAL

FAMOTIDINEAB NOVEL LABS INC40MG/5MLA201695 001 Dec 17, 2012

TABLET; ORAL

FAMOTIDINEAB ALEMBIC PHARMS LTD20MGA078916 001 May 22, 2009AB40MGA078916 002 May 22, 2009AB APOTEX20MGA075611 001 Jul 23, 2001AB40MGA075611 002 Jul 23, 2001AB CARLSBAD20MGA075805 001 Apr 16, 2001AB40MGA075805 002 Apr 16, 2001AB DR REDDYS LABS LTD20MGA075718 001 Apr 16, 2001AB40MGA075718 002 Apr 16, 2001AB IVAX SUB TEVA PHARMS20MGA075511 001 Apr 16, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-146 (of 362)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
<u>PEPCID</u>					
<u>AB</u>	MARATHON PHARMS	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG; 800MG	N022519	001	Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

ULORIC

	TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009
+		80MG	N021856	002	Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
<u>FELBATOL</u>					
<u>AB</u>	+	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993
TABLET; ORAL					
<u>FELBAMATE</u>					
<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
<u>FELBATOL</u>					
<u>AB</u>	MEDA PHARMS	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG</u>	<u>A201964</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>		<u>5MG</u>	<u>A201964</u>	<u>002</u>	Nov 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A201964</u>	<u>003</u>	Nov 08, 2013
<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	+	<u>10MG</u>	<u>A078855</u>	<u>003</u>	Apr 17, 2008
<u>AB</u>	RANBAXY LABS LTD	<u>2.5MG</u>	<u>A091200</u>	<u>001</u>	Dec 13, 2013
<u>AB</u>		<u>5MG</u>	<u>A091200</u>	<u>002</u>	Dec 13, 2013
<u>AB</u>		<u>10MG</u>	<u>A091200</u>	<u>003</u>	Dec 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011
<u>AB</u>	WOCKHARDT LTD	<u>2.5MG</u>	<u>A091484</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		<u>5MG</u>	<u>A091484</u>	<u>002</u>	Aug 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A091484</u>	<u>003</u>	Aug 15, 2012
<u>PLENDIL</u>					
<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019834</u>	<u>004</u>	Sep 22, 1994
<u>AB</u>		<u>5MG</u>	<u>N019834</u>	<u>001</u>	Jul 25, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-147 (of 362)

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

<u>AB</u>		<u>10MG</u>	<u>N019834</u>	<u>002</u>	Jul 25, 1991

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

<u>AB</u>	LUPIN ATLANTIS	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004

<u>AB</u>	+	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004

FENOFIBRATE (MICRONIZED)

<u>AB</u>	APOTEX INC	<u>43MG</u>	<u>A202252</u>	<u>001</u>	Jul 26, 2013

<u>AB</u>		<u>130MG</u>	<u>A202252</u>	<u>002</u>	Jul 26, 2013

<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012

<u>AB</u>		<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012

<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003

<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003

<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003

<u>AB</u>	MYLAN PHARMS INC	<u>43MG</u>	<u>A202579</u>	<u>001</u>	Jan 10, 2013

<u>AB</u>		<u>67MG</u>	<u>A202676</u>	<u>001</u>	Oct 23, 2012

<u>AB</u>		<u>130MG</u>	<u>A202579</u>	<u>002</u>	Jan 10, 2013

<u>AB</u>		<u>134MG</u>	<u>A202676</u>	<u>002</u>	Oct 23, 2012

<u>AB</u>		<u>200MG</u>	<u>A202676</u>	<u>003</u>	Oct 23, 2012

<u>AB</u>	TEVA	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002

<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002

<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002

ANTARA (MICRONIZED)

	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013

		90MG	N021695	005	Oct 18, 2013

LIPOFEN

	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006

+		150MG	N021612	003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008

<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008

<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011

<u>AB</u>		<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011

<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007

<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007

<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012

<u>AB</u>		<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012

<u>AB</u>	RANBAXY	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005

<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005

<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005

<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005

<u>AB</u>	VALEANT INTL	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012

<u>AB</u>		<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012

TRICOR

<u>AB</u>	ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004

<u>AB</u>	+	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004

TRIGLIDE

BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005

FENOFIBRATE

	RANBAXY	107MG	A076635	002	Oct 31, 2005

FENOGLIDE

	SALIX PHARMS INC	40MG	N022118	001	Aug 10, 2007

+		120MG	N022118	002	Aug 10, 2007

TRIGLIDE

	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009

+		105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997

FENOLDOPAM MESYLATE

<u>AP</u>		BEDFORD LABS	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004

<u>AP</u>		SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-148 (of 362)

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+ XSPIRE

EQ 200MG BASE

N017604 003

EQ 400MG BASE

N017604 004 Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

+ MYLAN PHARMS INC

EQ 600MG BASE

A072267 001 Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100AB JANSSEN PHARMS100MCG/HRN019813 001 Aug 07, 1990DURAGESIC-12AB JANSSEN PHARMS12.5MCG/HRN019813 005 Feb 04, 2005DURAGESIC-25AB + JANSSEN PHARMS25MCG/HRN019813 004 Aug 07, 1990DURAGESIC-50AB JANSSEN PHARMS50MCG/HRN019813 003 Aug 07, 1990DURAGESIC-75AB JANSSEN PHARMS75MCG/HRN019813 002 Aug 07, 1990FENTANYL-100AB AVEVA100MCG/HRA077449 004 Oct 20, 2008AB LAVIPHARM LABS100MCG/HRA077051 004 Aug 04, 2006AB MALLINCKRODT INC100MCG/HRA077154 004 Feb 09, 2011AB MYLAN TECHNOLOGIES100MCG/HRA076258 004 Jan 28, 2005AB NOVEN100MCG/HRA077775 004 Oct 16, 2009AB PAR PHARM INC100MCG/HRA077062 004 Aug 20, 2007AB WATSON LABS100MCG/HRA076709 004 Aug 20, 2007FENTANYL-12AB MYLAN TECHNOLOGIES12.5MCG/HRA076258 005 Jan 23, 2007FENTANYL-25AB AVEVA25MCG/HRA077449 001 Oct 20, 2008AB LAVIPHARM LABS25MCG/HRA077051 001 Aug 04, 2006AB MALLINCKRODT INC25MCG/HRA077154 001 Feb 09, 2011AB MYLAN TECHNOLOGIES25MCG/HRA076258 001 Jan 28, 2005AB NOVEN25MCG/HRA077775 001 Oct 16, 2009AB PAR PHARM INC25MCG/HRA077062 001 Aug 20, 2007AB WATSON LABS25MCG/HRA076709 001 Aug 20, 2007FENTANYL-50AB AVEVA50MCG/HRA077449 002 Oct 20, 2008AB LAVIPHARM LABS50MCG/HRA077051 002 Aug 04, 2006AB MALLINCKRODT INC50MCG/HRA077154 002 Feb 09, 2011AB MYLAN TECHNOLOGIES50MCG/HRA076258 002 Jan 28, 2005AB NOVEN50MCG/HRA077775 002 Oct 16, 2009AB PAR PHARM INC50MCG/HRA077062 002 Aug 20, 2007AB WATSON LABS50MCG/HRA076709 002 Aug 20, 2007FENTANYL-75AB AVEVA75MCG/HRA077449 003 Oct 20, 2008AB LAVIPHARM LABS75MCG/HRA077051 003 Aug 04, 2006AB MALLINCKRODT INC75MCG/HRA077154 003 Feb 09, 2011AB MYLAN TECHNOLOGIES75MCG/HRA076258 003 Jan 28, 2005AB NOVEN75MCG/HRA077775 003 Oct 16, 2009AB PAR PHARM INC75MCG/HRA077062 003 Aug 20, 2007AB WATSON LABS75MCG/HRA076709 003 Aug 20, 2007

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

0.1MG

N202788 001 Jan 04, 2012

0.2MG

N202788 002 Jan 04, 2012

+

0.4MG

N202788 003 Jan 04, 2012

0.6MG

N202788 004 Jan 04, 2012

0.8MG

N202788 005 Jan 04, 2012

1.2MG

N202788 006 Aug 30, 2012

1.6MG

N202788 007 Aug 30, 2012

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATEAP HOSPIRAEQ 0.05MG BASE/MLN019115 001 Jan 12, 1985FENTANYL CITRATE PRESERVATIVE FREEAP + HIKMA MAPLEEQ 0.05MG BASE/MLN019101 001 Jul 11, 1984AP HOSPIRAEQ 0.05MG BASE/MLA072786 001 Sep 24, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-149 (of 362)

FENTANYL CITRATE

INJECTABLE; INJECTION

SUBLIMAZE PRESERVATIVE FREE

AP	+	AKORN	EQ 0.05MG BASE/ML	N016619	001	
		SPRAY, METERED; NASAL				
		LAZANDA				
		DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
	+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET; BUCCAL

FENTANYL CITRATE

AB		WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
AB			EQ 0.2MG BASE	A079075	002	Jan 07, 2011
AB			EQ 0.4MG BASE	A079075	003	Jan 07, 2011
AB			EQ 0.6MG BASE	A079075	004	Jan 07, 2011
AB			EQ 0.8MG BASE	A079075	005	Jan 07, 2011

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB		CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
AB			EQ 0.2MG BASE	N021947	002	Sep 25, 2006
AB	+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
AB			EQ 0.6MG BASE	N021947	004	Sep 25, 2006
AB			EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TABLET; SUBLINGUAL

ABSTRAL

		GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
			EQ 0.2MG BASE	N022510	002	Jan 07, 2011
			EQ 0.3MG BASE	N022510	003	Jan 07, 2011
	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011
			EQ 0.6MG BASE	N022510	005	Jan 07, 2011
			EQ 0.8MG BASE	N022510	006	Jan 07, 2011

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

AB		CEPHALON	EQ 0.2MG BASE	N020747	001	Nov 04, 1998
AB	+		EQ 0.4MG BASE	N020747	002	Nov 04, 1998
AB			EQ 0.6MG BASE	N020747	003	Nov 04, 1998
AB			EQ 0.8MG BASE	N020747	004	Nov 04, 1998
AB			EQ 1.2MG BASE	N020747	005	Nov 04, 1998
AB			EQ 1.6MG BASE	N020747	006	Nov 04, 1998

FENTANYL CITRATE

AB		MALLINCKRODT	EQ 0.2MG BASE	A078907	001	Oct 30, 2009
AB			EQ 0.4MG BASE	A078907	002	Oct 30, 2009
AB			EQ 0.6MG BASE	A078907	003	Oct 30, 2009
AB			EQ 0.8MG BASE	A078907	004	Oct 30, 2009
AB			EQ 1.2MG BASE	A078907	005	Oct 30, 2009
AB			EQ 1.6MG BASE	A078907	006	Oct 30, 2009
AB		PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009
AB			EQ 0.4MG BASE	A077312	002	Oct 30, 2009
AB			EQ 0.6MG BASE	A077312	003	Oct 30, 2009
AB			EQ 0.8MG BASE	A077312	004	Oct 30, 2009
AB			EQ 1.2MG BASE	A077312	005	Oct 30, 2009
AB			EQ 1.6MG BASE	A077312	006	Oct 30, 2009

FERRIC CARBOXYMALTOSE

INJECTABLE; INTRAVENOUS

INJECTAFER

	+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

	+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

	+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

TOVIAZ

		PFIZER	4MG	N022030	001	Oct 31, 2008
	+		8MG	N022030	002	Oct 31, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-150 (of 362)

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006

FEXOFENADINE HYDROCHLORIDE

AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB		BARR	30MG	A076191	001	Aug 31, 2005
AB			60MG	A076191	002	Aug 31, 2005
AB			180MG	A076191	003	Aug 31, 2005
AB		DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006
AB			60MG	A076502	002	Apr 11, 2006
AB			180MG	A076502	003	Apr 11, 2006
AB		MYLAN	30MG	A077081	002	Apr 11, 2008
AB			60MG	A077081	003	Apr 11, 2008
AB			180MG	A077081	001	Apr 16, 2007
AB		TEVA	30MG	A076447	001	Sep 01, 2005
AB			60MG	A076447	002	Sep 01, 2005
AB			180MG	A076447	003	Sep 01, 2005

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AB		BARR	60MG;120MG	A076236	001	Apr 14, 2005
AB		IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010

FIDAXOMICIN

TABLET; ORAL

DIFICID

+	OPTIMER PHARMS	200MG	N201699	001	May 27, 2011

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB		ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010
AB		ACCORD HLTHCARE INC	1MG	A091643	001	Nov 05, 2013
AB		ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013
AB			5MG	A077914	001	Mar 28, 2007
AB		AUROBINDO PHARMA	5MG	A078341	001	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	1MG	A203687	001	Nov 05, 2013
AB		DR REDDYS LABS INC	1MG	A076436	001	Jul 28, 2006
AB		DR REDDYS LABS LTD	5MG	A076437	001	Feb 28, 2007
AB		GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006
AB		HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013
AB			5MG	A090061	001	Jun 07, 2010
AB		MYLAN	5MG	A077578	001	Dec 18, 2006
AB		MYLAN PHARMS INC	1MG	A078161	001	Nov 05, 2013
AB		SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013
AB			5MG	A090507	001	Aug 16, 2011
AB		TEVA	1MG	A076905	001	Nov 05, 2013
AB			5MG	A076511	001	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	5MG	A078900	001	Dec 28, 2009

PROPECIA

AB	+	MERCK	1MG	N020788	001	Dec 19, 1997

PROSCAR

AB	+	MERCK	5MG	N020180	001	Jun 19, 1992

FINGOLIMOD

CAPSULE; ORAL

GILENYA

+	NOVARTIS	0.5MG	N022527	001	Sep 21, 2010

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	100MG	A076835	001	Nov 30, 2005
AB		IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003
AB	+	PADDOCK LLC	100MG	A076831	001	Dec 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-151 (of 362)

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	BARR	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>	+	<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012
+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012
+		10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	+	BEDFORD	<u>500MG/VIAL</u>	<u>A075387</u>	<u>001</u>	Apr 16, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A075837</u>	<u>001</u>	Feb 22, 2001

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG/5ML</u>	<u>N020090</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>200MG/5ML</u>	<u>N020090</u>	<u>002</u>	Dec 23, 1993

FLUCONAZOLE

<u>AB</u>	AUROBINDO PHARM	<u>50MG/5ML</u>	<u>A079150</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>200MG/5ML</u>	<u>A079150</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG/5ML</u>	<u>A077523</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A077523</u>	<u>002</u>	Sep 12, 2007
<u>AB</u>	RANBAXY	<u>50MG/5ML</u>	<u>A076332</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076332</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	ROXANE	<u>50MG/5ML</u>	<u>A076246</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076246</u>	<u>002</u>	Jul 29, 2004

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>003</u>	Sep 29, 1992
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>005</u>	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>001</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>006</u>	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>002</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>004</u>	Jan 29, 1990

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104</u>	<u>001</u>	Jul 30, 2009
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A079104</u>	<u>002</u>	Jul 30, 2009

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077988</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077988</u>	<u>002</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078764</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078764</u>	<u>002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076304</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	BEDFORD	<u>200MG/100ML (2MG/ML)</u>	<u>A076087</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087</u>	<u>003</u>	Jul 29, 2004
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077947</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077947</u>	<u>002</u>	May 26, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076145</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736</u>	<u>001</u>	Aug 23, 2005
<u>AP</u>	TEVA PHARMS USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076653</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076653</u>	<u>002</u>	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-152 (of 362)

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	BEDFORD LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107</u>	<u>001</u>	Jul 30, 2008
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077909</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909</u>	<u>002</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078698</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078698</u>	<u>002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	TEVA PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A076837</u>	<u>001</u>	Jan 13, 2005
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076837</u>	<u>002</u>	Jan 13, 2005
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%				
	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

TABLET; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
BX	DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004
BX		100MG	A076658	002	Jul 29, 2004
BX		150MG	A076658	003	Jul 29, 2004
BX		200MG	A076658	004	Jul 29, 2004

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	VALEANT	<u>250MG</u>	<u>N017001</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017001</u>	<u>002</u>	

FLUCYTOSINE

<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-153 (of 362)

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	+ FRESENIUS KABI USA	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	+ HOSPIRA	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/2ML (25MG/ML)</u>	<u>A200647</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200648</u>	<u>001</u>	Oct 16, 2012
<u>AP</u>	+ SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007
<u>AP</u>	TEVA PHARMS USA	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>		<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F-18

<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>FLUDEOXYGLUCOSE F18</u>					
<u>AP</u>	+ FEINSTEIN	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>	+	<u>20-300mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	+ HOUSTON CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
	MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013
	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014
	+ WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	WEST-WARD PHARM CORP	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	AGILA SPECLTS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	+	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	HIKMA MAPLE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ ACTON PHARMS

EQ 78MG BASE/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
<u>SYNALAR</u>					
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-154 (of 362)

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALARAT + 0.025% N012787 005

IMPLANT; INTRAVITREAL

RETISERT

+ BAUSCH AND LOMB 0.59MG

N021737 001 Apr 08, 2005

OIL; TOPICAL

DERMA-SMOOTH/FSAT + HILL DERMAC 0.01% N019452 001 Feb 03, 1988AT + 0.01% N019452 002 Nov 09, 2005FLUOCINOLONE ACETONIDEAT IDENTI PHARMS INC 0.01% A201759 001 Oct 17, 2011AT 0.01% A201764 001 Oct 17, 2011AT PERRIGO ISRAEL 0.01% A202847 001 Aug 09, 2013AT 0.01% A202848 001 Aug 09, 2013

OIL/DROPS; OTIC

DERMOTICAT + HILL DERMAC 0.01% N019452 003 Nov 09, 2005FLUOCINOLONE ACETONIDEAT IDENTI PHARMS INC 0.01% A091306 001 Oct 17, 2011

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDEAT FOUGERA 0.025% A088168 001 Dec 16, 1982AT G AND W LABS 0.025% A089524 001 Jul 26, 1988AT TARO 0.025% A040041 001 Sep 15, 1994SYNALARAT + MEDIMETRIKS PHARMS 0.025% N013960 001

SHAMPOO; TOPICAL

CAPEX

+ GALDERMA LABS LP 0.01%

N020001 001 Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDEAT FOUGERA 0.01% A088167 001 Dec 16, 1982AT TARO 0.01% A089124 001 Sep 11, 1985SYNALARAT + MEDIMETRIKS PHARMS 0.01% N015296 001FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ GALDERMA LABS LP 0.01%; 4%; 0.05%

N021112 001 Jan 18, 2002

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDEAB PERRIGO ISRAEL 0.1% A090256 001 Jan 14, 2014VANOSAB + MEDICIS 0.1% N021758 001 Feb 11, 2005FLUOCINONIDEAB1 FOUGERA 0.05% A073030 001 Oct 17, 1994AB1 G AND W LABS INC 0.05% A073085 001 Feb 14, 1992AB1 + TARO 0.05% N019117 001 Jun 26, 1984AB1 TEVA 0.05% A072488 001 Feb 06, 1989FLUOCINONIDE EMULSIFIED BASEAB2 FOUGERA PHARMS 0.05% A076586 001 Jun 23, 2004AB2 + TARO 0.05% A072494 001 Jan 19, 1989AB2 TEVA 0.05% A072490 001 Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDEAB FOUGERA 0.05% A072933 001 Dec 30, 1994AB + TARO 0.05% A074935 001 Jul 29, 1997AB TEVA 0.05% A072537 001 Feb 07, 1989

OINTMENT; TOPICAL

FLUOCINONIDEAB FOUGERA PHARMS 0.05% A074905 001 Aug 26, 1997AB + TARO 0.05% A075008 001 Jun 30, 1999AB TEVA 0.05% A073481 001 Dec 27, 1991

SOLUTION; TOPICAL

FLUOCINONIDEAT ACTAVIS MID ATLANTIC 0.05% A071535 001 Dec 02, 1988AT FOUGERA 0.05% A072934 001 Feb 27, 1995AT + TARO 0.05% A074799 001 Dec 31, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-155 (of 362)

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

AT	TEVA	0.05%	A072511	001	Feb 07, 1989

FLUORESCENIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

AP	AKORN	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022186	001	Aug 08, 2008

FLUORESCITE

AP	+ ALCON PHARMS LTD	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006

AK-FLUOR 25%

	+ AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N017760	001	Sep 04, 1985

SUSPENSION/DROPS; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N016851	002	Jul 28, 1982

FML FORTE

	ALLERGAN	0.25%	N019216	001	Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

	+ ALCON	0.1%	N019079	001	Feb 11, 1986

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

AB	+ VALEANT PHARM INTL	5%	N016831	003	

FLUOROURACIL

AB	SPEAR PHARMS	5%	A077524	001	Apr 11, 2008

AB	TARO	5%	A090368	001	Mar 05, 2010

CARAC

	+ VALEANT BERMUDA	0.5%	N020985	001	Oct 27, 2000

FLUOROPLEX

	+ AQUA PHARMS	1%	N016988	001	

INJECTABLE; INJECTION

FLUOROURACIL

AP	+ ACCORD HLTHCARE	1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007

AP	+	2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007

AP	+	5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007

AP	+	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007

AP	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008

AP	+ FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998

AP	+	2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998

AP	+	5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998

AP	+	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998

AP	ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012

AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012

AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012

AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012

AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011

AP		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011

AP	+ TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000

AP	+	5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000

AP	+	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000

SOLUTION; TOPICAL

EFUDEX

AT	+ VALEANT PHARM INTL	2%	N016831	001	

AT	+	5%	N016831	002	

FLUOROURACIL

AT	TARO	2%	A076526	001	Nov 05, 2003

AT		5%	A076526	002	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 40MG BASE	A090223	003	Mar 19, 2009

AB	AUROBINDO PHARMA	EQ 40MG BASE	A078619	003	Jan 31, 2008

AB	DR REDDYS LABS LTD	EQ 40MG BASE	A075465	003	Aug 02, 2001

AB	HERITAGE PHARMS INC	EQ 40MG BASE	A201336	003	Oct 01, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-156 (of 362)

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245</u>	<u>003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207</u>	<u>003</u>	May 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922</u>	<u>003</u>	Dec 16, 2004
<u>AB</u>	RANBAXY	<u>EQ 40MG BASE</u>	<u>A076990</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452</u>	<u>003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+ ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936</u>	<u>003</u>	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223</u>	<u>001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223</u>	<u>002</u>	Mar 19, 2009
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619</u>	<u>001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619</u>	<u>002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336</u>	<u>001</u>	Oct 01, 2012
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A201336</u>	<u>002</u>	Oct 01, 2012
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076287</u>	<u>001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287</u>	<u>002</u>	May 20, 2008

SARAFEM

<u>AB2</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>007</u>	Jul 06, 2000
<u>AB2</u>	+	<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572</u>	<u>001</u>	Mar 22, 2010

PROZAC WEEKLY

<u>AB</u>	+ LILLY	<u>EQ 90MG BASE</u>	<u>N021235</u>	<u>001</u>	Feb 26, 2001

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>	+ PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
	EDGEMONT PHARMS LLC	<u>EQ 60MG BASE</u>	<u>N202133</u>	<u>001</u>	Oct 06, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-157 (of 362)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

+ MYLAN

EQ 20MG BASE

A075755 002 Aug 02, 2001

SARAFEM

WARNER CHILCOTT LLC

EQ 10MG BASE

N021860 001 May 19, 2006

EQ 15MG BASE

N021860 002 May 19, 2006

+

EQ 20MG BASE

N021860 003 May 19, 2006

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE**AB** PAR PHARMEQ 25MG BASE;EQ 3MG BASEA077742 001 Nov 02, 2012**AB**EQ 25MG BASE;EQ 6MG BASEA077742 002 Nov 02, 2012**AB**EQ 25MG BASE;EQ 12MG BASEA077742 003 Nov 02, 2012**AB**EQ 50MG BASE;EQ 6MG BASEA077742 004 Nov 02, 2012**AB**EQ 50MG BASE;EQ 12MG BASEA077742 005 Nov 02, 2012**AB** SANDOZEQ 25MG BASE;EQ 3MG BASEA078901 005 Nov 16, 2012**AB**EQ 25MG BASE;EQ 6MG BASEA078901 001 Nov 16, 2012**AB**EQ 25MG BASE;EQ 12MG BASEA078901 003 Nov 16, 2012**AB**EQ 50MG BASE;EQ 6MG BASEA078901 002 Nov 16, 2012**AB**EQ 50MG BASE;EQ 12MG BASEA078901 004 Nov 16, 2012**AB** TEVA PHARMSEQ 25MG BASE;EQ 3MG BASEA202074 001 Mar 25, 2013**AB**EQ 25MG BASE;EQ 6MG BASEA077528 001 Jun 19, 2012**AB**EQ 25MG BASE;EQ 12MG BASEA077528 002 Jun 19, 2012**AB**EQ 50MG BASE;EQ 6MG BASEA077528 003 Jun 19, 2012**AB**EQ 50MG BASE;EQ 12MG BASEA077528 004 Jun 19, 2012SYMBYAX**AB** LILLYEQ 25MG BASE;EQ 3MG BASEN021520 001 Apr 09, 2007**AB**EQ 25MG BASE;EQ 6MG BASEN021520 002 Dec 24, 2003**AB**EQ 25MG BASE;EQ 12MG BASEN021520 004 Dec 24, 2003**AB** +EQ 50MG BASE;EQ 6MG BASEN021520 003 Dec 24, 2003**AB**EQ 50MG BASE;EQ 12MG BASEN021520 005 Dec 24, 2003FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

+ USL PHARMA

10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE**AO** BEDFORD25MG/MLA074531 001 Aug 30, 1996**AO** + FRESENIUS KABI USA25MG/MLA071413 001 Jul 14, 1987FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE**AB** LANNETT1MGA089740 001 Aug 25, 1988**AB**2.5MGA089741 001 Aug 25, 1988**AB**5MGA089742 001 Aug 25, 1988**AB**10MGA089743 001 Aug 25, 1988**AB** MYLAN1MGA089804 002 Aug 12, 1988**AB**2.5MGA089804 003 Aug 12, 1988**AB**5MGA089804 004 Aug 12, 1988**AB** +10MGA089804 001 Aug 12, 1988**AB** SANDOZ1MGA089583 001 Oct 16, 1987**AB**2.5MGA089584 001 Oct 16, 1987**AB**5MGA089585 001 Oct 16, 1987**AB**10MGA089586 001 Oct 16, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-158 (of 362)

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+ AQUA PHARMS

0.025%

N012806 003

+

0.05%

N012806 002

LOTION; TOPICAL

CORDRAN

+ AQUA PHARMS

0.05%

N013790 001

TAPE; TOPICAL

CORDRAN

+ WATSON PHARMS

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE**AB** MYLAN PHARMS INC**15MG****A070345 002** Nov 27, 1985**AB** +**30MG****A070345 001** Nov 27, 1985**AB** WATSON LABS**15MG****A071205 001** Nov 25, 1986**AB****30MG****A071068 001** Nov 25, 1986**AB****30MG****A072369 001** Mar 30, 1989FLURBIPROFEN

TABLET; ORAL

ANSAID**AB** PHARMACIA AND UPJOHN**50MG****N018766 002** Oct 31, 1988**AB** +**100MG****N018766 003** Oct 31, 1988FLURBIPROFEN**AB** CARACO**50MG****A075058 001** Apr 27, 2001**AB****100MG****A075058 002** Apr 27, 2001**AB** MYLAN**50MG****A074358 001** Jun 20, 1994**AB****100MG****A074358 002** Jun 20, 1994**AB** TEVA**100MG****A074431 001** May 31, 1995FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM**AT** BAUSCH AND LOMB**0.03%****A074447 001** Jan 04, 1995OCUFEN**AT** + ALLERGAN**0.03%****N019404 001** Dec 31, 1986FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE**AB** + IVAX SUB TEVA PHARMS**125MG****A075780 001** Sep 19, 2001**AB**

MYLAN

125MG**A076224 001** May 09, 2003**AB**

PAR PHARM

125MG**A075298 001** Sep 18, 2001**AB** WATSON LABS INC FL**125MG****A075820 001** Sep 18, 2001FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+ GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013

+

121.5mCi/30ML (4.05mCi/ML)

N203137 002 Oct 25, 2013

FLUTICASONE FUROATE

SPRAY, METERED; NASAL

VERAMYST

+ GLAXOSMITHKLINE

0.0275MG/INH

N022051 001 Apr 27, 2007

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+ GLAXO GRP LTD

0.1MG/INH; EQ 0.025MG BASE/INH

N204275 001 May 10, 2013

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+ GLAXO GRP LTD

0.044MG/INH

N021433 003 May 14, 2004

+

0.11MG/INH

N021433 002 May 14, 2004

+

0.22MG/INH

N021433 001 May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATE**AB** FOUGERA PHARMS**0.05%****A076451 001** May 14, 2004**AB**

G AND W LABS

0.05%**A077055 001** Jun 30, 2006**AB**

PERRIGO NEW YORK

0.05%**A076793 001** May 14, 2004**AB**

TOLMAR

0.05%**A076633 001** May 14, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-159 (of 362)

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	<u>0.05%</u>	<u>N021152</u>	<u>001</u>	Mar 31, 2005

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	<u>0.05%</u>	<u>A090759</u>	<u>001</u>	May 02, 2011

AB		PERRIGO ISRAEL	<u>0.05%</u>	<u>A091553</u>	<u>001</u>	Jul 30, 2013

OINTMENT; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004

AB		G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006

AB		PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000

SPRAY, METERED; NASAL

FLONASE

AB	+	GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994

FLUTICASONE PROPIONATE

AB		APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007

AB		HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008

AB		ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006

AB		WOCKHARDT	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADV AIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006

+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006

+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER; INHALATION

ADV AIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000

ADV AIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000

ADV AIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012

AB			<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012

AB		TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012

AB			<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

AB		NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993

AB	+		<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL

+	NOVARTIS	80MG	N021192	001	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013

AB			<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013

AB		ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013

AB			<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013

LUVOX CR

AB		JAZZ PHARMS	<u>100MG</u>	<u>N022033</u>	<u>001</u>	Feb 28, 2008

AB	+		<u>150MG</u>	<u>N022033</u>	<u>002</u>	Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

AB		APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001

AB			<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001

AB			<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001

AB		BARR	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-160 (of 362)

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002
<u>LUVOX</u>					
<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

+ FRESENIUS KABI USA

5MG/ML

A089202 001 Feb 18, 1986

TABLET; ORAL

FOLIC ACID

<u>AA</u>	+	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>		BICON PHARM	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>		CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>		EXCELLIUM	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>		INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>		JUBILANT CADISTA	<u>1MG</u>	<u>A040514</u>	<u>001</u>	Jun 14, 2005
<u>AA</u>		VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	
<u>AA</u>		WEST WARD	<u>1MG</u>	<u>A080600</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+ ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

+

150 IU/0.5ML

N021273 002 Aug 26, 2005

+

300 IU/0.36ML

N021211 001 Mar 23, 2004

+

600 IU/0.72ML

N021211 002 Mar 23, 2004

+

900 IU/1.08ML

N021211 004 Feb 11, 2005

GONAL-F

+ EMD SERONO

450 IU/VIAL

N020378 005 Mar 26, 2004

1,050 IU/VIAL

N020378 004 Feb 28, 2001

GONAL-F RFF

+ EMD SERONO

75 IU/VIAL

N021765 002 Mar 25, 2004

GONAL-F RFF PEN

+ EMD SERONO

300 IU/0.5ML

N021684 001 May 25, 2004

+

450 IU/0.75ML

N021684 002 May 25, 2004

+

900 IU/1.5ML

N021684 003 May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<u>AP</u>	+	PALADIN LABS	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696</u>	<u>001</u>	Dec 04, 1997
<u>FOMEPIZOLE</u>						
<u>AP</u>		LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>		MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A079033</u>	<u>001</u>	Apr 07, 2009
<u>AP</u>			<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
<u>AP</u>		NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

<u>AP</u>	+	GLAXOSMITHKLINE	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
<u>AP</u>	+		<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
<u>AP</u>	+		<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
<u>AP</u>	+		<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004
<u>FONDAPARINUX SODIUM</u>						
<u>AP</u>		DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
<u>AP</u>			<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
<u>AP</u>			<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-161 (of 362)

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

FONDAPARINUX SODIUM

AP	10MG/0.8ML	A091316 004	Jul 11, 2011

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ NOVARTIS

0.012MG/INH

N020831 001 Feb 16, 2001

SOLUTION; INHALATION

PERFORMIST

+ MYLAN SPECLT

0.02MG/2ML

N022007 001 May 11, 2007

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+ MERCK SHARP DOHME

0.005MG/INH; 0.1MG/INH

N022518 001 Jun 22, 2010

+

0.005MG/INH; 0.2MG/INH

N022518 002 Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+ VIIV HLTHCARE

EQ 50MG BASE/ML

N022116 001 Jun 14, 2007

TABLET; ORAL

LEXIVA

+ VIIV HLTHCARE

EQ 700MG BASE

N021548 001 Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+ MERCK AND CO INC

EQ 150MG BASE/VIAL

N022023 002 Nov 12, 2010

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP	HOSPIRA	2.4GM/100ML	A077174 001	May 31, 2005

FOSCAVIR

AP	+ CLINIGEN HLTHCARE	2.4GM/100ML	N020068 001	Sep 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+ ZAMBON SPA

EQ 3GM BASE/PACKET

N050717 001 Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	APOTEX INC	10MG	A076906 001	May 17, 2005
AB		20MG	A076906 002	May 17, 2005
AB		40MG	A076906 003	May 17, 2005
AB	AUROBINDO PHARMA LTD	10MG	A091163 001	Mar 30, 2011
AB		20MG	A091163 002	Mar 30, 2011
AB		40MG	A091163 003	Mar 30, 2011
AB	INVAGEN PHARMS	10MG	A077222 001	Apr 20, 2005
AB		20MG	A077222 002	Apr 20, 2005
AB		40MG	A077222 003	Apr 20, 2005
AB	SANDOZ	10MG	A076483 001	Apr 23, 2004
AB		20MG	A076483 002	Apr 23, 2004
AB		40MG	A076483 003	Apr 23, 2004
AB	TEVA	10MG	A076139 001	Nov 25, 2003
AB		20MG	A076139 002	Nov 25, 2003
AB	+	40MG	A076139 003	Nov 25, 2003
AB	WATSON LABS	10MG	A077531 001	Aug 31, 2006
AB		20MG	A077531 002	Aug 31, 2006
AB		40MG	A077531 003	Aug 31, 2006
AB	WATSON LABS FLORIDA	10MG	A076620 001	Oct 15, 2004
AB		20MG	A076620 002	Oct 15, 2004
AB		40MG	A076620 003	Oct 15, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA	10MG; 12.5MG	A079245 001	Jul 09, 2009
AB		20MG; 12.5MG	A079245 002	Jul 09, 2009
AB	INVAGEN PHARMS	10MG; 12.5MG	A090228 001	Jul 09, 2009
AB		20MG; 12.5MG	A090228 002	Jul 09, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-162 (of 362)

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739</u>	<u>002</u>	Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG;12.5MG</u>	<u>A076608</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608</u>	<u>002</u>	Dec 03, 2004

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079025</u>	<u>002</u>	Sep 17, 2010

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

<u>AP</u>	AMNEAL PHARMS	<u>EQ 50MG PNEYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>	HIKMA MAPLE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099</u>	<u>001</u>	May 13, 2010
<u>AP</u>	STRIDES ARCOLAB	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

	+ ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

	+ ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	+ LUITPOLD	<u>10MG/ML</u>	<u>N018579</u>	<u>001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+ ROXANE	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
	ROXANE	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	EXCELLIUM	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-163 (of 362)

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A070412</u>	<u>001</u>	Feb 26, 1986
<u>AB</u>		<u>20MG</u>	<u>A070449</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>20MG</u>	<u>A071379</u>	<u>001</u>	Jan 02, 1987
<u>AB</u>		<u>40MG</u>	<u>A070450</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>80MG</u>	<u>A070528</u>	<u>001</u>	Jan 07, 1986
<u>AB</u>		<u>80MG</u>	<u>A071594</u>	<u>001</u>	Feb 09, 1988

LASIX

<u>AB</u>	SANOFI AVENTIS US	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	RANBAXY	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075485</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A075485</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>400MG</u>	<u>A075485</u>	<u>001</u>	May 11, 2007

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403</u>	<u>001</u>	May 01, 2012
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024</u>	<u>001</u>	Mar 23, 2012
<u>AA</u>	HI TECH PHARMA	<u>250MG/5ML</u>	<u>A078974</u>	<u>001</u>	Feb 18, 2011
<u>AA</u>	TARO	<u>250MG/5ML</u>	<u>A076672</u>	<u>001</u>	Jul 03, 2013

NEURONTIN

<u>AA</u>	+	<u>PARKE DAVIS</u>	<u>250MG/5ML</u>	<u>N021129</u>	<u>001</u>	Mar 02, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-164 (of 362)

GABAPENTIN

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	ALLIED PHARMA INC	<u>600MG</u>	<u>A203244</u>	<u>002</u>	Jul 12, 2013
<u>AB</u>		<u>800MG</u>	<u>A203244</u>	<u>001</u>	Jul 12, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078782</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>800MG</u>	<u>A078782</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764</u>	<u>001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764</u>	<u>002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926</u>	<u>001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926</u>	<u>002</u>	Feb 11, 2011

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>	+	<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998
	GRALISE				
BX	+	300MG	N022544	001	Jan 28, 2011
BX	+	600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	XENOPORT INC	300MG	N022399	002	Dec 13, 2011
	+	600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+	GE HEALTHCARE	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007
+		287MG/ML	N020123	001	Jan 08, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-165 (of 362)

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

+ LANTHEUS MEDCL

2440MG/10ML (244MG/ML)

N021711 001 Dec 22, 2008

+

3660MG/15ML (244MG/ML)

N021711 002 Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE

469.01MG/ML

N019596 001 Jun 02, 1988

+

469.01MG/ML

N021037 001 Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+ GUERBET

3.769GM/10ML (376.9MG/ML)

N204781 002 Mar 20, 2013

+

5.6535GM/15ML (376.9MG/ML)

N204781 003 Mar 20, 2013

+

7.538GM/20ML (376.9MG/ML)

N204781 004 Mar 20, 2013

+

37.69GM/100ML (376.9MG/ML)

N204781 001 Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+ BRACCO

279.3MG/ML

N020131 001 Nov 16, 1992

PROHANCE MULTIPACK

+ BRACCO

279.3MG/ML

N021489 001 Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ MALLINCKRODT

16.545GM/50ML (330.9MG/ML)

N020975 001 Dec 08, 1999

+

1654.5MG/5ML (330.9MG/ML)

N020937 001 Dec 08, 1999

+

3309MG/10ML (330.9MG/ML)

N020937 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020937 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020937 004 Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ MALLINCKRODT

3309MG/10ML (330.9MG/ML)

N020976 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020976 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020976 004 Dec 08, 1999

+

9927MG/30ML (330.9MG/ML)

N020976 001 Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE

1.8143GM/10ML (181.43MG/ML)

N022090 001 Jul 03, 2008

2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE**AB** BARR**EQ 8MG BASE****A078189 001** Sep 15, 2008**AB****EQ 16MG BASE****A078189 002** Sep 15, 2008**AB****EQ 24MG BASE****A078189 003** Sep 15, 2008**AB** IMPAX LABS**EQ 8MG BASE****A078484 001** May 27, 2009**AB****EQ 16MG BASE****A078484 002** May 27, 2009**AB****EQ 24MG BASE****A078484 003** May 27, 2009**AB** MYLAN**EQ 8MG BASE****A090900 001** Jan 24, 2011**AB****EQ 16MG BASE****A090900 002** Jan 24, 2011**AB****EQ 24MG BASE****A090900 003** Jan 24, 2011**AB** SUN PHARMA GLOBAL**EQ 8MG BASE****A090178 001** Feb 02, 2011**AB****EQ 16MG BASE****A090178 002** Feb 02, 2011**AB****EQ 24MG BASE****A090178 003** Feb 02, 2011**AB** WATSON LABS**EQ 8MG BASE****A079028 001** Dec 15, 2008**AB****EQ 16MG BASE****A079028 002** Dec 15, 2008**AB****EQ 24MG BASE****A079028 003** Dec 15, 2008RAZADYNE ER**AB** + JANSSEN PHARMS**EQ 8MG BASE****N021615 001** Apr 01, 2005**AB****EQ 16MG BASE****N021615 002** Apr 01, 2005**AB****EQ 24MG BASE****N021615 003** Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE**AA** ROXANE**4MG/ML****A078185 001** Jan 30, 2009RAZADYNE**AA** + JANSSEN PHARMS**4MG/ML****N021224 001** Jun 22, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-166 (of 362)

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781 001</u>	Sep 27, 2011
AB		<u>EQ 8MG BASE</u>	<u>A077781 002</u>	Sep 27, 2011
AB		<u>EQ 12MG BASE</u>	<u>A077781 003</u>	Sep 27, 2011
AB	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957 001</u>	Mar 29, 2011
AB		<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
AB		<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
AB	BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
AB		<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
AB		<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
AB	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
AB		<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
AB		<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
AB	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590 001</u>	May 29, 2009
AB		<u>EQ 4MG BASE</u>	<u>A077603 001</u>	Aug 28, 2008
AB		<u>EQ 8MG BASE</u>	<u>A077590 002</u>	May 29, 2009
AB		<u>EQ 8MG BASE</u>	<u>A077603 002</u>	Aug 28, 2008
AB		<u>EQ 12MG BASE</u>	<u>A077590 003</u>	May 29, 2009
AB		<u>EQ 12MG BASE</u>	<u>A077603 003</u>	Aug 28, 2008
AB	ROXANE	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
AB		<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
AB		<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
AB	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
AB		<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
AB		<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
AB	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587 001</u>	Jul 09, 2009
AB		<u>EQ 8MG BASE</u>	<u>A077587 002</u>	Jul 09, 2009
AB		<u>EQ 12MG BASE</u>	<u>A077587 003</u>	Jul 09, 2009
AB	ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
AB		<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
AB		<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011
<u>RAZADYNE</u>				
AB	+ JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
AB		<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
AB		<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478 001	
BS	MALLINCKRODT	2mCi/ML	N018058 001	

GANCICLOVIR

GEL; OPHTHALMIC

ZIRGAN

+	BAUSCH AND LOMB	0.15%	N022211 001	Sep 15, 2009

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

AP	+ ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661 001</u>	Jun 23, 1989
<u>GANCICLOVIR</u>				
AP	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658 001</u>	Jun 21, 2010
AP	LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202624 001</u>	Sep 18, 2013

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057 001	Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT	LUPIN LTD	<u>0.5%</u>	<u>A202653 001</u>	Aug 28, 2013
<u>ZYMAR</u>				
AT	+ ALLERGAN	<u>0.3%</u>	<u>N021493 001</u>	Mar 28, 2003
<u>ZYMAXID</u>				
AT	+ ALLERGAN	<u>0.5%</u>	<u>N022548 001</u>	May 18, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-167 (of 362)

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 1GM BASE/VIAL</u>	<u>A079160</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A079160</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	CIPLA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202997</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202063</u>	<u>002</u>	Sep 11, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202063</u>	<u>001</u>	Sep 11, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u>	May 16, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u>	May 16, 2011
<u>AP</u>	HAMELN RDS GMBH	<u>EQ 1GM BASE/VIAL</u>	<u>A090663</u>	<u>002</u>	Sep 10, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090663</u>	<u>001</u>	Sep 10, 2012
<u>AP</u>	HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	+ HOSPIRA INC	<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u>	Nov 15, 2010
<u>AP</u>	JIANGSU HANSON PHARM	<u>EQ 1GM BASE/VIAL</u>	<u>A202485</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202485</u>	<u>001</u>	May 07, 2013
<u>AP</u>	LUITPOLD	<u>EQ 1GM BASE/VIAL</u>	<u>A202031</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202031</u>	<u>001</u>	May 07, 2013
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200145</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A200145</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091597</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091597</u>	<u>001</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	Jan 25, 2011
<u>GEMZAR</u>					
<u>AP</u>	+ LILLY	<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
<u>GEMCITABINE HYDROCHLORIDE</u>					
	+ HOSPIRA INC	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011
		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011
		200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	CARACO	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A074442</u>	<u>001</u>	Apr 28, 1995

LOPID

<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062531</u>	<u>001</u>	Jul 05, 1984
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307</u>	<u>001</u>	
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062427</u>	<u>001</u>	May 26, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-168 (of 362)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A062366</u>	<u>002</u>	Feb 06, 1986
AP	+	<u>EQ 40MG BASE/ML</u>	<u>A062366</u>	<u>001</u>	Aug 04, 1983
AP	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420</u>	<u>001</u>	Aug 15, 1983
AP		<u>EQ 10MG BASE/ML</u>	<u>A062612</u>	<u>004</u>	Feb 20, 1986
AP		<u>EQ 40MG BASE/ML</u>	<u>A062420</u>	<u>002</u>	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>EQ 0.8MG BASE/ML</u>	<u>A062814</u>	<u>001</u>	Aug 28, 1987
AP	+		<u>EQ 1.2MG BASE/ML</u>	<u>A062814</u>	<u>002</u>	Aug 28, 1987
AP	+		<u>EQ 1.4MG BASE/ML</u>	<u>A062814</u>	<u>003</u>	Aug 28, 1987
AP	+		<u>EQ 1.6MG BASE/ML</u>	<u>A062814</u>	<u>004</u>	Aug 28, 1987
AP	+		<u>EQ 1.8MG BASE/ML</u>	<u>A062814</u>	<u>005</u>	Aug 28, 1987
AP	+		<u>EQ 2MG BASE/ML</u>	<u>A062814</u>	<u>006</u>	Aug 28, 1987
AP	+		<u>EQ 2.4MG BASE/ML</u>	<u>A062814</u>	<u>007</u>	Aug 28, 1987
AP	+		<u>EQ 40MG BASE/100ML</u>	<u>A062814</u>	<u>008</u>	Aug 28, 1987
AP	+		<u>EQ 60MG BASE/100ML</u>	<u>A062814</u>	<u>009</u>	Aug 28, 1987
AP	+		<u>EQ 70MG BASE/100ML</u>	<u>A062814</u>	<u>010</u>	Aug 28, 1987
AP	+		<u>EQ 80MG BASE/100ML</u>	<u>A062814</u>	<u>011</u>	Aug 28, 1987
AP	+		<u>EQ 90MG BASE/100ML</u>	<u>A062814</u>	<u>012</u>	Aug 28, 1987
AP	+		<u>EQ 100MG BASE/100ML</u>	<u>A062814</u>	<u>013</u>	Aug 28, 1987
AP	+		<u>EQ 120MG BASE/100ML</u>	<u>A062814</u>	<u>014</u>	Aug 28, 1987
AP		HOSPIRA	<u>EQ 1.2MG BASE/ML</u>	<u>A062414</u>	<u>001</u>	Aug 15, 1983
AP			<u>EQ 1.4MG BASE/ML</u>	<u>A062414</u>	<u>002</u>	Aug 15, 1983
AP			<u>EQ 1.6MG BASE/ML</u>	<u>A062414</u>	<u>003</u>	Aug 15, 1983
AP			<u>EQ 1.8MG BASE/ML</u>	<u>A062414</u>	<u>004</u>	Aug 15, 1983
AP			<u>EQ 2MG BASE/ML</u>	<u>A062414</u>	<u>005</u>	Aug 15, 1983
AP			<u>EQ 60MG BASE/100ML</u>	<u>A062414</u>	<u>006</u>	Aug 15, 1983
AP			<u>EQ 70MG BASE/100ML</u>	<u>A062414</u>	<u>007</u>	Aug 15, 1983
AP			<u>EQ 80MG BASE/100ML</u>	<u>A062414</u>	<u>008</u>	Aug 15, 1983
AP			<u>EQ 90MG BASE/100ML</u>	<u>A062414</u>	<u>009</u>	Aug 15, 1983
AP			<u>EQ 100MG BASE/100ML</u>	<u>A062414</u>	<u>010</u>	Aug 15, 1983

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>EQ 0.8MG BASE/ML</u>	<u>A062373</u>	<u>001</u>	Sep 07, 1982
AP		<u>EQ 1.2MG BASE/ML</u>	<u>A062373</u>	<u>007</u>	Sep 07, 1982
AP		<u>EQ 1.6MG BASE/ML</u>	<u>A062373</u>	<u>008</u>	Sep 07, 1982
AP		<u>EQ 2MG BASE/ML</u>	<u>A062373</u>	<u>009</u>	Sep 07, 1982
AP		<u>EQ 2.4MG BASE/ML</u>	<u>A062373</u>	<u>010</u>	Sep 07, 1982
AP		<u>EQ 40MG BASE/100ML</u>	<u>A062373</u>	<u>003</u>	Sep 07, 1982
AP		<u>EQ 60MG BASE/100ML</u>	<u>A062373</u>	<u>004</u>	Sep 07, 1982
AP		<u>EQ 80MG BASE/100ML</u>	<u>A062373</u>	<u>002</u>	Sep 07, 1982
AP		<u>EQ 100MG BASE/100ML</u>	<u>A062373</u>	<u>005</u>	Sep 07, 1982
AP		<u>EQ 120MG BASE/100ML</u>	<u>A062373</u>	<u>006</u>	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	+	AKORN	<u>EQ 0.3% BASE</u>	<u>A064093</u>	<u>001</u>	Aug 31, 1995
AT		PERRIGO CO TENNESSEE	<u>EQ 0.3% BASE</u>	<u>A065024</u>	<u>001</u>	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT		FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062533</u>	<u>001</u>	Oct 05, 1984
AT	+	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062351</u>	<u>001</u>	Feb 18, 1982
AT		TARO	<u>EQ 0.1% BASE</u>	<u>A062477</u>	<u>001</u>	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT		ALLERGAN	<u>EQ 0.3% BASE</u>	<u>A062452</u>	<u>001</u>	Oct 10, 1984

GENTAK

AT		AKORN	<u>EQ 0.3% BASE</u>	<u>A064163</u>	<u>001</u>	Oct 12, 2001

GENTAMICIN SULFATE

AT		AKORN	<u>EQ 0.3% BASE</u>	<u>A062635</u>	<u>001</u>	Jan 08, 1987
AT	+	BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A064048</u>	<u>001</u>	May 11, 1994
AT		FALCON PHARMS	<u>EQ 0.3% BASE</u>	<u>A062196</u>	<u>001</u>	
AT		PERRIGO CO TENNESSEE	<u>EQ 0.3% BASE</u>	<u>A065121</u>	<u>001</u>	Jan 30, 2004

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE; 0.6%

N050612 001 Dec 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE; 1%

N050586 001 Jun 10, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-169 (of 362)

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

+ TEVA PHARMS USA 20MG/ML

N020622 002 Feb 12, 2002

GLIMEPIRIDE

TABLET; ORAL

AMARYLAB + SANOFI AVENTIS US1MGN020496 001 Nov 30, 1995AB 2MGN020496 002 Nov 30, 1995AB 4MGN020496 003 Nov 30, 1995GLIMEPIRIDEAB ACCORD HLTHCARE 1MGA078181 001 Aug 23, 2007AB 2MGA078181 002 Aug 23, 2007AB 4MGA078181 003 Aug 23, 2007AB AUROBINDO PHARMA LTD 1MGA202759 001 Jun 29, 2012AB 2MGA202759 002 Jun 29, 2012AB 4MGA202759 003 Jun 29, 2012AB CARLSBAD 1MGA077911 001 Sep 22, 2009AB 2MGA077911 002 Sep 22, 2009AB 4MGA077911 003 Sep 22, 2009AB DR REDDYS LABS LTD 1MGA077091 001 Oct 06, 2005AB 2MGA077091 002 Oct 06, 2005AB 4MGA077091 003 Oct 06, 2005AB HIKMA PHARMS 1MGA078952 001 Aug 01, 2013AB 2MGA078952 002 Aug 01, 2013AB 4MGA078952 003 Aug 01, 2013AB INDOCO REMEDIES 1MGA202112 001 Apr 17, 2013AB 2MGA202112 002 Apr 17, 2013AB 4MGA202112 003 Apr 17, 2013AB INVAGEN PHARMS 1MGA077295 001 Oct 06, 2005AB 2MGA077295 002 Oct 06, 2005AB 4MGA077295 003 Oct 06, 2005AB MICRO LABS LTD INDIA 1MGA091220 001 Jun 29, 2012AB 2MGA091220 002 Jun 29, 2012AB 4MGA091220 004 Jun 29, 2012AB 8MGA091220 006 Jun 29, 2012AB MYLAN 1MGA077624 001 Nov 28, 2005AB 2MGA077624 002 Nov 28, 2005AB 4MGA077624 003 Nov 28, 2005AB TEVA 1MGA076802 001 Oct 06, 2005AB 2MGA076802 002 Oct 06, 2005AB 4MGA076802 003 Oct 06, 2005AB VINTAGE 1MGA077370 001 Dec 23, 2005AB 2MGA077370 002 Dec 23, 2005AB 4MGA077370 003 Dec 23, 2005AB 8MGA077370 004 Dec 23, 2005AB WATSON LABS 1MGA077280 001 Feb 03, 2006AB 2MGA077280 002 Feb 03, 2006AB 4MGA077280 003 Feb 03, 2006AB WATSON LABS FLORIDA 1MGA076995 001 Apr 27, 2010AB 2MGA076995 002 Apr 27, 2010AB 4MGA076995 003 Apr 27, 2010

MICRO LABS LTD INDIA 3MG

A091220 003 Jun 29, 2012

6MG

A091220 005 Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACTAB + TAKEDA PHARMS USA 2MG; 30MGN021925 001 Jul 28, 2006AB 4MG; 30MGN021925 002 Jul 28, 2006PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDEAB SANDOZ 2MG; 30MGA201049 001 Jan 04, 2013AB 4MG; 30MGA201049 002 Jan 04, 2013GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+ SB PHARMC0 1MG; 4MG

N021700 001 Nov 23, 2005

2MG; 4MG

N021700 002 Nov 23, 2005

2MG; 8MG

N021700 004 Mar 30, 2007

4MG; 4MG

N021700 003 Nov 23, 2005

4MG; 8MG

N021700 005 Mar 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-170 (of 362)

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550 001	Sep 11, 1997
AB		10MG	A074550 002	Sep 11, 1997
AB	APOTEX	5MG	A075795 001	Jun 13, 2001
AB		10MG	A075795 002	Jun 13, 2001
AB	CARACO	5MG	A077820 001	Jul 11, 2006
AB		10MG	A077820 002	Jul 11, 2006
AB	IVAX SUB TEVA PHARMS	5MG	A074497 001	Aug 31, 1995
AB		10MG	A074497 002	Aug 31, 1995
AB	MYLAN	5MG	A074226 001	May 10, 1994
AB		5MG	A074438 001	Jun 20, 1995
AB		10MG	A074226 002	May 10, 1994
AB		10MG	A074438 002	Jun 20, 1995
AB	SANDOZ	5MG	A074305 001	Apr 07, 1995
AB		10MG	A074305 002	Apr 07, 1995
AB	WATSON LABS	5MG	A074223 001	Feb 27, 1995
AB		5MG	A074370 001	Nov 22, 1994
AB		10MG	A074223 002	Feb 27, 1995
AB		10MG	A074370 002	Nov 22, 1994

GLUCOTROL

AB	PFIZER	5MG	N017783 001	May 08, 1984
AB	+	10MG	N017783 002	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	PAR PHARM	5MG	A076159 002	Sep 20, 2013
AB		10MG	A076159 001	Sep 20, 2013
AB	WATSON LABS	2.5MG	A076467 003	Mar 27, 2006
AB		5MG	A076467 001	Sep 08, 2003
AB		10MG	A076467 002	Nov 07, 2003

GLUCOTROL XL

AB	PFIZER	2.5MG	N020329 003	Aug 10, 1999
AB		5MG	N020329 001	Apr 26, 1994
AB	+	10MG	N020329 002	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	CARACO	2.5MG; 250MG	A077620 001	Jan 11, 2008
AB		2.5MG; 500MG	A077620 002	Jan 11, 2008
AB		5MG; 500MG	A077620 003	Jan 11, 2008
AB	COREPHARMA	2.5MG; 250MG	A077507 001	Oct 27, 2005
AB		2.5MG; 500MG	A077507 002	Oct 27, 2005
AB		5MG; 500MG	A077507 003	Oct 27, 2005
AB	HERITAGE PHARMS INC	2.5MG; 250MG	A078728 001	Jun 23, 2010
AB		2.5MG; 500MG	A078728 002	Jun 23, 2010
AB		5MG; 500MG	A078728 003	Jun 23, 2010
AB	MYLAN	2.5MG; 250MG	A078083 001	Apr 12, 2007
AB		2.5MG; 500MG	A078083 002	Apr 12, 2007
AB		5MG; 500MG	A078083 003	Apr 12, 2007
AB	TEVA PHARMS	2.5MG; 250MG	A077270 001	Oct 28, 2005
AB		2.5MG; 500MG	A077270 002	Oct 28, 2005
AB	+	5MG; 500MG	A077270 003	Oct 28, 2005
AB	ZYDUS PHARMS USA INC	2.5MG; 250MG	A078905 001	Jan 31, 2011
AB		2.5MG; 500MG	A078905 002	Jan 31, 2011
AB		5MG; 500MG	A078905 003	Jan 31, 2011

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+ NOVO NORDISK EQ 1MG BASE/VIAL

N020918 001 Jun 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+ LILLY 1MG/VIAL

N020928 001 Sep 11, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-171 (of 362)

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL

5GM/PACKET

N021667 001 Jun 10, 2004

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537</u>	<u>001</u>	Oct 18, 2007
<u>AB</u>		<u>2.5MG</u>	<u>A077537</u>	<u>002</u>	Oct 18, 2007
<u>AB</u>		<u>5MG</u>	<u>A077537</u>	<u>003</u>	Oct 18, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076257</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>		<u>5MG</u>	<u>A076257</u>	<u>003</u>	Jun 27, 2002
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090937</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A090937</u>	<u>003</u>	Feb 28, 2011
<u>AB</u>	TEVA	<u>1.25MG</u>	<u>A074388</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>2.5MG</u>	<u>A074388</u>	<u>002</u>	Aug 29, 1995
<u>AB</u>	+	<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995

GLYBURIDE (MICRONIZED)

<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591</u>	<u>001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591</u>	<u>002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591</u>	<u>003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591</u>	<u>004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>6MG</u>	<u>A075890</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792</u>	<u>001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792</u>	<u>002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792</u>	<u>003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686</u>	<u>004</u>	Apr 20, 1999

GLYNASE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051</u>	<u>001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051</u>	<u>002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051</u>	<u>004</u>	Sep 24, 1993

DIABETA

BX	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984
BX		2.5MG	N017532	002	May 01, 1984
BX	+	5MG	N017532	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1.25MG; 250MG</u>	<u>N021178</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	+	<u>2.5MG; 500MG</u>	<u>N021178</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>		<u>5MG; 500MG</u>	<u>N021178</u>	<u>003</u>	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG; 250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG; 250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG; 250MG</u>	<u>A076731</u>	<u>001</u>	Nov 19, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076731</u>	<u>002</u>	Nov 19, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076731</u>	<u>003</u>	Nov 19, 2004
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG; 250MG</u>	<u>A079009</u>	<u>001</u>	Jun 03, 2009
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A079009</u>	<u>002</u>	Jun 03, 2009
<u>AB</u>		<u>5MG; 500MG</u>	<u>A079009</u>	<u>003</u>	Jun 03, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG; 250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+ HYPERION THERAP INC

1.1GM/ML

N203284 001 Feb 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-172 (of 362)

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>	

GLYCINE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>	

<u>AT</u>	HOSPIRA	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>	

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011

<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986

ROBINUL

<u>AP</u>	+ HIKMA MAPLE	<u>0.2MG/ML</u>	<u>N017558</u>	<u>001</u>	

SOLUTION;ORAL

CUVPOSA

	+ MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010

TABLET;ORAL

GLYCOPYRROLATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675</u>	<u>001</u>	Apr 15, 2013

<u>AA</u>	BOCA PHARMA LLC	<u>1MG</u>	<u>A090020</u>	<u>001</u>	Oct 19, 2011

<u>AA</u>		<u>2MG</u>	<u>A090020</u>	<u>002</u>	Oct 19, 2011

<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008

<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008

<u>AA</u>	EXCELLIUM	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012

<u>AA</u>		<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012

<u>AA</u>	NEXGEN PHARMA	<u>1.5MG</u>	<u>A091522</u>	<u>001</u>	Mar 12, 2012

<u>AA</u>	PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006

<u>AA</u>		<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006

<u>AA</u>	RANBAXY	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009

<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009

<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008

<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008

ROBINUL

<u>AA</u>	+ SHIONOGI INC	<u>1MG</u>	<u>N012827</u>	<u>001</u>	

ROBINUL FORTE

<u>AA</u>	+ SHIONOGI INC	<u>2MG</u>	<u>N012827</u>	<u>002</u>	

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016</u>	<u>007</u>	

<u>AP</u>	+ FRESENIUS KABI USA	<u>10,000 UNITS/VIAL</u>	<u>N017067</u>	<u>002</u>	

PREGNYL

<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692</u>	<u>001</u>	

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989

	+	EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u>	Jan 31, 1996

<u>AT</u>	LUITPOLD	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005

NEOSPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+ PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119</u>	<u>001</u>	Sep 10, 2009

<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009

<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-173 (of 362)

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
AP	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
AP	DSM PHARMS INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
AP	EBEWE PHARMA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008
AP	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
AP	HIKMA MAPLE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
AP	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274</u>	<u>001</u>	Sep 22, 2010
AP	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137</u>	<u>002</u>	Apr 09, 2010
AP	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136</u>	<u>001</u>	Apr 09, 2010
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136</u>	<u>002</u>	Apr 09, 2010
AP	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
AP	+ TEVA PHARMS USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
AP	+	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963</u>	<u>001</u>	Jan 03, 2008
AP	+	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
AP	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566</u>	<u>001</u>	Feb 29, 2008
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565</u>	<u>001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	DSM PHARMS INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
AP	+ FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008

GRANISTERON HYDROCHLORIDE

AP	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009

SOLUTION; ORAL

GRANISETRON HYDROCHLORIDE

+ PEDIATRAX

EQ 2MG BASE/10ML

A078334 001 Feb 28, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
AB	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
AB	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260</u>	<u>001</u>	Dec 31, 2007
AB	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
AB	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725</u>	<u>001</u>	Jan 30, 2008
AB	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
AB	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
AB	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
AB	TARO	<u>EQ 1MG BASE</u>	<u>A090817</u>	<u>001</u>	May 28, 2010
AB	+ TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080</u>	<u>001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT LUXEMBOURG	<u>125MG/5ML</u>	<u>A062483</u>	<u>001</u>	Jan 26, 1984

GRISEOFULVIN

AB	ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
AB	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
AB	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005
AB	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438</u>	<u>001</u>	Oct 08, 2010

TABLET; ORAL

GRIFULVIN V

AB	+ VALEANT LUXEMBOURG	<u>500MG</u>	<u>A062279</u>	<u>003</u>	

GRISEOFULVIN

AB	SANDOZ	<u>500MG</u>	<u>A091592</u>	<u>002</u>	Aug 07, 2013
AB	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482</u>	<u>001</u>	Oct 22, 2012
	SANDOZ	250MG	A091592	001	Aug 07, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-174 (of 362)

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRIS-PEG

AB	PEDINOL	125MG	N050475	001	
AB	+	250MG	N050475	002	

GRISEOFULVIN, ULTRAMICROSIZED

AB	RICONPHARMA LLC	125MG	A204371	001	Jan 09, 2014
AB		250MG	A204371	002	Jan 09, 2014

GRISEOFULVIN, ULTRAMICROSIZED

AB	SIGMAPHARM LABS LLC	125MG	A202545	001	Oct 22, 2012
AB		250MG	A202545	002	Oct 22, 2012

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

IVAX SUB TEVA PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
+	EQ 8MG BASE	A074149	002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	AMNEAL PHARM	EQ 1MG BASE	A075109	001	Nov 25, 1998
AB		EQ 2MG BASE	A075109	002	Nov 25, 1998
AB	EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997
AB		EQ 2MG BASE	A074673	002	Feb 28, 1997
AB	MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997
AB		EQ 2MG BASE	A074796	002	Jan 27, 1997
AB	WATSON LABS	EQ 1MG BASE	A074145	001	Oct 17, 1995
AB		EQ 2MG BASE	A074145	002	Oct 17, 1995

TENEX

AB	PROMIUS PHARMA	EQ 1MG BASE	N019032	001	Oct 27, 1986
AB	+	EQ 2MG BASE	N019032	002	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881	001	Oct 05, 2012
AB		EQ 2MG BASE	A200881	002	Oct 05, 2012
AB		EQ 3MG BASE	A200881	003	Oct 05, 2012
AB		EQ 4MG BASE	A200881	004	Oct 05, 2012

INTUNIV

AB	SHIRE	EQ 1MG BASE	N022037	001	Sep 02, 2009
AB		EQ 2MG BASE	N022037	002	Sep 02, 2009
AB		EQ 3MG BASE	N022037	003	Sep 02, 2009
AB	+	EQ 4MG BASE	N022037	004	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME	125MG	N001546	001	

HALCINONIDE

CREAM; TOPICAL

HALOG

+	RANBAXY	0.1%	N017556	001

OINTMENT; TOPICAL

HALOG

+	RANBAXY	0.1%	N017824	001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004
AB	G AND W LABS	0.05%	A078162	001	Apr 24, 2007
AB	PERRIGO ISRAEL	0.05%	A077123	001	Dec 16, 2004
AB	TARO	0.05%	A077227	001	Aug 04, 2005

ULTRAVATE

AB	+	RANBAXY	0.05%	N019967	001	Dec 27, 1990

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	G AND W LABS	0.05%	A077721	001	Sep 07, 2006
AB	PERRIGO	0.05%	A076872	001	Dec 16, 2004

ULTRAVATE

AB	+	RANBAXY	0.05%	N019968	001	Dec 17, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-175 (of 362)

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>	+	<u>2MG</u>	<u>A071208</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+	JANSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>	TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993
<u>AA</u>	+ TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
		<u>HALOPERIDOL</u>				
<u>AP</u>		AGILA SPECLTS	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>	+	HIKMA MAPLE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>		HOSPIRA	<u>5,000 UNITS/ML</u>	<u>A088100</u>	<u>001</u>	Apr 28, 1983
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091659</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002</u>	<u>001</u>	Jun 08, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-176 (of 362)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992

AP		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992

AP		HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992

AP	+		<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992

AP		HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985

AP			<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989

AP			<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985

AP	+		<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985

AP	+		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985

AP	+		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>010</u>	Apr 28, 1986

AP	+	HOSPIRA	<u>10,000 UNITS/ML</u>	<u>A089522</u>	<u>001</u>	May 04, 1987

AP		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810</u>	<u>001</u>	Jun 30, 2010

HEPARIN SODIUM

		PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011

			5,000 UNITS/ML	N201370	002	Jul 21, 2011

			10,000 UNITS/ML	N201370	003	Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

		HOSPIRA	<u>5,000 UNITS/100ML</u>	N019339	001	Mar 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		HOSPIRA	<u>5,000 UNITS/100ML</u>	N018916	006	Jan 31, 1984

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		HOSPIRA	<u>5,000 UNITS/100ML</u>	N018916	007	Jan 31, 1984

			<u>10,000 UNITS/100ML</u>	N018916	008	Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

		PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

	+	SANOFI AVENTIS US	3%	N006882	001	

SPONGE; TOPICAL

PRE-OP

AT	+	DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>001</u>	

PRE-OP II

AT		DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>002</u>	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

	+	ENDO PHARM	50MG	N022058	001	May 03, 2007

VANTAS

	+	ENDO PHARM	50MG	N021732	001	Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ACTAVIS MID ATLANTIC	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A088017</u>	<u>001</u>	Jul 05, 1983

AA	+	HI TECH PHARMA	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A040613</u>	<u>001</u>	Feb 08, 2008

AA		WOCKHARDT	<u>1.5MG/5ML; 5MG/5ML</u>	<u>A088008</u>	<u>001</u>	Mar 03, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-177 (of 362)

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

<u>AA</u>	NOVEL LABS INC	<u>1.5MG;5MG</u>	<u>A091528</u>	<u>001</u>	Apr 20, 2011
<u>TUSSIGON</u>					
<u>AA</u>	+ KING PHARMS	<u>1.5MG;5MG</u>	<u>A088508</u>	<u>001</u>	Jul 30, 1985

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+ AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004

VITRASE

+ BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+ HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>	+ LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997
<u>AP</u>	NAVINTA LLC	<u>20MG/ML</u>	<u>A202938</u>	<u>001</u>	Mar 28, 2013

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS GRP PTC	<u>10MG</u>	<u>A091679</u>	<u>001</u>	Mar 04, 2013
<u>AA</u>		<u>25MG</u>	<u>A091679</u>	<u>002</u>	Mar 04, 2013
<u>AA</u>		<u>50MG</u>	<u>A091679</u>	<u>003</u>	Mar 04, 2013
<u>AA</u>		<u>100MG</u>	<u>A091679</u>	<u>004</u>	Mar 04, 2013
<u>AA</u>	ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AA</u>		<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AA</u>		<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AA</u>		<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012
<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	MYLAN	<u>10MG</u>	<u>A090413</u>	<u>001</u>	Dec 08, 2010
<u>AA</u>		<u>25MG</u>	<u>A090413</u>	<u>002</u>	Dec 08, 2010
<u>AA</u>		<u>50MG</u>	<u>A090413</u>	<u>003</u>	Dec 08, 2010
<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>		<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>		<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>		<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	STRIDES ARCOLAB LTD	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013
<u>AA</u>	WATSON LABS	<u>25MG</u>	<u>A084504</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A084503</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-178 (of 362)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

PAR PHARM

25MG; 25MG

A088957 001 Oct 21, 1985

+

50MG; 50MG

A088946 001 Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+ ARBOR PHARMS INC

37.5MG; 20MG

N020727 001 Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDEAB ALEMBIC PHARMS LTD12.5MGA200645 001 Nov 30, 2010AB APOTEX12.5MGA078389 001 May 16, 2008AB AUROBINDO PHARMA12.5MGA078164 001 Sep 18, 2007AB IPCA LABS LTD12.5MGA079237 001 Apr 02, 2009AB IVAX SUB TEVA PHARMS12.5MGA077005 001 Jul 13, 2005AB JUBILANT CADISTA12.5MGA078391 001 Feb 11, 2008AB LANNETT HOLDINGS INC12.5MGA091662 001 Jan 27, 2012AB MYLAN12.5MGA075640 001 Jan 28, 2000AB UNICHEM12.5MGA090510 001 Jan 19, 2010AB VINTAGE PHARMS12.5MGA075907 001 Sep 17, 2002MICROZIDEAB + WATSON LABS12.5MGN020504 001 Dec 27, 1996

TABLET; ORAL

HYDROCHLOROTHIAZIDEAB ACCORD HLTHCARE12.5MGA202556 001 Sep 24, 2012AB25MGA202556 002 Sep 24, 2012AB50MGA202556 003 Sep 24, 2012AB ACTAVIS ELIZABETH12.5MGA040707 001 Feb 27, 2007AB APOTEX25MGA040774 001 Oct 03, 2007AB50MGA040774 002 Oct 03, 2007AB AUROBINDO PHARMA25MGA040780 001 Jul 20, 2007AB50MGA040780 002 Jul 20, 2007AB CARACO12.5MGA040857 001 May 30, 2008AB25MGA040810 001 Mar 27, 2007AB50MGA040810 002 Mar 27, 2007AB DAVA PHARMS INC25MGA087059 001AB50MGA087068 001AB EXCELLIUM25MGA040702 001 Mar 16, 2007AB50MGA040702 002 Mar 16, 2007AB HERITAGE PHARMS INC25MGA085182 002AB50MGA085182 001AB IPCA LABS LTD12.5MGA040807 001 Jul 20, 2007AB25MGA040807 002 Jul 20, 2007AB50MGA040807 003 Jul 20, 2007AB IVAX SUB TEVA PHARMS25MGA083177 001AB +50MGA083177 002AB JUBILANT CADISTA25MGA040809 001 Sep 04, 2007AB50MGA040809 002 Sep 04, 2007AB LANNETT25MGA084325 001AB50MGA084324 001AB MYLAN PHARMS INC12.5MGA040770 001 Jan 23, 2007AB25MGA040735 002 Jan 23, 2007AB50MGA040735 003 Jan 23, 2007AB UNICHEM25MGA040907 001 Aug 15, 2008AB50MGA040907 002 Aug 15, 2008AB VINTAGE PHARMS25MGA040412 001 Mar 29, 2002AB50MGA040412 002 Mar 29, 2002AB WEST WARD50MGA084878 001ORETICAB ABBVIE50MGN011971 002HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDEAB + SANOFI AVENTIS US12.5MG; 150MGN020758 002 Sep 30, 1997AB +12.5MG; 300MGN020758 003 Aug 31, 1998IRBESARTAN AND HYDROCHLOROTHIAZIDEAB ALEMBIC LTD12.5MG; 150MGA091370 001 Oct 15, 2012AB12.5MG; 300MGA091370 002 Oct 15, 2012AB APOTEX INC12.5MG; 150MGA201505 001 Oct 15, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-179 (of 362)

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201505</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG;150MG</u>	<u>A203630</u>	<u>001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203630</u>	<u>002</u>	Feb 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG;150MG</u>	<u>A203500</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203500</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG;150MG</u>	<u>A201524</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201524</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A202414</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;150MG</u>	<u>A077969</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077969</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>12.5MG;150MG</u>	<u>A090351</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A090351</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077446</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG;150MG</u>	<u>A077369</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077369</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG;150MG</u>	<u>A091539</u>	<u>001</u>	Oct 22, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A091539</u>	<u>002</u>	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674</u>	<u>001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674</u>	<u>002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674</u>	<u>003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u>	Mar 14, 2006
<u>AB</u>	HIKMA PHARMS LLC	<u>12.5MG;10MG</u>	<u>A076265</u>	<u>001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265</u>	<u>002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265</u>	<u>003</u>	Jul 08, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194</u>	<u>002</u>	Jul 01, 2002

PRINZIDE

<u>AB</u>	MERCK	<u>12.5MG;10MG</u>	<u>N019778</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>		<u>12.5MG;20MG</u>	<u>N019778</u>	<u>001</u>	Feb 16, 1989

ZESTORETIC

<u>AB</u>	ASTRAZENECA	<u>12.5MG;10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>12.5MG;50MG</u>	<u>N020387</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387</u>	<u>003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387</u>	<u>002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617</u>	<u>002</u>	Feb 17, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-180 (of 362)

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		<u>25MG;100MG</u>	<u>A091617</u>	<u>003</u>	Feb 17, 2012
AB	APOTEX	<u>12.5MG;50MG</u>	<u>A090150</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A090150</u>	<u>002</u>	Aug 11, 2010
AB		<u>25MG;100MG</u>	<u>A090150</u>	<u>003</u>	Oct 06, 2010
AB	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A091629</u>	<u>002</u>	Oct 06, 2010
AB		<u>25MG;100MG</u>	<u>A091629</u>	<u>003</u>	Jan 06, 2010
AB	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845</u>	<u>001</u>	Sep 18, 2012
AB		<u>12.5MG;100MG</u>	<u>A201845</u>	<u>002</u>	Sep 18, 2012
AB		<u>25MG;100MG</u>	<u>A201845</u>	<u>003</u>	Sep 18, 2012
AB	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682</u>	<u>001</u>	Mar 01, 2013
AB		<u>12.5MG;100MG</u>	<u>A201682</u>	<u>002</u>	Mar 01, 2013
AB		<u>25MG;100MG</u>	<u>A201682</u>	<u>003</u>	Mar 01, 2013
AB	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A078245</u>	<u>002</u>	May 21, 2010
AB		<u>25MG;100MG</u>	<u>A078245</u>	<u>003</u>	Oct 06, 2010
AB	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289</u>	<u>001</u>	Aug 09, 2012
AB		<u>12.5MG;100MG</u>	<u>A202289</u>	<u>002</u>	Aug 09, 2012
AB		<u>25MG;100MG</u>	<u>A202289</u>	<u>003</u>	Aug 09, 2012
AB	MYLAN	<u>12.5MG;50MG</u>	<u>A091652</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A091652</u>	<u>002</u>	Apr 06, 2010
AB		<u>25MG;100MG</u>	<u>A091652</u>	<u>003</u>	Oct 06, 2010
AB	ROXANE	<u>12.5MG;50MG</u>	<u>A077732</u>	<u>002</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A077732</u>	<u>001</u>	Apr 06, 2010
AB		<u>25MG;100MG</u>	<u>A077732</u>	<u>003</u>	Oct 06, 2010
AB	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A077948</u>	<u>003</u>	Aug 19, 2010
AB		<u>25MG;100MG</u>	<u>A077948</u>	<u>002</u>	Oct 06, 2010
AB	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157</u>	<u>001</u>	Apr 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A077157</u>	<u>002</u>	Apr 06, 2010
AB		<u>25MG;100MG</u>	<u>A077157</u>	<u>003</u>	Apr 06, 2010
AB	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528</u>	<u>001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A090528</u>	<u>003</u>	Apr 06, 2010
AB		<u>25MG;100MG</u>	<u>A090528</u>	<u>002</u>	Oct 06, 2010
AB	WATSON LABS	<u>12.5MG;50MG</u>	<u>A200180</u>	<u>001</u>	Jan 12, 2011
AB		<u>12.5MG;100MG</u>	<u>A200180</u>	<u>002</u>	Jan 12, 2011
AB		<u>25MG;100MG</u>	<u>A200180</u>	<u>003</u>	Jan 12, 2011
AB	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385</u>	<u>001</u>	Oct 06, 2010
AB		<u>25MG;100MG</u>	<u>A078385</u>	<u>002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG;250MG	A070264	001	Jan 23, 1986
+	25MG;250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	US PHARMS HOLDINGS I	<u>25MG;50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
AB	+	<u>25MG;100MG</u>	<u>N018303</u>	<u>002</u>	Dec 31, 1984
<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>					
AB	ALEMBIC PHARMS LTD	<u>25MG;50MG</u>	<u>A202870</u>	<u>001</u>	Nov 06, 2013
AB		<u>25MG;100MG</u>	<u>A202870</u>	<u>002</u>	Nov 06, 2013
AB		<u>50MG;100MG</u>	<u>A202870</u>	<u>003</u>	Nov 06, 2013
AB	MYLAN	<u>25MG;50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
AB		<u>25MG;100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
AB		<u>50MG;100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004
AB	SUN PHARM INDS	<u>25MG;50MG</u>	<u>A090654</u>	<u>001</u>	Jan 19, 2012
AB		<u>25MG;100MG</u>	<u>A090654</u>	<u>002</u>	Jan 19, 2012
AB		<u>50MG;100MG</u>	<u>A090654</u>	<u>003</u>	Jan 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-181 (of 362)

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS	<u>12.5MG; 7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
AB		<u>12.5MG; 15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
AB		<u>25MG; 15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
AB	TEVA	<u>12.5MG; 7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
AB		<u>12.5MG; 15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
AB		<u>25MG; 15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007
<u>UNIRETIC</u>					
AB	UCB INC	<u>12.5MG; 7.5MG</u>	<u>N020729</u>	<u>001</u>	Jun 27, 1997
AB		<u>12.5MG; 15MG</u>	<u>N020729</u>	<u>003</u>	Feb 14, 2002
AB	+	<u>25MG; 15MG</u>	<u>N020729</u>	<u>002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

DAIICHI SANKYO

12.5MG; 20MG

N021532 002 Jun 05, 2003

12.5MG; 40MG

N021532 003 Jun 05, 2003

+

25MG; 40MG

N021532 005 Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+	WYETH PHARMS INC	<u>25MG; 40MG</u>	<u>N018031</u>	<u>001</u>	
<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>						
AB		MYLAN	<u>25MG; 40MG</u>	<u>A070946</u>	<u>001</u>	Mar 04, 1987
AB	+		<u>25MG; 80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
AB		PLIVA	<u>25MG; 40MG</u>	<u>A072042</u>	<u>001</u>	Mar 14, 1988
AB			<u>25MG; 80MG</u>	<u>A072043</u>	<u>001</u>	Mar 14, 1988

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB		PFIZER PHARMS	<u>12.5MG; EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
AB	+		<u>25MG; EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999
<u>QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>						
AB		APOTEX CORP	<u>12.5MG; EQ 10MG BASE</u>	<u>A091524</u>	<u>001</u>	Mar 12, 2013
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>A091524</u>	<u>002</u>	Mar 12, 2013
AB			<u>25MG; EQ 20MG BASE</u>	<u>A091524</u>	<u>003</u>	Mar 12, 2013
AB		AUROBINDO PHARMA	<u>12.5MG; EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
AB			<u>25MG; EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
AB		INVAGEN PHARMS	<u>12.5MG; 10MG</u>	<u>A201356</u>	<u>001</u>	Apr 20, 2011
AB			<u>12.5MG; 20MG</u>	<u>A201356</u>	<u>002</u>	Apr 20, 2011
AB			<u>25MG; 20MG</u>	<u>A201356</u>	<u>003</u>	Apr 20, 2011
AB		MYLAN	<u>12.5MG; EQ 10MG BASE</u>	<u>A077093</u>	<u>001</u>	Mar 28, 2005
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>A077093</u>	<u>002</u>	Mar 28, 2005
AB			<u>25MG; EQ 20MG BASE</u>	<u>A077093</u>	<u>003</u>	Mar 28, 2005
AB		RANBAXY	<u>12.5MG; EQ 10MG BASE</u>	<u>A078211</u>	<u>001</u>	Mar 04, 2009
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>A078211</u>	<u>002</u>	Mar 04, 2009
AB			<u>25MG; EQ 20MG BASE</u>	<u>A078211</u>	<u>003</u>	Mar 04, 2009
<u>QUINARETIC</u>						
AB		GAVIS PHARMS	<u>12.5MG; EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
AB			<u>12.5MG; EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
AB			<u>25MG; EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB		GD SEARLE LLC	<u>25MG; 25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>						
AB		MUTUAL PHARM	<u>25MG; 25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
AB		MYLAN	<u>25MG; 25MG</u>	<u>A086513</u>	<u>001</u>	
AB		WATSON LABS	<u>25MG; 25MG</u>	<u>A087398</u>	<u>001</u>	
<u>ALDACTAZIDE</u>						
	+	GD SEARLE LLC	50MG; 50MG	N012616	005	Dec 30, 1982

PRESCRIPTION DRUG PRODUCT LIST

3-182 (of 362)

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

BOEHRINGER INGELHEIM 12.5MG; 40MG
 12.5MG; 80MG
 + 25MG; 80MG

N021162 001 Nov 17, 2000
 N021162 002 Nov 17, 2000
 N021162 003 Apr 19, 2004

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDEAB + GLAXOSMITHKLINE LLC 25MG; 37.5MGN016042 003 Mar 03, 1994TRIAMTERENE AND HYDROCHLOROTHIAZIDEAB DURAMED PHARMS BARR 25MG; 37.5MGA075052 001 Jun 18, 1999AB IVAX SUB TEVA PHARMS 25MG; 50MGA074259 001 Mar 30, 1995AB LANNETT HOLDINGS INC 25MG; 37.5MGA201407 001 Dec 09, 2011AB MYLAN 25MG; 37.5MGA074701 001 Jun 07, 1996AB SANDOZ 25MG; 37.5MGA074821 001 Jun 05, 1997AB + 25MG; 50MGA073191 001 Jul 31, 1991

TABLET; ORAL

MAXZIDEAB + MYLAN PHARMS INC 50MG; 75MGN019129 001 Oct 22, 1984MAXZIDE-25AB MYLAN PHARMS INC 25MG; 37.5MGN019129 003 May 13, 1988TRIAMTERENE AND HYDROCHLOROTHIAZIDEAB APOTEX INC 25MG; 37.5MGA071251 002 May 05, 1998AB 50MG; 75MGA071251 001 Apr 17, 1988AB PLIVA 25MG; 37.5MGA074026 001 Apr 26, 1996AB 50MG; 75MGA073467 001 Jan 31, 1996AB SANDOZ 25MG; 37.5MGA073281 001 Apr 30, 1992AB 50MG; 75MGA072011 001 Jun 17, 1988AB WATSON LABS 25MG; 37.5MGA073449 001 Sep 23, 1993AB 50MG; 75MGA071851 001 Nov 30, 1988HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCTAB NOVARTIS 12.5MG; 80MGN020818 001 Mar 06, 1998AB 12.5MG; 160MGN020818 002 Mar 06, 1998AB 12.5MG; 320MGN020818 004 Apr 28, 2006AB 25MG; 160MGN020818 003 Jan 17, 2002AB + 25MG; 320MGN020818 005 Apr 28, 2006VALSARTAN AND HYDROCHLOROTHIAZIDEAB ALEMBIC LTD 12.5MG; 80MGA201662 001 Mar 21, 2013AB 12.5MG; 160MGA201662 002 Mar 21, 2013AB 12.5MG; 320MGA201662 003 Mar 21, 2013AB 25MG; 160MGA201662 004 Mar 21, 2013AB 25MG; 320MGA201662 005 Mar 21, 2013AB APOTEX INC 12.5MG; 80MGA203026 001 Mar 21, 2013AB 12.5MG; 160MGA203026 002 Mar 21, 2013AB 12.5MG; 320MGA203026 003 Mar 21, 2013AB 25MG; 160MGA203026 004 Mar 21, 2013AB 25MG; 320MGA203026 005 Mar 21, 2013AB AUROBINDO PHARMA LTD 12.5MG; 80MGA202519 001 Mar 21, 2013AB 12.5MG; 160MGA202519 002 Mar 21, 2013AB 12.5MG; 320MGA202519 003 Mar 21, 2013AB 25MG; 160MGA202519 004 Mar 21, 2013AB 25MG; 320MGA202519 005 Mar 21, 2013AB LUPIN LTD 12.5MG; 80MGA078946 003 Mar 21, 2013AB 12.5MG; 160MGA078946 004 Mar 21, 2013AB 12.5MG; 320MGA078946 001 Mar 21, 2013AB 25MG; 160MGA078946 005 Mar 21, 2013AB 25MG; 320MGA078946 002 Mar 21, 2013AB MACLEODS PHARMS LTD 12.5MG; 80MGA203145 001 Apr 19, 2013AB 12.5MG; 160MGA203145 002 Apr 19, 2013AB 12.5MG; 320MGA203145 003 Apr 19, 2013AB 25MG; 160MGA203145 004 Apr 19, 2013AB 25MG; 320MGA203145 005 Apr 19, 2013AB MYLAN PHARMS INC 12.5MG; 80MGA078020 001 Sep 21, 2012AB 12.5MG; 160MGA078020 002 Sep 21, 2012AB 12.5MG; 320MGA078020 004 Sep 21, 2012AB 25MG; 160MGA078020 003 Sep 21, 2012AB 25MG; 320MGA078020 005 Sep 21, 2012AB WATSON LABS INC 12.5MG; 80MGA091519 001 Mar 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-183 (of 362)

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	<u>12.5MG;160MG</u>	<u>A091519</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>	<u>12.5MG;320MG</u>	<u>A091519</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>	<u>25MG;160MG</u>	<u>A091519</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>	<u>25MG;320MG</u>	<u>A091519</u>	<u>005</u>	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+ ZOGENIX INC

10MG

N202880 001 Oct 25, 2013

15MG

N202880 002 Oct 25, 2013

20MG

N202880 003 Oct 25, 2013

30MG

N202880 004 Oct 25, 2013

40MG

N202880 005 Oct 25, 2013

50MG

N202880 006 Oct 25, 2013

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>2.5MG;200MG</u>	<u>A091633</u>	<u>001</u>	May 28, 2013
<u>AB</u>		<u>5MG;200MG</u>	<u>A091633</u>	<u>002</u>	May 28, 2013
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A091633</u>	<u>003</u>	May 28, 2013
<u>AB</u>		<u>10MG;200MG</u>	<u>A091633</u>	<u>004</u>	May 28, 2013
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG;200MG</u>	<u>A077454</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003
<u>REPREXAIN</u>					
<u>AB</u>	AMNEAL PHARMS NY	<u>2.5MG;200MG</u>	<u>A076642</u>	<u>003</u>	Oct 19, 2007
<u>AB</u>		<u>10MG;200MG</u>	<u>A076642</u>	<u>004</u>	Oct 19, 2007
<u>VICOPROFEN</u>					
<u>AB</u>	+ ABBVIE	<u>7.5MG;200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+ CYPRESS PHARM

5MG/5ML; 60MG/5ML

N022442 001 Jun 08, 2011

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>1%</u>	<u>A080706</u>	<u>006</u>	
<u>ANUSOL HC</u>					
<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
<u>HYDROCORTISONE</u>					
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
<u>AT</u>	+ FOUGERA	<u>1%</u>	<u>A080693</u>	<u>003</u>	
<u>AT</u>	+	<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
<u>AT</u>	LYNE	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086155</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004
<u>SYNACORT</u>					
<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087457</u>	<u>001</u>	
ENEMA; RECTAL					
<u>COLOCORT</u>					
<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999
<u>CORTENEMA</u>					
<u>AB</u>	+ ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>	
<u>HYDROCORTISONE</u>					
<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u>	<u>001</u>	May 27, 1994
LOTION; TOPICAL					
<u>ALA-CORT</u>					
<u>AT</u>	CROWN LABS	<u>1%</u>	<u>A083201</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-184 (of 362)

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000
AT		TARO	2.5%	A040247 001	Jul 23, 1999
AT		VINTAGE PHARMS	2.5%	A040417 001	Jul 30, 2003

NUTRACORT

AT		DOW PHARM	1%	A080443 003	
AT			2.5%	A087644 001	Aug 24, 1982

STIE-CORT

AT		PERRIGO	2.5%	A089074 001	Nov 26, 1985
		ALA-SCALP			
		CROWN LABS	2%	A083231 001	

OINTMENT; TOPICAL

HYDROCORTISONE

AT		ACTAVIS MID ATLANTIC	1%	A087796 001	Oct 13, 1982
AT	+	FOUGERA	2.5%	A081203 001	May 28, 1993
AT	+	FOUGERA PHARMS	1%	A080692 001	
AT		PERRIGO NEW YORK	2.5%	A085027 001	
AT		TARO	1%	A086257 001	

HYDROCORTISONE IN ABSORBABLE

AT		CAROLINA MEDCL	1%	A088138 001	Sep 06, 1985
		POWDER; FOR RX COMPOUNDING			
		HYDRO-RX			
	+	X GEN PHARMS	100%	A085982 001	
		SOLUTION; TOPICAL			
		TEXACORT			
	+	MISSION PHARMA	2.5%	A081271 001	Apr 17, 1992

TABLET; ORAL

CORTEF

AB		PHARMACIA AND UPJOHN	5MG	N008697 003	
AB			10MG	N008697 001	
AB	+		20MG	N008697 002	

HYDROCORTISONE

AB		AMEDRA PHARMS	5MG	A040646 001	Mar 30, 2007
AB			10MG	A040646 002	Mar 30, 2007
AB			20MG	A040646 003	Mar 30, 2007
AB		VINTAGE	5MG	A040761 001	Jul 16, 2007
AB			10MG	A040761 002	Jul 16, 2007
AB			20MG	A040761 003	Jul 16, 2007

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+	MEDA PHARMS	10%	N017351 001	Feb 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+	FERNDAL LABS	2.5%	A040259 001	Jul 29, 1999

MICORT-HC

+	SEBELA IRELAND LTD	2%	A040398 001	Mar 29, 2002

		2.5%	A040396 001	Feb 27, 2001

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

	X GEN PHARMS	100%	A085981 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+	MONARCH PHARMS	0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050218 001	Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX		MEDA PHARMS	1%; 1%	A086457 001

PROCTOFOAM HC

BX		MEDA PHARMS	1%; 1%	A086195 001

CREAM; TOPICAL

PRAMOSONE

	SEBELA IRELAND LTD	0.5%; 1%	A083778 001

		1%; 1%	A085368 001

LOTION; TOPICAL

PRAMOSONE

	SEBELA IRELAND LTD	1%; 1%	A085980 001

		2.5%; 1%	A085979 001

PRESCRIPTION DRUG PRODUCT LIST

3-185 (of 362)

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO

1%;10%

A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB** GLENMARK GENERICS0.1%**A202145 001** Sep 27, 2013**AB** TARO PHARM INDS0.1%**A076654 001** Aug 03, 2005LOCOID**AB** + PRECISION DERMAT0.1%**N018514 001** Mar 31, 1982LOCOID LIPOCREAM**AB** + PRECISION DERMAT0.1%**N020769 001** Sep 08, 1997

LOTION; TOPICAL

LOCOID

+ PRECISION DERMAT

0.1%

N022076 001 May 18, 2007

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE**AB** TARO0.1%**A076842 001** Dec 27, 2004LOCOID**AB** + PRECISION DERMAT0.1%**N018652 001** Oct 29, 1982

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE**AT** TARO PHARM INDS0.1%**A076364 001** Jan 14, 2004LOCOID**AT** + PRECISION DERMAT0.1%**N019116 001** Feb 25, 1987HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ FOUGERA PHARMS

0.1%

N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT**AP** HOSPIRAEQ 100MG BASE/VIAL**A040666 001** Apr 06, 2006SOLU-CORTEF**AP** + PHARMACIA AND UPJOHNEQ 1GM BASE/VIAL**N009866 004****AP** +EQ 100MG BASE/VIAL**N009866 001****AP** +EQ 250MG BASE/VIAL**N009866 002****AP** +EQ 500MG BASE/VIAL**N009866 003**HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE**AB** PERRIGO NEW YORK0.2%**A075666 001** May 24, 2000**AB** + TARO0.2%**A075042 001** Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

+ TARO

0.2%

A075043 001 Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN**AT** + MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**N050479 001**NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A062423 001** Aug 25, 1983**AT** BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A064053 001** Dec 29, 1995**AT** LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A065216 001** Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

+ ALCON PHARMS LTD

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORIN**AT** + CITRON PHARMA LLC1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A060613 001**NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A062488 001** Nov 06, 1985**AT** LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A065219 001** May 01, 2006OTICAIR**AT** BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A064065 001** Aug 28, 1996PEDIOTIC**AT** MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**A062822 001** Sep 29, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-186 (of 362)

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	<u>N011949</u>	<u>001</u>	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+	PURDUE PHARM PRODS	1MG/ML	<u>N019034</u>	<u>003</u>	Apr 30, 2009
AP	+		2MG/ML	<u>N019034</u>	<u>004</u>	Apr 30, 2009
AP	+		4MG/ML	<u>N019034</u>	<u>005</u>	Apr 30, 2009

DILAUDID-HP

AP	+	PURDUE PHARM PRODS	10MG/ML	<u>N019034</u>	<u>001</u>	Jan 11, 1984

HYDROMORPHONE HYDROCHLORIDE

AP		AKORN	10MG/ML	<u>A078228</u>	<u>001</u>	Apr 14, 2010
AP			10MG/ML	<u>A078261</u>	<u>001</u>	Apr 14, 2010
AP		BARR	10MG/ML	<u>A076444</u>	<u>001</u>	Apr 25, 2003
AP		HOSPIRA	10MG/ML	<u>A074598</u>	<u>001</u>	Jun 19, 1997
AP		HOSPIRA INC	1MG/ML	<u>N200403</u>	<u>001</u>	Dec 01, 2011
AP			2MG/ML	<u>N200403</u>	<u>002</u>	Dec 01, 2011
AP			4MG/ML	<u>N200403</u>	<u>003</u>	Dec 01, 2011
AP			10MG/ML	<u>A078591</u>	<u>001</u>	Jun 17, 2008

DILAUDID-HP

+	PURDUE PHARM PRODS	250MG/VIAL

N019034	002	Aug 04, 1994

SOLUTION; ORAL

DILAUDID

AA	+	PURDUE PHARM PRODS	5MG/5ML	<u>N019891</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AA		ROXANE	5MG/5ML	<u>A074653</u>	<u>001</u>	Jul 29, 1998

TABLET; ORAL

DILAUDID

AB		PURDUE PHARM PRODS	2MG	<u>N019892</u>	<u>003</u>	Nov 09, 2007
AB			4MG	<u>N019892</u>	<u>002</u>	Nov 09, 2007
AB	+		8MG	<u>N019892</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AB		ELITE LABS	8MG	<u>A076723</u>	<u>001</u>	Oct 18, 2005
AB		LANNETT	2MG	<u>A078439</u>	<u>001</u>	Dec 09, 2009
AB			4MG	<u>A078439</u>	<u>002</u>	Dec 09, 2009
AB			8MG	<u>A077471</u>	<u>001</u>	Dec 09, 2009
AB		MALLINCKRODT	8MG	<u>A076855</u>	<u>001</u>	Dec 23, 2004
AB		MALLINCKRODT INC	2MG	<u>A078273</u>	<u>001</u>	Sep 19, 2007
AB			4MG	<u>A078273</u>	<u>002</u>	Sep 19, 2007
AB		ROXANE	4MG	<u>A074597</u>	<u>003</u>	May 29, 2009
AB			8MG	<u>A074597</u>	<u>001</u>	Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC

8MG

N021217	001	Mar 01, 2010

12MG

N021217	002	Mar 01, 2010

16MG

N021217	003	Mar 01, 2010

+

32MG

N021217	004	Aug 24, 2012

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+	MERCK SANTE SAS	5GM/VIAL (5GM/KIT)

N022041	001	Apr 08, 2011

HYDROXOCOBALAMIN

+	WATSON LABS	1MG/ML

A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	1%; 0.25%

N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		IPCA LABS LTD	200MG	<u>A040766</u>	<u>001</u>	Jun 14, 2007
AB		MYLAN	200MG	<u>A040274</u>	<u>001</u>	May 29, 1998
AB		SANDOZ	200MG	<u>A040104</u>	<u>001</u>	Nov 30, 1995
AB		TEVA PHARMS	200MG	<u>A040081</u>	<u>001</u>	Sep 30, 1994
AB		WATSON LABS	200MG	<u>A040133</u>	<u>001</u>	Nov 30, 1995
AB		WEST WARD	200MG	<u>A040760</u>	<u>001</u>	Aug 15, 2007
AB		ZYDUS PHARMS USA INC	200MG	<u>A040657</u>	<u>001</u>	Sep 21, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-187 (of 362)

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

PLAQUENIL

AB	+	SANOFI AVENTIS US	200MG	<u>N009768</u>	<u>001</u>	

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ KV PHARM

1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+ ATON

5MG

N018771 001

HYDROXYUREA

CAPSULE; ORAL

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	<u>N016295</u>	<u>001</u>	

HYDROXYUREA

AB		BARR	500MG	<u>A075143</u>	<u>001</u>	Oct 16, 1998

AB		PAR PHARM	500MG	<u>A075340</u>	<u>001</u>	Feb 24, 1999

DROXIA

BRISTOL MYERS SQUIBB

200MG

N016295 002 Feb 25, 1998

300MG

N016295 003 Feb 25, 1998

400MG

N016295 004 Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	25MG/ML	<u>A087329</u>	<u>001</u>	

AP	+		50MG/ML	<u>A087329</u>	<u>002</u>	

AP		LUITPOLD	25MG/ML	<u>A087408</u>	<u>001</u>	

AP			50MG/ML	<u>A087408</u>	<u>002</u>	

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	+	HI TECH PHARMA	10MG/5ML	<u>A040010</u>	<u>001</u>	Oct 28, 1994

AA		SILARX PHARMS INC	10MG/5ML	<u>A201674</u>	<u>001</u>	Aug 21, 2013

AA	+	VINTAGE PHARMS	10MG/5ML	<u>A040391</u>	<u>001</u>	Apr 10, 2002

AA	+	WOCKHARDT	10MG/5ML	<u>A087294</u>	<u>001</u>	Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	10MG	<u>A040808</u>	<u>001</u>	Sep 24, 2008

AB			25MG	<u>A040808</u>	<u>002</u>	Sep 24, 2008

AB			50MG	<u>A040808</u>	<u>003</u>	Sep 24, 2008

AB		CARACO	10MG	<u>A040899</u>	<u>001</u>	Jun 10, 2008

AB			25MG	<u>A040899</u>	<u>002</u>	Jun 10, 2008

AB			50MG	<u>A040899</u>	<u>003</u>	Jun 10, 2008

AB		HERITAGE PHARMS INC	10MG	<u>A040804</u>	<u>001</u>	Jun 30, 2008

AB			25MG	<u>A040804</u>	<u>002</u>	Jun 30, 2008

AB			50MG	<u>A040804</u>	<u>003</u>	Jun 30, 2008

AB		HETERO LABS LTD III	10MG	<u>A040805</u>	<u>001</u>	May 29, 2008

AB			25MG	<u>A040805</u>	<u>002</u>	May 29, 2008

AB			50MG	<u>A040805</u>	<u>003</u>	May 29, 2008

AB		INVAGEN PHARMS	10MG	<u>A040812</u>	<u>001</u>	Mar 12, 2008

AB			25MG	<u>A040812</u>	<u>002</u>	Mar 12, 2008

AB			50MG	<u>A040812</u>	<u>003</u>	Mar 12, 2008

AB		KVK TECH	10MG	<u>A040786</u>	<u>001</u>	Mar 20, 2007

AB			25MG	<u>A040787</u>	<u>001</u>	Mar 20, 2007

AB			50MG	<u>A040788</u>	<u>001</u>	Mar 20, 2007

AB		MUTUAL PHARM	10MG	<u>A089381</u>	<u>001</u>	May 19, 1986

AB			25MG	<u>A089382</u>	<u>001</u>	May 19, 1986

AB			50MG	<u>A089383</u>	<u>001</u>	May 19, 1986

AB		MYLAN	10MG	<u>A091176</u>	<u>001</u>	Jun 07, 2010

AB			25MG	<u>A091176</u>	<u>002</u>	Jun 07, 2010

AB			50MG	<u>A091176</u>	<u>003</u>	Jun 07, 2010

AB		NORTHSTAR HLTHCARE	10MG	<u>A040841</u>	<u>001</u>	Mar 31, 2008

AB			25MG	<u>A040842</u>	<u>001</u>	Mar 31, 2008

AB			50MG	<u>A040840</u>	<u>001</u>	Mar 31, 2008

AB	+	PLIVA	10MG	<u>A088617</u>	<u>001</u>	Jan 10, 1986

AB	+		25MG	<u>A088618</u>	<u>001</u>	Jan 10, 1986

AB	+		50MG	<u>A088619</u>	<u>001</u>	Jan 10, 1986

AB		VINTAGE PHARMS	10MG	<u>A040579</u>	<u>001</u>	May 27, 2005

AB			25MG	<u>A040574</u>	<u>001</u>	May 27, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-188 (of 362)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A040580</u>	<u>001</u>	May 27, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A081149</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>10MG</u>	<u>A088348</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A081150</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>25MG</u>	<u>A088349</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A081151</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>50MG</u>	<u>A088350</u>	<u>001</u>	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>	EMCURE PHARMS USA	<u>25MG</u>	<u>A201507</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>50MG</u>	<u>A201507</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479</u>	<u>001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>EQ 25MG HCL</u>	<u>A040156</u>	<u>001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 25MG HCL</u>	<u>A081165</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156</u>	<u>002</u>	Jul 15, 1996

VISTARIL

<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459</u>	<u>004</u>	
	HYDROXYZINE PAMOATE				
	BARR	EQ 100MG HCL	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE

EQ 3MG BASE/3ML

N021858 001 Jan 06, 2006

TABLET; ORAL

BONIVA

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 150MG BASE</u>	<u>N021455</u>	<u>002</u>	Mar 24, 2005
		<u>IBANDRONATE SODIUM</u>				
<u>AB</u>		APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		MUTUAL PHARM CO INC	<u>EQ 150MG BASE</u>	<u>A078996</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078995</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 150MG BASE</u>	<u>A079003</u>	<u>001</u>	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

+ PHARMACYCLICS INC

140MG

N205552 001 Nov 13, 2013

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

+ CUMBERLAND PHARMS

800MG/8ML (100MG/ML)

N022348 002 Jun 11, 2009

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>		PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925</u>	<u>001</u>	Sep 23, 2004

TABLET; ORAL

IBU-TAB

<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071267</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A072300</u>	<u>001</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	+	<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-189 (of 362)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	DR REDDYS LABS INC	400MG	A076112 001	Oct 31, 2001
AB		600MG	A076112 002	Oct 31, 2001
AB		800MG	A076112 003	Oct 31, 2001
AB	MARKSANS PHARMA	400MG	A090796 001	Dec 21, 2010
AB		600MG	A090796 002	Dec 21, 2010
AB		800MG	A090796 003	Dec 21, 2010
AB	PERRIGO R AND D	400MG	A077114 001	Jul 18, 2005
AB		600MG	A077114 002	Jul 18, 2005
AB		800MG	A077114 003	Jul 18, 2005
AB	SHASUN USA	400MG	A078329 001	Feb 05, 2009
AB		600MG	A078329 002	Feb 05, 2009
AB		800MG	A078329 003	Feb 05, 2009
AB	VINTAGE PHARMS	300MG	A071230 001	Oct 22, 1986
AB		400MG	A071231 001	Oct 22, 1986
AB		400MG	A071644 001	Feb 01, 1988
AB		600MG	A071232 001	Oct 22, 1986
AB		800MG	A072004 001	Nov 18, 1987
AB	WATSON LABS	400MG	A070436 001	Aug 21, 1985
AB		600MG	A070437 001	Aug 21, 1985

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

AB	ACTAVIS ELIZABETH	400MG; 5MG	A078769 001	Jan 04, 2008
AB	+ BARR LABS INC	400MG; 5MG	A078316 001	Nov 29, 2007
AB	WATSON LABS	400MG; 5MG	A078394 001	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

AP	+ PHARMACIA AND UPJOHN	0.1MG/ML	N020491 001	Dec 28, 1995
	<u>IBUTILIDE FUMARATE</u>			
AP	LUITPOLD	0.1MG/ML	A090240 001	Jan 11, 2010
AP	MYLAN INSTITUTIONAL	0.1MG/ML	A090643 001	Jan 11, 2010
AP		0.1MG/ML	A090924 001	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+ SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N022150 001 Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+ BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 1GM N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

AP	+ PHARMACIA AND UPJOHN	1MG/ML	N050734 001	Feb 17, 1997
	<u>IDARUBICIN HYDROCHLORIDE</u>			
AP	BEDFORD LABS	1MG/ML	A065275 001	Dec 14, 2006
AP		1MG/ML	A065288 001	May 15, 2007
AP	FRESENIUS KABI USA	1MG/ML	A065440 001	Aug 04, 2009
AP	ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012
AP	SANDOZ	1MG/ML	A091293 001	Mar 29, 2011
	<u>IDARUBICIN HYDROCHLORIDE PFS</u>			
AP	TEVA PHARMS USA	1MG/ML	A065036 001	May 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-190 (of 362)

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC

DENDRID

AT	+	ALCON	0.1%	N014169	001	

HERPLEX

AT	+	ALLERGAN	0.1%	N013935	002	

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

AP		BAXTER HLTHCARE	1GM/VIAL	N019763	001	Dec 30, 1988
AP			3GM/VIAL	N019763	002	Dec 30, 1988

IFOSFAMIDE

AP		BEDFORD LABS	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011
AP			3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011
AP	+	FRESENIUS KABI USA	1GM/VIAL	A076078	001	May 28, 2002
AP			1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
AP	+		3GM/VIAL	A076078	002	May 28, 2002
AP			3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
AP		ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012
AP			3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012
AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007
AP	+		3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002
+		3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

FANAPT

+	NOVARTIS	1MG	N022192	001	May 06, 2009
		2MG	N022192	002	May 06, 2009
		4MG	N022192	003	May 06, 2009
		6MG	N022192	004	May 06, 2009
		8MG	N022192	005	May 06, 2009
		10MG	N022192	006	May 06, 2009
		12MG	N022192	007	May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003
+		EQ 400MG BASE	N021588	002	Apr 18, 2003

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB		EXCELLIUM	10MG	A040903	001	Oct 24, 2012
AB			25MG	A040903	002	Oct 24, 2012
AB			50MG	A040903	003	Oct 24, 2012
AB		LUPIN LTD	10MG	A090443	001	Mar 11, 2010
AB			25MG	A090442	001	Mar 11, 2010
AB			50MG	A090441	001	Mar 11, 2010
AB		MUTUAL PHARM	10MG	A081048	001	Jun 05, 1990
AB			25MG	A081049	001	Jun 05, 1990
AB			50MG	A081050	001	Jun 05, 1990
AB		PAR PHARM	10MG	A088292	001	Oct 21, 1983
AB			10MG	A089422	001	Jul 14, 1987
AB			25MG	A088262	001	Oct 21, 1983
AB			50MG	A088276	001	Oct 21, 1983
AB		SANDOZ	10MG	A084936	002	

PRESCRIPTION DRUG PRODUCT LIST

3-191 (of 362)

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
<u>TOFRANIL</u>					
<u>AB</u>	MALLINCKRODT INC	<u>10MG</u>	<u>A087844</u>	<u>001</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087845</u>	<u>001</u>	May 22, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	LUPIN LTD	<u>EQ 75MG HCL</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG HCL</u>	<u>A202338</u>	<u>001</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A202338</u>	<u>002</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A202338</u>	<u>003</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A202338</u>	<u>004</u>	Jun 28, 2013
<u>AB</u>	ROXANE	<u>EQ 75MG HCL</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010
<u>TOFRANIL-PM</u>					
<u>AB</u>	+	<u>EQ 75MG HCL</u>	<u>N017090</u>	<u>001</u>	
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>N017090</u>	<u>004</u>	
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>N017090</u>	<u>003</u>	
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>N017090</u>	<u>002</u>	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	<u>MEDICIS</u>	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
<u>IMIQUIMOD</u>						
<u>AB</u>	APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012	
<u>AB</u>	FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010	
<u>AB</u>	GLENMARK GENERICS	<u>5%</u>	<u>A201994</u>	<u>001</u>	Mar 06, 2012	
<u>AB</u>	PERRIGO ISRAEL	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010	
<u>AB</u>	TARO	<u>5%</u>	<u>A200173</u>	<u>001</u>	Apr 15, 2011	
<u>AB</u>	TEVA PHARMS USA	<u>5%</u>	<u>A200481</u>	<u>001</u>	Apr 18, 2011	
<u>AB</u>	TOLMAR	<u>5%</u>	<u>A091044</u>	<u>001</u>	Feb 28, 2011	
ZYCLARA						
	+	<u>MEDICIS</u>	<u>2.5%</u>	<u>N022483</u>	<u>002</u>	Jul 15, 2011
	+		<u>3.75%</u>	<u>N022483</u>	<u>001</u>	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

+	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A075513</u>	<u>001</u>	May 09, 2000

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+	NOVARTIS	<u>EQ 75MCG BASE</u>	<u>N022383</u>	<u>001</u>	Jul 01, 2011

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>	MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+	<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A074585</u>	<u>001</u>	Sep 26, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074585</u>	<u>002</u>	Sep 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-192 (of 362)

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME EQ 200MG BASE
+ EQ 400MG BASE

N020685 003 Mar 13, 1996
N020685 001 Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+ GE HEALTHCARE 2mCi/0.2ML
INDIUM IN 111 CHLORIDE
+ MALLINCKRODT 5mCi/0.5ML

N019862 001 Dec 29, 1992
N019841 001 Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+ GE HEALTHCARE 1mCi/ML

N019044 001 Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+ GE HEALTHCARE 1mCi/ML

N017707 001 Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+ MALLINCKRODT 3mCi/ML

N020314 001 Jun 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREENAP + AKORN 25MG/VIALN011525 001INDOCYANINE GREENAP PULSION MEDCL 25MG/VIALA040811 001 Nov 21, 2007INDOMETHACIN

CAPSULE; ORAL

INDOMETHACINAB CARACO 25MGA091401 001 Mar 28, 2013AB 50MGA091401 002 Mar 28, 2013AB GLENMARK GENERICS 25MGA091276 001 Dec 22, 2010AB 50MGA091276 002 Dec 22, 2010AB HERITAGE PHARMS INC 25MGN018851 001 May 18, 1984AB 50MGN018851 002 May 18, 1984AB HETERO LABS LTD III 25MGA091240 001 Apr 12, 2011AB 50MGA091240 002 Apr 12, 2011AB IVAX SUB TEVA PHARMS 25MGA070719 001 Feb 12, 1986AB 50MGA070756 001 Feb 12, 1986AB MYLAN 25MGN018858 001 Apr 20, 1984AB + 50MGA070624 001 Sep 04, 1985AB SANDOZ 25MGA070673 001 Apr 29, 1987AB 50MGA070674 001 Apr 29, 1987AB ZYDUS PHARMS USA INC 25MGA090403 001 Nov 15, 2010AB 50MGA090403 002 Nov 15, 2010

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACINAB AMNEAL PHARMS 75MGA091549 001 Dec 01, 2010AB AVANTHI INC 75MGA079175 001 Mar 06, 2009AB HETERO LABS LTD III 75MGA201807 001 Sep 28, 2012AB PADDOCK LLC 75MGA200529 001 Nov 30, 2010AB + SANDOZ 75MGA074464 001 May 28, 1998AB WATSON LABS INC 75MGA202572 001 Dec 09, 2013

INJECTABLE; INJECTION

INDOMETHACIN

+ FRESENIUS KABI USA EQ 1MG BASE/VIAL

N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

+ G AND W LABS 50MG

A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+ IROKO PHARMS 25MG/5ML

N018332 001 Oct 10, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-193 (of 362)

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP + RECORDATI RARE

EQ 1MG BASE/VIALN018878 001 Jan 30, 1985INDOMETHACIN SODIUM

AP BEDFORD

EQ 1MG BASE/VIALA078713 001 Jul 16, 2008INGENOL MEBUTATE

GEL; TOPICAL

PICATO

LEO PHARMA AS

0.015%

N202833 001 Jan 23, 2012

+

0.05%

N202833 002 Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+ NOVO NORDISK INC

700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)

N021172 001 Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC

210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 004 May 03, 2002

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK INC

1000 UNITS/10ML (100 UNITS/ML)

N020986 001 Jun 07, 2000

NOVOLOG FLEXPEN

+ NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N020986 003 Jan 19, 2001

NOVOLOG PENFILL

+ NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N020986 002 Jun 07, 2000

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+ NOVO NORDISK INC

1000 UNITS/10ML (100 UNITS/ML)

N021536 001 Jun 16, 2005

LEVEMIR FLEXPEN

+ NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N021536 002 Jun 16, 2005

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ SANOFI AVENTIS US

100 UNITS/ML

N021081 001 Apr 20, 2000

LANTUS SOLOSTAR

+ SANOFI AVENTIS US

300 UNITS/3ML (100 UNITS/ML)

N021081 002 Apr 27, 2007

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION)-SC

APIDRA

+ SANOFI AVENTIS US

1000 UNITS/10ML (100 UNITS/ML)

N021629 001 Apr 16, 2004

+

300 UNITS/3ML (100 UNITS/ML)

N021629 002 Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US

300 UNITS/3ML

N021629 003 Feb 24, 2009

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY

50 UNITS/ML; 50 UNITS/ML

N021018 001 Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+ LILLY

50 UNITS/ML; 50 UNITS/ML

N021018 002 Sep 06, 2007

HUMALOG MIX 75/25

+ LILLY

75 UNITS/ML; 25 UNITS/ML

N021017 001 Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+ LILLY

75 UNITS/ML; 25 UNITS/ML

N021017 002 Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY

100 UNITS/ML

N020563 001 Jun 14, 1996

HUMALOG KWIKPEN

+ LILLY

100 UNITS/ML

N020563 003 Sep 06, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-194 (of 362)

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY

500 UNITS/ML

N018780 004 Mar 31, 1994

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE

10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO

52%

N009321 003

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE

55%

N020351 001 Mar 22, 1996

55%

N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE

65.2%

N020351 002 Mar 22, 1996

65.2%

N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+ GE HLTHCARE INC

5mCi/2.5ML (2mCi/ML)

N022454 001 Jan 14, 2011

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140

+ GE HEALTHCARE

30.2%

N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+ GE HEALTHCARE

75.5%

N018956 004 Dec 26, 1985

75.5%

N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+ GE HEALTHCARE

38.8%

N018956 001 Dec 26, 1985

OMNIPAQUE 240

+ GE HEALTHCARE

51.8%

N018956 002 Dec 26, 1985

51.8%

N020608 001 Oct 24, 1995

OMNIPAQUE 300

+ GE HEALTHCARE

64.7%

N018956 003 Dec 26, 1985

64.7%

N020608 002 Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250AP FRESenius KABI USA51%A074679 001 Apr 02, 1997IOPAMIDOL-300AP FRESenius KABI USA61%A074679 002 Apr 02, 1997IOPAMIDOL-370AP FRESenius KABI USA76%A074679 003 Apr 02, 1997ISOVUE-200AP + BRACCO41%N018735 006 Jul 07, 1987ISOVUE-250AP + BRACCO51%N018735 007 Jul 06, 1992AP +51%N020327 002 Oct 12, 1994ISOVUE-300AP + BRACCO61%N018735 002 Dec 31, 1985AP +61%N020327 003 Oct 12, 1994ISOVUE-370AP + BRACCO76%N018735 003 Dec 31, 1985AP +76%N020327 004 Oct 12, 1994SCANLUX-300AP SANOCHEMIA CORP USA61%A090394 001 Jun 18, 2010SCANLUX-370AP SANOCHEMIA CORP USA76%A090394 002 Jun 18, 2010

ISOVUE-M 200

+ BRACCO

41%

N018735 001 Dec 31, 1985

ISOVUE-M 300

+ BRACCO

61%

N018735 004 Dec 31, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-195 (of 362)

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+	BAYER HLTHCARE	49.9%	N021425 003	Mar 12, 2004
+		62.3%	N021425 001	Sep 20, 2002
+		76.9%	N021425 002	Sep 20, 2002

ULTRAVIST 150

+	BAYER HLTHCARE	31.2%	N020220 004	May 10, 1995

ULTRAVIST 240

+	BAYER HLTHCARE	49.9%	N020220 003	May 10, 1995

ULTRAVIST 300

+	BAYER HLTHCARE	62.3%	N020220 002	May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+	BAYER HLTHCARE	62.3%	N020220 005	Nov 18, 2008

ULTRAVIST 370

+	BAYER HLTHCARE	76.9%	N020220 001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+	MALLINCKRODT	60%	N013295 001	

CONRAY 30

+	MALLINCKRODT	30%	N016983 001	

CONRAY 43

+	MALLINCKRODT	43%	N013295 002	

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

MALLINCKRODT	17.2%	N017057 002		

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX	250-300uCi/ML	N017279 001		

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	MALLINCKRODT	51%	N019710 002	Dec 30, 1988

OPTIRAY 300

+	MALLINCKRODT	64%	N019710 004	Jan 22, 1992

+		64%	N020923 004	May 13, 1999

OPTIRAY 320

+	MALLINCKRODT	68%	N019710 001	Dec 30, 1988

OPTIRAY 350

+	MALLINCKRODT	74%	N019710 005	Jan 22, 1992

+		74%	N020923 003	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

+	GUERBET	39.3%; 19.6%	N018905 002	Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET	62%	N020316 001	Dec 21, 1995	

OXILAN-350

GUERBET	73%	N020316 002	Dec 21, 1995	

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+	BOEHRINGER INGELHEIM	0.021MG/INH	N021527 001	Nov 27, 2004

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	BAUSCH AND LOMB	0.02%	A075835 001	Oct 15, 2001

AN	+	DEY	0.02%	A074755 001	Jan 10, 1997

AN		LANDELA PHARM	0.02%	A077072 001	Jul 19, 2005

AN		NEPHRON	0.02%	A075562 001	Sep 27, 2001

AN		RITEDOSE CORP	0.02%	A075693 001	Jan 26, 2001

AN		WATSON LABS	0.02%	A076291 001	May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

AB	+	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393 001	Oct 20, 1995

AB	+		0.042MG/SPRAY	N020394 001	Oct 20, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-196 (of 362)

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

<u>AB</u>	BAUSCH AND LOMB	<u>0.021MG/SPRAY</u>	<u>A076025</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076103</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	DEY	<u>0.021MG/SPRAY</u>	<u>A075552</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A075553</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	ROXANE	<u>0.021MG/SPRAY</u>	<u>A076664</u>	<u>001</u>	Nov 05, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET;ORAL

AVAPRO

<u>AB</u>	SANOFI AVENTIS US	<u>75MG</u>	<u>N020757</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>		<u>150MG</u>	<u>N020757</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A200832</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A200832</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A200832</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	CIPLA LTD	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>75MG</u>	<u>A090201</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>75MG</u>	<u>A090720</u>	<u>001</u>	Oct 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090720</u>	<u>002</u>	Oct 12, 2012
<u>AB</u>		<u>300MG</u>	<u>A090720</u>	<u>003</u>	Oct 12, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213</u>	<u>003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>		ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-197 (of 362)

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009
<u>AP</u>	BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219</u>	<u>001</u>	Feb 20, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077219</u>	<u>002</u>	Feb 20, 2008
<u>AP</u>	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953</u>	<u>001</u>	Apr 15, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078953</u>	<u>002</u>	Apr 15, 2010
<u>AP</u>	EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137</u>	<u>001</u>	Nov 12, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090137</u>	<u>002</u>	Nov 12, 2009
<u>AP</u>	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771</u>	<u>001</u>	Feb 14, 2012
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A200771</u>	<u>002</u>	Feb 14, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078188</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032</u>	<u>001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032</u>	<u>002</u>	Dec 20, 2010
<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675</u>	<u>002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675</u>	<u>001</u>	Dec 16, 2011
<u>AP</u>	MYLAN INSTITUTIONAL	<u>40MG/2ML (20MG/ML)</u>	<u>A090393</u>	<u>002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393</u>	<u>003</u>	May 13, 2011
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805</u>	<u>001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805</u>	<u>002</u>	Apr 21, 2008
<u>AP</u>	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101</u>	<u>003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
	CAMPTOSAR				
	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
	INFED				
BP	+ WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001	
	PROFERDEX				
BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

+

EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)
 EQ 100MG BASE/5ML (EQ 20MG BASE/ML)
 EQ 200MG BASE/10ML (EQ 20MG BASE/ML)

N021135 002 Mar 20, 2005
 N021135 001 Nov 06, 2000
 N021135 004 Feb 09, 2007

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+ VALIDUS PHARMS INC

10MG

N011961 001

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624</u>	<u>001</u>

ISOFLURANE

<u>AN</u>	HALOCARBON PRODS	<u>99.9%</u>	<u>A075225</u>	<u>001</u>	Oct 20, 1999
<u>AN</u>	HOSPIRA	<u>99.9%</u>	<u>A074097</u>	<u>001</u>	Jan 25, 1993
<u>AN</u>	PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416</u>	<u>001</u>	Sep 30, 1994
<u>AN</u>	RHODIA	<u>99.9%</u>	<u>A074502</u>	<u>001</u>	Jun 27, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-198 (of 362)

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

+ SANDOZ

100MG/ML

A040648 001 Jul 05, 2005

SYRUP; ORAL

ISONIAZID

+ CAROLINA MEDCL

50MG/5ML

A088235 001 Nov 10, 1983

TABLET; ORAL

ISONIAZID**AA** BARR**100MG****A080936 001****AA****300MG****A080937 002****AA** + SANDOZ**100MG****N008678 002****AA** +**300MG****N008678 003**LANIAZID**AA** LANNETT**300MG****A089776 001** Jun 13, 1988ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+ SANOFI AVENTIS US

50MG; 300MG; 120MG

N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+ SANOFI AVENTIS US

150MG; 300MG

A061884 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

+ HOSPIRA

0.2MG/ML

N010515 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ ACTIENT PHARMS

40MG

N019790 001 Sep 02, 1988

TABLET; ORAL

ISORDIL**AB** VALEANT BERMUDA**5MG****N012093 007** Jul 29, 1988**AB****10MG****N012093 002** Jul 29, 1988**AB****20MG****N012093 006** Jul 29, 1988**AB** +**30MG****N012093 005** Jul 29, 1988ISOSORBIDE DINITRATE**AB** PAR PHARM**5MG****A086923 001** Mar 12, 1987**AB****10MG****A086925 001** Mar 12, 1987**AB****20MG****A087537 001** Oct 02, 1987**AB****30MG****A087946 001** Jan 12, 1988**AB** SANDOZ**5MG****A086221 001** Jan 07, 1988**AB****10MG****A086223 001** Jan 07, 1988**AB****20MG****A089367 001** Apr 07, 1988**AB** WEST WARD**5MG****A086067 001** Oct 29, 1987**AB****10MG****A086066 001** Oct 29, 1987**AB****20MG****A088088 001** Nov 02, 1987**AB****30MG****A040591 001** Jan 10, 2007

ISORDIL

+ VALEANT BERMUDA

40MG

N012093 001 Jul 29, 1988

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE**AB** + CARACO**40MG****A040009 001** Dec 30, 1998**AB** COREPHARMA**40MG****A040723 001** Mar 17, 2008ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE**AB** ACTAVIS ELIZABETH**10MG****A075037 002** Oct 30, 1998**AB****20MG****A075037 001** Oct 30, 1998**AB** TEVA**20MG****A075147 001** Nov 27, 1998**AB** WEST WARD**20MG****A075361 001** Oct 05, 2000MONOKET**AB** KREMERS URBAN PHARMS**10MG****N020215 002** Jun 30, 1993**AB** +**20MG****N020215 001** Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE**AB** ACTAVIS ELIZABETH**30MG****A075306 001** Dec 31, 1998**AB****60MG****A075306 002** Dec 31, 1998**AB** DEXCEL LTD**60MG****A075522 001** Apr 17, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-199 (of 362)

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	HIKMA PHARMS	<u>30MG</u>	<u>A076813</u>	<u>002</u>	Mar 30, 2006
<u>AB</u>		<u>60MG</u>	<u>A076813</u>	<u>001</u>	Jan 07, 2005
<u>AB</u>	KREMERS URBAN PHARMS	<u>30MG</u>	<u>A075155</u>	<u>002</u>	Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	+	<u>120MG</u>	<u>A075155</u>	<u>003</u>	Aug 04, 2000
<u>AB</u>	NESHER PHARMS	<u>30MG</u>	<u>A075395</u>	<u>001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395</u>	<u>002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395</u>	<u>003</u>	Mar 16, 2000
<u>AB</u>	TORRENT PHARMS	<u>30MG</u>	<u>A200270</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>60MG</u>	<u>A200495</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>120MG</u>	<u>A200495</u>	<u>002</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS	<u>30MG</u>	<u>A090598</u>	<u>001</u>	Aug 11, 2010
<u>AB</u>		<u>60MG</u>	<u>A090598</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>120MG</u>	<u>A090598</u>	<u>003</u>	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1%</u>	<u>A090874</u>	<u>001</u>	Jul 20, 2010
<u>AP</u>	+	<u>1%</u>	<u>N018310</u>	<u>001</u>	

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945</u>	<u>001</u>	Nov 08, 2002
<u>AB</u>		<u>20MG</u>	<u>A075945</u>	<u>002</u>	Nov 08, 2002
<u>AB</u>		<u>40MG</u>	<u>A075945</u>	<u>003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135</u>	<u>002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135</u>	<u>003</u>	May 11, 2006
<u>AB</u>	+	<u>40MG</u>	<u>A076135</u>	<u>001</u>	Apr 11, 2003

MYORISAN

<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A076485</u>	<u>003</u>	Jan 19, 2012

SOTRET

<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076041</u>	<u>001</u>	Dec 24, 2002
<u>AB</u>		<u>20MG</u>	<u>A076041</u>	<u>002</u>	Dec 24, 2002
<u>AB</u>		<u>30MG</u>	<u>A076503</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>40MG</u>	<u>A076041</u>	<u>003</u>	Dec 24, 2002

ZENATANE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202099</u>	<u>002</u>	Mar 25, 2013
<u>AB</u>		<u>40MG</u>	<u>A202099</u>	<u>003</u>	Mar 25, 2013

ABSORICA

BX	RANBAXY	10MG	N021951	001	May 25, 2012
BX		20MG	N021951	002	May 25, 2012
BX		30MG	N021951	003	May 25, 2012
BX	+	40MG	N021951	004	May 25, 2012

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	MIKAH PHARMA	<u>2.5MG</u>	<u>A077169</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A077317</u>	<u>001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317</u>	<u>002</u>	Jan 05, 2006

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A200463</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A076104</u>	<u>001</u>	May 28, 2004

SPORANOX

<u>AB</u>	+	<u>100MG</u>	<u>N020083</u>	<u>001</u>	Sep 11, 1992

SOLUTION; ORAL

SPORANOX

	+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-200 (of 362)

ITRACONAZOLE

TABLET; ORAL

ONMEL

+ MERZ PHARMS

200MG

N022484 001 Apr 29, 2010

IVACAFTOR

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVERMECTIN

LOTION; TOPICAL

SKLICE

+ SANOFI PASTEUR INC

0.5%

N202736 001 Feb 07, 2012

TABLET; ORAL

STROMECTOL

+ MERCK SHARP DOHME

3MG

N050742 002 Oct 08, 1998

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+ BRISTOL MYERS SQUIBB

15MG/VIAL

N022065 001 Oct 16, 2007

+

45MG/VIAL

N022065 002 Oct 16, 2007

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

+ FRESenius KABI USA

EQ 1GM BASE/3ML

A065111 002 Dec 17, 2002

EQ 500MG BASE/2ML

A065111 001 Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR**AP** + JHP PHARMS**EQ 10MG BASE/ML****N016812 001****AP** +**EQ 50MG BASE/ML****N016812 002****AP** +**EQ 100MG BASE/ML****N016812 003**KETAMINE HYDROCHLORIDE**AP** BEDFORD**EQ 50MG BASE/ML****A074524 001** Mar 22, 1996**AP****EQ 100MG BASE/ML****A074524 002** Mar 22, 1996**AP** HOSPIRA**EQ 50MG BASE/ML****A074549 001** Jun 27, 1996**AP****EQ 100MG BASE/ML****A074549 002** Jun 27, 1996**AP** MYLAN INSTITUTIONAL**EQ 10MG BASE/ML****A076092 001** Sep 30, 2008**AP****EQ 50MG BASE/ML****A076092 002** Dec 28, 2001**AP****EQ 100MG BASE/ML****A076092 003** Oct 25, 2002KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA**AT** + STIEFEL LABS INC**2%****N021738 001** Jun 12, 2007KETOCONAZOLE**AT** PERRIGO ISRAEL**2%****A091550 001** Aug 25, 2011

CREAM; TOPICAL

KETOCONAZOLE**AB** FOUGERA PHARMS**2%****A076294 001** Apr 28, 2004**AB** + TEVA**2%****A075581 001** Apr 25, 2000KETOZOLE**AB** TARO**2%****A075638 001** Dec 18, 2002

GEL; TOPICAL

XOLEGEL

+ AQUA PHARMS

2%

N021946 001 Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLE**AB** PERRIGO NEW YORK**2%****A076419 001** Jan 07, 2004**AB** TOLMAR**2%****A076942 001** Apr 11, 2005NIZORAL**AB** + JANSSEN PHARMS**2%****N019927 001** Aug 31, 1990

TABLET; ORAL

KETOCONAZOLE**AB** APOTEX**200MG****A075912 001** Jan 10, 2002**AB** MUTUAL PHARMA**200MG****A075314 001** Jun 15, 1999**AB** MYLAN**200MG****A075597 001** Dec 23, 1999**AB** PLIVA**200MG****A075362 001** Jun 15, 1999**AB** TARO**200MG****A075319 001** Jun 15, 1999**AB** TEVA**200MG****A075273 001** Jun 15, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-201 (of 362)

KETOCONAZOLE

TABLET; ORAL

NIZORAL

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>200MG</u>	<u>N018533</u>	<u>001</u>	

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>		DORADO PHARMA	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>			<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>			<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>		TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
<u>AB</u>	+		<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
		DORADO PHARMA	25MG	<u>A074014</u>	<u>001</u>	Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>		MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
<u>AB</u>			<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
<u>AB</u>	+		<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>		WATSON LABS FLORIDA	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999
<u>AB</u>			<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
<u>AB</u>			<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>		AGILA SPECLTS	<u>15MG/ML</u>	<u>A078299</u>	<u>001</u>	Jul 16, 2007
<u>AP</u>			<u>30MG/ML</u>	<u>A078299</u>	<u>002</u>	Jul 16, 2007
<u>AP</u>	+	BEDFORD	<u>15MG/ML</u>	<u>A075222</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>	+		<u>30MG/ML</u>	<u>A075222</u>	<u>002</u>	Apr 26, 1999
<u>AP</u>	+		<u>30MG/ML</u>	<u>A075228</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>		FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>			<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>		HIKMA MAPLE	<u>15MG/ML</u>	<u>A075299</u>	<u>001</u>	Nov 03, 1999
<u>AP</u>			<u>15MG/ML</u>	<u>A075772</u>	<u>001</u>	Jul 21, 2004
<u>AP</u>			<u>30MG/ML</u>	<u>A075299</u>	<u>002</u>	Nov 03, 1999
<u>AP</u>			<u>30MG/ML</u>	<u>A075772</u>	<u>002</u>	Jul 21, 2004
<u>AP</u>		HOSPIRA	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>			<u>15MG/ML</u>	<u>A074993</u>	<u>001</u>	Jan 27, 1999
<u>AP</u>			<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>			<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>		SAGENT PHARMS	<u>15MG/ML</u>	<u>A091065</u>	<u>001</u>	Nov 27, 2013
<u>AP</u>			<u>30MG/ML</u>	<u>A091065</u>	<u>002</u>	Nov 27, 2013
<u>AP</u>		SANDOZ	<u>15MG/ML</u>	<u>A076271</u>	<u>001</u>	Oct 06, 2004
<u>AP</u>			<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>		SUN PHARMA GLOBAL	<u>15MG/ML</u>	<u>A078737</u>	<u>001</u>	Oct 06, 2008
<u>AP</u>			<u>30MG/ML</u>	<u>A078737</u>	<u>002</u>	Oct 06, 2008
<u>AP</u>		WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>			<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007
<u>AP</u>			<u>30MG/ML</u>	<u>A077943</u>	<u>001</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992

ACULAR LS

<u>AT</u>	+	ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003

KETOROLAC TROMETHAMINE

<u>AT</u>		AKORN	<u>0.4%</u>	<u>A078399</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>			<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>			<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>			<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009

ACUVAIL

+ ALLERGAN

0.45%

N022427 001 Jul 22, 2009

SPRAY, METERED; NASAL

SPRIX

+ LUITPOLD

15.75MG/SPRAY

N022382 001 May 14, 2010

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+	MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>		PLIVA	<u>10MG</u>	<u>A075284</u>	<u>001</u>	Jun 23, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-202 (of 362)

KETOROLAC TROMETHAMINE

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	BEDFORD	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699</u>	<u>001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999

LABETALOL HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134</u>	<u>001</u>	Feb 03, 2010

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908</u>	<u>001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908</u>	<u>002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908</u>	<u>003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+ UCB INC

200MG/20ML (10MG/ML)

N022254 001 Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+ UCB INC

10MG/ML

N022255 001 Apr 20, 2010

TABLET; ORAL

VIMPAT

UCB INC

50MG

N022253 001 Oct 28, 2008

100MG

N022253 002 Oct 28, 2008

150MG

N022253 003 Oct 28, 2008

+

200MG

N022253 004 Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+ CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997

+

20GM/PACKET

A074712 002 Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988

CONSTULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992

SOLUTION; ORAL, RECTAL

CHOLAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988

ENULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988

GENERLAC

<u>AA</u>	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-203 (of 362)

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	HI TECH PHARMA	10GM/15ML	A074077	001	Jul 03, 1995

LAMIVUDINE

SOLUTION; ORAL

EPIVIR

+ VIIV HLTHCARE

10MG/ML

N020596 001 Nov 17, 1995

EPIVIR-HBV

+ GLAXOSMITHKLINE

5MG/ML

N021004 001 Dec 08, 1998

TABLET; ORAL

EPIVIR

AB	VIIV HLTHCARE	150MG	N020564	001	Nov 17, 1995

AB	+	300MG	N020564	003	Jun 24, 2002

EPIVIR-HBV

AB	+	GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998

LAMIVUDINE

AB	APOTEX	150MG	A091606	001	Dec 02, 2011

AB		300MG	A091606	002	Dec 02, 2011

AB	APOTEX INC	100MG	A202941	001	Jan 02, 2014

AB	AUROBINDO PHARMA LTD	150MG	A202032	001	Nov 17, 2011

AB		300MG	A202032	002	Nov 17, 2011

AB	HETERO LABS LTD V	100MG	A203260	001	Jan 02, 2014

AB		150MG	A203277	001	Jan 06, 2014

AB		300MG	A203277	002	Jan 06, 2014

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB	+	VIIV HLTHCARE	150MG; 300MG	N020857	001	Sep 26, 1997

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG; 300MG	A202418	001	May 15, 2012

AB	LUPIN LTD	150MG; 300MG	A090246	001	May 15, 2012

AB	TEVA PHARMS	150MG; 300MG	A079081	001	May 25, 2011

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994

AB		100MG	N020241	001	Dec 27, 1994

AB		150MG	N020241	002	Dec 27, 1994

AB		200MG	N020241	003	Dec 27, 1994

LAMOTRIGINE

AB	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011

AB		100MG	A078669	002	Apr 08, 2011

AB		150MG	A078669	003	Apr 08, 2011

AB		200MG	A078669	004	Apr 08, 2011

AB	ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011

AB		100MG	A090607	002	Jan 13, 2011

AB		150MG	A090607	003	Jan 13, 2011

AB		200MG	A090607	004	Jan 13, 2011

AB	ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013

AB		100MG	A200694	002	Jun 14, 2013

AB		150MG	A200694	003	Jun 14, 2013

AB		200MG	A200694	004	Jun 14, 2013

AB	APOTEX INC	25MG	A078625	001	Jan 27, 2009

AB		100MG	A078625	002	Jan 27, 2009

AB		150MG	A078625	003	Jan 27, 2009

AB		200MG	A078625	004	Jan 27, 2009

AB	AUROBINDO PHARMA	25MG	A078956	001	Jan 27, 2009

AB		100MG	A078956	002	Jan 27, 2009

AB		150MG	A078956	003	Jan 27, 2009

AB		200MG	A078956	004	Jan 27, 2009

AB	CADISTA PHARMS	25MG	A079132	001	Jan 27, 2009

AB		100MG	A079132	002	Jan 27, 2009

AB		150MG	A079132	003	Jan 27, 2009

AB		200MG	A079132	004	Jan 27, 2009

AB	CIPLA LTD	25MG	A077783	001	Nov 01, 2010

AB		100MG	A077783	002	Nov 01, 2010

AB		150MG	A077783	003	Nov 01, 2010

AB		200MG	A077783	004	Nov 01, 2010

AB	DR REDDYS LABS LTD	25MG	A076708	001	Jan 27, 2009

AB		100MG	A076708	002	Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-204 (of 362)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A078134</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>100MG</u>	<u>A078134</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>150MG</u>	<u>A078134</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>200MG</u>	<u>A078134</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
BX	UPSHER SMITH	25MG	A078310	001	Feb 04, 2009
BX		100MG	A078310	002	Feb 04, 2009
BX		150MG	A078310	003	Feb 04, 2009
BX		200MG	A078310	004	Feb 04, 2009
	ZYDUS PHARMS USA	50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998
	<u>LAMOTRIGINE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT LIFE	<u>5MG</u>	<u>A200220</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420</u>	<u>001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420</u>	<u>002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-205 (of 362)

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115</u>	<u>001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>200MG</u>	<u>N022115</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115</u>	<u>006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115</u>	<u>005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672</u>	<u>003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672</u>	<u>004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672</u>	<u>001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672</u>	<u>002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733</u>	<u>001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672</u>	<u>005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374</u>	<u>001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374</u>	<u>002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374</u>	<u>003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374</u>	<u>004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374</u>	<u>005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374</u>	<u>006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383</u>	<u>001</u>	Jun 19, 2013
<u>AB</u>		<u>50MG</u>	<u>A202383</u>	<u>002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383</u>	<u>003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383</u>	<u>004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383</u>	<u>005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791</u>	<u>001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791</u>	<u>002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791</u>	<u>003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791</u>	<u>004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791</u>	<u>005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791</u>	<u>006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370</u>	<u>002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370</u>	<u>003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370</u>	<u>004</u>	Dec 23, 2013
<u>AB</u>	WILSHIRE PHARMS INC	<u>25MG</u>	<u>A202887</u>	<u>001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887</u>	<u>002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887</u>	<u>003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887</u>	<u>004</u>	Jun 17, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498</u>	<u>002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498</u>	<u>003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498</u>	<u>004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498</u>	<u>005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251</u>	<u>001</u>	May 08, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022251</u>	<u>002</u>	May 08, 2009
<u>AB</u>		<u>100MG</u>	<u>N022251</u>	<u>003</u>	May 08, 2009
<u>AB</u>		<u>200MG</u>	<u>N022251</u>	<u>004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	WATSON LABS INC	<u>25MG</u>	<u>A200828</u>	<u>001</u>	Jul 15, 2013
<u>AB</u>		<u>50MG</u>	<u>A200828</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828</u>	<u>004</u>	Jul 15, 2013

LANREOTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE	N022074	001	Aug 30, 2007
+		EQ 90MG BASE	N022074	002	Aug 30, 2007
+		EQ 120MG BASE	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-206 (of 362)

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366</u>	<u>001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366</u>	<u>002</u>	Aug 19, 2013

LANSOPRAZOLE

<u>AB</u>	KRKA TOVARNA ZDRAVIL	<u>15MG</u>	<u>A091212</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>30MG</u>	<u>A091212</u>	<u>002</u>	Sep 16, 2013

PREVACID

<u>AB</u>	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
PREVACID

	TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002
	+	30MG	N021428	002	Aug 30, 2002

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

	+ SHIRE LLC	EQ 1GM BASE	N021468	004	Nov 23, 2005
		EQ 500MG BASE	N021468	002	Oct 26, 2004
		EQ 750MG BASE	N021468	003	Nov 23, 2005

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

	+ SMITHKLINE BEECHAM	EQ 250MG BASE	N022059	001	Mar 13, 2007

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887</u>	<u>001</u>	Jul 19, 2011
<u>AT</u>	ALCON RES	<u>0.005%</u>	<u>A091449</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	DR REDDYS LABS LTD	<u>0.005%</u>	<u>A202077</u>	<u>001</u>	Feb 11, 2013
<u>AT</u>	LUITPOLD	<u>0.005%</u>	<u>A200925</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	MYLAN	<u>0.005%</u>	<u>A201786</u>	<u>001</u>	Mar 22, 2011

XALATAN

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>0.005%</u>	<u>N020597</u>	<u>001</u>	Jun 05, 1996

LEFLUNOMIDE

TABLET;ORAL

ARAVA

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N020905</u>	<u>001</u>	Sep 10, 1998
<u>AB</u>	+	<u>20MG</u>	<u>N020905</u>	<u>002</u>	Sep 10, 1998

LEFLUNOMIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A091369</u>	<u>001</u>	Nov 21, 2011
<u>AB</u>		<u>20MG</u>	<u>A091369</u>	<u>002</u>	Nov 21, 2011
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077090</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077090</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	BARR	<u>10MG</u>	<u>A077083</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077083</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077086</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A077087</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077087</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A077084</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077084</u>	<u>002</u>	Sep 13, 2005

ARAVA

	+ SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-207 (of 362)

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE

2.5MG

N021880 005 Dec 21, 2011

5MG

N021880 001 Dec 27, 2005

10MG

N021880 002 Dec 27, 2005

15MG

N021880 003 Jun 29, 2006

20MG

N021880 006 Jun 05, 2013

+

25MG

N021880 004 Jun 29, 2006

LETROZOLE

TABLET; ORAL

FEMARA**AB** + NOVARTIS PHARMS**2.5MG****N020726 001** Jul 25, 1997LETROZOLE**AB** ACCORD HLTHCARE**2.5MG****A090934 001** Jun 03, 2011**AB** ACTAVIS TOTOWA**2.5MG****A090292 001** Jul 13, 2011**AB** APOTEX INC**2.5MG****A091303 001** Apr 19, 2012**AB** DR REDDYS LABS LTD**2.5MG****A091191 001** Jun 03, 2011**AB** FRESENIUS KABI ONCOL**2.5MG****A090491 001** Jun 03, 2011**AB** IMPAX LABS**2.5MG****A091638 001** Jun 03, 2011**AB** INDICUS PHARMA**2.5MG****A201804 001** Jun 03, 2011**AB** JIANGSU HENGRUI MED**2.5MG****A202716 001** May 16, 2013**AB** KUDCO IRELAND**2.5MG****A091098 001** Jun 03, 2011**AB** MYLAN**2.5MG****A078190 001** Dec 24, 2008**AB** NATCO PHARMA LTD**2.5MG****A200161 001** Jun 03, 2011**AB** ROXANE**2.5MG****A090838 001** Jun 03, 2011**AB** SUN PHARM INDS LTD**2.5MG****A091466 001** Jun 03, 2011**AB** TEVA PHARMS**2.5MG****A090289 001** Jun 03, 2011**AB** VINTAGE PHARMS LLC**2.5MG****A090789 001** Jun 03, 2011LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM**AP** + BEDFORD**EQ 50MG BASE/VIAL****A089384 001** Sep 14, 1987**AP** +**EQ 100MG BASE/VIAL****A089717 001** Mar 28, 1988**AP** TEVA PHARMS USA**EQ 100MG BASE/VIAL****A081277 001** Sep 28, 1993**AP****EQ 350MG BASE/VIAL****A040174 001** Jun 12, 1997LEUCOVORIN CALCIUM PRESERVATIVE FREE**AP** + BEDFORD**EQ 200MG BASE/VIAL****A040056 001** May 23, 1995**AP** +**EQ 350MG BASE/VIAL****A040335 001** Apr 20, 2000**AP** FRESENIUS KABI USA**EQ 200MG BASE/VIAL****A040258 001** Feb 26, 1999**AP** SAGENT PHARMS**EQ 50MG BASE/VIAL****A200753 001** Sep 06, 2012**AP****EQ 100MG BASE/VIAL****A200753 002** Sep 06, 2012**AP****EQ 200MG BASE/VIAL****A200753 003** Sep 06, 2012**AP****EQ 350MG BASE/VIAL****A200855 001** Sep 06, 2012

+ BEDFORD

EQ 10MG BASE/ML

A040347 001 Apr 25, 2000

+ FRESENIUS KABI USA

EQ 500MG BASE/VIAL

A040286 001 Feb 26, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM**AB** BARR**EQ 5MG BASE****A071198 001** Sep 24, 1987**AB****EQ 25MG BASE****A071199 001** Sep 24, 1987**AB** ROXANE**EQ 5MG BASE****A072733 001** Feb 22, 1993**AB****EQ 15MG BASE****A072735 001** Feb 22, 1993**AB** +**EQ 25MG BASE****A072736 001** Feb 22, 1993

EQ 10MG BASE

A072734 001 Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE**AP** + SANDOZ**1MG/0.2ML****A074728 001** Aug 04, 1998**AP** SUN PHARMA GLOBAL**1MG/0.2ML****A078885 001** Mar 09, 2009**AP** TEVA PHARMS USA**1MG/0.2ML****A075471 001** Oct 25, 2000

LUPRON DEPOT

+ ABBVIE ENDOCRINE INC

3.75MG/VIAL

N020011 001 Oct 22, 1990

+

7.5MG/VIAL

N019732 001 Jan 26, 1989

+

11.25MG/VIAL

N020708 001 Mar 07, 1997

+

22.5MG/VIAL

N020517 001 Dec 22, 1995

+

30MG/VIAL

N020517 002 May 30, 1997

+

45MG/VIAL

N020517 003 Jun 17, 2011

LUPRON DEPOT-PED

+ ABBVIE ENDOCRINE INC

7.5MG/VIAL

N020263 002 Apr 16, 1993

+

11.25MG/VIAL

N020263 005 Jan 21, 1994

+

11.25MG/VIAL

N020263 007 Aug 15, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-208 (of 362)

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT-PED

+	15MG/VIAL	N020263	006	Jan 21, 1994
+	30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

+	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
+		22.5MG/VIAL	N021379	001	Jul 24, 2002
+		30MG/VIAL	N021488	001	Feb 13, 2003
+		45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

	ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012
+		11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171</u>	<u>002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171</u>	<u>003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171</u>	<u>001</u>	Dec 13, 2013
<u>AN</u>	DEY	<u>EQ 0.0103% BASE</u>	<u>A077800</u>	<u>001</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800</u>	<u>002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800</u>	<u>003</u>	Mar 15, 2013
<u>AN</u>	MYLAN SPEC LT	<u>EQ 0.25% BASE</u>	<u>A078309</u>	<u>001</u>	Mar 20, 2009
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297</u>	<u>001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297</u>	<u>002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297</u>	<u>003</u>	Apr 26, 2013
<u>AN</u>	WATSON LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756</u>	<u>003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756</u>	<u>001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756</u>	<u>002</u>	Apr 09, 2008
	<u>XOPENEX</u>				
<u>AN</u>	+	SUNOVION	<u>EQ 0.0103% BASE</u>	<u>N020837</u>	<u>003</u> Jan 30, 2002
<u>AN</u>	+		<u>EQ 0.021% BASE</u>	<u>N020837</u>	<u>001</u> Mar 25, 1999
<u>AN</u>	+		<u>EQ 0.042% BASE</u>	<u>N020837</u>	<u>002</u> Mar 25, 1999
<u>AN</u>	+		<u>EQ 0.25% BASE</u>	<u>N020837</u>	<u>004</u> Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+	UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872</u>	<u>001</u> Jul 31, 2006
		<u>LEVETIRACETAM</u>			
<u>AP</u>		FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813</u>	<u>001</u> May 26, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981</u>	<u>001</u> Oct 13, 2011
<u>AP</u>		HOSPIRA INC	<u>500MG/ML (100MG/ML)</u>	<u>A202869</u>	<u>001</u> Apr 06, 2012
<u>AP</u>		LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143</u>	<u>001</u> Jan 31, 2012
<u>AP</u>		SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627</u>	<u>001</u> Jun 26, 2013
<u>AP</u>		SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754</u>	<u>001</u> Jun 16, 2010
<u>AP</u>		X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485</u>	<u>001</u> Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

+	HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011
+		1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011
+		1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+	UCB INC	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u> Jul 15, 2003
		<u>LEVETIRACETAM</u>			
<u>AA</u>		ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u> Jan 15, 2009
<u>AA</u>		AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u> Oct 27, 2009
<u>AA</u>		AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u> Jan 15, 2009
<u>AA</u>		BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u> Jan 16, 2009
<u>AA</u>		HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052</u>	<u>001</u> Feb 28, 2013
<u>AA</u>		HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601</u>	<u>001</u> Feb 28, 2012
<u>AA</u>		LUPIN LTD	<u>100MG/ML</u>	<u>A090893</u>	<u>001</u> Oct 17, 2011
<u>AA</u>		ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067</u>	<u>001</u> May 09, 2013
<u>AA</u>		ROXANE	<u>100MG/ML</u>	<u>A078582</u>	<u>001</u> Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-209 (of 362)

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET;ORAL

KEPPRA

<u>AB</u>	+ UCB INC	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006
<u>AB</u>		<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	BOCA PHARMA LLC	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>		<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	METHAPHARM	<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>		<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>		<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	PRINSTON INC	<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>		<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>	ROXANE	<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-210 (of 362)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	SANDOZ	<u>1GM</u>	<u>A077324</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A077324</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A077324</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A077324</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TARO	<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>	WATSON LABS INC	<u>1GM</u>	<u>A078797</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078797</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078797</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078797</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	WOCKHARDT	<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009
<u>AB</u>		<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009
	<u>LEVETIRACETAM</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	BOCA PHARMA LLC	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MUTUAL PHARM CO INC	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475</u>	<u>001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475</u>	<u>002</u>	Dec 19, 2011
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-211 (of 362)

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+ ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

<u>AP</u>	+ SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992

LEVOCARNITINE

<u>AP</u>	BEDFORD	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PHARMS USA	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION;ORAL

CARNITOR

<u>AA</u>	+ SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET;ORAL

CARNITOR

<u>AB</u>	+ SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985

LEVOCARNITINE

<u>AB</u>	COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>	SYNTHON PHARMS	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>	TARO PHARM INDS	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

XYZAL

<u>AA</u>	+ UCB INC	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090486</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+ UCB INC	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>001</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>004</u>	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>002</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>003</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>005</u>	Dec 20, 1996

LEVOFLOXACIN

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436</u>	<u>001</u>	Jun 05, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>001</u>	Jun 20, 2011
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>002</u>	Jun 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-212 (of 362)

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>001</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>002</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>003</u>	Aug 08, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>001</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>002</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>003</u>	Jun 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+ JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721</u>	<u>001</u>	Oct 21, 2004

LEVOFLOXACIN

<u>AA</u>	HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678</u>	<u>001</u>	Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>	HI TECH PHARMA	<u>0.5%</u>	<u>A076826</u>	<u>001</u>	Feb 10, 2011
<u>AT</u>	NEXUS PHARMS	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010

QUIXIN

<u>AT</u>	+ SANTEN	<u>0.5%</u>	<u>N021199</u>	<u>001</u>	Aug 18, 2000

IQUIX

	+ SANTEN	1.5%	N021571	001	Mar 01, 2004

TABLET; ORAL

LEVAQUIN

<u>AB</u>	JANSSEN PHARMS	<u>250MG</u>	<u>N020634</u>	<u>001</u>	Dec 20, 1996
<u>AB</u>		<u>500MG</u>	<u>N020634</u>	<u>002</u>	Dec 20, 1996
<u>AB</u>	+	<u>750MG</u>	<u>N020634</u>	<u>003</u>	Sep 08, 2000

LEVOFLOXACIN

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A090787</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>500MG</u>	<u>A090787</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>750MG</u>	<u>A090787</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839</u>	<u>001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839</u>	<u>002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839</u>	<u>003</u>	Mar 22, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076276</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076276</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077097</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	WATSON LABS INC	<u>250MG</u>	<u>A201484</u>	<u>001</u>	Nov 22, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-213 (of 362)

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB		500MG	A201484	002	Nov 22, 2013
AB		750MG	A201484	003	Nov 22, 2013
AB	WOCKHARDT	250MG	A090367	001	Jun 20, 2011
AB		500MG	A090367	002	Jun 20, 2011
AB		750MG	A090367	003	Jun 20, 2011
AB	ZYDUS PHARMS USA INC	250MG	A077652	001	Sep 07, 2012
AB		500MG	A077652	002	Sep 07, 2012
AB		750MG	A077652	003	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008

SOLUTION; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS

EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

N020140 002 Apr 29, 2011

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

FOREST LABS INC

EQ 20MG BASE

N204168 001 Jul 25, 2013

EQ 40MG BASE

N204168 002 Jul 25, 2013

EQ 80MG BASE

N204168 003 Jul 25, 2013

+

EQ 120MG BASE

N204168 004 Jul 25, 2013

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

+ DEPROCO

0.05MG/ML; 2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

+ BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

TABLET; ORAL

LEVONORGESTREL

AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
AB	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
AB	+ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009
AB		0.75MG	A078666	001	Jun 24, 2009
AB	WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
PLAN B					
AB	+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

ROXANE

2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

0.013MG

N022121 001 Aug 01, 2007

INSTITUT BIOCHIMIQUE

0.025MG

N021924 002 Oct 13, 2006

0.05MG

N021924 003 Oct 13, 2006

0.075MG

N021924 004 Oct 13, 2006

0.088MG

N021924 010 Oct 02, 2009

0.1MG

N021924 005 Oct 13, 2006

0.112MG

N021924 008 Oct 02, 2009

0.125MG

N021924 006 Oct 13, 2006

0.137MG

N021924 009 Oct 02, 2009

+

0.15MG

N021924 007 Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+ FRESENIUS KABI USA

100MCG/VIAL

N202231 001 Jun 24, 2011

+

200MCG/VIAL

N202231 002 Jun 24, 2011

+

500MCG/VIAL

N202231 003 Jun 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-214 (of 362)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

-->	ABBVIE	--> <u>AB1,AB2</u>	<u>0.025MG</u>	N021402 001	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.05MG</u>	N021402 002	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.075MG</u>	N021402 003	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.088MG</u>	N021402 004	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.1MG</u>	N021402 005	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.112MG</u>	N021402 006	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.125MG</u>	N021402 007	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.137MG</u>	N021402 008	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.15MG</u>	N021402 009	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.175MG</u>	N021402 010	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.2MG</u>	N021402 012	Jul 24, 2002
-->	+	--> <u>AB1,AB2</u>	<u>0.3MG</u>	N021402 011	Jul 24, 2002

LEVO-T

-->	ALARA PHARM	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021342 001	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021342 002	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021342 003	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021342 004	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021342 005	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021342 006	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021342 007	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021342 012	Dec 08, 2003
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342 008	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342 009	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342 010	Mar 01, 2002
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342 011	Mar 01, 2002

UNITHROID

-->	STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210 006	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210 007	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210 012	Feb 08, 2008
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210 008	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210 009	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210 010	Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210 011	Aug 21, 2000

LEVOTHYROXINE SODIUM

-->	MYLAN	-->	<u>0.025MG</u>	A076187 001	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.05MG</u>	A076187 002	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.075MG</u>	A076187 003	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.088MG</u>	A076187 004	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.1MG</u>	A076187 005	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.112MG</u>	A076187 006	Jun 05, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-215 (of 362)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

	<u>AB3, AB4</u>	<u>0.112MG</u>			
-->	-->	<u>0.125MG</u>	A076187	007	Jun 05, 2002
	<u>AB1, AB2, AB3, AB4</u>				
-->	-->	<u>0.137MG</u>	A076187	012	Dec 13, 2006
	<u>AB1, AB2, AB3, AB4</u>				
-->	-->	<u>0.15MG</u>	A076187	008	Jun 05, 2002
	<u>AB1, AB2, AB3, AB4</u>				
-->	-->	<u>0.175MG</u>	A076187	009	Jun 05, 2002
	<u>AB1, AB2, AB3, AB4</u>				
-->	-->	<u>0.2MG</u>	A076187	010	Jun 05, 2002
	<u>AB1, AB2, AB3, AB4</u>				
-->	-->	<u>0.3MG</u>	A076187	011	Jun 05, 2002
	<u>AB1, AB2, AB3, AB4</u>				

LEVOXYL

-->	KING PHARMS R AND D	--> <u>AB1, AB3</u>	<u>0.025MG</u>	N021301	001	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.05MG</u>	N021301	002	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.075MG</u>	N021301	003	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.088MG</u>	N021301	004	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.1MG</u>	N021301	005	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.112MG</u>	N021301	006	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.125MG</u>	N021301	007	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.137MG</u>	N021301	008	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.15MG</u>	N021301	009	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.175MG</u>	N021301	010	May 25, 2001
-->	+	--> <u>AB1, AB3</u>	<u>0.2MG</u>	N021301	011	May 25, 2001

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.025MG</u>	<u>N021116</u>	<u>001</u>	Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>	<u>N021116</u>	<u>002</u>	Oct 24, 2002
<u>AB4</u>		<u>0.075MG</u>	<u>N021116</u>	<u>003</u>	Oct 24, 2002
<u>AB4</u>		<u>0.088MG</u>	<u>N021116</u>	<u>010</u>	Oct 24, 2002
<u>AB4</u>		<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u>	+	<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	+	FOUGERA	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>		NOVOCOL INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>		TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>		WATSON LABS INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012

LIDODERM

<u>AB</u>	+	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+ AKORN

3.5%

N022221 001 Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>		AGILA SPECLTS	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010
<u>AP</u>			<u>0.5%</u>	<u>A091058</u>	<u>001</u>	Sep 30, 2010
<u>AP</u>			<u>1%</u>	<u>A091056</u>	<u>002</u>	Dec 08, 2010
<u>AP</u>			<u>1%</u>	<u>A091058</u>	<u>002</u>	Sep 30, 2010
<u>AP</u>		HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>			<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>			<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>			<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>		INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>			<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>		LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-216 (of 362)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u>	<u>003</u>	Nov 05, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
AP	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
AP		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
AP		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	AGILA SPECITS	<u>2%</u>	<u>A090665</u>	<u>001</u>	Sep 27, 2010
AP	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040</u>	<u>001</u>	Mar 14, 2013
AP		<u>1%</u>	<u>A203082</u>	<u>001</u>	Mar 14, 2013
AP		<u>2%</u>	<u>A203040</u>	<u>002</u>	Mar 14, 2013
AP		<u>2%</u>	<u>A203082</u>	<u>002</u>	Mar 14, 2013
AP	FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	
AP		<u>2%</u>	<u>A080404</u>	<u>003</u>	
AP		<u>2%</u>	<u>N017584</u>	<u>001</u>	
AP		<u>4%</u>	<u>N017584</u>	<u>002</u>	
AP	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	
AP		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
AP		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
AP	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
AP		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

LIDOPEN

AP	MERIDIAN MEDCL TECHN	<u>10%</u>	<u>N017549</u>	<u>001</u>	

XYLOCAINE

AP	+	FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>
AP	+		<u>1%</u>	<u>N006488</u>	<u>007</u>
AP	+		<u>1.5%</u>	<u>N006488</u>	<u>010</u>
AP	+		<u>2%</u>	<u>N006488</u>	<u>002</u>

XYLOCAINE 4% PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>001</u>

XYLOCAINE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988
AP	+		<u>2%</u>	<u>N016801</u>	<u>001</u>	
AP	+		<u>4%</u>	<u>N016801</u>	<u>002</u>	
AP	+		<u>10%</u>	<u>N016801</u>	<u>003</u>	
AP	+		<u>20%</u>	<u>N016801</u>	<u>004</u>	

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

	+	HOSPIRA	<u>5%</u>	<u>A083914</u>	<u>001</u>

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003
AT	HI TECH PHARMA	<u>2%</u>	<u>A040837</u>	<u>001</u>	Mar 23, 2011
AT	INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	

XYLOCAINE

AT	+	OAK PHARMS	<u>2%</u>	<u>N008816</u>	<u>001</u>

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995
AT	WOCKHARDT	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	VINTAGE	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007

LIDOCAINE VISCOUS

AT	ROXANE	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985

XYLOCAINE VISCOUS

AT	+	FRESENIUS KABI USA	<u>2%</u>	<u>N009470</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3-217 (of 362)

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

LARYNG-O-JET KIT

AT	INTL MEDICATION	4%	A086364	001	

LIDOCAINE HYDROCHLORIDE

AT	ROXANE	4%	A088803	001	Apr 03, 1985

AT	VINTAGE	4%	A040710	001	Feb 27, 2007

AT	WOCKHARDT	4%	A087881	001	Nov 18, 1982

LTA II KIT

AT	HOSPIRA	4%	A080409	001	

XYLOCAINE 4% PRESERVATIVE FREE

AT	+ FRESENIUS KABI USA	4%	N010417	002	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+ OAK PHARMS	2.5%;2.5%	N019941	001	Dec 30, 1992

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003

AB	HI TECH PHARMA	2.5%;2.5%	A076290	001	Sep 25, 2003

AB	TOLMAR	2.5%;2.5%	A076320	001	Aug 27, 2003

GEL; PERIODONTAL

ORAQIX

	+ DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

	+ GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006

PATCH; TOPICAL

SYNERA

	+ GALEN SPECIALTY	70MG;70MG	N021623	001	Jun 23, 2005

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	FOREST LABS INC	145MCG	N202811	001	Aug 30, 2012

	+	290MCG	N202811	002	Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

	+ BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	+ BOEHRINGER INGELHEIM	2.5MG;1GM	N201281	003	Jan 30, 2012

		2.5MG;500MG	N201281	001	Jan 30, 2012

		2.5MG;850MG	N201281	002	Jan 30, 2012

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001	

LINDANE

LOTION; TOPICAL

LINDANE

AT	OLTA PHARMS	1%	A087313	001	

AT	+ WOCKHARDT	1%	A088190	001	Aug 16, 1984

SHAMPOO; TOPICAL

LINDANE

AT	OLTA PHARMS	1%	A087266	001	

AT	+ WOCKHARDT	1%	A088191	001	Sep 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX

	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222	001	Jun 27, 2012

ZYVOX

AP	+ PHARMACIA AND UPJOHN	200MG/100ML	N021131	001	Apr 18, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-218 (of 362)

LINEZOLID

TABLET; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN

600MG

N021130 002 Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUMAP X GEN PHARMSEQ 0.01MG BASE/MLA076923 001 Aug 17, 2005TRIOSTATAP + JHP PHARMSEQ 0.01MG BASE/MLN020105 001 Dec 31, 1991

TABLET; ORAL

CYTOMELAB KING PHARMS R AND DEQ 0.005MG BASEN010379 001ABEQ 0.025MG BASEN010379 002AB +EQ 0.05MG BASEN010379 003LIOTHYRONINE SODIUMAB COASTAL PHARMSEQ 0.005MG BASEA090097 001 Mar 20, 2009ABEQ 0.025MG BASEA090097 002 Mar 20, 2009ABEQ 0.05MG BASEA090097 003 Mar 20, 2009AB MYLANEQ 0.005MG BASEA090326 001 Jul 14, 2009ABEQ 0.025MG BASEA090326 002 Jul 14, 2009ABEQ 0.05MG BASEA090326 003 Jul 14, 2009AB SIGMAPHARM LABS LLCEQ 0.005MG BASEA200295 001 Nov 29, 2012ABEQ 0.025MG BASEA200295 002 Nov 29, 2012ABEQ 0.05MG BASEA200295 003 Nov 29, 2012LIOTRIX (T4; T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS

0.0031MG; 0.0125MG

N016807 001

THYROLAR-0.5

FOREST LABS

0.0063MG; 0.025MG

N016807 005

THYROLAR-1

FOREST LABS

0.0125MG; 0.05MG

N016807 004

THYROLAR-2

FOREST LABS

0.025MG; 0.1MG

N016807 002

THYROLAR-3

+ FOREST LABS

0.0375MG; 0.15MG

N016807 003

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

VICTOZA

+ NOVO NORDISK INC

18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT

20MG

N021977 004 Dec 10, 2007

30MG

N021977 001 Feb 23, 2007

40MG

N021977 005 Dec 10, 2007

50MG

N021977 002 Feb 23, 2007

60MG

N021977 006 Dec 10, 2007

+

70MG

N021977 003 Feb 23, 2007

LISINOPRIL

TABLET; ORAL

LISINOPRILAB ACCORD HLTHCARE2.5MGA202554 001 Jul 30, 2013AB5MGA202554 002 Jul 30, 2013AB10MGA202554 003 Jul 30, 2013AB20MGA202554 004 Jul 30, 2013AB30MGA202554 005 Jul 30, 2013AB40MGA202554 006 Jul 30, 2013AB APOTEX INC2.5MGA076102 001 Sep 30, 2002AB5MGA076102 002 Sep 30, 2002AB10MGA076102 003 Sep 30, 2002AB20MGA076102 004 Sep 30, 2002AB30MGA076102 005 Sep 30, 2002AB40MGA076102 006 Sep 30, 2002AB AUROBINDO2.5MGA077622 001 Feb 22, 2006AB5MGA077622 002 Feb 22, 2006AB10MGA077622 003 Feb 22, 2006AB20MGA077622 004 Feb 22, 2006AB30MGA077622 005 Feb 22, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-219 (of 362)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>40MG</u>	<u>A077622</u>	<u>006</u>	Feb 22, 2006
<u>AB</u>	HIKMA PHARMS	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508</u>	<u>003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508</u>	<u>004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508</u>	<u>005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508</u>	<u>006</u>	Oct 29, 2013
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075752</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321</u>	<u>006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A076180</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>2.5MG</u>	<u>A075944</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944</u>	<u>006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007

PRINIVIL

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-220 (of 362)

LISINOPRIL

TABLET; ORAL

PRINIVIL

<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988

ZESTRIL

<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812</u>	<u>001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987
<u>AB</u>	WEST WARD	<u>150MG</u>	<u>A076243</u>	<u>002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243</u>	<u>001</u>	Jun 27, 2002

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>300MG</u>	<u>N018558</u>	<u>001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027</u>	<u>001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	GLENMARK GENERICS	<u>300MG</u>	<u>A091544</u>	<u>001</u>	Dec 27, 2010
<u>AB</u>		<u>450MG</u>	<u>A091616</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A202288</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>		<u>450MG</u>	<u>A202219</u>	<u>001</u>	Aug 08, 2012
<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>	+	<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004
<u>AB</u>	WEST WARD	<u>450MG</u>	<u>A076490</u>	<u>001</u>	Jun 17, 2003

LITHOBID

<u>AB</u>	+	NOVEN THERAP	<u>300MG</u>	<u>N018027</u>	<u>001</u>

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421</u>	<u>001</u>	
<u>AA</u>		WOCKHARDT	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755</u>	<u>001</u>	May 21, 1986

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

+ ALCON

EQ 0.1% BASE

N020191 001 Sep 23, 1993

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

AEGERION

EQ 5MG BASE

N203858 001 Dec 21, 2012

EQ 10MG BASE

N203858 002 Dec 21, 2012

+

EQ 20MG BASE

N203858 003 Dec 21, 2012

LOMUSTINE

CAPSULE; ORAL

CEENU

CORDEN PHARMA

10MG

N017588 001

40MG

N017588 002

+

100MG

N017588 003

PRESCRIPTION DRUG PRODUCT LIST

3-221 (of 362)

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

AB	+	MCNEIL CONS	2MG	N017694	001	

LOPERAMIDE HYDROCHLORIDE

AB		MYLAN	2MG	A072741	001	Sep 18, 1991

AB		TEVA	2MG	A073192	001	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

+	ABBVIE	133.3MG; 33.3MG	N021226	001	Sep 15, 2000

SOLUTION; ORAL

KALETRA

+	ABBVIE	80MG/ML; 20MG/ML	N021251	001	Sep 15, 2000

TABLET; ORAL

KALETRA

	ABBVIE	100MG; 25MG	N021906	002	Nov 09, 2007

+		200MG; 50MG	N021906	001	Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		AMNEAL PHARMS	2MG/ML	A091383	001	Dec 23, 2009

AA		HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012

AA		LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013

AA		PADDOCK LLC	2MG/ML	A079244	001	Apr 28, 2009

AA		PHARM ASSOC	2MG/ML	A090260	001	Jun 15, 2010

LORAZEPAM INTENSOL

AA	+	ROXANE	2MG/ML	A072755	001	Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN

AP	+	BAXTER HLTHCARE CORP	2MG/ML	N018140	001	

AP	+		4MG/ML	N018140	002	

LORAZEPAM

AP		AKORN	2MG/ML	A075025	001	Jul 23, 1998

AP		HOSPIRA	2MG/ML	A074243	001	Apr 12, 1994

AP			2MG/ML	A074282	001	May 27, 1994

AP			4MG/ML	A074243	002	Apr 12, 1994

AP			4MG/ML	A074282	002	May 27, 1994

AP		INTL MEDICATION SYS	2MG/ML	A076150	001	Nov 15, 2004

LORAZEPAM PRESERVATIVE FREE

AP		BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005

AP			4MG/ML	A077074	002	Jul 13, 2005

TABLET; ORAL

ATIVAN

AB		VALEANT INTL	0.5MG	N017794	001	

AB			1MG	N017794	002	

AB	+		2MG	N017794	003	

LORAZEPAM

AB		AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010

AB			1MG	A078826	002	Jun 23, 2010

AB			2MG	A078826	003	Jun 23, 2010

AB		EXCELLIUM	0.5MG	A078203	001	Jul 30, 2007

AB			1MG	A078203	002	Jul 30, 2007

AB			2MG	A078203	003	Jul 30, 2007

AB		IVAX SUB TEVA PHARMS	0.5MG	A077396	001	Dec 13, 2006

AB			1MG	A077396	002	Dec 13, 2006

AB			2MG	A077396	003	Dec 13, 2006

AB		MYLAN	0.5MG	A071589	001	Oct 13, 1987

AB			0.5MG	A077657	001	Mar 16, 2006

AB			1MG	A071590	001	Oct 13, 1987

AB			1MG	A077657	002	Mar 16, 2006

AB			2MG	A071591	001	Oct 13, 1987

AB			2MG	A077657	003	Mar 16, 2006

AB		RANBAXY	0.5MG	A076045	001	Aug 29, 2001

AB			1MG	A076045	002	Aug 29, 2001

AB			2MG	A076045	003	Aug 29, 2001

AB		SANDOZ	0.5MG	A071403	001	Apr 21, 1987

AB			1MG	A071404	001	Apr 21, 1987

AB			2MG	A071141	001	Apr 21, 1987

AB		VINTAGE PHARMS	0.5MG	A077754	001	May 10, 2006

AB			1MG	A077754	002	May 10, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-222 (of 362)

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A071118</u>	<u>001</u>	Jul 24, 1986
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+ EISAI INC

10MG

N022529 001 Jun 27, 2012

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	VIVIMED LABS	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-223 (of 362)

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>	<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N202872	001	Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+	BAUSCH AND LOMB	0.5%; 0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075935</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551</u>	<u>001</u>	Dec 17, 2001

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

	ANDRX LABS LLC	20MG	N021316	002	Jun 26, 2002

		40MG	N021316	003	Jun 26, 2002

+		60MG	N021316	004	Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	ABBVIE	20MG; 1GM	N021249	003	Dec 17, 2001

+		20MG; 500MG	N021249	001	Dec 17, 2001

+		20MG; 750MG	N021249	002	Dec 17, 2001

+		40MG; 1GM	N021249	004	Apr 27, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-224 (of 362)

LOXAPINE

POWDER; INHALATION

ADASUVE

+ TEVA PHARMS USA INC 10MG

N022549 001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>	LANNETT HOLDINGS INC	<u>EQ 5MG BASE</u>	<u>A090695 001</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090695 002</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A090695 003</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695 004</u>	Sep 26, 2011
<u>AB</u>	MIKAH PHARMA	<u>EQ 5MG BASE</u>	<u>A076868 001</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076868 002</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076868 003</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076868 004</u>	Aug 04, 2005
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762 001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762 002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762 003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762 004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205 001</u>	Jun 15, 1988
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072206 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062 001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

SUCAMPO PHARMS

8MCG

N021908 002 Apr 29, 2008

+

24MCG

N021908 001 Jan 31, 2006

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+ DISCOVERY LABS

8.5ML

N021746 001 Mar 06, 2012

LULICONAZOLE

CREAM; TOPICAL

LUZU

MEDICIS

1%

N204153 001 Nov 14, 2013

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

SUNOVION PHARMS INC

20MG

N200603 003 Dec 07, 2011

+

40MG

N200603 001 Oct 28, 2010

60MG

N200603 005 Jul 12, 2013

80MG

N200603 002 Oct 28, 2010

120MG

N200603 004 Apr 26, 2012

MACITENTAN

TABLET; ORAL

OPSUMIT

+ ACTELION PHARMS LTD

10MG

N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLOX

+ MYLAN INSTITUTIONAL

EQ 85MG BASE/GM

N016763 001

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

<u>AB</u>	PAR FORM	<u>5%</u>	<u>A201511 001</u>	Feb 12, 2013
<u>AB</u>	+	<u>SULFAMYLOX</u>	<u>N019832 003</u>	Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE

32MG/100ML; 128MG/100ML; 234MG/100ML

N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+ B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019696 001 Sep 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-225 (of 362)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML</u>	<u>N017378</u>	<u>001</u>	

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML</u>	<u>N017378</u>	<u>002</u>	Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017586	001	

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+ DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+ DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	<u>500MG/ML</u>	<u>N019316</u>	<u>001</u>	Sep 08, 1986
AP		HOSPIRA	<u>500MG/ML</u>	<u>A075151</u>	<u>001</u>	Apr 25, 2000

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995

+	2GM/100ML	N020488	002	Jul 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007

+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994

+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994

	20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995

	40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+ BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+ BRAINTREE LABS	1.6GM; 210GM; 0.74GM; 3.13GM; 2.86GM; 5.6GM; 17.5GM	N203595	001	Jan 18, 2013

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

AT	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018508</u>	<u>001</u>	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018336</u>	<u>001</u>	

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	<u>0.5%</u>	<u>A078743</u>	<u>001</u>	Mar 06, 2009

AT	SUVEN LIFE	<u>0.5%</u>	<u>A091559</u>	<u>001</u>	May 23, 2012

OVIDE

AT	+	TARO PHARMS NORTH	<u>0.5%</u>	<u>N018613</u>	<u>001</u>	Aug 02, 1982

PRESCRIPTION DRUG PRODUCT LIST

3-226 (of 362)

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

AP B BRAUN

10GM/100ML

N016080 002

MANNITOL 10% IN PLASTIC CONTAINER

AP B BRAUN

10GM/100ML

N020006 002 Jul 26, 1993

AP HOSPIRA

10GM/100ML

N019603 002 Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

AP B BRAUN

10GM/100ML

N016080 006

MANNITOL 15%

AP B BRAUN

15GM/100ML

N016080 003

MANNITOL 15% IN PLASTIC CONTAINER

AP B BRAUN

15GM/100ML

N020006 003 Jul 26, 1993

AP HOSPIRA

15GM/100ML

N019603 003 Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

AP B BRAUN

15GM/100ML

N016080 005

MANNITOL 20%

AP B BRAUN

20GM/100ML

N016080 004

MANNITOL 20% IN PLASTIC CONTAINER

AP B BRAUN

20GM/100ML

N020006 004 Jul 26, 1993

AP HOSPIRA

20GM/100ML

N019603 004 Jan 08, 1990

MANNITOL 25%

AP FRESENIUS KABI USA

12.5GM/50ML

A080677 001

AP HOSPIRA

12.5GM/50ML

N016269 006 Aug 25, 1994

AP INTL MEDICATION

12.5GM/50ML

A083051 001

AP LUITPOLD

12.5GM/50ML

A087409 001 Jan 21, 1982

MANNITOL 5%

AP B BRAUN

5GM/100ML

N016080 001

MANNITOL 5% IN PLASTIC CONTAINER

AP B BRAUN

5GM/100ML

N020006 001 Jul 26, 1993

AP HOSPIRA

5GM/100ML

N019603 001 Jan 08, 1987

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

AP B BRAUN

5GM/100ML

N016080 007

OSMITROL 10% IN WATER

AP BAXTER HLTHCARE

10GM/100ML

N013684 002

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

10GM/100ML

N013684 006

OSMITROL 15% IN WATER

AP BAXTER HLTHCARE

15GM/100ML

N013684 004

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

15GM/100ML

N013684 008

OSMITROL 20% IN WATER

AP BAXTER HLTHCARE

20GM/100ML

N013684 003

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

20GM/100ML

N013684 007

OSMITROL 5% IN WATER

AP BAXTER HLTHCARE

5GM/100ML

N013684 001

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML

N013684 005

POWDER; INHALATION

ARIDOL KIT

+ PHARMAXIS LTD

N/A, 5MG, 10MG, 20MG, 40MG

N022368 001 Oct 05, 2010

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N016772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N018316 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN

25MG

A072285 002 Oct 03, 1988

+

50MG

A072285 001 Oct 03, 1988

75MG

A072285 003 Oct 03, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-227 (of 362)

MARAVIROC

TABLET; ORAL

SELZENTRY

VIIV HLTHCARE

150MG

N022128 001 Aug 06, 2007

+

300MG

N022128 002 Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+ TEVA PHARMS

100MG

A073580 001 Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA

2.5MG

A204054 001 Mar 19, 2013

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+ IPSEN INC

40MG/4ML (10MG/ML)

N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+ ACTELION PHARMS LTD

0.02%

N202317 001 Aug 23, 2013

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE

10MG/VIAL

N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT**AA** + CITRON PHARMA LLC**12.5MG****N010721 006****AA** +**25MG****N010721 004****AA** +**50MG****N010721 001** Jan 20, 1982**MECLIZINE HYDROCHLORIDE****AA** AMNEAL PHARMS**12.5MG****A201451 001** Feb 23, 2011**AA****25MG****A201451 002** Feb 23, 2011**AA****50MG****A201451 003** Feb 23, 2011**AA** EPIC PHARMA LLC**12.5MG****A200294 001** Apr 13, 2012**AA****25MG****A200294 002** Apr 13, 2012**AA** JUBILANT CADISTA**12.5MG****A040659 001** Jun 04, 2010**AA****25MG****A040659 002** Jun 04, 2010**AA** MYLAN PHARMS INC**12.5MG****A202640 001** Sep 17, 2012**AA****25MG****A202640 002** Sep 17, 2012**AA****50MG****A202640 003** Sep 17, 2012**AA** PAR PHARM**12.5MG****A087127 001****AA****25MG****A087128 001****AA****50MG****A089674 001** Mar 31, 1988**AA** SANDOZ**12.5MG****A084843 002** May 22, 1989**AA****25MG****A084092 003** May 22, 1989**AA** VINTAGE PHARMS**12.5MG****A040179 001** Jan 30, 1997**AA****25MG****A040179 002** Jan 30, 1997**AA** WATSON LABS**25MG****A085740 001**MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

+

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA**AB** + PHARMACIA AND UPJOHN**150MG/ML****N020246 001** Oct 29, 1992**MEDROXYPROGESTERONE ACETATE****AB** SANDOZ**150MG/ML****A078711 001** May 20, 2009**AB** TEVA PHARMS USA**150MG/ML****A076553 001** Jul 28, 2004

DEPO-PROVERA

+ PHARMACIA AND UPJOHN

400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN

104MG/0.65ML

N021583 001 Dec 17, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-228 (of 362)

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>		<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996
<u>PROVERA</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>		<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N011839</u>	<u>004</u>	
MEDROXYPROGESTERONE ACETATE					
BP	USL PHARMA	10MG	A088484	001	Jul 26, 1984

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	MICRO LABS LTD	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
<u>PONSTEL</u>					
<u>AB</u>	+	<u>250MG</u>	<u>N015034</u>	<u>003</u>	

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
<u>MEGESTROL ACETATE</u>						
<u>AB</u>		PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>		ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>		WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004
MEGACE ES						
	+	PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM

7.5MG/5ML

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-229 (of 362)

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES ARCOLAB LTD	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+ GLAXOSMITHKLINE 2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
		<u>MELPHALAN HYDROCHLORIDE</u>				
<u>AP</u>		BEDFORD LABS	<u>EQ 50MG BASE/VIAL</u>	<u>A090303</u>	<u>001</u>	Oct 28, 2010
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

		FOREST LABS	7MG	N022525	001	Jun 21, 2010
			14MG	N022525	002	Jun 21, 2010
			21MG	N022525	003	Jun 21, 2010
	+		28MG	N022525	004	Jun 21, 2010

SOLUTION; ORAL

NAMENDA

	+	FOREST LABS	2MG/ML	N021627	001	Apr 18, 2005

TABLET; ORAL

NAMENDA

		FOREST LABS	5MG	N021487	001	Oct 16, 2003
	+		10MG	N021487	002	Oct 16, 2003

MENOTROPINS (FSH; LH)

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

	+	FERRING	75 IU/VIAL; 75 IU/VIAL	N021047	001	Aug 27, 1999

INJECTABLE; SUBCUTANEOUS

MENOPUR

	+	FERRING	75 IU/VIAL; 75 IU/VIAL	N021663	001	Oct 29, 2004

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

	+	SANOFI AVENTIS US	25MG	N010679	003	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>	
<u>AP</u>	+		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>	
<u>AP</u>	+		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		HIKMA MAPLE	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>	
<u>AP</u>			<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-230 (of 362)

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>	
<u>AP</u>		<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>	
<u>AP</u>	WATSON LABS	<u>50MG/ML</u>	<u>A073444</u>	<u>001</u>	Mar 17, 1992
<u>AP</u>		<u>100MG/ML</u>	<u>A073445</u>	<u>001</u>	Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	HIKMA MAPLE	<u>10MG/ML</u>	<u>A081002</u>	<u>001</u>	Jul 30, 1993
<u>AP</u>	+ HOSPIRA	<u>10MG/ML</u>	<u>A088432</u>	<u>001</u>	Aug 16, 1984
<u>AP</u>	INTL MEDICATION	<u>10MG/ML</u>	<u>A081309</u>	<u>001</u>	Aug 30, 1993
<u>AP</u>	WATSON LABS	<u>10MG/ML</u>	<u>A073443</u>	<u>001</u>	Mar 17, 1992

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE

50MG/5ML

A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	+ SANOFI AVENTIS US	<u>50MG</u>	<u>N005010</u>	<u>001</u>	
<u>AA</u>	+	<u>100MG</u>	<u>N005010</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AA</u>	BARR	<u>50MG</u>	<u>A088639</u>	<u>001</u>	Jul 02, 1984
<u>AA</u>		<u>100MG</u>	<u>A088640</u>	<u>001</u>	Sep 19, 1984
<u>AA</u>	CARACO	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>	EPIC PHARMA	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>		<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>	MALLINCKRODT	<u>50MG</u>	<u>A040352</u>	<u>001</u>	Jun 13, 2000
<u>AA</u>		<u>100MG</u>	<u>A040352</u>	<u>002</u>	Jun 13, 2000
<u>AA</u>	MIKART	<u>50MG</u>	<u>A040893</u>	<u>001</u>	Jun 24, 2009
<u>AA</u>		<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>	ROXANE	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
<u>AA</u>	WATSON LABS	<u>50MG</u>	<u>A040186</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>		<u>100MG</u>	<u>A040186</u>	<u>002</u>	Jun 30, 1997
	MIKART	75MG	A040893	002	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+ HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+	<u>2%</u>	<u>N012250</u>	<u>002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+ NOVOCOL	<u>3%</u>	<u>A080925</u>	<u>001</u>	

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
<u>AP</u>	WATSON LABS	<u>1%</u>	<u>A088769</u>	<u>001</u>	Nov 20, 1984
<u>AP</u>		<u>2%</u>	<u>A088770</u>	<u>001</u>	Nov 20, 1984

POLOCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+ DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>		<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>	INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>		<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	+ WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	+	<u>400MG</u>	<u>A083308</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-231 (of 362)

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>	PROMETHEUS LABS	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004

PURINETHOL

<u>AB</u>	+ TEVA	<u>50MG</u>	<u>N009053</u>	<u>002</u>	

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>	ACS DOBFAR	<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>		<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>	HOSPIRA INC	<u>1GM/VIAL</u>	<u>A090940</u>	<u>002</u>	Jun 22, 2010
<u>AP</u>		<u>500MG/VIAL</u>	<u>A090940</u>	<u>001</u>	Jun 22, 2010
<u>AP</u>	SANDOZ	<u>1GM/VIAL</u>	<u>A091201</u>	<u>002</u>	Mar 29, 2011
<u>AP</u>		<u>500MG/VIAL</u>	<u>A091201</u>	<u>001</u>	Mar 29, 2011

MERREM

<u>AP</u>	+ ASTRAZENECA	<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996
<u>AP</u>		<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

	+ WARNER CHILCOTT LLC	400MG	N204412	001	Feb 01, 2013

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

	+ SALIX PHARMS	375MG	N022301	001	Oct 31, 2008

PENTASA

	SHIRE	250MG	N020049	001	May 10, 1993

		500MG	N020049	002	Jul 08, 2004

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004
<u>AB</u>	TEVA	<u>4GM/60ML</u>	<u>A076841</u>	<u>001</u>	Sep 30, 2004

ROWASA

<u>AB</u>	+ MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618</u>	<u>001</u>	Dec 24, 1987

SFROWASA

<u>AB</u>	MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618</u>	<u>002</u>	Jun 20, 2008

SUPPOSITORY; RECTAL

CANASA

	+ APTALIS PHARMA US	1GM	N021252	002	Nov 05, 2004

TABLET, DELAYED RELEASE; ORAL

ASACOL

	+ WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992

ASACOL HD

	+ WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008

LIALDA

	+ SHIRE	1.2GM	N022000	001	Jan 16, 2007

MESNA

INJECTABLE; INTRAVENOUS

MESNA

<u>AP</u>	BEDFORD	<u>100MG/ML</u>	<u>A075739</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A075811</u>	<u>001</u>	Apr 26, 2001
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A076488</u>	<u>001</u>	Mar 08, 2012
<u>AP</u>	SAGENT PHARMS	<u>100MG/ML</u>	<u>A090913</u>	<u>001</u>	Apr 13, 2010
<u>AP</u>	TEVA PHARMS USA	<u>100MG/ML</u>	<u>A075764</u>	<u>001</u>	Apr 27, 2001

MESNEX

<u>AP</u>	+ BAXTER HLTHCARE	<u>100MG/ML</u>	<u>N019884</u>	<u>001</u>	Dec 30, 1988

TABLET; ORAL

MESNEX

	+ BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

	+ WATSON LABS	0.05MG; 1MG	N016659	001	

PRESCRIPTION DRUG PRODUCT LIST

3-232 (of 362)

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

<u>AN</u>	+	DEY	<u>0.4%</u>	<u>A071786</u>	<u>001</u>	Aug 05, 1988
<u>AN</u>	+		<u>0.6%</u>	<u>A070804</u>	<u>001</u>	Aug 17, 1987
<u>AN</u>		WOCKHARDT	<u>0.4%</u>	<u>A075586</u>	<u>001</u>	May 30, 2002
<u>AN</u>			<u>0.6%</u>	<u>A075586</u>	<u>002</u>	May 30, 2002
SYRUP; ORAL						
METAPROTERENOL SULFATE						
	+	SILARX	10MG/5ML	A073632	001	Jul 22, 1992
TABLET; ORAL						
METAPROTERENOL SULFATE						
		PAR PHARM	10MG	A072024	001	Jun 28, 1988
	+		20MG	A072025	001	Jun 28, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

+	FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	

METAXALONE

TABLET; ORAL

METAXALONE

<u>AB</u>		AMNEAL PHARMS	<u>800MG</u>	<u>A203399</u>	<u>001</u>	Jun 21, 2013
<u>AB</u>		SANDOZ	<u>800MG</u>	<u>A040445</u>	<u>001</u>	Mar 31, 2010
<u>SKELAXIN</u>						
<u>AB</u>	+	KING PHARMS	<u>800MG</u>	<u>N013217</u>	<u>003</u>	Aug 30, 2002

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003

TABLET; ORAL

GLUCOPHAGE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>1GM</u>	<u>N020357</u>	<u>005</u>	Nov 05, 1998
<u>AB</u>			<u>500MG</u>	<u>N020357</u>	<u>001</u>	Mar 03, 1995
<u>AB</u>			<u>850MG</u>	<u>N020357</u>	<u>002</u>	Mar 03, 1995

METFORMIN HYDROCHLORIDE

<u>AB</u>		ALKEM	<u>1GM</u>	<u>A091184</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>			<u>500MG</u>	<u>A091184</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>			<u>850MG</u>	<u>A091184</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		ALVOGEN	<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>			<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>			<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		AMNEAL PHARMS NY	<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>			<u>500MG</u>	<u>A077880</u>	<u>001</u>	Jun 05, 2006
<u>AB</u>			<u>850MG</u>	<u>A077880</u>	<u>002</u>	Jun 05, 2006
<u>AB</u>		APOTEX	<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>			<u>1GM</u>	<u>A090666</u>	<u>003</u>	Dec 07, 2011
<u>AB</u>			<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>			<u>500MG</u>	<u>A090666</u>	<u>001</u>	Dec 07, 2011
<u>AB</u>			<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>			<u>850MG</u>	<u>A090666</u>	<u>002</u>	Dec 07, 2011
<u>AB</u>		AUROBINDO	<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>			<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>			<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		CARACO	<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>			<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>			<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		CHARTWELL LIFE SCI	<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>			<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>			<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		DR REDDYS LABS INC	<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>			<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>			<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		GLENMARK GENERICS	<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>			<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>			<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		GRANULES INDIA	<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>			<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>			<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>		INDICUS PHARMA	<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>			<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>			<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-233 (of 362)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	MARKSANS PHARMA	<u>1GM</u>	<u>A090888</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>		<u>500MG</u>	<u>A090888</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>	MUTUAL PHARMA	<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>		<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>		<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075976</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>		<u>500MG</u>	<u>A075969</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075969</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>	PROVIDENT PHARM	<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>		<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	TEVA	<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>		<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS	<u>1GM</u>	<u>A075979</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>		<u>500MG</u>	<u>A075979</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075979</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>	ZYDUS PHARMS USA	<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003

METFORMIN HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	IMPAX LABS	<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000

METFORMIN HYDROCHLORIDE

<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB1</u>	INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-234 (of 362)

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB1</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB1</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004
<u>AB2</u>		<u>500MG</u>	<u>N021574</u>	<u>001</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>	LUPIN LTD	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>		<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB2</u>		<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012

GLUMETZA

<u>AB3</u>	+ SALIX PHARMS INC	<u>1GM</u>	<u>N021748</u>	<u>002</u>	Jun 03, 2005
<u>AB3</u>		<u>500MG</u>	<u>N021748</u>	<u>001</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>	LUPIN LTD	<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>		<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

<u>AB</u>	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>002</u>	Feb 25, 2011
<u>AB</u>	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

	SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003
		500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002
		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007
		500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-235 (of 362)

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

500MG; EQ 50MG BASE

N202270 001 Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ METHAPHARM

100MG/VIAL

N019193 001 Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDEAA ROXANE 10MG/MLA040180 001 Apr 30, 1998AA VISTAPHARM 10MG/MLA040088 001 Nov 30, 1994METHADONE HYDROCHLORIDE INTENSOLAA ROXANE 10MG/MLA089897 001 Sep 06, 1988METHADOSEAA + MALLINCKRODT 10MG/MLN017116 002

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+ MYLAN INSTITUTIONAL

10MG/ML

N021624 001

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT

50GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SOLUTION; ORAL

METHADONE HYDROCHLORIDEAA + ROXANE 5MG/5MLA087393 001AA + 10MG/5MLA087997 001 Aug 30, 1982AA VISTAPHARM 5MG/5MLA090707 001 Jun 30, 2010AA 10MG/5MLA090707 002 Jun 30, 2010

TABLET; ORAL

DOLOPHINE HYDROCHLORIDEAA + ROXANE 5MGN006134 002AA + 10MGN006134 010METHADONE HYDROCHLORIDEAA MALLINCKRODT 5MGA040517 001 Apr 27, 2004AA 10MGA040517 002 Apr 27, 2004AA SANDOZ 10MGA040241 002 May 29, 1998AA THE PHARMANETWORK 10MGA090635 001 Nov 25, 2009METHADOSEAA MALLINCKRODT 5MGA040050 001 Apr 15, 1993AA 10MGA040050 002 Apr 15, 1993

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDEAA MALLINCKRODT INC 40MGA077142 001 Jul 12, 2005AA + ROXANE 40MGN017058 001AA SANDOZ 40MGA075082 001 Mar 25, 1998METHADOSEAA MALLINCKRODT 40MGA074184 001 Apr 29, 1993METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYNAA + RECORDATI RARE 5MGN005378 002METHAMPHETAMINE HYDROCHLORIDEAA COASTAL PHARMS 5MGA091189 001 Apr 21, 2010METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDEAB MIKART 25MGA040062 001 Jan 27, 1994AB + 50MGA040062 002 Jan 27, 1994AB SANDOZ 25MGA040036 001 Jun 30, 1993AB 50MGA040036 002 Jun 30, 1993AB TEVA PHARMS 25MGA040001 001 Jun 30, 1993AB 50MGA040001 002 Jun 30, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-236 (of 362)

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+	SANOFI AVENTIS US	<u>1GM</u>	<u>N017681</u>	<u>001</u>	

METHENAMINE HIPPURATE

<u>AB</u>		COREPHARMA	<u>1GM</u>	<u>A076411</u>	<u>001</u>	Jun 20, 2003

UREX

<u>AB</u>		CNTY LINE PHARMS	<u>1GM</u>	<u>N016151</u>	<u>001</u>	

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>		BOCA PHARMA LLC	<u>5MG</u>	<u>A202068</u>	<u>001</u>	Mar 07, 2012

<u>AB</u>			<u>10MG</u>	<u>A202068</u>	<u>002</u>	Mar 07, 2012

<u>AB</u>		CARACO	<u>5MG</u>	<u>A040870</u>	<u>001</u>	Sep 25, 2007

<u>AB</u>			<u>10MG</u>	<u>A040870</u>	<u>002</u>	Sep 25, 2007

<u>AB</u>		CEDAR PHARMS	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005

<u>AB</u>			<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005

<u>AB</u>		EMCURE PHARMS USA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007

<u>AB</u>			<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007

<u>AB</u>		MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000

<u>AB</u>	+		<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000

<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001

<u>AB</u>			<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001

TAPAZOLE

<u>AB</u>		KING PHARMS	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000

<u>AB</u>			<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

INJECTABLE; INJECTION

ROBAXIN

+	HIKMA MAPLE	100MG/ML	<u>N011790</u>	<u>001</u>	

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>		AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011

<u>AA</u>			<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011

<u>AA</u>		HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009

<u>AA</u>			<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009

<u>AA</u>		HIKMA PHARMS	<u>750MG</u>	<u>A085123</u>	<u>001</u>	

<u>AA</u>		LANNETT HOLDINGS INC	<u>500MG</u>	<u>A084756</u>	<u>002</u>	Mar 31, 2003

<u>AA</u>			<u>750MG</u>	<u>A084756</u>	<u>001</u>	

<u>AA</u>		PRINSTON INC	<u>500MG</u>	<u>A086989</u>	<u>001</u>	

<u>AA</u>			<u>750MG</u>	<u>A086988</u>	<u>001</u>	

<u>AA</u>		SANDOZ	<u>500MG</u>	<u>A084616</u>	<u>001</u>	

<u>AA</u>			<u>750MG</u>	<u>A084615</u>	<u>001</u>	

<u>AA</u>		VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003

<u>AA</u>			<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003

<u>AA</u>		WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	

<u>AA</u>			<u>500MG</u>	<u>A085180</u>	<u>001</u>	

<u>AA</u>			<u>750MG</u>	<u>A084276</u>	<u>002</u>	

<u>AA</u>			<u>750MG</u>	<u>A085192</u>	<u>001</u>	

<u>AA</u>		WEST WARD	<u>500MG</u>	<u>A085159</u>	<u>001</u>	

ROBAXIN

<u>AA</u>	+	ACTIENT PHARMS	<u>500MG</u>	<u>N011011</u>	<u>004</u>	

ROBAXIN-750

<u>AA</u>	+	ACTIENT PHARMS	<u>750MG</u>	<u>N011011</u>	<u>006</u>	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	JHP PHARMS	2.5GM/VIAL	<u>N011559</u>	<u>002</u>	

+		200MG/VIAL	<u>N011559</u>	<u>004</u>	Dec 21, 2012

+		500MG/VIAL	<u>N011559</u>	<u>001</u>	

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

	ANTARES PHARMA INC	10MG/0.4ML	<u>N204824</u>	<u>001</u>	Oct 11, 2013

		15MG/0.4ML	<u>N204824</u>	<u>002</u>	Oct 11, 2013

		20MG/0.4ML	<u>N204824</u>	<u>003</u>	Oct 11, 2013

+		25MG/0.4ML	<u>N204824</u>	<u>004</u>	Oct 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-237 (of 362)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A200171</u>	<u>001</u>	Feb 27, 2012

METHOTREXATE SODIUM

<u>AP</u>	+	BEDFORD	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+	FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+	ACCORD HLTHCARE	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+	BEDFORD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>		EBEWE PHARMA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>		ONCO THERAPIES LTD	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853</u>	<u>001</u>	Jan 11, 2010

METHOTREXATE SODIUM

+ BEDFORD

EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ BEDFORD

EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u>		ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
		TREXALL				
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	+		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

8-MOP

+ VALEANT PHARM INTL

10MG

N009048 001

OXSORALEN-ULTRA

+ DOW PHARM

10MG

N019600 001 Oct 30, 1986

INJECTABLE; INJECTION

UVADEX

+ THERAKOS

0.02MG/ML

N020969 001 Feb 25, 1999

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL

1%

N009048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>		BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602</u>	<u>001</u>	Sep 24, 2012
<u>AA</u>			<u>5MG</u>	<u>A200602</u>	<u>002</u>	Sep 24, 2012
<u>AA</u>		BOCA PHARMA LLC	<u>2.5MG</u>	<u>A040624</u>	<u>001</u>	Dec 28, 2006
<u>AA</u>			<u>5MG</u>	<u>A040624</u>	<u>002</u>	Dec 28, 2006
<u>AA</u>		BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642</u>	<u>001</u>	Dec 06, 2011
<u>AA</u>			<u>5MG</u>	<u>A040642</u>	<u>002</u>	Dec 06, 2011

PAMINE

<u>AA</u>	+	FOUGERA PHARMS	<u>2.5MG</u>	<u>N008848</u>	<u>001</u>	

PAMINE FORTE

<u>AA</u>	+	FOUGERA PHARMS	<u>5MG</u>	<u>N008848</u>	<u>002</u>	Mar 25, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-238 (of 362)

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

PARKE DAVIS

150MG

N010596 007

+

300MG

N010596 008

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+ MYLAN PHARMS INC

5MG

A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPA**AB** ACCORD HLTHCARE**250MG****A070084 001** Oct 15, 1985**AB****500MG****A070085 001** Oct 15, 1985**AB** IVAX SUB TEVA PHARMS**250MG****A070098 001** Feb 20, 1986**AB****500MG****A070343 001** Feb 20, 1986**AB** MYLAN**250MG****A070075 001** Apr 18, 1985**AB** +**500MG****A070076 001** Apr 18, 1985**AB** WATSON LABS**500MG****A070625 001** Jun 06, 1986METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE**AP** + LUITPOLD**50MG/ML****A071279 001** Oct 02, 1987METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE**AP** + US PHARMS HOLDINGS I**0.2MG/ML****N006035 004**METHYLERGONOVINE MALEATE**AP** ERGOJECT**0.2MG/ML****A040889 001** Sep 13, 2010**AP** LUITPOLD**0.2MG/ML****A090193 001** Nov 24, 2008

TABLET; ORAL

METHERGINE**AB** + US PHARMS HOLDINGS I**0.2MG****N006035 003**METHYLERGONOVINE MALEATE**AB** NOVEL LABS INC**0.2MG****A091577 001** May 02, 2011METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

NOVEN PHARMS INC

10MG/9HR (1.1MG/HR)

N021514 001 Apr 06, 2006

15MG/9HR (1.6MG/HR)

N021514 002 Apr 06, 2006

20MG/9HR (2.2MG/HR)

N021514 003 Apr 06, 2006

+

30MG/9HR (3.3MG/HR)

N021514 004 Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE**AB1** BARR LABS INC**20MG****A079031 001** Jul 13, 2012**AB1****30MG****A079031 002** Jul 13, 2012**AB1****40MG****A079031 003** Jul 13, 2012**AB1** WATSON LABS INC**20MG****A078458 001** Dec 01, 2011**AB1****30MG****A078458 002** Dec 01, 2011**AB1****40MG****A078458 003** Dec 01, 2011RITALIN LA**AB1** NOVARTIS**20MG****N021284 001** Jun 05, 2002**AB1****30MG****N021284 002** Jun 05, 2002**AB1** +**40MG****N021284 003** Jun 05, 2002METADATE CD**AB2** UCB INC**10MG****N021259 003** May 27, 2003**AB2****20MG****N021259 001** Apr 03, 2001**AB2****30MG****N021259 002** Jun 19, 2003**AB2****40MG****N021259 004** Feb 19, 2006**AB2****50MG****N021259 005** Feb 19, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-239 (of 362)

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METADATE CD

<u>AB2</u>	+	<u>60MG</u>	<u>N021259</u>	<u>006</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>	TEVA PHARMS	<u>10MG</u>	<u>A077707</u>	<u>001</u>	Jul 19, 2012

<u>AB2</u>		<u>20MG</u>	<u>A077707</u>	<u>002</u>	Jul 19, 2012

<u>AB2</u>		<u>30MG</u>	<u>A077707</u>	<u>003</u>	Jul 19, 2012

<u>AB2</u>		<u>40MG</u>	<u>A078873</u>	<u>001</u>	Jul 19, 2012

<u>AB2</u>		<u>50MG</u>	<u>A078873</u>	<u>002</u>	Jul 19, 2012

<u>AB2</u>		<u>60MG</u>	<u>A078873</u>	<u>003</u>	Jul 19, 2012

RITALIN LA

BX	NOVARTIS	10MG	N021284	004	Apr 10, 2004

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+ NEXTWAVE PHARMS 5MG/ML

N202100	001	Sep 27, 2012

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+	MALLINCKRODT	<u>5MG/5ML</u>	<u>N021419</u>	<u>001</u>	Dec 19, 2002

<u>AA</u>	+		<u>10MG/5ML</u>	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>	CARACO	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013

<u>AA</u>		<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013

<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010

<u>AA</u>		<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	CARACO	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012

<u>AB</u>		<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012

<u>AB</u>		<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012

<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998

<u>AB</u>		<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998

<u>AB</u>		<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998

<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429</u>	<u>001</u>	

<u>AB</u>		<u>10MG</u>	<u>A085799</u>	<u>001</u>	

<u>AB</u>		<u>20MG</u>	<u>A086428</u>	<u>001</u>	

<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997

<u>AB</u>		<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997

<u>AB</u>		<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997

RITALIN

<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	

<u>AB</u>		<u>10MG</u>	<u>N010187</u>	<u>006</u>	

<u>AB</u>	+	<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE;ORAL

METHYLIN

MALLINCKRODT 2.5MG

N021475	001	Apr 15, 2003

5MG

N021475	002	Apr 15, 2003

+ 10MG

N021475	003	Apr 15, 2003

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

<u>AB</u>	JANSSEN PHARMS	<u>18MG</u>	<u>N021121</u>	<u>001</u>	Aug 01, 2000

<u>AB</u>		<u>27MG</u>	<u>N021121</u>	<u>004</u>	Apr 01, 2002

<u>AB</u>		<u>36MG</u>	<u>N021121</u>	<u>002</u>	Aug 01, 2000

<u>AB</u>	+	<u>54MG</u>	<u>N021121</u>	<u>003</u>	Dec 08, 2000

METADATE ER

<u>AB</u>	+	UCB INC	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988

METHYLIN ER

<u>AB</u>	MALLINCKRODT INC	<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	KUDCO IRELAND	<u>18MG</u>	<u>A091695</u>	<u>001</u>	Jul 09, 2013

<u>AB</u>		<u>27MG</u>	<u>A091695</u>	<u>002</u>	Jul 09, 2013

<u>AB</u>		<u>36MG</u>	<u>A091695</u>	<u>003</u>	Sep 23, 2013

<u>AB</u>		<u>54MG</u>	<u>A091695</u>	<u>004</u>	Sep 23, 2013

<u>AB</u>	MALLINCKRODT INC	<u>27MG</u>	<u>A202608</u>	<u>001</u>	Dec 28, 2012

<u>AB</u>		<u>36MG</u>	<u>A202608</u>	<u>002</u>	Dec 28, 2012

<u>AB</u>		<u>54MG</u>	<u>A202608</u>	<u>003</u>	Dec 28, 2012

<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A040410</u>	<u>001</u>	Feb 09, 2001

RITALIN-SR

<u>AB</u>	NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u>	Mar 30, 1982

METHYLIN ER

MALLINCKRODT INC 10MG

A075629	001	May 09, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-240 (of 362)

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

<u>AB</u>	PHARMACIA AND UPJOHN	<u>2MG</u>	<u>N011153</u>	<u>002</u>	
<u>AB</u>		<u>4MG</u>	<u>N011153</u>	<u>001</u>	
<u>AB</u>		<u>8MG</u>	<u>N011153</u>	<u>004</u>	
<u>AB</u>		<u>16MG</u>	<u>N011153</u>	<u>003</u>	
<u>AB</u>	+	<u>32MG</u>	<u>N011153</u>	<u>006</u>	

METHYLPREDNISOLONE

<u>AB</u>	DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497</u>	<u>001</u>	Feb 21, 1984
<u>AB</u>	JUBILANT CADISTA	<u>4MG</u>	<u>A040189</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189</u>	<u>004</u>	Jul 20, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u>	Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>
<u>AB</u>	+		<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>

METHYLPREDNISOLONE ACETATE

<u>AB</u>	SANDOZ	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>	TEVA PHARMS USA	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>		<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>		<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>		<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006

DEPO-MEDROL

+ PHARMACIA AND UPJOHN 20MG/ML N011757 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

<u>AP</u>	HOSPIRA	<u>EQ 40MG BASE/VIAL</u>	<u>A040664</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040665</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>	HOSPIRA INC	<u>EQ 40MG BASE/VIAL</u>	<u>A040793</u>	<u>001</u>	Nov 25, 2008
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040827</u>	<u>001</u>	Nov 25, 2008

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>	MUSTAFA NEVSAT	<u>EQ 1GM BASE/VIAL</u>	<u>A040888</u>	<u>004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888</u>	<u>005</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A040888</u>	<u>001</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040888</u>	<u>002</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040888</u>	<u>003</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N011856</u>	<u>007</u>
<u>AP</u>	+		<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>
<u>AP</u>	+		<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

+ VALEANT PHARM INTL 10MG A083976 001

TABLET; ORAL

ANDROID 10

BP VALEANT PHARM INTL 10MG A086450 001

ANDROID 25

BP + VALEANT PHARM INTL 25MG A087147 001

METHYLTESTOSTERONE

BP IMPAX LABS 10MG A080767 002

BP 25MG A084310 001

PRESCRIPTION DRUG PRODUCT LIST

3-241 (of 362)

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

AT	FALCON PHARMS	0.3%	A075720 001	Aug 06, 2001

OPTIPRANOLOL

AT	+ BAUSCH AND LOMB	0.3%	N019907 001	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204756 001	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP	BD RX	EQ 5MG BASE/ML	A091392 001	Apr 19, 2013

AP	HOSPIRA	EQ 5MG BASE/ML	A073118 001	Jan 17, 1991

AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991

REGLAN

AP	+ BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	N017862 001	

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	ANI PHARMS	EQ 5MG BASE/5ML	A071402 001	Jun 25, 1993

AA	PHARM ASSOC	EQ 5MG BASE/5ML	A072744 001	May 28, 1991

AA	SILARX	EQ 5MG BASE/5ML	A073680 001	Oct 27, 1992

AA	VISTAPHARM	EQ 5MG BASE/5ML	A075051 001	Jan 26, 2001

AA	+ WOCKHARDT	EQ 5MG BASE/5ML	A074703 001	Oct 31, 1997

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	IPCA LABS LTD	EQ 5MG BASE	A078807 001	Jun 12, 2008

AB		EQ 10MG BASE	A078807 002	Jun 12, 2008

AB	MUTUAL PHARM	EQ 5MG BASE	A071536 002	Jan 16, 1997

AB	NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374 001	Nov 30, 2007

AB		EQ 10MG BASE	A078374 002	Nov 30, 2007

AB	PAR PHARM INC	EQ 10MG BASE	A070581 001	Oct 17, 1985

AB	TEVA	EQ 5MG BASE	A072801 001	Jun 15, 1993

AB		EQ 10MG BASE	A070184 001	Jul 29, 1985

AB	VINTAGE PHARMS	EQ 5MG BASE	A077878 001	Aug 28, 2006

AB		EQ 10MG BASE	A077878 002	Aug 28, 2006

AB	WATSON LABS	EQ 5MG BASE	A072750 001	Dec 28, 1995

AB		EQ 10MG BASE	A071250 001	Feb 03, 1988

REGLAN

AB	ANI PHARMS	EQ 5MG BASE	N017854 002	May 05, 1987

AB	+	EQ 10MG BASE	N017854 001	

TABLET, ORALLY DISINTEGRATING;ORAL

METOZOLV ODT

+ SALIX PHARMS

EQ 5MG BASE

N022246 001 Sep 04, 2009

METOLAZONE

TABLET;ORAL

METOLAZONE

AB	MYLAN	2.5MG	A076698 001	Dec 23, 2003

AB		5MG	A076698 002	Oct 19, 2004

AB		10MG	A076698 003	Oct 19, 2004

AB	SANDOZ	2.5MG	A076732 001	Dec 19, 2003

AB		5MG	A076466 001	Dec 19, 2003

AB		10MG	A076466 002	Dec 19, 2003

ZAROXOLYN

AB	UCB INC	2.5MG	N017386 001	

AB	+	5MG	N017386 002	

AB	+	10MG	N017386 003	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012

AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012

AB	MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033 001	Dec 15, 2011

AB		EQ 50MG TARTRATE	A202033 002	Dec 15, 2011

AB		EQ 100MG TARTRATE	A202033 003	Dec 15, 2011

AB		EQ 200MG TARTRATE	A202033 004	Dec 15, 2011

AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012

AB		EQ 200MG BASE	A078889 002	Aug 15, 2012

AB	WATSON LABS FLORIDA	EQ 25MG TARTRATE	A077118 001	Aug 03, 2009

AB		EQ 50MG TARTRATE	A076862 001	Aug 03, 2009

AB		EQ 100MG TARTRATE	A077298 001	Apr 15, 2010

AB		EQ 200MG TARTRATE	A077298 002	Apr 15, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-242 (of 362)

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615</u>	<u>001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615</u>	<u>002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615</u>	<u>003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615</u>	<u>004</u>	Jul 22, 2010

TOPROL-XL

<u>AB</u>	ASTRAZENECA	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704</u>	<u>001</u>	Mar 30, 1984

METOPROLOL TARTRATE

<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
<u>AP</u>		CLARIS LIFESCIENCES	<u>1MG/ML</u>	<u>A078950</u>	<u>001</u>	Apr 29, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045</u>	<u>001</u>	Oct 25, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
<u>AP</u>			<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
<u>AP</u>			<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A090386</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>			<u>1MG/ML</u>	<u>A091307</u>	<u>001</u>	Dec 29, 2010
<u>AP</u>		SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317</u>	<u>001</u>	Apr 19, 2010
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007

TABLET; ORAL

LOPRESSOR

<u>AB</u>		US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
<u>AB</u>			<u>100MG</u>	<u>N017963</u>	<u>002</u>	

METOPROLOL TARTRATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871</u>	<u>001</u>	May 28, 2013
<u>AB</u>			<u>50MG</u>	<u>A202871</u>	<u>002</u>	May 28, 2013
<u>AB</u>			<u>100MG</u>	<u>A202871</u>	<u>003</u>	May 28, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>			<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>			<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>		CARACO	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>			<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>			<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>			<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>			<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>		MUTUAL PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
<u>AB</u>			<u>50MG</u>	<u>A073653</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>			<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>			<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A073288</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>			<u>100MG</u>	<u>A073289</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>		TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>			<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994
<u>AB</u>			<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995

METRONIDAZOLE

<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004
<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-243 (of 362)

METRONIDAZOLE

CREAM; TOPICAL

NORITATE

+ VALEANT BERMUDA 1%

N020743 001 Sep 26, 1997

GEL; TOPICAL

METROGELAB + GALDERMA LABS LP 0.75%N019737 001 Nov 22, 1988AB + 1%N021789 001 Jun 30, 2005METRONIDAZOLEAB FOUGERA PHARMS 0.75%A077018 001 Jun 06, 2006AB G AND W LABS INC 0.75%A078178 001 Jan 19, 2011AB TARO 0.75%A077819 001 Jul 18, 2006AB TOLMAR 0.75%A077547 001 Jul 13, 2006AB 1%A090903 001 Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINALAB + MEDICIS 0.75%N020208 001 Aug 17, 1992METRONIDAZOLEAB TOLMAR 0.75%A077264 001 Oct 31, 2006

VANDAZOLE

BX TEVA PHARMS 0.75%

N021806 001 May 20, 2005

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINERAP + BAXTER HLTHCARE 500MG/100MLN018657 001AP + PFIZER 500MG/100MLN018353 002METRO I.V. IN PLASTIC CONTAINERAP + B BRAUN 500MG/100MLN018900 001 Sep 29, 1983METRONIDAZOLE IN PLASTIC CONTAINERAP CLARIS LIFESCIENCES 500MG/100MLA078084 001 Mar 31, 2008AP + HOSPIRA 500MG/100MLN018890 002 Nov 18, 1983

LOTION; TOPICAL

METROLOTIONAB + GALDERMA LABS LP 0.75%N020901 001 Nov 24, 1998METRONIDAZOLEAB FOUGERA PHARMS 0.75%A077197 001 May 24, 2006

TABLET; ORAL

FLAGYLAB GD SEARLE LLC 250MGN012623 001AB + 500MGN012623 003METRONIDAZOLEAB ALEMBIC PHARMS LTD 250MGA079067 001 Mar 13, 2009AB 500MGA079067 002 Mar 13, 2009AB MUTUAL PHARM 250MGA070772 001 Jul 16, 1986AB 500MGA070773 001 Jul 16, 1986AB PLIVA 500MGA070033 001 Dec 06, 1984AB TEVA 500MGA070044 001 Feb 08, 1985AB TEVA PHARMS USA 250MGA070027 001 Nov 06, 1984AB WATSON LABS 250MGA070035 001 Dec 20, 1984AB 250MGN018764 001 Sep 17, 1982AB 500MGN018764 002 Dec 20, 1982

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ERAB + GD SEARLE LLC 750MGN020868 001 Nov 26, 1997METRONIDAZOLEAB ALEMBIC LTD 750MGA090222 001 May 05, 2010METYRAPONE

CAPSULE; ORAL

METOPIRONE

+ HRA PHARMA 250MG

N012911 002 Aug 09, 1996

METYROSINE

CAPSULE; ORAL

DEMSEER

+ ATON PHARMA VPNA 250MG

N017871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

TEVA 150MG

A074377 001 May 16, 1995

200MG

A074377 002 May 16, 1995

+ 250MG

A074377 003 May 16, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-244 (of 362)

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS

50MG/VIAL

N021506 002 Mar 16, 2005

+

100MG/VIAL

N021506 003 Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ VESTIQ PHARMS

50MG

N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATEAB ACTAVIS MID ATLANTIC200MGA073508 001 Nov 19, 1993MONISTAT 3AB + INSIGHT PHARMS200MGN018888 001 Aug 15, 1984MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+ STIEFEL LABS INC

0.25%; 81.35%; 15%

N021026 001 Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDEAP AKORN INCEQ 1MG BASE/MLA075494 001 Jun 30, 2000APEQ 5MG BASE/MLA075481 001 Jun 30, 2000APEQ 5MG BASE/MLA075494 002 Jun 30, 2000AP BEDFORDEQ 1MG BASE/MLA075247 002 Jun 23, 2000APEQ 5MG BASE/MLA075247 001 Jun 23, 2000AP BEN VENUEEQ 1MG BASE/MLA075421 002 Jun 20, 2000APEQ 5MG BASE/MLA075421 001 Jun 20, 2000AP FRESENIUS KABI USAEQ 1MG BASE/MLA075154 002 Jun 20, 2000APEQ 5MG BASE/MLA075154 001 Jun 20, 2000AP GLAND PHARMA LTDEQ 1MG BASE/MLA090696 001 Feb 29, 2012APEQ 5MG BASE/MLA090850 001 Jan 25, 2012AP HIKMA MAPLEEQ 1MG BASE/MLA075243 001 Jun 20, 2000APEQ 1MG BASE/MLA075324 001 Jun 20, 2000APEQ 5MG BASE/MLA075243 002 Jun 20, 2000APEQ 5MG BASE/MLA075324 002 Jun 20, 2000AP + HOSPIRAEQ 1MG BASE/MLA075293 001 Jun 20, 2000APEQ 1MG BASE/MLA075856 001 Jun 13, 2002AP +EQ 5MG BASE/MLA075293 002 Jun 20, 2000APEQ 5MG BASE/MLA075856 002 Jun 13, 2002AP WOCKHARDTEQ 1MG BASE/MLA078141 001 May 30, 2008APEQ 1MG BASE/MLA078511 001 Nov 10, 2008APEQ 5MG BASE/MLA078141 002 May 30, 2008APEQ 5MG BASE/MLA078511 002 Nov 10, 2008MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREEAP + HOSPIRAEQ 1MG BASE/MLA075857 001 Jul 22, 2002AP +EQ 5MG BASE/MLA075857 002 Jul 22, 2002AP SAGENT STRIDESEQ 1MG BASE/MLA090315 001 Nov 29, 2010APEQ 5MG BASE/MLA090315 002 Nov 29, 2010MIDOZALAM HYDROCHLORIDEAP SAGENT STRIDESEQ 1MG BASE/MLA090316 001 May 04, 2011APEQ 5MG BASE/MLA090316 002 May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDEAA HI TECH PHARMAEQ 2MG BASE/MLA075958 001 Sep 04, 2003AA PADDOCK LLCEQ 2MG BASE/MLA076379 001 May 02, 2005AA RANBAXYEQ 2MG BASE/MLA076058 001 Mar 15, 2002AA + ROXANEEQ 2MG BASE/MLA075873 001 Apr 30, 2002MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDEAB APOTEX INC2.5MGA077746 001 Sep 12, 2006AB5MGA077746 002 Sep 12, 2006AB10MGA077746 003 Sep 12, 2006AB IMPAX PHARMS2.5MGA076449 001 May 27, 2004AB5MGA076449 002 May 27, 2004AB10MGA076449 003 Dec 16, 2005AB MYLAN PHARMS INC2.5MGA076577 001 Sep 10, 2003AB +5MGA076577 002 Sep 10, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-245 (of 362)

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514</u>	<u>001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514</u>	<u>002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514</u>	<u>003</u>	Jul 02, 2004

ORVATEN

<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012

MIFEPREX

+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000

MIGLITOL

TABLET; ORAL

GLYSET

	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996
		50MG	N020682	002	Dec 18, 1996
+		100MG	N020682	003	Dec 18, 1996

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+	ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009
		25MG	N022256	002	Jan 14, 2009
+		50MG	N022256	003	Jan 14, 2009
		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	+	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075660</u>	<u>001</u>	May 28, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936</u>	<u>001</u>	May 28, 2002
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u>	<u>001</u>	Oct 31, 2006
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966</u>	<u>001</u>	Dec 03, 2010
<u>AP</u>		HIKMA MAPLE	<u>EQ 1MG BASE/ML</u>	<u>A075530</u>	<u>001</u>	May 28, 2002
<u>AP</u>		INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u>	<u>001</u>	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	APOTEX INC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>002</u>	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414</u>	<u>001</u>	Aug 18, 2004	
<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>002</u>	May 28, 2002
<u>AP</u>	BEDFORD LABS	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>001</u>	May 21, 2008	
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>002</u>	May 21, 2008	
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>001</u>	May 28, 2002	
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>002</u>	May 28, 2002	

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>002</u>	Jan 21, 2010

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	MEDICIS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	CARACO	<u>EQ 50MG BASE</u>	<u>A090867</u>	<u>001</u>	May 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-246 (of 362)

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867</u>	<u>002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867</u>	<u>003</u>	May 13, 2013
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

+ REMPEX PHARMS INC

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+ ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261</u>	<u>005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 45MG BASE</u>	<u>A065485</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A065485</u>	<u>004</u>	May 18, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485</u>	<u>005</u>	May 18, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911</u>	<u>001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911</u>	<u>002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911</u>	<u>003</u>	Jul 20, 2010
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009

SOLODYN

<u>AB</u>	MEDICIS	<u>EQ 65MG BASE</u>	<u>N050808</u>	<u>004</u>	Jul 23, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>N050808</u>	<u>005</u>	Jul 23, 2009
	+	EQ 55MG BASE	N050808	008	Aug 27, 2010
	+	EQ 80MG BASE	N050808	007	Aug 27, 2010
		EQ 105MG BASE	N050808	006	Aug 27, 2010

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-247 (of 362)

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+ GENZYME CORP

200MG/ML (200MG/ML)

N203568 001 Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

APGDI

25MG

N202611 001 Jun 28, 2012

+

50MG

N202611 002 Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINEAB APOTEX INC15MGA077666 001 Aug 22, 2007AB30MGA077666 002 Aug 22, 2007AB45MGA077666 003 Aug 22, 2007AB AUROBINDO7.5MGA076921 001 Oct 22, 2004AB15MGA076921 002 Oct 22, 2004AB30MGA076921 003 Oct 22, 2004AB45MGA076921 004 Oct 22, 2004AB CARACO7.5MGA076541 004 Apr 22, 2004AB15MGA076541 001 Apr 22, 2004AB30MGA076541 002 Apr 22, 2004AB45MGA076541 003 Apr 22, 2004AB MYLAN15MGA076122 001 Jun 19, 2003AB30MGA076122 002 Jun 19, 2003AB45MGA076122 003 Jun 19, 2003AB MYLAN PHARMS INC15MGA076176 001 Jun 19, 2003AB30MGA076176 002 Jun 19, 2003AB45MGA076176 003 Jun 19, 2003AB SANDOZ15MGA076219 001 Jun 19, 2003AB30MGA076219 002 Jun 19, 2003AB45MGA076219 003 Jun 19, 2003AB TEVA15MGA076119 001 Jan 24, 2003AB30MGA076119 002 Jan 24, 2003AB45MGA076119 003 Jun 19, 2003AB WATSON LABS15MGA076312 001 Jun 19, 2003AB30MGA076312 002 Jun 19, 2003AB45MGA076312 003 Jun 19, 2003AB WATSON LABS FLORIDA15MGA076336 001 Jun 20, 2003AB30MGA076336 002 Jun 20, 2003AB45MGA076336 003 Jun 20, 2003REMERONAB + ORGANON USA INC15MGN020415 001 Jun 14, 1996AB30MGN020415 002 Jun 14, 1996AB45MGN020415 003 Mar 17, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINEAB AUROBINDO PHARMA LTD15MGA077376 002 Dec 08, 2005AB30MGA077376 003 Dec 08, 2005AB45MGA077376 004 Feb 28, 2006AB TEVA15MGA076901 001 Jun 28, 2005AB30MGA076901 002 Jun 28, 2005AB45MGA076901 003 Jun 28, 2005AB WATSON LABS15MGA076307 001 Dec 17, 2003AB30MGA076307 002 Dec 17, 2003AB45MGA076307 003 Feb 28, 2006REMERON SOLTABAB + ORGANON USA INC15MGN021208 001 Jan 12, 2001AB30MGN021208 002 Jan 12, 2001AB45MGN021208 003 Jan 12, 2001MISOPROSTOL

TABLET;ORAL

CYTOTECAB GD SEARLE LLC0.1MGN019268 003 Sep 21, 1990AB

+

0.2MGN019268 001 Dec 27, 1988MISOPROSTOLAB IVAX SUB TEVA PHARMS0.1MGA076095 001 Jul 10, 2002AB0.2MGA076095 002 Jul 10, 2002AB NOVEL LABS INC0.1MGA091667 001 Jul 25, 2012AB0.2MGA091667 002 Jul 25, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-248 (of 362)

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+ MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCINAP + ACCORD HLTHCARE5MG/VIALA064144 001 Apr 30, 1998AP +20MG/VIALA064144 002 Apr 30, 1998AP +40MG/VIALA064144 003 Aug 11, 2009AP BEDFORD5MG/VIALA064117 001 Apr 19, 1995AP20MG/VIALA064117 002 Apr 19, 1995AP HIKMA MAPLE5MG/VIALA064180 001 Dec 23, 1999AP20MG/VIALA064180 002 Dec 23, 1999MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDEAP BEDFORDEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A076611 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A076611 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A076611 003 Apr 11, 2006AP FRESenius KABI USAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A077496 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A077496 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A077496 003 Apr 11, 2006AP + HOSPIRAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A076871 001 Apr 11, 2006AP +EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A076871 002 Apr 11, 2006AP +EQ 30MG BASE/15ML (EQ 2MG BASE/ML)A076871 003 Apr 11, 2006AP MYLAN INSTITUTIONALEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A078980 001 Apr 13, 2009APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A078980 002 Apr 13, 2009AP ONCO THERAPIES LTDEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A201014 001 Dec 11, 2012APEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A077356 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A077356 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A077356 003 Apr 11, 2006MODAFINIL

TABLET; ORAL

MODAFINILAB ALEMBIC LTD100MGA202700 001 Oct 18, 2012AB200MGA202700 002 Oct 18, 2012AB AUROBINDO PHARMA LTD100MGA202566 001 Sep 27, 2012AB200MGA202566 002 Sep 27, 2012AB CARLSBAD100MGA076715 001 Nov 01, 2012AB200MGA076715 002 Nov 01, 2012AB HIKMA PHARMS100MGA090543 001 Sep 26, 2012AB200MGA090543 002 Sep 26, 2012AB MYLAN PHARMS INC100MGA076594 001 Jul 16, 2012AB200MGA076594 002 Jul 16, 2012AB ORCHID HLTHCARE100MGA078963 001 Sep 26, 2012AB200MGA078963 002 Sep 26, 2012PROVIGILAB CEPHALON100MGN020717 001 Dec 24, 1998AB +200MGN020717 002 Dec 24, 1998MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDEAB APOTEX INC7.5MGA078454 001 Jun 02, 2008AB15MGA078454 002 Jun 02, 2008AB GLENMARK GENERICS7.5MGA090416 001 Mar 30, 2010AB15MGA090416 002 Mar 30, 2010AB PADDOCK LLC7.5MGA077536 001 Nov 30, 2006AB15MGA077536 002 Nov 30, 2006AB TEVA7.5MGA076204 001 May 08, 2003AB15MGA076204 002 May 08, 2003UNIVASCAB UCB INC7.5MGN020312 001 Apr 19, 1995AB +15MGN020312 002 Apr 19, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-249 (of 362)

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625</u>	<u>001</u>	May 06, 1987
<u>AB</u>		<u>0.1%</u>	<u>N019625</u>	<u>002</u>	Apr 19, 2013

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591</u>	<u>001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543</u>	<u>001</u>	Apr 30, 1987

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

	SCHERING	0.11MG/INH	N021067	002	Feb 01, 2008
+		0.22MG/INH	N021067	001	Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 10MG BASE</u>	<u>A201522</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 10MG BASE</u>	<u>A090655</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 10MG BASE</u>	<u>N020829</u>	<u>002</u>	Feb 20, 1998

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581</u>	<u>002</u>	Aug 06, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 4MG BASE</u>	<u>A200405</u>	<u>001</u>	Aug 03, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-250 (of 362)

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142 002</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A091128 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128 002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588 002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

<u>AB1</u>	+	WATSON LABS INC	<u>10MG</u>	<u>N020616 008</u>	Apr 20, 2007
<u>AB1</u>			<u>20MG</u>	<u>N020616 001</u>	Jul 03, 1996
<u>AB1</u>			<u>30MG</u>	<u>N020616 004</u>	Mar 09, 2001
<u>AB1</u>			<u>50MG</u>	<u>N020616 002</u>	Jul 03, 1996
<u>AB1</u>			<u>60MG</u>	<u>N020616 005</u>	Mar 09, 2001
<u>AB1</u>			<u>80MG</u>	<u>N020616 006</u>	Oct 27, 2006
<u>AB1</u>	+		<u>100MG</u>	<u>N020616 003</u>	Jul 03, 1996
<u>AB1</u>	+		<u>200MG</u>	<u>N020616 007</u>	Feb 27, 2007

MORPHINE SULFATE

<u>AB1</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812 001</u>	Nov 10, 2011
<u>AB1</u>		<u>30MG</u>	<u>A200812 002</u>	Nov 10, 2011
<u>AB1</u>		<u>50MG</u>	<u>A200812 003</u>	Nov 10, 2011
<u>AB1</u>		<u>60MG</u>	<u>A200812 004</u>	Nov 10, 2011
<u>AB1</u>		<u>80MG</u>	<u>A200812 005</u>	Nov 10, 2011
<u>AB1</u>		<u>100MG</u>	<u>A200812 006</u>	Nov 10, 2011
<u>AB1</u>	UPSHER SMITH	<u>10MG</u>	<u>A202104 001</u>	Jun 03, 2013
<u>AB1</u>		<u>20MG</u>	<u>A202104 002</u>	Jun 03, 2013
<u>AB1</u>		<u>30MG</u>	<u>A202104 003</u>	Jun 03, 2013
<u>AB1</u>		<u>50MG</u>	<u>A202104 004</u>	Jun 03, 2013
<u>AB1</u>		<u>60MG</u>	<u>A202104 005</u>	Jun 03, 2013
<u>AB1</u>		<u>80MG</u>	<u>A202104 006</u>	Jun 03, 2013
<u>AB1</u>		<u>100MG</u>	<u>A202104 007</u>	Jun 03, 2013

AVINZA

<u>AB2</u>	KING PFIZER	<u>30MG</u>	<u>N021260 001</u>	Mar 20, 2002
<u>AB2</u>		<u>45MG</u>	<u>N021260 005</u>	Dec 18, 2008
<u>AB2</u>		<u>60MG</u>	<u>N021260 002</u>	Mar 20, 2002
<u>AB2</u>		<u>75MG</u>	<u>N021260 006</u>	Dec 18, 2008
<u>AB2</u>		<u>90MG</u>	<u>N021260 003</u>	Mar 20, 2002
<u>AB2</u>	+	<u>120MG</u>	<u>N021260 004</u>	Mar 20, 2002

MORPHINE SULFATE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A079040 001</u>	Jan 16, 2013
<u>AB2</u>		<u>45MG</u>	<u>A079040 002</u>	Jan 16, 2013
<u>AB2</u>		<u>60MG</u>	<u>A079040 003</u>	Jan 16, 2013
<u>AB2</u>		<u>75MG</u>	<u>A079040 004</u>	Jan 16, 2013
<u>AB2</u>		<u>90MG</u>	<u>A079040 005</u>	Jan 16, 2013
<u>AB2</u>		<u>120MG</u>	<u>A079040 006</u>	Jan 16, 2013

KADIAN

	WATSON LABS INC	40MG	N020616 009	Jul 09, 2012
		70MG	N020616 010	Jul 09, 2012
		130MG	N020616 011	Jul 09, 2012
		150MG	N020616 012	Jul 09, 2012

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050 001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051 001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052 001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053 001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+	HIKMA MAPLE	<u>0.5MG/ML</u>	<u>N018565 001</u>	Sep 18, 1984
<u>AP</u>	+		<u>1MG/ML</u>	<u>N018565 002</u>	Sep 18, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-251 (of 362)

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+	<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>	WATSON LABS	<u>0.5MG/ML</u>	<u>A073373</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073375</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073374</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073376</u>	<u>001</u>	Sep 30, 1991

INFUMORPH

+ HIKMA MAPLE

10MG/ML

N018565 003 Jul 19, 1991

+

25MG/ML

N018565 004 Jul 19, 1991

MORPHINE SULFATE

+ HOSPIRA

5MG/ML

N019916 002 Oct 27, 2006

+ HOSPIRA INC

2MG/ML

N202515 001 Nov 14, 2011

+

4MG/ML

N202515 002 Nov 14, 2011

+

8MG/ML

N202515 003 Nov 14, 2011

+

10MG/ML

N202515 004 Nov 14, 2011

+

15MG/ML

N202515 005 Nov 14, 2011

+ MERIDIAN MEDCL TECHN

15MG/ML

N019999 001 Jul 12, 1990

SOLUTION; IM-IV

MORPHINE SULFATE

+ BD RX

2MG/ML (2MG/ML)

N204223 001 Oct 30, 2013

+

4MG/ML (4MG/ML)

N204223 002 Oct 30, 2013

+

5MG/ML (5MG/ML)

N204223 003 Oct 30, 2013

+

8MG/ML (8MG/ML)

N204223 004 Oct 30, 2013

+

10MG/ML (10MG/ML)

N204223 005 Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>	MALLINCKRODT INC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>	ROXANE	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
<u>AA</u>	VISTAPHARM	<u>10MG/5ML</u>	<u>A201947</u>	<u>001</u>	Jan 05, 2012
<u>AA</u>		<u>20MG/5ML</u>	<u>A201947</u>	<u>002</u>	Jan 05, 2012
	LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011

TABLET; ORAL

MORPHINE SULFATE

ROXANE

15MG

N022207 001 Mar 17, 2008

+

30MG

N022207 002 Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	CLONMEL HLTHCARE	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A200824</u>	<u>001</u>	Oct 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A200824</u>	<u>002</u>	Oct 18, 2011
<u>AB</u>		<u>60MG</u>	<u>A200824</u>	<u>003</u>	Oct 18, 2011
<u>AB</u>		<u>100MG</u>	<u>A200824</u>	<u>004</u>	Oct 18, 2011
<u>AB</u>		<u>200MG</u>	<u>A200824</u>	<u>005</u>	Oct 18, 2011
<u>AB</u>	NESHER PHARMS	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	RANBAXY LABS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-252 (of 362)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

	ALPHARMA KING	20MG; 0.8MG	N022321	001	Aug 13, 2009
		30MG; 1.2MG	N022321	002	Aug 13, 2009
		50MG; 2MG	N022321	003	Aug 13, 2009
	+	60MG; 2.4MG	N022321	004	Aug 13, 2009
		80MG; 3.2MG	N022321	005	Aug 13, 2009
		100MG; 4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010

VIGAMOX

+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003

TABLET;ORAL

AVELOX

+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999

MUPIROICIN

OINTMENT;TOPICAL

BACTROBAN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>2%</u>	<u>N050591</u>	<u>001</u>	Dec 31, 1987

MUPIROICIN

<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>		GLENMARK PHARMS	<u>2%</u>	<u>A090480</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>		TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>		TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003

CENTANY

BX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

MUPIROICIN CALCIUM

CREAM;TOPICAL

BACTROBAN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 2% BASE</u>	<u>N050746</u>	<u>001</u>	Dec 11, 1997

MUPIROICIN

<u>AB</u>		GLENMARK GENERICS	<u>EQ 2% BASE</u>	<u>A201587</u>	<u>001</u>	Jan 24, 2013

OINTMENT;NASAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

<u>AB</u>	+	ROCHE PALO	<u>250MG</u>	<u>N050722</u>	<u>001</u>	May 03, 1995

MYCOPHENOLATE MOFETIL

<u>AB</u>		ACCORD HLTHCARE	<u>250MG</u>	<u>A090253</u>	<u>001</u>	May 04, 2009
<u>AB</u>		ALKEM LABS LTD	<u>250MG</u>	<u>A200197</u>	<u>001</u>	Jun 13, 2013
<u>AB</u>		APOTEX CORP	<u>250MG</u>	<u>A090419</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>		DR REDDYS LABS LTD	<u>250MG</u>	<u>A091315</u>	<u>001</u>	Oct 27, 2011
<u>AB</u>		MYLAN	<u>250MG</u>	<u>A065520</u>	<u>001</u>	May 04, 2009
<u>AB</u>		ROXANE	<u>250MG</u>	<u>A065410</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A065379</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>		STRIDES ARCOLAB LTD	<u>250MG</u>	<u>A090055</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>		TEVA PHARMS	<u>250MG</u>	<u>A065491</u>	<u>001</u>	May 06, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-253 (of 362)

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB	VINTAGE PHARMS LLC	250MG	<u>A090111</u>	<u>001</u>	Dec 22, 2009

SUSPENSION; ORAL

CELLCEPT

+ ROCHE PALO

200MG/ML

N050759 001 Oct 01, 1998

TABLET; ORAL

CELLCEPT

AB	+ ROCHE PALO	500MG	<u>N050723</u>	<u>001</u>	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	500MG	<u>A065416</u>	<u>001</u>	May 04, 2009

AB	ALKEM LABS LTD	500MG	<u>A091249</u>	<u>001</u>	Nov 04, 2011

AB	APOTEX	500MG	<u>A090499</u>	<u>001</u>	Apr 22, 2009

AB	MYLAN	500MG	<u>A065521</u>	<u>001</u>	May 04, 2009

AB	ROXANE	500MG	<u>A065413</u>	<u>001</u>	Jul 29, 2008

AB	SANDOZ	500MG	<u>A065451</u>	<u>001</u>	Oct 15, 2008

AB	STRIDES ARCOLAB LTD	500MG	<u>A090456</u>	<u>001</u>	Jun 10, 2010

AB	TEVA PHARMS	500MG	<u>A065457</u>	<u>001</u>	May 04, 2009

AB	VINTAGE PHARMS LLC	500MG	<u>A090606</u>	<u>001</u>	Jul 16, 2010

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

+ ROCHE PALO

500MG/VIAL

N050758 001 Aug 12, 1998

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB	APOTEX INC	180MG	<u>A091558</u>	<u>001</u>	Aug 21, 2012

AB	MYLAN PHARMS INC	180MG	<u>A091248</u>	<u>002</u>	Jan 08, 2014

AB		360MG	<u>A091248</u>	<u>001</u>	Jan 08, 2014

MYFORTIC

AB	NOVARTIS	180MG	<u>N050791</u>	<u>001</u>	Feb 27, 2004

AB	+	360MG	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

+ MEDA PHARMS

1MG

N018677 001 Dec 26, 1985

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	APOTEX INC	500MG	<u>A090427</u>	<u>001</u>	Dec 30, 2011

AB		750MG	<u>A090427</u>	<u>002</u>	Dec 30, 2011

AB	INVAGEN PHARMS	500MG	<u>A078671</u>	<u>001</u>	Mar 07, 2008

AB		750MG	<u>A078671</u>	<u>002</u>	Mar 07, 2008

AB	LUPIN LTD	500MG	<u>A090445</u>	<u>001</u>	Jan 12, 2011

AB		750MG	<u>A090445</u>	<u>002</u>	Jan 12, 2011

AB	MYLAN PHARMS INC	500MG	<u>A090516</u>	<u>001</u>	Jul 12, 2010

AB		750MG	<u>A090516</u>	<u>002</u>	Jul 12, 2010

AB	PAR PHARM	500MG	<u>A076009</u>	<u>001</u>	Jan 24, 2003

AB		750MG	<u>A076009</u>	<u>002</u>	Jan 24, 2003

AB	SANDOZ	500MG	<u>A075280</u>	<u>001</u>	Feb 25, 2002

AB		750MG	<u>A075280</u>	<u>002</u>	Feb 25, 2002

AB	TEVA	500MG	<u>A075189</u>	<u>001</u>	May 26, 2000

AB	+	750MG	<u>A075189</u>	<u>002</u>	Sep 24, 2001

AB	WATSON LABS	500MG	<u>A091083</u>	<u>001</u>	Jun 13, 2011

AB		750MG	<u>A091083</u>	<u>002</u>	Jun 13, 2011

NADOLOL

TABLET; ORAL

CORGARD

AB	KING PHARMS	20MG	<u>N018063</u>	<u>005</u>	Oct 28, 1986

AB		40MG	<u>N018063</u>	<u>001</u>	

AB	+	80MG	<u>N018063</u>	<u>002</u>	

NADOLOL

AB	IVAX SUB TEVA PHARMS	20MG	<u>A074229</u>	<u>001</u>	Aug 30, 1996

AB		40MG	<u>A074229</u>	<u>002</u>	Aug 30, 1996

AB		80MG	<u>A074255</u>	<u>001</u>	Jan 24, 1996

AB	MYLAN	20MG	<u>A074172</u>	<u>001</u>	Oct 31, 1993

AB		40MG	<u>A074172</u>	<u>002</u>	Oct 31, 1993

AB		80MG	<u>A074172</u>	<u>003</u>	Oct 31, 1993

AB	SANDOZ	20MG	<u>A074501</u>	<u>001</u>	Nov 09, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-254 (of 362)

NADOLOL

TABLET; ORAL

NADOLOL

<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+ GD SEARLE LLC

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	IBI	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	+ SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062527</u>	<u>004</u>	Aug 02, 1984
	NALLPEN IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989
	+	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019599 001 Feb 29, 1988

+

2%

N019599 002 Jan 13, 2012

GEL; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019356 001 Jun 18, 1990

+

2%

N204286 001 Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+	<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+	<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+	<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+	<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+	<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+	<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+	<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

<u>AB</u>	GAVIS PHARMS	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
<u>AB</u>	RANBAXY	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
<u>AB</u>	+ WATSON LABS	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+ ALKERMES

380MG/VIAL

N021897 001 Apr 13, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-255 (of 362)

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A091205</u>	<u>001</u>	Aug 17, 2011
<u>AB</u>	BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
<u>AB</u>	ELITE LABS	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A090356</u>	<u>001</u>	Feb 24, 2012
<u>REVIA</u>					
<u>AB</u>	+ TEVA WOMENS	<u>50MG</u>	<u>N018932</u>	<u>001</u>	Nov 20, 1984
	NALTREXONE HYDROCHLORIDE				
	MALLINCKRODT	25MG	A076264	001	Mar 22, 2002
		100MG	A076264	003	Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+ PHARMAFORCE 200MG/ML

A091252 001 Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

<u>AT</u>	+ ALLERGAN	<u>0.1%</u>	<u>A080248</u>	<u>001</u>	

NAPHAZOLINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.1%</u>	<u>A083590</u>	<u>001</u>	

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<u>AB</u>	+ ROCHE PALO	<u>25MG/ML</u>	<u>N018965</u>	<u>001</u>	Mar 23, 1987

NAPROXEN

<u>AB</u>	ROXANE	<u>25MG/ML</u>	<u>A074190</u>	<u>001</u>	Mar 30, 1994

TABLET; ORAL

NAPROSYN

<u>AB</u>	ROCHE PALO	<u>250MG</u>	<u>N017581</u>	<u>002</u>	

<u>AB</u>		<u>375MG</u>	<u>N017581</u>	<u>003</u>	

<u>AB</u>	+	<u>500MG</u>	<u>N017581</u>	<u>004</u>	Apr 15, 1982

NAPROXEN

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927</u>	<u>001</u>	Dec 18, 2001

<u>AB</u>		<u>375MG</u>	<u>A075927</u>	<u>002</u>	Dec 18, 2001

<u>AB</u>		<u>500MG</u>	<u>A075927</u>	<u>003</u>	Dec 18, 2001

<u>AB</u>	AUROBINDO PHARMA USA	<u>250MG</u>	<u>A200429</u>	<u>001</u>	Nov 08, 2011

<u>AB</u>		<u>375MG</u>	<u>A200429</u>	<u>002</u>	Nov 08, 2011

<u>AB</u>		<u>500MG</u>	<u>A200429</u>	<u>003</u>	Nov 08, 2011

<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A074410</u>	<u>001</u>	Apr 28, 1995

<u>AB</u>		<u>375MG</u>	<u>A074410</u>	<u>002</u>	Apr 28, 1995

<u>AB</u>		<u>500MG</u>	<u>A074410</u>	<u>003</u>	Apr 28, 1995

<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A078250</u>	<u>001</u>	Mar 28, 2007

<u>AB</u>		<u>375MG</u>	<u>A078250</u>	<u>002</u>	Mar 28, 2007

<u>AB</u>		<u>500MG</u>	<u>A078250</u>	<u>003</u>	Mar 28, 2007

<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A091305</u>	<u>001</u>	Aug 24, 2011

<u>AB</u>		<u>375MG</u>	<u>A091305</u>	<u>002</u>	Aug 24, 2011

<u>AB</u>		<u>500MG</u>	<u>A091305</u>	<u>003</u>	Aug 24, 2011

<u>AB</u>	MARKSANS PHARMA	<u>250MG</u>	<u>A091416</u>	<u>001</u>	Feb 14, 2011

<u>AB</u>		<u>375MG</u>	<u>A091416</u>	<u>002</u>	Feb 14, 2011

<u>AB</u>		<u>500MG</u>	<u>A091416</u>	<u>003</u>	Feb 14, 2011

<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121</u>	<u>001</u>	Dec 21, 1993

<u>AB</u>		<u>375MG</u>	<u>A074121</u>	<u>002</u>	Dec 21, 1993

<u>AB</u>		<u>500MG</u>	<u>A074121</u>	<u>003</u>	Dec 21, 1993

<u>AB</u>	PERRIGO R AND D	<u>250MG</u>	<u>A077339</u>	<u>001</u>	Apr 27, 2005

<u>AB</u>		<u>375MG</u>	<u>A077339</u>	<u>002</u>	Apr 27, 2005

<u>AB</u>		<u>500MG</u>	<u>A077339</u>	<u>003</u>	Apr 27, 2005

<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A074140</u>	<u>001</u>	Dec 21, 1993

<u>AB</u>		<u>375MG</u>	<u>A074140</u>	<u>002</u>	Dec 21, 1993

<u>AB</u>		<u>500MG</u>	<u>A074140</u>	<u>003</u>	Dec 21, 1993

<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201</u>	<u>001</u>	Dec 21, 1993

<u>AB</u>		<u>375MG</u>	<u>A074201</u>	<u>002</u>	Dec 21, 1993

<u>AB</u>		<u>500MG</u>	<u>A074201</u>	<u>003</u>	Dec 21, 1993

<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A074457</u>	<u>001</u>	May 31, 1995

<u>AB</u>		<u>375MG</u>	<u>A074457</u>	<u>002</u>	May 31, 1995

<u>AB</u>		<u>500MG</u>	<u>A074457</u>	<u>003</u>	May 31, 1995

<u>AB</u>	WEST WARD PHARM CORP	<u>250MG</u>	<u>A076494</u>	<u>001</u>	Jan 14, 2004

<u>AB</u>		<u>375MG</u>	<u>A076494</u>	<u>002</u>	Jan 14, 2004

<u>AB</u>		<u>500MG</u>	<u>A076494</u>	<u>003</u>	Jan 14, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-256 (of 362)

NAPROXEN

TABLET; ORAL

NAPROXEN

<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>		INVAGEN PHARMS	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>			<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>			<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>		PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>			<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>		SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
<u>AB</u>			<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>			<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

<u>AB</u>		HOFFMANN LA ROCHE	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	

ANAPROX DS

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987

NAPROXEN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		WATSON LABS	<u>EQ 250MG BASE</u>	<u>A074455</u>	<u>001</u>	May 31, 1995
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074455</u>	<u>002</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

		ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996
			EQ 500MG BASE	N020353	002	Jan 05, 1996
	+		EQ 750MG BASE	N020353	003	Jan 05, 1996

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

	+	SMITHKLINE BEECHAM	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

<u>AB</u>		APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373</u>	<u>001</u>	Apr 22, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091373</u>	<u>002</u>	Apr 22, 2011
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552</u>	<u>001</u>	Feb 14, 2011

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>		GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+		<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A200502</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431</u>	<u>001</u>	May 31, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A202431</u>	<u>002</u>	May 31, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091441</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-257 (of 362)

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+ ALCON

5%

N050514 001

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462</u>	<u>002</u>	Mar 30, 2011

STARLIX

<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204</u>	<u>001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204</u>	<u>002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

FOREST LABS

EQ 2.5MG BASE

N021742 002 Dec 17, 2007

EQ 5MG BASE

N021742 003 Dec 17, 2007

EQ 10MG BASE

N021742 004 Dec 17, 2007

+

EQ 20MG BASE

N021742 005 Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRI

<u>AT</u>	+	ALLERGAN	<u>2%</u>	<u>N021009</u>	<u>001</u>	Dec 08, 1999
<u>AT</u>		<u>NEDOCROMIL SODIUM</u>				
<u>AT</u>		AKORN	<u>2%</u>	<u>A090638</u>	<u>001</u>	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076409</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076409</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076409</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076409</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A076409</u>	<u>005</u>	Sep 16, 2003
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076037</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076037</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076037</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076037</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>	+	<u>250MG</u>	<u>A076037</u>	<u>005</u>	Sep 16, 2003
BX	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
BX		100MG	A076309	002	Sep 16, 2003
BX		150MG	A076309	003	Sep 16, 2003
BX		200MG	A076309	004	Sep 16, 2003
BX		250MG	A076309	005	Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+ SMITHKLINE BEECHAM

250MG/50ML (5MG/ML)

N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N020779 001 Mar 14, 1997

+

EQ 625MG BASE

N021503 001 Apr 30, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-258 (of 362)

NEOMYCIN SULFATE

SOLUTION; ORAL

NEO-FRADIN

+ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002

TABLET; ORAL

NEOMYCIN SULFATEAA OMAN PHARM PRODUCTS500MGA065468 001 Mar 29, 2010AA + TEVA500MGA060304 001AA X GEN PHARMS500MGA065220 001 Jul 28, 2006NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATEAT WATSON LABSEQ 40MG BASE/ML; 200,000 UNITS/MLA062664 001 Apr 08, 1986AT X GEN PHARMSEQ 40MG BASE/ML; 200,000 UNITS/MLA065106 001 Jan 31, 2006ATEQ 40MG BASE/ML; 200,000 UNITS/MLA065108 001 Jan 31, 2006NEOSPORIN G.U. IRRIGANTAT + MONARCH PHARMSEQ 40MG BASE/ML; 200,000 UNITS/MLA060707 001NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ ECLAT PHARMS LLC

5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013

+

10MG/10ML (1MG/ML)

N204078 002 May 31, 2013

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+ ALCON RES LTD

0.3%

N203491 001 Oct 16, 2012

NEVANAC

+ ALCON PHARMS LTD

0.1%

N021862 001 Aug 19, 2005

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ SCIOS LLC

1.5MG/VIAL

N020920 001 Aug 10, 2001

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINEAA AUROBINDO50MG/5MLA077702 001 May 22, 2012VIRAMUNEAA + BOEHRINGER INGELHEIM50MG/5MLN020933 001 Sep 11, 1998

TABLET; ORAL

NEVIRAPINEAB APOTEX INC200MGA203021 001 May 22, 2012AB AUROBINDO200MGA077521 001 May 22, 2012AB CIPLA200MGA077956 001 May 22, 2012AB HETERO LABS LTD III200MGA078584 001 May 22, 2012AB MICRO LABS LTD200MGA203080 001 May 22, 2012AB MYLAN LABS200MGA078864 001 May 22, 2012AB MYLAN PHARMS INC200MGA202523 001 May 22, 2012AB PRINSTON INC200MGA078644 001 May 22, 2012AB SCIEGEN PHARMS INC200MGA203176 001 May 22, 2012AB STRIDES200MGA078195 001 May 22, 2012VIRAMUNEAB + BOEHRINGER INGELHEIM200MGN020636 001 Jun 21, 1996

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

BOEHRINGER INGELHEIM

100MG

N201152 002 Nov 08, 2012

+

400MG

N201152 001 Mar 25, 2011

NIACIN

TABLET; ORAL

NIACINAA WOCKHARDT500MGA081134 001 Apr 28, 1992NIACORAA + UPSHER SMITH500MGA040378 001 May 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIACINAB BARR1GMA076250 001 Apr 14, 2005AB500MGA076378 001 Apr 26, 2005AB750MGA076378 002 Apr 26, 2005NIASPANAB + ABBVIE1GMN020381 004 Jul 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-259 (of 362)

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIASPAN

AB		500MG	N020381	002	Jul 28, 1997
AB	+	750MG	N020381	003	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE;ORAL

SIMCOR

+	ABBVIE	1GM;20MG	N022078	003	Feb 15, 2008
+		1GM;40MG	N022078	005	Jul 28, 2010
+		500MG;20MG	N022078	001	Feb 15, 2008
+		500MG;40MG	N022078	004	Jul 28, 2010
+		750MG;20MG	N022078	002	Feb 15, 2008

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

AB	EKR THERAP	20MG	N019488	001	Dec 21, 1988
AB	+	30MG	N019488	002	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

AB	BARR	20MG	A074439	001	Dec 10, 1996
AB		30MG	A074439	002	Dec 10, 1996
AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998
AB		30MG	A074928	002	Mar 19, 1998
AB	MYLAN	20MG	A074642	001	Jul 18, 1996
AB		30MG	A074642	002	Jul 18, 1996
AB	TEVA	20MG	A074540	001	Oct 28, 1996
AB		30MG	A074540	002	Oct 28, 1996
AB	WATSON LABS	20MG	A074670	001	Oct 28, 1996
AB		30MG	A074670	002	Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

+	EKR THERAP	30MG	N020005	001	Feb 21, 1992
+		60MG	N020005	003	Feb 21, 1992

INJECTABLE;INJECTION

CARDENE

AP	+	EKR THERAP	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

AP	BEDFORD	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009
AP	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008
AP	MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009
AP	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009
AP	PHARMAFORCE	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009
AP	SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009
AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008

NICOTINE

INHALANT;ORAL

NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

+	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB	ACTAVIS ELIZABETH	10MG	A072579	001	Jan 08, 1991
AB		20MG	A072556	001	Sep 20, 1990
AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013
AB		20MG	A202644	002	Apr 25, 2013
AB	INTERGEL PHARM	10MG	A072781	001	Jul 30, 1993

PROCARDIA

AB	+	PFIZER	10MG	N018482	001

PRESCRIPTION DRUG PRODUCT LIST

3-260 (of 362)

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993
<u>AB1</u>	+	<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>	VALEANT INTL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007
<u>AB2</u>	VALEANT INTL	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000

PROCARDIA XL

<u>AB2</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u>	+	<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010
+	EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

+	COVIS PHARMA SARL	150MG	N020169	002	Apr 30, 1999

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<u>AB</u>	+	BANNER PHARMACAPS	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u>		BARR LABS INC	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>		SUN PHARM INDS INC	<u>30MG</u>	<u>A077067</u>	<u>001</u>	Apr 17, 2007

SOLUTION;ORAL

NYMALIZE

+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<u>AB</u>	MYLAN	<u>8.5MG</u>	<u>A091001</u>	<u>001</u>	Jan 26, 2011
<u>AB</u>		<u>17MG</u>	<u>A091001</u>	<u>002</u>	Jan 26, 2011
<u>AB</u>		<u>34MG</u>	<u>A091001</u>	<u>004</u>	Jan 26, 2011

SULAR

<u>AB</u>	+	SHIONOGI INC	<u>8.5MG</u>	<u>N020356</u>	<u>008</u>	Jan 02, 2008
<u>AB</u>	+		<u>17MG</u>	<u>N020356</u>	<u>007</u>	Jan 02, 2008
<u>AB</u>	+		<u>34MG</u>	<u>N020356</u>	<u>005</u>	Jan 02, 2008

NISOLDIPINE

MYLAN	20MG	A079051	001	Jul 25, 2008
	25.5MG	A091001	003	Jan 26, 2011
+	30MG	A079051	002	Jul 25, 2008
+	40MG	A079051	003	Jul 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-261 (of 362)

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+ ROMARK

100MG/5ML

N021498 001 Nov 22, 2002

TABLET; ORAL

ALINIA

+ ROMARK

500MG

N021497 001 Jul 21, 2004

NITISINONE

CAPSULE; ORAL

ORFADIN

SWEDISH ORPHAN

2MG

N021232 001 Jan 18, 2002

5MG

N021232 002 Jan 18, 2002

+

10MG

N021232 003 Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION

INOMAX

INO

100PPM

N020845 002 Dec 23, 1999

+

800PPM

N020845 003 Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTINAB + SHIONOGI INC25MG/5MLN009175 001NITROFURANTOINAB AMNEAL PHARMS25MG/5MLA201679 001 May 11, 2011AB CARACO25MG/5MLA201355 001 Aug 14, 2013NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTINAB ALVOGEN INC50MGN016620 001AB +100MGN016620 002NITROFURANTOINAB IVAX SUB TEVA PHARMS50MGA073671 001 Jan 28, 1993AB100MGA073652 001 Jan 28, 1993AB

MYLAN

50MGA074967 001 Jul 09, 1997AB100MGA077025 001 Aug 18, 2004

MACRODANTIN

ALVOGEN INC

25MG

N016620 003

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBIDAB + ALVOGEN INC75MG; 25MGN020064 001 Dec 24, 1991NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)AB MYLAN75MG; 25MGA076648 001 Mar 22, 2004AB

SANDOZ

75MG; 25MGA077066 001 Apr 05, 2005NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+ MIST PHARMS LLC

0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRANAB1 MEDICIS0.1MG/HRA089771 001 Aug 30, 1996AB10.2MG/HRA089772 001 Aug 30, 1996AB10.4MG/HRA089773 001 Aug 30, 1996AB10.6MG/HRA089774 001 Aug 30, 1996NITRO-DURAB1 + MERCK SHARP DOHME0.1MG/HRN020145 001 Apr 04, 1995AB1 +0.2MG/HRN020145 002 Apr 04, 1995AB1 +0.4MG/HRN020145 004 Apr 04, 1995AB1 +0.6MG/HRN020145 005 Apr 04, 1995NITROGLYCERINAB1 KREMERS URBAN PHARMS0.2MG/HRA075115 001 Aug 10, 2004AB10.4MG/HRA075115 002 Aug 10, 2004AB2

HERCON PHARM

0.2MG/HRA089884 001 Oct 30, 1998AB20.4MG/HRA089885 001 Oct 30, 1998AB20.6MG/HRA089886 001 Oct 30, 1998AB2 +

MYLAN TECHNOLOGIES

0.2MG/HRA074559 003 Aug 30, 1996AB2 +0.4MG/HRA074559 002 Aug 30, 1996AB2 +0.6MG/HRA074559 001 Aug 30, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-262 (of 362)

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

+	MERCK SHARP DOHME	0.3MG/HR	N020145	003	Apr 04, 1995
+		0.8MG/HR	N020145	006	Apr 04, 1995

NITROGLYCERIN

+	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%AP + BAXTER HLTHCARE 10MG/100MLN019970 001 Dec 29, 1989AP + 20MG/100MLN019970 002 Dec 29, 1989AP + 40MG/100MLN019970 003 Dec 29, 1989AP HOSPIRA 10MG/100MLA071846 001 Aug 31, 1990AP 20MG/100MLA071847 001 Aug 31, 1990AP 40MG/100MLA071848 001 Aug 31, 1990

NITROGLYCERIN

+	LUITPOLD	5MG/ML	A072034	001	May 24, 1988

OINTMENT;INTRA-ANAL

RECTIV

+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011

OINTMENT;TRANSDERMAL

NITROGLYCERIN

+	FOUGERA	2%	A087355	001	Jul 08, 1988

SPRAY, METERED;SUBLINGUAL

NITROGLYCERINAB PERRIGO ISRAEL 0.4MG/SPRAYA091496 001 Sep 20, 2013NITROLINGUAL PUMPSPRAYAB + POHL BOSKAMP 0.4MG/SPRAYN018705 002 Jan 10, 1997

TABLET;SUBLINGUAL

NITROSTAT

	PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000

		0.4MG	N021134	002	May 01, 2000

+		0.6MG	N021134	003	May 01, 2000

NIZATIDINE

CAPSULE;ORAL

NIZATIDINEAB DR REDDYS LABS LTD 150MGA077314 001 Sep 15, 2005AB 300MGA077314 002 Sep 15, 2005AB GLENMARK GENERICS 150MGA090618 001 Jul 15, 2011AB 300MGA090618 002 Jul 15, 2011AB MYLAN PHARMS INC 150MGA075806 001 Jul 05, 2002AB + 300MGA075806 002 Jul 05, 2002AB SANDOZ 150MGA076178 001 Jul 05, 2002AB 300MGA076178 002 Jul 05, 2002AB TEVA 150MGA075668 001 Sep 12, 2002AB 300MGA075668 002 Sep 12, 2002AB WATSON LABS 150MGA075616 001 Jul 09, 2002AB 300MGA075616 002 Jul 09, 2002

SOLUTION;ORAL

AXIDAA + BRAINTREE 15MG/MLN021494 001 May 25, 2004NIZATIDINEAA AMNEAL PHARMS 15MG/MLA090576 001 Nov 18, 2009NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHEDAP + HOSPIRA EQ 1MG BASE/MLN007513 001NOREPINEPHRINE BITARTRATEAP BEDFORD EQ 1MG BASE/MLA040462 001 Oct 31, 2003AP CLARIS LIFESCIENCES EQ 1MG BASE/MLA040859 001 Mar 27, 2012AP TEVA PHARMS USA EQ 1MG BASE/MLA040455 001 Mar 03, 2003NORETHINDRONE

TABLET;ORAL-28

CAMILAAB1 BARR 0.35MGA076177 001 Oct 21, 2002HEATHERAB1 GLENMARK GENERICS 0.35MGA090454 001 Apr 23, 2010NOR-QDAB1 + WATSON LABS (UTAH) 0.35MGN017060 001

PRESCRIPTION DRUG PRODUCT LIST

3-263 (of 362)

NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE

AB1	FAMY CARE LTD	<u>0.35MG</u>	<u>A201483</u>	<u>001</u>	Jun 24, 2013
AB1	HAUPT PHARMA	<u>0.35MG</u>	<u>A202260</u>	<u>001</u>	Aug 01, 2013
AB1	LUPIN LTD	<u>0.35MG</u>	<u>A091325</u>	<u>001</u>	Sep 19, 2011
AB1	NOVAST LABS LTD	<u>0.35MG</u>	<u>A202014</u>	<u>001</u>	Sep 13, 2013

ERRIN

AB2	BARR	<u>0.35MG</u>	<u>A076225</u>	<u>001</u>	Oct 21, 2002

JENCYCLA

AB2	LUPIN LTD	<u>0.35MG</u>	<u>A091323</u>	<u>001</u>	Mar 28, 2013

MICRONOR

AB2	+ JANSSSEN PHARMS	<u>0.35MG</u>	<u>N016954</u>	<u>001</u>	

NORETHINDRONE

AB2	GLENMARK GENERICS	<u>0.35MG</u>	<u>A091209</u>	<u>001</u>	Jul 21, 2010

NORETHINDRONE

AB2	FAMY CARE LTD	<u>0.35MG</u>	<u>A200980</u>	<u>001</u>	Jun 12, 2013

AB2	NOVAST LABS	<u>0.35MG</u>	<u>A200961</u>	<u>001</u>	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB	+ DURAMED RES	<u>5MG</u>	<u>N018405</u>	<u>001</u>	Apr 21, 1982

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	<u>5MG</u>	<u>A200275</u>	<u>001</u>	Jul 30, 2012

AB	BARR	<u>5MG</u>	<u>A075951</u>	<u>001</u>	May 25, 2001

AB	GLENMARK GENERICS	<u>5MG</u>	<u>A091090</u>	<u>001</u>	Jul 21, 2010

NORFLOXACIN

TABLET; ORAL

NOROXIN

+ MERCK	400MG	<u>N019384</u>	<u>002</u>	Oct 31, 1986

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB	MYLAN	<u>EQ 10MG BASE</u>	<u>A074234</u>	<u>001</u>	Jul 26, 1993

AB		<u>EQ 25MG BASE</u>	<u>A074234</u>	<u>002</u>	Jul 26, 1993

AB		<u>EQ 50MG BASE</u>	<u>A074234</u>	<u>003</u>	Jul 26, 1993

AB		<u>EQ 75MG BASE</u>	<u>A074234</u>	<u>004</u>	Jul 26, 1993

AB	TARO	<u>EQ 10MG BASE</u>	<u>A075520</u>	<u>004</u>	May 08, 2000

AB		<u>EQ 25MG BASE</u>	<u>A075520</u>	<u>003</u>	May 08, 2000

AB		<u>EQ 50MG BASE</u>	<u>A075520</u>	<u>001</u>	May 08, 2000

AB		<u>EQ 75MG BASE</u>	<u>A075520</u>	<u>002</u>	May 08, 2000

AB	TEVA	<u>EQ 10MG BASE</u>	<u>A074132</u>	<u>001</u>	Mar 27, 1995

AB		<u>EQ 25MG BASE</u>	<u>A074132</u>	<u>002</u>	Mar 27, 1995

AB		<u>EQ 50MG BASE</u>	<u>A074132</u>	<u>003</u>	Mar 27, 1995

AB		<u>EQ 75MG BASE</u>	<u>A074132</u>	<u>004</u>	Mar 27, 1995

AB	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A073553</u>	<u>001</u>	Mar 30, 1992

AB		<u>EQ 25MG BASE</u>	<u>A073554</u>	<u>001</u>	Mar 30, 1992

AB		<u>EQ 50MG BASE</u>	<u>A073555</u>	<u>001</u>	Mar 30, 1992

AB		<u>EQ 75MG BASE</u>	<u>A073556</u>	<u>001</u>	Mar 30, 1992

PAMELOR

AB	MALLINCKRODT LLC	<u>EQ 10MG BASE</u>	<u>N018013</u>	<u>001</u>	

AB		<u>EQ 25MG BASE</u>	<u>N018013</u>	<u>002</u>	

AB		<u>EQ 50MG BASE</u>	<u>N018013</u>	<u>004</u>	

AB	+	<u>EQ 75MG BASE</u>	<u>N018013</u>	<u>003</u>	

SOLUTION; ORAL

AVENTYL HYDROCHLORIDE

AA	+ RANBAXY	<u>EQ 10MG BASE/5ML</u>	<u>N014685</u>	<u>001</u>	

NORTRIPTYLINE HYDROCHLORIDE

AA	PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606</u>	<u>001</u>	Aug 28, 2000

AA	TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965</u>	<u>001</u>	Jun 20, 2006

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949</u>	<u>001</u>	Jun 13, 1988

AT	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129</u>	<u>001</u>	

AT	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225</u>	<u>001</u>	

AT	+	<u>100,000 UNITS/GM</u>	<u>A064022</u>	<u>001</u>	Jan 29, 1993

AT	VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315</u>	<u>001</u>	May 31, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-264 (of 362)

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840</u>	<u>001</u>	Nov 13, 1987
<u>AT</u>	+ FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124</u>	<u>002</u>	Sep 23, 1982
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	+ COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>	GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>	UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>	X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>	PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
<u>AA</u>	FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
<u>AA</u>	HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422</u>	<u>001</u>	Mar 07, 2011
<u>AA</u>	+ WOCKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474</u>	<u>001</u>	Dec 22, 1983
<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
<u>AA</u>	+ TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

	+ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	+ BEDFORD	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.2MG BASE/ML</u>	<u>A090986</u>	<u>001</u>	May 11, 2011
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A090986</u>	<u>002</u>	May 11, 2011

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	+ BEDFORD	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-265 (of 362)

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457 002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457 003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198 001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198 002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198 003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834 002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834 003</u>	Nov 12, 2013
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.05MG BASE/ML</u>	<u>A090985 001</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090985 002</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090985 003</u>	May 11, 2011

SANDOSTATIN

<u>AP</u>	+	NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667 001</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.1MG BASE/ML</u>	<u>N019667 002</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.2MG BASE/ML</u>	<u>N019667 004</u>	Jun 12, 1991
<u>AP</u>	+		<u>EQ 0.5MG BASE/ML</u>	<u>N019667 003</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 1MG BASE/ML</u>	<u>N019667 005</u>	Jun 12, 1991
		SANDOSTATIN LAR			
		NOVARTIS	EQ 10MG BASE/VIAL	N021008 001	Nov 25, 1998
			EQ 20MG BASE/VIAL	N021008 002	Nov 25, 1998
		+	EQ 30MG BASE/VIAL	N021008 003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+	ALLERGAN	<u>0.3%</u>	<u>N019921 001</u>	Jul 30, 1993

OFLOXACIN

<u>AT</u>		AKORN	<u>0.3%</u>	<u>A076407 001</u>	Apr 15, 2008
<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A076231 001</u>	May 14, 2004
<u>AT</u>		ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692 001</u>	Apr 29, 2013
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622 001</u>	May 14, 2004
<u>AT</u>		FDC LTD	<u>0.3%</u>	<u>A078559 001</u>	Feb 25, 2009
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A076830 001</u>	Aug 31, 2004
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076615 001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+	DAIICHI	<u>0.3%</u>	<u>N020799 001</u>	Dec 16, 1997

OFLOXACIN

<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A078222 001</u>	Mar 17, 2008
<u>AT</u>		APOTEX INC	<u>0.3%</u>	<u>A076527 001</u>	Sep 28, 2007
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128 001</u>	Mar 17, 2008
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A090395 001</u>	Aug 11, 2009
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076616 001</u>	Mar 17, 2008

TABLET; ORAL

OFLOXACIN

<u>AB</u>		DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098 001</u>	Feb 10, 2006
<u>AB</u>			<u>300MG</u>	<u>A077098 002</u>	Feb 10, 2006
<u>AB</u>			<u>400MG</u>	<u>A077098 003</u>	Feb 10, 2006
<u>AB</u>		TEVA	<u>200MG</u>	<u>A076182 001</u>	Sep 02, 2003
<u>AB</u>			<u>300MG</u>	<u>A076182 002</u>	Sep 02, 2003
<u>AB</u>	+		<u>400MG</u>	<u>A076182 003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>		LUITPOLD	<u>10MG/VIAL</u>	<u>A201741 001</u>	Mar 20, 2012
<u>AP</u>		SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588 001</u>	Oct 24, 2011

ZYPREXA

<u>AP</u>	+	LILLY	<u>10MG/VIAL</u>	<u>N021253 001</u>	Mar 29, 2004

TABLET; ORAL

OLANZAPINE

<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A090798 001</u>	Apr 23, 2012
<u>AB</u>			<u>5MG</u>	<u>A090798 002</u>	Apr 23, 2012
<u>AB</u>			<u>7.5MG</u>	<u>A090798 003</u>	Apr 23, 2012
<u>AB</u>			<u>10MG</u>	<u>A090798 004</u>	Apr 23, 2012
<u>AB</u>			<u>15MG</u>	<u>A090798 005</u>	Apr 23, 2012
<u>AB</u>			<u>20MG</u>	<u>A090798 006</u>	Apr 23, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050 001</u>	Apr 23, 2012
<u>AB</u>			<u>5MG</u>	<u>A202050 002</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-266 (of 362)

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>7.5MG</u>	<u>A202050</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	JUBILANT ORGANOSYS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-267 (of 362)

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011

ZYPREXA ZYDIS

<u>AB</u>	+	LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u>	Apr 06, 2000
<u>AB</u>			<u>10MG</u>	<u>N021086</u>	<u>002</u>	Apr 06, 2000
<u>AB</u>			<u>15MG</u>	<u>N021086</u>	<u>003</u>	Apr 06, 2000
<u>AB</u>			<u>20MG</u>	<u>N021086</u>	<u>004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ZYPREXA RELPREVV

	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLIVE OIL; SOYBEAN OIL

INJECTABLE; INJECTION

CLINOLIPID 20%

+	BAXTER HLTHCARE	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

	DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002
		20MG	N021286	003	Apr 25, 2002
+		40MG	N021286	004	Apr 25, 2002

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PATADAY

+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004

PATANOL

+	ALCON	EQ 0.1% BASE	N020688	001	Dec 18, 1996

SPRAY, METERED; NASAL

PATANASE

+	ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+	MEDA PHARMS	250MG	N019715	001	Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+	IVAX INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076048</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A076048</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A076048</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A075576</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A078490</u>	<u>002</u>	Mar 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A075576</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A078490</u>	<u>003</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>		<u>40MG</u>	<u>A078490</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>A075410</u>	<u>001</u>	Nov 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-268 (of 362)

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>		<u>20MG</u>	<u>A075410</u>	<u>002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410</u>	<u>003</u>	Jan 23, 2009
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876</u>	<u>001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876</u>	<u>002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757</u>	<u>001</u>	Jan 28, 2003
<u>AB</u>		<u>20MG</u>	<u>A075757</u>	<u>002</u>	Jan 28, 2003
<u>AB</u>		<u>40MG</u>	<u>A076515</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A075347</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347</u>	<u>003</u>	May 30, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352</u>	<u>003</u>	Nov 19, 2012

PRIOSEC

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N019810</u>	<u>003</u>	Oct 05, 1995
<u>AB</u>	+	<u>20MG</u>	<u>N019810</u>	<u>001</u>	Sep 14, 1989
<u>AB</u>	+	<u>40MG</u>	<u>N019810</u>	<u>002</u>	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRIOSEC

	ASTRAZENECA	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966</u>	<u>001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966</u>	<u>002</u>	May 25, 2010
<u>AB</u>					
<u>AB</u>					
<u>AB</u>	SALIX PHARMS INC	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	PAR PHARM	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>002</u>	Apr 19, 2013
<u>AB</u>					
<u>AB</u>					
<u>AB</u>	SALIX PHARMS INC	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>001</u>	Jun 15, 2004
<u>AB</u>	+	<u>40MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>002</u>	Dec 21, 2004

ONDANSETRON

FILM;ORAL

ZUPLENZ

	VESTIQ PHARMS	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	RANBAXY	<u>4MG</u>	<u>A078602</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602</u>	<u>002</u>	Feb 24, 2011
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810</u>	<u>002</u>	Jun 25, 2007

ZOFRAN ODT

<u>AB</u>	GLAXOSMITHKLINE	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-269 (of 362)

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	AGILA SPECILTS	<u>EQ 2MG BASE/ML</u>	<u>A078257</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>	BEDFORD	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 2MG BASE/ML</u>	<u>A078288</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424</u>	<u>001</u>	Apr 16, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090648</u>	<u>001</u>	Jun 15, 2012
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA MAPLE	<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840</u>	<u>001</u>	Jan 19, 2007
<u>AP</u>	LANNETT	<u>EQ 2MG BASE/ML</u>	<u>A090116</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090883</u>	<u>001</u>	Aug 05, 2010
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079039</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS (IN)	<u>EQ 2MG BASE/ML</u>	<u>A077172</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AGILA SPECILTS	<u>EQ 2MG BASE/ML</u>	<u>A078244</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>	BD RX	<u>EQ 2MG BASE/ML</u>	<u>A202253</u>	<u>001</u>	Jul 19, 2013
<u>AP</u>	BEDFORD LABS	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 2MG BASE/ML</u>	<u>A078287</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945</u>	<u>001</u>	Jan 03, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA MAPLE	<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014</u>	<u>001</u>	Mar 21, 2008
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>001</u>	Jan 04, 1991

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>003</u>	Dec 10, 1993

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539</u>	<u>003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112</u>	<u>001</u>	Jun 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-270 (of 362)

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252</u>	<u>003</u>	Jun 25, 2007
<u>ZOFRAN</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 24MG BASE</u>	<u>N020103</u>	<u>003</u>	Aug 27, 1999
	ONDANSETRON HYDROCHLORIDE				
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006

ORLISTAT

CAPSULE; ORAL

XENICAL

+ HOFFMANN LA ROCHE

120MG

N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

<u>AP</u>	+	MEDICIS	<u>30MG/ML</u>	<u>N013055</u>	<u>001</u>

ORPHENADRINE CITRATE

<u>AP</u>		AKORN	<u>30MG/ML</u>	<u>A040484</u>	<u>001</u>	May 24, 2006
<u>AP</u>		BEDFORD LABS	<u>30MG/ML</u>	<u>A040463</u>	<u>001</u>	Mar 04, 2003
<u>AP</u>		SAGENT PHARMS	<u>30MG/ML</u>	<u>A090585</u>	<u>001</u>	Aug 30, 2011
<u>AP</u>		WATSON LABS	<u>30MG/ML</u>	<u>A084779</u>	<u>001</u>	Mar 15, 1982
<u>AP</u>			<u>30MG/ML</u>	<u>A087062</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>		GAVIS PHARMS	<u>100MG</u>	<u>A040284</u>	<u>001</u>	Jun 19, 1998
<u>AB</u>		IMPAX PHARMS	<u>100MG</u>	<u>A040368</u>	<u>001</u>	Jun 23, 2000
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A091158</u>	<u>001</u>	Jul 27, 2012
<u>AB</u>	+	SANDOZ	<u>100MG</u>	<u>A040327</u>	<u>001</u>	Feb 15, 2000
<u>AB</u>		TEDOR PHARMA INC	<u>100MG</u>	<u>A040249</u>	<u>001</u>	Jan 29, 1999

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

ROCHE

EQ 30MG BASE

N021087 003 Jul 02, 2007

EQ 45MG BASE

N021087 002 Jul 02, 2007

+

EQ 75MG BASE

N021087 001 Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE

EQ 6MG BASE/ML

N021246 002 Mar 21, 2011

OSPEMIFENE

TABLET; ORAL

OSPHEA

+ SHIONOGI INC

60MG

N203505 001 Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539</u>	<u>001</u>	Jan 18, 2013
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A201539</u>	<u>002</u>	Jan 18, 2013
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A201538</u>	<u>001</u>	Jan 18, 2013
<u>AP</u>		SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246</u>	<u>001</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091246</u>	<u>002</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091245</u>	<u>001</u>	Mar 30, 2012
<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061490</u>	<u>003</u>	
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A062737</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A061490</u>	<u>004</u>	
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A062737</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A061490</u>	<u>006</u>	May 09, 1991
		BACTOCILL IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-271 (of 362)

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759</u>	<u>001</u>	Jan 31, 2005
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N021759</u>	<u>002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>		ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078803</u>	<u>002</u>	Aug 08, 2012
<u>AP</u>		EBEWE PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A078812</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078812</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>		FRESENIUS KABI ONCOL	<u>50MG/10ML (5MG/ML)</u>	<u>A078811</u>	<u>001</u>	Jun 10, 2010
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078811</u>	<u>002</u>	Jun 10, 2010
<u>AP</u>			<u>50MG/VIAL</u>	<u>A078810</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078810</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>		FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A078819</u>	<u>001</u>	Jun 02, 2010
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078819</u>	<u>002</u>	Jun 02, 2010
<u>AP</u>		HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078815</u>	<u>002</u>	Sep 30, 2009
<u>AP</u>		HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>		ONCO THERAPIES LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358</u>	<u>001</u>	Aug 07, 2012
<u>AP</u>			<u>50MG/VIAL</u>	<u>A200979</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A091358</u>	<u>002</u>	Aug 07, 2012
<u>AP</u>			<u>100MG/VIAL</u>	<u>A200979</u>	<u>002</u>	Aug 08, 2012
<u>AP</u>		SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817</u>	<u>001</u>	Jan 24, 2011
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078817</u>	<u>002</u>	Jan 24, 2011
<u>AP</u>	+	SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+		<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	+	TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
		ELOXATIN				
	+	SANOFI AVENTIS US	<u>200MG/40ML (5MG/ML)</u>	<u>N021759</u>	<u>003</u>	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>		SAVIENT PHARMS	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001

OXANDROLONE

<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>			<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>		UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>			<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+	GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992

OXAPROZIN

<u>AB</u>		APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>		CARACO	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>		DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>		SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>		TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		WATSON LABS	<u>600MG</u>	<u>A075848</u>	<u>001</u>	Feb 09, 2001

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>			<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	+		<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A070943</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>			<u>15MG</u>	<u>A070944</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>			<u>30MG</u>	<u>A070945</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>		SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>			<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>			<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A072952</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>			<u>15MG</u>	<u>A072953</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>			<u>30MG</u>	<u>A072954</u>	<u>001</u>	Sep 28, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-272 (of 362)

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961</u>	<u>001</u>	Sep 17, 2012
AB	RANBAXY	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
AB	ROXANE	<u>300MG/5ML</u>	<u>A201193</u>	<u>001</u>	Oct 03, 2012

TRILEPTAL

AB	+ NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

AB	APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
AB		<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
AB		<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
AB	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
AB		<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
AB		<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
AB	CADISTA PHARMS	<u>150MG</u>	<u>A090239</u>	<u>001</u>	Jan 25, 2010
AB		<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
AB		<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
AB	GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
AB		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
AB		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
AB	ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
AB		<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
AB		<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
AB	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
AB		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
AB		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
AB	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
AB		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
AB		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007

TRILEPTAL

AB	NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
AB		<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
AB	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
	300MG	N202810	002	Oct 19, 2012
+	600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+ FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988

LOTION; TOPICAL

OXISTAT

+ FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
+	600MG	A086742	001	

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+ WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003

GEL, METERED; TRANSDERMAL

GELNIQUE 3%

+ WATSON LABS INC	3%	N202513	001	Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS	10% (100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

AA	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
AA	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
AA	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004
AA	+ WOCKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-273 (of 362)

OXYBUTYNIN CHLORIDE

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	+ VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644</u>	<u>002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	+ LEHIGH VALLEY	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	ROXANE	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	+ VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN INC	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-274 (of 362)

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>30MG</u>	<u>A077712</u>	<u>002</u>	Jan 31, 2007

ROXICODONE

<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

OXECTA

KING PHARMS R AND D

5MG

N202080 001

Jun 17, 2011

7.5MG

N202080 002

Jun 17, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

PURDUE PHARMA LP

10MG

N022272 001

Apr 05, 2010

15MG

N022272 002

Apr 05, 2010

20MG

N022272 003

Apr 05, 2010

30MG

N022272 004

Apr 05, 2010

+

40MG

N022272 005

Apr 05, 2010

60MG

N022272 006

Apr 05, 2010

80MG

N022272 007

Apr 05, 2010

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+ MEDA PHARMS

50MG

N016848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

+ ENDO PHARMS

1MG/ML

N011707 002

TABLET; ORAL

OPANA

<u>AB</u>	ENDO PHARMS	<u>5MG</u>	<u>N021611</u>	<u>001</u>	Jun 22, 2006
<u>AB</u>	+	<u>10MG</u>	<u>N021611</u>	<u>002</u>	Jun 22, 2006

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A203601</u>	<u>001</u>	Jan 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A203601</u>	<u>002</u>	Jan 30, 2013
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A202321</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A202321</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A090964</u>	<u>001</u>	Sep 27, 2010
<u>AB</u>		<u>10MG</u>	<u>A090964</u>	<u>002</u>	Sep 27, 2010
<u>AB</u>	TEVA	<u>5MG</u>	<u>A091443</u>	<u>002</u>	Feb 15, 2011
<u>AB</u>		<u>10MG</u>	<u>A091443</u>	<u>001</u>	Feb 15, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A079046</u>	<u>003</u>	Jul 11, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A079046</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>10MG</u>	<u>A079046</u>	<u>004</u>	Jul 11, 2013
<u>AB</u>		<u>15MG</u>	<u>A079046</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>20MG</u>	<u>A079046</u>	<u>005</u>	Jul 11, 2013
<u>AB</u>		<u>30MG</u>	<u>A079046</u>	<u>006</u>	Jul 11, 2013
<u>AB</u>		<u>40MG</u>	<u>A079046</u>	<u>007</u>	Jul 11, 2013
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A079087</u>	<u>001</u>	Jun 14, 2010
<u>AB</u>		<u>7.5MG</u>	<u>A079087</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>10MG</u>	<u>A079087</u>	<u>003</u>	Jun 14, 2010
<u>AB</u>		<u>15MG</u>	<u>A079087</u>	<u>004</u>	Dec 21, 2010
<u>AB</u>		<u>20MG</u>	<u>A079087</u>	<u>005</u>	Jun 14, 2010
<u>AB</u>		<u>30MG</u>	<u>A079087</u>	<u>006</u>	Jul 22, 2010
<u>AB</u>		<u>40MG</u>	<u>A079087</u>	<u>007</u>	Jun 14, 2010
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A200822</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200822</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>10MG</u>	<u>A200822</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>		<u>15MG</u>	<u>A200822</u>	<u>005</u>	Jul 15, 2013
<u>AB</u>		<u>20MG</u>	<u>A200822</u>	<u>006</u>	Jul 15, 2013
<u>AB</u>		<u>30MG</u>	<u>A200822</u>	<u>007</u>	Jul 15, 2013
<u>AB</u>		<u>40MG</u>	<u>A200822</u>	<u>001</u>	Jul 15, 2013

OPANA ER

ENDO PHARMS

5MG

N201655 001

Dec 09, 2011

7.5MG

N201655 002

Dec 09, 2011

10MG

N201655 003

Dec 09, 2011

15MG

N201655 004

Dec 09, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-275 (of 362)

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

20MG

N201655 005 Dec 09, 2011

30MG

N201655 006 Dec 09, 2011

+

40MG

N201655 007 Dec 09, 2011

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER

EQ 5MG BASE/GM; 10,000 UNITS/GM

A061015 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCINAP + BAXTER HLTHCARE CORP10USP UNITS/ML (10USP UNITS/ML)N018243 001AP

+

100USP UNITS/10ML (10USP UNITS/ML)N018243 002

Jan 10, 2007

AP

+

FRESENIUS KABI USA

10USP UNITS/ML (10USP UNITS/ML)N018248 001AP

+

HIKMA FARMACEUTICA

100USP UNITS/10ML (10USP UNITS/ML)N018248 002AP

+

HIKMA FARMACEUTICA

10USP UNITS/ML (10USP UNITS/ML)A200219 001

Feb 13, 2013

PITOCINAP + JHP PHARMS10USP UNITS/ML (10USP UNITS/ML)N018261 001AP

+

JHP PHARMS

100USP UNITS/10ML (10USP UNITS/ML)N018261 002

Jul 27, 2007

OXYTOCIN

+ FRESENIUS KABI USA

300USP UNITS/30ML (10USP UNITS/ML)

N018248 003 Jul 27, 2007

PITOCIN

JHP PHARMS

500USP UNITS/50ML (10USP UNITS/ML)

N018261 003 Sep 05, 2012

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE

100MG/VIAL

N021660 001 Jan 07, 2005

INJECTABLE; INJECTION

PACLITAXELAP ACTAVIS TOTOWA6MG/MLA090130 001

Dec 09, 2009

AP

+

BEDFORD

6MG/MLA075190 001

Jan 28, 2002

AP

+

EBEWE PHARMA

6MG/MLA078167 001

Dec 26, 2007

AP

+

FRESENIUS KABI ONCOL

6MG/MLA077574 001

Nov 27, 2006

AP

+

HOSPIRA

6MG/MLA076131 001

May 08, 2002

AP

+

MYLAN

6MG/MLA075278 001

Jan 25, 2002

AP

+

ONCO THERAPIES LTD

6MG/MLA091540 001

Sep 29, 2011

AP

+

TEVA PHARMS

6MG/MLA075184 001

Jan 25, 2002

TAXOLAP HQ SPCLT PHARMA6MG/MLN020262 001

Dec 29, 1992

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS

1.5MG

N021999 006 Aug 26, 2008

3MG

N021999 001 Dec 19, 2006

+

6MG

N021999 002 Dec 19, 2006

9MG

N021999 003 Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

JANSSEN PHARMS

39MG/0.25ML (39MG/0.25ML)

N022264 001 Jul 31, 2009

78MG/0.5ML (78MG/0.5ML)

N022264 002 Jul 31, 2009

+

117MG/0.75ML (117MG/0.75ML)

N022264 003 Jul 31, 2009

156MG/ML (156MG/ML)

N022264 004 Jul 31, 2009

234MG/1.5ML (156MG/ML)

N022264 005 Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+ HELSINN HLTHCARE

EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

N021372 002 Feb 29, 2008

+

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N021372 001 Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUMAP AGILA SPECLTS30MG/10ML (3MG/ML)A078520 001

Oct 31, 2008

AP

+

AREVA PHARMS

90MG/10ML (9MG/ML)A078520 002

Oct 31, 2008

AP

+

AREVA PHARMS

30MG/VIALA077433 001

Nov 26, 2008

AP

+

AREVA PHARMS

60MG/VIALA077433 002

Nov 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-276 (of 362)

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>		<u>90MG/VIAL</u>	<u>A077433</u>	<u>003</u>	Nov 26, 2008
<u>AP</u>	BEDFORD	<u>30MG/VIAL</u>	<u>A075290</u>	<u>001</u>	Apr 30, 2001
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>N021113</u>	<u>001</u>	Mar 04, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075290</u>	<u>003</u>	Apr 30, 2001
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>N021113</u>	<u>002</u>	Mar 04, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>30MG/VIAL</u>	<u>A075773</u>	<u>001</u>	May 06, 2002
<u>AP</u>		<u>30MG/10ML (3MG/ML)</u>	<u>A076207</u>	<u>001</u>	May 17, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075773</u>	<u>002</u>	May 06, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076207</u>	<u>002</u>	May 17, 2002
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>A075841</u>	<u>001</u>	Jun 27, 2002
<u>AP</u>	+	<u>60MG/10ML (6MG/ML)</u>	<u>A075841</u>	<u>002</u>	Jun 27, 2002
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>A075841</u>	<u>003</u>	Jun 27, 2002
<u>AP</u>	LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942</u>	<u>001</u>	Jul 25, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078942</u>	<u>002</u>	Jul 25, 2008
<u>AP</u>	MN PHARMS	<u>30MG/VIAL</u>	<u>A078300</u>	<u>001</u>	Mar 10, 2009
<u>AP</u>		<u>90MG/VIAL</u>	<u>A078300</u>	<u>002</u>	Mar 10, 2009
<u>AP</u>	MUSTAFA NEVZAT	<u>30MG/10ML (3MG/ML)</u>	<u>A078373</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078373</u>	<u>002</u>	Dec 23, 2008
<u>AP</u>	PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156</u>	<u>001</u>	Aug 19, 2008
<u>AP</u>		<u>60MG/10ML (6MG/ML)</u>	<u>A078156</u>	<u>002</u>	Aug 19, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078156</u>	<u>003</u>	Aug 19, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077703</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	TEVA PHARMS USA	<u>30MG/10ML (3MG/ML)</u>	<u>A076153</u>	<u>001</u>	Mar 27, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076153</u>	<u>002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE	12,000USP UNITS\;38,000USP UNITS\;60,000USP UNITS\	N020725	002	Apr 30, 2009
	15,000USP UNITS\;3,000USP UNITS\;9,500USP UNITS\	N020725	004	Jul 12, 2011
	19,000USP UNITS\;30,000USP UNITS\;6,000USP UNITS\	N020725	001	Apr 30, 2009
	114,000USP UNITS;180,000USP UNITS;36,000USP UNITS	N020725	005	Mar 14, 2013
+	120,000USP UNITS\;24,000USP UNITS\;76,000USP UNITS\	N020725	003	Apr 30, 2009

PANCREAZE

JANSSEN PHARMS	10,000USP/ UNITS;17,500USP/ UNITS;4,200USP/ UNITS	N022523	001	Apr 12, 2010
	10,500USP/ UNITS;25,000USP/ UNITS;43,750USP/ UNITS	N022523	002	Apr 12, 2010
	16,800USP/ UNITS;40,000USP/ UNITS;70,000USP/ UNITS	N022523	004	Apr 12, 2010
+	21,000USP/ UNITS;37,000USP/ UNITS;61,000USP/ UNITS	N022523	003	Apr 12, 2010

PERTZYE

DIGESTIVE CARE INC	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175	001	May 17, 2012
+	60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175	002	May 17, 2012

ULTRESA

APTALIS PHARMA US	13,800USP UNITS;27,600USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012
	20,700USP UNITS;41,400USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012
+	23,000USP UNITS;46,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012

ZENPEP

APTALIS PHARMA US	10,000USP UNITS;16,000USP UNITS;3,000USP UNITS	N022210	005	Jun 15, 2011
	10,000USP UNITS;34,000USP UNITS;55,000USP UNITS	N022210	002	Aug 27, 2009
	15,000USP UNITS;51,000USP UNITS;82,000USP UNITS	N022210	003	Aug 27, 2009
	17,000USP UNITS;27,000USP UNITS;5,000USP UNITS	N022210	001	Aug 27, 2009
	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009
+	136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-277 (of 362)

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

TABLET;ORAL

VIOKACE

APTALIS PHARMA US 10440USPU;39150USPU;39150USPU
+ 20880USPU;78300USPU;78300USPU

N022542 001 Mar 01, 2012
N022542 002 Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

AP HOSPIRA 1MG/ML
AP + TEVA PHARMS USA 1MG/ML
AP + 2MG/ML

A072320 001 Jan 19, 1989
A072759 001 Jul 31, 1990
A072760 001 Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+ WYETH PHARMS INC EQ 40MG BASE

N022020 001 Nov 14, 2007

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUMAP AKORN INC EQ 40MG BASE/VIALA079197 001 Nov 08, 2012PROTONIX IVAP + WYETH PHARMS INC EQ 40MG BASE/VIALN020988 001 Mar 22, 2001

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUMAB ACTAVIS TOTOWA EQ 20MG BASEA090797 001 Feb 07, 2011AB EQ 40MG BASEA090797 002 Feb 07, 2011AB APOTEX INC EQ 20MG BASEA090807 001 May 02, 2012AB EQ 40MG BASEA090807 002 May 02, 2012AB AUROBINDO PHARMA LTD EQ 20MG BASEA202038 001 Sep 28, 2012AB EQ 40MG BASEA202038 002 Sep 28, 2012AB DR REDDYS LABS LTD EQ 20MG BASEA077619 001 Jan 19, 2011AB EQ 40MG BASEA077619 002 Jan 19, 2011AB JUBILANT ORGANOSYS EQ 20MG BASEA090901 001 Aug 30, 2011AB EQ 40MG BASEA090901 002 Aug 30, 2011AB KUDCO IRELAND EQ 20MG BASEA078281 001 Jan 20, 2011AB EQ 40MG BASEA078281 002 Jan 20, 2011AB MACLEODS PHARMS LTD EQ 20MG BASEA200821 001 Feb 16, 2012AB EQ 40MG BASEA200821 002 Feb 16, 2012AB MYLAN PHARMS INC EQ 20MG BASEA090970 001 Jan 19, 2011AB EQ 40MG BASEA090970 002 Jan 19, 2011AB RANBAXY LABS LTD EQ 20MG BASEA200794 001 May 02, 2012AB EQ 40MG BASEA200794 002 May 02, 2012AB SUN PHARMA GLOBAL EQ 20MG BASEA077058 001 Sep 10, 2007AB EQ 40MG BASEA077058 002 Sep 10, 2007AB TEVA EQ 20MG BASEA077056 001 Aug 02, 2007AB EQ 40MG BASEA077056 002 Aug 02, 2007AB TORRENT PHARMS EQ 20MG BASEA090074 001 Jan 19, 2011AB EQ 40MG BASEA090074 002 Jan 19, 2011AB WOCKHARDT EQ 20MG BASEA091231 001 Jan 19, 2011AB EQ 40MG BASEA091231 002 Jan 19, 2011PROTONIXAB WYETH PHARMS INC EQ 20MG BASEN020987 002 Jun 12, 2001AB + EQ 40MG BASEN020987 001 Feb 02, 2000PARICALCITOL

CAPSULE;ORAL

PARICALCITOLAB TEVA PHARMS USA 1MCGA090829 001 Sep 27, 2013AB 2MCGA090829 002 Sep 27, 2013AB 4MCGA090829 003 Sep 27, 2013ZEMPLARAB ABBVIE 1MCGN021606 001 May 26, 2005AB 2MCGN021606 002 May 26, 2005AB + 4MCGN021606 003 May 26, 2005

INJECTABLE;INJECTION

PARICALCITOLAP SANDOZ CANADA INC 0.002MG/MLA091108 001 Jul 27, 2011AP 0.005MG/MLA091108 002 Jul 27, 2011ZEMPLARAP + ABBVIE 0.002MG/MLN020819 002 Feb 01, 2000AP + 0.005MG/MLN020819 001 Apr 17, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-278 (of 362)

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	+	CARACO	<u>EQ 250MG BASE</u>	<u>A064171</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>		HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173</u>	<u>001</u>	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 10MG BASE/5ML</u>	<u>N020710</u>	<u>001</u>	Jun 25, 1997

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 10MG BASE</u>	<u>A075356</u>	<u>001</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075356</u>	<u>002</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A075356</u>	<u>003</u>	Jul 30, 2003
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A075356</u>	<u>004</u>	Jul 30, 2003
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078406</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078406</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078406</u>	<u>004</u>	Jul 25, 2007
<u>AB</u>		CARACO	<u>EQ 10MG BASE</u>	<u>A078194</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078194</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078194</u>	<u>003</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078194</u>	<u>004</u>	Jun 29, 2007
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A078902</u>	<u>001</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078902</u>	<u>002</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078902</u>	<u>003</u>	Mar 13, 2008
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078902</u>	<u>004</u>	Mar 13, 2008
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075716</u>	<u>002</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A075716</u>	<u>003</u>	Mar 08, 2004
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A075716</u>	<u>004</u>	Mar 08, 2004
<u>AB</u>		PROSAM LABS	<u>EQ 10MG BASE</u>	<u>A076968</u>	<u>001</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076968</u>	<u>002</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076968</u>	<u>003</u>	Jun 21, 2010
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076968</u>	<u>004</u>	Jun 21, 2010
<u>AB</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A076618</u>	<u>001</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076618</u>	<u>002</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076618</u>	<u>003</u>	Aug 15, 2005
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076618</u>	<u>004</u>	Aug 15, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A077584</u>	<u>002</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A077584</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077584</u>	<u>004</u>	Mar 07, 2007

PAXIL

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 10MG BASE</u>	<u>N020031</u>	<u>001</u>	Dec 29, 1992
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>N020031</u>	<u>002</u>	Dec 29, 1992
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>N020031</u>	<u>003</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020031</u>	<u>005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A077873</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>			<u>EQ 37.5MG BASE</u>	<u>A091427</u>	<u>001</u>	Apr 14, 2011

PAXIL CR

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 12.5MG BASE</u>	<u>N020936</u>	<u>001</u>	Feb 16, 1999
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>N020936</u>	<u>002</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 37.5MG BASE</u>	<u>N020936</u>	<u>003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

+ NOVEN THERAP

EQ 7.5MG BASE

N204516 001 Jun 28, 2013

TABLET; ORAL

PEXEVA

NOVEN THERAP

EQ 10MG BASE

N021299 001 Jul 03, 2003

EQ 20MG BASE

N021299 002 Jul 03, 2003

EQ 30MG BASE

N021299 003 Jul 03, 2003

+

EQ 40MG BASE

N021299 004 Jul 03, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-279 (of 362)

PASIREOTIDE DIASPARTATESOLUTION; SUBCUTANEOUS
SIGNIFOR

NOVARTIS

EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)

N200677 001 Dec 14, 2012

EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)

N200677 002 Dec 14, 2012

+

EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)

N200677 003 Dec 14, 2012

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+ GLAXOSMITHKLINE

EQ 200MG BASE

N022465 001 Oct 19, 2009

EQ 400MG BASE

N022465 002 Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ SIGMA TAU

250 UNITS/ML

N019818 001 Mar 21, 1990

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ VALEANT PHARMS LLC

EQ 0.3MG ACID/0.09ML

N021756 001 Dec 17, 2004

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN

10MG/VIAL

N021106 001 Mar 25, 2003

+

15MG/VIAL

N021106 002 Mar 25, 2003

+

20MG/VIAL

N021106 003 Mar 25, 2003

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY

EQ 100MG BASE/VIAL

N021462 002 Sep 07, 2007

+

EQ 500MG BASE/VIAL

N021462 001 Feb 04, 2004

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

ALAMAST

+ SANTEN

0.1%

N021079 001 Sep 24, 1999

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ ACTIENT PHARMS

20MG

N018976 004 Jan 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+ DENCO ASSET

1%

N020629 001 Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON

250MG

N019853 001

TABLET; ORAL

DEPEN

+ MEDA PHARMS

250MG

N019854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS

600,000 UNITS/ML

N050141 001

PERMAPEN

BC PFIZER

600,000 UNITS/ML

A060014 001

BICILLIN L-A

+ KING PHARMS

300,000 UNITS/ML

N050141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS

150,000 UNITS/ML; 150,000 UNITS/ML

N050138 002

+

300,000 UNITS/ML; 300,000 UNITS/ML

N050138 001

BICILLIN C-R 900/300

+ KING PHARMS

900,000 UNITS/2ML; 300,000 UNITS/2ML

N050138 003

PRESCRIPTION DRUG PRODUCT LIST

3-280 (of 362)

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u>	HANFORD GC	<u>5,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>002</u>	Jul 23, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>003</u>	Jul 23, 2009
<u>AP</u>	IBI	<u>5,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>001</u>	Aug 18, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>002</u>	Aug 18, 2009
<u>AP</u>	SANDOZ	<u>5,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>002</u>	Aug 30, 2002
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>003</u>	Aug 30, 2002

PFIZERPEN

<u>AP</u>	+ PFIZER	<u>5,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>002</u>	
<u>AP</u>	+	<u>20,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>003</u>	
	PENICILLIN G POTASSIUM				
	HANFORD GC	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
	+	40,000 UNITS/ML	N050638	002	Jun 25, 1990
	+	60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+	KING PHARMS	300,000 UNITS/ML	A060101	002	
+		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

+	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

<u>AA</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062981</u>	<u>001</u>	Feb 10, 1989
<u>AA</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062981</u>	<u>002</u>	Feb 10, 1989

PENICILLIN-VK

<u>AA</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A060456</u>	<u>001</u>	
<u>AA</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A060456</u>	<u>002</u>	

TABLET; ORAL

PENICILLIN V POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A065435</u>	<u>001</u>	Apr 29, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065435</u>	<u>002</u>	Apr 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062936</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062935</u>	<u>001</u>	Nov 23, 1988
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE</u>	<u>A090549</u>	<u>001</u>	Oct 11, 2013
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090549</u>	<u>002</u>	Oct 11, 2013
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064071</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A064071</u>	<u>002</u>	Nov 30, 1995

PENICILLIN-VK

<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A060711</u>	<u>002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A060711</u>	<u>003</u>	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

<u>AP</u>	+ FRESENIUS KABI USA	<u>300MG/VIAL</u>	<u>N019264</u>	<u>001</u>	Oct 16, 1984

PENTAMIDINE ISETHIONATE

<u>AP</u>	WATSON LABS	<u>300MG/VIAL</u>	<u>A074303</u>	<u>001</u>	Aug 17, 1995

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+	HOSPIRA	EQ 30MG BASE/ML	N016194	001	

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246	001	

PRESCRIPTION DRUG PRODUCT LIST

3-281 (of 362)

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JANSEN PHARMS

100MG

N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC10MG/VIALN020122 001 Oct 11, 1991PENTOSTATINAP BEDFORD LABS10MG/VIALA077841 001 Aug 07, 2007PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX400MGA075191 001 Jun 09, 1999AB IMPAX LABS400MGA075093 001 Aug 10, 1999AB MYLAN400MGA074425 001 Jul 08, 1997AB PLIVA400MGA074874 001 May 25, 1999AB VALEANT INTL400MGA075028 001 Jul 20, 1998AB WATSON LABS400MGA075107 001 Sep 04, 1998PENTOXILAB UPSHER SMITH400MGA074962 001 Mar 31, 1999TRENTALAB + SANOFI AVENTIS US400MGN018631 001 Aug 30, 1984PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

2MG

N202834 001 Oct 22, 2012

4MG

N202834 002 Oct 22, 2012

6MG

N202834 003 Oct 22, 2012

8MG

N202834 004 Oct 22, 2012

10MG

N202834 005 Oct 22, 2012

+

12MG

N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEONAB KOMA2MGN020184 001 Dec 30, 1993AB4MGN020184 002 Dec 30, 1993AB +8MGN020184 003 Dec 30, 1993PERINDOPRIL ERBUMINEAB APOTEX2MGA090463 001 Aug 30, 2010AB4MGA090463 002 Aug 30, 2010AB8MGA090463 003 Aug 30, 2010AB AUROBINDO PHARMA2MGA079070 001 Nov 10, 2009AB4MGA079070 002 Nov 10, 2009AB8MGA079070 003 Nov 10, 2009AB IVAX PHARMS2MGA078138 001 Nov 10, 2009AB4MGA078138 002 Nov 10, 2009AB8MGA078138 003 Nov 10, 2009AB LUPIN LTD2MGA078263 001 Jan 27, 2010AB4MGA078263 002 Jan 27, 2010AB8MGA078263 003 Jan 27, 2010AB ROXANE2MGA090072 001 Nov 10, 2009AB4MGA090072 002 Nov 10, 2009AB8MGA090072 003 Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITEAB + RENAISSANCE PHARMA5%N019855 001 Aug 25, 1989PERMETHRINAB ACTAVIS MID ATLANTIC5%A074806 001 Jan 23, 1998AB PERRIGO NEW YORK5%A076369 001 Apr 21, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-282 (of 362)

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089683</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>4MG</u>	<u>A089684</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>8MG</u>	<u>A089685</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	+	<u>16MG</u>	<u>A089686</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>		<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998
<u>AB</u>		<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC	VALEANT	105MG	A088021	001	Sep 21, 1982
BC	PHENDIMETRAZINE TARTRATE				
BC	+	105MG	N018074	001	

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	+	VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>
<u>AA</u>	KVK TECH	<u>35MG</u>	<u>A091042</u>	<u>001</u>	Aug 31, 2010
<u>AA</u>	MIKAH PHARMA	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008
<u>AA</u>	MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991
<u>AA</u>	SANDOZ	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+	PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>
<u>AB</u>	NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLIN

<u>AB</u>	+	WELLSPRING PHARM	<u>10MG</u>	<u>N008708</u>	<u>001</u>
<u>AB</u>	ROXANE	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>
<u>AA</u>	BARR	<u>15MG</u>	<u>A090591</u>	<u>001</u>	Mar 18, 2010
<u>AA</u>		<u>30MG</u>	<u>A090591</u>	<u>002</u>	Mar 18, 2010
<u>AA</u>	ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012
<u>AA</u>		<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012
<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>		<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		<u>30MG</u>	<u>A091359</u>	<u>001</u>	Jul 16, 2010
<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>	MUTUAL PHARM	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>	+	SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>
<u>AA</u>	+	<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	+	<u>30MG</u>	<u>A087190</u>	<u>001</u>	

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>
<u>AA</u>	BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
<u>AA</u>	CARACO	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
<u>AA</u>	ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>	LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>	MIRROR PHARMS	<u>37.5MG</u>	<u>A091451</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>	MUTUAL PHARM	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>	VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-283 (of 362)

PHENTERMINE HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011
	30MG	N202088	002	Jun 13, 2011
+	37.5MG	N202088	003	Mar 27, 2012

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
	EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
	EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
+	EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
+		EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP	BEDFORD	5MG/VIAL	A040235	001	Mar 11, 1998

REGITINE

AP	+	NOVARTIS	5MG/VIAL	N008278	003

ORAVerse

+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
+		10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	VINTAGE	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006

PROMETH VC PLAIN

AA	+	ACTAVIS MID ATLANTIC	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA	AMNEAL PHARMS	5MG/5ML; 6.25MG/5ML	A040902	001	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB	+	PARKE DAVIS	125MG/5ML	N008762	001

PHENYTOIN

AB	TARO	125MG/5ML	A040521	001	Mar 08, 2004

AB	VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001

AB		125MG/5ML	A040610	001	Aug 18, 2005

AB	WOCKHARDT	125MG/5ML	A040420	001	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

AB	+	PFIZER PHARMS	50MG	A084427	001

PHENYTOIN

AB	MYLAN PHARMS INC	50MG	A200691	001	Dec 26, 2012

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

AB	+	PARKE DAVIS	30MG EXTENDED	A084349	001

AB	+		100MG EXTENDED	A084349	002

EXTENDED PHENYTOIN SODIUM

AB	AMNEAL PHARMS NY	100MG EXTENDED	A040765	001	Nov 12, 2008

AB	MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998

AB	SUN PHARM INDS	200MG EXTENDED	A040731	001	Jun 30, 2008

AB		300MG EXTENDED	A040731	002	Jun 30, 2008

AB	SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006

AB	TARO	100MG EXTENDED	A040684	001	Sep 05, 2006

AB	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-284 (of 362)

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

AB	WOCKHARDT USA	100MG EXTENDED	A040732 001	Jan 30, 2008

PHENYTEK

AB	MYLAN	200MG EXTENDED	A040298 002	Dec 06, 2001

AB	+	300MG EXTENDED	A040298 003	Dec 06, 2001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	A084307 001

AP		HOSPIRA	50MG/ML	A089521 001 Mar 17, 1987

AP		LUITPOLD	50MG/ML	A040781 001 Dec 04, 2007

AP		X-GEN PHARMS	50MG/ML	A040573 001 Sep 13, 2006

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001

VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	A087954 001 Jul 25, 1983

+

A087955 001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

+

VALEANT PHARMS

5MG

N010104 003

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

+

ALCON

4%

N018796 001 Oct 01, 1984

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

ALCON RES

1%

N200890 001 Jun 22, 2010

2%

N200890 002 Jun 22, 2010

+

4%

N200890 003 Jun 22, 2010

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	COREPHARMA	5MG	A076746 001	Nov 16, 2004

AB	IMPAX LABS	5MG	A077248 001	Mar 31, 2006

AB		7.5MG	A077248 002	Mar 31, 2006

AB	LANNETT	5MG	A077220 001	Oct 14, 2005

AB		7.5MG	A077220 002	May 06, 2009

AB	ROXANE	5MG	A076963 001	Dec 22, 2004

AB		7.5MG	A076963 002	Feb 27, 2007

SALAGEN

AB	EISAI INC	5MG	N020237 001	Mar 22, 1994

AB	+	7.5MG	N020237 002	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+

VALEANT BERMUDA

1%

N021302 001 Dec 13, 2001

PIMOZIDE

TABLET; ORAL

ORAP

TEVA

1MG

N017473 003 Aug 27, 1997

+

2MG

N017473 001 Jul 31, 1984

PINDOLOL

TABLET; ORAL

PINDOLOL

MYLAN PHARMS INC

5MG

A074019 001 Sep 03, 1992

+

10MG

A074019 002 Sep 03, 1992

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB	TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999

AB		EQ 30MG BASE	N021073 002	Jul 15, 1999

AB	+	EQ 45MG BASE	N021073 003	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044 001	Feb 13, 2013

AB		EQ 30MG BASE	A200044 002	Feb 13, 2013

AB		EQ 45MG BASE	A200044 003	Feb 13, 2013

AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268 001	Feb 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-285 (of 362)

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A200268</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A200268</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE</u>	<u>A078383</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078383</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078383</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467</u>	<u>001</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202467</u>	<u>002</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202467</u>	<u>003</u>	Feb 06, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076801</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076801</u>	<u>003</u>	Aug 17, 2012
<u>AB</u>	SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078670</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078670</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	SYNTHON PHARMS	<u>EQ 15MG BASE</u>	<u>A078472</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078472</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078472</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210</u>	<u>001</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077210</u>	<u>002</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A077210</u>	<u>003</u>	Jan 10, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A091298</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A091298</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A091298</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	WATSON LABS	<u>EQ 15MG BASE</u>	<u>A076798</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076798</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076798</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202456</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202456</u>	<u>003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	IBI	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498</u>	<u>001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498</u>	<u>002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498</u>	<u>003</u>	May 23, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386</u>	<u>003</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>	IBI	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523</u>	<u>001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523</u>	<u>002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523</u>	<u>003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498</u>	<u>001</u>	May 31, 2011
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363</u>	<u>003</u>	Oct 21, 2010

ZOSYN

<u>AP</u>	+	WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684</u>	<u>001</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684</u>	<u>002</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684</u>	<u>003</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684</u>	<u>004</u>	Oct 22, 1993
<u>ZOSYN IN PLASTIC CONTAINER</u>						
	+	WYETH PHARMS INC	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998
	+		EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-286 (of 362)

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+ MEDICIS

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992

PIROXICAM

CAPSULE; ORAL

FELDENEAB PFIZER10MGN018147 002 Apr 06, 1982AB +20MGN018147 003 Apr 06, 1982PIROXICAMAB MUTUAL PHARM10MGA073535 001 Mar 12, 1993AB MYLAN10MGA074102 001 Jul 31, 1992AB20MGA074102 002 Jul 31, 1992AB NOSTRUM LABS10MGA074116 001 Jun 15, 1993AB20MGA074118 001 Jun 15, 1993AB TEVA10MGA074131 001 Dec 11, 1992AB20MGA074131 002 Dec 11, 1992AB WATSON LABS10MGA074287 001 May 16, 1996AB20MGA074460 001 Sep 29, 1995AB20MGA074287 002 May 16, 1996AB20MGA074460 002 Sep 29, 1995PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO

EQ 1MG BASE

N022363 001 Aug 03, 2009

EQ 2MG BASE

N022363 002 Aug 03, 2009

+

EQ 4MG BASE

N022363 003 Aug 03, 2009

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

+ GENZYME

24MG/1.2ML (20MG/ML)

N022311 001 Dec 15, 2008

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ WATSON PHARMS

0.5%

N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOXAT + WATSON PHARMS0.5%N019795 001 Dec 13, 1990PODOFILOXAT PADDOCK LLC0.5%A075600 001 Jan 29, 2002AT PRECISION DERMAT0.5%A090184 001 Jul 21, 2010POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

CHEMISCH FBRK KRSSLR

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

+

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

VARITHENA

+ PROVENIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAXAA KREMERS URBAN PHARMS17GM/SCOOPFULA076652 001 Jul 02, 2004POLYETHYLENE GLYCOL 3350AA BRECKENRIDGE PHARM17GM/SCOOPFULA077736 001 May 26, 2006AA NEXGEN PHARMA INC17GM/SCOOPFULA077706 001 Sep 27, 2006AA PADDOCK LLC17GM/SCOOPFULA077893 001 May 26, 2006POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKSAA PADDOCK LLC420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTA079232 001 Feb 25, 2010NULYTELYAA + BRAINTREE420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTN019797 001 Apr 22, 1991NULYTELY-FLAVOREDAA + BRAINTREE420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTN019797 002 Nov 18, 1994PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEAA MYLAN420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTA090409 001 Apr 02, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-287 (of 362)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

AA	NOVEL LABS INC	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	A090019 001	May 27, 2009

TRILYTE

AA	MEDA PHARMS	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	A076491 001	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

AA	+ BRAINTREE	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	N019011 001	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA	MYLAN	<u>236GM; 2.97GM; 6.74GM; 5.86GM; 22.74GM</u>	A090928 001	Jan 28, 2010

AA	NOVEL LABS INC	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	A090231 001	Jun 01, 2009

AA		<u>240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT</u>	A090186 001	Jun 01, 2009

COLYTE

	MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983 010	Jan 31, 1989

COLYTE WITH FLAVOR PACKS

	MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983 012	Oct 08, 1998

GOLYTELY

	+ BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011 002	Jun 02, 1992

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP	SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	A090110 001	Jun 29, 2011

POLYMYXIN B SULFATE

AP	+ BEDFORD	<u>EQ 500,000 U BASE/VIAL</u>	A060716 001	

AP	FRESENIUS KABI USA	<u>EQ 500,000 U BASE/VIAL</u>	A065372 001	Jan 10, 2008

AP	X GEN PHARMS	<u>EQ 500,000 U BASE/VIAL</u>	A063000 001	Sep 30, 1994

AP	XELLIA PHARMS APS	<u>EQ 500,000 U BASE/VIAL</u>	A202766 001	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT	+ ALLERGAN	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	N050567 001	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	A065006 001	Dec 17, 1998

AT	BAUSCH AND LOMB	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	A064120 001	Feb 14, 1997

AT	FALCON PHARMS	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	A064211 001	Apr 13, 1998

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

	CELGENE	1MG	N204026 001	Feb 08, 2013

		2MG	N204026 002	Feb 08, 2013

		3MG	N204026 003	Feb 08, 2013

		4MG	N204026 004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

	ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012

		EQ 45MG BASE	N203469 002	Dec 14, 2012

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+ CORNERSTONE THERAP	80MG/ML	N020744 001	Nov 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

	PINNACLE BIOLGS	75MG/VIAL	N020451 001	Dec 27, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-288 (of 362)

POSACONAZOLE

SUSPENSION; ORAL

NOXAFIL

+ SCHERING 40MG/ML

N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

+ MERCK SHARP DOHME 100MG

N205053 001 Nov 25, 2013

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA 2MEQ/ML

N018896 001 Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K**AB** NESHER PHARMS 8MEQ**N018238 001**MICRO-K 10**AB** NESHER PHARMS 10MEQ**N018238 002** May 14, 1984POTASSIUM CHLORIDE**AB** AMNEAL PHARMS 10MEQ**A202128 001** Feb 22, 2013**AB** ANCHEN PHARMS 8MEQ**A202886 001** Dec 26, 2013**AB** 10MEQ**A202886 002** Dec 26, 2013**AB** PADDOCK LLC 8MEQ**A200185 001** May 18, 2011**AB** 10MEQ**A200185 002** May 18, 2011**AB** WATSON LABS FLORIDA 8MEQ**A077419 001** Jun 02, 2008**AB** + 10MEQ**A077419 002** Jun 02, 2008

INJECTABLE; INJECTION

POTASSIUM CHLORIDE**AP** B BRAUN 2MEQ/ML**A085870 001****AP** BAXTER HLTHCARE 2MEQ/ML**A085499 001****AP** FRESenius KABI USA 2MEQ/ML**A080225 001****AP** + HOSPIRA 2MEQ/ML**A080205 001****AP** INTL MEDICATION 2MEQ/ML**A083163 001**POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 14.9MG/ML**N019904 001** Dec 26, 1989**AP** + 746MG/100ML**N019904 005** Dec 17, 1990**AP** HOSPIRA 14.9MG/ML**N020161 005** Nov 30, 1992**AP** 745MG/100ML**N020161 001** Nov 30, 1992POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 1.49GM/100ML**N019904 006** Dec 17, 1990**AP** + 29.8MG/ML**N019904 002** Dec 26, 1989**AP** HOSPIRA 1.49GM/100ML**N020161 002** Nov 30, 1992**AP** + 29.8MG/ML**N020161 006** Aug 11, 1998POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 2.24GM/100ML**N019904 003** Dec 26, 1989**AP** + HOSPIRA 2.24GM/100ML**N020161 003** Aug 11, 1998POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER**AP** + BAXTER HLTHCARE 2.98GM/100ML**N019904 004** Dec 26, 1989**AP** + HOSPIRA 2.98GM/100ML**N020161 004** Aug 11, 1998POTASSIUM CHLORIDE IN PLASTIC CONTAINER**AP** FRESenius KABI USA 2MEQ/ML**A088901 001** Jan 25, 1985**AP** 2MEQ/ML**A088908 001** Jan 25, 1985

POTASSIUM CHLORIDE

+ FRESenius KABI USA 3MEQ/ML

A080225 003

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10**AB** UPSHER SMITH LABS 10MEQ**A074726 002** Aug 09, 2000KLOR-CON M20**AB** + UPSHER SMITH LABS 20MEQ**A074726 001** Nov 20, 1998POTASSIUM CHLORIDE**AB** EURAND 20MEQ**A076368 001** Aug 18, 2004**AB** WATSON LABS FLORIDA 10MEQ**A075604 001** Apr 10, 2002**AB** 20MEQ**A075604 002** Apr 10, 2002

K-TAB

BC ABBVIE 20MEQ

N018279 003 Nov 25, 2013

KLOR-CON

BC + UPSHER-SMITH LABS 10MEQ

N019123 002 Apr 17, 1986

8MEQ

N019123 001 Apr 17, 1986

KLOR-CON M15

UPSHER SMITH LABS 15MEQ

A074726 003 Jun 06, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-289 (of 362)

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	149MG/100ML; 450MG/100ML	A078446	001	Sep 10, 2008

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	150MG/100ML; 900MG/100ML	N019708	004	Sep 29, 1989

AP	BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001	

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002	

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	149MG/100ML; 900MG/100ML	N019686	001	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	298MG/100ML; 900MG/100ML	N019686	002	Oct 17, 1988

	POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
	BAXTER HLTHCARE	224MG/100ML; 900MG/100ML	N017648	003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB	COREPHARMA	5MEQ	A077440	001	Jun 09, 2006

AB		10MEQ	A077440	002	Jun 09, 2006

UROCIT-K

AB	MISSION PHARMA	5MEQ	N019071	001	Aug 30, 1985

AB		10MEQ	N019071	002	Aug 31, 1992

	+	15MEQ	N019071	003	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

	+ ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009

	+	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

	+ MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983

PROTOPAM CHLORIDE

	+ BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

AB	BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997

AB	+	0.25MG	N020667	002	Jul 01, 1997

AB		0.5MG	N020667	006	Feb 12, 1998

AB		0.75MG	N020667	007	Jul 30, 2007

AB		1MG	N020667	003	Jul 01, 1997

AB		1.5MG	N020667	005	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010

AB		0.25MG	A091254	002	Nov 30, 2010

AB		0.5MG	A091254	003	Nov 30, 2010

AB		0.75MG	A091254	004	Nov 30, 2010

AB		1MG	A091254	005	Nov 30, 2010

AB		1.5MG	A091254	006	Nov 30, 2010

AB	ALEMBIC LTD	0.125MG	A078894	001	Oct 08, 2010

AB		0.25MG	A078894	002	Oct 08, 2010

AB		0.5MG	A078894	003	Oct 08, 2010

AB		1MG	A078894	004	Oct 08, 2010

AB		1.5MG	A078894	005	Oct 08, 2010

AB	APOTEX INC	0.125MG	A090151	001	Apr 30, 2012

AB		0.25MG	A090151	002	Apr 30, 2012

AB		0.5MG	A090151	003	Apr 30, 2012

AB		0.75MG	A090151	006	Apr 30, 2012

AB		1MG	A090151	004	Apr 30, 2012

AB		1.5MG	A090151	005	Apr 30, 2012

AB	AUROBINDO PHARMA LTD	0.125MG	A202633	001	Oct 26, 2012

AB		0.25MG	A202633	002	Oct 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-290 (of 362)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		0.5MG	A202633	003	Oct 26, 2012
AB		0.75MG	A202633	004	Oct 26, 2012
AB		1MG	A202633	005	Oct 26, 2012
AB		1.5MG	A202633	006	Oct 26, 2012
AB	BARR	0.125MG	A077724	001	Feb 19, 2008
AB		0.25MG	A077724	002	Feb 19, 2008
AB		0.5MG	A077724	003	Feb 19, 2008
AB		1MG	A077724	004	Feb 19, 2008
AB		1.5MG	A077724	005	Feb 19, 2008
AB	BRECKENRIDGE PHARM	0.125MG	A091450	001	Oct 08, 2010
AB		0.25MG	A091450	002	Oct 08, 2010
AB		0.5MG	A091450	003	Oct 08, 2010
AB		1MG	A091450	004	Oct 08, 2010
AB		1.5MG	A091450	005	Oct 08, 2010
AB	GLENMARK GENERICS	0.125MG	A090781	001	Oct 08, 2010
AB		0.25MG	A090781	002	Oct 08, 2010
AB		0.5MG	A090781	003	Oct 08, 2010
AB		1MG	A090781	004	Oct 08, 2010
AB		1.5MG	A090781	005	Oct 08, 2010
AB	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
AB		0.25MG	A202164	002	Sep 20, 2012
AB		0.5MG	A202164	003	Sep 20, 2012
AB		1MG	A202164	004	Sep 20, 2012
AB		1.5MG	A202164	005	Sep 20, 2012
AB	MYLAN	0.125MG	A077854	001	Oct 08, 2010
AB		0.25MG	A077854	002	Oct 08, 2010
AB		0.5MG	A077854	003	Oct 08, 2010
AB		0.75MG	A090764	001	Apr 09, 2010
AB		1MG	A077854	004	Oct 08, 2010
AB		1.5MG	A077854	005	Oct 08, 2010
AB	SANDOZ	0.125MG	A090190	001	Jul 06, 2010
AB		0.25MG	A090190	002	Jul 06, 2010
AB		0.5MG	A090190	003	Jul 06, 2010
AB		0.75MG	A090190	006	Oct 08, 2010
AB		1MG	A090190	004	Jul 06, 2010
AB		1.5MG	A090190	005	Jul 06, 2010
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
AB		0.25MG	A091683	002	Mar 27, 2013
AB		0.5MG	A091683	003	Mar 27, 2013
AB		0.75MG	A091683	004	Mar 27, 2013
AB		1MG	A091683	005	Mar 27, 2013
AB		1.5MG	A091683	006	Mar 27, 2013
AB	TEVA PHARMS	0.125MG	A090241	001	Oct 08, 2010
AB		0.25MG	A090241	002	Oct 08, 2010
AB		0.5MG	A090241	003	Oct 08, 2010
AB		0.75MG	A090241	004	Oct 08, 2010
AB		1MG	A090241	005	Oct 08, 2010
AB		1.5MG	A090241	006	Oct 08, 2010
AB	TORRENT PHARMS	0.125MG	A090865	001	Oct 08, 2010
AB		0.25MG	A090865	002	Oct 08, 2010
AB		0.5MG	A090865	003	Oct 08, 2010
AB		0.75MG	A090865	004	Oct 08, 2010
AB		1MG	A090865	005	Oct 08, 2010
AB		1.5MG	A090865	006	Oct 08, 2010
AB	WATSON LABS	0.125MG	A078551	001	Oct 08, 2010
AB		0.25MG	A078551	002	Oct 08, 2010
AB		0.5MG	A078551	003	Oct 08, 2010
AB		1MG	A078551	004	Oct 08, 2010
AB		1.5MG	A078551	005	Oct 08, 2010
AB	ZYDUS PHARMS USA INC	0.125MG	A078920	001	Jul 06, 2010
AB		0.25MG	A078920	002	Jul 06, 2010
AB		0.5MG	A078920	003	Jul 06, 2010
AB		1MG	A078920	004	Jul 06, 2010
AB		1.5MG	A078920	005	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010
		0.75MG	N022421	002	Feb 19, 2010
		1.5MG	N022421	003	Feb 19, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-291 (of 362)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

2.25MG

N022421 006 Jun 17, 2011

3MG

N022421 004 Feb 19, 2010

3.75MG

N022421 007 Jun 17, 2011

4.5MG

N022421 005 Feb 19, 2010

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

AMYLIN PHARMS LLC

EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)

N021332 002 Sep 25, 2007

+

EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)

N021332 003 Sep 25, 2007

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

ELI LILLY AND CO

EQ 5MG BASE

N022307 001 Jul 10, 2009

+

EQ 10MG BASE

N022307 002 Jul 10, 2009

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOLAB BRISTOL MYERS SQUIBB10MGN019898 002 Oct 31, 1991AB20MGN019898 003 Oct 31, 1991AB40MGN019898 004 Mar 22, 1993AB

+

80MGN019898 008 Dec 18, 2001PRAVASTATIN SODIUMAB APOTEX10MGA076341 001 Oct 23, 2006AB20MGA076341 002 Oct 23, 2006AB40MGA076341 003 Oct 23, 2006AB80MGA076341 004 Dec 28, 2007AB CIPLA LTD10MGA077904 001 Oct 23, 2006AB20MGA077904 002 Oct 23, 2006AB40MGA077904 003 Oct 23, 2006AB DR REDDYS LABS INC10MGA076714 001 Oct 23, 2006AB20MGA076714 002 Oct 23, 2006AB40MGA076714 003 Oct 23, 2006AB80MGA076714 004 Dec 28, 2007AB GLENMARK GENERICS10MGA077987 001 May 11, 2007AB20MGA077987 002 May 11, 2007AB40MGA077987 003 May 11, 2007AB80MGA077987 004 Dec 28, 2007AB LUPIN PHARMS10MGA077917 001 Jan 08, 2008AB20MGA077917 002 Jan 08, 2008AB40MGA077917 003 Jan 08, 2008AB80MGA077917 004 Jan 08, 2008AB MYLAN10MGA077013 001 Oct 23, 2006AB20MGA077013 002 Oct 23, 2006AB40MGA077013 003 Oct 23, 2006AB80MGA077013 004 Dec 28, 2007AB MYLAN PHARMS INC10MGA079187 001 May 27, 2010AB20MGA079187 002 May 27, 2010AB40MGA079187 003 May 27, 2010AB80MGA079187 004 May 27, 2010AB TEVA10MGA076056 001 Apr 24, 2006AB20MGA076056 002 Apr 24, 2006AB40MGA076056 003 Apr 24, 2006AB TEVA PHARMS80MGA077793 001 Jan 15, 2008AB10MGA076939 004 Oct 23, 2006AB20MGA076939 003 Oct 23, 2006AB40MGA076939 002 Oct 23, 2006AB80MGA076939 001 Dec 28, 2007AB ZYDUS PHARMS USA10MGA077751 001 Apr 30, 2008AB20MGA077751 002 Apr 30, 2008AB40MGA077751 003 Apr 30, 2008AB80MGA077751 004 Apr 30, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-292 (of 362)

PRAZICQUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE

600MG

N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESSAB PFIZEREQ 1MG BASEN017442 002AB +EQ 2MG BASEN017442 003ABEQ 5MG BASEN017442 001PRAZOSIN HYDROCHLORIDEAB IVAX SUB TEVA PHARMSEQ 1MG BASEA071994 001 Sep 12, 1988AB MYLANEQ 1MG BASEA072575 003 May 16, 1989ABEQ 2MG BASEA072575 002 May 16, 1989ABEQ 5MG BASEA072575 001 May 16, 1989AB TEVA PHARMSEQ 2MG BASEA071995 001 Sep 12, 1988ABEQ 5MG BASEA071745 001 Sep 12, 1988PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENTAB + VALEANT BERMUDA0.1%N020279 001 Oct 29, 1993PREDNICARBATEAB FOUGERA PHARMS0.1%A077287 001 Sep 19, 2006

OINTMENT; TOPICAL

DERMATOPAB + VALEANT BERMUDA0.1%N019568 001 Sep 23, 1991PREDNICARBATEAB FOUGERA PHARMS0.1%A077236 001 Mar 09, 2007PREDNISOLONE

SYRUP; ORAL

PREDNISOLONEAA ALPHARMA15MG/5MLA040323 001 May 13, 1999AA + HI TECH PHARMA CO15MG/5MLA040401 001 Feb 27, 2003AA PHARM ASSOC15MG/5MLA040399 001 Mar 05, 2003AA VINTAGE15MG/5MLA040775 001 Sep 21, 2007AA WOCKHARDT15MG/5MLA040313 001 Sep 10, 2003PRELONEAA TEVA15MG/5MLA089081 001 Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

+ WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

+ TARO

EQ 15MG BASE/5ML

N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPREDAB ALCON1%N017469 001PRED FORTEAB + ALLERGAN1%N017011 001

PRED MILD

+ ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN

0.2%; 10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN

0.2%; 10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPREDAA + CONCORDIA PHARMS INCEQ 15MG BASE/5MLA075117 001 Dec 14, 2000PEDIAPREDAA + SETON PHARMEQ 5MG BASE/5MLN019157 001 May 28, 1986PREDNISOLONE SODIUM PHOSPHATEAA AMNEAL PHARMSEQ 15MG BASE/5MLA078345 001 Mar 10, 2009AA HI TECH PHARMAEQ 5MG BASE/5MLA075183 001 Mar 26, 2003AA PADDOCK LLCEQ 5MG BASE/5MLA075988 001 May 25, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-293 (of 362)

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
<u>AA</u>	VINTAGE	<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009
<u>AA</u>	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004
+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010
+	PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
+		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

+	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

<u>AB</u>	CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N021959</u>	<u>001</u>	Jun 01, 2006
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>N021959</u>	<u>002</u>	Jun 01, 2006
<u>AB</u>	+	<u>EQ 30MG BASE</u>	<u>N021959</u>	<u>003</u>	Jun 01, 2006
<u>PREDNISOLONE SODIUM PHOSPHATE</u>					
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A202179</u>	<u>001</u>	Apr 10, 2013
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A202179</u>	<u>002</u>	Apr 10, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202179</u>	<u>003</u>	Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

<u>AT</u>	ALCON PHARMS LTD	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995
<u>VASOCIDIN</u>					
<u>AT</u>	+ NOVARTIS	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>N018988</u>	<u>001</u>	Aug 26, 1988

PREDNISONE

SOLUTION;ORAL

PREDNISONE

+	ROXANE	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISONE INTENSOL

+	ROXANE	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

PREDNISONE

<u>AB</u>	CONTRACT PHARMACAL	<u>5MG</u>	<u>A080209</u>	<u>001</u>	
<u>AB</u>	HIKMA PHARMS	<u>1MG</u>	<u>A040890</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>2.5MG</u>	<u>A040538</u>	<u>001</u>	Jan 08, 2004
<u>AB</u>		<u>5MG</u>	<u>A080292</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A088832</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A083677</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A088465</u>	<u>001</u>	Jun 01, 1984
<u>AB</u>	JUBILANT CADISTA	<u>1MG</u>	<u>A040611</u>	<u>001</u>	Jun 06, 2005
<u>AB</u>		<u>5MG</u>	<u>A040362</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>10MG</u>	<u>A040362</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	+ ROXANE	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A085161</u>	<u>001</u>	

TABLET, DELAYED RELEASE;ORAL

RAYOS

	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012
		2MG	N202020	002	Jul 26, 2012
+		5MG	N202020	003	Jul 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-294 (of 362)

PREGABALIN

CAPSULE; ORAL

LYRICA

<u>AB</u>	PF PRISM	<u>25MG</u>	<u>N021446</u>	<u>001</u>	Dec 30, 2004
<u>AB</u>		<u>50MG</u>	<u>N021446</u>	<u>002</u>	Dec 30, 2004
<u>AB</u>		<u>75MG</u>	<u>N021446</u>	<u>003</u>	Dec 30, 2004
<u>AB</u>		<u>100MG</u>	<u>N021446</u>	<u>004</u>	Dec 30, 2004
<u>AB</u>		<u>150MG</u>	<u>N021446</u>	<u>005</u>	Dec 30, 2004
<u>AB</u>		<u>200MG</u>	<u>N021446</u>	<u>006</u>	Dec 30, 2004
<u>AB</u>		<u>225MG</u>	<u>N021446</u>	<u>007</u>	Dec 30, 2004
<u>AB</u>	+	<u>300MG</u>	<u>N021446</u>	<u>008</u>	Dec 30, 2004

PREGABALIN

<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A091040</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091040</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091040</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091040</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091040</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091040</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091040</u>	<u>007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091040</u>	<u>008</u>	Jul 03, 2012
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A091219</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091219</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091224</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091224</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091224</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091224</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091224</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091224</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>	WATSON LABS INC	<u>25MG</u>	<u>A091221</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091221</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091221</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091221</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091221</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091221</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091221</u>	<u>007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091221</u>	<u>008</u>	Jul 03, 2012

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001	

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+	VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>
<u>AB</u>			<u>250MG</u>	<u>N009170</u>	<u>002</u>

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A040717</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>250MG</u>	<u>A040717</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-295 (of 362)

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>	LANNETT	500MG	<u>A080966</u>	<u>001</u>	

PROBENECID

<u>AB</u>	+	MYLAN	500MG	<u>A084211</u>	<u>002</u>

<u>AB</u>		WATSON LABS	500MG	<u>A084442</u>	<u>004</u>	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	100MG/ML	<u>A089069</u>	<u>001</u>	Feb 12, 1986

<u>AP</u>	+		500MG/ML	<u>A089070</u>	<u>001</u>	Feb 12, 1986

<u>AP</u>		INTL MEDICATION	100MG/ML	<u>A088636</u>	<u>001</u>	Jul 31, 1984

<u>AP</u>			500MG/ML	<u>A088637</u>	<u>001</u>	Jul 31, 1984

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+	SIGMA TAU	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>		PADDOCK LLC	25MG	<u>A040246</u>	<u>001</u>	Jun 28, 2000

PROCHLORPERAZINE

<u>AB</u>	+	G AND W LABS	25MG	<u>A040058</u>	<u>001</u>	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>		BEDFORD	EQ 5MG BASE/ML	<u>A040540</u>	<u>001</u>	May 28, 2004

<u>AP</u>		EMCURE PHARMS LTD	EQ 5MG BASE/ML	<u>A204147</u>	<u>001</u>	Oct 15, 2013

<u>AP</u>	+	HIKMA MAPLE	EQ 5MG BASE/ML	<u>A089903</u>	<u>001</u>	Aug 29, 1989

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>		MYLAN	EQ 5MG BASE	<u>A040185</u>	<u>002</u>	Oct 28, 1996

<u>AB</u>			EQ 10MG BASE	<u>A040185</u>	<u>001</u>	Oct 28, 1996

<u>AB</u>		SANDOZ	EQ 5MG BASE	<u>A040101</u>	<u>001</u>	Jul 19, 1996

<u>AB</u>	+		EQ 10MG BASE	<u>A040101</u>	<u>002</u>	Jul 19, 1996

<u>AB</u>		TEVA PHARMS	EQ 5MG BASE	<u>A040120</u>	<u>001</u>	Jul 11, 1996

<u>AB</u>			EQ 10MG BASE	<u>A040120</u>	<u>002</u>	Jul 11, 1996

PROCOMP

<u>AB</u>		JUBILANT CADISTA	EQ 5MG BASE	<u>A040268</u>	<u>001</u>	Feb 27, 1998

<u>AB</u>			EQ 10MG BASE	<u>A040268</u>	<u>002</u>	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>		BANNER PHARMACAPS	100MG	<u>A200900</u>	<u>001</u>	Aug 16, 2013

<u>AB</u>			200MG	<u>A200900</u>	<u>002</u>	Aug 16, 2013

<u>AB</u>		SOFGEN PHARMS	100MG	<u>A200456</u>	<u>001</u>	Sep 28, 2012

<u>AB</u>			200MG	<u>A200456</u>	<u>002</u>	Sep 28, 2012

<u>AB</u>		TEVA PHARMS	100MG	<u>A202121</u>	<u>001</u>	Feb 29, 2012

<u>AB</u>			200MG	<u>A202121</u>	<u>002</u>	Feb 29, 2012

PROMETRIUM

<u>AB</u>		ABBVIE INC	100MG	<u>N019781</u>	<u>001</u>	May 14, 1998

<u>AB</u>	+		200MG	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

		WATSON LABS	4%	N020701	001	Jul 31, 1997

+			8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>		FRESENIUS KABI USA	50MG/ML	<u>A075906</u>	<u>001</u>	Apr 25, 2001

<u>AO</u>		HIKMA FARMACEUTICA	50MG/ML	<u>A091033</u>	<u>001</u>	Oct 28, 2010

<u>AO</u>		LUITPOLD	50MG/ML	<u>A090845</u>	<u>001</u>	Jun 22, 2009

<u>AO</u>	+	WATSON LABS (UTAH)	50MG/ML	<u>N017362</u>	<u>002</u>	

INSERT; VAGINAL

ENDOMETRIN

+	FERRING	100MG	N022057	001	Jun 21, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-296 (of 362)

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	HIKMA MAPLE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>25MG/ML</u>	<u>A040372</u>	<u>001</u>	Jun 08, 2000
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A040515</u>	<u>001</u>	Mar 19, 2003
<u>AP</u>	+ TEVA PHARMS USA	<u>25MG/ML</u>	<u>A040454</u>	<u>001</u>	Aug 22, 2002
<u>AP</u>	+	<u>50MG/ML</u>	<u>A040454</u>	<u>002</u>	Aug 22, 2002
<u>AP</u>	WOCKHARDT	<u>25MG/ML</u>	<u>A040785</u>	<u>001</u>	Sep 26, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040785</u>	<u>002</u>	Sep 26, 2008
<u>AP</u>	X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>	WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

+ G AND W LABS

50MG

A087165 001 Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	CARACO	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	+ WOCKHARDT	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>	CARACO	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	EMCURE PHARMS USA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	IMPAX LABS	<u>12.5MG</u>	<u>A040724</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>25MG</u>	<u>A040724</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>		<u>50MG</u>	<u>A040791</u>	<u>001</u>	May 20, 2008
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040713</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A091054</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>		<u>25MG</u>	<u>A091054</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>		<u>50MG</u>	<u>A091054</u>	<u>003</u>	Aug 30, 2011
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084234</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-297 (of 362)

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

RYTHMOL SR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>		<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000

RYTHMOL

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151</u>	<u>001</u>	Nov 27, 1989
<u>AB</u>		<u>225MG</u>	<u>N019151</u>	<u>003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151</u>	<u>002</u>	Nov 27, 1989

PROPANTHELINE BROMIDE

TABLET;ORAL

PROPANTHELINE BROMIDE

+ ROXANE 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

<u>AT</u>	ALCON	<u>0.5%</u>	<u>A080027</u>	<u>001</u>	

OPHTHAINE

<u>AT</u>	+	APOTHECON	<u>0.5%</u>	<u>N008883</u>	<u>001</u>

OPHTHETIC

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N012583</u>	<u>001</u>

PROPARACAINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.5%</u>	<u>A040277</u>	<u>001</u>	Mar 16, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074</u>	<u>001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

<u>AB</u>	+	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N019627</u>	<u>002</u> Jun 11, 1996

PROPOFOL

<u>AB</u>	HOSPIRA	<u>10MG/ML</u>	<u>A077908</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>	TEVA PHARMS USA	<u>10MG/ML</u>	<u>A075102</u>	<u>001</u>	Jan 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

<u>AB</u>	AKRIMAX PHARMS	<u>60MG</u>	<u>N018553</u>	<u>004</u>	Mar 18, 1987
<u>AB</u>		<u>80MG</u>	<u>N018553</u>	<u>002</u>	Apr 19, 1983
<u>AB</u>		<u>120MG</u>	<u>N018553</u>	<u>003</u>	Apr 19, 1983
<u>AB</u>	+	<u>160MG</u>	<u>N018553</u>	<u>001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>		<u>80MG</u>	<u>A078494</u>	<u>002</u>	Aug 10, 2007
<u>AB</u>		<u>120MG</u>	<u>A078494</u>	<u>003</u>	Aug 10, 2007
<u>AB</u>		<u>160MG</u>	<u>A078494</u>	<u>004</u>	Aug 10, 2007
<u>AB</u>	APTALIS PHARMATECH	<u>60MG</u>	<u>A078703</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>		<u>80MG</u>	<u>A078703</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>		<u>120MG</u>	<u>A078703</u>	<u>003</u>	Jul 15, 2011
<u>AB</u>		<u>160MG</u>	<u>A078703</u>	<u>004</u>	Jul 15, 2011
<u>AB</u>	GLATT AIR	<u>60MG</u>	<u>A078065</u>	<u>001</u>	Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065</u>	<u>002</u>	Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065</u>	<u>003</u>	Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065</u>	<u>004</u>	Jan 26, 2007
<u>AB</u>	MYLAN	<u>60MG</u>	<u>A078022</u>	<u>001</u>	Feb 15, 2007
<u>AB</u>		<u>80MG</u>	<u>A078022</u>	<u>002</u>	Feb 15, 2007
<u>AB</u>		<u>120MG</u>	<u>A078022</u>	<u>003</u>	Feb 15, 2007
<u>AB</u>		<u>160MG</u>	<u>A078022</u>	<u>004</u>	Feb 15, 2007
<u>AB</u>	UPSHER SMITH	<u>60MG</u>	<u>A078311</u>	<u>001</u>	Mar 06, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-298 (of 362)

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>80MG</u>	<u>A078311</u>	<u>002</u>	Mar 06, 2009
<u>AB</u>		<u>120MG</u>	<u>A078311</u>	<u>003</u>	Mar 06, 2009
<u>AB</u>		<u>160MG</u>	<u>A078311</u>	<u>004</u>	Mar 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A090321</u>	<u>001</u>	Mar 25, 2011
<u>AB</u>		<u>80MG</u>	<u>A090321</u>	<u>002</u>	Mar 25, 2011
<u>AB</u>		<u>120MG</u>	<u>A090321</u>	<u>003</u>	Mar 25, 2011
<u>AB</u>		<u>160MG</u>	<u>A090321</u>	<u>004</u>	Mar 25, 2011
	INNOPRAN XL				
BX	GLAXOSMITHKLINE LLC	80MG	N021438	001	Mar 12, 2003
BX		120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>	+	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>N016419</u>	<u>001</u>	
<u>AP</u>		BEDFORD	<u>1MG/ML</u>	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

+	ROXANE	20MG/5ML	A070979	001	May 15, 1987
+		40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

INDERAL

<u>AB</u>		WYETH PHARMS INC	<u>40MG</u>	<u>N016418</u>	<u>002</u>	
<u>AB</u>			<u>60MG</u>	<u>N016418</u>	<u>009</u>	Oct 18, 1982
<u>AB</u>	+		<u>80MG</u>	<u>N016418</u>	<u>004</u>	

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>			<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>			<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>			<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>			<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>			<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>			<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>			<u>60MG</u>	<u>A070213</u>	<u>005</u>	Apr 08, 2011
<u>AB</u>			<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>			<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>			<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>			<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>			<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>		PLIVA	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>20MG</u>	<u>A071973</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>40MG</u>	<u>A071974</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>60MG</u>	<u>A071975</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	+		<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		VINTAGE PHARMS	<u>10MG</u>	<u>A070217</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>20MG</u>	<u>A070218</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>40MG</u>	<u>A070219</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>60MG</u>	<u>A070220</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>			<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+	DAVA PHARMS INC	N006188	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-299 (of 362)

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078913</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913</u>	<u>002</u>	Sep 16, 2008
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462</u>	<u>001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462</u>	<u>002</u>	May 03, 2010

VIVACTIL

<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644</u>	<u>001</u>	Aug 24, 1995
<u>AB</u>	+	<u>10MG</u>	<u>A073645</u>	<u>001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u>	<u>001</u>
<u>AB</u>		MIKART	<u>500MG</u>	<u>A081319</u>	<u>001</u>

Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830</u>	<u>001</u>

REGONOL

<u>AP</u>		SANDOZ	<u>5MG/ML</u>	<u>N017398</u>	<u>001</u>

SYRUP; ORAL

MESTINON

+	VALEANT PHARM INTL	60MG/5ML	N015193	001	

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>60MG</u>	<u>N009829</u>	<u>002</u>

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>

Apr 24, 2003

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+	VALEANT PHARMS LLC	180MG	N011665	001	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

+	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	AMEDRA PHARMS	25MG	N008578	001	

QUAZEPAM

TABLET; ORAL

DORAL

+	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	ACTAVIS GRP PTC	<u>EQ 25MG BASE</u>	<u>A201762</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201762</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201762</u>	<u>003</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201762</u>	<u>004</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201762</u>	<u>005</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201762</u>	<u>006</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201762</u>	<u>007</u>	Feb 27, 2013
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504</u>	<u>001</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201504</u>	<u>002</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201504</u>	<u>003</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201504</u>	<u>004</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201504</u>	<u>005</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201504</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201504</u>	<u>007</u>	Feb 12, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-300 (of 362)

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960 006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388 007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380 007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT LIFE	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323 001</u>	Mar 27, 2012
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A090120 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012
<u>SEROQUEL</u>				
<u>AB</u>	+ ASTRAZENECA	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-301 (of 362)

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

SEROQUEL XR

ASTRAZENECA

EQ 50MG BASE

N022047 001 May 17, 2007

EQ 150MG BASE

N022047 005 Aug 11, 2008

+

EQ 200MG BASE

N022047 002 May 17, 2007

EQ 300MG BASE

N022047 003 May 17, 2007

EQ 400MG BASE

N022047 004 May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRILAB PFIZER PHARMSEQ 5MG BASEN019885 001 Nov 19, 1991ABEQ 10MG BASEN019885 002 Nov 19, 1991ABEQ 20MG BASEN019885 003 Nov 19, 1991AB +EQ 40MG BASEN019885 004 Nov 19, 1991QUINAPRIL HYDROCHLORIDEAB AUROBINDO PHARMA LTDEQ 5MG BASEA202725 001 Apr 29, 2013ABEQ 10MG BASEA202725 002 Apr 29, 2013ABEQ 20MG BASEA202725 003 Apr 29, 2013ABEQ 40MG BASEA202725 004 Apr 29, 2013AB INVAGEN PHARMSEQ 5MG BASEA078457 001 Aug 24, 2007ABEQ 10MG BASEA078457 002 Aug 24, 2007ABEQ 20MG BASEA078457 003 Aug 24, 2007ABEQ 40MG BASEA078457 004 Aug 24, 2007AB LUPINEQ 5MG BASEA077690 001 Jun 20, 2006ABEQ 10MG BASEA077690 002 Jun 20, 2006ABEQ 20MG BASEA077690 003 Jun 20, 2006ABEQ 40MG BASEA077690 004 Jun 20, 2006AB MYLANEQ 5MG BASEA076694 001 Dec 23, 2004ABEQ 10MG BASEA076694 002 Dec 23, 2004ABEQ 20MG BASEA076694 003 Dec 23, 2004ABEQ 40MG BASEA076694 004 Dec 23, 2004AB RANBAXYEQ 5MG BASEA076607 001 Dec 15, 2004ABEQ 10MG BASEA076607 002 Dec 15, 2004ABEQ 20MG BASEA076607 003 Dec 15, 2004ABEQ 40MG BASEA076607 004 Dec 15, 2004AB SUN PHARM INDS LTDEQ 5MG BASEA090800 001 Jun 18, 2009ABEQ 10MG BASEA090800 002 Jun 18, 2009ABEQ 20MG BASEA090800 003 Jun 18, 2009ABEQ 40MG BASEA090800 004 Jun 18, 2009AB TEVAEQ 5MG BASEA075504 001 Aug 24, 2007ABEQ 10MG BASEA075504 002 Aug 24, 2007ABEQ 20MG BASEA075504 003 Aug 24, 2007ABEQ 40MG BASEA075504 004 Aug 24, 2007AB WATSON LABS FLORIDAEQ 5MG BASEA076049 001 Jan 14, 2005ABEQ 10MG BASEA076049 002 Jan 14, 2005ABEQ 20MG BASEA076049 003 Jan 14, 2005ABEQ 40MG BASEA076049 004 Jan 14, 2005QUINIDINE GLUCONATE

INJECTABLE;INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM

324MG

A089338 001 Feb 11, 1987

BX WATSON LABS

324MG

A087810 001 Sep 29, 1982

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATEAB MUTUAL PHARM200MGA081030 001 Apr 14, 1989AB300MGA081031 001 Apr 14, 1989AB SANDOZ200MGA088072 002AB300MGA088072 001 Sep 26, 1983AB + WATSON LABS200MGA083288 001AB +300MGA085583 001

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

+ TEVA PHARMS

300MG

A040045 001 Jun 30, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-302 (of 362)

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+	MUTUAL PHARM CO INC	324MG	N021799	001	Aug 12, 2005

QUININE SULFATE

AB		MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012

AB		TEVA PHARMS	324MG	A091661	001	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

EISAI INC

5MG

N204736 001 Mar 26, 2013

+

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

AB	+	EISAI INC	20MG	N020973	002	Aug 19, 1999

RABEPRAZOLE SODIUM

AB		DR REDDYS LABS LTD	20MG	A076824	001	Nov 08, 2013

AB		KREMERS URBAN DEV	20MG	A090678	001	Nov 08, 2013

AB		LUPIN LTD	20MG	A078964	001	Nov 08, 2013

AB		MYLAN PHARMS INC	20MG	A076885	001	Nov 08, 2013

AB		TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013

AB		TORRENT PHARMS LTD	20MG	A202376	001	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+ BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

+ LILLY

60MG

N020815 001 Dec 09, 1997

RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 400MG BASE

N022145 001 Oct 12, 2007

TABLET, CHEWABLE; ORAL

ISENTRESS

MERCK SHARP DOHME

EQ 25MG BASE

N203045 001 Dec 21, 2011

+

EQ 100MG BASE

N203045 002 Dec 21, 2011

RAMELTEON

TABLET; ORAL

RAMELTEON

AB		TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013

ROZEREM

AB	+	TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005

RAMIPRIL

CAPSULE; ORAL

ALTACE

AB		KING PHARMS	1.25MG	N019901	001	Jan 28, 1991

AB			2.5MG	N019901	002	Jan 28, 1991

AB			5MG	N019901	003	Jan 28, 1991

AB	+		10MG	N019901	004	Jan 28, 1991

RAMIPRIL

AB		APOTEX	1.25MG	A079116	001	Jun 20, 2008

AB			2.5MG	A079116	002	Jun 20, 2008

AB			5MG	A079116	003	Jun 20, 2008

AB			10MG	A079116	004	Jun 20, 2008

AB		AUROBINDO PHARMA LTD	1.25MG	A091604	001	Jun 08, 2011

AB			2.5MG	A091604	002	Jun 08, 2011

AB			5MG	A091604	003	Jun 08, 2011

AB			10MG	A091604	004	Jun 08, 2011

AB		DR REDDYS LABS LTD	1.25MG	A078191	001	Jun 18, 2008

AB			2.5MG	A078191	002	Jun 18, 2008

AB			5MG	A078191	003	Jun 18, 2008

AB			10MG	A078191	004	Jun 18, 2008

AB		INVAGEN PHARMS	1.25MG	A078745	001	Jun 18, 2008

AB			2.5MG	A078745	002	Jun 18, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-303 (of 362)

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

<u>AB</u>		<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>		<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>		<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>	ROXANE	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A077514</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077514</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077514</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077514</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A090650</u>	<u>001</u>	Jun 30, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090650</u>	<u>002</u>	Jun 30, 2011
<u>AB</u>		<u>5MG</u>	<u>A090650</u>	<u>003</u>	Jun 30, 2011
<u>AB</u>		<u>10MG</u>	<u>A090650</u>	<u>004</u>	Jun 30, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>10MG</u>	<u>A090697</u>	<u>004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>	BEN VENUE	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>	ZYDUS PHARMS USA INC	<u>25MG/ML</u>	<u>A091534</u>	<u>001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+	COVIS PHARMA	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623</u>	<u>001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	CARACO	<u>EQ 15MG BASE/ML</u>	<u>A091091</u>	<u>001</u>	Sep 20, 2011
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078</u>	<u>001</u>	Mar 22, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476</u>	<u>001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054</u>	<u>001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890</u>	<u>001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+	GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-304 (of 362)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824</u>	<u>001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824</u>	<u>002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	MYLAN	<u>EQ 150MG BASE</u>	<u>A074023</u>	<u>001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023</u>	<u>002</u>	Aug 22, 1997
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488</u>	<u>001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488</u>	<u>002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208</u>	<u>001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078701</u>	<u>001</u>	Nov 12, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208</u>	<u>002</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078701</u>	<u>002</u>	Dec 11, 2009
<u>ZANTAC 150</u>					
<u>AB</u>	GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703</u>	<u>001</u>	Jun 09, 1983
<u>ZANTAC 300</u>					
<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703</u>	<u>002</u>	Dec 09, 1985
TABLET, EFFERVESCENT; ORAL					
ZANTAC 25					
	+ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+ GILEAD	<u>1GM</u>	<u>N021526</u>	<u>001</u>	Feb 12, 2007
<u>AB</u>		<u>500MG</u>	<u>N021526</u>	<u>002</u>	Jan 27, 2006
<u>RANOLAZINE</u>					
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046</u>	<u>001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046</u>	<u>002</u>	Jul 29, 2013

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641</u>	<u>001</u>	May 16, 2006
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021641</u>	<u>002</u>	May 16, 2006
<u>RASAGILINE MESYLATE</u>					
<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950</u>	<u>001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950</u>	<u>002</u>	Sep 12, 2013
<u>AB</u>	WATSON LABS INC	<u>EQ 0.5MG BASE</u>	<u>A201823</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201823</u>	<u>002</u>	Jul 01, 2013

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+ ASTELLAS 0.4MG/5ML (0.08MG/ML)

N022161 001 Apr 10, 2008

REGORAFENIB

TABLET; ORAL

STIVARGA

+ BAYER HLTHCARE 40MG

N203085 001 Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

MYLAN INSTITUTIONAL EQ 1MG BASE/VIAL

N020630 001 Jul 12, 1996

EQ 2MG BASE/VIAL

N020630 002 Jul 12, 1996

+ EQ 5MG BASE/VIAL

N020630 003 Jul 12, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-305 (of 362)

REPAGLINIDE

TABLET; ORAL

PRANDIN

<u>AB</u>	NOVO NORDISK INC	<u>0.5MG</u>	<u>N020741</u>	<u>001</u>	Dec 22, 1997
<u>AB</u>		<u>1MG</u>	<u>N020741</u>	<u>002</u>	Dec 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>N020741</u>	<u>003</u>	Dec 22, 1997
<u>REPAGLINIDE</u>					
<u>AB</u>	CARACO	<u>1MG</u>	<u>A077571</u>	<u>002</u>	Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571</u>	<u>003</u>	Jul 11, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252</u>	<u>001</u>	Aug 23, 2013
<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189</u>	<u>001</u>	Jul 17, 2013
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078555</u>	<u>001</u>	Nov 22, 2013

RESERPINE

TABLET; ORAL

RESERPINE

BP	SANDOZ	0.1MG	N009838	001	
BP	+	0.25MG	N009838	002	

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	GLAXO GRP LTD	1%	N022055	001	Apr 12, 2007

RIBAVIRIN

CAPSULE; ORAL

REBETOL

<u>AB</u>	+	MERCK SHARP DOHME	<u>200MG</u>	<u>N020903</u>	<u>002</u>	Jul 25, 2001

RIBASPHERE

<u>AB</u>	THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203</u>	<u>001</u>	Apr 06, 2004

RIBAVARIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A079117</u>	<u>001</u>	Sep 17, 2009

RIBAVIRIN

<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A076192</u>	<u>001</u>	Apr 06, 2004
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076277</u>	<u>001</u>	Oct 04, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224</u>	<u>001</u>	Oct 28, 2005

REBETOL

+	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy**	N020903	001	Jun 03, 1998

FOR SOLUTION; INHALATION

VIRAZOLE

+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985

SOLUTION; ORAL

REBETOL

+	SCHERING	40MG/ML	N021546	001	Jul 29, 2003

TABLET; ORAL

COPEGUS

<u>AB</u>	ROCHE	<u>200MG</u>	<u>N021511</u>	<u>001</u>	Dec 03, 2002

RIBAVIRIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A079111</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A077743</u>	<u>001</u>	Oct 03, 2006
<u>AB</u>	TEVA	<u>200MG</u>	<u>A077053</u>	<u>001</u>	Dec 05, 2005
<u>AB</u>	THREE RIVERS PHARMS	<u>200MG</u>	<u>A077456</u>	<u>001</u>	Dec 05, 2005
<u>AB</u>		<u>400MG</u>	<u>A077456</u>	<u>002</u>	Dec 05, 2005
<u>AB</u>	+	<u>600MG</u>	<u>A077456</u>	<u>003</u>	Dec 05, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>200MG</u>	<u>A077094</u>	<u>001</u>	Dec 05, 2005
<u>AB</u>		<u>400MG</u>	<u>A077094</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>		<u>600MG</u>	<u>A077094</u>	<u>003</u>	Mar 16, 2007
		500MG	A077094	004	Apr 18, 2008

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992

RIFAMPIN

CAPSULE; ORAL

RIFADIN

<u>AB</u>	SANOFI AVENTIS US	<u>150MG</u>	<u>A062303</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N050420</u>	<u>001</u>	
<u>RIFAMPIN</u>					
<u>AB</u>	LANNETT	<u>150MG</u>	<u>A065390</u>	<u>001</u>	Mar 28, 2008
<u>AB</u>		<u>300MG</u>	<u>A065390</u>	<u>002</u>	Mar 28, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-306 (of 362)

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

AB	LUPIN PHARMS	150MG	A090034 001	Aug 21, 2013
AB		300MG	A090034 002	Aug 21, 2013
AB	SANDOZ	150MG	A064150 002	Jan 02, 1998
AB		300MG	A064150 001	May 28, 1997
AB	VERSAPHARM	150MG	A065028 001	Mar 14, 2001
AB		300MG	A065028 002	Mar 14, 2001

RIMACTANE

AB	PROSAM LABS	300MG	N050429 001	

INJECTABLE; INJECTION

RIFADIN

AP	+ SANOFI AVENTIS US	600MG/VIAL	N050627 001	May 25, 1989

RIFAMPIN

AP	AGILA SPECLTS	600MG/VIAL	A065421 001	May 22, 2008
AP	BEDFORD	600MG/VIAL	A064217 001	Oct 29, 1999
AP	VERSAPHARM INC	600MG/VIAL	A065502 001	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

	+ SANOFI AVENTIS US	150MG	N021024 001	Jun 22, 1998

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+ SALIX PHARMS	200MG	N021361 001	May 25, 2004
		550MG	N022554 001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

	+ JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011

RILUZOLE

TABLET; ORAL

RILUTEK

AB	+ COVIS PHARMA SARL	50MG	N020599 001	Dec 12, 1995

RILUZOLE

AB	APOTEX CORP	50MG	A091300 001	Jun 18, 2013
AB	GLENMARK GENERICS	50MG	A091394 001	Jun 18, 2013
AB	IMPAX LABS	50MG	A076173 001	Jan 29, 2003
AB	MYLAN PHARMS INC	50MG	A203042 001	Jul 01, 2013
AB	SUN PHARM INDS LTD	50MG	A091417 001	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

AB	+ CARACO	100MG	N019649 001	Sep 17, 1993

RIMANTADINE HYDROCHLORIDE

AB	IMPAX LABS	100MG	A076132 001	Aug 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

	+ ALCON	1%	N020474 001	Dec 30, 1994

RIOCIGUAT

TABLET; ORAL

ADEMPAS

	BAYER HLTHCARE	0.5MG	N204819 001	Oct 08, 2013
		1MG	N204819 002	Oct 08, 2013
		1.5MG	N204819 003	Oct 08, 2013
		2MG	N204819 004	Oct 08, 2013
		2.5MG	N204819 005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000
AB		30MG	N020835 001	Mar 27, 1998
AB		35MG	N020835 003	May 25, 2002

RISEDRONATE SODIUM

AB	TEVA PHARMS	5MG	A077132 001	Oct 05, 2007
AB		30MG	A077132 002	Oct 05, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-307 (of 362)

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

AB		35MG	A077132	003	Oct 05, 2007
	ACTONEL				
	+ WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008
	TABLET, DELAYED RELEASE; ORAL				
	ATELVIA				
	+ WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
+		25MG/VIAL	N021346	001	Oct 29, 2003
		37.5MG/VIAL	N021346	002	Oct 29, 2003
		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011
AA		APOTEX INC	1MG/ML	A077719	001	Jul 29, 2009
AA		AUROBINDO PHARMA	1MG/ML	A078452	001	Sep 04, 2009
AA		BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009
AA		PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010
AA		ROXANE	1MG/ML	A076904	001	Jul 29, 2009
AA		TARO	1MG/ML	A090347	001	Feb 07, 2011
AA		TEVA	1MG/ML	A076440	001	Jan 30, 2009
AA		TRIS PHARMA INC	1MG/ML	A079059	001	Dec 12, 2012
AA		VINTAGE	1MG/ML	A079158	001	Dec 03, 2010
AA		WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009

TABLET; ORAL

RISPERDAL

AB		JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999
AB			0.5MG	N020272	007	Jan 27, 1999
AB	+		1MG	N020272	001	Dec 29, 1993
AB			2MG	N020272	002	Dec 29, 1993
AB			3MG	N020272	003	Dec 29, 1993
AB			4MG	N020272	004	Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	0.25MG	A201003	001	Aug 24, 2011
AB			0.5MG	A201003	002	Aug 24, 2011
AB			1MG	A201003	003	Aug 24, 2011
AB			2MG	A201003	004	Aug 24, 2011
AB			3MG	A201003	005	Aug 24, 2011
AB			4MG	A201003	006	Aug 24, 2011
AB		APOTEX INC	0.25MG	A077953	001	Sep 15, 2008
AB			0.5MG	A077953	002	Sep 15, 2008
AB			1MG	A077953	003	Sep 15, 2008
AB			2MG	A077953	004	Sep 15, 2008
AB			3MG	A077953	005	Sep 15, 2008
AB			4MG	A077953	006	Sep 15, 2008
AB		AUROBINDO PHARMA	0.25MG	A078269	001	Oct 08, 2008
AB			0.5MG	A078269	002	Oct 08, 2008
AB			1MG	A078269	003	Oct 08, 2008
AB			2MG	A078269	004	Oct 08, 2008
AB			3MG	A078269	005	Oct 08, 2008
AB			4MG	A078269	006	Oct 08, 2008
AB		CIPLA	0.25MG	A077543	001	May 18, 2011
AB			0.5MG	A077543	002	May 18, 2011
AB			1MG	A077543	003	May 18, 2011
AB			2MG	A077543	004	May 18, 2011
AB			3MG	A077543	005	May 18, 2011
AB			4MG	A077543	006	May 18, 2011
AB		DR REDDYS LABS LTD	0.25MG	A076879	001	Oct 24, 2008
AB			0.5MG	A076879	002	Oct 24, 2008
AB			1MG	A076879	003	Oct 24, 2008
AB			2MG	A076879	004	Oct 24, 2008
AB			3MG	A076879	005	Oct 24, 2008
AB			4MG	A076879	006	Oct 24, 2008
AB		MYLAN	0.25MG	A076288	001	Sep 15, 2008
AB			0.5MG	A076288	002	Sep 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-308 (of 362)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	PROSAM LABS	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WATSON LABS	<u>0.25MG</u>	<u>A077860</u>	<u>001</u>	Dec 05, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077860</u>	<u>002</u>	Dec 05, 2008
<u>AB</u>		<u>1MG</u>	<u>A077860</u>	<u>003</u>	Dec 05, 2008
<u>AB</u>		<u>2MG</u>	<u>A077860</u>	<u>004</u>	Dec 05, 2008
<u>AB</u>		<u>3MG</u>	<u>A077860</u>	<u>005</u>	Dec 05, 2008
<u>AB</u>		<u>4MG</u>	<u>A077860</u>	<u>006</u>	Dec 05, 2008
<u>AB</u>	WEST WARD PHARMS	<u>0.25MG</u>	<u>A078740</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078740</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>1MG</u>	<u>A078740</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>2MG</u>	<u>A078740</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>3MG</u>	<u>A078740</u>	<u>005</u>	May 29, 2009
<u>AB</u>		<u>4MG</u>	<u>A078740</u>	<u>006</u>	May 29, 2009
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-309 (of 362)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008
TABLET, ORALLY DISINTEGRATING; ORAL					

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	JUBILANT ORGANOSYS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A091537</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077494</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	WATSON LABS FLORIDA	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009

RITONAVIR

CAPSULE; ORAL

NORVIR

+ ABBVIE

100MG

N020945 001 Jun 29, 1999

SOLUTION; ORAL

NORVIR

+ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET; ORAL

NORVIR

+ ABBVIE

100MG

N022417 001 Feb 10, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-310 (of 362)

RIVAROXABAN

TABLET; ORAL

XARELTO

+	JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011
		15MG	N022406	002	Nov 04, 2011
+		20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

	NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007
+		9.5MG/24HR	N022083	002	Jul 06, 2007
		13.3MG/24HR	N022083	005	Aug 31, 2012

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

<u>AB</u>	+	NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823</u>	<u>003</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020823</u>	<u>004</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>N020823</u>	<u>005</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>N020823</u>	<u>006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091689</u>	<u>002</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091689</u>	<u>003</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091689</u>	<u>004</u>	Jun 12, 2012
<u>AB</u>		APOTEX INC	<u>EQ 1.5MG BASE</u>	<u>A091072</u>	<u>001</u>	May 16, 2013
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091072</u>	<u>002</u>	May 16, 2013
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091072</u>	<u>003</u>	May 16, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091072</u>	<u>004</u>	May 16, 2013
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007
<u>AB</u>		SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007
<u>AB</u>		WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

SOLUTION; ORAL

EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

<u>AB</u>		MERCK	<u>EQ 5MG BASE</u>	<u>N020864</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N020864</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>		APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202244</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202490</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A077526</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077526</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090</u>	<u>001</u>	Nov 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204090</u>	<u>002</u>	Nov 26, 2013
<u>AB</u>		GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201967</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204339</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201993</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A200482</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A079230</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A202047</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202047</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077263</u>	<u>002</u>	Dec 31, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-311 (of 362)

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201914</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739</u>	<u>002</u>	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	SAGENT STRIDES	<u>50MG/5ML (10MG/ML)</u>	<u>A091458</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	SANDOZ	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115</u>	<u>001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115</u>	<u>002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717</u>	<u>002</u>	Nov 26, 2008

ZEMURON

<u>AP</u>	+	ORGANON USA INC	<u>50MG/5ML (10MG/ML)</u>	<u>N020214</u>	<u>001</u>	Mar 17, 1994
<u>AP</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N020214</u>	<u>003</u>	Mar 17, 1994

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

+	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 0.25MG BASE</u>	<u>N020658</u>	<u>001</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>N020658</u>	<u>002</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>N020658</u>	<u>003</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N020658</u>	<u>004</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020658</u>	<u>006</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N020658</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>N020658</u>	<u>005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010
<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165</u>	<u>001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165</u>	<u>002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165</u>	<u>003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165</u>	<u>004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165</u>	<u>005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165</u>	<u>006</u>	Feb 07, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-312 (of 362)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165</u>	<u>007</u>	Feb 07, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135</u>	<u>002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135</u>	<u>003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135</u>	<u>004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135</u>	<u>005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135</u>	<u>006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135</u>	<u>007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229</u>	<u>003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229</u>	<u>004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229</u>	<u>005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229</u>	<u>006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229</u>	<u>007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110</u>	<u>007</u>	Jul 11, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852</u>	<u>007</u>	May 19, 2008
<u>AB</u>	TEVA	<u>EQ 0.25MG BASE</u>	<u>A077460</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460</u>	<u>007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050</u>	<u>001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050</u>	<u>002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050</u>	<u>003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050</u>	<u>004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050</u>	<u>005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N022008</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N022008</u>	<u>006</u>	Apr 10, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N022008</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N022008</u>	<u>005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869</u>	<u>002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869</u>	<u>003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869</u>	<u>004</u>	May 17, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-313 (of 362)

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869</u>	<u>005</u>	May 17, 2012
<u>AB</u>	ALEMBIC LTD	<u>EQ 2MG BASE</u>	<u>A202786</u>	<u>001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786</u>	<u>002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786</u>	<u>003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786</u>	<u>004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786</u>	<u>005</u>	Apr 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200462</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200462</u>	<u>004</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200462</u>	<u>005</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200462</u>	<u>006</u>	Oct 15, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047</u>	<u>006</u>	Jun 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200431</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200431</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200431</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395</u>	<u>003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395</u>	<u>004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395</u>	<u>005</u>	Aug 27, 2012
	MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NAROPIN

FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996
	5MG/ML	N020533	003	Sep 24, 1996
	7.5MG/ML	N020533	004	Sep 24, 1996
+	10MG/ML	N020533	005	Sep 24, 1996

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

<u>AB</u>	SB PHARMC0	<u>EQ 2MG BASE</u>	<u>N021071</u>	<u>002</u>	May 25, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021071</u>	<u>003</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021071</u>	<u>004</u>	May 25, 1999

ROSIGLITAZONE MALEATE

<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747</u>	<u>001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747</u>	<u>002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747</u>	<u>003</u>	Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

IPR	5MG	N021366	002	Aug 12, 2003
	10MG	N021366	003	Aug 12, 2003
	20MG	N021366	004	Aug 12, 2003
+	40MG	N021366	005	Aug 12, 2003

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NEUPRO

UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+	2MG/24HR	N021829	001	May 09, 2007
	3MG/24HR	N021829	005	Apr 02, 2012
	4MG/24HR	N021829	002	May 09, 2007
	6MG/24HR	N021829	003	May 09, 2007
	8MG/24HR	N021829	006	Apr 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-314 (of 362)

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011

TABLET; ORAL

BANZEL

EISAI INC

200MG

N021911 002 Nov 14, 2008

+

400MG

N021911 003 Nov 14, 2008

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

INCYTE CORP

EQ 5MG BASE

N202192 001 Nov 16, 2011

EQ 10MG BASE

N202192 002 Nov 16, 2011

EQ 15MG BASE

N202192 003 Nov 16, 2011

EQ 20MG BASE

N202192 004 Nov 16, 2011

+

EQ 25MG BASE

N202192 005 Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N020772 001 Apr 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+ HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

+ HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ GLAXO GRP LTD

EQ 0.05MG BASE/INH

N020692 001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ LANTHEUS MEDICAL

50mCi/ML

N020570 001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+ BIOMARIN PHARM

100MG/PACKET

N205065 001 Dec 19, 2013

TABLET; ORAL

KUVAN

+ BIOMARIN PHARM

100MG

N022181 001 Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HOFFMANN LA ROCHE

EQ 200MG BASE

N020628 001 Dec 06, 1995

TABLET; ORAL

INVIRASE

+ HOFFMAN LA ROCHE

EQ 500MG BASE

N021785 001 Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

BRISTOL MYERS SQUIBB

EQ 2.5MG BASE

N022350 001 Jul 31, 2009

+

EQ 5MG BASE

N022350 002 Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM SCOP

+ NOVARTIS

1MG/72HR

N017874 001

PRESCRIPTION DRUG PRODUCT LIST

3-315 (of 362)

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ MARATHON PHARMS

50MG

A086101 001 Oct 03, 1983

+

100MG

A086101 002 Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ CHIRHOCLIN

16MCG/VIAL

N021256 001 Apr 09, 2004

40MCG/VIAL

N021256 002 Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+ SOMERSET

6MG/24HR

N021336 001 Feb 27, 2006

9MG/24HR

N021336 002 Feb 27, 2006

12MG/24HR

N021336 003 Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYLAB + SOMERSET5MGN020647 001 May 15, 1996SELEGILINE HYDROCHLORIDEAB APOTEX5MGA075321 001 Dec 04, 1998AB DAVA PHARMS INC5MGA075352 001 Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDEAB + APOTEX INC5MGA074871 001 Jun 06, 1997AB MYLAN5MGA074866 001 Nov 26, 1997AB STASON5MGA074912 001 Apr 30, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+ VALEANT PHARM INTL

1.25MG

N021479 001 Jun 14, 2006

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDEAT PERRIGO NEW YORK2.5%A089996 001 Jan 10, 1991AT WOCKHARDT2.5%A088228 001 Sep 01, 1983SELSUNAT + CHATTEM2.5%N007936 001SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+ VALEANT LUXEMBOURG

2%

N021385 001 Dec 10, 2003

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDEAA AUROBINDO PHARMAEQ 20MG BASE/MLA078861 001 Oct 31, 2008ZOLOFTAA + PFIZEREQ 20MG BASE/MLN020990 001 Dec 07, 1999

TABLET; ORAL

SERTRALINE HYDROCHLORIDEAB APOTEX INCEQ 25MG BASEA076882 001 Feb 06, 2007ABEQ 50MG BASEA076882 002 Feb 06, 2007ABEQ 100MG BASEA076882 003 Feb 06, 2007AB AUROBINDO PHARMAEQ 25MG BASEA077206 001 Feb 06, 2007ABEQ 50MG BASEA077206 002 Feb 06, 2007ABEQ 100MG BASEA077206 003 Feb 06, 2007AB AUSTARPHARMA LLCEQ 25MG BASEA078677 001 Mar 04, 2009ABEQ 50MG BASEA078677 002 Mar 04, 2009ABEQ 100MG BASEA078677 003 Mar 04, 2009AB HIKMA PHARMSEQ 25MG BASEA077864 001 Aug 10, 2009ABEQ 50MG BASEA077864 002 Aug 10, 2009ABEQ 100MG BASEA077864 003 Aug 10, 2009AB INVAGEN PHARMSEQ 25MG BASEA077397 001 Feb 06, 2007ABEQ 50MG BASEA077397 002 Feb 06, 2007ABEQ 100MG BASEA077397 003 Feb 06, 2007AB LUPINEQ 25MG BASEA077670 001 Feb 06, 2007ABEQ 50MG BASEA077670 002 Feb 06, 2007ABEQ 100MG BASEA077670 003 Feb 06, 2007AB MYLANEQ 25MG BASEA076671 001 Feb 06, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-316 (of 362)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	PROSAM LABS	<u>EQ 25MG BASE</u>	<u>A078175</u>	<u>001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175</u>	<u>002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175</u>	<u>003</u>	Jul 21, 2010
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A077977</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465</u>	<u>001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465</u>	<u>002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465</u>	<u>003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A077663</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077663</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077663</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106</u>	<u>003</u>	Feb 06, 2007

ZOLOFT

<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839</u>	<u>005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839</u>	<u>002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE				
	RANBAXY	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

REVELA

+ GENZYME

2.4GM/PACKET
800MG/PACKETN022318 002 Feb 18, 2009
N022318 001 Aug 12, 2009

TABLET; ORAL

REVELA

+ GENZYME

800MG

N022127 001 Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

+ GENZYME

400MG
800MGN021179 001 Jul 12, 2000
N021179 002 Jul 12, 2000SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
	<u>SOJOURN</u>				
<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007
	<u>ULTANE</u>				
<u>AN</u>	+	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER

EQ 10MG BASE/ML

N203109 001 Aug 30, 2012

SOLUTION; INTRAVENOUS

REVATIO

+ PFIZER

EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)

N022473 001 Nov 18, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-317 (of 362)

SILDENAFIL CITRATE

TABLET; ORAL

REVATIO

AB	+	PFIZER	<u>EQ 20MG BASE</u>	<u>N021845 001</u>	Jun 03, 2005

SILDENAFIL CITRATE

AB		ACTAVIS GRP PTC	<u>EQ 20MG BASE</u>	<u>A200149 001</u>	Feb 25, 2013
AB		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A202025 001</u>	Feb 28, 2013
AB		APOTEX CORP	<u>EQ 20MG BASE</u>	<u>A091379 001</u>	Nov 06, 2012
AB		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A202598 001</u>	Nov 06, 2012
AB		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203814 001</u>	Dec 17, 2013
AB		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150 001</u>	Nov 09, 2012
AB		TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380 001</u>	Jan 07, 2013
AB		TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479 001</u>	Nov 06, 2012
AB		WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503 001</u>	Nov 06, 2012

VIAGRA

PFIZER IRELAND

EQ 25MG BASE

N020895 001 Mar 27, 1998

EQ 50MG BASE

N020895 002 Mar 27, 1998

+

EQ 100MG BASE

N020895 003 Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ WATSON LABS

4MG

N022206 001 Oct 08, 2008

8MG

N022206 002 Oct 08, 2008

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENE

AB	+	KING PHARMS	<u>1%</u>	<u>N017381 001</u>	

SSD

AB		DR REDDYS LA	<u>1%</u>	<u>N018578 001</u>	Feb 25, 1982

THERMAZENE

AB		THEPHARMANETWORK LLC	<u>1%</u>	<u>N018810 001</u>	Dec 23, 1985

SSD AF

BX		DR REDDYS LA	<u>1%</u>	<u>N018578 003</u>	Jul 11, 1990

SIMEPREVIR

CAPSULE; ORAL

OLYSIO

+ JANSSEN RES AND DEV

150MG

N205123 001 Nov 22, 2013

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	<u>10MG</u>	<u>A078155 002</u>	Feb 26, 2008
AB			<u>20MG</u>	<u>A078155 003</u>	Feb 26, 2008
AB			<u>40MG</u>	<u>A078155 004</u>	Feb 26, 2008
AB			<u>80MG</u>	<u>A078155 001</u>	Feb 26, 2008
AB		AUROBINDO PHARMA	<u>5MG</u>	<u>A077691 001</u>	Dec 20, 2006
AB			<u>10MG</u>	<u>A077691 002</u>	Dec 20, 2006
AB			<u>20MG</u>	<u>A077691 003</u>	Dec 20, 2006
AB			<u>40MG</u>	<u>A077691 004</u>	Dec 20, 2006
AB			<u>80MG</u>	<u>A077691 005</u>	Dec 20, 2006
AB		BLU CARIBE	<u>5MG</u>	<u>A078034 001</u>	Dec 20, 2006
AB			<u>10MG</u>	<u>A078034 002</u>	Dec 20, 2006
AB			<u>20MG</u>	<u>A078034 003</u>	Dec 20, 2006
AB			<u>40MG</u>	<u>A078034 004</u>	Dec 20, 2006
AB			<u>80MG</u>	<u>A078034 005</u>	Dec 20, 2006
AB		DR REDDYS LABS INC	<u>5MG</u>	<u>A077752 005</u>	Jan 23, 2008
AB			<u>10MG</u>	<u>A077752 001</u>	Dec 20, 2006
AB			<u>20MG</u>	<u>A077752 002</u>	Dec 20, 2006
AB			<u>40MG</u>	<u>A077752 003</u>	Dec 20, 2006
AB			<u>80MG</u>	<u>A077752 004</u>	Dec 20, 2006
AB		IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052 001</u>	Jun 23, 2006
AB			<u>10MG</u>	<u>A076052 002</u>	Jun 23, 2006
AB			<u>20MG</u>	<u>A076052 003</u>	Jun 23, 2006
AB			<u>40MG</u>	<u>A076052 004</u>	Jun 23, 2006
AB			<u>80MG</u>	<u>A076052 005</u>	Dec 20, 2006
AB		LUPIN	<u>5MG</u>	<u>A078103 005</u>	Apr 14, 2009
AB			<u>10MG</u>	<u>A078103 001</u>	May 11, 2007
AB			<u>20MG</u>	<u>A078103 002</u>	May 11, 2007
AB			<u>40MG</u>	<u>A078103 003</u>	May 11, 2007
AB			<u>80MG</u>	<u>A078103 004</u>	May 11, 2007
AB		MICRO LABS LTD	<u>5MG</u>	<u>A090383 001</u>	Sep 16, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-318 (of 362)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u>	Jan 25, 2010

SIROLIMUS

<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A201676</u>	<u>003</u>	Jan 08, 2014

RAPAMUNE

PF PRISM CV

1MG

N021110 001 Aug 25, 2000

+

2MG

N021110 002 Aug 22, 2002

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME

EQ 25MG BASE

N021995 001 Oct 16, 2006

EQ 50MG BASE

N021995 002 Oct 16, 2006

+

EQ 100MG BASE

N021995 003 Oct 16, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-319 (of 362)

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA 2MEQ/ML

N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

+ UCYCLOYD 10%; 10% (5GM/50ML; 5GM/50ML)

N020645 001 Feb 17, 2005

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+ HOSPIRA 0.9MEQ/ML

A077394 001 Nov 09, 2005

+ 1MEQ/ML

A077394 002 Nov 09, 2005

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP FRESenius KABI USA 9MG/MLA088911 001 Feb 07, 1985AP + HOSPIRA 9MG/MLN018800 001 Oct 29, 1982SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINERAP B BRAUN 450MG/100MLN019635 001 Mar 09, 1988AP BAXTER HLTHCARE 450MG/100MLN018016 001AP HOSPIRA 450MG/100MLN018090 001AP 450MG/100MLN019759 001 Jun 08, 1988SODIUM CHLORIDE 0.9%AP HIKMA (MAPLE) 9MG/MLA201850 001 Jan 20, 2012SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP + B BRAUN 900MG/100MLN017464 001AP + 900MG/100MLN019635 002 Mar 09, 1988AP + BAXTER HLTHCARE 9MG/MLN016677 004 Oct 30, 1985AP 9MG/MLN020178 002 Dec 07, 1992AP + 900MG/100MLN016677 001AP + 900MG/100MLN020178 001 Dec 07, 1992AP + FRESenius KABI USA 9MG/MLA088912 001 Jan 10, 1985AP FRESenius MEDCL 900MG/100MLA078177 001 Apr 12, 2007AP HAEMONETICS 900MG/100MLA076316 001 Oct 27, 2004AP + HOSPIRA 9MG/MLN018803 001 Oct 29, 1982AP + 9MG/MLN019217 001 Jul 13, 1984AP 9MG/MLN019465 002 Jul 15, 1985AP + 900MG/100MLN016366 001AP + 900MG/100MLN019465 001 Jul 15, 1985AP + 900MG/100MLN019480 001 Sep 17, 1985AP + TARO PHARMS IRELAND 9MG/MLA077407 001 Aug 11, 2006

SODIUM CHLORIDE 0.9%

MEDEFIL INC 18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012

90MG/10ML (9MG/ML)

N202832 006 Jan 06, 2012

SODIUM CHLORIDE 0.9%

HIKMA MAPLE 9MG/ML

A201833 001 Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ MALLINCKRODT 45MG/50ML (9MG/ML)

N021569 001 Jul 27, 2006

112.5MG/125ML (9MG/ML)

N021569 002 Jul 27, 2006

MEDEFIL INC 9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N019022 001 Nov 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML

N019022 002 Nov 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA 2.5MEQ/ML

N018897 001 Jul 20, 1984

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAT B BRAUN 900MG/100MLN016733 001AT BAXTER HLTHCARE 900MG/100MLN017427 001AT 900MG/100MLN017867 001AT HOSPIRA 900MG/100MLN017514 001AT 900MG/100MLN018314 001

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-320 (of 362)

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		HIKMA PHARMS	62.5MG/5ML	A078215	001	Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP	+	HOUSTON CYCLOTRON	10-200mCi/ML	A203544	001	Dec 26, 2012

AP		UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013

	+	MCPRF	10-91.5MCI/ML	A203605	001	Jun 28, 2013

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HLTH 414	100uCi	N018671	001	May 27, 1982

AA	+		200uCi	N018671	002	May 27, 1982

AA		MALLINCKRODT	100uCi	A071909	001	Feb 28, 1989

AA			200uCi	A071910	001	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+	MALLINCKRODT	0.8-100mCi	N016517	001	

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE	9-100mCi	N021305	006	May 19, 2005

SOLUTION; ORAL

HICON

+	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011

SODIUM IODIDE I 131

+	MALLINCKRODT	3.5-150mCi/VIAL	N016515	001	

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	1.87GM/100ML	N016692	001	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP		B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

+	HOSPIRA	25MG/ML	A071961	001	Aug 01, 1988

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+	HYPERION THERAPS INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996

SODIUM PHENYLBUTYRATE

AB		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013

TABLET; ORAL

BUPHENYL

AB	+	HYPERION THERAPS INC	500MG	N020572	001	May 13, 1996

SODIUM PHENYLBUTYRATE

AB		AMPOLGEN	500MG	A090910	001	Nov 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-321 (of 362)

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS

0.398GM; 1.102GM

N021892 001 Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA

142MG/ML; 276MG/ML

N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE**AA** KVK TECH**454GM/BOT****A040905 001** Mar 30, 2009**KAYEXALATE****AA** + COVIS PHARMA SARL**453.6GM/BOT****N011287 001****KIONEX****AA** PADDOCK LLC**454GM/BOT****A040029 001** Feb 06, 1998**SODIUM POLYSTYRENE SULFONATE****AA** CAROLINA MEDCL**454GM/BOT****A089910 001** Jan 19, 1989**AA** CEDAR PHARMS**453.6GM/BOT****A090313 001** Dec 21, 2011

SUSPENSION; ORAL, RECTAL

KIONEX**AA** PADDOCK LLC**15GM/60ML****A040028 001** Sep 17, 2007**SODIUM POLYSTYRENE SULFONATE****AA** PADDOCK LLC**15GM/60ML****A090590 001** May 13, 2011**AA** ROXANE**15GM/60ML****A089049 001** Nov 17, 1986**SPS****AA** + CAROLINA MEDCL**15GM/60ML****A087859 001** Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

MYLAN INSTITUTIONAL

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

+

60MG/2ML (30MG/ML)

A040541 002 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012

SOFOSBUVIR

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC

400MG

N204671 001 Dec 06, 2013

SOLIFENACIN SUCCINATE

TABLET; ORAL

VESICARE

ASTELLAS

5MG

N021518 001 Nov 19, 2004

+

10MG

N021518 002 Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX + PHARMACIA AND UPJOHN

5.8MG/VIAL

N020280 006 Aug 24, 1995

GENOTROPIN PRESERVATIVE FREE

BX PHARMACIA AND UPJOHN

1.5MG/VIAL

N020280 004 Aug 24, 1995

HUMATROPE

BX + LILLY

5MG/VIAL

N019640 004 Mar 08, 1987

BX 6MG/VIAL

N019640 005 Feb 04, 1999

NORDITROPIN FLEXPRO

BX NOVO NORDISK INC

5MG/1.5ML

N021148 008 Mar 01, 2010

BX 10MG/1.5ML

N021148 009 Mar 01, 2010

NUTROPIN

BX GENENTECH

5MG/VIAL

N020168 001 Nov 17, 1993

OMNITROPE

BX SANDOZ

1.5MG/VIAL

N021426 002 May 30, 2006

BX 5MG/1.5ML

N021426 003 Jan 16, 2008

BX 5.8MG/VIAL

N021426 001 May 30, 2006

BX 10MG/1.5ML

N021426 004 Aug 25, 2008

SAIZEN

BX EMD SERONO

5MG/VIAL

N019764 002 Oct 08, 1996

SEROSTIM

BX EMD SERONO

4MG/VIAL

N020604 003 Jul 25, 1997

BX 5MG/VIAL

N020604 002 Aug 23, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-322 (of 362)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SEROSTIM

BX		6MG/VIAL	N020604	001	Aug 23, 1996
	TEV-TROPIN				
BX	+ FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
	VALTROPIN				
BX	LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007
	GENOTROPIN				
	+ PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996
	GENOTROPIN PRESERVATIVE FREE				
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
		0.4MG/VIAL	N020280	002	Jan 27, 1998
		0.6MG/VIAL	N020280	003	Jan 27, 1998
		0.8MG/VIAL	N020280	005	Jan 27, 1998
		1MG/VIAL	N020280	008	Jan 27, 1998
		1.2MG/VIAL	N020280	009	Jan 27, 1998
		1.4MG/VIAL	N020280	010	Jan 27, 1998
		1.6MG/VIAL	N020280	011	Jan 27, 1998
		1.8MG/VIAL	N020280	012	Jan 27, 1998
	+ HUMATROPE	2MG/VIAL	N020280	013	Jan 27, 1998
	+ LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
	+ NORDITROPIN FLEXPRO	24MG/VIAL	N019640	007	Feb 04, 1999
	NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
	NORDITROPIN NORDIFLEX				
	NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009
	NUTROPIN				
	+ GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993
	NUTROPIN AQ				
	+ GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
	+ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
	+ GENENTECH	20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
	NUTROPIN AQ PEN				
	+ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
	SAIZEN				
	+ EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
	ZORBTIVE				
	+ EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+ BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ACADEMIC PHARMS 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

TABLET; ORAL

BETAPACE

<u>AB1</u>	BAYER HLTHCARE	<u>80MG</u>	<u>N019865</u>	<u>001</u>	Oct 30, 1992
<u>AB1</u>		<u>120MG</u>	<u>N019865</u>	<u>005</u>	Apr 20, 1994
<u>AB1</u>	+	<u>160MG</u>	<u>N019865</u>	<u>002</u>	Oct 30, 1992
<u>AB1</u>		<u>240MG</u>	<u>N019865</u>	<u>003</u>	Oct 30, 1992

SORINE

<u>AB1</u>	UPSHER SMITH	<u>80MG</u>	<u>A075500</u>	<u>001</u>	Apr 27, 2001
<u>AB1</u>		<u>120MG</u>	<u>A075500</u>	<u>004</u>	Apr 27, 2001
<u>AB1</u>		<u>160MG</u>	<u>A075500</u>	<u>002</u>	Apr 27, 2001
<u>AB1</u>		<u>240MG</u>	<u>A075500</u>	<u>003</u>	Apr 27, 2001

SOTALOL HYDROCHLORIDE

<u>AB1</u>	APOTEX INC	<u>80MG</u>	<u>A076140</u>	<u>001</u>	Sep 26, 2002
<u>AB1</u>		<u>120MG</u>	<u>A076140</u>	<u>002</u>	Sep 26, 2002
<u>AB1</u>		<u>160MG</u>	<u>A076140</u>	<u>003</u>	Sep 26, 2002
<u>AB1</u>		<u>240MG</u>	<u>A076140</u>	<u>004</u>	Sep 26, 2002
<u>AB1</u>	IMPAX PHARMS	<u>80MG</u>	<u>A075663</u>	<u>001</u>	Nov 07, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-323 (of 362)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB1</u>		<u>120MG</u>	<u>A075663</u>	<u>002</u>	Nov 07, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075663</u>	<u>003</u>	Nov 07, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075663</u>	<u>004</u>	Nov 07, 2000
<u>AB1</u>	MYLAN	<u>80MG</u>	<u>A075237</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>80MG</u>	<u>A075725</u>	<u>001</u>	Dec 19, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075237</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075725</u>	<u>002</u>	Dec 19, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075237</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075725</u>	<u>003</u>	Dec 19, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075237</u>	<u>004</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075725</u>	<u>004</u>	Dec 19, 2000
<u>AB1</u>	SANDOZ	<u>80MG</u>	<u>A075366</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075366</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075366</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075366</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	TEVA	<u>80MG</u>	<u>A075429</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075429</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075429</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075429</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	VINTAGE PHARMS	<u>80MG</u>	<u>A075563</u>	<u>001</u>	Nov 07, 2003
<u>AB1</u>		<u>120MG</u>	<u>A075563</u>	<u>002</u>	Nov 07, 2003
<u>AB1</u>		<u>160MG</u>	<u>A075563</u>	<u>003</u>	Nov 07, 2003
<u>AB1</u>		<u>240MG</u>	<u>A075563</u>	<u>004</u>	Nov 07, 2003

BETAPACE AF

<u>AB2</u>	BAYER HLTHCARE	<u>80MG</u>	<u>N021151</u>	<u>001</u>	Feb 22, 2000
<u>AB2</u>		<u>120MG</u>	<u>N021151</u>	<u>002</u>	Feb 22, 2000
<u>AB2</u>	+	<u>160MG</u>	<u>N021151</u>	<u>003</u>	Feb 22, 2000

SOTALOL HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB2</u>	EPIC PHARMA INC	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
<u>INTRALIPID 20%</u>						
<u>AP</u>	+	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
<u>AP</u>	+		<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
<u>INTRALIPID 30%</u>						
<u>AP</u>	+	FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
<u>LIPOSYN III 10%</u>						
<u>AP</u>	+	HOSPIRA	<u>10%</u>	<u>N018969</u>	<u>001</u>	Sep 24, 1984
<u>LIPOSYN III 20%</u>						
<u>AP</u>	+	HOSPIRA	<u>20%</u>	<u>N018970</u>	<u>001</u>	Sep 25, 1984
<u>LIPOSYN III 30%</u>						
<u>AP</u>	+	HOSPIRA	<u>30%</u>	<u>N020181</u>	<u>001</u>	Jan 13, 1998
<u>NUTRILIPID 10%</u>						
<u>AP</u>	+	B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
<u>NUTRILIPID 20%</u>						
<u>AP</u>	+	B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	<u>N022408</u>	<u>001</u>	Jan 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-324 (of 362)

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>		<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>	+	<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983

SPIRONOLACTONE

<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>50MG</u>	<u>A091426</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>100MG</u>	<u>A091426</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A089424</u>	<u>001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424</u>	<u>001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424</u>	<u>002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424</u>	<u>003</u>	Aug 20, 2001
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809</u>	<u>001</u>	
<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750</u>	<u>001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750</u>	<u>002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750</u>	<u>003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A078957</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A078775</u>	<u>001</u>	Jan 05, 2009
<u>AB</u>		<u>40MG</u>	<u>A078775</u>	<u>002</u>	Jan 05, 2009
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A079069</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A079069</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069</u>	<u>004</u>	Dec 29, 2008

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	<u>HOSPIRA</u>	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	<u>B BRAUN</u>	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+		<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+	<u>HOSPIRA</u>	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		<u>TARO PHARMS IRELAND</u>	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>100%</u>	<u>N017428</u>	<u>001</u>	

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>	<u>B BRAUN</u>	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>100%</u>	<u>N017866</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-325 (of 362)

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	HOSPIRA	100%	<u>N017513</u>	<u>001</u>	
AT		100%	<u>N018313</u>	<u>001</u>	

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

+	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	+	GE HEALTHCARE	1mCi/ML	<u>N020134</u>	<u>001</u>	Jun 18, 1993

STRONTIUM CHLORIDE SR-89

AP		BIO NUCLEONICS	1mCi/ML	<u>A075941</u>	<u>001</u>	Jan 06, 2003

SUCCIMER

CAPSULE;ORAL

CHEMET

+	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	+	SANDOZ	20MG/ML	<u>N008453</u>	<u>002</u>	

QUELICIN

AP	+	HOSPIRA	20MG/ML	<u>N008845</u>	<u>006</u>	

QUELICIN PRESERVATIVE FREE

AP	+	HOSPIRA	20MG/ML	<u>N008845</u>	<u>001</u>	

+		100MG/ML	N008845	004	

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

+	APTALIS PHARMA US	1GM/10ML	N019183	001	Dec 16, 1993

TABLET;ORAL

CARAFATE

AB	+	APTALIS PHARMA US	1GM	<u>N018333</u>	<u>001</u>	

SUCRALFATE

AB		NOSTRUM LABS	1GM	<u>A074415</u>	<u>001</u>	Jun 08, 1998

AB		TEVA	1GM	<u>A070848</u>	<u>001</u>	Mar 29, 1996

SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE;ORAL

VELPHORO

+	VIFOR FRESENIUS	500MG	N205109	001	Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTA PRESERVATIVE FREE

AP	+	AKORN	EQ 0.05MG BASE/ML	<u>N019050</u>	<u>001</u>	May 04, 1984

SUFENTANIL CITRATE

AP		HIKMA MAPLE	EQ 0.05MG BASE/ML	<u>A074413</u>	<u>001</u>	Dec 15, 1995

AP		HOSPIRA	EQ 0.05MG BASE/ML	<u>A074534</u>	<u>001</u>	Dec 11, 1996

SULCONAZOLE NITRATE

CREAM;TOPICAL

EXELDERM

+	RANBAXY	1%	N018737	001	Feb 28, 1989

SOLUTION;TOPICAL

EXELDERM

+	RANBAXY	1%	N018738	001	Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	+	VALEANT BERMUDA	10%	<u>N019931</u>	<u>001</u>	Dec 23, 1996

SULFACETAMIDE SODIUM

AB		FOUGERA PHARMS	10%	<u>A077015</u>	<u>001</u>	Nov 17, 2006

AB		PERRIGO CO TENNESSEE	10%	<u>A078649</u>	<u>001</u>	Mar 23, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-326 (of 362)

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	TARO	10%	A078668 001	May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDE

AT	+ ALCON	10%	A080021 001	

SULFACETAMIDE SODIUM

AT	PERRIGO CO TENNESSEE	10%	A080029 001	

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

AT	+ ALLERGAN	10%	A080028 001	

SULFACETAMIDE SODIUM

AT	ALCON PHARMS LTD	10%	A089560 001	Oct 18, 1988

AT	BAUSCH AND LOMB	10%	A040066 001	Dec 28, 1994

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

	+ SANDOZ	500MG	A040091 001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	+ TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303 001	Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348 001	Jun 08, 2010

AB	+ HI TECH PHARMA	200MG/5ML; 40MG/5ML	A074650 001	Dec 29, 1997

AB	VINTAGE	200MG/5ML; 40MG/5ML	A077785 001	Jan 24, 2007

SULFATRIM PEDIATRIC

AB	STI PHARMA LLC	200MG/5ML; 40MG/5ML	N018615 001	Jan 07, 1983

TABLET; ORAL

BACTRIM

AB	MUTUAL PHARM	400MG; 80MG	N017377 001	

BACTRIM DS

AB	+ MUTUAL PHARM	800MG; 160MG	N017377 002	

SEPTRA

AB	MONARCH PHARMS	400MG; 80MG	N017376 001	

SEPTRA DS

AB	MONARCH PHARMS	800MG; 160MG	N017376 002	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	AMNEAL PHARMS NY	400MG; 80MG	A076899 001	Jan 27, 2005

AB		800MG; 160MG	A076899 002	Jan 27, 2005

AB	AUROBINDO PHARMA	400MG; 80MG	A090624 001	Feb 16, 2010

AB		800MG; 160MG	A090624 002	Feb 16, 2010

AB	GLENMARK GENERICS	400MG; 80MG	A090828 002	Dec 22, 2010

AB		800MG; 160MG	A090828 001	Dec 22, 2010

AB	MUTUAL PHARM	800MG; 160MG	A071017 001	Aug 25, 1986

AB	VINTAGE	400MG; 80MG	A078060 002	Jan 25, 2007

AB		800MG; 160MG	A078060 001	Jan 25, 2007

AB	VISTA PHARMS	400MG; 80MG	A076817 001	Oct 07, 2005

AB		800MG; 160MG	A076817 002	Oct 07, 2005

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	TEVA	800MG; 160MG	A070037 001	Jun 02, 1987

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB	TEVA PHARMS	400MG; 80MG	A070030 001	Jun 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

	+ MEDA PHARMS	15%	N006530 003	Jan 27, 1987

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

	+ PHARMACIA AND UPJOHN	250MG/5ML	A086983 001	

TABLET; ORAL

AZULFIDINE

AB	+ PHARMACIA AND UPJOHN	500MG	N007073 001	

SULFASALAZINE

AB	VINTAGE PHARMS	500MG	A040349 001	Jan 11, 2002

AB	WATSON LABS	500MG	A085828 001	

AB		500MG	A087197 001	

PRESCRIPTION DRUG PRODUCT LIST

3-327 (of 362)

SULFASALAZINE

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB	+	PHARMACIA AND UPJOHN	500MG	N007073	002	Apr 06, 1983

SULFASALAZINE

AB		VINTAGE PHARMS	500MG	A075339	001	Jan 11, 2002

SULINDAC

TABLET;ORAL

CLINORIL

AB	+	MERCK	200MG	N017911	002	

SULINDAC

AB		EPIC PHARMA	150MG	A072710	001	Mar 25, 1991

AB			200MG	A072711	001	Mar 25, 1991

AB		HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991

AB			200MG	A073262	001	Sep 06, 1991

AB		MUTUAL PHARM	150MG	A072050	001	Apr 17, 1991

AB			200MG	A072051	001	Apr 17, 1991

AB		MYLAN	150MG	A073039	002	Jun 22, 1993

AB			200MG	A073039	001	Jun 22, 1993

AB		WATSON LABS	150MG	A071891	001	Apr 03, 1990

AB			200MG	A071795	001	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

+ GLAXOSMITHKLINE

5MG/SPRAY

N020626 001 Aug 26, 1997

+

20MG/SPRAY

N020626 003 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		SUN PHARMA GLOBAL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011

IMITREX

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP		AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013

AP		BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009

AP		FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079242	001	Mar 02, 2009

AP		HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001	Sep 16, 2013

AP		INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010

AP		JHP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009

AP		PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009

AP		SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010

AP		SAGENT STRIDES	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010

AP		TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009

AP		WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078593	001	Feb 06, 2009

ALSUMA

BX		MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010

SUMAVEL DOSEPRO

BX	+	ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009

IMITREX STATDOSE

+ GLAXOSMITHKLINE

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

N020080 002 Feb 01, 2006

SYSTEM;IONTOPHORESIS

ZECURITY

+ NUPATHE

EQ 6.5MG BASE/4HR

N202278 001 Jan 17, 2013

TABLET;ORAL

IMITREX

AB		GLAXOSMITHKLINE	EQ 25MG BASE	N020132	002	Jun 01, 1995

AB			EQ 50MG BASE	N020132	003	Jun 01, 1995

AB	+		EQ 100MG BASE	N020132	001	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	EQ 25MG BASE	A200263	001	Jun 19, 2012

AB			EQ 50MG BASE	A200263	002	Jun 19, 2012

AB			EQ 100MG BASE	A200263	003	Jun 19, 2012

AB		AUROBINDO PHARMA	EQ 25MG BASE	A078327	001	Aug 10, 2009

AB			EQ 50MG BASE	A078327	002	Aug 10, 2009

AB			EQ 100MG BASE	A078327	003	Aug 10, 2009

AB		DR REDDYS LABS INC	EQ 25MG BASE	A076847	001	Aug 10, 2009

AB			EQ 50MG BASE	A076847	002	Aug 10, 2009

AB			EQ 100MG BASE	A076847	003	Aug 10, 2009

AB		HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-328 (of 362)

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078298 002</u>	May 21, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078298 003</u>	May 21, 2013
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076976 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076976 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

CPPI CV	EQ 12.5MG BASE	N021938 001	Jan 26, 2006
	EQ 25MG BASE	N021938 002	Jan 26, 2006
	EQ 37.5MG BASE	N021938 004	Mar 31, 2009
+	EQ 50MG BASE	N021938 003	Jan 26, 2006

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A090402 001</u>	Jul 01, 2010

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

ASTELLAS	EQ 0.5MG BASE	N204096 001	Jul 19, 2013
	EQ 1MG BASE	N204096 002	Jul 19, 2013
+	EQ 5MG BASE	N204096 003	Jul 19, 2013

INJECTABLE; INJECTION

PROGRAF

+	ASTELLAS	EQ 5MG BASE/ML	N050709 001	Apr 08, 1994

OINTMENT; TOPICAL

PROTOPIC

+	ASTELLAS	0.03%	N050777 001	Dec 08, 2000
+		0.1%	N050777 002	Dec 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-329 (of 362)

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO

20MG

N022332 001 May 22, 2009

CIALIS

LILLY

2.5MG

N021368 004 Jan 07, 2008

5MG

N021368 001 Nov 21, 2003

10MG

N021368 002 Nov 21, 2003

+

20MG

N021368 003 Nov 21, 2003

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ MERCK SHARP DOHME

0.0015%

N202514 001 Feb 10, 2012

TALC

AEROSOL, METERED; INTRAPLEURAL

SCLEROSOL

+ BRYAN

400MG/SPRAY

N020587 001 Dec 24, 1997

POWDER; INTRAPLEURAL

TALC

+ BRYAN

5GM/BOT

N021388 001 Dec 15, 2003

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+ PFIZER

200 UNITS/VIAL

N022458 001 May 01, 2012

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

DARA BIOSCIENCES

EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

TABLET; ORAL

TAMOXIFEN CITRATEAB APOTEXEQ 10MG BASEA090878 001 Sep 23, 2011ABEQ 20MG BASEA090878 002 Sep 23, 2011AB MYLANEQ 10MG BASEA074732 002 Feb 20, 2003ABEQ 20MG BASEA074732 001 Feb 20, 2003AB TEVAEQ 10MG BASEA075797 001 Feb 20, 2003AB + TEVA PHARMSEQ 20MG BASEA074858 001 Feb 20, 2003AB WATSON LABSEQ 10MG BASEA070929 001 Feb 20, 2003ABEQ 20MG BASEA070929 002 Feb 20, 2003AB WATSON LABS FLORIDAEQ 10MG BASEA076179 001 Feb 20, 2003ABEQ 20MG BASEA076179 002 Feb 20, 2003TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAXAB + BOEHRINGER INGELHEIM0.4MGN020579 001 Apr 15, 1997TAMSULOSIN HYDROCHLORIDEAB ANCHEN PHARMS0.4MGA202010 001 Jan 04, 2013AB AUROBINDO PHARMA LTD0.4MGA202433 001 Apr 30, 2013AB IMPAX LABS0.4MGA090377 001 Mar 02, 2010AB MYLAN0.4MGA090408 001 Apr 27, 2010AB SANDOZ0.4MGA078015 001 Apr 27, 2010AB SUN PHARM INDS LTD0.4MGA090931 001 Jul 15, 2010AB SYNTHON PHARMS0.4MGA078801 001 Apr 27, 2010AB TEVA PHARMS0.4MGA077630 001 Apr 27, 2010AB WOCKHARDT0.4MGA078938 001 Apr 27, 2010AB ZYDUS PHARMS USA INC0.4MGA078225 001 Apr 27, 2010TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ JANSSEN PHARMS

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TABLET; ORAL

NUCYNTA

JANSSEN PHARMS

EQ 50MG BASE

N022304 001 Nov 20, 2008

EQ 75MG BASE

N022304 002 Nov 20, 2008

+

EQ 100MG BASE

N022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

JANSSEN PHARMS

EQ 50MG BASE

N200533 001 Aug 25, 2011

EQ 100MG BASE

N200533 002 Aug 25, 2011

EQ 150MG BASE

N200533 003 Aug 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-330 (of 362)

TAPENTADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

EQ 200MG BASE

N200533 004 Aug 25, 2011

+

EQ 250MG BASE

N200533 005 Aug 25, 2011

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+ STIEFEL LABS INC

0.1%

N202428 001 May 11, 2012

CREAM; TOPICAL

AVAGE

+ ALLERGAN

0.1%

N021184 003 Sep 30, 2002

TAZORAC

+ ALLERGAN

0.05%

N021184 001 Sep 29, 2000

+

0.1%

N021184 002 Sep 29, 2000

GEL; TOPICAL

TAZORAC

+ ALLERGAN

0.05%

N020600 001 Jun 13, 1997

+

0.1%

N020600 002 Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS JUBILANT DRAXIMAGE N/A

N017776 001

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS DRAXIMAGE N/A

N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL N/A

N020256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

PHARMALUCENCE N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+ GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC**AP + BRACCO N/A****N018963 001** Jan 21, 1987**TECHNETIUM TC-99M MEBROFENIN****AP PHARMALUCENCE N/A****A078242 001** Jan 29, 2008TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+ JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP**AP PHARMALUCENCE N/A****N018124 001****MDP-BRACCO****AP BRACCO N/A****N018107 001**TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3

+ MALLINCKRODT N/A

N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+ MALLINCKRODT N/A

N018321 001

PRESCRIPTION DRUG PRODUCT LIST

3-331 (of 362)

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA**AP** JUBILANT DRAXIMAGE **N/A****N017714 001**DTPA**AP** DRAXIMAGE **N/A****N018511 001** Dec 29, 1989TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO**AP** PHARMALUCENCE **N/A****N019039 001** Jun 30, 1987TECHNESCAN PYP KIT**AP** MALLINCKRODT **N/A****N017538 001**TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAGMALLINCKRODT **N/A****N019981 001** Jun 10, 1991TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE**AP** + LANTHEUS MEDCL **N/A****N019785 001** Dec 21, 1990TECHNETIUM TC 99M SESTAMIBI**AP** CARDINAL HEALTH 414 **N/A****A078809 001** Apr 28, 2009**AP** DRAXIMAGE **N/A****A078806 001** Apr 29, 2009**AP** PHARMALUCENCE **10-30mCi****A079157 001** Jul 10, 2009TECHNETIUM TC-99 SESTAMIBI**AP** MALLINCKRODT **N/A****A078098 001** Sep 22, 2008TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

+ LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR

N017771 001ULTRA-TECHNEKOW FM

+ MALLINCKRODT 0.25-3 CI/GENERATOR

N017243 002TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENTGE HEALTHCARE **N/A****N017944 001** May 18, 1982TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID+ PHARMALUCENCE **N/A****N017858 001**TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE+ GE HEALTHCARE **N/A****N020372 001** Feb 09, 1996MYOVUE 30ML+ GE HEALTHCARE **N/A****N020372 002** Jul 07, 2005TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT+ NAVIDEA BIOPHARMS **N/A****N202207 001** Mar 13, 2013TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+ NPS PHARMS INC 5MG/VIAL

N203441 001 Dec 21, 2012TELAPREVIR

TABLET; ORAL

INCIVEK

+ VERTEX PHARMS 375MG

N201917 001 May 23, 2011TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

THERAVANCE INC EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

+ EQ 750MG BASE/VIAL

N022110 002 Sep 11, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-332 (of 362)

TELBIVUDINE

TABLET; ORAL

TYZEKA

+ NOVARTIS

600MG

N022011 001 Oct 25, 2006

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005

+

400MG

N021144 001 Apr 01, 2004

TELMISARTAN

TABLET; ORAL

MICARDISAB BOEHRINGER INGELHEIM20MGN020850 003 Apr 04, 2000AB 40MGN020850 001 Nov 10, 1998AB + 80MGN020850 002 Nov 10, 1998TELMISARTANAB WATSON LABS20MGA078710 001 Jan 08, 2014AB 40MGA078710 002 Jan 08, 2014AB 80MGA078710 003 Jan 08, 2014TEMAZEPAM

CAPSULE; ORAL

RESTORILAB MALLINCKRODT INC7.5MGN018163 003 Oct 25, 1991AB 15MGN018163 001AB 22.5MGN018163 004 Nov 02, 2004AB + 30MGN018163 002TEMAZEPAMAB ACTAVIS ELIZABETH15MGA071638 001 Aug 07, 1987AB 30MGA071620 001 Aug 07, 1987AB MUTUAL PHARM7.5MGA078581 001 Sep 08, 2009AB 22.5MGA071175 002 Sep 14, 2009AB MYLAN7.5MGA070920 002 May 21, 2010AB 15MGA070920 004 Jul 07, 1986AB 22.5MGA070920 003 Jun 12, 2009AB 30MGA070920 001 Jul 10, 1986AB NOVEL LABS INC7.5MGA071457 002 Jun 22, 2012AB 15MGA071456 001 Apr 21, 1987AB 22.5MGA071457 003 Jun 22, 2012AB 30MGA071457 001 Apr 21, 1987AB SANDOZ15MGA071427 001 Jan 12, 1988AB 30MGA071428 001 Jan 12, 1988AB WATSON LABS15MGA071446 001 May 21, 1993AB 30MGA071447 001 May 21, 1993TEMOZOLOMIDE

CAPSULE; ORAL

TEMODARAB MERCK SHARP DOHME5MGN021029 001 Aug 11, 1999AB 20MGN021029 002 Aug 11, 1999AB 100MGN021029 003 Aug 11, 1999AB 140MGN021029 005 Oct 19, 2006AB 180MGN021029 006 Oct 19, 2006AB + 250MGN021029 004 Aug 11, 1999TEMOZOLOMIDEAB BARR5MGA078879 001 Mar 01, 2010AB 20MGA078879 002 Mar 01, 2010AB 100MGA078879 003 Mar 01, 2010AB 140MGA078879 005 Mar 01, 2010AB 180MGA078879 006 Mar 01, 2010AB 250MGA078879 004 Mar 01, 2010

POWDER; INTRAVENOUS

TEMODAR

+ MERCK SHARP DOHME

100MG/VIAL

N022277 001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+ PF PRISM CV

25MG/ML (25MG/ML)

N022088 001 May 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-333 (of 362)

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA 10MG/ML

N020119 001 Jul 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL

N022577 001 Jan 18, 2012

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC 150MG

N021356 002 Jan 18, 2012

200MG

N021356 003 Jan 18, 2012

+ 250MG

N021356 004 Jan 18, 2012

+ 300MG

N021356 001 Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRINAB ABBOTTEQ 1MG BASEN020347 001 Dec 14, 1994AB +EQ 2MG BASEN020347 002 Dec 14, 1994ABEQ 5MG BASEN020347 003 Dec 14, 1994ABEQ 10MG BASEN020347 004 Dec 14, 1994TERAZOSIN HYDROCHLORIDEAB APOTEXEQ 1MG BASEA075498 001 Apr 12, 2001ABEQ 2MG BASEA075498 002 Apr 12, 2001ABEQ 5MG BASEA075498 003 Apr 12, 2001ABEQ 10MG BASEA075498 004 Apr 12, 2001AB IVAX SUB TEVA PHARMSEQ 1MG BASEA075614 002 Jan 30, 2001ABEQ 2MG BASEA075614 001 Jan 30, 2001ABEQ 5MG BASEA075614 003 Jan 30, 2001ABEQ 10MG BASEA075614 004 Jan 30, 2001AB JUBILANT CADISTAEQ 1MG BASEA075317 001 Dec 20, 2004ABEQ 2MG BASEA075317 002 Dec 20, 2004ABEQ 5MG BASEA075317 003 Dec 20, 2004ABEQ 10MG BASEA075317 004 Dec 20, 2004AB MYLANEQ 1MG BASEA075140 002 Feb 11, 2000ABEQ 2MG BASEA075140 003 Feb 11, 2000ABEQ 5MG BASEA075140 001 Feb 11, 2000ABEQ 10MG BASEA075140 004 Feb 11, 2000AB SANDOZEQ 1MG BASEA074823 001 Mar 30, 1998ABEQ 2MG BASEA074823 002 Mar 30, 1998ABEQ 5MG BASEA074823 003 Mar 30, 1998ABEQ 10MG BASEA074823 004 Mar 30, 1998

TABLET; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE

N019057 001 Aug 07, 1987

+

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

EQ 10MG BASE

N019057 004 Aug 07, 1987

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

TABLET; ORAL

LAMISILAB + NOVARTISEQ 250MG BASEN020539 001 May 10, 1996TERBINAFINE HYDROCHLORIDEAB APOTEXEQ 250MG BASEA078199 001 Jul 02, 2007AB AUROBINDO PHARMAEQ 250MG BASEA078297 001 Jul 02, 2007AB BRECKENRIDGE PHARMEQ 250MG BASEA077714 001 Jun 04, 2010AB CIPLA LTDEQ 250MG BASEA077137 001 Jul 02, 2007AB DR REDDYS LABS INCEQ 250MG BASEA076390 001 Jul 02, 2007AB GLENMARK GENERICSEQ 250MG BASEA078157 001 Jul 02, 2007AB HARRIS PHARMEQ 250MG BASEA077919 001 Jul 02, 2007AB INVAGEN PHARMSEQ 250MG BASEA077533 001 Jul 02, 2007AB MYLANEQ 250MG BASEA077195 001 Jul 02, 2007AB ORCHID HLTHCAREEQ 250MG BASEA078163 001 Jul 02, 2007AB TEVAEQ 250MG BASEA076377 001 Jul 02, 2007AB WOCKHARDTEQ 250MG BASEA078229 001 Jul 02, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-334 (of 362)

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>	AKORN	<u>1MG/ML</u>	<u>A078151</u>	<u>001</u>	Jan 07, 2008
<u>AP</u>	+	BEDFORD	<u>1MG/ML</u>	<u>A076770</u>	<u>001</u> Apr 23, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887</u>	<u>001</u>	May 26, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630</u>	<u>001</u>	May 20, 2009
<u>AP</u>	UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122</u>	<u>001</u>	Nov 08, 2013

TABLET; ORAL

TERBUTALINE SULFATE

<u>AB</u>	IMPAX LABS	<u>2.5MG</u>	<u>A075877</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>	+		<u>5MG</u>	<u>A075877</u>	<u>002</u> Jun 26, 2001
<u>AB</u>	LANNETT	<u>2.5MG</u>	<u>A077152</u>	<u>001</u>	Mar 25, 2005
<u>AB</u>		<u>5MG</u>	<u>A077152</u>	<u>002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>0.8%</u>	<u>N019964</u>	<u>001</u> Feb 21, 1991

TERAZOL 7

<u>AB</u>	+	JANSSEN PHARMS	<u>0.4%</u>	<u>N019579</u>	<u>001</u> Dec 31, 1987

TERCONAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>0.4%</u>	<u>A076712</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>	TARO	<u>0.4%</u>	<u>A076043</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.8%</u>	<u>A075953</u>	<u>001</u>	Apr 06, 2004
BX	+	NYCOMED US	0.8%	N021735	001 Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>80MG</u>	<u>N019641</u>	<u>001</u> May 24, 1988

TERCONAZOLE

<u>AB</u>	PERRIGO NEW YORK	<u>80MG</u>	<u>A077149</u>	<u>001</u>	Mar 17, 2006

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

SANOFI AVENTIS US

7MG

N202992 001 Sep 12, 2012

+

14MG

N202992 002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+

LILLY

0.6MG/2.4ML (0.25MG/ML)

N021318 002 Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+

EMD SERONO

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+

WATSON LABS

2MG/24HR

N020489 003 Oct 20, 2011

+

4MG/24HR

N020489 004 Oct 20, 2011

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBVIE	1% (50MG/5GM PACKET)	N021015	002 Feb 28, 2000

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001 Oct 31, 2002

ANDROGEL

ABBVIE

1% (25MG/2.5GM PACKET)

N021015 001 Feb 28, 2000

1.62% (20.25MG/1.25GM PACKET)

N022309 002 Sep 07, 2012

+

1.62% (40.5MG/2.5GM PACKET)

N022309 003 Sep 07, 2012

TESTOSTERONE

PERRIGO ISRAEL

25MG/2.5GM PACKET

N203098 002 Jan 31, 2013

50MG/5GM PACKET

N203098 003 Jan 31, 2013

TEVA PHARMS

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012

50MG/5GM PACKET

N202763 002 Feb 14, 2012

GEL, METERED; TRANSDERMAL

ANDROGEL

+

ABBVIE

1% (12.5MG/1.25GM ACTUATION)

N021015 003 Sep 26, 2003

+

1.62% (20.25MG/1.25GM ACTUATION)

N022309 001 Apr 29, 2011

FORTESTA

+

ENDO PHARMS

10MG/0.5GM ACTUATION

N021463 001 Dec 29, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-335 (of 362)

TESTOSTERONE

GEL, METERED; TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL 12.5MG/1.25GM ACTUATION

N203098 001 Jan 31, 2013

PELLET; IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS 75MG

A080911 001

SOLUTION, METERED; TRANSDERMAL

AXIRON

+ ELI LILLY AND CO 30MG/1.5ML ACTUATION

N022504 001 Nov 23, 2010

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ ACTIENT PHARMS 30MG

N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONEAO + PHARMACIA AND UPJOHN100MG/MLA085635 002AO +200MG/MLA085635 003TESTOSTERONE CYPIONATEAO BEDFORD100MG/MLA090387 001 Jul 15, 2010AO200MG/MLA090387 002 Jul 15, 2010AO HIKMA FARMACEUTICA200MG/MLA091244 001 May 01, 2012AO MYLAN INSTITUTIONAL200MG/MLA040652 001 Dec 11, 2006AO PADDOCK LLC200MG/MLA040530 001 Jan 31, 2005AO SANDOZ100MG/MLA040615 001 Aug 10, 2006AO200MG/MLA040615 002 Aug 10, 2006AO SUN PHARM INDS LTD100MG/MLA201720 001 Jun 03, 2013AO200MG/MLA201720 002 Jun 03, 2013AO WATSON LABS200MG/MLA086030 001TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYLAO + ENDO PHARMS200MG/MLN009165 003TESTOSTERONE ENANTHATEAO HIKMA FARMACEUTICA200MG/MLA091120 001 Sep 18, 2012AO MYLAN INSTITUTIONAL200MG/MLA040647 001 Oct 05, 2009AO PADDOCK LLC200MG/MLA040575 001 Jun 14, 2006AO WATSON LABS200MG/MLA085598 001TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT BERMUDA 12.5MG

N021894 001 Aug 15, 2008

+ 25MG

N021894 002 Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN VAB HERITAGE PHARMS INC250MGN050278 003AB500MGN050278 001TETRACYCLINE HYDROCHLORIDEAB IMPAX LABS250MGA060469 001AB500MGA060469 003AB IVAX SUB TEVA PHARMS250MGA060704 001AB +500MGA060704 002AB WATSON LABS250MGA061837 001AB500MGA061837 002

IMPAX LABS 100MG

A060469 002

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+ FOUGERA PHARMS 0.05%

A086576 002

0.1%

A086576 001

SPRAY; NASAL

TYZINE

+ FOUGERA PHARMS 0.1%

A086576 003

PRESCRIPTION DRUG PRODUCT LIST

3-336 (of 362)

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE

50MG

N020785 001 Jul 16, 1998

100MG

N020785 002 Jan 17, 2003

150MG

N020785 004 Jan 10, 2007

+

200MG

N020785 003 Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201AP + GE HEALTHCARE1mCi/MLN018110 002 Feb 27, 1996AP + LANTHEUS MEDCL1mCi/MLN017806 001AP + MALLINCKRODT1mCi/MLN018150 001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201AP + LANTHEUS MEDCL2mCi/MLN017806 002 Oct 09, 1998THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

ACTIENT PHARMS

100MG

A087942 001 Aug 22, 1983

200MG

A087943 001 Aug 22, 1983

300MG

A087944 001 Aug 22, 1983

+

400MG

A081034 001 Feb 28, 1992

ELIXIR; ORAL

ELIXOPHYLLIN

+ CARACO

80MG/15ML

A085186 001

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN40MG/100MLN019826 001 Aug 14, 1992THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN80MG/100MLN019826 002 Aug 14, 1992THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN160MG/100MLN019826 003 Aug 14, 1992THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN320MG/100MLN019826 006 Aug 14, 1992THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINERAP + HOSPIRA INC4MG/MLN019211 007 Dec 14, 1984AP +40MG/100MLN019211 001 Dec 14, 1984AP +160MG/100MLN019211 003 Dec 14, 1984AP +320MG/100MLN019211 006 Jan 20, 1988

SOLUTION; ORAL

THEOPHYLLINEAA + SILARX80MG/15MLA091156 001 Apr 13, 2011AA TRIS PHARMA INC80MG/15MLA091586 001 Jun 15, 2012

TABLET; ORAL

THEOLAIR

+ MEDICIS

125MG

A086399 001

+

250MG

A086399 002

TABLET, EXTENDED RELEASE; ORAL

THEOCHRONAB CARACO100MGA088320 001 Feb 21, 1985AB200MGA088321 001 Feb 21, 1985AB300MGA087400 002 Jan 11, 1983THEOPHYLLINEAB ALEMBIC LTD300MGA090430 001 Oct 27, 2010AB450MGA090430 002 Oct 27, 2010AB GLENMARK GENERICS400MGA090355 001 Jul 13, 2010AB600MGA090355 002 Jul 13, 2010AB NOSTRUM400MGA040595 001 Apr 21, 2006AB +600MGA040560 002 Apr 21, 2006AB +

PLIVA

100MGA089807 001 Apr 30, 1990AB +200MGA089808 001 Apr 30, 1990AB300MGA089763 001 Apr 30, 1990AB RHODES PHARMS600MGA040086 001 Apr 15, 1996AB + TEVA PHARMS450MGA081236 001 Nov 09, 1992UNIPHYLAB RHODES PHARMS400MGA087571 001 Sep 01, 1982

PRESCRIPTION DRUG PRODUCT LIST

3-337 (of 362)

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080556	001	
AP		MYLAN INSTITUTIONAL	100MG/ML	A091623	001	Jun 25, 2012
AP		WATSON LABS	100MG/ML	A080571	001	
	+		200MG/ML	A080571	002	

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	ASPEN GLOBAL INC	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB		MUTUAL PHARM	10MG	A089953	004	Aug 01, 1986
AB			25MG	A089953	003	Aug 01, 1986
AB			50MG	A089953	002	Aug 01, 1986
AB			100MG	A089953	001	Oct 07, 1988
AB		MYLAN	10MG	A088004	002	Mar 15, 1983
AB			25MG	A088004	003	Mar 15, 1983
AB			50MG	A088004	004	Mar 15, 1983
AB	+		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

	BEDFORD	15MG/VIAL	A075547	001	Apr 02, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB		PFIZER	1MG	N016584	001	
AB			2MG	N016584	002	
AB	+		5MG	N016584	003	
AB			10MG	N016584	004	

THIOTHIXENE

AB		MYLAN	1MG	A071093	002	Jun 23, 1987
AB			2MG	A071093	003	Jun 23, 1987
AB			5MG	A071093	004	Jun 23, 1987
AB			10MG	A071093	001	Jun 23, 1987
AB		SANDOZ	1MG	A071610	001	Jun 24, 1987
AB			2MG	A071570	001	Jun 24, 1987
AB			5MG	A071529	001	Jun 24, 1987
AB			10MG	A071530	001	Jun 24, 1987
AB		WATSON LABS	2MG	A070601	001	Jun 05, 1987
AB			5MG	A070602	001	Jun 05, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

AB		CEPHALON	2MG	N020646	005	Apr 16, 1999
AB	+		4MG	N020646	001	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB		SUN PHARM INDS	2MG	A077555	001	Nov 04, 2011
AB			4MG	A077555	002	Nov 04, 2011

GABITRIL

	CEPHALON	12MG	N020646	002	Sep 30, 1997
		16MG	N020646	003	Sep 30, 1997

TICAGRELOR

TABLET; ORAL

BRILINTA

+	ASTRAZENECA LP	90MG	N022433	001	Jul 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-338 (of 362)

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB	APOTEX	250MG	A075089	001	Jul 01, 1999
AB	CARACO	250MG	A075526	001	Sep 26, 2002
AB	+ TEVA	250MG	A075149	001	Aug 20, 1999

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TYGACIL

+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+	SANTEN OY	EQ 0.25% BASE	N020439	001	Mar 31, 1995
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	FALCON PHARMS	EQ 0.25% BASE	N020963	001	Oct 21, 1998
AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998
<u>TIMOPTIC-XE</u>					
AB	+ VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993
AB	+	EQ 0.5% BASE	N020330	002	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997
AT		EQ 0.5% BASE	A074516	001	Mar 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	A074778	001	Mar 25, 1997
AT		EQ 0.5% BASE	A074776	001	Mar 25, 1997
AT	FALCON PHARMS	EQ 0.25% BASE	A074261	001	Apr 28, 1995
AT		EQ 0.5% BASE	A074262	001	Apr 28, 1995
AT	FDC LTD	EQ 0.25% BASE	A077259	001	Apr 30, 2008
AT		EQ 0.5% BASE	A077259	002	Apr 30, 2008
AT	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002
AT	PACIFIC PHARMA	EQ 0.25% BASE	A074746	001	Mar 25, 1997
AT		EQ 0.5% BASE	A074747	001	Mar 25, 1997
AT	WOCKHARDT	EQ 0.25% BASE	A078771	001	Sep 28, 2009
AT		EQ 0.5% BASE	A078771	002	Sep 28, 2009

TIMOPTIC

AT	+ ATON	EQ 0.25% BASE	N018086	001	
AT	+	EQ 0.5% BASE	N018086	002	
ISTALOL					
BT	+ BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004
TIMOPTIC IN OCUDOSE					
	+ ATON	EQ 0.25% BASE	N019463	001	Nov 05, 1986
	+	EQ 0.5% BASE	N019463	002	Nov 05, 1986
TABLET; ORAL					
TIMOLOL MALEATE					
	MYLAN	5MG	A072668	002	Jun 08, 1990
		10MG	A072668	003	Jun 08, 1990
	+	20MG	A072668	001	Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB	MISSION PHARMA	250MG	N021618	001	May 17, 2004
AB	+	500MG	N021618	002	May 17, 2004

TINIDAZOLE

AB	NOVEL LABS INC	250MG	A202044	001	Apr 30, 2012
AB		500MG	A202044	002	Apr 30, 2012
AB	ROXANE	250MG	A201172	001	Apr 30, 2012
AB		500MG	A201172	002	Apr 30, 2012
AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013
AB		500MG	A202489	002	Oct 09, 2013

TIOPRONIN

TABLET; ORAL

THIOLA

+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-339 (of 362)

TIOTROPIUM BROMIDE MONOHYDRATE

POWDER; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE/INH

N021395 001 Jan 30, 2004

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM 250MG

N021814 001 Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM 100MG/ML

N022292 001 Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+

EQ 12.5MG BASE/250ML (EQ 0.05MG
BASE/ML)

N020913 003 Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEX INCEQ 2MG BASEA078868 001 Feb 03, 2012ABEQ 4MG BASEA078868 002 Feb 03, 2012ABEQ 6MG BASEA078868 003 Feb 03, 2012AB MYLAN PHARMS INCEQ 2MG BASEA091502 001 Nov 09, 2012ABEQ 4MG BASEA091502 002 Nov 09, 2012ABEQ 6MG BASEA091502 003 Nov 09, 2012ZANAFLEXAB ACORDAEQ 2MG BASEN021447 001 Aug 29, 2002ABEQ 4MG BASEN021447 002 Aug 29, 2002AB +EQ 6MG BASEN021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEXEQ 2MG BASEA076533 001 Jan 16, 2004ABEQ 4MG BASEA076533 002 Jan 16, 2004AB CARACOEQ 2MG BASEA076416 001 Sep 29, 2003ABEQ 4MG BASEA076416 002 Sep 29, 2003AB COREPHARMAEQ 2MG BASEA076347 001 Oct 11, 2002ABEQ 4MG BASEA076347 002 Oct 11, 2002AB DR REDDYS LABS INCEQ 2MG BASEA076286 001 Jul 03, 2002ABEQ 4MG BASEA076286 002 Jul 03, 2002AB MYLANEQ 2MG BASEA076354 001 Mar 28, 2003ABEQ 4MG BASEA076354 002 Mar 28, 2003AB PROSAM LABSEQ 2MG BASEA076281 001 Oct 20, 2003ABEQ 4MG BASEA076281 002 Oct 20, 2003AB SANDOZ INCEQ 2MG BASEA076280 001 Nov 26, 2002ABEQ 4MG BASEA076280 002 Jun 27, 2002AB TEVAEQ 2MG BASEA076284 001 Jul 03, 2002ABEQ 4MG BASEA076284 002 Jul 03, 2002AB UNICHEM LABS LTDEQ 2MG BASEA091283 001 Nov 28, 2012ABEQ 4MG BASEA091283 002 Nov 28, 2012ZANAFLEXAB + ACORDAEQ 4MG BASEN020397 001 Nov 27, 1996TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+ ALCON

0.3%

N050555 001

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS

28MG

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

TOBIAN + NOVARTIS PHARMS300MG/5MLN050753 001 Dec 22, 1997TOBRAMYCINAN TEVA PHARMS USA300MG/5MLA091589 001 Oct 10, 2013

BETHKIS

CORNERSTONE THERAP

300MG/4ML

N201820 001 Oct 12, 2012

SOLUTION/DROPS; OPHTHALMIC

AKTOBAT AKORN0.3%A064096 001 Jan 31, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-340 (of 362)

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	BAUSCH AND LOMB	0.3%	A064052 001	Nov 29, 1993
AT	FERA PHARMS	0.3%	A065026 001	Sep 11, 2001

TOBREX

AT	ALCON	0.3%	A062535 001	Dec 13, 1984
AT	+ FALCON PHARMS	0.3%	N050541 001	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	AGILA SPECILTS	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008
AP	FRESENIUS KABI USA	EQ 1.2GM BASE/VIAL	N050789 001	Jul 13, 2004
AP		EQ 10MG BASE/ML	A065122 001	Nov 29, 2002
AP	+	EQ 40MG BASE/ML	A065122 002	Nov 29, 2002
AP	HIKMA MAPLE	EQ 40MG BASE/ML	A063117 001	Apr 26, 1991
AP	+	EQ 10MG BASE/ML	A063112 001	Apr 30, 1991
AP		EQ 40MG BASE/ML	A063111 001	Apr 30, 1991
AP	+	EQ 40MG BASE/ML	A063116 001	May 18, 1992
AP	MARSAM PHARMS LLC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
AP	TEVA PHARMS USA	EQ 40MG BASE/ML	A063100 001	Jan 30, 1992
AP	+	EQ 1.2GM BASE/VIAL	A065013 001	Aug 17, 2001

TOBRAMYCIN SULFATE (PHARMACY BULK)

AP	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120 001	Nov 29, 2002
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+	EQ 1.2MG BASE/ML	A063081 003	Jul 31, 1990
	+	EQ 1.6MG BASE/ML	A063081 006	Jun 02, 1993
	+	EQ 80MG BASE/100ML	A063081 001	Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214 001	Nov 06, 2012

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	MYLAN PHARMS INC	250MG	A070259 001	Jan 02, 1986
+		500MG	A070259 003	Mar 17, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001	

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

AB	MYLAN	EQ 400MG BASE	A073393 001	May 27, 1993
AB	+	EQ 400MG BASE	A073290 001	Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUM

AB	MUTUAL PHARM	EQ 200MG BASE	A073310 001	Nov 27, 1991
AB	+	EQ 600MG BASE	A074473 001	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

AB	PHARMACIA AND UPJOHN	2MG	N021228 001	Dec 22, 2000
AB	+	4MG	N021228 002	Dec 22, 2000

TOLTERODINE TARTRATE

AB	MYLAN PHARMS INC	2MG	A201486 001	Oct 31, 2013
AB		4MG	A201486 002	Oct 31, 2013

TABLET; ORAL

DETROL

AB	PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998
AB	+	2MG	N020771 002	Mar 25, 1998

TOLTERODINE TARTRATE

AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012
AB		2MG	A200164 002	Sep 25, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-341 (of 362)

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A202641</u>	<u>001</u>	Nov 27, 2012
<u>AB</u>		<u>2MG</u>	<u>A202641</u>	<u>002</u>	Nov 27, 2012

TOLVAPTAN

TABLET; ORAL

SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
+		30MG	N022275	002	May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	JANSSEN PHARMS	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A078418</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>		<u>25MG</u>	<u>A078418</u>	<u>002</u>	Oct 14, 2009
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>		<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009
<u>AB</u>		<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>		<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

TROKENDI XR

	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013
		50MG	N201635	002	Aug 16, 2013
		100MG	N201635	003	Aug 16, 2013
+		200MG	N201635	004	Aug 16, 2013

TABLET; ORAL

TOPAMAX

<u>AB</u>	JANSSEN PHARMS	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996
<u>AB</u>		<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996
<u>AB</u>	+	<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996
<u>AB</u>		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	ACTIVIS TOTOWA LLC	<u>25MG</u>	<u>A078637</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>50MG</u>	<u>A078637</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A078637</u>	<u>003</u>	Feb 27, 2013
<u>AB</u>		<u>200MG</u>	<u>A078637</u>	<u>004</u>	Feb 27, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	LUPIN	<u>25MG</u>	<u>A078410</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>50MG</u>	<u>A078410</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>100MG</u>	<u>A078410</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>		<u>200MG</u>	<u>A078410</u>	<u>004</u>	Sep 11, 2013
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-342 (of 362)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077643</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077643</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077643</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077643</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	WOCKHARDT USA	<u>25MG</u>	<u>A090353</u>	<u>001</u>	Sep 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090353</u>	<u>002</u>	Sep 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A090353</u>	<u>003</u>	Sep 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A090353</u>	<u>004</u>	Sep 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPIRAMATE

<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A091185</u>	<u>001</u>	Nov 25, 2013
<u>AB</u>		<u>50MG</u>	<u>A091185</u>	<u>002</u>	Nov 25, 2013
<u>AB</u>		<u>100MG</u>	<u>A091185</u>	<u>003</u>	Nov 25, 2013
<u>AB</u>		<u>200MG</u>	<u>A091185</u>	<u>004</u>	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

GLAXO WELLCOME

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCANTIN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 4MG BASE/VIAL</u>	<u>A091376</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A202203</u>	<u>001</u>	Aug 29, 2013
<u>AP</u>	THREE RIVERS PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-343 (of 362)

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC

EQ 60MG BASE

N020497 001 May 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDEAP + BEDFORD LABS20MG/2ML (10MG/ML)A078007 001 Jun 11, 2008AP +50MG/5ML (10MG/ML)A078007 002 Jun 11, 2008AP LUITPOLD20MG/2ML (10MG/ML)A090656 001 Apr 21, 2010AP50MG/5ML (10MG/ML)A090656 002 Apr 21, 2010

TABLET; ORAL

DEMADEXAB MEDA PHARMS5MGN020136 001 Aug 23, 1993AB10MGN020136 002 Aug 23, 1993AB +20MGN020136 003 Aug 23, 1993AB100MGN020136 004 Aug 23, 1993TORSEMIDEAB APOTEX INC5MGA076894 001 May 31, 2005AB10MGA076894 002 May 31, 2005AB20MGA076894 003 May 31, 2005AB100MGA076894 004 May 31, 2005AB AUROBINDO PHARMA5MGA078249 001 Oct 17, 2007AB10MGA078249 002 Oct 17, 2007AB20MGA078249 003 Oct 17, 2007AB100MGA078249 004 Oct 17, 2007AB HETERO LABS LTD III5MGA079234 001 Jan 27, 2009AB10MGA079234 002 Jan 27, 2009AB20MGA079234 003 Jan 27, 2009AB100MGA079234 004 Jan 27, 2009AB PAR PHARM5MGA076226 001 May 27, 2003AB10MGA076226 002 May 27, 2003AB20MGA076226 003 May 27, 2003AB100MGA076226 004 May 27, 2003AB PLIVA PHARM IND5MGA076346 001 May 30, 2003AB10MGA076346 002 May 30, 2003AB20MGA076346 003 May 30, 2003AB100MGA076346 004 Oct 19, 2004AB ROXANE5MGA076943 001 Mar 01, 2005AB10MGA076943 002 Mar 01, 2005AB20MGA076943 003 Mar 01, 2005AB SUN PHARM INDS5MGA078478 001 Feb 26, 2008AB10MGA078478 002 Feb 26, 2008AB20MGA078478 003 Feb 26, 2008AB100MGA078478 004 Feb 26, 2008AB TEVA5MGA076110 001 May 14, 2002AB10MGA076110 002 May 14, 2002AB20MGA076110 003 May 14, 2002AB100MGA076110 004 May 14, 2002AB VINTAGE PHARMS5MGA090613 001 Mar 22, 2011AB10MGA090613 002 Mar 22, 2011AB20MGA090613 003 Mar 22, 2011AB100MGA090613 004 Mar 22, 2011TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+ CIPHER PHARMS INC

100MG

N022370 001 May 07, 2010

150MG

N022370 004 Aug 01, 2011

200MG

N022370 002 May 07, 2010

300MG

N022370 003 May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDEAB ACCORD HLTHCARE INC50MGA202390 001 May 16, 2013AB ALVOGEN50MGA202075 001 Nov 28, 2011AB AMNEAL PHARMS50MGA076003 001 Jun 20, 2002AB APOTEX50MGA075981 001 Jul 10, 2002AB CARACO50MGA075964 001 Jun 19, 2002AB CSPC OUYI PHARM CO50MGA091498 001 Mar 29, 2013AB IPCA LABS LTD50MGA201973 001 Nov 16, 2012AB MALLINCKRODT50MGA075983 001 Jun 25, 2002AB MUTUAL PHARM50MGA076100 001 Jun 20, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-344 (of 362)

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A075962</u>	<u>001</u>	Jun 24, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+	JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011

ULTRAM ER

<u>AB1</u>	+	VALEANT INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB1</u>			<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005
<u>AB1</u>			<u>300MG</u>	<u>N021692</u>	<u>003</u>	Sep 08, 2005

TRAMADOL HYDROCHLORIDE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012	
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012	
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012	
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012	
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012	
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012	
<u>AB2</u>	+	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011	
<u>AB2</u>		<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011	

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

GLAXOSMITHKLINE LLC

EQ 0.5MG NON-SOLVATED PARENT

N204114 001 May 29, 2013

EQ 1MG NON-SOLVATED PARENT

N204114 002 May 29, 2013

+

EQ 2MG NON-SOLVATED PARENT

N204114 003 May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBVIE	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077256</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077256</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077256</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-345 (of 362)

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBVIE	<u>1MG;240MG</u>	<u>N020591</u>	<u>003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591</u>	<u>001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591</u>	<u>004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591</u>	<u>002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135</u>	<u>001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135</u>	<u>002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135</u>	<u>003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281</u>	<u>001</u>	Dec 30, 1986

TRANEXAMIC ACID

<u>AP</u>		FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596</u>	<u>001</u>	Mar 02, 2012
<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A201885</u>	<u>001</u>	Aug 10, 2011
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657</u>	<u>001</u>	Nov 03, 2011
<u>AP</u>		VERSAPHARM INC	<u>100MG/ML</u>	<u>A202373</u>	<u>001</u>	Nov 17, 2011
<u>AP</u>		X-GEN PHARMS INC	<u>100MG/ML</u>	<u>A201580</u>	<u>001</u>	Jun 14, 2013

TABLET; ORAL

LYSTEDA

<u>AB</u>	+	FERRING PHARMS AS	<u>650MG</u>	<u>N022430</u>	<u>001</u>	Nov 13, 2009

TRANEXAMIC ACID

<u>AB</u>		WATSON LABS INC FL	<u>650MG</u>	<u>A202093</u>	<u>001</u>	Dec 27, 2012

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	COVIS PHARMA	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985

TRANLYCYPROMINE SULFATE

<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006

TRAVOPROST

PAR PHARM	0.004%	A091340	001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>			<u>100MG</u>	<u>A071514</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>	+	APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>			<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>			<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999
<u>AB</u>		MUTUAL PHARM	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993
<u>AB</u>			<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993
<u>AB</u>			<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A090514</u>	<u>001</u>	Jun 02, 2009
<u>AB</u>			<u>100MG</u>	<u>A090514</u>	<u>002</u>	Jun 02, 2009
<u>AB</u>			<u>150MG</u>	<u>A090514</u>	<u>003</u>	Jun 02, 2009
<u>AB</u>			<u>300MG</u>	<u>A090514</u>	<u>004</u>	Jun 02, 2009
<u>AB</u>		PLIVA	<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988
<u>AB</u>		TEVA PHARMS USA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>			<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>		TORRENT PHARMS LTD	<u>50MG</u>	<u>A202180</u>	<u>001</u>	Nov 27, 2013
<u>AB</u>			<u>100MG</u>	<u>A202180</u>	<u>002</u>	Nov 27, 2013
<u>AB</u>			<u>150MG</u>	<u>A202180</u>	<u>003</u>	Nov 27, 2013
<u>AB</u>			<u>300MG</u>	<u>A202180</u>	<u>004</u>	Nov 27, 2013
<u>AB</u>		VINTAGE	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>			<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-346 (of 362)

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	WATSON LABS	50MG	<u>A070857</u>	<u>001</u>	Oct 10, 1986
AB		100MG	<u>A070858</u>	<u>001</u>	Oct 10, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010
		300MG	N022411	002	Feb 02, 2010

TREPROSTINIL

INJECTABLE; IV (INFUSION) - SC

REMODULIN

	UNITED THERAP	1MG/ML	N021272	001	May 21, 2002
		2.5MG/ML	N021272	002	May 21, 2002
		5MG/ML	N021272	003	May 21, 2002
+		10MG/ML	N021272	004	May 21, 2002

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

	UNITED THERAP	0.125MG	N203496	001	Dec 20, 2013
		0.25MG	N203496	002	Dec 20, 2013
		1MG	N203496	003	Dec 20, 2013
+		2.5MG	N203496	004	Dec 20, 2013

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB	ANCHEN PHARMS	10MG	<u>A201687</u>	<u>001</u>	Oct 24, 2012
AB	+	10MG	<u>A077684</u>	<u>001</u>	Jun 22, 2007

CREAM; TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	<u>N020404</u>	<u>003</u>	Jan 14, 1997

RETIN-A

AB	+	0.025%	<u>N019049</u>	<u>001</u>	Sep 16, 1988
AB	+	0.1%	<u>N017340</u>	<u>001</u>	

TRETINOIN

AB	PRECISION DERMAT	0.025%	<u>A075264</u>	<u>001</u>	Dec 24, 1998
AB		0.1%	<u>A075213</u>	<u>001</u>	Dec 24, 1998

RETIN-A

AB1	+	0.05%	<u>N017522</u>	<u>001</u>	

TRETINOIN

AB1	PRECISION DERMAT	0.05%	<u>A075265</u>	<u>001</u>	Dec 24, 1998

RENOVA

AB2	+	0.05%	<u>N019963</u>	<u>001</u>	Dec 29, 1995

TRETINOIN

AB2	SUNEVA MEDCL	0.05%	<u>A076498</u>	<u>001</u>	Sep 15, 2005

RENOVA

+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000

TRETINOIN

+	PRECISION DERMAT	0.0375%	A090098	001	Mar 22, 2010
		0.075%	A202209	001	Oct 11, 2012

GEL; TOPICAL

RETIN-A

AB	+	0.01%	<u>N017955</u>	<u>001</u>	
AB	+	0.025%	<u>N017579</u>	<u>002</u>	

RETIN-A MICRO

AB	+	0.04%	<u>N020475</u>	<u>002</u>	May 10, 2002
AB	+	0.1%	<u>N020475</u>	<u>001</u>	Feb 07, 1997

TRETINOIN

AB	PRECISION DERMAT	0.01%	<u>A075589</u>	<u>001</u>	Jun 11, 2002
AB		0.025%	<u>A075529</u>	<u>001</u>	Feb 22, 2000
AB	SPEAR PHARMS INC	0.04%	<u>A202567</u>	<u>001</u>	Jul 17, 2013
AB		0.1%	<u>A202026</u>	<u>001</u>	Jul 17, 2013

AVITA

BT	MYLAN	0.025%	N020400	001	Jan 29, 1998

ATRALIN

+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007

SOLUTION; TOPICAL

RETIN-A

AT	+	0.05%	<u>N016921</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-347 (of 362)

TRETINOIN

SOLUTION; TOPICAL

TRETINOIN

AT	WOCKHARDT	0.05%	A075260 001	Jan 25, 1999

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	+	FOUGERA PHARMS	0.025%	A085692 001	
AT	+		0.1%	A085692 003	
AT	+		0.5%	A085692 002	
AT		PERRIGO NEW YORK	0.025%	A086415 001	
AT			0.1%	A086414 001	
AT			0.5%	A086413 001	
AT		TARO	0.1%	A040039 001	Nov 26, 1997
AT		VINTAGE	0.025%	A040671 001	Jun 09, 2006
AT			0.1%	A040671 002	Jun 09, 2006

TRIDERM

AT	CROWN LABS	0.1%	A088042 001	Mar 19, 1984

INJECTABLE; INJECTION

KENALOG-10

AB	APOTHECON	10MG/ML	N012041 001	

KENALOG-40

AB	+	APOTHECON	40MG/ML	N014901 001	

TRIAMCINOLONE ACETONIDE

AB	SANDOZ	10MG/ML	A090166 001	May 27, 2009
AB	SANDOZ CANADA INC	40MG/ML	A090164 001	Jun 01, 2009

INJECTABLE; INTRAVITREAL

TRIESENCE

+

ALCON

40MG/ML (40MG/ML)

N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	
AT		0.1%	A040467 002	Apr 21, 2003	
AT	TARO	0.1%	A089129 001	Aug 14, 1986	
AT	VERSAPHARM INC	0.025%	A202374 001	May 08, 2013	
AT		0.1%	A202374 002	May 08, 2013	
AT	VINTAGE	0.1%	A040672 002	Dec 13, 2006	
AT	+	WOCKHARDT	0.1%	A088451 001	Apr 03, 1985
AT	+	WOCKHARDT EU OPERATN	0.025%	A088450 001	Apr 01, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691 001		
AT		0.1%	A085691 003		
AT		0.5%	A085691 002		
AT	+	PERRIGO NEW YORK	0.025%	A087356 001	
AT	+		0.1%	A087357 001	
AT	+		0.5%	A087385 001	
AT	TARO	0.1%	A040037 001	Sep 30, 1994	

TRIAMCINOLONE ACETONIDE IN ABSORBASE

+

CAROLINA MEDCL

0.05%

A089595 001 Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	LYNE	0.1%	A040771 001	Jul 01, 2010	
AT	+	TARO	0.1%	A070730 001	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

+

RANBAXY

0.147MG/GM

N012104 001

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

TEVA PHARMS

0.055MG/SPRAY

A078104 001 Jul 30, 2009

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+

SANDOZ

5MG/ML

N016466 001

+

20MG/ML

N016466 002

PRESCRIPTION DRUG PRODUCT LIST

3-348 (of 362)

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

WELLSPRING PHARM

50MG

N013174 001

+

100MG

N013174 002

TRIAZOLAM

TABLET; ORAL

HALCIONAB PHARMACIA AND UPJOHN0.125MGN017892 003 Apr 26, 1985AB +0.25MGN017892 001 Nov 15, 1982TRIAZOLAMAB MYLAN PHARMS INC0.125MGA074031 001 Mar 25, 1994AB0.25MGA074031 002 Mar 25, 1994AB

ROXANE

0.125MGA074224 001 Jun 01, 1994AB0.25MGA074224 002 Jun 01, 1994AB

WATSON LABS

0.125MGA074445 001 Oct 20, 1995AB0.25MGA074445 002 Oct 20, 1995TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

+ ATON

250MG

N019194 001 Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDEAB MYLANEQ 1MG BASEA040209 001 Jul 07, 1997ABEQ 2MG BASEA040209 002 Jul 07, 1997ABEQ 5MG BASEA040209 003 Jul 07, 1997AB +EQ 10MG BASEA040209 004 Jul 07, 1997AB

SANDOZ

EQ 1MG BASEA085785 001ABEQ 2MG BASEA085786 001ABEQ 5MG BASEA085789 001ABEQ 10MG BASEA085788 001TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINEAT ALCON PHARMS LTD1%A074311 001 Oct 06, 1995VIROPTICAT + MONARCH PHARMS1%N018299 001TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDEAA MIKART2MG/5MLA040251 001 Sep 27, 1999AA +

PHARM ASSOC

2MG/5MLA040177 001 Apr 17, 1997

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDEAA NATCO PHARMA LTD2MGA091630 001 Nov 17, 2010AA5MGA091630 002 Nov 17, 2010AA

VINTAGE PHARMS

2MGA040254 001 Dec 24, 1998AA5MGA040254 002 Dec 24, 1998AA

WATSON LABS

2MGA040184 001 Feb 06, 1998AA +2MGA084363 001AA5MGA040184 002 Feb 06, 1998AA +5MGA084364 001TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+ ABBVIE

150MG

N005856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGANAB + KING PHARMS300MGN017531 006 Dec 13, 2001TRIMETHOBENZAMIDE HYDROCHLORIDEAB GAVIS PHARMS300MGA076546 001 Aug 20, 2003AB

MUTUAL PHARMA

300MGA076570 001 Aug 28, 2003

INJECTABLE; INJECTION

TIGANAP + JHP PHARMS100MG/MLN017530 001

PRESCRIPTION DRUG PRODUCT LIST

3-349 (of 362)

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011

AB	+	TEVA	100MG	N018679 001	Jul 30, 1982

AB	WATSON LABS	100MG	A070049 001	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+ FSC

EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB	ODYSSEY PHARMS	EQ 25MG BASE	N016792 001	

AB		EQ 50MG BASE	N016792 002	

AB	+	EQ 100MG BASE	N016792 003	Sep 15, 1982

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006

AB		EQ 50MG BASE	A077361 002	Aug 02, 2006

AB		EQ 100MG BASE	A077361 003	Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ WATSON LABS

EQ 3.75MG BASE/VIAL

N020715 001 Jun 15, 2000

+

EQ 11.25MG BASE/VIAL

N021288 001 Jun 29, 2001

+

EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA

3.6GM/100ML

N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

AT	+	ALCON	0.5%	A084305 001	

AT	+		1%	A084306 001	

TROPICACYL

AT	AKORN	0.5%	A040314 001	Sep 29, 2000

AT		1%	A040315 001	Sep 29, 2000

TROPICAMIDE

AT	BAUSCH AND LOMB	0.5%	A040067 001	Jul 27, 1994

AT		1%	A040064 001	Jul 27, 1994

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

AB	+	ALLERGAN	60MG	N022103 001	Aug 03, 2007

TROSPIMUM CHLORIDE

AB	PADDOCK LLC	60MG	A201291 001	May 24, 2013

AB	WATSON LABS INC FL	60MG	A091289 001	Oct 12, 2012

TABLET; ORAL

SANCTURA

AB	+	ALLERGAN	20MG	N021595 001	May 28, 2004

TROSPIMUM CHLORIDE

AB	APOTEX	20MG	A091513 001	Dec 06, 2011

AB	GLENMARK GENERICS	20MG	A091575 001	Aug 13, 2010

AB	PADDOCK LLC	20MG	A091573 001	Nov 17, 2010

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+ DORC

0.15%

N022278 001 Feb 20, 2009

VISIONBLUE

+ DORC

0.06%

N021670 001 Dec 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-350 (of 362)

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+ LAB HRA PHARMA 30MG

N022474 001 Aug 13, 2010

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+ GLAXO GRP LTD EQ 0.0625MG BASE/INH; EQ 0.025MG
BASE/INH

N203975 001 Dec 18, 2013

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

SUCAMPO PHARMS 0.15%

N021214 001 Aug 03, 2000

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

+ OTSUKA AMERICA EQ 75MG /POUCH

N020586 002 May 10, 2001

UREA, C-14

CAPSULE; ORAL

PYTEST

+ AVENT 1uCi

N020617 001 May 09, 1997

PYTEST KIT

+ AVENT 1uCi

N020617 002 May 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+ FERRING 75 IU/VIAL

N021289 001 May 06, 2002

URSODIOL

CAPSULE; ORAL

ACTIGALLAB + WATSON PHARMS300MGN019594 002 Dec 31, 1987URSODIOLAB COREPHARMA300MGA077895 001 Jul 27, 2006AB EPIC PHARMA300MGA075517 001 Mar 14, 2000AB LANNETT300MGA079082 001 Dec 15, 2008AB MYLAN300MGA090530 001 Feb 17, 2010AB TEVA PHARMS300MGA075592 001 May 25, 2000

TABLET; ORAL

URSO 250AB APTALIS PHARMA US250MGN020675 001 Dec 10, 1997URSO FORTEAB + APTALIS PHARMA US500MGN020675 002 Jul 21, 2004URSODIOLAB GLENMARK GENERICS250MGA090801 001 Jul 12, 2011AB PAR PHARM500MGA090801 002 Jul 12, 2011AB PAR PHARM250MGA202540 001 Feb 14, 2013AB PAR PHARM500MGA202540 002 Feb 14, 2013AB WATSON LABS INC250MGA200826 001 Dec 23, 2011AB WATSON LABS INC500MGA200826 002 Dec 23, 2011VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDEAB ACTAVIS GRP PTCEQ 1GM BASEA090370 002 Mar 16, 2011AB AUROBINDO PHARMAEQ 500MG BASEA090370 001 Mar 16, 2011AB AUROBINDO PHARMAEQ 1GM BASEA090682 002 May 24, 2010AB DR REDDYS LABS LTDEQ 500MG BASEA090682 001 May 24, 2010AB DR REDDYS LABS LTDEQ 1GM BASEA079012 002 May 24, 2010AB JUBILANT ORGANOSYSEQ 500MG BASEA079012 001 May 24, 2010AB JUBILANT ORGANOSYSEQ 1GM BASEA201506 002 Apr 03, 2012AB MYLANEQ 500MG BASEA201506 001 Apr 03, 2012AB MYLANEQ 1GM BASEA078070 002 May 24, 2010AB MYLAN PHARMS INCEQ 500MG BASEA078070 001 May 24, 2010AB MYLAN PHARMS INCEQ 1GM BASEA078518 002 May 24, 2010AB RANBAXYEQ 500MG BASEA078518 001 May 24, 2010AB RANBAXYEQ 1GM BASEA076588 002 Jan 31, 2007AB ROXANEEQ 500MG BASEA076588 001 Jan 31, 2007AB ROXANEEQ 1GM BASEA078656 002 May 24, 2010AB SANDOZEQ 500MG BASEA078656 001 May 24, 2010AB SANDOZEQ 1GM BASEA077478 002 May 24, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-351 (of 362)

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1GM BASE</u>	<u>A077655</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077655</u>	<u>001</u>	May 24, 2010
<u>AB</u>	WATSON LABS	<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
<u>AB</u>	WOCKHARDT	<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010

VALTREX

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 1GM BASE</u>	<u>N020487</u>	<u>002</u>	Jun 23, 1995
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>N020487</u>	<u>001</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+ HOFFMANN LA ROCHE

50MG/ML

N022257 001 Aug 28, 2009

TABLET; ORAL

VALCYTE

+ HOFFMANN LA ROCHE

EQ 450MG BASE

N021304 001 Mar 29, 2001

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

<u>AP</u>	+	ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593</u>	<u>001</u>	Dec 30, 1996

VALPROATE SODIUM

<u>AP</u>		BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	+	ABBVIE	<u>250MG</u>	<u>N018081</u>	<u>001</u>	

VALPROIC ACID

<u>AB</u>		BANNER PHARMACAPS	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037</u>	<u>001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+	ABBVIE	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	

VALPROIC ACID

<u>AA</u>		ALPHARMA	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>		SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>		TEVA PHARMS	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992
<u>AA</u>		VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006
<u>AA</u>		WOCKHARDT	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+ ENDO PHARM

40MG/ML

N020892 001 Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

NOVARTIS

40MG

N021283 004 Aug 14, 2002

80MG

N021283 001 Jul 18, 2001

160MG

N021283 002 Jul 18, 2001

+

320MG

N021283 003 Jul 18, 2001

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>		VIROPHARMA	<u>EQ 125MG BASE</u>	<u>N050606</u>	<u>001</u>	Apr 15, 1986
<u>AB</u>	+		<u>EQ 250MG BASE</u>	<u>N050606</u>	<u>002</u>	Apr 15, 1986

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		AKORN	<u>EQ 125MG BASE</u>	<u>A065478</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065478</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		FRESENIUS KABI USA	<u>EQ 125MG BASE</u>	<u>A065453</u>	<u>001</u>	Jun 18, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065453</u>	<u>002</u>	Jun 18, 2012
<u>AB</u>		STRIDES ARCOLAB LTD	<u>EQ 125MG BASE</u>	<u>A065490</u>	<u>001</u>	Apr 09, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-352 (of 362)

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065490</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>	WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065510</u>	<u>002</u>	Apr 09, 2012

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	AGILA SPECILTS	<u>EQ 1GM BASE/VIAL</u>	<u>A065397</u>	<u>002</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A065432</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091469</u>	<u>001</u>	Jul 01, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202275</u>	<u>002</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202464</u>	<u>001</u>	Oct 09, 2013
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A202274</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A202275</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>	+ FRESSENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>	+ HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A090250</u>	<u>002</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090250</u>	<u>001</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048</u>	<u>002</u>	Aug 10, 2012
<u>AP</u>	STRIDES ARCOLAB LTD	<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
	VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011
	+	300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	BAYER HLTHCARE	<u>2.5MG</u>	<u>N021400</u>	<u>003</u>	Aug 19, 2003
<u>AB</u>		<u>5MG</u>	<u>N021400</u>	<u>001</u>	Aug 19, 2003
<u>AB</u>		<u>10MG</u>	<u>N021400</u>	<u>002</u>	Aug 19, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021400</u>	<u>004</u>	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A091347</u>	<u>001</u>	May 03, 2012
<u>AB</u>		<u>5MG</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
<u>AB</u>		<u>10MG</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
<u>AB</u>		<u>20MG</u>	<u>A091347</u>	<u>004</u>	May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
	+	EQ 1MG BASE	N021928	002	May 10, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-353 (of 362)

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	AGILA SPECLTS	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
<u>AP</u>	MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>	+ TEVA PHARMS USA	<u>10MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999
<u>AP</u>	WATSON LABS	<u>10MG/VIAL</u>	<u>A074334</u>	<u>001</u>	Aug 31, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074334</u>	<u>002</u>	Aug 31, 1995

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+ HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N020699</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N020699</u>	<u>004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087</u>	<u>001</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078087</u>	<u>002</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078087</u>	<u>003</u>	Mar 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A200834</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200834</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421</u>	<u>001</u>	May 06, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078421</u>	<u>002</u>	May 06, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078421</u>	<u>003</u>	May 06, 2011
<u>AB</u>	MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078789</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078789</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123</u>	<u>001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123</u>	<u>002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123</u>	<u>003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565</u>	<u>002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565</u>	<u>003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	VALEANT BERMUDA	<u>EQ 37.5MG BASE</u>	<u>A090071</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071</u>	<u>003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078865</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174</u>	<u>003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932</u>	<u>005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098</u>	<u>001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098</u>	<u>002</u>	May 11, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-354 (of 362)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		<u>EQ 50MG BASE</u>	<u>A079098</u>	<u>003</u>	May 11, 2010
AB		<u>EQ 75MG BASE</u>	<u>A079098</u>	<u>004</u>	May 11, 2010
AB		<u>EQ 100MG BASE</u>	<u>A079098</u>	<u>005</u>	May 11, 2010
AB	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555</u>	<u>001</u>	Apr 07, 2010
AB		<u>EQ 37.5MG BASE</u>	<u>A090555</u>	<u>002</u>	Apr 07, 2010
AB		<u>EQ 50MG BASE</u>	<u>A090555</u>	<u>003</u>	Apr 07, 2010
AB		<u>EQ 75MG BASE</u>	<u>A090555</u>	<u>004</u>	Apr 07, 2010
AB		<u>EQ 100MG BASE</u>	<u>A090555</u>	<u>005</u>	Apr 07, 2010
AB	CARACO	<u>EQ 25MG BASE</u>	<u>A078627</u>	<u>001</u>	Jun 13, 2008
AB		<u>EQ 37.5MG BASE</u>	<u>A078627</u>	<u>002</u>	Jun 13, 2008
AB		<u>EQ 50MG BASE</u>	<u>A078627</u>	<u>003</u>	Jun 13, 2008
AB		<u>EQ 75MG BASE</u>	<u>A078627</u>	<u>004</u>	Jun 13, 2008
AB		<u>EQ 100MG BASE</u>	<u>A078627</u>	<u>005</u>	Jun 13, 2008
AB	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301</u>	<u>001</u>	Jun 13, 2008
AB		<u>EQ 37.5MG BASE</u>	<u>A078301</u>	<u>002</u>	Jun 13, 2008
AB		<u>EQ 50MG BASE</u>	<u>A078301</u>	<u>003</u>	Jun 13, 2008
AB		<u>EQ 75MG BASE</u>	<u>A078301</u>	<u>004</u>	Jun 13, 2008
AB		<u>EQ 100MG BASE</u>	<u>A078301</u>	<u>005</u>	Jun 13, 2008
AB	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554</u>	<u>001</u>	Jan 09, 2009
AB		<u>EQ 37.5MG BASE</u>	<u>A078554</u>	<u>002</u>	Jan 09, 2009
AB		<u>EQ 50MG BASE</u>	<u>A078554</u>	<u>003</u>	Jan 09, 2009
AB		<u>EQ 75MG BASE</u>	<u>A078554</u>	<u>004</u>	Jan 09, 2009
AB		<u>EQ 100MG BASE</u>	<u>A078554</u>	<u>005</u>	Jan 09, 2009
AB	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166</u>	<u>001</u>	Jun 13, 2008
AB		<u>EQ 37.5MG BASE</u>	<u>A077166</u>	<u>002</u>	Jun 13, 2008
AB		<u>EQ 50MG BASE</u>	<u>A077166</u>	<u>003</u>	Jun 13, 2008
AB		<u>EQ 75MG BASE</u>	<u>A077166</u>	<u>004</u>	Jun 13, 2008
AB		<u>EQ 100MG BASE</u>	<u>A077166</u>	<u>005</u>	Jun 13, 2008
AB	TEVA	<u>EQ 25MG BASE</u>	<u>A076690</u>	<u>001</u>	Aug 03, 2006
AB		<u>EQ 37.5MG BASE</u>	<u>A076690</u>	<u>002</u>	Aug 03, 2006
AB	+	<u>EQ 50MG BASE</u>	<u>A076690</u>	<u>003</u>	Aug 03, 2006
AB		<u>EQ 75MG BASE</u>	<u>A076690</u>	<u>004</u>	Aug 03, 2006
AB		<u>EQ 100MG BASE</u>	<u>A076690</u>	<u>005</u>	Aug 03, 2006
AB	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027</u>	<u>001</u>	Aug 04, 2010
AB		<u>EQ 37.5MG BASE</u>	<u>A090027</u>	<u>002</u>	Aug 04, 2010
AB		<u>EQ 50MG BASE</u>	<u>A090027</u>	<u>003</u>	Aug 04, 2010
AB		<u>EQ 75MG BASE</u>	<u>A090027</u>	<u>004</u>	Aug 04, 2010
AB		<u>EQ 100MG BASE</u>	<u>A090027</u>	<u>005</u>	Aug 04, 2010
AB	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653</u>	<u>001</u>	Jun 13, 2008
AB		<u>EQ 37.5MG BASE</u>	<u>A077653</u>	<u>002</u>	Jun 13, 2008
AB		<u>EQ 50MG BASE</u>	<u>A077653</u>	<u>003</u>	Jun 13, 2008
AB		<u>EQ 75MG BASE</u>	<u>A077653</u>	<u>004</u>	Jun 13, 2008
AB		<u>EQ 100MG BASE</u>	<u>A077653</u>	<u>005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104</u>	<u>001</u>	May 20, 2008
AB		<u>EQ 75MG BASE</u>	<u>N022104</u>	<u>002</u>	May 20, 2008
AB	+	<u>EQ 150MG BASE</u>	<u>N022104</u>	<u>003</u>	May 20, 2008
AB	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272</u>	<u>001</u>	Aug 18, 2010
AB		<u>EQ 75MG BASE</u>	<u>A091272</u>	<u>002</u>	Aug 18, 2010
AB		<u>EQ 150MG BASE</u>	<u>A091272</u>	<u>003</u>	Aug 18, 2010
AB	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	MYLAN	<u>100MG</u>	<u>A078306</u>	<u>001</u>	Aug 09, 2007
AB		<u>120MG</u>	<u>A075138</u>	<u>001</u>	Apr 20, 1999
AB		<u>180MG</u>	<u>A075138</u>	<u>002</u>	Apr 20, 1999
AB		<u>200MG</u>	<u>A078306</u>	<u>002</u>	Aug 09, 2007
AB		<u>240MG</u>	<u>A075138</u>	<u>003</u>	Apr 20, 1999
AB		<u>300MG</u>	<u>A078306</u>	<u>003</u>	Aug 09, 2007
<u>VERELAN</u>					
AB	ALKERMES GAINESVILLE	<u>120MG</u>	<u>N019614</u>	<u>001</u>	May 29, 1990
AB		<u>180MG</u>	<u>N019614</u>	<u>003</u>	Jan 09, 1992
AB		<u>240MG</u>	<u>N019614</u>	<u>002</u>	May 29, 1990
<u>VERELAN PM</u>					
AB	ALKERMES GAINESVILLE	<u>100MG</u>	<u>N020943</u>	<u>001</u>	Nov 25, 1998
AB		<u>200MG</u>	<u>N020943</u>	<u>002</u>	Nov 25, 1998
AB	+	<u>300MG</u>	<u>N020943</u>	<u>003</u>	Nov 25, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-355 (of 362)

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

+ ALKERMES GAINESVILLE 360MG

N019614 004 May 10, 1996

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDEAP HOSPIRA2.5MG/MLA070737 001 May 06, 1987AP2.5MG/MLA070738 001 May 06, 1987AP2.5MG/MLA075136 001 Oct 20, 1998

TABLET; ORAL

CALANAB GD SEARLE LLC40MGN018817 003 Feb 23, 1988AB80MGN018817 001 Sep 10, 1984AB +120MGN018817 002 Sep 10, 1984VERAPAMIL HYDROCHLORIDEAB HERITAGE PHARMS INC80MGA071880 001 Apr 05, 1988AB120MGA071881 001 Apr 05, 1988AB MYLAN80MGA071482 001 Feb 15, 1989AB120MGA071483 001 Feb 15, 1989AB WATSON LABS40MGA072923 001 Jun 29, 1993AB40MGA072924 001 Jun 29, 1993AB80MGA070855 001 Sep 24, 1986AB80MGA070995 001 Oct 01, 1986AB80MGA071366 001 Oct 01, 1986AB120MGA070856 001 Sep 24, 1986AB120MGA070994 001 Oct 01, 1986AB120MGA071367 001 Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SRAB + PFIZER120MGN019152 003 Mar 06, 1991AB +180MGN019152 002 Dec 15, 1989AB +240MGN019152 001 Dec 16, 1986VERAPAMIL HYDROCHLORIDEAB APOTEX CORP120MGA200878 001 Apr 20, 2012AB180MGA200878 002 Apr 20, 2012AB240MGA200878 003 Apr 20, 2012AB CARACO120MGA090529 001 Dec 30, 2011AB180MGA090529 002 Dec 30, 2011AB240MGA090529 003 Dec 30, 2011AB GLENMARK GENERICS120MGA090700 001 Aug 03, 2011AB180MGA090700 002 Aug 03, 2011AB240MGA078906 001 Sep 17, 2009AB IVAX SUB TEVA PHARMS120MGA073568 002 Oct 10, 1997AB180MGA074330 001 Jan 31, 1994AB240MGA073568 001 Jul 31, 1992AB MYLAN120MGA074587 002 Feb 21, 1997AB180MGA074587 003 Sep 09, 1997AB240MGA074587 001 Mar 23, 1996AB PAR PHARM120MGA075072 001 May 25, 1999AB240MGA075072 003 May 25, 1999

COVERA-HS

BC + GD SEARLE LLC

180MG

N020552 001 Feb 26, 1996

BC +

240MG

N020552 002 Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+ VALEANT PHARMS INC 15MG/VIAL

N021119 001 Apr 12, 2000

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+ LUNDBECK LLC

500MG/PACKET

N022006 001 Aug 21, 2009

TABLET; ORAL

SABRIL

+ LUNDBECK LLC

500MG

N020427 001 Aug 21, 2009

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+ FOREST LABS INC

10MG

N022567 001 Jan 21, 2011

20MG

N022567 002 Jan 21, 2011

40MG

N022567 003 Jan 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-356 (of 362)

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+	BEDFORD	10MG/VIAL	A089395	001	Apr 09, 1987
+	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

AP	+	HOSPIRA	<u>1MG/ML</u>	<u>A071484</u>	<u>001</u>	Apr 19, 1988
AP		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A075493</u>	<u>001</u>	Sep 01, 1999
INJECTABLE, LIPOSOMAL; INTRAVENOUS						
MARQIBO KIT						
	+	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP		ONCO THERAPIES LTD	<u>EQ 10MG BASE/ML</u>	<u>A200148</u>	<u>001</u>	Aug 31, 2012

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP	+	PIERRE FABRE	<u>EQ 10MG BASE/ML</u>	<u>N020388</u>	<u>001</u>	Dec 23, 1994

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	<u>EQ 10MG BASE/ML</u>	<u>A078011</u>	<u>001</u>	Jul 22, 2009
AP		BEDFORD	<u>EQ 10MG BASE/ML</u>	<u>A076461</u>	<u>001</u>	Dec 11, 2003
AP		DR REDDYS LABS LTD	<u>EQ 10MG BASE/ML</u>	<u>A202017</u>	<u>001</u>	Sep 12, 2013
AP		EBEWE PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A078408</u>	<u>001</u>	Feb 13, 2008
AP		FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A076849</u>	<u>001</u>	Apr 18, 2005
AP		HIKMA MAPLE	<u>EQ 10MG BASE/ML</u>	<u>A075992</u>	<u>001</u>	Jun 10, 2003
AP		HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A076827</u>	<u>001</u>	Jun 02, 2005
AP		JIANGSU HANSON PHARM	<u>EQ 10MG BASE/ML</u>	<u>A091106</u>	<u>001</u>	Sep 26, 2012
AP		TEVA PHARMS USA	<u>EQ 10MG BASE/ML</u>	<u>A076028</u>	<u>001</u>	Feb 03, 2003

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+	PFIZER	<u>200MG/5ML</u>	<u>N021630</u>	<u>001</u>	Dec 19, 2003

VORICONAZOLE

AB		MYLAN PHARMS INC	<u>200MG/5ML</u>	<u>A202361</u>	<u>001</u>	May 28, 2013

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	<u>200MG/VIAL</u>	<u>N021267</u>	<u>001</u>	May 24, 2002

VORICONAZOLE

AP		SANDOZ INC	<u>200MG/VIAL</u>	<u>A090862</u>	<u>001</u>	May 30, 2012

TABLET; ORAL

VFEND

AB		PFIZER	<u>50MG</u>	<u>N021266</u>	<u>001</u>	May 24, 2002

AB	+		<u>200MG</u>	<u>N021266</u>	<u>002</u>	May 24, 2002

VORICONAZOLE

AB		MYLAN PHARMS INC	<u>50MG</u>	<u>A090547</u>	<u>001</u>	Apr 22, 2010

AB			<u>200MG</u>	<u>A090547</u>	<u>002</u>	Apr 22, 2010

AB		SANDOZ INC	<u>50MG</u>	<u>A200265</u>	<u>001</u>	Dec 12, 2011

AB			<u>200MG</u>	<u>A200265</u>	<u>002</u>	Dec 12, 2011

AB		TEVA PHARMS	<u>50MG</u>	<u>A091658</u>	<u>001</u>	Apr 06, 2012

AB			<u>200MG</u>	<u>A091658</u>	<u>002</u>	Apr 06, 2012

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+	MERCK	100MG	N021991	001	Oct 06, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-357 (of 362)

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

BRINTELLIX

TAKEDA PHARMS USA

EQ 5MG BASE

N204447 001 Sep 30, 2013

EQ 10MG BASE

N204447 002 Sep 30, 2013

EQ 15MG BASE

N204447 003 Sep 30, 2013

+

EQ 20MG BASE

N204447 004 Sep 30, 2013

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

+ BRISTOL MYERS SQUIBB

5MG/VIAL

N009218 024 Feb 07, 1995

TABLET; ORAL

COUMADINAB BRISTOL MYERS SQUIBB1MGN009218 022 Mar 01, 1990AB 2MGN009218 013AB 2.5MGN009218 018AB 3MGN009218 025 Nov 18, 1996AB 4MGN009218 023 Aug 24, 1993AB 5MGN009218 007AB 6MGN009218 026 Nov 18, 1996AB 7.5MGN009218 016AB + 10MGN009218 005JANTOVENAB USL PHARMA1MGA040416 001 Oct 02, 2003AB 2MGA040416 002 Oct 02, 2003AB 2.5MGA040416 003 Oct 02, 2003AB 3MGA040416 004 Oct 02, 2003AB 4MGA040416 005 Oct 02, 2003AB 5MGA040416 006 Oct 02, 2003AB 6MGA040416 007 Oct 02, 2003AB 7.5MGA040416 008 Oct 02, 2003AB 10MGA040416 009 Oct 02, 2003WARFARIN SODIUMAB AMNEAL PHARMS1MGA202202 001 Mar 04, 2013AB 2MGA202202 002 Mar 04, 2013AB 2.5MGA202202 003 Mar 04, 2013AB 3MGA202202 004 Mar 04, 2013AB 4MGA202202 005 Mar 04, 2013AB 5MGA202202 006 Mar 04, 2013AB 6MGA202202 007 Mar 04, 2013AB 7.5MGA202202 008 Mar 04, 2013AB 10MGA202202 009 Mar 04, 2013AB 1MGA040145 001 Mar 26, 1997AB 2MGA040145 002 Mar 26, 1997AB 2.5MGA040145 003 Mar 26, 1997AB 3MGA040145 008 Nov 05, 1998AB 4MGA040145 004 Mar 26, 1997AB 5MGA040145 005 Mar 26, 1997AB 6MGA040145 009 Nov 05, 1998AB 7.5MGA040145 006 Mar 26, 1997AB 10MGA040145 007 Mar 26, 1997AB 1MGA090935 001 May 25, 2011AB 2MGA090935 002 May 25, 2011AB 2.5MGA090935 003 May 25, 2011AB 3MGA090935 004 May 25, 2011AB 4MGA090935 005 May 25, 2011AB 5MGA090935 006 May 25, 2011AB 6MGA090935 007 May 25, 2011AB 7.5MGA090935 008 May 25, 2011AB 10MGA090935 009 May 25, 2011AB 1MGA200104 001 Jun 27, 2013AB 2MGA200104 002 Jun 27, 2013AB 2.5MGA200104 003 Jun 27, 2013AB 3MGA200104 004 Jun 27, 2013AB 4MGA200104 005 Jun 27, 2013AB 5MGA200104 006 Jun 27, 2013AB 6MGA200104 007 Jun 27, 2013AB 7.5MGA200104 008 Jun 27, 2013AB 10MGA200104 009 Jun 27, 2013AB 1MGA040415 001 Sep 27, 2004AB 2MGA040415 002 Sep 27, 2004AB 2.5MGA040415 003 Sep 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-358 (of 362)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>3MG</u>	<u>A040415</u>	<u>004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415</u>	<u>005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415</u>	<u>006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON_XE-133

GAS; INHALATION

XENON_XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
		10mCi/VIAL	N017284	001	

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
	<u>ZAFIRLUKAST</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999
	<u>ZALEPLON</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-359 (of 362)

ZALEPLON

CAPSULE; ORAL

ZALEPLON**AB** WEST WARD**5MG****A078147 001** Nov 25, 2008**AB****10MG****A078147 002** Nov 25, 2008ZANAMIVIR

POWDER; INHALATION

RELENZA

+ GLAXOSMITHKLINE

5MG

N021036 001 Jul 26, 1999

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+ JAZZ PHARMS INTL

100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004

+

500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004

+

500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR**AB** + VIIV HLTHCARE**100MG****N019655 001** Mar 19, 1987ZIDOVUDINE**AB** AUROBINDO PHARMA LTD**100MG****A078128 001** Mar 27, 2006**AB** CIPLA LTD**100MG****A078349 001** May 23, 2007

INJECTABLE; INJECTION

RETROVIR**AP** + VIIV HLTHCARE**10MG/ML****N019951 001** Feb 02, 1990ZIDOVUDINE**AP** LIAONING CHENGDA**10MG/ML****A204538 001** Nov 26, 2013**AP** LUITPOLD**10MG/ML****A091457 001** May 06, 2010

SYRUP; ORAL

RETROVIR**AA** + VIIV HLTHCARE**50MG/5ML****N019910 001** Sep 28, 1989ZIDOVUDINE**AA** AUROBINDO**50MG/5ML****A077268 001** Sep 19, 2005**AA** CIPLA LTD**50MG/5ML****A077981 001** Jun 26, 2008

TABLET; ORAL

ZIDOVUDINE**AB** AUROBINDO**300MG****A077267 001** Sep 19, 2005**AB** CIPLA**300MG****A090561 001** Oct 27, 2010**AB** + HETERO LABS LTD III**300MG****A090092 001** Apr 25, 2008**AB** MYLAN PHARMS INC**300MG****A078922 001** Feb 14, 2008**AB** ROXANE**300MG****A076844 001** Sep 19, 2005**AB** SUNSHINE LAKE**300MG****A202058 001** Oct 07, 2011ZILEUTON

TABLET; ORAL

ZYFLO

+ CORNERSTONE THERAP

600MG

N020471 003 Dec 09, 1996

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+ CORNERSTONE THERAP

600MG

N022052 001 May 30, 2007

ZINC ACETATE

CAPSULE; ORAL

GALZIN

TEVA

EQ 25MG ZINC

N020458 001 Jan 28, 1997

+

EQ 50MG ZINC

N020458 002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1MG ZINC/ML

N018959 001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON**AB** + PFIZER**EQ 20MG BASE****N020825 001** Feb 05, 2001**AB****EQ 40MG BASE****N020825 002** Feb 05, 2001**AB****EQ 60MG BASE****N020825 003** Feb 05, 2001**AB****EQ 80MG BASE****N020825 004** Feb 05, 2001ZIPRASIDONE HYDROCHLORIDE**AB** APOTEX CORP**EQ 20MG BASE****A077561 001** Mar 02, 2012**AB****EQ 40MG BASE****A077561 002** Mar 02, 2012**AB****EQ 60MG BASE****A077561 003** Mar 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-360 (of 362)

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077561</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 20MG BASE</u>	<u>A077565</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077565</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077565</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077565</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	LUPIN PHARMS	<u>EQ 20MG BASE</u>	<u>A077560</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077560</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077560</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077560</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A202395</u>	<u>001</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202395</u>	<u>002</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202395</u>	<u>003</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202395</u>	<u>004</u>	Oct 10, 2013
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562</u>	<u>003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562</u>	<u>004</u>	Jun 01, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348</u>	<u>004</u>	Sep 05, 2012

SUSPENSION; ORAL

GEODON

+ PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLAST

<u>AP</u>	+ NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817</u>	<u>001</u>	Apr 16, 2007
	<u>ZOLEDRONIC ACID</u>				
<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 4MG BASE/100ML</u>	<u>N203231</u>	<u>001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828</u>	<u>001</u>	Sep 23, 2013
<u>AP</u>	ACTAVIS INC	<u>EQ 4MG BASE/5ML</u>	<u>A202472</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>	AGILA SPECLTS	<u>EQ 4MG BASE/5ML</u>	<u>A202650</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363</u>	<u>001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783</u>	<u>001</u>	Mar 12, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801</u>	<u>001</u>	Mar 29, 2013
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182</u>	<u>001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 5MG BASE/100ML</u>	<u>A202837</u>	<u>001</u>	Apr 05, 2013
<u>AP</u>	PHARMACEUTICS	<u>EQ 4MG BASE/5ML</u>	<u>A091170</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A202571</u>	<u>001</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 4MG BASE/5ML</u>	<u>A202746</u>	<u>001</u>	Mar 04, 2013

ZOMETA

<u>AP</u>	+ NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223</u>	<u>002</u>	Mar 07, 2003
<u>AP</u>	+ ZOLEDRONIC ACID	<u>EQ 4MG BASE/100ML</u>	<u>N021223</u>	<u>003</u>	Jun 17, 2011
	+ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

ASTRAZENECA

2.5MG/SPRAY

N021450 003 Sep 16, 2013

+

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078</u>	<u>002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779</u>	<u>002</u>	May 14, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186</u>	<u>002</u>	May 14, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-361 (of 362)

ZOLMITRIPTAN

TABLET; ORAL

ZOMIGAB IPR 2.5MGN020768 001 Nov 25, 1997AB + 5MGN020768 002 Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTANAB APOTEX INC 2.5MGA202476 001 May 14, 2013AB 5MGA202476 002 May 14, 2013AB GLENMARK GENERICS 2.5MGA202560 001 May 14, 2013AB 5MGA202560 002 May 14, 2013AB ZYDUS PHARMS USA INC 2.5MGA202890 001 May 15, 2013AB 5MGA202890 002 May 15, 2013ZOMIG-ZMTAB ASTRAZENECA 2.5MGN021231 001 Feb 13, 2001AB + 5MGN021231 002 Sep 17, 2001ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ NOVADEL

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIENAB SANOFI AVENTIS US 5MGN019908 001 Dec 16, 1992AB + 10MGN019908 002 Dec 16, 1992ZOLPIDEM TARTRATEAB APOTEX INC 5MGA077884 001 Apr 23, 2007AB 10MGA077884 002 Apr 23, 2007AB AUROBINDO PHARMA 5MGA078413 001 May 04, 2007AB 10MGA078413 002 May 04, 2007AB CARACO 5MGA077359 001 Apr 23, 2007AB 10MGA077359 002 Apr 23, 2007AB CARLSBAD 5MGA077990 001 Apr 23, 2007AB 10MGA077990 002 Apr 23, 2007AB CIPLA LTD 5MGA077388 001 Jul 30, 2012AB 10MGA077388 002 Jul 30, 2012AB HIKMA 5MGA078129 001 Apr 30, 2008AB 10MGA078129 002 Apr 30, 2008AB INVAGEN PHARMS 5MGA078184 001 Sep 07, 2007AB 10MGA078184 002 Sep 07, 2007AB LEK PHARMS DD 5MGA077322 001 Apr 23, 2007AB 10MGA077322 002 Apr 23, 2007AB MYLAN 5MGA076578 001 Apr 23, 2007AB 10MGA076578 002 Apr 23, 2007AB RANBAXY 5MGA078055 001 Apr 23, 2007AB 10MGA078055 002 Apr 23, 2007AB ROXANE 5MGA077214 001 Apr 23, 2007AB 10MGA077214 002 Apr 23, 2007AB TEVA 5MGA076410 001 Apr 23, 2007AB 10MGA076410 002 Apr 23, 2007AB TORRENT PHARMS 5MGA077903 001 Aug 17, 2007AB 10MGA077903 002 Aug 17, 2007AB VINTAGE 5MGA078616 001 Nov 21, 2008AB 10MGA078616 002 Nov 21, 2008AB WATSON LABS 5MGA077773 001 Apr 23, 2007AB 10MGA077773 002 Apr 23, 2007AB WOCKHARDT 5MGA078426 001 May 15, 2007AB 10MGA078426 002 May 15, 2007

TABLET; SUBLINGUAL

EDLUAR

MEDA PHARMS

5MG

N021997 001 Mar 13, 2009

+

10MG

N021997 002 Mar 13, 2009

INTERMEZZO

PURDUE PHARMA

1.75MG

N022328 001 Nov 23, 2011

+

3.5MG

N022328 002 Nov 23, 2011

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CRAB SANOFI AVENTIS US 6.25MGN021774 002 Sep 02, 2005AB + 12.5MGN021774 001 Sep 02, 2005ZOLPIDEM TARTRATEAB ACTAVIS ELIZABETH 6.25MGA078179 002 Oct 13, 2010AB 12.5MGA078179 001 Jun 06, 2011AB ANCHEN PHARMS 6.25MGA078148 002 Apr 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-362 (of 362)

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

<u>AB</u>		<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266</u>	<u>001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266</u>	<u>002</u>	Sep 10, 2013
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>	WATSON LABS INC FL	<u>6.25MG</u>	<u>A090153</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A090153</u>	<u>002</u>	Mar 25, 2013

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789</u>	<u>002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	BARR	<u>25MG</u>	<u>A077639</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077639</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077639</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077644</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077644</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077644</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

4-1 (of 17)

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

A072237 001 Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987

650MG

A070608 001 Dec 01, 1986

TARO PHARMS NORTH

120MG

N018337 003 Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

INFANTS' FEVERALL

TARO PHARMS NORTH

80MG

N018337 004 Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001 Mar 19, 2002

PERRIGO

650MG

A075077 001 Feb 25, 2000

RANBAXY LABS LTD

650MG

A078569 001 Dec 14, 2011

TYLENOL

+ MCNEIL CONS

650MG

N019872 001 Jun 08, 1994

+

650MG

N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG; 250MG; 65MG

A075794 001 Nov 26, 2001

EXCEDRIN (MIGRAINE)

+ NOVARTIS

250MG; 250MG; 65MG

N020802 001 Jan 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

+ NOVARTIS

500MG; EQ 0.25MG BASE; 30MG

N021082 001 Mar 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

+ SCHERING PLOUGH

500MG; 3MG; 60MG

N019453 001 May 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+ 3M

61%; 1%

N021074 001 Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG; 20MG

A071793 001 Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG; 20MG

N018685 001 Dec 09, 1983

+

160MG; 40MG

N018685 002 Dec 09, 1983

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+ PLX PHARMA

325MG

N203697 001 Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA

2%; 2%; 10%

N021502 001 Jul 21, 2006

CAPITAL SOLEIL 15

+ LOREAL USA

2%; 3%; 10%

N021501 001 Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA

2%; 2%; 10%; 2%

N021471 001 Oct 05, 2006

ANTHELIOS 40

+ LOREAL USA

2%; 3%; 10%; 5%

N022009 001 Mar 31, 2008

+

2%; 3%; 10%; 5%

N022009 002 Oct 29, 2009

OTC DRUG PRODUCT LIST

4-2 (of 17)

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ SCHERING PLOUGH 3%; 7.5%; 3%

N020045 001 Dec 07, 1992

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+ STAND HOMEOPATH 5%

N020532 001 Aug 26, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

LOTTRIMIN ULTRA

+ SCHERING PLOUGH 1%

N021307 001 Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2%

N020421 001 Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG; 10MG; 165MG

A077355 001 Feb 06, 2008

PEPCID COMPLETE

+ MCNEIL CONS 800MG; 10MG; 165MG

N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER PHARMACAPS 5MG

N022429 001 Jul 23, 2009

+ 10MG

N022429 004 Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER PHARMACAPS 5MG

N022429 003 Jul 23, 2009

+ 10MG

N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML

A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML

A090750 002 Feb 02, 2010

BIO PHARM INC 5MG/5ML

A090474 002 Mar 30, 2009

CARACO 5MG/5ML

A091327 001 Oct 17, 2011

CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008

PERRIGO R AND D 5MG/5ML

A204226 001 Sep 09, 2013

5MG/5ML

A090254 002 Apr 09, 2008

SILARX 5MG/5ML

A091130 001 Apr 22, 2011

TARO 5MG/5ML

A090182 002 Apr 22, 2008

5MG/5ML

A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML

A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML

A090765 001 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML

A090750 001 Feb 02, 2010

BIO PHARM INC 5MG/5ML

A090474 001 Mar 30, 2009

CARACO 5MG/5ML

A091327 002 Oct 17, 2011

CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008

PERRIGO R AND D 5MG/5ML

A090254 001 Apr 09, 2008

SILARX 5MG/5ML

A091130 002 Apr 22, 2011

TARO 5MG/5ML

A090182 001 Apr 22, 2008

5MG/5ML

A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML

A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER 5MG/5ML

N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ MCNEIL CONSUMER 5MG/5ML

N022155 001 Nov 16, 2007

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG

A078780 001 Jan 21, 2010

10MG

A078780 004 Jan 21, 2010

APOTEX INC 5MG

A078317 001 Dec 27, 2007

10MG

A078317 002 Dec 27, 2007

CADISTA PHARMS 5MG

A078933 001 Jun 15, 2010

10MG

A078933 002 Jun 15, 2010

CARACO 5MG

A077499 001 Dec 27, 2007

10MG

A077499 002 Dec 27, 2007

CIPLA LTD 5MG

A077318 001 Jul 25, 2013

10MG

A077318 002 Jul 25, 2013

OTC DRUG PRODUCT LIST

4-3 (of 17)

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
RANBAXY	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
CARACO	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

Zyrtec Allergy

MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

Zyrtec Hives Relief

MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CARACO	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008
SANDOZ	5MG	A078692	001	Feb 14, 2008
+	10MG	A078692	002	Feb 14, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CARACO	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
	10MG	A090142	002	Aug 30, 2011

OTC DRUG PRODUCT LIST

4-4 (of 17)

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARMA GLOBAL

5MG

A090142 003 Aug 30, 2011

10MG

A090142 004 Aug 30, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

ZYRTEC ALLERGY

+ MCNEIL CONSUMER

10MG

N022578 001 Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

5MG;120MG

A077170 001 Feb 25, 2008

SANDOZ

5MG;120MG

A077991 001 Mar 05, 2008

SUN PHARM INDS LTD

5MG;120MG

A090922 001 Sep 28, 2012

ZYRTEC-D 12 HOUR

+ MCNEIL

5MG;120MG

N021150 002 Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+ XTTRIUM

4%

N019127 001 Dec 24, 1984

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS

2%

N021669 001 Apr 25, 2005

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO

4%

A071419 001 Dec 17, 1987

CHG SCRUB

ECOLAB

4%

N019258 002 Jul 22, 1986

CIDA-STAT

ECOLAB

2%

N019258 001 Jul 22, 1986

DYNA-HEX

BAJAJ MEDICAL LLC

0.75%

N020111 001 Sep 11, 1997

EXIDINE

+ XTTRIUM

2%

N019422 001 Dec 17, 1985

4%

N019125 001 Dec 24, 1984

HIBICLENS

+ MOLNLYCKE HLTH

4%

N017768 001

HIBISTAT

+ MOLNLYCKE HLTH

0.5%

N018300 001

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN

4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

BECTON DICKINSON

4%

A072525 001 Oct 24, 1989

PHARMASEAL SCRUB CARE

+ CAREFUSION

4%

N019793 001 Dec 02, 1988

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ CAREFUSION

2%;70% (3ML)

N020832 001 Jul 14, 2000

+

2%;70% (10.5ML)

N020832 004 Aug 20, 2003

+

2%;70% (26ML)

N020832 006 Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+ CAREFUSION

2%;70% (1.5ML)

N020832 003 Apr 26, 2002

CHLORAPREP WITH TINT

+ CAREFUSION

2%;70% (26ML)

N020832 002 May 03, 2005

+

2%;70% (10.5ML)

N020832 005 Apr 03, 2006

+

2%;70% (3ML)

N020832 007 Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION

2%;70% (0.67ML)

N021555 001 Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION

2%;70% (1.75ML)

N021555 002 May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION

2%;70% (5.25ML)

N021555 003 Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+ PROF DSPLS

3.15%;70% (5.1ML)

N021524 003 Jun 03, 2005

PREVANTICS SWAB

+ PROF DSPLS

3.15%;70% (1ML)

N021524 001 Jun 03, 2005

OTC DRUG PRODUCT LIST

4-5 (of 17)

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

PREVANTICS SWABSTICK

+ PROF DSPLS	3.15%; 70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH	12MG	N007638	002	

CHLORPHENIRAMINE MALEATE

AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+ PFIZER	4MG; 200MG; 10MG	N022113	001	Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ PFIZER	1MG/5ML; 100MG/5ML; 15MG/5ML	N021587	001	Feb 24, 2004

TABLET; ORAL

ADVIL ALLERGY SINUS

+ PFIZER	2MG; 200MG; 30MG	N021441	001	Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH	8MG; 120MG	N018397	001	

CIMETIDINE

TABLET; ORAL

CIMETIDINE

APOTEX	100MG	A074948	001	Jun 19, 1998

	200MG	A074948	002	Jul 26, 2002

CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998

	200MG	A074963	001	Jun 19, 1998

IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999

PERRIGO	200MG	A075285	001	Oct 29, 1998

WATSON LABS	200MG	A075425	001	Jul 29, 1999

TAGAMET HB

+ MEDTECH PRODS	200MG	N020238	002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

PERRIGO	1.34MG	A074512	001	Nov 22, 1995

SANDOZ	1.34MG	A073458	001	Oct 31, 1993

TAVIST-1

+ NOVARTIS	1.34MG	N020925	001	Aug 21, 1992

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993

TARO	1%	A072641	001	Dec 04, 1995

GYNE-LOTRIMIN

+ SCHERING PLOUGH	1%	N018052	002	Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH	2%	N020574	001	Nov 24, 1998

MYCELEX-7

BAYER	1%	N018230	002	Dec 26, 1991

TRIVAGIZOLE 3

TARO	2%	N021143	001	Apr 12, 2000

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ SCHERING PLOUGH	200MG; 200MG	N020526	002	Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ SCHERING PLOUGH	100MG; 100MG	N020289	002	Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER	1%; 100MG	N020389	002	Jun 23, 1994

TABLET; VAGINAL

GYNE-LOTRIMIN

+ SCHERING PLOUGH	100MG	N017717	002	Nov 30, 1990

OTC DRUG PRODUCT LIST

4-6 (of 17)

CLOTRIMAZOLE

TABLET;VAGINAL

GYNE-LOTIMIN 3

+ SCHERING PLOUGH 200MG N020525 001 Jul 29, 1996

MYCELEX-7

BAYER 100MG N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY A075427 001 Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG A078648 001 Feb 27, 2013

DISOPHROL

SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982

DRIXORAL

SCHERING PLOUGH 6MG;120MG N013483 003 Sep 13, 1982

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX DM

RECKITT BENCKISER 30MG;600MG N021620 002 Apr 29, 2004

+ 60MG;1.2GM N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+ PFIZER 38MG;200MG N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG;200MG A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+ PFIZER 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER PHARMACAPS 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A090397 001 Nov 22, 2010

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A200888 001 Mar 05, 2012

DOCOSANOL

CREAM;TOPICAL

ABREVA

+ GLAXOSMITHKLINE 10% N020941 001 Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

LNK 25MG A040564 001 Aug 27, 2004

PERRIGO 25MG A040167 001 Sep 18, 1996

UNISOM

+ CHATTEM 25MG N018066 001

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

DR REDDYS LABS LTD 10MG A075758 001 Aug 17, 2001

20MG A077367 001 Sep 25, 2006

IVAX SUB TEVA PHARMS 10MG A075512 001 Jul 26, 2001

MYLAN 10MG A075674 001 Dec 21, 2001

PERRIGO 10MG A075400 001 Mar 18, 2005

20MG A077351 001 Sep 25, 2006

RANBAXY 10MG A090283 001 Nov 17, 2009

OTC DRUG PRODUCT LIST

4-7 (of 17)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	20MG	A090283	002	Nov 17, 2009
TEVA	10MG	A075312	001	May 31, 2001
WATSON LABS	10MG	A075404	001	Nov 28, 2001
WOCKHARDT	10MG	A077146	001	Mar 07, 2005
	20MG	A090837	001	Aug 04, 2010
PEPCID AC				
MCNEIL CONS	10MG	N020325	001	Apr 28, 1995
+	20MG	N020325	002	Sep 23, 2003
PEPCID AC				
MCNEIL CONS	10MG	N020902	001	Aug 05, 1999
TABLET, CHEWABLE; ORAL				
FAMOTIDINE				
PERRIGO	10MG	A075715	001	Aug 22, 2003
PEPCID AC				
+	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES					
+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
+	180MG	N020872	010	Jan 24, 2011
ALLEGRA HIVES				
SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011
+	180MG	N020872	009	Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
MYLAN	30MG	A077081	004	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
TEVA	30MG	A076447	004	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
MYLAN	30MG	A077081	005	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
TEVA	30MG	A076447	005	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
	180MG	A076502	008	Apr 12, 2011
MYLAN	60MG	A077081	006	Jul 21, 2011
	180MG	A077081	008	Jul 21, 2011
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
	180MG	A076447	009	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

OTC DRUG PRODUCT LIST

4-8 (of 17)

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG

N021909 002 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N021909 003 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 60MG;120MG

N020786 002 Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 180MG;240MG

N021704 002 Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD 180MG;240MG

A079043 002 Jun 22, 2011

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

PERRIGO R AND D 600MG

A078912 001 Nov 23, 2011

MUCINEX

+ RECKITT BENCKISER 1.2GM

N021282 002 Dec 18, 2002

600MG

N021282 001 Jul 12, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

+ RECKITT BENCKISER 1.2GM;120MG

N021585 002 Jun 22, 2004

600MG;60MG

N021585 001 Jun 22, 2004

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS

EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

BANNER PHARMACAPS

EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

+ CONTRACT PHARMACAL

200MG

A074782 001 Jul 06, 1998

MARKSANS PHARMA

EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

PLD ACQUISITIONS

EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS

200MG

N021472 001 Oct 18, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL

PFIZER

100MG/5ML

N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER

100MG/5ML

N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

ALTERNA TCHP LLC

100MG/5ML

N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO

100MG/5ML

A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL

100MG/5ML

N020516 001 Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC

100MG/5ML

A074916 001 Apr 30, 1999

AMNEAL PHARMS

100MG/5ML

A200457 001 Aug 18, 2011

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS

40MG/ML

N020603 001 Jun 10, 1996

IBUPROFEN

PERRIGO

40MG/ML

A075217 001 Dec 16, 1998

TRIS PHARMA INC

40MG/ML

A079058 001 Aug 31, 2009

PEDIATRIC ADVIL

+ PFIZER

100MG/2.5ML

N020812 001 Jan 30, 1998

TABLET; ORAL

ADVIL

PFIZER

200MG

N018989 001 May 18, 1984

OTC DRUG PRODUCT LIST

4-9 (of 17)

IBUPROFEN

TABLET; ORAL

IBU-TAB 200					
ALRA	200MG	A071057	001	Aug 11, 1988	
IBUPROFEN					
AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987	
	200MG	A072199	001	May 23, 1988	
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	
CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987	
	200MG	A071735	001	Sep 10, 1987	
	200MG	A072299	001	Jul 01, 1988	
	200MG	A074931	001	Jul 20, 1998	
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001	
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001	
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010	
LNK	100MG	A076741	001	Jun 17, 2004	
	200MG	A075010	001	Mar 01, 1999	
	200MG	A075139	001	Mar 01, 1999	
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	
	200MG	A091239	001	Feb 01, 2011	
MCNEIL	200MG	A073019	001	Mar 30, 1994	
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	
OHM	200MG	A071163	001	Jul 15, 1986	
PAR PHARM	200MG	A070481	001	Sep 24, 1986	
PERRIGO	200MG	A072096	001	Dec 08, 1987	
	200MG	A075995	001	Mar 14, 2002	
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005	
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	
	200MG	A091355	001	Apr 04, 2011	
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987	
	200MG	A071639	001	Feb 02, 1988	
WATSON LABS	200MG	A070435	001	Mar 05, 1986	
IBUPROHM					
OHM LABS	200MG	A071214	001	Dec 01, 1986	
JUNIOR STRENGTH ADVIL					
PFIZER	100MG	N020267	002	Dec 13, 1996	
JUNIOR STRENGTH IBUPROFEN					
PERRIGO	100MG	A075367	001	Apr 22, 1999	
JUNIOR STRENGTH MOTRIN					
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996	
MOTRIN IB					
+ MCNEIL	200MG	N019012	003	Dec 17, 1990	
MOTRIN MIGRAINE PAIN					
+ MCNEIL	200MG	N019012	004	Feb 25, 2000	
PROFEN					
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986	
TAB-PROFEN					
PERRIGO	200MG	A072095	001	Dec 08, 1987	
TABLET, CHEWABLE; ORAL					
CHILDREN'S ADVIL					
PFIZER	50MG	N020944	001	Dec 18, 1998	
CHILDREN'S MOTRIN					
MCNEIL CONS	50MG	N020601	001	Nov 15, 1996	
IBUPROFEN					
PERRIGO	50MG	A076359	001	Jan 16, 2004	
	100MG	A076359	002	Jan 16, 2004	
JUNIOR STRENGTH ADVIL					
PFIZER	100MG	N020944	002	Dec 18, 1998	
JUNIOR STRENGTH MOTRIN					
+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996	

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL					
+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF					
+ PFIZER	200MG; 10MG	N022565	001	May 27, 2010	

OTC DRUG PRODUCT LIST

4-10 (of 17)

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM
SALT; 30MG

N021374 001 May 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

PFIZER

100MG/5ML; 15MG/5ML

N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+ MCNEIL CONS

100MG/5ML; 15MG/5ML

N021128 001 Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO

100MG/5ML; 15MG/5ML

A076478 001 Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS

+ PFIZER

200MG; 30MG

N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL

200MG; 30MG

A075588 001 Apr 08, 2002

DR REDDYS LABS LTD

200MG; 30MG

A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS

200MG; 30MG

A074567 001 Apr 17, 2001

SINE-AID IB

MCNEIL CONS

200MG; 30MG

N019899 001 Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY

100 UNITS/ML

N018780 001 Oct 28, 1982

HUMULIN R PEN

+ LILLY

100 UNITS/ML

N018780 005 Aug 06, 1998

NOVOLIN R

+ NOVO NORDISK INC

100 UNITS/ML

N019938 001 Jun 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY

30 UNITS/ML; 70 UNITS/ML

N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY

30 UNITS/ML; 70 UNITS/ML

N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY

100 UNITS/ML

N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC

100 UNITS/ML

N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M

EQ 0.7% IODINE; 74% (6ML)

N021586 001 Sep 29, 2006

+

EQ 0.7% IODINE; 74% (26ML)

N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ MCNEIL CONS

1%

N020310 001 Oct 10, 1997

KETOPROFEN

FILM; ORAL

NEXCEDE

+ NOVARTIS

12.5MG

N022470 001 Nov 25, 2009

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB

EQ 0.025% BASE

N021996 001 Dec 01, 2006

KETOTIFEN FUMARATE

AKORN

EQ 0.025% BASE

A077958 001 Jul 26, 2007

ALCON PHARMS LTD

EQ 0.025% BASE

A077200 001 Sep 02, 2008

ZADITOR

+ ALCON PHARMA

EQ 0.025% BASE

N021066 002 Oct 19, 2006

OTC DRUG PRODUCT LIST

4-11 (of 17)

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR				
+ NOVARTIS	15MG	N022327	001	May 18, 2009

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
+ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009
WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
PLAN B				
+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006
PLAN B ONE-STEP				
+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS	1MG	N021855	001	Aug 04, 2005
+	2MG	N021855	002	Aug 04, 2005

SOLUTION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

TABLET; ORAL

IMODIUM A-D

+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992
PERRIGO	2MG	A075232	001	Jan 06, 2000

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ MCNEIL	2MG	N020448	001	Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL CONS	2MG; 125MG	N021140	001	Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

RANBAXY	2MG; 125MG	A077500	001	Sep 06, 2006

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL	2MG; 125MG	N020606	001	Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO	2MG; 125MG	A076029	001	Aug 30, 2002

LORATADINE

CAPSULE; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N021952	001	Jun 16, 2008

SUSPENSION; ORAL

LORATADINE

+ TARO	1MG/ML	N021734	001	Oct 04, 2005

SYRUP; ORAL

CLARITIN

+ SCHERING PLOUGH	1MG/ML	N020641	002	Nov 27, 2002

OTC DRUG PRODUCT LIST

4-12 (of 17)

LORATADINE

SYRUP; ORAL

LORATADINE

PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
SILARX	1MG/ML	A077421	001	Jun 29, 2006
TARO	1MG/ML	A076805	001	Aug 20, 2004
TEVA	1MG/ML	A075505	001	Nov 07, 2003
WOCKHARDT	1MG/ML	A075815	001	Aug 20, 2004

TABLET; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N019658	002	Nov 27, 2002

CLARITIN HIVES RELIEF

+ SCHERING PLOUGH	10MG	N019658	003	Nov 19, 2003

LORATADINE

APOTEX INC	10MG	A076471	001	Feb 14, 2006
MYLAN	10MG	A075790	001	Nov 07, 2008
	10MG	A076154	001	Aug 20, 2003
	10MG	A078447	001	Aug 12, 2011
PERRIGO	10MG	A076301	001	Jun 25, 2004
RANBAXY	10MG	A076134	001	Aug 18, 2003
SANDOZ	10MG	A075209	001	Jan 21, 2003

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH	5MG	N021891	001	Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

PFIZER	10MG	N021375	001	Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ SCHERING PLOUGH	10MG	N020704	003	Nov 19, 2003

CLARITIN REDITABS

+ SCHERING PLOUGH	5MG	N021993	001	Dec 12, 2006

	10MG	N020704	002	Nov 27, 2002

LORATADINE

IMPAX LABS	10MG	A076011	001	Sep 29, 2003
PFIZER	10MG	A075822	001	Feb 10, 2003
WATSON LABS FLORIDA	10MG	A075990	001	Nov 03, 2003

LORATADINE REDIDOSE

RANBAXY	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH	5MG; 120MG	N019670	002	Nov 27, 2002

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH	10MG; 240MG	N020470	002	Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS	5MG; 120MG	A076050	001	Jan 30, 2003
	10MG; 240MG	A075989	001	Mar 04, 2004
RANBAXY	10MG; 240MG	A076557	001	Sep 22, 2004
WATSON LABS FLORIDA	10MG; 240MG	A075706	001	Feb 21, 2003

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU PHARM CO	3%; 10%	N022029	001	Feb 20, 2008
	3%; 10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO	2%; 4%	A076357	001	Mar 30, 2004

MONISTAT 3 COMBINATION PACK

INSIGHT PHARMS	2%; 4%	N021261	003	Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ INSIGHT PHARMS	2%; 4%	N021261	001	Feb 02, 2001

CREAM; VAGINAL

MICONAZOLE 3

TARO	4%	A076773	001	Mar 02, 2005

MICONAZOLE 7

ACTAVIS MID ATLANTIC	2%	A074164	001	Mar 29, 1996

MICONAZOLE NITRATE

G AND W LABS INC	2%	A074366	001	Feb 22, 1996
PERRIGO	2%	A074760	001	May 15, 1997
PERRIGO R AND D	4%	A091366	001	Jan 15, 2010

OTC DRUG PRODUCT LIST

4-13 (of 17)

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO 2%

A074444 001 Jan 13, 1997

MONISTAT 3

+ INSIGHT PHARMS 4%

N020827 001 Mar 30, 1998

MONISTAT 7

+ INSIGHT PHARMS 2%

N017450 002 Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%;200MG

A074926 001 Apr 16, 1999

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 100MG;2%

A076585 001 Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D 1.2GM;2%

A079114 001 Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 200MG;200MG

A075329 001 Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+ INSIGHT PHARMS 1.2GM;2%

N021308 001 Jun 29, 2001

MONISTAT 7 COMBINATION PACK

+ INSIGHT PHARMS 100MG;2%

N020288 002 Apr 26, 1993

MONISTAT-3 COMBINATION PACK

+ INSIGHT PHARMS 2%;200MG

N020670 002 Apr 16, 1996

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

A073507 001 Nov 19, 1993

G AND W LABS 100MG

A074414 001 Apr 30, 1997

+ PERRIGO 100MG

A074395 001 Mar 20, 1997

MONISTAT 7

+ INSIGHT PHARMS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5%

A091344 001 Apr 28, 2011

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

A074588 001 Apr 05, 1996

HI TECH PHARMA 2%

A074731 001 Dec 24, 1996

PERRIGO 2%

A075357 001 Jul 30, 1999

WOCKHARDT 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2%

A074731 002 May 11, 2005

PERRIGO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

A075518 001 Nov 17, 2000

AVACOR PRODS 5%

A075619 001 Nov 17, 2000

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

WOCKHARDT 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315%

A078208 001 Sep 27, 2010

NAPHCN-A

+ ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

OPCON-A

+ BAUSCH AND LOMB 0.02675%;0.315%

N020065 001 Jun 08, 1994

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996

OTC DRUG PRODUCT LIST

4-14 (of 17)

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS EQ 200MG BASE

N021920 001 Feb 17, 2006

TABLET;ORAL

ALEVE

+ BAYER EQ 200MG BASE

N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE

A079096 001 Dec 16, 2008

CONTRACT PHARMACAL EQ 200MG BASE

A074635 001 Jan 13, 1997

EQ 200MG BASE

A074789 001 Feb 27, 1997

DR REDDYS LABS INC EQ 200MG BASE

A075168 001 Jul 28, 1998

GRANULES INDIA EQ 200MG BASE

A091353 001 Sep 20, 2011

MARKSANS PHARMA EQ 200MG BASE

A090545 001 Mar 16, 2011

PERRIGO EQ 200MG BASE

A074661 001 Jan 13, 1997

RANBAXY LABS LTD EQ 200MG BASE

A091183 001 May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ BAYER 200MG;120MG

N021076 001 Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC EQ 220MG BASE;120MG

A077381 001 Sep 27, 2006

PERRIGO EQ 200MG BASE;120MG

A076518 001 Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ NOVARTIS 7MG/24HR

N020076 004 Nov 12, 1999

+ 14MG/24HR

N020076 005 Nov 12, 1999

+ 21MG/24HR

N020076 006 Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US 7MG/24HR

N020165 006 Aug 02, 1996

+ 14MG/24HR

N020165 005 Aug 02, 1996

+ 21MG/24HR

N020165 004 Aug 02, 1996

NICOTINE

AVEVA 7MG/24HR

A074612 002 Jul 28, 2003

14MG/24HR

A074612 003 Oct 20, 1997

21MG/24HR

A074612 001 Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE

N018612 002 Feb 09, 1996

EQ 2MG BASE

N018612 004 Sep 25, 2000

+ EQ 4MG BASE

N020066 002 Feb 09, 1996

EQ 4MG BASE

N020066 004 Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE EQ 2MG BASE

N018612 003 Dec 23, 1998

EQ 4MG BASE

N020066 003 Dec 23, 1998

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS EQ 2MG BASE

A076880 001 Feb 18, 2009

EQ 4MG BASE

A077850 001 Feb 18, 2009

PERRIGO EQ 2MG BASE

A076775 001 Sep 16, 2004

EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 2MG BASE

A076777 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

WATSON LABS EQ 2MG BASE

A074507 001 Mar 15, 1999

EQ 2MG BASE

A076569 001 Jul 29, 2004

EQ 2MG BASE

A078699 001 Dec 29, 2008

EQ 2MG BASE

A079044 001 Jul 08, 2009

EQ 2MG BASE

A079216 001 Jul 08, 2009

EQ 4MG BASE

A074707 001 Mar 19, 1999

EQ 4MG BASE

A076568 002 Jul 29, 2004

OTC DRUG PRODUCT LIST

4-15 (of 17)

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

EQ 4MG BASE
EQ 4MG BASE
EQ 4MG BASEA078697 001 Dec 29, 2008
A079038 001 Jul 08, 2009
A079219 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE
EQ 4MG BASEA077658 001 Jun 19, 2007
A077656 001 Jun 19, 2007

TROCHE/LOZENGE;ORAL

COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE
EQ 4MG BASEN021330 001 Oct 31, 2002
N021330 002 Oct 31, 2002

+

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE
EQ 4MG BASEN022360 001 May 18, 2009
N022360 002 May 18, 2009

+

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE
EQ 2MG BASE
EQ 2MG BASE
EQ 2MG BASE
EQ 4MG BASE
EQ 4MG BASE
EQ 4MG BASE
EQ 4MG BASEA077007 001 Jan 31, 2006
A090711 001 Jul 10, 2009
A090821 001 Jul 10, 2009
A203690 001 Oct 09, 2012
A077007 002 Jan 31, 2006
A090711 002 Jul 10, 2009
A090821 002 Jul 10, 2009
A203690 002 Oct 09, 2012NIZATIDINE

TABLET;ORAL

AXID AR

+ PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ AZTIQ PHARMA

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+ DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD

EQ 20MG BASE

A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL

PRILOSEC OTC

+ ASTRAZENECA

EQ 20MG BASE

N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG;1.1GM

N022281 001 Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013

ORLISTAT

CAPSULE;ORAL

ALLI

+ GLAXOSMITHKLINE CONS

60MG

N021887 001 Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ MSD CONSUMER

3.9MG/24HR

N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

SCHERING PLOUGH

0.025%

N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON

0.025%

N019407 001 Mar 31, 1989

OTC DRUG PRODUCT LIST

4-16 (of 17)

PERMETHRIN

LOTION; TOPICAL

NIX

+ INSIGHT PHARMS 1% N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC 1% A075014 001 Mar 28, 2000

PERRIGO NEW YORK 1% A076090 001 Dec 20, 2001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

+ BAYER 4%;EQ 0.33% BASE N021043 001 Mar 07, 2000

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

KREMERS URBAN PHARMS 17GM/PACKET A090600 001 Oct 06, 2009

17GM/SCOOPFUL A090600 002 Oct 06, 2009

MIRALAX

+ SCHERING PLOUGH 17GM/SCOOPFUL N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

EMCURE PHARMS USA 17GM/SCOOPFUL A202071 001 Dec 28, 2012

MYLAN 17GM/PACKET A078915 001 Oct 06, 2009

17GM/SCOOPFUL A078915 002 Oct 06, 2009

NEXGEN PHARMA 17GM/SCOOPFUL A090812 001 Oct 07, 2009

NOVEL LABS INC 17GM/SCOOPFUL A091077 001 Oct 06, 2009

PAR PHARM 17GM/SCOOPFUL A079214 001 Jan 31, 2013

PERRIGO R AND D 17GM/PACKET A090685 001 Oct 06, 2009

17GM/SCOOPFUL A090685 002 Oct 06, 2009

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

+ ARCO PHARMS LLC 65MG/ML A077218 001 Jan 12, 2005

TABLET; ORAL

IOSAT

ANBEX 65MG N018664 002 May 12, 2011

+ 130MG N018664 001 Oct 14, 1982

THYROSAFE

+ RECIP 65MG A076350 001 Sep 10, 2002

POVIDONE-IODINE

SOLUTION; TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE 1% N019522 001 Mar 31, 1989

SPONGE; TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON 20% N019240 001 Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON 10% N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 120MG A075153 001 Feb 26, 1999

RANBAXY 120MG A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS 120MG A073585 001 Oct 31, 1991

SUDAFED 24 HOUR

+ MCNEIL CONS 240MG N020021 002 Dec 15, 1992

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS 98.3% N022305 001 Sep 01, 2011

OTC DRUG PRODUCT LIST

4-17 (of 17)

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012
CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
	EQ 150MG BASE	A078192	001	Aug 31, 2007
IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
	EQ 150MG BASE	A091429	002	May 11, 2011
SHASUN CHEMS	EQ 75MG BASE	A201745	001	Feb 29, 2012
SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011
TORPHARM	EQ 75MG BASE	A075167	001	May 04, 2000
WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
	EQ 75MG BASE	A078884	001	Jul 31, 2008
	EQ 150MG BASE	A078653	001	Nov 26, 2007
ZANTAC 150				
+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004
	EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 75				
BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED;INHALATION
BRONCHO SALINE

+ BLAIREX	0.9%	N019912	001	Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+ NOVARTIS	1%	N020980	001	Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO

	1%	A077511	001	Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021124	001	Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

PERRIGO

	6.5%	A075915	001	Nov 21, 2001

VAGISTAT-1

+ NOVARTIS	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013

34TH EDITION - 2014 - APPROVED DRUG PRODUCT LIST

5 - 1 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N100855

Jun 03, 1959

FRESENIUS MEDICAL

N160918

Mar 17, 1978

CARE NORTH AMERICA

N110912

Sep 02, 1959

MILES INC

N100102

Dec 14, 1961

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL
SYSTEMS, INC

A110057

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL
CARE NORTH AMERICA

N780519

Apr 23, 1980

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

34TH EDITION - 2014 - APPROVED DRUG PRODUCT LIST

5 - 2 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD
COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

FRESENIUS MEDICAL
CARE NORTH AMERICA

N811012

Jun 28, 1983

HAEMONETICS
MANUFACTURING INC

N160907

May 16, 1973

MILES INC

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N160527

Jun 22, 1970

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS 0.042GM/100ML;0.276GM/100ML;
MANUFACTURING INC 0.410GM/100ML;0.30GM/100ML;
1.10GM/100ML;0.588GM/100ML

N820915

Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP 0.042GM/100ML;0.285GM/100ML;
0.718GM/100ML;0.017GM/100ML;
0.396GM/100ML;0.588GM/100ML

N820915

Sep 22, 1983

34TH EDITION - 2014 - APPROVED DRUG PRODUCT LIST

5 - 3 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT ETHYLENEDIAMINE TETRAACETIC ACID (EDTA)

INJECTABLE; INJECTION

NONE

FENWAL INC

N090480

Mar 07, 1955

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL
CARE NORTH AMERICA

N770822

May 17, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS
CORPORATION

N980123

Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL
LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N770923

Jan 20, 1978

FRESENIUS MEDICAL
CARE NORTH AMERICA

N160702

Dec 28, 1970

TERUMO MEDICAL CORP

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;5GM/100ML

N840619

Feb 22, 1985

LMD IN GLASS BOTTLE

HOSPIRA INC 10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;5GM/100ML

N160375

Jul 25, 1967

MILES INC 10GM/100ML;5GM/100ML

N160653

Sep 23, 1969

PHARMACHEM CORP 10GM/100ML;5GM/100ML

N160836

Nov 14, 1972

34TH EDITION - 2014 - APPROVED DRUG PRODUCT LIST

5 - 4 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP	10GM/100ML;0.9GM/100ML	N840620		Feb 22, 1985
LMD IN PLASTIC CONTAINER				

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	ANDA	Oct 30, 1992

NONE

B BRAUN MEDICAL INC	10GM/100ML;0.9GM/100ML	N160767		Apr 06, 1970

HOSPIRA INC	10GM/100ML;0.9GM/100ML	N160375		Jul 25, 1967

MILES INC	10GM/100ML;0.9GM/100ML	N160653		Sep 23, 1969

PHARMACHEM CORP	10GM/100ML;0.9GM/100ML	N160836		Nov 14, 1972

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAIN 70

BAXTER HLTHCARE CORP		N160607		Jan 26, 1970

NONE

B BRAUN MEDICAL INC	6GM/100ML;0.9 GM/100ML	N090024		Aug 18, 1969

MILES INC	6GM/100ML;0.9 GM/100ML	N080716		Mar 13, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

PHARMACHEM CORP	6GM/100ML;0.9GM/100ML	N080564		Sep 19, 1952

	6GM/100ML;0.9GM/100ML	N160759		Aug 19, 1970

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952		Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	ANDA	Jan 30, 1995

HESPAN

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N160889		Jul 17, 1972

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105		Apr 04, 1991

NONE

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	A740283	ANDA	Oct 21, 1998

TEVA PARENTERAL	6GM/100ML;0.9GM/100ML	A740592	ANDA	Nov 12, 1998

MEDICINES INC

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION

NONE

HOSPIRA INC	6GM/100ML;0.9 GM/100ML	A720746	ANDA	Feb 07, 1996

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

VOLUVEN

FRESENIUS KABI	6GM/100ML;0.9GM/100ML	N070012	NDA	Dec 27, 2007

DEUTSCHLAND GMBH

34TH EDITION - 2014 - APPROVED DRUG PRODUCT LIST

5 - 5 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

INJECTABLE; INJECTION
ISOPLATE SOLUTION
HAEMONETICS CORP

N90067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION
LEUKOSEP HWB-600-XL
HAEMONETICS CORP

N110059 Apr 25, 2013

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN
B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML
PENTASPAN IN PLASTIC CONTAINER
B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N841207 May 19, 1987

N890104 Apr 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION
FLUOSOL
ALPHA THERAPEUTIC 17.5GM/100ML;7.5GM/100ML
CORP

N860909 Dec 26, 1989

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION
REJUVESOL
CITRA LABS LLC

N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION
INTERSOL SOLUTION
FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML;
1.53G/500ML; 0.465G/500ML

N080041 NDA Dec 09, 2009

DISCONTINUED DRUG PRODUCT LIST

6-1 (of 322)

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL

N021320 001 Nov 25, 2003

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML

N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG

A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG

A073106 001 Feb 27, 1995

325MG

A073107 001 Feb 27, 1995

650MG

A073108 001 Feb 27, 1995

ROXANE 120MG

A071010 001 May 12, 1987

650MG

A071011 001 May 12, 1987

TYLENOL

MCNEIL CONS 120MG

N017756 002

650MG

N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

RANBAXY 650MG

A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG

A081095 001 Oct 26, 1990

150MG; 180MG; 30MG

A081096 001 Oct 26, 1990

150MG; 180MG; 60MG

A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG

A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG

A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG

A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG

A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG

A088991 001 Jun 28, 1985

TENCON

MALLINCKRODT 650MG; 50MG

A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG

A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG

A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG

A087550 001 Oct 19, 1984

PHRENILIN

VALEANT 325MG; 50MG

A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND 650MG; 50MG

A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG

A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG; 50MG; 40MG

A088743 001 Jul 18, 1985

325MG; 50MG; 40MG

A088765 001 Mar 27, 1985

325MG; 50MG; 40MG

A089067 001 Apr 19, 1985

MALLINCKRODT 325MG; 50MG; 40MG

A088758 001 Mar 27, 1985

WEST WARD 500MG; 50MG; 40MG

A040261 001 Oct 28, 1998

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG; 50MG; 40MG

A088825 001 Dec 05, 1984

FEMCET

MALLINCKRODT 325MG; 50MG; 40MG

A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG; 50MG; 40MG

A089115 001 Jan 14, 1986

DISCONTINUED DRUG PRODUCT LIST

6-2 (of 322)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

TRIAD

MALLINCKRODT	325MG; 50MG; 40MG	A089023	001	Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG; 50MG; 40MG	A040390	001	Jul 23, 2001

	500MG; 50MG; 40MG	A040394	001	Jul 23, 2001

GILBERT LABS	325MG; 50MG; 40MG	A087629	001	Nov 13, 1984

MIRROR PHARMS LLC	500MG; 50MG; 40MG	A040883	001	Dec 23, 2008

MUTUAL PHARM	325MG; 50MG; 40MG	A040601	001	Jul 29, 2005

WATSON LABS	325MG; 50MG; 40MG	A089536	001	Feb 16, 1988

WEST WARD	500MG; 50MG; 40MG	A040336	001	Aug 18, 1999

ESGIC

FOREST PHARMS	325MG; 50MG; 40MG	A089660	001	Dec 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE	325MG; 50MG; 40MG; 30MG	A076528	001	Aug 21, 2003

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG; 30MG; 16MG	A040109	001	Aug 26, 1997

WRASER PHARMS LLC	356.4MG; 30MG; 16MG	A040688	001	Apr 03, 2007

DHC PLUS

PHARM RES ASSOC	356.4MG; 30MG; 16MG	A088584	001	Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS	356.4MG; 30MG; 16MG	A089166	001	May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG; 60MG; 32MG	A040701	001	Apr 03, 2007

MIKART	712.8MG; 60MG; 32MG	A040316	001	Apr 28, 1999

WEST-WARD PHARM CORP	712.8MG; 60MG; 32MG	A040637	001	Sep 22, 2006

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG; 15MG	A088537	001	Jun 04, 1984

	300MG; 30MG	A088324	001	Dec 29, 1983

	300MG; 60MG	A088599	001	Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH	325MG; 15MG	A084444	001	

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH	325MG; 30MG	A084445	001	

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH	325MG; 60MG	A084446	001	

PROVAL #3

SOLVAY	325MG; 30MG	A085685	001	

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM	300MG; 30MG	A087422	001	

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM	300MG; 60MG	A087421	001	

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML; 12MG/5ML	A085861	001	

CLONMEL	120MG/5ML; 12MG/5ML	A040098	001	Sep 20, 1996

ROXANE	120MG/5ML; 12MG/5ML	A086366	001	

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM	120MG/5ML; 12MG/5ML	A085057	001	

SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML; 12MG/5ML	A085883	001	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG; 30MG	A040452	001	Aug 01, 2002

	300MG; 60MG	A040459	001	Aug 01, 2002

AM THERAP	300MG; 15MG	A089478	001	Mar 03, 1987

	300MG; 15MG	A089481	001	Mar 03, 1987

	300MG; 30MG	A089479	001	Mar 03, 1987

	300MG; 30MG	A089482	001	Mar 03, 1987

	300MG; 60MG	A089480	001	Mar 03, 1987

	300MG; 60MG	A089483	001	Mar 03, 1987

DISCONTINUED DRUG PRODUCT LIST

6-3 (of 322)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG	A085363	001	
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons			
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;15MG	A089671	001	Feb 10, 1988
	300MG;30MG	A085794	001	
	300MG;30MG	A089672	001	Feb 10, 1988
	300MG;60MG	A087653	001	Apr 13, 1982
	300MG;60MG	A089673	001	Feb 10, 1988
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A081249	001	Jul 16, 1992
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	

DISCONTINUED DRUG PRODUCT LIST

6-4 (of 322)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

CAPITAL AND CODEINE

CARNRICK 325MG; 30MG A083643 001

CODRIX

WATSON LABS FLORIDA 500MG; 15MG A040447 001 Feb 26, 2003

500MG; 30MG A040441 001 Mar 27, 2003

500MG; 60MG A040488 001 Mar 28, 2003

EMPRACET W/ CODEINE PHOSPHATE #3

GLAXOSMITHKLINE 300MG; 30MG A083951 001

EMPRACET W/ CODEINE PHOSPHATE #4

GLAXOSMITHKLINE 300MG; 60MG A083951 002

PAPA-DEINE #3

VANGARD 300MG; 30MG A088037 001 Mar 20, 1984

PAPA-DEINE #4

VANGARD 300MG; 60MG A088715 001 Mar 20, 1984

PHENAPHEN-650 W/ CODEINE

ROBINS AH 650MG; 30MG A085856 001

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM 325MG; 7.5MG A085056 001

325MG; 15MG A085056 002

325MG; 30MG A085056 003

325MG; 60MG A085056 004

TYLENOL W/ CODEINE NO. 1

JANSSEN PHARMS 300MG; 7.5MG A085055 001

TYLENOL W/ CODEINE NO. 2

JANSSEN PHARMS 300MG; 15MG A085055 002

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS 500MG; 5MG A088898 001 Mar 27, 1985

ALLAY

IVAX PHARMS 500MG; 5MG A089907 001 Jan 13, 1989

BANCAP HC

FOREST PHARMS 500MG; 5MG A087961 001 Mar 17, 1983

CO-GESIC

CENT PHARMS 500MG; 5MG A089360 001 Mar 02, 1988

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT 500MG; 5MG A088956 001 Jul 19, 1985

500MG; 5MG A089006 001 Aug 09, 1985

MIKART 500MG; 5MG A081067 001 Nov 30, 1989

500MG; 5MG A081068 001 Nov 30, 1989

500MG; 5MG A081069 001 Nov 30, 1989

500MG; 5MG A081070 001 Nov 30, 1989

500MG; 5MG A089008 001 Feb 21, 1986

LORCET-HD

MALLINCKRODT 500MG; 5MG A087336 001 Jul 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT INC 500MG/15ML; 10MG/15ML A040508 001 Aug 29, 2003

MIKART 500MG/15ML; 5MG/15ML A081226 001 Oct 27, 1992

500MG/15ML; 5MG/15ML A089557 001 Apr 29, 1992

NESHER PHARMS 500MG/15ML; 7.5MG/15ML A040366 001 Jan 23, 2002

TABLET; ORAL

CO-GESIC

UCB INC 500MG; 5MG A087757 001 May 03, 1982

DURADYNE DHC

FOREST PHARMS 500MG; 5MG A087809 001 Mar 17, 1983

HY-PHEN

ASCHER 500MG; 5MG A087677 001 May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE 325MG; 5MG A040478 001 Nov 08, 2002

325MG; 7.5MG A040464 001 Oct 23, 2002

325MG; 10MG A040464 002 Oct 23, 2002

500MG; 5MG A040477 001 Nov 06, 2002

500MG; 7.5MG A040490 001 May 21, 2003

500MG; 10MG A040473 001 Nov 06, 2002

650MG; 7.5MG A040474 001 Jan 02, 2003

650MG; 10MG A040476 001 Oct 23, 2002

750MG; 7.5MG A040469 001 Oct 25, 2002

BARR 500MG; 2.5MG A040307 001 Jul 26, 2000

500MG; 5MG A040308 001 Jul 26, 2000

DISCONTINUED DRUG PRODUCT LIST

6-5 (of 322)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

500MG; 5MG	A088577	001	Dec 21, 1984
500MG; 7.5MG	A040307	002	Jul 26, 2000
500MG; 10MG	A040309	001	Jul 26, 2000
650MG; 7.5MG	A040307	003	Jul 26, 2000
650MG; 10MG	A040307	004	Jul 26, 2000
750MG; 7.5MG	A040308	002	Jul 26, 2000
HALSEY	500MG; 5MG	A089554	001 Jun 12, 1987
IVAX PHARMS	500MG; 5MG	A089696	001 Apr 21, 1988
MIKART	500MG; 2.5MG	A089698	001 Aug 25, 1989
	500MG; 5MG	A089271	001 Jul 16, 1986
	500MG; 5MG	A089697	001 Jan 28, 1992
	650MG; 5MG	A040849	001 Jun 09, 2010
MUTUAL PHARM	500MG; 5MG	A040236	001 Sep 25, 1997
	650MG; 7.5MG	A040240	002 Nov 26, 1997
	650MG; 10MG	A040240	001 Nov 26, 1997
	750MG; 7.5MG	A040236	002 Sep 25, 1997
RANBAXY	500MG; 5MG	A040825	001 Aug 16, 2007
	500MG; 10MG	A040824	001 Aug 16, 2007
RANBAXY LABS LTD	325MG; 10MG	A040826	001 Aug 16, 2007
	750MG; 7.5MG	A040822	001 Aug 16, 2007
SANDOZ	500MG; 5MG	A040149	001 Jan 27, 1997
	750MG; 7.5MG	A040149	002 Jan 27, 1997
UCB INC	500MG; 10MG	A040210	001 Aug 13, 1997
	650MG; 7.5MG	A040134	001 Nov 21, 1996
USL PHARMA	500MG; 5MG	A089290	001 May 29, 1987
	500MG; 5MG	A089291	001 May 29, 1987
VINTAGE PHARMS	500MG; 5MG	A089831	001 Sep 07, 1988
VINTAGE PHARMS LLC	500MG; 5MG	A040281	001 Sep 30, 1998
	500MG; 7.5MG	A040280	001 Sep 30, 1998
	650MG; 7.5MG	A040280	002 Sep 30, 1998
	650MG; 10MG	A040280	003 Sep 30, 1998
	750MG; 7.5MG	A040281	002 Sep 30, 1998
WATSON LABS	325MG; 7.5MG	A040248	001 Apr 28, 2000
	325MG; 10MG	A040248	002 Apr 28, 2000
	500MG; 2.5MG	A040123	003 Mar 04, 1996
	500MG; 5MG	A040122	001 Mar 04, 1996
	500MG; 7.5MG	A040123	004 Mar 04, 1996
	650MG; 7.5MG	A040123	001 Mar 04, 1996
	650MG; 10MG	A040123	002 Mar 04, 1996
	750MG; 7.5MG	A040122	002 Mar 04, 1996
WATSON LABS FLORIDA	500MG; 5MG	A040493	001 May 28, 2003
	750MG; 7.5MG	A040494	001 May 28, 2003
NORCET			
ABANA	500MG; 5MG	A088871	001 May 15, 1986
TYCOLET			
ORTHO MCNEIL PHARM	500MG; 5MG	A089385	001 Aug 27, 1986
VICODIN			
ABBOTT	500MG; 5MG	A085667	001
ABBVIE	500MG; 5MG	A088058	001 Jan 07, 1983
VICODIN ES			
ABBVIE	750MG; 7.5MG	A089736	001 Dec 09, 1988
VICODIN HP			
ABBVIE	660MG; 10MG	A040117	001 Sep 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS TOTOWA	500MG; 5MG	A040199	001 Dec 30, 1998
BARR	500MG; 5MG	A040304	001 Oct 02, 2000
HALSEY	500MG; 5MG	A089994	001 May 04, 1989
MUTUAL PHARM	500MG; 5MG	A040219	001 Jan 22, 1998
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001 Dec 30, 1999
TYLOX-325			
ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001 Nov 08, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001 Sep 29, 2006

DISCONTINUED DRUG PRODUCT LIST

6-6 (of 322)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE 2.5/APAP 500			
BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001
OXYCODONE 5/APAP 500			
BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001
OXYCODONE AND ACETAMINOPHEN			
ACTAVIS TOTOWA	325MG; 5MG	A040203	001 Mar 15, 1999
BARR	325MG; 5MG	A087406	001
DURAMED PHARMS BARR	325MG; 5MG	A040272	001 Jun 30, 1998
MIKART	400MG; 2.5MG	A040679	001 May 16, 2006
PERCOCET			
VINTAGE PHARMS LLC	325MG; 5MG	A085106	002
ROXICET 5/500			
ROXANE	500MG; 5MG	A089775	001 Jan 12, 1989

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX			
ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALACEN			
SANOFI AVENTIS US	650MG; EQ 25MG BASE	N018458	001 Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET			
AAIPHARMA LLC	325MG; 32.5MG	N016844	001
DOLENE AP-65			
LEDERLE	650MG; 65MG	A085100	001
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN			
MYLAN	325MG; 32MG	A083689	001
	650MG; 65MG	A083978	001
SANDOZ	650MG; 65MG	A089959	001 Jul 18, 1989
VINTAGE PHARMS	650MG; 65MG	A040507	001 Jul 30, 2003
WATSON LABS	650MG; 65MG	A040139	001 Dec 16, 1996
WYGESIC			
CARACO	650MG; 65MG	A084999	001

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500			
XANODYNE PHARM	500MG; 100MG	A076429	001 Sep 10, 2003
DARVOCET-N 100			
XANODYNE PHARM	650MG; 100MG	N017122	002
DARVOCET-N 50			
XANODYNE PHARM	325MG; 50MG	N017122	001
PROPACET 100			
TEVA	650MG; 100MG	A070107	001 Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
ABLE	650MG; 100MG	A075838	001 Jul 11, 2001
ACTAVIS ELIZABETH	650MG; 100MG	A070910	001 Jan 02, 1987
CORNERSTONE	325MG; 100MG	A076743	001 May 07, 2004
	500MG; 100MG	A076750	001 Jun 28, 2004
HALSEY	325MG; 50MG	A072105	001 May 13, 1988
	650MG; 100MG	A072106	001 May 13, 1988
IVAX SUB TEVA PHARMS	650MG; 100MG	A070146	001 Aug 02, 1985
MALLINCKRODT	650MG; 100MG	A075738	001 Feb 02, 2001
MIRROR PHARMS	650MG; 100MG	A077821	001 Feb 11, 2008
MUTUAL PHARM	325MG; 50MG	A070115	001 Jun 12, 1985
	650MG; 100MG	A070116	001 Jun 12, 1985
	650MG; 100MG	A070615	001 Mar 21, 1986
	650MG; 100MG	A070771	001 Mar 21, 1986
	650MG; 100MG	A070775	001 Mar 21, 1986
MYLAN	650MG; 100MG	A072195	001 Feb 16, 1988
MYLAN PHARMS INC	650MG; 100MG	A070145	001 Jun 12, 1985
SANDOZ	650MG; 100MG	A070443	001 Jan 23, 1986
SUPERPHARM	650MG; 100MG	A071319	001 Jan 06, 1987
TEVA	650MG; 100MG	A070732	001 Jan 03, 1986
	650MG; 100MG	A074119	001 Dec 19, 1994
VINTAGE PHARMS	325MG; 50MG	A074843	002 Feb 15, 2001
	650MG; 100MG	A074843	001 Feb 12, 1997

DISCONTINUED DRUG PRODUCT LIST

6-7 (of 322)

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

WATSON LABS	325MG; 50MG	A070398	001	Dec 18, 1986
	650MG; 100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG; 100MG	A077196	001	Jun 28, 2005
	650MG; 100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG; 50MG	A077677	001	Mar 16, 2007
	650MG; 100MG	A077677	002	Mar 16, 2007

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
MUTUAL PHARM	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	
	250MG	A088882	001	Oct 22, 1985

DIAMOX

DURAMED PHARMS BARR	125MG	N008943	001	
	250MG	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
DIAMOX				
TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	

ACETIC ACID

KV PHARM	2%	A085493	001	

ORLEX

WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR	2%; 0.79%	A088606	001	Aug 21, 1985

DOMEBORO

BAYER PHARMS	2%; 0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS	2%; 0.05%	N017914	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%; 1%	A085492	001	

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%; 1%	A040097	001	Oct 31, 1994

WOCKHARDT	2%; 1%	A040168	001	Aug 30, 1996

ORLEX HC

WARNER CHILCOTT	2%; 1%	A086844	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS	2%; 1%; EQ 0.35% BASE	N050238	001	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

BARR	250MG	A070869	001	Feb 09, 1987
	500MG	A070870	001	Feb 09, 1987
USL PHARMA	250MG	A070753	001	Nov 03, 1986
	500MG	A070754	001	Nov 03, 1986

DYMELOR

LILLY	250MG	N013378	002	
	500MG	N013378	001	

DISCONTINUED DRUG PRODUCT LIST

6-8 (of 322)

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING

20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53%

N009008 001

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA

10%

A071364 001 May 01, 1989

20%

A071365 001 May 01, 1989

ROXANE

10%

A072621 001 Sep 30, 1992

20%

A072622 001 Sep 30, 1992

MUCOMYST

APOTHECON

10%

N013601 002

20%

N013601 001

MUCOSIL-10

DEY

10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY

20%

A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%; 0.05%

N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS

0.1MG

N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING

2MG/GM

N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG

A074906 001 Aug 26, 1997

DAVA PHARMS INC

200MG

A074872 001 Apr 22, 1997

HERITAGE PHARMS INC

200MG

A074889 001 Oct 31, 1997

IVAX SUB TEVA PHARMS

200MG

A074674 001 Apr 22, 1997

LEK PHARM

200MG

A074750 001 Apr 22, 1997

MYLAN

200MG

A074977 001 Apr 13, 1998

ROXANE

200MG

A074570 002 Apr 22, 1997

TEVA

200MG

A074828 001 Apr 22, 1997

TEVA PHARMS

200MG

A074914 001 Nov 26, 1997

WATSON LABS

200MG

A075101 001 Apr 15, 1998

TABLET; BUCCAL

SITAVIG

BIOALLIANCE PHARMA

50MG

N203791 001 Apr 12, 2013

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

400MG

A074870 001 Jun 05, 1997

800MG

A074870 002 Jun 05, 1997

DAVA PHARMS INC

400MG

A074834 001 Apr 24, 1997

800MG

A074834 002 Apr 24, 1997

HERITAGE PHARMS INC

400MG

A074891 001 Oct 31, 1997

800MG

A074891 002 Oct 31, 1997

IVAX SUB TEVA PHARMS

400MG

A074836 001 Apr 22, 1997

800MG

A074836 002 Apr 22, 1997

LEK PHARM

400MG

A074658 001 Apr 22, 1997

800MG

A074658 002 Apr 22, 1997

MYLAN

400MG

A074976 001 Apr 13, 1998

800MG

A074976 002 Apr 13, 1998

TEVA

200MG **Federal Register determination

A074556 001 Apr 22, 1997

DISCONTINUED DRUG PRODUCT LIST

6-9 (of 322)

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

TEVA PHARMS

400MG

A075021 001 Mar 18, 1998

800MG

A075021 002 Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE

EQ 50MG BASE/ML

A075114 001 Jul 26, 1999

ACYCLOVIR SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A074897 002 Feb 27, 1998

EQ 500MG BASE/VIAL

A074897 001 Feb 27, 1998

HOSPIRA

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

EQ 25MG BASE/ML

A074720 001 Apr 22, 1997

EQ 50MG BASE/ML

A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

TEVA PARENTERAL

EQ 1GM BASE/VIAL

A074969 002 Aug 26, 1997

EQ 50MG BASE/ML

A075627 001 Mar 28, 2001

EQ 500MG BASE/VIAL

A074969 001 Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N018603 002 Jun 29, 1989

EQ 250MG BASE/VIAL

N018603 003 Aug 30, 1983

EQ 500MG BASE/VIAL

N018603 001 Oct 22, 1982

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP

0.1%

N020338 001 May 31, 1996

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

HIKMA MAPLE

3MG/ML

A076501 001 Jun 16, 2004

TEVA PHARMS USA

3MG/ML

A076564 001 Jun 16, 2004

3MG/ML

A078676 001 Jul 31, 2008

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER

EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX

100uCi/VIAL

N017835 001

250uCi/VIAL

N017835 002

500uCi/VIAL

N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS

2.5uCi/AMP

N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT

6.67uCi/ML

N017844 003

10uCi/ML

N017844 001

100uCi/ML

N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX

2mCi/VIAL

N017837 003

5uCi/AMP

N017837 004

20uCi/AMP

N017837 005

DISCONTINUED DRUG PRODUCT LIST

6-10 (of 322)

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987
	EQ 0.5% BASE	N019243	001	Jan 14, 1987
VENTOLIN				
GLAXOSMITHKLINE	EQ 0.083% BASE	N019773	001	Apr 23, 1992
	EQ 0.5% BASE	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
SCHERING	EQ 2MG BASE/5ML	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072859	001	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
SANDOZ	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072152	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991
PROVENTIL				
SCHERING	EQ 2MG BASE	N017853	001	May 07, 1982
	EQ 4MG BASE	N017853	002	May 07, 1982

DISCONTINUED DRUG PRODUCT LIST

6-11 (of 322)

ALBUTEROL SULFATE

TABLET; ORAL

VENTOLIN

GLAXOSMITHKLINE EQ 2MG BASE
EQ 4MG BASEN019112 001 Jul 10, 1986
N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

SCHERING EQ 4MG BASE

N019383 001 Jul 13, 1987

VOLMAX

MURO EQ 4MG BASE
EQ 8MG BASEN019604 002 Dec 23, 1992
N019604 001 Dec 23, 1992ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC EQ 0.083% BASE; 0.017%
SANDOZ INC EQ 0.083% BASE; 0.017%A077117 001 Dec 31, 2007
A076867 001 Dec 21, 2006ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES 5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

HOSPIRA 5ML/100ML; 5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE 5ML/100ML; 5GM/100ML

A083256 001

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN EQ 35MG BASE
EQ 70MG BASE
SANDOZ EQ 5MG BASE
EQ 10MG BASE
EQ 35MG BASE
EQ 40MG BASE
EQ 70MG BASE
TEVA PHARMS EQ 35MG BASE
EQ 70MG BASEA078638 001 Aug 04, 2008
A078638 002 Aug 04, 2008
A075871 001 Apr 22, 2009
A075871 002 Apr 22, 2009
A075871 004 Apr 22, 2009
A075871 003 Apr 22, 2009
A075871 005 Apr 22, 2009
A076184 002 Aug 04, 2008
A076184 001 Feb 06, 2008

FOSAMAX

MERCK AND CO INC EQ 5MG BASE
EQ 10MG BASE
EQ 35MG BASE
EQ 40MG BASEN020560 003 Apr 25, 1997
N020560 001 Sep 29, 1995
N020560 004 Oct 20, 2000
N020560 002 Sep 29, 1995ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME 10 UNITS/ML
80 UNITS/MLN020057 004 May 08, 1992
N020057 003 Apr 05, 1991ALKAVERVIR

TABLET; ORAL

VERILOID

3M 2MG
3MGN007336 002
N007336 003ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM 100MG
300MG
PURACAP PHARM 100MG
300MG
PUREPAC PHARM 100MG
300MG
SANDOZ 100MG
300MG
SUPERPHARM 100MG
300MG
WATSON LABS 100MG
100MG
300MGA070466 001 Dec 24, 1985
A070467 001 Dec 24, 1985
A070150 001 Dec 10, 1985
A070147 001 Dec 10, 1985
A070579 001 Apr 14, 1986
A070580 001 Apr 14, 1986
A070268 001 Dec 31, 1985
A070269 001 Dec 31, 1985
A070950 001 Nov 30, 1988
A070951 001 Nov 30, 1988
N018241 001 Nov 16, 1984
N018785 001 Sep 28, 1984
N018241 002 Nov 16, 1984

DISCONTINUED DRUG PRODUCT LIST

6-12 (of 322)

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

300MG

N018785 002 Sep 28, 1984

LOPURIN

ABBOTT

100MG

N018297 001

300MG

N018297 002

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE

0.5MG/5ML

A074314 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

IVAX SUB TEVA PHARMS

0.25MG

A074294 001 Jul 29, 1994

0.5MG

A074294 002 Jul 29, 1994

1MG

A074294 003 Jul 29, 1994

2MG

A074294 004 Jul 29, 1994

ROXANE

0.25MG

A074199 001 Oct 19, 1993

0.5MG

A074199 002 Oct 19, 1993

1MG

A074199 003 Oct 19, 1993

TEVA

0.25MG

A074085 001 Feb 16, 1994

0.5MG

A074085 002 Feb 16, 1994

1MG

A074085 003 Feb 16, 1994

2MG

A074085 004 Feb 26, 1996

WATSON LABS

0.25MG

A074456 001 Aug 31, 1995

0.25MG

A074479 001 Jan 21, 1997

0.5MG

A074456 002 Aug 31, 1995

0.5MG

A074479 002 Jan 21, 1997

1MG

A074456 003 Aug 31, 1995

1MG

A074479 003 Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006

1MG

A077777 002 Jun 30, 2006

2MG

A077777 003 Jun 30, 2006

3MG

A077777 004 Jun 30, 2006

TEVA PHARMS USA

0.5MG

A077979 001 Feb 28, 2007

1MG

A077979 002 Feb 28, 2007

2MG

A077979 003 Feb 28, 2007

3MG

A077979 004 Feb 28, 2007

VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007

1MG

A078442 002 Oct 15, 2007

2MG

A078442 003 Oct 15, 2007

3MG

A078442 004 Oct 15, 2007

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER

0.005MG/ML

N020755 001 Oct 31, 1997

0.01MG/ML

N020755 002 Oct 01, 1997

0.02MG/ML

N020755 003 Oct 01, 1997

EDEX

ACTIENT PHARMS

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

RAUWILOID

3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX

80MG; 20MG

A089449 001 Nov 27, 1987

FOAMICON

NOVARTIS

80MG; 20MG

A072687 001 Jun 28, 1989

DISCONTINUED DRUG PRODUCT LIST

6-13 (of 322)

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006
WATSON LABS	100MG	A071382	001	Jan 21, 1987

SYMADINE

SOLVAY	100MG	A071000	001	Sep 04, 1986

SYMMETREL

ENDO PHARMS	100MG	N016020	001	

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	50MG/5ML	A072655	001	Oct 30, 1990
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991

SYMMETREL

ENDO PHARMS	50MG/5ML	N016023	002	

TABLET; ORAL

SYMMETREL

ENDO PHARMS	100MG	N018101	001	

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

ASTELLAS	0.025%	N018116	001	
	0.1%	N018116	002	

LOTION; TOPICAL

CYCLOCORT

ASTELLAS	0.1%	N019729	001	Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

ASTELLAS	0.1%	N018498	001	

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE	1GM/VIAL	N050565	003	Dec 21, 1984
	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

MEDIMMUNE	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
ASTRAZENECA	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
HIKMA MAPLE	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997

AMIKIN

APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
	EQ 50MG BASE/ML	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
	EQ 250MG BASE/ML	N050495	002	

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

DISCONTINUED DRUG PRODUCT LIST

6-14 (of 322)

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS; 50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS; 50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS; 50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
MERCK	EQ 5MG ANHYDROUS; 50MG	N018201	001	

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986

AMINOSYN II 5%

HOSPIRA	5% (5GM/100ML)	N019438	002	Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984

FREAMINE 8.5%

B BRAUN	8.5% (8.5GM/100ML)	N016822	001	

FREAMINE II 8.5%

B BRAUN	8.5% (8.5GM/100ML)	N016822	002	

NEOPHAM 6.4%

HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984

NOVAMINE 11.4%

HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982

NOVAMINE 15%

HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE	15% (15GM/100ML)	N020107	001	Feb 05, 1993

NOVAMINE 8.5%

HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	001	Sep 12, 1988

HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	001	Nov 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	002	Sep 12, 1988

HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	004	Sep 12, 1988

HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	003	Sep 12, 1988

HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	004	Nov 07, 1988

DISCONTINUED DRUG PRODUCT LIST

6-15 (of 322)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

DISCONTINUED DRUG PRODUCT LIST

6-16 (of 322)

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019564 001	Dec 16, 1986
	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019712 001	Sep 08, 1988
HOSPIRA INC	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019682 001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%; 10GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 10GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 002	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 15GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 003	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 20GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 004	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 25GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 005	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 5GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 001	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 007	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 15GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 008	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 009	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 010	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789 005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%; 32MG/100ML; 128MG/100ML; 222MG/100ML; 49MG/100ML	N019493 001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA INC	8%; 61MG/100ML; 211MG/100ML; 56MG/100ML; 388MG/100ML	N017957 001	

DISCONTINUED DRUG PRODUCT LIST

6-17 (of 322)

<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE</u>				
INJECTABLE; INJECTION				
AMINOSYN II 7% W/ ELECTROLYTES				
HOSPIRA	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 4 10MG/100ML	N019437 006	Apr 03, 1986	
<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</u>				
INJECTABLE; INJECTION				
AMINOSYN II 3.5% M				
HOSPIRA	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986	
<u>AMINOCAPROIC ACID</u>				
INJECTABLE; INJECTION				
AMICAR				
CLOVER PHARMS	250MG/ML	N015229 002		
AMINOCAPROIC ACID				
ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986	
BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982	
HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988	
<u>AMINOGLUTETHIMIDE</u>				
TABLET; ORAL				
CYTADREN				
NOVARTIS	250MG	N018202 001		
<u>AMINOPHYLLINE</u>				
ENEMA; RECTAL				
SOMOPHYLLIN				
FISONS	300MG/5ML	N018232 001	Apr 02, 1982	
INJECTABLE; INJECTION				
AMINOPHYLLIN				
GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982	
	25MG/ML	A087621 001	May 24, 1982	
AMINOPHYLLINE				
ABRAXIS PHARM	25MG/ML	A084568 001		
	25MG/ML	A087200 001		
	25MG/ML	A087250 001	Jan 06, 1982	
	25MG/ML	A087886 001	Aug 30, 1983	
	25MG/ML	A088407 001	Jan 25, 1984	
ELKINS SINN	25MG/ML	A087239 001		
HOSPIRA	25MG/ML	A087601 001	Jul 23, 1982	
INTL MEDICATION	25MG/ML	A087209 001	Feb 01, 1982	
	25MG/ML	A087867 001	Nov 10, 1983	
	25MG/ML	A087868 001	Nov 10, 1983	
KING PHARMS	25MG/ML	A086606 001		
LUITPOLD	25MG/ML	A087240 001		
LYPHOMED	25MG/ML	A087431 001		
PHARMA SERVE NY	25MG/ML	A087387 001	Jun 03, 1983	
	25MG/ML	A087392 001	Dec 15, 1983	
SMITH AND NEPHEW	25MG/ML	A088429 001	May 30, 1985	
	25MG/ML	A088749 001	May 30, 1985	
TEVA PARENTERAL	25MG/ML	A081142 001	Sep 25, 1991	
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100MG/100ML	A088147 002	May 03, 1983	
	200MG/100ML	A088147 003	May 03, 1983	
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	100MG/100ML	N018924 001	Dec 12, 1984	
	200MG/100ML	N018924 002	Dec 12, 1984	
	400MG/100ML	N018924 003	Dec 12, 1984	
	500MG/100ML	N018924 004	Dec 12, 1984	
SOLUTION; ORAL				
AMINOPHYLLINE				
MORTON GROVE	105MG/5ML	A088156 001	Dec 05, 1983	
ROXANE	105MG/5ML	A088126 001	Aug 19, 1983	
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727 001	Apr 16, 1982	
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466 001		
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045 001		

DISCONTINUED DRUG PRODUCT LIST

6-18 (of 322)

AMINOPHYLLINE

SUPPOSITORY;RECTAL

TRUPHYLLINE

G AND W LABS

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET;ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

AMINOPHYLLINE

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

BARR

100MG

A088297 001 Aug 19, 1983

200MG

A088298 001 Aug 19, 1983

DURAMED PHARMS BARR

100MG

A088182 001 Mar 31, 1983

200MG

A088183 001 Mar 31, 1983

HALSEY

100MG

A084674 001

HIKMA PHARMS LLC

100MG

A084540 001

200MG

A085003 001

IMPAX LABS

100MG

A084574 001

200MG

A084576 001

KV PHARM

100MG

A085284 001

200MG

A085289 001

LANNETT

100MG

A084588 001

200MG

A084588 002

PAL PAK

100MG

A084533 001

PANRAY

100MG

A084552 001

200MG

A084552 002

PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

ROXANE

100MG

A087500 001 Feb 09, 1982

200MG

A087501 001 Feb 09, 1982

SANDOZ

100MG

A085261 003

100MG

A085262 002

200MG

A085261 002

VALEANT PHARM INTL

200MG

A084563 001

VANGARD

100MG

A088314 001 Oct 03, 1983

200MG

A088319 001 Oct 03, 1983

VINTAGE PHARMS

100MG

A085409 001

200MG

A085410 001

WATSON LABS

100MG

A085567 001

200MG

A085564 001

TABLET, DELAYED RELEASE;ORAL

AMINOPHYLLINE

IMPAX LABS

100MG

A084577 001

200MG

A084575 001

TABLICAPS

100MG

A084632 002

VALE

100MG

A084531 001

200MG

A084530 001

TABLET, EXTENDED RELEASE;ORAL

PHYLLOCONTIN

PHARM RES ASSOC

225MG

A086760 001

AMINOSALICYLATE SODIUM

POWDER;ORAL

P.A.S. SODIUM

CENTURY PHARMS

4GM/PACKET

A080947 001

SODIUM AMINOSALICYLATE

HEXCEL

100%

A080097 001

TABLET;ORAL

PARASAL SODIUM

PANRAY

1GM

N006811 011

500MG

N006811 006

SODIUM P.A.S.

LANNETT

500MG

A080138 002

TEEBACIN

CONSOLIDATED MIDLAND

500MG

N007320 002

DISCONTINUED DRUG PRODUCT LIST

6-19 (of 322)

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC

846MG; 112MG

A080059 002

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY

1GM

N006811 002

500MG

N006811 001

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB

EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD

50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS

50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE

50MG/ML

A076088 001 Oct 15, 2002

HOSPIRA

50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS

50MG/ML

N021594 001 Feb 04, 2004

JHP PHARMS LLC

50MG/ML

A076394 001 Apr 25, 2003

TEVA PHARMS USA

50MG/ML

A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC

50MG/ML

N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA

200MG

A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE

40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A085594 001

ELAVIL

ASTRAZENECA

10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB

10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT

10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP

25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

COPLY PHARM

10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY

10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

50MG

A087557 001 Mar 05, 1982

75MG

A085926 001 May 20, 1983

100MG

A085927 001 May 20, 1983

LEDERLE

10MG

A086744 001

10MG

A087366 001 Jan 04, 1982

DISCONTINUED DRUG PRODUCT LIST

6-20 (of 322)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A084910	003	
	10MG	A086610	001	
	25MG	A085031	001	
	25MG	A086859	001	
	50MG	A085032	001	
	50MG	A086857	001	
	75MG	A085030	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	

DISCONTINUED DRUG PRODUCT LIST

6-21 (of 322)

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
ASTRAZENECA	10MG	N012703	001	
	25MG	N012703	003	
	50MG	N012703	004	
	75MG	N012703	005	
	100MG	N012703	006	
	150MG	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
LIMBITROL				
VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001	
LIMBITROL DS				
VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10

SCHERING	10MG;2MG	N014713	007	
ETRAFON 2-25				
SCHERING	25MG;2MG	N014713	004	
ETRAFON-A				
SCHERING	10MG;4MG	N014713	002	
ETRAFON-FORTE				
SCHERING	25MG;4MG	N014713	006	

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986

DISCONTINUED DRUG PRODUCT LIST

6-22 (of 322)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	25MG; 2MG	A070297	001	Nov 12, 1986
	25MG; 4MG	A071079	001	Nov 12, 1986
PAR PHARM	10MG; 2MG	A070565	001	Sep 11, 1986
	10MG; 4MG	A070620	001	Sep 11, 1986
	25MG; 2MG	A070621	001	Sep 11, 1986
	25MG; 4MG	A070595	001	Sep 11, 1986
	50MG; 4MG	A070574	001	Sep 11, 1986
SANDOZ	10MG; 2MG	A071062	001	Nov 27, 1987
	10MG; 4MG	A071862	001	Dec 21, 1987
	25MG; 2MG	A071063	001	Nov 27, 1987
	25MG; 4MG	A071064	001	Nov 27, 1987
	50MG; 4MG	A071863	001	Dec 21, 1987
WATSON LABS	10MG; 2MG	A070373	001	Aug 25, 1986
	10MG; 2MG	A072539	001	Feb 15, 1989
	10MG; 2MG	A073007	001	Oct 17, 1991
	10MG; 4MG	A070375	001	Aug 25, 1986
	10MG; 4MG	A072540	001	Feb 15, 1989
	10MG; 4MG	A073009	001	Oct 17, 1991
	25MG; 2MG	A070374	001	Aug 25, 1986
	25MG; 2MG	A072541	001	Feb 15, 1989
	25MG; 2MG	A073008	001	Oct 17, 1991
	25MG; 4MG	A070376	001	Aug 25, 1986
	25MG; 4MG	A072134	001	Feb 15, 1989
	25MG; 4MG	A073010	001	Oct 17, 1991
	50MG; 4MG	A070377	001	Nov 04, 1986
	50MG; 4MG	A071558	001	Mar 02, 1987
	50MG; 4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG; 2MG	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG; 2MG	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG; 4MG	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG; 4MG	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG; 4MG	N014715	006	

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU

5%

N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

MUTUAL PHARMA

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

EQ 10MG BASE

A078081 003 Jan 31, 2008

SANDOZ

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

SYNTHON PHARMS

EQ 2.5MG BASE

A077080 001 Jun 27, 2007

EQ 5MG BASE

A077080 002 Jun 27, 2007

EQ 10MG BASE

A077080 003 Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS

EQ 2.5MG BASE

N022026 001 Sep 27, 2007

EQ 5MG BASE

N022026 002 Sep 27, 2007

EQ 10MG BASE

N022026 003 Sep 27, 2007

DISCONTINUED DRUG PRODUCT LIST

6-23 (of 322)

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC

2.5MG

N021435 001 Oct 31, 2003

5MG

N021435 002 Oct 31, 2003

10MG

N021435 003 Oct 31, 2003

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT

5MEQ/ML

A083130 001

GD SEARLE LLC

3MEQ/ML

A086205 001

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW

900MG/100ML

N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN

40MEQ/100ML

A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS

EQ 200MG BASE

N006441 001

AMOXAPINE

TABLET; ORAL

AMOXAPINE

SANDOZ

25MG

A072943 001 Jun 28, 1991

50MG

A072944 001 Jun 28, 1991

100MG

A072878 001 Jun 28, 1991

150MG

A072879 001 Jun 28, 1991

WATSON LABS

25MG

A072418 001 May 11, 1989

50MG

A072419 001 May 11, 1989

100MG

A072420 001 May 11, 1989

150MG

A072421 001 May 11, 1989

ASENDIN

LEDERLE

25MG

N018021 001

50MG

N018021 002

100MG

N018021 003

150MG

N018021 004

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL

250MG

A062528 001 Aug 07, 1985

500MG

A062528 002 Aug 07, 1985

MYLAN

250MG

A062067 001

500MG

A062067 002

TEVA

250MG

A062853 001 Dec 22, 1987

250MG

A063030 001 Feb 28, 1989

500MG

A062854 001 Dec 22, 1987

500MG

A063031 001 Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE

250MG

N050459 001

500MG

N050459 002

TRIMOX

APOTHECON

250MG

A061885 001

250MG

A062098 001

250MG

A062152 001

250MG

A063099 001 Mar 20, 1992

500MG

A061885 002

500MG

A062098 002

500MG

A062152 002

500MG

A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS

250MG

A062107 001

500MG

A062107 002

WYMOX

WYETH AYERST

250MG

A062120 001

500MG

A062120 002

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS

125MG/5ML

A062059 001

250MG/5ML

A062059 002

MYLAN

125MG/5ML

A062090 001

250MG/5ML

A062090 002

DISCONTINUED DRUG PRODUCT LIST

6-24 (of 322)

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

RANBAXY

200MG/5ML

A065113 001 Nov 29, 2002

400MG/5ML

A065113 002 Nov 29, 2002

TEVA

125MG/5ML

A062946 001 Nov 01, 1988

250MG/5ML

A063001 001 Jan 06, 1989

AMOXIL

GLAXOSMITHKLINE

50MG/ML

N050460 005

125MG/5ML

N050460 001

250MG/5ML

N050460 002

LAROTID

GLAXOSMITHKLINE

50MG/ML

N050460 006

POLYMOX

APOTHECON

125MG/5ML

A061851 001

125MG/5ML

A062323 001

250MG/5ML

A061851 002

250MG/5ML

A062323 002

TRIMOX

APOTHECON

50MG/ML

A061886 001

125MG/5ML

A061886 002

125MG/5ML

A062099 001

125MG/5ML

A062154 001

125MG/5ML

A062885 001 Mar 08, 1988

250MG/5ML

A061886 003

250MG/5ML

A062099 002

250MG/5ML

A062154 002

250MG/5ML

A062885 002 Mar 08, 1988

UTIMOX

PARKE DAVIS

125MG/5ML

A062127 001

250MG/5ML

A062127 002

WYMOX

WYETH AYERST

125MG/5ML

A062131 001

250MG/5ML

A062131 002

TABLET; ORAL

AMOXICILLIN

DAVA PHARMS INC

875MG

A065344 001 Jan 15, 2009

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON

125MG

A064131 001 May 06, 1996

250MG

A064131 002 May 06, 1996

DAVA PHARMS INC

125MG

A064139 001 Jan 29, 1996

250MG

A064139 002 Jan 29, 1996

RANBAXY

200MG

A065060 001 Nov 29, 2000

400MG

A065060 002 Nov 29, 2000

TEVA

125MG

A064031 001 Dec 19, 1996

250MG

A064031 002 Dec 19, 1996

AMOXIL

DR REDDYS LABS INC

200MG

N050761 001 Apr 15, 1999

400MG

N050761 002 Apr 15, 1999

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD

200MG

A065324 001 Jan 17, 2007

400MG

A065324 002 Jan 17, 2007

DISPERMOX

RANBAXY LABS LTD

200MG

A065080 002 Aug 11, 2003

400MG

A065080 001 Aug 11, 2003

600MG

A065159 001 Dec 04, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC

250MG;EQ 125MG BASE

A065333 001 Feb 24, 2009

500MG;EQ 125MG BASE

A065333 002 Feb 24, 2009

875MG;EQ 125MG BASE

A065317 003 Oct 20, 2008

RANBAXY LABS

500MG;EQ 125MG BASE

A065109 001 Nov 04, 2002

DISCONTINUED DRUG PRODUCT LIST

6-25 (of 322)

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESSE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG **Federal A083564 001
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

2.5MG;2.5MG;2.5MG;2.5MG **Federal A083564 002
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

3.75MG;3.75MG;3.75MG;3.75MG **Federal A083564 003
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

5MG;5MG;5MG;5MG **Federal Register A083564 004
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

TABLET; ORAL

DELCOBESSE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG **Federal A083563 004
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

2.5MG;2.5MG;2.5MG;2.5MG **Federal A083563 003
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

3.75MG;3.75MG;3.75MG;3.75MG **Federal A083563 002
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

5MG;5MG;5MG;5MG **Federal Register A083563 001
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS

2.5MG;2.5MG;2.5MG;2.5MG **Federal N011522 007 Feb 13, 1996
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

ADDERALL 12.5

TEVA WOMENS

3.125MG;3.125MG;3.125MG;3.125MG N011522 012 Aug 31, 2000
 **Federal Register determination that
 product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

ADDERALL 15

TEVA WOMENS

3.75MG;3.75MG;3.75MG;3.75MG **Federal N011522 013 Aug 31, 2000
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

ADDERALL 20

TEVA WOMENS

5MG;5MG;5MG;5MG **Federal Register N011522 008 Feb 13, 1996
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

ADDERALL 30

TEVA WOMENS

7.5MG;7.5MG;7.5MG;7.5MG **Federal N011522 010 May 12, 1997
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

ADDERALL 5

TEVA WOMENS

1.25MG;1.25MG;1.25MG;1.25MG **Federal N011522 009 May 12, 1997
 Register determination that product was
 not discontinued or withdrawn for
 safety or efficacy reasons**

ADDERALL 7.5

TEVA WOMENS

1.875MG;1.875MG;1.875MG;1.875MG N011522 011 Aug 31, 2000
 **Federal Register determination that
 product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

DISCONTINUED DRUG PRODUCT LIST

6-26 (of 322)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040472 001	Sep 30, 2003
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A040472 002	Sep 30, 2003
	5MG; 5MG; 5MG; 5MG	A040472 003	Sep 30, 2003
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A040472 004	Sep 30, 2003
WATSON LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040456 001	May 06, 2003
	2.5MG; 2.5MG; 2.5MG; 2.5MG	A040456 002	May 06, 2003
	5MG; 5MG; 5MG; 5MG	A040456 003	May 06, 2003
	7.5MG; 7.5MG; 7.5MG; 7.5MG	A040456 004	May 06, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5			
UCB INC	EQ 6.25MG BASE; EQ 6.25MG BASE	N010093 007	
BIPHETAMINE 20			
UCB INC	EQ 10MG BASE; EQ 10MG BASE	N010093 003	
BIPHETAMINE 7.5			
UCB INC	EQ 3.75MG BASE; EQ 3.75MG BASE	N010093 009	

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT	5MG	A083901 001	Aug 31, 1984
	10MG	A083901 002	Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON	3%	N050314 001	

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT	50MG/VIAL	A064141 001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728 001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062 001	Mar 31, 1995

FUNGIZONE

APOTHECON	50MG/VIAL	A060517 001	

LOTION; TOPICAL

FUNGIZONE

APOTHECON	3%	A060570 001	

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON	3%	N050313 001	

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB	100MG/ML	N050341 003	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009
	EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009
	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009
	EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009
APOTHECON	EQ 1GM BASE/VIAL	A062860 004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860 005	Feb 05, 1988
	EQ 125MG BASE/VIAL	A062860 001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860 002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860 003	Feb 05, 1988
CONSOLIDATED PHARM	EQ 1GM BASE/VIAL	A061936 003	
	EQ 2GM BASE/VIAL	A061936 004	
	EQ 125MG BASE/VIAL	A061936 005	
	EQ 250MG BASE/VIAL	A061936 001	
	EQ 500MG BASE/VIAL	A061936 002	
HANFORD GC	EQ 1GM BASE/VIAL	A063139 001	Apr 15, 1993
	EQ 2GM BASE/VIAL	A063141 001	Apr 15, 1993
	EQ 125MG BASE/VIAL	A063143 001	Apr 15, 1993
	EQ 500MG BASE/VIAL	A063147 001	Apr 15, 1993
HIKMA MAPLE	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986

DISCONTINUED DRUG PRODUCT LIST

6-27 (of 322)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634 003	Jan 09, 1987
LILLY	EQ 1GM BASE/VIAL	A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062565 001	Apr 04, 1985
MARSAM PHARMS LLC	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988
	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
OMNIPEN-N			
WYETH AYERST	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986
	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
PENBRITIN-S			
WYETH AYERST	EQ 1GM BASE/VIAL	N050072 004	
	EQ 2GM BASE/VIAL	N050072 005	
	EQ 4GM BASE/VIAL	N050072 006	
	EQ 125MG BASE/VIAL	N050072 001	
	EQ 250MG BASE/VIAL	N050072 002	
	EQ 500MG BASE/VIAL	N050072 003	
POLYCILLIN-N			
BRISTOL	EQ 1GM BASE/VIAL	N050309 004	
	EQ 2GM BASE/VIAL	N050309 005	
	EQ 125MG BASE/VIAL	N050309 001	
	EQ 250MG BASE/VIAL	N050309 002	
	EQ 500MG BASE/VIAL	N050309 003	
TOTACILLIN-N			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	
	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL

N050608 003 Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE

A062041 001

EQ 500MG BASE

A062041 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE

A061602 001

EQ 500MG BASE

A061602 002

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A060765 001

EQ 500MG BASE

A060765 002

LEDERLE

EQ 250MG BASE

A062208 001

EQ 500MG BASE

A062208 002

MYLAN

EQ 250MG BASE

A061755 001

EQ 500MG BASE

A061755 002

PUREPAC PHARM

EQ 250MG BASE

A061853 001

EQ 500MG BASE

A061853 002

TEVA

EQ 250MG BASE

A061502 001

EQ 500MG BASE

A061502 002

VITARINE

EQ 250MG BASE

A061387 001

DISCONTINUED DRUG PRODUCT LIST

6-28 (of 322)

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

	EQ 500MG BASE	A061387 003	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	250MG	A060624 001	
	500MG	A060624 002	
PENBRITIN			
WYETH AYERST	EQ 250MG BASE	A060908 001	
	EQ 500MG BASE	A060908 002	
PFIZERPEN-A			
PFIZER	EQ 250MG BASE	A062050 001	
	EQ 500MG BASE	A062050 002	
POLYCILLIN			
BRISTOL	EQ 250MG BASE	N050310 001	
	EQ 500MG BASE	N050310 002	
PRINCIPEN			
APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE	A062157 002	
	EQ 250MG BASE	N050056 001	
PRINCIPEN '500'			
APOTHECON	EQ 500MG BASE	A062157 001	
	EQ 500MG BASE	N050056 002	
TOTACILLIN			
GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
	EQ 250MG BASE	A062212 001	
	EQ 500MG BASE	A060060 002	
	EQ 500MG BASE	A062212 002	

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
	EQ 250MG BASE/5ML	A062030 002	
AMPICILLIN TRIHYDRATE			
AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601 001	
	EQ 250MG BASE/5ML	A061601 002	
MYLAN	EQ 125MG BASE/5ML	A061829 002	
	EQ 250MG BASE/5ML	A061829 001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001	
	EQ 250MG BASE/5ML	A061980 002	
TEVA	EQ 125MG BASE/5ML	A061370 001	
	EQ 250MG BASE/5ML	A061370 002	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	100MG/ML	A060625 001	
	125MG/5ML	A060625 002	
	250MG/5ML	A060625 003	
	500MG/5ML	A060625 004	
PENBRITIN			
WYETH AYERST	EQ 100MG BASE/ML	N050019 001	
	EQ 125MG BASE/5ML	N050019 002	
	EQ 250MG BASE/5ML	N050019 003	
PFIZERPEN-A			
PFIZER	EQ 125MG BASE/5ML	A062049 001	
	EQ 250MG BASE/5ML	A062049 002	
POLYCILLIN			
APOTHECON	EQ 125MG BASE/5ML	A062297 001	
	EQ 250MG BASE/5ML	A062297 002	
BRISTOL	EQ 100MG BASE/ML	N050308 004	
	EQ 125MG BASE/5ML	N050308 001	
	EQ 250MG BASE/5ML	N050308 002	
	EQ 500MG BASE/5ML	N050308 003	
PRINCIPEN			
APOTHECON	EQ 100MG BASE/ML	A061394 001	
	EQ 125MG BASE/5ML	A061394 002	
	EQ 250MG BASE/5ML	A061394 003	
PRINCIPEN '125'			
APOTHECON	EQ 125MG BASE/5ML	A060127 002	
	EQ 125MG BASE/5ML	A062151 001	

DISCONTINUED DRUG PRODUCT LIST

6-29 (of 322)

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE/5ML

A060127 001

EQ 250MG BASE/5ML

A062151 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A060666 001

EQ 125MG BASE/5ML

A062223 001

EQ 250MG BASE/5ML

A060666 002

EQ 250MG BASE/5ML

A062223 002

TABLET, CHEWABLE; ORAL

POLYCILLIN

BRISTOL

EQ 125MG BASE

N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE; 111MG

A062150 001

EQ 389MG BASE; 111MG

N050488 001

FOR SUSPENSION; ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT; 1GM/BOT

A061898 001

BRISTOL

EQ 3.5GM BASE/BOT; 1GM/BOT

N050457 001

PROBAMPACIN

TEVA

EQ 3.5GM BASE/BOT; 1GM/BOT

A061741 001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE

50MG

N021007 001 Apr 15, 1999

150MG

N021007 002 Apr 15, 1999

SOLUTION; ORAL

AGENERASE

GLAXOSMITHKLINE

15MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

SHIRE LLC

EQ 1MG BASE

N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

ROXANE

EQ 0.5MG BASE

A076489 001 Apr 18, 2005

EQ 1MG BASE

A076489 002 Apr 18, 2005

SANDOZ INC

EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

KUDCO IRELAND

1MG

A091331 001 Jan 05, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

DISCONTINUED DRUG PRODUCT LIST

6-30 (of 322)

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%; 0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 002 May 23, 1997

10,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 004 Jun 07, 2006

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N021875 002 Mar 26, 2009

200MG

N021875 005 Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML; 0.03MG/ML; 0.0025MG/ML; 7.5MG/ML;
100
IU/ML; 0.2MG/ML; 20MG/ML; 2MG/ML; 1.8MG/ML;

N006071 003 Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018440 002 Aug 08, 1985

DISCONTINUED DRUG PRODUCT LIST

6-31 (of 322)

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N008809 004 Aug 08, 1985

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

ASTRAZENECA

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4
MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001
MG/VIAL; 400
IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI
AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/
VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ
2,300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

NOVEL LABS INC

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

MEASURIN

BAYER

650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS

650MG; 50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM

325MG; 50MG; 40MG

A078149 001 Jun 13, 2007

WATSON LABS

325MG; 50MG; 40MG

A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH

325MG; 50MG; 40MG

A086710 002 Aug 23, 1983

HALSEY

325MG; 50MG; 40MG

A089448 001 Dec 01, 1986

IVAX PHARMS

325MG; 50MG; 40MG

A085441 002 Oct 31, 1984

PURACAP PHARM

325MG; 50MG; 40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS

325MG; 50MG; 40MG

A088972 001 Jun 18, 1985

SANDOZ

325MG; 50MG; 40MG

A086398 002 Apr 06, 1984

WATSON LABS

325MG; 50MG; 40MG

A086237 002 Mar 23, 1984

FIORINAL

WATSON LABS INC

325MG; 50MG; 40MG

N017534 003 Apr 16, 1986

DISCONTINUED DRUG PRODUCT LIST

6-32 (of 322)

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

LANNETT

325MG; 50MG; 40MG

A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC

325MG; 50MG; 40MG; 30MG

A075351 001 Mar 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ

385MG; 30MG; 25MG

A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ

770MG; 60MG; 50MG

A074817 002 Nov 27, 1996

ORPHENGESIC

PRINSTON INC

385MG; 30MG; 25MG

A075141 001 May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC

770MG; 60MG; 50MG

A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA

389MG; 32.4MG; 65MG

A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM

389MG; 32.4MG; 32MG

N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM

389MG; 32.4MG; 65MG

N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS

389MG; 32.4MG; 65MG

A083077 002 Dec 07, 1984

SANDOZ

389MG; 32.4MG; 65MG

A080044 002 Sep 16, 1983

TEVA

389MG; 32.4MG; 65MG

A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ

389MG; 32.4MG; 65MG

A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS

389MG; 32.4MG; 65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS

325MG; 200MG

A088809 001 Oct 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA

500MG; 5MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT

500MG; 5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO

325MG; 200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ

325MG; 200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM

325MG; 200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC

325MG; 200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS

325MG; 200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS

325MG; 400MG

A087211 001 Dec 22, 1982

MCNEIL

325MG; 400MG

A089193 001 Feb 12, 1986

PAR PHARM

325MG; 400MG

A089657 001 Nov 04, 1988

ROBAXISAL

ROBINS AH

325MG; 400MG

N012281 001

DISCONTINUED DRUG PRODUCT LIST

6-33 (of 322)

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY	325MG; 4.5MG; 0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN				
MUTUAL PHARM	325MG; 4.5MG; 0.38MG	A040260	001	Jul 17, 1998
	325MG; 4.5MG; 0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)				
ROXANE	325MG; 2.25MG; 0.19MG	A087742	001	Jun 04, 1982
PERCODAN				
ENDO PHARMS	325MG; 4.5MG; 0.38MG	N007337	006	
PERCODAN-DEMI				
ENDO PHARMS	325MG; 2.25MG; 0.19MG	N007337	005	
ROXIPRIN				
ROXANE	325MG; 4.5MG; 0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US	325MG; EQ 12.5MG BASE	N016891	001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG, N/A; N/A, 80MG	N021387	006	Jun 24, 2003

TABLET, TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003
	81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003
	81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003
	325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003
	325MG, N/A; N/A, 40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG; 65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016829	001	

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016863	001	

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058	001	Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907	001	Jul 30, 2004
	50MG	A076907	002	Jul 30, 2004
	100MG	A076907	003	Jul 30, 2004
APOTHECON	50MG	A073317	001	Mar 20, 1992
	100MG	A073318	001	Mar 20, 1992
MYLAN	25MG	A074126	003	Aug 26, 1998
	50MG	A074126	001	Mar 23, 1994
	100MG	A074126	002	Mar 23, 1994
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SANDOZ	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993

DISCONTINUED DRUG PRODUCT LIST

6-34 (of 322)

ATENOLOL

TABLET; ORAL

ATENOLOL

TEVA PHARMS

50MG

A074120 001 Feb 24, 1995

100MG

A074120 002 Feb 24, 1995

WATSON LABS

50MG

A073352 001 Dec 27, 1991

100MG

A073353 001 Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS

50MG; 25MG

A074404 001 May 14, 1998

100MG; 25MG

A074404 002 May 14, 1998

PLIVA

50MG; 25MG

A074107 001 Sep 24, 1997

100MG; 25MG

A074107 002 Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC

18MG

A079017 001 Sep 17, 2010

25MG

A079017 002 Sep 17, 2010

40MG

A079017 003 Sep 17, 2010

60MG

A079017 004 Sep 17, 2010

80MG

A079017 005 Sep 17, 2010

100MG

A079017 006 Sep 17, 2010

STRATTERA

LILLY

5MG

N021411 001 Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS

EQ 10MG BASE

A078773 001 May 29, 2012

EQ 20MG BASE

A078773 002 May 29, 2012

EQ 40MG BASE

A078773 003 May 29, 2012

EQ 80MG BASE

A078773 004 May 29, 2012

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

MARSAM PHARMS LLC

10MG/ML

A074945 001 Jul 28, 1998

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

MARSAM PHARMS LLC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

HOSPIRA

10MG/ML

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA

10MG/ML

N018831 001 Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

DISCONTINUED DRUG PRODUCT LIST

6-35 (of 322)

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT

0.025MG; 0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG; 2.5MG

A086440 001

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG/5ML; 2.5MG/5ML

A085735 001

LOMANATE

ALPHARMA US PHARMS

0.025MG/5ML; 2.5MG/5ML

A085746 001

LOMOTIL

GD SEARLE LLC

0.025MG/5ML; 2.5MG/5ML

N012699 001

TABLET; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG; 2.5MG

A085737 001

DI-ATRO

MD PHARM

0.025MG; 2.5MG

A085266 001

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE

0.025MG; 2.5MG

A040395 001 Nov 27, 2000

ASCOT

0.025MG; 2.5MG

A087934 001 Jul 19, 1983

HEATHER

0.025MG; 2.5MG

A086798 001

INWOOD LABS

0.025MG; 2.5MG

A085509 001

IVAX PHARMS

0.025MG; 2.5MG

A086727 001

KV PHARM

0.025MG; 2.5MG

A085659 001

LEDERLE

0.025MG; 2.5MG

A086950 001

MUTUAL PHARM

0.025MG; 2.5MG

A085506 001

PARKE DAVIS

0.025MG; 2.5MG

A087131 001

PVT FORM

0.025MG; 2.5MG

A085766 001

R AND S PHARMA

0.025MG; 2.5MG

A085035 001

ROXANE

0.025MG; 2.5MG

A086057 001

SANDOZ

0.025MG; 2.5MG

A086173 001

USL PHARMA

0.025MG; 2.5MG

A087842 001 Mar 29, 1982

VALEANT PHARM INTL

0.025MG; 2.5MG

A087195 001 Feb 16, 1982

WATSON LABS

0.025MG; 2.5MG

A085876 001

WEST WARD

0.025MG; 2.5MG

A087765 001 Mar 15, 1982

LO-TROL

VANGARD

0.025MG; 2.5MG

A088009 001 Mar 25, 1983

LOGEN

SUPERPHARM

0.025MG; 2.5MG

A088962 001 May 10, 1985

LOW-QUEL

HALSEY

0.025MG; 2.5MG

A085211 001

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL

0.14MG/ML; 10MG/ML

N019677 001 Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE

0.4MG/ML; 50MG/ML

A087853 001 Nov 26, 1982

0.4MG/ML; 75MG/ML

A087847 001 Nov 26, 1982

0.4MG/ML; 100MG/ML

A087848 001 Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST

0.4MG/ML; 50MG/ML

A085121 001

0.4MG/ML; 75MG/ML

A085121 002

0.4MG/ML; 100MG/ML

A085121 003

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY

2.1MG/0.7ML; 600MG/0.7ML; 600MG/0.7ML

N021175 001 Jan 17, 2002

DISCONTINUED DRUG PRODUCT LIST

6-36 (of 322)

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING

1MG

N017601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

SCHERING

1MG; 120MG

N018506 001 Mar 23, 1982

AZATHIOPRINE

TABLET; ORAL

IMURAN

PROMETHEUS LABS

25MG

N016324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

PROMETHEUS LABS

EQ 100MG BASE/VIAL

N017391 001

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

MEDA PHARMS

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

PFIZER

EQ 250MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE; INJECTION

AZITHROMYCIN

PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB

500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB

10MG/ML

N050632 003 May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

DISCONTINUED DRUG PRODUCT LIST

6-37 (of 322)

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

PFIZER

50,000 UNITS/VIAL

A060282 001

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN

500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

CITRON PHARMA LLC

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050416 002

ZINC BACITRACIN, NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT; TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM; 40MG/GM; EQ 5MG BASE/GM; 5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM; EQ 3.5MG BASE/GM; 5,000 UNITS/GM

A062167 001

NEO-POLYCIN

DOW PHARM

500 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A060647 001

NEOSPORIN

CITRON PHARMA LLC

400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050417 001

OINTMENT; TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM; EQ 3.5MG BASE/GM; 5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM; 2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT; OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM; 10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM; 10,000 UNITS/GM

A061229 001

DISCONTINUED DRUG PRODUCT LIST

6-38 (of 322)

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM; 10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A061048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM; 5,000 UNITS/GM

N050598 001 Sep 22, 1986

BACLOFEN

TABLET; ORAL

BACLOFEN

TEVA

10MG

A073043 001 Feb 27, 1992

20MG

A073044 001 Feb 27, 1992

USL PHARMA

10MG

A071260 001 May 06, 1988

20MG

A071261 001 May 06, 1988

WATSON LABS

10MG

A073092 001 Jan 28, 1994

10MG

A074698 001 Aug 20, 1996

20MG

A073093 001 Jan 28, 1994

20MG

A074698 002 Aug 20, 1996

LIORESAL

NOVARTIS

10MG

N017851 001

20MG

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

UCB INC

10MG

N021589 001 Oct 30, 2003

20MG

N021589 002 Oct 30, 2003

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE

0.042MG/INH

N018153 001

VANCERIL

SCHERING

0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING

0.084MG/INH

N020486 001 Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE

0.042MG/INH

N018584 001

VANCENASE

SCHERING

0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING

EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN PHARMS INC

5MG; 6.25MG

A076612 001 Feb 11, 2004

10MG; 12.5MG

A076612 002 Feb 11, 2004

20MG; 12.5MG

A076612 003 Feb 11, 2004

20MG; 25MG

A076612 004 Feb 11, 2004

DISCONTINUED DRUG PRODUCT LIST

6-39 (of 322)

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON

10MG

N012164 003

NATURETIN-2.5

APOTHECON

2.5MG

N012164 001

NATURETIN-5

APOTHECON

5MG

N012164 002

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND

0.4%

A084149 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS

500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

COREPHARMA

50MG

A040714 001 Oct 29, 2007

DIDREX

PHARMACIA AND UPJOHN

25MG

N012427 003

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

LANNETT HOLDINGS INC

0.5MG

A088877 001 Apr 11, 1985

1MG

A088894 001 Apr 11, 1985

2MG

A088895 001 Apr 11, 1985

MUTUAL PHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008

1MG

A040705 001 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

DISCONTINUED DRUG PRODUCT LIST

6-40 (of 322)

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING

EQ 0.1% BASE

N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS

EQ 0.05% BASE

A071085 001 Feb 03, 1987

PHARMADERM

EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO

EQ 0.05% BASE

A072276 001 Aug 24, 1988

EQ 0.05% BASE

A074272 001 Sep 30, 1994

DISCONTINUED DRUG PRODUCT LIST

6-41 (of 322)

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

TEVA PHARMS EQ 0.05% BASE

A071882 001 Jun 06, 1988

DIPROSONE

SCHERING EQ 0.05% BASE

N017781 001

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE

N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML

A085738 001

CELESTONE

SCHERING EQ 3MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017561 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE

N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070485 001 May 29, 1987

TARO EQ 0.1% BASE

A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE

A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETA-VAL

TEVA EQ 0.1% BASE

A070069 001 Dec 19, 1985

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018863 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC EQ 0.5% BASE

A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG
20MG

N019507 001 Oct 27, 1989

N019507 002 Oct 27, 1989

DISCONTINUED DRUG PRODUCT LIST

6-42 (of 322)

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US

5MG; 12.5MG

N019807 001 Oct 30, 1992

10MG; 12.5MG

N019807 002 Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE; 1.75%

N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS

5MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001 Jul 27, 2004

10MG

A040483 001 Jul 27, 2004

25MG

A040485 001 Jul 27, 2004

50MG

A040509 001 Jul 27, 2004

ACTAVIS TOTOWA

5MG

A040552 001 Oct 28, 2004

10MG

A040553 001 Oct 28, 2004

25MG

A040554 001 Oct 28, 2004

50MG

A040551 001 Oct 28, 2004

ASCOT

10MG

A088288 001 Jun 08, 1983

25MG

A088289 001 Jun 08, 1983

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

LANNETT HOLDINGS INC

5MG

A040703 001 Mar 27, 2008

50MG

A040677 001 Mar 27, 2008

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

WATSON LABS

5MG

A084402 001

5MG

A085230 002

5MG

A085841 001

10MG

A084408 001

10MG

A085228 001

10MG

A085842 001

25MG

A084441 001

25MG

A085229 001

25MG

A085839 001

50MG

A087397 001

50MG

A087444 001

MYOTONACHOL

GLENWOOD

5MG

A084188 001

10MG

A084188 003

25MG

A084188 004

URECHOLINE

ODYSSEY PHARMS

5MG

N006536 003

10MG

N006536 002

25MG

N006536 004

50MG

N006536 005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG

N017675 001

25MG

N017675 002

DISCONTINUED DRUG PRODUCT LIST

6-43 (of 322)

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

KUDCO IRELAND

50MG

A077995 001 Jul 06, 2009

SYNTHON PHARMS

50MG

A077973 001 Jul 06, 2009

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE

5MG/ML

N012418 002

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG; 6.25MG

A075672 001 Sep 25, 2000

5MG; 6.25MG

A075672 002 Sep 25, 2000

10MG; 6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG; 6.25MG

A075642 002 Dec 27, 2000

5MG; 6.25MG

A075642 001 Dec 27, 2000

10MG; 6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG

A075632 001 Sep 27, 2000

5MG; 6.25MG

A075632 002 Sep 27, 2000

10MG; 6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG; 6.25MG

A075527 001 Sep 25, 2000

5MG; 6.25MG

A075527 003 Sep 25, 2000

10MG; 6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG; 6.25MG

A075686 001 Jan 19, 2001

5MG; 6.25MG

A075686 002 Jan 19, 2001

10MG; 6.25MG

A075686 003 Jan 19, 2001

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

BRISTOL MYERS SQUIBB

EQ 15 UNITS BASE/VIAL

N050443 001

EQ 30 UNITS BASE/VIAL

N050443 002 Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007

TEVA PARENTERAL

EQ 15 UNITS BASE/VIAL

A064084 001 Jun 01, 1996

EQ 30 UNITS BASE/VIAL

A064084 002 Jun 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM

50MG/ML

A070134 001 Apr 29, 1986

100MG/ML

A071298 001 Feb 13, 1987

ASTRAZENECA

50MG/ML

A071151 001 Aug 10, 1987

50MG/ML

A071152 001 Aug 10, 1987

50MG/ML

A071153 001 Aug 10, 1987

HIKMA MAPLE

50MG/ML

A070545 001 May 14, 1986

50MG/ML

A070546 001 May 14, 1986

HOSPIRA

50MG/ML

N019030 001 Apr 29, 1986

50MG/ML

N019033 001 Apr 29, 1986

INTL MEDICATION

50MG/ML

A070119 001 Apr 29, 1986

LUITPOLD

50MG/ML

A070891 001 Jul 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT

200MG/100ML

N019005 002 Apr 29, 1986

400MG/100ML

N019005 003 Apr 29, 1986

800MG/100ML

N019005 001 Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

200MG/100ML

N019837 002 Apr 12, 1989

400MG/100ML

N019837 001 Apr 12, 1989

DISCONTINUED DRUG PRODUCT LIST

6-44 (of 322)

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA INC

200MG/100ML

N019008 002 Apr 29, 1986

400MG/100ML

N019008 003 Apr 29, 1986

800MG/100ML

N019008 001 Apr 29, 1986

BRETYLOL

HOSPIRA

50MG/ML

N017954 001

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

ALLERGAN

0.2%

N020613 001 Sep 06, 1996

0.5%

N020490 001 Mar 13, 1997

BRIMONIDINE TARTRATE

TEVA PARENTERAL

0.2%

A076372 001 Sep 10, 2004

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

ISTA PHARMS INC

EQ 0.09% ACID

N021664 001 Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM

EQ 5MG BASE

A075100 001 Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS

25MG

N007984 001

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS

12.5MG/5ML; 10MG/5ML

N009319 006 Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS

12.5MG/5ML; 10MG/5ML

A088343 001 Aug 15, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT

12.5MG/5ML; 10MG/5ML

A088626 001 Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS

2MG/5ML

A086936 001

KV PHARM

2MG/5ML

A085466 001

PHARM ASSOC

2MG/5ML

A087517 001

USL PHARMA

2MG/5ML

A087964 001 Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS

10MG/ML

A083821 001

100MG/ML

A083820 001

DIMETANE-TEN

WYETH AYERST

10MG/ML

N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR

4MG

A084468 001

IVAX SUB TEVA PHARMS

4MG

A084351 001

NEWTRON PHARMS

4MG

A086987 001

NEXGEN PHARMA INC

4MG

A086187 001

PAR PHARM

4MG

A087009 001

PIONEER PHARMS

4MG

A088604 001 Jul 13, 1984

SANDOZ

4MG

A083215 001

VITARINE

4MG

A085850 001

WATSON LABS

4MG

A083123 001

4MG

A085769 001

DIMETANE

WYETH CONS

4MG

N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS

8MG

N010799 010 Jun 10, 1983

12MG

N010799 011 Jun 10, 1983

DISCONTINUED DRUG PRODUCT LIST

6-45 (of 322)

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DC

ALPHARMA US PHARMS 2MG/5ML; 10MG/5ML; 12.5MG/5ML

A088723 001 Feb 25, 1985

DIMETANE-DC

ROBINS AH 2MG/5ML; 10MG/5ML; 12.5MG/5ML

N011694 006 Mar 29, 1984

MYPHETANE DC

WOCKHARDT 2MG/5ML; 10MG/5ML; 12.5MG/5ML

A088904 001 Feb 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS 2MG/5ML; 10MG/5ML; 30MG/5ML

A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT 2MG/5ML; 10MG/5ML; 30MG/5ML

A089681 001 Dec 22, 1988

DIMETANE-DX

ROBINS AH 2MG/5ML; 10MG/5ML; 30MG/5ML

N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP

MORTON GROVE 4MG/5ML; 25MG/5ML

A088687 001 Sep 26, 1984

BROMANATE

ALPHARMA US PHARMS 4MG/5ML; 25MG/5ML

A088688 001 Feb 06, 1985

DIMETAPP

WYETH CONS 2MG/5ML; 12.5MG/5ML

N013087 003 Mar 29, 1984

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP

COPLEY PHARM 12MG; 75MG

A071099 001 Jul 02, 1987

DIMETAPP

WYETH CONS 12MG; 75MG

N012436 003 May 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA 16MG; 240MG

N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS 50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA 0.032MG/INH

N020233 001 Feb 14, 1994

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA 0.16MG/INH

N020441 002 Jun 24, 1997

0.32MG/INH

N020441 003 Jun 24, 1997

SPRAY, METERED; NASAL

RHINOCORT

ASTRAZENECA 0.064MG/INH

N020746 002 Oct 01, 1999

SUSPENSION; INHALATION

BUDESONIDE

APOTEX INC 0.25MG/2ML

A078202 001 Mar 30, 2009

0.5MG/2ML

A078202 002 Mar 30, 2009

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA 0.25MG/ML

A074160 001 Oct 30, 1997

TEVA PARENTERAL 0.25MG/ML

A074613 001 Nov 18, 1997

BUMEX

VALIDUS PHARMS INC 0.25MG/ML

N018226 001 Feb 28, 1983

TABLET; ORAL

BUMEX

VALIDUS PHARMS INC 0.5MG

N018225 002 Feb 28, 1983

1MG

N018225 001 Feb 28, 1983

2MG

N018225 003 Jun 14, 1985

DISCONTINUED DRUG PRODUCT LIST

6-46 (of 322)

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

PACIRA PHARMS INC 133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA

0.075%

N019978 001 Sep 03, 1992

0.114%

N019978 002 Sep 03, 1992

0.23%

N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED

0.25%

A076012 001 Jan 09, 2002

0.5%

A076012 002 Jan 09, 2002

0.75%

A076012 003 Jan 09, 2002

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA

0.25%; 0.005MG/ML

A071166 001 Jun 16, 1988

0.5%; 0.005MG/ML

A071169 001 Jun 16, 1988

0.75%; 0.005MG/ML

A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)

N021496 001 May 23, 2003

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

RECKITT BENCKISER

EQ 2MG BASE

N020732 002 Oct 08, 2002

EQ 8MG BASE

N020732 003 Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER

EQ 2MG BASE; EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020733 001 Oct 08, 2002

EQ 8MG BASE; EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020733 002 Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ

75MG

A075613 002 Oct 10, 2000

100MG

A075613 001 Oct 10, 2000

TEVA

75MG

A075310 001 Nov 29, 1999

100MG

A075310 002 Nov 29, 1999

WELLBUTRIN

GLAXOSMITHKLINE

50MG

N018644 001 Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

IMPAX LABS

300MG

A077415 002 Dec 15, 2006

SANDOZ

100MG

A076845 001 Jul 14, 2005

150MG

A076834 001 Jul 14, 2005

150MG

A076845 002 Jul 14, 2005

WELLBUTRIN SR

GLAXOSMITHKLINE

50MG

N020358 001 Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE

100MG

N020711 002 May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB

5MG

N021190 001 Dec 20, 2000

7.5MG

N021190 002 Dec 20, 2000

10MG

N021190 003 Dec 20, 2000

15MG

N021190 004 Dec 20, 2000

DISCONTINUED DRUG PRODUCT LIST

6-47 (of 322)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N018731	001	Sep 29, 1986
	10MG	N018731	002	Sep 29, 1986
	15MG	N018731	003	Apr 22, 1996
	30MG	N018731	004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

APOTEX	5MG	A075521	001	Apr 05, 2002
	10MG	A075521	002	Apr 05, 2002
	15MG	A075521	003	Apr 05, 2002
EGIS	5MG	A075119	001	Mar 14, 2002
	10MG	A075119	002	Mar 14, 2002
	15MG	A075119	003	Jan 23, 2003
IVAX SUB TEVA PHARMS	5MG	A075385	001	Mar 01, 2002
	10MG	A075385	002	Mar 01, 2002
	15MG	A075385	003	Mar 01, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
PROSAM LABS	5MG	A075388	001	May 09, 2002
	10MG	A075388	002	May 09, 2002
	15MG	A075388	003	May 09, 2002
SANDOZ	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873	001	
BUTABARBITAL SODIUM				
WOCKHARDT	30MG/5ML	A085383	001	
BUTALAN				
LANNETT	33.3MG/5ML	A085880	001	
SARISOL				
HALSEY	30MG/5ML	A084723	001	

TABLET; ORAL

BUTABARBITAL

BUNDY	30MG	A085550	001	

BUTABARBITAL SODIUM

SANDOZ	15MG	A084292	003	Feb 09, 1982
	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	

BUTISOL SODIUM

MEDA PHARMS	15MG	N000793	002	
	100MG	N000793	005	

SARISOL NO. 1

HALSEY	15MG	A084719	001	

SARISOL NO. 2

HALSEY	30MG	A084719	002	

SODIUM BUTABARBITAL

IVAX SUB TEVA PHARMS	15MG	A083484	001	
	30MG	A084040	001	
LANNETT	15MG	A085849	001	
	30MG	A085866	001	

DISCONTINUED DRUG PRODUCT LIST

6-48 (of 322)

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

	100MG	A085881 001
MARSHALL PHARMA	16.2MG	A083524 001
	32.4MG	A083858 001
WEST WARD	15MG	A085418 001
	30MG	A085432 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO	2%	N019215 001	Nov 25, 1985

GYNAZOLE-1

KV PHARM	2%	N019881 001	Feb 07, 1997

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO	100MG	N019359 001	Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

APOTEX INC	2MG/ML	A075697 001	Oct 23, 2001
HOSPIRA	1MG/ML	A075342 001	Nov 04, 1999
	1MG/ML	A075559 001	Mar 20, 2000
	2MG/ML	A075342 002	Nov 04, 1999
	2MG/ML	A075559 002	Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

APOTEX INC	1MG/ML	A075695 001	Oct 23, 2001
	2MG/ML	A075695 002	Oct 23, 2001
HOSPIRA	1MG/ML	A074620 001	Jan 22, 1997
	1MG/ML	A075170 001	Sep 28, 1998
	2MG/ML	A074620 002	Jan 22, 1997
	2MG/ML	A075170 002	Sep 28, 1998

STADOL

APOTHECON	2MG/ML	N017857 004

STADOL PRESERVATIVE FREE

APOTHECON	1MG/ML	N017857 001
	2MG/ML	N017857 002

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890 001	Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN	0.5MG	N020664 001	Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS	100MG; 2MG	N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS	100MG; 1MG	N006620 001

WIGRAINE

ORGANON USA INC	100MG; 1MG	A086562 001

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC	0.02MG	N018312 001
	0.05MG	N018312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARMA AS	0.005%	N020273 001	Dec 29, 1993

CALCITONIN HUMAN

INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS	0.5MG/VIAL	N018470 001	Oct 31, 1986

DISCONTINUED DRUG PRODUCT LIST

6-49 (of 322)

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCIMAR

SANOFI AVENTIS US 200 IU/ML
400 IU/VIAL

N017769 001
N017497 001

CALCITONIN-SALMON

ASTRAZENECA 200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

NOVARTIS 100 IU/ML

N017808 001 Jul 03, 1986

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

HOSPIRA 0.001MG/ML
0.002MG/ML
TEVA PARENTERAL 0.001MG/ML

A075816 001 Jan 16, 2004
A075816 002 Jan 16, 2004
A075823 001 Mar 31, 2003

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL EQ 84.5MG CALCIUM
EQ 169MG CALCIUM

N021160 001 Apr 02, 2001
N021160 002 Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

ROXANE EQ 169MG CALCIUM

A077693 001 Jan 30, 2008

PHOSLO

FRESENIUS MEDCL EQ 169MG CALCIUM

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT EQ 500MG BASE, N/A; N/A, 35MG **Federal
Register determination that product was
not discontinued or withdrawn for
safety or efficacy reasons**

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/100
0ML; 7.07GM/1000ML

N021703 012 Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.0
5GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML
; 6.46GM/1000ML

N021703 005 Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/100
0ML; 6.46GM/1000ML

N021703 008 Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05
GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46
GM/1000ML

N021703 007 Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS 3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3
.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000
ML; 6.46GM/1000ML

N021703 009 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/1
00ML; 330MG/100ML; 88MG/100ML

N018271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/10
0ML; 640MG/100ML; 500MG/100ML; 74MG/100ML

N019867 001 Dec 20, 1993

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/10
0ML; 640MG/100ML; 500MG/100ML; 74MG/100ML

N018269 002 Jan 17, 1983

DISCONTINUED DRUG PRODUCT LIST

6-50 (of 322)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	004	
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER				
B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634	002	Feb 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510	001	
MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499	001	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988
	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395	001	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395	002	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 448MG/100ML	N019395	003	Mar 26, 1986

DISCONTINUED DRUG PRODUCT LIST

6-51 (of 322)

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT

16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML;
16.1MG/ML

N019399 001 Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/
100ML; 500MG/100ML; 74MG/100ML

N018899 001 Oct 31, 1983

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG
/100ML

N018725 001 Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN

33MG/100ML; 30MG/100ML; 860MG/100ML

N018721 001 Nov 09, 1982

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT

33MG/100ML; 30MG/100ML; 860MG/100ML

N018462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N019485 001 Oct 24, 1985

B BRAUN

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018023 001

MILES

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018417 001

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT

EQ 90MG CALCIUM/5ML

A080001 001

EQ 90MG CALCIUM/5ML

A083159 001

ABRAXIS PHARM

EQ 90MG CALCIUM/5ML

A089373 001 Apr 30, 1987

LILLY

EQ 90MG CALCIUM/5ML

N006470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE

0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML

N016847 001

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE

0.35MG/ML; 140.1MG/ML; 461.8MG/ML

N017506 001

CANDICIDIN

OINTMENT; VAGINAL

VANOBI

SANOFI AVENTIS US

0.6MG/GM

A061596 001

TABLET; VAGINAL

VANOBI

SANOFI AVENTIS US

3MG

A061613 001

CAPTOPRIL

TABLET; ORAL

CAPOTEN

PAR PHARM

37.5MG

N018343 006 Sep 17, 1986

75MG

N018343 007 Jun 13, 1995

150MG

N018343 004 Jun 13, 1995

CAPTOPRIL

APOTHECON

12.5MG

A074472 001 Mar 31, 1995

25MG

A074472 002 Mar 31, 1995

50MG

A074472 003 Mar 31, 1995

100MG

A074472 004 Mar 31, 1995

CLONMEL HLTHCARE

12.5MG

A074423 001 Feb 13, 1996

25MG

A074423 002 Feb 13, 1996

50MG

A074423 003 Feb 13, 1996

100MG

A074423 004 Feb 13, 1996

DISCONTINUED DRUG PRODUCT LIST

6-52 (of 322)

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
	25MG	A074748 002	May 29, 1997
	50MG	A074748 001	May 29, 1997
	100MG	A074748 003	May 29, 1997
IVAX SUB TEVA PHARMS	12.5MG	A074590 004	Aug 30, 1996
	25MG	A074590 002	Aug 30, 1996
	50MG	A074590 001	Aug 30, 1996
	100MG	A074590 003	Aug 30, 1996
PAR PHARM	12.5MG	A074493 001	Feb 13, 1996
	25MG	A074493 002	Feb 13, 1996
	50MG	A074493 003	Feb 13, 1996
	100MG	A074493 004	Feb 13, 1996
PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996
	25MG	A074477 002	Feb 13, 1996
	50MG	A074477 003	Feb 13, 1996
	100MG	A074477 004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
	25MG	A074640 002	Mar 31, 1997
	50MG	A074640 003	Mar 31, 1997
	100MG	A074640 004	Mar 31, 1997
SANDOZ	12.5MG	A074481 001	Feb 13, 1996
	12.5MG	A074519 001	Feb 13, 1996
	25MG	A074481 002	Feb 13, 1996
	25MG	A074519 002	Feb 13, 1996
	50MG	A074481 003	Feb 13, 1996
	50MG	A074519 003	Feb 13, 1996
	100MG	A074481 004	Feb 13, 1996
	100MG	A074519 004	Feb 13, 1996
TEVA	12.5MG	A074433 001	Feb 13, 1996
	12.5MG	A074483 001	Feb 13, 1996
	25MG	A074433 002	Feb 13, 1996
	25MG	A074483 002	Feb 13, 1996
	50MG	A074433 003	Feb 13, 1996
	50MG	A074483 003	Feb 13, 1996
	100MG	A074433 004	Feb 13, 1996
	100MG	A074483 004	Feb 13, 1996
TEVA PHARMS	12.5MG	A074462 001	Feb 13, 1996
	25MG	A074462 002	Feb 13, 1996
	50MG	A074462 003	Feb 13, 1996
	100MG	A074462 004	Feb 13, 1996
VINTAGE PHARMS LLC	12.5MG	A074418 001	Feb 13, 1996
	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
WATSON LABS	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	25MG; 15MG	A075055 001	Jun 18, 1998
	25MG; 25MG	A075055 002	Jun 18, 1998
	50MG; 15MG	A075055 004	Jun 18, 1998
	50MG; 25MG	A075055 003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG; 15MG	A074788 001	Dec 29, 1997
	25MG; 25MG	A074788 002	Dec 29, 1997
	50MG; 15MG	A074788 004	Dec 29, 1997
	50MG; 25MG	A074788 003	Dec 29, 1997
WATSON LABS	50MG; 25MG	A074832 001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292 001	May 21, 1986
CARBASTAT			
NOVARTIS	0.01%	A073677 001	Apr 28, 1995

DISCONTINUED DRUG PRODUCT LIST

6-53 (of 322)

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001 Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001 Nov 09, 1987

INWOOD LABS

200MG

A070231 001 Aug 14, 1986

PLIVA

200MG

A071479 001 Jul 24, 1987

USL PHARMA

200MG

A070300 001 May 15, 1986

WARNER CHILCOTT

200MG

A070429 001 Jan 02, 1987

TERIL

TARO

200MG

A076525 001 Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG

EQ 1GM BASE/VIAL

N050306 001

EQ 2GM BASE/VIAL

N050306 004

EQ 5GM BASE/VIAL

N050306 002

EQ 10GM BASE/VIAL

N050306 006

EQ 30GM BASE/VIAL

N050306 007

PYOPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050298 001

EQ 2GM BASE/VIAL

N050298 002

EQ 5GM BASE/VIAL

N050298 003

EQ 10GM BASE/VIAL

N050298 006

EQ 20GM BASE/VIAL

N050298 007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER

EQ 382MG BASE

N050435 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

SANDOZ

10MG; 100MG

A073586 001 Jun 29, 1995

25MG; 100MG

A073587 001 Jun 29, 1995

25MG; 250MG

A073620 001 Jun 29, 1995

SCS

10MG; 100MG

A074080 001 Mar 25, 1994

25MG; 100MG

A074080 002 Mar 25, 1994

25MG; 250MG

A074080 003 Mar 25, 1994

WATSON LABS

10MG; 100MG

A073381 001 Sep 28, 1993

25MG; 100MG

A073382 001 Sep 28, 1993

25MG; 250MG

A073383 001 Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM

50MG; 200MG

A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY

10MG; 100MG

A076643 001 Jun 10, 2005

25MG; 100MG

A076643 002 Jun 10, 2005

25MG; 250MG

A076643 003 Jun 10, 2005

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

MCNEIL

4MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N008955 001

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM

4MG

N008915 001

DISCONTINUED DRUG PRODUCT LIST

6-54 (of 322)

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

450MG/VIAL

A076602 003 Nov 16, 2004

PARAPLATIN

CORDEN PHARMA

50MG/VIAL

N019880 001 Mar 03, 1989

150MG/VIAL

N019880 002 Mar 03, 1989

450MG/VIAL

N019880 003 Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

FRESENIUS KABI USA

50MG/5ML (10MG/ML)

A077247 001 Oct 21, 2004

50MG/5ML (10MG/ML)

A077266 001 Feb 15, 2006

150MG/15ML (10MG/ML)

A077247 002 Oct 21, 2004

150MG/15ML (10MG/ML)

A077266 002 Feb 15, 2006

PHARMACHEMIE BV

50MG/5ML (10MG/ML)

A077679 001 Feb 25, 2009

150MG/15ML (10MG/ML)

A077679 002 Feb 25, 2009

450MG/45ML (10MG/ML)

A077679 003 Feb 25, 2009

TEVA PARENTERAL

50MG/5ML (10MG/ML)

A077389 001 Mar 30, 2007

150MG/15ML (10MG/ML)

A077389 002 Mar 30, 2007

450MG/45ML (10MG/ML)

A077389 003 Mar 30, 2007

PARAPLATIN

CORDENPHARMA

50MG/5ML (10MG/ML)

N020452 001 Jul 14, 2003

150MG/15ML (10MG/ML)

N020452 002 Jul 14, 2003

450MG/45ML (10MG/ML)

N020452 003 Jul 14, 2003

600MG/60ML (10MG/ML)

N020452 004 Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS

250MG

N011792 003

TABLET; ORAL

CARISOPRODOL

ABLE

350MG

A040421 001 Jun 21, 2001

COREPHARMA

350MG

A040397 001 Sep 21, 2000

PIONEER PHARMS

350MG

A089390 001 Oct 13, 1988

PROSAM LABS

350MG

A040188 001 Mar 07, 1997

SANDOZ

350MG

A081025 001 Apr 13, 1989

350MG

A089566 001 Aug 30, 1988

WATSON LABS

350MG

A040152 001 Dec 03, 1996

350MG

A085433 001

350MG

A086179 001

WEST WARD

350MG

A040124 001 Jan 24, 1996

RELA

SCHERING

350MG

N012155 001

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST

50MG/ML

N014173 001

TABLET; ORAL

PROKETAZINE

WYETH AYERST

12.5MG

N012768 001

25MG

N012768 002

50MG

N012768 004

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE

100MG

N018550 002 Dec 31, 1987

150MG

N018550 003 Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC

1%

A076097 001 Feb 06, 2002

TABLET; ORAL

CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

DISCONTINUED DRUG PRODUCT LIST

6-55 (of 322)

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET; ORAL

CARVEDILOL

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

CEFACLOL

CAPSULE; ORAL

CECLOR

LILLY

EQ 250MG BASE

N050521 001

EQ 500MG BASE

N050521 002

CEFACLOL

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

CLONMEL HLTHCARE

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

MARSAM PHARMS LLC

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

FOR SUSPENSION; ORAL

CECLOR

LILLY

EQ 125MG BASE/5ML

N050522 001

EQ 250MG BASE/5ML

N050522 002

CEFACLOL

CLONMEL HLTHCARE

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

MARSAM PHARMS LLC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

EQ 375MG BASE/5ML

A064207 001 Feb 18, 1998

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

TABLET, CHEWABLE; ORAL

RANICLOL

RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003

EQ 187MG BASE

A065092 002 Dec 22, 2003

EQ 250MG BASE

A065092 003 Dec 22, 2003

EQ 375MG BASE

A065092 004 Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY

EQ 375MG BASE

N050673 001 Jun 28, 1996

EQ 500MG BASE

N050673 002 Jun 28, 1996

CEFACLOL

WORLD GEN

EQ 500MG BASE

A065057 001 Jan 05, 2001

DISCONTINUED DRUG PRODUCT LIST

6-56 (of 322)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE	N050512 001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982

FOR SUSPENSION; ORAL

CEFADROXIL

APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	
TEVA	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527 002	
	EQ 250MG BASE/5ML	N050527 003	
	EQ 500MG BASE/5ML	N050527 001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999

DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528 001	

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	
	EQ 500MG BASE/VIAL	N050504 001	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050461 003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
	EQ 10GM BASE/VIAL	N050461 005	
	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
	EQ 500MG BASE/VIAL	N050461 002	

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986

DISCONTINUED DRUG PRODUCT LIST

6-57 (of 322)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
BEDFORD	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
	EQ 500MG BASE/VIAL	A064169 001	Aug 14, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
HIKMA MAPLE	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
MARSAM PHARMS LLC	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
TEVA PHARMS	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
KEFZOL			
ACS DOBFAR	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
	EQ 250MG BASE/VIAL	A061773 001	
LILLY	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985
	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

ABBVIE
FOR SUSPENSION; ORAL

OMNICEF

ABBVIE

300MG

N050739 001 Dec 04, 1997

125MG/5ML
250MG/5MLN050749 001 Dec 04, 1997
N050749 002 Jul 29, 2004CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 500MG BASE/VIALA090291 002 Dec 21, 2010
A090291 003 Dec 21, 2010
A090291 001 Dec 21, 2010CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

LEDERLE

TABLET; ORAL

SUPRAX

LEDERLE

100MG/5ML

N050622 001 Apr 28, 1989

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**
400MGN050621 001 Apr 28, 1989
N050621 002 Apr 28, 1989

DISCONTINUED DRUG PRODUCT LIST

6-58 (of 322)

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 500MG BASE/VIALN050571 002 Dec 30, 1987
N050571 003 Dec 30, 1987
N050571 001 Dec 30, 1987CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIALN050637 001 Dec 11, 1989
N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN

EQ 20MG BASE/ML
EQ 40MG BASE/MLN050683 001 Dec 29, 1992
N050683 002 Dec 29, 1992CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL
EQ 500MG BASE/VIALA063295 001 Jul 26, 1993
N050579 002 May 23, 1984
N050579 003 May 23, 1984
N050579 004 May 23, 1984
N050579 001 May 23, 1984CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIALA063333 001 Mar 31, 1995
N050551 001 Nov 18, 1982
A063333 002 Mar 31, 1995
N050551 002 Nov 18, 1982
N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML
EQ 40MG BASE/MLN050613 002 Jul 31, 1987
N050613 001 Jul 23, 1986CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

1GM/VIAL
2GM/VIAL
10GM/VIAL
20GM/VIAL
500MG/VIALA062579 002 Nov 26, 1984
A062579 003 Nov 26, 1984
A062579 004 Nov 26, 1984
A062579 005 Nov 26, 1984
A062579 001 Nov 26, 1984

BRISTOL

1GM/VIAL
2GM/VIAL
10GM/VIAL
20GM/VIAL
500MG/VIALN050554 002 May 24, 1984
N050554 003 May 24, 1984
N050554 004 May 24, 1984
N050554 005 May 24, 1984
N050554 001 May 24, 1984CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL
EQ 20GM BASE/VIAL
EQ 500MG BASE/VIALA064200 002 Mar 24, 2000
A064200 003 Mar 24, 2000
A064201 001 Mar 24, 2000
A064201 002 Mar 24, 2000
A064200 001 Mar 24, 2000

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN

EQ 2GM BASE

N050792 001 Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN

EQ 1GM BASE

N050792 002 Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 500MG BASE/VIALA065517 002 Nov 06, 2009
A065517 003 Nov 06, 2009
A065517 001 Nov 06, 2009

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065516 001 Nov 06, 2009

CEPHAZONE PHARMA

EQ 10GM BASE/VIAL

A065348 001 Jan 25, 2010

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 20MG BASE/ML
EQ 40MG BASE/MLN050596 001 May 20, 1985
N050596 003 May 20, 1985

DISCONTINUED DRUG PRODUCT LIST

6-59 (of 322)

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

ASTRAZENECA

EQ 1GM BASE/VIAL

A063293 001 Apr 29, 1993

EQ 1GM BASE/VIAL

N050588 001 Dec 27, 1985

EQ 2GM BASE/VIAL

A063293 002 Apr 29, 1993

EQ 2GM BASE/VIAL

N050588 002 Dec 27, 1985

EQ 10GM BASE/VIAL

N050588 003 Apr 25, 1988

CEFOTAN IN PLASTIC CONTAINER

ASTRAZENECA

EQ 20MG BASE/ML

N050694 002 Jul 30, 1993

EQ 40MG BASE/ML

N050694 001 Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA

EQ 1GM BASE/VIAL

N050601 001 Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A065012 001 Jul 03, 2000

EQ 2GM BASE/VIAL

A065012 002 Jul 03, 2000

EQ 10GM BASE/VIAL

A065011 001 Jul 03, 2000

MEFOXIN

MYLAN INSTITUTIONAL

EQ 1GM BASE/VIAL

A062757 001 Jan 08, 1987

EQ 1GM BASE/VIAL

N050517 001

EQ 2GM BASE/VIAL

A062757 002 Jan 08, 1987

EQ 2GM BASE/VIAL

N050517 002

EQ 10GM BASE/VIAL

N050517 003

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MERCK

EQ 20MG BASE/ML

N050581 003 Sep 20, 1984

EQ 40MG BASE/ML

N050581 004 Sep 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCK

EQ 20MG BASE/ML

N050581 002 Sep 20, 1984

EQ 40MG BASE/ML

N050581 001 Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST

EQ 1GM BASE/VIAL

N050633 002 Jan 31, 1989

EQ 2GM BASE/VIAL

N050633 003 Jan 31, 1989

EQ 10GM BASE/VIAL

N050633 005 Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

EQ 50MG BASE/5ML

N050688 002 Aug 07, 1992

EQ 100MG BASE/5ML

N050688 001 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML

N050675 001 Aug 07, 1992

EQ 100MG BASE/5ML

N050675 002 Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

EQ 100MG BASE

N050687 001 Aug 07, 1992

EQ 200MG BASE

N050687 002 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 100MG BASE

N050674 001 Aug 07, 1992

EQ 200MG BASE

N050674 002 Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

125MG/5ML

A065202 001 Jun 30, 2006

250MG/5ML

A065202 002 Jun 30, 2006

CEFZIL

CORDEN PHARMA

125MG/5ML

N050665 001 Dec 23, 1991

250MG/5ML

N050665 002 Dec 23, 1991

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006

500MG

A065198 002 Dec 13, 2006

CEFZIL

CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991

500MG

N050664 002 Dec 23, 1991

DISCONTINUED DRUG PRODUCT LIST

6-60 (of 322)

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010
	500MG/VIAL	A065481	001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990
	500MG/VIAL	N050646	001	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

CEDAX

PERNIX THERAP	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
STERI PHARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006

DISCONTINUED DRUG PRODUCT LIST

6-61 (of 322)

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

ROCEPHIN

HOFFMANN LA ROCHE

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL

N050585 003 Dec 21, 1984
N050585 004 Dec 21, 1984
N050585 001 Dec 21, 1984
N050585 002 Dec 21, 1984

INJECTABLE; INJECTION

CEFTRIAXONE

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008

FRESENIUS KABI USA

EQ 10GM BASE/VIAL

A065252 001 Feb 15, 2006

TEVA

EQ 10GM BASE/VIAL

A065274 001 May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL
EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL

A062654 002 Apr 30, 1987
A062654 003 Apr 30, 1987
N050585 005 Dec 21, 1984
A063239 001 Aug 13, 1993
A062654 001 Apr 30, 1987
A062510 003 Mar 12, 1985
A062510 001 Mar 12, 1985
A062510 002 Mar 12, 1985

ROCHE

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

HOFFMANN LA ROCHE

EQ 10MG BASE/ML
EQ 20MG BASE/ML
EQ 40MG BASE/ML

N050624 001 Feb 11, 1987
N050624 002 Feb 11, 1987
N050624 003 Feb 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE

EQ 1GM BASE/VIAL, N/A; N/A, 1%
EQ 500MG BASE/VIAL, N/A; N/A, 1%

N050585 006 May 08, 1996
N050585 007 May 08, 1996

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD

EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE
EQ 250MG BASE
EQ 500MG BASE

A065043 003 Feb 15, 2002
A065043 002 Feb 15, 2002
A065043 001 Feb 15, 2002
A065126 001 Oct 28, 2003
A065126 002 Oct 28, 2003

SANDOZ

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

FRESENIUS KABI USA

EQ 750MG BASE/VIAL

A065001 001 May 30, 2001

MARSAM PHARMS LLC

EQ 750MG BASE/VIAL

A064035 001 Feb 26, 1993

TEVA PHARMS

EQ 1.5GM BASE/VIAL

A064192 001 Apr 16, 1998

EQ 750MG BASE/VIAL

A064192 002 Apr 16, 1998

KEFUROX

ACS DOBFAR

EQ 750MG BASE/VIAL

A062591 001 Jan 10, 1986

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA

EQ 1.5GM BASE/VIAL

A065001 002 May 30, 2001

EQ 7.5GM BASE/VIAL

A065002 001 Sep 28, 1998

MARSAM PHARMS LLC

EQ 1.5GM BASE/VIAL

A064035 002 Feb 26, 1993

EQ 7.5GM BASE/VIAL

A064036 001 Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL

EQ 75GM BASE/VIAL
EQ 225GM BASE/VIAL

A065251 001 Dec 30, 2009
A065251 002 Dec 30, 2009

KEFUROX

ACS DOBFAR

EQ 1.5GM BASE/VIAL
EQ 7.5GM BASE/VIAL

A062591 002 Jan 10, 1986
A062591 003 Dec 17, 1987

LILLY

EQ 1.5GM BASE/VIAL

A062592 002 Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY

EQ 1.5GM BASE/VIAL

A062590 002 Jan 10, 1986

ZINACEF IN PLASTIC CONTAINER

COVIS PHARMA SARL

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY

EQ 750MG BASE/VIAL

A062592 001 Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY

EQ 750MG BASE/VIAL

A062590 001 Jan 10, 1986

DISCONTINUED DRUG PRODUCT LIST

6-62 (of 322)

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA

2.5GM/PACKET

N018757 002 Dec 28, 1982

300GM/BOT

N018757 003 Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON

EQ 250MG BASE

A062973 001 Nov 08, 1988

EQ 250MG BASE

A063063 001 Sep 29, 1989

EQ 250MG BASE

A063186 001 Dec 30, 1994

EQ 500MG BASE

A062974 001 Nov 23, 1988

EQ 500MG BASE

A063063 002 Sep 29, 1989

EQ 500MG BASE

A063186 002 Dec 30, 1994

BARR

EQ 250MG BASE

A062773 001 Jun 26, 1987

EQ 500MG BASE

A062775 001 Apr 22, 1987

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A061969 001

EQ 500MG BASE

A061969 002

PUREPAC PHARM

EQ 250MG BASE

A062809 001 Apr 22, 1987

EQ 500MG BASE

A062809 002 Apr 22, 1987

STEVENS J

EQ 500MG BASE

A062869 001 Mar 17, 1988

TEVA

EQ 250MG BASE

A062760 001 Apr 24, 1987

EQ 250MG BASE

A062821 001 Feb 05, 1988

EQ 500MG BASE

A062761 001 Apr 24, 1987

EQ 500MG BASE

A062823 001 Feb 05, 1988

YOSHITOMI

EQ 250MG BASE

A062872 001 Jun 20, 1988

EQ 500MG BASE

A062871 001 Jul 05, 1988

KEFLEX

SHIONOGI INC

EQ 333MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050405 004 May 12, 2006

FOR SUSPENSION; ORAL

CEPHALEXIN

APOTHECON

EQ 125MG BASE/5ML

A062986 001 Apr 18, 1991

EQ 250MG BASE/5ML

A062987 001 Jul 25, 1989

BARR

EQ 125MG BASE/5ML

A062778 001 Aug 06, 1987

EQ 250MG BASE/5ML

A062777 001 Aug 06, 1987

FACTA FARMA

EQ 100MG BASE/ML

A062117 001

TEVA

EQ 125MG BASE/5ML

A062767 001 Jun 16, 1987

EQ 125MG BASE/5ML

A062873 001 May 23, 1988

EQ 250MG BASE/5ML

A062768 001 Jun 16, 1987

EQ 250MG BASE/5ML

A062867 001 Apr 15, 1988

VITARINE

EQ 125MG BASE/5ML

A062779 001 Dec 22, 1987

EQ 250MG BASE/5ML

A062781 001 Dec 22, 1987

KEFLEX

SHIONOGI INC

EQ 100MG BASE/ML

N050406 003

EQ 125MG BASE/5ML

N050406 001

EQ 250MG BASE/5ML

N050406 002

TABLET; ORAL

CEPHALEXIN

BARR

EQ 250MG BASE

A062826 001 Aug 17, 1987

EQ 500MG BASE

A062827 001 Aug 17, 1987

VITARINE

EQ 1GM BASE

A062863 003 Aug 11, 1988

EQ 250MG BASE

A062863 001 Aug 11, 1988

EQ 500MG BASE

A062863 002 Aug 11, 1988

KEFLET

LILLY

EQ 1GM BASE

N050440 002

EQ 250MG BASE

A062745 001 Dec 01, 1986

EQ 250MG BASE

N050440 003 Feb 26, 1987

EQ 500MG BASE

A062745 002 Dec 01, 1986

EQ 500MG BASE

N050440 001

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD

EQ 125MG BASE

A065100 002 Sep 11, 2003

EQ 250MG BASE

A065100 001 Sep 11, 2003

DISCONTINUED DRUG PRODUCT LIST

6-63 (of 322)

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY

EQ 250MG BASE

N050614 001 Oct 29, 1987

EQ 333MG BASE

N050614 003 May 16, 1988

EQ 500MG BASE

N050614 002 Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 1GM BASE/VIAL

A061769 001

EQ 1GM BASE/VIAL

A062724 001 Dec 23, 1986

EQ 1GM BASE/VIAL

A062961 002 Sep 20, 1988

EQ 1GM BASE/VIAL

N050446 001

EQ 2GM BASE/VIAL

A061769 002

EQ 2GM BASE/VIAL

A062724 002 Dec 23, 1986

EQ 2GM BASE/VIAL

A062961 003 Sep 20, 1988

EQ 2GM BASE/VIAL

N050446 002

EQ 4GM BASE/VIAL

A061769 003

EQ 4GM BASE/VIAL

A062961 004 Sep 20, 1988

EQ 4GM BASE/VIAL

N050446 003

EQ 20GM BASE/VIAL

N050446 004

EQ 500MG BASE/VIAL

A062961 001 Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062723 002 Nov 17, 1986

EQ 2GM BASE/VIAL

A062723 003 Nov 17, 1986

EQ 4GM BASE/VIAL

A062723 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062723 005 Nov 17, 1986

DISCONTINUED DRUG PRODUCT LIST

6-64 (of 322)

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

	EQ 500MG BASE/VIAL	A062723 001	Nov 17, 1986
HIKMA MAPLE	EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987
	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859 001	
	500MG	A061859 002	

CEPHRADINE

BARR	250MG	A062850 001	Apr 22, 1988
	500MG	A062851 001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762 001	Mar 06, 1987
	500MG	A062762 002	Mar 06, 1987
TEVA	250MG	A062683 001	Jan 09, 1987
	500MG	A062683 002	Jan 09, 1987
VITARINE	250MG	A062813 001	Feb 25, 1988
	500MG	A062813 002	Feb 25, 1988

VELOSEF

APOTHECON	250MG	A061764 001	
	500MG	A061764 002	

VELOSEF '250'

ERSANA	250MG	N050548 001	

VELOSEF '500'

ERSANA	500MG	N050548 002	

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE	125MG/5ML	A061866 001	
	250MG/5ML	A061866 002	

CEPHRADINE

BARR	125MG/5ML	A062858 001	May 19, 1988
	250MG/5ML	A062859 001	May 19, 1988
TEVA	125MG/5ML	A062693 001	Jan 09, 1987
	250MG/5ML	A062693 002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763 001	

VELOSEF '250'

APOTHECON	250MG/5ML	A061763 002	

INJECTABLE; INJECTION

VELOSEF

APOTHECON	1GM/VIAL	A061976 004	
	2GM/VIAL	A061976 003	
	4GM/VIAL	A061976 005	
	250MG/VIAL	A061976 001	
	500MG/VIAL	A061976 002	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530 001	

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS	0.05MG	N020740 001	Jun 26, 1997
	0.1MG	N020740 002	Jun 26, 1997
	0.2MG	N020740 003	Jun 26, 1997
	0.3MG	N020740 004	Jun 26, 1997
	0.4MG	N020740 005	May 24, 1999
	0.8MG	N020740 006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296 001	

DISCONTINUED DRUG PRODUCT LIST

6-65 (of 322)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS	5MG	N021621	003	Nov 16, 2007
	10MG	N021621	004	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

MCNEIL CONS	5MG	N021621	005	Nov 16, 2007
	10MG	N021621	006	Nov 16, 2007

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE	12MG/VIAL; 108MG/VIAL; 8MG/VIAL	N020044	001	Aug 02, 1990

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU	250MG	N018513	002	Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M	25MG/5ML	N012126	001	

CHLORAMPHENICOL

CAPSULE; ORAL

AMPHICOL

FERRANTE	100MG	A060058	001	

CHLOROMYCETIN

PARKEDALE	50MG	A060591	001	
	100MG	A060591	003	

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS	1%	N050183	001	

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE	25MG/VIAL	N050143	001	

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS	250MG/ML	N050153	001	

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

ALTANA	1%	A060133	001	

CHLOROFAIR

PHARMAFAIR	1%	A062439	001	Apr 21, 1983

CHLOROMYCETIN

PARKEDALE	1%	N050156	001	

CHLOROPTIC S.O.P.

ALLERGAN	1%	A061187	001	

ECONOCHLOR

ALCON	1%	A061648	001	

DISCONTINUED DRUG PRODUCT LIST

6-66 (of 322)

CHLORAMPHENICOL

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL

AKORN 0.5%

A062042 001

ALCON 0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5%

N050091 001

ECONOCHLOR

ALCON 0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE 0.5%

A061220 001

OPTOMYCIN

OPTOPICS 0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN

PARKEDALE 0.5%

N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION;ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS EQ 150MG BASE/5ML

A062301 001

EQ 150MG BASE/5ML

N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

PARKEDALE EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL

A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT;TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS 10MG/GM;666 UNITS/GM;1 UNITS/GM

N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL;25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM;5MG/GM;10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CHLOROMYXIN

PARKE DAVIS 1%;10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT;OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN 1%;0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE;ORAL

LIBRELEASE

VALEANT PHARM INTL 30MG

N017813 001 Sep 12, 1983

TABLET;ORAL

LIBRITABS

VALEANT PHARM INTL 5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

DISCONTINUED DRUG PRODUCT LIST

6-67 (of 322)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT	5MG	A085447	001	
	5MG	A085517	001	
	10MG	A085447	002	
	10MG	A085518	001	
	25MG	A085447	003	
	25MG	A085513	001	
CHLORDIAZACHEL				
RACHELLE	5MG	A085086	001	
	10MG	A084639	001	
	25MG	A085087	001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
ASCOT	5MG	A087525	001	Jan 07, 1982
	10MG	A087524	001	Jan 07, 1982
	25MG	A087512	001	Jan 07, 1982
FERRANTE	5MG	A085118	001	
	10MG	A085119	001	
	25MG	A085120	001	
HALSEY	5MG	A085340	001	
	10MG	A085339	001	
	25MG	A084685	001	
IMPAX LABS	5MG	A086213	001	
	10MG	A085113	001	
	25MG	A086212	001	
IVAX SUB TEVA PHARMS	5MG	A083741	001	
	10MG	A083742	001	
	25MG	A083570	001	
LEDERLE	5MG	A086892	001	
	5MG	A087234	001	
	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	

DISCONTINUED DRUG PRODUCT LIST

6-68 (of 322)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

VALEANT PHARM INTL	5MG	N012249 002
	10MG	N012249 001
	25MG	N012249 003

LYGEN

ALRA	5MG	A085107 001
	10MG	A085009 001
	25MG	A085108 001

INJECTABLE; INJECTION

LIBRIUM

VALEANT PHARMS LLC	100MG/AMP	N012301 001

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE	10MG; 0.4MG	N014740 006

MENRIUM 5-2

ROCHE	5MG; 0.2MG	N014740 002

MENRIUM 5-4

ROCHE	5MG; 0.4MG	N014740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

APOTEX INC	0.12%	A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTTRIUM	2.5%	N019421 001 Dec 17, 1985

MICRODERM

J AND J	4%	A072255 001 Apr 15, 1991

PREVACARE R

J AND J	0.5%	A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL	4%	A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL	4%	N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON	4%	A073416 001 Mar 14, 2000

HIBICLENS

MOLNLYCKE HLTH	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018423 001

MICRODERM

J AND J	4%	A072295 001 Feb 28, 1991

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO	0.6-1.4mCi/ML	N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US	100MG	N011467 003
	200MG	N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA	2%	N009435 003
	3%	N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002 002

DISCONTINUED DRUG PRODUCT LIST

6-69 (of 322)

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM	EQ 150MG BASE	A087228	001	
PUREPAC PHARM	EQ 150MG BASE	A080886	001	
TEVA	EQ 150MG BASE	A087504	001	Jan 13, 1982
WATSON LABS	EQ 150MG BASE	A087979	001	Dec 21, 1982
	EQ 300MG BASE	A088030	001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US	EQ 300MG BASE; EQ 45MG BASE	N014860	002	

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569	001	
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
WEST WARD	250MG	A086028	001	Jul 14, 1982
	500MG	A087736	001	Jul 14, 1982
DIURIL				
OAK PHARMS AKORN	250MG	N011145	004	
	500MG	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK	150MG; 250MG	N016016	001	

ALDOCLOR-250

MERCK	250MG; 250MG	N016016	002	

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM	150MG; 250MG	A070783	001	Nov 06, 1987
	250MG; 250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

WEST WARD	250MG; 0.125MG	A088557	001	Dec 22, 1983
	500MG; 0.125MG	A088365	001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	250MG; 0.125MG	A084853	001	
	500MG; 0.125MG	A088151	001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN	250MG; 0.125MG	A087744	001	May 06, 1982
	500MG; 0.125MG	A087745	001	May 06, 1982

DIUPRES-250

MERCK	250MG; 0.125MG	N011635	003	Aug 26, 1987

DIUPRES-500

MERCK	500MG; 0.125MG	N011635	006	Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS	12MG	A084652	001	

TACE

SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB	2%	N017594	001	

DISCONTINUED DRUG PRODUCT LIST

6-70 (of 322)

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN	400MG	N014217	002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ	12MG	A070797	001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE	8MG	N017369	001

12MG	N017369	002

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH	10MG/ML	N008826	001

100MG/ML	N008794	001

CHLORPHENIRAMINE MALEATE

BEL MAR	10MG/ML	A080821	001

ELKINS SINN	10MG/ML	A080797	001

WATSON LABS	10MG/ML	A083593	001

10MG/ML	A086096	001

100MG/ML	A086095	001

PYRIDAMAL 100

BEL MAR	100MG/ML	A083733	001

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING	2MG/5ML	N006921	006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC	2MG/5ML	A087520	001 Feb 10, 1982

TABLET; ORAL

ANTAGONATE

BAYER PHARMS	4MG	A083381	001

CHLOR-TRIMETON

SCHERING	4MG	N006921	002

CHLORPHENIRAMINE MALEATE

ANABOLIC	4MG	A083078	001

BELL PHARMA	4MG	A083062	001

ELKINS SINN	4MG	A080938	001

IMPAX LABS	4MG	A080809	001

IVAX SUB TEVA PHARMS	4MG	A080779	001

KV PHARM	4MG	A087164	001

LEDERLE	4MG	A086941	001

MUTUAL PHARM	4MG	A080700	001

NEWTORN PHARMS	4MG	A086519	001

PANRAY	4MG	A083243	001

PHARMAVITE	4MG	A085104	001

PHARMERAL	4MG	A083753	001

PIONEER PHARMS	4MG	A088556	001 Jul 13, 1984

PUREPAC PHARM	4MG	A086306	001

PVT FORM	4MG	A080786	001

ROXANE	4MG	A080626	001

SANDOZ	4MG	A080961	001

VITARINE	4MG	A085837	001

WATSON LABS	4MG	A080696	001

4MG	A080791	001

4MG	A085139	001

WEST WARD	4MG	A083787	001

KLOROMIN

HALSEY	4MG	A083629	001

PHENETRON

LANNETT	4MG	A080846	001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH	8MG	N007638	001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002 Nov 18, 1994

DISCONTINUED DRUG PRODUCT LIST

6-71 (of 322)

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

WATSON LABS 12MG; 75MG

A088681 001 Sep 29, 1987

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

SANDOZ 12MG; 75MG

A088940 001 Jan 26, 1989

COLD CAPSULE IV

GRAHAM DM 12MG; 75MG

N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG; 75MG

N018794 001 Apr 23, 1985

CONTAC 12 HOUR

GLAXOSMITHKLINE 8MG; 75MG

N018099 001

DRIZE

ASCHER 12MG; 75MG

A088359 001 Feb 13, 1986

ORNADE

GLAXOSMITHKLINE 12MG; 75MG

N012152 004

PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG; 75MG

N018809 001 May 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC

NOVARTIS 12MG; 75MG

N019613 001 Jun 13, 1986

DEMAZIN

SCHERING PLOUGH 4MG; 25MG

N018556 001 May 14, 1984

TRIAMINIC-12

NOVARTIS 12MG; 75MG

N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA 12MG; 120MG

N018935 001 Apr 15, 1985

ISOCLOL

FISONS 8MG; 120MG

N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG; 120MG

N019428 001 Aug 02, 1988

GRAHAM DM 8MG; 120MG

N018844 001 Mar 20, 1985

12MG; 120MG

N018843 001 Mar 18, 1985

KV PHARM 12MG; 120MG

A071455 001 Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML

N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML

N018928 001 Aug 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM

UCB INC EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML

N018050 001 Jan 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS EQ 65MG BASE

N014696 001

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N009149 024

100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N009149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE 30MG

N011120 016

75MG

N011120 017

150MG

N011120 018

200MG

N011120 019

300MG

N011120 020

DISCONTINUED DRUG PRODUCT LIST

6-72 (of 322)

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983
SONAZINE				
SANDOZ	30MG/ML	A080983	004	
	100MG/ML	A080983	005	

THORAZINE

GLAXOSMITHKLINE	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	032	
	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	043	

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A080365	001	
	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	
THORAZINE				
GLAXOSMITHKLINE	25MG/ML	N009149	011	

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001	
SONAZINE				
SANDOZ	10MG/5ML	A083040	001	
THORAZINE				
GLAXOSMITHKLINE	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	022	

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
ROXANE	10MG	A085331	001	
	25MG	A085331	002	

DISCONTINUED DRUG PRODUCT LIST

6-73 (of 322)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG	N009149	002	
	25MG	N009149	007	
	50MG	N009149	013	
	100MG	N009149	018	
	200MG	N009149	020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

BARR	100MG	A088812	001	Oct 19, 1984
	100MG	A089446	001	Nov 17, 1986
	250MG	A088813	001	Oct 19, 1984
	250MG	A089447	001	Nov 17, 1986
CLONMEL HLTHCARE	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
DURAMED PHARMS BARR	100MG	A088918	001	Oct 16, 1984
	250MG	A088919	001	Oct 16, 1984
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
IVAX PHARMS	100MG	A088840	001	Oct 25, 1984
	250MG	A087353	001	
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	100MG	A088725	001	Aug 31, 1984
	250MG	A084669	001	
	250MG	A088726	001	Aug 31, 1984
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
TEVA	100MG	A088768	001	Oct 11, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS INC	100MG	A088852	001	Sep 26, 1984
	250MG	A088826	001	Sep 26, 1984
GLUCAMIDE				
TEVA	250MG	A088641	001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149	002

INJECTABLE; INJECTION

TARACTAN

ROCHE	12.5MG/ML	N012487	001

DISCONTINUED DRUG PRODUCT LIST

6-74 (of 322)

CHLORPROTHIXENE

TABLET; ORAL

TARACTAN

ROCHE	10MG	N012486	005
	25MG	N012486	004
	50MG	N012486	003
	100MG	N012486	001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE	1%	N050404	001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT	25MG	A087364	001
	50MG	A087384	001
ASCOT	25MG	A087698	001 Oct 20, 1982
	50MG	A087699	001 Oct 20, 1982
BARR LABS INC	25MG	A088902	001 Sep 19, 1985
	50MG	A088903	001 Sep 19, 1985
DAVA PHARMS INC	25MG	A087451	001
	50MG	A087450	001
IVAX PHARMS	25MG	A087555	001
	25MG	A088164	001 Jan 09, 1984
	50MG	A087176	001
	50MG	A087947	001 Feb 27, 1984
KV PHARM	25MG	A087311	001
	50MG	A087312	001
MUTUAL PHARM	25MG	A087292	001
	25MG	A089285	001 Jul 21, 1986
	25MG	A089738	001 Sep 19, 1988
	50MG	A087293	001
	50MG	A089286	001 Jul 21, 1986
	50MG	A089739	001 Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001 Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001 Jul 16, 1986
	50MG	A088140	001 Aug 11, 1983
SANDOZ	25MG	A087380	001
	50MG	A087118	001
	50MG	A087381	001
SUPERPHARM	25MG	A087473	001 Feb 09, 1983
	50MG	A087247	001 Feb 09, 1983
TEVA	50MG	A088651	001 May 30, 1985
USL PHARMA	25MG	A089051	001 Jun 01, 1987
	50MG	A089052	001 Jun 01, 1987
VANGARD	25MG	A088012	001 Jul 14, 1982
	50MG	A088073	001 Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001 Jan 24, 1983
	50MG	A087516	001 Feb 09, 1983
WATSON LABS	25MG	A087050	001
	25MG	A087100	001
	25MG	A087296	001
	25MG	A087706	001
	50MG	A087029	001
	50MG	A087082	001
	50MG	A087521	001
	50MG	A087689	001
HYGROTON			
SANOFI AVENTIS US	25MG	N012283	004
	50MG	N012283	003
THALITONE			
CITRON PHARMA LLC	25MG	N019574	002 Feb 12, 1992
MONARCH PHARMS	25MG	A088051	001 Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG; 0.1MG	A071179	001 Dec 16, 1987
	15MG; 0.2MG	A071178	001 Dec 16, 1987
	15MG; 0.3MG	A071142	001 Dec 16, 1987

DISCONTINUED DRUG PRODUCT LIST

6-75 (of 322)

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

COMBIPRES

BOEHRINGER INGELHEIM 15MG; 0.1MG
 15MG; 0.2MG
 15MG; 0.3MG

N017503 001
 N017503 002
 N017503 003 Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS 25MG; 100MG
 25MG; 200MG

N019451 001 Dec 31, 1987
 N019451 002 Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGOTON

SANOFI AVENTIS US 25MG; 0.125MG

N015103 002

REGOTON

SANOFI AVENTIS US 50MG; 0.25MG

N015103 001

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS TOTOWA 250MG
 500MG

A088928 001 May 08, 1987
 A040113 001 Sep 29, 1995

MUTUAL PHARM 500MG

A089970 001 Sep 27, 1990

OHM LABS 250MG

A081298 001 Dec 29, 1993

500MG

A081299 001 Dec 29, 1993

PAR PHARM 250MG

A087981 001 Sep 20, 1983

PIONEER PHARMS 250MG

A089592 001 Jan 06, 1989

500MG

A089948 001 Jan 06, 1989

SANDOZ 250MG

A089852 001 May 04, 1988

500MG

A089853 001 May 04, 1988

WATSON LABS 250MG

A086901 001

250MG

A086948 001 Aug 09, 1982

500MG

A081019 001 Jul 29, 1991

PARAFLEX

ORTHO MCNEIL PHARM 250MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N011300 003

STRIFON FORTE DSC

FERNDAL LABS 500MG

A081008 001 Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS EQ 4GM RESIN/BAR
 EQ 4GM RESIN/BAR

A071621 001 May 26, 1988
 A071739 001 May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

A074771 001 Jul 09, 1997
 A074771 002 Jul 09, 1997

TEVA EQ 4GM RESIN/PACKET

A074347 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074347 002 May 28, 1998

TEVA PHARMS EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996

CHOLESTYRAMINE LIGHT

TEVA EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

A074348 001 May 28, 1998
 A074348 002 May 28, 1998

TEVA PHARMS EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

LOCHOLEST

SANDOZ EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

A074561 001 Aug 15, 1996
 A074561 002 Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

A074562 001 Aug 15, 1996
 A074562 002 Aug 15, 1996

QUESTRAN

BRISTOL MYERS EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

N016640 001
 N016640 003

QUESTRAN LIGHT

BRISTOL MYERS EQ 4GM RESIN/PACKET
 EQ 4GM RESIN/SCOOPFUL

N019669 001 Dec 05, 1988
 N019669 003 Dec 05, 1988

DISCONTINUED DRUG PRODUCT LIST

6-76 (of 322)

CHOLESTYRAMINE

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 1GM RESIN

A073403 001 Apr 28, 1994

EQ 800MG RESIN

A073403 002 Dec 27, 1999

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO

0.25MG/VIAL

N021149 001 Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

MALLINCKRODT

5mCi/ML

N017084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL

4,000 UNITS/VIAL

N018663 002 Aug 21, 1984

10,000 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018663 001 Nov 10, 1982

DISCASE

ABBOTT

12,500 UNITS/VIAL

N018625 001 Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND

750 UNITS/VIAL

N011837 001

CATARASE

CIBA

300 UNITS/VIAL

N016938 001

NOVARTIS

150 UNITS/VIAL

N018121 001

ZOLYSE

ALCON

750 UNITS/VIAL

N011903 001

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

APOTEX INC

8%

A078172 001 Sep 18, 2007

MYLAN PHARMS INC

8%

A078567 001 Sep 18, 2007

TEVA PHARMS

8%

A078079 001 Sep 18, 2007

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK

EQ 750MG BASE/VIAL; 750MG/VIAL

N050630 002 Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS TOTOWA

100MG

A077028 002 Nov 26, 2004

COREPHARMA

50MG

A077150 001 Mar 11, 2005

100MG

A077022 001 Nov 23, 2004

IVAX SUB TEVA PHARMS

100MG

A077020 002 Mar 01, 2005

MUTUAL PHARM

50MG

A077208 002 Mar 29, 2006

100MG

A077208 001 Mar 29, 2006

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE

200MG/20ML

N020951 001 Jul 09, 1999

TABLET; ORAL

CIMETIDINE

IVAX SUB TEVA PHARMS

200MG

A074401 001 May 30, 1995

300MG

A074401 002 May 30, 1995

400MG

A074401 003 May 30, 1995

800MG

A074402 001 May 30, 1995

LEK PHARMS

100MG

A075122 001 Jun 19, 1998

200MG

A074250 001 Jun 29, 1995

200MG

A075122 002 Jun 19, 1998

DISCONTINUED DRUG PRODUCT LIST

6-77 (of 322)

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	300MG	A074250 002	Jun 29, 1995
	400MG	A074250 003	Jun 29, 1995
	800MG	A074250 004	Jun 29, 1995
PERRIGO	100MG	A074972 001	Jun 19, 1998
ROXANE	300MG	A074361 001	Dec 23, 1994
	400MG	A074361 002	Dec 23, 1994
	800MG	A074371 001	Dec 23, 1994
SANDOZ	200MG	A074100 001	Jan 31, 1995
	200MG	A074506 001	Jan 24, 1996
	300MG	A074100 002	Jan 31, 1995
	300MG	A074506 002	Jan 24, 1996
	400MG	A074100 003	Jan 31, 1995
	400MG	A074506 003	Jan 24, 1996
	800MG	A074100 004	Jan 31, 1995
	800MG	A074506 004	Jan 24, 1996
TEVA	200MG	A074365 001	Feb 28, 1995
	300MG	A074365 002	Feb 28, 1995
	400MG	A074365 003	Feb 28, 1995
	800MG	A074365 004	Feb 28, 1995
VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994
	300MG	A074281 002	May 17, 1994
	400MG	A074281 003	May 17, 1994
	800MG	A074329 001	May 17, 1994
WATSON LABS INC	200MG	A074349 001	Aug 30, 1996
	300MG	A074349 002	Aug 30, 1996
	400MG	A074349 003	Aug 30, 1996
	800MG	A074316 001	Feb 28, 1996
TAGAMET HB			
MEDTECH PRODS	100MG	N020238 001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994
TAGAMET			
GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939 002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434 001	Oct 31, 1985
SOLUTION; ORAL			
CIMETIDINE HYDROCHLORIDE			
ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
APOTEX INC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000
DURAMED PHARMS BARR	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
ROXANE	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
TEVA PHARMS	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994
TAGAMET			
GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N017924 001	

DISCONTINUED DRUG PRODUCT LIST

6-78 (of 322)

CINOXACIN

CAPSULE; ORAL

CINOBAC

LILLY

250MG

N018067 001

500MG

N018067 002

CINOXACIN

TEVA

250MG

A073005 001 Feb 28, 1992

500MG

A073006 001 Feb 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

BAYER HLTHCARE

1200MG/120ML (10MG/ML)

N019847 003 Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS

200MG/100ML

N019858 001 Dec 26, 1990

CIPROFLOXACIN

BEDFORD LABS

200MG/20ML (10MG/ML)

A076992 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076992 002 Aug 28, 2006

1200MG/120ML (10MG/ML)

A076993 001 Aug 28, 2006

FRESENIUS KABI USA

200MG/20ML (10MG/ML)

A076484 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076484 002 Aug 28, 2006

TEVA PHARMS USA

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA

200MG/100ML

A076757 001 Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

200MG/100ML

A077888 001 Mar 18, 2008

400MG/200ML

A077888 002 Mar 18, 2008

BEDFORD

200MG/100ML

A078114 001 Mar 18, 2008

400MG/200ML

A078114 002 Mar 18, 2008

TEVA PHARMS

200MG/100ML

A077138 001 Mar 18, 2008

400MG/200ML

A077138 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

APOTEX INC

EQ 0.3% BASE

A075928 001 Jun 09, 2004

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR

EQ 250MG BASE

A074124 001 Jun 09, 2004

EQ 500MG BASE

A074124 002 Jun 09, 2004

EQ 750MG BASE

A074124 003 Jun 09, 2004

NOSTRUM LABS

EQ 250MG BASE

A076138 001 Jun 09, 2004

EQ 500MG BASE

A076138 002 Jun 09, 2004

EQ 750MG BASE

A076138 003 Jun 09, 2004

PLIVA

EQ 100MG BASE

A076426 001 Jun 15, 2005

EQ 250MG BASE

A076426 002 Jun 15, 2005

EQ 500MG BASE

A076426 003 Jun 15, 2005

EQ 750MG BASE

A076426 004 Jun 15, 2005

SANDOZ

EQ 100MG BASE

A075939 001 Mar 03, 2005

EQ 250MG BASE

A075939 002 Jun 09, 2004

EQ 250MG BASE

A076593 002 Jun 09, 2004

EQ 500MG BASE

A075939 003 Jun 09, 2004

EQ 500MG BASE

A076593 003 Jun 09, 2004

EQ 750MG BASE

A075939 004 Jun 09, 2004

EQ 750MG BASE

A076593 004 Jun 09, 2004

TEVA

EQ 250MG BASE

A076136 001 Jun 09, 2004

EQ 500MG BASE

A076136 002 Jun 09, 2004

EQ 750MG BASE

A076136 003 Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE

212.6MG; EQ 287.5MG BASE

N021473 001 Dec 13, 2002

425.2MG; EQ 574.9MG BASE

N021473 002 Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

DR REDDYS LABS LTD

212.6MG; EQ 287.5MG BASE

A077701 002 Oct 31, 2007

SANDOZ

212.6MG; EQ 287.5MG BASE

A078712 001 Dec 11, 2007

DISCONTINUED DRUG PRODUCT LIST

6-79 (of 322)

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS

EQ 1MG BASE/ML

N020398 001 Sep 15, 1995

TABLET; ORAL

PROPULSID

JANSSEN PHARMS

EQ 10MG BASE

N020210 001 Jul 29, 1993

EQ 20MG BASE

N020210 002 Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA

EQ 20MG BASE

N020767 001 Nov 07, 1997

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD

10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

TEVA PHARMS USA

1MG/ML

A074814 001 May 16, 2000

PLATINOL

HQ SPCLT PHARMA

10MG/VIAL

N018057 001

50MG/VIAL

N018057 002

PLATINOL-AQ

HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CELEXA

FOREST LABS

EQ 10MG BASE/5ML

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

APOTEX INC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET; ORAL

CELEXA

FOREST LABS

EQ 60MG BASE

N020822 004 Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH

EQ 10MG BASE

A077033 001 Oct 28, 2004

EQ 20MG BASE

A077033 002 Oct 28, 2004

EQ 40MG BASE

A077033 003 Oct 28, 2004

COREPHARMA

EQ 10MG BASE

A077036 001 Oct 28, 2004

EQ 20MG BASE

A077036 002 Oct 28, 2004

EQ 40MG BASE

A077036 003 Oct 28, 2004

MUTUAL PHARM

EQ 10MG BASE

A077052 001 Jul 03, 2006

EQ 20MG BASE

A077052 002 Jul 03, 2006

EQ 40MG BASE

A077052 003 Jul 03, 2006

NATCO PHARMA LTD

EQ 20MG BASE

A077141 002 Apr 10, 2008

EQ 40MG BASE

A077141 001 Apr 10, 2008

ROXANE

EQ 10MG BASE

A077041 001 Nov 23, 2004

EQ 20MG BASE

A077041 002 Nov 23, 2004

EQ 40MG BASE

A077041 003 Nov 23, 2004

SANDOZ

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TEVA PHARMS

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 40MG BASE

A077213 003 Mar 31, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018904 001 May 27, 1983

DISCONTINUED DRUG PRODUCT LIST

6-80 (of 322)

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

JANSSEN PHARMS

1MG/ML

N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE

187MG/5ML

N050698 003 Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS

250MG

A065137 001 May 31, 2005

500MG

A065137 002 May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY

1GM

A065210 001 Jan 26, 2005

SANDOZ

500MG

A065250 001 Aug 25, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC

EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993

APOTEX INC

EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000

SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997

TEVA PHARMS

EQ 0.5MG BASE/5ML

A073095 001 Apr 21, 1992

TAVIST

NOVARTIS

EQ 0.5MG BASE/5ML

N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

TEVA

1.34MG

A073282 001 Jan 31, 1992

1.34MG

A073282 002 Dec 03, 1992

TAVIST

NOVARTIS

2.68MG

N017661 001

TAVIST-1

NOVARTIS

1.34MG

N017661 002

1.34MG

N017661 003 Aug 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

NOVARTIS

EQ 1MG BASE; 75MG

N018298 001 Dec 15, 1982

1.34MG; 75MG

N018298 002 Aug 21, 1992

1.34MG; 75MG

N020640 001 Aug 09, 1996

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE/5ML

A061827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN

EQ 150MG BASE/ML

A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

ASTRAZENECA

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

DISCONTINUED DRUG PRODUCT LIST

6-81 (of 322)

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

HIKMA MAPLE	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982

CLINDAMYCIN PHOSPHATE

ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988
BOCA PHARMA LLC	EQ 1% BASE	A062930	001	Jun 28, 1989
COPLEY PHARM	EQ 1% BASE	A062944	001	Jan 11, 1989
RENAISSANCE PHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM; 100,000 UNITS/GM	N050235	001	

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

G AND W LABS INC	0.05%	A074139	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

RENAISSANCE PHARMA	0.05%	A075733	001	Aug 22, 2001

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995

TEMOVATE

FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST	500MG	N016099	002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

DISCONTINUED DRUG PRODUCT LIST

6-82 (of 322)

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX

50MG

A072196 001 Dec 20, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ

25MG

A074953 001 Jun 25, 1997

50MG

A074953 002 Jun 25, 1997

75MG

A074953 003 Jun 25, 1997

TEVA

25MG

A074849 001 Apr 04, 1997

50MG

A074849 002 Apr 04, 1997

75MG

A074849 003 Apr 04, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

APOTEX INC

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE

0.125MG

N020813 001 Dec 23, 1997

0.25MG

N020813 002 Dec 23, 1997

0.5MG

N020813 003 Dec 23, 1997

1MG

N020813 004 Dec 23, 1997

2MG

N020813 005 Dec 23, 1997

CLONIDINE

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

TRIS PHARMA INC

EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

TRIS PHARMA INC

EQ 0.17MG BASE

N022500 001 Dec 03, 2009

EQ 0.26MG BASE

N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

SANDOZ

0.1MG

A070887 001 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A071294 001 Aug 31, 1988

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

DISCONTINUED DRUG PRODUCT LIST

6-83 (of 322)

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986
	0.3MG	A070397	001	Mar 23, 1987

TABLET, EXTENDED RELEASE;ORAL

JENLOGA

CONCORDIA PHARMS INC	0.1MG	N022331	001	Sep 30, 2009
	0.2MG	N022331	002	May 25, 2010

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
CLONMEL HLTHCARE	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
RECORDATI RARE	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987

DISCONTINUED DRUG PRODUCT LIST

6-84 (of 322)

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

SANDOZ

3.75MG

A072512 001 May 11, 1990

7.5MG

A072513 001 May 11, 1990

15MG

A072514 001 May 11, 1990

WARNER CHILCOTT

3.75MG

A071828 001 Mar 03, 1988

7.5MG

A071829 001 Mar 03, 1988

15MG

A071830 001 Mar 03, 1988

TRANXENE SD

RECORDATI RARE

11.25MG

N017105 005

22.5MG

N017105 004

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

SCHERING PLOUGH

1%

N017619 001

MYCELEX

BAYER

1%

N018183 001

LOTION; TOPICAL

LOTRIMIN

SCHERING

1%

N018813 001 Feb 17, 1984

SOLUTION; TOPICAL

LOTRIMIN

SCHERING PLOUGH

1%

N017613 001

MYCELEX

BAYER HLTHCARE

1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018181 001

TABLET; VAGINAL

GYNIX

TEVA PHARMS

100MG

A073249 001 Feb 13, 1998

MYCELEX-G

BAYER PHARMS

500MG

N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061452 001

EQ 500MG BASE

A061452 002

TEVA

EQ 250MG BASE

A062240 001

EQ 500MG BASE

A062240 002

CLOXAPEN

GLAXOSMITHKLINE

EQ 250MG BASE

A061806 001

EQ 250MG BASE

A062233 001

EQ 500MG BASE

A061806 002

EQ 500MG BASE

A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA

EQ 125MG BASE/5ML

A062268 001

EQ 125MG BASE/5ML

A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON

EQ 125MG BASE/5ML

A061453 001

EQ 125MG BASE/5ML

N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM

25MG

A075162 001 Apr 26, 2005

100MG

A075162 002 Apr 26, 2005

SANDOZ

25MG

A074546 001 Aug 30, 1996

100MG

A074546 002 Aug 30, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III

50MG

N021590 003 Jun 03, 2005

DISCONTINUED DRUG PRODUCT LIST

6-85 (of 322)

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-57 KIT

BRACCO

N/A;N/A;N/A;N/A

N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-60 KIT

BRACCO

N/A;N/A;N/A;N/A

N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML;5MG/5ML;6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML;5MG/5ML;6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML;5MG/5ML;6.25MG/5ML

A088896 001 Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

ANI PHARMS

10MG/5ML;6.25MG/5ML

N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY

10MG/5ML;6.25MG/5ML

A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC

10MG/5ML;6.25MG/5ML

A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI

10MG/5ML;6.25MG/5ML

A088814 001 Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE

10MG/5ML;30MG/5ML;1.25MG/5ML

N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI

10MG/5ML;30MG/5ML;1.25MG/5ML

A089018 001 Jul 23, 1986

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

WOCKHARDT

10MG/5ML;30MG/5ML;1.25MG/5ML

A088833 001 Nov 16, 1984

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

MERCK

0.5MG;500MG

N012383 001

PROBEN-C

WATSON LABS

0.5MG;500MG

A085552 001

PROBENECID AND COLCHICINE

BEECHAM

0.5MG;500MG

A084321 001

IMPAX LABS

0.5MG;500MG

A083720 002

IVAX SUB TEVA PHARMS

0.5MG;500MG

A083734 001

SANDOZ

0.5MG;500MG

A086130 001

PROBENECID W/ COLCHICINE

LEDERLE

0.5MG;500MG

A086954 001

WATSON LABS

0.5MG;500MG

A083221 001

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL

DAIICHI SANKYO

375MG

N021141 001 May 26, 2000

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

PARKE DAVIS

EQ 25MG BASE/5ML

N050355 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL

ASTELLAS

20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

CU-7

GD SEARLE LLC

89MG

N017408 001

TATUM-T

GD SEARLE LLC

120MG

N018205 001

DISCONTINUED DRUG PRODUCT LIST

6-86 (of 322)

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE	25 UNITS/VIAL	N008317 002
	40 UNITS/VIAL	N008317 004

ACTHAR

SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002
	40 UNITS/VIAL	N007504 003

CORTICOTROPIN

ORGANICS LAGRANGE	40 UNITS/ML	N010831 001
	80 UNITS/ML	N010831 002
WATSON LABS	40 UNITS/VIAL	A088772 001 Nov 21, 1984

H.P. ACTHAR GEL

QUESTCOR PHARMS	40 UNITS/ML	N008372 006

PURIFIED CORTROPHIN GEL

ORGANON USA INC	40 UNITS/ML	N008975 001
	80 UNITS/ML	N008975 002

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ORGANON USA INC	40 UNITS/ML	N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126 002
WATSON LABS	25MG/ML	A083147 003
	25MG/ML	A085677 001
	50MG/ML	A083147 004
	50MG/ML	A085677 002

CORTONE

MERCK	25MG/ML	N007110 002
	50MG/ML	N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR	25MG	A083471 001
ELKINS SINN	25MG	A080836 001
EVERYLIFE	25MG	A084246 001
HEATHER	25MG	A085736 001
IMPAX LABS	25MG	N009458 001
INWOOD LABS	25MG	A080731 001
IVAX SUB TEVA PHARMS	25MG	A080630 001
	25MG	A083536 001
LANNETT	25MG	A080694 001
PANRAY	5MG	N008284 002
	25MG	N008284 001
PHARMACIA AND UPJOHN	5MG	N008126 003
	10MG	N008126 004
	25MG	N008126 001
PUREPAC PHARM	25MG	A080493 001
VITARINE	25MG	A080333 001
WATSON LABS	25MG	A085884 001
WHITEWORTH TOWN PLSN	25MG	A080341 001

CORTONE

MERCK	25MG	N007750 003

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PFIZER	0.8MG/INH	N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

SANOFI AVENTIS US	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC	100MG	N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS	100MG/5ML	A090954 001 Dec 18, 2009

DISCONTINUED DRUG PRODUCT LIST

6-87 (of 322)

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 10MG/ML

A075067 001 Jul 19, 1999

APOTEX INC 10MG/ML

A075333 001 Apr 30, 2002

PHARMASCIENCE INC 10MG/ML

A075437 001 Apr 21, 2000

ROXANE 10MG/ML

A075175 001 Sep 30, 1999

INTAL

KING PHARMS 10MG/ML

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

APOTEX INC 4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS 4%

A075088 001 Apr 27, 1999

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P 5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

BLACKSMITH BRANDS 5.2MG/SPRAY **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020463 001 Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC 260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC 260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

ABRAXIS PHARM EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOCAL

PAR PHARM 0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN 1MG/ML

N006798 001

BETALIN 12

LILLY 0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS 0.1MG/ML

A083013 001

1MG/ML

A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM 0.03MG/ML

A080510 003

0.1MG/ML

A080510 001

1MG/ML

A080510 002

AKORN 1MG/ML

A087969 001 Nov 10, 1983

DELL LABS 0.03MG/ML

A080689 001

0.1MG/ML

A080689 002

1MG/ML

A080689 003

FRESENIUS KABI USA 0.1MG/ML

A080557 002

HIKMA MAPLE 1MG/ML

A080515 002

LUITPOLD 0.03MG/ML

A080668 001

LYPHOMED 1MG/ML

A083075 001

MYLAN INSTITUTIONAL 1MG/ML

A040451 001 Sep 23, 2003

SANOFI AVENTIS US 1MG/ML

A080564 001

SOLOPAK 1MG/ML

A087551 001 Feb 29, 1984

WARNER CHILCOTT 1MG/ML

N007085 002

WATSON LABS 0.1MG/ML

A080573 002

0.1MG/ML

A083120 001

1MG/ML

A080573 001

1MG/ML

A083120 002

WYETH AYERST 0.1MG/ML

A080554 001

1MG/ML

A080554 002

DISCONTINUED DRUG PRODUCT LIST

6-88 (of 322)

CYANOCOBALAMIN

INJECTABLE; INJECTION

REDISOL			
MERCK	1MG/ML	N006668	010
RUBIVITE			
BEL MAR	0.03MG/ML	N010791	004
	0.05MG/ML	N010791	001
	0.1MG/ML	N010791	002
	0.12MG/ML	N010791	005
	1MG/ML	N010791	003
RUBRAMIN PC			
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002
	1MG/ML	N006799	004
	1MG/ML	N006799	010 Apr 28, 1988
RUVITE			
SAVAGE LABS	1MG/ML	A080570	002
VI-TWEL			
BAYER HLTHCARE	1MG/ML	N007012	002
SPRAY, METERED; NASAL			
CALOMIST			
PAR PHARM	25MCG/SPRAY	N022102	001 Jul 27, 2007
TABLET; ORAL			
CYANOCOBALAMIN			
WEST WARD	1MG	A084264	001

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57			
BRACCO	0.5-1uCi	N016089	002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60			
BRACCO	0.5-1uCi	N016090	002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT			
GE HEALTHCARE	N/A; N/A; N/A	N017406	001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT			
MALLINCKRODT	0.1MG; 0.5uCi; 60MG	N016635	001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR			
ARMOUR PHARM	0.5MG/ML; 2.3MG/ML; 1MG/ML	N011208	001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W			
WYETH AYERST	125MG/5ML	N050508	001
	250MG/5ML	N050508	002
	500MG/5ML	N050508	003

TABLET; ORAL

CYCLACILLIN			
TEVA	250MG	A062895	001 Aug 04, 1988
	500MG	A062895	002 Aug 04, 1988
CYCLAPEN-W			
WYETH AYERST	250MG	N050509	001
	500MG	N050509	002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE			
GLAXOSMITHKLINE	50MG/ML	N009495	001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE			
PROSAM LABS	5MG	A077291	001 Feb 03, 2006
SANDOZ	5MG	A072854	002 Feb 03, 2006
	10MG	A072854	001 Nov 19, 1991
	10MG	A073683	001 Feb 26, 1993

DISCONTINUED DRUG PRODUCT LIST

6-89 (of 322)

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

WATSON LABS	10MG	A073143 001	Nov 27, 1991
	10MG	A074436 001	Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV	5MG	N017821 001	
	10MG	N017821 002	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN	1%	A085555 001	

AKPENTOLATE

AKORN	2%	A040165 001	Jan 13, 1997

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD	1%	A089162 001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150 001	
	1%	A084863 001	

PENTOLAIR

PHARMAFAIR	0.5%	A088643 001	Feb 09, 1987
	1%	A088150 001	Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE	1GM/VIAL	A088374 001	Sep 24, 1986
	100MG/VIAL	A088371 001	Jul 03, 1986
	200MG/VIAL	A088372 001	Jul 03, 1986
	500MG/VIAL	A088373 001	Jul 03, 1986

CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142 001	
	200MG/VIAL	N012142 002	

CYTOXAN (LYOPHILIZED)

BAXTER HLTHCARE	1GM/VIAL	N012142 010	Sep 24, 1985
	2GM/VIAL	N012142 009	Dec 10, 1985
	500MG/VIAL	N012142 008	Jan 04, 1984

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142 006	Dec 05, 1985
	200MG/VIAL	N012142 007	Dec 10, 1985

NEOSAR

TEVA PARENTERAL	1GM/VIAL	A040015 004	Apr 29, 1993
	1GM/VIAL	A087442 004	Jul 08, 1983
	2GM/VIAL	A040015 005	Apr 29, 1993
	2GM/VIAL	A087442 005	Mar 30, 1989
	100MG/VIAL	A040015 001	Apr 29, 1993
	100MG/VIAL	A087442 001	Feb 16, 1982
	200MG/VIAL	A040015 002	Apr 29, 1993
	200MG/VIAL	A087442 002	Feb 16, 1982
	500MG/VIAL	A040015 003	Apr 29, 1993
	500MG/VIAL	A087442 003	Feb 16, 1982

TABLET; ORAL

CYTOXAN

BAXTER HLTHCARE	25MG	N012141 002	
	50MG	N012141 001	

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

NOVARTIS	50MG	N050715 003	Jul 14, 1995

SOLUTION; ORAL

CYCLOSPORINE

APOTEX INC	100MG/ML	A065167 001	Jan 05, 2005

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY	2MG	N013157 002	

FLUIDIL

PHARMACIA AND UPJOHN	2MG	N018173 001	

DISCONTINUED DRUG PRODUCT LIST

6-90 (of 322)

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY

1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

2MG/5ML

A086833 001

HALSEY

2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE

2MG/5ML

A087001 001 Nov 04, 1982

NASKA

2MG/5ML

A089021 001 Dec 21, 1987

PERIACTIN

MERCK

2MG/5ML

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

SANDOZ

4MG

A086808 001

SUPERPHARM

4MG

A087405 001

TG UNITED LABS

4MG

A088212 001 May 26, 1983

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCK

4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA

7.25% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL

1GM/VIAL

N016793 003 Dec 21, 1987

2GM/VIAL

N016793 004 Dec 21, 1987

100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL

A070962 001 Aug 28, 1986

200MG/VIAL

A070990 001 Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL

N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

EISAI INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002

DISCONTINUED DRUG PRODUCT LIST

6-91 (of 322)

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ORGANON USA INC

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS

0.5%

N019849 001 Dec 31, 1990

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

CUBIST

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 300MG BASE

N021976 001 Jun 23, 2006

EQ 400MG BASE

N021976 003 Oct 21, 2008

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET; ORAL

DECLOMYCIN

COREPHARMA

75MG

N050261 001

150MG

N050261 002

300MG

N050261 003

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE

0.125MG; 25MG

N012148 001

ORETICYL 50

ABBVIE

0.125MG; 50MG

N012148 003

ORETICYL FORTE

ABBVIE

0.25MG; 25MG

N012148 002

DISCONTINUED DRUG PRODUCT LIST

6-92 (of 322)

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT 0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT 0.5MG; 5MG

N012775 002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS 0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US 25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

BARR LABS INC 150MG

A071804 001 May 29, 1997

PLIVA 25MG

A071800 001 Dec 08, 1987

50MG

A071801 001 Dec 08, 1987

75MG

A071802 001 Dec 08, 1987

100MG

A071803 001 May 29, 1997

USL PHARMA 25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS 0.2MG/ML

N009282 002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

SANOFI AVENTIS US 0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD 0.004MG/ML

A074575 001 Feb 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD 0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING 0.01%

N019776 001 Dec 26, 1990

SPRAY, METERED; NASAL

DDAVP

SANOFI AVENTIS US 0.01MG/SPRAY

N017922 002 Feb 06, 1989

STIMATE

CSL BEHRING 0.15MG/SPRAY

N020355 001 Mar 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC 0.15MG; 0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR 0.15MG; 0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS 0.15MG; 0.03MG

N020301 001 Dec 14, 1992

DESONIDE

CREAM; TOPICAL

DESONIDE

TEVA PHARMS 0.05%

A074027 001 Sep 28, 1992

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH 0.25%

N017856 001

TOPICORT LP

TARO PHARMS NORTH 0.05%

N018309 001

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH 0.05%

N018586 001 Mar 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA 0.25%

A073440 001 Apr 01, 1998

DISCONTINUED DRUG PRODUCT LIST

6-93 (of 322)

DESOXIMETASONE

OINTMENT; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.25%

N018763 001 Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC

5MG/ML

N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS

125MG

N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A083296 002

DECASPRAY

MERCK

0.04% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

HEXADROL

ORGANON USA INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 004

0.5MG

N011664 001

0.75MG

N011664 002

1.5MG

N011664 003

4MG

N011664 005

6MG

N011664 006 Jul 30, 1982

DEXAMETHASONE

IMPAX LABS

0.75MG

A085376 001

MUTUAL PHARM

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

PAR PHARM

0.25MG

A088149 001 Apr 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SANDOZ

0.75MG

A080399 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

WATSON LABS

0.25MG

A085455 001

0.5MG

A085458 001

0.75MG

A080968 001

0.75MG

A084457 001

DISCONTINUED DRUG PRODUCT LIST

6-94 (of 322)

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

0.75MG	A085818	001
1.5MG	A085456	001
1.5MG	A085840	001
WHITEWORTH TOWN PLSN 0.75MG	A084327	001

DEXONE 0.5

SOLVAY

0.5MG	A084991	001

DEXONE 0.75

SOLVAY

0.75MG	A084993	001

DEXONE 1.5

SOLVAY

1.5MG	A084990	001

DEXONE 4

SOLVAY

4MG	A084992	001

HEXADROL

ORGANON USA INC

0.5MG	N012675	004
0.75MG	N012675	007
1.5MG	N012675	009
4MG	N012675	010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCK

EQ 8MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016675	001

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML	A084315	001
EQ 16MG BASE/ML	A087711	001

May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N014242	001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N013413	001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE	N011983	002

INJECTABLE; INJECTION

DECADRON

MERCK

EQ 4MG PHOSPHATE/ML	N012071	002
EQ 24MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071	004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML	A084342	001

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML	A088448	001

FRESENIUS KABI USA

EQ 10MG PHOSPHATE/ML	A088469	001

Jan 25, 1984

Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 4MG PHOSPHATE/ML	A084493	001

BEL MAR

EQ 4MG PHOSPHATE/ML	A084752	001

DELL LABS

EQ 4MG PHOSPHATE/ML	A083161	001

HIKMA MAPLE

EQ 4MG PHOSPHATE/ML	A084282	001

INTL MEDICATION

EQ 20MG PHOSPHATE/ML	A088522	001

Feb 17, 1984

LYPHOMED

EQ 4MG PHOSPHATE/ML	A087065	001

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML	A081125	001

Aug 31, 1990

EQ 10MG PHOSPHATE/ML	A081126	001

Aug 31, 1990

WATSON LABS

EQ 4MG PHOSPHATE/ML	A083702	001

EQ 4MG PHOSPHATE/ML	A084355	001

EQ 4MG PHOSPHATE/ML	A089169	001

Apr 09, 1986

EQ 10MG PHOSPHATE/ML	A087668	001

Jul 01, 1982

EQ 24MG PHOSPHATE/ML	A085606	001

WYETH AYERST

EQ 4MG PHOSPHATE/ML	A085641	001

HEXADROL

ORGANON USA INC

EQ 4MG PHOSPHATE/ML	N014694	002

EQ 10MG PHOSPHATE/ML	N014694	003

EQ 20MG PHOSPHATE/ML	N014694	004

DISCONTINUED DRUG PRODUCT LIST

6-95 (of 322)

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

DECADRON

MERCK EQ 0.05% PHOSPHATE N011977 001

DEXAIR

PHARMAFAIR EQ 0.05% PHOSPHATE A088071 001 Dec 28, 1982

MAXIDEX

ALCON EQ 0.05% PHOSPHATE A083342 001

SOLUTION/DROPS;OPHTHALMIC

DEXAIR

PHARMAFAIR EQ 0.1% PHOSPHATE A088433 001 Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND EQ 0.1% PHOSPHATE A084170 001

EQ 0.1% PHOSPHATE A084173 001

SOLUTION/DROPS;OPHTHALMIC, OTIC

DECADRON

MERCK EQ 0.1% PHOSPHATE N011984 001

SOLUTION/DROPS;OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN EQ 0.1% PHOSPHATE A084855 001

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

DECADRON W/ XYLOCAINE

MERCK EQ 4MG PHOSPHATE/ML;10MG/ML N013334 002

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEODECADRON

MERCK EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM N050324 001

SOLUTION/DROPS;OPHTHALMIC

NEODECADRON

MERCK EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML N050322 001

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A064055 001 Oct 30, 1995

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A062714 001 Jul 21, 1986

PHARMAFAIR EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A062539 001 Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

DEXACIDIN

NOVARTIS 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062566 001 Feb 22, 1985

DEXASPORIN

PHARMAFAIR 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062411 001 May 16, 1983

SUSPENSION/DROPS;OPHTHALMIC

DEXACIDIN

NOVARTIS 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062544 001 Oct 29, 1984

DEXASPORIN

PHARMAFAIR 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062428 001 May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING 2MG/5ML N011814 002

TABLET;ORAL

DISOMER

SCHERING 2MG N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING 2MG;60MG N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM 6MG;120MG A089116 001 Jan 22, 1987

DISOBROM

SANDOZ 6MG;120MG A070770 001 Sep 30, 1991

RESPORAL

PIONEER PHARMS 6MG;120MG A089139 001 Jun 16, 1988

DISCONTINUED DRUG PRODUCT LIST

6-96 (of 322)

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLARAMINE

SCHERING

2MG/5ML

A086837 001 Jul 19, 1982

TABLET; ORAL

DEXCHLORPHENIRAMINE MALEATE

PLIVA

2MG

A088682 001 Jan 17, 1986

POLARAMINE

SCHERING

2MG

A086835 001

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DEXAMPEX

TEVA

15MG

A085355 001

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

ABLE

5MG

A076814 001 Aug 25, 2004

10MG

A076814 002 Aug 25, 2004

15MG

A076814 003 Aug 25, 2004

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE

5MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A083902 001

TABLET; ORAL

DEXAMPEX

TEVA

5MG

A083735 001

10MG

A083735 002

DEXEDRINE

GLAXOSMITHKLINE

5MG

A084935 001

DEXTROAMPHETAMINE SULFATE

HALSEY

10MG

A083930 001

LANNETT

5MG

A083903 001

10MG

A083903 003

15MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A085652 001

MAST MM

5MG

A086521 001

NESHER PHARMS

5MG

A040365 001 Oct 31, 2002

10MG

A040367 001 Oct 31, 2002

PUREPAC PHARM

5MG

A084125 001

SANDOZ

5MG

A085370 001

10MG

A085371 001

VINTAGE PHARMS LLC

5MG

A040299 001 May 13, 1999

VITARINE

5MG

A084986 001

10MG

A085892 001

DEXTROSTAT

SHIRE

5MG

A084051 001

10MG

A084051 002

FERNDEX

FERNDAL LABS

5MG

A084001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY

15MG/5ML; 6.25MG/5ML

A088913 001 Mar 02, 1987

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

ANI PHARMS

15MG/5ML; 6.25MG/5ML

N011265 002 Apr 02, 1984

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN

10GM/100ML

N018046 001

MILES

10GM/100ML

N018504 001

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN

2.5GM/100ML

N018358 001

2.5GM/100ML

N019626 001 Feb 02, 1988

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT

38.5GM/100ML

N018923 001 Sep 19, 1984

DEXTROSE 5% IN PLASTIC CONTAINER

DHL

5GM/100ML

N019971 001 Sep 28, 1995

DISCONTINUED DRUG PRODUCT LIST

6-97 (of 322)

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 60%

B BRAUN 60GM/100ML

N017995 002 Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN 60GM/100ML

N017995 001

BAXTER HLTHCARE 60GM/100ML

N020047 002 Jul 02, 1991

HOSPIRA 60GM/100ML

N019346 001 Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN 7.7GM/100ML

N019626 003 Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML

N019025 001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML

N018273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N018274 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 37MG/100ML

N019699 001 Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 75MG/100ML

N019699 002 Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 110MG/100ML

N019699 003 Sep 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 220MG/100ML

N018744 003 Nov 09, 1982

5GM/100ML; 220MG/100ML

N019699 005 Sep 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG/100ML; 207MG/100ML

N019514 001 May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML

N018270 001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN 5GM/100ML; 75MG/100ML; 200MG/100ML

N018268 009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 150MG/100ML; 200MG/100ML

N018268 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 220MG/100ML; 200MG/100ML

N018268 005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 300MG/100ML; 200MG/100ML

N018268 006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 75MG/100ML; 330MG/100ML

N018268 011 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 150MG/100ML; 330MG/100ML

N018268 012 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 220MG/100ML; 330MG/100ML

N018268 013 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 300MG/100ML; 330MG/100ML

N018268 014 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN 5GM/100ML; 75MG/100ML; 450MG/100ML

N018268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 150MG/100ML; 450MG/100ML

N018268 001

DISCONTINUED DRUG PRODUCT LIST

6-98 (of 322)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER		
BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
B BRAUN	10GM/100ML; 200MG/100ML	N018386 001
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	10GM/100ML; 450MG/100ML	N018229 001
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	10GM/100ML; 900MG/100ML	N018047 001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
B BRAUN	2.5GM/100ML; 450MG/100ML	N018030 001
HOSPIRA	2.5GM/100ML; 450MG/100ML	N018096 001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
B BRAUN	2.5GM/100ML; 900MG/100ML	N018376 001
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
ABBOTT	3.3GM/100ML; 300MG/100ML	N018055 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML; 110MG/100ML	N018030 005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML; 200MG/100ML	N018030 004
MILES	5GM/100ML; 200MG/100ML	N018399 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		
ABBOTT	5GM/100ML; 225MG/100ML	N019482 001 Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
ABBOTT	5GM/100ML; 300MG/100ML	N019486 001 Oct 04, 1985
MILES	5GM/100ML; 300MG/100ML	N018501 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML; 330MG/100ML	N018030 003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
ABBOTT	5GM/100ML; 450MG/100ML	N019484 001 Oct 04, 1985
B BRAUN	5GM/100ML; 450MG/100ML	N018030 002
MILES	5GM/100ML; 450MG/100ML	N018400 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
ABBOTT	5GM/100ML; 900MG/100ML	N019483 001 Oct 04, 1985
B BRAUN	5GM/100ML; 900MG/100ML	N018026 001
MILES	5GM/100ML; 900MG/100ML	N018500 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN		
ABBVIE	1MG	N012302 005
	2MG	N012302 002
	4MG	N012302 004
	6MG	N012302 006

DEZOCINE

INJECTABLE; INJECTION

DALGAN		
ASTRAZENECA	5MG/ML	N019082 001 Dec 29, 1989
	10MG/ML	N019082 002 Dec 29, 1989
	15MG/ML	N019082 003 Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282		
BAYER HLTHCARE	60%	A087726 001 Sep 23, 1982
CARDIOGRAFIN		
BRACCO	85%	N011620 002
DIATRIZOATE MEGLUMINE		
BRACCO	76%	N010040 017
HYPAAQUE		
GE HEALTHCARE	30%	N016403 002

DISCONTINUED DRUG PRODUCT LIST

6-99 (of 322)

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE

60%

N016403 001

RENO-60

BRACCO

60%

N010040 016

RENO-DIP

BRACCO

30%

N010040 012

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE

30%

A087739 001 Sep 23, 1982

SOLUTION; URETERAL

RENO-30

BRACCO

30%

N010040 021

UROVIST CYSTO

BAYER HLTHCARE

30%

A087729 001 Sep 23, 1982

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE

30%

A087731 001 Sep 23, 1982

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE

30%

N016403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE

52%; 8%

A087724 001 Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE

66%; 10%

A087723 001 Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION

52%; 8%

A088166 001 Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE

66%; 10%

A086505 001

HYPAQUE-M, 75%

GE HEALTHCARE

50%; 25%

N010220 003

HYPAQUE-M, 90%

GE HEALTHCARE

60%; 30%

N010220 002

MD-60

MALLINCKRODT

52%; 8%

A087074 001

MD-76

MALLINCKRODT

66%; 10%

A087073 001

RENOCAL-76

BRACCO

66%; 10%

A089347 001 Jun 01, 1988

RENOGRAFIN-60

BRACCO

52%; 8%

N010040 006

RENOVIST

BRACCO

34.3%; 35%

N010040 020

RENOVIST II

BRACCO

28.5%; 29.1%

N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE

66%; 10%

A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

100%

N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE

25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT

50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE

50%

A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE

20%

N009561 002

DISCONTINUED DRUG PRODUCT LIST

6-100 (of 322)

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE

15MG

N018179 001

GEL; RECTAL

DIASTAT

VALEANT

5MG/ML (5MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**
10MG/2ML (5MG/ML)
15MG/3ML (5MG/ML)
20MG/4ML (5MG/ML)

N020648 002 Jul 29, 1997

N020648 003 Jul 29, 1997

N020648 004 Jul 29, 1997

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM

5MG/ML

A070662 001 Jun 25, 1986

HIKMA MAPLE

5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A070313 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

HOSPIRA

5MG/ML

A071584 001 Oct 13, 1987

MARSAM PHARMS LLC

5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072371 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

PARENTA PHARMS

5MG/ML

A076815 001 Apr 15, 2004

US ARMY

5MG/ML

N020124 001 Dec 05, 1990

WARNER CHILCOTT

5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS

5MG/ML

A070296 001 Feb 12, 1986

5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

DIZAC

PHARMACIA AND UPJOHN

5MG/ML

N019287 001 Jun 18, 1993

VALIUM

ROCHE

5MG/ML

N016087 001

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH

2MG

A070781 001 Mar 19, 1986

5MG

A070706 001 Mar 19, 1986

10MG

A070707 001 Mar 19, 1986

DAVA PHARMS INC

5MG

A070227 001 Sep 26, 1985

10MG

A070228 001 Sep 26, 1985

DURAMED PHARMS BARR

2MG

A070894 001 Aug 27, 1986

5MG

A070895 001 Aug 27, 1986

10MG

A070896 001 Aug 27, 1986

FERNDAL LABS

2MG

A070903 001 Apr 01, 1987

5MG

A070904 001 Apr 01, 1987

10MG

A070905 001 Apr 01, 1987

HALSEY

2MG

A070987 001 Aug 15, 1986

5MG

A070996 001 Aug 15, 1986

10MG

A070956 001 Aug 15, 1986

IVAX SUB TEVA PHARMS

2MG

A070360 001 Sep 04, 1985

5MG

A070361 001 Sep 04, 1985

10MG

A070362 001 Sep 04, 1985

MARTEC USA LLC

10MG

A072402 001 Apr 25, 1989

PAR PHARM

2MG

A070462 001 Feb 25, 1986

5MG

A070463 001 Feb 25, 1986

10MG

A070464 001 Feb 25, 1986

PIONEER PHARMS

2MG

A070787 001 Aug 02, 1988

5MG

A070788 001 Aug 02, 1988

10MG

A070776 001 Aug 02, 1988

ROXANE

2MG

A070356 001 Jun 17, 1986

5MG

A070357 001 Jun 17, 1986

10MG

A070358 001 Jun 17, 1986

SANDOZ

2MG

A070302 001 Dec 20, 1985

5MG

A070303 001 Dec 20, 1985

10MG

A070304 001 Dec 20, 1985

TEVA PHARMS

5MG

A070153 001 Nov 01, 1985

WARNER CHILCOTT

2MG

A070209 001 Sep 04, 1985

5MG

A070210 001 Sep 04, 1985

DISCONTINUED DRUG PRODUCT LIST

6-101 (of 322)

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985

Q-PAM

QUANTUM PHARMICS

2MG	A070423	001	Dec 12, 1985
2MG	A072431	001	Apr 29, 1988
5MG	A070424	001	Dec 12, 1985
5MG	A072432	001	Apr 29, 1988
10MG	A070425	001	Dec 12, 1985
10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM

50MG	N017425	001
100MG	N017425	002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM

15MG/ML	A071519	001	Aug 26, 1987

HYPERSTAT

SCHERING

15MG/ML	N016996	001

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCALINE

NOVARTIS

2.5MG/ML	N006203	001

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

TARO

50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011366	001

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020142	001	Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM

50MG	A075470	001	Feb 21, 2002

SANDOZ

50MG	A075582	001	Feb 23, 2001

WATSON LABS

50MG	A075152	001	Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC

0.1%	A077600	001	Nov 13, 2008

FALCON PHARMS

0.1%	N020809	001	May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS

50MG	A074986	001	Feb 26, 1999

75MG	A074986	002	Feb 26, 1999

PLIVA

50MG	A074432	002	Jul 29, 1999

75MG	A074432	003	Jul 29, 1999

ROXANE

25MG	A074391	001	Jun 29, 1995

50MG	A074391	002	Jun 29, 1995

75MG	A074391	003	Jun 29, 1995

TEVA

50MG	A074723	001	Mar 30, 1999

75MG	A074390	001	Aug 15, 1996

TEVA PHARMS

25MG	A074459	001	Jun 25, 1997

50MG	A074459	002	Jun 25, 1997

75MG	A074459	003	Jun 25, 1997

VOLTAREN

NOVARTIS

25MG	N019201	001	Jul 28, 1988

50MG	N019201	002	Jul 28, 1988

75MG	N019201	003	Jul 28, 1988

DISCONTINUED DRUG PRODUCT LIST

6-102 (of 322)

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET; ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM

10MG

A084505 001 Oct 21, 1986

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

WATSON LABS

10MG

A083179 001 Feb 12, 1986

WEST WARD

10MG

A040204 001 Feb 28, 1997

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM

20MG

A084600 001 Jul 29, 1985

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

WATSON LABS

20MG

A084361 001 Feb 06, 1986

WEST WARD

20MG

A040161 001 Oct 01, 1996

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

BRISTOL MYERS SQUIBB

100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB

25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM

0.01%

N006110 005

DV

SANOFI AVENTIS US

0.01%

A083518 001

ESTRAGUARD

SOLVAY

0.01%

A084436 001

DISCONTINUED DRUG PRODUCT LIST

6-103 (of 322)

DIENESTROL

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US	0.7MG	A083517	001

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE	50MG	N006459	001

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ	25MG	A085916	001

TEVA	25MG	A088642	001

TG UNITED LABS	25MG	A088267	001	Sep 20, 1984

	25MG	A088268	001	Aug 25, 1983

UCB INC	25MG	A085544	001

WATSON LABS	25MG	A085741	001

TENUATE

SANOFI AVENTIS US	25MG	N017668	001

TEPANIL

3M	25MG	N011673	001

TABLET, EXTENDED RELEASE;ORAL

TENUATE

SANOFI AVENTIS US	75MG	N017669	001

TEPANIL TEN-TAB

3M	75MG	N017956	001

DIETHYLSTILBESTROL

INJECTABLE;INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056	003

	0.5MG/ML	N004056	004

	1MG/ML	N004056	005

	5MG/ML	N004056	006

SUPPOSITORY;VAGINAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004040	001

	0.5MG	N004040	002

STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056	001

	0.5MG	N004056	002

TABLET;ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004041	002

	0.5MG	N004041	003

	1MG	N004041	004

	5MG	N004041	005

STILBESTROL

TABLICAPS	0.5MG	A083004	001

	1MG	A083002	001

	5MG	A083006	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	007

	0.25MG	N004056	017

	0.5MG	N004056	008

	1MG	N004056	009

	5MG	N004056	010

TABLET, DELAYED RELEASE;ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004039	002

	0.25MG	N004039	005

	0.5MG	N004039	003

	1MG	N004039	004

	5MG	N004039	006

STILBESTROL

TABLICAPS	0.5MG	A083003	001

	1MG	A083005	001

	5MG	A083007	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	011

	0.5MG	N004056	012

	1MG	N004056	013

DISCONTINUED DRUG PRODUCT LIST

6-104 (of 322)

DIETHYLSTILBESTROLTABLET, DELAYED RELEASE; ORAL
STILBETIN

5MG

N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS

250MG/5ML

N010010 001

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS

50MG

N010010 002

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS

0.05%

A075187 001 Mar 30, 1998

FLORONE

PHARMACIA AND UPJOHN

0.05%

N017741 001

FLORONE E

PHARMACIA AND UPJOHN

0.05%

N019259 001 Aug 28, 1985

PSORCON

TARO PHARMS NORTH

0.05%

N020205 001 Nov 20, 1992

OINTMENT; TOPICAL

PSORCON

PHARMACIA AND UPJOHN

0.05%

N019260 001 Aug 28, 1985

PSORCON E

PHARMACIA AND UPJOHN

0.05%

N017994 001

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

PUREPAC PHARM

250MG

A074285 001 May 07, 1996

500MG

A074285 002 May 07, 1996

ROXANE

250MG

A073562 001 Nov 27, 1992

500MG

A073563 001 Nov 27, 1992

SANDOZ

500MG

A074604 001 Jun 10, 1996

TEVA

250MG

A073679 001 Jul 31, 1992

WATSON LABS

250MG

A074400 001 Jul 17, 1997

500MG

A074400 002 Jul 17, 1997

DOLOBID

MERCK

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**
500MG

N018445 001 Apr 19, 1982

N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

DIGOXIN

CARACO

0.125MG

A076363 001 Jan 31, 2003

0.25MG

A076363 002 Jan 31, 2003

MYLAN PHARMS INC

0.125MG

A040282 001 Dec 23, 1999

0.25MG

A040282 002 Dec 23, 1999

LANOXIN

COVIS PHARMA

0.0625MG

N020405 001 Sep 30, 1997

DISCONTINUED DRUG PRODUCT LIST

6-105 (of 322)

DIGOXIN

TABLET; ORAL

LANOXIN

0.1875MG

N020405 003 Sep 30, 1997

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML
0.5MG/0.7ML; 5,000
UNITS/0.7ML; 7.46MG/0.7ML

N018885 001 Nov 30, 1984

N018885 002 Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

BIOVAIL

60MG

N019471 001 Jan 23, 1989

90MG

N019471 002 Jan 23, 1989

120MG

N019471 003 Jan 23, 1989

180MG

N019471 004 Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

TEVA

60MG

A074079 001 Nov 30, 1993

90MG

A074079 002 Nov 30, 1993

120MG

A074079 003 Nov 30, 1993

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL

100MG/VIAL

N020792 001 Sep 05, 1997

BIOVAIL LABS INTL

5MG/ML

N020027 001 Oct 24, 1991

25MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020027 003 Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

APOTEX INC

5MG/ML

A075375 001 Sep 30, 1999

HOSPIRA

5MG/ML

A075004 001 Feb 16, 2000

5MG/ML

A075106 001 Apr 29, 1999

TEVA PHARMS USA

5MG/ML

A074894 001 Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON

30MG

A074051 001 Mar 31, 1993

60MG

A074051 002 Mar 31, 1993

90MG

A074051 003 Mar 31, 1993

120MG

A074051 004 Mar 31, 1993

DAVA PHARMS INC

30MG

A074093 001 Nov 05, 1992

60MG

A074093 002 Nov 05, 1992

90MG

A074093 003 Nov 05, 1992

120MG

A074093 004 Nov 05, 1992

IVAX SUB TEVA PHARMS

30MG

A074168 001 Mar 03, 1995

60MG

A074168 002 Mar 03, 1995

90MG

A074168 003 Mar 03, 1995

120MG

A074168 004 Mar 03, 1995

TEVA

30MG

A074084 001 Feb 25, 1994

60MG

A074084 002 Feb 25, 1994

TEVA PHARMS

30MG

A074067 001 Nov 05, 1992

60MG

A074067 002 Nov 05, 1992

90MG

A074067 003 Nov 05, 1992

120MG

A074067 004 Nov 05, 1992

DISCONTINUED DRUG PRODUCT LIST

6-106 (of 322)

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK

EQ 120MG HCL

N020506 001 Oct 04, 1996

EQ 180MG HCL

N020506 002 Oct 04, 1996

EQ 240MG HCL

N020506 003 Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL

EQ 180MG HCL; 5MG

N020507 001 Oct 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE

50MG/ML

A084767 001

WATSON LABS

50MG/ML

A080615 001

50MG/ML

A083531 001

WYETH AYERST

50MG/ML

A084316 001

LIQUID; ORAL

DIMENHYDRINATE

ALRA

12.5MG/4ML

A080715 001

TABLET; ORAL

DIMENHYDRINATE

HEATHER

50MG

A080841 001

NEXGEN PHARMA INC

50MG

A085985 001

WATSON LABS

50MG

A085166 001

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

IMCOR PHARMS CO

0.92MG/VIAL; 0.092MG/VIAL

N021191 001 May 31, 2002

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN

EQ 5MG BASE/ML

N017434 001

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING

100MG

N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS

25MG

N005845 007

50MG

N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA

25MG

A080519 004

50MG

A080519 003

ANABOLIC

50MG

A083275 001

ELKINS SINN

25MG

A085701 001

50MG

A085701 002

HALSEY

50MG

A087914 001

Jun 04, 1984

HEATHER

25MG

A084524 001

50MG

A083953 001

IMPAX LABS

25MG

A080807 001

50MG

A080807 002

IVAX SUB TEVA PHARMS

25MG

A080762 001

50MG

A080762 002

LANNETT

25MG

A080868 001

50MG

A080868 002

LEDERLE

25MG

A086874 001

50MG

A086875 001

LNK

25MG

A087977 001

Jan 27, 1983

50MG

A087978 001

Jan 27, 1983

MK LABS

25MG

A083087 001

50MG

A083087 002

MUTUAL PHARM

25MG

A084506 001

25MG

A089488 001

Jan 02, 1987

50MG

A089489 001

Jan 02, 1987

NEWTRON PHARMS

25MG

A086543 001

50MG

A086544 001

NEXGEN PHARMA INC

25MG

A083634 001

DISCONTINUED DRUG PRODUCT LIST

6-107 (of 322)

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SANDOZ	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A080727	001	
	50MG	A083797	002	
	50MG	A085083	001	
WEST WARD	50MG	A083567	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	

DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
	50MG/ML	N006146	002	

BENADRYL PRESERVATIVE FREE

MCNEIL CONS	50MG/ML	N009486	001	

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822	001	
HIKMA MAPLE	50MG/ML	A083183	001	
LYPHOMED	10MG/ML	A087066	001	
WATSON LABS	10MG/ML	A083533	001	
WATSON LABS INC	10MG/ML	A080873	001	
	50MG/ML	A080873	002	
WYETH AYERST	50MG/ML	A080577	001	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002	

DISCONTINUED DRUG PRODUCT LIST

6-108 (of 322)

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

WATSON LABS INC 50MG/ML A080873 003

SYRUP; ORAL

ANTITUSSIVE

PERRIGO 12.5MG/5ML A071292 001 Apr 10, 1987

BELDIN

HALSEY 12.5MG/5ML A089179 001 Jun 05, 1986

BENYLIN

PARKE DAVIS 12.5MG/5ML N006514 004

DIPHEN

MORTON GROVE 12.5MG/5ML A070118 001 Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS 12.5MG/5ML A070497 001 Apr 25, 1989

CUMBERLAND SWAN 12.5MG/5ML A073611 001 Aug 20, 1992

HI TECH PHARMA 12.5MG/5ML A072416 001 Sep 28, 1990

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A070205 001 Jan 28, 1986

SILPHEN

SILARX 12.5MG/5ML A072646 001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT 12.5MG/5ML A070524 001 Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS 12.5MG/5ML; 30MG/5ML N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE EQ 25MG BASE N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE 5MG N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1% A074188 001 May 19, 1995

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AGILA SPECLTS 5MG/ML A075769 001 Nov 27, 2002

HOSPIRA 5MG/ML A074601 001 Dec 19, 1997

TEVA PHARMS USA 5MG/ML A074952 001 Nov 26, 1997

IV PERSANTINE

BOEHRINGER INGELHEIM 5MG/ML N019817 001 Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

PROSAM LABS 25MG A040542 001 Apr 21, 2006

50MG A040542 002 Apr 21, 2006

75MG A040542 003 Apr 21, 2006

PUREPAC PHARM 50MG A089426 001 Jul 12, 1990

75MG A089427 001 Jul 12, 1990

SANDOZ 25MG A086944 002 Apr 16, 1991

50MG A087562 001 Feb 25, 1992

75MG A087561 001 Feb 25, 1992

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS 250MG N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM EQ 100MG BASE A071190 001 Jan 15, 1987

EQ 150MG BASE A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS EQ 100MG BASE A070186 001 Nov 18, 1985

EQ 150MG BASE A070187 001 Nov 18, 1985

MUTUAL PHARM EQ 100MG BASE A070351 001 Dec 17, 1985

DISCONTINUED DRUG PRODUCT LIST

6-109 (of 322)

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

	EQ 150MG BASE	A070352 001	Dec 17, 1985
MYLAN	EQ 100MG BASE	A070138 001	Jun 14, 1985
	EQ 150MG BASE	A070139 001	Jun 14, 1985
SANDOZ	EQ 100MG BASE	A070470 001	Dec 10, 1985
	EQ 150MG BASE	A070471 001	Dec 10, 1985
SUPERPHARM	EQ 100MG BASE	A070940 001	Feb 09, 1987
	EQ 150MG BASE	A070941 001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240 001	Feb 02, 1986
	EQ 150MG BASE	A070241 001	Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987

DISULFIRAM

TABLET; ORAL

ANTABUSE

TEVA WOMENS	250MG	N007883 003	
	500MG	N007883 002	

DISULFIRAM

PAR PHARM	250MG	A088792 001	Aug 14, 1984
	500MG	A088793 001	Aug 14, 1984
WATSON LABS	250MG	A086889 001	
	250MG	A087973 001	Aug 05, 1983
	500MG	A086890 001	
	500MG	A087974 001	Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794 001	Jul 11, 1990
	EQ 500MG BASE	N019794 002	Jul 11, 1990

DIVALPROEX SODIUM

MYLAN	EQ 125MG VALPROIC ACID	A077254 001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A077254 002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A077254 003	Jul 29, 2008

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700 001	Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA	EQ 12.5MG BASE/ML	A074098 001	Feb 21, 1995
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381 001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634 001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545 001	Jun 25, 1998
MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	A074279 001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995 001	Mar 31, 1998
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206 001	Oct 19, 1993
DOBUTREX			
LILLY	EQ 12.5MG BASE/ML	N017820 002	

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012
	80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020449 001	May 14, 1996

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719 001	Oct 18, 2004

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011
	10MG	A201335 002	Aug 29, 2011

DISCONTINUED DRUG PRODUCT LIST

6-110 (of 322)

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

MUTUAL PHARM

5MG

A077975 002 Dec 11, 2009

10MG

A077975 001 Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT

40MG/ML

A070656 001 Jan 24, 1989

80MG/ML

A070657 001 Jan 24, 1989

ABRAXIS PHARM

40MG/ML

A070012 001 Jun 12, 1985

40MG/ML

A070058 001 Mar 20, 1985

80MG/ML

A070013 001 Jun 12, 1985

80MG/ML

A070059 001 Mar 20, 1985

160MG/ML

A070364 001 Dec 04, 1985

ASTRAZENECA

40MG/ML

A070087 001 Oct 23, 1985

40MG/ML

N018656 001 Jun 28, 1983

80MG/ML

A070089 001 Oct 23, 1985

80MG/ML

A070090 001 Oct 23, 1985

80MG/ML

A070091 001 Oct 23, 1985

160MG/ML

A070092 001 Oct 23, 1985

160MG/ML

A070093 001 Oct 23, 1985

160MG/ML

A070094 001 Oct 23, 1985

BAXTER HLTHCARE

40MG/ML

N018398 001

80MG/ML

N018398 002 Mar 22, 1982

HOSPIRA

40MG/ML

A074403 001 May 23, 1996

INTL MEDICATION

40MG/ML

N018014 001

LYPHOMED

40MG/ML

N018549 001 Mar 11, 1983

SMITH AND NEPHEW

40MG/ML

A070011 001 Aug 29, 1985

40MG/ML

A070046 001 Aug 29, 1985

80MG/ML

A070047 001 Aug 29, 1985

TEVA PARENTERAL

40MG/ML

A072999 001 Oct 23, 1991

80MG/ML

A073000 001 Oct 23, 1991

WARNER CHILCOTT

40MG/ML

A070558 001 Sep 20, 1985

40MG/ML

N018138 001

80MG/ML

A070559 001 Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

1.6MG/ML

N020542 001 Aug 30, 1995

INTROPIN

HOSPIRA

40MG/ML

N017395 001

80MG/ML

N017395 002

160MG/ML

N017395 003

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC

EQ 2% BASE

A078395 001 Oct 28, 2008

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC

EQ 2% BASE; EQ 0.5% BASE

A078201 001 Oct 28, 2008

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE

EQ 1MG BASE/ML

N019946 001 Mar 07, 1991

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH

EQ 1MG BASE

A075574 001 Oct 18, 2000

EQ 2MG BASE

A075574 002 Oct 18, 2000

EQ 4MG BASE

A075574 003 Oct 18, 2000

EQ 8MG BASE

A075574 004 Oct 18, 2000

GENPHARM

EQ 1MG BASE

A075466 001 Oct 18, 2000

EQ 2MG BASE

A075466 002 Oct 18, 2000

EQ 4MG BASE

A075466 003 Oct 18, 2000

EQ 8MG BASE

A075466 004 Oct 18, 2000

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A075453 001 Oct 18, 2000

EQ 2MG BASE

A075453 002 Oct 18, 2000

EQ 4MG BASE

A075453 003 Oct 18, 2000

EQ 8MG BASE

A075453 004 Oct 18, 2000

NESHER PHARMS

EQ 1MG BASE

A075609 001 Oct 18, 2000

DISCONTINUED DRUG PRODUCT LIST

6-111 (of 322)

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

	EQ 2MG BASE	A075609 002	Oct 18, 2000
	EQ 4MG BASE	A075609 003	Oct 18, 2000
	EQ 8MG BASE	A075609 004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075432 001	Oct 18, 2000
	EQ 1MG BASE	A075646 001	Oct 18, 2000
	EQ 2MG BASE	A075432 002	Oct 18, 2000
	EQ 2MG BASE	A075646 002	Oct 18, 2000
	EQ 4MG BASE	A075432 003	Oct 18, 2000
	EQ 4MG BASE	A075646 003	Oct 18, 2000
	EQ 8MG BASE	A075432 004	Oct 18, 2000
	EQ 8MG BASE	A075646 004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353 001	Jan 12, 2001
	EQ 2MG BASE	A075353 002	Jan 12, 2001
	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000

DOXEPIH HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
MUTUAL PHARM	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987
	EQ 25MG BASE	A071437 001	Nov 09, 1987
	EQ 50MG BASE	A071595 001	Nov 09, 1987
	EQ 75MG BASE	A071608 001	Nov 09, 1987
	EQ 100MG BASE	A071422 001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 50MG BASE	A072987 001	Mar 29, 1991

DISCONTINUED DRUG PRODUCT LIST

6-112 (of 322)

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

EQ 75MG BASE	A071326 001	Apr 30, 1987
EQ 75MG BASE	A071763 001	Feb 09, 1988
EQ 100MG BASE	A070955 001	May 15, 1986
EQ 100MG BASE	A071239 001	Apr 30, 1987
EQ 150MG BASE	A071764 001	Feb 09, 1988

SINEQUAN

PFIZER

EQ 10MG BASE	N016798 003	
EQ 25MG BASE	N016798 001	
EQ 50MG BASE	N016798 002	
EQ 75MG BASE	N016798 006	
EQ 100MG BASE	N016798 005	
EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 007	

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC

EQ 10MG BASE/ML	A075924 001	Jan 15, 2004

SINEQUAN

PFIZER

EQ 10MG BASE/ML	N017516 001	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML	A063165 001	Jan 30, 1991
2MG/ML	N050629 001	Dec 23, 1987
200MG/100ML	A063165 002	Jan 30, 1991
200MG/100ML	N050629 002	May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN

10MG/VIAL	N050467 001	
20MG/VIAL	N050467 003	May 20, 1985
50MG/VIAL	N050467 002	
150MG/VIAL	N050467 004	Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL	A062926 001	Apr 13, 1989
50MG/VIAL	A062926 002	Apr 13, 1989
100MG/VIAL	A062926 003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM

EQ 75MG BASE	A065055 004	Apr 18, 2005

SANDOZ INC

EQ 50MG BASE	A065032 001	Jun 30, 2000
EQ 100MG BASE	A065032 002	Jun 30, 2000

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML	A061720 001	

TABLET; ORAL

DOXYCYCLINE

MUTUAL PHARM

EQ 50MG BASE	A065471 001	Apr 17, 2009
EQ 75MG BASE	A065471 002	Apr 17, 2009
EQ 100MG BASE	A065471 003	Apr 17, 2009

SANDOZ INC

EQ 50MG BASE	A065353 001	Nov 27, 2006
EQ 75MG BASE	A065353 002	Nov 27, 2006
EQ 100MG BASE	A065353 003	Nov 27, 2006

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

TEVA

EQ 50MG BASE	A062497 001	Aug 23, 1984
EQ 100MG BASE	A062497 002	Jun 15, 1984

DOXYCYCLINE HYCLATE

HALSEY

EQ 50MG BASE	A062119 002	May 24, 1985
EQ 100MG BASE	A062119 001	May 24, 1985

HEATHER

EQ 50MG BASE	A062463 001	Dec 07, 1983
EQ 100MG BASE	A062463 002	Dec 07, 1983

INTERPHARM

EQ 50MG BASE	A062763 001	Sep 02, 1988
EQ 100MG BASE	A062763 002	Sep 02, 1988

MUTUAL PHARM

EQ 50MG BASE	A062418 001	Jan 28, 1983
EQ 100MG BASE	A062418 002	Jan 28, 1983

MYLAN

EQ 50MG BASE	A062337 001	Mar 29, 1982

DISCONTINUED DRUG PRODUCT LIST

6-113 (of 322)

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

	EQ 100MG BASE	A062337 002	Mar 29, 1982
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984
	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	

PERIOSTAT

COLLAGENEX

EQ 20MG BASE	N050744 001	Sep 30, 1998

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA

EQ 100MG BASE	A063187 001	Jun 30, 1992

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL

EQ 75MG BASE	N050582 002	Aug 13, 2001
EQ 100MG BASE	N050582 001	Jul 22, 1985
EQ 100MG BASE	A062653 001	Oct 30, 1985

WARNER CHILCOTT

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE

EQ 100MG BASE/VIAL	A061953 001	

DOXYCYCLINE

BEDFORD

EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988

HIKMA MAPLE

EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983

EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983

DOXYCYCLINE HYCLATE

HIKMA MAPLE

EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989

EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989

VIBRAMYCIN

PFIZER

EQ 100MG BASE/VIAL	N050442 002	

EQ 200MG BASE/VIAL	N050442 001	

TABLET; ORAL

DOXY-LEMMON

TEVA

EQ 100MG BASE	A062581 001	Mar 15, 1985

DOXYCYCLINE HYCLATE

BLU CARIBE INC

EQ 50MG BASE	A062269 003	

HEATHER

EQ 100MG BASE	A062462 001	May 11, 1983

INTERPHARM

EQ 100MG BASE	A062764 001	Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE	A062391 001	Sep 30, 1982

MYLAN

EQ 100MG BASE	A062432 001	Feb 15, 1983

SUPERPHARM

EQ 100MG BASE	A062494 001	Feb 20, 1985

WARNER CHILCOTT

EQ 100MG BASE	A062593 001	Aug 28, 1985

WATSON LABS

EQ 50MG BASE	A062392 001	Mar 31, 1983

EQ 100MG BASE	A062392 002	Mar 31, 1983

VIBRA-TABS

PFIZER

EQ 100MG BASE	N050533 001	

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG	N019440 001	Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG	N006412 015	

25MG	N006412 014	

DOXY-SLEEP-AID

PAR PHARM

25MG	A070156 001	Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG	A088900 002	Feb 12, 1988

QUANTUM PHARMICS

25MG	A088603 001	Aug 07, 1984

DISCONTINUED DRUG PRODUCT LIST

6-114 (of 322)

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM

2.5MG/ML

A070992 001 Nov 17, 1986

2.5MG/ML

A070993 001 Nov 17, 1986

ASTRAZENECA

2.5MG/ML

A072018 001 Oct 20, 1988

2.5MG/ML

A072019 001 Oct 19, 1988

2.5MG/ML

A072020 001 Oct 19, 1988

2.5MG/ML

A072021 001 Oct 19, 1988

HOSPIRA

2.5MG/ML

A071645 001 Apr 07, 1988

2.5MG/ML

A072272 001 Aug 31, 1995

LUITPOLD

2.5MG/ML

A072335 001 Oct 24, 1988

SMITH AND NEPHEW

2.5MG/ML

A071750 001 Sep 06, 1988

SOLOPAK

2.5MG/ML

A071754 001 Sep 06, 1988

2.5MG/ML

A071755 001 Sep 06, 1988

WATSON LABS

2.5MG/ML

A073520 001 Nov 27, 1991

2.5MG/ML

A073521 001 Nov 27, 1991

2.5MG/ML

A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA

2.5MG/ML; EQ 0.05MG BASE/ML

A072026 001 Apr 13, 1989

2.5MG/ML; EQ 0.05MG BASE/ML

A072027 001 Apr 13, 1989

2.5MG/ML; EQ 0.05MG BASE/ML

A072028 001 Apr 13, 1989

HOSPIRA

2.5MG/ML; EQ 0.05MG BASE/ML

A071982 001 May 04, 1988

INNOVAR

AKORN MFG

2.5MG/ML; EQ 0.05MG BASE/ML

N016049 001

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA

0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 002

1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 001

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY

5MG

N017388 001

10MG

N017388 002

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA

160MG/15ML

N007794 003

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA

250MG/ML

N009088 001

TABLET; ORAL

DILOR

SAVAGE LABS

200MG

A084514 001

DILOR-400

SAVAGE LABS

400MG

A084751 001

NEOTHYLLINE

TEVA

200MG

N007794 001

400MG

N007794 002

DISCONTINUED DRUG PRODUCT LIST

6-115 (of 322)

ECHOTHIOPHATE IODIDEFOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

WYETH PHARMS INC

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

ECONAZOLE NITRATE

CREAM;TOPICAL

SPECTAZOLE

ORTHO JANSSEN

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET;ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

EFAVIRENZ

CAPSULE;ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020972 002 Sep 17, 1998

TABLET;ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021360 001 Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE

INJECTABLE;INJECTION

ORNIDYL

SANOFI AVENTIS US

200MG/ML

N019879 002 Nov 28, 1990

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

APOTHECON

2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

IVAX SUB TEVA PHARMS

2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO

2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

MYLAN

2.5MG

A075472 001 Aug 22, 2000

5MG

A075472 002 Aug 22, 2000

10MG

A075472 003 Aug 22, 2000

20MG

A075472 004 Aug 22, 2000

RANBAXY

2.5MG

A075556 001 Aug 22, 2000

5MG

A075556 002 Aug 22, 2000

10MG

A075556 003 Aug 22, 2000

20MG

A075556 004 Aug 22, 2000

SANDOZ

2.5MG

A075048 001 Aug 22, 2000

5MG

A075048 002 Aug 22, 2000

10MG

A075048 003 Aug 22, 2000

20MG

A075048 004 Aug 22, 2000

SANDOZ INC

2.5MG

A075496 001 Aug 22, 2000

2.5MG

A075621 001 Aug 22, 2000

5MG

A075496 002 Aug 22, 2000

DISCONTINUED DRUG PRODUCT LIST

6-116 (of 322)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

5MG	A075621	002	Aug 22, 2000
10MG	A075459	001	Aug 22, 2000
10MG	A075621	003	Aug 22, 2000
20MG	A075459	002	Aug 22, 2000
20MG	A075621	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXCEL

ASTRAZENECA

5MG; 2.5MG
5MG; 5MG

N020668	002	Oct 28, 1998
N020668	001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

5MG; 12.5MG
10MG; 25MG

A075736	001	Mar 25, 2003
A075736	002	Mar 25, 2003

SANDOZ INC

5MG; 12.5MG
10MG; 25MG

A076116	001	Sep 19, 2001
A076116	002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA

1.25MG/ML
1.25MG/ML

A075456	001	Aug 22, 2000
A075571	001	Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL

1.25MG/ML

N019309 001 Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT

99.9%

A070803 001 Sep 08, 1987

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG
400MG

N019616	004	Dec 31, 1991
N019616	005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US

90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020164 006 Jun 02, 2000

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING

0.25MG/INH

N016803 001

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS

0.2MG/INH

N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS

1.5MG/AMP
5MG/ML

N007942	003	Feb 05, 1999
N007942	001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPEC LT

0.15MG/DELIVERY

N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPEC LT

0.3MG/DELIVERY

N019430 003 Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

DISCONTINUED DRUG PRODUCT LIST

6-117 (of 322)

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML; 1%	N017751	006
	0.005MG/ML; 1.5%	N017751	007
DENTSPLY PHARM	0.005MG/ML; 1.5%	N021384	001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA	0.005MG/ML; 4%	N014763	008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML; 0.5%	N017751	004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML; 2%	A084720	001

	0.02MG/ML; 2%	A084732	001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

GRAHAM CHEM	0.01MG/ML; 2%	A080504	004	Oct 19, 1983

	0.02MG/ML; 2%	A080504	005	Oct 19, 1983

HIKMA MAPLE	0.01MG/ML; 1%	A080406	001

	0.01MG/ML; 2%	A080406	002

HOSPIRA	0.005MG/ML; 1%	A089649	001	Jun 21, 1988

	0.005MG/ML; 1.5%	A089650	001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML; 1%	A083154	001

BEL MAR	0.01MG/ML; 1%	A080820	001

	0.01MG/ML; 2%	A080757	001

DELL LABS	0.01MG/ML; 1%	A083389	001

	0.01MG/ML; 2%	A083390	001

INTL MEDICATION	0.01MG/ML; 1%	A086402	001

WATSON LABS	0.01MG/ML; 1%	A080377	003

	0.01MG/ML; 1%	A085463	001

	0.01MG/ML; 2%	A080377	004

LIDOCATON

PHARMATON	0.01MG/ML; 2%	A084729	001	Aug 17, 1983

	0.02MG/ML; 2%	A084728	001	Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM	0.01MG/ML; 2%	N021381	001

	0.02MG/ML; 2%	N021381	002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA	0.005MG/ML; 1%	N010418	006

	0.005MG/ML; 1.5%	N010418	010

	0.005MG/ML; 2%	N010418	008

FRESENIUS KABI USA	0.01MG/ML; 2%	N006488	003

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS	1.05MG/PATCH; 100MG/PATCH	N021504	001	May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED	0.01MG/ML; 2%	N020530	001	Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI	0.01MG/ML; 2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR	0.02MG/ML; 1%	A080758	001

	0.02MG/ML; 2%	A080759	001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007

	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA	200MG/VIAL	N050807	002	Sep 15, 2006

DISCONTINUED DRUG PRODUCT LIST

6-118 (of 322)

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE

EQ 300MG BASE

N020738 004 Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

1MG

A087244 001 Aug 16, 1982

GERIMAL

WATSON LABS

1MG

A088207 001 Mar 22, 1984

HYDERGINE

NOVARTIS

0.5MG

N017993 003

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG

A085153 001

1MG

A087417 001

CIRCANOL

3M

0.5MG

A084868 001

1MG

A085809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG

A085020 002

ERGOLOID MESYLATES

KV PHARM

0.5MG

A085899 001

0.5MG

A086265 001

1MG

A085900 001

1MG

A086264 001

LEDERLE

0.5MG

A086984 001

1MG

A086985 001

MUTUAL PHARM

0.5MG

A087407 001

1MG

A087552 001

SUPERPHARM

0.5MG

A089233 001 Sep 23, 1986

1MG

A089234 001 Sep 23, 1986

VANGARD

0.5MG

A088013 001 Sep 20, 1982

1MG

A088014 001 Sep 20, 1982

WATSON LABS

0.5MG

A084930 001

1MG

A085177 001

1MG

A087183 001

GERIMAL

WATSON LABS

0.5MG

A086189 001

1MG

A086188 001

HYDERGINE

NOVARTIS

0.5MG

N009087 002

1MG

N009087 001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG

A087186 001

1MG

A087185 001

DISCONTINUED DRUG PRODUCT LIST

6-119 (of 322)

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH

N012102 001

TABLET; SUBLINGUAL

ERGOSTAT

PARKE DAVIS

2MG

A088337 001 Jun 08, 1984

WIGRETTES

ORGANON USA INC

2MG

A086750 001 Jul 29, 1982

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

PARKE DAVIS

250MG

A062546 001 Jul 25, 1985

250MG

A062618 001 Sep 25, 1985

WARNER CHILCOTT LLC

250MG

A062338 001

ERYC 125

PARKE DAVIS

125MG

A062648 001 Oct 24, 1985

ERYC SPRINKLES

HOSPIRA

125MG

N050593 001 Jul 22, 1985

ERYTHROMYCIN

BARR

250MG

A063098 001 May 04, 1989

GEL; TOPICAL

E-GLADES

RENAISSANCE PHARMA

2%

A065009 001 Mar 18, 2002

EMGEL

ALTANA

2%

A063107 001 Aug 23, 1991

LOTION; TOPICAL

E-SOLVE 2

SYOSSET

2%

A062467 001 Jul 03, 1985

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

PHARMADERM

5MG/GM

A062446 001 Sep 26, 1983

PHARMAFAIR

5MG/GM

A062481 001 Apr 05, 1984

ILOTYCIN

DISTA

0.5%

N050368 001

POWDER; FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC

100%

N050610 001 Nov 07, 1986

SOLUTION; TOPICAL

A/T/S

TARO PHARMS NORTH

2%

A062405 001 Nov 18, 1982

ERYDERM

ARBOR PHARMS INC

2%

A062290 001

ERYMAX

MERZ PHARMS

2%

A062508 002 Jul 11, 1985

ERYTHROMYCIN

ALPHARMA US PHARMS

1.5%

A062328 001 Apr 19, 1982

2%

A062326 001 Apr 19, 1982

2%

A062327 001 Apr 19, 1982

2%

A062342 001 Feb 25, 1982

2%

A062957 001 Jul 21, 1988

BAUSCH AND LOMB

2%

A064039 001 Jan 27, 1994

LILLY

2%

N050532 001

PHARMAFAIR

1.5%

A062485 001 Jul 11, 1984

2%

A062616 001 Jul 25, 1985

RENAISSANCE PHARMA

2%

A064127 001 Feb 14, 1997

SANSAC

DOW PHARM

2%

A062522 001 Jan 24, 1985

STATICIN

WESTWOOD SQUIBB

1.5%

N050526 001

T-STAT

WESTWOOD SQUIBB

2%

A062436 001 Mar 09, 1983

SWAB; TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS

2%

A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON

2%

N050594 001 Feb 15, 1985

ERYTHROMYCIN

RENAISSANCE PHARMA

2%

A064128 001 Jul 03, 1996

T-STAT

WESTWOOD SQUIBB

2%

A062748 001 Jul 23, 1987

DISCONTINUED DRUG PRODUCT LIST

6-120 (of 322)

ERYTHROMYCIN

TABLET, DELAYED RELEASE;ORAL

E-BASE

BARR

333MG

A063028 001 May 15, 1990

333MG

A063086 001 May 15, 1990

500MG

A062999 001 Nov 25, 1988

E-MYCIN

ARBOR PHARMS INC

250MG

A060272 001

333MG

A060272 002

ILOTYCIN

DISTA

250MG

A061910 001

R-P MYCIN

SOLVAY

250MG

A061659 001

ROBIMYCIN

ROBINS AH

250MG

A061633 001

ERYTHROMYCIN ESTOLATE

CAPSULE;ORAL

ERYTHROMYCIN ESTOLATE

BARR

EQ 125MG BASE

A062162 001

EQ 250MG BASE

A062162 002

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A062237 001

WATSON LABS

EQ 250MG BASE

A062087 001

ILOSONE

LILLY

EQ 125MG BASE

A061897 001

EQ 250MG BASE

A061897 002

FOR SUSPENSION;ORAL

ILOSONE

DISTA

EQ 125MG BASE/5ML

A061893 001

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS

EQ 125MG BASE/5ML

A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML

A062409 001 Dec 16, 1982

BARR

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990

LIFE LABS

EQ 250MG BASE/5ML

A062362 001 Dec 17, 1982

ILOSONE

LILLY

EQ 125MG BASE/5ML

A061894 001

EQ 125MG BASE/5ML

N050010 001

EQ 250MG BASE/5ML

A061894 002

EQ 250MG BASE/5ML

N050010 002

SUSPENSION/DROPS;ORAL

ILOSONE

LILLY

EQ 100MG BASE/ML

A061894 003

TABLET;ORAL

ILOSONE

LILLY

EQ 500MG BASE

A061896 001

TABLET, CHEWABLE;ORAL

ILOSONE

DISTA

EQ 125MG BASE

A061895 001

EQ 250MG BASE

A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

ILOSONE SULFA

LILLY

EQ 125MG BASE/5ML;EQ 600MG BASE/5ML

N050599 001 Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BARR

EQ 200MG BASE/5ML

A062055 001

PEDIAMYCIN

ROSS LABS

EQ 200MG BASE/5ML

A062305 001

SUSPENSION;ORAL

E-MYCIN E

PHARMACIA AND UPJOHN

EQ 200MG BASE/5ML

A062198 001

EQ 400MG BASE/5ML

A062198 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS

EQ 200MG BASE/5ML

A062200 001

EQ 400MG BASE/5ML

A062200 002

DISTA

EQ 200MG BASE/5ML

A062177 001

EQ 400MG BASE/5ML

A062177 002

NASKA

EQ 400MG BASE/5ML

A062674 001 Mar 10, 1987

PARKE DAVIS

EQ 200MG BASE/5ML

A062231 001

DISCONTINUED DRUG PRODUCT LIST

6-121 (of 322)

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	EQ 400MG BASE/5ML	A062231 002	
PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
	EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985

WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
	EQ 400MG BASE/5ML	A062123 001	

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	

TABLET; ORAL

E.E.S. 400

ARBOR PHARMS INC	EQ 400MG BASE	A061905 001	

ERYTHROMYCIN ETHYLSUCCINATE

BARR	EQ 400MG BASE	A062256 001	
MYLAN	EQ 400MG BASE	A062847 001	Sep 14, 1988

TABLET, CHEWABLE; ORAL

E.E.S.

ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	

ERYPED

ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE	A062306 001	

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	A062758 001	Jun 15, 1988

PEDIAZOLE

ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N050529 001	

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA	EQ 1GM BASE/VIAL	N050370 003	
	EQ 250MG BASE/VIAL	N050370 001	
	EQ 500MG BASE/VIAL	N050370 002	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT	EQ 1GM BASE/VIAL	A062586 002	Jan 04, 1988
	EQ 500MG BASE/VIAL	A062586 001	Jan 04, 1988
HOSPIRA	EQ 1GM BASE/VIAL	N050182 003	
	EQ 1GM BASE/VIAL	N050609 002	Sep 24, 1986
	EQ 500MG BASE/VIAL	N050182 002	

ERYTHROMYCIN

ELKINS SINN	EQ 1GM BASE/VIAL	A062563 002	Mar 28, 1985
	EQ 500MG BASE/VIAL	A062563 001	Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062604 002	Nov 24, 1986
	EQ 500MG BASE/VIAL	A062604 001	Nov 24, 1986
BAXTER HLTHCARE	EQ 1GM BASE/VIAL	A062993 002	May 09, 1989
	EQ 500MG BASE/VIAL	A062993 001	May 09, 1989
TEVA PARENTERAL	EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993
	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL	EQ 250MG BASE	A061304 001	
	EQ 250MG BASE	A061887 001	

ERYPAR

PARKE DAVIS	EQ 250MG BASE	A062032 001	
	EQ 500MG BASE	A062032 002	
WARNER CHILCOTT	EQ 250MG BASE	A062322 001	

ERYTHROCIN STEARATE

ARBOR PHARMS INC	EQ 125MG BASE	A060359 002	
	EQ 500MG BASE	A060359 003	

ERYTHROMYCIN STEARATE

BARR	EQ 250MG BASE	A061591 001	
	EQ 500MG BASE	A063179 001	May 15, 1990

DISCONTINUED DRUG PRODUCT LIST

6-122 (of 322)

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061461	001
	EQ 500MG BASE	A061461	002
LEDERLE	EQ 250MG BASE	A062089	001
	EQ 500MG BASE	A062089	002
MYLAN	EQ 250MG BASE	A061505	001
	EQ 500MG BASE	A061505	002
PUREPAC PHARM	EQ 250MG BASE	A061743	001
WATSON LABS	EQ 250MG BASE	A062121	002
	EQ 500MG BASE	A062121	001
ETHRIL 250			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605	001
ETHRIL 500			
BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605	002
PFIZER-E			
PFIZER	EQ 250MG BASE	A061791	001
	EQ 500MG BASE	A061791	002
WYAMYCIN S			
WYETH AYERST	EQ 250MG BASE	A061675	001
	EQ 500MG BASE	A061675	002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660	001	Jul 31, 2007
	EQ 10MG BASE	A077660	002	Jul 31, 2007
	EQ 20MG BASE	A077660	003	Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386	003	Aug 15, 1988
	20MG/ML	N019386	007	May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT	1MG	N019080	001	Dec 26, 1990
	2MG	N019080	002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
	0.0375MG/24HR	N020847	002	Aug 04, 1998
	0.05MG/24HR	N020847	003	Aug 04, 1998
	0.075MG/24HR	N020847	004	Aug 04, 1998
	0.1MG/24HR	N020847	005	Aug 04, 1998
ESTRADIOL				
ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
	0.075MG/24HR	N021048	002	Sep 20, 1999
	0.1MG/24HR	N021048	003	Sep 20, 1999
FEMPATCH				
PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996
VIVELLE				
NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000
	0.0375MG/24HR	N020323	001	Oct 28, 1994
	0.075MG/24HR	N020323	003	Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND	0.06%	N021166	001	Feb 09, 2004

TABLET; ORAL

ESTRACE

BRISTOL MYERS SQUIBB	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A081295	001	Jun 30, 1993
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084499	001	
	2MG **Federal Register determination that product was not discontinued or	A084500	001	

DISCONTINUED DRUG PRODUCT LIST

6-123 (of 322)

ESTRADIOL

TABLET; ORAL

ESTRACE

withdrawn for safety or efficacy reasons**

ESTRADIOL

AAI PHARMA INC

0.5MG

A040138 001 Jan 30, 1998

1MG

A040138 002 Jan 30, 1998

2MG

A040138 003 Jan 30, 1998

HERITAGE PHARMS INC

0.5MG

A040275 001 Dec 29, 1998

1MG

A040275 002 Dec 29, 1998

2MG

A040275 003 Dec 29, 1998

GYNODIOL

DURAMED PHARMS BARR

0.5MG

A040212 001 Dec 29, 1997

1MG

A040212 002 Dec 29, 1997

1.5MG

A040212 003 Dec 29, 1997

2MG

A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC

0.5MG

A040312 001 Nov 19, 1999

1MG

A040312 002 Nov 19, 1999

2MG

A040312 003 Nov 19, 1999

TABLET; VAGINAL

VAGIFEM

NOVO NORDISK INC

25MCG

N020908 001 Mar 26, 1999

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN

1MG/ML

A085470 001

3MG/ML

A085470 002

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN 5MG/0.5ML; 25MG/0.5ML

N020874 001 Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN

2MG/ML; 50MG/ML

N017968 001

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS

2MG/ML; 50MG/ML

A085603 001 Mar 13, 1986

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

WATSON LABS

10MG/ML

A083546 001

40MG/ML

A083714 001

WATSON LABS INC

20MG/ML

A083547 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS

8MG/ML; 180MG/ML

A086423 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS

4MG/ML; 90MG/ML

A085865 001

8MG/ML; 180MG/ML

A085860 001

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC

2.5MG

N004782 002

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS

0.625MG/GM

N021788 001 Nov 28, 2008

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC

0.625MG; 0.625MG; N/A, 5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC

0.625MG; 0.625MG; 2.5MG; 2.5MG

N020303 001 Dec 30, 1994

DISCONTINUED DRUG PRODUCT LIST

6-124 (of 322)

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200			
MEDPOINTE PHARM HLC	0.45MG; 200MG	N011045	002
MILPREM-400			
MEDPOINTE PHARM HLC	0.45MG; 400MG	N011045	001
PMB 200			
WYETH AYERST	0.45MG; 200MG	N010971	005
PMB 400			
WYETH AYERST	0.45MG; 400MG	N010971	003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN			
BRISTOL MYERS SQUIBB	0.3MG	A083266	001
	0.625MG	A083266	002
	1.25MG	A083266	003
	2.5MG	A083266	004
ESTERIFIED ESTROGENS			
PVT FORM	0.625MG	A083414	001
	1.25MG	A083765	001
	2.5MG	A085907	001
SANDOZ	1.25MG	A085302	001
ESTRATAB			
SOLVAY	0.3MG	A086715	001
	0.625MG	A083209	001
	1.25MG	A083856	001
	2.5MG	A083857	001
EVEX			
ROCHE PALO	0.625MG	A084215	001
	1.25MG	A083376	002
FEMOGEN			
PVT FORM	0.625MG	A085076	001
	1.25MG	A085008	001
	2.5MG	A085007	001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE			
WYETH AYERST	2MG/ML	A083488	001
ESTRONE			
WATSON LABS	2MG/ML	A083397	001
	5MG/ML	A085239	001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
WATSON LABS	2MG/ML	A085237	001 Nov 23, 1982
THEELIN			
PARKEDALE	1MG/ML	N003977	001
	2MG/ML	N003977	002
	5MG/ML	N003977	003

ESTROPIPATE

CREAM; VAGINAL

OGEN			
PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001

TABLET; ORAL

ESTROPIPATE			
DURAMED PHARMS BARR	0.75MG	A040296	001 Nov 01, 1999
	1.5MG	A040296	002 Nov 01, 1999
	3MG	A040296	003 Nov 01, 1999
MYLAN	3MG	A040359	003 Aug 26, 1999
ORTHO-EST			
CARACO	0.75MG	A089567	001 Feb 27, 1991
	1.5MG	A089582	001 Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE			
LUPIN LTD	1MG	A091124	001 Sep 13, 2011
	2MG	A091124	002 Sep 13, 2011
	3MG	A091124	003 Sep 13, 2011
TEVA	1MG	A091169	001 May 23, 2011
	2MG	A091169	002 May 23, 2011
	3MG	A091169	003 May 23, 2011
WOCKHARDT LTD	1MG	A091165	001 Jul 14, 2011

DISCONTINUED DRUG PRODUCT LIST

6-125 (of 322)

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

2MG

A091165 002 Jul 14, 2011

3MG

A091165 003 Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

ATON

50MG

N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

WEST WARD

100MG

A075095 001 Nov 30, 1999

400MG

A075095 002 Nov 30, 1999

MYAMBUTOL

STI PHARMA LLC

200MG

N016320 002

500MG

N016320 004

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS

100MG

A084463 001

200MG

A084463 002

500MG

A084463 003

750MG

A084463 004

PLACIDYL

ABBVIE

100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA

500MG

N009750 001

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING

0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN

0.05MG

N016649 001

LYNORAL

ORGANON USA INC

0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG; 1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG; 1MG

N016927 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG; 1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG; 1MG

A072722 001 Dec 30, 1991

TABLET; ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG; 1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG; 1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG; 75MG; 1MG

N018926 001 Jul 18, 1986

DISCONTINUED DRUG PRODUCT LIST

6-126 (of 322)

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG; 75MG; 1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG; 75MG; 2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LYBREL

WYETH PHARMS INC

0.02MG; 0.09MG

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG; 0.25MG

N020946 001 Sep 01, 1998

TABLET; ORAL-21

ALESSE

WYETH PHARMS

0.02MG; 0.1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG; 0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.1
25MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR

0.02MG; 0.1MG

A075803 001 Mar 20, 2002

LEVLITE

BAYER HLTHCARE

0.02MG; 0.1MG

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG; 0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS

0.03MG; 0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM

0.03MG; 0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR

0.03MG; 0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

WYETH PHARMS

0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.1
25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019192 001 Nov 01, 1984

TRIVORA-21

WATSON LABS

0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.1
25MG

A074538 001 Dec 18, 1997

TABLET; ORAL-28

ALESSE

WYETH PHARMS

0.02MG; 0.1MG

N020683 002 Mar 27, 1997

LEVLITE

BAYER HLTHCARE

0.02MG; 0.1MG

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG; 0.1MG

A075862 002 Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC

0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.1
25MG

N019190 001 Nov 01, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR

0.035MG; 0.4MG

A076198 001 Apr 22, 2004

BREVICON 21-DAY

WATSON LABS

0.035MG; 0.5MG

N017566 001

GENCEPT 10/11-21

BARR

0.035MG; 0.035MG; 0.5MG; 1MG

A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM

0.035MG; 0.5MG

N017488 001

N.E.E. 1/35 21

LPI

0.035MG; 1MG

A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071545 001 Feb 09, 1989

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG; 0.5MG

A070684 001 Jan 29, 1987

NORTREL 0.5/35-21

BARR

0.035MG; 0.5MG

A072692 001 Feb 28, 1992

DISCONTINUED DRUG PRODUCT LIST

6-127 (of 322)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

ORTHO-NOVUM 1/35-21				
ORTHO MCNEIL PHARM	0.035MG;1MG	N017489	002	
ORTHO-NOVUM 10/11-21				
ORTHO MCNEIL JANSSEN	0.035MG;0.035MG;0.5MG;1MG	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21				
ORTHO MCNEIL PHARM	0.035MG;0.035MG;0.5MG;1MG	N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21				
JANSSEN PHARMS	0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG	N018985	001	Apr 04, 1984
OVCON-35				
WARNER CHILCOTT	0.035MG;0.4MG	N018127	001	
OVCON-50				
WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY				
WATSON LABS	0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG	N018977	001	Apr 13, 1984

TABLET; ORAL-28

GENCEPT 10/11-28				
BARR	0.035MG;0.035MG;0.5MG;1MG	A072697	001	Feb 28, 1992
N.E.E. 1/35 28				
LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28				
ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
ORTHO-NOVUM 10/11-28				
ORTHO MCNEIL JANSSEN	0.035MG;0.035MG;0.5MG;1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28				
ORTHO MCNEIL PHARM	0.035MG;0.035MG;0.5MG;1MG	N019004	002	Apr 04, 1984
OVCON-50				
WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013

TABLET; ORAL

FEMHRT				
WARNER CHILCOTT LLC	0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021065	002	Oct 15, 1999

TABLET; ORAL-21

ESTROSTEP 21				
WARNER CHILCOTT LLC	0.02MG;0.035MG;0.03MG;1MG;1MG;1MG	N020130	001	Oct 09, 1996
NORLESTRIN 21 1/50				
PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50				
PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TABLET; ORAL-28				
NORLESTRIN 28 1/50				
PARKE DAVIS	0.05MG;1MG	N016723	001	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO CYCLEN-21				
JANSSEN PHARMS	0.035MG;0.25MG	N019653	001	Dec 29, 1989
ORTHO TRI-CYCLEN				
JANSSEN PHARMS	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	N019697	002	Jul 03, 1992
TABLET; ORAL-28				
TRI LO SPRINTAC				
BARR LABS INC	0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG	A076784	001	Jun 29, 2009

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL				
WYETH PHARMS INC	0.03MG;0.3MG	N017612	001	
OGESTREL 0.5/50-21				
WATSON LABS	0.05MG;0.5MG	A075406	001	Dec 15, 1999
OVRAL				
WYETH PHARMS	0.05MG;0.5MG	N016672	001	

DISCONTINUED DRUG PRODUCT LIST

6-128 (of 322)

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

OVRAL-28

WYETH PHARMS

0.05MG; 0.5MG

N016806 001

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

GUERBET

99%

N009190 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS

10MG

N009078 003

50MG

N009078 006

100MG

N009078 008

ETHOTOIN

TABLET; ORAL

PEGANONE

RECORDATI RARE

500MG

N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN

62.5MG

N011047 002

125MG

N011047 001

ETHAMIDE

ALLERGAN

125MG

N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC

2MG/5ML

N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC

2MG

N014005 002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC

1MG; 0.1MG

N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC

1MG; 0.1MG

N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC

1MG; 0.1MG

N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.5%

N017751 003

1%

N017751 005

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AAIPHARMA LLC

300MG

A074929 001 Jan 30, 1998

IVAX SUB TEVA PHARMS

200MG

A074899 001 Jul 08, 1997

300MG

A074899 002 Jul 08, 1997

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074840 001 Aug 29, 1997

200MG

A074942 001 Sep 30, 1997

300MG

A074840 002 Aug 29, 1997

300MG

A074942 002 Sep 30, 1997

TEVA

200MG

A075126 001 Sep 16, 1999

VINTAGE PHARMS LLC

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

DISCONTINUED DRUG PRODUCT LIST

6-129 (of 322)

ETODOLAC

CAPSULE; ORAL

ETODOLAC

WATSON LABS	200MG	A074844 001	Dec 23, 1997
	300MG	A074844 002	Dec 23, 1997

LODINE

WYETH PHARMS INC	200MG	N018922 002	Jan 31, 1991
	300MG	N018922 003	Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC	400MG	A074927 001	Oct 30, 1997
IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997
	500MG	A074883 002	Nov 20, 1998
MYLAN	400MG	A075012 001	Sep 30, 1998
	500MG	A075012 002	Sep 30, 1998
PROSAM LABS	400MG	A074819 001	Feb 28, 1997
	500MG	A074819 002	Apr 28, 1998
RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
	500MG	A075226 002	Nov 24, 1998
SANDOZ	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
TEVA	400MG	A074847 001	Apr 23, 1999
	500MG	A074847 002	Apr 23, 1999
VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

LODINE

WYETH PHARMS INC	400MG	N018922 004	Jul 29, 1993
	500MG	N018922 005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
SANDOZ	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG	N020584 001	Oct 25, 1996
	500MG	N020584 003	Jan 20, 1998
	600MG	N020584 002	Oct 25, 1996

ETOPOSIDE

CAPSULE; ORAL

VEPESID

CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986
	100MG	N019557 002	Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA	20MG/ML	A074320 001	Aug 30, 1995
	20MG/ML	A074351 001	Aug 30, 1995
MARSAM PHARMS LLC	20MG/ML	A074968 001	Jan 09, 1998
PHARMACHEMIE	20MG/ML	A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510 001	Jun 29, 1995
WATSON LABS	20MG/ML	A074228 001	Oct 15, 1996

TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166 001	Feb 27, 1995

VEPESID

CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 1GM BASE/VIAL	N020906 002	Feb 27, 1998
	EQ 500MG BASE/VIAL	N020906 001	Feb 27, 1998

DISCONTINUED DRUG PRODUCT LIST

6-130 (of 322)

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG

N019369 001 Sep 30, 1986

25MG

N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS

0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008041 001

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC

10MG/ML

A075942 001 Aug 02, 2002

APOTHECON

10MG/ML

A075707 001 Apr 16, 2001

HIKMA MAPLE

10MG/ML

A075799 001 Apr 30, 2002

HOSPIRA

10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075870 001 Nov 23, 2001

10MG/ML

A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC

10MG/ML

A076324 001 Nov 27, 2002

APOTHECON

10MG/ML

A075708 001 Apr 16, 2001

HIKMA MAPLE

10MG/ML

A075789 001 Apr 30, 2002

HOSPIRA

10MG/ML

A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC

10MG/ML

A076322 001 Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE

0.4MG/ML

A075729 001 Dec 17, 2001

PEPCID

MERCK

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019510 001 Nov 04, 1986

PEPCID PRESERVATIVE FREE

MERCK

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019510 004 Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME

0.4MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020249 001 Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH

20MG

A075650 001 Sep 14, 2001

40MG

A075650 002 Sep 14, 2001

APOTEX

10MG

A075610 001 Mar 12, 2002

MUTUAL PHARM

20MG

A075639 002 Dec 12, 2001

40MG

A075639 001 Dec 12, 2001

MYLAN PHARMS INC

20MG

A075457 001 Apr 18, 2001

40MG

A075457 002 Apr 18, 2001

SANDOZ

10MG

A076101 001 Oct 21, 2002

20MG

A075302 001 Apr 16, 2001

20MG

A075607 001 May 10, 2001

20MG

A075793 001 Apr 16, 2001

40MG

A075302 002 Apr 16, 2001

40MG

A075607 002 May 10, 2001

40MG

A075793 002 Apr 16, 2001

WATSON LABS

20MG

A075062 002 Apr 16, 2001

40MG

A075062 001 Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

MCNEIL CONS

10MG

N020801 001 Sep 24, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC

20MG

N021712 001 Sep 24, 2004

40MG

N021712 002 Sep 24, 2004

PEPCID RPD

MERCK

20MG

N020752 001 May 28, 1998

40MG

N020752 002 May 28, 1998

DISCONTINUED DRUG PRODUCT LIST

6-131 (of 322)

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS

87MG

N021695 002 Nov 30, 2004

LIPIDIL

ABBVIE

100MG

N019304 001 Dec 31, 1993

LIPOFEN

CIPHER PHARMS INC

100MG

N021612 002 Jan 11, 2006

TRICOR (MICRONIZED)

ABBVIE

67MG

N019304 002 Feb 09, 1998

134MG

N019304 003 Jun 30, 1999

200MG

N019304 004 Jun 30, 1999

TABLET; ORAL

FENOFIBRATE

MYLAN

107MG

A076520 002 Dec 29, 2005

TRICOR

ABBOTT

54MG

N021203 001 Sep 04, 2001

160MG

N021203 003 Sep 04, 2001

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

LUITPOLD

EQ 10MG BASE/ML

A076656 001 Dec 01, 2003

TEVA PARENTERAL

EQ 10MG BASE/ML

A077826 001 Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP

EQ 200MG BASE

A072307 001 Aug 22, 1988

EQ 300MG BASE

A072308 001 Aug 22, 1988

HALSEY

EQ 200MG BASE

A072355 001 Aug 17, 1988

EQ 300MG BASE

A072356 001 Aug 17, 1988

PAR PHARM

EQ 200MG BASE

A072437 001 Aug 22, 1988

EQ 300MG BASE

A072438 001 Aug 22, 1988

QUANTUM PHARMICS

EQ 200MG BASE

A072214 001 Aug 17, 1988

EQ 300MG BASE

A071738 001 Aug 17, 1988

SANDOZ

EQ 200MG BASE

A072394 001 Oct 17, 1988

EQ 300MG BASE

A072395 001 Oct 17, 1988

WARNER CHILCOTT

EQ 200MG BASE

A072946 001 Apr 30, 1991

EQ 300MG BASE

A072472 001 Apr 30, 1991

WATSON LABS

EQ 200MG BASE

A072294 001 Aug 17, 1988

EQ 200MG BASE

A072981 001 Aug 19, 1991

EQ 300MG BASE

A072293 001 Aug 17, 1988

EQ 300MG BASE

A072982 001 Aug 19, 1991

NALFON

XSPIRE

EQ 300MG BASE

N017604 002

TABLET; ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A072274 001 May 02, 1988

AM THERAP

EQ 600MG BASE

A072309 001 Aug 17, 1988

CLONMEL HLTHCARE

EQ 600MG BASE

A072326 001 Aug 17, 1988

HALSEY

EQ 600MG BASE

A072357 001 Aug 17, 1988

IVAX SUB TEVA PHARMS

EQ 600MG BASE

A072557 001 Aug 29, 1988

MUTUAL PHARM

EQ 600MG BASE

A072902 001 Dec 21, 1990

PAR PHARM

EQ 600MG BASE

A072429 001 Aug 17, 1988

QUANTUM PHARMICS

EQ 600MG BASE

A072194 001 Aug 17, 1988

SANDOZ

EQ 600MG BASE

A072396 001 Oct 17, 1988

USL PHARMA

EQ 600MG BASE

A072362 001 Aug 17, 1988

WATSON LABS

EQ 600MG BASE

A072165 001 Aug 17, 1988

EQ 600MG BASE

A072407 001 Aug 17, 1988

EQ 600MG BASE

A072602 001 Oct 11, 1988

NALFON

DISTA

EQ 600MG BASE

N017710 001

FENTANYL CITRATE

FILM; BUCCAL

ONSOLIS

MEDA PHARMS

EQ 0.2MG BASE

N022266 001 Jul 16, 2009

EQ 0.4MG BASE

N022266 002 Jul 16, 2009

EQ 0.6MG BASE

N022266 003 Jul 16, 2009

EQ 0.8MG BASE

N022266 004 Jul 16, 2009

EQ 1.2MG BASE

N022266 005 Jul 16, 2009

DISCONTINUED DRUG PRODUCT LIST

6-132 (of 322)

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

MARSAM PHARMS LLC

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

TABLET; BUCCAL, SUBLINGUAL

FENTORA

CEPHALON

EQ 0.3MG BASE

N021947 006 Mar 02, 2007

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

INCLINE THERAP

10.8MCG

N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG; 0.33MG

N006012 003

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

FERUMOXSYL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US

60MG

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001 Jul 13, 2005

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE

154uCi/VIAL

N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT

140uCi/ML

N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS

5MG

A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS

ORTHO MCNEIL JANSSEN

100MG

N016769 001

DISCONTINUED DRUG PRODUCT LIST

6-133 (of 322)

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC

50MG

A079164 001 Jul 09, 2009

100MG

A079164 002 Jul 09, 2009

150MG

A079164 003 Jul 09, 2009

SANDOZ

50MG

A076030 001 Oct 28, 2002

100MG

A076030 002 Oct 28, 2002

150MG

A076030 003 Oct 28, 2002

TAMBOCOR

MEDICIS

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018830 004 Aug 23, 1988

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018830 001 Oct 31, 1985

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018830 003 Jun 03, 1988

200MG

N018830 002 Oct 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

HOSPIRA

500MG/VIAL

N016929 001

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

TARO PHARM INDS

50MG/5ML

A076918 001 Dec 18, 2006

200MG/5ML

A076918 002 Dec 18, 2006

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AGILA SPECLTS

200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AGILA SPECLTS

200MG/100ML (2MG/ML)

A076889 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076889 002 Mar 25, 2005

HOSPIRA

200MG/100ML (2MG/ML)

A076617 001 Jul 29, 2004

400MG/200ML (2MG/ML)

A076617 002 Jul 29, 2004

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA

50MG

A076432 001 Jul 29, 2004

100MG

A076432 002 Jul 29, 2004

150MG

A076432 003 Jul 29, 2004

200MG

A076432 004 Jul 29, 2004

HARRIS PHARM

50MG

A078423 001 Mar 07, 2011

100MG

A078423 002 Mar 07, 2011

150MG

A078423 003 Mar 07, 2011

200MG

A078423 004 Mar 07, 2011

MYLAN PHARMS INC

50MG

A076042 001 Jul 29, 2004

100MG

A076042 002 Jul 29, 2004

150MG

A076042 003 Jul 29, 2004

200MG

A076042 004 Jul 29, 2004

PLIVA

50MG

A076424 001 Jul 29, 2004

100MG

A076424 002 Jul 29, 2004

150MG

A076424 003 Jul 29, 2004

200MG

A076424 004 Jul 29, 2004

RANBAXY LABS LTD

50MG

A076386 001 Jul 29, 2004

100MG

A076386 002 Jul 29, 2004

150MG

A076386 003 Jul 29, 2004

200MG

A076386 004 Jul 29, 2004

ROXANE

50MG

A076213 001 Jul 29, 2004

100MG

A076213 002 Jul 29, 2004

150MG

A076213 003 Jul 29, 2004

200MG

A076213 004 Jul 29, 2004

SANDOZ

50MG

A076086 001 Jul 29, 2004

100MG

A076086 002 Jul 29, 2004

150MG

A076086 003 Jul 29, 2004

200MG

A076086 004 Jul 29, 2004

DISCONTINUED DRUG PRODUCT LIST

6-134 (of 322)

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

GENZYME CORP

50MG/VIAL

N020038 001 Apr 18, 1991

TABLET; ORAL

OFORTA

SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

DOWNSTATE CLINCL

4-40mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020306 001 Aug 19, 1994

4-90mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020306 002 Sep 25, 2001

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

CITRON PHARMA LLC

0.1MG

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

APOTEX INC

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004

TEVA PHARMS USA

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

ROMAZICON

HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML)

N020073 001 Dec 20, 1991

0.5MG/5ML (0.1MG/ML)

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

DISCONTINUED DRUG PRODUCT LIST

6-135 (of 322)

FLUOCINOLONE ACETONIDE

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT 0.025% A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM 0.025% A088046 001 Dec 16, 1982

PHARMAFAIR 0.025% A088507 001 Feb 27, 1984

USL PHARMA 0.025% A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT 0.025% A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS 0.025% A088172 001 Mar 09, 1983

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.01% A087159 001 Jun 16, 1982

BAUSCH AND LOMB 0.01% A040059 001 Dec 20, 1993

MORTON GROVE 0.01% A088312 001 Jan 27, 1984

PHARMADERM 0.01% A088048 001 Dec 16, 1982

PHARMAFAIR 0.01% A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT 0.01% A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS 0.01% A088171 001 Mar 09, 1983

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

MEDIMETRIKS PHARMS 0.025%; EQ 3.5MG BASE/GM A060700 001

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK 0.05% A071790 001 Jul 13, 1988

TARO 0.05% A071500 001 Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC 0.05% A074204 001 Jun 13, 1995

LIDEX

CNTY LINE PHARMS 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N016908 002

LIDEX-E

CNTY LINE PHARMS 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N016908 003

GEL; TOPICAL

LIDEX

CNTY LINE PHARMS 0.05% N017373 001

OINTMENT; TOPICAL

LIDEX

CNTY LINE PHARMS 0.05% N016909 002

SOLUTION; TOPICAL

FLUOCINONIDE

TARO 0.05% A072857 001 Aug 02, 1989

TEVA PHARMS 0.05% A072522 001 Sep 28, 1990

LIDEX

CNTY LINE PHARMS 0.05% N018849 001 Apr 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS 25% N017869 001

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN 0.025% N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS 0.1% A070185 001 Feb 27, 1986

DISCONTINUED DRUG PRODUCT LIST

6-136 (of 322)

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRASONE

ALCON

0.1%;0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS;OPHTHALMIC

FML-S

ALLERGAN

0.1%;10%

N019525 001 Sep 29, 1989

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN

50MG/ML

A081222 001 Jun 28, 1991

50MG/ML

N017959 001

TEVA PARENTERAL

50MG/ML

A040023 001 Oct 18, 1991

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC

50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM

50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

A089519 001 Mar 12, 1987

50MG/ML

A089508 001 Jan 26, 1988

FRESENIUS KABI USA

50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

A040379 001 Nov 15, 2000

MARCHAR

50MG/ML

A087791 001 Jan 18, 1983

SMITH AND NEPHEW

50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

SPECTRUM PHARMS

50MG/ML

A087792 001 Oct 13, 1982

VALEANT

500MG/10ML (50MG/ML)

N012209 001

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC

1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

MUTUAL PHARMA

EQ 10MG BASE

A075787 001 Jan 29, 2002

EQ 20MG BASE

A075787 002 Jan 29, 2002

WATSON LABS

EQ 10MG BASE

A075662 001 Jan 29, 2002

EQ 20MG BASE

A075662 002 Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

BARR

EQ 40MG BASE

A076251 001 May 18, 2005

CARLSBAD

EQ 10MG BASE

A076022 001 Jan 30, 2002

EQ 20MG BASE

A076022 002 Jan 30, 2002

CR DOUBLE CRANE

EQ 10MG BASE

A076165 001 Feb 01, 2002

EQ 20MG BASE

A076165 002 Feb 01, 2002

PAR PHARM

EQ 10MG BASE

A076922 001 Dec 16, 2004

EQ 20MG BASE

A076922 002 Dec 16, 2004

SANDOZ

EQ 10MG BASE

A075807 001 Jan 29, 2002

EQ 20MG BASE

A075807 002 Jan 29, 2002

WOCKHARDT LTD

EQ 10MG BASE

A078143 001 Jan 16, 2008

EQ 20MG BASE

A078143 002 Jan 16, 2008

EQ 40MG BASE

A078143 003 Jan 16, 2008

PROZAC

ELI LILLY AND CO

EQ 60MG BASE

N018936 004 Jun 15, 1999

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 20MG BASE/5ML

A075690 001 Jan 31, 2002

APOTEX INC

EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002

HI TECH PHARMA

EQ 20MG BASE/5ML

A075525 001 Jun 27, 2002

PROZAC

LILLY

EQ 20MG BASE/5ML

N020101 001 Apr 24, 1991

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR

EQ 10MG BASE

A075810 001 Feb 01, 2002

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075865 001 Feb 28, 2002

EQ 40MG BASE

A075865 003 Aug 30, 2004

SANDOZ

EQ 10MG BASE

A076024 001 Jan 29, 2002

PROZAC

LILLY

EQ 10MG BASE

N020974 001 Mar 09, 1999

EQ 20MG BASE

N020974 002 Mar 09, 1999

DISCONTINUED DRUG PRODUCT LIST

6-137 (of 322)

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983
HALOTESTIN				
PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	
ORA-TESTRYL				
BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001
HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
BRISTOL MYERS SQUIBB	25MG/ML	N016727	001	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110	001	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
APOTHECON	2.5MG/5ML	N012145	003	

INJECTABLE; INJECTION

PROLIXIN

APOTHECON	2.5MG/ML	N011751	005	

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987
PERMITIL				
SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	

PROLIXIN

APOTHECON	1MG	N011751	004	
	2.5MG	N011751	001	
	5MG	N011751	003	
	10MG	N011751	002	

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING	1MG	N012419	004	

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN	1.5MG	N012259	002	

DISCONTINUED DRUG PRODUCT LIST

6-138 (of 322)

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS

0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS

0.025% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012806 004

0.05% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012806 001

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

LILLY

0.05%; EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN-N

LILLY

0.05%; EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL

15MG

N016721 001

30MG

N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

MUTUAL PHARM

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

PAR PHARM

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SANDOZ

15MG

A071716 001 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

WATSON LABS

15MG

A072368 001 Mar 30, 1989

WEST WARD

15MG

A071107 001 Dec 08, 1986

30MG

A071108 001 Dec 08, 1986

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS

50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

PLIVA

50MG

A074647 001 Apr 01, 1997

100MG

A074647 002 Apr 01, 1997

SANDOZ

50MG

A074448 001 Jul 28, 1995

100MG

A074448 002 Jul 28, 1995

TEVA

50MG

A074405 002 May 24, 1995

100MG

A074405 001 May 24, 1995

THERAGEN

100MG

A074560 002 May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING

125MG

N018554 001 Jan 27, 1989

FLUTAMIDE

SANDOZ

125MG

A075818 001 Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020548 001 Mar 27, 1996

0.11MG/INH

N020548 002 Mar 27, 1996

0.22MG/INH

N020548 003 Mar 27, 1996

DISCONTINUED DRUG PRODUCT LIST

6-139 (of 322)

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

FOUGERA PHARMS

0.05%

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

CARACO

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

IVAX SUB TEVA PHARMS

25MG

A075898 001 Mar 12, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075898 003 Mar 12, 2001

MUTUAL PHARM

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

MYLAN

50MG

A075950 001 Oct 15, 2001

100MG

A075950 002 Oct 15, 2001

SANDOZ

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

WATSON LABS

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

LUVOX

SOLVAY

25MG

N020243 001 Dec 05, 1994

50MG

N020243 002 Dec 05, 1994

100MG

N020243 003 Dec 05, 1994

150MG

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

HIKMA (MAPLE)

5MG/ML

N005897 008

TABLET; ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

IMPAX LABS

1MG

A080686 001

IVAX SUB TEVA PHARMS

1MG

A083000 001

LANNETT

1MG

A080816 001

LILLY

1MG

N006135 003

MK LABS

1MG

A083526 001

MUTUAL PHARM

1MG

A040582 001 Jul 18, 2005

NEXGEN PHARMA INC

1MG

A084915 001

PHARMERAL

1MG

A084158 001

PIONEER PHARMS

1MG

A088949 001 Sep 13, 1985

PUREPAC PHARM

1MG

A080784 001

SANDOZ

1MG

A084472 001

TABLICAPS

1MG

A083133 002

UDL

1MG

A088199 001 Mar 29, 1983

USL PHARMA

1MG

A087828 001 May 13, 1982

VALEANT PHARM INTL

1MG

A080903 001

DISCONTINUED DRUG PRODUCT LIST

6-140 (of 322)

FOLIC ACID

TABLET; ORAL

FOLIC ACID

VANGARD	1MG	A088730 001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296 001	
WATSON LABS	1MG	A083141 001	
	1MG	A085141 002	
WHITEWORTH TOWN PLSN	1MG	A080691 002	
FOLICET			
MISSION PHARMA	1MG	A087438 001	
FOLVITE			
HIKMA (MAPLE)	1MG	N005897 004	

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582 001	Sep 29, 1997
	150 IU/VIAL	N020582 002	Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC	150 IU/0.18ML	N021211 003	Feb 11, 2004

GONAL-F

EMD SERONO	37.5 IU/VIAL	N020378 003	May 25, 2000
	37.5 IU/VIAL	N021765 001	Mar 25, 2004
	75 IU/VIAL	N020378 001	Sep 29, 1997
	150 IU/VIAL	N020378 002	Sep 29, 1997
	150 IU/VIAL	N021765 003	Mar 25, 2004

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961 001	Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS	0.0085MG/INH	N021592 001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023 001	Jan 25, 2008

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004
	20MG	A076580 002	Apr 23, 2004
	40MG	A076580 003	Apr 23, 2004
SANDOZ	10MG	A076188 001	Oct 08, 2004
	20MG	A076188 002	Oct 08, 2004
	40MG	A076188 003	Oct 08, 2004
WATSON LABS	10MG	A076987 001	Dec 23, 2004
	20MG	A076987 002	Dec 23, 2004
	40MG	A076987 003	Dec 23, 2004

MONOPRIL

BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991
	20MG	N019915 003	May 16, 1991
	40MG	N019915 004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

MYLAN	10MG; 12.5MG	A077705 001	Aug 14, 2006
	20MG; 12.5MG	A077705 002	Aug 14, 2006
TEVA	10MG; 12.5MG	A076945 001	Jul 05, 2006
	20MG; 12.5MG	A076945 002	Jul 05, 2006
WATSON LABS	10MG; 12.5MG	A077144 001	Aug 16, 2005
	20MG; 12.5MG	A077144 002	Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB	10MG; 12.5MG	N020286 002	Nov 30, 1994
	20MG; 12.5MG	N020286 001	Nov 30, 1994

DISCONTINUED DRUG PRODUCT LIST

6-141 (of 322)

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

PARKE DAVIS

EQ 50MG PHENYTOIN NA/ML

N020450 001 Aug 05, 1996

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML

A078126 001 Aug 06, 2007

TEVA PHARMS USA

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC

1050MG/30ML (35MG/ML)

N022244 001 Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001 Jul 30, 1982

10MG/ML

N019036 001 Aug 13, 1984

ASTRAZENECA

10MG/ML

A070014 001 Sep 09, 1985

10MG/ML

A070095 001 Sep 09, 1985

10MG/ML

A070096 001 Sep 09, 1985

HIKMA MAPLE

10MG/ML

A071439 001 Sep 14, 1990

10MG/ML

N018267 001

HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987

10MG/ML

A072080 001 Aug 13, 1991

10MG/ML

A074337 001 Oct 31, 1994

INTL MEDICATION

10MG/ML

N018025 001

MARSAM PHARMS LLC

10MG/ML

A074017 001 Jun 30, 1994

ORGANON USA INC

10MG/ML

A070017 001 Dec 15, 1986

SMITH AND NEPHEW

10MG/ML

A070023 001 Feb 05, 1986

10MG/ML

A070078 001 Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001 Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001 Sep 22, 1986

10MG/ML

A070604 001 Jan 02, 1987

WYETH AYERST

10MG/ML

N018670 001 Jul 20, 1982

LASIX

SANOFI AVENTIS US

10MG/ML

N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

DAVA PHARMS INC

20MG

N018415 001 Jul 27, 1982

40MG

N018415 002 Jul 27, 1982

80MG

N018415 003 Nov 26, 1984

INTL MEDICATION

20MG

N018753 001 Feb 28, 1984

40MG

N018753 002 Feb 28, 1984

KALAPHARM

20MG

N018868 001 Jun 28, 1983

40MG

N018868 002 Jun 28, 1983

MUTUAL PHARM

20MG

A070043 001 Sep 26, 1985

40MG

N018790 001 Nov 29, 1983

80MG

A070100 001 Jan 26, 1988

SANDOZ

40MG

N018750 002 Jul 30, 1984

SUPERPHARM

20MG

N018370 002 Jun 26, 1984

40MG

N018370 001 Feb 10, 1983

WARNER CHILCOTT

20MG

N018419 001 Jan 31, 1983

40MG

N018419 002 Jan 31, 1983

80MG

N018419 003 Nov 13, 1984

WATSON LABS

20MG

N018369 001 May 14, 1982

40MG

A070413 001 Feb 26, 1986

40MG

N018369 002 May 14, 1982

DISCONTINUED DRUG PRODUCT LIST

6-142 (of 322)

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005

TABLET; ORAL

GABAPENTIN

RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YABAO BIOPHARMS	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001	
	100MG/ML	N007842 002	

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001	
NEOSCAN			
GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE	25MG/ML	N019961 002	Jan 17, 1991

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 002	Dec 12, 1997

GANCICLOVIR

RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003
	500MG	A076457 002	Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB	4.5MG	N020569 001	Mar 04, 1996

DISCONTINUED DRUG PRODUCT LIST

6-143 (of 322)

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

BEDFORD

EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET; ORAL

GEMFIBROZIL

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SANDOZ

600MG

A074615 001 Sep 29, 1995

WATSON LABS

600MG

A074156 001 Oct 24, 1994

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

BAUSCH AND LOMB

EQ 0.1% BASE

A064056 001 Apr 29, 1994

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING

EQ 1MG BASE/ML

A061716 002

EQ 10MG BASE/ML

A061739 001

EQ 40MG BASE/ML

A061716 001

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003 Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004 Aug 11, 1983

EQ 2MG BASE/ML

A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007 Aug 11, 1983

EQ 80MG BASE/100ML

A062413 008 Aug 11, 1983

EQ 90MG BASE/100ML

A062413 009 Aug 11, 1983

EQ 100MG BASE/100ML

A062413 010 Aug 11, 1983

FRESENIUS KABI USA

EQ 10MG BASE/ML

A062356 001 Mar 04, 1982

EQ 40MG BASE/ML

A062356 002 Mar 04, 1982

HIKMA MAPLE

EQ 10MG BASE/ML

A062251 002

DISCONTINUED DRUG PRODUCT LIST

6-144 (of 322)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

	EQ 40MG BASE/ML	A062251	001	
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

SCHERING	EQ 2MG BASE/ML	N050505	001	

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE	A060463	001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
BAUSCH AND LOMB	EQ 0.1% BASE	A064054	001	Apr 29, 1994
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050039	002	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984

GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983

GENTAMICIN SULFATE

ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513	001	

TAMPON; VAGINAL

GENAPAX

KEY PHARMS	5MG	A085017	001	

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996

DISCONTINUED DRUG PRODUCT LIST

6-145 (of 322)

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

COREPHARMA	1MG	A077274	001	Oct 06, 2005
	2MG	A077274	002	Oct 06, 2005
	4MG	A077274	003	Oct 06, 2005
MYLAN	1MG	A077486	001	Feb 10, 2006
	2MG	A077486	002	Feb 10, 2006
	4MG	A077486	003	Feb 10, 2006
RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005
	2MG	A076875	002	Oct 06, 2005
	4MG	A076875	003	Oct 06, 2005
	8MG	A076875	004	Oct 06, 2005

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

BARR LABS INC	5MG	A074619	001	Apr 04, 1997
	10MG	A074619	002	Apr 04, 1997
SANDOZ	5MG	A074542	001	Jun 20, 1995
	10MG	A074542	002	Jun 20, 1995
TEVA	5MG	A074387	001	Mar 04, 1996
	10MG	A074387	002	Mar 04, 1996
VINTAGE PHARMS LLC	5MG	A074378	001	Nov 28, 1994
	10MG	A074378	002	Nov 28, 1994
GLUCOTROL				
PFIZER	2.5MG	N017783	003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

BRISTOL MYERS SQUIBB	2.5MG; 250MG	N021460	001	Oct 21, 2002
	2.5MG; 500MG	N021460	002	Oct 21, 2002
	5MG; 500MG	N021460	003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

LILLY	EQ 1MG BASE/VIAL	N012122	001	
	EQ 10MG BASE/VIAL	N012122	002	

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	

TABLET; ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
SANDOZ	500MG	A083234	002	
UCB INC	500MG	A085171	001	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000

DISCONTINUED DRUG PRODUCT LIST

6-146 (of 322)

GLYBURIDE

TABLET; ORAL

GLYNASE

PHARMACIA AND UPJOHN 4.5MG

N020051 003 Sep 24, 1993

MICRONASE

PHARMACIA AND UPJOHN 1.25MG

N017498 001 May 01, 1984

2.5MG

N017498 002 May 01, 1984

5MG

N017498 003 May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA 1.25MG; 250MG

A076821 001 Jan 27, 2005

2.5MG; 500MG

A076821 002 Jan 27, 2005

5MG; 500MG

A076821 003 Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 1.5GM/100ML

N018522 001 Feb 19, 1982

HOSPIRA 1.5GM/100ML

N017633 001

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM 0.2MG/ML

A088475 001 Jun 12, 1984

HOSPIRA 0.2MG/ML

A089393 001 Jun 15, 1988

TEVA PARENTERAL 0.2MG/ML

A081169 001 Sep 10, 1991

WATSON LABS 0.2MG/ML

A086947 001 Jun 24, 1983

ROBINUL

ROBINS AH 0.2MG/ML

N014764 001

TABLET; ORAL

GLYCOPYRROLATE

COREPHARMA 1MG

A040568 001 Dec 22, 2004

2MG

A040568 002 Dec 22, 2004

WATSON LABS 1MG

A085562 001

1MG

A086902 001

2MG

A085563 001

2MG

A086178 001

2MG

A086900 001

WEST WARD 1MG

A040836 001 Mar 05, 2009

2MG

A040836 002 Mar 05, 2009

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING 0.8MG/VIAL

N019687 001 Oct 10, 1989

3.2MG/VIAL

N019687 002 Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA (MAPLE) EQ 0.1MG BASE/VIAL

N018123 001 Sep 30, 1982

EQ 0.2MG BASE/VIAL

N018123 002 Sep 30, 1982

EQ 0.5MG BASE/VIAL

N018123 003 Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING 5,000 UNITS/VIAL

N017055 001

10,000 UNITS/VIAL

N017055 002

20,000 UNITS/VIAL

N017055 003

CHORIONIC GONADOTROPIN

BEL MAR 5,000 UNITS/VIAL

N017054 001

10,000 UNITS/VIAL

N017054 002

FERRING 2,000 UNITS/VIAL

N017016 009 Dec 27, 1984

2,000 UNITS/VIAL

N017016 011 Feb 16, 1990

5,000 UNITS/VIAL

N017016 006

15,000 UNITS/VIAL

N017016 010 Feb 15, 1985

20,000 UNITS/VIAL

N017016 004

FRESENIUS KABI USA 5,000 UNITS/VIAL

N017067 001

15,000 UNITS/VIAL

N017067 004

20,000 UNITS/VIAL

N017067 003

FOLLUTEIN

BRISTOL MYERS SQUIBB 10,000 UNITS/VIAL

N017056 001

DISCONTINUED DRUG PRODUCT LIST

6-147 (of 322)

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEO-POLYCIN

DOW PHARM

0.025MG/ML;EQ 1.75MG BASE/ML;10,000
UNITS/ML

A060427 001

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM

0.025MG/ML;EQ 1.75MG BASE/ML;10,000
UNITS/ML

A062818 001 Oct 11, 1988

WATSON LABS

0.025MG/ML;EQ 1.75MG BASE/ML;10,000
UNITS/ML

A062788 001 Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR

0.025MG/ML;EQ 1.75MG BASE/ML;10,000
UNITS/ML

A062383 001 Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

APOTEX INC

EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

A078197 001 Dec 31, 2007

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078198 001 Jun 30, 2008

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A078198 002 Jun 30, 2008

EBEWE PHARMA

EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

A078808 001 Apr 29, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PHARMS USA

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A077165 001 Dec 31, 2007

KYTRIL

ROCHE

EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

N020239 003 Sep 17, 2004

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N020239 004 Mar 11, 1994

EQ 3MG BASE/ML

N020239 001 Dec 29, 1993

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N020239 002 Mar 11, 1994

SOLUTION;ORAL

KYTRIL

ROCHE

EQ 2MG BASE/10ML

N021238 001 Jun 27, 2001

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

BARR

EQ 1MG BASE

A078221 001 Dec 31, 2007

KYTRIL

ROCHE

EQ 1MG BASE

N020305 001 Mar 16, 1995

EQ 2MG BASE

N020305 002 Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL

RAXAR

OTSUKA

EQ 200MG BASE

N020695 001 Nov 06, 1997

EQ 400MG BASE

N020695 002 May 14, 1998

EQ 600MG BASE

N020695 003 May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL

GRISACTIN

WYETH AYERST

125MG

N050051 002

250MG

N050051 001

SUSPENSION;ORAL

GRIFULVIN V

JOHNSON AND JOHNSON

125MG/5ML

N050448 001

TABLET;ORAL

FULVICIN-U/F

ELORAC

250MG

A060569 002

500MG

A060569 001

GRIFULVIN V

J AND J

125MG

A060618 001

250MG

A060618 002

500MG

A060618 003

VALEANT LUXEMBOURG

125MG

A062279 001

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A062279 002

GRISACTIN

WYETH AYERST

500MG

A060212 001

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

ELORAC

125MG

A061996 001

250MG

A061996 002

DISCONTINUED DRUG PRODUCT LIST

6-148 (of 322)

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G 165				
ELORAC	165MG	A061996	003	Apr 06, 1982
FULVICIN P/G 330				
ELORAC	330MG	A061996	004	Apr 06, 1982
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

SANDOZ	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074267	002	Jun 01, 1994
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994
WYTENSIN				
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN				
NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS	10MG; 25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
	EQ 2MG BASE	A074762	002	Jun 25, 1997
TENEX				
PROMIUS PHARMA	EQ 3MG BASE	N019032	003	Nov 07, 1988

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING	20MG	N017736	003	
	40MG	N017736	004	

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB	0.025%	N017818	001	
HALOG-E				
RANBAXY	0.1%	N018234	001	

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB	0.025%	N018125	001	

DISCONTINUED DRUG PRODUCT LIST

6-149 (of 322)

HALCINONIDE

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

G AND W LABS INC

0.05%

A077109 001 Jun 14, 2005

TARO

0.05%

A076994 001 Dec 16, 2004

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

10MG

A071173 001 Jan 07, 1988

20MG

A071177 001 Jan 07, 1988

PAR PHARM

20MG

A071328 001 Jul 20, 1987

PUREPAC PHARM

0.5MG

A071071 001 Nov 03, 1986

1MG

A071072 001 Nov 03, 1986

2MG

A071073 001 Nov 03, 1986

5MG

A071074 001 Nov 03, 1986

10MG

A071075 001 Aug 04, 1987

20MG

A071076 001 Aug 04, 1987

QUANTUM PHARMICS

0.5MG

A071255 001 Feb 17, 1987

1MG

A071269 001 Feb 17, 1987

2MG

A071256 001 Feb 17, 1987

5MG

A071257 001 Feb 17, 1987

ROXANE

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

2MG

A071130 001 Feb 17, 1987

5MG

A071131 001 Feb 17, 1987

10MG

A071132 001 May 12, 1987

20MG

A071133 001 May 12, 1987

ROYCE LABS

0.5MG

A071722 001 Dec 24, 1987

1MG

A071723 001 Dec 24, 1987

2MG

A071724 001 Dec 24, 1987

5MG

A071725 001 Dec 24, 1987

10MG

A072121 001 Dec 24, 1987

20MG

A072122 001 Dec 24, 1987

SCS

0.5MG

A070720 001 Jun 10, 1986

1MG

A070721 001 Jun 10, 1986

2MG

A070722 001 Jun 10, 1986

5MG

A070723 001 Jun 10, 1986

DISCONTINUED DRUG PRODUCT LIST

6-150 (of 322)

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000
	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000
HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987

HALOPERIDOL INTENSOL

ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942	001	

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943	001	

DISCONTINUED DRUG PRODUCT LIST

6-151 (of 322)

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST

99.99%

N011338 001

HALOTHANE

BH

99.99%

A084977 001

HALOCARBON

99.99%

A080810 001

HOSPIRA

99.99%

A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US

25,000 UNITS/ML

N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA

100 UNITS/ML

N005264 010

INTL MEDICATION

10 UNITS/ML

A086357 001

500 UNITS/ML

A086357 002

LUITPOLD

10 UNITS/ML

A089063 001

Oct 09, 1985

100 UNITS/ML

A089064 001

Oct 09, 1985

PARKE DAVIS

10 UNITS/ML

N017346 006

SMITH AND NEPHEW

10 UNITS/ML

A087904 001

Apr 20, 1983

10 UNITS/ML

A087958 001

Apr 20, 1983

10 UNITS/ML

A088458 001

Jul 26, 1984

10 UNITS/ML

A088580 001

Oct 25, 1984

100 UNITS/ML

A087906 001

Apr 20, 1983

100 UNITS/ML

A087959 001

Apr 20, 1983

100 UNITS/ML

A088460 001

Jul 26, 1984

100 UNITS/ML

A088581 001

Oct 25, 1984

SOLOPAK

10 UNITS/ML

A087903 001

Apr 20, 1983

10 UNITS/ML

A088457 001

Oct 25, 1984

100 UNITS/ML

A087905 001

Apr 20, 1983

100 UNITS/ML

A088459 001

Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM

1,000 UNITS/ML

N017033 001

1,000 UNITS/ML

N017979 001

5,000 UNITS/ML

N017979 003

10,000 UNITS/ML

N017979 002

AKORN

1,000 UNITS/ML

N017486 001

5,000 UNITS/ML

N017486 002

10,000 UNITS/ML

N017486 003

20,000 UNITS/ML

N017486 004

40,000 UNITS/ML

N017486 005

BAXTER HLTHCARE CORP

1,000 UNITS/ML

N017007 001

2,500 UNITS/ML

N017007 007

5,000 UNITS/ML

N017007 002

5,000 UNITS/0.5ML

N017007 010

7,500 UNITS/ML

N017007 003

10,000 UNITS/ML

N017007 004

15,000 UNITS/ML

N017007 005

20,000 UNITS/ML

N017007 006

CHAMBERLIN PARENTERL

1,000 UNITS/ML

N017130 001

5,000 UNITS/ML

N017130 002

10,000 UNITS/ML

N017130 003

20,000 UNITS/ML

N017130 004

DELL LABS

1,000 UNITS/ML

N017540 001

5,000 UNITS/ML

N017540 002

10,000 UNITS/ML

N017540 003

20,000 UNITS/ML

N017540 004

40,000 UNITS/ML

N017540 005

FRESENIUS KABI USA

1,000 UNITS/ML

N017651 005

5,000 UNITS/ML

N017029 002

10,000 UNITS/ML

N017651 003

20,000 UNITS/ML

N017651 008

HIKMA MAPLE

5,000 UNITS/0.5ML

N017037 013

Apr 07, 1986

HOSPIRA

2,500 UNITS/ML

A088099 001

Apr 28, 1983

10,000 UNITS/ML

A040095 001

Jul 26, 1996

LILLY

1,000 UNITS/ML

N005521 001

10,000 UNITS/ML

N005521 002

20,000 UNITS/ML

N005521 004

LUITPOLD

1,000 UNITS/ML

A087452 001

Oct 31, 1983

DISCONTINUED DRUG PRODUCT LIST

6-152 (of 322)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

MARSAM PHARMS LLC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985

DISCONTINUED DRUG PRODUCT LIST

6-153 (of 322)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802 005	Jul 20, 1992
	10,000 UNITS/100ML	N019802 002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911 004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135 001	Mar 29, 1985
	5,000 UNITS/100ML	N019802 003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916 009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609 003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130 002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911 002	Jan 30, 1985
	100 UNITS/ML	N018916 004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	1,000 UNITS/100ML	N018916 001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	1,000 UNITS/100ML	N019042 004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE			
HOSPIRA	2,000 UNITS/ML	N005264 013	Apr 07, 1986
	2,500 UNITS/ML	N005264 014	Apr 07, 1986
MARSAM PHARMS LLC	1,000 UNITS/ML	A089464 001	Jun 03, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129 001	
LIPO-HEPIN			
3M	1,000 UNITS/0.5ML	N017027 001	
	1,000 UNITS/ML	N017027 006	
	5,000 UNITS/0.5ML	N017027 002	
	5,000 UNITS/ML	N017027 008	
	7,500 UNITS/0.5ML	N017027 010	
	10,000 UNITS/0.5ML	N017027 003	
	10,000 UNITS/ML	N017027 009	
	15,000 UNITS/0.5ML	N017027 011	
	20,000 UNITS/0.5ML	N017027 004	
	20,000 UNITS/ML	N017027 007	
	40,000 UNITS/ML	N017027 005	
LIQUAEMIN LOCK FLUSH			
ORGANON USA INC	100 UNITS/ML	N000552 007	
LIQUAEMIN SODIUM			
ORGANON USA INC	1,000 UNITS/ML	N000552 004	
	5,000 UNITS/ML	N000552 003	
	10,000 UNITS/ML	N000552 005	
	20,000 UNITS/ML	N000552 001	
	40,000 UNITS/ML	N000552 002	
LIQUAEMIN SODIUM PRESERVATIVE FREE			
ORGANON USA INC	1,000 UNITS/ML	N000552 011	Apr 11, 1986
	5,000 UNITS/ML	N000552 012	Apr 11, 1986
	10,000 UNITS/ML	N000552 013	Apr 11, 1986
PANHEPRIN			
HOSPIRA	1,000 UNITS/ML	N005264 004	
	5,000 UNITS/ML	N005264 006	
	10,000 UNITS/ML	N005264 007	
	20,000 UNITS/ML	N005264 008	
	40,000 UNITS/ML	N005264 009	
SODIUM HEPARIN			
ABRAXIS PHARM	5,000 UNITS/ML	N017033 002	
	10,000 UNITS/ML	N017033 003	
	20,000 UNITS/ML	N017033 004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036 001	Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001
	EQ 112.5MG AMPICIL/5ML	N050060 001
	EQ 112.5MG AMPICIL/ML	N050060 003
	EQ 225MG AMPICIL/5ML	A061398 002

DISCONTINUED DRUG PRODUCT LIST

6-154 (of 322)

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK

5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

DISCONTINUED DRUG PRODUCT LIST

6-155 (of 322)

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA

10MG

A086308 001

HOMAPIN-5

MISSION PHARMA

5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA

3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS

1.5MG/5ML; 5MG/5ML

N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS

1.5MG/5ML; 5MG/5ML

A040285 001 Jul 19, 1999

HYDROPANE

HALSEY

1.5MG/5ML; 5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS TOTOWA

1.5MG; 5MG

A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS

1.5MG; 5MG

N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC

150 UNITS/ML

N021716 001 Oct 25, 2005

VITRASE

BAUSCH AND LOMB

6,200 UNITS/VIAL

N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE

150 UNITS/ML

N006343 002

150 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N006343 006

1,500 UNITS/VIAL **Federal Register

N006343 005

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS

20MG/ML

N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM

20MG/ML

A089532 001 Aug 11, 1987

SMITH AND NEPHEW

20MG/ML

A088518 001 Apr 20, 1984

SOLOPAK

20MG/ML

A088517 001 Aug 22, 1985

TEVA PARENTERAL

20MG/ML

A040373 001 Feb 23, 2000

TABLET; ORAL

APRESOLINE

NOVARTIS

10MG

N008303 004

25MG

N008303 001

50MG

N008303 002

100MG

N008303 005

DRALZINE

TEVA

25MG

A084301 001

HYDRALAZINE HYDROCHLORIDE

ACTAVIS TOTOWA

25MG

A088560 001 Oct 04, 1984

50MG

A088649 001 Oct 18, 1984

ASCOT

25MG

A088310 001 Dec 19, 1984

50MG

A088311 001 Dec 19, 1984

HALSEY

10MG

A089218 001 Jan 22, 1986

25MG

A089130 001 Jan 15, 1986

50MG

A089222 001 Jan 22, 1986

100MG

A089178 001 Jan 15, 1986

IMPAX LABS

25MG

A084922 001

50MG

A084923 001

IVAX SUB TEVA PHARMS

10MG

A084443 001

25MG

A084437 001

50MG

A084469 002

100MG

A084581 001

MUTUAL PHARM

10MG

A088728 001 Apr 11, 1985

10MG

A089359 001 Jul 25, 1986

DISCONTINUED DRUG PRODUCT LIST

6-156 (of 322)

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	25MG	A084106 002	
	25MG	A089258 001	May 05, 1986
	50MG	A084107 002	
	50MG	A089259 001	May 05, 1986
	100MG	A088729 001	Apr 11, 1985
PUREPAC PHARM	25MG	A088177 001	Jul 29, 1983
	50MG	A088178 001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671 001	May 01, 1984
	25MG	A088657 001	Jun 15, 1984
	50MG	A088652 001	May 08, 1984
	100MG	A088686 001	May 01, 1984
SANDOZ	10MG	A083241 001	
	25MG	A083560 001	
	50MG	A083561 001	
	50MG	A085088 001	
SUPERPHARM	10MG	A088787 001	Aug 28, 1984
	25MG	A088788 001	Aug 28, 1984
	50MG	A088789 001	Aug 28, 1984
TG UNITED LABS	10MG	A088846 001	Feb 26, 1985
	25MG	A088847 001	Feb 26, 1985
	50MG	A088848 001	Feb 26, 1985
	100MG	A088849 001	Feb 26, 1985
USL PHARMA	25MG	A087780 001	Mar 29, 1982
	50MG	A087751 001	Mar 29, 1982
VANGARD	25MG	A087712 001	
	50MG	A087908 001	May 07, 1982
VITARINE	25MG	A086088 001	
WATSON LABS	25MG	A085532 002	May 24, 1982
	50MG	A085533 002	May 25, 1982
WEST WARD	25MG	A088240 001	May 27, 1983
	50MG	A088241 001	May 27, 1983
ZYDUS PHARMS USA	10MG	A040858 001	Feb 26, 2010
	25MG	A040858 002	Feb 26, 2010
	50MG	A040858 003	Feb 26, 2010
	100MG	A040858 004	Feb 26, 2010

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735 001	
	50MG; 50MG	A084810 001	
	100MG; 50MG	A084811 001	
HYDRA-ZIDE			
PAR PHARM	100MG; 50MG	A088961 001	Oct 21, 1985
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE			
SOLVAY	25MG; 25MG	A087608 001	Feb 08, 1982
	50MG; 50MG	A087213 001	Feb 08, 1982
	100MG; 50MG	A087609 001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200 001	Feb 09, 1987
	50MG; 50MG	A089201 001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457 001	Mar 04, 1982
	50MG; 50MG	A085446 001	Mar 04, 1982
	100MG; 50MG	A085440 001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50			
IVAX PHARMS	100MG; 50MG	A088358 001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25			
IVAX PHARMS	25MG; 25MG	A088356 001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50			
IVAX PHARMS	50MG; 50MG	A088357 001	Apr 10, 1984

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026 002	
HYDRALAZINE AND HYDROCHLOROTHIAZIDE			
WATSON LABS	25MG; 15MG	A085827 001	
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE			
WATSON LABS	25MG; 15MG	A085373 001	

DISCONTINUED DRUG PRODUCT LIST

6-157 (of 322)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS 25MG;15MG;0.1MG A084897 001

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A084291 001

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN 25MG;15MG;0.1MG A087085 001

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 25MG;15MG;0.1MG A085771 001

HYDRAP-ES

SANDOZ 25MG;15MG;0.1MG A084876 001

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS 25MG;15MG;0.1MG A083770 001

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A083877 001

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM 25MG;15MG;0.1MG A088570 001 Apr 10, 1984

SOLVAY 25MG;15MG;0.1MG A088376 001 Oct 28, 1983

WATSON LABS 25MG;15MG;0.1MG A085549 001

25MG;15MG;0.1MG A087556 001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE 25MG;15MG;0.1MG A087709 001 May 13, 1982

SER-A-GEN

SOLVAY 25MG;15MG;0.1MG A087210 001

SER-AP-ES

NOVARTIS 25MG;15MG;0.1MG N012193 005

UNIPRES

SOLVAY 25MG;15MG;0.1MG A085893 001

25MG;15MG;0.1MG A086298 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ 25MG;0.1MG A084617 001

SERPASIL-APRESOLINE

NOVARTIS 25MG;0.1MG N009296 004

50MG;0.2MG N009296 002

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

WEST WARD 12.5MG A077885 001 Nov 26, 2007

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE 50MG/5ML A089661 001 Jun 20, 1988

ROXANE 50MG/5ML A088587 001 Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE 100MG/ML A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS 25MG N011793 005

50MG N011793 008

100MG N011793 009

HYDRO-D

HALSEY 25MG A086504 001

50MG A083891 002

HYDROCHLOROTHIAZIDE

ABC HOLDING 50MG A085672 001

ACTAVIS ELIZABETH 25MG A085054 002

50MG A085208 001

ALRA 25MG A086369 001

50MG A083554 001

ASCOT 25MG A087539 001 Feb 03, 1982

50MG A087540 001 Feb 03, 1982

BARR 50MG A084771 001

DAVA PHARMS INC 100MG A087060 001

ELKINS SINN 50MG A085152 002

HEATHER 50MG A084135 001

IMPAX LABS 25MG A084029 001

50MG A083607 002

100MG A085098 001

INWOOD LABS 25MG A084776 001

DISCONTINUED DRUG PRODUCT LIST

6-158 (of 322)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MUTUAL PHARM	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SANDOZ	25MG	A083899	001	
	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	
	50MG	A085219	001	
SOLVAY	25MG	A085323	001	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
TG UNITED LABS	25MG	A085683	001	
	50MG	A083965	001	
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083232	001	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WEST WARD	25MG	A084878	002	Jul 12, 2006
	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRODIURIL				
MERCK	25MG	N011835	003	
	50MG	N011835	006	
	100MG	N011835	007	
ORETIC				
ABBVIE	25MG	N011971	001	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	001	Sep 30, 1997
	25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	004	Mar 15, 2005

DISCONTINUED DRUG PRODUCT LIST

6-159 (of 322)

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

TEVA 25MG; 300MG

A077369 003 Mar 30, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING 25MG; 100MG

N019046 001 Apr 06, 1987

25MG; 200MG

N019046 002 Apr 06, 1987

25MG; 300MG

N019046 003 Apr 06, 1987

25MG; 400MG

N019046 004 Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE 25MG; 100MG

N019174 001 Apr 10, 1987

25MG; 200MG

N019174 002 Apr 10, 1987

25MG; 300MG

N019174 003 Apr 10, 1987

25MG; 400MG

N019174 004 Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ 12.5MG; 10MG

A075926 001 Jul 01, 2002

12.5MG; 20MG

A075926 002 Jul 01, 2002

25MG; 20MG

A075926 003 Jul 01, 2002

TEVA 12.5MG; 10MG

A075869 001 Jul 01, 2002

12.5MG; 20MG

A075869 002 Jul 01, 2002

25MG; 20MG

A075869 003 Jul 01, 2002

PRINZIDE

MERCK 25MG; 20MG

N019778 002 Feb 16, 1989

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK 15MG; 250MG

N013402 001

ALDORIL 25

MERCK 25MG; 250MG

N013402 002

ALDORIL D30

MERCK 30MG; 500MG

N013402 003

ALDORIL D50

MERCK 50MG; 500MG

N013402 004

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CLONMEL HLTHCARE 15MG; 250MG

A072507 001 Jun 02, 1989

25MG; 250MG

A072508 001 Jun 02, 1989

30MG; 500MG

A072509 001 Jun 02, 1989

50MG; 500MG

A072510 001 Jun 02, 1989

IVAX SUB TEVA PHARMS 15MG; 250MG

A071458 001 Mar 08, 1988

25MG; 250MG

A071459 001 Mar 08, 1988

30MG; 500MG

A071460 001 Mar 08, 1988

50MG; 500MG

A071461 001 Mar 08, 1988

PAR PHARM 15MG; 250MG

A070616 001 Feb 02, 1987

25MG; 250MG

A070612 001 Feb 02, 1987

30MG; 500MG

A070613 001 Feb 02, 1987

50MG; 500MG

A070614 001 Feb 02, 1987

PARKE DAVIS 15MG; 250MG

A071897 001 Nov 23, 1987

25MG; 250MG

A071898 001 Nov 23, 1987

30MG; 500MG

A071899 001 Nov 23, 1987

50MG; 500MG

A071900 001 Nov 23, 1987

PUREPAC PHARM 15MG; 250MG

A070853 001 Oct 08, 1986

25MG; 250MG

A070688 001 Apr 24, 1986

30MG; 500MG

A070854 001 Oct 08, 1986

50MG; 500MG

A070689 001 Apr 24, 1986

SANDOZ 15MG; 250MG

A070182 001 Jan 15, 1986

15MG; 250MG

A070829 001 Mar 09, 1987

25MG; 250MG

A070183 001 Jan 15, 1986

25MG; 250MG

A070830 001 Mar 09, 1987

30MG; 500MG

A070543 001 Jan 15, 1986

50MG; 500MG

A070544 001 Jan 15, 1986

TEVA 15MG; 250MG

A071819 001 Apr 08, 1988

25MG; 250MG

A071820 001 Apr 08, 1988

30MG; 500MG

A071821 001 Apr 08, 1988

50MG; 500MG

A071822 001 Apr 08, 1988

WATSON LABS 15MG; 250MG

A070365 001 Mar 19, 1986

15MG; 250MG

A070958 001 Feb 06, 1989

15MG; 250MG

A071920 001 Aug 29, 1988

DISCONTINUED DRUG PRODUCT LIST

6-160 (of 322)

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

25MG; 250MG	A070366	001	Apr 16, 1986
25MG; 250MG	A070959	001	Jan 19, 1989
25MG; 250MG	A071921	001	Aug 29, 1988
30MG; 500MG	A070367	001	Mar 19, 1986
30MG; 500MG	A071069	001	Jan 19, 1989
30MG; 500MG	A071922	001	Aug 29, 1988
50MG; 500MG	A070368	001	Apr 16, 1986
50MG; 500MG	A070960	001	Feb 06, 1989
50MG; 500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

US PHARMS HOLDINGS I 50MG; 100MG

N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

PADDOCK LLC 12.5MG; 7.5MG	A090096	001	Sep 25, 2008
12.5MG; 15MG	A090096	002	Sep 25, 2008
25MG; 15MG	A090096	003	Sep 25, 2008

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VSKAZIDE

NOVARTIS 25MG; 5MG	N018872	001	Jul 22, 1987
25MG; 10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST 50MG; 120MG	N019059	002	Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST 50MG; 160MG	N019059	003	Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST 50MG; 80MG	N019059	001	Jul 03, 1985

TABLET; ORAL

INDERIDE-80/25

WYETH PHARMS INC 25MG; 80MG	N018031	002	

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR 25MG; 40MG	A071126	001	Mar 02, 1987
25MG; 80MG	A071127	001	Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH 25MG; 40MG	A070851	001	May 15, 1986

25MG; 80MG	A070852	001	May 15, 1986

BARR 25MG; 40MG	A070704	001	Oct 01, 1986

25MG; 80MG	A070705	001	Oct 01, 1986

IVAX SUB TEVA PHARMS 25MG; 40MG	A071552	001	Dec 01, 1988

25MG; 80MG	A071553	001	Dec 01, 1988

SANDOZ 25MG; 40MG	A071060	001	Aug 26, 1987

25MG; 80MG	A071061	001	Aug 26, 1987

WARNER CHILCOTT 25MG; 40MG	A071771	001	Jan 26, 1988

25MG; 80MG	A071772	001	Jan 26, 1988

WATSON LABS 25MG; 40MG	A070301	001	Apr 18, 1986

25MG; 40MG	A071498	001	Dec 18, 1991

25MG; 80MG	A070305	001	Apr 18, 1986

25MG; 80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50

WHITEWORTH TOWN PLSN 50MG; 0.125MG	A085338	001	

HYDRO-RESERP

ABC HOLDING 50MG; 0.125MG	A084714	002	Jun 29, 1982

HYDRO-SERP "25"

SANDOZ 25MG; 0.125MG	A084827	001	

HYDRO-SERP "50"

SANDOZ 50MG; 0.125MG	A085213	001	

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS 25MG; 0.1MG	A083572	001	

25MG; 0.125MG	A083571	001	

50MG; 0.1MG	A083568	001	

DISCONTINUED DRUG PRODUCT LIST

6-161 (of 322)

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

	50MG; 0.125MG	A083573	001	
PHARMERAL	25MG; 0.125MG	A085421	001	
	50MG; 0.125MG	A085420	001	
ROXANE	50MG; 0.125MG	A084603	001	
WATSON LABS	25MG; 0.125MG	A084466	001	
	25MG; 0.125MG	A085317	001	
	25MG; 0.125MG	A086330	002	
	50MG; 0.125MG	A083666	001	
	50MG; 0.125MG	A084467	001	
	50MG; 0.125MG	A086331	001	
HYDOPRES 25				
MERCK	25MG; 0.125MG	N011958	002	
HYDOPRES 50				
MERCK	50MG; 0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG; 0.125MG	A084580	001	
	50MG; 0.125MG	A084579	001	
SANDOZ	50MG; 0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG; 0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG; 0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG; 0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG; 25MG	A087267	001	
PUREPAC PHARM	25MG; 25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG; 25MG	A086881	001	
SUPERPHARM	25MG; 25MG	A089137	001	Aug 26, 1985
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG; 25MG	A087004	002	May 24, 1982
LEDERLE	25MG; 25MG	A087511	001	
PARKE DAVIS	25MG; 25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG; 25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553	001	
USL PHARMA	25MG; 25MG	A087651	001	
VANGARD	25MG; 25MG	A087655	001	
WATSON LABS	25MG; 25MG	A085974	001	
	25MG; 25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC	25MG; 50MG	N016042	002	

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

BARR	25MG; 37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG; 37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG; 50MG	A071737	001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG; 75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG; 75MG	A071969	001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103	001	Sep 29, 2000

HYCOMINE

ENDO PHARMS	5MG/5ML; 25MG/5ML	N019410	001	Aug 17, 1990

HYCOMINE PEDIATRIC

ENDO PHARMS	2.5MG/5ML; 12.5MG/5ML	N019411	001	Aug 17, 1990

DISCONTINUED DRUG PRODUCT LIST

6-162 (of 322)

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER

0.5%

N010554 001

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT

0.5%

A085805 001

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS

0.5%

N009585 003

1%

N009585 001

DERMACORT

MONARCH PHARMS

1%

A083011 002

ELDECORT

VALEANT PHARM INTL

1%

A080459 001

2.5%

A084055 001

FLEXICORT

WESTWOOD SQUIBB

0.5%

A087136 003 Apr 08, 1982

1%

A087136 002 Apr 08, 1982

2.5%

A087136 001 Apr 08, 1982

H-CORT

PHARM ASSOC

0.5%

A086823 001

HC #1

BAYER PHARMS

0.5%

A080438 001

HC #4

BAYER PHARMS

1%

A080438 002

HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080482 003

1%

A080482 004

HI-COR

C AND M PHARMA

2.5%

A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS

2.5%

A089754 001 Feb 01, 1989

ALTANA

0.5%

A080848 002

1%

A080848 003

AMBIX

1%

A086080 001

2.5%

A086271 001

EVERYLIFE

0.5%

A080452 001

1%

A080452 002

G AND W LABS

1%

A084059 001

INGRAM PHARM

0.5%

A080456 002

1%

A080456 003

IVAX PHARMS

1%

A085733 001

NASKA

1%

A089706 001 Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084970 002

1%

A085026 001

PHARMADERM

1%

A088845 001 Feb 27, 1986

2.5%

A089413 001 Dec 16, 1986

PHARMAFAIR

1%

A087838 001 Jul 28, 1982

STIEFEL

1%

A086170 001

SYOSSET

0.5%

A085527 001

TARO

0.5%

A086154 001

TEVA

0.5%

A080400 002

1%

A080400 003

1%

A085191 001

2.5%

A080400 004

TOPIDERM

1%

A089273 001 Feb 17, 1989

USL PHARMA

1%

A088027 001 Sep 27, 1983

2.5%

A088029 001 Sep 27, 1983

WHITEWORTH TOWN PLSN

1%

A080496 002

HYTONE

VALEANT INTL

1%

A080472 003

2.5%

A080472 004

NOGENIC HC

IVAX PHARMS

1%

A087427 001 Apr 04, 1988

NUTRACORT

DOW PHARM

0.5%

A080442 002

1%

A080442 003

PENECORT

ALLERGAN HERBERT

1%

A088216 001 Jun 06, 1984

DISCONTINUED DRUG PRODUCT LIST

6-163 (of 322)

HYDROCORTISONE

CREAM; TOPICAL

PROCTOCORT

MONARCH PHARMS

1%

A083011 001

SYNACORT

MEDICIS

0.5%

A087459 001

GEL; TOPICAL

NUTRACORT

HEALTHPOINT

1%

A084698 001

PENECORT

ALLERGAN HERBERT

1%

A088215 001 Jun 06, 1984

INJECTABLE; INJECTION

CORTEF

PHARMACIA AND UPJOHN

50MG/ML

N009864 001

LOTION; TOPICAL

ACTICORT

BAKER NORTON

1%

A086535 001

BALNEOL-HC

SOLVAY

1%

A088041 001 Dec 03, 1982

BETA-HC

BETA DERMAC

1%

A089495 001 Jan 25, 1988

CETACORT

DOW PHARM

0.5%

A080426 002

1%

A080426 001

CORT-DOME

BAYER PHARMS

0.5%

N009895 003

1%

N009895 001

DERMACORT

SOLVAY

0.5%

A084573 002

1%

A086462 001

EPICORT

BLULINE

0.5%

A083219 002

GLYCORT

HERAN

1%

A087489 001 Oct 03, 1983

H-CORT

PHARM ASSOC

0.5%

A086824 001

HYDROCORTISONE

ALPHARMA US PHARMS

0.5%

A087317 001 Jun 07, 1982

1%

A087315 001 Jun 07, 1982

MERICON

0.5%

A085282 001

1%

A085282 002 Feb 26, 1987

NASKA

1%

A089705 001 Apr 25, 1988

PERRIGO NEW YORK

0.5%

A085662 001

1%

A085663 001

TARO

1%

A089024 001 Feb 12, 1986

HYTONE

VALEANT INTL

1%

A080473 003

2.5%

A080473 004 Nov 30, 1982

NUTRACORT

DOW PHARM

0.5%

A080443 002

STIE-CORT

PERRIGO CO

1%

A089066 001 Nov 25, 1985

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL

1%

N009176 001

2.5%

N009176 002

HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080481 001

1%

A080481 002

HYDROCORTISONE

ALTANA

0.5%

A080489 002

1%

A080489 003

AMBIX

1%

A086079 001

2.5%

A086272 001

NASKA

1%

A089704 001 Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084969 003

1%

A085028 001

PHARMADERM

1%

A088842 001 Feb 09, 1987

TARO

0.5%

A086256 001

2.5%

A040310 001 Dec 29, 2000

USL PHARMA

1%

A088061 001 Sep 27, 1983

2.5%

A088039 001 Sep 27, 1983

DISCONTINUED DRUG PRODUCT LIST

6-164 (of 322)

HYDROCORTISONE

OINTMENT; TOPICAL

HYTONE

DERMIK LABS

1%

A080474 003

2.5%

A080474 004

PENECORT

ALLERGAN HERBERT

2.5%

A088217 001 Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH

100%

A087834 001 Mar 29, 1982

HYDROCORTISONE

PADDOCK LLC

100%

A088082 001 Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT

1%

A088214 001 Jun 06, 1984

TEXACORT

MISSION PHARMA

1%

A080425 001

TABLET; ORAL

CORTRIL

PFIZER

10MG

N009127 005

20MG

N009127 003

HYDROCORTISONE

BARR

20MG

A083999 001

ELKINS SINN

20MG

A080624 001

FERRANTE

10MG

A080568 001

20MG

A080568 002

IMPAX LABS

20MG

A080781 001

INWOOD LABS

20MG

A080732 001

LANNETT

20MG

A085070 001

NEXGEN PHARMA INC

20MG

A083140 001

PANRAY

10MG

N009659 001

20MG

N009659 002

PARKE DAVIS

20MG

A084243 001

PUREPAC PHARM

10MG

A084247 003 Aug 31, 1982

20MG

A080395 001

20MG

A084247 002

ROXANE

10MG

A088539 001 Mar 21, 1984

SANDOZ

20MG

A080642 002

WATSON LABS

20MG

A080355 001

WEST WARD

20MG

A083365 001

WHITEWORTH TOWN PLSN

10MG

A080344 001

20MG

A080344 002

HYDROCORTONE

MERCK

10MG

N008506 007

20MG

N008506 011

TABLET; VAGINAL

CORTRIL

PFIPHARMECS

10MG

N009796 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE

1%

A081274 001 Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI

1%

A080419 001 Jan 25, 1982

PARKE DAVIS

1%

A089914 001 Jan 03, 1989

PUREPAC PHARM

0.5%

A086050 001

1%

A086052 001

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN

50MG/ML

N009378 002

CORTRIL

PFIZER

25MG/ML

N009164 001

HYDROCORTISONE ACETATE

AKORN

25MG/ML

N009637 001

50MG/ML

N009637 002

BEL MAR

25MG/ML

A083739 001

50MG/ML

A083739 002

WATSON LABS

25MG/ML

A083128 001

25MG/ML

A083759 001

50MG/ML

A083759 002

50MG/ML

A085214 001

DISCONTINUED DRUG PRODUCT LIST

6-165 (of 322)

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK

25MG/ML

N008228 001

50MG/ML

N008228 004

LOTION; TOPICAL

DRICORT

INGRAM PHARM

0.5%

A086207 001

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS

0.5%

A080828 001

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK

1.5%

N009018 003

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN

1%

N008917 002

2.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008917 001

PASTE; TOPICAL

ORABASE HCA

COLGATE

0.5%

A083205 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN

1%;EQ 3.5MG BASE/GM

A061049 001

2.5%;EQ 3.5MG BASE/GM

A061049 002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN

0.5%;EQ 3.5MG BASE/GM

A060610 001

1.5%;EQ 3.5MG BASE/GM

A060610 002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN

0.5%;EQ 3.5MG BASE/GM

A060751 001

1%;EQ 3.5MG BASE/GM

A060751 002

2.5%;EQ 3.5MG BASE/GM

A060751 003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN

1.5%;EQ 3.5MG BASE/ML

A060188 001

NEO-CORTEF

PHARMACIA AND UPJOHN

0.5%;EQ 3.5MG BASE/ML

A060612 002

1.5%;EQ 3.5MG BASE/ML

A060612 001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTIL

PFIZER

1.5%;EQ 5MG BASE/ML

A061016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

BOCA PHARMA LLC

1%;1%

A089440 001 May 17, 1988

LOTION; TOPICAL

PRAMOSONE

FERNDAL LABS

0.5%;1%

A083213 002

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS

1%;10%

A080505 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001 Jan 07, 1983

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001 Jul 03, 1984

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001 Sep 15, 1988

DISCONTINUED DRUG PRODUCT LIST

6-166 (of 322)

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK	EQ 50MG BASE/ML	N012052	001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989

EQ 100MG BASE/VIAL	A085928	001	

EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989

EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989

EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989

HOSPIRA	EQ 1GM BASE/VIAL	A085932	001

EQ 100MG BASE/VIAL	A085929	001	

EQ 250MG BASE/VIAL	A085930	001	

EQ 500MG BASE/VIAL	A085931	001	

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 1GM BASE/VIAL	A088670	001	Jun 08, 1984

EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984

EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984

EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984

EQ 500MG BASE/VIAL	A088669	001	Jun 08, 1984

BAXTER HLTHCARE	EQ 1GM BASE/VIAL	A087569	001

EQ 100MG BASE/VIAL	A086619	001	

EQ 250MG BASE/VIAL	A087567	001	

EQ 500MG BASE/VIAL	A087568	001	

INTL MEDICATION	EQ 100MG BASE/VIAL	A087532	001 Mar 19, 1982

WATSON LABS	EQ 1GM BASE/VIAL	A084748	001

EQ 100MG BASE/VIAL	A084737	002	

EQ 100MG BASE/VIAL	A084738	001	

EQ 250MG BASE/VIAL	A084737	001	

EQ 500MG BASE/VIAL	A084747	001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

TEVA PHARMS

0.2%	A074489	001	Aug 12, 1998

WESTCORT

RANBAXY

0.2%	N017950	001	

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS

0.2%	A075085	001	Jul 31, 2001

WESTCORT

RANBAXY

0.2% **Federal Register determination	N018726	001	Aug 08, 1983

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984

1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985

DISCONTINUED DRUG PRODUCT LIST

6-167 (of 322)

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

OTICAIR

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982

OTOBIONE

SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	

OTOCORT

WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	

PYOCIDIN

FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC

ACHROMYCIN

LEDERLE	1.5%;1%	N050272 001	

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM

BIOGLAN	1%;10%	A086008 001	

CALMURID HC

PHARMACIA AND UPJOHN	1%;10%	A083947 001	

HYDROFLUMETHIAZIDE

TABLET;ORAL

DIUCARDIN

WYETH AYERST	50MG	A083383 001	

HYDROFLUMETHIAZIDE

PAR PHARM	50MG	A088850 001	May 31, 1985

WATSON LABS	50MG	A088031 001	Apr 06, 1983

	50MG	A088528 001	Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983

WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983

	50MG;0.125MG	A088110 001	Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985

PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985

SALUTENSIN

SHIRE	50MG;0.125MG	N012359 003	

SALUTENSIN-DEMI

SHIRE	25MG;0.125MG	N012359 004	

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PALLADONE

PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004

	16MG	N021044 002	Sep 24, 2004

	24MG	N021044 003	Sep 24, 2004

	32MG	N021044 004	Sep 24, 2004

INJECTABLE;INJECTION

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS	2MG	A077311 001	Nov 09, 2005

	4MG	A077311 002	Nov 09, 2005

	8MG	A077311 003	Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

ALPHAREDISOL

MERCK	1MG/ML	A080778 001	

CYANOKIT

MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM	1MG/ML	A084921 001	

WATSON LABS	1MG/ML	A085528 001	

DISCONTINUED DRUG PRODUCT LIST

6-168 (of 322)

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010347 004

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016911 001

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010347 002

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016911 002

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

WATSON LABS

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW

25MG/ML

A087592 001

SOLOPAK

25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

DISCONTINUED DRUG PRODUCT LIST

6-169 (of 322)

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A085779	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAx				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
PFIZER	25MG/ML	N011111	001	
	50MG/ML	N011111	002	
SYRUP; ORAL				
ATARAX				
ROERIG	10MG/5ML	N010485	001	
HYDROXYZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
STI PHARMA LLC	10MG/5ML	A086880	001	
TABLET; ORAL				
ATARAX				
PFIZER	10MG	N010392	001	
	25MG	N010392	004	
	50MG	N010392	006	
	100MG	N010392	005	
HYDROXYZINE HYDROCHLORIDE				
ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS TOTOWA	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004
	25MG	A040602	001	Dec 28, 2004
	50MG	A040604	001	Dec 28, 2004
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
	100MG	A087862	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	10MG	A087869	001	Dec 20, 1982
	25MG	A085247	001	
	25MG	A087870	001	Dec 20, 1982
	50MG	A087245	001	
	50MG	A087871	001	Dec 20, 1982
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986

DISCONTINUED DRUG PRODUCT LIST

6-170 (of 322)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A086827	001	
	25MG	A086829	001	
	50MG	A086836	001	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982
	EQ 50MG HCL	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982
	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HCL	A086698	001	
	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982
VISTARIL				
PFIZER	EQ 100MG HCL	N011459	006	
SUSPENSION; ORAL				
VISTARIL				
PFIZER	EQ 25MG HCL/5ML	N011795	001	

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

HOFFMANN LA ROCHE	EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021455	001	May 16, 2003

IBUPROFEN

CAPSULE; ORAL

MIDOL

BAYER	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A070626	001	Sep 02, 1987
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A071002	001	Sep 02, 1987

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS	100MG/5ML	N019833	002	Sep 19, 1989

IBU

ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989

DISCONTINUED DRUG PRODUCT LIST

6-171 (of 322)

IBUPROFEN

SUSPENSION; ORAL

MOTRIN

MCNEIL CONSUMER

100MG/5ML

N019842 001 Sep 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001 May 25, 1995

TABLET; ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001 Dec 08, 1987

IBU

BASF

400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA

800MG

A071965 001 Aug 11, 1988

IBUPRIN

PLIVA

200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001 Jun 14, 1985

800MG

A071264 001 Jul 25, 1986

CONTRACT PHARMACAL

200MG

A073691 001 Feb 25, 1994

HALSEY

200MG

A071027 001 Sep 29, 1987

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS

200MG

A071144 001 Jan 20, 1987

200MG

A071154 001 Oct 27, 1987

200MG

A072040 001 Apr 29, 1988

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

LEDERLE

400MG

A070629 001 Sep 19, 1986

600MG

A070630 001 Sep 19, 1986

LEINER

300MG

A071266 001 Oct 15, 1986

MCNEIL

400MG

A070081 001 Jun 16, 1986

600MG

A070476 001 Jun 16, 1986

MUTUAL PHARM

200MG

A070493 001 Dec 24, 1985

200MG

A070908 001 Sep 26, 1986

200MG

A071462 001 Oct 02, 1986

400MG

A070079 001 Jul 24, 1985

600MG

A070080 001 Jul 24, 1985

800MG

A071448 001 Feb 18, 1987

MYLAN

200MG

A071870 001 May 05, 1988

400MG

A070045 001 Sep 24, 1985

600MG

A070057 001 Sep 24, 1985

800MG

A071999 001 Dec 03, 1987

NORTHSTAR HLTHCARE

400MG

A078132 001 Sep 10, 2007

600MG

A078132 002 Sep 10, 2007

800MG

A078132 003 Sep 10, 2007

OHM LABS

400MG

A070818 001 Dec 26, 1985

PAR PHARM

200MG

A071575 001 May 08, 1987

300MG

A070328 001 Aug 06, 1985

400MG

A070329 001 Aug 06, 1985

600MG

A070330 001 Aug 06, 1985

800MG

A070986 001 Jul 25, 1986

PERRIGO

200MG

A072098 001 Dec 08, 1987

PLIVA

400MG

A071666 001 Jun 18, 1987

600MG

A071667 001 Jun 18, 1987

800MG

A071668 001 Jun 18, 1987

PUREPAC PHARM

200MG

A071122 001 Oct 03, 1986

200MG

A071664 001 Feb 03, 1987

300MG

A071123 001 Sep 19, 1986

400MG

A071124 001 Sep 19, 1986

600MG

A071125 001 Sep 19, 1986

DISCONTINUED DRUG PRODUCT LIST

6-172 (of 322)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	800MG	A071964	001	Feb 01, 1988
SANDOZ	200MG	A070733	001	Sep 19, 1986
	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	300MG	A070734	001	Jun 12, 1986
	400MG	A070735	001	Jun 12, 1986
	400MG	A072064	001	Jan 14, 1988
	600MG	A070736	001	Jun 12, 1986
	600MG	A072065	001	Jan 14, 1988
	800MG	A071938	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
SUPERPHARM	600MG	A070709	001	Apr 25, 1986
TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249	001	Jan 10, 1989
WATSON LABS	200MG	A071765	001	Sep 04, 1987
	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	600MG	A070041	001	Sep 06, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987
IBUPROHM				
OHM LABS	400MG	A070469	001	Aug 29, 1985
MEDIPREN				
MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986
MIDOL				
BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987
MOTRIN				
MCNEIL CONSUMER	300MG	N017463	003	
	400MG	N017463	002	
	600MG	N017463	004	
	800MG	N017463	005	May 22, 1985
MCNEIL PED	100MG	N020418	001	Nov 16, 1994
NUPRIN				
BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
MCNEIL	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987
RUFEN				
BASF	600MG	N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL				
MOTRIN				
MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS

400MG; 5MG

N021378 001 Nov 26, 2004

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN

5MG/VIAL

N050661 002 Sep 27, 1990

10MG/VIAL

N050661 001 Sep 27, 1990

20MG/VIAL

N050661 003 Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

TEVA PARENTERAL

5MG/VIAL

A065037 003 May 01, 2002

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

DISCONTINUED DRUG PRODUCT LIST

6-173 (of 322)

IDOXURIDINE

OINTMENT;OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%

N015868 001

SOLUTION/DROPS;OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.1%

N013934 001

IFOSFAMIDE; MESNA

INJECTABLE;INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL;100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL;100MG/ML

N019763 004 Oct 10, 1992

ILOPROST

SOLUTION;INHALATION

VENTAVIS

ACTELION PHARMS LTD

20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE;ORAL

GLEEVEC

NOVARTIS

EQ 50MG BASE

N021335 001 May 10, 2001

EQ 100MG BASE

N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE;ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE;INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

25MG

A089497 001 Jul 14, 1987

PROSAM LABS

10MG

A040753 001 Feb 28, 2008

25MG

A040752 001 Feb 28, 2008

50MG

A040751 001 Feb 28, 2008

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

DISCONTINUED DRUG PRODUCT LIST

6-174 (of 322)

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP EQ 5MG BASE/ML

A075542 001 May 10, 2000

HOSPIRA EQ 5MG BASE/ML

A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US EQ 5MG BASE/ML

N018700 001 Jul 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

CADISTA PHARMS 1.25MG

A075201 001 Dec 04, 1998

2.5MG

A075201 002 Dec 04, 1998

SANDOZ 1.25MG

A074594 001 May 23, 1996

2.5MG

A074594 002 May 23, 1996

TEVA 1.25MG

A074498 002 Feb 12, 1998

1.25MG

A074665 001 Apr 04, 1997

2.5MG

A074498 001 Oct 31, 1996

2.5MG

A074665 002 Apr 04, 1997

LOZOL

SANOFI AVENTIS US 1.25MG

N018538 002 Apr 29, 1993

2.5MG

N018538 001 Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY EQ 50MG BASE

N019693 001 Dec 29, 1989

EQ 75MG BASE

N019693 002 Dec 29, 1989

EQ 100MG BASE

N019693 003 Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME EQ 100MG BASE

N020685 006 Apr 19, 2000

EQ 333MG BASE

N020685 005 Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN 10MG/VIAL

N011525 003

40MG/VIAL

N011525 004

50MG/VIAL

N011525 002

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA 25MG

A070266 001 Nov 07, 1985

50MG

A070267 001 Nov 07, 1985

INDOCIN

ICEUTICA OPERATIONS 25MG

N016059 001

50MG

N016059 002

INDOMETHACIN

ABLE 25MG

A076666 001 Dec 17, 2003

50MG

A076666 002 Dec 17, 2003

DURAMED PHARMS BARR 25MG

A070326 001 Oct 18, 1985

50MG

A070327 001 Oct 18, 1985

HALSEY 25MG

A070782 001 Jun 03, 1987

50MG

A070635 001 Jun 03, 1987

IVAX SUB TEVA PHARMS 25MG

N018730 001 May 04, 1984

50MG

N018730 002 May 04, 1984

MUTUAL PHARM 25MG

A070067 001 Oct 03, 1986

25MG

A070899 001 Feb 09, 1987

50MG

A070068 001 Oct 03, 1986

50MG

A070900 001 Feb 09, 1987

MYLAN 50MG

N018858 002 Apr 20, 1984

PARKE DAVIS 25MG

N018806 001 Nov 23, 1984

50MG

N018806 002 Nov 23, 1984

PIONEER PHARMS 25MG

A070813 001 Aug 11, 1986

50MG

A070592 001 Aug 11, 1986

PLIVA 25MG

A071148 001 Mar 18, 1987

50MG

A071149 001 Mar 18, 1987

ROXANE 25MG

A070353 001 Jun 18, 1985

50MG

A070354 001 Jun 18, 1985

SUPERPHARM 25MG

A070487 001 Oct 10, 1986

50MG

A070488 001 Oct 10, 1986

DISCONTINUED DRUG PRODUCT LIST

6-175 (of 322)

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
VINTAGE	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

IROKO PHARMS	75MG	N018185	001	Feb 23, 1982

INDOMETHACIN

ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989

SUPPOSITORY; RECTAL

INDOCIN

IROKO PHARMS	50MG	N017814	001	Aug 13, 1984

SUSPENSION; ORAL

INDOMETHACIN

ROXANE	25MG/5ML	A071412	001	Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML; 50 UNITS/ML	N021810	001	Aug 26, 2008

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001
	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005

LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

LILLY	50 UNITS/ML; 50 UNITS/ML	N021018	003	Dec 22, 1999

HUMALOG MIX 75/25 PEN

LILLY	75 UNITS/ML; 25 UNITS/ML	N021017	003	Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998

INSULIN PORK

INJECTABLE; INJECTION

ILETIN I

LILLY	500 UNITS/ML	N017931	001	

INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926	001	

REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926	003	

DISCONTINUED DRUG PRODUCT LIST

6-176 (of 322)

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001 Jan 27, 2006

3MG/INH

N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML; 50 UNITS/ML

N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML; 70 UNITS/ML

N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017929 001

100 UNITS/ML

N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017936 001

100 UNITS/ML

N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY

100 UNITS/ML

N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC

100 UNITS/ML

N018194 001

NPH ILETIN II (PORK)

LILLY

100 UNITS/ML

N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018623 001

DISCONTINUED DRUG PRODUCT LIST

6-177 (of 322)

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC 100 UNITS/ML

N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML

N019065 001 Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY 40 UNITS/ML

N017932 001

100 UNITS/ML

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY 100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB 40 UNITS/ML

N017928 001

100 UNITS/ML

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY 100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC 40 UNITS/ML

N017998 001

100 UNITS/ML

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC 100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY 40 UNITS/ML

N019571 001 Jun 10, 1987

100 UNITS/ML

N019571 002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC 100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY 100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC 100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC 100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML

N018347 001

DISCONTINUED DRUG PRODUCT LIST

6-178 (of 322)

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY

100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX

100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE

10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE

2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT

750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO

65%

N017902 001

RENOVUE-DIP

BRACCO

24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO

10.3%

N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO

20%

N009321 001

ODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

ODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIP PURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

ODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

ODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

DISCONTINUED DRUG PRODUCT LIST

6-179 (of 322)

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA

61%

A074636 003 Dec 30, 1997

61%

A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING

76%

A074881 004 Jul 28, 2000

HOSPIRA

76%

A074898 004 Dec 30, 1997

76%

A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA

76%

A074636 004 Dec 30, 1997

ISOVUE-128

BRACCO

26%

N018735 005 Oct 21, 1986

ISOVUE-200

BRACCO

41%

N020327 001 Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE

500MG

N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON

100%

N005319 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT

52%; 26%

N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT

80%

N013319 001

CONRAY 325

MALLINCKRODT

54.3%

N017685 001

CONRAY 400

MALLINCKRODT

66.8%

N014295 001

DISCONTINUED DRUG PRODUCT LIST

6-180 (of 322)

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE

40.6%

N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE

51.3%

N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

MALLINCKRODT

34%

N019710 003 Dec 30, 1988

OPTIRAY 240

MALLINCKRODT

51%

N020923 001 May 28, 1998

OPTIRAY 320

MALLINCKRODT

68%

N020923 002 May 29, 1998

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO

3GM/PACKET

N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE

500MG

A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO

500MG

N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.02%

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC

0.02%

A075111 001 Apr 22, 1999

APOTEX INC

0.02%

A075441 001 Mar 28, 2001

PHARMASCIENCE INC

0.02%

A075507 001 Jan 19, 2001

ROXANE

0.02%

A075867 001 Jul 22, 2002

TEVA PHARMS USA

0.02%

A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC

0.021MG/SPRAY

A076156 001 Apr 18, 2003

0.042MG/SPRAY

A076155 001 Apr 18, 2003

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ

40MG/2ML (20MG/ML)

A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML)

A077994 002 Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON

1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US

0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS

1%

A087101 001

ASTRAZENECA

0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

DISCONTINUED DRUG PRODUCT LIST

6-181 (of 322)

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

	0.167%	A088470 001	Mar 14, 1984
	0.167%	A089616 001	Jun 13, 1991
	0.2%	A088471 001	Mar 14, 1984
	0.2%	A089617 001	Jun 13, 1991
	0.25%	A088472 001	Mar 14, 1984
	0.25%	A089618 001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144 001	Jul 29, 1983
	0.14%	A088145 001	Mar 26, 1984
	0.25%	A088146 001	Aug 01, 1983
DEY	0.08%	A088187 001	Dec 03, 1982
	0.1%	A087389 001	
	0.17%	A087390 001	
	0.25%	A088188 001	Dec 03, 1982
	1%	A086763 001	
INTL MEDICATION	0.077%	A086651 001	
	0.08%	A086651 002	
	0.1%	A086651 003	
	0.143%	A086651 004	
	0.167%	A086651 005	
	0.2%	A086651 006	
	0.25%	A086651 007	
	1%	A086651 008	
PARKE DAVIS	0.5%	A085997 001	
	1%	A085889 001	
ROXANE	0.1%	A087396 001	
	0.125%	A087025 001	
	0.167%	A088226 001	Sep 16, 1983
	0.2%	A087324 001	
	0.25%	A088275 001	Jun 03, 1983
	1%	A086899 001	
ISOETHARINE HYDROCHLORIDE S/F			
DEY	0.08%	A089817 001	Nov 22, 1988
	0.1%	A089818 001	Nov 22, 1988
	0.17%	A089819 001	Nov 22, 1988
	0.25%	A089820 001	Nov 22, 1988
	1%	A089252 001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339 007	
ISOETHARINE MESYLATE			
ALPHARMA US PHARMS	0.34MG/INH	A087858 001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

MARSAM PHARMS LLC	99.9%	A074393 001	May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656 001	

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML	N008662 001	

RIMIFON

ROCHE	25MG/ML	N008420 002	
	100MG/ML	N008420 003	

SYRUP; ORAL

ISONIAZID

MIKART	50MG/5ML	A081118 001	Jul 21, 1997

LANIAZID

LANNETT	50MG/5ML	A089243 001	Feb 03, 1986

RIMIFON

ROCHE	50MG/5ML	N008420 001	

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330 002	

DISCONTINUED DRUG PRODUCT LIST

6-182 (of 322)

ISONIAZID

TABLET; ORAL

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003
	300MG	A080134	004

INH

NOVARTIS	300MG	A080935	001

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
HALSEY	50MG	A083632	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MIKART	100MG	A040090	001	Jun 26, 1997
	300MG	A040090	002	Jun 26, 1997
MK LABS	100MG	A080941	001	
MUTUAL PHARM	100MG	A080136	001	
	300MG	A083633	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WEST WARD	100MG	A080212	001	
	300MG	A087425	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	

LANIAZID

LANNETT	50MG	A080140	001
	100MG	A080140	002

NYDRAZID

BRISTOL MYERS SQUIBB	100MG	N008392	003

STANOZIDE

EVERYLIFE	100MG	A080126	001
	300MG	A080126	002

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

WEST WARD PHARM CORP	150MG; 300MG	A065221	001	Jul 29, 2005

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004
ALPHARMA US PHARMS	0.12MG/INH	A085904	001

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001
BAXTER HLTHCARE	0.2MG/ML	A083486	001

DISCONTINUED DRUG PRODUCT LIST

6-183 (of 322)

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

HOSPIRA	0.02MG/ML	A083283	001
	0.2MG/ML	A083346	001
INTL MEDICATION	0.2MG/ML	A083724	001

SOLUTION; INHALATION

AEROLONE

LILLY	0.25%	N007245	001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002
	1%	N006327	003

VAPO-ISO

FISONS	0.5%	N016813	001

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US	10MG	N006328	001
	15MG	N006328	002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M	0.08MG/INH	N010375	003

POWDER; INHALATION

NORISODRINE

ABBVIE	10%	N006905	003
	25%	N006905	002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON	100GM/220ML	N017063	001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988

TABLET; ORAL

ISOSORBIDE DINITRATE

MUTUAL PHARM	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986
SUPERPHARM	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988

SORBITRATE

ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996
	20MG	A086405	002	Aug 21, 1990
	30MG	A088124	001	Aug 21, 1990
	40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL	2.5MG	N012940	004	Jul 29, 1988
	5MG	N012940	003	Jul 29, 1988
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012940	005	Jul 29, 1988

DISCONTINUED DRUG PRODUCT LIST

6-184 (of 322)

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

MUTUAL PHARM

2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

WATSON LABS

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A086033 001 Feb 26, 1988

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A086031 001 Sep 29, 1987

WEST WARD

2.5MG

A086054 001 Oct 29, 1987

WEST WARD PHARM CORP

5MG

A086055 001 Nov 02, 1987

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA

5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST

40MG

N012882 001 Jul 29, 1988

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA

20MG

N019091 001 Dec 30, 1991

TABLET, EXTENDED RELEASE;ORAL

IMDUR

SCHERING PLOUGH

30MG

N020225 001 Aug 12, 1993

60MG

N020225 002 Aug 12, 1993

120MG

N020225 003 Mar 30, 1995

ISOSORBIDE MONONITRATE

ALKERMES GAINESVILLE

60MG

A075041 001 Sep 22, 1998

IVAX SUB TEVA PHARMS

30MG

A075448 002 Aug 07, 2001

60MG

A075448 001 Jun 19, 2000

120MG

A075448 003 Aug 07, 2001

SKYEPHARMA AG

60MG

A075166 001 Oct 07, 1999

ISOTRETINOIN

CAPSULE;ORAL

ACCUTANE

HOFFMANN LA ROCHE

10MG

N018662 002 May 07, 1982

20MG

N018662 004 Mar 28, 1983

40MG

N018662 003 May 07, 1982

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

SMITHKLINE BEECHAM

2.5MG

N019546 001 Dec 20, 1990

5MG

N019546 002 Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

GLAXOSMITHKLINE LLC

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020336 001 Jun 01, 1994

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020336 002 Jun 01, 1994

ITRACONAZOLE

INJECTABLE;INJECTION

SPORANOX

JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

DISCONTINUED DRUG PRODUCT LIST

6-185 (of 322)

IVERMECTIN

TABLET; ORAL

STROMEKTOL

MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

HIKMA MAPLE

EQ 1GM BASE/3ML

A062324 003

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

INTL MEDICATION

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

LOCH

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

PHARMAFAIR

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

SOLOPAK

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 1GM BASE/3ML

A062170 003

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

TEVA

200MG

A074971 001 Jun 15, 1999

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

SANDOZ

50MG

A074024 001 Dec 29, 1995

75MG

A074024 002 Dec 29, 1995

TEVA

25MG

A073515 001 Dec 22, 1992

ORUDIS

WYETH AYERST

25MG

N018754 001 Jul 31, 1987

50MG

N018754 002 Jan 09, 1986

75MG

N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ALKERMES GAINESVILLE

200MG

A074879 001 Dec 10, 1997

DISCONTINUED DRUG PRODUCT LIST

6-186 (of 322)

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

WYETH PHARMS INC

100MG

N019816 003 Feb 08, 1995

150MG

N019816 002 Feb 08, 1995

200MG

N019816 001 Sep 24, 1993

TABLET; ORAL

ACTRON

BAYER

12.5MG

N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO

12.5MG

A075364 001 Feb 07, 2002

ORUDIS KT

WYETH CONS

12.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM

15MG/ML

A076209 001 Jul 21, 2004

30MG/ML

A076209 002 Jul 21, 2004

APOTEX INC

15MG/ML

A075631 002 Jun 29, 2001

30MG/ML

A075626 001 Jul 24, 2001

30MG/ML

A075631 001 Jun 29, 2001

30MG/ML

A077201 001 Oct 14, 2005

APOTHECON

15MG/ML

A075348 001 Nov 28, 2000

30MG/ML

A075348 002 Nov 28, 2000

BEDFORD

15MG/ML

A075230 002 Oct 25, 1999

30MG/ML

A075230 001 Oct 25, 1999

GLAND PHARMA LTD

15MG/ML

A076722 001 Jul 27, 2004

30MG/ML

A076722 002 Jul 27, 2004

HOSPIRA

15MG/ML

A074801 001 Jun 05, 1997

30MG/ML

A074801 002 Jun 05, 1997

LUITPOLD

15MG/ML

A078145 001 Jan 14, 2008

30MG/ML

A078145 002 Jan 14, 2008

TORADOL

ROCHE PALO

15MG/ML

N019698 001 Nov 30, 1989

30MG/ML

N019698 002 Nov 30, 1989

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

ALLERGAN

0.5%

N020811 001 Nov 03, 1997

TABLET; ORAL

KETOROLAC TROMETHAMINE

ROXANE

10MG

A074790 001 Jun 26, 1997

WATSON LABS

10MG

A074955 001 Sep 19, 1997

TORADOL

ROCHE PALO

10MG

N019645 001 Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE

N/A

N018088 001

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

APOTEX INC

5MG/ML

A076051 001 Jul 05, 2002

APOTHECON

5MG/ML

A075355 001 Nov 29, 1999

HOSPIRA

5MG/ML

A075242 001 Sep 30, 1999

NORMODYNE

SCHERING

5MG/ML

N018686 001 Aug 01, 1984

TRANDATE

PROMETHEUS LABS

5MG/ML

N019425 001 Dec 31, 1985

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON

100MG

A075223 001 Nov 20, 1998

200MG

A075223 002 Nov 20, 1998

300MG

A075223 003 Nov 20, 1998

MUTUAL PHARM

100MG

A075215 001 Jul 29, 1999

DISCONTINUED DRUG PRODUCT LIST

6-187 (of 322)

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

	200MG	A075215 002	Jul 29, 1999
	300MG	A075215 003	Jul 29, 1999
TEVA	100MG	A074989 001	Sep 30, 1998
	200MG	A074989 002	Sep 30, 1998
	300MG	A074989 003	Sep 30, 1998
NORMODYNE			
SCHERING	100MG	N018687 001	Aug 31, 1987
	200MG	N018687 002	Aug 01, 1984
	300MG	N018687 003	Aug 01, 1984
	400MG	N018687 004	Aug 01, 1984
TRANDATE			
PROMETHEUS LABS	100MG	N018716 001	May 24, 1985
	200MG	N018716 002	Aug 01, 1984
	300MG	N018716 003	Aug 01, 1984
	400MG	N018716 004	Aug 01, 1984

LACTULOSE

SOLUTION; ORAL

CHRONULAC

SANOFI AVENTIS US	10GM/15ML	N017884 001	
DUPHALAC			
SOLVAY	10GM/15ML	A072372 001	Mar 22, 1989
EVALOSE			
TEVA PHARMS	10GM/15ML	A073497 001	May 28, 1993
LACTULOSE			
APOTEX INC	10GM/15ML	A075911 001	Feb 21, 2002
MORTON GROVE	10GM/15ML	A071841 001	Sep 22, 1988
PACO	10GM/15ML	A073160 001	Aug 25, 1992
LAXILOSE			
NOSTRUM LABS	10GM/15ML	A073686 001	May 28, 1993
SOLUTION; ORAL, RECTAL			
ACILAC			
NOSTRUM LABS	10GM/15ML	A073685 001	May 28, 1993
CEPHULAC			
SANOFI AVENTIS US	10GM/15ML	N017657 001	
GENERLAC			
MORTON GROVE	10GM/15ML	A071842 001	Sep 27, 1988
HEPTALAC			
TEVA PHARMS	10GM/15ML	A073504 001	May 28, 1993
LACTULOSE			
APOTEX INC	10GM/15ML	A076645 001	Jul 28, 2003
PACO	10GM/15ML	A072029 001	Aug 25, 1992
ROXANE	10GM/15ML	A073590 001	May 29, 1992
SOLVAY	10GM/15ML	N017906 001	
PORTALAC			
SOLVAY	10GM/15ML	A072374 001	Mar 22, 1989

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE LLC	50MG	N020241 006	Dec 27, 1994
	250MG	N020241 004	Dec 27, 1994
LAMOTRIGINE			
MATRIX LABS LTD	25MG	A078443 001	Feb 11, 2009
	100MG	A078443 002	Feb 11, 2009
	150MG	A078443 003	Feb 11, 2009
	200MG	A078443 004	Feb 11, 2009
MYLAN	25MG	A077428 001	Jan 27, 2009
	100MG	A077428 002	Jan 27, 2009
	150MG	A077428 003	Jan 27, 2009
	200MG	A077428 004	Jan 27, 2009
ROXANE	25MG	A077392 001	Jan 27, 2009
	100MG	A077392 002	Jan 27, 2009
	150MG	A077392 003	Jan 27, 2009
	200MG	A077392 004	Jan 27, 2009
SANDOZ	25MG	A078645 001	Jan 27, 2009
	100MG	A078645 002	Jan 27, 2009
	150MG	A078645 003	Jan 27, 2009
	200MG	A078645 004	Jan 27, 2009
WOCKHARDT	25MG	A078982 001	Jan 27, 2009

DISCONTINUED DRUG PRODUCT LIST

6-188 (of 322)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC

100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281 001 May 03, 2001

30MG/PACKET

N021281 002 May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566 001 May 27, 2004

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

TEVA PHARMS

15MG

A078730 001 Oct 15, 2010

30MG

A078730 002 Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 250MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021507 002 Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 375MG

N021507 003 Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA

15MG, N/A; N/A, 500MG

N021507 004 Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE LLC

EQ 250MG BASE

N021468 001 Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS

0.5%; 1.8%

N011914 001

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

APOTEX INC

0.005%

A077697 001 Mar 22, 2011

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

SANDOZ

10MG

A077085 001 Sep 13, 2005

20MG

A077085 002 Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

BAYER HLTHCARE

50MG/VIAL

N020807 001 Mar 06, 1998

LETROZOLE

TABLET; ORAL

LETROZOLE

SYNTHON PHARMS

2.5MG

A090196 001 Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

HOSPIRA

EQ 60MG BASE/VIAL

N008107 003 Jan 30, 1987

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABIC

EQ 3MG BASE/ML

A089352 001 Jun 01, 1988

EQ 50MG BASE/VIAL

A089353 001 Jun 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6-189 (of 322)

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML	N008107	001	
	EQ 50MG BASE/VIAL	N008107	002	
	EQ 100MG BASE/VIAL	N008107	004	May 23, 1988
	EQ 350MG BASE/VIAL	N008107	005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
LEUCOVORIN CALCIUM PRESERVATIVE FREE				
HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997
LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN				
GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA	EQ 5MG BASE	A074544	001	Aug 28, 1997
	EQ 25MG BASE	A074544	002	Aug 28, 1997
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
SANDOZ	EQ 15MG BASE	A075327	001	Mar 24, 1999
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN				
GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983
	EQ 25MG BASE	N018342	002	Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
LUPRON				
ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985
LUPRON DEPOT-PED				
ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL; 3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993
	7.5MG/VIAL, 7.5MG/VIAL; 7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE	1MG/ML	N010423	001	

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011

TABLET; ORAL

LEVETIRACETAM

MYLAN	1GM	A078731	004	Feb 10, 2009
	250MG	A078731	001	Feb 10, 2009
	500MG	A078731	002	Feb 10, 2009
	750MG	A078731	003	Feb 10, 2009
WATSON LABS FLORIDA	250MG	A077408	001	Mar 02, 2009

DISCONTINUED DRUG PRODUCT LIST

6-190 (of 322)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

500MG

A077408 002 Mar 02, 2009

750MG

A077408 003 Mar 02, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

SANDOZ

500MG

A091668 001 Nov 01, 2012

750MG

A091668 002 Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD

EQ 0.5% BASE

N021114 001 Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC

0.25%

A075473 001 Aug 03, 2000

0.5%

A075475 001 Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML

N020997 001 Aug 05, 1999

EQ 5MG BASE/ML

N020997 002 Aug 05, 1999

EQ 7.5MG BASE/ML

N020997 003 Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001 Nov 10, 1993

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

SIGMA TAU

1GM/10ML

N018948 002 Apr 27, 1988

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL

100MG

N016948 003

250MG

N016948 001

500MG

N016948 002

DOPAR

SHIRE

100MG

N016913 003

250MG

N016913 001

500MG

N016913 002

LARODOPA

ROCHE

100MG

N016912 002

250MG

N016912 001

500MG

N016912 006

TABLET; ORAL

DOPAR

SHIRE

250MG

N016913 004

500MG

N016913 005

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AKORN

EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011

EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

APOTEX INC

0.5%

A078282 001 Dec 20, 2010

DISCONTINUED DRUG PRODUCT LIST

6-191 (of 322)

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

SPECTRUM PHARMS

EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 003 Apr 29, 2011

LEVOMEPRIMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020315 001 Jul 09, 1993

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

NOVOCOL

0.05MG/ML; 2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

GRAHAM CHEM

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM

0.05MG/ML; 2%

A089517 001 Apr 14, 1988

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT II

POPULATION COUNCIL

75MG/IMPLANT

N020544 001 Nov 01, 1996

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET; ORAL

PLAN B

TEVA BRANDED PHARM

0.75MG

N021045 001 Jul 28, 1999

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

VINTAGE

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

DISCONTINUED DRUG PRODUCT LIST

6-192 (of 322)

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

0.137MG	N021137	008	Jun 06, 2003
0.15MG	N021137	009	Jun 06, 2003
0.175MG	N021137	010	Jun 06, 2003
0.2MG	N021137	011	Jun 06, 2003
0.3MG	N021137	012	Jun 06, 2003

LEVOTHYROXINE SODIUM

MERCK KGAA

0.025MG	A076752	001	Jun 16, 2005
0.05MG	A076752	002	Jun 16, 2005
0.075MG	A076752	003	Jun 16, 2005
0.088MG	A076752	004	Jun 16, 2005
0.1MG	A076752	005	Jun 16, 2005
0.112MG	A076752	006	Jun 16, 2005
0.125MG	A076752	007	Jun 16, 2005
0.15MG	A076752	008	Jun 16, 2005
0.175MG	A076752	009	Jun 16, 2005
0.2MG	A076752	010	Jun 16, 2005
0.3MG	A076752	011	Jun 16, 2005

LEVOXYL

KING PHARMS R AND D

0.3MG	N021301	012	May 25, 2001

NOVOTHYROX

MERCK KGAA

0.025MG	N021292	001	May 31, 2002
0.05MG	N021292	002	May 31, 2002
0.075MG	N021292	003	May 31, 2002
0.088MG	N021292	004	May 31, 2002
0.1MG	N021292	005	May 31, 2002
0.112MG	N021292	006	May 31, 2002
0.125MG	N021292	007	May 31, 2002
0.137MG	N021292	008	May 31, 2002
0.15MG	N021292	009	May 31, 2002
0.175MG	N021292	010	May 31, 2002
0.2MG	N021292	011	May 31, 2002
0.3MG	N021292	012	May 31, 2002

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%	N014394	001	

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH	N020575	001	May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%	A084944	001	
5%	A084946	001	
5%	A084947	001	

LIDOCAINE

GRAHAM CHEM

5%	A080210	001	

XYLOCAINE

ASTRAZENECA

5%	N008048	001	

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH	N020575	002	May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%	N014127	001	

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG	N013077	001	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE

2%	A084721	001	

LIDOCAINE HYDROCHLORIDE

ABBOTT

10%	A087980	001	Feb 02, 1983
20%	A089362	001	May 25, 1988

ABRAXIS PHARM

1%	A080420	001	
1%	A086761	001	
1.5%	A080420	005	
2%	A080420	002	

DISCONTINUED DRUG PRODUCT LIST

6-193 (of 322)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

	2%	A080420	004	
	2%	A086761	002	
	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
BEL MAR	1%	A080710	001	
	2%	A080760	001	
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
GRAHAM CHEM	2%	A080504	001	
HIKMA MAPLE	1%	A080407	001	
	2%	A080407	002	
HOSPIRA	1%	A040013	001	Jun 23, 1995
	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
INTL MEDICATION	1%	N017701	002	
	1GM/VIAL	N018543	001	
	2%	N017701	001	
	2GM/VIAL	N018543	002	
LUITPOLD	2%	A083198	001	
LYPHOMED	1%	A080390	001	
	2%	A080390	002	
MILES	1%	A080414	001	
	2%	A080414	002	
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
HIKMA MAPLE	1%	A084625	001	
	2%	A084625	002	
INTL MEDICATION	4%	N017702	002	
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	
	1.5%	N010418	009	
	2%	N010418	007	
XYLOCAINE DENTAL				
DENTSPLY PHARM	2%	N021380	001	

DISCONTINUED DRUG PRODUCT LIST

6-194 (of 322)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; SPINAL

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

FRESENIUS KABI USA 1.5%

N016297 001

XYLOCAINE 5% W/ GLUCOSE 7.5%

ASTRAZENECA 5%

N010496 002 Jul 07, 1982

JELLY; TOPICAL

ANESTACON

POLYMEDICA 2%

A080429 001

LIDOCAINE HYDROCHLORIDE

TEVA PHARMS USA 2%

A081318 001 Apr 29, 1993

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

ACTAVIS MID ATLANTIC 2%

A086578 001

INTL MEDICATION 2%

A086389 001 Feb 02, 1982

SOLUTION; TOPICAL

LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL 4%

A087931 001 Jun 10, 1983

LIDOCAINE HYDROCHLORIDE

PACO 4%

A089688 001 Jun 30, 1989

LTA II KIT

HOSPIRA 4%

A088542 001 Jul 31, 1984

PEDIATRIC LTA KIT

ABBOTT 2%

A088572 001 Jul 31, 1984

HOSPIRA 2%

A085995 001

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER 2%; 50MG/ML

A060567 001

2%; 125MG/ML

A060567 002

LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA 2.5%; 2.5%

N020962 001 Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN EQ 250MG BASE

N050316 001

EQ 500MG BASE

N050316 002

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK 1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND 1%

A084989 001

KWELL

REED AND CARNRICK 1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL 1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND 1%

A084988 001

KWELL

REED AND CARNRICK 1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL 1%

A087940 001 Apr 08, 1983

DISCONTINUED DRUG PRODUCT LIST

6-195 (of 322)

LINEZOLID

TABLET;ORAL

ZYVOX

PHARMACIA AND UPJOHN

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET;ORAL

EUTHROID-0.5

PARKE DAVIS

0.0075MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.015MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.03MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.045MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.0625MG;0.25MG

N016807 006

LISINOPRIL

TABLET;ORAL

LISINOPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCK

2.5MG

N019558 006 Jan 28, 1994

LITHIUM CARBONATE

CAPSULE;ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

WEST WARD

600MG

A078763 001 Apr 15, 2008

LITHONATE

SOLVAY

300MG

N016782 001

TABLET;ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

PFIZER

300MG

N016834 001

WEST WARD

300MG

A078715 001 Dec 28, 2010

DISCONTINUED DRUG PRODUCT LIST

6-196 (of 322)

LITHIUM CARBONATE

TABLET; ORAL

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

JDS PHARMS

450MG

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

LITHIUM CITRATE

SYRUP; ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

MCNEIL PED

2MG

N017690 001

LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

SANDOZ

2MG

A072993 001 Aug 28, 1992

TEVA

2MG

A073122 001 Aug 30, 1991

SOLUTION; ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

PERRIGO

2MG

A074194 001 Oct 30, 1992

LORACARBEEF

CAPSULE; ORAL

LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

FOR SUSPENSION; ORAL

LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

SCHERING PLOUGH

1MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020641 003 Nov 19, 2003

LORATADINE

APOTEX INC

1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD

1MG/ML

A076529 001 Aug 20, 2004

TABLET; ORAL

LORATADINE

PERRIGO

10MG

N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

WATSON LABS INC FL

5MG; 120MG

A076208 001 Jan 28, 2004

DISCONTINUED DRUG PRODUCT LIST

6-197 (of 322)

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN	2MG/ML	A074974	001	Jul 23, 1998
BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
	4MG/ML	A077076	002	Jul 13, 2005
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
HIKMA MAPLE	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	2MG/ML	A074300	001	Apr 12, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
MARSAM PHARMS LLC	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
	4MG/ML	A074276	002	Apr 15, 1994

SOLUTION; ORAL

LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	0.5MG	A072553	001	Mar 29, 1991
	1MG	A070473	001	Dec 10, 1985
	1MG	A072554	001	Mar 29, 1991
	2MG	A070474	001	Dec 10, 1985
	2MG	A072555	001	Mar 29, 1991
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK	10MG	N019643	002	Mar 28, 1991
	20MG	N019643	003	Aug 31, 1987
	40MG	N019643	004	Dec 14, 1988

DISCONTINUED DRUG PRODUCT LIST

6-198 (of 322)

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC

10MG

N021316 001 Jun 26, 2002

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

WATSON LABS

EQ 25MG BASE/ML

N017658 001

INJECTABLE; INJECTION

LOXITANE IM

WATSON LABS

EQ 50MG BASE/ML

N018039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

WATSON LABS

EQ 5MG BASE

N017525 001

EQ 10MG BASE

N017525 002

EQ 25MG BASE

N017525 003

EQ 50MG BASE

N017525 004

TABLET; ORAL

LOXITANE

WATSON LABS

EQ 10MG BASE

N017525 006

EQ 25MG BASE

N017525 007

EQ 50MG BASE

N017525 008

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO

75 IU/VIAL

N021322 001 Oct 08, 2004

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS

0.185MG/ML

N016755 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019006 001 Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC

14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N018406 001

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N018406 002 Jul 08, 1982

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE

30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML

N019326 001 Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS

343MG; 20MG; 750MG

N022456 001 Dec 04, 2009

343MG; 40MG; 750MG

N022456 002 Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS

700MG; 20MG; 600MG

N021850 001 Mar 24, 2006

700MG; 40MG; 600MG

N021850 002 Mar 24, 2006

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE

37.9MG/ML

N020652 001 Nov 26, 1997

DISCONTINUED DRUG PRODUCT LIST

6-199 (of 322)

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO

3.49MG/GM

N020686 001 Dec 19, 1997

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM

EQ 0.1MG MANGANESE/ML

N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

HOSPIRA

10GM/100ML

N016269 002

MILES

10GM/100ML

N016472 002

MANNITOL 15%

HOSPIRA

15GM/100ML

N016269 003

MILES

15GM/100ML

N016472 005

MANNITOL 20%

B BRAUN

20GM/100ML

N014738 001

HOSPIRA

20GM/100ML

N016269 004

MILES

20GM/100ML

N016472 004

MANNITOL 25%

ABRAXIS PHARM

12.5GM/50ML

A086754 001

ASTRAZENECA

12.5GM/50ML

A089239 001 May 06, 1987

12.5GM/50ML

A089240 001 May 06, 1987

HOSPIRA

12.5GM/50ML

N016269 005

MERCK

12.5GM/50ML

N005620 001

WATSON LABS

12.5GM/50ML

A087460 001 Jun 27, 1983

MANNITOL 5%

HOSPIRA

5GM/100ML

N016269 001

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN

5GM/100ML

N016704 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA

540MG/100ML; 2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS

25MG

N017543 001

50MG

N017543 002

75MG

N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

25MG

A072129 001 Jan 14, 1988

50MG

A072130 001 Jan 14, 1988

75MG

A072131 001 Jan 14, 1988

WATSON LABS

25MG

A071943 001 Dec 30, 1987

25MG

A072162 001 Jun 01, 1988

50MG

A071944 001 Dec 30, 1987

50MG

A072163 001 Jun 01, 1988

75MG

A071945 001 Dec 30, 1987

75MG

A072164 001 Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR

10%

N019940 001 Sep 04, 1992

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST

1MG

N017980 002

2MG

N017980 001

SANOREX

NOVARTIS

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017247 001

2MG **Federal Register determination
that product was not discontinued or

N017247 002

DISCONTINUED DRUG PRODUCT LIST

6-200 (of 322)

MAZINDOLTABLET; ORAL
SANOREXwithdrawn for safety or efficacy
reasons**MEBENDAZOLETABLET, CHEWABLE; ORAL
VERMOX
JANSSEN PHARMS

100MG

N017481 001

MEBUTAMATETABLET; ORAL
DORMATE

MEDPOINTE PHARM HLC

600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDETABLET; ORAL
INVERSINE

TARGACEPT

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N010251 001

MECASERMIN RINFABATE RECOMBINANTINJECTABLE; SUBCUTANEOUS
IPLEX

INSMED

36MG/0.6ML

N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING

12.5MG

A085253 001

25MG

A085252 001

ANABOLIC

25MG

A085891 001

BUNDY

12.5MG

A084382 001

25MG

A084872 001

IVAX SUB TEVA PHARMS

12.5MG

A083784 001

12.5MG

A084975 001

25MG

A084657 001

KV PHARM

12.5MG

A085524 001

25MG

A085523 001

PLIVA

12.5MG

A088732 001 Dec 11, 1985

25MG

A088734 001 Dec 11, 1985

SUPERPHARM

12.5MG

A089113 001 Aug 20, 1985

25MG

A089114 001 Aug 20, 1985

UDL

12.5MG

A088256 001 Jun 13, 1983

25MG

A088257 001 Jun 13, 1983

VANGARD

12.5MG

A087877 001 Apr 20, 1982

25MG

A087620 001 Jan 04, 1982

WATSON LABS

12.5MG

A085195 001

12.5MG

A085269 001

TABLET, CHEWABLE; ORAL

ANTIVERT

CITRON PHARMA LLC

25MG

N010721 005

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

25MG

A084976 001

NEXGEN PHARMA INC

25MG

A086392 001

PLIVA

25MG

A088733 001 Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON

1%

N050518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS

EQ 50MG BASE

A071380 001 Jul 14, 1987

EQ 100MG BASE

A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP

EQ 50MG BASE

A071362 001 Feb 10, 1987

EQ 100MG BASE

A071363 001 Feb 10, 1987

BARR

EQ 50MG BASE

A072848 001 Mar 20, 1989

EQ 100MG BASE

A072809 001 Mar 20, 1989

PAR PHARM

EQ 50MG BASE

A072077 001 Mar 10, 1988

DISCONTINUED DRUG PRODUCT LIST

6-201 (of 322)

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

	EQ 100MG BASE	A072078 001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710 001	Jun 15, 1988
	EQ 100MG BASE	A071684 001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400 001	Nov 25, 1986
	EQ 50MG BASE	A071468 001	Apr 15, 1987
	EQ 50MG BASE	A071640 001	Aug 11, 1987
	EQ 100MG BASE	A070401 001	Nov 25, 1986
	EQ 100MG BASE	A071469 001	Apr 15, 1987
	EQ 100MG BASE	A071641 001	Aug 11, 1987
MECLOMEN			
PARKE DAVIS	EQ 50MG BASE	N018006 001	
	EQ 100MG BASE	N018006 002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012541 002	

MEDROXYPROGESTERONE ACETATE

TEVA PHARMS USA	150MG/ML	A076552 001	Oct 27, 2004
TABLET; ORAL			
AMEN			
AMARIN PHARMS	10MG	A083242 001	
CURRETAB			
SOLVAY	10MG	A085686 001	
CYCRIN			
ESI	2.5MG	A081239 001	Oct 30, 1992
	5MG	A081240 001	Oct 30, 1992
	10MG	A089386 001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE			
DURAMED PHARMS BARR	2.5MG	A040311 001	Dec 01, 1999
	5MG	A040311 002	Dec 01, 1999
	10MG	A040311 003	Dec 01, 1999

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN	1%	N016624 003	

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE	250MG	N019591 001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE			
US ARMY WALTER REED	250MG	N019578 001	May 02, 1989
WEST WARD PHARM CORP	250MG	A077699 001	Apr 21, 2010

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

APOTEX INC	40MG/ML	A077404 001	Feb 16, 2006

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB	20MG	N016979 001	
	40MG	N016979 002	
MEGESTROL ACETATE			
TEVA	40MG	A074745 001	Feb 27, 1998
USL PHARMA	20MG	A070646 001	Oct 02, 1987
	40MG	A070647 001	Oct 02, 1987

DISCONTINUED DRUG PRODUCT LIST

6-202 (of 322)

MELOXICAM

TABLET; ORAL

MELOXICAM

COREPHARMA	7.5MG	A077930 001	Jul 19, 2006
	15MG	A077930 002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039 001	Dec 14, 2006
	15MG	A078039 002	Dec 14, 2006
MUTUAL PHARM	7.5MG	A077935 001	Jul 19, 2006
	15MG	A077935 002	Jul 19, 2006
MYLAN	7.5MG	A077934 001	Jul 20, 2006
	15MG	A077934 002	Jul 20, 2006
ROXANE	7.5MG	A077925 001	Jul 19, 2006
	15MG	A077925 002	Jul 19, 2006
YABAO BIOPHARMS	7.5MG	A077933 001	Jul 19, 2006
	15MG	A077933 002	Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299 001	Oct 27, 2009

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

SUN PHARMA GLOBAL	5MG	A090058 001	May 05, 2010
	10MG	A090058 002	May 05, 2010
MEMANTINE HYDROCHLORIDE			
DR REDDYS LABS LTD	5MG	A090048 001	Apr 14, 2010
	10MG	A090048 002	Apr 14, 2010
ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
	10MG	A090044 002	Mar 12, 2012
TEVA PHARMS	5MG	A090052 001	Oct 25, 2011
	10MG	A090052 002	Oct 25, 2011

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY	10MG/ML	N005725 001	
SYNKAYVITE			
ROCHE	5MG/ML	N003718 004	
	10MG/ML	N003718 006	
	37.5MG/ML	N003718 008	

TABLET; ORAL

SYNKAYVITE

ROCHE	5MG	N003718 010	

MENADIONE

TABLET; ORAL

MENADIONE

LILLY	5MG	N002139 003	

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC	75 IU/VIAL; 75 IU/VIAL	N020328 001	Sep 01, 1994
	150 IU/VIAL; 150 IU/VIAL	N020328 002	Sep 01, 1994

MENOTROPINS

FERRING	75 IU/VIAL; 75 IU/VIAL	A073598 001	Jan 30, 1997
	150 IU/VIAL; 150 IU/VIAL	A073599 001	Jan 30, 1997

PERGONAL

SERONO	75 IU/AMP; 75 IU/AMP	N017646 001	
	150 IU/AMP; 150 IU/AMP	N017646 002	May 20, 1985

REPRONEX

FERRING	150 IU/VIAL; 150 IU/VIAL	N021047 002	Aug 27, 1999

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US	25MG/5ML	N010679 004	

DISCONTINUED DRUG PRODUCT LIST

6-203 (of 322)

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

SANOFI AVENTIS US	25MG/ML	N005010 007
	50MG/ML	N005010 002
	75MG/ML	N005010 009
	100MG/ML	N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML	A080388 001
50MG/ML	A080385 001
50MG/ML	A080387 001
75MG/ML	A080389 001
100MG/ML	A080386 001

ASTRAZENECA

25MG/ML	A089781 001	Mar 31, 1989
50MG/ML	A089782 001	Mar 31, 1989
50MG/ML	A089783 001	Mar 31, 1989
50MG/ML	A089784 001	Mar 31, 1989
75MG/ML	A089785 001	Mar 31, 1989
100MG/ML	A089786 001	Mar 31, 1989
100MG/ML	A089787 001	Mar 31, 1989
100MG/ML	A089788 001	Mar 31, 1989

BAXTER HLTHCARE

25MG/ML	A088279 001	Jun 15, 1984
50MG/ML	A088280 001	Jun 15, 1984
75MG/ML	A088281 001	Jun 15, 1984
100MG/ML	A088282 001	Jun 15, 1984

INTL MEDICATION

10MG/ML	A086332 001

PARKE DAVIS

50MG/ML	A080364 002
75MG/ML	A080364 003
100MG/ML	A080364 001

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML	A040305 001	Mar 10, 1999

MALLINCKRODT

10MG/ML	A040163 001	May 12, 1997

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US	50MG/5ML	N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG	A040318 001	Oct 05, 1999
100MG	A040318 002	Oct 05, 1999

MUTUAL PHARM

50MG	A080448 001
100MG	A080448 002

WYETH AYERST

50MG	A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP	25MG/ML; 25MG/ML	N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248 002
	EQ 30MG BASE/ML	N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY

3%	A084777 002	Apr 18, 1982

CARBOCAINE

EASTMAN KODAK

3%	N012125 003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM

3%	A083559 001

INTL MEDICATION

1%	A087509 001	Oct 05, 1982

POLOCAINE

DENTSPLY PHARM

3%	A088653 001	Aug 21, 1984

DISCONTINUED DRUG PRODUCT LIST

6-204 (of 322)

MEPREDNISONE

TABLET;ORAL

BETAPAR

SCHERING

4MG

N016053 002

MEPROBAMATE

CAPSULE;ORAL

EQUANIL

WYETH AYERST

400MG

N012455 002

CAPSULE, EXTENDED RELEASE;ORAL

MEPROSPAN

MEDPOINTE PHARM HLC

200MG

N011284 001

400MG

N011284 002

TABLET;ORAL

AMOSENE

FERNDAL LABS

400MG

A084030 001

BAMATE

ALRA

200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST

200MG

N010028 005

400MG

N010028 004

MEPRIAM

TEVA

400MG

N016069 001

MEPROBAMATE

BARR

600MG

A084230 001

ELKINS SINN

200MG

N015426 002

400MG

N015426 001

HEATHER

400MG

N016928 003

600MG

A084329 001

IMPAX LABS

200MG

N014322 002

400MG

N014322 001

IVAX SUB TEVA PHARMS

200MG

N015438 001

400MG

N015438 002

600MG

A084181 001

IVC INDS

400MG

A084153 001

LANNETT

200MG

N014882 002

400MG

N014882 001

LEDERLE

400MG

A086299 001

LEE KM

400MG

A089538 001

Nov 25, 1987

MALLARD

400MG

N015072 002

MK LABS

200MG

N014368 004

400MG

N014368 002

MUTUAL PHARM

200MG

A080699 001

400MG

A080699 002

MYLAN

400MG

A083618 001

NEXGEN PHARMA INC

200MG

A084220 001

400MG

A084589 001

PARKE DAVIS

200MG

A084744 001

400MG

A084744 002

PERRIGO

200MG

A084546 001

400MG

A084547 001

PHARMAVITE

400MG

A084438 001

PUREPAC PHARM

200MG

A084804 001

400MG

A084804 002

PVT FORM

400MG

N014601 001

ROXANE

600MG

A084332 001

SANDOZ

200MG

N014547 002

400MG

A080655 001

400MG

N014547 001

SCHERER LABS

400MG

A083343 001

SOLVAY

200MG

A084435 001

STANLABS PHARM

200MG

N014474 002

400MG

N014474 004

TABLICAPS

400MG

A083494 001

TARO

200MG

A200998 001

May 23, 2011

400MG

A200998 002

May 23, 2011

USL PHARMA

200MG

A087825 001

Mar 18, 1982

400MG

A087826 001

Mar 18, 1982

VALEANT PHARM INTL

200MG

N015139 006

400MG

N015139 005

VANGARD

400MG

A088011 001

Jul 14, 1982

WATSON LABS

200MG

A085720 001

DISCONTINUED DRUG PRODUCT LIST

6-205 (of 322)

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	400MG	A085721 001
	600MG	A084274 001
	600MG	A085719 001
WEST WARD	200MG	N015417 003
	400MG	N015417 002
WHITEWORTH TOWN PLSN	200MG	A083830 001
	400MG	A083442 001
MILTOWN		
MEDPOINTE PHARM HLC	200MG	N009698 004
	400MG	N009698 002
	600MG	A083919 001
NEURAMATE		
HALSEY	200MG	N014359 002
	400MG	N014359 001
TRANMEP		
SOLVAY	400MG	A084369 001
	400MG	N016249 001

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

AQUA PHARMS	2%; 0.01%	N020922 001	Dec 10, 1999

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML; 50MG/ML	A084875 001

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

APTALIS PHARMA US	500MG	N021252 001	Jan 05, 2001

ROWASA

MEDA PHARMS	500MG	N019919 001	Dec 18, 1990

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016997 001

INJECTABLE; INJECTION

SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS	EQ 10MG BASE	N016774 001
	EQ 25MG BASE	N016774 002
	EQ 50MG BASE	N016774 003
	EQ 100MG BASE	N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

WATSON LABS	0.1MG; 2MG	N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS	0.05MG; 1MG	A071539 001	Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS	0.05MG; 1MG	A070758 001	Jul 01, 1988

NORINYL 1+50 21-DAY

WATSON LABS	0.05MG; 1MG	N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC	0.08MG; 1MG	N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM	0.05MG; 1MG	N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM	0.08MG; 1MG	N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM	0.06MG; 10MG	N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM	0.1MG; 2MG	N012728 005

DISCONTINUED DRUG PRODUCT LIST

6-206 (of 322)

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS

0.05MG; 1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC

0.08MG; 1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN

0.05MG; 1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM

0.08MG; 1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC

0.075MG; 5MG

N010976 008

0.15MG; 9.85MG

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC

0.075MG; 5MG

N010976 004

ENOVID-E

GD SEARLE LLC

0.1MG; 2.5MG

N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG; 2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

APOTEX INC

0.4%

A075402 001 Feb 28, 2001

0.6%

A075403 001 Feb 28, 2001

ASTRAZENECA

0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY

0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

NEPHRON

0.4%

A071855 001 Jul 14, 1988

0.6%

A071726 001 Jul 14, 1988

WOCKHARDT

5%

A072190 001 Jun 07, 1988

PROMETA

MURO

5%

A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML

N017571 001

METAPROTERENOL SULFATE

APOTEX INC

10MG/5ML

A075235 001 Jan 27, 2000

MORTON GROVE

10MG/5ML

A071656 001 Oct 13, 1987

TEVA

10MG/5ML

A072761 001 Feb 27, 1992

TEVA PHARMS

10MG/5ML

A073034 001 Aug 30, 1991

WOCKHARDT

10MG/5ML

A074702 001 Mar 24, 1997

PROMETA

MURO

10MG/5ML

A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG

N015874 002

20MG

N015874 001

METAPROTERENOL SULFATE

AM THERAP

10MG

A072054 001 Jun 23, 1988

20MG

A072055 001 Jun 23, 1988

TEVA

10MG

A072519 001 Mar 30, 1990

20MG

A072520 001 Mar 30, 1990

USL PHARMA

10MG

A071013 001 Jan 25, 1988

20MG

A071014 001 Jan 25, 1988

WATSON LABS

10MG

A073013 001 Jan 31, 1991

20MG

A072795 001 Jan 31, 1991

DISCONTINUED DRUG PRODUCT LIST

6-207 (of 322)

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK

EQ 10MG BASE/ML

N009509 002 Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML

A080431 001

ELKINS SINN

EQ 10MG BASE/ML

A083363 001

GD SEARLE LLC

EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS

400MG

N013217 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB

625MG

N020357 003 Nov 05, 1998

750MG

N020357 004 Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR

1GM

A075971 003 Jan 25, 2002

500MG

A075971 001 Jan 25, 2002

850MG

A075971 002 Jan 25, 2002

IPCA LABS LTD

1GM

A078422 003 Aug 06, 2007

500MG

A078422 001 Aug 06, 2007

850MG

A078422 002 Aug 06, 2007

IVAX SUB TEVA PHARMS

1GM

A075975 003 Jan 24, 2002

500MG

A075975 001 Jan 24, 2002

625MG

A075975 004 Jan 24, 2002

750MG

A075975 005 Jan 24, 2002

850MG

A075975 002 Jan 24, 2002

TEVA

1GM

A076328 003 Dec 16, 2002

500MG

A076328 001 Dec 16, 2002

850MG

A076328 002 Dec 16, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH

500MG

A076450 001 Oct 01, 2004

750MG

A076878 001 Apr 13, 2005

BARR

500MG

A076496 001 Nov 25, 2005

IVAX SUB TEVA PHARMS

500MG

A076545 001 Dec 01, 2003

MUTUAL PHARM

500MG

A077124 001 Dec 21, 2005

RANBAXY LABS LTD

500MG

A076413 001 Jun 18, 2004

750MG

A077211 001 Jun 29, 2005

SANDOZ

500MG

A076223 001 Dec 14, 2004

TORRENT PHARMS LTD

750MG

A079226 001 Feb 18, 2010

WATSON LABS INC

500MG

A076818 001 Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO

500MG; EQ 1MG BASE

N021410 001 Oct 10, 2002

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 140MG BASE

A060641 001

EQ 280MG BASE

A060641 002

SYRUP; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 70MG BASE/5ML

A060641 003

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE

10MG/30ML

N006134 004

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE

5MG

A088108 001 Mar 08, 1983

10MG

A088109 001 Mar 08, 1983

40MG

A074081 001 Apr 28, 1995

SANDOZ

5MG

A040241 001 May 29, 1998

DISCONTINUED DRUG PRODUCT LIST

6-208 (of 322)

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ

2.5MG

N017108 001

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ

5MG

N017108 002

10MG

N017108 003

40MG

N017108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPEX

TEVA

10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE

5MG

A040529 001 Feb 25, 2004

REXAR

5MG

A084931 001

10MG

A084931 002

TEVA

5MG

A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESODYN

RECORDATI RARE

5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE

50MG

N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE

100MG

N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL

25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

SANDOZ

25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE

25MG

N011721 002 Nov 25, 1991

50MG

N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB

3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS

4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB

4MG/5ML

N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB

8MG

N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON

EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

DISCONTINUED DRUG PRODUCT LIST

6-209 (of 322)

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS

15MG

A040619 003 Jul 12, 2005

20MG

A040547 004 Feb 18, 2005

MYLAN

20MG

A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS

5MG

N007517 002

10MG

N007517 004

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS

1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC

100MG/ML

A089849 001 Dec 27, 1991

WATSON LABS

100MG/ML

A086459 001

TABLET; ORAL

DELAXIN

FERNDAL LABS

500MG

A085454 001

FORBAXIN

FOREST LABS

750MG

A085136 001

METHOCARBAMOL

ABLE

500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987

ASCOT

500MG

A087660 001 Oct 27, 1982

750MG

A087661 001 Oct 27, 1982

CLONMEL HLTHCARE

500MG

A085961 001

750MG

A085963 001

HEATHER

500MG

A084675 001

750MG

A084924 001

IMPAX LABS

500MG

A084927 001

750MG

A084928 001

INWOOD LABS

500MG

A085137 001

IVAX SUB TEVA PHARMS

500MG

A084648 001

750MG

A084649 001

KV PHARM

500MG

A085660 001

750MG

A085658 001

MUTUAL PHARM

500MG

A084488 001

750MG

A084486 001

MYLAN

500MG

A084259 001

750MG

A084323 001

NYLOS

750MG

A085033 001

PIONEER PHARMS

500MG

A088731 001 Dec 13, 1985

750MG

A089082 001 Dec 13, 1985

PURACAP PHARM

500MG

A084231 002

750MG

A084471 001

PUREPAC PHARM

500MG

A085718 001

750MG

A085718 002

ROXANE

500MG

A088646 001 Feb 29, 1984

750MG

A088647 001 Feb 29, 1984

SANDOZ

500MG

A087283 001

750MG

A087282 001

SOLVAY

500MG

A084448 001

750MG

A084449 001

SUPERPHARM

500MG

A087589 001 Jan 22, 1982

750MG

A087590 001 Jan 22, 1982

TABLICAPS

500MG

A084846 001

UPSHER SMITH

500MG

A087453 001

750MG

A087454 001

WATSON LABS

500MG

A083605 001

750MG

A083605 002

DISCONTINUED DRUG PRODUCT LIST

6-210 (of 322)

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

JHP PHARMS

5GM/VIAL

N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML

A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL

A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL

A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL

A089356 001 Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ 25MG BASE/VIAL

A087695 001 Apr 08, 1983

EQ 50MG BASE/VIAL

A087695 002 Apr 08, 1983

EQ 100MG BASE/VIAL

A087695 003 Apr 08, 1983

EQ 250MG BASE/VIAL

A088954 001 Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ 25MG BASE/ML

A081242 001 Aug 23, 1991

EQ 25MG BASE/ML

A089180 001 Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ 25MG BASE/ML

N011719 007 Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

FRESENIUS KABI USA

EQ 25MG BASE/ML

A040265 001 Feb 26, 1999

HOSPIRA

EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)

N011719 011 Apr 13, 2005

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N011719 014 Apr 13, 2005

EQ 500MG BASE/20ML (EQ 25MG BASE/ML)

N011719 013 Apr 13, 2005

**Federal Register determination that
product was not discontinued or
withdrawn for safety or efficacy
reasons**

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML

A089323 001 Jun 13, 1986

EQ 20MG BASE/VIAL

A088935 001 Oct 11, 1985

EQ 25MG BASE/ML

A089263 001 Jun 13, 1986

EQ 25MG BASE/ML

A089322 001 Jun 13, 1986

EQ 50MG BASE/VIAL

A088936 001 Oct 11, 1985

EQ 100MG BASE/VIAL

A088937 001 Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML

N011719 004

EQ 20MG BASE/VIAL

N011719 001

EQ 25MG BASE/ML

N011719 005

EQ 50MG BASE/VIAL

N011719 003

EQ 100MG BASE/VIAL

N011719 006

NORBROOK

EQ 25MG BASE/ML

A088648 001 May 09, 1986

PHARMACHEMIE USA

EQ 25MG BASE/ML

A089158 001 Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL

N011719 009 Apr 07, 1988

MEXATE

BRISTOL

EQ 20MG BASE/VIAL

A086358 001

EQ 50MG BASE/VIAL

A086358 002

EQ 100MG BASE/VIAL

A086358 003

EQ 250MG BASE/VIAL

A086358 004

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML

A088760 001 Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML

A089887 001 Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ 2.5MG BASE

A040233 001 Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE

10MG/ML

N006772 002

20MG/ML

N006772 001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

SANDOZ

10MG

A087781 001 Jun 08, 1982

DISCONTINUED DRUG PRODUCT LIST

6-211 (of 322)

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM

2.5MG

A080970 001

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC

5MG

N017364 001

ENDURON

ABBVIE

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**
5MG

N012524 001

N012524 004

METHYCLOTHIAZIDE

IVAX PHARMS

2.5MG

A087913 001 Jun 03, 1982

5MG

A087786 001 May 18, 1982

MYLAN

2.5MG

A087671 001 Aug 17, 1982

PAR PHARM

2.5MG

A089135 001 Feb 12, 1986

5MG

A089136 001 Feb 12, 1986

SANDOZ

2.5MG

A089835 001 Aug 18, 1988

5MG

A089837 001 Aug 18, 1988

USL PHARMA

5MG

A088745 001 Mar 21, 1985

WATSON LABS

2.5MG

A085487 001 Mar 11, 1982

2.5MG

A088750 001 Sep 06, 1984

5MG

A085476 001 Mar 11, 1982

5MG

A088724 001 Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT

5MG; 25MG

N016047 001

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC

2.5MG; 0.1MG

N012708 005

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP

EQ 16.8% BASE

N021415 001 Jul 27, 2004

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK

250MG/5ML

N018389 001

TABLET; ORAL

ALDOMET

MERCK

125MG

N013400 003

250MG

N013400 001

500MG

N013400 002

METHYLDOPA

ACCORD HLTHCARE

125MG

A070070 003 Oct 15, 1985

DURAMED PHARMS BARR

250MG

A071006 001 Dec 16, 1986

500MG

A071009 001 Dec 16, 1986

HALSEY

125MG

A071751 001 Mar 28, 1988

250MG

A071752 001 Mar 28, 1988

500MG

A071753 001 Mar 28, 1988

MUTUAL PHARM

125MG

A070073 001 Oct 09, 1986

250MG

A070060 001 Oct 09, 1986

500MG

A070074 001 Oct 09, 1986

PAR PHARM

125MG

A070535 001 Jan 02, 1987

250MG

A070536 001 Jan 02, 1987

500MG

A070537 001 Jan 02, 1987

PARKE DAVIS

125MG

A070331 001 Apr 15, 1986

250MG

A070332 001 Apr 15, 1986

500MG

A070333 001 Apr 15, 1986

PLIVA

125MG

A072126 001 Jul 07, 1988

250MG

A072127 001 Jul 07, 1988

500MG

A072128 001 Jul 07, 1988

PUREPAC PHARM

125MG

A070749 001 Feb 07, 1986

250MG

A070750 001 Feb 07, 1986

500MG

A070452 001 Feb 07, 1986

DISCONTINUED DRUG PRODUCT LIST

6-212 (of 322)

METHYLDOPA

TABLET; ORAL

METHYLDOPA

ROXANE	125MG	A070192 001	Apr 25, 1986
	250MG	A070193 001	Apr 25, 1986
	500MG	A070194 001	Apr 25, 1986
SANDOZ	125MG	A071700 001	Mar 02, 1988
	250MG	N018934 001	Jun 29, 1984
	500MG	N018934 002	Jun 29, 1984
SUPERPHARM	250MG	A070669 001	Jun 23, 1989
	500MG	A070670 001	Jun 23, 1989
TEVA	125MG	A071105 001	Dec 05, 1986
	250MG	A071106 001	Dec 05, 1986
	500MG	A071067 001	Dec 05, 1986
WATSON LABS	125MG	A070245 001	Feb 25, 1986
	125MG	A070260 001	Jun 24, 1985
	250MG	A070246 001	Feb 25, 1986
	250MG	A070261 001	Jun 24, 1985
	250MG	A070703 001	Jun 06, 1986
	500MG	A070247 001	Feb 25, 1986
	500MG	A070262 001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK	50MG/ML	N013401 001	
METHYLDOPATE HYDROCHLORIDE			
ABRAXIS PHARM	50MG/ML	A070652 001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291 001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691 001	Jun 19, 1987
	50MG/ML	A070698 001	Jun 15, 1987
	50MG/ML	A070699 001	Jun 15, 1987
	50MG/ML	A070849 001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812 001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841 001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974 001	Nov 22, 1991

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404 001	Mar 29, 2001
	10MG	A040404 002	Mar 29, 2001
	20MG	A040404 003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321 001	Feb 05, 2002
	10MG	A040321 002	Feb 05, 2002
	20MG	A040321 003	Feb 05, 2002

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040306 001	Oct 20, 1999

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032 001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450 001	Dec 21, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153 005	
METHYLPREDNISOLONE			
HEATHER	4MG	A085650 001	
PAR PHARM	16MG	A089207 001	Apr 25, 1988
	24MG	A089208 001	Apr 25, 1988
	32MG	A089209 001	Apr 25, 1988
SANDOZ	4MG	A087341 001	
WATSON LABS	4MG	A086161 001	Feb 09, 1982
	16MG	A086159 001	Feb 09, 1982

DISCONTINUED DRUG PRODUCT LIST

6-213 (of 322)

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666	001
	80MG/ML	A087135	001

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001
	1%	N012421	002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%; EQ 3.5MG BASE/GM	A060611	002
	1%; EQ 3.5MG BASE/GM	A060611	001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
HOSPIRA	EQ 1GM BASE/VIAL	A085852	001	
	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987

METHYLPREDNISOLONE

ELKINS SINN	EQ 1GM BASE/VIAL	A086906	004	
	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
ORGANON USA INC	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982
	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
BEDFORD LABS	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
INTL MEDICATION	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
TEVA PARENTERAL	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
WATSON LABS	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

DISCONTINUED DRUG PRODUCT LIST

6-214 (of 322)

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

EQ 40MG BASE/VIAL

A086953 001 Jul 22, 1982

EQ 125MG BASE/VIAL

A087030 001 Jul 22, 1982

EQ 500MG BASE/VIAL

A088523 001 Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN 0.1%; EQ 3.5MG BASE/GM

A060645 001

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER

10MG

A084967 001

VIRILON

STAR PHARMS FL

10MG

A087750 001 Nov 24, 1982

TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL

5MG

A087222 001

ORETON

SCHERING

10MG

A080281 001

TABLET; BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS

5MG

N003240 004

10MG

N003240 001

10MG

N003240 005

25MG

N003240 003

METHYLTESTOSTERONE

IMPAX LABS

10MG

A084287 001

LILLY

10MG

A080256 001

25MG

A080256 002

PUREPAC PHARM

10MG

A080308 001

10MG

A080475 001

10MG

A080475 002

25MG

A080475 003

PVT FORM

5MG

A083836 001

TABLICAPS

10MG

A085125 001

USL PHARMA

10MG

A080271 001

TABLET; ORAL

METHYLTESTOSTERONE

INWOOD LABS

10MG

A080839 001

25MG

A080973 001

KV PHARM

10MG

A084312 001

LANNETT

10MG

A087092 001 Nov 05, 1982

25MG

A087111 001 Jan 27, 1983

PARKE DAVIS

10MG

A084244 001

25MG

A084241 001

PUREPAC PHARM

10MG

A080309 001

25MG

A080310 001

PVT FORM

5MG

A080214 001

10MG

A080214 002

25MG

A080214 003

TABLICAPS

10MG

A080313 001

25MG

A085270 001

WATSON LABS

10MG

A080933 001

25MG

A080931 001

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR; ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

DISCONTINUED DRUG PRODUCT LIST

6-215 (of 322)

METHYPRYLON

TABLET; ORAL

NOLUDAR

ROCHE

50MG

N009660 002

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001 Jan 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001 Mar 30, 1992

EQ 5MG BASE/ML

A072244 001 Mar 30, 1992

EQ 5MG BASE/ML

A072247 001 May 18, 1992

HOSPIRA

EQ 5MG BASE/ML

A070505 001 Jun 23, 1989

EQ 5MG BASE/ML

A070506 001 Jun 22, 1989

EQ 5MG BASE/ML

A070847 001 Nov 07, 1988

EQ 5MG BASE/ML

A071291 001 Mar 03, 1989

EQ 5MG BASE/ML

A071990 001 Jan 18, 1989

EQ 5MG BASE/ML

A073117 001 Jan 17, 1991

EQ 5MG BASE/ML

A074147 001 Aug 02, 1996

LYPHOMED

EQ 10MG BASE/2ML

A070293 001 Jan 24, 1986

NORBROOK

EQ 10MG BASE/2ML

A070892 001 Aug 26, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070623 001 Mar 02, 1987

EQ 10MG BASE/2ML

A070622 001 Mar 02, 1987

REGLAN

BAXTER HLTHCARE CORP

EQ 10MG BASE/ML

N017862 004 May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 5MG BASE/5ML

A071340 001 Aug 18, 1988

MORTON GROVE

EQ 5MG BASE/5ML

A070949 001 Mar 06, 1987

PACO

EQ 5MG BASE/5ML

A071665 001 Dec 05, 1988

ROXANE

EQ 5MG BASE/5ML

A072038 001 Dec 05, 1988

TEVA

EQ 5MG BASE/5ML

A070819 001 Jul 10, 1987

EQ 5MG BASE/5ML

A071315 001 Jun 30, 1993

REGLAN

ROBINS AH

EQ 5MG BASE/5ML

N018821 001 Mar 25, 1983

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS

EQ 5MG BASE

A072384 001 Jun 02, 1988

EQ 10MG BASE

A070294 001 Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS

EQ 10MG BASE

A070632 001 Oct 28, 1985

MAXOLON

KING PHARMS

EQ 10MG BASE

A070106 001 Mar 04, 1986

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL HLTHCARE

EQ 10MG BASE

A072639 001 May 09, 1991

HALSEY

EQ 10MG BASE

A070906 001 Oct 28, 1986

INTERPHARM

EQ 10MG BASE

A071213 001 Sep 24, 1986

MUTUAL PHARM

EQ 10MG BASE

A070660 001 Feb 10, 1987

EQ 10MG BASE

A071536 001 Apr 28, 1993

PAR PHARM

EQ 10MG BASE

A070342 001 Mar 25, 1986

SANDOZ

EQ 5MG BASE

A072436 001 Jun 22, 1989

EQ 5MG BASE

A074478 001 Oct 05, 1995

EQ 10MG BASE

A070850 001 Feb 03, 1987

EQ 10MG BASE

A072215 001 Jan 30, 1990

EQ 10MG BASE

A074478 002 Oct 05, 1995

SCHERING

EQ 10MG BASE

A070598 001 Feb 02, 1987

SUPERPHARM

EQ 10MG BASE

A070926 001 Jun 26, 1987

USL PHARMA

EQ 10MG BASE

A070339 001 Jul 29, 1985

WATSON LABS

EQ 10MG BASE

A070363 001 Mar 02, 1987

EQ 10MG BASE

A070453 001 Jun 06, 1986

EQ 10MG BASE

A070511 001 Jan 22, 1986

EQ 10MG BASE

A070645 001 May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

SALIX PHARMS

EQ 10MG BASE

N022246 002 Sep 04, 2009

DISCONTINUED DRUG PRODUCT LIST

6-216 (of 322)

METOCLOPRAMIDE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

REGLAN ODT

MEDA PHARMS

EQ 5MG BASE

N021793 001 Jun 10, 2005

EQ 10MG BASE

N021793 002 Jun 10, 2005

METOCURINE IODIDE

INJECTABLE;INJECTION

METUBINE IODIDE

LILLY

2MG/ML

N006632 003

METOLAZONE

TABLET;ORAL

DIULO

GD SEARLE LLC

2.5MG

N018535 001

5MG

N018535 002

10MG

N018535 003

METOLAZONE

ROXANE

10MG

A076482 002 Apr 29, 2004

TEVA

2.5MG

A076600 001 Jan 06, 2004

5MG

A076833 001 Mar 01, 2004

10MG

A075543 003 Dec 24, 2003

WATSON LABS

10MG

A076891 001 Jul 21, 2004

MYKROX

UCB INC

0.5MG

N019532 001 Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE;ORAL

LOPRESSOR

NOVARTIS

EQ 100MG TARTRATE

N019786 001 Dec 27, 1989

EQ 200MG TARTRATE

N019786 002 Dec 27, 1989

EQ 300MG TARTRATE

N019786 003 Dec 27, 1989

EQ 400MG TARTRATE

N019786 004 Dec 27, 1989

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

NESHER PHARMS

EQ 25MG TARTRATE

A077779 001 Mar 20, 2008

EQ 50MG TARTRATE

A077176 001 May 14, 2008

EQ 100MG TARTRATE

A076640 002 May 18, 2007

EQ 200MG TARTRATE

A076640 001 May 18, 2007

SANDOZ

EQ 25MG TARTRATE

A076969 001 Jul 31, 2006

EQ 50MG TARTRATE

A076969 002 May 18, 2007

EQ 100MG TARTRATE

A076969 003 Mar 20, 2008

EQ 200MG TARTRATE

A076969 004 Mar 20, 2008

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

WATSON LABS

1MG/ML

A074032 001 Dec 21, 1993

TABLET;ORAL

METOPROLOL TARTRATE

APOTHECON

50MG

A074258 001 Jan 27, 1994

100MG

A074258 002 Jan 27, 1994

MYLAN

50MG

A073666 001 Dec 21, 1993

100MG

A073666 002 Dec 21, 1993

PRINSTON INC

50MG

A074453 001 Apr 27, 1995

100MG

A074453 002 Apr 27, 1995

PUREPAC PHARM

50MG

A074380 001 Jul 29, 1994

100MG

A074380 002 Jul 29, 1994

TEVA

50MG

A074143 001 Sep 30, 1994

100MG

A074143 002 Sep 30, 1994

TEVA PHARMS

50MG

A074333 001 Jan 27, 1994

100MG

A074333 002 Jan 27, 1994

METRIZAMIDE

INJECTABLE;INJECTION

AMIPAQUE

GE HEALTHCARE

2.5GM/VIAL

N017982 003 Sep 12, 1983

3.75GM/VIAL

N017982 001

6.75GM/VIAL

N017982 002

13.5GM/VIAL

N017982 004 Sep 12, 1983

DISCONTINUED DRUG PRODUCT LIST

6-217 (of 322)

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE

375MG

A076505 001 Nov 13, 2003

INJECTABLE; INJECTION

METRO I.V.

B BRAUN

500MG/100ML

N018674 001 Aug 31, 1982

METRONIDAZOLE

ABBOTT

500MG/100ML

N018889 001 Nov 18, 1983

ABRAXIS PHARM

500MG/100ML

A070071 001 Dec 03, 1984

HIKMA MAPLE

500MG/100ML

N018907 001 Mar 30, 1984

INTL MEDICATION

500MG/100ML

A070004 001 May 08, 1985

WATSON LABS

500MG/100ML

A070042 001 Dec 20, 1984

500MG/100ML

A070170 001 Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF

250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE

250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

HALSEY

250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS

250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK

250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM

250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

PAR PHARM

250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

SANDOZ

250MG

N018620 001 Mar 04, 1982

250MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

SUPERPHARM

250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

WATSON LABS

250MG

N018599 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

WORLD GEN

250MG

A070040 001 Jan 29, 1985

500MG

A070039 001 Jan 29, 1985

PROTOSTAT

ORTHO MCNEIL PHARM

250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS

250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE

750MG

A076462 001 Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ

150MG

A074450 001 May 16, 1996

200MG

A074450 002 May 16, 1996

250MG

A074450 003 May 16, 1996

WATSON LABS

150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

DISCONTINUED DRUG PRODUCT LIST

6-218 (of 322)

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXITIL

BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
	200MG	N018873	003	Dec 30, 1985
	250MG	N018873	004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017494	001	

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%, 100MG	A074586	001	Jul 17, 1997

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017739	001	

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ASTRAZENECA	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004

VERSED

HLR	EQ 1MG BASE/ML	N018654	002	May 26, 1987
	EQ 5MG BASE/ML	N018654	001	Dec 20, 1985

DISCONTINUED DRUG PRODUCT LIST

6-219 (of 322)

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077115 001 Sep 09, 2005

VERSED

ROCHE

EQ 2MG BASE/ML

N020942 001 Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

5MG

N019815 002 Sep 06, 1996

10MG

N019815 003 Mar 20, 2002

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

APOTEX INC

EQ 1MG BASE/ML

A076427 001 Sep 21, 2004

HIKMA MAPLE

EQ 1MG BASE/ML

A075852 001 May 28, 2002

HOSPIRA

EQ 1MG BASE/ML

A075830 001 May 28, 2002

EQ 1MG BASE/ML

A075884 001 May 28, 2002

MYLAN INSTITUTIONAL

EQ 1MG BASE/ML

A076428 001 Jun 16, 2003

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

APOTEX INC

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A077151 001 Jul 20, 2005

BAXTER HLTHCARE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A076259 001 Aug 08, 2002

HIKMA MAPLE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A075510 001 May 28, 2002

PRIMACOR

SANOFI AVENTIS US

EQ 1MG BASE/ML

N019436 001 Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 10MG BASE/100ML

N020343 001 Aug 09, 1994

EQ 15MG BASE/100ML

N020343 002 Aug 09, 1994

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

N020343 003 Aug 09, 1994

EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)

N020343 004 Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

MEDICIS

EQ 50MG BASE

A063066 001 Aug 14, 1990

MINOCIN

PRECISION DERMAT

EQ 75MG BASE

N050649 003 Feb 12, 2001

TRIAx PHARMS

EQ 50MG BASE

N050315 002

EQ 100MG BASE

N050315 001

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

RANBAXY LABS LTD

EQ 45MG BASE

N201922 001 Jul 11, 2012

EQ 67.5MG BASE

N201922 002 Jul 11, 2012

EQ 90MG BASE

N201922 003 Jul 11, 2012

EQ 112.5MG BASE

N201922 004 Jul 11, 2012

EQ 135MG BASE

N201922 005 Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE

EQ 100MG BASE/VIAL

A062139 001

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT

EQ 50MG BASE/5ML

N050445 001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS

EQ 50MG BASE

N050451 003 Aug 10, 1982

EQ 100MG BASE

N050451 002 Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

LUPIN LTD

EQ 55MG BASE

A091424 002 Nov 30, 2011

SOLODYN

MEDICIS

EQ 45MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050808 001 May 08, 2006

EQ 90MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050808 002 May 08, 2006

EQ 135MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050808 003 May 08, 2006

DISCONTINUED DRUG PRODUCT LIST

6-220 (of 322)

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924	001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPLY PHARM	2%	A074500	001	May 23, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

APOTEX INC	2%	A074924	002	Apr 29, 1998
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001

TABLET; ORAL

LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	
	10MG	N018154	003	

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076308	001	Jun 20, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS TOTOWA	15MG	A076241	001	Jun 25, 2003
	30MG	A076241	002	Jun 25, 2003
	45MG	A076241	003	Jun 25, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
SANDOZ	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011
	30MG	A077959	002	Feb 14, 2011
	45MG	A077959	003	Feb 14, 2011
ACTAVIS TOTOWA	15MG	A076689	001	Aug 31, 2005
	30MG	A076689	002	Aug 31, 2005
	45MG	A076689	003	Aug 31, 2005

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995

MITOZYTREX

SUPERGEN	5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050763	001	Nov 14, 2002

MUTAMYCIN

BRISTOL	5MG/VIAL	N050450	001	
	20MG/VIAL	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

DISCONTINUED DRUG PRODUCT LIST

6-221 (of 322)

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008

NOVANTRONE

EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297 002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297 003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON

ABBVIE	EQ 2MG BASE/ML	N020098 001	Jan 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992

MIVACURIUM CHLORIDE

STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS	5MG	N017111 001	
	10MG	N017111 002	
	25MG	N017111 003	

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS	20MG/ML	N017938 001	

TABLET; ORAL

MOBAN

ENDO PHARMS	5MG	N017111 004	
	10MG	N017111 005	
	25MG	N017111 006	
	50MG	N017111 007	
	100MG	N017111 008	

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

TARO	0.1%	A076624 001	Dec 03, 2004

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

VALEANT PHARM INTL	20%	N008173 003	

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

ETHITEK	100%	N019368 001	Oct 29, 1985

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE	200MG	N019753 001	Jun 19, 1990
	250MG	N019753 002	Jun 19, 1990
	300MG	N019753 003	Jun 19, 1990

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA	0.5MG/ML	N019917 001	Oct 30, 1992
MALLINCKRODT	1MG/ML	N020631 001	Jul 03, 1996
	2MG/ML	N020631 002	Jul 03, 1996

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671 003	May 18, 2004

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

WATSON LABS	100MG	A075656 001	Jan 30, 2001

DISCONTINUED DRUG PRODUCT LIST

6-222 (of 322)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

ORAMORPH SR

XANODYNE PHARMS INC

15MG

N019977 004 Nov 23, 1994

30MG

N019977 001 Aug 15, 1991

60MG

N019977 002 Aug 15, 1991

100MG

N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE;INJECTION

MOXAM

LILLY

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

ZYDUS PHARMS USA INC

250MG

A065433 001 May 04, 2009

TABLET;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD

500MG

A090464 001 Sep 13, 2010

ZYDUS PHARMS USA INC

500MG

A065477 001 May 04, 2009

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM

750MG

A075179 001 Jun 06, 2000

DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008

750MG

A078420 002 Sep 24, 2008

PROSAM LABS

500MG

A079093 001 Feb 27, 2009

750MG

A079093 002 Feb 27, 2009

SANDOZ

500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM

500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

KING PHARMS

120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS

120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE;INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

EQ 500MG BASE/VIAL

A061984 001

MARSAM PHARMS LLC

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

NALLPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

DISCONTINUED DRUG PRODUCT LIST

6-223 (of 322)

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NALLPEN

EQ 2GM BASE/VIAL	A061999	003	
EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
EQ 10GM BASE/VIAL	A061999	004	
EQ 500MG BASE/VIAL	A061999	001	

UNIPEN

WYETH AYERST

EQ 1GM BASE/VIAL	A062717	002	Dec 16, 1986
EQ 2GM BASE/VIAL	A062717	004	Dec 16, 1986
EQ 2GM BASE/VIAL	N050320	003	
EQ 4GM BASE/VIAL	N050320	004	
EQ 10GM BASE/VIAL	N050320	005	
EQ 20GM BASE/VIAL	N050320	006	
EQ 500MG BASE/VIAL	A062717	001	Dec 16, 1986
EQ 500MG BASE/VIAL	N050320	001	

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL	N050320	002	

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE	N050462	001	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML	A070751	001	Jul 02, 1986
20MG/ML	A070752	001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

20MG/ML	A070917	001	Feb 03, 1989

ABBVIE

1.5MG/ML	N020200	001	Mar 12, 1993

ASTRAZENECA

10MG/ML	A072070	001	Apr 10, 1989
10MG/ML	A072071	001	Apr 10, 1989
10MG/ML	A072072	001	Apr 10, 1989
20MG/ML	A072073	001	Apr 10, 1989
20MG/ML	A072074	001	Apr 10, 1989
20MG/ML	A072075	001	Apr 10, 1989
10MG/ML	A074471	001	Mar 19, 1998
20MG/ML	A074471	002	Mar 19, 1998

BARR

NUBAIN

ENDO PHARMS

10MG/ML	N018024	001	
20MG/ML	N018024	002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML	N017430	001	

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM

1GM	A070272	001	Jun 29, 1988
250MG	A070270	001	Jun 29, 1988
500MG	A070271	001	Jun 29, 1988
1GM	A071919	001	Jun 29, 1988
250MG	A071936	001	Jun 29, 1988
500MG	A072061	001	Jun 29, 1988

WATSON LABS

NEGGRAM

SANOFI AVENTIS US

1GM	N014214	005	
250MG	N014214	002	
500MG	N014214	004	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

BAXTER HLTHCARE CORP

EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995
EQ 1MG BASE/ML	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

HIKMA MAPLE

0.4MG/ML	A070298	001	Sep 24, 1986
0.4MG/ML	A070299	001	Sep 24, 1986
0.4MG/ML	A070496	001	Sep 24, 1986
0.02MG/ML	A070188	001	Sep 24, 1986
0.02MG/ML	A070189	001	Sep 24, 1986
0.4MG/ML	A070190	001	Sep 24, 1986

WYETH AYERST

DISCONTINUED DRUG PRODUCT LIST

6-224 (of 322)

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

	0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE				
ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989
	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
HIKMA MAPLE	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN				
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988
	1MG/ML	A071311	001	Jul 28, 1988
ENDO PHARMS	0.02MG/ML	N016636	002	
	0.4MG/ML	N016636	001	
	1MG/ML	N016636	003	Jun 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733	001	Dec 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

SANDOZ	50MG	A075434	001	Mar 08, 2000

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ORGANON USA INC	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
	200MG/ML	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE				
ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AKORN	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
	200MG/ML	A088128	001	Dec 05, 1983

DISCONTINUED DRUG PRODUCT LIST

6-225 (of 322)

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC	25MG/ML
	50MG/ML

N011891	001
N011891	002

NANDROLONE PHENPROPIONATE

WATSON LABS	25MG/ML
	50MG/ML

A086386	001	Jun 17, 1983
A087488	001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAFAZAIR

BAUSCH AND LOMB	0.1%
PHARMAFAIR	0.1%

A040073	001	May 25, 1994
A088101	001	Apr 15, 1983

NAPHCN FORTE

ALCON	0.1%

A080229	001

OPCON

BAUSCH AND LOMB	0.1%

A087506	001

VASOCON

NOVARTIS	0.1%

A080235	002	Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC	250MG
	375MG
	500MG

A074105	001	Dec 21, 1993
A074105	002	Dec 21, 1993
A074105	003	Dec 21, 1993

HAMILTON PHARMS	250MG
	375MG
	500MG

A074110	001	Oct 30, 1992
A074110	002	Oct 30, 1992
A074110	003	Oct 30, 1992

IVAX SUB TEVA PHARMS	250MG
	375MG
	500MG

A074111	001	Feb 28, 1995
A074111	002	Feb 28, 1995
A074111	003	Feb 28, 1995

PLIVA	250MG
	375MG
	500MG

A074182	001	Jun 27, 1996
A074182	002	Jun 27, 1996
A074182	003	Jun 27, 1996

PUREPAC PHARM	250MG
	375MG
	500MG

A074263	001	Dec 21, 1993
A074263	002	Dec 21, 1993
A074263	003	Dec 21, 1993

ROXANE	250MG
	375MG
	500MG

A074211	001	Feb 28, 1994
A074211	002	Feb 28, 1994
A074211	003	Feb 28, 1994

TEVA	250MG
	250MG
	375MG
	375MG
	500MG
	500MG

A074129	001	Dec 21, 1993
A074216	001	Apr 11, 1996
A074129	002	Dec 21, 1993
A074216	002	Apr 11, 1996
A074129	003	Dec 21, 1993
A074216	003	Apr 11, 1996

TEVA PHARMS	250MG
	375MG
	500MG

A074207	001	Dec 21, 1993
A074207	002	Dec 21, 1993
A074207	003	Dec 21, 1993

WATSON LABS	250MG
	375MG
	500MG

A074163	001	Feb 10, 1995
A074163	002	Feb 10, 1995
A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG
	500MG

A074936	001	Feb 24, 1998
A074936	002	Feb 24, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE
	EQ 500MG BASE

A076544	001	Aug 22, 2003
A076544	002	Aug 22, 2003

HAMILTON PHARMS	EQ 250MG BASE
	EQ 500MG BASE

A074106	001	Aug 31, 1993
A074106	002	Aug 31, 1993

IVAX SUB TEVA PHARMS	EQ 250MG BASE
	EQ 500MG BASE

A074230	001	Mar 14, 1995
A074230	002	Mar 14, 1995

MYLAN	EQ 250MG BASE
	EQ 500MG BASE

A074367	001	Aug 31, 1994
A074367	002	Aug 31, 1994

PLIVA	EQ 250MG BASE
	EQ 500MG BASE

A074242	001	Jun 20, 1996
A074242	002	Jun 20, 1996

PUREPAC PHARM	EQ 250MG BASE
	EQ 500MG BASE

A074319	001	Mar 20, 1995
A074319	002	Mar 20, 1995

DISCONTINUED DRUG PRODUCT LIST

6-226 (of 322)

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ROXANE

EQ 250MG BASE

A074257 001 Dec 21, 1993

EQ 500MG BASE

A074257 002 Dec 21, 1993

SANDOZ

EQ 200MG BASE

A074646 001 Jan 13, 1997

EQ 250MG BASE

A074162 001 Dec 21, 1993

EQ 250MG BASE

A074495 001 Dec 05, 1994

EQ 500MG BASE

A074162 002 Dec 21, 1993

EQ 500MG BASE

A074495 002 Dec 05, 1994

TEVA

EQ 250MG BASE

A074142 001 Dec 21, 1993

EQ 500MG BASE

A074142 002 Dec 21, 1993

TEVA PHARMS

EQ 250MG BASE

A074289 001 Jan 27, 1994

EQ 500MG BASE

A074289 002 Jan 27, 1994

WATSON LABS

EQ 250MG BASE

A074195 001 Dec 21, 1993

EQ 500MG BASE

A074195 002 Dec 21, 1993

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM

WATSON LABS FLORIDA

EQ 375MG BASE

A075416 002 Apr 23, 2003

EQ 500MG BASE

A075416 001 Aug 27, 2002

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

TEVA PHARMS

60MG

A077467 001 Sep 09, 2009

120MG

A077467 002 Sep 09, 2009

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS

1.75MG/INH

N019660 001 Dec 30, 1992

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US

0.5%

N020750 001 Oct 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

50MG

A075763 001 Sep 16, 2003

100MG

A075763 002 Sep 16, 2003

150MG

A075763 003 Sep 16, 2003

200MG

A075763 004 Sep 16, 2003

250MG

A075763 005 Sep 16, 2003

MYLAN

100MG

A076129 002 Sep 16, 2003

150MG

A076129 003 Sep 16, 2003

200MG

A076129 004 Sep 16, 2003

250MG

A076129 005 Sep 16, 2003

ROXANE

50MG

A076196 001 Sep 16, 2003

100MG

A076196 002 Sep 16, 2003

150MG

A076196 003 Sep 16, 2003

200MG

A076196 004 Sep 16, 2003

250MG

A076196 005 Sep 16, 2003

SANDOZ

50MG

A076072 001 Sep 16, 2003

50MG

A076302 001 Sep 16, 2003

100MG

A076072 002 Sep 16, 2003

100MG

A076302 002 Sep 16, 2003

150MG

A076072 003 Sep 16, 2003

150MG

A076302 003 Sep 16, 2003

200MG

A076072 004 Sep 16, 2003

200MG

A076302 004 Sep 16, 2003

250MG

A076072 005 Sep 16, 2003

250MG

A076302 005 Sep 16, 2003

WATSON LABS

100MG

A076073 002 Sep 16, 2003

150MG

A076073 003 Sep 16, 2003

200MG

A076073 004 Sep 16, 2003

250MG

A076073 005 Sep 16, 2003

SERZONE

BRISTOL MYERS SQUIBB

50MG

N020152 001 Dec 22, 1994

100MG

N020152 002 Dec 22, 1994

150MG

N020152 003 Dec 22, 1994

200MG

N020152 004 Dec 22, 1994

250MG

N020152 005 Dec 22, 1994

300MG

N020152 006 Dec 22, 1994

DISCONTINUED DRUG PRODUCT LIST

6-227 (of 322)

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS

100%

A061579 001

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 87.5MG BASE/5ML

N050285 001

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 350MG BASE

A060520 001

NEOBIOTIC

PFIZER

EQ 350MG BASE

A060475 001

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB

500MG

A060365 001

LANNETT

500MG

A060607 001

LILLY

500MG

A060385 001

ROXANE

500MG

A062173 001

SANDOZ

500MG

A061586 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050176 002 Jan 14, 1985

OINTMENT; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050344 002

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

A062339 001 Nov 30, 1984

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

N050456 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN

EQ 0.35% BASE; 10,000 UNITS/ML; 0.5%

N050081 002

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/GM; 0.25%

A061039 002

EQ 3.5MG BASE/GM; 0.5%

A061039 001

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/ML; 0.25%

A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MERCK

EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYTREX A

SAVAGE LABS

EQ 3.5MG BASE/GM; 0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM; 0.1%

A062600 001 Jul 21, 1986

PHARMADERM

EQ 3.5MG BASE/GM; 0.1%

A062595 001 Jul 21, 1986

OINTMENT; TOPICAL

MYTREX A

SAVAGE LABS

EQ 3.5MG BASE/GM; 0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM; 0.1%

A062608 001 May 23, 1986

PHARMADERM

EQ 3.5MG BASE/GM; 0.1%

A062607 001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING

EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

DISCONTINUED DRUG PRODUCT LIST

6-228 (of 322)

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC

500MG

N011073 003

TABLET; ORAL

NIACIN

EVERYLIFE

500MG

A083203 001

HALSEY

500MG

A083453 001

IMPAX LABS

500MG

A083115 001

IVAX SUB TEVA PHARMS

500MG

A083180 001

MK LABS

500MG

A083525 001

PUREPAC PHARM

500MG

A083271 001

SANDOZ

500MG

A083306 001

TABLICAPS

500MG

A084237 001

WATSON LABS

500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

WEST WARD

500MG

A083718 001

NICOLAR

SANOFI AVENTIS US

500MG

A083823 001

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

ABBVIE

375MG

N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE

375MG

N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS

15MG/5ML; 3.75MG/5ML; 600MG/5ML

N008378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

EKR THERAP

45MG

N020005 002 Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS

500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS

15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA

11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

WATSON LABS

EQ 2MG BASE

A076568 001 Jul 29, 2004

EQ 4MG BASE

A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS

10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT

10MG

A073250 001 Oct 08, 1991

20MG

A074045 001 Apr 30, 1992

CHASE LABS NJ

10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA

10MG

A072651 001 Feb 19, 1992

PROCARDIA

PFIZER

20MG

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

MARTEC USA LLC

90MG

A075414 003 Mar 23, 2004

MYLAN

30MG

A075108 001 Dec 17, 1999

DISCONTINUED DRUG PRODUCT LIST

6-229 (of 322)

NILUTAMIDE

TABLET; ORAL

NILANDRON

COVIS PHARMA SARL 50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMOTOP

BAYER PHARMS 30MG

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

SHIONOGI INC 10MG
20MG
25.5MG
30MG
40MGN020356 001 Feb 02, 1995
N020356 002 Feb 02, 1995
N020356 006 Jan 02, 2008
N020356 003 Feb 02, 1995
N020356 004 Feb 02, 1995NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS 50MG
100MGA084326 001
A084326 002

TABLET; ORAL

FURADANTIN

PROCTER AND GAMBLE 50MG
100MGN008693 001
N008693 002

FURALAN

LANNETT 50MG
100MGA080017 001
A080017 002

NITROFURANTOIN

ELKINS SINN 50MG
100MGA080003 001
A080003 002IVAX SUB TEVA PHARMS 50MG
100MGA080078 002
A080078 001SANDOZ 50MG
100MGA080043 001
A080043 002WATSON LABS 50MG
50MGA080447 001
A085797 001100MG
100MGA080447 002
A085796 001

WHITEWORTH TOWN PLSN 100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE EQ 180MG BASE/VIAL

N012402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

MYLAN 100MG
SANDOZ 25MG
50MGA074967 002 Jul 09, 1997
A074336 001 Jan 25, 1995
A074336 002 Jan 25, 1995

100MG

A074336 003 Jan 25, 1995

WATSON LABS 25MG
50MGA073696 001 Dec 31, 1992
A073696 002 Dec 31, 1992

100MG

A073696 003 Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS 50MG
100MGA070248 001 Jun 24, 1988
A070249 001 Jun 24, 1988NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD 75MG; 25MG

A076951 001 Mar 30, 2005

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE 0.2%

A083789 001

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL 0.2%

N017343 001

DISCONTINUED DRUG PRODUCT LIST

6-230 (of 322)

NITROFURAZONE

OINTMENT; TOPICAL

FURACIN

SHIRE	0.2%	N005795	001

NITROFURAZONE

AMBIX	0.2%	A086077	001

LANNETT	0.2%	A084393	001

PERRIGO NEW YORK	0.2%	A084968	001

TARO	0.2%	A086156	001

WENDT	0.2%	A086766	001

POWDER; TOPICAL

FURACIN

SHIRE	0.2%	A083791	001

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001

WENDT	0.2%	A087081	001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999

	0.2MG/HR	A074992	003	Nov 12, 1999

	0.4MG/HR	A074992	002	Nov 12, 1999

	0.6MG/HR	A074992	001	Nov 12, 1999

TRANSDERM-NITRO

NOVARTIS

	0.1MG/HR	N020144	001	Feb 27, 1996

	0.2MG/HR	N020144	002	Feb 27, 1996

	0.4MG/HR	N020144	003	Feb 27, 1996

	0.6MG/HR	N020144	004	Feb 27, 1996

	0.8MG/HR	N020144	005	Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983

NITRO-BID

SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982

	10MG/ML	A071159	001	Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985

	5MG/ML	A071203	001	May 08, 1987

HOSPIRA	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018531	001	

INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985

LUITPOLD	5MG/ML	A071492	001	May 24, 1988

SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986

	5MG/ML	A070634	001	Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994

NITROL

RORER	0.8MG/ML	N018774	001	Jan 19, 1983

NITRONAL

POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588	001	

	5MG/ML	A070863	001	Jan 08, 1987

	5MG/ML	N018588	002	Dec 23, 1983

	10MG/ML	A070871	001	Jan 08, 1987

	10MG/ML	A070872	001	Jan 08, 1987

TRIDIL

HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983

	5MG/ML	N018537	001	

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988

	300MG	N019508	002	Apr 12, 1988

DISCONTINUED DRUG PRODUCT LIST

6-231 (of 322)

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

APOTEX INC	150MG	A076383 001	Jan 23, 2003
	300MG	A076383 002	Jan 23, 2003
IVAX SUB TEVA PHARMS	150MG	A075461 001	Jul 08, 2002
	300MG	A075461 002	Jul 08, 2002
MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002
	300MG	A075934 002	Jul 09, 2002

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS	12.5%	N014349 002	

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM	EQ 1MG BASE/ML	A040522 001	Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK	EQ 0.033MG BASE/ML; 2%; 0.4%	N008592 003	

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS	5MG	N010895 002	

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS	5MG	N012184 002	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK	0.3%	N019757 001	Jun 17, 1991

NORGESTREL

TABLET; ORAL

OVRETTE

WYETH PHARMS	0.075MG	N017031 001	

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY	EQ 10MG BASE	N014684 001	
	EQ 25MG BASE	N014684 002	

NORTRIPTYLINE HYDROCHLORIDE

SANDOZ	EQ 10MG BASE	A074054 001	Dec 31, 1992
	EQ 10MG BASE	A074835 001	Jun 30, 1997
	EQ 25MG BASE	A074054 002	Dec 31, 1992
	EQ 25MG BASE	A074835 002	Jun 30, 1997
	EQ 50MG BASE	A074054 003	Dec 31, 1992
	EQ 50MG BASE	A074835 003	Jun 30, 1997
	EQ 75MG BASE	A074054 004	Dec 31, 1992
	EQ 75MG BASE	A074835 004	Jun 30, 1997
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996
	EQ 25MG BASE	A073667 002	Apr 11, 1996
	EQ 50MG BASE	A073667 003	Apr 11, 1996
	EQ 75MG BASE	A073667 004	Apr 11, 1996

SOLUTION; ORAL

PAMELOR

MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001	

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/GM	A061810 001	

MYCOSTATIN

BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575 001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982

DISCONTINUED DRUG PRODUCT LIST

6-232 (of 322)

NYSTATIN

CREAM; TOPICAL

NILSTAT

LEDERLE	100,000 UNITS/GM	A061445	001	

NYSTATIN

TARO	100,000 UNITS/GM	A062457	001	Jul 28, 1983

TEVA	100,000 UNITS/GM	A061966	001	

LOTION; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233	001	

OINTMENT; TOPICAL

MYCOSTATIN

WESTWOOD SQUIBB	100,000 UNITS/GM	A060571	001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731	001	Sep 22, 1986

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444	001	

PASTILLE; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	200,000 UNITS	N050619	001	Apr 09, 1987

POWDER; ORAL

BARSTATIN 100

BARLAN	100%	A062489	001	Apr 27, 1988

NILSTAT

DAVA PHARMS INC	100%	N050576	001	Dec 22, 1983

NYSTATIN

PADDOCK LLC	100%	A062613	001	Nov 26, 1985

POWDER; TOPICAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578	001	

NYSTATIN

NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT	100,000 UNITS	N050478	001	

SUSPENSION; ORAL

MYCOSTATIN

APOTHECON	100,000 UNITS/ML	A061533	001	

NILSTAT

GLENMARK GENERICS	100,000 UNITS/ML	N050299	001	

NYSTATIN

ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985

MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987

PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984

PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985

ROXANE	100,000 UNITS/ML	A062832	001	Dec 27, 1991

TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987

	100,000 UNITS/ML	A062776	001	Dec 17, 1987

NYSTEX

SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984

TABLET; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	500,000 UNITS	A060574	001	

NILSTAT

LEDERLE	500,000 UNITS	A061151	001	

NYSTATIN

QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984

SANDOZ	500,000 UNITS	A062065	001	

USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985

WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718	001	

MYCOSTATIN

BRISTOL MYERS SQUIBB	100,000 UNITS	A060577	001	

NILSTAT

LEDERLE	100,000 UNITS	A061325	001	

NYSTATIN

FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983

PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983

QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984

SANDOZ	100,000 UNITS	A061965	001	

DISCONTINUED DRUG PRODUCT LIST

6-233 (of 322)

NYSTATIN

TABLET;VAGINAL

NYSTATIN

TEVA	100,000 UNITS	A062502 001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176 001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A061954 002	Sep 20, 1985

MYCOLOG-II

APOTHECON	100,000 UNITS/GM;0.1%	A060576 002	May 01, 1985
	100,000 UNITS/GM;0.1%	A062606 001	May 15, 1985

MYKACET

G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597 001	Oct 08, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010 001	Dec 20, 1988

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186 002	Jun 06, 1985

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657 001	Jul 30, 1986

TARO	100,000 UNITS/GM;0.1%	A062347 001	Mar 30, 1987

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596 001	Oct 08, 1985

OINTMENT;TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A062045 002	Nov 26, 1985

MYCOLOG-II

APOTHECON	100,000 UNITS/GM;0.1%	A060572 001	Jun 28, 1985

MYKACET

G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601 001	Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280 002	Oct 10, 1985

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656 001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603 001	Oct 09, 1985

OFLOXACIN

INJECTABLE;INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087 002	Mar 31, 1992
	40MG/ML	N020087 003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087 001	Mar 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087 004	Mar 31, 1992
	400MG/100ML	N020087 005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762 001	Jan 16, 2002

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

APOTEX INC	0.3%	A076513 001	May 14, 2004

SANDOZ	0.3%	A076848 001	Nov 25, 2008

TABLET;ORAL

FLOXIN

JANSSEN PHARMS	200MG	N019735 001	Dec 28, 1990
	300MG	N019735 002	Dec 28, 1990
	400MG	N019735 003	Dec 28, 1990

OFLOXACIN

LARKEN LABS	200MG	A076093 001	Sep 02, 2003
	300MG	A076093 002	Sep 02, 2003
	400MG	A076093 003	Sep 02, 2003

RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003

	300MG	A076220 002	Sep 02, 2003

	400MG	A076220 003	Sep 02, 2003

DISCONTINUED DRUG PRODUCT LIST

6-234 (of 322)

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
	8MG	A077717	002	Jun 25, 2007
PAR PHARM	4MG	A076506	001	Dec 26, 2006
	8MG	A076506	002	Dec 26, 2006
	16MG	A077406	001	Dec 26, 2006
	24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

BEDFORD LABS	EQ 0.64MG BASE/ML	A078291	001	Apr 13, 2009
CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008
HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007
TEVA PHARMS	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915	002	Dec 27, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006

ZOFTRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403	001	Jan 31, 1995

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007
	EQ 8MG BASE	A077303	002	Jun 25, 2007
	EQ 24MG BASE	A077303	004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
	EQ 8MG BASE	A077729	002	Mar 28, 2011
	EQ 24MG BASE	A077729	003	Mar 28, 2011
WEST WARD PHARM CORP	EQ 4MG BASE	A077545	001	Sep 06, 2007
	EQ 8MG BASE	A077545	002	Sep 06, 2007
	EQ 24MG BASE	A077545	003	Sep 06, 2007

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS	100MG	N012157	001	

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M	50MG	N010653	001	

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	

OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE	A061450	002	
	EQ 500MG BASE	A061450	001	
TEVA	EQ 250MG BASE	A062222	001	
	EQ 500MG BASE	A062222	002	

DISCONTINUED DRUG PRODUCT LIST

6-235 (of 322)

OXACILLIN SODIUM

CAPSULE; ORAL

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL

A061334 010

EQ 500MG BASE/VIAL

A061334 009 Mar 26, 1982

OXACILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

N050195 003

EQ 2GM BASE/VIAL

N050195 004

EQ 4GM BASE/VIAL

N050195 005

EQ 250MG BASE/VIAL

N050195 001

EQ 500MG BASE/VIAL

N050195 002

ELKINS SINN

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

IBI

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

MARSAM PHARMS LLC

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

WATSON LABS

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**
100MG/VIAL

N021492 001 Aug 09, 2002

N021492 002 Aug 09, 2002

OXALIPLATIN

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

DISCONTINUED DRUG PRODUCT LIST

6-236 (of 322)

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
MUTUAL PHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007
	300MG	A078005	002	Dec 11, 2007
	600MG	A078005	003	Dec 11, 2007

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	

OXTRIPHYLLINE

WATSON LABS	100MG	A087866	001	Aug 25, 1983
	200MG	A087835	001	Aug 25, 1983

DISCONTINUED DRUG PRODUCT LIST

6-237 (of 322)

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN 5MG/5ML

N018211 001

OXYBUTYNIN CHLORIDE

APOTEX INC 5MG/5ML

A074997 001 Oct 15, 1997

MIKART 5MG/5ML

A075039 001 Jan 29, 1999

TABLET; ORAL

DITROPAN

JANSSEN PHARMS 5MG

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS 5MG

A072296 001 Dec 08, 1988

USL PHARMA 5MG

A070746 001 Mar 10, 1988

WATSON LABS 5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROXICODONE

ROXANE 10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS 1.5MG/ML

N011707 001

SUPPOSITORY; RECTAL

NUMOREPHAN

ENDO PHARMS 5MG

N011738 004

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS 5MG

N021610 001 Jun 22, 2006

7.5MG

N021610 005 Feb 29, 2008

10MG

N021610 002 Jun 22, 2006

15MG

N021610 006 Feb 29, 2008

20MG

N021610 003 Jun 22, 2006

30MG

N021610 007 Feb 29, 2008

40MG

N021610 004 Jun 22, 2006

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS 100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS 100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER 10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL

ANTRENYL

NOVARTIS 5MG

N008492 002

OXYTETRACYCLINE

TABLET; ORAL

TERRAMYCIN

PFIZER 250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL

TERRAMYCIN

PFIZER EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXY-KESSO-TETRA

FERRANTE EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

IMPAX LABS EQ 250MG BASE

A060760 001

PROTER EQ 250MG BASE

A060869 001

PUREPAC PHARM EQ 250MG BASE

A060634 001

WEST WARD EQ 250MG BASE

A060770 001

TERRAMYCIN

PFIZER EQ 125MG BASE

N050286 001

DISCONTINUED DRUG PRODUCT LIST

6-238 (of 322)

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TERRAMYCIN

EQ 250MG BASE

N050286 002

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM; 10,000 UNITS/GM

A061841 001

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE; 100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

TEVA PHARMS USA

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML

N019185 004 Mar 29, 1985

2USP UNITS/100ML

N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

ABBOTT

2USP UNITS/100ML

N019185 002 Mar 29, 1985

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML

N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS

10USP UNITS/ML

N018245 001

SOLUTION; NASAL

SYNTOCINON

NOVARTIS

40USP UNITS/ML

N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE

6MG/ML

A075436 001 Nov 12, 2004

HOSPIRA

6MG/ML

A076233 001 Aug 01, 2002

PLIVA LACHEMA

6MG/ML

A077413 001 Mar 12, 2008

TEVA PHARMS USA

6MG/ML

A075297 001 Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS

12MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

HELSINN HLTHCARE

EQ 0.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N022233 001 Aug 22, 2008

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC

30000USPU; 30000USPU; 8000USPU

N020580 001 Dec 09, 1996

DISCONTINUED DRUG PRODUCT LIST

6-239 (of 322)

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ASTRAZENECA

1MG/ML

A072210 001 Mar 31, 1988

2MG/ML

A072211 001 Mar 31, 1988

2MG/ML

A072212 001 Mar 31, 1988

2MG/ML

A072213 001 Mar 31, 1988

ELKINS SINN

1MG/ML

A072058 001 Mar 23, 1988

2MG/ML

A072059 001 Mar 23, 1988

2MG/ML

A072060 001 Mar 23, 1988

HOSPIRA

2MG/ML

A072321 001 Jan 19, 1989

PAVULON

ORGANON USA INC

1MG/ML

N017015 002

2MG/ML

N017015 001

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

150MG

N006800 003

300MG

N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE

300MG/ML

N006800 002

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

1MG

N012772 005

2MG

N012772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

GLAXOSMITHKLINE

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 001 Oct 09, 1998

EQ 20MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 002 Oct 09, 1998

EQ 30MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 003 Oct 09, 1998

EQ 40MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 004 Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

ROXANE

EQ 10MG BASE

A078026 001 Jun 29, 2007

EQ 20MG BASE

A078026 002 Jun 29, 2007

EQ 30MG BASE

A078026 003 Jun 29, 2007

EQ 40MG BASE

A078026 004 Jun 29, 2007

SANDOZ

EQ 10MG BASE

A075566 001 Mar 08, 2004

EQ 20MG BASE

A075566 002 Mar 08, 2004

DISCONTINUED DRUG PRODUCT LIST

6-240 (of 322)

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

EQ 30MG BASE	A075566	003	Mar 08, 2004
EQ 40MG BASE	A075566	004	Mar 08, 2004
TEVA PHARMS	EQ 10MG BASE	A077082	001 Jun 29, 2007
	EQ 20MG BASE	A077082	002 Jun 29, 2007
	EQ 30MG BASE	A077082	003 Jun 29, 2007
	EQ 40MG BASE	A077082	004 Jun 29, 2007
PAXIL			
GLAXOSMITHKLINE	EQ 50MG BASE	N020031	004 Dec 29, 1992

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007 Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008 Mar 27, 2012
OMONTYS PRESERVATIVE FREE			
TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001 Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002 Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003 Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004 Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005 Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006 Mar 27, 2012

PEMOLINE

TABLET; ORAL

CYLERT

ABBOTT	18.75MG	N016832	001
	37.5MG	N016832	002
	75MG	N016832	003

PEMOLINE

ACTAVIS TOTOWA	18.75MG	A075595	001 Feb 28, 2000
	37.5MG	A075595	002 Feb 28, 2000
	75MG	A075595	003 Feb 28, 2000
MALLINCKRODT	18.75MG	A075726	003 Mar 30, 2001
	37.5MG	A075726	002 Mar 30, 2001
	75MG	A075726	001 Mar 30, 2001
SANDOZ	18.75MG	A075286	001 Dec 27, 1999
	37.5MG	A075286	002 Jun 30, 1999
	75MG	A075286	003 Jun 30, 1999
TEVA PHARMS	18.75MG	A075030	003 Feb 22, 2000
	37.5MG	A075030	001 Jan 29, 1999
	75MG	A075030	002 Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001 Apr 19, 2000
	37.5MG	A075328	002 Apr 19, 2000
	75MG	A075328	003 Apr 19, 2000
WATSON LABS	18.75MG	A075287	001 Jun 13, 2001
	37.5MG	A075287	002 Sep 18, 2000
	75MG	A075287	003 Sep 18, 2000

TABLET, CHEWABLE; ORAL

CYLERT

ABBOTT	37.5MG	N017703	001

PEMOLINE

ACTAVIS TOTOWA	37.5MG	A075678	001 Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

ACTIENT PHARMS	10MG	N018976	001 Dec 30, 1987

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

ATON	125MG	N019853	002

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

WYETH AYERST	300,000 UNITS/ML	N050131	001

SUSPENSION; ORAL

BICILLIN

WYETH AYERST	300,000 UNITS/5ML	N050126	002

DISCONTINUED DRUG PRODUCT LIST

6-241 (of 322)

PENICILLIN G BENZATHINE

TABLET;ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

MARSAM PHARMS LLC

1,000,000 UNITS/VIAL

A062991 001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991 002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991 003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991 004

Sep 13, 1988

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL

A065079 001

Aug 30, 2002

PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL

A060657 001

TABLET;ORAL

PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

800,000 UNITS

A060781 004

PUREPAC PHARM

200,000 UNITS

A061588 001

250,000 UNITS

A061588 002

400,000 UNITS

A061588 003

TEVA

200,000 UNITS

A060306 001

250,000 UNITS

A060306 002

400,000 UNITS

A060306 003

500,000 UNITS

A060306 004

WYETH AYERST

200,000 UNITS

A060413 001

250,000 UNITS

A060413 002

400,000 UNITS

A060413 003

PENTIDS '200'

APOTHECON

200,000 UNITS

A062155 001

DISCONTINUED DRUG PRODUCT LIST

6-242 (of 322)

PENICILLIN G POTASSIUM

TABLET; ORAL

PENTIDS '250'			
APOTHECON	250,000 UNITS		A062155 002
PENTIDS '400'			
APOTHECON	400,000 UNITS		A060392 004
	400,000 UNITS		A062155 003
PENTIDS '800'			
APOTHECON	800,000 UNITS		A060392 005
	800,000 UNITS		A062155 004
PFIZERPEN G			
PFIZER	50,000 UNITS		A060075 001
	100,000 UNITS		A060075 002
	200,000 UNITS		A060075 003
	250,000 UNITS		A060075 004
	400,000 UNITS		A060075 005
	800,000 UNITS		A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.			
LILLY	300,000 UNITS/ML		A060093 001
PENICILLIN G PROCAINE			
CONSOLIDATED PHARM	300,000 UNITS/ML		A060800 001
	600,000 UNITS/1.2ML		A060800 002
PARKE DAVIS	300,000 UNITS/ML		A062029 001
PFIZER	300,000 UNITS/VIAL		A060099 001
	1,500,000 UNITS/VIAL		A060099 002
PFIZERPEN-AS			
PFIZER	300,000 UNITS/ML		A060286 001
	600,000 UNITS/ML		A060286 002

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM			
MARSAM PHARMS LLC	5,000,000 UNITS/VIAL		A063014 001 Sep 13, 1988
INJECTABLE; INJECTION			
PENICILLIN G SODIUM			
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL		A061935 001
COPANOS	5,000,000 UNITS/VIAL		A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL		A061046 001

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN			
LILLY	125MG/0.6ML		A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK			
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A062270 001
	EQ 250MG BASE/5ML		A062270 002
BETAPEN-VK			
APOTHECON	EQ 125MG BASE/5ML		A061149 001
	EQ 250MG BASE/5ML		A061149 002
LEDERCILLIN VK			
LEDERLE	EQ 125MG BASE/5ML		A060136 001
	EQ 250MG BASE/5ML		A060136 002
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001
	EQ 250MG BASE/5ML		A060007 002
PENAPAR-VK			
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001
	EQ 250MG BASE/5ML		A062002 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 125MG BASE/5ML		A061529 001
	EQ 250MG BASE/5ML		A061529 002
MYLAN	EQ 125MG BASE/5ML		A061624 002
	EQ 250MG BASE/5ML		A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001
	EQ 250MG BASE/5ML		A061758 002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML		A061815 001
	EQ 250MG BASE/5ML		A061815 002

DISCONTINUED DRUG PRODUCT LIST

6-243 (of 322)

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE

A062273 001

EQ 500MG BASE

A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE

A061150 001

EQ 500MG BASE

A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE

A060134 001

EQ 500MG BASE

A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE

A062001 001

EQ 500MG BASE

A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE

A061528 001

EQ 500MG BASE

A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE

A060518 001

EQ 250MG BASE

A060518 002

EQ 500MG BASE

A060518 003

MYLAN

EQ 250MG BASE

A061530 001

EQ 500MG BASE

A061530 002

PUREPAC PHARM

EQ 125MG BASE

A061571 001

EQ 250MG BASE

A061571 002

EQ 500MG BASE

A061571 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE

A061836 001

EQ 500MG BASE

A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE

A061651 001

EQ 500MG BASE

A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE

A060003 001

EQ 250MG BASE

A060003 002

EQ 500MG BASE

A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE

A061411 001

EQ 500MG BASE

A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE

A061164 001

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

WYETH AYERST

0.25MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017048 001

DISCONTINUED DRUG PRODUCT LIST

6-244 (of 322)

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT			
ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M	2mCi/ML	N017518 001	

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751 001	Aug 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS	18.2MG/5ML	A083244 001	

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS	30MG	A084095 001	
	50MG	A084093 001	
	100MG	A083245 001	

PENTOBARBITAL SODIUM

LANNETT	50MG	A085937 001	

	100MG	A085915 001	

VITARINE	100MG	A083284 001	

WHITEWORTH TOWN PLSN	100MG	A083338 001	

SODIUM PENTOBARBITAL

ANABOLIC	100MG	A084590 001	

ELKINS SINN	100MG	A083368 001	

EVERYLIFE	100MG	A083259 001	

HALSEY	100MG	A084677 001	

IVAX SUB TEVA PHARMS	50MG	A083461 001	

	100MG	A083461 002	

PARKE DAVIS	100MG	A084156 001	

PERRIGO	100MG	A084560 001	

PUREPAC PHARM	100MG	A083301 001	

VALEANT PHARM INTL	100MG	A083264 001	

WATSON LABS	100MG	A085791 001	

WYETH AYERST	100MG	A083239 001	

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN	50MG/ML	A083270 001	

SODIUM PENTOBARBITAL

WYETH AYERST	50MG/ML	A083261 001	

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS	30MG	A083247 001	Jan 25, 1982

DISCONTINUED DRUG PRODUCT LIST

6-245 (of 322)

PENTOBARBITAL SODIUM

SUPPOSITORY; RECTAL

NEMBUTAL

60MG

A083247 002 Jan 25, 1982

120MG

A083247 003 Jan 25, 1982

200MG

A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE

100MG

A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC

100MG

A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST

10MG/ML

N009372 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH

400MG

A074878 001 Jul 09, 1997

HERITAGE PHARMS INC

400MG

A074877 001 Jul 08, 1997

TEVA

400MG

A075199 001 Sep 03, 1999

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM

100%

N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY

50%; 50%

N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS

EQ 0.05MG BASE

A076094 001 Sep 04, 2003

EQ 0.25MG BASE

A076094 002 Sep 04, 2003

EQ 1MG BASE

A076094 003 Sep 04, 2003

PAR PHARM

EQ 0.05MG BASE

A076061 001 Nov 27, 2002

EQ 0.25MG BASE

A076061 002 Nov 27, 2002

EQ 1MG BASE

A076061 003 Nov 27, 2002

PERMAX

VALEANT PHARM INTL

EQ 0.05MG BASE

N019385 001 Dec 30, 1988

EQ 0.25MG BASE

N019385 002 Dec 30, 1988

EQ 1MG BASE

N019385 003 Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE

1%

N019435 001 Mar 31, 1986

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC

16MG/5ML

A040360 001 May 25, 2001

TRILAFON

SCHERING

16MG/5ML

N011557 001

INJECTABLE; INJECTION

TRILAFON

SCHERING

5MG/ML

N011213 002

SYRUP; ORAL

TRILAFON

SCHERING

2MG/5ML

N011294 002

TABLET; ORAL

PERPHENAZINE

IVAX PHARMS

2MG

A089707 001 Sep 10, 1987

4MG

A089708 001 Sep 10, 1987

8MG

A089456 001 Sep 10, 1987

16MG

A089457 001 Sep 10, 1987

TRILAFON

SCHERING

2MG

N010775 001

4MG

N010775 002

8MG

N010775 003

16MG

N010775 004

DISCONTINUED DRUG PRODUCT LIST

6-246 (of 322)

PERPHENAZINE

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE

100MG; 500MG

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE

200MG; 800MG; 160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE

50MG; 500MG

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL

MELFIAT-105

NUMARK

105MG

A087487 001 Oct 13, 1982

PHENDIMETRAZINE TARTRATE

GRAHAM DM

105MG

A087214 001 May 26, 1982

105MG

A088020 001 Aug 16, 1982

105MG

A088028 001 Aug 16, 1982

105MG

A088062 001 Sep 13, 1982

105MG

A088063 001 Sep 10, 1982

105MG

A088111 001 Oct 18, 1982

SANDOZ

105MG

A087378 001

SPRX-105

NUMARK

105MG

A088024 001 Dec 22, 1982

X-TROZINE L.A.

SHIRE RICHWOOD

105MG

A087371 001 Aug 24, 1982

TABLET; ORAL

ADPHEN

FERNDAL LABS

35MG

A083655 001

ALPHAZINE

SANDOZ

35MG

A085034 001

CAM-METRAZINE

ABC HOLDING

35MG

A085511 001

CAMALL

35MG

A085756 001

DISCONTINUED DRUG PRODUCT LIST

6-247 (of 322)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

CAM-METRAZINE

TG UNITED LABS

35MG

A083922 001

35MG

A085318 001

35MG

A085320 001

35MG

A085321 001

DI-METREX

PVT FORM

35MG

A085698 001

MELFIAT

NUMARK

35MG

A083790 002

METRA

FOREST PHARMS

35MG

A083754 001

PHENAZINE

MAST MM

35MG

A087305 001

PHENAZINE-35

ABC HOLDING

35MG

A085512 001

PHENDIMETRAZINE TARTRATE

BARR

35MG

A083644 001

35MG

A083684 001

35MG

A083686 001

35MG

A083687 001

35MG

A084831 001

35MG

A084834 001

35MG

A084835 001

FERNDAL LABS

35MG

A086834 001

Sep 15, 1983

INWOOD LABS

35MG

A084740 001

35MG

A084741 001

35MG

A084742 001

35MG

A084743 001

IVAX PHARMS

35MG

A085611 001

35MG

A085612 001

IVAX SUB TEVA PHARMS

35MG

A083682 001

KV PHARM

35MG

A084138 001

35MG

A084141 001

35MG

A085525 001

MFG CHEMISTS

35MG

A085914 001

NEXGEN PHARMA INC

35MG

A086020 001

NUMARK

35MG

A083790 001

PVT FORM

35MG

A085199 001

35MG

A085697 001

SANDOZ

35MG

A085402 001

35MG

A085497 001

35MG

A085830 001

35MG

A086365 001

35MG

A086370 001

SOLVAY

35MG

A083993 001

TG UNITED LABS

35MG

A085761 001

35MG

A085941 001

Jun 27, 1983

USL PHARMA

35MG

A083805 001

35MG

A084398 001

35MG

A084399 001

VITARINE

35MG

A085519 001

35MG

A086005 001

35MG

A086106 001

WATSON LABS

35MG

A085767 001

35MG

A085768 001

35MG

A085770 001

35MG

A085773 001

PLEGINE

WYETH AYERST

35MG

N012248 001

STATOBEX

TEVA

35MG

A086013 001

STATOBEX-G

TEVA

35MG

A085095 001

X-TROZINE

SHIRE RICHWOOD

35MG

A086550 001

35MG

A086551 001

35MG

A086552 001

35MG

A086553 001

35MG

A086554 001

DISCONTINUED DRUG PRODUCT LIST

6-248 (of 322)

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US

50MG

N008767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM

25MG

N010460 005

TABLET, EXTENDED RELEASE; ORAL

PRELUDIN

BOEHRINGER INGELHEIM

50MG

N011752 004

75MG

N011752 003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC

3MG

N011228 001

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS

500MG

N008855 004

PHTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE

30MG

N017352 001

OBESTIN-30

FERNDAL LABS

30MG

A087144 001

OBY-TRIM

SHIRE RICHWOOD

30MG

A087764 001 Mar 18, 1982

ONA-MAST

MAST MM

30MG

A086511 001

30MG

A086516 001

PHTERMINE HYDROCHLORIDE

ABC HOLDING

30MG

A085411 001

ABLE

15MG

A040497 001 Mar 13, 2003

30MG

A040403 001 Aug 30, 2001

30MG

A040427 001 Aug 30, 2001

CAMALL

15MG

A086735 001

30MG

A087226 001

DURAMED PHARMS BARR

30MG

A088948 001 Apr 25, 1986

IVAX PHARMS

30MG

A086329 001

MIKAH PHARMA

15MG

A040460 001 Jan 14, 2003

30MG

A040227 001 Jun 18, 1997

30MG

A040448 001 Jan 22, 2003

37.5MG

A040228 001 Jun 19, 1997

MUTUAL PHARM

37.5MG

A040527 001 Oct 23, 2003

SANDOZ

30MG

A087208 001

30MG

A087223 001

37.5MG

A088414 001 Oct 19, 1983

TEVA

30MG

A086911 001

30MG

A087126 001

30MG

A087777 001 Nov 01, 1985

30MG

A088612 001 Apr 04, 1984

30MG

A088613 001 Apr 09, 1984

30MG

A088614 001 Apr 09, 1984

TG UNITED INC

30MG

A040083 001 Mar 07, 1997

TG UNITED LABS

18.75MG

A088576 001 May 23, 1984

30MG

A085417 001

30MG

A086732 002

30MG

A087215 001

37.5MG

A087915 001 Dec 22, 1983

37.5MG

A087918 001 Dec 22, 1983

37.5MG

A087930 001 Oct 14, 1983

37.5MG

A088610 001 Jun 04, 1984

37.5MG

A088611 001 Jun 04, 1984

37.5MG

A088625 001 Aug 23, 1984

USL PHARMA

30MG

A084487 001 Apr 09, 1982

30MG

A088430 001 Mar 27, 1984

30MG

A088797 001 Dec 10, 1984

VITARINE

30MG

A087202 001

30MG

A087235 001

DISCONTINUED DRUG PRODUCT LIST

6-249 (of 322)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

WATSON LABS

30MG

A086740 001 Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM

8MG

A086260 001

PHENTERMINE HYDROCHLORIDE

ABLE

37.5MG

A040402 001 Aug 30, 2001

ACTAVIS ELIZABETH

37.5MG

A040276 001 Nov 25, 1998

IVAX PHARMS

8MG

A085553 001

MIKAH PHARMA

37.5MG

A040190 001 May 30, 1997

SANDOZ

8MG

A085671 001

8MG

A085689 001

SANDOZ INC

30MG

A088605 001 Sep 28, 1987

TG UNITED LABS

8MG

A083923 001

8MG

A085319 001

37.5MG

A087805 001 Dec 06, 1982

37.5MG

A088596 001 Apr 04, 1984

USL PHARMA

8MG

A083804 001

37.5MG

A088910 001 Jul 17, 1985

37.5MG

A088917 001 Jul 17, 1985

VITARINE

8MG

A086453 001

8MG

A086456 001

WATSON LABS

8MG

A085739 001

TORA

SOLVAY

8MG

A084035 001

WILPO

SANDOZ

8MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012737 001

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC

EQ 15MG BASE

N011613 004

EQ 30MG BASE

N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS

EQ 30MG BASE

A089120 001 Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

50%

N011695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

500MG

N011695 003

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087260 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 009

PHENYLBUTAZONE

IVAX PHARMS

100MG

A088218 001 Jun 24, 1983

MUTUAL PHARM

100MG

A088994 001 Dec 04, 1985

SANDOZ

100MG

A087774 001 Jun 16, 1982

WATSON LABS

100MG

A087756 001 Dec 17, 1982

TABLET; ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087091 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 008

PHENYLBUTAZONE

MUTUAL PHARM

100MG

A088863 001 Dec 04, 1985

SANDOZ

100MG

A084339 001

WATSON LABS

100MG

A086151 001

100MG

A087674 001 Apr 21, 1982

DISCONTINUED DRUG PRODUCT LIST

6-250 (of 322)

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS

5MG/5ML; 6.25MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY

5MG/5ML; 6.25MG/5ML

A088868 001 Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML; 6.25MG/5ML

A088815 001 Nov 22, 1985

WOCKHARDT

5MG/5ML; 6.25MG/5ML

A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%; 0.1%

N007953 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001 Sep 25, 1992

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

BARR

100MG EXTENDED

A040435 001 Jun 20, 2003

PLIVA

100MG EXTENDED

A089441 001 Dec 18, 1986

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

IVAX SUB TEVA PHARMS

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

PHENYTOIN SODIUM

FRESENIUS KABI USA

50MG/ML

A089003 001 May 31, 1985

HOSPIRA

50MG/ML

A089744 001 Dec 18, 1987

MARSAM PHARMS LLC

50MG/ML

A089501 001 Oct 13, 1987

50MG/ML

A089779 001 Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001 Dec 19, 1984

50MG/ML

A088521 001 Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001 Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001 Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

BIOVAIL TECHNOLOGIES

1MG/0.5ML

N012223 002

10MG/ML

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

DISCONTINUED DRUG PRODUCT LIST

6-251 (of 322)

PILOCARPINE

INSERT, EXTENDED RELEASE;OPHTHALMIC

OCUSERT PILO-20

AKORN

5MG

N017431 001

OCUSERT PILO-40

AKORN

11MG

N017548 001

PINACIDIL

CAPSULE, EXTENDED RELEASE;ORAL

PINDAC

LEO PHARM

12.5MG

N019456 001 Dec 28, 1989

25MG

N019456 002 Dec 28, 1989

PINDOLOL

TABLET;ORAL

PINDOLOL

IVAX SUB TEVA PHARMS

5MG

A073687 001 Feb 26, 1993

10MG

A073687 002 Feb 26, 1993

MUTUAL PHARM

5MG

A074063 001 Jan 27, 1994

10MG

A074063 002 Jan 27, 1994

MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992

10MG

A074018 001 Sep 24, 1992

NOSTRUM LABS

5MG

A074474 001 Oct 28, 1996

10MG

A074474 002 Oct 28, 1996

PUREPAC PHARM

5MG

A074125 001 Apr 28, 1993

10MG

A074125 002 Apr 28, 1993

SANDOZ

5MG

A073608 001 Mar 29, 1993

10MG

A073609 001 Mar 29, 1993

TEVA

5MG

A073661 001 Oct 31, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

10MG

A074123 002 Apr 17, 1997

WATSON LABS

5MG

A074437 001 Feb 27, 1995

10MG

A074437 002 Feb 27, 1995

VISKEN

NOVARTIS

5MG

N018285 001 Sep 03, 1982

10MG

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE;INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET;ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPRACIL

WYETH PHARMS INC

EQ 2GM BASE/VIAL

A062750 001 Oct 13, 1987

EQ 2GM BASE/VIAL

N050545 002

EQ 3GM BASE/VIAL

A062750 002 Oct 13, 1987

EQ 3GM BASE/VIAL

N050545 003

EQ 4GM BASE/VIAL

A062750 003 Oct 13, 1987

EQ 4GM BASE/VIAL

N050545 004

EQ 40GM BASE/VIAL

N050545 006 Sep 30, 1985

PIPERAZINE CITRATE

SYRUP;ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE/5ML

N009102 001

BRYREL

SANOFI AVENTIS US

EQ 500MG BASE/5ML

N017796 001

MULTIFUGE

BLULINE

EQ 500MG BASE/5ML

N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS

EQ 500MG BASE/5ML

A080774 001

LANNETT

EQ 500MG BASE/5ML

A080963 001

LUITPOLD

EQ 500MG BASE/5ML

A080671 001

VERMIDOL

SOLVAY

EQ 500MG BASE/5ML

A080992 001

DISCONTINUED DRUG PRODUCT LIST

6-252 (of 322)

PIPERAZINE CITRATE

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE

N009102 003

PIPERAZINE CITRATE

IMPAX LABS

EQ 250MG BASE

A080874 001

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

MEDICIS

EQ 0.2MG BASE/INH

N019009 001 Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

EGIS

10MG

A074808 001 Jul 08, 1997

20MG

A074808 002 Jul 08, 1997

IVAX SUB TEVA PHARMS

10MG

A074148 001 Jun 03, 1996

20MG

A074148 002 Jun 03, 1996

MUTUAL PHARM

20MG

A073536 001 Mar 12, 1993

MYLAN

10MG

A074043 001 Sep 22, 1992

20MG

A074043 002 Sep 22, 1992

ROXANE

10MG

A073651 001 Feb 26, 1993

20MG

A073651 002 Feb 26, 1993

SCS

10MG

A074036 001 May 29, 1992

20MG

A074036 002 May 29, 1992

TEVA

10MG

A073637 001 Jan 28, 1994

20MG

A073638 001 Jan 28, 1994

TEVA PHARMS

10MG

A074103 001 Aug 28, 1992

20MG

A074103 002 Aug 28, 1992

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL

N050109 001

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP

N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC

17GM/SCOOPFUL

A090567 001 Oct 15, 2009

TEVA PHARMS

17GM/SCOOPFUL

A077445 001 May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A090769 001 Jun 07, 2010

SOLUTION; ORAL

OCL

HOSPIRA

6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML

N019284 001 Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS

120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET

N018983 005 Oct 26, 1984

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

N018983 004 Oct 26, 1984

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N018983 007 Jun 12, 1987

360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET

N018983 006 Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 008 Nov 14, 1991

DISCONTINUED DRUG PRODUCT LIST

6-253 (of 322)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE-FLAVORED

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N018983 009 Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

A090712 001 Feb 25, 2010

FOR SUSPENSION; ORAL

CO-LAV

BOCA PHARMA LLC

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

A073428 001 Jan 28, 1992

COLOVAGE

DYNAPHARM

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

A071320 001 Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A071278 001 Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A072319 001 Dec 23, 1988

GO-EVAC

BOCA PHARMA LLC

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER

0.5MG; EQ 1MG BASE

N017986 001

0.5MG; EQ 2MG BASE

N017986 002

0.5MG; EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER

2MG; 0.25MG

N013636 001

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET; ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS

8MEQ

A073398 001 Jan 28, 1992

10MEQ

A072427 001 Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS

10MEQ

A070980 001 Feb 17, 1987

TEVA

8MEQ

A073531 001 Apr 26, 1996

DISCONTINUED DRUG PRODUCT LIST

6-254 (of 322)

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

10MEQ

A073532 001 Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MICRO-K LS

KV PHARM

20MEQ/PACKET

N019561 003 Aug 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM

2MEQ/ML

A080204 001

2MEQ/ML

A084290 001

2MEQ/ML

A086713 001

2MEQ/ML

A086714 001

2MEQ/ML

A087787 001 Apr 20, 1982

2MEQ/ML

A087885 001 Feb 03, 1983

AKORN

2MEQ/ML

A088286 001 Sep 05, 1985

BAXTER HLTHCARE

2MEQ/ML

A080203 001

FRESENIUS KABI USA

2MEQ/ML

A087817 001 Oct 20, 1982

GD SEARLE LLC

1MEQ/ML

A086219 001

2MEQ/ML

A086219 002

2MEQ/ML

A086220 002

3MEQ/ML

A086219 003

3MEQ/ML

A086220 001

4MEQ/ML

A086219 004

HOSPIRA

1MEQ/ML

A080205 003

1MEQ/ML

A083345 003

1.5MEQ/ML

A083345 001

2MEQ/ML

A083345 002

2.4MEQ/ML

A080205 004

3.2MEQ/ML

A080205 005

LILLY

2MEQ/ML

N007865 002

LUITPOLD

2MEQ/ML

A080221 001

2MEQ/ML

A080736 001

2MEQ/ML

A087584 001

2MEQ/ML

A087585 001

MILES

1MEQ/ML

A080195 002

2MEQ/ML

A080195 001

3MEQ/ML

A080195 003

4MEQ/ML

A080195 004

PHARMA SERVE NY

2MEQ/ML

A086297 001

2MEQ/ML

A087362 001 Mar 08, 1983

WATSON LABS

2MEQ/ML

A086208 001

2MEQ/ML

A089163 001 Mar 10, 1988

2MEQ/ML

A089421 001 Jan 02, 1987

3MEQ/ML

A086210 001

TABLET, EXTENDED RELEASE;ORAL

K+10

FUTURE PAK

10MEQ

A070999 001 Oct 22, 1987

K+8

FUTURE PAK

8MEQ

A070998 001 Jan 25, 1993

K-TAB

ABBVIE

10MEQ

N018279 001

KAON CL

SAVAGE LABS

6.7MEQ

N017046 001

KAON CL-10

SAVAGE LABS

10MEQ

N017046 002

KLOTRIX

APOTHECON

10MEQ

N017850 001

POTASSIUM CHLORIDE

ABBVIE

8MEQ

N018279 002 Aug 01, 1988

COPLY PHARM

8MEQ

A070618 001 Sep 09, 1987

NESHER PHARMS

20MEQ

A076044 001 Apr 05, 2002

SCHERING

10MEQ

N019439 002 Jun 13, 1986

20MEQ

N019439 001 Jun 13, 1986

SLOW-K

NOVARTIS

8MEQ

N017476 002

TEN-K

NOVARTIS

10MEQ

N019381 001 Apr 16, 1986

DISCONTINUED DRUG PRODUCT LIST

6-255 (of 322)

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	37MG/100ML; 900MG/100ML	N019708 001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	75MG/100ML; 900MG/100ML	N019708 002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	110MG/100ML; 900MG/100ML	N019708 003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	220MG/100ML; 900MG/100ML	N019708 005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	300MG/100ML; 900MG/100ML	N019708 006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
B BRAUN	75MG/100ML; 900MG/100ML	N018722 001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648 004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	150MG/100ML; 900MG/100ML	N018722 002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	220MG/100ML; 900MG/100ML	N018722 003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	300MG/100ML; 900MG/100ML	N018722 004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA	370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL	N013025 001	

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

NOVA K	10MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 002	Oct 13, 1988
	20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE	1GM/ML	N018551 001	Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDPOINTE PHARM HLC	130MG	N018307 001	

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT	200MG	N017551 001	

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD	10%	N019382 001	Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD	5%	N019382 002	Jul 25, 1989

E-Z PREP 220

CLINIPAD	5%	N019382 003	Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP	300MG/ML	N018799 001	Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST	500MG	N014122 002	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM	1.25MG	N020667 004	Jul 01, 1997

DISCONTINUED DRUG PRODUCT LIST

6-256 (of 322)

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

AMYLIN PHARMS LLC

EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)

N021332 001 Mar 16, 2005

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007

SANDOZ

10MG

A076397 003 Oct 23, 2006

20MG

A076397 002 Oct 23, 2006

40MG

A076397 001 Oct 23, 2006

80MG

A077491 001 Feb 11, 2008

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001 May 16, 1989

EQ 2MG BASE

A072783 001 May 16, 1989

EQ 5MG BASE

A072784 001 May 16, 1989

CLONMEL HLTHCARE

EQ 1MG BASE

A072705 001 May 16, 1989

EQ 2MG BASE

A072706 001 May 16, 1989

EQ 5MG BASE

A072707 001 May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001 May 16, 1989

EQ 2MG BASE

A072921 001 May 16, 1989

EQ 5MG BASE

A072992 001 May 16, 1989

SANDOZ

EQ 1MG BASE

A072576 001 May 16, 1989

EQ 2MG BASE

A072577 001 May 16, 1989

EQ 5MG BASE

A072578 001 May 16, 1989

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

0.5%

N010209 002

SYRUP; ORAL

PREDNISOLONE

APOTEX INC

5MG/5ML

A040570 001 Aug 25, 2005

15MG/5ML

A040571 001 Aug 25, 2005

IVAX SUB TEVA PHARMS

15MG/5ML

A040287 001 May 28, 1999

NESHER PHARMS

5MG/5ML

A040423 001 Oct 22, 2001

15MG/5ML

A040364 001 Apr 10, 2002

TEVA PHARMS

15MG/5ML

A040322 001 Jan 19, 2000

WE PHARMS

15MG/5ML

A040192 001 May 28, 1998

PRELONE

MURO

5MG/5ML

A089654 001 Jan 17, 1989

DISCONTINUED DRUG PRODUCT LIST

6-257 (of 322)

PREDNISOLONE

TABLET; ORAL

CORTALONE

HALSEY	1MG	A080304	003
	2.5MG	A080304	002
	5MG	A080304	001
DELTA-CORTEF			
PHARMACIA AND UPJOHN	5MG	N009987	004
FERNISOLONE-P			
FERNDAL LABS	5MG	A083941	001
PREDNISOLONE			
BARR	5MG	A084426	002
BUNDY	5MG	A083675	001
ELKINS SINN	5MG	A080625	001
EVERYLIFE	1MG	A084439	001
	2.5MG	A084439	002
	5MG	A084439	003
FERRANTE	2.5MG	A080562	001
	5MG	A080562	002
HEATHER	5MG	A080326	001
IMPAX LABS	5MG	A080780	001
INWOOD LABS	5MG	A080748	001
IVAX SUB TEVA PHARMS	5MG	A080378	001
LANNETT	5MG	A080531	002
MARSHALL PHARMA	5MG	A080307	001
PANRAY	1MG	A080351	001
	5MG	A080351	002
PERRIGO	5MG	A084542	001
PHOENIX LABS NY	5MG	A080322	001
PUREPAC PHARM	5MG	A080325	001
PVT FORM	5MG	A080211	001
ROXANE	5MG	A080327	002
SANDOZ	5MG	A080339	001
	5MG	A084773	001
SPERTI	1MG	A080358	001
	2.5MG	A080358	002
	5MG	A080358	003
SUPERPHARM	5MG	A088892	001
TABLICAPS	5MG	A085170	001
TEVA	5MG	A080398	001
UDL	5MG	A087987	001
VALEANT PHARM INTL	5MG	A080236	001
VITARINE	5MG	A080534	001
WATSON LABS	5MG	A085085	002
	5MG	A085415	001
	5MG	A085416	001
WEST WARD	5MG	A080324	001
WHITEWORTH TOWN PLSN	5MG	A080342	001
STERANE			
PFIZER	5MG	N009996	001

Feb 26, 1985

Jan 18, 1983

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTEONE

SCHERING	25MG/ML	N010255	002
PREDNISOLONE ACETATE			
AKORN	25MG/ML	A083032	001
	50MG/ML	A084492	001
BEL MAR	25MG/ML	A083738	001
	50MG/ML	A083738	002
CENT PHARMS	25MG/ML	A084717	001
	50MG/ML	A084717	002
WATSON LABS	25MG/ML	A083398	001
	25MG/ML	A083654	001
	40MG/ML	A083767	001
	50MG/ML	A083764	001
	50MG/ML	A085781	001
STERANE			
PFIZER	25MG/ML	N011446	001

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008

DISCONTINUED DRUG PRODUCT LIST

6-258 (of 322)

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

ECONOPRED

ALCON

0.125%

N017468 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

CETAPRED

ALCON

0.25%;10%

A087771 001 Aug 06, 1993

METIMYD

SCHERING

0.5%;10%

N010210 002 Sep 09, 1984

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088032 001 Apr 15, 1983

VASOCIDIN

NOVARTIS

0.5%;10%

A088791 001 Oct 05, 1984

SUSPENSION;OPHTHALMIC

ISOPTO CETAPRED

ALCON

0.25%;10%

A087547 001

SUSPENSION/DROPS;OPHTHALMIC

METIMYD

SCHERING

0.5%;10%

N010210 001

PREDAMIDE

AKORN

0.5%;10%

A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR

0.2%;10%

A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB

0.5%;10%

A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HYDELTRASOL

MERCK

EQ 20MG PHOSPHATE/ML

N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS

EQ 20MG PHOSPHATE/ML

A080517 001

OINTMENT;OPHTHALMIC, OTIC

HYDELTRASOL

MERCK

EQ 0.25% PHOSPHATE

N011028 001

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

NESHER PHARMS

EQ 5MG BASE/5ML

A076982 001 May 24, 2005

EQ 15MG BASE/5ML

A076988 001 May 24, 2005

PHARM ASSOC

EQ 5MG BASE/5ML

A076123 001 Dec 23, 2002

VINTAGE PHARMS

EQ 5MG BASE/5ML

A078416 001 Oct 31, 2007

WE PHARMS

EQ 5MG BASE/5ML

A075181 001 Dec 23, 2002

EQ 15MG BASE/5ML

A075250 001 Jul 12, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

NOVARTIS

EQ 0.9% PHOSPHATE

A080751 002

INFLAMASE MILD

NOVARTIS

EQ 0.11% PHOSPHATE

A080751 001

METRETON

SCHERING

EQ 0.5% PHOSPHATE

A083834 001

PREDAIR

PHARMAFAIR

EQ 0.11% PHOSPHATE

A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR

EQ 0.9% PHOSPHATE

A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN

EQ 0.11% PHOSPHATE

A083358 001

EQ 0.9% PHOSPHATE

A083358 002

ALCON PHARMS LTD

EQ 0.11% PHOSPHATE

A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE

A081044 001 Oct 24, 1991

BAUSCH AND LOMB

EQ 0.11% PHOSPHATE

A040065 001 Jul 29, 1994

SOLA BARNES HIND

EQ 0.11% PHOSPHATE

A084171 001

EQ 0.9% PHOSPHATE

A084168 001

EQ 0.9% PHOSPHATE

A084169 001

EQ 0.9% PHOSPHATE

A084172 001

DISCONTINUED DRUG PRODUCT LIST

6-259 (of 322)

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULSTER

AKORN

EQ 0.23% PHOSPHATE;10%

A074511 001 Jul 30, 1996

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISONE

SOLUTION;ORAL

PREDNISONE

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP;ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET;ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

PHARMACIA AND UPJOHN

2.5MG

N009986 005

5MG

N009986 002

10MG

N009986 006

20MG

N009986 007

50MG

N009986 008

FERNISONE

FERNDALE LABS

5MG

A083364 001

METICORTEN

SCHERING

1MG

N009766 002

5MG

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISONE

AM THERAP

5MG

A089387 001 Nov 06, 1986

10MG

A089388 001 Nov 06, 1986

20MG

A089389 001 Nov 06, 1986

AMNEAL PHARMS NY

5MG

A089597 001 Oct 05, 1987

10MG

A089598 001 Oct 05, 1987

20MG

A089599 001 Oct 05, 1987

BUNDY

5MG

A083676 001

DURAMED PHARMS BARR

5MG

A088394 001 Oct 04, 1983

10MG

A088395 001 Oct 04, 1983

20MG

A088396 001 Oct 04, 1983

ELKINS SINN

5MG

A080491 001

20MG

A085811 001

EVERYLIFE

1MG

A084440 001

2.5MG

A084440 002

5MG

A084440 003

FERRANTE

2.5MG

A080563 001

5MG

A080563 002

HALSEY

5MG

A080300 001

HEATHER

5MG

A080320 001

10MG

A084341 001

20MG

A084417 001

20MG

A085543 001

50MG

A086946 001

IMPAX LABS

5MG

A080782 001

INWOOD LABS

1MG

A080328 001

2.5MG

A080306 001

5MG

A080279 001

DISCONTINUED DRUG PRODUCT LIST

6-260 (of 322)

PREDNISONE

TABLET; ORAL

PREDNISONE

IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
	50MG	A086596	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PERRIGO	5MG	A083059	001	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1%	N014763	004
	2%	N014763	005
	3%	N014763	003

DISCONTINUED DRUG PRODUCT LIST

6-261 (of 322)

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN

ASTRAZENECA

4%

N014763 007

CITANEST PLAIN DENTAL

DENTSPLY PHARM

4%

N021382 001

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA

250MG/5ML

N010401 001

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD

50MG

A040862 001 Oct 03, 2008

250MG

A040862 002 Oct 03, 2008

WATSON LABS

250MG

A085052 001

WEST WARD

50MG

A040667 001 Jul 27, 2006

PROBENECID

TABLET; ORAL

BENEMID

MERCK

500MG

N007898 004

PROBENECID

IVAX SUB TEVA PHARMS

500MG

A083740 001 May 09, 1984

LEDERLE

500MG

A086917 001

WATSON LABS

500MG

A086150 002 Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US

250MG

N017535 001

500MG

N017535 002 Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT

250MG

A087542 001 Jan 08, 1982

375MG

A087697 001 Mar 01, 1983

500MG

A087543 001 Jan 08, 1982

IVAX SUB TEVA PHARMS

250MG

A084604 001

375MG

A084595 001

500MG

A084606 001

LANNETT

250MG

A083693 001

500MG

A084696 001

LEDERLE

250MG

A086942 001

375MG

A086952 001

500MG

A086943 001

ROXANE

250MG

A088989 001 Apr 26, 1985

500MG

A088990 001 Apr 26, 1985

SANDOZ

250MG

A089219 001 Jul 01, 1986

375MG

A089220 001 Jul 01, 1986

500MG

A089221 001 Jul 01, 1986

VANGARD

250MG

A087643 001 Jun 01, 1982

500MG

A087875 001 Jun 01, 1982

WATSON LABS

250MG

A083287 001

250MG

A083795 001

250MG

A085167 001

375MG

A084403 001

375MG

A087020 001

500MG

A084280 001

500MG

A084357 001

500MG

A087021 001

PROCAN

PARKE DAVIS

250MG

A085804 001

375MG

A087502 001

500MG

A085079 001

PROCAPAN

PANRAY

250MG

A083553 002

PRONESTYL

APOTHECON

250MG

N007335 001

375MG

N007335 004

500MG

N007335 003

DISCONTINUED DRUG PRODUCT LIST

6-262 (of 322)

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	
PRONESTYL				
APOTHECON	100MG/ML	N007335	002	
	500MG/ML	N007335	005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

COPLEY PHARM	1GM	A040111	001	Dec 13, 1996
	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
PLIVA	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
SANDOZ	250MG	A089369	001	Aug 14, 1987
	500MG	A089284	001	Jun 23, 1986
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
WATSON LABS	1GM	A089520	001	Jan 15, 1987
	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
PROCAN SR				
PARKE DAVIS	250MG	A086468	001	
PARKEDALE	1GM	A088489	001	Jan 16, 1985
	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
PROCANBID				
KING PHARMS	1GM	N020545	002	Jan 31, 1996
	500MG	N020545	001	Jan 31, 1996
PRONESTYL-SR				
APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	

DISCONTINUED DRUG PRODUCT LIST

6-263 (of 322)

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE

	2%	A080416	002
MILES	1%	A080415	001
	2%	A080415	002
WATSON LABS	1%	A080658	001
	1%	A083535	001
	2%	A080658	002
	2%	A083535	002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL; 100MG/VIAL	N050276	001
	40MG/VIAL; 250MG/VIAL	N050276	003

TETRACYN

PFIZER	40MG/VIAL; 100MG/VIAL	A060285	002
	40MG/VIAL; 250MG/VIAL	A060285	003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY	100MG/ML; 50MG/ML	N008869	001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE	2.5MG	N011127	003
	5MG	N011127	001
	25MG	N011127	002

PROCHLORPERAZINE

ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001

PROCHLORPERAZINE

ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/ML	N010742	002

PROCHLORPERAZINE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988

HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988

MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988

SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986

TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003

WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987

WYETH AYERST	EQ 5MG BASE/ML	A086348	001

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982

MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	

DISCONTINUED DRUG PRODUCT LIST

6-264 (of 322)

PROCHLORPERAZINE MALEATE

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE	N010571 001
	EQ 10MG BASE	N010571 002
	EQ 25MG BASE	N010571 003

PROCHLORPERAZINE

WATSON LABS	EQ 5MG BASE	A085580 001
	EQ 10MG BASE	A085178 001
	EQ 25MG BASE	A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR	EQ 5MG BASE	A040207 001	May 01, 1997
	EQ 5MG BASE	A089484 001	Jan 20, 1987
	EQ 10MG BASE	A040207 002	May 01, 1997
	EQ 10MG BASE	A089485 001	Jan 20, 1987
	EQ 25MG BASE	A089486 001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162 001	Jan 20, 1998
	EQ 10MG BASE	A040162 002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101 003	Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS	2MG	N009818 005
	5MG	N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBVIE INC	300MG	N019781 003	Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY	25MG/ML	N009238 002
	50MG/ML	N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA	38MG	N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST	30MG/ML	N010942 001
	100MG/ML	N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS	25MG/ML	A084510 001
	50MG/ML	A084517 001

SPARINE

BAXTER HLTHCARE CORP	25MG/ML	N010349 008
	50MG/ML	N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST	10MG/5ML	N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST	10MG	N010348 006
	25MG	N010348 001
	50MG	N010348 002
	100MG	N010348 003
	200MG	N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST	25MG/ML	N008857 002
	50MG/ML	N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT	25MG/ML	A084223 001	
	50MG/ML	A084222 001	
AKORN	25MG/ML	A083955 002	
	50MG/ML	A083955 001	
BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
	50MG/ML	A040524 002	Mar 17, 2004
HOSPIRA	50MG/ML	A040372 002	Jun 08, 2000

DISCONTINUED DRUG PRODUCT LIST

6-265 (of 322)

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

	50MG/ML	A083838	002	
MARSAM PHARMS LLC	25MG/ML	A089463	001	May 02, 1988
	50MG/ML	A089477	001	May 02, 1988
MYLAN INSTITUTIONAL	25MG/ML	A040471	001	Nov 21, 2002
SANDOZ	25MG/ML	A040593	001	Nov 08, 2006
	50MG/ML	A040593	002	Nov 08, 2006
WATSON LABS	25MG/ML	A083532	001	
	25MG/ML	A084591	001	
	50MG/ML	A080629	002	
	50MG/ML	A083532	002	
ZIPAN-25				
ALTANA	25MG/ML	A083997	001	
ZIPAN-50				
ALTANA	50MG/ML	A083997	002	

SUPPOSITORY; RECTAL

PHENERGAN

SHIONOGI INC	12.5MG	N010926	002	
	25MG	N010926	001	
	50MG	N011689	001	

PROMETHACON

POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	

PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983

PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772	001	

PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	

PROMETHAZINE

CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985

PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	

PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS	6.25MG/5ML	N008381	004	Apr 18, 1984
	25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008381	003	

TABLET; ORAL

PHENERGAN

WYETH PHARMS INC	12.5MG	N007935	002	
	25MG	N007935	003	
	50MG	N007935	004	

PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
IMPAX LABS	25MG	A084214	002	Jul 07, 1982
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
LANNETT	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	
MUTUAL PHARM	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	

DISCONTINUED DRUG PRODUCT LIST

6-266 (of 322)

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

SANDOZ	12.5MG	A084176 002	May 22, 2009
	12.5MG	A084233 001	
	25MG	A085146 001	
	50MG	A085146 002	
TABLICAPS	12.5MG	A084080 001	
	25MG	A084027 001	
TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	
REMSSED			
BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843 001	

TABLET; ORAL

PRO-BANTHINE

SHIRE	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732 003	
	15MG	N008732 002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
ROXANE	7.5MG	A080927 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
PARACAINE			
OPTOPICS	0.5%	A087681 001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE			
SOLA BARNES HIND	0.5%	A084144 001	
	0.5%	A084151 001	

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS	N/A	N011657 001	

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

HIKMA MAPLE	20MG/ML	N012382 002	

DISCONTINUED DRUG PRODUCT LIST

6-267 (of 322)

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

FRESENIUS KABI USA 10MG/ML N019627 001 Oct 02, 1989

PROPOFOL

BEDFORD 10MG/ML A074848 001 Apr 19, 2005

TEVA PARENTERAL 10MG/ML A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM 32MG N010997 001

65MG N010997 003

DOLENE

HERITAGE PHARMS INC 65MG A080530 001

KESSO-GESIC

MK LABS 65MG A083544 001

PROPHENE 65

HALSEY 65MG A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG A083184 001

IMPAX LABS 65MG A083317 001

IVAX SUB TEVA PHARMS 32MG A083597 001

MUTUAL PHARM 65MG A083186 001

MYLAN 32MG A083528 001

65MG A040569 001 Dec 16, 2004

65MG A083299 001

NEXGEN PHARMA INC 65MG A083185 001

PAR PHARM 65MG A080269 001

PUREPAC PHARM 65MG A083278 001

PVT FORM 32MG A083464 001

65MG A083113 001

ROXANE 32MG A083089 001

65MG A083089 002

SANDOZ 32MG A084014 001

65MG A083125 002

65MG A083688 001

65MG A083870 002

65MG A086495 001

TEVA 65MG A088615 001 Oct 22, 1984

VALEANT PHARM INTL 65MG A080783 001

VINTAGE PHARMS 65MG A040908 001 Jul 17, 2009

WATSON LABS 65MG A080908 002

65MG A085190 001

WEST WARD 65MG A083501 001

WHITEWORTH TOWN PLSN 65MG A084551 001

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG A083786 001

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET; ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

DISCONTINUED DRUG PRODUCT LIST

6-268 (of 322)

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE

20MG/5ML

A071984 001 Mar 03, 1989

40MG/5ML

A071985 001 Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST

10MG/ML

N019536 001 Dec 12, 1986

TABLET; ORAL

INDERAL

WYETH PHARMS INC

10MG

N016418 001

20MG

N016418 003

90MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016418 010 Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

CLONMEL HLTHCARE

10MG

A070125 001 Jul 30, 1985

20MG

A070126 001 Jul 30, 1985

40MG

A070127 001 Jul 30, 1985

60MG

A071495 001 Dec 31, 1987

80MG

A070128 001 Jul 30, 1985

90MG

A071496 001 Dec 31, 1987

DURAMED PHARMS BARR

10MG

A070306 001 Sep 09, 1985

20MG

A070307 001 Sep 09, 1985

40MG

A070308 001 Sep 09, 1985

60MG

A070309 001 Oct 01, 1986

80MG

A070310 001 Sep 09, 1985

90MG

A071327 001 Oct 01, 1986

INTERPHARM

10MG

A071368 001 May 05, 1987

20MG

A071369 001 May 05, 1987

40MG

A071370 001 May 05, 1987

80MG

A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS

10MG

A072063 001 Jul 29, 1988

20MG

A072066 001 Jul 29, 1988

40MG

A072067 001 Jul 29, 1988

60MG

A072068 001 Jul 29, 1988

80MG

A072069 001 Jul 29, 1988

LEDERLE

10MG

A072117 001 Jun 23, 1988

20MG

A072118 001 Jun 23, 1988

40MG

A072119 001 Jun 23, 1988

80MG

A072120 001 Jun 23, 1988

MUTUAL PHARM

10MG

A070319 001 Oct 22, 1985

20MG

A070320 001 Oct 22, 1985

40MG

A070103 001 Oct 22, 1985

60MG

A070321 001 Sep 24, 1986

80MG

A070322 001 Aug 04, 1986

MYLAN

60MG

A072275 001 Jun 09, 1989

PAR PHARM

90MG

A071288 001 Oct 22, 1986

PLIVA

10MG

A071977 001 Apr 06, 1988

PUREPAC PHARM

10MG

A070814 001 Nov 03, 1986

20MG

A070815 001 Nov 03, 1986

40MG

A070816 001 Nov 03, 1986

60MG

A070817 001 Nov 03, 1986

80MG

A070757 001 Nov 03, 1986

ROXANE

10MG

A070516 001 Jul 07, 1986

20MG

A070517 001 Jul 07, 1986

40MG

A070518 001 Jul 07, 1986

60MG

A070519 001 Sep 24, 1986

80MG

A070520 001 Jul 07, 1986

90MG

A070521 001 Sep 24, 1986

SANDOZ

10MG

A070663 001 Jun 13, 1986

10MG

A071658 001 Jul 05, 1988

20MG

A070664 001 Jun 13, 1986

20MG

A071687 001 Jul 05, 1988

40MG

A070665 001 Jun 13, 1986

40MG

A071688 001 Jul 05, 1988

60MG

A070666 001 Oct 10, 1986

60MG

A072197 001 Jul 05, 1988

80MG

A070667 001 Jun 13, 1986

80MG

A071689 001 Jul 05, 1988

90MG

A072198 001 Jul 05, 1988

SCHERING

10MG

A070120 001 Aug 06, 1985

DISCONTINUED DRUG PRODUCT LIST

6-269 (of 322)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309	001

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309	002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
HALSEY	50MG	A080015	001
IMPAX LABS	50MG	A080159	001
IVAX SUB TEVA PHARMS	50MG	A080215	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001
WEST WARD	50MG	A080154	001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

HIKMA MAPLE	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
LILLY	10MG/ML	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

DISCONTINUED DRUG PRODUCT LIST

6-270 (of 322)

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE

5%

N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN

5%

N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT

0.5MG/ML

N017638 001

THYREL TRH

FERRING

0.5MG/ML

N018087 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US

2MG

A083459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS

5MG

N016012 001

10MG

N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US

120MG

N017603 001

SUDAFED 12 HOUR

GLAXOSMITHKLINE

120MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE

120MG; 5MG

N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG; 5MG

A071798 001 Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI

30MG/5ML; 1.25MG/5ML

A088344 001 Feb 09, 1984

HISTAFED

CENCI

30MG/5ML; 1.25MG/5ML

A088283 001 Apr 20, 1984

MYFED

USL PHARMA

30MG/5ML; 1.25MG/5ML

A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS

30MG/5ML; 1.25MG/5ML

A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM

60MG; 2.5MG

A088860 001 Jan 31, 1985

CORPHED

SANDOZ

60MG; 2.5MG

A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ

60MG; 2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS

60MG; 2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA

60MG; 2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS

60MG; 2.5MG

A088318 002 Jan 13, 1984

WEST WARD

60MG; 2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

60MG; 2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM

60MG; 2.5MG

A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG; 5MG

A072758 001 Nov 25, 1991

DISCONTINUED DRUG PRODUCT LIST

6-271 (of 322)

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC

EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

BARR

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

COREPHARMA

60MG

A040457 001 Dec 26, 2002

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

WATSON LABS

100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

PRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE

25MG;500MG

N018557 001

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET;ORAL

DORAL

SCIECURE PHARMA INC

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

ASTRAZENECA

EQ 150MG BASE

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS TOTOWA

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

EQ 40MG BASE

A076240 004 Jan 26, 2006

MYLAN

EQ 5MG BASE

A076036 001 Jan 28, 2005

EQ 10MG BASE

A076036 002 Jan 28, 2005

EQ 20MG BASE

A076036 003 Jan 28, 2005

EQ 40MG BASE

A076036 004 Jan 28, 2005

DISCONTINUED DRUG PRODUCT LIST

6-272 (of 322)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

SANDOZ

EQ 5MG BASE

A076803 001 Mar 02, 2005

EQ 10MG BASE

A076803 002 Mar 02, 2005

EQ 20MG BASE

A076803 003 Mar 02, 2005

EQ 40MG BASE

A076803 004 Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS

0.1MG

N016768 002

0.2MG

N016768 003

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE

50MG

N013264 001

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE

50MG; 0.125MG

N013927 001

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLTHCARE

266MG

A085978 001

400MG

A086099 001

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT

330MG

N017917 001

QUINAGLUTE

BAYER HLTHCARE

324MG

N016647 001

QUINALAN

LANNETT

324MG

A088081 001 Feb 10, 1986

QUINATIME

WATSON LABS

324MG

A087448 001

QUINIDINE GLUCONATE

ASCOT

324MG

A088582 001 Jun 17, 1985

HALSEY

324MG

A089476 001 Apr 10, 1987

ROXANE

324MG

A088431 001 Jan 06, 1984

SANDOZ

324MG

A089894 001 Dec 15, 1988

SUPERPHARM

324MG

A089164 001 Nov 21, 1985

WATSON LABS

324MG

A087785 001 Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC

275MG

N011642 002

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG

A085296 001

300MG

A085297 001

QUINIDINE SULFATE

LILLY

200MG

A085103 001

TABLET; ORAL

CIN-QUIN

SOLVAY

100MG

A085299 001

200MG

A084932 001

300MG

A085298 001

QUINIDINE SULFATE

BARR

200MG

A084177 001

CLONMEL HLTHCARE

200MG

A087011 001

CONTRACT PHARMACAL

200MG

A083808 001

ELKINS SINN

200MG

A083622 001

EVERYLIFE

200MG

A083439 001

HALSEY

200MG

A083583 001

IMPAX LABS

200MG

A083347 001

IVAX SUB TEVA PHARMS

200MG

A084549 001

KING PHARMS

200MG

A085175 001

KV PHARM

200MG

A085276 001

LANNETT

200MG

A083743 001

DISCONTINUED DRUG PRODUCT LIST

6-273 (of 322)

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
ROXANE	200MG	A083640	001	
	300MG	A085632	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WEST WARD	200MG	A083862	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001
SCHERING	300MG	A085222	001

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

EISAI INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020973	001	May 29, 2002

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009

TABLET;ORAL

ALTACE

KING PFIZER	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	001	Feb 27, 2007
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	002	Feb 27, 2007
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	003	Feb 27, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	004	Feb 27, 2007

DISCONTINUED DRUG PRODUCT LIST

6-274 (of 322)

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

GLAXOSMITHKLINE

400MG

N020559 001 Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE

N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

COVIS PHARMA SARL

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

MYLAN

EQ 150MG BASE

A074552 001 Jul 30, 1998

EQ 300MG BASE

A074552 002 Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075132 001 Jan 14, 2000

EQ 75MG BASE

A075254 001 Jan 14, 2000

EQ 150MG BASE

A075000 001 Jan 30, 1998

EQ 150MG BASE

A075439 001 Apr 19, 2000

EQ 300MG BASE

A075000 002 Jan 30, 1998

EQ 300MG BASE

A075439 002 Apr 19, 2000

SANDOZ

EQ 75MG BASE

A075519 001 Sep 26, 2002

WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 150MG BASE

A074864 001 Oct 20, 1997

EQ 300MG BASE

A074864 002 Oct 20, 1997

WATSON LABS INC

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A077426 002 Dec 19, 2005

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE

N020251 001 Mar 31, 1994

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020745 001 Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001 Aug 18, 1999

200MG/VIAL

N020984 002 Aug 18, 1999

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS

50MG

N009276 003

50MG

N009276 005

100MG

N009276 004

HYSERPIN

PHYS PRODS VA

50MG

N010581 001

KONGLUCOID

PANRAY

50MG

N009278 001

100MG

N009278 002

DISCONTINUED DRUG PRODUCT LIST

6-275 (of 322)

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDAL LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

RESCINNAMINE

CAPSULE;ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET;ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

RESERPINE

ELIXIR;ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE;INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET;ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

RAU-SED

BRISTOL MYERS SQUIBB

0.1MG

N009357 001

0.25MG

N009357 004

0.5MG

N009357 006

1MG

N009357 008

RESERPINE

BARR

0.25MG

A080721 002

BELL PHARMA

0.1MG

A083058 001

0.25MG

A083058 002

BUNDY

0.1MG

N009663 001

0.25MG

N009663 003

ELKINS SINN

0.1MG

A083145 001

0.25MG

A083145 002

EVERYLIFE

0.1MG

N010441 001

0.25MG

N010441 002

DISCONTINUED DRUG PRODUCT LIST

6-276 (of 322)

RESERPINE

TABLET; ORAL

RESERPINE

	0.5MG	N010441 003	
	1MG	N010441 004	
HALSEY	0.1MG	A080457 002	
	0.25MG	A080457 001	
	1MG	A080457 003	
IMPAX LABS	0.1MG	N009627 001	
	0.25MG	N009627 002	
IVAX SUB TEVA PHARMS	0.1MG	N011185 001	
	0.25MG	N011185 002	
MARSHALL PHARMA	0.1MG	A080492 001	
	0.25MG	A080492 002	
MK LABS	0.1MG	A080525 002	
	0.25MG	A080525 001	
MYLAN	1MG	A084974 001	
PHARMAVITE	0.25MG	A084663 001	
PUREPAC PHARM	0.1MG	A080753 002	
	0.25MG	A080753 001	
PVT FORM	0.1MG	A086117 001	
	0.25MG	A080582 001	
	0.25MG	A085775 001	
	1MG	A080582 002	
REXALL	0.25MG	A080637 001	
ROXANE	0.1MG	N009859 001	
	0.25MG	N009859 002	
SOLVAY	0.25MG	A080446 001	
TABLICAPS	0.25MG	A085207 001	
TEVA	0.1MG	A089020 001	Mar 07, 1985
	0.25MG	A089019 001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667 001	
	0.25MG	N009667 002	
WATSON LABS	0.1MG	A080679 001	
	0.25MG	A080393 001	
	0.25MG	A085401 001	
	1MG	A080749 001	
WEST WARD	0.1MG	A080975 001	
	0.25MG	A080975 002	
	1MG	A080975 003	
WHITEWORTH TOWN PLSN	0.1MG	A080723 001	
	0.25MG	A080723 002	
	1MG	A080723 003	
SANDRIL			
LILLY	0.1MG	N009376 004	
	0.25MG	N009376 001	
SERPALAN			
LANNETT	0.1MG	N010124 001	
	0.25MG	N010124 002	
SERPANRAY			
PANRAY	0.1MG	N009391 001	
	0.25MG	N009391 002	
	1MG	N009391 004	
SERPASIL			
NOVARTIS	0.1MG	N009115 001	
	0.25MG	N009115 003	
	1MG	N009115 004	
SERPATE			
VALE	0.1MG	N009453 001	
	0.25MG	N009453 002	
SERPIVITE			
VITARINE	0.25MG	N009645 002	

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2		
SANOFI AVENTIS US	0.1MG; 2MG	N012972 001
METATENSIN #4		
SANOFI AVENTIS US	0.1MG; 4MG	N012972 002
NAQUIVAL		
SCHERING	0.1MG; 4MG	N012265 003

DISCONTINUED DRUG PRODUCT LIST

6-277 (of 322)

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS

0.1MG; 4MG

A085248 001

RIBAVIRIN

TABLET; ORAL

COPEGUS

ROCHE

400MG

N021511 002 Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS

50MG/5ML

N019650 001 Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS TOTOWA

100MG

A076375 001 Jan 14, 2003

COREPHARMA

100MG

A075916 001 Nov 02, 2001

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

WARNER CHILCOTT LLC

75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020835 004 Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005 Dec 29, 1993

RISPERIDONE

CADISTA PHARMS

0.25MG

A078828 001 Mar 23, 2009

0.5MG

A078828 002 Mar 23, 2009

1MG

A078828 003 Mar 23, 2009

2MG

A078828 004 Mar 23, 2009

3MG

A078828 005 Mar 23, 2009

4MG

A078828 006 Mar 23, 2009

RATIOPHARM

0.25MG

A077784 001 Jun 08, 2010

0.5MG

A077784 002 Jun 08, 2010

1MG

A077784 003 Jun 08, 2010

2MG

A077784 004 Jun 08, 2010

3MG

A077784 005 Jun 08, 2010

4MG

A077784 006 Jun 08, 2010

SYNTHON PHARMS

0.25MG

A078187 001 Oct 22, 2009

0.5MG

A078187 002 Oct 22, 2009

1MG

A078187 003 Oct 22, 2009

2MG

A078187 004 Oct 22, 2009

3MG

A078187 005 Oct 22, 2009

4MG

A078187 006 Oct 22, 2009

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM

10MG/ML

A071188 001 Jul 23, 1987

15MG/ML

A071189 001 Jul 23, 1987

HOSPIRA

10MG/ML

A071618 001 Feb 28, 1991

15MG/ML

A071619 001 Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001 Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001 Mar 01, 1996

DISCONTINUED DRUG PRODUCT LIST

6-278 (of 322)

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

ORGANON USA INC

10MG/ML (10MG/ML)

N020214 002 Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001 May 20, 1999

25MG/5ML

N021052 002 May 20, 1999

TABLET; ORAL

VIOXX

MERCK

12.5MG

N021042 001 May 20, 1999

25MG

N021042 002 May 20, 1999

50MG

N021042 003 Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

COREPHARMA

EQ 0.25MG BASE

A078230 001 May 20, 2008

EQ 0.5MG BASE

A078230 002 May 20, 2008

EQ 1MG BASE

A078230 003 May 20, 2008

EQ 2MG BASE

A078230 004 May 20, 2008

EQ 3MG BASE

A078230 005 May 20, 2008

EQ 4MG BASE

A078230 006 May 20, 2008

EQ 5MG BASE

A078230 007 May 20, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

GLAXOSMITHKLINE LLC

EQ 3MG BASE

N022008 002 Jun 13, 2008

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL

N016224 001

1mCi/VIAL

N016224 002

2mCi/VIAL

N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML

N017318 001

RUFINAMIDE

TABLET; ORAL

BANZEL

EISAI INC

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021911 001 Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

HOFFMANN LA ROCHE

200MG

N020828 001 Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

DISCONTINUED DRUG PRODUCT LIST

6-279 (of 322)

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

KV PHARM	100MG	A085285	001
LANNETT	50MG	A085909	001
	100MG	A085903	001
PARKE DAVIS	100MG	A084762	001
PERRIGO	100MG	A084561	001
PUREPAC PHARM	100MG	A085867	001
VALEANT PHARM INTL	100MG	A085477	001
VITARINE	100MG	A085898	001
	100MG	A086273	001
WATSON LABS	100MG	A085792	001
WEST WARD	100MG	A084926	001
WHITEWORTH TOWN PLSN	100MG	A085798	001
WYETH AYERST	100MG	A086390	001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN	100MG/VIAL	A083281	001
WYETH AYERST	50MG/ML	A083262	001

SECONAL SODIUM

LILLY	50MG/ML	N007392	002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY	30MG	A086530	001
	60MG	A086530	002
	120MG	A086530	003
	200MG	A086530	004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING	75CU/VIAL	N018290	001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFOLO

CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

AAIPHARMA LLC	5MG	A075145	001	Sep 15, 2003

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996
IVAX SUB TEVA PHARMS	5MG	A074756	001	Nov 25, 1998
SIEGFRIED	5MG	A074672	001	Apr 01, 1997
SOMERSET	5MG	N019334	001	Jun 05, 1989
TEVA	5MG	A074537	001	Aug 02, 1996
	5MG	A074744	001	Jan 27, 1997
VINTAGE PHARMS LLC	5MG	A074565	001	Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT	2.5%	A083892	001

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC	2.5%	A084394	001
IVAX PHARMS	2.5%	A085777	001
TARO	2.5%	A086209	001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001
MALLINCKRODT	100uCi/ML	N017098	001
PHARMALUCENCE	500uCi/ML	N017322	001

SETHOTOPE

BRACCO	85-550uCi/ML	N017047	001

DISCONTINUED DRUG PRODUCT LIST

6-280 (of 322)

SERACTIDE ACETATE

INJECTABLE; INJECTION

ACTHAR GEL-SYNTHETIC

ARMOUR PHARM

40 UNITS/ML

N017861 001

80 UNITS/ML

N017861 002

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

EMD SERONO

EQ 0.05MG BASE/AMP

N019863 001 Dec 28, 1990

EMD SERONO INC

EQ 0.5MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020443 001 Sep 26, 1997

EQ 1MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD

EQ 20MG BASE/ML

A078053 001 Feb 05, 2007

ROXANE

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

CIPLA LTD

EQ 25MG BASE

A077162 001 Feb 06, 2007

EQ 50MG BASE

A077162 002 Feb 06, 2007

EQ 100MG BASE

A077162 003 Feb 06, 2007

DR REDDYS LABS LTD

EQ 25MG BASE

A076442 001 Apr 30, 2007

EQ 50MG BASE

A076442 002 Apr 30, 2007

EQ 100MG BASE

A076442 003 Apr 30, 2007

IVAX SUB TEVA PHARMS

EQ 25MG BASE

A075719 003 Jun 30, 2006

EQ 50MG BASE

A075719 001 Jun 30, 2006

EQ 100MG BASE

A075719 002 Jun 30, 2006

MUTUAL PHARM

EQ 25MG BASE

A077818 001 Feb 06, 2007

EQ 50MG BASE

A077818 002 Feb 06, 2007

EQ 100MG BASE

A077818 003 Feb 06, 2007

MYLAN PHARMS INC

EQ 25MG BASE

A076540 001 Mar 20, 2007

EQ 50MG BASE

A076540 002 Mar 20, 2007

EQ 100MG BASE

A076540 003 Mar 20, 2007

PLIVA HRVATSKA DOO

EQ 25MG BASE

A077299 001 Feb 06, 2007

EQ 50MG BASE

A077299 002 Feb 06, 2007

EQ 100MG BASE

A077299 003 Feb 06, 2007

ROXANE

EQ 25MG BASE

A076881 001 Feb 06, 2007

EQ 50MG BASE

A076881 002 Feb 06, 2007

EQ 100MG BASE

A076881 003 Feb 06, 2007

SANDOZ

EQ 25MG BASE

A077713 001 Feb 06, 2007

EQ 50MG BASE

A077713 002 Feb 06, 2007

EQ 100MG BASE

A077713 003 Feb 06, 2007

ZOLOFT

PFIZER

EQ 150MG BASE

N019839 003 Dec 30, 1991

EQ 200MG BASE

N019839 004 Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME

403MG

N020926 001 Oct 30, 1998

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT

5MG

N020632 001 Nov 22, 1997

10MG

N020632 002 Nov 22, 1997

15MG

N020632 003 Nov 22, 1997

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS

1%

N019608 001 Nov 30, 1989

DISCONTINUED DRUG PRODUCT LIST

6-281 (of 322)

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO

7.5MG/ML

N020773 001 Oct 29, 1998

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

SANDOZ INC

5MG

A077766 001 Dec 20, 2006

10MG

A077766 002 Dec 20, 2006

20MG

A077766 003 Dec 20, 2006

40MG

A077766 004 Dec 20, 2006

80MG

A077766 005 Dec 20, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS

10MG

N021961 001 Oct 09, 2007

20MG

N021961 002 Oct 09, 2007

40MG

N021961 003 Oct 09, 2007

80MG

N021961 004 Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

MERCK SHARP DOHME

10MG; EQ 50MG BASE

N202343 004 Sep 18, 2012

10MG; EQ 100MG BASE

N202343 001 Oct 07, 2011

20MG; EQ 50MG BASE

N202343 005 Sep 18, 2012

20MG; EQ 100MG BASE

N202343 002 Oct 07, 2011

40MG; EQ 50MG BASE

N202343 006 Sep 18, 2012

40MG; EQ 100MG BASE

N202343 003 Oct 07, 2011

SIROLIMUS

TABLET; ORAL

RAPAMUNE

PF PRISM CV

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

B BRAUN

100MG/ML; 100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT

0.9MEQ/ML

N019443 001 Jun 03, 1986

1MEQ/ML

N019443 002 Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM

9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT

20GM/100ML

N017013 001

B BRAUN

20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN

450MG/100ML

N018184 001

MILES

450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

N019218 001 Jul 13, 1984

MILES

900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM

234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN

3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE

450MG/100ML

N017864 001

DISCONTINUED DRUG PRODUCT LIST

6-282 (of 322)

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

450MG/100ML
 HOSPIRA 450MG/100ML
 450MG/100ML

N018497 001 Feb 19, 1982
 N017670 001
 N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES 900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

BRACCO 2mCi/VIAL
 200uCi/ML

N013993 002
 N013993 001

SODIUM CHROMATE CR 51

MALLINCKRODT 100uCi/ML

N016708 001

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE 2mCi/ML **Federal Register
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD 10-200mCi/ML

N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HLTH 414 400uCi
 GE HEALTHCARE 100uCi

N018671 003 May 27, 1982
 N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE 2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO 1-130mCi
 1-150mCi

N010929 001
 N010929 003

SODIUM IODIDE I 131

CIS 50uCi
 100uCi

N017316 001
 N017316 002

MALLINCKRODT 0.8-100mCi
 15-100uCi

N016515 002
 N016517 002

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE 2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE 1-250mCi/0.25ML
 1-500mCi/0.5ML
 1-1000mCi/ML

N021305 002 Jan 24, 2003
 N021305 003 Jan 24, 2003
 N021305 005 Apr 04, 2006

IODOTOPE

BRACCO 7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS 50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN 1.87GM/100ML
 HOSPIRA 1.87GM/100ML

N018186 001
 N018249 001

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS 1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS 1.2%

N019518 001 Jun 03, 1987

DISCONTINUED DRUG PRODUCT LIST

6-283 (of 322)

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE 50MG/VIAL

N017546 001

NITROPRESS

ABBOTT 50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE 50MG/VIAL

N018450 001

HOSPIRA 50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM 50MG/VIAL

A070031 001 Jan 17, 1985

BAXTER HLTHCARE 50MG/VIAL

N018581 001 Jul 28, 1982

TEVA PARENTERAL 25MG/ML

A073465 001 Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO 1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT 0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS 0.398GM; 1.102GM

N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC 0.398GM; 1.102GM

A079247 001 Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA 454GM/BOT

A040909 001 Dec 03, 2008

WOCKHARDT 453.6GM/BOT

A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE 15GM/60ML

A088717 001 Sep 11, 1984

ROXANE 15GM/60ML

A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN 30%

A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN 1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N005970 004

3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY 250MG/ML

N020166 001 Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH 5MG/VIAL

N019107 001 Oct 17, 1985

10MG/VIAL

N019107 002 Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO 10 IU/VIAL

N017726 001

ASELLACRIN 2

SERONO 2 IU/VIAL

N017726 002 Jul 21, 1983

CRESCORMON

GENENTECH 4 IU/VIAL

N017992 001

DISCONTINUED DRUG PRODUCT LIST

6-284 (of 322)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

CANGENE	5MG/ML (5MG/ML)	N021538 001	Jan 23, 2008
BIO-TROPIN			
FERRING	4.8MG/VIAL	N019774 001	May 25, 1995
HUMATROPE			
LILLY	2MG/VIAL	N019640 001	Jun 23, 1987
NORDITROPIN			
NOVO NORDISK INC	4MG/VIAL	N019721 001	May 08, 1995
	5MG/1.5ML	N021148 001	Jun 20, 2000
	8MG/VIAL	N019721 002	May 08, 1995
	10MG/1.5ML	N021148 002	Jun 20, 2000
	15MG/1.5ML	N021148 003	Jun 20, 2000
NORDITROPIN NORDIFLEX			
NOVO NORDISK INC	5MG/1.5ML	N021148 004	Oct 01, 2004
	10MG/1.5ML	N021148 005	Oct 01, 2004
	15MG/1.5ML	N021148 006	Oct 01, 2004
NUTROPIN DEPOT			
GENENTECH	13.5MG/VIAL	N021075 001	Dec 22, 1999
	18MG/VIAL	N021075 002	Dec 22, 1999
	22.5MG/VIAL	N021075 003	Dec 22, 1999
SAIZEN			
EMD SERONO	4MG/VIAL	N019764 005	Jan 16, 2007
	6MG/VIAL	N019764 001	Oct 08, 1996
SEROSTIM			
EMD SERONO	8.8MG/VIAL	N020604 004	Sep 06, 2001
ZORBTIVE			
EMD SERONO	4MG/VIAL	N021597 001	Dec 01, 2003
	5MG/VIAL	N021597 002	Dec 01, 2003
	6MG/VIAL	N021597 003	Dec 01, 2003

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604 005	Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N018512 001	May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

BAYER HLTHCARE	320MG	N019865 004	Oct 30, 1992
BETAPACE AF			
BAYER HLTHCARE	40MG	N021151 006	Apr 02, 2003
	60MG	N021151 007	Apr 02, 2003
	100MG	N021151 005	Mar 14, 2003

SOTALOL HYDROCHLORIDE

MUTUAL PHARM	80MG	A075515 001	Oct 15, 2001
	80MG	A076576 001	Apr 08, 2004
	120MG	A075515 004	Oct 15, 2001
	120MG	A076576 002	Apr 08, 2004
	160MG	A075515 002	Oct 15, 2001
	160MG	A076576 003	Apr 08, 2004
	240MG	A075515 003	Oct 15, 2001
WATSON LABS	80MG	A075238 001	Jul 13, 2000
	120MG	A075238 002	Jul 13, 2000
	160MG	A075238 003	Jul 13, 2000
	240MG	A075238 004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

SOYACAL 10%

ALPHA THERA	10%	N018465 001	Jun 29, 1983

SOYACAL 20%

ALPHA THERA	20%	N018786 001	Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE	10%	N018660 001	Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE	20%	N018758 001	Feb 15, 1983

DISCONTINUED DRUG PRODUCT LIST

6-285 (of 322)

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB 5MG

N020412 001 Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB 37.5MG

N021453 001 Dec 31, 2002

50MG

N021453 002 Dec 31, 2002

75MG

N021453 003 Dec 31, 2002

100MG

N021453 004 Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM

100%

A089099 001 Dec 29, 1987

100%

A089100 001 Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN

100%

N019077 001 Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES

100%

N018246 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS

EQ 500MG BASE/ML

A060684 001

LILLY

EQ 1GM BASE/VIAL

A060107 001

EQ 1GM BASE/2ML

A060404 001

EQ 5GM BASE/VIAL

A060107 002

PFIZER

EQ 1GM BASE/VIAL

A060076 001

EQ 1GM BASE/2.5ML

A060111 001

EQ 5GM BASE/VIAL

A060076 002

DISCONTINUED DRUG PRODUCT LIST

6-286 (of 322)

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ

1GM/VIAL

N008453 004

50MG/ML

N008453 003

500MG/VIAL

N008453 001

QUELICIN PRESERVATIVE FREE

HOSPIRA

50MG/ML

N008845 002

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION

100MG/VIAL

A085400 001 Feb 04, 1982

ORGANON USA INC

20MG/ML

A080997 001

SUOSTRIN

APOTHECON

20MG/ML

N008847 001

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

SCHERING

10%

N005963 001

30%

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

10%

A040215 001 May 25, 1999

30%

A040216 001 May 25, 1999

ALCON PHARMS LTD

30%

A089068 001 May 05, 1987

PHARMAFAIR

10%

A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001 Feb 03, 1983

DISCONTINUED DRUG PRODUCT LIST

6-287 (of 322)

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE

300MG

N004125 005

EVERYLIFE

500MG

A080088 001

IMPAX LABS

500MG

A080081 001

LANNETT

500MG

A080084 001

LEDERLE

500MG

N004054 001

LILLY

500MG

N004122 002

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM

LEDERLE

250MG/ML

N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX

LILLY

250MG/5ML; 250MG/5ML

N006317 007

SULFAMETER

TABLET; ORAL

SULLA

BAYER HLTHCARE

500MG

N016000 002

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS

1GM

A086012 001

PROKLAR

FOREST PHARMS

500MG

A080273 001

THIOSULFIL

WYETH AYERST

250MG

N008565 001

500MG

N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE

500MG/5ML

N013664 002

TABLET; ORAL

GANTANOL

ROCHE

500MG

N012715 002

GANTANOL-DS

ROCHE

1GM

N012715 003

SULFAMETHOXAZOLE

ASCOT

500MG

A087662 001 Oct 20, 1982

BARR

500MG

A087189 001 Jul 25, 1983

HEATHER

500MG

A086163 001

SANDOZ

500MG

A085844 001

WATSON LABS

1GM

A086000 001

500MG

A085053 001

UROBAK

SHIONOGI

500MG

A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM

80MG/ML; 16MG/ML

N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML; 16MG/ML

N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML; 16MG/ML

A070223 001 Dec 29, 1987

BEDFORD

80MG/ML; 16MG/ML

A072383 001 Apr 29, 1992

HIKMA MAPLE

80MG/ML; 16MG/ML

A070627 001 Dec 29, 1987

80MG/ML; 16MG/ML

A070628 001 Dec 29, 1987

HOSPIRA

80MG/ML; 16MG/ML

A073199 001 Sep 11, 1992

WATSON LABS

80MG/ML; 16MG/ML

A071556 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 001

DISCONTINUED DRUG PRODUCT LIST

6-288 (of 322)

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM PEDIATRIC

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA

200MG/5ML; 40MG/5ML

A070028 001 Jun 02, 1987

200MG/5ML; 40MG/5ML

N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML

N018812 002 Jun 10, 1983

TEVA PHARMS

200MG/5ML; 40MG/5ML

A077612 001 Nov 13, 2006

SULFATRIM

STI PHARMA LLC

200MG/5ML; 40MG/5ML

N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA

200MG/5ML; 40MG/5ML

A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA

200MG/5ML; 40MG/5ML

A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS

200MG/5ML; 40MG/5ML

A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML

A072398 001 May 23, 1988

NASKA

200MG/5ML; 40MG/5ML

A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA

400MG; 80MG

A070034 001 May 16, 1985

COTRIM D.S.

TEVA

800MG; 160MG

A070048 001 Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC

400MG; 80MG

A070022 001 Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC

800MG; 160MG

A070032 001 Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER

400MG; 80MG

N018946 001 Aug 10, 1984

800MG; 160MG

N018946 002 Aug 10, 1984

INTERPHARM

400MG; 80MG

A071299 001 Oct 27, 1987

800MG; 160MG

A071300 001 Oct 27, 1987

MARTEC USA LLC

400MG; 80MG

A072408 001 Dec 07, 1988

MUTUAL PHARM

400MG; 80MG

A070006 001 Nov 14, 1984

400MG; 80MG

A071016 001 Aug 25, 1986

PLIVA

400MG; 80MG

A070215 001 Sep 10, 1985

800MG; 160MG

A070216 001 Sep 10, 1985

ROXANE

400MG; 80MG

A072768 001 Aug 30, 1991

SANDOZ

400MG; 80MG

A070889 001 Nov 13, 1986

400MG; 80MG

N018598 003 May 19, 1982

800MG; 160MG

A070890 001 Nov 13, 1986

TEVA

400MG; 80MG

N018242 001

800MG; 160MG

N018242 002

USL PHARMA

400MG; 80MG

A070203 001 Nov 08, 1985

800MG; 160MG

A070204 001 Nov 08, 1985

WATSON LABS

400MG; 80MG

A070002 001 Nov 07, 1984

400MG; 80MG

N018852 001 May 09, 1983

800MG; 160MG

A070000 001 Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC

800MG; 160MG

A072417 001 Dec 07, 1988

MUTUAL PHARM

800MG; 160MG

A070007 001 Nov 14, 1984

ROXANE

800MG; 160MG

A072769 001 Aug 30, 1991

SANDOZ

800MG; 160MG

N018598 004 May 19, 1982

WATSON LABS

800MG; 160MG

N018854 001 May 09, 1983

SULFATRIM-DS

SUPERPHARM

800MG; 160MG

A070066 001 Jun 24, 1985

SULFATRIM-SS

SUPERPHARM

400MG; 80MG

A070065 002 Jun 24, 1985

UROPLUS DS

SHIONOGI

800MG; 160MG

A071816 001 Sep 28, 1987

UROPLUS SS

SHIONOGI

400MG; 80MG

A071815 001 Sep 28, 1987

DISCONTINUED DRUG PRODUCT LIST

6-289 (of 322)

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

TEVA

15%

A088718 001 Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

MEDA PHARMS

1.05GM

N006530 004 Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC

500MG/5ML

N013093 001

TABLET; ORAL

SULFABID

PURDUE FREDERICK

500MG

N013092 002

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY

500MG

N000159 001

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN

250MG/5ML

N018605 001

TABLET; ORAL

S.A.S.-500

SOLVAY

500MG

A083450 001

SULFASALAZINE

HERITAGE PHARMS INC

500MG

A080197 001

MUTUAL PHARM

500MG

A089590 001 Oct 19, 1987

SANDOZ

500MG

A086184 001

SUPERPHARM

500MG

A089339 001 Oct 26, 1987

WATSON LABS

500MG

A084964 001

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS

500MG

A088052 001 May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

NOVARTIS

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011556 004

SULFINPYRAZONE

BARR

200MG

A087666 001 Sep 17, 1982

IVAX PHARMS

200MG

A087770 001 Nov 19, 1982

PAR PHARM

200MG

A088934 001 Sep 06, 1985

VANGARD

200MG

A088666 001 Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011556 003

SULFINPYRAZONE

BARR

100MG

A087665 001 Sep 17, 1982

IVAX PHARMS

100MG

A087769 001 Jun 01, 1982

PAR PHARM

100MG

A088933 001 Sep 06, 1985

WATSON LABS

100MG

A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE

500MG

N006525 001

SOSOL

MK LABS

500MG

A080036 001

SOXAZOLE

ALRA

500MG

A080366 001

SULFALAR

PARKE DAVIS

500MG

A084955 001

SULFISOXAZOLE

BARR

500MG

A084031 001

HEATHER

500MG

A080189 001

IMPAX LABS

500MG

A080109 001

DISCONTINUED DRUG PRODUCT LIST

6-290 (of 322)

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

IVAX SUB TEVA PHARMS	500MG	A080142	001
LANNETT	500MG	A080085	001
LEDERLE	500MG	A087649	001
PHARMERAL	500MG	A084385	001
PUREPAC PHARM	500MG	A080087	001
ROXANE	500MG	A080082	001
SANDOZ	500MG	A085628	001
VALEANT PHARM INTL	500MG	A080268	002
VITARINE	500MG	A087332	001
WATSON LABS	500MG	A085534	001
WEST WARD	500MG	A080379	001

SULSOXIN

SOLVAY	500MG	A080040	001

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182	009

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182	004

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182	002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917	001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N008414	002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N007757	002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148	001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE	165MG	N006044	003

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS	33.32%	N002918	001

SULINDAC

TABLET; ORAL

CLINORIL

MERCK	150MG	N017911	001

SULINDAC

SANDOZ	150MG	A072712	001	Aug 30, 1991
	200MG	A072713	001	Aug 30, 1991
TEVA	150MG	A072972	001	Feb 28, 1992
	200MG	A072973	001	Feb 28, 1992

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240	002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240	001	Sep 18, 2009
SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009

DISCONTINUED DRUG PRODUCT LIST

6-291 (of 322)

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT; TOPICAL

TRAVASE

ABBOTT

82,000 UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TALBUTAL

TABLET; ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

ASTRAZENECA

EQ 10MG BASE

N017970 001

EQ 20MG BASE

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNESCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

DISCONTINUED DRUG PRODUCT LIST

6-292 (of 322)

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

PHARMALUCENCE N/A

N018263 001 Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERMENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNISCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNISCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

DISCONTINUED DRUG PRODUCT LIST

6-293 (of 322)

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE 2-100mCi/ML

N017471 001

MALLINCKRODT 10-60mCi/ML

N017725 001

PHARMALUCENCE 12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO 0.22-2.22 CI/GENERATOR

N017339 001

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE 830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML

N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A

N017784 001

TESULOID

BRACCO N/A

N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO N/A

N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

NOVARTIS EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELIVUDINE

SOLUTION; ORAL

TYZEKA

NOVARTIS 100MG/5ML

N022154 001 Apr 28, 2009

DISCONTINUED DRUG PRODUCT LIST

6-294 (of 322)

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
	30MG	A070547	001	Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
	30MG	A071709	001	Sep 29, 1988
MUTUAL PHARM	15MG	A071174	001	Jul 10, 1986
	30MG	A071175	001	Jul 10, 1986
USL PHARMA	15MG	A070489	001	Jul 07, 1986
	30MG	A070490	001	Jul 07, 1986
WATSON LABS	15MG	A070383	001	Mar 23, 1987
	30MG	A070384	001	Mar 23, 1987

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
	EQ 2MG BASE	A076021	002	Aug 22, 2002
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
SANDOZ	EQ 1MG BASE	A075667	001	Jul 28, 2000
	EQ 2MG BASE	A075667	002	Jul 28, 2000
	EQ 5MG BASE	A075667	003	Jul 28, 2000
	EQ 10MG BASE	A075667	004	Jul 28, 2000

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS	1%	N020846	001	Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS	1%	N020192	001	Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

NOVARTIS	1%	N020749	001	Oct 17, 1997

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984

BRICANYL

SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985

DISCONTINUED DRUG PRODUCT LIST

6-295 (of 322)

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC

1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

TERBUTALINE SULFATE

TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

LEHIGH VALLEY

2.5MG

N017849 001

5MG

N017849 002

BRICANYL

SANOFI AVENTIS US

2.5MG

N017618 001

5MG

N017618 002

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TARO

80MG

A077553 001 Mar 09, 2007

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

EMD SERONO

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG

N016118 001

250MG

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

WATSON LABS

2.5MG/24HR

N020489 001 Sep 29, 1995

5MG/24HR

N020489 002 May 02, 1997

TESTODERM

ALZA

4MG/24HR

N019762 001 Oct 12, 1993

6MG/24HR

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA

5MG/24HR

N020791 001 Dec 18, 1997

GEL; TRANSDERMAL

TESTOSTERONE

PAR PHARM

1% (2.5GM/PACKET)

A076744 001 May 23, 2007

1% (5GM/PACKET)

A076744 002 May 23, 2007

WATSON LABS

1% (2.5GM/PACKET)

A076737 001 Jan 27, 2006

1% (5GM/PACKET)

A076737 002 Jan 27, 2006

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS

25MG/ML

A086420 001 May 10, 1983

50MG/ML

A086419 001 Aug 23, 1983

100MG/ML

A086417 001 Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN

50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS

100MG/ML

A084401 001

100MG/ML

A086029 001

200MG/ML

A084401 002

DISCONTINUED DRUG PRODUCT LIST

6-296 (of 322)

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTYL

ENDO PHARMS

200MG/ML

N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS

100MG/ML

A083667 001

100MG/ML

A085599 001

200MG/ML

A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR

25MG/ML

A080741 001

50MG/ML

A080742 001

100MG/ML

A080743 001

ELKINS SINN

25MG/ML

A080276 001

LILLY

50MG/ML

A080254 002

WATSON LABS

25MG/ML

A080188 001

25MG/ML

A085490 001

50MG/ML

A080188 002

50MG/ML

A085490 002

100MG/ML

A080188 003

100MG/ML

A083595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL

250MG

A061658 001

250MG

A061888 001

500MG

A061658 002

500MG

A061888 002

CYCLOPAR

WARNER CHILCOTT

250MG

A061725 001

250MG

A062175 001

250MG

A062332 001

500MG

A061725 002

500MG

A062332 002

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A060347 001

RETET

SOLVAY

250MG

A061443 001

500MG

A061443 002

ROBITET

WYETH AYERST

250MG

A061734 001

500MG

A061734 002

SUMYCIN

APOTHECON

100MG

A060429 002

125MG

A060429 004

250MG

A060429 001

500MG

A060429 003

TETRACHEL

ANGUS

250MG

A060343 001

500MG

A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT

250MG

A061802 001

500MG

A061802 002

ELKINS SINN

250MG

A060059 001

FERRANTE

125MG

A060173 001

250MG

A060173 002

HEATHER

250MG

A061148 001

500MG

A061148 002

LABS ATRAL

250MG

A062752 001

500MG

A062752 002

Aug 12, 1988

Aug 12, 1988

MAST MM

250MG

A062085 001

MUTUAL PHARM

250MG

A060736 001

500MG

A060736 002

MYLAN

250MG

A060783 001

500MG

A060783 002

PUREPAC PHARM

250MG

A060290 001

500MG

A060290 002

PVT FORM

250MG

A062686 001

500MG

A062686 002

Jul 24, 1986

Jul 24, 1986

ROXANE

500MG

A061214 002

DISCONTINUED DRUG PRODUCT LIST

6-297 (of 322)

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

SANDOZ	250MG	A061471	001	
SUPERPHARM	250MG	A062540	001	Mar 21, 1985
	500MG	A062540	002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471	001	
	500MG	A060471	002	
WARNER CHILCOTT	250MG	A062300	001	
	500MG	A062300	002	
WATSON LABS	250MG	A062103	001	
	250MG	A062343	001	
	500MG	A062103	002	
	500MG	A062343	002	
WEST WARD	250MG	A060768	001	
	500MG	A060768	002	
WYETH AYERST	250MG	A061685	001	
	500MG	A061685	002	

TETRACYN

PFIPHARMECS	250MG	A060082	003
	500MG	A060082	004

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002
	500MG/VIAL	N050273	003

TETRACYN

PFIZER	250MG/VIAL	A060096	001
	500MG/VIAL	A060096	002

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ	10MG/GM	N050266	001

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE	125MG/5ML	N050263	002

SUMYCIN

PAR PHARM	125MG/5ML	A060400	001

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633	001
FERRANTE	125MG/5ML	A060174	001
PROTER	125MG/5ML	A060446	001
PUREPAC PHARM	125MG/5ML	A060291	001

TETRACYN

PFIPHARMECS	125MG/5ML	A060095	001

TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ	1%	N050268	001

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705	001
	500MG	A061705	002

SUMYCIN

PAR PHARM	50MG	A061147	003
	100MG	A061147	002
	250MG	A061147	001
	500MG	A061147	004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL	EQ 100MG HCL	A061653	001
	EQ 250MG HCL	A061653	002
	EQ 250MG HCL	A061889	002
	EQ 250MG HCL	N050212	002
	EQ 500MG HCL	A061653	003
	EQ 500MG HCL	A061889	001

DISCONTINUED DRUG PRODUCT LIST

6-298 (of 322)

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

EQ 500MG HCL

N050212 003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO

1mCi/ML

N018548 001 Dec 30, 1982

TRACE LIFE

1mCi/ML

A075569 001 Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

MALLINCKRODT

2mCi/ML

A077698 001 Nov 09, 2006

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US

100MG

A085264 001

200MG

A085264 002

ELIXOPHYLLIN

FOREST LABS

100MG

A085545 001 Jul 31, 1984

200MG

A083921 001 Jul 31, 1984

SOMOPHYLLIN-T

FISONS

100MG

A087155 001 Feb 25, 1985

200MG

A087155 002 Feb 25, 1985

250MG

A087155 003 Feb 25, 1985

THEOPHYLLINE

KV PHARM

100MG

A085263 001

200MG

A085263 002

SCHERER RP

100MG

A084731 002 Nov 07, 1986

200MG

A084731 001 Nov 07, 1986

250MG

A084731 003 Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS

65MG

A085075 003 Nov 24, 1986

AEROLATE JR

FLEMING PHARMS

130MG

A085075 002 Nov 24, 1986

AEROLATE SR

FLEMING PHARMS

260MG

A085075 001 Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS

125MG

A086826 001 Jan 29, 1985

250MG

A086826 002 Jan 29, 1985

SLO-BID

SANOFI AVENTIS US

50MG

A088269 001 Jan 31, 1985

75MG

A089539 001 May 10, 1989

100MG

A087892 001 Jan 31, 1985

125MG

A089540 001 May 10, 1989

200MG

A087893 001 Jan 31, 1985

300MG

A087894 001 Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US

60MG

A085206 001 May 24, 1982

125MG

A085203 001 May 24, 1982

250MG

A085205 001 May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM

50MG

A087763 001 Feb 27, 1985

100MG

A087194 001

200MG

A088382 001 Feb 27, 1985

250MG

A087193 001

300MG

A088383 001 Feb 27, 1985

THEO-DUR

SCHERING

50MG

A088022 001 Sep 10, 1985

75MG

A088015 001 Sep 10, 1985

125MG

A088016 001 Sep 10, 1985

200MG

A087995 001 Sep 10, 1985

THEOBID

WHITBY

260MG

A085983 001 Mar 20, 1985

THEOBID JR.

WHITBY

130MG

A087854 001 Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA

130MG

A086569 001 May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA

260MG

A086569 002 May 27, 1982

DISCONTINUED DRUG PRODUCT LIST

6-299 (of 322)

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985

HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995

INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994
SANDOZ	260MG	A087462	001	May 11, 1982

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986

THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

ELIXIR; ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984

LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	

THEOLIXIR

PANRAY	80MG/15ML	A084559	001	

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
HALSEY	80MG/15ML	A085169	001	
PERRIGO	80MG/15ML	A085952	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
	40MG/100ML	N018649	001	Jul 26, 1982
	80MG/100ML	N018649	002	Jul 26, 1982
	160MG/100ML	N018649	003	Jul 26, 1982
	200MG/100ML	N018649	004	Jul 26, 1982
	320MG/100ML	N018649	006	Nov 13, 1985
	400MG/100ML	N018649	005	Jul 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA INC	80MG/100ML	N019211	002	Dec 14, 1984
	200MG/100ML	N019211	004	Dec 14, 1984
	400MG/100ML	N019211	005	Dec 14, 1984

SOLUTION; ORAL

AEROLATE

FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986

THEOLAIR

3M	80MG/15ML	A086107	001	

DISCONTINUED DRUG PRODUCT LIST

6-300 (of 322)

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

ROXANE

80MG/15ML

A087449 001 Sep 15, 1983

SUSPENSION; ORAL

ELIXICON

FOREST LABS

100MG/5ML

A085502 001

SYRUP; ORAL

ACCURBRON

SANOFI AVENTIS US

150MG/15ML

A088746 001 Nov 22, 1985

AQUAPHYLLIN

FERNDAL LABS

80MG/15ML

A087917 001 Jan 18, 1983

SLO-PHYLLIN

SANOFI AVENTIS US

80MG/15ML

A085187 001

THEOCLEAR-80

CENT PHARMS

80MG/15ML

A087095 001 Mar 01, 1982

THEOPHYLLINE

ALPHARMA US PHARMS

80MG/15ML

A086001 001

150MG/15ML

A086545 001

TABLET; ORAL

QUIBRON-T

MONARCH PHARMS

300MG

A088656 001 Aug 22, 1985

SLO-PHYLLIN

SANOFI AVENTIS US

100MG

A085202 001

200MG

A085204 001

THEOCLEAR-100

CENT PHARMS

100MG

A085353 002

THEOCLEAR-200

CENT PHARMS

200MG

A085353 001

THEOPHYL-225

ORTHO MCNEIL PHARM

225MG

A084726 001

TABLET, CHEWABLE; ORAL

THEOPHYL

ORTHO MCNEIL PHARM

100MG

A086506 001 Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL

FOREST LABS

100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

LABID

WARNER CHILCOTT

250MG

A087225 001

QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

DISCONTINUED DRUG PRODUCT LIST

6-301 (of 322)

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL

SYNOHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET; ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE; ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

HIKMA MAPLE

100MG/ML

A080575 001

HOSPIRA

100MG/ML

A040079 001

May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE; INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET; ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION; RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS

30MG/ML

N011808 012

100MG/ML

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001

Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001

Apr 26, 1983

HI TECH PHARMA

30MG/ML

A040125 001

Aug 16, 1996

100MG/ML

A040126 001

Aug 16, 1996

PHARM ASSOC

30MG/ML

A040187 001

Aug 28, 1997

DISCONTINUED DRUG PRODUCT LIST

6-302 (of 322)

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HYDROCHLORIDE

	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
TEVA PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE	INTENSOL			
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985

TABLET; ORAL

MELLARIL

NOVARTIS	10MG	N011808	003	
	15MG	N011808	016	
	25MG	N011808	006	
	50MG	N011808	011	
	100MG	N011808	009	
	150MG	N011808	017	
	200MG	N011808	015	

THIORIDAZINE HYDROCHLORIDE

IVAX PHARMS	10MG	A088270	001	Apr 14, 1983
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	15MG	A088461	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
TEVA	10MG	A088493	001	May 17, 1985
	100MG	A088456	001	May 17, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984

DISCONTINUED DRUG PRODUCT LIST

6-303 (of 322)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

50MG	A088323	001	Jul 28, 1983
50MG	A088479	001	Nov 08, 1983
50MG	A088563	001	May 11, 1984
100MG	A088284	001	Aug 25, 1983
100MG	A088564	001	May 11, 1984
100MG	A088736	001	Jul 24, 1984
150MG	A088410	001	Mar 05, 1984
150MG	A088869	001	Jun 28, 1985
200MG	A088381	001	Mar 14, 1984
200MG	A088872	001	Apr 26, 1985
WEST WARD	A088658	001	Mar 26, 1984
10MG	A088659	001	Mar 26, 1984
15MG	A088660	001	Mar 26, 1984
25MG	A088661	001	Mar 26, 1984
50MG			

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX

15MG/VIAL

N020058 001 Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL

A075698 001 Sep 20, 2001

IMMUNEX

15MG/VIAL

N011683 001

TEVA PARENTERAL

15MG/VIAL

A075730 001 Apr 20, 2001

30MG/VIAL

A075730 002 Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER

20MG

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001 Aug 12, 1987

2MG

A071885 001 Aug 12, 1987

5MG

A071886 001 Aug 12, 1987

10MG

A071887 001 Aug 12, 1987

20MG

A072200 001 Dec 17, 1987

WATSON LABS

1MG

A070600 001 Jun 05, 1987

2MG

A071626 001 Jun 25, 1987

5MG

A071627 001 Jun 25, 1987

10MG

A070603 001 Jun 05, 1987

10MG

A071628 001 Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER

EQ 5MG BASE/ML

N016758 001

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS

EQ 5MG BASE/ML

A070969 001 Oct 16, 1987

PACO

EQ 1MG BASE/ML

A071917 001 Sep 20, 1989

EQ 5MG BASE/ML

A071939 001 Dec 16, 1988

TEVA

EQ 5MG BASE/ML

A071184 001 Jun 22, 1987

TEVA PHARMS

EQ 5MG BASE/ML

A071554 001 Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

ROXANE

EQ 5MG BASE/ML

A073494 001 Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER

EQ 2MG BASE/ML

N016904 001

EQ 10MG BASE/VIAL

N016904 002

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS

16MG

N002245 009

32MG

N002245 005

65MG

N002245 002

100MG

N002245 008

130MG

N002245 010

200MG

N002245 007

325MG

N002245 004

THYROGLOBULIN

IMPAX LABS

64.8MG

A080151 001

DISCONTINUED DRUG PRODUCT LIST

6-304 (of 322)

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US

10 IU/VIAL

N008682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON

6MG

N020646 006 Nov 29, 2005

8MG

N020646 007 Nov 29, 2005

10MG

N020646 008 Nov 29, 2005

20MG

N020646 004 Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050497 001

EQ 3GM BASE/VIAL

A062690 001 Dec 19, 1986

EQ 3GM BASE/VIAL

N050497 002

EQ 6GM BASE/VIAL

N050497 003

EQ 20GM BASE/VIAL

N050497 004

EQ 30GM BASE/VIAL

N050497 005 Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO

125MG

N019979 001 Mar 24, 1993

250MG

N019979 002 Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

250MG

A075253 001 Aug 20, 1999

MYLAN

250MG

A075161 001 Sep 13, 1999

250MG

A075316 001 Nov 02, 1999

SANDOZ

250MG

A075318 001 Aug 20, 1999

250MG

A075326 001 Aug 20, 1999

WATSON LABS

250MG

A075309 001 Apr 26, 2000

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

SANOFI AVENTIS US

EQ 200MG BASE

N020707 001 Mar 07, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN

EQ 0.25% BASE

A074465 001 Mar 25, 1997

EQ 0.25% BASE

A074515 001 Mar 25, 1997

APOTEX INC

EQ 0.25% BASE

A075411 001 Sep 08, 2000

EQ 0.5% BASE

A075412 001 Sep 08, 2000

FOUGERA

EQ 0.25% BASE

A074667 001 Mar 25, 1997

EQ 0.5% BASE

A074668 001 Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK

5MG

N018017 001

10MG

N018017 002

20MG

N018017 004

TIMOLOL MALEATE

QUANTUM PHARMICS

5MG

A072466 001 May 19, 1989

10MG

A072467 001 May 19, 1989

20MG

A072468 001 May 19, 1989

SANDOZ

5MG

A072550 001 Apr 13, 1989

10MG

A072551 001 Apr 13, 1989

20MG

A072552 001 Apr 13, 1989

TEVA

5MG

A072648 001 Jun 16, 1993

10MG

A072649 001 Jun 16, 1993

20MG

A072650 001 Jun 16, 1993

USL PHARMA

5MG

A072001 001 Apr 11, 1989

10MG

A072002 001 Apr 11, 1989

20MG

A072003 001 Apr 11, 1989

WATSON LABS

5MG

A072269 001 Apr 11, 1989

5MG

A072917 001 Jul 31, 1991

10MG

A072270 001 Apr 11, 1989

10MG

A072918 001 Jul 31, 1991

20MG

A072271 001 Apr 11, 1989

20MG

A072919 001 Jul 31, 1991

DISCONTINUED DRUG PRODUCT LIST

6-305 (of 322)

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER

1%

N018682 001 Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)

N020912 001 May 14, 1998

EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)

N020913 001 May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 2MG BASE

A076283 001 Jul 12, 2002

EQ 4MG BASE

A076283 002 Jul 12, 2002

BARR

EQ 2MG BASE

A076371 001 Apr 09, 2003

EQ 4MG BASE

A076371 002 Apr 09, 2003

IVAX SUB TEVA PHARMS

EQ 2MG BASE

A076321 001 Sep 30, 2004

EQ 4MG BASE

A076321 002 Sep 30, 2004

MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003

EQ 4MG BASE

A076282 002 Dec 16, 2003

ZANAFLEX

ACORDA

EQ 2MG BASE

N020397 002 Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD

0.3%

A063176 001 May 25, 1994

APOTEX INC

0.3%

A065087 001 Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY

EQ 1.2GM BASE/VIAL

N050519 001

EQ 10MG BASE/ML

A062008 004

EQ 10MG BASE/ML

A062707 001 Apr 29, 1987

EQ 10MG BASE/ML

N050477 005

EQ 40MG BASE/ML

A062008 001

TOBRAMYCIN SULFATE

APOTHECON

EQ 10MG BASE/ML

A064021 001 May 31, 1994

EQ 40MG BASE/ML

A064021 002 May 31, 1994

EQ 40MG BASE/ML

A064026 001 May 31, 1994

ASTRAZENECA

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994

HIKMA MAPLE

EQ 10MG BASE/ML

A063113 001 Apr 26, 1991

EQ 10MG BASE/ML

A063128 001 Nov 27, 1991

EQ 40MG BASE/ML

A063118 001 Jul 29, 1991

EQ 40MG BASE/ML

A063127 001 Nov 27, 1991

HOSPIRA

EQ 10MG BASE/ML

A063080 001 Apr 30, 1991

EQ 40MG BASE/ML

A063161 001 May 29, 1991

MARSAM PHARMS LLC

EQ 40MG BASE/ML

A062945 002 Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA

400MG

N018257 001 Nov 09, 1984

600MG

N018257 002 Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR

100MG

A070162 001 Jan 14, 1986

250MG

A070163 001 Jan 14, 1986

500MG

A070164 001 Jan 14, 1986

DURAMED PHARMS BARR

100MG

A070165 001 Jan 10, 1986

250MG

A070166 001 Jan 10, 1986

500MG

A070167 001 Jan 10, 1986

INTERPHARM

250MG

A071270 001 Sep 23, 1986

DISCONTINUED DRUG PRODUCT LIST

6-306 (of 322)

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	500MG	A071271 001	Sep 23, 1986
IVAX SUB TEVA PHARMS	100MG	N018894 001	Nov 02, 1984
	250MG	N018894 002	Nov 02, 1984
	500MG	N018894 003	Nov 02, 1984
MUTUAL PHARM	100MG	A071357 001	Jul 16, 1987
	250MG	A071358 001	Jul 16, 1987
	500MG	A071359 001	Jul 16, 1987
PAR PHARM	100MG	A070159 001	Jan 06, 1986
	250MG	A070160 001	Jan 06, 1986
	500MG	A070161 001	Jan 06, 1986
SANDOZ	100MG	A071633 001	Dec 09, 1987
	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986
SUPERPHARM	250MG	A070763 001	Jun 16, 1986
	500MG	A070764 001	Jun 16, 1986
USL PHARMA	100MG	A071355 001	Jan 11, 1988
	250MG	A070168 001	Apr 02, 1986
	500MG	A070169 001	Apr 02, 1986
WATSON LABS	100MG	A070242 001	Aug 01, 1986
	100MG	A070513 001	Jan 09, 1986
	250MG	A070243 001	Aug 01, 1986
	250MG	A070514 001	Jan 09, 1986
	500MG	A070244 001	Aug 01, 1986
	500MG	A070515 001	Jan 09, 1986
TOLINASE			
PHARMACIA AND UPJOHN	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500 002	
	250MG	N015500 004	
	500MG	N015500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403 005	Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG	N010670 002	
	500MG	N010670 001	
TOLBUTAMIDE			
ALRA	500MG	A086141 001	
ASCOT	500MG	A087541 001	Mar 01, 1983
BARR	500MG	A087121 001	
CLONMEL HLTHCARE	500MG	A086926 001	
IVAX PHARMS	500MG	A087093 001	
PARKE DAVIS	500MG	A086047 001	
PUREPAC PHARM	500MG	A088950 001	Jun 17, 1985
SANDOZ	500MG	A086574 001	
	500MG	N012678 001	
SUPERPHARM	500MG	A088893 001	Nov 19, 1984
VANGARD	500MG	A087876 001	Apr 20, 1982
WATSON LABS	250MG	A089110 001	May 29, 1987
	500MG	A086109 001	
	500MG	A087318 001	
	500MG	A089111 001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095 001	

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC	200MG	N020697 002	Jan 29, 1998

DISCONTINUED DRUG PRODUCT LIST

6-307 (of 322)

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN EQ 400MG BASE

N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH EQ 400MG BASE

A073308 001 Jan 24, 1992

IVAX SUB TEVA PHARMS EQ 400MG BASE

A073392 001 Jan 24, 1992

MUTUAL PHARM EQ 400MG BASE

A073311 001 Nov 27, 1991

SANDOZ EQ 400MG BASE

A073462 001 Apr 30, 1992

TEVA EQ 400MG BASE

A073519 001 May 29, 1992

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH EQ 600MG BASE

A073527 001 Jun 30, 1992

IVAX SUB TEVA PHARMS EQ 600MG BASE

A074399 001 Mar 28, 1996

SANDOZ EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

TEVA EQ 600MG BASE

A074729 001 Feb 27, 1997

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM 60MG

N022275 003 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG

N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

SANDOZ 15MG

A079206 001 Oct 14, 2009

25MG

A079206 002 Oct 14, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS 300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

TOPIRAMATE

BARR 25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE 25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

TOPOTECAN

SANDOZ INC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N200199 001 Feb 25, 2011

EQ 3MG BASE/3ML (EQ 1MG BASE/ML)

N200199 002 Feb 25, 2011

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200199 003 Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE 50MG/5ML (10MG/ML)

N020137 002 Aug 23, 1993

20MG/2ML (10MG/ML)

N020137 001 Aug 23, 1993

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH 50MG

A075960 001 Jun 19, 2002

ASTA 50MG

A075974 001 Jul 12, 2002

IVAX SUB TEVA PHARMS 50MG

A075963 001 Jul 03, 2002

SANDOZ 50MG

A075968 001 Jun 25, 2002

DISCONTINUED DRUG PRODUCT LIST

6-308 (of 322)

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRAM

JANSSEN PHARMS

100MG

N020281 001 Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

PURDUE PHARMA

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021745 001 Dec 30, 2008

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021745 002 Dec 30, 2008

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021745 003 Dec 30, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

SHIONOGI INC

50MG

N021693 001 May 05, 2005

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

CIPLA

1MG

A077307 002 Jun 12, 2007

2MG

A077307 001 Jun 12, 2007

4MG

A077307 003 Jun 12, 2007

DR REDDYS LABS LTD

1MG

A078493 001 Aug 25, 2008

2MG

A078493 002 Aug 25, 2008

4MG

A078493 003 Aug 25, 2008

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN

500MG

N019280 001 Dec 30, 1986

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

ALCON PHARMS LTD

0.004%

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON

50MG

N018207 001

100MG

N018207 002

150MG

N018207 003 Mar 25, 1985

300MG

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

50MG

A072484 001 Apr 30, 1990

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A071112 001 Nov 17, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE

10MG

N020438 001 Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

DISCONTINUED DRUG PRODUCT LIST

6-309 (of 322)

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

BRISTOL MYERS SQUIBB

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

8MG

A084268 001

8MG

A084320 001

IMPAX LABS

4MG

A084340 001

IVAX SUB TEVA PHARMS

4MG

A083750 001

MYLAN

2MG

A084406 001

PUREPAC PHARM

2MG

A084020 002

4MG

A084020 003

ROXANE

2MG

A084708 001

4MG

A084709 001

8MG

A084707 001

SANDOZ

4MG

A085601 001

TEVA

4MG

A084775 001

WATSON LABS

4MG

A084270 001

4MG

A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE

0.1MG/INH

N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US

0.055MG/INH

N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS

0.025%

A083017 003

0.1%

A083016 004

0.5%

A083015 002

ARISTOCORT A

ASTELLAS

0.025%

A083017 004

0.025%

A088818 001 Oct 16, 1984

0.1%

A083016 005

0.1%

A088819 001 Oct 16, 1984

0.5%

A083015 003

0.5%

A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS

0.025%

A085539 001

0.1%

A085539 002

0.5%

A085539 003

KENALOG

APOTHECON

0.025% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011601 003

0.1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011601 006

0.5%

A083943 001

KENALOG-H

APOTHECON

0.1%

A086240 001

TRIACET

TEVA

0.025%

A084908 001

0.1%

A084908 002

0.5%

A084908 003

DISCONTINUED DRUG PRODUCT LIST

6-310 (of 322)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAACORT

SOLVAY	0.1%	A087113	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
G AND W LABS	0.025%	A089797	001	May 31, 1991
	0.1%	A089798	001	May 31, 1991
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
	0.025%	A086277	001	
	0.1%	A086276	001	
	0.5%	A086275	001	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989
	0.1%	A089275	001	Feb 21, 1989
	0.5%	A089276	001	Feb 21, 1989
TRIAATEX				
IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
	0.1%	A087429	001	Nov 01, 1988
	0.5%	A087428	001	Nov 01, 1988
TRYMEX				
SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
	0.1%	A088197	001	Mar 25, 1983
	0.5%	A088198	001	Mar 25, 1983

GEL; TOPICAL

ARISTOGEL

ASTELLAS	0.1%	A083380	001	

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL	3MG/ML	N019503	001	Oct 16, 1987
WATSON LABS	40MG/ML	A085825	001	

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008

LOTION; TOPICAL

KENALOG

APOTHECON	0.025%	A084343	001	
	0.1%	A084343	002	
BRISTOL MYERS SQUIBB	0.025%	N011602	003	
	0.1%	N011602	001	
TRIAMCINOLONE ACETONIDE				
ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
	0.1%	A087192	001	Sep 08, 1982

OINTMENT; TOPICAL

ARISTOCORT

ASTELLAS	0.1%	A080750	004	
	0.5%	A080745	002	

ARISTOCORT A

ASTELLAS	0.1%	A080750	003	
	0.1%	A088780	001	Oct 01, 1984
	0.5%	A080745	003	
	0.5%	A088781	001	Oct 05, 1984

FLUTEX

IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
	0.1%	A087377	001	Nov 01, 1988
	0.5%	A087376	001	Nov 01, 1988

KENALOG

APOTHECON	0.025%	N011600	003	
	0.1%	N011600	001	
	0.5%	A083944	001	

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982

DISCONTINUED DRUG PRODUCT LIST

6-311 (of 322)

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
G AND W LABS	0.025%	A089795	001	Dec 23, 1988
	0.1%	A089796	001	Dec 23, 1988
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
PHARMADERM	0.025%	A088692	001	Aug 02, 1984
	0.1%	A088690	001	Aug 02, 1984
TARO	0.025%	A040040	001	Sep 30, 1994
	0.025%	A040374	001	Jun 05, 2001
	0.1%	A087902	001	Dec 27, 1982
	0.5%	A040386	001	Jun 05, 2001
TRYMEX				
SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
	0.1%	A088691	001	Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

APOTHECON	0.1%	N012097	001	

ORALONE

TARO	0.1%	A071383	001	Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ	25MG/ML	N011685	003	
	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012802	001	

TRIAMCINOLONE DIACETATE

AKORN	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	

SYRUP; ORAL

ARISTOCORT

ASTELLAS	2MG/5ML	N011960	004	

KENACORT

BRISTOL MYERS SQUIBB	EQ 4MG BASE/5ML	N012515	001	

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN	0.5MG	N017892	002	Nov 15, 1982

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988

NAQUA

SCHERING	2MG	N012265	001	
	4MG	N012265	002	

TRICHLOREX

LANNETT	4MG	A083436	001	
	4MG	A085630	001	

TRICHLORMAS

MAST MM	4MG	A086259	001	

TRICHLORMETHIAZIDE

IMPAX LABS	4MG	A083967	001	
PAR PHARM	2MG	A087007	001	
	4MG	A087005	001	
SANDOZ	4MG	A086171	001	
TG UNITED LABS	4MG	A085568	001	
WATSON LABS	2MG	A083847	001	
	2MG	A086458	001	

DISCONTINUED DRUG PRODUCT LIST

6-312 (of 322)

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL

PATHILON

LEDERLE

25MG

N009489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE/ML

A085787 001 Apr 15, 1982

WOCKHARDT

EQ 10MG BASE/ML

A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

GLAXOSMITHKLINE

EQ 2MG BASE/ML

N011552 005

TABLET; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 1MG BASE

N011552 001

EQ 2MG BASE

N011552 002

EQ 5MG BASE

N011552 003

EQ 10MG BASE

N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR

EQ 1MG BASE

A088967 001 Apr 23, 1985

EQ 2MG BASE

A088968 001 Apr 23, 1985

EQ 5MG BASE

A088969 001 Apr 23, 1985

EQ 10MG BASE

A088970 001 Apr 23, 1985

IVAX PHARMS

EQ 1MG BASE

A087612 001 Nov 19, 1982

EQ 2MG BASE

A087613 001 Nov 19, 1982

EQ 5MG BASE

A087328 001 Nov 19, 1982

EQ 10MG BASE

A087614 001 Nov 19, 1982

SANDOZ

EQ 1MG BASE

A040153 001 Oct 25, 1996

EQ 2MG BASE

A040153 002 Oct 25, 1996

EQ 5MG BASE

A040153 003 Oct 25, 1996

EQ 10MG BASE

A040153 004 Oct 25, 1996

WATSON LABS

EQ 1MG BASE

A085975 001 Jun 23, 1988

EQ 2MG BASE

A085976 001 Jun 23, 1988

EQ 5MG BASE

A085973 001 Jun 23, 1988

EQ 10MG BASE

A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON

EQ 50MG HCL/5ML

N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON

3MG/ML

N011325 005

10MG/ML

N011325 004

20MG/ML

N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB

10MG

N011123 001

25MG

N011123 002

50MG

N011123 003

DISCONTINUED DRUG PRODUCT LIST

6-313 (of 322)

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE

5MG

N006773 010

5MG

N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE

2MG/5ML

N006773 009

TRIHEXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES

2MG/5ML

A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE

2MG

N006773 005

5MG

N006773 003

TREMIN

SCHERING

2MG

A080381 001

5MG

A080381 003

TRIHEXYPHENIDYL HYDROCHLORIDE

NYLOS

5MG

A085622 001

VANGARD

2MG

A088035 001 Jul 30, 1982

WATSON LABS

2MG

A085117 001

5MG

A085105 001

WEST WARD

2MG

A040337 002 Feb 16, 2000

5MG

A040337 001 Feb 16, 2000

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION

30MG

N018719 002 Dec 31, 1984

60MG

N018719 001 Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001 Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE

200MG/5ML

N005856 002

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE

50MG/ML

N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA

100MG/ML

A088804 001 Apr 03, 1987

SMITH AND NEPHEW

100MG/ML

A088960 001 Apr 04, 1986

100MG/ML

A089043 001 Apr 04, 1986

SOLOPAK

100MG/ML

A089094 001 Apr 04, 1986

WATSON LABS

100MG/ML

A086577 001 Oct 19, 1982

100MG/ML

A087939 001 Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS

100MG

N017943 001

200MG

N017943 003 Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM

100MG

A070494 001 Jan 22, 1986

DISCONTINUED DRUG PRODUCT LIST

6-314 (of 322)

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

200MG

A070495 001 Sep 24, 1986

TEVA

200MG

A071259 001 Jun 18, 1987

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002 Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HCL/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

2.86%; 3.42%; 3.7%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

2.86%; 3.42%; 3.7%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

2.86%; 3.42%; 3.7%

A087864 001 Sep 01, 1982

FOUGERA

2.86%; 3.42%; 3.7%

A086424 001

PERRIGO NEW YORK

2.86%; 3.42%; 3.7%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

2.86%; 3.42%; 3.7%

A087887 001 Jul 23, 1982

VAGILIA

TEVA

3.42%; 3.42%; 3.42%

A088821 001 Nov 09, 1987

DISCONTINUED DRUG PRODUCT LIST

6-315 (of 322)

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

TABLET;VAGINAL

SULTRIN

ORTHO MCNEIL PHARM 143.75MG;172.5MG;184MG N005794 002

TRIPLE SULFA

FOUGERA 172.5MG;172.5MG;172.5MG A088463 001 Jan 03, 1985

PHARMADERM 172.5MG;172.5MG;172.5MG A088462 001 Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA 1.25MG/5ML A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML A085940 001

HALSEY 1.25MG/5ML A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML A087514 001 Feb 10, 1982

TABLET;ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG A085610 001

WATSON LABS 2.5MG A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL

LANTRISUL

LANNETT 167MG/5ML;167MG/5ML;167MG/5ML A080123 002

NEOTRIZINE

LILLY 167MG/5ML;167MG/5ML;167MG/5ML N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML;167MG/5ML;167MG/5ML A080100 001

SULFOSE

WYETH AYERST 167MG/5ML;167MG/5ML;167MG/5ML A080013 002

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML;167MG/5ML;167MG/5ML N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/ML;167MG/ML;167MG/ML A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML;167MG/5ML;167MG/5ML N006920 003

TABLET;ORAL

NEOTRIZINE

LILLY 167MG;167MG;167MG N006317 011

SULFA-TRIPLE #2

IMPAX LABS 167MG;167MG;167MG A080079 001

SULFALOID

FOREST PHARMS 167MG;167MG;167MG A080099 001

SULFOSE

WYETH AYERST 167MG;167MG;167MG A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG;167MG;167MG N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG;167MG;167MG A080086 001

TRIPLE SULFAS

LEDERLE 167MG;167MG;167MG N006920 002

TRIPLE SULFOID

PAL PAK 167MG;167MG;167MG A080094 001

TROGLITAZONE

TABLET;ORAL

PRELAY

SANKYO 200MG N020719 001 Jan 29, 1997

300MG N020719 003 Aug 04, 1997

400MG N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG N020720 001 Jan 29, 1997

300MG N020720 003 Aug 04, 1997

400MG N020720 002 Jan 29, 1997

DISCONTINUED DRUG PRODUCT LIST

6-316 (of 322)

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC

CERUMENEX

PHARM RES ASSOC

10%

N011340 002

TROLEANDOMYCIN

CAPSULE;ORAL

TAO

PFIZER

EQ 250MG BASE

N050336 002

SUSPENSION;ORAL

TAO

PFIZER

EQ 125MG BASE/5ML

N050332 001

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON

0.5%

N012111 002

1%

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001 Sep 16, 1983

1%

A088230 001 Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001 Aug 28, 1985

ALCON PHARMS LTD

1%

A089172 001 Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001 Jul 30, 1982

1%

A087637 001 Aug 09, 1982

WATSON LABS

0.5%

A089171 001 Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001 Dec 18, 1997

EQ 200MG BASE

N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE;INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE;ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

URACIL MUSTARD

CAPSULE;ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE;INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION;ORAL

HELICOSOL

METABOLIC SOLUTIONS

125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA

125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES

100MG/VIAL

N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE;INTRAMUSCULAR

METRODIN

SERONO

75 IU/AMP

N019415 002 Sep 18, 1986

150 IU/AMP

N019415 003 Sep 18, 1986

INJECTABLE;SUBCUTANEOUS

FERTINEX

SERONO

75 IU/AMP

N019415 005 Aug 23, 1996

150 IU/AMP

N019415 004 Aug 23, 1996

DISCONTINUED DRUG PRODUCT LIST

6-317 (of 322)

UROKINASE

INJECTABLE; INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS

5,000 IU/VIAL

N021846 003

9,000 IU/VIAL

N021846 002

250,000 IU/VIAL

N021846 001

URSODIOL

CAPSULE; ORAL

ACTIGALL

WATSON PHARMS

150MG

N019594 001 Dec 31, 1987

TABLET; ORAL

URSODIOL

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

BANNER PHARMACAPS

125MG

N022152 001 Jul 29, 2008

250MG

N022152 002 Jul 29, 2008

500MG

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

VIROPHARMA

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

VIROPHARMA

EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL

A062812 003 Nov 17, 1987

EQ 500MG BASE/VIAL

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL

A062812 001 Nov 17, 1987

VANCOLED

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL

A062682 005 May 11, 1988

EQ 500MG BASE/VIAL

A062682 001 Jul 22, 1986

VANCOMYCIN HYDROCHLORIDE

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6-318 (of 322)

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC

10MG/VIAL

N018776 002 Apr 30, 1984

20MG/VIAL

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HIKMA MAPLE

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC

200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE

N020151 001 Dec 28, 1993

EQ 25MG BASE

N020151 002 Dec 28, 1993

EQ 37.5MG BASE

N020151 006 Dec 28, 1993

EQ 50MG BASE

N020151 003 Dec 28, 1993

EQ 75MG BASE

N020151 004 Dec 28, 1993

EQ 100MG BASE

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE

A078517 001 Jun 13, 2008

EQ 37.5MG BASE

A078517 002 Jun 13, 2008

EQ 50MG BASE

A078517 003 Jun 13, 2008

EQ 75MG BASE

A078517 004 Jun 13, 2008

EQ 100MG BASE

A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE

A077515 001 Jun 13, 2008

EQ 37.5MG BASE

A077515 002 Jun 13, 2008

EQ 50MG BASE

A077515 003 Jun 13, 2008

EQ 75MG BASE

A077515 004 Jun 13, 2008

EQ 100MG BASE

A077515 005 Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC

2.5MG/ML

N018925 001 Mar 30, 1984

2.5MG/ML

N019038 001 Mar 30, 1984

ISOPTIN

FSC

2.5MG/ML

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML

A070348 001 May 01, 1986

BEDFORD

2.5MG/ML

A072888 001 Jul 28, 1995

HOSPIRA

2.5MG/ML

A070577 001 Feb 02, 1987

2.5MG/ML

A070739 001 May 06, 1987

2.5MG/ML

A070740 001 May 06, 1987

INTL MEDICATION

2.5MG/ML

A070451 001 Dec 16, 1985

LUITPOLD

2.5MG/ML

A070225 001 Nov 12, 1985

2.5MG/ML

A070617 001 Nov 12, 1985

MARSAM PHARMS LLC

2.5MG/ML

A072233 001 Feb 26, 1993

2.5MG/ML

A073485 001 Sep 27, 1993

SMITH AND NEPHEW

2.5MG/ML

A070696 001 Jul 31, 1987

2.5MG/ML

A070697 001 Jul 31, 1987

SOLOPAK

2.5MG/ML

A070695 001 Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC

160MG

N018817 004 Feb 23, 1988

ISOPTIN

FSC

40MG

N018593 003 Nov 23, 1987

80MG

N018593 001 Mar 08, 1982

120MG

N018593 002 Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH

80MG

A071019 001 Sep 24, 1986

DISCONTINUED DRUG PRODUCT LIST

6-319 (of 322)

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	80MG	A071489 002	Jan 13, 1988
	120MG	A070483 001	Sep 24, 1986
	120MG	A071489 001	Jan 13, 1988
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SANDOZ	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523 001	

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE	3%	N050486 001	

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY	10MG/VIAL	N012665 001	

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985

HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY	1MG/VIAL	N014103 001	
	1MG/ML	N014103 003	Mar 07, 1984
	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988

VINCRISTINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987

ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986

FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002

	1MG/ML	A076401 001	Oct 28, 2003

HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988

	2MG/VIAL	A071560 001	Apr 11, 1988

	5MG/VIAL	A071561 001	Apr 11, 1988

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086 001	

	EQ 5GM BASE/VIAL	A061086 002	

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002	

	50,000USP UNITS	A083080 001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001	

CHASE CHEM	50,000 IU	A083351 001	

DISCONTINUED DRUG PRODUCT LIST

6-320 (of 322)

VITAMIN A

CAPSULE; ORAL

VITAMIN A

EVERYLIFE	50,000 IU	A083134	001
IMPAX LABS	50,000 USP UNITS	A080952	001
WEST WARD	50,000 USP UNITS	A080985	001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187	001

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883	001

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830	001

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972	001

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702	001

BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860	001

CHASE CHEM	EQ 50,000 UNITS BASE	A080746	001

	EQ 50,000 UNITS BASE	A083207	001

ELKINS SINN	EQ 50,000 UNITS BASE	A085479	001

EVERYLIFE	EQ 50,000 UNITS BASE	A080943	001

	EQ 50,000 UNITS BASE	A083114	001

IMPAX LABS	EQ 50,000 UNITS BASE	A080953	001

	EQ 50,000 UNITS BASE	A080955	001

IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035	001

	EQ 50,000 UNITS BASE	A083190	001

MK LABS	EQ 25,000 UNITS BASE	A083457	002

	EQ 50,000 UNITS BASE	A083457	001

WEST WARD	EQ 50,000 UNITS BASE	A080967	001

WHARTON LABS	EQ 50,000 UNITS BASE	A083665	001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311	001

	EQ 50,000 UNITS BASE	A083321	001

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948	001

	EQ 50,000 UNITS BASE	A083981	001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921	001

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771	007
	5MG	N011771	004
	10MG	N011771	005
	25MG	N011771	006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	50MG/VIAL	N009218	020
	75MG/VIAL	N009218	012

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771	003
	10MG	N011771	002
	25MG	N011771	001

PANWARFIN

ABBOTT	2MG	N017020	001
	2.5MG	N017020	002
	5MG	N017020	003
	7.5MG	N017020	004
	10MG	N017020	005

WARFARIN SODIUM

SANDOZ	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997

DISCONTINUED DRUG PRODUCT LIST

6-321 (of 322)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

5MG	A040196 005	Sep 30, 1997
6MG	A040196 009	Jul 26, 2000
7.5MG	A040196 006	Sep 30, 1997
10MG	A040196 007	Sep 30, 1997
USL PHARMA	A088719 001	Jun 27, 1985
2MG	A088720 001	Aug 06, 1985
2.5MG	A088721 001	Jul 02, 1985
WATSON LABS	A086123 001	Aug 17, 1982
2MG	A086120 001	Aug 17, 1982
2.5MG	A086119 001	Aug 17, 1982
5MG	A086118 001	Aug 17, 1982
7.5MG	A086122 001	Aug 17, 1982
10MG		

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT

5mCi/VIAL	N018536 001	Oct 01, 1982
10mCi/VIAL	N018536 002	Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE

1 CI/AMP	N017256 002	
10mCi/VIAL	N017687 002	
20mCi/VIAL	N017687 003	
GEN ELECTRIC	N017550 001	
5-100 CI/CYLINDER	N017550 003	
0.25-5 CI/AMP	N018327 001	Mar 09, 1982
MALLINCKRODT	N018327 002	Mar 09, 1982
10mCi/VIAL		
20mCi/VIAL		

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL	N017687 001	

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP	N017256 001	

LANTHEUS MEDCL

6.3mCi/ML	N017283 001	

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP	N017262 002	

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT	N017605 001	

XYLOSE

LYNE

25GM/BOT	N018856 001	Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG	N020199 001	Jun 19, 1992
0.75MG	N020199 002	Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

SANDOZ

5MG	A078095 001	Jun 06, 2008
10MG	A078095 002	Jun 06, 2008

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004

ZIDOVUDINE

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG	N020518 001	Dec 19, 1995
300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020518 002	Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG	N022294 001	Jul 23, 2009

DISCONTINUED DRUG PRODUCT LIST

6-322 (of 322)

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

MATRIX LABS LTD	100MG
RANBAXY LABS LTD	300MG

N200732	001	Feb 23, 2011
A077327	001	Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CORNERSTONE THERAP	300MG

N020471	001	Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM	EQ 1MG ZINC/ML

N019229	002	May 05, 1987

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS	EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021223	001	Aug 20, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG
	10MG
MUTUAL PHARMA	5MG
	10MG
MYLAN PHARMS INC	5MG
	10MG
SYNTHON PHARMS	5MG
	10MG
WORLD GEN	5MG
	10MG

A077985	001	Apr 23, 2007
A077985	002	Apr 23, 2007
A077288	001	Apr 23, 2007
A077288	002	Apr 23, 2007
A078016	001	Apr 23, 2007
A078016	002	Apr 23, 2007
A077540	001	Apr 23, 2007
A077540	002	Apr 23, 2007
A076062	001	Apr 23, 2007
A076062	002	Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL	5MG
	10MG

N021412	001	Apr 25, 2007
N021412	002	Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

COREPHARMA	25MG
	50MG
	100MG
DR REDDYS LABS LTD	25MG
	50MG
	100MG
MUTUAL PHARM	25MG
	50MG
	100MG
ROXANE	25MG
	50MG
	100MG
TEVA PHARMS	25MG
	50MG
	100MG
WATSON LABS	25MG
	50MG
	100MG

A077876	001	Feb 21, 2007
A077876	002	Feb 21, 2007
A077876	003	Feb 21, 2007
A077645	002	Sep 29, 2006
A077645	003	Sep 29, 2006
A077645	001	Dec 22, 2005
A077635	001	Dec 22, 2005
A077635	002	Dec 22, 2005
A077635	003	Dec 22, 2005
A077648	001	Dec 22, 2005
A077648	002	Dec 22, 2005
A077648	003	Dec 22, 2005
A077641	003	Dec 22, 2005
A077641	002	Dec 22, 2005
A077641	001	Dec 22, 2005
A077650	001	Apr 20, 2006
A077650	002	Apr 20, 2006
A077650	003	Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
 ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 160-165MG;160-165MG;50MG
 325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
 CAFFEINE
 CAPSULE OR TABLET; ORAL
 160-165MG;160-165MG;50MG;40MG
 325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
 TABLET; ORAL
 325MG;200MG

ACETAMINOPHEN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG;50MG

ASPIRIN;CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
 TABLET; ORAL
 325MG;200MG

AMINOPHYLLINE
 TABLET; ORAL
 100MG;200MG

ASPIRIN;METHOCARBAMOL
 TABLET; ORAL
 325MG;400MG

ASPIRIN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG;50MG
 650MG;50MG

CHLOROTHIAZIDE
 TABLET; ORAL
 250MG

ASPIRIN;BUTALBITAL;CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG;50MG;40MG
 650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
 TABLET; ORAL
 10MG;25MG;
 50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
 TABLET; ORAL
 160MG;32MG;200MG

PREDNISONE
 TABLET; ORAL
 1MG;2.5MG;5MG;10MG;
 20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX**** 8 ****

8-MOP, METHOXSALEN

**** A ****

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIRAZOLE
ABILIFY MAINTENA KIT, ARIPIRAZOLE
ABLAVAR, GADOFOSVESET TRISODIUM
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACARBOSE , ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACOVA, ARGATROBAN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL

APPENDIX A - PRODUCT NAME INDEX**** A ****

ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENAClick, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOLX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCCEIN SODIUM
AK-FLUOR 25%, FLUORESCCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAIN HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX**** A ****

ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALSUMA, SUMATRIPTAN SUCCINATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX**** A ****

AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMTURNIDE, ALISKIREN HEMIFUMARATE
AMYVID, FLORBETAPIR F-18
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX, NAPROXEN SODIUM
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANSAID, FLURBIPROFEN

APPENDIX A - PRODUCT NAME INDEX**** A ****

ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARALEN, CHLOROQUINE PHOSPHATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIMIDEX, ANASTROZOLE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ASACOL, MESALAMINE
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN, ASPIRIN (OTC)
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATIVAN, LORAZEPAM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROVENT, IPRATROPIUM BROMIDE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE

APPENDIX A - PRODUCT NAME INDEX**** A ****

AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID, NIZATIDINE
AXID AR, NIZATIDINE (OTC)
AXIRON, TESTOSTERONE
AYGESTIN, NORETHINDRONE ACETATE
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR

APPENDIX A - PRODUCT NAME INDEX**** B ****

BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BELVIQ, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAFLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BIAXIN, CLARITHROMYCIN
BIAXIN XL, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONTRIL, PHENDIMETRAZINE TARTRATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BOSULIF, BOSUTINIB MONOHYDRATE
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREATHTEK UBT FOR H-PYLORI, UREA C-13
BREO ELLIPTA, FLUTICASONE FUROATE
BRETILUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIELLYN, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** B ****

BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRINTELLIX, VORTIOXETINE HYDROBROMIDE
BRISDELLE, PAROXETINE MESYLATE
BROMDAY, BROMFENAC SODIUM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

C-SOLVE-2, ERYTHROMYCIN
CABERGOLINE, CABERGOLINE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALDOLOR, IBUPROFEN
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPRAL, ACAMPROSATE CALCIUM
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANTIL, MEPENZOLATE BROMIDE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEDAX, CEFTIBUTEN DIHYDRATE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFdinir

*** C ***

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOTETAN, CEFOTETAN DISODIUM
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
 CEFTIN, CEFUROXIME AXETIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
 CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 CELEBREX, CELECOXIB
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CELEXA, CITALOPRAM HYDROBROMIDE
 CELLCEPT, MYCOPHENOLATE MOFETIL
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 CELONTIN, METHSUXIMIDE
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
 CENTANY, MUPIROCIN
 CEPHALEXIN, CEPHALEXIN
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 CEREZYME, IMIGLUCERASE
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CERVIDIL, DINOPROSTONE
 CESAMET, NABILONE
 CETAMIDE, SULFACETAMIDE SODIUM
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
 CETROTIDE, CETRORELIX
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHANTIX, VARENICLINE TARTRATE
 CHEMET, SUCCIMER
 CHENODIOL, CHENODIOL
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** C ****

CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN, CEFOTAXIME SODIUM
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLINORIL, SULINDAC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLOROTHALIDONE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT, ALBUTEROL SULFATE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN

APPENDIX A - PRODUCT NAME INDEX**** C ****

COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM
CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALIRESP, ROFLUMILAST
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARAPRIM, PYRIMETHAMINE
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
Delflex W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSE, METYROSINE
DENAVID, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPAON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLOTATADINE, DESLOTATADINE
DESLOTATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLOTATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE , DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE FUMARATE, DESVENLAFAXINE FUMARATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXFERRUM, IRON DEXTRAN
 DEXILANT, DEXLANSOPRAZOLE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX**** D ****

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLIN, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM , DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DISULFIRAM , DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCEFREZ, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIBAX, DORIPENEM
DORYX, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT

APPENDIX A - PRODUCT NAME INDEX**** D ****

DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUONEB, ALBUTEROL SULFATE
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DUTASTERIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE

APPENDIX A - PRODUCT NAME INDEX**** E ****

EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRIVA, EMTRICITABINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENFLURANE, ENFLURANE
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENTACAPONE, ENTACAPONE
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EOVIST, GADOXETATE DISODIUM
EPANED KIT, ENALAPRIL MALEATE
EPIDUO, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESGIC-PLUS, ACETAMINOPHEN

APPENDIX A - PRODUCT NAME INDEX**** E ****

ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTIN

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FASLODEX, FULVESTRANT
FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM

APPENDIX A - PRODUCT NAME INDEX**** F ****

FELODIPINE, FELODIPINE
 FEMARA, LETROZOLE
 FEMCON FE, ETHINYL ESTRADIOL
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
 FEMTRACE, ESTRADIOL ACETATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOGLIDE, FENOFIBRATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FENTANYL CITRATE, FENTANYL CITRATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 FENTORA, FENTANYL CITRATE
 FERAHEME, FERUMOXYTOL
 FERRIPROX, DEFERIPRONE
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FIBRICOR, FENOFIBRIC ACID
 FINACEA, AZELAIC ACID
 FINASTERIDE, FINASTERIDE
 FIORICET, ACETAMINOPHEN
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FIORINAL, ASPIRIN
 FIORINAL W/CODEINE, ASPIRIN
 FIRAZYR, ICATIBANT ACETATE
 FIRMAGON, DEGARELIX ACETATE
 FLAGYL, METRONIDAZOLE
 FLAGYL ER, METRONIDAZOLE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLAREX, FLUOROMETHOLONE ACETATE
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLECTOR, DICLOFENAC EPOLAMINE
 FLO-PRED, PREDNISOLONE ACETATE
 FLOLAN, EPOPROSTENOL SODIUM
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 FLONASE, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 FLOVENT HFA, FLUTICASONE PROPIONATE
 FLOXIN OTIC, OFLOXACIN
 FLOXURIDINE, FLOXURIDINE
 FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUDEOXYGLUCOSE F-18, FLUDEOXYGLUCOSE F-18

APPENDIX A - PRODUCT NAME INDEX**** F ****

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUMADINE, RIMANTADINE HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL
 FLUNISOLIDE, FLUNISOLIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUORESCITE, FLUORESCEIN SODIUM
 FLUOROPLEX, FLUOROURACIL
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUOXYMESTERONE, FLUOXYMESTERONE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 FLUTAMIDE, FLUTAMIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FML, FLUROMETHOLONE
 FML FORTE, FLUROMETHOLONE
 FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 FOLOTYN, PRALATREXATE
 FOMEPIZOLE, FOMEPIZOLE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FORADIL, FORMOTEROL FUMARATE
 FORANE, ISOFLURANE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 FORTAMET, METFORMIN HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN
 FORTESTA, TESTOSTERONE
 FORTICAL, CALCITONIN SALMON RECOMBINANT
 FOSAMAX, ALENDRONATE SODIUM
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSCAVIR, FOSCARNET SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FOSRENOL, LANTHANUM CARBONATE
 FRAGMIN, DALTEPARIN SODIUM
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FULYZAQ, CROFELEMER
 FURADANTIN, NITROFURANTOIN
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVIRTIDE
 FYCOMPA, PERAMPANEL

**** G ****

APPENDIX A - PRODUCT NAME INDEX**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GELNIQUE 3%, OXYBUTYNIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD
GILOTTRIF, AFATINIB DIMALEATE
GLEEVEC, IMATINIB MESYLATE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON RECOMBINANT
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** G ****

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRIFULVIN V, GRISEOFULVIN, MICROSIZE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUANABENZ ACETATE, GUANABENZ ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GYNE-LOTTRIMIN, CLOTRIMAZOLE (OTC)
 GYNE-LOTTRIMIN 3, CLOTRIMAZOLE (OTC)
 GYNE-LOTTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HALAVEN, ERIBULIN MESYLATE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALFLYTELY, BISACODYL
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HELIDAC, BISMUTH SUBSALICYLATE
 HEMABATE, CARBOPROST TROMETHAMINE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPATASOL 8%, AMINO ACIDS
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
 HEPSERA, ADEFOVIR DIPIVOXIL
 HERPLEX, IDOXURIDINE
 HEXABRIX, IOXAGLATE MEGLUMINE
 HEXALEN, ALTRETAMINE
 HIBICLEN, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX**** H ****

HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN RECOMBINANT HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 HYDERGINE, ERGOLOID MESYLATES
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDRO-RX, HYDROCORTISONE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
 HYTRIN, TERAZOSIN HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBU-TAB, IBUPROFEN
 IBU-TAB 200, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROHM, IBUPROFEN (OTC)
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 IC-GREEN, INDOCYANINE GREEN
 ICLUSIG, PONATINIB HYDROCHLORIDE
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IDKIT:HP, CITRIC ACID
 IFEX, IFOSFAMIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 ILEVRO, NEPAFENAC
 IMBRUVICA, IBRUTINIB
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IMIQUIMOD, IMIQUIMOD
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE

APPENDIX A - PRODUCT NAME INDEX**** I ****

IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPLANON, ETONOGESTREL
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCIVEK, TELAPREVIR
INCRELEX, MECASERMIN RECOMBINANT
INDAPAMIDE, INDAPAMIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSpra, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKANA, CANAGLIFLOZIN
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN RECOMBINANT
IQUIX, LEVOFLOXACIN
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX**** I ****

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE

**** K ****

K-TAB, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM

APPENDIX A - PRODUCT NAME INDEX**** K ****

KEPPRA XR, LEVETIRACETAM
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETEK, TELITHROMYCIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KHEDEZLA, DESVENLAFAXINE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYNAMRO, MIPOMERSEN SODIUM
KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFFINE HYDROCHLORIDE
LAMISIL AT, TERBINAFFINE (OTC)
LAMISIL AT, TERBINAFFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPRENE, CLOFAZIMINE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE , LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1/20, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** L ****

LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LESCOL, FLUVASTATIN SODIUM
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVAQUIN, LEVOFLOXACIN
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHROID, LEVOTHYROXINE SODIUM **
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** L ****

LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LIPTRUZET, ATORVASTATIN CALCIUM
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOMOTIL, ATROPINE SULFATE
LONOX, ATROPINE SULFATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORTAB, ACETAMINOPHEN
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** L ****

LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUVOX CR, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHAZURIN, ISOSULFAN BLUE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYRICA, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE

APPENDIX A - PRODUCT NAME INDEX**** M ****

MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEBENDAZOLE, MEBENDAZOLE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MENTAX-TC, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX**** M ****

METHYLDOPA, METHYLDOPA
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPIRONE, METYRAPONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 METRONIDAZOLE, METRONIDAZOLE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIACALCIN, CALCITONIN SALMON
 MICARDIS, TELMISARTAN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICORT-HC, HYDROCORTISONE ACETATE
 MICRO-K, POTASSIUM CHLORIDE
 MICRO-K 10, POTASSIUM CHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 MICRONOR, NORETHINDRONE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIFEPREX, MIFEPRISTONE
 MIGERGOT, CAFFEINE
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 MILRINONE LACTATE, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 MINIPRESS, PRAZOSIN HYDROCHLORIDE
 MINIRIN, DESMOPRESSIN ACETATE
 MINITRAN, NITROGLYCERIN
 MINIVELLE, ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** M ****

MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN

APPENDIX A - PRODUCT NAME INDEX**** M ****

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 MYDRIACYL, TROPICAMIDE
 MYFORTIC, MYCOPHENOLIC ACID
 MYLERAN, BUSULFAN
 MYORISAN, ISOTRETINOIN
 MYOVIEU, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYOVIEU 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYRBETRIQ, MIRABEGRON
 MYSOLINE, PRIMIDONE
 MYTELASE, AMBENONIUM CHLORIDE
 MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHIAZIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NAFACILLIN SODIUM, NAFACILLIN SODIUM
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFACILLIN SODIUM
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NANDROLONE DECANOATE, NANDROLONE DECANOATE
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN, NAPROXEN
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE MONOHYDRATE
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATRECOR, NESIRITIDE RECOMBINANT
 NATROBA, SPINOSAD
 NAVANE, THIOTHIXENE
 NAVELBINE, VINORELBINE TARTRATE
 NAVSTEL, CALCIUM CHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-FRADIN, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC

APPENDIX A - PRODUCT NAME INDEX**** N ****

NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NEUPRO, ROTIGOTINE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXCEDE, KETOPROFEN (OTC)
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETNOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NIPENT, PENTOSTATIN
NIRAVAM, ALPRAZOLAM
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHIDRONE, NORETHINDRONE
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE

APPENDIX A - PRODUCT NAME INDEX**** N ****

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORFLEX, ORPHENADRINE CITRATE
 NORGESIC, ASPIRIN
 NORGESIC FORTE, ASPIRIN
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORITATE, METRONIDAZOLE
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 NOROXIN, NORFLOXACIN
 NORPACE, DISOPYRAMIDE PHOSPHATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NORVASC, AMLODIPINE BESYLATE
 NORVIR, RITONAVIR
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOXAFIL, POSACONAZOLE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUTRACORT, HYDROCORTISONE
 NUTRESTORE, GLUTAMINE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUTROPIN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ, SOMATROPIN RECOMBINANT
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
 NUVARING, ETHINYL ESTRADIOL
 NUVIGIL, ARMODAFINIL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

**** O ****

OCTOCAINE, EPINEPHRINE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
 OCUFEN, FLURBIPROFEN SODIUM

APPENDIX A - PRODUCT NAME INDEX**** 0 ****

OCUFLOX, OFLOXACIN
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLEPTRO, TRAZODONE HYDROCHLORIDE
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OLYSIO, SIMEPREVIR
OMEPRazole, OMEPRazole (OTC)
OMEPRazole, OMEPRazole
OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPSUMIT, MACITENTAN
OPTICROM, CROMOLYN SODIUM
OPTIMARK, GADOVERSETAMIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORENITRAM, TREPROSTINIL
ORETIC, HYDROCHLOROTHIAZIDE
ORFADIN, NITISINONE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORSYTHIA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** O ****

ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO EVRA, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO-CEPT, DESOGESTREL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OSENI, ALOGLIPTIN BENZOATE
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 OSPHENA, OSPEMIFENE
 OTICAIR, HYDROCORTISONE
 OTREXUP, METHOTREXATE
 OVCON-35, ETHINYL ESTRADIOL
 OVIDE, MALATHION
 OVIDREL, CHORIOGONADOTROPIN ALFA
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXANDRIN, OXANDROLONE
 OXANDROLONE, OXANDROLONE
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 OXCARBAZEPINE, OXCARBAZEPINE
 OXECTA, OXYCODONE HYDROCHLORIDE
 OXILAN-300, IOXILAN
 OXILAN-350, IOXILAN
 OXISTAT, OXICONAZOLE NITRATE
 OXSORALEN, METHOXSALEN
 OXSORALEN-ULTRA, METHOXSALEN
 OXTELLAR XR, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PAMINE, METHSCOPOLAMINE BROMIDE
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE
 PANCREAZE, PANCRELIPASE (AMYLASE
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAFON FORTE DSC, CHLORZOXAZONE
 PARAGARD T 380A, COPPER

APPENDIX A - PRODUCT NAME INDEX**** P ****

PARCOPA, CARBIDOPA
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIOTIC, HYDROCORTISONE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC , FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERTZYE, PANCRELIPASE (AMYLASE)
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX

APPENDIX A - PRODUCT NAME INDEX**** P ****

PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PHENYTOIN, PHENYTOIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHILITH, ETHINYL ESTRADIOL
 PHISOHEX, HEXACHLOROPHENE
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PHOTOFRIN, PORFIMER SODIUM
 PHRENILIN FORTE, ACETAMINOPHEN
 PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PICATO, INGENOL MEBUTATE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PILOPINE HS, PILOCARPINE HYDROCHLORIDE
 PIMTREA, DESOGESTREL
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIPERACILLIN, PIPERACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PIROXICAM, PIROXICAM
 PITOCIN, OXYTOCIN
 PLAN B, LEVONORGESTREL (OTC)
 PLAN B, LEVONORGESTREL
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLENDIL, FELODIPINE
 PLETAL, CILOSTAZOL
 PLIAGLIS, LIDOCAINE
 PODOFILOX, PODOFILOX
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PORTIA-28, ETHINYL ESTRADIOL
 POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

**** P ****

[illegible]

APPENDIX A - PRODUCT NAME INDEX**** P ****

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 POTIGA, EZOGABINE
 POVIDONE IODINE, POVIDONE-IODINE (OTC)
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAMOSONE, HYDROCORTISONE ACETATE
 PRANDIMET, METFORMIN HYDROCHLORIDE
 PRANDIN, REPAGLINIDE
 PRAVACHOL, PRAVASTATIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PRE-OP, HEXACHLOROPHENE
 PRE-OP II, HEXACHLOROPHENE
 PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PRECOSE, ACARBOSE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PREDNICARBATE, PREDNICARBATE
 PREDNISOLONE, PREDNISOLONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISON, PREDNISON
 PREDNISON INTENSOL, PREDNISON
 PREFEST, ESTRADIOL
 PREGABALIN, PREGABALIN
 PREGNYL, GONADOTROPIN, CHORIONIC
 PRELONE, PREDNISOLONE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMPHASE 14/14, ESTROGENS, CONJUGATED

APPENDIX A - PRODUCT NAME INDEX**** P ****

PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PUR-WASH, PURIFIED WATER (OTC)
PURINETHOL, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUIXIN, LEVOFLOXACIN

APPENDIX A - PRODUCT NAME INDEX**** Q ****

QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
REVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REPRONEX, MENOTROPINS (FSH
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESERPINE, RESERPINE
RESTASIS, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVIA, NALTREXONE HYDROCHLORIDE
REVLIMID, LENALIDOMIDE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT, BUDESONIDE
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN

APPENDIX A - PRODUCT NAME INDEX**** R ****

RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROWASA, MESALAMINE
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROZEREM, RAMELTEON
RYTHMOL, PROPAFENONE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SALURON, HYDROFLUMETHIAZIDE
SAMSCA, TOLVAPTAN
SANCTURA, TROSPIMUM CHLORIDE
SANCTURA XR, TROSPIMUM CHLORIDE
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM

APPENDIX A - PRODUCT NAME INDEX**** S ****

SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SFLOWASA, MESALAMINE
SHADE UVAGUARD, AVOBENZONE (OTC)
SIGNIFOR, PASIREOTIDE DIASPARTATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMCOR, NIACIN
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAPHIN, DIATRIZOATE MEGLUMINE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLTAMOX, TAMOXIFEN CITRATE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA, CARISOPRODOL
SOMA COMPOUND, ASPIRIN
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTRET, ISOTRETINOIN
SOVALDI, SOFOSBUVIR
SPECTRACEF, CEFDITOREN PIVOXIL
SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD, SILVER SULFADIAZINE
SSD AF, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCLEAR, MAGNESIUM SULFATE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPRENZA, PHENTERMINE HYDROCHLORIDE
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
SURFAXIN, LUCINACTANT
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMLIN, PRAMLINTIDE ACETATE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNAREL, NAFARELIN ACETATE
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TAFINLAR, DABRAFENIB MESYLATE
TAGAMET, CIMETIDINE
TAGAMET HB, CIMETIDINE (OTC)
TALC, TALC
TALWIN, PENTAZOCINE LACTATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

APPENDIX A - PRODUCT NAME INDEX**** T ****

TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKURNA, ALISKIREN HEMIFUMARATE
TEKURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE, CLOBETASOL PROPIONATE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON, EDROPHONIUM CHLORIDE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEV-TROPIN, SOMATROPIN RECOMBINANT
TEVETEN, EPROSARTAN MESYLATE
TEVETEN HCT, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE

APPENDIX A - PRODUCT NAME INDEX**** T ****

THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA
THYROLAR-0.25, LIOTRIX (T4
THYROLAR-0.5, LIOTRIX (T4
THYROLAR-1, LIOTRIX (T4
THYROLAR-2, LIOTRIX (T4
THYROLAR-3, LIOTRIX (T4
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TIMENTIN, CLAVULANATE POTASSIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIVICAY, DOLUTEGRAVIR SODIUM
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPIRAMATE , TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM

APPENDIX A - PRODUCT NAME INDEX**** T ****

TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
 TRAVATAN Z, TRAVOPROST
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRECATOR, ETHIONAMIDE
 TRELSTAR, TRIPTORELIN PAMOATE
 TRENAL, PENTOXIFYLLINE
 TRETINOIN, TRETINOIN
 TREXALL, METHOTREXATE SODIUM
 TREXIMET, NAPROXEN SODIUM
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 TRIACIN-C, CODEINE PHOSPHATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIBENZOR, AMLODIPINE BESYLATE
 TRICOR, FENOFIBRATE
 TRIDERM, TRIAMCINOLONE ACETONIDE
 TRIDIONE, TRIMETHADIONE
 TRIENCE, TRIAMCINOLONE ACETONIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRIFLURIDINE, TRIFLURIDINE
 TRIGLIDE, FENOFIBRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRILEPTAL, OXCARBAZEPINE
 TRILIPIX, CHOLINE FENOFIBRATE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 TRIOSTAT, LIOTHYRONINE SODIUM
 TRISENOX, ARSENIC TRIOXIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 TRIVORA-28, ETHINYL ESTRADIOL
 TRIZIVIR, ABACAVIR SULFATE
 TROKENDI XR, TOPIRAMATE
 TROPHAMINE, AMINO ACIDS
 TROPHAMINE 10%, AMINO ACIDS
 TROPICACYL, TROPICAMIDE
 TROPICAMIDE, TROPICAMIDE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE
TWINSTA, AMLODIPINE BESYLATE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL , ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYVASO, TREPROSTINIL
TYZEKA, TELBIVUDINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UCERIS, BUDESONIDE
ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRAM ER, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
ULTRESA, PANCRELIPASE (AMYLASE
UNASYN, AMPICILLIN SODIUM
UNIPHYL, THEOPHYLLINE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN

**** V ****

VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN

APPENDIX A - PRODUCT NAME INDEX**** V ****

VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VALTURNA, ALISKIREN HEMIFUMARATE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARITHENA, POLIDOCANOL
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOTEC, ENALAPRIL MALEATE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTIN, CLINDAMYCIN PHOSPHATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAMYST, FLUTICASONE FUROATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VESICARE, SOLIFENACIN SUCCINATE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICOPROFEN, HYDROCODONE BITARTRATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VICTRELIS, BOCEPREVIR
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE, VINORELBINE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE

APPENDIX A - PRODUCT NAME INDEX**** V ****

VIROPTIC, TRIFLURIDINE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRASE, HYALURONIDASE
VITUZ, CHLORPHENIRAMINE MALEATE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIZAMYL, FLUTEMETAMOL F-18
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VUMON, TENIPOSIDE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**** W ****

WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL

**** X ****

XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
XELJANZ, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENON XE 133, XENON XE-133
XERESE, ACYCLOVIR
XIFAXAN, RIFAXIMIN
XOFIGO, RADIUM RA-223 DICHLORIDE
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XTANDI, ENZALUTAMIDE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** Y ****

YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 25, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEBETA, BISOPROLOL FUMARATE
ZECUITY, SUMATRIPTAN SUCCINATE
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMPLAR, PARICALCITOL
ZEMURON, ROCURONIUM BROMIDE
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZINACEF, CEFUROXIME SODIUM
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUPLENZ, ONDANSETRON
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDONE, ACETAMINOPHEN
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAYID, GATIFLOXACIN
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3M**

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)
- * 3M PHARMACEUTICALS INC
PROVENTIL-HFA, ALBUTEROL SULFATE

**** A ******AAIPHARMA LLC**

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBOTT

- * ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
HYTRIN, TERAZOSIN HYDROCHLORIDE

ABBVIE

- * ABBVIE INC
ADVICOR, LOVASTATIN
AKINETON, BIPERIDEN HYDROCHLORIDE
ANDROGEL, TESTOSTERONE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
CALCIJEX, CALCITRIOL
CREON, PANCRELIPASE (AMYLASE
CYCLOSPORINE, CYCLOSPORINE
DEPAON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
ORETIC, HYDROCHLOROTHIAZIDE
SIMCOR, NIACIN
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
VICOPROFEN, HYDROCODONE BITARTRATE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC

- * ABBVIE INC
PROMETRIUM, PROGESTERONE

ABRAXIS BIOSCIENCE

- * ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ABRAXIS PHARM**

- * ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADEMIC PHARMS

- * ACADEMIC PHARMACEUTICALS INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ACCELRX LABS

- * ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

- * ACCORD HEALTHCARE INC
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DOCETAXEL, DOCETAXEL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETOPOSIDE, ETOPOSIDE
FINASTERIDE, FINASTERIDE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LISINAPRIL, LISINAPRIL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

ACCORD HLTHCARE INC

- * ACCORD HEALTHCARE INC USA
FINASTERIDE, FINASTERIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACELLA PHARMS LLC

- * ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACORDA

- * ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
QUTENZA, CAPSAICIN
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACS DOBFAR

- * ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOTAXIME SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
KEFZOL, CEFZOLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACS DOBFAR SPA
MEROPENEM, MEROPENEM

ACS DOBFAR INFO SA

* ACS DOBFAR INFO SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM

ACTAVIS

* ACTAVIS SOUTHATLANTIC LLC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
MORPHINE SULFATE, MORPHINE SULFATE
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS GRP PTC

* ACTAVIS GROUP PTC EHF
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACETASOL HC, ACETIC ACID, GLACIAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS MID ATLANTIC LLC
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CICLOPIROX, CICLOPIROX
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 CONSTULOSE, LACTULOSE
 ENULOSE, LACTULOSE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLUOCINONIDE, FLUOCINONIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 VALNAC, BETAMETHASONE VALERATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
 OPSUMIT, MACITENTAN
 TRACLEER, BOSENTAN
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VELETRI, EPOPROSTENOL SODIUM
 VENTAVIS, ILOPROST
 ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
 DILATRATE-SR, ISOSORBIDE DINITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTIENT PHARMACEUTICALS LLC
EDEX, ALPROSTADIL
LEVATOL, PENBUTOLOL SULFATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
STRIANT, TESTOSTERONE
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

ACTIVIS TOTOWA LLC

* ACTIVIS TOTOWA LLC
TOPIRAMATE, TOPIRAMATE

ACTON PHARMS

* ACTON PHARMACEUTICALS INC
AEROSPAN HFA, FLUNISOLIDE

AEGERION

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AGILA SPECLTS

* AGILA SPECIALTIES PRIVATE LTD
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
RIFAMPIN, RIFAMPIN
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AGOURON

* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AJANTA PHARMA

* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
RISPERIDONE, RISPERIDONE

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCIN SODIUM
AK-FLUOR 25%, FLUORESCIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

CAPASTAT SULFATE, CAPREOMYCIN SULFATE
 CARBOPLATIN, CARBOPLATIN
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ENDOSOL EXTRA, CALCIUM CHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IC-GREEN, INDOCYANINE GREEN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LATANOPROST, LATANOPROST
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 OFLOXACIN, OFLOXACIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TROPICACYL, TROPICAMIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

AKORN INC*** AKORN INC**

APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INAPSINE, DROPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

AKRIMAX PHARMS*** AKRIMAX PHARMACEUTICALS LLC**

INDERAL LA, PROPRANOLOL HYDROCHLORIDE

ALARA PHARM*** ALARA PHARMACEUTICAL CORPORATION**

LEVO-T, LEVOTHYROXINE SODIUM **

ALCON*** ALCON INC**

TRIESENCE, TRIAMCINOLONE ACETONIDE

*** ALCON LABORATORIES INC**

ALCAINE, PROPARACAINE HYDROCHLORIDE
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALCON LABORATORIES INC
 CETAMIDE, SULFACETAMIDE SODIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 DENDRID, IDOXURIDINE
 EMADINE, EMEDASTINE DIFUMARATE
 FLAREX, FLUOROMETHOLONE ACETATE
 IOPIDINE, APRACLOLONIDINE HYDROCHLORIDE
 MAXIDEX, DEXAMETHASONE
 MAXITROL, DEXAMETHASONE
 MIOSTAT, CARBACHOL
 MYDRIACYL, TROPICAMIDE
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NATACYN, NATAMYCIN
 OMNIPRED, PREDNISOLONE ACETATE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PILOPINE HS, PILOCARPINE HYDROCHLORIDE
 TOBRADEX, DEXAMETHASONE
 TOBREX, TOBRAMYCIN
 VEXOL, RIMEXOLONE

ALCON LABS INC

* ALCON LABORATORIES INC
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMA

* ALCON RESEARCH LTD
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 ZADITOR, KETOTIFEN FUMARATE (OTC)

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
 AZOPT, BRINZOLAMIDE
 BETADINE, POVIDONE-IODINE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DUREZOL, DIFLUPREDNATE
 FLUORESCITE, FLUORESCIN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
 NAVSTEL, CALCIUM CHLORIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEVANAC, NEPAFENAC
 OFLOXACIN, OFLOXACIN
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 QOLIANA, BRIMONIDINE TARTRATE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TOBRADEX ST, DEXAMETHASONE
 TRAVATAN Z, TRAVOPROST
 TRIFLURIDINE, TRIFLURIDINE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

ALCON RES

* ALCON RESEARCH LTD
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 LATANOPROST, LATANOPROST

ALCON RES LTD

* ALCON RESEARCH LTD
 ILEVRO, NEPAFENAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALCON RESEARCH LTD
SIMBRINZA, BRIMONIDINE TARTRATE

ALEMBIC LTD

* ALEMBIC LTD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALKERMES

* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES GAINESVILLE

* ALKERMES GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

ALKOPHARMA USA

* ALKOPHARMA USA INC
AMPHOTEC, AMPHOTERICIN B

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
Zymaxid, Gatifloxacin
* ALLERGAN INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALLERGAN INC**

ACULAR, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACZONE, DAPSONE
 ALBALON, NAPHAZOLINE HYDROCHLORIDE
 ALOCRI, NEDOCROMIL SODIUM
 ALPHAGAN P, BRIMONIDINE TARTRATE
 AVAGE, TAZAROTENE
 AZELEX, AZELAIC ACID
 COMBIGAN, BRIMONIDINE TARTRATE
 ELESTAT, EPINASTINE HYDROCHLORIDE
 LASTACAF, ALCAFTADINE
 LATISSE, BIMATOPROST
 LUMIGAN, BIMATOPROST
 OCUFLOX, OFLOXACIN
 OPTICROM, CROMOLYN SODIUM
 OZURDEX, DEXAMETHASONE
 POLYTRIM, POLYMYXIN B SULFATE
 RESTASIS, CYCLOSPORINE
 SANCTURA XR, TROSPIMUM CHLORIDE
 SANCTURA, TROSPIMUM CHLORIDE
 TAZORAC, TAZAROTENE
 ZYMAR, GATIFLOXACIN

*** ALLERGAN PHARMACEUTICAL**

BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLEPHAMIDE, PREDNISOLONE ACETATE
 FML FORTE, FLUOROMETHOLONE
 FML, FLUOROMETHOLONE
 HERPLEX, IDOXURIDINE
 OCUFEN, FLURBIPROFEN SODIUM
 OPHTHETIC, PROPARACAINE HYDROCHLORIDE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERQUEST*** ALLERQUEST LLC**

PRE-PEN, BENZYL PENICILLOYL POLYLYSINE

ALLIED PHARMA INC*** ALLIED PHARMA INC**

CLARITHROMYCIN, CLARITHROMYCIN
 GABAPENTIN, GABAPENTIN

ALLOS*** ALLOS THERAPEUTICS INC**

FOLOTYN, PRALATREXATE

ALMATICA PHARMA INC*** ALMATICA PHARMA INC**

NAPRELAN, NAPROXEN SODIUM

ALPHARMA*** ALPHARMA USPD INC**

PREDNISOLONE, PREDNISOLONE
 VALPROIC ACID, VALPROIC ACID

ALPHARMA KING*** ALPHARMA PHARMACEUTICALS LLC KING PHARMACEUTICALS**

EMBEDA, MORPHINE SULFATE

ALRA*** ALRA LABORATORIES INC**

CHOLAC, LACTULOSE
 CONSTILAC, LACTULOSE
 GEN-XENE, CLORAZEPATE DIPOTASSIUM
 IBU-TAB 200, IBUPROFEN (OTC)
 IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC*** ALTAIRE PHARMACEUTICALS INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALTAIRE PHARMACEUTICALS INC
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OFLOXACIN, OFLOXACIN

ALTERNA TCHP LLC

* ALTERNA TCHP LLC
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

ALVOGEN

* ALVOGEN INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

* ALVOGEN INC
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK INC
 DISULFIRAM, DISULFIRAM

AM ANTIBIOTICS

* AMERICAN ANTIBIOTICS INC
 AMOXICILLIN, AMOXICILLIN

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
 FERAHEME, FERUMOXYTOL

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
 VASCEPA, ICOSAPENT ETHYL

AMDERMA PHARMS

* AMDERMA PHARMACEUTICALS LLC
 ECOZA, ECONAZOLE NITRATE

AMEDRA PHARMS

* AMEDRA PHARMACEUTICALS LLC
 ADRENALINE, EPINEPHRINE
 ALBENZA, ALBENDAZOLE
 DARAPRIM, PYRIMETHAMINE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 TWINJECT 0.15, EPINEPHRINE
 TWINJECT 0.3, EPINEPHRINE

AMGEN

* AMGEN INC
 SENSIPAR, CINACALCET HYDROCHLORIDE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOXYCLINE HYDROCHLORIDE, DEMECLOXYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AMNEAL PHARMACEUTICALS**

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELBAMATE, FELBAMATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN (OTC)
 INDOMETHACIN, INDOMETHACIN
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

*** AMNEAL PHARMACEUTICALS LLC**

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

*** AMNEAL PHARMACEUTICALS OF NEW YORK LLC**

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

AMNEAL PHARMS NY*** AMNEAL PHARMACEUTICALS NY LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REPREXAIN, HYDROCODONE BITARTRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR PHARM*** AMPHASTAR PHARMACEUTICAL INC**

AMPHADASE, HYALURONIDASE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC*** AMPHASTAR PHARMACEUTICALS INC**

CORTROSYN, COSYNTROPIN

AMPOLGEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMPOLGEN PHARMACEUTICALS LLC
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

AMYLIN

* AMYLIN PHARMACEUTICALS INC
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC

AMYLIN PHARMS LLC

* AMYLIN PHARMACEUTICALS LLC
SYMLIN, PRAMLINTIDE ACETATE

ANBEX

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
ALTOPREV, LOVASTATIN
FORTAMET, METFORMIN HYDROCHLORIDE

ANGELINI PHARMA

* ANGELINI PHARMA INC
OLEPTRO, TRAZODONE HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANTARES PHARMA INC

* ANTARES PHARMA INC
OTREXUP, METHOTREXATE

ANTIBIOTICE

* ANTIBIOTICE SA
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTIBIOTICOS BRASIL

* ANTIBIOTICOS DO BRASIL LTDA
CEFOXITIN, CEFOXITIN SODIUM

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

APOPHARMA INC

* APOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX CORP
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

* APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE, LAMIVUDINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPiUM CHLORIDE, TROSPiUM CHLORIDE

APOTEX CORP

* APOTEX CORP
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
CABERGOLINE, CABERGOLINE
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******APOTEX INC**

* APOTEX INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CEVIMELINE, CEVIMELINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC ETOBICOKE SITE
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DILTZAC, DILTIAZEM HYDROCHLORIDE
 - ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 - ETODOLAC, ETODOLAC
 - FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 - GABAPENTIN, GABAPENTIN
 - LEFLUNOMIDE, LEFLUNOMIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LORATADINE, LORATADINE (OTC)
 - MELOXICAM, MELOXICAM
 - MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 - MIRTAZAPINE, MIRTAZAPINE
 - OXAPROZIN, OXAPROZIN
 - SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 - SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - TORSEMIDE, TORSEMIDE
 - ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 - FLUNISOLIDE, FLUNISOLIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - RISPERIDONE, RISPERIDONE
- * APOTEX INC.
 - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
 - CAPOZIDE 25/15, CAPTOPRIL
 - CAPOZIDE 25/25, CAPTOPRIL
 - CAPOZIDE 50/15, CAPTOPRIL
 - CAPOZIDE 50/25, CAPTOPRIL
 - KENALOG-10, TRIAMCINOLONE ACETONIDE
 - KENALOG-40, TRIAMCINOLONE ACETONIDE
 - OPHTHAINE, PROPARACAINE HYDROCHLORIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APTALIS PHARMA

- * APTALIS PHARMA LTD
 - RECTIV, NITROGLYCERIN

APTALIS PHARMA US

- * APTALIS PHARMA US INC
 - BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 - BENTYL, DICYCLOMINE HYDROCHLORIDE
 - CANASA, MESALAMINE
 - CARAFATE, SUCRALFATE
 - PYLERA, BISMUTH SUBCITRATE POTASSIUM
 - ULTRESA, PANCRELIPASE (AMYLASE)
 - URSO 250, URSODIOL
 - URSO FORTE, URSODIOL
 - VIOKACE, PANCRELIPASE (AMYLASE)
 - ZENPEP, PANCRELIPASE (AMYLASE)

APTALIS PHARMATECH

- * APTALIS PHARMATECH INC
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

AQUA PHARMS

- * AQUA PHARMACEUTICALS
 - CORDRAN SP, FLURANDRENOLIDE
 - CORDRAN, FLURANDRENOLIDE
 - MONODOX, DOXYCYCLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AQUA PHARMACEUTICALS LLC
 FLUOROPLEX, FLUOROURACIL
 XOLEGEL, KETOCONAZOLE

ARBOR PHARMS INC

* ARBOR PHARMACEUTICALS INC
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BIDIL, HYDRALAZINE HYDROCHLORIDE
 E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 ERY-TAB, ERYTHROMYCIN
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROMYCIN, ERYTHROMYCIN
 NYMALIZE, NIMODIPINE
 PCE, ERYTHROMYCIN
 PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
 PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE

ARBOR PHARMS LLC

* ARBOR PHARMACEUTICALS LLC
 EDARBI, AZILSARTAN KAMEDOXOMIL
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
 GLIADEL, CARMUSTINE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
 THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
 ICLUSIG, PONATINIB HYDROCHLORIDE

ASCEND

* ASCEND THERAPEUTICS INC
 ESTROGEL, ESTRADIOL

ASPEN GLOBAL

* ASPEN GLOBAL INC
 MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
 LEUKERAN, CHLORAMBUCIL
 THIOGUANINE, THIOGUANINE

ASTELLAS

* ASTELLAS PHARMA US INC
 ADENOCARD, ADENOSINE
 ADENOSCAN, ADENOSINE
 AMBISOME, AMPHOTERICIN B
 ASTAGRAF XL, TACROLIMUS
 LEXISCAN, REGADENOSON
 MYCAMINE, MICAFUNGIN SODIUM
 PROGRAF, TACROLIMUS
 PROTOPIC, TACROLIMUS
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
 VESICARE, SOLIFENACIN SUCCINATE
 XTANDI, ENZALUTAMIDE

ASTRAZENECA

* ASTRAZENECA LP
 DUTOPROL, HYDROCHLOROTHIAZIDE
 ENTOCORT EC, BUDESONIDE
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PRILOSEC, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ASTRAZENECA LP
 - PRILOSEC, OMEPRAZOLE MAGNESIUM
 - PULMICORT FLEXHALER, BUDESONIDE
 - PULMICORT RESPULES, BUDESONIDE
 - RHINOCORT, BUDESONIDE
 - SEROQUEL, QUETIAPINE FUMARATE
 - SYMBICORT, BUDESONIDE
 - TENORMIN, ATENOLOL
 - TOPROL-XL, METOPROLOL SUCCINATE
- * ASTRAZENECA PHARMACEUTICALS LP
 - ATACAND HCT, CANDESARTAN CILEXETIL
 - ATACAND, CANDESARTAN CILEXETIL
 - FASLODEX, FULVESTRANT
 - PLENDIL, FELODIPINE
 - SEROQUEL XR, QUETIAPINE FUMARATE
 - TENORETIC 100, ATENOLOL
 - TENORETIC 50, ATENOLOL
 - ZOMIG, ZOLMITRIPTAN
 - ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
 - ACCOLATE, ZAFIRLUKAST
 - ARIMIDEX, ANASTROZOLE
 - CASODEX, BICALUTAMIDE
 - MERREM, MEROPENEM
 - ZESTORETIC, HYDROCHLOROTHIAZIDE
 - ZESTRIL, LISINOPRIL
 - ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA LP

- * ASTRAZENECA LP
 - BRILINTA, TICAGRELOR

ATON

- * ATON PHARMA INC
 - CUPRIMINE, PENICILLAMINE
 - EDECIN, ETHACRYNATE SODIUM
 - EDECIN, ETHACRYNIC ACID
 - LACRISERT, HYDROXYPROPYL CELLULOSE
 - LODOSYN, CARBIDOPA
 - SYPRINE, TRIENTINE HYDROCHLORIDE
 - TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 - TIMOPTIC, TIMOLOL MALEATE

ATON PHARMA VPNA

- * ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
 - DEMSER, METYROSINE

AUROBINDO

- * AUROBINDO PHARMA LTD
 - AMOXICILLIN, AMOXICILLIN
 - CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - DIDANOSINE, DIDANOSINE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MIRTAZAPINE, MIRTAZAPINE
 - NEVIRAPINE, NEVIRAPINE
 - ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARM

- * AUROBINDO PHARMA USA INC
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - GABAPENTIN, GABAPENTIN
 - LEVETIRACETAM, LEVETIRACETAM
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ATENOLOL, ATENOLOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROBINDO PHARMA LTD**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FAMCICLOVIR, FAMCICLOVIR
 FELODIPINE, FELODIPINE
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 GLIMEPIRIDE, GLIMEPIRIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

*** AUROBINDO PHARMA LTD INC**

CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 MIRTAZAPINE, MIRTAZAPINE
 ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA*** AUROBINDO PHARMA USA INC**

ALPRAZOLAM, ALPRAZOLAM
 NAPROXEN, NAPROXEN

AUROLIFE PHARMA LLC*** AUROLIFE PHARMA LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AUSTARPHARMA LLC**

- * AUSTARPHARMA LLC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS

- * AUXILIUM PHARMACEUTICALS INC
TESTIM, TESTOSTERONE

AVACOR PRODS

- * AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS

- * AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

- * AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA

- * AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

- * AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEVA

- * AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

- * AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AZTIQ PHARMA

- * AZTIQ PHARMA INC
TODAY, NONOXYNOL-9 (OTC)

**** B ******B BRAUN**

- * B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
 MANNITOL 10%, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
 MANNITOL 15%, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
 MANNITOL 5%, MANNITOL
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PROCALAMINE, AMINO ACIDS

RESECTISOL IN PLASTIC CONTAINER, MANNITOL

RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

BAJAJ MEDICAL LLC*** BAJAJ MEDICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

BANNER PHARMACAPS*** BANNER PHARMACAPS INC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CALCITRIOL, CALCITRIOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DUTASTERIDE, DUTASTERIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NIMODIPINE, NIMODIPINE
 PROGESTERONE, PROGESTERONE
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL
 ZONISAMIDE, ZONISAMIDE

BARR*** BARR LABORATORIES INC**

ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAMILA, NORETHINDRONE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE, CLONIDINE
 DANAZOL, DANAZOL
 DEMECLOXYCLINE HYDROCHLORIDE, DEMECLOXYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIDANOSINE, DIDANOSINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ERRIN, NORETHINDRONE
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BARR LABORATORIES INC
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 ONDANSETRON, ONDANSETRON
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PORTIA-28, ETHINYL ESTRADIOL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 SPRINTEC, ETHINYL ESTRADIOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM
 ZONISAMIDE, ZONISAMIDE
- * BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
- BARR LABS DIV TEVA**
- * BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
- BARR LABS INC**
- * BARR LABORATORIES INC
 ACITRETIN, ACITRETIN
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 ESTRADIOL, ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 TRETINOIN, TRETINOIN
- BAUSCH AND LOMB**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAUSCH AND LOMB INC**

ALAWAY, KETOTIFEN FUMARATE (OTC)
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALREX, LOTEPIREDNOL ETABONATE
 BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 ISTALOL, TIMOLOL MALEATE
 LATANOPROST, LATANOPROST
 LOTEMAX, LOTEPIREDNOL ETABONATE
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 OFLOXACIN, OFLOXACIN
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 PROLENSA, BROMFENAC SODIUM
 RETISERT, FLUOCINOLONE ACETONIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VITRASE, HYALURONIDASE
 ZIRGAN, GANCICLOVIR
 ZYLET, LOTEPIREDNOL ETABONATE

*** BAUSCH AND LOMB PHARMACEUTICALS INC**

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CROLOM, CROMOLYN SODIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUNISOLIDE, FLUNISOLIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 OFLOXACIN, OFLOXACIN
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 OTICAIR, HYDROCORTISONE
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICAMIDE, TROPICAMIDE

BAXTER HLTHCARE*** BAXTER HEALTHCARE CORP**

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CLINOLIPID 20%, OLIVE OIL
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 ETHRANE, ENFLURANE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPATASOL 8%, AMINO ACIDS
 IFEX, IFOSFAMIDE
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RENAMIN W/O ELECTROLYTES, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

*** BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV**
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

*** BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE**
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

*** BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE**

ATIVAN, LORAZEPAM
 OXYTOCIN, OXYTOCIN
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

BAYER*** BAYER HEALTHCARE LLC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAYER HEALTHCARE LLC**

ALEVE, NAPROXEN SODIUM (OTC)
 ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
 FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 MYCELEX-7, CLOTRIMAZOLE (OTC)
 RID MOUSSE, PIPERONYL BUTOXIDE (OTC)

BAYER HLTHCARE*** BAYER HEALTHCARE PHARMACEUTICALS INC**

ADALAT CC, NIFEDIPINE
 ADEMPAS, RIOCIGUAT
 ANGELIQ, DROSPIRENONE
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 BETAPACE AF, SOTALOL HYDROCHLORIDE
 BETAPACE, SOTALOL HYDROCHLORIDE
 BEYAZ, DROSPIRENONE
 BILTRICIDE, PRAZIQUANTEL
 CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CLIMARA PRO, ESTRADIOL
 CLIMARA, ESTRADIOL
 DESONATE, DESONIDE
 DTIC-DOME, DACARBAZINE
 EOVIIST, GADOXETATE DISODIUM
 FINACEA, AZELAIC ACID
 GADAVIST, GADOBUTROL
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 MENOSTAR, ESTRADIOL
 MIRENA, LEVONORGESTREL
 NATAZIA, DIENOGEST
 NEXAVAR, SORAFENIB TOSYLATE
 PRECOSE, ACARBOSE
 SAFYRAL, DROSPIRENONE
 SKYLA, LEVONORGESTREL
 STAXYN, VARDENAFIL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 150, IOPROMIDE
 ULTRAVIST 240, IOPROMIDE
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC*** BAYSHORE PHARMACEUTICALS LLC**

METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE

BD RX*** BD RX INC**

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

BECTON DICKINSON*** BECTON DICKINSON AND CO**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BEDFORD*** BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC**

ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZTREONAM, AZTREONAM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBOPLATIN, CARBOPLATIN
CEFTRIAZONE, CEFTRIAZONE SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DICYCLIMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLIMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
MESNA, MESNA
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 VALPROATE SODIUM, VALPROATE SODIUM
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

BEDFORD LABS

* BEDFORD LABORATORIES
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 CAFCIT, CAFFEINE CITRATE
 CARBOPLATIN, CARBOPLATIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PENTOSTATIN, PENTOSTATIN
 TORSEMIDE, TORSEMIDE

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
 CEPHALEXIN, CEPHALEXIN
 DESLORATADINE, DESLORATADINE

BEN VENUE

* BEN VENUE LABORATORIES INC
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
 CARVEDILOL, CARVEDILOL

BICON PHARM

* BICON PHARMACEUTICAL INC
 FOLIC ACID, FOLIC ACID

BIO NUCLEONICS

* BIO NUCLEONICS INC
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC

* BIO PHARM INC
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BIO PHARM INC
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE

BIOCODEX INC

* BIOCODEX INC
 TOTECT, DEXRAZOXANE HYDROCHLORIDE

BIOGEN IDEC INC

* BIOGEN IDEC INC
 TECFIDERA, DIMETHYL FUMARATE

BIOKEY

* BIOKEY INC
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BLAIREX

* BLAIREX LABORATORIES INC
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLU CARIBE

* BLU CARIBE INC
 GEMFIBROZIL, GEMFIBROZIL
 SIMVASTATIN, SIMVASTATIN

BLU CARIBE INC

* BLU CARIBE INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

BOCA PHARMA LLC

* BOCA PHARMACAL LLC
 ALPRAZOLAM, ALPRAZOLAM
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LEVETIRACETAM, LEVETIRACETAM
 METHIMAZOLE, METHIMAZOLE
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
 CATAPRES, CLONIDINE HYDROCHLORIDE
 CATAPRES-TTS-1, CLONIDINE
 CATAPRES-TTS-2, CLONIDINE
 CATAPRES-TTS-3, CLONIDINE
 GILOTRIF, AFATINIB DIMALEATE
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICARDIS, TELMISARTAN
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 AGGRENOX, ASPIRIN
 APTIVUS, TIPRANAVIR
 ATROVENT HFA, IPRATROPIUM BROMIDE
 ATROVENT, IPRATROPIUM BROMIDE
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 COMBIVENT, ALBUTEROL SULFATE
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 JENTADUETO, LINAGLIPTIN
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MOBIC, MELOXICAM
 PERSANTINE, DIPYRIDAMOLE
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
 TRADJENTA, LINAGLIPTIN
 TWYNSTA, AMLODIPINE BESYLATE
 VIRAMUNE XR, NEVIRAPINE
 VIRAMUNE, NEVIRAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BRACCO**

* BRACCO DIAGNOSTICS INC
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
 MULTIANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 SINOGRAFIN, DIATRIZOATE MEGLUMINE

BRAINTREE

* BRAINTREE LABORATORIES INC
 AXID, NIZATIDINE
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 HALFLYTELY, BISACODYL
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUCLEAR, MAGNESIUM SULFATE
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 LEVETIRACETAM, LEVETIRACETAM
 MEFENAMIC ACID, MEFENAMIC ACID
 MELOXICAM, MELOXICAM
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
 AZACTAM, AZTREONAM
 BARACLUDE, ENTECAVIR
 GLUCOVANCE, GLYBURIDE
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 LYSODREN, MITOTANE
 MEGACE, MEGESTROL ACETATE
 PRAVACHOL, PRAVASTATIN SODIUM

* BRISTOL MYERS SQUIBB CO
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM
 DROXIA, HYDROXYUREA
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 IXEMPRA KIT, IXABEPILONE
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 REYATAZ, ATAZANAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BRISTOL MYERS SQUIBB CO
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
VIDEX, DIDANOSINE
ZERIT, STAVUDINE
- * BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

BRYAN

- * BRYAN CORP
SCLEROSOL, TALC
TALC, TALC

**** C ******CADENCE PHARMS**

- * CADENCE PHARMACEUTICALS INC
OFIRMEV, ACETAMINOPHEN

CADILA PHARMS LTD

- * CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR

CADISTA PHARMS

- * CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OXCARBAZEPINE, OXCARBAZEPINE

CARACO

- * CARACO PHARMACEUTICAL LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BENZONATATE, BENZONATATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
ELIXOPHYLLIN, THEOPHYLLINE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MELOXICAM, MELOXICAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CARACO PHARMACEUTICAL LABORATORIES LTD
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NITROFURANTOIN, NITROFURANTOIN
 OXAPROZIN, OXAPROZIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 SYNALGOS-DC, ASPIRIN
 THEOCHRON, THEOPHYLLINE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 * CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
 AMMONIA N 13, AMMONIA N-13

CARDINAL HLTH 414

* CARDINAL HEALTH 414
 SODIUM IODIDE I 123, SODIUM IODIDE I-123

CAREFUSION

* CAREFUSION 213 LLC
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
 PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

CARLSBAD

* CARLSBAD TECHNOLOGY INC
 ACYCLOVIR, ACYCLOVIR
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FAMOTIDINE, FAMOTIDINE
 GLIMEPIRIDE, GLIMEPIRIDE
 LOVASTATIN, LOVASTATIN
 MELOXICAM, MELOXICAM
 MODAFINIL, MODAFINIL
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CAROLINA MEDCL

* CAROLINA MEDICAL PRODUCTS CO
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 ISONIAZID, ISONIAZID
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SPS, SODIUM POLYSTYRENE SULFONATE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALENT

* CATALENT PHARMA SOLUTIONS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CATALENT PHARMA SOLUTIONS LLC
VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS

* CEDAR PHARMACEUTICALS LLC
METHIMAZOLE, METHIMAZOLE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CELGENE

* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CEPHALON

* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CEREXA

* CEREXA INC
TEFLARO, CEFTAROLINE FOSAMIL

CHARTWELL LIFE SCI

* CHARTWELL LIFE SCIENCE LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHATTEM

* CHATTEM INC
SELSUN, SELENIUM SULFIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
NEVIRAPINE, NEVIRAPINE
RISPERIDONE, RISPERIDONE
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBOPLATIN, CARBOPLATIN
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FAMCICLOVIR, FAMCICLOVIR
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 STAVUDINE, STAVUDINE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CITIUS PHARMS

* CITIUS PHARMACEUTICALS LLC
 SUPRENZA, PHENTERMINE HYDROCHLORIDE

CITRON PHARMA LLC

* CITRON PHARMA LLC
 ANTIVERT, MECLIZINE HYDROCHLORIDE
 CORTISPORIN, HYDROCORTISONE
 THALITONE, CHLORTHALIDONE

CLARIS LIFESCIENCES

* CLARIS LIFESCIENCES LIMITED
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 * CLARIS LIFESCIENCES LTD
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
 FOSSCAVIR, FOSSCARNET SODIUM

CLONMEL HLTHCARE

* CLONMEL HEALTHCARE LTD
 MORPHINE SULFATE, MORPHINE SULFATE

CLOVER PHARMS

* CLOVER PHARMACEUTICALS CORP
 AMICAR, AMINOCAPROIC ACID

CNTY LINE PHARMS

* COUNTY LINE PHARMACEUTICALS LLC
 UREX, METHENAMINE HIPPURATE

COASTAL PHARMS

* COASTAL PHARMACEUTICALS
 BROMFENAC SODIUM, BROMFENAC SODIUM
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

COLGATE

* COLGATE ORAL PHARMACEUTICALS INC
 PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

* COLGATE PALMOLIVE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE (OTC)
FOLIC ACID, FOLIC ACID
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
CEENU, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
ALPRAZOLAM, ALPRAZOLAM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEVOCARNITINE, LEVOCARNITINE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

CORNERSTONE THERAP

* CORNERSTONE THERAPEUTICS INC
BETHKIS, TOBRAMYCIN
CUROSURF, PORACTANT ALFA
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

COVIDIEN

* COVIDIEN
LYMPHAZURIN, ISOSULFAN BLUE

COVIS PHARMA

* COVIS PHARMA SARL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
PARNATE, TRANLYCYPROMINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

- * COVIS PHARMA SARL
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM

COVIS PHARMA SARL

- * COVIS PHARMA SARL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
NILANDRON, NILUTAMIDE
RILUTEK, RILUZOLE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CPPI CV

- * CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CREALTA PHARMS LLC

- * CREALTA PHARMACEUTICALS LLC
MIGERGOT, CAFFEINE

CROWN LABS

- * CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CSL BEHRING

- * CSL BEHRING LLC
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

CSPC OUYI PHARM CO

- * CSPC OUYI PHARMACEUTICAL CO LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST

- * CUBIST PHARMACEUTICALS INC
CUBICIN, DAPTOMYCIN

CUBIST PHARMS

- * CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUMBERLAND PHARMS

- * CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE

CYPRESS BIOSCIENCE

- * CYPRESS BIOSCIENCE INC
SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM

- * CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ELIPHOS, CALCIUM ACETATE
REZIRA, HYDROCODONE BITARTRATE
VITUZ, CHLORPHENIRAMINE MALEATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**** D ******DAIICHI**

- * DAIICHI PHARMACEUTICAL CORP
FLOXIN OTIC, OFLOXACIN

DAIICHI SANKYO

- * DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
EVOXAC, CEVIMELINE HYDROCHLORIDE
TRIBENZOR, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DAIICHI SANKYO INC
WELCHOL, COLESEVELAM HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARA BIOSCIENCES

* DARA BIOSCIENCES INC
SOLTAMOX, TAMOXIFEN CITRATE

DAVA INTL INC

* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NAPROXEN, NAPROXEN
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DELCOR ASSET

* DELCOR ASSET CORP
EVOCLIN, CLINDAMYCIN PHOSPHATE
LUXIQ, BETAMETHASONE VALERATE
OLUX E, CLOBETASOL PROPIONATE
ZOVIRAX, ACYCLOVIR

DELCOR ASSET CORP

* DELCOR ASSET CORP
ERYGEL, ERYTHROMYCIN

DENCO ASSET

* DENCO ASSET LLC
DENA VIR, PENCICLOVIR SODIUM

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

* DEPOMED INC
GRALISE, GABAPENTIN
LAZANDA, FENTANYL CITRATE
ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******DEXCEL LTD**

- * DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

- * DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRazole, OMEPRazole (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY

- * DEY LP
ACCUNEb, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DUONEb, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

DIALYSIS SUPS

- * DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC

- * DIGESTIVE CARE INC
PERTZYE, PANCRELIPASE (AMYLASE)

DISCOVERY LABS

- * DISCOVERY LABORATORIES INC
SURFAXIN, LUCINACTANT

DORADO PHARMA

- * DORADO PHARMA LLC
KETOPROFEN, KETOPROFEN

DORC

- * DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

- * DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

- * DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE
AKNE-MYCIN, ERYTHROMYCIN
ATRALIN, TRETINOIN
NUTRACORT, HYDROCORTISONE
OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA

- * DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

- * DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

- * DR REDDYS LABORATORIES INC
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LAROTID, AMOXICILLIN
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
- DR REDDYS LABS LTD**
- * DR REDDYS LABORATORIES LIMITED
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- * DR REDDYS LABORATORIES LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZACITIDINE, AZACITIDINE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DECITABINE, DECITABINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TACROLIMUS, TACROLIMUS
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 ZAFIRLUKAST, ZAFIRLUKAST
 ZENATANE, ISOTRETINOIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
 FENOFRIBATE (MICRONIZED), FENOFRIBATE

DRAXIMAGE

* DRAXIMAGE INC
 DTPA, TECHNETIUM TC-99M PENTETATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DSM PHARMS INC

* DSM PHARMACEUTICALS INC
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

DUCHESNAY

* DUCHESNAY INC
 DICLEGIS, DOXYLAMINE SUCCINATE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
 AVIANE-28, ETHINYL ESTRADIOL
 CRYSELLE, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DIAMOX, ACETAZOLAMIDE
 ENPRESSE-28, ETHINYL ESTRADIOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

- * DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DURAMED RES

- * DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE

DUSA

- * DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS

- * DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******EAGLE PHARMS**

- * EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN

EASTMAN KODAK

- * EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

EBEWE PHARMA

- * EBEWE PHARMA
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
- * EBEWE PHARMA GES MBH NFG KG
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ECLAT PHARMS LLC

- * ECLAT PHARMACEUTICALS LLC
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE

ECOLAB

- * ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

- * ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

EDGEMONT PHARMS LLC

- * EDGEMONT PHARMACEUTICALS LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

EI INC

- * EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

- * EISAI INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
DACOGEN, DECITABINE
FRAGMIN, DALTEPARIN SODIUM
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EISAI INC
 PANRETIN, ALITRETINOIN
 SALAGEN, PILOCARPINE HYDROCHLORIDE
 ZONEGRAN, ZONISAMIDE

EKR THERAP

* EKR THERAPEUTICS INC
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE SR, NICARDIPINE HYDROCHLORIDE
 CARDENE, NICARDIPINE HYDROCHLORIDE

ELI LILLY AND CO

* ELI LILLY AND CO
 AXIRON, TESTOSTERONE
 EFFIENT, PRASUGREL HYDROCHLORIDE
 PROZAC, FLUOXETINE HYDROCHLORIDE
 SARAFEM, FLUOXETINE HYDROCHLORIDE

ELI LILLY CO

* ELI LILLY CO
 ADCIRCA, TADALAFIL
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA

* EMCURE PHARMACEUTICALS LTD INDIA
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
 ACARBOSE, ACARBOSE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BICNU, CARMUSTINE
 CIDOFOVIR, CIDOFOVIR
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMCURE PHARMS USA

* EMCURE PHARMACEUTICALS USA INC
 DIFLUNISAL, DIFLUNISAL
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 METHIMAZOLE, METHIMAZOLE
 NIFEDIPINE, NIFEDIPINE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

EMCURE USA

* EMCURE PHARMACEUTICALS USA INC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

EMD SERONO

* EMD SERONO INC
 EGRIFTA, TESAMORELIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EMD SERONO INC
 GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 OVIDREL, CHORIOGONADOTROPIN ALFA
 SAIZEN, SOMATROPIN RECOMBINANT
 SEROPHENE, CLOMIPHENE CITRATE
 SEROSTIM, SOMATROPIN RECOMBINANT
 ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC

* EMD SERONO INC
 CETROTIDE, CETRORELIX

EMMAUS MEDCL

* EMMAUS MEDICAL INC
 NUTRESTORE, GLUTAMINE

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
 SUPPRELIN LA, HISTRELIN ACETATE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
 DELATESTRYL, TESTOSTERONE ENANTHATE
 FORTESTA, TESTOSTERONE
 FROVA, FROVATRIPTAN SUCCINATE
 OPANA ER, OXYMORPHONE HYDROCHLORIDE
 OPANA, OXYMORPHONE HYDROCHLORIDE
 PERCODAN, ASPIRIN

EPIC PHARMA

* EPIC PHARMA INC
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 SULINDAC, SULINDAC
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

ERGOJECT

* ERGOJECT LLC
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ETHYPHARM

* ETHYPHARM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EURAND

* EURAND AMERICA INC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
 IDKIT:HP, CITRIC ACID

EXCELLIUM

* EXCELLIUM PHARMACEUTICAL INC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 FOLIC ACID, FOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EXCELLIUM PHARMACEUTICAL INC
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

FOUGERA

* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ******FACTA FARMA**

* FACTA FARMACEUTICI SPA
CEPHALEXIN, CEPHALEXIN

FALCON PHARMS

* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FALCON PHARMACEUTICALS LTD**

DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 MAXITROL, DEXAMETHASONE
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBREX, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FAMY CARE LTD*** FAMY CARE LTD**

DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE

FDC LTD*** FDC LTD**

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 OFLOXACIN, OFLOXACIN
 TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN*** FEINSTEIN INSTITUTE MEDICAL RESEARCH**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS*** FERA PHARMACEUTICALS LLC**

OFLOXACIN, OFLOXACIN
 TOBRAMYCIN, TOBRAMYCIN

FERNDAL LABS*** FERNDAL LABORATORIES INC**

HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

FERRING*** FERRING PHARMACEUTICALS INC**

ACTHREL, CORTICORELIN OVINE TRIFLUTATE
 BRAVELLE, UROFOLLITROPIN
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 ENDOMETRIN, PROGESTERONE
 FIRMAGON, DEGARELIX ACETATE
 MENOPUR, MENOTROPINS (FSH)
 MINIRIN, DESMOPRESSIN ACETATE
 REPRONEX, MENOTROPINS (FSH)
 TEV-TROPIN, SOMATROPIN RECOMBINANT

FERRING CONTROLLED*** FERRING CONTROLLED THERAPEUTICS LTD**

CERVIDIL, DINOPROSTONE

FERRING PHARMS AS*** FERRING PHARMACEUTICALS AS**

LYSTEDA, TRANEXAMIC ACID
 PREPOPIK, CITRIC ACID

FOREST LABS*** FOREST LABORATORIES INC**

BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CAMPRAL, ACAMPROSATE CALCIUM
 CELEXA, CITALOPRAM HYDROBROMIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 THYROLAR-0.25, LIOTRIX (T4)
 THYROLAR-0.5, LIOTRIX (T4)
 THYROLAR-1, LIOTRIX (T4)
 THYROLAR-2, LIOTRIX (T4)
 THYROLAR-3, LIOTRIX (T4)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******FOREST LABS INC**

* FOREST LABORATORIES INC
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 LINZESS, LINACLOTIDE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 VIIBRYD, VILAZODONE HYDROCHLORIDE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
 DALIRESP, ROFLUMILAST

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
 ACLOVATE, ALCLOMETASONE DIPROPIONATE
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMCINONIDE, AMCINONIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 C-SOLVE-2, ERYTHROMYCIN
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CUTIVATE, FLUTICASONE PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 OXISTAT, OXICONAZOLE NITRATE
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE
 PAMINE, METHSCOPOLAMINE BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TEMOVATE E, CLOBETASOL PROPIONATE
 TEMOVATE, CLOBETASOL PROPIONATE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
 ZONALON, DOXEPIN HYDROCHLORIDE

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FRESENIUS KABI ONCOLOGY PLC**

ANASTROZOLE, ANASTROZOLE

BICALUTAMIDE, BICALUTAMIDE

CARBOPLATIN, CARBOPLATIN

EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

LETROZOLE, LETROZOLE

OXALIPLATIN, OXALIPLATIN

PACLITAXEL, PACLITAXEL

TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA*** FRESENIUS KABI USA LLC**

ACYCLOVIR SODIUM, ACYCLOVIR SODIUM

ADENOSINE, ADENOSINE

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

ASTRAMORPH PF, MORPHINE SULFATE

AZITHROMYCIN, AZITHROMYCIN

AZTREONAM, AZTREONAM

BACITRACIN, BACITRACIN

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

BLEOMYCIN SULFATE, BLEOMYCIN SULFATE

CAFFEINE CITRATE, CAFFEINE CITRATE

CALCITRIOL, CALCITRIOL

CARBOPLATIN, CARBOPLATIN

CEFOTETAN, CEFOTETAN DISODIUM

CEFTRIAZONE, CEFTRIAZONE SODIUM

CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM

CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC

CISPLATIN, CISPLATIN

CLADRIBINE, CLADRIBINE

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM

CYTARABINE, CYTARABINE

DACARBAZINE, DACARBAZINE

DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE

DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE

DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

DIMENHYDRINATE, DIMENHYDRINATE

DIPRIVAN, PROPOFOL

DIPYRIDAMOLE, DIPYRIDAMOLE

DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

DOXY 100, DOXYCYCLINE HYCLATE

DOXY 200, DOXYCYCLINE HYCLATE

EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE

ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE

ETOPOSIDE, ETOPOSIDE

FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE

FAMOTIDINE, FAMOTIDINE

FLOXURIDINE, FLOXURIDINE

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

FLUMAZENIL, FLUMAZENIL

FLUOROURACIL, FLUOROURACIL

FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE

FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

FOLIC ACID, FOLIC ACID

FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

FUROSEMIDE, FUROSEMIDE

GANCICLOVIR, GANCICLOVIR SODIUM

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

GENTAMICIN SULFATE, GENTAMICIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FRESENIUS KABI USA LLC**

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FRESSENIUS KABI USA LLC**

TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

FRESSENIUS MEDCL*** FRESSENIUS MEDICAL CARE NORTH AMERICA**

CALCITRIOL, CALCITRIOL
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FSC*** FSC LABORATORIES INC**

PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**** G ******G AND W LABS***** G AND W LABORATORIES INC**

ACEPHEN, ACETAMINOPHEN (OTC)
 CICLOPIROX, CICLOPIROX
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 INDOMETHACIN, INDOMETHACIN
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE

G AND W LABS INC*** G AND W LABORATORIES INC**

CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 FLUOCINONIDE, FLUOCINONIDE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

GALDERMA LABS*** GALDERMA LABORATORIES INC**

CLOBEX, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******GALDERMA LABS LP**

- * GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
- * GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
PERIOSTAT, DOXYCYCLINE HYCLATE
PLIAGLIS, LIDOCAINE
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALEN (UK)

- * GALLEN LTD
DAUNOXOME, DAUNORUBICIN CITRATE

GALEN SPECIALTY

- * GALLEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GALENA BIOPHARMA

- * GALENA BIOPHARMA
ABSTRAL, FENTANYL CITRATE

GAMBRO RENAL PRODS

- * GAMBRO RENAL PRODUCTS
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

GASTROENTERO

- * GASTROENTERO LOGIC LLC
OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS

- * GATE PHARMACEUTICALS
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

GAVIS PHARMS

- * GAVIS PHARMACEUTICALS LLC
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GD SEARLE

- * GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC

- * GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
COVERA-HS, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GD SEARLE LLC
 CYTOTEC, MISOPROSTOL
 FLAGYL ER, METRONIDAZOLE
 FLAGYL, METRONIDAZOLE
 INSPRA, EPLERENONE
 LOMOTIL, ATROPINE SULFATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
 ADREVIEW, IOBENGUANE SULFATE I-123
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 INDICLOR, INDIUM IN-111 CHLORIDE
 INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
 METASTRON, STRONTIUM CHLORIDE SR-89
 MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
 MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
 OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL
 OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNISCAN, GADODIAMIDE
 OPTISON, ALBUMIN HUMAN
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
 DATSCAN, IOFLUPANE I-123

GEDEON RICHTER USA

* GEDEON RICHTER USA INC
 FINASTERIDE, FINASTERIDE

GENENTECH

* GENENTECH INC
 ERIVEDGE, VISMODEGIB
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ, SOMATROPIN RECOMBINANT
 NUTROPIN, SOMATROPIN RECOMBINANT

GENZYME

* GENZYME CORP
 CEREZYME, IMIGLUCERASE
 CLOLAR, CLOFARABINE
 MOZOBIL, PLERIXAFOR
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENVELA, SEVELAMER CARBONATE
 THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORP
 HECTOROL, DOXERCALCIFEROL
 KYNAMRO, MIPOMERSEN SODIUM

GILEAD

* GILEAD SCIENCES INC
 ATRIPLA, EFAVIRENZ
 CAYSTON, AZTREONAM
 EMTRIVA, EMTRICITABINE
 HEPSERA, ADEFOVIR DIPIVOXIL
 LETAIRIS, AMBRISANTAN
 RANEXA, RANOLAZINE
 TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GILEAD SCIENCES INC
 COMPLERA, EMTRICITABINE
 SOVALDI, SOFOSBUVIR
 STRIBILD, COBICISTAT
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VISTIDE, CIDOFOVIR

GLAND PHARMA LTD

* GLAND PHARMA LTD
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 HALOPERIDOL, HALOPERIDOL LACTATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLATT AIR

* GLATT AIR TECHNIQUES INC
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
 ALTABAX, RETAPAMULIN
 FLOVENT HFA, FLUTICASONE PROPIONATE
 SEREVENT, SALMETEROL XINAFOATE
 * GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 BREO ELLIPTA, FLUTICASONE FUROATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 VENTOLIN HFA, ALBUTEROL SULFATE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 25, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE

GLAXO WELLCOME

* GLAXOSMITHKLINE
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
 ABREVA, DOCOSANOL (OTC)
 ALKERAN, MELPHALAN
 ALKERAN, MELPHALAN HYDROCHLORIDE
 ARIXTRA, FONDAPARINUX SODIUM
 AVODART, DUTASTERIDE
 BACTROBAN, MUPIROCIN
 BACTROBAN, MUPIROCIN CALCIUM
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 CEFTIN, CEFUROXIME AXETIL
 EPIVIR-HBV, LAMIVUDINE
 FLONASE, FLUTICASONE PROPIONATE
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 JALYN, DUTASTERIDE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALARONE, ATOVAQUONE
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLAXOSMITHKLINE**

PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 POTIGA, EZOGABINE
 PROMACTA, ELTROMBOPAG OLAMINE
 RELENZA, ZANAMIVIR
 TAFINLAR, DABRAFENIB MESYLATE
 TAGAMET, CIMETIDINE
 TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
 TIMENTIN, CLAVULANATE POTASSIUM
 VALTREX, VALACYCLOVIR HYDROCHLORIDE
 VERAMYST, FLUTICASONE FUROATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN, BUPROPION HYDROCHLORIDE
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR
 ZYBAN, BUPROPION HYDROCHLORIDE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
 ALLI, ORLISTAT (OTC)
 COMMIT, NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 DYZIDE, HYDROCHLOROTHIAZIDE
 FLOLAN, EPOPROSTENOL SODIUM
 INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL ODT, LAMOTRIGINE
 LAMICTAL XR, LAMOTRIGINE
 LAMICTAL, LAMOTRIGINE
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 MEPRON, ATOVAQUONE
 REQUIP XL, ROPINIROLE HYDROCHLORIDE
 REQUIP, ROPINIROLE HYDROCHLORIDE
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 IMIQUIMOD, IMIQUIMOD
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN CALCIUM
 NIZATIDINE, NIZATIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

* GLENMARK GENERICS LIMITED
 BRIELLYN, ETHINYL ESTRADIOL
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* GLENMARK GENERICS LTD
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 CARVEDILOL, CARVEDILOL
 CICLOPIROX, CICLOPIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK GENERICS LTD
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - DESOXIMETASONE, DESOXIMETASONE
 - FELODIPINE, FELODIPINE
 - FLUCONAZOLE, FLUCONAZOLE
 - GABAPENTIN, GABAPENTIN
 - HEATHER, NORETHINDRONE
 - HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 - LAMOTRIGINE, LAMOTRIGINE
 - LEVOFLOXACIN, LEVOFLOXACIN
 - LITHIUM CARBONATE, LITHIUM CARBONATE
 - MARLISSA, ETHINYL ESTRADIOL
 - MELOXICAM, MELOXICAM
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM
 - NAPROXEN SODIUM, NAPROXEN SODIUM
 - NAPROXEN, NAPROXEN
 - NORETHINDRONE, NORETHINDRONE
 - NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON, ONDANSETRON
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 - RILUZOLE, RILUZOLE
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - THEOPHYLLINE, THEOPHYLLINE
 - TOPIRAMATE, TOPIRAMATE
 - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 - TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 - URSODIOL, URSODIOL
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - VIORELE, DESOGESTREL
 - ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
 - INDOMETHACIN, INDOMETHACIN
 - LITHIUM CARBONATE, LITHIUM CARBONATE
 - NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

- * GLENMARK PHARMACEUTICALS INC USA
 - CICLOPIROX, CICLOPIROX
 - CLOTRIMAZOLE, CLOTRIMAZOLE
 - MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
 - MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

GLENMARK PHARMS LTD

- * GLENMARK PHARMACEUTICALS LTD
 - HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

GRANULES INDIA

- * GRANULES INDIA LTD
 - IBUPROFEN, IBUPROFEN (OTC)
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GUARDIAN DRUG

- * GUARDIAN DRUG CO INC
 - FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

- * GUERBET LLC
 - DOTAREM, GADOTERATE MEGLUMINE
 - HEXABRIX, IOXAGLATE MEGLUMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GUERBET LLC
 - OXILAN-300, IOXILAN
 - OXILAN-350, IOXILAN

HANFORD GC

- * GC HANFORD MANUFACTURING CO
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - AMPICILLIN SODIUM, AMPICILLIN SODIUM
 - PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

**** H ******HAEMONETICS**

- * HAEMONETICS CORP
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS

- * HALOCARBON PRODUCTS CORP
 - ISOFLURANE, ISOFLURANE
 - SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

- * HALOZYME THERAPEUTICS INC
 - HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN RDS GMBH

- * HAMELN RDS GMBH
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HANMI PHARM CO LTD

- * HANMI PHARMACEUTICAL CO LTD
 - ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

HARRIS PHARM

- * HARRIS PHARMACEUTICAL INC
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HAUPT PHARMA

- * HAUPT PHARMA INC
 - NORETHINDRONE, NORETHINDRONE

HELSINN HLTHCARE

- * HELSINN HEALTHCARE SA
 - ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

- * HERCON PHARMACEUTICAL LLC
 - NITROGLYCERIN, NITROGLYCERIN

HERITAGE PHARMS INC

- * HERITAGE PHARMACEUTICALS INC
 - ACETAZOLAMIDE, ACETAZOLAMIDE
 - ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
 - CARISOPRODOL AND ASPIRIN, ASPIRIN
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - DOXYCYCLINE, DOXYCYCLINE
 - FELODIPINE, FELODIPINE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 - GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 - GLYBURIDE, GLYBURIDE
 - HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 - HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 - INDOMETHACIN, INDOMETHACIN
 - LEFLUNOMIDE, LEFLUNOMIDE
 - NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 - NYSTATIN, NYSTATIN
 - PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 - SULINDAC, SULINDAC
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HETERO LABS LTD III

- * HETERO LABS LTD UNIT III
 - ABACAVIR SULFATE, ABACAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HETERO LABS LTD UNIT III**

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 STAVUDINE, STAVUDINE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V*** HETERO LABS LTD UNIT V**

ACYCLOVIR, ACYCLOVIR
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE, LAMIVUDINE

HEYL CHEMISCH*** HEYL CHEMISCH PHARMAZEUTISCHE FABRIK**

RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA*** HI TECH PHARMACAL CO INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CICLOPIROX, CICLOPIROX
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CORMAX, CLOBETASOL PROPIONATE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 EMBELINE E, CLOBETASOL PROPIONATE
 EMBELINE, CLOBETASOL PROPIONATE
 ERYTHRO-STATIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO*** HI TECH PHARMACAL CO INC**

FLUNISOLIDE, FLUNISOLIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HI TECH PHARMACAL CO INC
PREDNISOLONE, PREDNISOLONE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

HI-TECH PHARMA CO

- * HI-TECH PHARMACAL CO INC
LORAZEPAM, LORAZEPAM

HI-TECH PHARMACAL

- * HI-TECH PHARMACAL CO INC
LEVETIRACETAM, LEVETIRACETAM

HIGH TECH PHARMA

- * HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA

- * HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
- * HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYBURIDE (MICRONIZED), GLYBURIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

HIKMA (MAPLE)

- * HIKMA (MAPLE) LTD
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

HIKMA FARMACEUTICA

- * HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOTAXIME SODIUM
CEFTRIAZONE, CEFTRIAZONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISTERON HYDROCHLORIDE, GRANISTERON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA FARMACEUTICA PORTUGAL SA
 OXYTOCIN, OXYTOCIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

* HIKMA FARMACEUTICA SA
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA MAPLE

* HIKMA MAPLE LTD
 ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 BUMETANIDE, BUMETANIDE
 CEFOXITIN, CEFOXITIN SODIUM
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIGOXIN, DIGOXIN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DURAMORPH PF, MORPHINE SULFATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 INFUMORPH, MORPHINE SULFATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 ROBAXIN, METHOCARBAMOL
 ROBINUL, GLYCOPYRROLATE
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
 ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 DIGOXIN, DIGOXIN
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 GABAPENTIN, GABAPENTIN
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HIKMA PHARMACEUTICALS
 - ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 - LAMOTRIGINE, LAMOTRIGINE
 - LISINOPRIL, LISINOPRIL
 - METHOCARBAMOL, METHOCARBAMOL
 - MODAFINIL, MODAFINIL
 - PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TOPIRAMATE, TOPIRAMATE
- * HIKMA PHARMACEUTICALS LLC
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - PREDNISONE, PREDNISONE
 - SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
- HIKMA PHARMS LLC**
- * HIKMA PHARMACEUTICALS LLC
 - DOXERCALCIFEROL, DOXERCALCIFEROL
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- HILL DERMAC**
- * HILL DERMACEUTICALS INC
 - DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 - DERMOTIC, FLUOCINOLONE ACETONIDE
- HISAMITSU PHARM CO**
- * HISAMITSU PHARMACEUTICAL CO INC
 - SALONPAS, MENTHOL (OTC)
- HISUN PHARM HANGZHOU**
- * HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
 - EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
- HITECH PHARMA**
- * HITECH PHARMACAL CORP
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
- HOFFMAN LA ROCHE**
- * HOFFMAN LA ROCHE INC
 - INVIRASE, SAQUINAVIR MESYLATE
- HOFFMANN LA ROCHE**
- * HOFFMANN LA ROCHE INC
 - ANAPROX DS, NAPROXEN SODIUM
 - ANAPROX, NAPROXEN SODIUM
 - BONIVA, IBANDRONATE SODIUM
 - INVIRASE, SAQUINAVIR MESYLATE
 - ROCEPHIN, CEFTRIAXONE SODIUM
 - VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 - XELODA, CAPECITABINE
 - XENICAL, ORLISTAT
 - ZELBORAF, VEMURAFENIB
- HOPE PHARMS**
- * HOPE PHARMACEUTICALS
 - NITHIODOTE, SODIUM NITRITE
 - SODIUM NITRITE, SODIUM NITRITE
 - SODIUM THIOSULFATE, SODIUM THIOSULFATE
- HORIZON PHARMA**
- * HORIZON PHARMA INC
 - DUEXIS, FAMOTIDINE
 - RAYOS, PREDNISONE
 - VIMOVO, ESOMEPRAZOLE MAGNESIUM
- HOSPIRA**
- * HOSPIRA INC
 - A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
 - A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 - ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 - ACETYLCYSTEINE, ACETYLCYSTEINE
 - ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 - AMIDATE, ETOMIDATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AQUASOL A, VITAMIN A PALMITATE
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMOROL, MEPERIDINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIPOSYN II 10%, SAFFLOWER OIL
 LIPOSYN II 20%, SAFFLOWER OIL
 LIPOSYN III 10%, SOYBEAN OIL
 LIPOSYN III 20%, SOYBEAN OIL
 LIPOSYN III 30%, SOYBEAN OIL
 LORAZEPAM, LORAZEPAM
 LTA II KIT, LIDOCAINE HYDROCHLORIDE
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 25%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TALWIN, PENTAZOCINE LACTATE
 TAZICEF, CEFTAZIDIME
 THAM, TROMETHAMINE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 VITAMIN K1, PHYTONADIONE
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

*** HOSPIRA WORLDWIDE, INC**

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NITROPRESS, SODIUM NITROPRUSSIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC*** HOSPIRA INC**

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 DOCETAXEL, DOCETAXEL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMPENEM AND CILASTATIN, CILASTATIN SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 MAXIPIME, CEFEPIME HYDROCHLORIDE
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MORPHINE SULFATE, MORPHINE SULFATE
 NIPENT, PENTOSTATIN
 OXALIPLATIN, OXALIPLATIN
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

*** HOSPIRA WORLDWIDE PTY**
 OXALIPLATIN, OXALIPLATIN

HOUSTON CYCLOTRON

*** HOUSTON CYCLOTRON PARTNERS LP**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

*** HQ SPECIALTY PHARMA CORP**
 CISPLATIN, CISPLATIN
 TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA

*** HQ SPECIALITY PHARMA LLC**
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

*** HQ SPECIALTY PHARMA**
 VUMON, TENIPOSIDE

HRA PHARMA

*** HRA PHARMA LLC**
 METOPIRONE, METYRAPONE

HYPERION THERAP INC

*** HYPERION THERAPEUTICS INC**
 RAVICTI, GLYCEROL PHENYLBUTYRATE

HYPERION THERAPS INC

*** HYPERION THERAPEUTICS INC**
 BUPHENYL, SODIUM PHENYLBUTYRATE

ROCHE

*** HOFFMANN LA ROCHE INC**
 BONIVA, IBANDRONATE SODIUM
 COPEGUS, RIBAVIRIN
 FUZEON, ENFUVIRTIDE
 KLONOPIN, CLONAZEPAM
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 VALIUM, DIAZEPAM

**** I ******IBI**

*** ISTITUTO BIOCHIMICO ITALIANO SPA**
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* ISTITUTO BIOCHIMICO ITALIANO SPA
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIPERACILLIN, PIPERACILLIN SODIUM

IDENTI PHARMS INC

* IDENTI PHARMACEUTICALS INC
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IGI LABS INC

* IGI LABORATORIES INC
 ECONAZOLE NITRATE, ECONAZOLE NITRATE

IMPAX LABS

* IMPAX LABORATORIES INC
 ACARBOSE, ACARBOSE
 ALPRAZOLAM, ALPRAZOLAM
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LETROZOLE, LETROZOLE
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
 CABERGOLINE, CABERGOLINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX PHARMACEUTICALS
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

INCYTE CORP

* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETOZOLE, LETOZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
GLIMEPIRIDE, GLIMEPIRIDE

INJECTALIA

* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOPHARMA LICENSING

* INNOPHARMA LICENSING LLC
ACETYLCYSTEINE, ACETYLCYSTEINE

INO

* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INSIGHT PHARMS

* INSIGHT PHARMACEUTICALS CORP
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE

* INSTITUTE BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

INSYS THERAP

* INSYS THERAPEUTICS INC
DRONABINOL, DRONABINOL
SUBSYS, FENTANYL

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
LARYNG-0-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

- * INTERNATIONAL MEDICATION SYSTEM
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
- * INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

- * INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INVAGEN PHARMS

- * INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
WARFARIN SODIUM, WARFARIN SODIUM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVENTIA HLTHCARE

- * INVENTIA HEALTHCARE PRIVATE LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

IPCA LABS LTD

- * IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR

- * IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IPR PHARMACEUTICALS INC
 ATENOLOL, ATENOLOL
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPR PHARMS INC

* IPR PHARMACEUTICALS INC
 CAPRELSA, VANDETANIB

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 INCRELEX, MECASERMIN RECOMBINANT

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
 INDOCIN, INDOMETHACIN

IROKO PHARMS LLC

* IROKO PHARMACEUTICALS LLC
 ZORVOLEX, DICLOFENAC

ISO TEX

* ISO TEX DIAGNOSTICS INC
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM
 MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
 GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTA PHARMS INC

* ISTA PHARMACEUTICALS INC
 BEPREVE, BEPOTASTINE BESILATE
 BROMDAY, BROMFENAC SODIUM

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
 AMPICILLIN SODIUM, AMPICILLIN SODIUM

IVAX INTL

* IVAX INTERNATIONAL GMBH
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 SYNTRIBO, OMACETAXINE MEPESUCCINATE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUMETANIDE, BUMETANIDE
 CABERGOLINE, CABERGOLINE
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE
 CIMETIDINE, CIMETIDINE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTAMIDE, FLUTAMIDE
 FUROSEMIDE, FUROSEMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 GABAPENTIN, GABAPENTIN
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GUANABENZ ACETATE, GUANABENZ ACETATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 METHYLDOPA, METHYLDOPA
 MISOPROSTOL, MISOPROSTOL
 NADOLOL, NADOLOL
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SIMVASTATIN, SIMVASTATIN
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******JACOBUS**

* JACOBUS PHARMACEUTICAL CO
 DAPSONE, DAPSONE
 PASER, AMINOSALICYLIC ACID

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
 ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
 AXERT, ALMOTRIPTAN MALATE
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA, PALIPERIDONE
 INVOKANA, CANAGLIFLOZIN
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVAQUIN, LEVOFLOXACIN
 MICRONOR, NORETHINDRONE
 MODICON 28, ETHINYL ESTRADIOL
 NIZORAL, KETOCONAZOLE
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO EVRA, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO-CEPT, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JANSSEN PHARMACEUTICALS INC
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 PANCREAZE, PANCRELIPASE (AMYLASE
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 SPORANOX, ITRACONAZOLE
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TOPAMAX, TOPIRAMATE
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 TYLOX, ACETAMINOPHEN
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
 EDURANT, RILPIVIRINE HYDROCHLORIDE
 PREZISTA, DARUNAVIR ETHANOLATE

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
 INTELENCE, ETRAVIRINE
 PARAFON FORTE DSC, CHLORZOXAZONE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 OLYSIO, SIMEPREVIR

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
 SIRTURO, BEDAQUILINE FUMARATE

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
 LUVOX CR, FLUVOXAMINE MALEATE
 XYREM, SODIUM OXYBATE

JAZZ PHARMS III

* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
 FAZACLO ODT, CLOZAPINE
 * JAZZ PHARMACEUTICALS INTERNATIONAL III
 VERSACLOZ, CLOZAPINE

JAZZ PHARMS INTL

* JAZZ PHARMACEUTICALS INTERNATIONAL LTD
 PRIALT, ZICONOTIDE ACETATE

JHP PHARMS

* JHP PHARMACEUTICALS LLC
 ADRENALIN, EPINEPHRINE
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 COLY-MYCIN S, COLISTIN SULFATE
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 KETALAR, KETAMINE HYDROCHLORIDE
 PITOCIN, OXYTOCIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIOSTAT, LIOTHYRONINE SODIUM

JHP PHARMS LLC

* JHP PHARMACEUTICALS LLC
 ADRENALIN, EPINEPHRINE
 ETOMIDATE, ETOMIDATE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL CO LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JIANGSU HANSON PHARMACEUTICAL CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

- * JIANGSU HENGRUI MEDICINE CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE

JOHNSON AND JOHNSON

- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
- * JOHNSON AND JOHNSON HEALTHCARE PRODUCTS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)

JUBILANT CADISTA

- * JUBILANT CADISTA PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
SODIUM IODIDE I-131, SODIUM IODIDE I-131

JUBILANT LIFE

- * JUBILANT LIFE SCIENCES LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

JUBILANT ORGANOSYS

- * JUBILANT ORGANOSYS LTD
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RISPERIDONE, RISPERIDONE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

STEVENS J

- * JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

- * KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KING PFIZER

- * KING PHARMACEUTICALS INC SUB PFIZER INC
AVINZA, MORPHINE SULFATE

KING PHARMS

- * KING PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

- * KING PHARMACEUTICALS INC
 - ALTACE, RAMIPRIL
 - BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
 - BICILLIN C-R, PENICILLIN G BENZATHINE
 - BICILLIN L-A, PENICILLIN G BENZATHINE
 - CORGARD, NADOLOL
 - CORZIDE, BENDROFLUMETHIAZIDE
 - PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 - SILVADENE, SILVER SULFADIAZINE
 - SKELAXIN, METAXALONE
 - SYNERCID, DALFOPRISTIN
 - TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
 - TAPAZOLE, METHIMAZOLE
 - TUSSIGON, HOMATROPINE METHYLBROMIDE

KING PHARMS R AND D

- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC
 - CYTOMEL, LIOTHYRONINE SODIUM
 - LEVOXYL, LEVOTHYROXINE SODIUM **
- * KING PHARMACEUTICALS RESEARCH DEVELOPMENT INC
 - OXECTA, OXYCODONE HYDROCHLORIDE

KOWA CO

- * KOWA CO LTD
 - LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

- * KREITCHMAN PET CENTER
 - AMMONIA N 13, AMMONIA N-13

KREMERS URBAN DEV

- * KREMERS URBAN DEVELOPMENT CO
 - RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

KREMERS URBAN PHARMS

- * KREMERS URBAN PHARMACEUTICALS INC
 - GLYCOLAX, POLYETHYLENE GLYCOL 3350
 - GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 - ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 - MONOKET, ISOSORBIDE MONONITRATE
 - NITROGLYCERIN, NITROGLYCERIN
 - OMEPRAZOLE, OMEPRAZOLE

KRKA TOVARNA ZDRAVIL

- * KRKA TOVARNA ZDRAVIL DD NOVO MESTO
 - LANSOPRAZOLE , LANSOPRAZOLE

KUDCO IRELAND

- * KUDCO IRELAND LTD
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - LETROZOLE, LETROZOLE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

KV PHARM

- * KV PHARMACEUTICAL CO
 - CLINDESSE, CLINDAMYCIN PHOSPHATE
 - EVAMIST, ESTRADIOL
 - MAKENA, HYDROXYPROGESTERONE CAPROATE

KVK TECH

- * KVK TECH INC
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 - KALEXATE, SODIUM POLYSTYRENE SULFONATE
 - PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 - PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**** L ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******LAB HRA PHARMA**

- * LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LANDELA PHARM

- * LANDELA PHARMACEUTICAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

- * LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
- * LANNETT HOLDINGS INC
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
URSODIOL, URSODIOL

LANNETT HOLDINGS INC

- * LANNETT HOLDINGS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHOCARBAMOL, METHOCARBAMOL
MORPHINE SULFATE, MORPHINE SULFATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LANTHEUS MEDCL

- * LANTHEUS MEDICAL IMAGING INC
ABLAVAR, GADOFOSVESET TRISODIUM
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

- * LANTHEUS MEDICAL IMAGING INC
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

- * LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LAVIPHARM LABS

- * LAVIPHARM LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LAVIPHARM LABORATORIES INC
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

LEK PHARMS

* LEK PHARMACEUTICALS D D
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

LEK PHARMS DD

* LEK PHARMACEUTICALS DD
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LEO PHARM

* LEO PHARMACEUTICAL PRODUCTS LTD
 DOVONEX, CALCIPOTRIENE

LEO PHARMA AS

* LEO PHARMA AS
 DOVONEX, CALCIPOTRIENE
 PICATO, INGENOL MEBUTATE
 TACLONEX, BETAMETHASONE DIPROPIONATE

LG LIFE

* LG LIFE SCIENCES LTD
 VALTROPIN, SOMATROPIN RECOMBINANT

LG LIFE SCIENCES

* LG LIFE SCIENCES LTD
 FACTIVE, GEMIFLOXACIN MESYLATE

LIAONING CHENGDA

* LIAONING CHENGDA BIOTECHNOLOGY CO LTD
 ZIDOVUDINE, ZIDOVUDINE

LLOYD

* LLOYD INC
 LEVOTHROID, LEVOTHYROXINE SODIUM **

LNK

* LNK INTERNATIONAL INC
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
 ANTHELIOS 20, AVOBENZONE (OTC)
 ANTHELIOS 40, AVOBENZONE (OTC)
 ANTHELIOS SX, AVOBENZONE (OTC)
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
 LEVETIRACETAM, LEVETIRACETAM

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ADENOSINE, ADENOSINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOSPORINE, CYCLOSPORINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUITPOLD PHARMACEUTICALS INC
 DACTINOMYCIN, DACTINOMYCIN
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXFERRUM, IRON DEXTRAN
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 ETOMIDATE, ETOMIDATE
 FOMEPIZOLE, FOMEPIZOLE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 INJECTAFER, FERRIC CARBOXYMALTOSIDE
 LATANOPROST, LATANOPROST
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCARNITINE, LEVOCARNITINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROGESTERONE, PROGESTERONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SPRIX, KETOROLAC TROMETHAMINE
 TORSEMIDE, TORSEMIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 VENOFER, IRON SUCROSE
 ZIDOVUDINE, ZIDOVUDINE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK LLC

* LUNDBECK LLC
 ONFI, CLOBAZAM
 SABRIL, VIGABATRIN

LUPIN

* LUPIN LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOVASTATIN, LOVASTATIN
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

*** LUPIN ATLANTIS HOLDINGS SA**
 ANTARA (MICRONIZED), FENOFIBRATE

LUPIN LTD*** LUPIN LIMITED**

LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

*** LUPIN LTD**

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 DAYSEE, ETHINYL ESTRADIOL
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GATIFLOXACIN, GATIFLOXACIN
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NORETHINDRONE, NORETHINDRONE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 SUPRAX, CEFIXIME
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******LUPIN PHARMS**

* LUPIN PHARMACEUTICALS INC
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE

* LYNE LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 HYDROCORTISONE, HYDROCORTISONE
 LEVOCARNITINE, LEVOCARNITINE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LYNROSE LABS

* LYNROSE LABS LLC
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

PERRIGO

* L PERRIGO CO
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TAB-PROFEN, IBUPROFEN (OTC)
 TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MACLEODS PHARMS LTD**

* MACLEODS PHARMACEUTICALS LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FAMCICLOVIR, FAMCICLOVIR
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

MALLINCKRODT

* MALLINCKRODT CHEMICAL INC
 ANEXSIA 7.5/650, ACETAMINOPHEN
 ANEXSIA, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MALLINCKRODT CHEMICAL INC
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHADOSE, METHADONE HYDROCHLORIDE
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - * MALLINCKRODT INC
 - ANEXSIA 5/325, ACETAMINOPHEN
 - ANEXSIA 7.5/325, ACETAMINOPHEN
 - ANEXSIA, ACETAMINOPHEN
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - FENTANYL CITRATE, FENTANYL CITRATE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 - OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
 - OPTIMARK, GADOVERSETAMIDE
 - OXYCET, ACETAMINOPHEN
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - PENNSAID, DICLOFENAC SODIUM
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - * MALLINCKRODT MEDICAL INC
 - CONRAY 30, IOTHALAMATE MEGLUMINE
 - CONRAY 43, IOTHALAMATE MEGLUMINE
 - CONRAY, IOTHALAMATE MEGLUMINE
 - CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 - GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 - INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 - MD-76R, DIATRIZOATE MEGLUMINE
 - MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 - OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 - OPTIRAY 240, IOVERSOL
 - OPTIRAY 300, IOVERSOL
 - OPTIRAY 320, IOVERSOL
 - OPTIRAY 350, IOVERSOL
 - SODIUM IODIDE I 123, SODIUM IODIDE I-123
 - SODIUM IODIDE I 131, SODIUM IODIDE I-131
 - TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 - TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 - TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 - THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 - ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 - ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
- MALLINCKRODT INC**
- * MALLINCKRODT INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 - DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 - EXALGO, HYDROMORPHONE HYDROCHLORIDE
 - FENTANYL-100, FENTANYL
 - FENTANYL-25, FENTANYL
 - FENTANYL-50, FENTANYL
 - FENTANYL-75, FENTANYL
 - GABLOFEN, BACLOFEN
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MALLINCKRODT INC**

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE
 TOFRANIL-PM, IMIPRAMINE PAMOATE

MALLINCKRODT LLC*** MALLINCKRODT LLC**

ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

MARATHON PHARMS*** MARATHON PHARMACEUTICALS LLC**

PEPCID, FAMOTIDINE
 SECONAL SODIUM, SECOBARBITAL SODIUM

MARATHON PHARMS LLC*** MARATHON PHARMACEUTICALS LLC**

IPRIVASK, DESIRUDIN RECOMBINANT

MARKSANS PHARMA*** MARKSANS PHARMA LTD**

GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN

MARSAM PHARMS LLC*** MARSAM PHARMACEUTICALS LLC**

TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

MATRIX LABS LTD*** MATRIX LABORATORIES LTD**

AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
 NIFEDIPINE, NIFEDIPINE
 STAVUDINE, STAVUDINE

MAYNE PHARMA*** MAYNE PHARMA INTERNATIONAL PTY LTD**

DORYX, DOXYCYCLINE HYCLATE
 ERYC, ERYTHROMYCIN

MCNEIL*** MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC**

CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 MOTRIN IB, IBUPROFEN (OTC)
 MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

MCNEIL CONS*** MCNEIL CONSUMER HEALTHCARE**

CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM, LOPERAMIDE HYDROCHLORIDE
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 NIZORAL A-D, KETOCONAZOLE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 SINE-AID IB, IBUPROFEN (OTC)
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 TYLENOL, ACETAMINOPHEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MCNEIL CONSUMER**

- * MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC, CETIRIZINE HYDROCHLORIDE

MCPRE

- * MAYO CLINIC PET RADIOCHEMISTRY FACILITY
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MEDA PHARMS

- * MEDA PHARMACEUTICALS
 DYMISTA, AZELASTINE HYDROCHLORIDE
 EDLUAR, ZOLPIDEM TARTRATE
- * MEDA PHARMACEUTICALS INC
 ANADROL-50, OXYMETHOLONE
 ASTELIN, AZELASTINE HYDROCHLORIDE
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 AVC, SULFANILAMIDE
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 CESAMET, NABILONE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 COLYTE, POLYETHYLENE GLYCOL 3350
 CORTIFOAM, HYDROCORTISONE ACETATE
 DEMADEx, TORSEMIDE
 DEPEN, PENICILLAMINE
 DIPENTUM, OLSALAZINE SODIUM
 ELESTRIN, ESTRADIOL
 EPIFOAM, HYDROCORTISONE ACETATE
 FELBATOL, FELBAMATE
 GASTROCROM, CROMOLYN SODIUM
 LUFYLLIN, DYPHYLLINE
 MUSE, ALPROSTADIL
 OPTIVAR, AZELASTINE HYDROCHLORIDE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 ROWASA, MESALAMINE
 SFROWASA, MESALAMINE
 TRILYTE, POLYETHYLENE GLYCOL 3350
- * MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
 SOMA COMPOUND W/ CODEINE, ASPIRIN
 SOMA COMPOUND, ASPIRIN
 SOMA, CARISOPRODOL

MEDEFIL INC

- * MEDEFIL INC
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICIS

- * MEDICIS PHARMACEUTICAL CORP
 ALDARA, IMIQUIMOD
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 ESTRASORB, ESTRADIOL HEMIHYDRATE
 LOPROX, CICLOPIROX
 LUZU, LULICONAZOLE
 MAXAIR, PIRBUTEROL ACETATE
 METROGEL-VAGINAL, METRONIDAZOLE
 MINITRAN, NITROGLYCERIN
 NORFLEX, ORPHENADRINE CITRATE
 NORGESIC FORTE, ASPIRIN
 NORGESIC, ASPIRIN
 SOLODYN, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEDICIS PHARMACEUTICAL CORP
 SYNACORT, HYDROCORTISONE
 THEOLAIR, THEOPHYLLINE
 VANOS, FLUOCINONIDE
 ZIANA, CLINDAMYCIN PHOSPHATE
 ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
 VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
 LOPROX, CICLOPIROX
 SYNALAR, FLUOCINOLONE ACETONIDE

MEDIMMUNE

* MEDIMMUNE
 ETHYOL, AMIFOSTINE

MEDTECH PRODS

* MEDTECH PRODUCTS INC
 TAGAMET HB, CIMETIDINE (OTC)

MEDTRONIC NEURO

* MEDTRONIC NEUROMODULATION
 LIORESAL, BACLOFEN

MERCK

* MERCK AND CO INC
 AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
 CANCIDAS, CASPOFUNGIN ACETATE
 EMEND, APREPITANT
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSAMAX, ALENDRONATE SODIUM
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 PRIMAXIN, CILASTATIN SODIUM
 PROSCAR, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
 CLINORIL, SULINDAC
 NOROXIN, NORFLOXACIN
 PRINIVIL, LISINAPRIL
 PRINZIDE, HYDROCHLOROTHIAZIDE
 PROPECIA, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
 ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
 EMEND, FOSAPREPITANT DIMEGLUMINE
 FOSAMAX, ALENDRONATE SODIUM

MERCK SANTE SAS

* MERCK SANTE SAS
 CYANOKIT, HYDROXOCOBALAMIN

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 COZAAR, LOSARTAN POTASSIUM
 CRIXIVAN, INDINAVIR SULFATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPROLENE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LIPTRUZET, ATORVASTATIN CALCIUM
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NITRO-DUR, NITROGLYCERIN
 NOXAFIL, POSACONAZOLE
 REBETOL, RIBAVIRIN
 SINEMET CR, CARBIDOPA
 SINEMET, CARBIDOPA
 STROMEKTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 VICTRELIS, BOCEPREVIR
 ZIOPTAN, TAFLUPROST

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE
 * MERIDIAN MEDICAL TECHNOLOGIES INC SUB KING PHARMACEUTICALS INC
 ALSUMA, SUMATRIPTAN SUCCINATE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 LIDOPEN, LIDOCAINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRO PHARM

* MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 ONMEL, ITRACONAZOLE

METHAPHARM

* METHAPHARM INC
 LEVETIRACETAM, LEVETIRACETAM
 PROVOCHOLINE, METHACHOLINE CHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
 MEFENAMIC ACID, MEFENAMIC ACID
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
 CROMOLYN SODIUM, CROMOLYN SODIUM
 GLIMEPIRIDE, GLIMEPIRIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIKAH PHARMA

* MIKAH PHARMA LLC
 DANTROLENE SODIUM, DANTROLENE SODIUM
 ISRADIPINE, ISRADIPINE
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

MIKART

* MIKART INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MIKART INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC, AMINOCAPROIC ACID
 BENZONATATE, BENZONATATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTAPAP, ACETAMINOPHEN
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CHLORZOXAZONE, CHLORZOXAZONE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ESGIC-PLUS, ACETAMINOPHEN
 ETHOSUXIMIDE, ETHOSUXIMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PYRAZINAMIDE, PYRAZINAMIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS*** MILLENNIUM PHARMACEUTICALS INC**
VELCADE, BORTEZOMIB**MIRROR PHARMS***** MIRROR PHARMACEUTICALS LLC**
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROBENECID AND COLCHICINE, COLCHICINE**MISSION PHARMA***** MISSION PHARMACAL CO**
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE**MIST PHARMS LLC***** MIST PHARMACEUTICALS LLC**
NITROMIST, NITROGLYCERIN**MN PHARMS***** MN PHARMACEUTICALS**
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM**MOBIUS THERAP***** MOBIUS THERAPEUTICS LLC**
MITOSOL, MITOMYCIN**MOLNLYCKE HLTH***** MOLNLYCKE HEALTH CARE**
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)**MONARCH PHARMS***** MONARCH PHARMACEUTICALS INC**
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MONARCH PHARMACEUTICALS INC
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MORTON GROVE

* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE

MORTON GROVE PHARMS

* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSD CONSUMER

* MSD CONSUMER CARE INC
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVSAT

* MUSTAFA NEVSAT ILAC SANAYII AS
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

MUSTAFA NEVZAT

* MUSTAFA NEVZAT ILAC SANAYII AS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
VECURONIUM BROMIDE, VECURONIUM BROMIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MUTUAL PHARMACEUTICAL CO INC
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

MUTUAL PHARM CO INC

* MUTUAL PHARMACEUTICAL CO INC
 FIBRICOR, FENOFIBRIC ACID
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 QUALAQUIN, QUININE SULFATE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 KETOCONAZOLE, KETOCONAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

MYLAN

* MYLAN LABORATORIES INC
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 ETODOLAC, ETODOLAC
 OLANZAPINE, OLANZAPINE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

* MYLAN PHARMACEUTICALS INC
 ACARBOSE, ACARBOSE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALLOPURINOL, ALLOPURINOL
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 AVITA, TRETINOIN
 AZATHIOPRINE, AZATHIOPRINE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLORPRES, CHLORTHALIDONE
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ESTRADIOL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
 ETOPOSIDE, ETOPOSIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUTAMIDE, FLUTAMIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN PHARMACEUTICALS INC**

HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MENTAX-TC, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHAZIDE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PACLITAXEL, PACLITAXEL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN PHARMACEUTICALS INC**

PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 STAVUDINE, STAVUDINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

MYLAN INSTITUTIONAL*** MYLAN INSTITUTIONAL INC**

SULFAMYLON, MAFENIDE ACETATE

*** MYLAN INSTITUTIONAL LLC**

ALOPRIM, ALLOPURINOL SODIUM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 CARBOPLATIN, CARBOPLATIN
 CIDOFOVIR, CIDOFOVIR
 COSYNTROPIN, COSYNTROPIN
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 DURACLON, CLONIDINE HYDROCHLORIDE
 ENLON, EDROPHONIUM CHLORIDE
 ENLON-PLUS, ATROPINE SULFATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN INSTITUTIONAL LLC**

FOMEPIZOLE, FOMEPIZOLE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 RIMSO-50, DIMETHYL SULFOXIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

MYLAN LABS*** MYLAN LABORATORIES LTD**

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 NEVIRAPINE, NEVIRAPINE

MYLAN PHARMS INC*** MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMNESTEEM, ISOTRETINOIN
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AVITA, TRETINOIN
 BACLOFEN, BACLOFEN
 CABERGOLINE, CABERGOLINE
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIDANOSINE, DIDANOSINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ENTACAPONE, ENTACAPONE
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 ESZOPICLONE, ESZOPICLONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDAPAMIDE, INDAPAMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LITHIUM CARBONATE, LITHIUM CARBONATE
MALATHION, MALATHION
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RAMIPRIL, RAMIPRIL
REPAGLINIDE, REPAGLINIDE
RILUZOLE, RILUZOLE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZONISAMIDE, ZONISAMIDE
* MYLAN PHARMACEUTICALS INC.

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIZATIDINE, NIZATIDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECLT

- * MYLAN SPECIALTY LP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES INC
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NITROGLYCERIN, NITROGLYCERIN

**** N ******NATCO PHARMA**

- * NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

- * NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
- * NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

NAUTILUS NEUROSCIENC

- * NAUTILUS NEUROSCIENCES INC
CAMBIA, DICLOFENAC POTASSIUM

NAVIDEA BIOPHARMS

- * NAVIDEA BIOPHARMACEUTICALS INC
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

NAVINTA LLC

- * NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

NEPHRON

- * NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
- * NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

NESHER PHARMS

- * NESHER PHARMACEUTICALS USA LLC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******NEW RIVER**

- * NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEXGEN PHARMA

- * NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

- * NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS

- * NEXTWAVE PHARMACEUTICALS INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS

- * NEXUS PHARMACEUTICALS INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
LEVOFLOXACIN, LEVOFLOXACIN

NIAGARA PHARMS

- * NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NORTHSTAR HLTHCARE

- * NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM

- * NOSTRUM PHARMACEUTICALS INC
CARBAMAZEPINE, CARBAMAZEPINE
THEOPHYLLINE, THEOPHYLLINE

NOSTRUM LABS

- * NOSTRUM LABORATORIES INC
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE

NOSTRUM PHARMS LLC

- * NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVADEL

- * NOVADEL PHARMA INC
ZOLPIMIST, ZOLPIDEM TARTRATE

NOVARTIS

- * NOVARTIS CONSUMER HEALTH INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
NEXCEDE, KETOPROFEN (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)
TRANSDERM SCOP, SCOPOLAMINE
VAGISTAT-1, TIOCONAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS CONSUMER HEALTH INC
VOLTAREN, DICLOFENAC SODIUM

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
AMTURNIDE, ALISKIREN HEMIFUMARATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
CATAFLAM, DICLOFENAC POTASSIUM
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
COMBIPATCH, ESTRADIOL
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
GILENYA, FINGOLIMOD
GLEEVEC, IMATINIB MESYLATE
HYDERGINE, ERGOLOID MESYLATES
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LOPRESSOR, METOPROLOL TARTRATE
LOTREL, AMLODIPINE BESYLATE
MIACALCIN, CALCITONIN SALMON
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
RECLAST, ZOLEDRONIC ACID
REGITINE, PHENTOLAMINE MESYLATE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKTURN HCT, ALISKIREN HEMIFUMARATE
TEKTURN, ALISKIREN HEMIFUMARATE
TOBI PODHALER, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
TYZEKA, TELBIVUDINE
VALTURN, ALISKIREN HEMIFUMARATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******NOVARTIS PHARM**

- * NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

- * NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE
TOBI, TOBRAMYCIN

NOVAST LABS

- * NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE

NOVAST LABS LTD

- * NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
PHILITH, ETHINYL ESTRADIOL
PIMTREA, DESOGESTREL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVEL LABS INC

- * NOVEL LABORATORIES INC
FAMOTIDINE, FAMOTIDINE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MISOPROSTOL, MISOPROSTOL
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIMETHOPRIM, TRIMETHOPRIM

NOVEN

- * NOVEN PHARMACEUTICALS INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

- * NOVEN PHARMACEUTICALS INC
DAYTRANA, METHYLPHENIDATE

NOVEN THERAP

- * NOVEN THERAPEUTICS LLC
BRISDELLE, PAROXETINE MESYLATE
LITHOBID, LITHIUM CARBONATE
PEXEVA, PAROXETINE MESYLATE

NOVEX

- * NOVEX PHARMA
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

NOVO NORDISK

- * NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVO NORDISK INC
 ACTIVELLA, ESTRADIOL
 LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 NORDITROPIN FLEXPEN, SOMATROPIN RECOMBINANT
 NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOVOLOG, INSULIN ASPART RECOMBINANT
 PRANDIMET, METFORMIN HYDROCHLORIDE
 PRANDIN, REPAGLINIDE
 VAGIFEM, ESTRADIOL
 VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL

* NOVOCOL PHARMACEUTICAL INC
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NOVOCOL INC

* NOVOCOL INC
 LIDOCAINE, LIDOCAINE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NU PHARM

* NU PHARM INC
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUPATHE

* NUPATHE INC
 ZECUITY, SUMATRIPTAN SUCCINATE

NYCOMED US

* NYCOMED US INC
 TERCONAZOLE, TERCONAZOLE

**** O ******OAK PHARMS**

* OAK PHARMACEUTICALS INC
 EMLA, LIDOCAINE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN

* OAK PHARMACEUTICALS INC SUB AKORN INC
 COGENTIN, BENZTROPINE MESYLATE
 DIURIL, CHLOROTHIAZIDE SODIUM
 * OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
 AZASITE, AZITHROMYCIN
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
 COSOPT, DORZOLAMIDE HYDROCHLORIDE

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
 ANTABUSE, DISULFIRAM
 NYSTATIN, NYSTATIN
 SURMONTIL, TRIMIPRAMINE MALEATE
 URECHOLINE, BETHANECHOL CHLORIDE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
 IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 0 ****

- * OHM LABORATORIES INC
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OLTA PHARMS

- * OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMAN PHARM PRODUCTS

- * OMAN PHARMACEUTICAL PRODUCTS CO LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

ONCO THERAPIES LTD

- * ONCO THERAPIES LTD
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CYTARABINE, CYTARABINE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE, VINORELBINE

ONY

- * ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX PHARMS

- * ONYX PHARMACEUTICALS INC
KYPROLIS, CARFILZOMIB

OPTIMER PHARMS

- * OPTIMER PHARMACEUTICALS INC
DIFICID, FIDAXOMICIN

ORAPHARMA

- * ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

- * ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 0 ****

* ORCHID HEALTHCARE
ZALEPLON, ZALEPLON

OREXO AB

* OREXO AB
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC SUB MERCK AND CO INC
SAPHRIS, ASENAPINE MALEATE

ORGANON USA INC

* ORGANON USA INC
CYCLESSA, DESOGESTREL
DESOGEN, DESOGESTREL
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
IMPLANON, ETNOGESTREL
NEXPLANON, ETNOGESTREL
NUVARING, ETHINYL ESTRADIOL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
ZEMURON, ROCURONIUM BROMIDE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
LEVETIRACETAM, LEVETIRACETAM

ORPHAN EUROPE

* ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID

ORTHO MCNEIL JANSSEN

* ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC
NIZORAL, KETOCONAZOLE

OSI PHARMS

* OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP

* OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
PLETAL, CILOSTAZOL
* OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA

* OTSUKA AMERICA PHARMACEUTICALS INC
BREATHTEK UBT FOR H-PYLORI, UREA C-13

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**** P ******PACIFIC PHARMA**

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE

* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

* PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

PACK PHARMS LLC

* PACK PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM

PADDOCK

* PADDOCK LABORATORIES INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

PADDOCK LABS

* PADDOCK LABORATORIES INC
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

PADDOCK LLC

* PADDOCK LABORATORIES LLC
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ERYTHRA-DERM, ERYTHROMYCIN
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LORAZEPAM, LORAZEPAM
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PAI**

- * PHARMACEUTICAL ASSOCIATES INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

PALADIN LABS

- * PALADIN LABS USA INC
ANTIZOL, FOMEPIZOLE

PANACEA BIOTEC LTD

- * PANACEA BIOTEC LTD
TACROLIMUS, TACROLIMUS

PAR FORM

- * PAR FORMULATIONS PRIVATE LTD
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE

PAR PHARM

- * PAR PHARMACEUTICAL
NABUMETONE, NABUMETONE
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
- * PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CAPOTEN, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NASCOBAL, CYANOCOBALAMIN
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
OXANDROLONE, OXANDROLONE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

PARAGON BIOTECK

* PARAGON BIOTECK INC
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 NARDIL, PHENELZINE SULFATE
 NEURONTIN, GABAPENTIN
 ZARONTIN, ETHOSUXIMIDE
 * PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
 ZARONTIN, ETHOSUXIMIDE

PEDIATRX

* PEDIATRX INC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

PEDINOL

* PEDINOL PHARMACAL INC
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

PERNIX THERAP

* PERNIX THERAPEUTICS LLC
 CEDAX, CEFTIBUTEN DIHYDRATE

PERNIX THERAPS LLC

* PERNIX THERAPEUTICS LLC
 SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO

* PERRIGO CO
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CICLOPIROX, CICLOPIROX
 CIMETIDINE, CIMETIDINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 IBUPROFEN, IBUPROFEN (OTC)
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PERRIGO CO
 - MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

- * PERRIGO CO TENNESSEE INC
 - BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 - BACITRACIN, BACITRACIN
 - BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
 - ERYTHROMYCIN, ERYTHROMYCIN
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 - NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 - NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

- * PERRIGO ISRAEL PHARMACEUTICALS
 - FLUOCINONIDE, FLUOCINONIDE
- * PERRIGO ISRAEL PHARMACEUTICALS LTD
 - BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
 - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - IMIQUIMOD, IMIQUIMOD
 - KETOCONAZOLE, KETOCONAZOLE
 - MESALAMINE, MESALAMINE
 - MINOXIDIL, MINOXIDIL (OTC)
 - NITROGLYCERIN, NITROGLYCERIN
 - TESTOSTERONE, TESTOSTERONE

PERRIGO NEW YORK

- * PERRIGO NEW YORK INC
 - ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CENTANY, MUPIROCIN
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - DESONIDE, DESONIDE
 - DESOXIMETASONE, DESOXIMETASONE
 - ECONAZOLE NITRATE, ECONAZOLE NITRATE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - HYDROCORTISONE, HYDROCORTISONE
 - KETOCONAZOLE, KETOCONAZOLE
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MUPIROCIN, MUPIROCIN
 - NYSTATIN, NYSTATIN
 - PERMETHRIN, PERMETHRIN
 - PERMETHRIN, PERMETHRIN (OTC)
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - SELENIUM SULFIDE, SELENIUM SULFIDE
 - TERCONAZOLE, TERCONAZOLE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO R AND D

- * PERRIGO R AND D CO
 - CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PERRIGO R AND D CO**

CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN, NAPROXEN
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

PETNET

* PETNET SOLUTIONS INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PF PRISM

* PF PRISM CV
 LYRICA, PREGABALIN

PF PRISM CV

* PF PRISM CV
 RAPAMUNE, SIROLIMUS
 TORISEL, TEMSIROLIMUS
 TYGACIL, TIGECYCLINE
 XALKORI, CRIZOTINIB
 XELJANZ, TOFACITINIB CITRATE
 ZMAX, AZITHROMYCIN

PFIZER

* PFIZER CENTRAL RESEARCH
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN
 * PFIZER CHEMICALS DIV PFIZER INC
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN
 * PFIZER INC
 ACOVA, ARGATROBAN
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ADVIL, IBUPROFEN (OTC)
 ALAVERT, LORATADINE (OTC)
 AXID AR, NIZATIDINE (OTC)
 CADUET, AMLODIPINE BESYLATE
 CALAN SR, VERAPAMIL HYDROCHLORIDE
 CARDURA XL, DOXAZOSIN MESYLATE
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PFIZER INC
 ELELYSO, TALIGLUCERASE ALFA
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 GLUCOTROL XL, GLIPIZIDE
 GLUCOTROL, GLIPIZIDE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 INLYTA, AXITINIB
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
 LIPITOR, ATORVASTATIN CALCIUM
 LORATADINE, LORATADINE (OTC)
 NAVANE, THIOTHIXENE
 NORVASC, AMLODIPINE BESYLATE
 PEDIATRIC ADVIL, IBUPROFEN (OTC)
 PROCARDIA, NIFEDIPINE
 REVATIO, SILDENAFIL CITRATE
 SONATA, ZALEPLON
 TESSALON, BENZONATATE
 TOVIAZ, FESOTERODINE FUMARATE
 UNASYN, AMPICILLIN SODIUM
 VFEND, VORICONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER LABORATORIES DIV PFIZER INC
 CARDURA, DOXAZOSIN MESYLATE
 DIABINESE, CHLORPROPAMIDE
 FELDENE, PIROXICAM
 MINIPRESS, PRAZOSIN HYDROCHLORIDE
 PERMAPEN, PENICILLIN G BENZATHINE
 PFIZERPEN, PENICILLIN G POTASSIUM
 PROCARDIA XL, NIFEDIPINE
 TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
 UNASYN, AMPICILLIN SODIUM
 VIBRAMYCIN, DOXYCYCLINE
 VIBRAMYCIN, DOXYCYCLINE CALCIUM
 VIBRAMYCIN, DOXYCYCLINE HYCLATE
 VISTARIL, HYDROXYZINE PAMOATE

* PFIZER PHARMACEUTICALS INC
 ZOLOFT, SERTRALINE HYDROCHLORIDE

* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
 TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

* PFIZER CONSUMER HEALTHCARE
 ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

* PFIZER INC
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 CHANTIX, VARENICLINE TARTRATE
 ELLENCE, EPIRUBICIN HYDROCHLORIDE
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 NICOTROL, NICOTINE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
 RELPAX, ELETRIPTAN HYDROBROMIDE
 VIAGRA, SILDENAFIL CITRATE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
 ACCUPRIL, QUINAPRIL HYDROCHLORIDE
 ACCURETIC, HYDROCHLOROTHIAZIDE
 DILANTIN, PHENYTOIN
 LOPID, GEMFIBROZIL
 NEURONTIN, GABAPENTIN
 NITROSTAT, NITROGLYCERIN

PHARM ASSOC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PHARMACEUTICAL ASSOC INC
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - LORAZEPAM, LORAZEPAM
 - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 - ETHOSUXIMIDE, ETHOSUXIMIDE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 - HALOPERIDOL, HALOPERIDOL LACTATE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - LACTULOSE, LACTULOSE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 - PREDNISOLONE, PREDNISOLONE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE
 - VALPROIC ACID, VALPROIC ACID
- * PHARMACEUTICAL ASSOCIATES INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

PHARMACEUTICS

- * PHARMACEUTICS INTERNATIONAL INC
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

PHARMACHEMIE

- * PHARMACHEMIE BV
 - CARBOPLATIN, CARBOPLATIN
 - CISPLATIN, CISPLATIN
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

PHARMACHEMIE BV

- * PHARMACHEMIE BV
 - METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 - METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

- * PHARMACIA AND UPJOHN
 - XANAX XR, ALPRAZOLAM
- * PHARMACIA AND UPJOHN CO
 - ANSAID, FLURBIPROFEN
 - AROMASIN, EXEMESTANE
 - AZULFIDINE EN-TABS, SULFASALAZINE
 - AZULFIDINE, SULFASALAZINE
 - BACITRACIN, BACITRACIN
 - CAVERJECT IMPULSE, ALPROSTADIL
 - CAVERJECT, ALPROSTADIL
 - CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 - CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 - CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - CLEOCIN T, CLINDAMYCIN PHOSPHATE
 - CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 - CLEOCIN, CLINDAMYCIN PHOSPHATE
 - COLESTID, COLESTIPOL HYDROCHLORIDE
 - CORTEF, HYDROCORTISONE
 - CORVERT, IBUTILIDE FUMARATE
 - CYKLOKAPRON, TRANEXAMIC ACID
 - DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 - DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 - DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 - DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 - DETROL LA, TOLTERODINE TARTRATE
 - DETROL, TOLTERODINE TARTRATE
 - DIDREX, BENZPHETAMINE HYDROCHLORIDE
 - EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PHARMACIA AND UPJOHN CO
 - ESTRING, ESTRADIOL
 - FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 - GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
 - GENOTROPIN, SOMATROPIN RECOMBINANT
 - GLYNASE, GLYBURIDE
 - GLYSET, MIGLITOL
 - HALCION, TRIAZOLAM
 - HEMABATE, CARBOPROST TROMETHAMINE
 - IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 - LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 - MEDROL, METHYLPREDNISOLONE
 - MYCOBUTIN, RIFABUTIN
 - NICOTROL, NICOTINE
 - OGEN .625, ESTROPIPATE
 - OGEN 1.25, ESTROPIPATE
 - OGEN 2.5, ESTROPIPATE
 - OGEN 5, ESTROPIPATE
 - PREPIDIL, DINOPROSTONE
 - PROSTIN E2, DINOPROSTONE
 - PROSTIN VR PEDIATRIC, ALPROSTADIL
 - PROVERA, MEDROXYPROGESTERONE ACETATE
 - R-GENE 10, ARGININE HYDROCHLORIDE
 - SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 - SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
 - SOMAVERT, PEGVISOMANT
 - XALATAN, LATANOPROST
 - XANAX, ALPRAZOLAM
 - ZINECARD, DEXRAZOXANE HYDROCHLORIDE
 - ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
 - DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
- PHARMACYCLICS INC**
- * PHARMACYCLICS INC
 - IMBRUVICA, IBRUTINIB
- PHARMAFORCE**
- * PHARMAFORCE INC
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - NANDROLONE DECANOATE, NANDROLONE DECANOATE
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
- PHARMALUCENCE**
- * PHARMALUCENCE INC
 - AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 - CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 - CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 - HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
 - TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 - TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
- PHARMAX**
- * PHARMAX GROUP INC
 - BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
- PHARMAXIS LTD**
- * PHARMAXIS LTD
 - ARIDOL KIT, MANNITOL
- PHARMS**
- * PHARMACEUTICALS INTERNATIONAL
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID
- PHOTOCURE ASA**
- * PHOTOCURE ASA
 - CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
- PIERRE FABRE**
- * PIERRE FABRE MEDICAMENT
 - NAVELBINE, VINORELBINE TARTRATE
- PIERREL**
- * PIERREL S.P.A.

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PIERREL S.P.A.
ORABLOC, ARTICAIN HYDROCHLORIDE

PINNACLE BIOLGS

* PINNACLE BIOLOGICS INC
PHOTOFIN, PORFIMER SODIUM

PIRAMAL CRITICAL

* PIRAMAL CRITICAL CARE INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

PLD ACQUISITIONS

* PLD ACQUISITIONS LLC
IBUPROFEN, IBUPROFEN (OTC)

PLIVA

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
PENTOXIFYLLINE, PENTOXIFYLLINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA

* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
NEOPAP, ACETAMINOPHEN (OTC)

PRECISION DERMAT

* PRECISION DERMATOLOGY INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PRECISION DERMATOLOGY INC
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCOID, HYDROCORTISONE BUTYRATE
 MINOCIN, MINOCYCLINE HYDROCHLORIDE
 PODOFILOX, PODOFILOX
 TRETINOIN, TRETINOIN

PRECISION DOSE

* PRECISION DOSE INC
 RISPERIDONE, RISPERIDONE

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

PROCTER AND GAMBLE

* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO
 DIDRONEL, ETIDRONATE DISODIUM

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROMETHEUS LABS

* PROMETHEUS LABORATORIES INC
 HELIDAC, BISMUTH SUBSALICYLATE
 IMURAN, AZATHIOPRINE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 RIDAURA, AURANOFIN
 ZYLOPRIM, ALLOPURINOL

PROMIUS PHARMA

* PROMIUS PHARMA LLC
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE
 TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

* PROMIUS PHARMA LLC
 CLODERM, CLOCORTOLONE PIVALATE

PROSAM LABS

* PROSAM LABS LLC
 BACLOFEN, BACLOFEN
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 RIMACTANE, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

PROSTRAKAN INC

* PROSTRAKAN INC
 FARESTON, TOREMIFENE CITRATE
 SANCUSO, GRANISETRON

PROVENSIS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PROVENISIS LTD
VARITHENA, POLIDOCANOL

PROVIDENT PHARM

* PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULSION MEDCL

* PULSION MEDICAL SYSTEMS AG
INDOCYANINE GREEN, INDOCYANINE GREEN

PURACAP PHARM

* PURACAP PHARMACEUTICAL LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
MELOXICAM, MELOXICAM

PURDUE GMP

* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS

* PURDUE PHARMACEUTICAL PRODUCTS LP
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA

* PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP

* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM

* PUREPAC PHARMACEUTICAL CO
DIPYRIDAMOLE, DIPYRIDAMOLE

**** Q ******QOL MEDCL**

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUESTCOR PHARMS

* QUESTCOR PHARMACEUTICALS INC
H.P. ACTHAR GEL, CORTICOTROPIN

**** R ******RANBAXY**

* RANBAXY INC
ABSORICA, ISOTRETINOIN
GLYCOPYRROLATE, GLYCOPYRROLATE

* RANBAXY LABORATORIES INC
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOG, HALCINONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LAC-HYDRIN, AMMONIUM LACTATE
RISPERIDONE, RISPERIDONE
ULTRAVATE, HALOBETASOL PROPIONATE

* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

- * RANBAXY LABORATORIES LTD
 - CEFUROXIME AXETIL, CEFUROXIME AXETIL
 - CEPHALEXIN, CEPHALEXIN
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 - CLARITHROMYCIN, CLARITHROMYCIN
 - CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 - CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - DOXYCYCLINE, DOXYCYCLINE
 - FENOFIBRATE, FENOFIBRATE
 - FLECAINIDE ACETATE, FLECAINIDE ACETATE
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 - GABAPENTIN, GABAPENTIN
 - LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 - LORATADINE REDIDOSE, LORATADINE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - LORAZEPAM, LORAZEPAM
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 - ONDANSETRON, ONDANSETRON
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SIMVASTATIN, SIMVASTATIN
 - SOTRET, ISOTRETINOIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TOPIRAMATE, TOPIRAMATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * RANBAXY PHARMACEUTICALS INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - AMOXICILLIN, AMOXICILLIN
 - AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINAPRIL, LISINAPRIL
 - LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 - RIOMET, METFORMIN HYDROCHLORIDE
 - SOTRET, ISOTRETINOIN

RANBAXY LABS LTD

- * RANBAXY LABORATORIES LIMITED
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
- * RANBAXY LABORATORIES LTD
 - ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - FELODIPINE, FELODIPINE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

RAPTOR PHARMS

- * RAPTOR PHARMACEUTICALS CORP
 - PROCYSBI, CYSTEAMINE BITARTRATE

RARE DIS THERAP

- * RARE DISEASE THERAPEUTICS INC
 - CYSTADANE, BETAINE HYDROCHLORIDE

RECIP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RECIP AB
 THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

* RECKITT BENCKISER LLC
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MUCINEX, GUAIFENESIN (OTC)

* RECKITT BENCKISER PHARMACEUTICALS INC
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

RECORDATI RARE

* RECORDATI RARE DISEASES INC
 CHEMET, SUCCIMER
 COSMEGEN, DACTINOMYCIN
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 INDOCIN, INDOMETHACIN SODIUM
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
 NEOPROFEN, IBUPROFEN LYSINE
 PEGANONE, ETHOTOIN
 TRANXENE, CLORAZEPATE DIPOTASSIUM

REMPEX PHARMS INC

* REMPEX PHARMACEUTICALS INC
 MINOCIN, MINOCYCLINE HYDROCHLORIDE

RENAISSANCE PHARMA

* RENAISSANCE PHARMA US HOLDINGS INC
 ELIMITE, PERMETHRIN

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 UNIPHYL, THEOPHYLLINE

RHODIA

* RHODIA LTD
 ISOFLURANE, ISOFLURANE

RICONPHARMA LLC

* RICONPHARMA LLC
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE

ROCHE PALO

* ROCHE PALO ALTO LLC
 CELLCEPT, MYCOPHENOLATE MOFETIL
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 CYTOVENE, GANCICLOVIR SODIUM
 EC-NAPROSYN, NAPROXEN
 NAPROSYN, NAPROXEN

ROCKWELL MEDCL

* ROCKWELL MEDICAL TECHNOLOGIES INC
 CALCITRIOL, CALCITRIOL

ROMARK

* ROMARK LABORATORIES
 ALINIA, NITAZOXANIDE

ROSEDALE THERAPEUTIC

* ROSEDALE THERAPEUTICS
 ERGOMAR, ERGOTAMINE TARTRATE

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
 LEVETIRACETAM, LEVETIRACETAM

ROXANE

* ROXANE LABORATORIES INC
 ACARBOSE, ACARBOSE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* ROXANE LABORATORIES INC
ANASTROZOLE, ANASTROZOLE
AZATHIOPRINE, AZATHIOPRINE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CODEINE SULFATE, CODEINE SULFATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******* ROXANE LABORATORIES INC**

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROXICET, ACETAMINOPHEN
 ROXILOX, ACETAMINOPHEN
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TINIDAZOLE, TINIDAZOLE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** S ******SAGE PRODS***** SAGE PRODUCTS INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA*** SAGENT AGILA LLC**

ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SAGENT PHARMS*** SAGENT PHARMACEUTICALS INC**

ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MESNA, MESNA
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT STRIDES

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SAGENT STRIDES LLC**

AZITHROMYCIN, AZITHROMYCIN
 BACITRACIN, BACITRACIN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SALIX PHARMS*** SALIX PHARMACEUTICALS INC**

ANUSOL HC, HYDROCORTISONE
 APRISO, MESALAMINE
 COLAZAL, BALSALAZIDE DISODIUM
 DIURIL, CHLOROTHIAZIDE
 FULYZAQ, CROFELEMER
 GIAZO, BALSALAZIDE DISODIUM
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 PEPCID, FAMOTIDINE
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SALIX PHARMS INC*** SALIX PHARMACEUTICALS INC**

FENOGLIDE, FENOFIBRATE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 ZEGERID, OMEPRAZOLE

SAMSON MEDCL*** SAMSON MEDICAL TECHNOLOGIES LLC**

CEFAZOLIN SODIUM, CEFAZOLIN SODIUM

SANDOZ*** SANDOZ**

DOCETAXEL, DOCETAXEL

*** SANDOZ CANADA INC**

ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 COSYNTROPIN, COSYNTROPIN
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

*** SANDOZ INC**

ALPRAZOLAM, ALPRAZOLAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
ALTAVERA, ETHINYL ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ANASTROZOLE, ANASTROZOLE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFERGOT, CAFFEINE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinir
CEFPodoxime Proxetil, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ESTARYLLA, ETHINYL ESTRADIOL
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INTROVALE, ETHINYL ESTRADIOL
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LONOX, ATROPINE SULFATE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRazole, OMEPRazole

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 OMNITROPE, SOMATROPIN RECOMBINANT
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 RESERPINE, RESERPINE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFADIAZINE, SULFADIAZINE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYEDA, DROSPIRENONE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

SANDOZ CANADA INC

* SANDOZ CANADA INC
 PARICALCITOL, PARICALCITOL
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

SANDOZ INC

* SANDOZ INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

OLANZAPINE, OLANZAPINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

SANOCHEMIA CORP USA*** SANOCHEMIA CORP USA**

SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI AVENTIS US*** SANOFI AVENTIS US INC**

JEVTANA KIT, CABAZITAXEL

*** SANOFI AVENTIS US LLC**

ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ANZEMET, DOLASETRON MESYLATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARALEN, CHLOROQUINE PHOSPHATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AUVI-Q, EPINEPHRINE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CANTIL, MEPENZOLATE BROMIDE
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DIABETA, GLYBURIDE
DRISDOL, ERGOCALCIFEROL
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
HIPREX, METHENAMINE HIPPURATE
KETEK, TELITHROMYCIN
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LASIX, FUROSEMIDE
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
MYTELASE, AMBENONIUM CHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANOFI AVENTIS US LLC
 RIFATER, ISONIAZID
 TAXOTERE, DOCETAXEL
 TRENTAL, PENTOXIFYLLINE

SANOFI PASTEUR INC

* SANOFI PASTEUR INC
 SKLICE, IVERMECTIN

SANTARUS

* SANTARUS INC
 UCERIS, BUDESONIDE

SANTEN

* SANTEN INC
 ALAMAST, PEMIROLAST POTASSIUM
 IQUIX, LEVOFLOXACIN
 QUIXIN, LEVOFLOXACIN

SANTEN OY

* SANTEN OY
 BETIMOL, TIMOLOL

SANTOS BIOTECH

* SANTOS BIOTECH INDUSTRIES INC
 ANASTROZOLE, ANASTROZOLE

SAVIENT PHARMS

* SAVIENT PHARMACEUTICALS INC
 OXANDRIN, OXANDROLONE

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
 AVANDAMET, METFORMIN HYDROCHLORIDE
 AVANDARYL, GLIMEPIRIDE
 AVANDIA, ROSIGLITAZONE MALEATE
 COREG CR, CARVEDILOL PHOSPHATE

SCHERING

* SCHERING CORP
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 INTEGRILIN, EPTIFIBATIDE
 NOXAFIL, POSACONAZOLE
 REBETOL, RIBAVIRIN

SCHERING CORP

* SCHERING CORP
 LOTRISONE, BETAMETHASONE DIPROPIONATE

SCHERING PLOUGH

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
 AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 CLARITIN HIVES RELIEF, LORATADINE (OTC)
 CLARITIN REDITABS, LORATADINE (OTC)
 CLARITIN, LORATADINE (OTC)
 CLARITIN-D 24 HOUR, LORATADINE (OTC)
 CLARITIN-D, LORATADINE (OTC)
 DISOPHROL, DEKBROMPHENIRAMINE MALEATE (OTC)
 DRIXORAL PLUS, ACETAMINOPHEN (OTC)
 DRIXORAL, DEKBROMPHENIRAMINE MALEATE (OTC)
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 NASONEX, MOMETASONE FUROATE MONOHYDRATE
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
 SHADE UVAGUARD, AVOBENZONE (OTC)

SCIECURE PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SCIECURE PHARMA INC
DORAL, QUAZEPAM

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE

SCIOS LLC

* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD

* SEBELA IRELAND LTD
MICORT-HC, HYDROCORTISONE ACETATE
PRAMOSONE, HYDROCORTISONE ACETATE

SECAN PHARMS

* SECAN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

SEPTODONT

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS
ORAVVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SHASUN CHEMS

* SHASUN CHEMICALS AND DRUGS LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SHASUN USA

* SHASUN USA INC
IBUPROFEN, IBUPROFEN

SHIONOGI INC

* SHIONOGI INC
DORIBAX, DORIPENEM
FURADANTIN, NITROFURANTOIN
KEFLEX, CEPHALEXIN
MOXATAG, AMOXICILLIN
OSPHENA, OSPEMIFENE
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
SULAR, NISOLDIPINE
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

- * SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE
SALURON, HYDROFLUMETHIAZIDE

SHIRE ORPHAN THERAP

- * SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIGMA TAU

- * SIGMA TAU PHARMACEUTICALS INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC

- * SIGMAPHARM LABORATORIES LLC
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILARX

- * SILARX PHARMACEUTICALS INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

SILARX PHARMS INC

- * SILARX PHARMACEUTICALS INC
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE

SILVERGATE PHARMS

- * SILVERGATE PHARMACEUTICALS INC
EPANED KIT, ENALAPRIL MALEATE

SKINMEDICA

- * SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

- * SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

- * SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
 ARRANON, NELARABINE
 COREG, CARVEDILOL
 TREXIMET, NAPROXEN SODIUM
 TYKERB, LAPATINIB DITOSYLATE

SOAPCO

* SOAPCO INC
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS LLC
 PROGESTERONE, PROGESTERONE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
 ELDEPRYL, SELEGILINE HYDROCHLORIDE
 EMSAM, SELEGILINE

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
 FLUOROURACIL, FLUOROURACIL

SPEAR PHARMS INC

* SPEAR PHARMACEUTICALS INC
 TRETINOIN, TRETINOIN

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS INC
 FUSILEV, LEVOLEUCOVORIN CALCIUM

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
 IVY BLOCK, BENTOQUATAM (OTC)

STASON

* STASON INDUSTRIAL CORP
 ACYCLOVIR, ACYCLOVIR
 CAPTOPRIL, CAPTOPRIL
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

STASON PHARMS

* STASON PHARMACEUTICALS INC
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

STERI PHARMA

* STERI PHARMA LLC
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM

STI PHARMA LLC

* STI PHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 DEXAMETHASONE, DEXAMETHASONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
 DUAC, BENZOYL PEROXIDE

STIEFEL GSK

* STIEFEL A GSK CO
 VELTIN, CLINDAMYCIN PHOSPHATE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
 EXTINA, KETOCONAZOLE
 FABIOR, TAZAROTENE
 OLUX, CLOBETASOL PROPIONATE
 SORIATANE, ACITRETIN
 SORILUX, CALCIPOTRIENE
 VERDESO, DESONIDE
 VUSION, MICONAZOLE NITRATE

STRIDES

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRIDES INC
NEVIRAPINE, NEVIRAPINE

STRIDES ARCOLAB

* STRIDES ARCOLAB LIMITED
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

STRIDES ARCOLAB LTD

* STRIDES ARCOLAB LTD
ACARBOSE, ACARBOSE
ADENOSINE, ADENOSINE
CEFTRIAZONE, CEFTRIAZONE SODIUM
ERGOCALCIFEROL, ERGOCALCIFEROL
ETOMIDATE, ETOMIDATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
MELOXICAM, MELOXICAM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SUCAMPO PHARMS

* SUCAMPO PHARMACEUTICALS INC
AMITIZA, LUBIPROSTONE
RESCULA, UNOPROSTONE ISOPROPYL

SUMMERS

* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ERGOCALCIFEROL, ERGOCALCIFEROL
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LITHIUM CARBONATE, LITHIUM CARBONATE
NIMODIPINE, NIMODIPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

SUN PHARM INDS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES LTD**

AZITHROMYCIN, AZITHROMYCIN
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 GABAPENTIN, GABAPENTIN
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 NARATRIPTAN, NARATRIPTAN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RILUZOLE, RILUZOLE
 RISPERIDONE, RISPERIDONE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

*** SUN PHARMACEUTICAL INDUSTRIES LTD.**

ANASTROZOLE, ANASTROZOLE

SUN PHARMA GLOBAL*** SUN PHARMA GLOBAL FZE**

AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOCEFREZ, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 FINASTERIDE, FINASTERIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

*** SUN PHARMA GLOBAL INC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIFOSTINE, AMIFOSTINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMA GLOBAL INC
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 VECURONIUM BROMIDE, VECURONIUM BROMIDE

SUNEVA MEDCL

* SUNEVA MEDICAL INC
 TRETINOIN, TRETINOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
 BROVANA, ARFORMOTEROL TARTRATE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
 APTIOM, ESLICARBAZEPINE ACETATE
 LATUDA, LURASIDONE HYDROCHLORIDE
 LUNESTA, ESZOPICLONE

SUNSHINE LAKE

* SUNSHINE LAKE PHARMA CO LTD
 ZIDOVUDINE, ZIDOVUDINE

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
 PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
 OXTELLAR XR, OXCARBAZEPINE
 TROKENDI XR, TOPIRAMATE

SUVEN LIFE

* SUVEN LIFE SCIENCES LTD
 MALATHION, MALATHION

SVADS HOLDINGS SA

* SVADS HOLDINGS SA
 IBUPROFEN, IBUPROFEN (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SVC PHARMA

* SVC PHARMA LP
 DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
 ORFADIN, NITISINONE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** T ******MEDICINES CO**

* THE MEDICINES CO
 ANGIOMAX, BIVALIRUDIN
 CLEVIPREX, CLEVIDIPINE

RITEDOSE CORP

* THE RITEDOSE CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

TAKEDA GMBH

* TAKEDA GMBH
 ALVESCO, CICLESONIDE
 OMNARIS, CICLESONIDE
 ZETONNA, CICLESONIDE

TAKEDA PHARMS

* TAKEDA PHARMACEUTICALS NORTH AMERICA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TAKEDA PHARMACEUTICALS NORTH AMERICA INC
DEXILANT, DEXLANSOPRAZOLE

TAKEDA PHARMS USA

- * TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
BRINTELLIX, VORTIOXETINE HYDROBROMIDE
COLCRYS, COLCHICINE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSEN, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
ULORIC, FEBUXOSTAT

TALON THERAP

- * TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

- * TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

- * TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN
- * TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TARO PHARMACEUTICALS INC
WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLO-PRED, PREDNISOLONE ACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCI, MUPIROCI
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE
- * TARO PHARMACEUTICALS, INC.
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
TOPICORT, DESOXIMETASONE

TARO PHARM INDS

- * TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

TARO PHARMS IRELAND

- * TARO PHARMACEUTICALS IRELAND LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICALS IRELAND LTD
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 OVIDE, MALATHION
 TOPICORT, DESOXIMETASONE

TEDOR PHARM

* TEDOR PHARMA INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEDOR PHARMA INC

* TEDOR PHARMA INC
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
 LIDODERM, LIDOCAINE

TEVA

* TEVA NEUROSCIENCE INC
 AZILECT, RASAGILINE MESYLATE

* TEVA PHARMACEUTICALS USA INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BETA-VAL, BETAMETHASONE VALERATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BICALUTAMIDE, BICALUTAMIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CEFACLOL, CEFACLOL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 ONDANSETRON, ONDANSETRON
 ORAP, PIMOZIDE
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 PURINETHOL, MERCAPTOPURINE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
 LOSEASONIQUE, ETHINYL ESTRADIOL
 MIRCETTE, DESOGESTREL
 NORDETTE-28, ETHINYL ESTRADIOL
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAN B, LEVONORGESTREL
 PLAN B, LEVONORGESTREL (OTC)
 PROAIR HFA, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 CALCITRIOL, CALCITRIOL

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
 ANASTROZOLE, ANASTROZOLE
 AZITHROMYCIN, AZITHROMYCIN
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEBENDAZOLE, MEBENDAZOLE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA**

TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE
 THEOPHYLLINE, THEOPHYLLINE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZALEPLON, ZALEPLON

TEVA PHARMS USA*** TEVA PHARMACEUTICALS USA**

ACITRETIN, ACITRETIN
 ADENOSINE, ADENOSINE
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CARBOPLATIN, CARBOPLATIN
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CLARAVIS, ISOTRETINOIN
 COPAXONE, GLATIRAMER ACETATE
 CYTOSAR-U, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESVENLAFAXINE FUMARATE, DESVENLAFAXINE FUMARATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 ETOPOSIDE, ETOPOSIDE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESNA, MESNA
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RAMELTEON, RAMELTEON
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN

* TEVA PHARMACEUTICALS USA INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CAPECITABINE, CAPECITABINE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 IMIQUIMOD, IMIQUIMOD
 METRONIDAZOLE, METRONIDAZOLE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
 ADASUVE, LOXAPINE

TEVA WOMENS

* TEVA WOMENS HEALTH INC
 ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
 PARAGARD T 380A, COPPER
 PREFEST, ESTRADIOL
 REVIA, NALTREXONE HYDROCHLORIDE
 ZEBETA, BISOPROLOL FUMARATE
 ZIAC, BISOPROLOL FUMARATE

THE PHARMA NETWORK

* THE PHARMA NETWORK LLC
 BENZONATATE, BENZONATATE

THE PHARMANETWORK

* THE PHARMANETWORK LLC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
 THERMAZENE, SILVER SULFADIAZINE

THERAKOS

* THERAKOS INC
 UVADEX, METHOXSALEN

THERAVANCE INC

* THERAVANCE INC
 VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

* THREE RIVERS PHARMACEUTICALS LLC
 ANASTROZOLE, ANASTROZOLE
 RIBASPHERE, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

TOLMAR

* TOLMAR INC
 ADAPALENE, ADAPALENE
 ATRIDOX, DOXYCYCLINE HYCLATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TOLMAR INC
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
 ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TORRENT PHARM

* TORRENT PHARMA INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
 LEVOFLOXACIN, LEVOFLOXACIN

* TORRENT PHARMACEUTICALS LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* TORRENT PHARMACEUTICALS LTD.
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 OLANZAPINE, OLANZAPINE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OLANZAPINE, OLANZAPINE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TRIS PHARMA INC

* TRIS PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TRIS PHARMA INC**

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 KARBINAL ER, CARBINOXAMINE MALEATE
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TWI PHARMS INC

*** TWI PHARMACEUTICALS INC**
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ******UCB INC**

*** UCB INC**
 KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 LORTAB, ACETAMINOPHEN
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEUPRO, ROTIGOTINE
 NIRAVAM, ALPRAZOLAM
 PARCOPA, CARBIDOPA
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 UNIRETIC, HYDROCHLOROTHIAZIDE
 UNIVASC, MOEXIPRIL HYDROCHLORIDE
 VIMPAT, LACOSAMIDE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
 ZAROXOLYN, METOLAZONE

UCLA BIOMEDICAL

*** UCLA BIOMEDICAL CYCLOTRON**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCYCLYD

*** UCYCLYD PHARMA INC**
 AMMONUL, SODIUM BENZOATE

UNICHEM

*** UNICHEM LABORATORIES LTD**
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MELOXICAM, MELOXICAM
 ZALEPLON, ZALEPLON

UNICHEM LABS LTD

*** UNICHEM LABORATORIES LIMITED**
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
*** UNICHEM LABORATORIES LTD**
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 LAMOTRIGINE, LAMOTRIGINE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)

*** UNICHEM PHARMACEUTICALS (USA) INC**
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******UNIQUE PHARM LABS**

- * UNIQUE PHARMACEUTICAL LABORATORIES
 - ATENOLOL, ATENOLOL
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - FLUCONAZOLE, FLUCONAZOLE
 - TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

- * UNITED BIOMEDICAL INC
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

- * UNITED GUARDIAN INC
 - RENACIDIN, CITRIC ACID

UNITED THERAP

- * UNITED THERAPEUTICS CORP
 - ORENITRAM, TREPROSTINIL
 - REMODULIN, TREPROSTINIL
 - TYVASO, TREPROSTINIL

UNIV TX MD ANDERSON

- * UNIV TEXAS MD ANDERSON CANCER CENTER
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH

- * UPSHER SMITH LABORATORIES INC
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DIVIGEL, ESTRADIOL
 - FORTICAL, CALCITONIN SALMON RECOMBINANT
 - LAMOTRIGINE, LAMOTRIGINE
 - LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NIACOR, NIACIN
 - NYSTATIN, NYSTATIN
 - ORVATEN, MIDODRINE HYDROCHLORIDE
 - OXANDROLONE, OXANDROLONE
 - PACERONE, AMIODARONE HYDROCHLORIDE
 - PENTOXIL, PENTOXIFYLLINE
 - PREVALITE, CHOLESTYRAMINE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - SORINE, SOTALOL HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - ZALEPLON, ZALEPLON

UPSHER SMITH LABS

- * UPSHER SMITH LABORATORIES INC
 - KLOR-CON M10, POTASSIUM CHLORIDE
 - KLOR-CON M15, POTASSIUM CHLORIDE
 - KLOR-CON M20, POTASSIUM CHLORIDE

UPSHER-SMITH LABS

- * UPSHER-SMITH LABORATORIES INC
 - KLOR-CON, POTASSIUM CHLORIDE

US PHARMS HOLDINGS I

- * US PHARMACEUTICALS HOLDINGS I LLC
 - LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 - LOPRESSOR, METOPROLOL TARTRATE
 - LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 - LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 - METHERGINE, METHYLERGONOVINE MALEATE
 - PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

- * US WORLDMEDS LLC
 - APOKYN, APOMORPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* US WORLDMEDS LLC
DANTROLENE SODIUM, DANTROLENE SODIUM

USL PHARMA

* USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**** V ******VALEANT**

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MOTOFEN, ATROPINE SULFATE
MYSOLINE, PRIMIDONE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
APLENZIN, BUPROPION HYDROBROMIDE
BENZACLIN, BENZOYL PEROXIDE
CARAC, FLUOROURACIL
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
ELIDEL, PIMECROLIMUS
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
NORITATE, METRONIDAZOLE
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE
XERESE, ACYCLOVIR
ZOVIRAX, ACYCLOVIR

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
TIAZAC, DILTIAZEM HYDROCHLORIDE
ULTRAM ER, TRAMADOL HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

- * VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
BENZAMYCIN PAK, BENZOYL PEROXIDE
ERTACZO, SERTACONAZOLE NITRATE
GRIFULVIN V, GRISEOFULVIN, MICROSIZE
TARGRETIN, BEXAROTENE

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
8-MOP, METHOXSALEN
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE

VALEANT PHARMS INC

- * VALEANT PHARMACEUTICALS INTERNATIONAL INC
VISUDYNE, VERTEPORFIN

VALEANT PHARMS LLC

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CAPITAL AND CODEINE, ACETAMINOPHEN
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALIDUS PHARMS

- * VALIDUS PHARMACEUTICALS LLC
ROCALTRON, CALCITRIOL

VALIDUS PHARMS INC

- * VALIDUS PHARMACEUTICALS INC
EQUETRO, CARBAMAZEPINE
MARPLAN, ISOCARBOXAZID

VANSEN PHARMA

- * VANSSEN PHARMA
SPECTRACEF, CEFDITOREN PIVOXIL

VEROSCIENCE

- * VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERSAPHARM

- * VERSAPHARM INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
ETHOSUXIMIDE, ETHOSUXIMIDE
RIFAMPIN, RIFAMPIN

VERSAPHARM INC

- * VERSAPHARM INC
RIFAMPIN, RIFAMPIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

- * VERSAPHARM INCORPORATED
TRANEXAMIC ACID, TRANEXAMIC ACID

VERTEX PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VERTEX PHARMACEUTICALS INC
INCIVEK, TELAPREVIR
KALYDECO, IVACAFTOR

VESTIQ PHARMS

* VESTIQ PHARMACEUTICALS INC
ORAVIG, MICONAZOLE
ZUPLLENZ, ONDANSETRON

VICURON

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE

* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
DISULFIRAM, DISULFIRAM
GILDAGIA, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******* VINTAGE PHARMACEUTICALS**

GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 LEVETIRACETAM, LEVETIRACETAM
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

*** VINTAGE PHARMACEUTICALS INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CARISOPRODOL, CARISOPRODOL
 CLONAZEPAM, CLONAZEPAM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SULFASALAZINE, SULFASALAZINE
 TORSEMIDE, TORSEMIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

VINTAGE PHARMS LLC*** VINTAGE PHARMACEUTICALS LLC**

CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 EMOQUETTE, DESOGESTREL
 FELODIPINE, FELODIPINE
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYZILRA, ETHINYL ESTRADIOL
 ORSYTHIA, ETHINYL ESTRADIOL
 PERCOCET, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

- * VINTAGE PHARMACEUTICALS LLC
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
ZYDONE, ACETAMINOPHEN

VIROPHARMA

- * VIROPHARMA INC
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

VIRTUS PHARM

- * VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE

VISTA PHARMS

- * VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

- * VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN

VIVIMED LABS

- * VIVIMED LABS ALATHUR PRIVATE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

VIVUS

- * VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE
STENDRA, AVANAFIL

**** W ******WARNER CHILCOTT**

- * WARNER CHILCOTT CO LLC
LO MINASTRIN FE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
- * WARNER CHILCOTT INC
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL

WARNER CHILCOTT LLC

- * WARNER CHILCOTT CO LLC
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
CHOLEDYL SA, OXTRIPHYLLINE
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMTRACE, ESTRADIOL ACETATE
LO LOESTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
OVCON-35, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE

WARNER CHILCOTT US

- * WARNER CHILCOTT US LLC
ESTRACE, ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WARNER IRELAND**

* WARNER CHILCOTT IRELAND LTD
FEMRING, ESTRADIOL ACETATE

WATSON LABS

* WATSON LABORATORIES
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ANASTROZOLE, ANASTROZOLE
FOLIC ACID, FOLIC ACID
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CABERGOLINE, CABERGOLINE
CAPTOPRIL, CAPTOPRIL
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COL-PROBENECID, COLCHICINE
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ESTAZOLAM, ESTAZOLAM
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
FAMOTIDINE, FAMOTIDINE (OTC)
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISRADIPINE, ISRADIPINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NATEGLINIDE, NATEGLINIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NIZATIDINE, NIZATIDINE
 NORCO, ACETAMINOPHEN
 NORETHIN 1/35E-21, ETHINYL ESTRADIOL
 NORETHIN 1/35E-28, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXAZEPAM, OXAZEPAM
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PIROXICAM, PIROXICAM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISON, PREDNISON
 PRIMIDONE, PRIMIDONE
 PROBENECID, PROBENECID
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RAPAFLO, SILODOSIN
 RISPERIDONE, RISPERIDONE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANDOLAPRIL, TRANDOLAPRIL
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRELSTAR, TRIPTORELIN PAMOATE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIVORA-28, ETHINYL ESTRADIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL

*** WATSON LABS INC**

LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)*** WATSON LABORATORIES INC**

INFED, IRON DEXTRAN
 NOR-QD, NORETHINDRONE
 OXYTROL, OXYBUTYNIN
 PROGESTERONE, PROGESTERONE

WATSON LABS FLORIDA*** WATSON LABORATORIES INC FLORIDA**

ALPRAZOLAM, ALPRAZOLAM
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARTIA XT, DILTIAZEM HYDROCHLORIDE
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CLARITHROMYCIN, CLARITHROMYCIN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 KETOPROFEN, KETOPROFEN
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIRTAZAPINE, MIRTAZAPINE
 OMEPRAZOLE, OMEPRAZOLE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE

WATSON LABS INC*** WATSON LABORATORIES INC**

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

AMMONIUM LACTATE, AMMONIUM LACTATE
 ARMODAFINIL, ARMODAFINIL
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CICLOPIROX, CICLOPIROX
 CYCLOSPORINE, CYCLOSPORINE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FIORINAL W/CODEINE, ASPIRIN
 FIORINAL, ASPIRIN
 GELNIQUE 3%, OXYBUTYNIN
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 KADIAN, MORPHINE SULFATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE, LIDOCAINE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 URSODIOL, URSODIOL
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC FL*** WATSON LABORATORIES INC FLORIDA**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FLUTAMIDE, FLUTAMIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

WATSON PHARMS*** WATSON PHARMACEUTICALS**

TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 TENUATE, DIETHYLPROPION HYDROCHLORIDE

*** WATSON PHARMACEUTICALS INC**

ACTIGALL, URSODIOL
 CONDYLOX, PODOFILOX
 CORDRAN, FLURANDRENOLIDE
 FIORICET, ACETAMINOPHEN

WEILL MEDCL COLL*** WEILL MEDICAL COLLEGE CORNELL UNIV**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WELLSPRING PHARM*** WELLSPRING PHARMACEUTICAL CORP**

DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
 DUVOID, BETHANECHOL CHLORIDE
 DYRENIUM, TRIAMTERENE

WEST WARD*** WEST WARD INC**

ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE

*** WEST WARD PHARMACEUTICAL CORP**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WEST WARD PHARMACEUTICAL CORP**

CAPTOPRIL, CAPTOPRIL
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CORTISONE ACETATE, CORTISONE ACETATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FOLIC ACID, FOLIC ACID
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 PRIMIDONE, PRIMIDONE
 ZALEPLON, ZALEPLON

WEST WARD PHARM CORP*** WEST WARD PHARMACEUTICAL CORP**

NAPROXEN, NAPROXEN
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

WEST WARD PHARMS*** WEST WARD PHARMACEUTICALS CORP**

RISPERIDONE, RISPERIDONE

WEST-WARD PHARM CORP*** WEST-WARD PHARMACEUTICAL CORP**

CEFOTETAN, CEFOTETAN DISODIUM
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE

WI MEDCL CYCLOTRON*** WISCONSIN MEDICAL CYCLOTRON LLC**

FLUDEOXYGLUCOSE F-18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC*** WILSHIRE PHARMACEUTICALS INC**

LAMOTRIGINE, LAMOTRIGINE

WOCKHARDT*** WOCKHARDT AMERICAS INC**

CAPTOPRIL, CAPTOPRIL
 FAMOTIDINE, FAMOTIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

*** WOCKHARDT EU OPERATIONS (SWISS) AG**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WOCKHARDT EU OPERATIONS (SWISS) AG
 - MEGESTROL ACETATE, MEGESTROL ACETATE
 - METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NYSTATIN, NYSTATIN
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 - PHENYTOIN, PHENYTOIN
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 - PREDNISOLONE, PREDNISOLONE
 - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 - PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 - PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 - SELENIUM SULFIDE, SELENIUM SULFIDE
 - TRETINOIN, TRETINOIN
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - VALPROIC ACID, VALPROIC ACID
- * WOCKHARDT LTD
 - ADENOSINE, ADENOSINE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - AZITHROMYCIN, AZITHROMYCIN
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 - CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 - CEFOTAXIME, CEFOTAXIME SODIUM
 - CEFPROZIL, CEFPROZIL
 - CEFTAZIDIME, CEFTAZIDIME
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CEFUROXIME AXETIL, CEFUROXIME AXETIL
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - FUROSEMIDE, FUROSEMIDE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN, LEVOFLOXACIN
 - LISINAPRIL, LISINAPRIL
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - NIACIN, NIACIN
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 - RISPERIDONE, RISPERIDONE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - TIMOLOL MALEATE, TIMOLOL MALEATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 - ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WOCKHARDT EU OPERATN**

- * WOCKHARDT EU OPERATIONS SWISS AG
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
DEXAMETHASONE, DEXAMETHASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

WOCKHARDT LTD

- * WOCKHARDT LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ENTACAPONE, ENTACAPONE
FELODIPINE, FELODIPINE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

- * WOCKHARDT USA INC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
- * WOCKHARDT USA LLC
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LANSOPRAZOLE, LANSOPRAZOLE
TOPIRAMATE, TOPIRAMATE

WORLD GEN

- * WORLD GEN LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

WRASER PHARMS

- * WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WYETH PHARMS

- * WYETH PHARMACEUTICALS INC SUB PFIZER INC
LO/OVRAL-28, ETHINYL ESTRADIOL

WYETH PHARMS INC

- * WYETH PHARMACEUTICALS INC
BOSULIF, BOSUTINIB MONOHYDRATE
CORDARONE, AMIODARONE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

WYETH PHARMS PFIZER

- * WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
DUAVEE, BAZEDOXIFENE ACETATE

**** X ******X GEN PHARMS**

- * X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ****

* X GEN PHARMACEUTICALS INC
 AMPHOTERICIN B, AMPHOTERICIN B
 BACIIM, BACITRACIN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 HYDRO-RX, HYDROCORTISONE
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
 LEVETIRACETAM, LEVETIRACETAM
 LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
 NEO-FRADIN, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NYSTATIN, NYSTATIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC

* X-GEN PHARMACEUTICALS INC
 TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

XENOPORT INC

* XENOPORT INC
 HORIZANT, GABAPENTIN ENACARBIL

XOMA

* XOMA (US) LLC
 ACEON, PERINDOPRIL ERBUMINE

XSPIRE

* XSPIRE LLC
 NALFON, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**** Y ******YUNG SHIN PHARM**

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
 CEFACLOX, CEFACLOX
 CEPHALEXIN, CEPHALEXIN

**** Z ******ZACH SYSTEMS**

* ZACH SYSTEMS SPA
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

ZAMBON SPA

* ZAMBON SPA ITALY
 MONUROL, FOSFOMYCIN TROMETHAMINE

ZOGENIX INC

* ZOGENIX INC
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
 ZOHYDRO ER, HYDROCODONE BITARTRATE

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
 LANSOPRAZOLE, LANSOPRAZOLE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******* ZYDUS PHARMACEUTICALS USA INC**

AZATHIOPRINE, AZATHIOPRINE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 LAMOTRIGINE, LAMOTRIGINE
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC*** ZYDUS PHARMACEUTICALS USA INC**

ACETAZOLAMIDE, ACETAZOLAMIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 BICALUTAMIDE, BICALUTAMIDE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 CARVEDILOL, CARVEDILOL
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 OMEPRAZOLE, OMEPRAZOLE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL
AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO

OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
SYSTEM, EXTENDED RELEASE
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, DELAYED RELEASE, ORALLY
DISINTEGRATING
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
FOR RX COMPOUNDING	NASAL
IMPLANTATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTRA-ANAL	ORAL-28
INTRACRANIAL	OTIC
INTRAMUSCULAR	PERFUSION, CARDIAC
INTRAOCULAR	PERIODONTAL
INTRAPERITONEAL	RECTAL
INTRAPLEURAL	SPINAL
INTRATHECAL	SUBCUTANEOUS
INTRATRACHEAL	SUBLINGUAL
INTRAUTERINE	TOPICAL
INTRAVENOUS	TRANSDERMAL
INTRAVESICAL	TRANSMUCOSAL
INTRAVITREAL	URETHRAL
IONTOPHORESIS	VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOURLY
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be

made effective for three years from the date of approval of the original supplement.

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book Query](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001	6294540	May 14, 2018	DS DP U-65			
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001	6294540	May 14, 2018	DS DP U-65			
	6641843	Feb 04, 2019	DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	5905082	May 18, 2016	DS DP			
	6294540	May 14, 2018	DS DP U-257			
	6417191	Mar 28, 2016	DP U-257			
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE</u>						
A 202912 001					PC	Jun 15, 2014
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205 001	5905082	May 18, 2016	DS DP U-248			
	6294540	May 14, 2018	DS DP U-65			
	6417191	Mar 28, 2016	DP U-248			
<u>ABARELIX - PLENAXIS</u>						
N 021320 001	5843901	Dec 01, 2015	DS DP			
	5968895	Dec 11, 2016	DP			
	6180608	Dec 11, 2016	DP U-549			
	6423686	Jun 07, 2015	DS			
	6455499	Jun 07, 2015	U-549			
	6699833	Dec 11, 2016	DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 020379 001	5604213	Dec 13, 2016	DS DP U-1126		I-663	Dec 10, 2015
	5604213	Dec 13, 2016	DS DP U-1314		NCE	Apr 28, 2016
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP		NP	Nov 02, 2013
	6992218	Jun 06, 2021	DP			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802 001	5972916	Jul 14, 2017	U-296			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 020450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
<u>ACYCLOVIR - SITAVIG</u>						
N 020379 001	8592434	Dec 09, 2029	DP U-1460		NP	Apr 12, 2016
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2017	DP U-1006			
	7223387	Feb 28, 2021	DP U-1006			
	RE39264	Feb 02, 2016	DP U-1006			
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023	U-1078			
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	7820186	Nov 23, 2025	DP		NPP	Feb 01, 2016
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
	8445543	Jul 12, 2027	U-1078			
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051 001					PC	Mar 02, 2014
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N 021449 001	5663159	Sep 02, 2014	DS DP			
	6451340	Jul 23, 2018	DS DP U-470			
<u>ADENOSINE - ADENOSCAN</u>						
N 020059 001	5731296	Mar 24, 2015	U-221			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 001	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 002	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001	6723303	Apr 20, 2021	DP		M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503 001	5605674	Feb 25, 2014				
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
<u>ALBUTEROL SULFATE - ACCUNEER</u>						
N 020949 001	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEER</u>						
N 020949 002	6702997	Dec 28, 2021	U-558			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6558651	Dec 19, 2016	DP	U-716		
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-716		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	5605674	Feb 25, 2014	DP			
	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N 020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950 001	6632842	Dec 28, 2021		U-532		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	5472143	Sep 29, 2013	DP		NP	Oct 07, 2014
	5662271	Sep 02, 2014	DP			
	5911851	Sep 29, 2013	DP			
	5964416	Oct 04, 2016	DP			
	6007676	Sep 29, 2013	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6503362	Sep 29, 2013	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	5468743	Apr 20, 2016	DS DP		NCE	Jul 28, 2015
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N 021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015		U-1008		
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP	U-1008		
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575 001	5462932	May 17, 2014				
	5994329	Jul 17, 2018		Y		
	6015801	Jul 17, 2018		Y		
	6225294	Jul 17, 2018		Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762 001	5994329	Jul 17, 2018	U-647	Y		
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287 001	6149940	Aug 22, 2017			M-97 PED	Dec 15, 2013 Jun 15, 2014
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217 001	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217 002	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALITRETINOIN - PANRETIN</u>						
N 020886 001	5932622	Aug 03, 2016	U-562			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 001	5565447	May 07, 2015	DS DP U-969			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 002	5565447	May 07, 2015	DS DP U-969			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 001	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 002	6284770	Oct 05, 2018	U-405			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - MUSE</u>						
N 020700 001	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 002	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 003	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 004	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 001	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 002	5716338	Feb 10, 2015	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	5250542	Mar 29, 2016	DS DP U-878		M-128	Oct 18, 2016
	5434171	Dec 08, 2013	DS DP U-878			
	6469030	Nov 29, 2020	U-879			
	8112290	Jul 31, 2030	DP U-1443			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	5703017	Dec 30, 2014	DS		ODE	Jun 15, 2014
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	5703017	Dec 30, 2014	DS		ODE	Jun 15, 2014
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 001	5994409	Dec 08, 2017	U-305			
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 002	5994409	Dec 08, 2017	U-305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	5079262	Sep 30, 2013	U-289			
	5954703	Oct 31, 2017	U-289			
	6709446	May 01, 2018	U-289			
	7723910	Jun 17, 2019	U-289			
	8216289	May 01, 2018	U-289			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 001	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 001	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 002	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 003	6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 001	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 002	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 003	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 004	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 005	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 006	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 007	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 008	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 009	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 010	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 011	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 002	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 003	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 004	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 005	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 006	6162802	Dec 19, 2017	DS DP U-185			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 007	6162802	Dec 19, 2017	DS DP U-185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 001	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 002	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 003	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 004	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 005	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 001	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 002	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 003	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 004	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N 022401 001	5591762	Jan 07, 2014	DS DP U-3			
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N 022401 002	5591762	Jan 07, 2014	DS DP U-3			
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N 022401 003	5591762	Jan 07, 2014	DS DP U-3			
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N 022401 004	5591762	Jan 07, 2014	DS DP U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 002	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 003	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 004	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 005	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
	8299052	May 07, 2027	U-1304			
	8357394	Dec 08, 2026	DP			
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785 001	6746692	Apr 04, 2020	DP			
	6783773	Apr 04, 2020	DP			
	6878386	Apr 04, 2020	U-926			
	7217430	Apr 04, 2020	DP U-926			
	7250176	Apr 04, 2020	U-926			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522 007	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522 008	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522 009	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522 010	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522 011	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522 012	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522 013	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303 001	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303 002	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303 003	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303 004	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303 005	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303 006	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724 001	5616334	Apr 01, 2014	DS			
	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N 050740 001	5874104	Feb 23, 2016	DP U-922			
	5965156	Oct 12, 2016	DP U-922			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014	U-257			
	5723490	Mar 03, 2015	U-257			
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 002	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014	U-257			
	5723490	Mar 03, 2015	U-257			
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021039 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014	U-257			
	5723490	Mar 03, 2015	U-257			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>APIXABAN - ELIQUIS</u>						
N 02155 001	6413980	Dec 22, 2019	DS DP U-1200		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APIXABAN - ELIQUIS</u>						
N 02155 002	6413980	Dec 22, 2019	DS DP U-1200		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549 001	5538982	Jul 23, 2013	U-745			
	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 002	5538982	Jul 23, 2013	U-745			
	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 003	5538982	Jul 23, 2013	U-745			
	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6589508	Apr 03, 2014	U-793			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021	U-793			
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ARGATROBAN - ACOVA</u>						
N 020883 001	5214052	Jun 30, 2014				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	6977257	Apr 24, 2022	DS DP			
	7053092	Jan 28, 2022		U-839		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	7053092	Jan 28, 2022				
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	5006528	Oct 20, 2014	DS DP U-761			
	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	5006528	Oct 20, 2014	DS DP U-761			
	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-763		I-633	Feb 16, 2014
	7115587	Jul 21, 2024	DS DP U-764			
	7550445	Jul 21, 2024	DP			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N 022268 001	5677331	Oct 14, 2014	DP U-977		NCE ODE	Apr 07, 2014 Apr 07, 2016
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		I-628	Sep 03, 2013
	7741358	Apr 06, 2026	DS DP U-1064		I-629 NCE	Sep 03, 2013 Aug 13, 2014
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		I-628	Sep 03, 2013
	7741358	Apr 06, 2026	DS DP U-1064		I-629 NCE	Sep 03, 2013 Aug 13, 2014
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOLX</u>						
N 020884 001	6015577	Jan 18, 2017	U-302			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 001	5622985	Apr 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 002	5622985	Apr 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 003	5622985	Apr 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 004	5622985	Apr 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 005	5622985	Apr 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N 021387 006	5622985	Apr 22, 2014	U-335			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 001	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 002	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 003	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 004	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 005	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 006	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 007	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 008	5658590	Nov 26, 2016	U-494			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 003	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 004	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATOVAQUONE - MEPRON</u>						
N 020500 001	6649659	Jul 10, 2016	DS DP U-69			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE</u>						
N 021078 001	5998449	Nov 25, 2013	U-990			
	6166046	Nov 25, 2013	U-406			
	6291488	Nov 25, 2013	U-406			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE PEDIATRIC</u>						
N 021078 002	5998449	Nov 25, 2013	U-990			
	6166046	Nov 25, 2013				
	6291488	Nov 25, 2013	U-406			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - ANTHELIOS SX</u>						
N 021502 001	5587150	Dec 24, 2013	DP U-752			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N 021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NC	May 01, 2015
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	5583141	Dec 10, 2013	DS DP U-3		NC	Dec 20, 2014
	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	5583141	Dec 10, 2013	DS DP U-3		NC	Dec 20, 2014
	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZMAX</u>						
N 050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
<u>AZITHROMYCIN - AZASITE</u>						
N 050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
	8399496	Dec 20, 2021	DP U-1377			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610 001	7452872	Aug 24, 2026	U-141		ODE	Dec 20, 2013
	7625884	Aug 24, 2026	U-141		PED	Jun 20, 2014
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594			
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5776432	Jul 07, 2015				
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5776432	Jul 07, 2015				
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		NCE	Dec 28, 2017
					ODE	Dec 28, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP		ODE	Oct 31, 2015
	8436190*PED	Apr 26, 2031			ODE	Mar 20, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8609863	Jan 12, 2026	DP		PED	Sep 20, 2013
	8609863*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP		ODE	Mar 20, 2015
	8436190*PED	Apr 26, 2031			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	Sep 20, 2013
	8609863	Jan 12, 2026	DP		PED	May 01, 2016
	8609863*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Oct 31, 2015
	8344006*PED	Mar 23, 2030			ODE	Mar 20, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Oct 31, 2015
	8344006*PED	Mar 23, 2030			ODE	Mar 20, 2015
	8445524	Mar 26, 2029	DS		PED	May 01, 2016
	8445524*PED	Sep 26, 2029			PED	Sep 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
N 050741 001	5466446	Feb 16, 2014	DS DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	5733886	Mar 31, 2015	DP U-124			
	8288434	Aug 05, 2029	DP U-124			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129 001	5858383	Aug 11, 2017	U-970		NCE	Apr 09, 2014
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP		NCE	Sep 08, 2014
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	5447926	Apr 13, 2016	DS DP U-80		NCE	May 28, 2014
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852 001	5763426	Jun 09, 2015	DS DP			
	6753013	Jan 27, 2020	DP U-88			
	6753013	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88		I-659	Oct 17, 2015
	6753013	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N 020934 001	6126920	Mar 01, 2016	U-484			
	7078058	May 24, 2017	DP			
<u>BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE - BETOPTIC PILO</u>						
N 020619 001	5635172	Jun 03, 2014	U-191			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001	5780676	Jul 14, 2015	U-509			
	5962731	Oct 05, 2016	U-475			
<u>BEXAROTENE - TARGRETIN</u>						
N 021056 001	5780676	Jul 14, 2015	U-510			
	5962731	Oct 05, 2016				
<u>BIMATOPROST - LUMIGAN</u>						
N 021275 001	5688819	Aug 19, 2014	U-446			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	5688819	Aug 19, 2014	U-1081		NP	Aug 31, 2013
	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025	U-1295			
	8309605	Mar 16, 2025	U-1293			
	8309605	Mar 16, 2025	U-1294			
	8338479	Mar 16, 2025	DP U-1295			
	8524777	Mar 16, 2025	U-1235			
	8586630	Mar 16, 2025	U-1458			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939			
	7388029	Jan 21, 2022	U-938			
	8038988	Aug 25, 2023	DS DP U-1208			
	8101161	May 25, 2024	U-1217			
	8101161	May 25, 2024	U-1218			
	8263054	Aug 25, 2023	U-1277			
	8541466	Jan 21, 2022	U-1217			
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551 003	7291324	Oct 22, 2022	U-837		NP	Jul 16, 2013
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786 001	6350468	Dec 14, 2018	U-932			
	6350468	Dec 14, 2018	U-956			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873 001	5196404	Dec 15, 2014	DS DP U-1040			
	5196404	Dec 15, 2014	DS DP U-1232			
	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	7772178	Nov 11, 2027	DP U-1128		M-126	Feb 27, 2016
	8119602	Mar 17, 2027	U-1233		NCE	May 13, 2016
	RE43298	Feb 22, 2022	DS DP U-1128		NPP	Feb 13, 2016
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DP		NR	Jan 23, 2015
	6083903	Oct 28, 2014	DP U-515			
	6297217	Oct 28, 2014	U-515			
	6297217	Oct 28, 2014	U-884			
	6297217	Oct 28, 2014	U-885			
	6617317	Oct 28, 2014	DS DP			
	6713446	Jan 25, 2022	DP			
	6747150	Oct 28, 2014	DP			
	6958319	Jan 25, 2022	DP			
	7119080	Oct 28, 2014	DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001	5292740	Nov 20, 2015				
<u>BOSENTAN - TRACLEER</u>						
N 021290 002	5292740	Nov 20, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	6562873	Jul 10, 2021				
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
<u>BRIMONIDINE TARTRATE - QOLIANA</u>						
N 021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	6562873	Jul 10, 2021	DP			
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7323463	Jan 19, 2023	DP	Y		
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - BROMDAY</u>						
N 021664 002					NP	Oct 16, 2013
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015	U-976			
	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 001	6291445	Apr 29, 2017		Y		
	6686346	Apr 29, 2017	DP U-557	Y		
	6986904	Apr 29, 2017	DP U-699	Y		
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 002	6291445	Apr 29, 2017				
	6686346	Apr 29, 2017	DP U-557			
	6986904	Apr 29, 2017	DP U-699			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 001	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 002	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 003	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001	5643602	Jul 01, 2014	U-655			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 001	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 002	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	6132766	Nov 16, 2013	DP		NP	Oct 28, 2014
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	6132766	Nov 16, 2013	DP		NP	Oct 28, 2014
	8182835	Sep 18, 2018	DP U-1246			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N 020358 001	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N 020358 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N 020358 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N 020358 004	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N 020711 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N 020711 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497 001	7674479	Jun 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUSULFAN - BUSULFEX</u>						
N 020954 001	5430057	Sep 30, 2013	U-263			
	5559148	Sep 30, 2013	U-264			
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N 019881 001	5993856	Nov 17, 2017	DP U-457			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5438072	Nov 22, 2013	DP		NCE	Jun 17, 2015
	5847170	Mar 26, 2016	DS DP			
	6331635	Mar 26, 2016	DS DP			
	6372780	Mar 26, 2016	U-1067			
	6387946	Mar 26, 2016	U-1067			
	7241907	Dec 10, 2025	DS			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
					ODE	Nov 29, 2019
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020554 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020611 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	May 26, 2026	DP U-1280		I-657	Sep 27, 2015
					NDF	Oct 06, 2013
<u>CALCITONIN SALMON - MIACALCIN</u>						
N 020313 002	5733569	Mar 31, 2015	U-227			
	5759565	Mar 31, 2015				
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	6440392	Feb 02, 2021	DP U-227			
	RE40812	Feb 02, 2021	DP			
	RE43580	Feb 02, 2021	DP U-227			
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 001	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 002	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
N 020958 001	5989588	Sep 30, 2015	U-349			
	6814978	Aug 26, 2021	DP			
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5994329	Jul 17, 2018	U-353			
	6015801	Jul 17, 2018	U-353			
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018	U-595			
	6465443	Aug 14, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193 001	7084130	Nov 29, 2021	DP U-891			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N 020838 001	5534534	Jul 09, 2013	DP			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N 020838 002	5534534	Jul 09, 2013	DP			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N 020838 003	5534534	Jul 09, 2013	DP			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N 020838 004	5534534	Jul 09, 2013	DP			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 001	5534534	Jul 09, 2013	DP			
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 002	5534534	Jul 09, 2013	DP			
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 003	5534534	Jul 09, 2013	DP			
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CAPECITABINE - XELODA</u>						
N 020896 001	5472949	Dec 14, 2013	DS DP U-271		M-131	Dec 10, 2016
	5472949*PED	Jun 14, 2014			PED	Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002	5472949	Dec 14, 2013	DS DP U-271		M-131	Dec 10, 2016
	5472949*PED	Jun 14, 2014			PED	Jun 10, 2017
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	6239180	Nov 06, 2016	DP		NCE ODE	Nov 16, 2014 Nov 16, 2016
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 001	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 002	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 003	5912013	Jun 15, 2016	U-277			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 001	5912013 6977253	Jun 15, 2016 May 19, 2024	DP U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 002	5912013 6977253	Jun 15, 2016 May 19, 2024	DP U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 003	5912013 6977253	Jun 15, 2016 May 19, 2024	DP U-693			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485 001	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485 002	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485 003	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485 004	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485 005	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485 006	5446194 6500867 6797732	Oct 19, 2013 Jun 29, 2020 Jun 29, 2020	DS DP U-219 DP			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 020714 001	7232818 7417042 7491704 7737112 8129346 8207125 8207126 8207127 8207297	Apr 14, 2025 Jun 07, 2026 Apr 14, 2025 Dec 07, 2027 Dec 25, 2026 Apr 14, 2025 Apr 14, 2025 Apr 14, 2025 Apr 14, 2025	DS DP DS DP U-1260 DP U-1260 DS DP DP U-1260 DS DP		NCE ODE	Jul 20, 2017 Jul 20, 2019
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					NCE ODE	Mar 18, 2015 Mar 18, 2017
<u>CARVEDILOL - COREG</u>						
N 020297 001	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 002	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 003	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 004	RE40000	Jun 07, 2015	U-233			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 001	6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 002	6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 003	6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 004	6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 001	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 002	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CEFEDITOREN PIVOXIL - SPECTRACEF</u>						
N 021222 001	5958915	Oct 14, 2016				
<u>CEFEDITOREN PIVOXIL - SPECTRACEF</u>						
N 021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N 050686 001	5599557	Feb 04, 2014	DP U-282			
	5599557	Feb 04, 2014	DP U-578			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N 050686 002	5599557	Feb 04, 2014	DP U-282			
	5599557	Feb 04, 2014	DP U-578			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	5466823	Nov 30, 2013	DS			
	5563165	Nov 30, 2013	DP			
	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	5466823	Nov 30, 2013	DS			
	5563165	Nov 30, 2013	DP			
	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	5466823	Nov 30, 2013	DS			
	5563165	Nov 30, 2013	DP			
	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	5466823	Nov 30, 2013	DS			
	5563165	Nov 30, 2013	DP			
	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 003	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 004	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 005	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 006	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150 002	6469009	Jul 13, 2019	DP U-295			
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022	U-295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CETRORELIX - CETROTIDE</u>						
N 021197 001	6319192	Apr 23, 2019	U-426			
	6863891	Feb 22, 2014	U-426			
	7605121	Feb 22, 2014	DP			
<u>CETRORELIX - CETROTIDE</u>						
N 021197 002	6319192	Apr 23, 2019	U-426			
	6863891	Feb 22, 2014	U-426			
	7605121	Feb 22, 2014	DP			
<u>CEVIMELINE HYDROCHLORIDE - EVOXAC</u>						
N 020989 002	5340821	Jul 07, 2013	U-309			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669 001	7066916	Feb 17, 2024	U-737			
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP U-1022			
	7717889	Feb 27, 2025	DP U-1022			
	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N 020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5772346	Apr 22, 2017	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003	D468424	Jan 07, 2017				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N 021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441 001	7863287	Feb 28, 2027	DP			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155 001				NCE W		Sep 12, 2017 Sep 12, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 002	7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 001	5767251	Jun 16, 2015				
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	5482934	Oct 24, 2017	DS DP U-557			
	6767901	Oct 21, 2020	DP			
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			
	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 02129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1357			
<u>CICLOPIROX - LOPROX</u>						
N 020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N 021159 001	7981909	Sep 16, 2017	U-1162			
	8227490	Sep 16, 2017	U-1256			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016	U-559		M-101	Feb 25, 2014
	6211244	Oct 23, 2015	DS DP U-560		ODE	Feb 25, 2018
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016			M-101	Feb 25, 2014
	6211244	Oct 23, 2015	DS DP U-560		ODE	Feb 25, 2018
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016	U-559		M-101	Feb 25, 2014
	6211244	Oct 23, 2015	DS DP U-560		ODE	Feb 25, 2018
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 001	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 002	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744 001	5972389	Sep 19, 2016	DP U-663			
	6340475	Sep 19, 2016	DP U-663			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP U-663			
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N 020805 001	5843930	Jun 06, 2015	U-646			
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N 020767 001	5648093	Jul 15, 2014				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP		NP	Jul 16, 2015
	8481083	Oct 10, 2028	DP			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
N 050775 001	6010718	Apr 11, 2017	DP U-924			
	6551616	Jul 15, 2017	U-924			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	5739152	Apr 14, 2015	DP U-893		NCE	Aug 01, 2013
	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	5739152	Apr 14, 2015	DP U-893		NCE	Aug 01, 2013
	5856346	Jan 05, 2021	DS DP U-893			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782 001	6387383	Aug 03, 2020	DP U-818			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802 001	6387383	Aug 03, 2020	DP U-916			
	RE41134	Feb 24, 2015	DP U-1033			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N 050803 001	5690923	Nov 25, 2014	DP			
<u>CLOBAZAM - ONFI</u>						
N 202067 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 002					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 003					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N 021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
<u>CLOFARABINE - CLOLAR</u>						
N 021673 001	5661136	Jan 14, 2018	U-626			
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N 022331 001	5869100	Oct 13, 2013	DP			
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N 022331 002	5869100	Oct 13, 2013	DP			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 003	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 004	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839 001	6429210	Jun 10, 2019	DS DP		M-61	May 06, 2014
	6504030	Jun 10, 2019	DS		PED	Nov 06, 2014
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839 002	6429210	Jun 10, 2019	DS DP		M-61	May 06, 2014
	6504030	Jun 10, 2019	DS		PED	Nov 06, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 001	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 002	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 003	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 004	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 005	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 006	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7635704	Oct 26, 2026	DS DP U-257			
	8148374	Sep 03, 2029	DS DP U-1279			
	8592397	Jan 13, 2024	DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029	U-1007		ODE	Jul 29, 2016
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021141 001	5607669	Jun 10, 2014		U-323		
	5679717	Apr 29, 2014		U-323		
	5693675	Dec 02, 2014				
	5917007	Apr 29, 2014		U-323		
	5919832	Jun 10, 2014				
	6066678	Jun 10, 2014		U-323		
	6433026	Jun 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176 001	5607669	Jun 10, 2014		U-323		
	5679717	Apr 29, 2014		U-323		
	5693675	Dec 02, 2014	DS			
	5917007	Apr 29, 2014	DS	U-323		
	5919832	Apr 29, 2014	DS			
	6066678	Apr 29, 2014	DS	U-323		
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7101960	Apr 29, 2014	DS DP	U-757		
	7229613	Apr 17, 2022		U-851		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001	5607669	Jun 10, 2014		U-757		
	5679717	Apr 29, 2014		U-757		
	5693675	Dec 02, 2014	DS			
	5917007	Apr 29, 2014	DS	U-757		
	5919832	Apr 29, 2014	DS			
	6066678	Apr 29, 2014	DS	U-757		
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7101960	Apr 29, 2014	DS DP	U-757		
	7229613	Apr 17, 2022		U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002	5607669	Jun 10, 2014		U-757		
	5679717	Apr 29, 2014		U-757		
	5693675	Dec 02, 2014	DS			
	5917007	Apr 29, 2014	DS	U-757		
	5919832	Apr 29, 2014	DS			
	6066678	Apr 29, 2014	DS	U-757		
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7101960	Apr 29, 2014	DS DP	U-757		
	7229613	Apr 17, 2022		U-493		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697 001	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697 002	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372 008					ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018		U-1319		
	8574634	Jan 11, 2018		U-1319		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Jun 11, 2024	DP U-817			
	7404489	Mar 12, 2024	DP			
	7879349	Jun 01, 2024	DP U-1152			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 002	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 003	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050716 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	5474979	May 17, 2014	DP			
	8629111	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					NP	Oct 02, 2015
					ODE	Oct 02, 2019
<u>CYTARABINE - DEPOCYT</u>						
N 021041 001	5723147	Mar 03, 2015	DP U-806			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALEFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030		NCE	Jan 22, 2015
	8007826	May 26, 2027	U-1030		ODE	Jan 22, 2017
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 001	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
	RE39071	Jun 15, 2016	DS DP U-728			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 001	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 002	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 16, 2015
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 13, 2014
	6037157	Jun 26, 2016	U-935		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 16, 2015
	6037157	Jun 26, 2016	U-935		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 13, 2014
	6037157	Jun 26, 2016	U-935		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-903		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 13, 2014
	6037157	Jun 26, 2016	U-935		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	5843946	Dec 01, 2015	DP U-1209		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-1305		NDF	Dec 16, 2014
	6037157	Jun 26, 2016	U-1209		PED	Jun 16, 2015
	6037157	Jun 26, 2016	U-1305		PED	Aug 01, 2016
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - EXJADE</u>						
N 021882 002	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - EXJADE</u>						
N 021882 003	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001					NCE	Oct 14, 2016
					ODE	Oct 14, 2018
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	5925730	May 18, 2021	DS DP U-943		NCE	Dec 24, 2013
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	5925730	May 18, 2021	DS DP U-943		NCE	Dec 24, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705 001	5563142	Oct 08, 2013				
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705 002	5563142	Oct 08, 2013				
	6177101	Jun 07, 2019				
<u>DESFLURANE - SUPRANE</u>						
N 020118 001	5617906	Apr 08, 2014	DP			
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N 021271 001	5733874	Mar 31, 2015				
<u>DESLOMATADINE - CLARINEX</u>						
N 021165 001	6100274	Jul 07, 2019				
	7211582	Dec 30, 2014			U-809	
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
	7405223	Jul 07, 2019			U-886	
<u>DESLOMATADINE - CLARINEX</u>						
N 021300 001	6514520	Jun 01, 2018	DP			
	7211582	Dec 30, 2014			U-809	
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
<u>DESLOMATADINE - CLARINEX</u>						
N 021312 001	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014			U-809	
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
	7618649	Dec 19, 2020	DP		U-1017	
<u>DESLOMATADINE - CLARINEX</u>						
N 021312 002	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014			U-809	
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
	7618649	Dec 19, 2020	DP		U-1017	
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313 001	6100274	Jul 07, 2019	DP			
	6709676	Feb 18, 2021	DP		U-707	
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
	7618649	Dec 19, 2020	DP		U-1017	
	8187630	Dec 19, 2020	DP		U-1017	
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605 001	6100274	Jul 07, 2019	DP			
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014			U-138	
	7618649	Dec 19, 2020	DP		U-1017	
	7820199	Mar 28, 2022	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 017922 001	5674850	Dec 23, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 017922 002	5674850	Dec 23, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP (NEEDS NO REFRIGERATION)</u>						
N 017922 003	5674850	Dec 23, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 001	5674850	Dec 23, 2013				
	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 002	5674850	Dec 23, 2013				
	7022340	Apr 30, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N 021795 001	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N 021795 002	7022340	Apr 30, 2023	DP			
<u>DESONIDE - DESONATE</u>						
N 021844 001	6387383	Aug 03, 2020	DS DP U-783			
<u>DESONIDE - VERDESO</u>						
N 021978 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	6726918	Oct 20, 2020	DP U-1204		ODE	Sep 24, 2017
	6726918	Oct 20, 2020	DP U-1205			
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	DP U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	DP U-1205			
	8506987	Jan 09, 2023	U-1204			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202580 001						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 001	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015				
			DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 002	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015				
			DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 003	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015				
			DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 001	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 002	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 003	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 004	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 005	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 006	5837284	Dec 04, 2015	DP	U-677		
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP U-678			
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020	U-829		ODE	Sep 06, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026	U-1093		NC	Oct 29, 2013
	8227484	Jul 17, 2023	U-1093			
	RE38115	Jan 26, 2016	DP			
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N 018658 001	5980882	Apr 16, 2017	DP			
<u>DIAZEPAM - DIASTAT</u>						
N 020648 001	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N 020648 002	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N 020648 003	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N 020648 004	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N 020648 005	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N 020648 006	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N 020648 007	5462740	Sep 17, 2013	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001					NP	Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002					NP	Oct 18, 2016
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2014	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	6974595	May 15, 2017	U-436			
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
N 020809 001	5603929	Nov 16, 2014	U-239			
	5653972	Nov 16, 2014	U-239			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N 021005 001	5639738	Jun 17, 2014	U-402			
	5792753	Aug 11, 2015				
	5852002	Jun 17, 2014	U-402			
	5914322	Aug 11, 2015				
	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N 020607 001	5601843	Feb 11, 2014				
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N 020607 002	5601843	Feb 11, 2014				
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252 001	6133251	Oct 25, 2016	DP U-1	Y	I-648	Mar 14, 2015
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-828	Y		
	6884793	Oct 25, 2016	DP	Y		
	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Sep 22, 2016
					PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 001	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 002	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 003	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 004	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 005	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 006	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N 021191 001	5605673	Feb 25, 2014				
	5626833	May 16, 2014	U-458			
	5639443	Jun 17, 2014				
	5695741	Dec 09, 2014	U-458			
	5720938	Feb 24, 2015				
	5798091	Aug 25, 2015	U-458			
	6280704	Jul 30, 2013				
	6280705	Jul 30, 2013				
	6287539	Jul 30, 2013				
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394 001	8263647	May 30, 2022	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 001	6419953	Dec 18, 2018				
	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6528091	Dec 18, 2018	U-106			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 002	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DOCETAXEL - TAXOTERE</u>						
N 020449 001	5438072	Nov 22, 2013	DP		PED	Nov 13, 2013
<u>DOCETAXEL - TAXOTERE</u>						
N 020449 003					PED	Nov 13, 2013
<u>DOCETAXEL - TAXOTERE</u>						
N 020449 004					PED	Nov 13, 2013
<u>DOCOSANOL - ABREVA</u>						
N 020941 001	4874794	Apr 28, 2014	U-815			
	5534554	Dec 13, 2013	DP U-815			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 001	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 002	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 003	6124363	Oct 09, 2018				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202542 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202723 001					PC	Jan 22, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720 001	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720 002	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP		NP	Jul 23, 2013
<u>DORIPENEM - DORIBAX</u>						
N 022106 001	5317016	Jun 05, 2015	DS DP U-282			
	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N 022106 002	5317016	Jun 05, 2015	DS DP U-282			
	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N 202667 001					NP	Feb 01, 2015
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027	U-620			
	8513299	Apr 14, 2030	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027	U-620			
	8513299	Apr 14, 2030	U-620			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001	5602116	Feb 11, 2014	U-278			
	5602116	Feb 11, 2014	U-987			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002	5602116	Feb 11, 2014	U-278			
	5602116	Feb 11, 2014	U-987			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 003	5602116	Feb 11, 2014	U-987			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 021027 001	5602116	Feb 11, 2014	U-321			
	6903083	Jul 18, 2021	DS DP	Y		
	7148211	Sep 14, 2023	DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 021027 002	5602116	Feb 11, 2014	U-321			
	7148211	Sep 14, 2023	DP	Y		
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL (LIPOSOMAL)</u>						
N 050718 001					ODE	May 17, 2014
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL (LIPOSOMAL)</u>						
N 050718 002					ODE	May 17, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	5789395	Aug 30, 2016	U-925	Y		
	5919775	Aug 30, 2016	U-925	Y		
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8603506	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992		NCE	Jul 01, 2014
	5223510	Jul 26, 2016	DS DP U-1261			
	7323493	Jun 19, 2018	DP			
	8318800	Jun 19, 2018	DP			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 001					NS	Mar 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098 001	5569652	Oct 29, 2013	U-1			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	5569652	Oct 29, 2013	U-1			
	5798338	Jul 10, 2015	DP			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017	U-758			
	7163931	Dec 20, 2021	U-1			
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	5798338	Jul 10, 2015	DP		NC	Sep 24, 2013
	6441168	Apr 17, 2020	DS		NP	Sep 24, 2013
	6958326	Dec 30, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
	RE43916	Jun 30, 2014	U-1326			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	5798338	Jul 10, 2015	DP		NP	Dec 16, 2013
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001	5508276	Jul 18, 2014	DP		I-632	Nov 04, 2013
	6596756	Sep 10, 2019	U-882		M-61	Oct 18, 2015
					PED	Apr 18, 2016
					PED	May 04, 2014
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002	5508276	Jul 18, 2014	DP		I-632	Nov 04, 2013
	6596756	Sep 10, 2019	U-882		M-61	Oct 18, 2015
					PED	May 04, 2014
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004	5508276	Jul 18, 2014	DP		I-632	Nov 04, 2013
	6596756	Sep 10, 2019	U-882		M-61	Oct 18, 2015
					PED	Apr 18, 2016
					PED	May 04, 2014
<u>DUTASTERIDE - AVODART</u>						
N 021319 001	5565467	Nov 20, 2015	DS DP			
	5846976	Sep 17, 2013	U-476			
	5998427	Sep 17, 2013	DS DP	U-477		
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N 022460 001	5565467	Nov 20, 2015	DS DP			
	5846976	Sep 17, 2013	U-1065			
	5998427	Sep 17, 2013	DS DP	U-1066		
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	5993830	Jan 16, 2018	DP	U-1449	NDF	Oct 24, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021*PED	Nov 21, 2013			NPP	May 02, 2016
	5663169	Sep 02, 2014		U-257	PED	Nov 02, 2016
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014		U-257		
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021*PED	Nov 21, 2013			NPP	May 02, 2016
	5663169	Sep 02, 2014		U-257	PED	Nov 02, 2016
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021*PED	Nov 21, 2013			NPP	May 02, 2016
	5663169	Sep 02, 2014		U-248	PED	Nov 02, 2016
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
	8592397	Jan 13, 2024	DP U-750			
	8592397	Jan 13, 2024	DP U-1170			
	8598185	May 01, 2028	DP			
<u>EFLORNITHINE HYDROCHLORIDE - VANIOA</u>						
N 021145 001	5648394	Jul 15, 2014	U-334			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 001	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 002	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-930		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-1306			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-930		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-1306			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-930		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-1306			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-930		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-1306			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-930		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-1306			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8052995	Aug 01, 2027	DP U-1306			
<u>EMEDASTINE DIFUMARATE - EMADINE</u>						
N 020706 001	5441958	Dec 08, 2013	U-404			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6642245	Nov 04, 2020	U-541			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	5814639	Sep 29, 2015	DS DP		NCE	May 20, 2016
	5914331	Jul 02, 2017	DS		NPP	Dec 13, 2016
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS DP U-248			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8592397	Jan 13, 2024	DP U-1170			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
<u>ENFUVIRTIDE - FUZEON</u>						
N 021481 001	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015	U-248			
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	5446194	Oct 19, 2013	DS			
	6599530	Sep 14, 2018	DP U-219			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 12, 2016
					PED	Apr 15, 2014
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 15, 2014
					PED	Apr 12, 2016
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Oct 12, 2015
					PED	Apr 12, 2016
					PED	Apr 12, 2016
					PED	Apr 15, 2014
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1281			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504 001	5246418	Sep 30, 2013	DS DP			
	5873850	Sep 30, 2013	DS DP			
	6377847	Sep 30, 2013	DS DP			
	6385488	Sep 30, 2013	DS DP			
	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			
	6862473	Sep 30, 2013	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N 021437 001	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 002	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 004	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 005	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 006	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 001	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 002	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jun 16, 2019	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019		U-1096		
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021		U-1096		
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERTAPENEM SODIUM - INVANZ</u>						
N 021337 001	5478820	Nov 21, 2015	DS DP	U-160		
	5952323	May 15, 2017		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5877192	May 27, 2014	DP U-373			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5877192	May 27, 2014	DP U-373			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
	6428810	Nov 03, 2019	DP U-1207			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-773			
	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504	Feb 03, 2015	DP U-1207			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-1207			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 003	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5877192	May 27, 2014	U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 004	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5877192	May 27, 2014	U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101 001	5690960	Nov 25, 2014	DP U-858			
	5714504	Feb 03, 2015	DP U-858			
	5877192	May 27, 2014	U-858			
	5900424	May 04, 2016	DS U-858			
	6369085	May 25, 2018	DS DP U-858			
	6428810	Nov 03, 2019	DP U-858			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6875872	May 27, 2014	DS			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643			
	6143771	May 27, 2014	DP U-643			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643			
	6143771	May 27, 2014	DP U-643			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 005	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 006	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 007	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 008	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 009	5656286	Aug 12, 2014	DP			
	6024976	Jan 07, 2014	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N 020908 002	5860946	Jul 01, 2017	DP			
	7018992	Sep 17, 2022	U-1023			
<u>ESTRADIOL - MENOSTAR</u>						
N 021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
<u>ESTRADIOL - ELESTRIN</u>						
N 021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6299900	Feb 19, 2017	DP U-888			
	6299900	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6978945	Nov 30, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 001	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 002	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 001	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 002	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 003	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N 021371 001	5629021	Jan 31, 2015	DP			
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040 001	6747019	Mar 20, 2020		U-311		
	7320970	Mar 30, 2020	DP	U-844		
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N 021258 001	5676968	Oct 14, 2014	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 001	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 002	5656286	Aug 12, 2014				
	6024976	Jan 07, 2014				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 001	5908638	Jul 26, 2015	DP			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 002	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 003	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 004	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 005	5908638	Jul 26, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 001	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 002	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 003	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 004	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 005	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N 020527 002	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 001	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 003	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 004	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 005	5547948	Jan 17, 2015				
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001	6444673	Feb 14, 2014	DS DP		M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002	6444673	Feb 14, 2014	DS DP		M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003	6444673	Feb 14, 2014	DS DP		M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241 001	6214815	Jun 09, 2019	U-112			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024	U-828			
	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187 001	5989581	Apr 08, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946 001	6156742	Dec 05, 2020	U-374			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N 021544 001	5898032	Jun 23, 2017	U-1			
	RE39861	Jun 23, 2017	U-828			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864 001	6500814	Sep 03, 2018	U-1			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N 021180 001	5876746	Nov 20, 2015	DP U-514			
	5972377	Jun 07, 2015	U-514			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573 001	5552394	Jul 22, 2014	U-828		NP	Dec 22, 2013
	6667050	Apr 06, 2019	DP U-828			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>						
N 021871 001	5552394	Jul 22, 2014	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501 001	5552394	Jul 22, 2014	U-1090		NP	Oct 21, 2013
	7704984	Feb 02, 2029	U-1090			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		NCE	Mar 30, 2014
	5665772*PED	Mar 09, 2020			PED	Oct 20, 2013
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		NCE	Mar 30, 2014
	5665772*PED	Mar 09, 2020			PED	Oct 20, 2013
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		NCE	Mar 30, 2014
	5665772*PED	Mar 09, 2020			PED	Sep 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Oct 20, 2013
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	7297703	Dec 06, 2019	DP		I-650	Apr 26, 2015
	8410131	May 22, 2025	DS DP U-1368		I-655	Jul 20, 2015
	8410131*PED	Nov 22, 2025			NCE	Mar 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		ODE	Oct 29, 2017
	8436010*PED	Aug 22, 2022			ODE	Apr 26, 2019
					ODE	May 05, 2018
					PED	Oct 26, 2015
					PED	Apr 29, 2018
					PED	Oct 26, 2019
					PED	Sep 30, 2014
					PED	Nov 05, 2018
					PED	Nov 05, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	7297703	Dec 06, 2019	DP		I-650	Apr 26, 2015
	8410131	May 22, 2025	DS DP U-1368		I-655	Jul 20, 2015
	8410131*PED	Nov 22, 2025			NCE	Mar 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		ODE	Apr 26, 2019
	8436010*PED	Aug 22, 2022			ODE	Oct 29, 2017
					ODE	May 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2018
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Oct 26, 2019
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	7297703	Dec 06, 2019	DP		I-650	Apr 26, 2015
	8410131	May 22, 2025	DS DP U-1368		I-655	Jul 20, 2015
	8410131*PED	Nov 22, 2025			NCE	Mar 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		ODE	Apr 26, 2019
	8436010*PED	Aug 22, 2022			ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2015
					PED	Oct 26, 2019
					PED	Apr 29, 2014
					PED	Apr 29, 2018
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Nov 05, 2018
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	7297703	Dec 06, 2019	DP		I-650	Apr 26, 2015
	8410131	May 22, 2025	DS DP U-1368		I-655	Jul 20, 2015
	8410131*PED	Nov 22, 2025			NCE	Mar 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		ODE	May 05, 2018
	8436010*PED	Aug 22, 2022			ODE	Apr 26, 2019
					ODE	Oct 29, 2017
					PED	Sep 30, 2014
					PED	Oct 26, 2019
					PED	Apr 29, 2018
					PED	Nov 05, 2018
					PED	Nov 05, 2014
					PED	Oct 26, 2015
					PED	Apr 29, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		NCE	Mar 30, 2014
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
					PED	Apr 29, 2018
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		NCE	Mar 30, 2014
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2018
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	6004973	Jul 12, 2016	DP		NCE	Mar 30, 2014
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Apr 29, 2018
					PED	Sep 30, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-1074		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-1074		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	5424286	Dec 01, 2016		U-1108	NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017		U-656		
	6872700	Jan 14, 2020		U-654		
	6956026	Jan 07, 2018		U-687		
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP	U-1223		
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP	U-1223		
	7741269	Jan 07, 2018		U-1224		
	8329648	Aug 18, 2026		U-1313		
	8431685	Apr 13, 2025	DP	U-412		
	8461105	Apr 13, 2025	DP	U-412		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	5846966	Sep 21, 2013	U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	U-474			
	5846966	Sep 21, 2013	U-1172			
	7030106	Jan 25, 2022	DP			
	7612058	Jan 25, 2022	U-1027			
	7612058	Jan 25, 2022	U-1173			
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 001	5846966	Sep 21, 2013	DP U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-593			
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 002	5846966	Sep 21, 2013	DP U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-593			
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 003	5846966	Sep 21, 2013	DP U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-593			
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 004	5846966	Sep 21, 2013	DP U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-593			
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZOGABINE - POTIGA</u>						
N 022345 001					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345 002					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345 003					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345 004					NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 001	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96		M-98	Jan 31, 2014
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 002	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96		M-98	Jan 31, 2014
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 003	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96		M-98	Jan 31, 2014
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020325 001	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 001	5667794	May 02, 2015		Y		
	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 002	6814978	Aug 26, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE - PEPCID AC</u>						
N 020902 001	5854267	Dec 29, 2015	U-368			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8067033	Jul 18, 2026	DP		NC	Apr 23, 2014
	8067451	Jul 18, 2026	DP U-1196			
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - TRICOR</u>						
N 021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N 021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 001	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 001	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 002	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 003	5545628	Jan 10, 2015	DP U-701			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRICOR</u>						
N 021656 001	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 002	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 001	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020			U-1106	
	7863331	Aug 08, 2020			U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 003	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020			U-1106	
	7863331	Aug 08, 2020			U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025			U-1447	
	8026281	Apr 22, 2025			U-1448	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	8026281	Apr 22, 2025			U-1447	
	8026281	Apr 22, 2025			U-1448	
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
	8216604	Oct 03, 2024	U-767			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015	U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6216033	Jun 05, 2015	DP			
	6425892	Jun 05, 2015	U-736			
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015	U-736			
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
<u>FERUMOXYTOL - FERAHME</u>						
N 022180 001	6599498	Mar 08, 2020	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020		U-1422		
	8591864	Mar 08, 2020	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	6858650	Jul 03, 2022	DS U-913		NCE	Oct 31, 2013
	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	6858650	Jul 03, 2022	DS U-913		NCE	Oct 31, 2013
	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 020625 001	5578610	Nov 26, 2013		U-192		
	5738872	Feb 28, 2015				
	5855912	Feb 28, 2015				
	5932247	Feb 28, 2015				
	6037353	Mar 14, 2017		U-138		
	6113942	Feb 28, 2015				
	7135571	May 18, 2014	DS			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1160			
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1160			
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1160			
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1160			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6037353	Mar 14, 2017	U-1466			
	6723348	Nov 26, 2021	DP U-1466			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017				
	6723348	Nov 26, 2021	DP			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 021963 001	5578610	Nov 26, 2013	DS DP U-772			
	6037353	Mar 14, 2017	U-772			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	6037353	Mar 14, 2017	U-1157			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	5578610	Nov 26, 2013	DS DP U-1157			
	6037353	Mar 14, 2017	U-1157			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786 002	5578610	Nov 26, 2013	DS DP U-1159			
	5855912	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1159			
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
	7135571	May 18, 2014	DS U-1159			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704 002	5578610	Nov 26, 2013	DS DP U-1159			
	6037353	Mar 14, 2017	U-1159			
	6613357	Dec 25, 2020	DP U-1159			
	7138524	May 18, 2014	DS			
	RE39069	May 29, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027	U-319			
	8586551	Apr 12, 2024	DS DP			
<u>FINASTERIDE - FINASTERIDE</u>						
A 076436 001					PC	Jul 01, 2013
<u>FINASTERIDE - PROSCAR</u>						
N 020180 001	5942519	Oct 23, 2018	U-280			
<u>FINASTERIDE - PROPECIA</u>						
N 020788 001	5547957	Oct 15, 2013	U-236			
	5571817	Nov 05, 2013	U-259			
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2014	DS U-1086		M-106	Jul 20, 2014
	6004565	Sep 23, 2017	U-1086		NCE	Sep 21, 2015
	8324283	Mar 29, 2026				
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273 001	7148207	Dec 20, 2022	DP U-944		ODE	Dec 18, 2015
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5776433	Jul 07, 2015	DP		M-128	Aug 28, 2016
	5980867	Dec 20, 2013	DP			
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737 001	6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N 021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N 020985 001	6670335	Jun 02, 2021	DP U-68			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N 021235 001	5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	NPP	Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8236282	May 21, 2024	DS DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8236282	May 21, 2024	DS DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	6858596	Aug 03, 2021	DP U-808			
	7101866	Aug 03, 2021	DS DP U-808			
	7541350	Aug 03, 2021	DP U-988			
	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
	8534281	Aug 10, 2029	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N 020833 001	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N 020833 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N 020833 003	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001	7300669	Oct 20, 2019	DP U-835			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003	5873360	Feb 23, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	5658549	Aug 19, 2014	DP U-738			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017				
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	5658549	Aug 19, 2014	DP U-738			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	5658549	Aug 19, 2014	DP U-738			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Jan 04, 2025	DP			
	7832351	Jun 19, 2023	DP			
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192 001	6242003	Apr 13, 2020				
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476 002					PC	Sep 09, 2013
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 001	7465462	May 10, 2020	DP U-929			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 002	7465462	May 10, 2020	DP U-929			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 002	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 003	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 004	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 005	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 001	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 002	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N 021684 001	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N 021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N 021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N 021765 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 003	5767251	Jun 16, 2015	DS			
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS DP			
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020	U-762			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP U-813			
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP U-813			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	5889015	Jan 27, 2014	U-1068			
	6057307	Jan 27, 2014	DP U-1068			
	6068832	Aug 27, 2017	DP U-1068			
	6677323	Jan 27, 2014	U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	5889015	Jan 27, 2014	U-1068			
	6057307	Jan 27, 2014	DP U-1068			
	6068832	Aug 27, 2017	DP U-1068			
	6677323	Jan 27, 2014	U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
	6514953	Jul 15, 2019	DS DP U-257		PED	Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
					PED	Oct 27, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5512570	Mar 04, 2014	U-850		D-128	Nov 12, 2013
	5538982	Jul 23, 2013	U-850			
	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244 001	6204257	Jul 01, 2022	DS DP U-945		NCE	Dec 12, 2013
	6872838	Aug 07, 2018	DS			
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N 021006 001	5464864	Nov 07, 2015	U-436			
	5616603	Apr 01, 2014	U-436			
	5637611	Jun 10, 2014	U-436			
	5827871	Oct 27, 2015	U-436			
	5962501	Dec 16, 2013	U-436			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	7456160	Jan 09, 2021	U-596		M-103	May 17, 2014
	8329680	Jan 09, 2021	U-596		M-123	Nov 09, 2015
	8466139	Jan 09, 2021	U-596		PED	Mar 09, 2014
	8466139*PED	Jul 09, 2021			PED	Nov 17, 2014
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 003	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 021129 001	6054482	Apr 25, 2017				
	7256216	May 28, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N 021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N 021358 002					I-654	Jul 06, 2015
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADODIAMIDE - OMNISCAN</u>						
N 020123 001	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N 022066 001	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N 022066 002	5560903	Oct 01, 2013	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	6676929	May 04, 2020	DP		NCE	Dec 22, 2013
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	6676929	May 04, 2020	DP		NCE	Dec 22, 2013
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015	U-1112			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOTERIDOL - PROHANCE</u>						
N 020131 001	5846519	Dec 08, 2015				
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N 021489 001	5846519	Dec 08, 2015				
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001	5798092	Aug 25, 2015	DS DP		NCE	Jul 03, 2013
	6039931	Nov 13, 2021		U-1239		
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 001	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 002	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 003	7160559	Dec 20, 2019		DP		
<u>GANCICLOVIR - ZIRGAN</u>						
N 022211 001					ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	5767082	Jun 16, 2015				
	6653286	Jun 16, 2018		U-1354		
<u>GATIFLOXACIN - GATIFLOXACIN</u>						
A 202653 001					PC	Mar 30, 2014
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493 001	5880283	Dec 05, 2015				
	6333045	Aug 20, 2019		DP		
<u>GATIFLOXACIN - ZYMAXID</u>						
N 022548 001	5880283	Dec 05, 2015		DS		
	6333045	Aug 20, 2019		DS DP		
<u>GEFITINIB - IRESSA</u>						
N 021399 001	5770599	May 05, 2017		DS DP U-881		
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158 001	5633262	Jun 15, 2015				
	5776944	Apr 04, 2017		DS DP		
	5962468	Jun 15, 2015			U-282	
	6262071	Sep 21, 2019			U-513	
	6331550	Sep 21, 2019			U-511	
	6340689	Sep 14, 2019			U-512	
	6455540	Sep 21, 2019			U-511	
	6723734	Mar 20, 2018		DS DP		
	6803376	Sep 21, 2019		DS DP	U-608	
	6803376	Sep 21, 2019		DS DP	U-609	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GEMTUZUMAB OZOGAMICIN - MYLOTARG</u>						
N 021174 001	5585089	Dec 17, 2013				
	5606040	Feb 25, 2014				
	5693762	Dec 02, 2014				
	5739116	Apr 14, 2015				
	5767285	Jun 16, 2015				
	5773001	Jun 30, 2015				
			U-320			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 001	5981589	May 24, 2014				
	6054430	May 24, 2014				
	6342476	May 24, 2014			U-441	
	6362161	May 24, 2014			U-441	
	6620847	May 24, 2014	DS			
	6939539	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	5981589	May 24, 2014				
	6054430	May 24, 2014				
	6342476	May 24, 2014			U-441	
	6362161	May 24, 2014			U-441	
	6620847	May 24, 2014	DS			
	6939539	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8367605	May 24, 2014	DS			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 001	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 002	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	5591454	Jan 07, 2014	U-150			
	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	5591454	Jan 07, 2014	U-150			
	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	5591454	Jan 07, 2014	U-111			
	RE44459	Mar 26, 2019	U-1431			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 001	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 002	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 003	6303146	Jul 14, 2019	U-412			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571 001	7638552	Aug 20, 2023	U-1076		NP	Jul 28, 2013
	7816396	Aug 20, 2023	U-1076		ODE	Jul 28, 2017
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Oct 22, 2024	DP U-1011			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 001	5952340	Sep 14, 2016	U-519		M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 002	5952340	Sep 14, 2016	U-519		M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 004	5952340	Sep 14, 2016	U-519		M-102	Apr 29, 2014
<u>GREPAFLOXACIN HYDROCHLORIDE - RAXAR</u>						
N 020695 001	5563138	Oct 08, 2013				
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP U-494			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP U-494			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP U-494			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP U-494			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	6034267	Mar 08, 2016	U-1087			
	7247655	Mar 08, 2016	DP U-1087			
	7348361	Apr 22, 2019	DP U-1087			
	7530461	Jan 11, 2017	DP U-1087			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058 001	8062652	Jun 16, 2026	U-1197		ODE	May 03, 2014
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727 001	6465463	Sep 08, 2020	U-71			
	6784177	Sep 08, 2020	U-71			
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 001	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 002	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 003	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 004	5994348	Jun 07, 2015	DP			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 002	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 005	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 001	5591762 6358986	Jan 07, 2014 Jan 10, 2020	DS DP U-3			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 002	5591762 6358986	Jan 07, 2014 Jan 10, 2020	DS DP U-3			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 001	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 002	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 003	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 004	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 005	6294197	Jun 18, 2017	U-3			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6902742	Nov 01, 2019	DP		NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N 020716 001	6348216 6599531	Jun 10, 2017 Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCOID LIPOCREAM</u>						
N 020769 001	5635497	Jun 03, 2014				
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N 022076 001	7378405 7981877	Dec 19, 2026 Jan 23, 2025	DP DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 003	6589960	Nov 09, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 001	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 002	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 003	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 004	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 002	5834448	Nov 14, 2016	DP U-789		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945 001					ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 001	6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 002	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021858 001	5662918	Sep 02, 2014	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP		ODE	Nov 13, 2020
	8476284	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1456			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
	8415337	Mar 02, 2032	DS DP			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128 001	6211246	Jun 10, 2019				
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2014	DS DP U-1187		NCE ODE	Aug 25, 2016 Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321 001	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030				
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	5521184	Jan 04, 2015	DS DP			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	5521184	Jan 04, 2015	DS DP U-649			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	5521184	Jan 04, 2015	DS DP		I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Oct 19, 2013
	6958335	Dec 19, 2021	U-791		ODE	Jan 25, 2020
	7544799	Jan 16, 2019	DS DP	Y	ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019			ODE	Oct 19, 2013
	RE43932	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	RE43932*PED	Jul 16, 2019			ODE	Oct 19, 2013
					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	5521184	Jan 04, 2015			I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Dec 19, 2015
	6958335	Dec 19, 2021	U-791		ODE	Oct 19, 2013
	7544799	Jan 16, 2019	DS DP	Y	ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019			ODE	Oct 19, 2013
	RE43932	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	RE43932*PED	Jul 16, 2019			ODE	Oct 19, 2013
					ODE	Jan 25, 2020
<u>IMIGLUCERASE - CERESZYME</u>						
N 020367 001	5549892	Aug 27, 2013	U-252			
<u>IMIGLUCERASE - CERESZYME</u>						
N 020367 002	5549892	Aug 27, 2013	U-252			
<u>IMIQUIMOD - ALDARA</u>						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	8236816	Dec 11, 2029	U-68		I-636	Mar 24, 2014
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	8222270	Dec 11, 2029	U-68		NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	5753627	May 19, 2015	U-1125			
	5776894	Jul 07, 2015	DS DP			
	6123916	Sep 26, 2017	U-1125			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N 021172 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 002	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 003	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 19, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N 021810 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5834422	Sep 28, 2013	DP U-471			
	5840680	Sep 28, 2013	DS DP U-471			
	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N 020986 001	5618913	Jun 07, 2014	DS DP			
	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	5618913	Jun 07, 2014	DS DP			
	5626566	May 06, 2014	DP			
	5693027	Dec 02, 2014	DP			
	5866538	Jun 20, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	5618913	Jun 07, 2014	DS DP			
	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986 004	5618913	Jun 07, 2014	DS DP			
	5866538	Jun 20, 2017	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5750497	Jun 16, 2019	DS DP U-668		M-115	Apr 06, 2015
	5866538	Jun 20, 2017	DS DP		M-117	May 18, 2015
	6011007	Feb 02, 2014	DS DP U-668			
	6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
	6004297	Jan 28, 2019	DP			
	6011007	Feb 02, 2014	DS DP U-668			
	6869930	Feb 02, 2014	DS DP U-668			
	RE41956	Jan 21, 2021	DP			
N 021536 003	RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
	6011007	Feb 02, 2014	DS DP U-668			
	6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
	6011007	Feb 02, 2014	DS DP U-668			
	6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081 001	5656722	Aug 12, 2014	DS DP U-948			
	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 002	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25</u>						
N 021017 001	5461031	Jun 16, 2014	DP U-948			
	5474978	Jun 16, 2014	DS DP U-948			
	5747642	Jun 16, 2014	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	5461031	Jun 16, 2014	DP U-948			
	5474978	Jun 16, 2014	DS DP U-948			
	5747642	Jun 16, 2014	DP			
	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50</u>						
N 021018 001	5461031	Jun 16, 2014	DP U-948			
	5474978	Jun 16, 2014	DS DP U-948			
	5747642	Jun 16, 2014	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	5461031	Jun 16, 2014	DP U-948			
	5474978	Jun 16, 2014	DS DP U-948			
	5747642	Jun 16, 2014	DP			
	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N 020563 001	5474978	Jun 16, 2014	DS DP U-534		NR	Oct 12, 2015
	5474978	Jun 16, 2014	DS DP U-948			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N 020563 002	5474978	Jun 16, 2014	U-534		NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	5474978	Jun 16, 2014	DS DP U-948			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N 018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N 018780 005					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 001	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014	U-704			
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019	U-704			
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019	U-704			
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014	U-704			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 002	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014	U-704			
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019	U-704			
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019	U-704			
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014	U-704			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290	001				I-669 NCE ODE	Mar 20, 2016 Sep 19, 2013 Sep 19, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454	001				NCE	Jan 14, 2016
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	5676930	Oct 14, 2014	DP		
		5683677	Nov 04, 2014	DP		
		6739333	May 26, 2020	DP		
		6983743	May 26, 2020	DP		
<u>IRBESARTAN - AVAPRO</u>						
N 020757	001	6342247	Jun 07, 2015			
<u>IRBESARTAN - AVAPRO</u>						
N 020757	002	6342247	Jun 07, 2015			
<u>IRBESARTAN - AVAPRO</u>						
N 020757	003	6342247	Jun 07, 2015			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	001	6403569	Apr 28, 2020	U-449		
		6794370	May 01, 2020	U-606		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	002	6403569	Apr 28, 2020	U-449		
		6794370	May 01, 2020	U-606		
<u>IRON DEXTRAN - DEXFERRUM</u>						
N 040024	001	5624668	Sep 29, 2015			
<u>IRON SUCROSE - VENOFER</u>						
N 021135	001				NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135	002				NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135	005				NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	001	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	002	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	003	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	004	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ITRACONAZOLE - SPORANOX</u>						
N 020083	001	5633015	May 27, 2014			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657	001	5707975	Jan 13, 2015			
		6407079	Jun 18, 2019			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966	001	6407079	Jun 18, 2019			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484	001	6509038	May 12, 2017	DP	U-1054	
		7081255	May 12, 2017	DP	U-1054	
		8486456	Oct 03, 2028	DP	U-1054	
		8591948	May 12, 2017	DP	U-1054	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
	8324242	Apr 18, 2027	U-1311		ODE	Jan 31, 2019
	8410274	Dec 28, 2026	DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 001	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 002	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>KETOCONAZOLE - NIZORAL A-D</u>						
N 020310 001	5456851	Apr 07, 2014				
<u>KETOCONAZOLE - EXTINA</u>						
N 021738 001	7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382 001	6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001	5654301	Aug 05, 2014	DS DP U-911		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-911			
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP U-914			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	6004968	Mar 20, 2018				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021003 001	5905082	May 18, 2016				
	RE39155	Jul 02, 2013	U-250			
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004 001	6004968	Mar 20, 2018				
	RE39155	Jul 02, 2013	U-250			
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N 020857 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006					I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001	5595760	Mar 08, 2020	DP U-831		D-131 ODE	Mar 04, 2014 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002	5595760	Mar 08, 2020	DP U-831		D-131 ODE	Mar 04, 2014 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003	5595760	Mar 08, 2020	DP U-831		D-131 ODE	Mar 04, 2014 Aug 30, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	NS	Jun 05, 2016
	6281230	Jul 24, 2016		U-1212	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 019732 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020011 001	5575987	Sep 02, 2013				
	5631021	May 20, 2014				
	5716640	Sep 02, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 002	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 005	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 006	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 007	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 008	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 002	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020708 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088 001	5728396	Jan 30, 2017	U-316			
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP U-801			
	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	5599552	Feb 04, 2014	DP U-621			
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP U-621			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	U-621			
<u>LEUPROLIDE ACETATE; LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 003	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE; LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 004	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001	5547994	Aug 20, 2013	U-636			
	5605674	Feb 25, 2014	DP			
	5836299	Nov 17, 2015	DP			
	7256310	Oct 08, 2024	DS DP U-636			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021505 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 002	7858122	Sep 17, 2028	DP			
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>						
N 021114 001	5540918	Jul 30, 2013	DP			
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 001	5708011	Oct 13, 2014	U-276			
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 002	5708011	Oct 13, 2014	U-276			
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 003	5708011	Oct 13, 2014	U-276			
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182 001	6335369	Jan 18, 2021	U-433			
	6429230	Jan 18, 2021	U-433			
	6696493	Jan 18, 2021	U-433			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N 022064 001	5698558	Jul 26, 2013	U-812			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N 022157 001	5698558	Jul 26, 2013	U-852			
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721 001	6806256	Feb 26, 2022	DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	5785053	Dec 05, 2015	DP			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO*	Apr 30, 2016
					RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 022121 001	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - LIDODERM</u>						
N 020612 001	5741510	Mar 30, 2014	DP			
	5827529	Oct 27, 2015	U-486			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	5630796	May 20, 2014				
	5899880	May 04, 2016	DP			
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
	8540665	Oct 22, 2029	U-1438			
<u>LIDOCAINE; PRILOCAINE - ORAOIX</u>						
N 021451 001	6031007	Apr 01, 2017	DP U-553			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6465709	Jul 07, 2020	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	6303661	Apr 24, 2017	U-774		M-118	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-121	Aug 13, 2015
	6890898	Feb 02, 2019	U-493		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1270			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	6303661	Apr 24, 2017	U-802		NC	Jan 30, 2015
	6890898	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6303661	Apr 24, 2017	U-802		NC	Jan 30, 2015
	6890898	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6303661	Apr 24, 2017	U-802		NC	Jan 30, 2015
	6890898	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	5688792	Nov 18, 2014	DS	U-319		
	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	5688792	Nov 18, 2014	DS	U-319		
	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	5688792	Nov 18, 2014		U-319		
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	5688792	Nov 18, 2014	DS	U-319		
	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019	DP		M-115	Apr 06, 2015
	6268343	Aug 22, 2022	DS DP	U-968	NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP	U-968		
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		NPP	Nov 10, 2013
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448 001	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 020606 001	5679376	Oct 21, 2014			Y	
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 021140 001	6103260	Jul 17, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226 001	5541206	Jul 30, 2013	DS U-348			
	5648497	Jul 15, 2014				
	5886036	Nov 19, 2013	DS DP			
	5914332	Dec 13, 2015			U-351	
	5948436	Sep 13, 2013	DP			
	6037157	Jun 26, 2016			U-346	
	6232333	Nov 07, 2017				
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-688			
	6458818	Nov 07, 2017				
	6521651	Nov 07, 2017	DP			
	6703403	Jun 26, 2016			U-257	
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	5484801	Jan 28, 2014	DP			
	5541206	Jul 30, 2013	DS DP U-348			
	5541206	Jul 30, 2013	DS DP U-895			
	5648497	Jul 15, 2014	DS			
	5886036	Nov 19, 2013	DS DP U-895			
	5914332	Dec 13, 2015	DS DP U-351			
	5914332	Dec 13, 2015	DS DP U-895			
	5948436	Sep 13, 2013	DP			
	6037157	Jun 26, 2016			U-346	
	6037157	Jun 26, 2016			U-895	
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-895			
	6703403	Jun 26, 2016			U-257	
	6703403	Jun 26, 2016			U-895	
	6911214	Nov 28, 2021	DP U-895			
	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	5541206	Jul 30, 2013	DS DP U-688			
	5648497	Jul 15, 2014	DS DP			
	5886036	Nov 19, 2013	DS DP U-895			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016			U-688	
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016			U-688	
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024			U-688	
	8377952	Oct 22, 2027			U-1372	
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	5541206	Jul 30, 2013	DS DP U-688			
	5648497	Jul 15, 2014	DS DP			
	5886036	Nov 19, 2013	DS DP U-895			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016	U-688			
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 020583 001	5540930	Oct 25, 2013				
	5747061	Oct 25, 2013	DP U-575			
<u>LOTEPREDNOL ETABONATE - ALREX</u>						
N 020803 001	5540930	Oct 25, 2013				
	5747061	Oct 25, 2013	DP U-576			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 020841 001	5540930	Oct 25, 2013				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 200738 001					NDF	Apr 15, 2014
					PED	Oct 15, 2014
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP		NDF	Sep 28, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - ZYLET</u>						
N 050804 001	5540930	Oct 25, 2013	DP			
	5747061	Oct 25, 2013	DP U-920			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 001	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
	7998506	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 002	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
	7998506	Sep 20, 2013	U-1137			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 003	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
	7998506	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 004	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
	7998506	Sep 20, 2013	U-1137			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP		NDF	Dec 21, 2015
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	5284858	Jul 14, 2014	DS		I-670	Apr 19, 2016
	6414016	Sep 05, 2020		U-717		
	6414016	Sep 05, 2020		U-1392		
	6583174	Oct 16, 2020	DP			
	6982283	Dec 04, 2022		U-1391		
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-1404		
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1203		
	8071613	Sep 05, 2020		U-1393		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022		U-1214		
	8097653	Nov 14, 2022		U-1394		
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP	U-1345		
	8389542	Nov 14, 2022	DP	U-1395		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	5284858	Jul 14, 2014	DS			
	6414016	Sep 05, 2020		U-874		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-873		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1202		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N 021746 001	5407914	Nov 17, 2014	DS DP	U-1242		
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2016	DS DP	U-540	NCE	Nov 14, 2018
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>LUTROPIN ALFA - LUVERIS</u>						
N 021322 001	5767251	Jun 16, 2015	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029	U-1446		ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910 001	5945449	Oct 31, 2017	DP U-785		ODE	Jul 26, 2013
	7300674	Mar 04, 2023	DP U-785			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910 002	5945449	Oct 31, 2017	DP U-785		ODE	Jul 26, 2013
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 001	6489346	Jul 16, 2016	DS DP U-588			
	6645988	Jul 16, 2016	DS DP U-588			
	6699885	Jul 16, 2016	U-588			
	7399772	Jul 16, 2016	U-588			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 002	6489346	Jul 16, 2016	DS DP U-623			
	6645988	Jul 16, 2016	DS DP U-623			
	6699885	Jul 16, 2016	U-623			
	7399772	Jul 16, 2016	U-623			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 001	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 002	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372 001	6946149	Mar 07, 2023	DP U-837		NC	Aug 05, 2013
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MALATHION - OVIDE</u>						
N 018613 001	7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MANNITOL - ARIDOL KIT</u>						
N 022368 001	5817028	Feb 23, 2015	U-1091		NP	Oct 05, 2013
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839 001	5681814	Sep 18, 2017	DP			
	5824642	Jul 08, 2014	U-681			
	6207640	Apr 07, 2014	U-681			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N 021884 001	5681818	Oct 28, 2014	U-697			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N 021583 001	6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
<u>MELOXICAM - MOBIC</u>						
N 021530 001	6184220	Mar 25, 2019	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539			
	8039009	Mar 24, 2029	U-539			
	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539			
	8039009	Mar 24, 2029	U-539			
	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539			
	8039009	Mar 24, 2029	U-539			
	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539			
	8039009	Mar 24, 2029	U-539			
	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
	8598233	Nov 22, 2025	DP			
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922 001	5194247	Dec 10, 2013	DP U-294			
	6353029	Aug 24, 2020				
<u>MESALAMINE - SFROWASA</u>						
N 019618 002	7645801	Jul 24, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MESALAMINE - ASACOL</u>						
N 019651 001	5541170	Jul 30, 2013	U-141			
	5541171	Jul 30, 2013	U-141			
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
	6893662	Nov 15, 2021	DP U-141			
	8580302	Nov 15, 2021	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000 001	6773720	Jun 08, 2020	DP		I-640	Jul 14, 2014
<u>MESALAMINE - APRISO</u>						
N 022301 001	6551620	Apr 20, 2018	DS DP U-907			
	8337886	Apr 20, 2018	DP U-1310			
	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
	6649180	Apr 13, 2020	DP			
<u>METAXALONE - SKELAXIN</u>						
N 013217 003	7122566	Feb 06, 2026	U-915			
	7714006	Dec 03, 2021	U-1050			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202 001	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202 004	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Sep 14, 2023	DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 001	6340475	Sep 19, 2016	DS DP U-669			
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	6488962	Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		NCE	Jul 31, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017			U-802	
	6699871	Jul 26, 2022	DS DP		U-802	
	6890898	Feb 02, 2019			U-803	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1038	
	7078381	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022	DP		U-803	
	7125873	Jul 26, 2022	DP		U-1036	
	7125873	Jul 26, 2022	DP		U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
	7459428	Feb 02, 2019			U-1036	
	8414921	Jul 21, 2028	DP		U-1036	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017			U-802	
	6699871	Jul 26, 2022	DS DP		U-802	
	6890898	Feb 02, 2019			U-803	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1038	
	7078381	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022	DP		U-803	
	7125873	Jul 26, 2022	DP		U-1036	
	7125873	Jul 26, 2022	DP		U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
	7459428	Feb 02, 2019			U-1036	
	8414921	Jul 21, 2028	DP		U-1036	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N 021415 001	6034267	Mar 08, 2016	U-804			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 004	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP U-472			
	6635284	Dec 04, 2015	DP U-591			
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP U-472			
	6635284	Dec 04, 2015	DP U-591			
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP U-472			
	6635284	Dec 04, 2015	DP U-591			
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP U-472			
	6635284	Dec 04, 2015	DP U-591			
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP		NDF	Sep 27, 2015
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 002	6413549	Jul 11, 2017	DP			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>METRONIDAZOLE - METROGEL-VAGINAL</u>						
N 020208 001	5536743	Jul 16, 2013	U-137			
<u>METRONIDAZOLE - METROGEL</u>						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806 001	7456207	Sep 22, 2024	DP			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001					NP	Feb 17, 2015
					ODE	Feb 17, 2019
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 001	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 002	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 003	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 004	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 002	5908838	Feb 19, 2018			U-917	
	7541347	Apr 02, 2027			U-917	
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 003	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	5908838	Feb 19, 2018			U-917	
	7790705	Jun 24, 2025			U-1078	
	7919483	Mar 07, 2027			U-1078	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-1078	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812 001	6946120	Apr 20, 2019	DP U-702			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	U-255			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	U-255			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 001	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	5889015	Jan 27, 2014	U-645			
	6057307	Jan 27, 2014	DP U-645			
	6240918	Feb 20, 2017	DP			
	6365581	Jan 27, 2014	U-645			
	6503537	Mar 17, 2018	DP			
	6677322	Jan 27, 2014	U-645			
	6949532	Jan 27, 2014	U-645			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 002	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	5889015	Jan 27, 2014	U-645			
	6057307	Jan 27, 2014	DP U-645			
	6240918	Feb 20, 2017	DP			
	6365581	Jan 27, 2014	U-645			
	6503537	Mar 17, 2018	DP			
	6677322	Jan 27, 2014	U-645			
	6949532	Jan 27, 2014	U-645			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N 020762 001	5837699	Jan 27, 2014	DP U-625		M-99	Jan 19, 2014
	6127353	Oct 03, 2017	DS DP			
	6723713	Jan 27, 2014	U-625			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409 001	8007830	Oct 24, 2022	DP		NPP	Mar 26, 2015
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 001	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 002	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 003	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1241			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6610327	Oct 29, 2019	DP U-298			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N 021598 001	5607942	Mar 04, 2014	DS DP U-709			
	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	U-709			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	5607942	Mar 04, 2014	DS DP U-709		NP	Nov 19, 2013
	6716830	Sep 29, 2019	DP		PED	May 19, 2014
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
<u>MUPIROCIIN - CENTANY</u>						
N 050788 001	6013657	Jul 08, 2018	DP			
<u>MUPIROCIIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013	U-1358			
	6025389	Oct 20, 2014	DP U-1122			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N 050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE - CELLCEPT</u>						
N 050758 001	5543408	Sep 15, 2013	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					NS	Jan 13, 2015
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NALTREXONE - VIVITROL</u>						
N 021897 001	5792477	May 02, 2017	DP		I-631	Oct 12, 2013
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
	7799345	May 25, 2020	DP			
	7919499	Oct 15, 2029	U-1123			
	7919499	Oct 15, 2029	U-1124			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N 020353 001	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N 020353 002	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N 020353 003	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6586458	Aug 14, 2017	DP U-867			
	7332183	Oct 02, 2025	DP U-867			
	8022095	Aug 14, 2017	DP U-867			
<u>NATEGLINIDE - STARLIX</u>						
N 021204 001	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N 021204 002	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 002	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 003	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 004	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 005	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N 021877 001	5424295	Jun 13, 2017	DS DP			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N 020778 001	5484926	Oct 07, 2013				
	5952343	Oct 07, 2013	U-257			
	6162812	Oct 07, 2013	U-248			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N 020779 001	5484926	Oct 07, 2013				
	5952343	Oct 07, 2013	U-257			
	6162812	Oct 07, 2013	U-248			
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N 021503 001	5484926	Oct 07, 2013				
	5952343	Oct 07, 2013	U-257			
	6162812	Oct 07, 2013	U-248			
<u>NEPAFENAC - NEVANAC</u>						
N 021862 001	5475034	Jun 06, 2014	U-100			
	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	5475034	Jun 06, 2014	U-100		NP	Oct 16, 2015
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NESIRITIDE RECOMBINANT - NATRECOR</u>						
N 020920 001	5114923	May 19, 2014	DS DP U-855			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409		NDF NPP	Mar 25, 2014 Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 002					NDF NPP	Mar 25, 2014 Nov 08, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N 020381 001	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN - NIASPAN</u>						
N 020381 002	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
	7998506	Sep 20, 2013	U-1141			
<u>NIACIN - NIASPAN</u>						
N 020381 003						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
	7998506	Sep 20, 2013	U-1141			
<u>NIACIN - NIASPAN</u>						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6746691	Sep 20, 2013	DP U-586			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
	7998506	Sep 20, 2013	U-1141			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N 020381 005	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6746691	Sep 20, 2013	U-586			
	7011848	Sep 20, 2013	U-712			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 001	6080428	May 27, 2017			U-862	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-1134	
	6129930	Sep 20, 2013	DP		U-862	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1134	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1149	
	6676967	Sep 20, 2013			U-862	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-862	
	7011848	Sep 20, 2013			U-1150	
	7011848	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
	7998506	Sep 20, 2013			U-1151	
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 002	6080428	May 27, 2017			U-862	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-1134	
	6129930	Sep 20, 2013	DP		U-862	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1134	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1149	
	6676967	Sep 20, 2013			U-862	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-862	
	7011848	Sep 20, 2013			U-1150	
	7011848	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
	7998506	Sep 20, 2013			U-1151	
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 003	6080428	May 27, 2017			U-862	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-1134	
	6129930	Sep 20, 2013	DP		U-862	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1134	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1149	
	6676967	Sep 20, 2013			U-862	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-862	
	7011848	Sep 20, 2013			U-1150	
	7011848	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
	7998506	Sep 20, 2013			U-1151	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 004	6080428	May 27, 2017		U-862		
	6080428	May 27, 2017		U-1132		
	6080428	May 27, 2017		U-1134		
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6469035	Mar 15, 2018		U-1129		
	6469035	Mar 15, 2018		U-1149		
	6676967	Sep 20, 2013		U-862		
	6676967	Sep 20, 2013		U-1132		
	6676967	Sep 20, 2013		U-1134		
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013		U-862		
	7011848	Sep 20, 2013		U-1150		
	7011848	Sep 20, 2013		U-1151		
	7998506	Sep 20, 2013		U-1150		
	7998506	Sep 20, 2013		U-1151		
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 005	6080428	May 27, 2017		U-862		
	6080428	May 27, 2017		U-1132		
	6080428	May 27, 2017		U-1134		
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6469035	Mar 15, 2018		U-1129		
	6469035	Mar 15, 2018		U-1149		
	6676967	Sep 20, 2013		U-862		
	6676967	Sep 20, 2013		U-1132		
	6676967	Sep 20, 2013		U-1134		
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013		U-862		
	7011848	Sep 20, 2013		U-1150		
	7011848	Sep 20, 2013		U-1151		
	7998506	Sep 20, 2013		U-1150		
	7998506	Sep 20, 2013		U-1151		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
	8455524	Apr 18, 2027		U-1029		
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8075911	May 22, 2021	DP			
<u>NICOTINE - NICOTROL</u>						
N 020385 001	5656255	Aug 12, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612 002	8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066 002	8323683	Apr 30, 2028	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		ODE	Oct 29, 2014
	8163904	Aug 23, 2028	DS DP			
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		I-627	Jun 17, 2014
	8163904	Aug 23, 2028	DS DP		ODE	Oct 29, 2014
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NISOLDIPINE - SULAR</u>						
N 020356 005	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 006	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 007	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 008	5626874	Nov 30, 2014	DP			
<u>NITAZOXANIDE - ALINIA</u>						
N 021497 001	5578621	Nov 26, 2013	DP U-525			
	5968961	May 07, 2017	DP			
	6020353	Sep 18, 2014	DS DP			
<u>NITAZOXANIDE - ALINIA</u>						
N 021498 001	5578621	Sep 08, 2014	U-525			
	5965590	Jul 03, 2017	U-523			
	5968961	May 07, 2017				
	6020353	Sep 08, 2014				
	6117894	May 07, 2017				
<u>NITISINONE - ORFADIN</u>						
N 021232 001	5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N 021232 002	5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N 021232 003	5550165	Aug 27, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	5558083	Nov 22, 2013	DP U-1226			
	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	5558083	Nov 22, 2013	DP U-1226			
	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 003	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - RECTIV</u>						
N 021359 001	7189761	May 27, 2014	DP U-1198		NP	Jun 21, 2014
<u>NITROGLYCERIN - NITROMIST</u>						
N 021780 001	5869082	Apr 16, 2016	DP			
<u>NIZATIDINE - AXID</u>						
N 021494 001	6930119	Jul 17, 2022	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 001	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 002	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 003	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 004	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 005	5753618	May 19, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 001	5538739	Jul 23, 2013	DP			
	5639480	Jun 17, 2014	DP			
	5688530	Nov 18, 2014	U-268			
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 002	5538739	Jul 23, 2013				
	5639480	Jun 17, 2014	DP			
	5688530	Nov 18, 2014	U-268			
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 003	5538739	Jul 23, 2013				
	5639480	Jun 17, 2014	DP			
	5688530	Nov 18, 2014	U-268			
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 001	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 002	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 003	6169084	Sep 30, 2018	DS DP U-1026			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 001	5616599	Apr 25, 2016	DS DP U-500		PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 003	5616599	Apr 25, 2016	DS DP U-500		PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 004	5616599	Apr 25, 2016	DS DP U-500		PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
N 020688 001	5641805	Jun 06, 2015	U-184			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765			
	6995186	Nov 12, 2023	DP U-765			
	7402609	Jun 19, 2022	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	7842687	Mar 16, 2019	DS DP U-1299		ODE	Oct 26, 2019
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N 021654 001	5656667	Apr 10, 2017	DS DP U-822			
	7732488	Jan 30, 2025	DS DP	Y		
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 001	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 002	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 003	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229 001	5690960	Nov 25, 2014				
	5753265	Jun 07, 2015				
	5817338	Oct 06, 2015				
	5900424	May 04, 2016				
	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5690960	Nov 25, 2014	DP U-864			
	5900424	May 04, 2016	DS U-864			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5690960	Nov 25, 2014	DP U-864			
	5900424	May 04, 2016	DS U-864			
	6428810	Nov 03, 2019	DP U-864			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 16, 2016	U-588			
	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 16, 2016	U-623			
	5840737	Jul 16, 2016	U-624			
	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016	U-623			
	7399772	Jul 16, 2016	U-624			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 16, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 16, 2016	U-623			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
	7399772	Jul 15, 2016	U-1025			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N 020781 001	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N 020781 002	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N 020605 001	5854270	Nov 20, 2015	DP U-44			
<u>ORLISTAT - XENICAL</u>						
N 020766 001	6004996	Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887 001	6004996	Jan 06, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001	5763483	Dec 27, 2016	DS U-376		NPP	Dec 21, 2015
	5763483	Dec 27, 2016	DS U-1113			
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Dec 27, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSPENIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 001	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 002	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 001	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 002	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 003	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 001	5872147	Dec 05, 2017	U-585			
	6090799	Jul 18, 2017	U-585			
	6576659	Dec 05, 2017	U-585			
	6828313	Dec 05, 2017	U-585			
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 002	5872147	Dec 05, 2017	U-585			
	6090799	Jul 18, 2017	U-585			
	6576659	Dec 05, 2017	U-585			
	6828313	Dec 05, 2017	U-585			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 001	7037525	Feb 12, 2018	U-724			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 002	7037525	Feb 12, 2018	U-724			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 003	7037525	Feb 12, 2018	U-724			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285 001	7037525	Feb 12, 2018	U-724			
	8119148	Dec 19, 2020	DP U-724			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
	8617600	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
	8617600	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
	8617600	Apr 13, 2027	DP			
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351 002	5601839	Apr 26, 2015				
	5834010	Apr 26, 2015				
	6743441	Apr 26, 2020	DP U-318			
	7081249	Apr 26, 2020	DP U-318			
	7081250	Apr 26, 2020	DP U-318			
	7081251	Apr 26, 2020	DP U-318			
	7081252	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	DS DP U-318			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYBUTYNIN - GELNIQUE 3%</u>						
N 202513 001	7029694	Apr 26, 2020	DP U-318		NP	Dec 07, 2014
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 001	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 002	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 003	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	8241662	Apr 26, 2020	U-318			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-443		
	8337888	Aug 06, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 001					PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 003					PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 005					PC	Jul 02, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 007					PC	Jul 07, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-658	Oct 11, 2015
	7820788	Mar 03, 2024	DP U-1092		I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP U-1290		ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
<u>PALIPERIDONE - INVEGA</u>						
N 021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 003					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 006					NPP	Apr 06, 2014
					PED	Oct 06, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528			
	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
	8518981	Jan 30, 2024	DP			
	8598218	Jan 30, 2024	DP			
	8598219	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901			
	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
	8518981	Jan 30, 2024	DP			
	8598218	Jan 30, 2024	DP			
	8598219	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 022233 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 001					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 002					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 003					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 004					M-93	Jul 29, 2019
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93	Jul 29, 2019
					NCE	Apr 30, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP			
	8562980	Feb 20, 2028	DP			
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 003					NCE	Mar 01, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 001					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 002					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 003					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 004					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 002					NCE	Mar 01, 2017
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987 001	5997903	Dec 07, 2016				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987 002	5997903	Dec 07, 2016				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	6780881	Nov 17, 2021	DP			
	7351723	Nov 17, 2021	DP			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024		U-859		
	7553498	Sep 30, 2024		U-859		
	7838027	Sep 30, 2024	DP	U-859		
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 001					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 002					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 003					PC	Dec 24, 2013
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001	5587497	Dec 24, 2013				
	5597815	Jul 13, 2015		U-1195		
	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002	5587497	Dec 24, 2013				
	5597815	Jul 13, 2015		U-1195		
	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001	5587497	Dec 24, 2013	DS			
	5597815	Jul 13, 2015		U-1195		
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002	5587497	Dec 24, 2013	DS			
	5597815	Jul 13, 2015		U-1195		
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003	5587497	Dec 24, 2013	DS			
	5597815	Jul 13, 2015		U-1195		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 005	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020710 001	5811436	Sep 22, 2015				
	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
	6172233	Jan 15, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 001	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 002	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 003	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 004	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 001	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 002	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N 021756 001	5919455	Oct 27, 2013	DS			
	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS	U-622		
	6113906	Oct 27, 2013	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 001	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 002	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 003	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	5344932 7772209 7772209	Jul 24, 2016 Nov 24, 2021 Nov 24, 2021	DS DP U-1077 U-1296		M-122 M-61 PED	Oct 17, 2015 Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	5344932 7772209	Jul 24, 2016 Nov 24, 2021	DS DP U-1296		M-122 M-61 PED	Oct 17, 2015 Mar 17, 2014 Sep 17, 2014
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N 020629 001	5840763 5866581 5916893 6124304 6469015 6579981	Sep 01, 2015 Oct 04, 2014 Sep 01, 2015 Oct 04, 2014 Oct 22, 2019 Jun 17, 2020	U-501 U-501 U-501 U-501 U-501 U-501			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N 021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	5527521 5585112 6033645	Feb 22, 2015 Dec 17, 2013 Jun 19, 2016	DP U-665 DP U-665			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	6149938 8440170	Jul 23, 2018 Mar 14, 2029	DP DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	6149938 8440170	Jul 23, 2018 Mar 14, 2029	DP DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	6149938 8440170	Jul 23, 2018 Mar 14, 2029	DP U-1243 DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	6764678	May 11, 2021	U-967			
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023	U-967			
	7575757	Apr 21, 2025	DP			
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302 001	5912238	Jun 15, 2016				
	6352998	Oct 26, 2015				
	6423722	Jun 26, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 001	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 002	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 003	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DS DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023	U-936		NCE	Dec 15, 2013
	7897590	Jul 22, 2023	U-936		ODE	Dec 15, 2015
	RE42152	Dec 10, 2018	DP			
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 002					NCE	Mar 30, 2015
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	6572873	May 26, 2020	U-1461			
	6846412	Jul 19, 2022	DP			
	6942165	May 26, 2020	DP			
	7025290	May 26, 2020	DP U-1461			
	7357336	May 26, 2020	U-1461			
	7604185	May 26, 2020	DS DP U-1462			
	7731986	Nov 17, 2024	DS DP U-1463			
	7814943	Nov 19, 2027	DP U-1461			
	7842282	May 26, 2020	U-1461			
	7842283	May 26, 2020	DP			
	8122917	Sep 09, 2024	DP			
	8323677	May 26, 2020	DS			
	RE38919	Oct 14, 2014	DS DP			
	RE40640	Oct 14, 2014	DS DP U-1462			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE ODE	Dec 14, 2017 Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE ODE	Dec 14, 2017 Dec 14, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003 001	5661151	Jul 19, 2019	DS DP U-760			
	5703079	Aug 26, 2014	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
	8263600	Apr 01, 2022	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 001	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 002	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 003	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 005	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 006	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 007	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	7695734	Apr 26, 2028	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	7695734	Apr 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-640			
	6608029	Sep 07, 2013	U-641			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
	6608029	Sep 07, 2013	U-637			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-641			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
	6608029	Sep 07, 2013	U-637			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-641			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N 019898 002	5622985	Apr 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N 019898 003	5622985	Apr 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N 019898 004	5622985	Apr 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N 019898 008	5622985	Apr 22, 2014	U-335			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 001	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 002	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 003	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8168218	Jan 07, 2028	DP U-1269		M-128	Jul 26, 2015
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 001	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 002	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 003	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 004	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 005	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 006	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 007	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 008	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 022488 001	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PROGESTERONE - CRINONE</u>						
N 020701 001	5543150	Sep 15, 2013	U-209			
<u>PROGESTERONE - CRINONE</u>						
N 020701 002	5543150	Sep 15, 2013	U-209			
<u>PROGESTERONE - ENDOMETRIN</u>						
N 022057 001	7300664	Nov 17, 2019	U-856			
	7320800	Nov 17, 2019	U-856			
	7393543	Nov 17, 2019	DP U-880			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 001	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 002	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	5714520	Mar 22, 2015				
	5731355	Mar 22, 2015		U-217		
	5731356	Mar 22, 2015		U-218		
	5908869	Mar 22, 2015		U-270		
	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 002	6500454	Oct 04, 2021	DP			
<u>QUAZEPAM - DORAL</u>						
N 018708 001	7608616	Jun 03, 2028		U-1012		
<u>QUAZEPAM - DORAL</u>						
N 018708 003	7608616	Jun 03, 2028		U-1012		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 001	5948437	May 28, 2017	DP	U-601		
	5948437	May 28, 2017	DP	U-814		
	5948437	May 28, 2017	DP	U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 002	5948437	May 28, 2017	DP	U-601		
	5948437	May 28, 2017	DP	U-814		
	5948437	May 28, 2017	DP	U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 003	5948437	May 28, 2017	DP	U-601		
	5948437	May 28, 2017	DP	U-814		
	5948437	May 28, 2017	DP	U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 004	5948437	May 28, 2017	DP	U-601		
	5948437	May 28, 2017	DP	U-814		
	5948437	May 28, 2017	DP	U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 005	5948437	May 28, 2017	DP	U-601		
	5948437	May 28, 2017	DP	U-814		
	5948437	May 28, 2017	DP	U-839		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 001	5684016	Nov 04, 2014		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 002	5684016	Nov 04, 2014		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 003	5684016	Nov 04, 2014		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 004	5684016	Nov 04, 2014		U-210		
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552*PED	Nov 08, 2013			NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552*PED	Nov 08, 2013			NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N 020815 001	5478847	Mar 02, 2014	U-114	Y	ODE	Sep 13, 2014
	5811120	Mar 02, 2014				
	5972383	Mar 02, 2014	U-287			
	6458811	Mar 10, 2017	DS DP U-825			
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP U-657			
	8030330	Mar 10, 2017	DP			
	RE39050	Mar 02, 2014	U-657			
	RE39050	Mar 02, 2014	U-662			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NPP	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001					NDF	Dec 20, 2016
<u>RAMELTEON - ROZEREM</u>						
N 021782 001	6034239	Jul 22, 2019	DS DP U-674			
<u>RAMIPRIL - ALTACE</u>						
N 019901 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 004	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 004	7368469	Aug 30, 2020	U-871			
<u>RANITIDINE BISMUTH CITRATE - TRITEC</u>						
N 020559 001	5601848	Feb 11, 2014	U-202			
	5629297	May 13, 2014	U-186			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>						
N 021526	001	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP	Y	
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RANOLAZINE - RANEXA</u>						
N 021526	002	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP		
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001	5453446	Feb 07, 2017	U-219		
		5532415	Jul 02, 2013	DS		
		6126968	Sep 18, 2016	DP		
		7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	002	5453446	Feb 07, 2017	U-219		
		5532415	Jul 02, 2013	DS		
		6126968	Sep 18, 2016	DP		
		7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	6403567	Apr 10, 2022	DS DP	U-869	
		6642210	Jun 22, 2019	DS DP	U-869	
		7144872	Jun 22, 2019	DS DP	U-116	
		7144872	Jun 22, 2019	DS DP	U-869	
		7144872	Jun 22, 2019	DS DP	U-870	
		7183264	Jun 22, 2019	DP	U-116	
		7183264	Jun 22, 2019	DP	U-869	
		7183264	Jun 22, 2019	DP	U-870	
		7582617	Jun 22, 2019		U-1003	
		7655636	Jun 22, 2019		U-869	
		7655637	Jun 22, 2019	DS DP	U-869	
		7683037	Jun 22, 2019		U-1042	
		8106029	Jun 22, 2019		U-1042	
		8106183	Feb 02, 2027	DS		
		8133879	Jun 22, 2019	DP		
		8183226	Jun 22, 2019		U-116	
		8470801	Jun 22, 2019		U-116	
		8536150	Jun 22, 2019		U-116	
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001	7351834	Jan 12, 2020	DS	I-667 NCE ODE	Feb 25, 2016 Sep 27, 2017 Feb 25, 2020
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	001	5866591	Sep 10, 2017	DP		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	002	5866591	Sep 10, 2017	DP		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	003	5866591	Sep 10, 2017	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571	002				PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571	003				PC	Jan 20, 2014
<u>RETAPAMULIN - ALTABAX</u>						
N 022055	001	7875630		DS		
		RE39128		DS DP U-805		
		RE43390		DS DP U-805		
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859	001	6150337		U-400		
<u>RIBAVIRIN - REBETOL</u>						
N 020903	001	6172046		U-377		
		6172046		U-1014		
		6177074		U-454		
		6177074		U-1013		
		6461605		U-478		
		6461605		U-1013		
		6472373		U-479		
		6472373		U-1014		
		6524570		U-499		
		6524570		U-1013		
<u>RIBAVIRIN - REBETOL</u>						
N 020903	002	6172046		U-377		
		6172046		U-1014		
		6177074		U-454		
		6177074		U-1013		
		6461605		U-478		
		6461605		U-1013		
		6472373		U-479		
		6472373		U-1014		
		6524570		U-499		
		6524570		U-1013		
<u>RIBAVIRIN - COPEGUS</u>						
N 021511	001				NPP	Aug 09, 2014
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001	6172046		U-521		
		6172046		U-1014		
		6177074		U-1013		
		6461605		U-521		
		6461605		U-1013		
		6472373		U-521		
		6524570		U-1013		
		6790837		DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	7045620		DS DP		
		7612199		DS DP		
		7902206		DS DP		
		7906542		DS DP		
		7928115		U-1121		
		8158644		DP		
		8158781		DS		
		8193196		DS DP		
		8518949		DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	7045620		DS	ODE	Mar 24, 2017
		7612199		DS DP		
		7902206		DS DP		
		7906542		DS DP		
		8158644		DP		
		8158781		DS		
		8193196		DS DP		
		8518949		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP	U-1153		
	7125879	Apr 14, 2023	DS DP	U-1307		
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 001	5583122	Dec 10, 2013		U-222		
	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 002	5583122	Dec 10, 2013		U-222		
	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 003	5583122	Dec 10, 2013	DS DP	U-222		
	5583122	Dec 10, 2013	DS DP	U-756		
	5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 004	5583122	Dec 10, 2013	DS DP	U-353		
	6165513	Jun 10, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	5583122	Dec 10, 2013	DS DP	U-353		
	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	5583122	Dec 10, 2013	DS DP	U-662	NDF	Oct 08, 2013
	5622721	Apr 21, 2014	DP	U-662		
	7645459	Jan 09, 2028	DP	U-662		
	7645460	Jan 09, 2028	DP	U-662		
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 020588 001	5453425	Jul 11, 2014	DP			
	RE39181	Jul 11, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	5965168	Nov 19, 2013	DP			
	6110921	Nov 19, 2013			U-543	
	6194006	Dec 30, 2018	DP			
	6368632	Nov 19, 2013			U-543	
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	7547452	Nov 19, 2013	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	5965168	Nov 19, 2013	DP			
	6110921	Nov 19, 2013			U-543	
	6194006	Dec 30, 2018	DP			
	6368632	Nov 19, 2013			U-543	
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	7547452	Nov 19, 2013	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	5965168	Nov 19, 2013	DP			
	6110921	Nov 19, 2013			U-543	
	6194006	Dec 30, 2018	DP			
	6368632	Nov 19, 2013			U-543	
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	7547452	Nov 19, 2013	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	5965168	Nov 19, 2013	DP			
	6110921	Nov 19, 2013			U-543	
	6194006	Dec 30, 2018	DP			
	6368632	Nov 19, 2013			U-543	
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	7547452	Nov 19, 2013	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 001	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 002	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 003	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 004	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 005	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RITONAVIR - NORVIR</u>						
N 020659 001	5484801	Jan 28, 2014				
	5541206	Jul 30, 2013		U-140		
	5635523	Jul 30, 2013		U-190		
	5648497	Jul 15, 2014				
	5674882	Jul 30, 2013		U-688		
	5948436	Sep 13, 2013	DP			
	6037157	Jun 26, 2016				
	6703403	Jun 26, 2016		U-564		
<u>RITONAVIR - NORVIR</u>						
N 020680 001	5541206	Jul 30, 2013		U-140		
	5635523	Jun 03, 2014		U-190		
	5648497	Jul 15, 2014				
	5948436	Sep 13, 2013				
<u>RITONAVIR - NORVIR</u>						
N 020945 001	5541206	Jul 30, 2013		U-348		
	5635523	Jul 30, 2013		U-347		
	5648497	Jul 15, 2014				
	5674882	Jul 30, 2013		U-895		
	5948436	Sep 13, 2013	DP			
	6037157	Jun 26, 2016		U-895		
	6232333	Nov 07, 2017				
	6703403	Jun 26, 2016		U-564		
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	5541206	Jul 30, 2013	DS DP	U-688		
	5635523	Jul 30, 2013		U-688		
	5648497	Jul 15, 2014	DS			
	5674882	Jul 30, 2013		U-688		
	6037157	Jun 26, 2016		U-688		
	6703403	Jun 26, 2016		U-688		
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP	U-688		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Feb 08, 2021	DS DP U-1301		I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1302		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Feb 08, 2021	DS DP U-1301		I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP U-1302		I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-661	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1200		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Feb 08, 2021	DS DP U-1301		I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP U-1302		I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-661	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1200		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 001	5602176	Feb 11, 2014	DS DP U-322			
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 002	5602176	Feb 11, 2014	DS DP U-322			
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005	5602176	Feb 11, 2014	DS DP U-322		NPP	Jun 27, 2016
	6316023	Jan 08, 2019	DP		NS	Aug 31, 2015
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N 020823 003	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N 020823 004	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N 020823 005	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N 020823 006	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N 021025 001	5602176	Feb 11, 2014	U-322			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864 002					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865 001	5457895	Oct 01, 2013	DP		NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865 002	5457895	Oct 01, 2013	DP		NPP	Dec 16, 2014
					PED	Jun 16, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFECOXIB - VIOXX</u>						
N 021042 001	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 002	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 003	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021052 001	5691374 6063811	May 18, 2015 May 06, 2017	U-266			
<u>ROFECOXIB - VIOXX</u>						
N 021052 002	5691374 6063811	May 18, 2015 May 06, 2017	U-266			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298 8431154 8536206 8604064	Jan 27, 2015 Feb 19, 2023 Mar 08, 2024 Mar 08, 2024	DS DP U-1115 DP U-1115 U-1115		NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393 001	4977138 7608280 7611724	Aug 22, 2013 Aug 22, 2021 Aug 22, 2021	DS DP DS DS		NCE ODE ODE	Nov 05, 2014 Nov 05, 2016 Jun 16, 2018
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524 5834489	Sep 23, 2014 May 26, 2014	DS DP U-833 DS DP U-838			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524 5834489	Sep 23, 2014 May 26, 2014	DS DP U-833 DS DP U-838			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524 5834489	Sep 23, 2014 May 26, 2014	DS DP U-833 DS DP U-838			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524 5834489	Sep 23, 2014 May 26, 2014	DS DP U-833 DS DP U-838			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018	U-106		ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018	U-106		ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018	U-106		ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018	U-106		ODE	Nov 14, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	7598257	Dec 24, 2027	DS DP U-1201		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	7598257	Dec 24, 2027	DS DP U-1201		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N 020692 001	5873360	Feb 23, 2016	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989			
	7612073	Nov 17, 2024	U-1010			
	7727987	Nov 17, 2024	DP			
	7947681	Nov 17, 2024	U-1156			
	8003126	Nov 16, 2025				
	8067416	Nov 17, 2024	U-989			
	8318745	Nov 17, 2024	DP			
	RE43797	Nov 17, 2024	U-1156			
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828 001	6008228	Jun 06, 2015				
	6352717	Nov 16, 2019				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N 021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N 021479 001	5648093	Jul 15, 2014	DP			
	6423342	Mar 01, 2016	DP			
<u>SERTACONAZOLE NITRATE - ERTACZO</u>						
N 021385 001	5135943	May 31, 2014	DS DP U-786			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001	5496545	Aug 11, 2013	DP U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
	7985418	Oct 27, 2025	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	5496545	Aug 11, 2013	DP U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	5496545	Aug 11, 2013	DP U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 020926 001	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 001	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 002	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVOFLURANE - ULTANE</u>						
N 020478 001	5990176	Jan 27, 2017				
	6074668	Jan 09, 2018				
	6288127	Jan 27, 2017				
	6444859	Jan 27, 2017				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 001	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 002	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 003	6469012	Oct 22, 2019	U-155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				M-61 PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				M-61 PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				NDF PED	Aug 30, 2015 Mar 01, 2016
<u>SILODOSIN - RAPAFLO</u>						
N 022206	001 5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
<u>SILODOSIN - RAPAFLO</u>						
N 022206	002 5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
<u>SIMEPREVIR - OLYSIO</u>						
N 205123	001 7671032	May 19, 2025	DS DP		NCE	Nov 22, 2018
	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020				U-172
	5968973	Apr 10, 2017				U-172
	7858662	Oct 02, 2026	DP			U-172
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001	5100899	Jul 07, 2013				U-290
	5536729	Sep 30, 2013	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5100899	Jul 07, 2013				U-290
	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5100899	Jul 07, 2013				U-290
	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5100899	Jul 07, 2013				U-290
	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5100899	Jul 07, 2013				U-290
	5989591	Mar 11, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP		ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024			U-1110	
	7765106	Jun 16, 2024			U-1069	
	7765107	Jun 16, 2024			U-1070	
	7851506	Dec 22, 2019			U-1101	
	7851506	Dec 22, 2019			U-1102	
	7895059	Dec 17, 2022			U-1110	
	8263650	Dec 22, 2019	DP		U-1101	
	8263650	Dec 22, 2019	DP		U-1102	
	8324275	Dec 22, 2019			U-1101	
	8324275	Dec 22, 2019			U-1102	
	8457988	Dec 17, 2022			U-1110	
	8589182	Dec 17, 2022			U-1110	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N 019640 001					ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N 019640 004					ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N 019640 005					ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N 019640 006					ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N 019640 007					ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 001	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 002	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 003	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 005	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 008	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 009	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 010	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 011	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 012	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 013	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N 020522 001	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N 020522 002	5763394	Jun 09, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 001	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 004	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 001	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 002	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 003	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 001	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 002	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 003	5633352	May 27, 2014			ODE	May 31, 2014
	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 004	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 005	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 006	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	5849700	Dec 15, 2015	U-340		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	5849700	Dec 15, 2015	U-1041		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	5849700	Dec 15, 2015	U-1041		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	5849700	Dec 15, 2015	U-1041		ODE	May 31, 2014
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N 021597 004	5898030	Apr 27, 2016	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	7235576	Jan 12, 2020	DS DP		I-677	Nov 22, 2016
	7351834	Jan 12, 2020	DS		ODE	Nov 16, 2014
	7897623	Jan 12, 2020	DP		ODE	Nov 22, 2020
	8124630	Jul 13, 2022	U-1459			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001					ODE	Jul 02, 2016
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jun 22, 2019	DP U-1105		NCE	Jan 18, 2016
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 003	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2016	DS U-1468		NP	Nov 27, 2016
<u>SUMATRIPTAN - IMITREX</u>						
N 020626 001	5554639	Sep 10, 2013	U-232			
<u>SUMATRIPTAN - IMITREX</u>						
N 020626 002	5554639	Sep 10, 2013	U-232			
<u>SUMATRIPTAN - IMITREX</u>						
N 020626 003	5554639	Sep 10, 2013	U-232			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 001	5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 002	5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-1184			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975		ODE	May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807 001	6127425	Jun 26, 2018	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001	6071970	Jun 06, 2017	U-931		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002	6071970	Jun 06, 2017	U-931		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003	6071970	Jun 06, 2017	U-931		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001	6071970	Jun 06, 2017	U-1289		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-1289			
	RE39593	Aug 05, 2022	DS DP U-1289			
<u>TAZAROTENE - TAZORAC</u>						
N 020600 001	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			
<u>TAZAROTENE - TAZORAC</u>						
N 020600 002	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N 020887 001	5645815	Jul 08, 2014				
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N 019882 001	5573748	Nov 12, 2013	DP			
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858 001					ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928 001	6056941	Jul 28, 2019	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2020	DS		NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		NCE	Dec 21, 2017
	7056886	Sep 18, 2022	DP U-1320		ODE	Dec 21, 2019
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	7820671	Feb 25, 2025	DS DP		NCE	May 23, 2016
	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021	U-282			
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021	U-282			
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELIVUDINE - TYZEKA</u>						
N 022011 001	6395716	Aug 10, 2019	U-782		M-124	Jan 28, 2016
	6444652	Aug 10, 2019	U-782			
	6566344	Aug 10, 2019	U-782			
	6569837	Oct 25, 2020	U-782			
	6569837	Oct 25, 2020	U-999			
	7589079	Sep 11, 2023	DS DP U-999			
	7795238	Aug 10, 2019	U-999			
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELIVUDINE - TYZEKA</u>						
N 022154 001	6395716	Aug 10, 2019	U-999		M-124	Jan 28, 2016
	6444652	Aug 10, 2019	U-999			
	6566344	Aug 10, 2019	U-999			
	6569837	Oct 25, 2020	U-999			
	7795238	Aug 10, 2019	U-999			
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 001	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 002	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELMISARTAN - MICARDIS</u>						
N 020850 001	5591762	Jan 07, 2014	U-3			
	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N 020850 002	5591762	Jan 07, 2014	DS DP U-3			
	6358986	Jan 10, 2020				
	7998953	Jun 06, 2020	U-1177			
	8003679	Oct 06, 2022	U-1176			
<u>TELMISARTAN - MICARDIS</u>						
N 020850 003	5591762	Jan 07, 2014	U-3			
	6358986	Jan 10, 2020				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 001	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 002	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 003	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 004	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 005	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 021029 006	5260291	Aug 11, 2013	DS DP U-619			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	5260291	Aug 11, 2013	DS DP U-619			
	6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Apr 18, 2014	DS DP		M-61	May 30, 2015
	8026276	Jan 20, 2026	DP		M-92	Jul 09, 2013
	8299116	Jul 25, 2023	DP		ODE	May 30, 2014
	8455539	Jul 25, 2023	DP		PED	Jan 09, 2014
	8455539*PED	Jan 25, 2024			PED	Oct 26, 2013
					PED	Nov 30, 2014
					PED	Nov 30, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-999		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TERBINAFINE - LAMISIL</u>						
N 020846 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFINE - LAMISIL AT</u>						
N 021958 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 001	5681849	Oct 28, 2014				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 002	5681849	Oct 28, 2014				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 003					NS	Oct 20, 2014
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 004					NS	Oct 20, 2014
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791 001	6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - FORTESTA</u>						
N 021463 001	6319913	Nov 09, 2018	U-490		NP	Dec 29, 2013
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - STRIANT</u>						
N 021543 001	6248358	Aug 23, 2019	U-527			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP		NP	Apr 29, 2014
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP		NP	Apr 29, 2014
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	6299900	Feb 19, 2017	DP U-1103		NP	Nov 23, 2013
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
	8071075	Feb 19, 2017	DP U-1103			
	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 202763 001					NP	Feb 14, 2015
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TETRABENAZINE - XENAZINE</u>						
N 021894 001					NCE	Aug 15, 2013
					ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N 021894 002					NCE	Aug 15, 2013
					ODE	Aug 15, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	5629327	May 13, 2014	U-731			
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	5629327	May 13, 2014	U-731			
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	5629327	May 13, 2014	U-731			
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	5629327	May 13, 2014	U-731			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N 020898 001	5840566	Nov 24, 2015			ODE	Dec 14, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 001	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 002	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 003	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 004	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 005	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	RE40183	Apr 09, 2016	DS DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 001	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 002	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6335335	Nov 02, 2018	DP			
	6645963	Nov 02, 2018	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7642268	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
<u>TIPRANAVIR - APTIVUS</u>						
N 021814 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
	6169181	May 06, 2014	DS			
	6231887	Jul 27, 2018	DP			
<u>TIPRANAVIR - APTIVUS</u>						
N 022292 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
	6169181	May 06, 2014	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
TIROFIBAN HYDROCHLORIDE - AGGRASTAT						
N 020912 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	May 01, 2023				
TIROFIBAN HYDROCHLORIDE - AGGRASTAT						
N 020913 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
TIROFIBAN HYDROCHLORIDE - AGGRASTAT						
N 020913 002	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
TIROFIBAN HYDROCHLORIDE - AGGRASTAT						
N 020913 003	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
TOBRAMYCIN - TOBI						
N 050753 001	5508269	Oct 19, 2014		DP U-909		
TOBRAMYCIN - TOBI PODHALER						
N 201688 001	7097827	Apr 16, 2016		DP	NP	Mar 22, 2016
	7368102	Dec 19, 2022		DP U-909		
	7442388	May 10, 2020		DP		
	7516741	Jan 11, 2024		DP		
	7559325	Oct 27, 2025		DP		
	8069851	Sep 24, 2024		DP		
	8349294	May 10, 2020		DP		
TOBRAMYCIN - BETHKIS						
N 201820 001	6987094	Sep 22, 2022		DP		
	7696178	Mar 17, 2023		DP		
	7939502	Jun 14, 2022		U-1324		
TOFACITINIB CITRATE - XELJANZ						
N 203214 001	6956041	Dec 08, 2020		DP	NCE	Nov 06, 2017
	6965027	Mar 25, 2023		DS		
	7091208	Dec 08, 2020		U-247		
	7265221	Dec 08, 2020		DS		
	7301023	May 23, 2022		DS		
	RE41783	Dec 08, 2020		DS		
TOLTERODINE TARTRATE - DETROL LA						
N 021228 001	6630162	Nov 11, 2019		DP U-544		
	6770295	Aug 26, 2019		DP U-544		
	6911217	Nov 11, 2019		DP U-544		
	6911217*PED	May 11, 2020				
TOLTERODINE TARTRATE - DETROL LA						
N 021228 002	6630162	Nov 11, 2019		DP U-544		
	6770295	Aug 26, 2019		DP U-544		
	6911217	Nov 11, 2019		DP U-544		
	6911217*PED	May 11, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP		NCE	May 19, 2014
	5753677	May 19, 2015	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003	5998380	Oct 13, 2015		U-598		
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006	5998380	Oct 13, 2015		U-598		
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7125560	Mar 01, 2019		U-766		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002	5998380	Oct 13, 2015		U-598	NPP	Jul 15, 2014
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7125560	Mar 01, 2019		U-766		
	7498311	Oct 13, 2015		U-955		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003	5998380	Oct 13, 2015		U-598		
	6503884	Oct 13, 2015		U-598		
	7018983	Oct 13, 2015		U-723		
	7125560	Mar 01, 2019		U-766		
	7498311	Oct 13, 2015		U-955		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020671 001	5674872	Oct 07, 2014	U-910			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 001	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 002	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693 001	6106861	Dec 05, 2017	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 001	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 002	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 003	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	8580304	Jan 28, 2032	DP		ODE	May 29, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 001	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 002	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 003	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 004	5721244	Feb 24, 2015				
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN</u>						
N 021257 001	5510383	Aug 03, 2013	DP U-383			
	5631287	Dec 22, 2014	U-382			
	5849792	Dec 22, 2014	DP U-383			
	5889052	Dec 02, 2014	DP U-383			
	6011062	Dec 22, 2014	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	5510383	Aug 03, 2013	DP U-383			
	5889052	Dec 02, 2014	DP U-383			
	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 001	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 002	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	5153222	Oct 16, 2014		U-1019	ODE	Jul 30, 2016
	6521212	Nov 13, 2018		U-1018		
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 001	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 002	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 003	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - ORENITRAM</u>						
N 203496 004	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 001	5955109	Sep 21, 2016	DP U-134			
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 002	5955109	Sep 21, 2016	U-134			
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - ATRALIN</u>						
N 022070 001	5670547	Sep 23, 2014	DP			
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N 022048 001	6395294	Jan 13, 2020	DP U-846			
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1257			
	8211880	Mar 10, 2029	U-1258			
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSQL</u>						
N 074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 020715 001	5776885	Jul 07, 2015				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 021288 001	5776885	Jul 07, 2015	DP			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	5776885	Jul 07, 2015	DP			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 001	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 002	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 003	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TROGLITAZONE - REZULIN</u>						
N 020720 001	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 002	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 003	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROSPIMUM CHLORIDE - SANCTURA XR</u>						
N 022103 001	7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 001	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 002	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N 022278 001					ODE	Feb 20, 2016
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389		NCE	Aug 13, 2015
	8512745	Feb 14, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	5873360	Feb 23, 2016	DP			
	7361787	Mar 23, 2023	DS DP	U-1476		
	7439393	Sep 11, 2022	DS DP	U-1476		
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025		U-1476		
	8309572	Apr 27, 2025		U-1476		
	8511304	Nov 11, 2025	DP	U-1476		
	8534281	Aug 10, 2029	DP			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP	U-1322		
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 005	5767067	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 001	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 002	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 002	5633272	Feb 13, 2015	U-462			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 003	5633272	Feb 13, 2015	U-462			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001	6083953	Mar 29, 2015	DS DP U-384		D-125	Aug 05, 2013
	6083953	Mar 29, 2015	DS DP U-854			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	6083953	Mar 29, 2015	DS DP U-384			
	6083953	Mar 29, 2015	DS DP U-854			
<u>VALSARTAN - DIOVAN</u>						
N 021283 001	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 002	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 003	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 004	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Sep 23, 2017	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Sep 23, 2017	DS DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	6362178	Oct 31, 2018	U-155			
	7696206	Oct 31, 2018	U-155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 03, 2022	DS DP U-56			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 03, 2022	DS DP U-56			
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 001					M-130 NCE	Nov 21, 2016 Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 002					M-130 NCE	Nov 21, 2016 Feb 26, 2015
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		ODE	Aug 17, 2018
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026		U-1418		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 001	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 002	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 003	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 004	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 001	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 002	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 003	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 004	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 001	6096339	Apr 04, 2017	U-365			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 002	6096339	Apr 04, 2017	U-365			
<u>VERTEPORFIN - VISUDYNE</u>						
N 021119 001	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016	U-357			
	5770619	Jan 06, 2015	U-357			
	5798349	Aug 25, 2015	U-357			
<u>VIGABATRIN - SABRIL</u>						
N 020427 001					NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					PED	Feb 21, 2015
					PED	Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006 001					NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2017
					PED	Apr 26, 2017
					PED	Feb 21, 2015
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N 202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020		U-1271		
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020		U-1271		
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORICONAZOLE - VORICONAZOLE</u>						
A 202361 001					PC	Mar 24, 2014
<u>VORICONAZOLE - VFEND</u>						
N 021266 001	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N 021266 002	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N 021267 001	5567817	May 24, 2016	DS DP U-540			
	6632803	Jun 02, 2018	DP			
<u>VORICONAZOLE - VFEND</u>						
N 021630 001	5567817	May 24, 2016	DS DP U-540			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	7399787	Feb 09, 2025		U-892	ODE	Oct 06, 2013
	7456219	Mar 11, 2027	DS			
	7652069	Mar 04, 2023	DP			
	7732490	Mar 04, 2023		U-892		
	7851509	Feb 21, 2024	DP	U-892		
	8067472	Mar 04, 2023		U-892		
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023		U-892		
	RE38506	Jul 07, 2015	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>ZAFIRLUKAST - ACCOLATE</u>						
N 020547 001	5612367	Mar 18, 2014		U-189		
<u>ZAFIRLUKAST - ACCOLATE</u>						
N 020547 003	5612367	Mar 18, 2014		U-189		
<u>ZANAMIVIR - RELENZA</u>						
N 021036 001	5360817	Jul 26, 2013	DS DP			
	5648379	Jul 15, 2014		U-274		
	5648379	Jul 15, 2014		U-721		
	5648379	Jul 15, 2014		U-722		
	6294572	Dec 15, 2014	DS DP			
<u>ZICONOTIDE - PRIALT</u>						
N 021060 003	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	5795864	Jun 27, 2015	DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	5795864	Jun 27, 2015	DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	5795864	Jun 27, 2015	DP			
<u>ZILEUTON - ZYFLO CR</u>						
N 022052 001	6183778	Sep 21, 2013	DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483 001	6150366	May 27, 2019	DP	U-719		
	6245766	Dec 18, 2018		U-601		
	7175855	May 18, 2020	DP			
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N 020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 002	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 003	7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004	6750237	Nov 28, 2020	DP			
	7220767	Nov 28, 2020	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 001	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 002	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	7632517	Oct 01, 2017	U-70			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 001	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 002	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 62

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

PATENT AND EXCLUSIVITY TERMS

ADB 2 of 62

EXCLUSIVITY DOSING SCHEDULE

D-34 EVERY FOUR MONTHS DOSAGE REGIMEN

D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS

D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY

D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)

D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION

D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."

D-40 ONCE-A-DAY DOSING REGIMEN

D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS

D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD

D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED

D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY

D-46 NEW DOSING REGIMEN OF 80MG DAILY

D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL

D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL

D-49 PEDIATRIC DOSING GUIDELINES

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

D-51 OPTIONAL STARTING DOSE OF 40MG/DAY

D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY

D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE

D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS

D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)

D-56 ADDITION OF POSTPRANDIAL DOSING

D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER

D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION

D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN

D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE

D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML

D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS

D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI

D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES

D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

D-70 80MG ONCE DAILY DOSING REGIMEN

D-71 EIGHT WEEK DOSING REGIMEN

D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPAON

D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH

PATENT AND EXCLUSIVITY TERMS

ADB 3 of 62

EXCLUSIVITY DOSING SCHEDULE

NEW CYCLE

- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 62

EXCLUSIVITY DOSING SCHEDULE

D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEOSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 62

EXCLUSIVITY INDICATION

I-14 SEBORRHEIC DERMATITIS
 I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
 I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
 I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
 I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
 I-19 HERNIOGRAPHY
 I-20 KNEE ARTHROGRAPHY
 I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
 I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
 I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
 I-24 TREATMENT OF RHEUMATOID ARTHRITIS
 I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
 I-26 TREATMENT OF LIVER FLUKES
 I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
 I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
 I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
 I-30 TREATMENT OF TINEA PEDIS
 I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
 I-32 PEDIATRIC MYELOGRAPHY
 I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
 I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
 I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
 I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
 I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
 I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
 I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION
 I-40 PRIMARY NOCTURNAL ENURESIS
 I-41 MIGRAINE HEADACHE PROPHYLAXIS
 I-42 HERPES ZOSTER
 I-43 HERPES SIMPLEX ENCEPHALITIS
 I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
 I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
 I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
 I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
 I-48 PEDIATRIC ANGIOCARDIOGRAPHY
 I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
 I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
 I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
 I-52 PEDIATRIC EXCRETORY UROGRAPHY
 I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
 I-54 RENAL CONCENTRATION CAPACITY TEST
 I-55 HYPERTENSION
 I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE
 I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
 I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
 I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
 I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
 I-61 FEMALE ANDROGENETIC ALOPECIA

PATENT AND EXCLUSIVITY TERMS

ADB 6 of 62

EXCLUSIVITY INDICATION

I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
 I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
 I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
 I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
 I-66 UNCOMPLICATED GONORRHEA
 I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
 I-68 CENTRAL PRECOCIOUS PUBERTY
 I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
 I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
 I-71 VARICELLA INFECTIONS (CHICKENPOX)
 I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
 I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
 I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
 I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
 I-76 PREVENTION OF OSTEOPOROSIS
 I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
 I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
 I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
 I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
 I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
 I-82 TREATMENT OF TRAVELERS' DIARRHEA
 I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
 I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
 I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
 I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY
 I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
 I-88 MANAGEMENT OF ENDOMETRIOSIS
 I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
 I-90 INTENSIVE CARE UNIT SEDATION
 I-91 MONOTHERAPY USE FOR HYPERTENSION
 I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
 I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
 I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
 I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
 I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
 I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
 I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
 I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
 I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
 I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
 I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
 I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
 I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
 I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
 I-106 TREATMENT OF ACROMEGALY
 I-107 VAGINAL CANDIDIASIS
 I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
 I-109 TYPHOID FEVER

PATENT AND EXCLUSIVITY TERMS

ADB 7 of 62

EXCLUSIVITY INDICATION

I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
 I-111 TREATMENT OF PAGET'S DISEASE OF BONE
 I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
 I-113 TREATMENT OF PROSTATITIS
 I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
 I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
 I-116 MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS
 I-117 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
 I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
 I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
 I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
 I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
 I-122 PSORIASIS OF THE SCALP
 I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
 I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
 I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
 I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
 I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
 I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCLARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
 I-129 TREATMENT OF ALCOHOL DEPENDENCE
 I-130 MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS
 I-131 PERIPHERAL ARTERIOGRAPHY
 I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
 I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
 I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
 I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
 I-136 IDIOPATHIC CHRONIC URTICARIA
 I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
 I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
 I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
 I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
 I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
 I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
 I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
 I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
 I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
 I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
 I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
 I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
 I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
 I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
 I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
 I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
 I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
 I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
 I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
 I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
 I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES

PATENT AND EXCLUSIVITY TERMS

ADB 8 of 62

EXCLUSIVITY INDICATION

I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER

I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS

I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY

I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE

I-163 TREATMENT OF PHOTOPHOBIA

I-164 CHRONIC BACTERIAL PROSTATITIS

I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

I-166 TREATMENT OF BULIMIA

I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS

I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)

I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER

I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS

I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD

I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES

I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY

I-174 PELVIC INFLAMMATORY DISEASE

I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS

I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS

I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN

I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE

I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)

I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION

I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME

I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11

I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)

I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)

I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS

I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS

I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS

I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING

I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION

I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY

I-194 CONGESTIVE HEART FAILURE

I-195 FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER

I-198 FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 62

EXCLUSIVITY INDICATION

I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES

I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR

I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS

I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA

I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-205 INITIAL ANTICONSULSANT TREATMENT OF STATUS EPILEPTICUS

I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE

I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS

I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION

I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)

I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS

I-211 FOR USE IN PEDIATRIC POPULATION

I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME

I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY

I-214 TREATMENT OF OSTEOPOROSIS

I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS

I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET

I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH

I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN

I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS

I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL

I-229 PRILOSEC (OMEPRazole), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 10 of 62

EXCLUSIVITY INDICATION

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER

I-245 TREATMENT OF ACUTE SINUSITIS

I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY

I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY

I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

PATENT AND EXCLUSIVITY TERMS

ADB 11 of 62

EXCLUSIVITY INDICATION

I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES

I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA

I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)

I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER

I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY

I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS

I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE

I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III

I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH

I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE

I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 12 of 62

EXCLUSIVITY INDICATION

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
 I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
 I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
 I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
 I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
 I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
 I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
 I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
 I-321 JUVENILE RHEUMATOID ARTHRITIS
 I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
 I-323 COLORECTAL CANCER
 I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
 I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
 I-326 GENERALIZED ANXIETY DISORDER
 I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
 I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
 I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
 I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
 I-331 TREATMENT OF MODERATE ACNE VULGARIS
 I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
 I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
 I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
 I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
 I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
 I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
 I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
 I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
 I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
 I-341 BREAST CANCER COMBINATION THERAPY
 I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
 I-343 USE OF COREG FOR SEVERE HEART FAILURE
 I-344 ACNE VULGARIS
 I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
 I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
 I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
 I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
 I-349 ACUTE CORONARY SYNDROME
 I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
 I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
 I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
 I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS

PATENT AND EXCLUSIVITY TERMS

ADB 13 of 62

EXCLUSIVITY INDICATION

I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
 I-355 PREMENSTRUAL DYSPHORIC DISORDER
 I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
 I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
 I-358 TREATMENT OF PANIC DISORDER
 I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
 I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
 I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
 I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
 I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
 I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
 I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
 I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
 I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
 I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
 I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
 I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
 I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
 I-372 NOSOCOMIAL PNEUMONIA
 I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
 I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
 I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
 I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
 I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
 I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
 I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
 I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
 I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
 I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
 I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
 I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
 I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
 I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
 I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
 I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
 I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
 I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &

PATENT AND EXCLUSIVITY TERMS

ADB 14 of 62

EXCLUSIVITY INDICATION

I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 15 of 62

EXCLUSIVITY INDICATION

I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 62

EXCLUSIVITY INDICATION

I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS

I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)

I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN

I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER

I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED

I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE

I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION

I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME

I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER

I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS

I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES

I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION

I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN

I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE

I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE

I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER

I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN

I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS

I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE

I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS

I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOETAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES

I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE

I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES

I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS

I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI

I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER

I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER

I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES

I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE

I-491 INFLUENZA PROPHYLAXIS

I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES

I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS

ADB 17 of 62

EXCLUSIVITY INDICATION

MIXED HYPERLIPIDEMIA

- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 62

EXCLUSIVITY INDICATION

I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESES

I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY

I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER

I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

I-566 MANAGEMENT OF FIBROMYALGIA

I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD

PATENT AND EXCLUSIVITY TERMS

ADB 19 of 62

EXCLUSIVITY INDICATION

PRESSURE GOALS

I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR

I-569 TREATMENT OF CHRONIC HEPATITIS B

I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE

I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER

I-572 TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.

I-573 TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET

I-574 MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION

I-575 MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA

I-576 ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA

I-577 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

I-578 EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS

I-579 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION

I-580 INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN

I-581 TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-582 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

I-583 ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)

I-584 TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOID FOR AT LEAST 12 MONTHS

I-585 TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS

I-586 COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

I-587 ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION

I-588 ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION

I-589 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE

I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)

I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE

I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)

I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)

I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING

I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS

I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY

I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE

I-603 GOUT FLARES

I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK

I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER

I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY

I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS

I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH

PATENT AND EXCLUSIVITY TERMS

ADB 20 of 62

EXCLUSIVITY INDICATION

HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
 I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
 I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
 I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
 I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
 I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
 I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
 I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
 I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
 I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
 I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
 I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
 I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
 I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
 I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
 I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
 I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
 I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
 I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
 I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
 I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
 I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
 I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
 I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
 I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
 I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
 I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
 I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
 I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
 I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
 I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
 I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
 I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
 I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
 I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
 I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
 I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 62

EXCLUSIVITY INDICATION

I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)

I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY

I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY

I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA

I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS

I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE

I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE

I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

I-657 PLAQUE PSORIASIS OF THE SCALP

I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY

I-659 PLAQUE PSORIASIS OF THE BODY

I-660 TREATMENT OF DEEP VEIN THROMBOSIS

I-661 TREATMENT OF PULMONARY EMBOLISM

I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM

I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT) SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L

I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY

I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE

I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA- APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE

I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

PATENT AND EXCLUSIVITY TERMS

ADB 22 of 62

EXCLUSIVITY MISCELLANEOUS

M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT
HEARTBURN ADDED TO CLINICAL STUDIES SECTION

M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1)
IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE
DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE

M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED
CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND
EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD

M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED
CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION

M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE
COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION

M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION

M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35
NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES
CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART
RATE, AND HEART RATE VARIABILITY

M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF
DOSING

M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

M-12 NEW LANGUAGE FOR PEDIATRIC USE

M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS,
AND DOSAGE AND ADMINISTRATION

M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT

M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART
DISEASE

M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS
WITH MAJOR DEPRESSIVE DISORDER (MDD)

M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER

M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME

M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR

M-22 CHANGE IN TIME TO ONSET OF ACTION

M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN
PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT

M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC
SAFETY INFORMATION

M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF
AGE ADDED TO PKG INSERT

M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE
REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION
WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01

M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE
FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY

M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL
CONDITION

M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN
ADOLESCENTS AGED 12 TO 16 YEARS

M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH
HYPERTENSION

M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5
(END-STAGE RENAL DISEASE)

M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES

M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH
ASTHMA

M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO
PEDIATRIC WRITTEN REQUEST

M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION
WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY

M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR
DISEASE

M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES
DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE
SUBSECTIONS

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 62

EXCLUSIVITY MISCELLANEOUS

M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL

M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS

M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"

M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION

M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION

M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18

M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY

M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY

M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS

M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES

M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN

M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION

M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY

M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT

M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL

M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.

M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL

M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS

M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS

M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS

M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA

M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES

M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY

M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS

M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)

M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER

M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL

M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY

M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 62

EXCLUSIVITY MISCELLANEOUS

	70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.

PATENT AND EXCLUSIVITY TERMS

ADB 25 of 62

EXCLUSIVITY MISCELLANEOUS

M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.

M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS

M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL

M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."

M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING

M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY

M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE

M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT

M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".

M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057

M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL

M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL

M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS

M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS

M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS

M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)

M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES

M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008

M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL

M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

M-119 LABELING CHANGES REGARDING MISSED DOSES

M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS

M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43

M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL

M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS

M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE

M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086

M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004

M-128 CLINICAL TRIAL STUDY RESULTS

M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE

M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT

M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 62

PATENT USE

U-1 PREVENTION OF PREGNANCY
U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3 TREATMENT OF HYPERTENSION
U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5 METHOD OF PRODUCING BRONCHODILATION
U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7 INCREASING CARDIAC CONTRACTILITY
U-8 ACUTE MYOCARDIAL INFARCTION
U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16 USE IN LUNG SCANNING PROCEDURES
U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19 TREATMENT OF INFLAMMATION
U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36 METHODS OF TREATING BACTERIAL ILLNESSES
U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39 ANGINA PECTORIS
U-40 METHOD OF TREATMENT OF BURNS
U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44 RELIEF OF NAUSEA AND VOMITING
U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
U-46 TREATMENT OF PANIC DISORDER
U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48 ANALGESIA
U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50 USE IN TREATING INFLAMMATORY DERMATOSES
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53 HYPERCALCEMIA OF MALIGNANCY

PATENT AND EXCLUSIVITY TERMS

ADB 27 of 62

PATENT USE

U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
 U-55 TREATMENT OF PAIN
 U-56 AID TO SMOKING CESSATION
 U-57 OPHTHALMIC USE OF NORFLOXACIN
 U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
 U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
 U-60 NASAL ADMINISTRATION OF BUTORPHANOL
 U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
 U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
 U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
 U-64 TREATMENT OF VIRAL INFECTIONS
 U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
 U-66 TRIPHASIC REGIMEN
 U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
 U-68 TREATMENT OF ACTINIC KERATOSIS
 U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
 U-70 TREATMENT OF TRANSIENT INSOMNIA
 U-71 METHOD OF TREATMENT OF HEART FAILURE
 U-72 TREATMENT OF MIGRAINE
 U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
 U-74 METHOD OF PROVIDING HYPNOTIC EFFECT
 U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
 U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
 U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
 U-78 ULCERATIVE COLITIS
 U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
 U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
 U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
 U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
 U-83 TREATMENT OF SEIZURES
 U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
 U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
 U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
 U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS
 U-89 TREATMENT OR PROPHYLAXIS OF EMESIS
 U-90 TREATMENT OF PYSCHOTIC DISORDERS
 U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
 U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
 U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT
 U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
 U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
 U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
 U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
 U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
 U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
 U-100 METHOD OF TREATING OCULAR INFLAMMATION
 U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
 U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
 U-103 TREATMENT OF OCULAR HYPERTENSION
 U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
 U-105 EMESIS
 U-106 TREATMENT OF EPILEPSY
 U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
 U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 62

PATENT USE

ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE USE AS A RETRIEVABLE PERSSARY

U-110

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

U-132 INHIBITING HIV PROTEASE

U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

PATENT AND EXCLUSIVITY TERMS

ADB 29 of 62

PATENT USE

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS

U-185 METHOD OF TREATING HYPERTENSION

U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT

U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER

U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE

U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR

U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

U-192 USE IN TREATING ALLERGIC REACTIONS

U-193 PSORIASIS

U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE

U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON

U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS

U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA

U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 62

PATENT USE

PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-205 METHOD FOR TREATING HEARTBURN

U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION

U-207 USE AS NASAL SPRAY

U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION

U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE

U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE

U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA

U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT

U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS

U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE

U-217 METHOD OF PRODUCING ANESTHESIA

U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT

U-219 TREATMENT OF PARKINSON'S DISEASE

U-220 METHOD OF DIAGNOSIS

U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION

U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL

U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS

U-224 CONTROLLING INTRAOCULAR PRESSURE

U-225 METHOD FOR DELIVERY

U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

U-227 NASAL ADMINISTRATION

U-228 ASTHMA

U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)

U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

U-231 USE IN PARKINSON'S DISEASE

U-232 METHOD OF TREATING MIGRAINE

U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS

U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY

U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS

U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....

U-239 TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID

U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS

U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION

U-243 TOPICAL ADMINISTRATION

U-244 PLATELET AGGREGATION INHIBITORS

U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-246 PHOSPHATE BINDING

U-247 TREATMENT OF RHEUMATOID ARTHRITIS

U-248 TREATMENT OF HIV

U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 62

PATENT USE

AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
 U-250 TREATMENT OF HEPATITIS B INFECTION
 U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
 U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
 U-253 ORAL TRANSMUCOSAL USE
 U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
 U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
 U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
 U-257 TREATMENT OF HIV INFECTION
 U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
 U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
 U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
 U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
 U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
 U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
 U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
 U-265 USE AS LAXATIVE
 U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
 U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
 U-268 ACROMEGALY
 U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
 U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
 U-271 METHOD OF TREATING TUMORS
 U-272 METHOD OF TREATING CARCINOMA
 U-273 CUTANEOUS T-CELL LYMPHOMA
 U-274 ZANAMIVIR FOR INHALATION
 U-275 METHOD OF USE OF THE DRUG SUBSTANCE
 U-276 METHOD OF USE OF LEVOBUPIVACAINE
 U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
 U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
 U-279 METHOD OF USE OF THE APPROVED PRODUCT
 U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
 U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
 U-282 METHOD OF TREATING BACTERIAL INFECTIONS
 U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
 U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
 U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
 U-286 DEPRESSION
 U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
 U-288 THERAPY OF INFLUENZA
 U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
 U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
 U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
 U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
 U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
 U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS

PATENT AND EXCLUSIVITY TERMS

ADB 32 of 62

PATENT USE

U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
 U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
 U-298 METHOD OF COMBATING BACTERIA IN A PATIENT
 U-299 TREATMENT OF ADENOMATOUS POLYPS
 U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
 U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
 U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
 U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
 U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
 U-305 METHODS FOR USING THE DRUG PRODUCT
 U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
 U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
 U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
 U-309 TREATING SJOEGREN SYNDROME
 U-310 TREATMENT OF XEROSTOMIA
 U-311 HORMONE REPLACEMENT
 U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
 U-313 TREATMENT OF CONGESTIVE HEART FAILURE
 U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
 U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
 U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
 U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
 U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
 U-319 TREATMENT OF MICROBIAL INFECTIONS
 U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
 U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
 U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
 U-323 USE AS A BILE ACID SEQUESTRANT
 U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
 U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
 U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
 U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
 U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
 U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
 U-330 TREATMENT OF NAUSEA AND VOMITING
 U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
 U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
 U-333 METHOD OF TREATING OCULAR HYPERTENSION
 U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
 U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
 U-336 DIAGNOSTIC RADIOIMAGING
 U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 62

PATENT USE

U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME

U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER

U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR

U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS

U-348 METHOD OF USE FOR INHIBITING HIV INFECTION

U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION

U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR

U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS

U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING

U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.

U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE

U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER

U-359 METHOD OF USE OF VISICOL

U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY

U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS

U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011

U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION

U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION

U-367 TREATMENT OF CARDIOVASCULAR DISORDERS

U-368 HEARTBURN

U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE

U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS

U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

PATENT AND EXCLUSIVITY TERMS

ADB 34 of 62

PATENT USE

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABILIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPATHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

PATENT AND EXCLUSIVITY TERMS

ADB 35 of 62

PATENT USE

U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE

U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-420 METHOD OF TREATMENT OF TYPE II DIABETES

U-421 USE FOR SEDATION

U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA

U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS

U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION

U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS

U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE

U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS

U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER

U-431 POSTTRAUMATIC STRESS DISORDER

U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE

U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS

U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG

U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION

U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE

U-439 TREATMENT OF OBESITY

U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE

U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE

U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG

U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

U-444 TREATMENT OF MIGRAINE

U-445 USE AS AN ANTIMYCOTIC AGENT

U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER

U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING

U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)

U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS

U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A

PATENT AND EXCLUSIVITY TERMS

ADB 36 of 62

PATENT USE

CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN

U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15

U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN

U-458 METHOD OF USE OF IMAGENT

U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE

U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE

U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA

U-463 VENOGRAPHY

U-464 PERIPHERAL ARTERIOGRAPHY

U-465 CT IMAGING OF THE HEAD

U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME

U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION

U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS

U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE

U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS

U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES

U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL

U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA

U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B

U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY

U-480 CONTRAST AGENT FOR MRI

U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY

U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....

U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND

U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION

U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE

U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA

U-489 EXPECTORANT

U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-491 METHOD OF DELIVERING A DRUG TO THE LUNG

U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP

PATENT AND EXCLUSIVITY TERMS

ADB 37 of 62

PATENT USE

CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID

U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

U-495 PERITONEAL DIALYSIS SOLUTION

U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE

U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST

U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION

U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505 ULTRASOUND CONTRAST AGENT

U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..

U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES

U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA

U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA

U-514 PREVENTION OF OVULATION IN A WOMAN

U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY

U-516 METHOD OF TREATING A PSYCHOTIC DISEASE

U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

U-518 OBSESSIVE COMPULSIVE DISORDER

U-519 POST OPERATIVE NAUSEA AND VOMITING

U-520 PREMENOPAUSAL OSTEOPOROSIS

U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA

U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL

U-524 METHOD OF TREATING DIARRHEA

U-525 METHOD OF TREATING PARASITIC INFECTIONS

U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION

U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE

U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE

U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES

U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES

U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR

U-533 ERECTILE DYSFUNCTION

U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA

U-535 TREATMENT OF SOCIAL ANXIETY DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 38 of 62

PATENT USE

U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE

U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS

U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-540 TREATMENT OF FUNGAL INFECTIONS

U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1

U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION

U-543 TREATMENT OF SCHIZOPHRENIA

U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.

U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT

U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER

U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER

U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID

U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS

U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING

U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

U-572 INTENSIVE CARE UNIT SEDATION

U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE

PATENT AND EXCLUSIVITY TERMS

ADB 39 of 62

PATENT USE

GLOBE.

- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTITROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 62

PATENT USE

U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA

U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA

U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.

U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER

U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-613 REDUCTION OF SERUM PHOSPHATE

U-614 TREATMENT OF SEXUAL DYSFUNCTION

U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER

U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.

U-619 TREATMENT OF MALIGNANT NEOPLASM

U-620 TREATMENT OF INSOMNIA

U-621 METHOD OF TREATING CANCER

U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.

U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

U-625 ALLERGIC RHINITIS OR NASAL POLYPS

U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS

U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE

U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE

U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN

U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 62

PATENT USE

U-646 METHOD OF TREATING OTITIS
 U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
 U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
 U-649 A METHOD FOR TREATING A TUMOR DISEASE
 U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
 U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
 U-652 TREATMENT OF CARDIAC ARRHYTHMIA
 U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
 U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4
 U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
 U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
 U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
 U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
 U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
 U-661 TREATMENT OF SEIZURE DISORDER
 U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
 U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
 U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
 U-666 METHOD OF TREATING ADHD
 U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
 U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
 U-669 INDICATION OF TYPE II DIABETES
 U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
 U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
 U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
 U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
 U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
 U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
 U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
 U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
 U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
 U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
 U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
 U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY
 U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
 U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
 U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
 U-685 EXPECTORANT AND COUGH SUPPRESSANT
 U-686 EXPECTORANT AND NASAL DECONGESTANT
 U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
 U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
 U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO

PATENT AND EXCLUSIVITY TERMS

ADB 42 of 62

PATENT USE

CHEMOTHERAPY REGIMENS

- U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
- U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
- U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA
- U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
- U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
- U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
- U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
- U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
- U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- U-707 ALLERGIC RHINITIS
- U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-709 METHOD OF COMBATING BACTERIA IN A PATIENT
- U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
- U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
- U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
- U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
- U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-718 TREATMENT OF FUNGAL INFECTIONS
- U-719 TREATMENT OF PSYCHOSIS
- U-720 TREATMENT OF NEUROLEPTIC DISEASES
- U-721 TREATMENT OF INFLUENZA
- U-722 PROPHYLAXIS OF INFLUENZA
- U-723 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-724 METHOD OF TREATING SEIZURES
- U-725 ALLERGIC RHINITIS AND URTICARIA
- U-726 ALLERGIC RHINITIS
- U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- U-728 METHOD FOR TREATING BACTERIAL INFECTION
- U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 62

PATENT USE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS

U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID

U-769 REVLMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT

U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

PATENT AND EXCLUSIVITY TERMS

ADB 44 of 62

PATENT USE

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY

U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE

U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER

U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS

U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA

U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS

U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)

U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE

U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

PATENT AND EXCLUSIVITY TERMS

ADB 45 of 62

PATENT USE

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 62

PATENT USE

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD

U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA

U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY

U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE

U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES

U-867 TREATMENT OF MIGRAINE

U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA

U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION

U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)

U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE

U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER

U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR

U-879 A METHOD OF TREATING OR PREVENTING ILEUS

U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER

U-882 MANAGEMENT OF FIBROMYALGIA (FM)

U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB

U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN

U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)

U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 47 of 62

PATENT USE

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE

PATENT AND EXCLUSIVITY TERMS

ADB 48 of 62

PATENT USE

HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER
- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION

PATENT AND EXCLUSIVITY TERMS

ADB 49 of 62

PATENT USE

U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE

U-978 METHOD OF TREATING HYPONATREMIA

U-979 RELIEF OF MUSCLE SPASM

U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

U-982 A METHOD OF TREATING OSTEOPOROSIS

U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE

U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE

U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)

U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL

PATENT AND EXCLUSIVITY TERMS

ADB 50 of 62

PATENT USE

REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
 U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
 U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
 U-1019 TREATMENT OF PULMONARY HYPERTENSION
 U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
 U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
 U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
 U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
 U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
 U-1025 TREATING FREQUENT HEARTBURN
 U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
 U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
 U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
 U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
 U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
 U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
 U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
 U-1033 TOPICAL TREATMENT OF ACNE VULGARIS
 U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
 U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
 U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
 U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
 U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
 U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
 U-1040 INHIBITION OF THROMBIN IN A PATIENT
 U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
 U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
 U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN
 U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS
 U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
 U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
 U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
 U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
 U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
 U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
 U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS
 U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
 U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
 U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
 U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
 U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
 U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
 U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
 U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
 U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID

PATENT AND EXCLUSIVITY TERMS

ADB 51 of 62

PATENT USE

LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
 U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
 U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
 U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
 U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY
 ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY
 ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
 U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY
 ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF
 DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
 U-1067 TREATMENT OF CANCER
 U-1068 TREATMENT OF ASTHMA
 U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE
 COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
 U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER
 PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL
 PHARMACY THAT MAINTAINS A CENTRAL DATABASE
 U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION
 U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A
 CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
 U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD
 U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
 U-1075 USE FOR THE TREATMENT OF ASTHMA
 U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC
 CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
 U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED
 DISODIUM ADMINISTRATION
 U-1078 TREATMENT OF ACNE
 U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH
 TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
 U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
 U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED
 INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
 U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION
 WHERE AN INFECTION OR RISK OF INFECTION EXISTS
 U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF
 CLUSTER HEADACHE EPISODES
 U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID
 RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
 U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL
 DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
 U-1086 TREATMENT OF AUTOIMMUNE DISEASE
 U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC
 CYSTOSCOPY
 U-1088 RELIEF OF MUSCLE SPASM
 U-1089 INHIBITION OF THROMBIN
 U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO
 USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
 U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER
 WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
 U-1092 TREATMENT OF BREAST CANCER
 U-1093 TREATMENT OF PSEUDOBULBAR AFFECT
 U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
 U-1095 METHOD OF TREATING OCULAR INFLAMMATION
 U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
 U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2
 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS
 APPROPRIATE
 U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
 U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL
 NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
 U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
 U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
 U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
 U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A

PATENT AND EXCLUSIVITY TERMS

ADB 52 of 62

PATENT USE

DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL

U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS

U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (≥ 18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C

U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING

PATENT AND EXCLUSIVITY TERMS

ADB 53 of 62

PATENT USE

OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C

U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION

U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)

U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA)

U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER

U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER

U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP

U-1163 METHOD OF TREATING THROMBOSIS

U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS

U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN

U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME

U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN

U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE

U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR

PATENT AND EXCLUSIVITY TERMS

ADB 54 of 62

PATENT USE

INJECTION PRIOR TO ADMINISTRATION

U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION

U-1176 TREATMENT OR PREVENTION OF STROKE

U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION

U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN

U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS

U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN

U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION

U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE

U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)

U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE

U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN

U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN

U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)

U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)

U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)

U-1194 METHOD FOR TREATING INSOMNIA

U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA

U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-1204 TREATMENT OF UVEITIS

U-1205 TREATMENT OF MACULAR EDEMA

U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX

U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND

PATENT AND EXCLUSIVITY TERMS

ADB 55 of 62

PATENT USE

TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS

U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER

U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS

U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER

U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA

U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE

U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA

U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS

U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE

U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG

U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT

PATENT AND EXCLUSIVITY TERMS

ADB 56 of 62

PATENT USE

U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
 U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
 U-1254 METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
 U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
 U-1256 TREATMENT OF SEBORRHEIC DERMATITIS
 U-1257 TREATMENT OF OPHTHALMIC DISORDERS
 U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES
 U-1259 PROPHYLAXIS OF HIV-1 INFECTION
 U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
 U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
 U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
 U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
 U-1264 TREATMENT OF A RESPIRATORY DISEASE
 U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
 U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
 U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
 U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
 U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
 U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
 U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES
 U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
 U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
 U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
 U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
 U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
 U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
 U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
 U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
 U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
 U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
 U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
 U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
 U-1284 A METHOD OF TREATING A NEOPLASM
 U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
 U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
 U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
 U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
 U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
 U-1290 TREATMENT OF LUNG CANCER
 U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
 U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
 U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
 U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT
 U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

PATENT AND EXCLUSIVITY TERMS

ADB 57 of 62

PATENT USE

U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION

U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS

U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES

U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)

U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM

U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES

U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS

U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1308 MULTIPLE MYELOMA

U-1309 BONE METASTASES

U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

U-1311 METHOD OF TREATING CYSTIC FIBROSIS

U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA

U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS

U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE

U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER

U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

PATENT AND EXCLUSIVITY TERMS

ADB 58 of 62

PATENT USE

U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR

U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN

U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN

U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN

U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION

U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE

U-1347 TREATMENT OF A SKIN DISORDER

U-1348 TREATMENT OF OSTEOARTHRITIS

U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS

U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS

U-1351 TREATMENT OF ACUTE PAIN

U-1352 TREATMENT OF PRIMARY DYSMENORRHEA

U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH

U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD

U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER

U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD

U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS

U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE

U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY

U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO

PATENT AND EXCLUSIVITY TERMS

ADB 59 of 62

PATENT USE

ANOVULATORY INFERTILE WOMEN

U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN

U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB

U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

U-1370 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE

U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA

U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION

U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS

U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)

U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER

U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE

U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS

U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF

U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS

U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1389 ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF

U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION

U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION

U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE

U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY

U-1398 METHOD OF TREATING CHRONIC HEPATITIS C

U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES

U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE

PATENT AND EXCLUSIVITY TERMS

ADB 60 of 62

PATENT USE

EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS

U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)

U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS

U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES

U-1406 TREATMENT OF MELANOMA

U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)

U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES

U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

U-1412 TREATMENT OF ATOPIC DERMATITIS

U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION

U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)

U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2

U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS

U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST

U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING

U-1420 METHOD OF ONCE A DAY ADMINISTRATION

U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE

U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT

U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR

U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX

U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1434 TREATMENT OF PANCREATIC CANCER

U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.

U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT

U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION

U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION

PATENT AND EXCLUSIVITY TERMS

ADB 61 of 62

PATENT USE

U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS

U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING

U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE

U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS

U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION

U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES

U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA

U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA

U-1449 METHOD OF ALLEVIATING A SKIN CONDITION

U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS

U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY

U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT

U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT

U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1455 TREATMENT OF PERIANAL WARTS

U-1456 TREATMENT OF MANTLE CELL LYMPHOMA

U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM

U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1459 TREATMENT OF CARCINOMA OF THE THYROID

U-1460 TREATMENT OF HERPES LABIALIS

U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE

U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1467 METHOD OF TREATING HEPATITIS C

U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

U-1470 FOR THE TREATMENT OF HEPATITIS C

U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.

U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY

PATENT AND EXCLUSIVITY TERMS

ADB 62 of 62

PATENT USE

EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA